<SEC-DOCUMENT>0001213900-25-022325.txt : 20250310
<SEC-HEADER>0001213900-25-022325.hdr.sgml : 20250310
<ACCEPTANCE-DATETIME>20250310172904
ACCESSION NUMBER:		0001213900-25-022325
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		128
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250310
DATE AS OF CHANGE:		20250310

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Inspira Technologies OXY B.H.N. Ltd
		CENTRAL INDEX KEY:			0001837493
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40303
		FILM NUMBER:		25725025

	BUSINESS ADDRESS:	
		STREET 1:		HATIDHAR 2
		STREET 2:		11TH FLOOR
		CITY:			RA'ANANA
		STATE:			L3
		ZIP:			4366504
		BUSINESS PHONE:		972-9-9664488

	MAIL ADDRESS:	
		STREET 1:		HATIDHAR 2
		STREET 2:		11TH FLOOR
		CITY:			RA'ANANA
		STATE:			L3
		ZIP:			4366504
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>ea0233226-20f_inspira.htm
<DESCRIPTION>ANNUAL REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Mar 10 18:58:49 UTC 2025 -->
<html xmlns:compsci="http://compsciresources.com" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:iinn="http://www.inspiratechnologies.com/20241231" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml">
<head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type"/>
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>
</div><p style="margin: 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>UNITED
STATES<br/>

SECURITIES AND EXCHANGE COMMISSION
<br/>
WASHINGTON, DC 20549</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>FORM
<ix:nonNumeric contextRef="c0" name="dei:DocumentType" id="ixv-25419">20-F</ix:nonNumeric></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; "><span style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:DocumentRegistrationStatement" id="ixv-25420">&#9744;</ix:nonNumeric>
REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; "><span style="font-family: Times New Roman, Times, Serif"><b>OR</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; "><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; "><span style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:DocumentAnnualReport" id="ixv-25421">&#9746;</ix:nonNumeric>
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">For
the fiscal year ended <ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="ixv-25422"><ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-en" name="dei:CurrentFiscalYearEndDate" id="ixv-25423">December 31</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalYearFocus" id="ixv-25424">2024</ix:nonNumeric></ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; "><span style="font-family: Times New Roman, Times, Serif"><b>OR</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; "><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; "><span style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="ixv-25425">&#9744;</ix:nonNumeric>
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; "><span style="font-family: Times New Roman, Times, Serif"><b>OR</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; "><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; "><span style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:DocumentShellCompanyReport" id="ixv-25426">&#9744;</ix:nonNumeric>
SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Commission
File No.: <ix:nonNumeric contextRef="c0" name="dei:EntityFileNumber" id="ixv-25427">001-40303</ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName" id="ixv-94"><span style="font-family: Times New Roman, Times, Serif"><b>INSPIRA
TECHNOLOGIES OXY B.H.N. LTD.</b></span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><i>(Exact
name of registrant as specified in its charter)</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><i>Translation
of registrant&#8217;s name into English: Not applicable</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; "><span style="font-family: Times New Roman, Times, Serif"><b>State
of <ix:nonNumeric contextRef="c0" format="ixt-sec:edgarprovcountryen" name="dei:EntityIncorporationStateCountryCode" id="ixv-25428">Israel</ix:nonNumeric>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; "><span style="font-family: Times New Roman, Times, Serif"><i>(Jurisdiction
of incorporation or organization)</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1" id="ixv-25429">2
Ha-Tidhar St</ix:nonNumeric>.,</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown" id="ixv-25430">Ra&#8217;anana</ix:nonNumeric>,
<ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode" id="ixv-25431">4366504</ix:nonNumeric> <ix:nonNumeric contextRef="c0" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry" id="ixv-25432">Israel</ix:nonNumeric></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; "><span style="font-family: Times New Roman, Times, Serif"><b>Tel:
+972.4.6230333</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; "><span style="font-family: Times New Roman, Times, Serif"><i>(Address
of principal executive offices)</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c1" name="dei:ContactPersonnelName" id="ixv-144"><span style="font-family: Times New Roman, Times, Serif"><b>Dagi
Ben-Noon</b></span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b><ix:nonNumeric contextRef="c1" name="dei:EntityAddressAddressLine1" id="ixv-25433">2
Ha-Tidhar St.</ix:nonNumeric>,</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b><ix:nonNumeric contextRef="c1" name="dei:EntityAddressCityOrTown" id="ixv-25434">Ra&#8217;anana</ix:nonNumeric>,
<ix:nonNumeric contextRef="c1" name="dei:EntityAddressPostalZipCode" id="ixv-25435">4366504</ix:nonNumeric> <ix:nonNumeric contextRef="c1" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry" id="ixv-25436">Israel</ix:nonNumeric></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; "><span style="font-family: Times New Roman, Times, Serif"><b>Tel:
<ix:nonNumeric contextRef="c1" name="dei:CityAreaCode" id="ixv-25437">+972</ix:nonNumeric>.<ix:nonNumeric contextRef="c1" name="dei:LocalPhoneNumber" id="ixv-25438">4.6230333</ix:nonNumeric></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; "><span style="font-family: Times New Roman, Times, Serif"><i>(Name,
Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Securities
registered or to be registered pursuant to Section 12(b) of the Act:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="text-align: center; border-bottom: Black 1.5pt solid; width: 32%; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Title of each class</i></span></td> <td style="text-align: center; padding-bottom: 1.5pt; width: 2%; vertical-align: bottom">&#160;</td> <td style="text-align: center; border-bottom: Black 1.5pt solid; width: 32%; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Trading Symbol(s)</i></span></td> <td style="text-align: center; padding-bottom: 1.5pt; width: 2%; vertical-align: bottom">&#160;</td> <td style="text-align: center; border-bottom: Black 1.5pt solid; width: 32%; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Name of each exchange on which registered </i></span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-align: center; vertical-align: top"><ix:nonNumeric contextRef="c2" name="dei:Security12bTitle" id="ixv-189"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ordinary Shares, no par value</b></span></ix:nonNumeric></td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="text-align: center; vertical-align: top"><ix:nonNumeric contextRef="c2" format="ixt:fixed-true" name="dei:NoTradingSymbolFlag" id="ixv-194"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IINN</b></span></ix:nonNumeric></td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="c2" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="ixv-25439">Nasdaq</ix:nonNumeric> Capital Market</b></span></td></tr> <tr style="vertical-align: top; "> <td style="text-align: center; vertical-align: top"><ix:nonNumeric contextRef="c3" name="dei:Security12bTitle" id="ixv-203"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants to purchase Ordinary Shares</b></span></ix:nonNumeric></td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="text-align: center; vertical-align: top"><ix:nonNumeric contextRef="c3" name="dei:TradingSymbol" id="ixv-208"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IINNW</b></span></ix:nonNumeric></td> <td style="text-align: center; vertical-align: top">&#160;</td> <td style="text-align: center; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><ix:nonNumeric contextRef="c3" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="ixv-25440">Nasdaq</ix:nonNumeric> Capital Market</b></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Securities
registered or to be registered pursuant to Section 12(g) of the Act: None</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Securities
for which there is a reporting obligation pursuant to Section 15(d) of the Act: None</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
the number of outstanding shares of each of the issuer&#8217;s classes of capital or common stock as of the close of the period covered
by the annual report:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-25441">24,252,096</ix:nonFraction>
ordinary shares, no par value, as of December 31, 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Yes
&#9744; <ix:nonNumeric contextRef="c0" name="dei:EntityWellKnownSeasonedIssuer" id="ixv-25442">No</ix:nonNumeric> &#9746;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">If
this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section
13 or 15(d) of the Exchange Act of 1934.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Yes
&#9744; <ix:nonNumeric contextRef="c0" name="dei:EntityVoluntaryFilers" id="ixv-25443">No</ix:nonNumeric> &#9746;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act of 1934
during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject
to such filing requirements for the past 90 days.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Yes
&#9744; <ix:nonNumeric contextRef="c0" name="dei:EntityCurrentReportingStatus" id="ixv-25444">No</ix:nonNumeric> &#9746;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="c0" name="dei:EntityInteractiveDataCurrent" id="ixv-25445">Yes</ix:nonNumeric>
&#9746; No &#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth
company. See definition of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; and &#8220;emerging growth company&#8221;
in Rule 12b-2 of the Exchange Act.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 4%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 25%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer </span></td> <td style="width: 21%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td> <td style="width: 32%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer </span></td> <td style="width: 18%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="ixv-329"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated filer</span></ix:nonNumeric></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging Growth Company </span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="ixv-336"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></ix:nonNumeric></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">If
an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards&#8224; provided
pursuant to Section 13(a) of the Exchange Act. <ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:EntityExTransitionPeriod" id="ixv-25446">&#9744;</ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#8224;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
term &#8220;new or revised financial accounting standard&#8221; refers to any update issued by the Financial Accounting Standards Board
to its Accounting Standards Codification after April 5, 2012.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Yes
&#9744; No <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:IcfrAuditorAttestationFlag" id="ixv-25447">&#9746;</ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">If
securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant
included in the filing reflect the correction of an error to previously issued financial statements. <ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:DocumentFinStmtErrorCorrectionFlag" id="ixv-25448">&#9744;</ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation
received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: hidden-fact-0">U.S.
GAAP</span> &#9746;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">International
Financial Reporting Standards as issued by the International Accounting Standards Board &#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Other
&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">If
&#8220;Other&#8221; has been checked in response to the previous question, indicate by check mark which financial statement item the
registrant has elected to follow.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#9744;
Item 17 &#9744; Item 18</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">If
this is an annual report, indicate by check mark whether the registrant is a shell company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Yes
&#9744; No <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityShellCompany" id="ixv-25449">&#9746;</ix:nonNumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>TABLE
OF CONTENTS</b>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="vertical-align: top; width: 9%">&#160;</td>
    <td style="vertical-align: top; width: 82%">&#160;</td>
    <td style="vertical-align: bottom; width: 9%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b>&#160;</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td colspan="2" style="vertical-align: top"><a href="#I_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">INTRODUCTION</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii</span></td></tr>
  <tr>
    <td colspan="2" style="vertical-align: top"><a href="#I_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></a></td>
    <td style="vertical-align: bottom; text-align: center">viii</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td colspan="2" style="vertical-align: top"><a href="#I_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SUMMARY RISK FACTORS</span></a></td>
    <td style="vertical-align: bottom; text-align: center">x</td></tr>
  <tr>
    <td colspan="2" style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART I</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 1.</span></td>
    <td style="vertical-align: top"><a href="#I_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 2.</span></td>
    <td style="vertical-align: top"><a href="#I_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OFFER STATISTICS AND EXPECTED TIMETABLE</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 3.</span></td>
    <td style="vertical-align: top"><a href="#I_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">KEY INFORMATION</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="vertical-align: top; text-align: justify"><a href="#I_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Reserved]</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="vertical-align: top"><a href="#I_084"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capitalization and Indebtedness.</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td style="vertical-align: top"><a href="#I_085"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reasons for the Offer and Use of Proceeds</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td style="vertical-align: top"><a href="#I_011"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 4.</span></td>
    <td style="vertical-align: top"><a href="#I_012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">INFORMATION ON THE COMPANY</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="vertical-align: top"><a href="#I_013"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">History and Development of the Company</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="vertical-align: top"><a href="#I_014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business Overview</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td style="vertical-align: top"><a href="#I_015"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Organizational Structure</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td style="vertical-align: top"><a href="#I_016"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property, Plants and Equipment</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 4A.</span></td>
    <td style="vertical-align: top"><a href="#I_017"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">UNRESOLVED STAFF COMMENTS</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 5.</span></td>
    <td style="vertical-align: top"><a href="#I_018"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OPERATING AND FINANCIAL REVIEW AND PROSPECTS</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="vertical-align: top"><a href="#I_020"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating Results</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="vertical-align: top"><a href="#I_021"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liquidity and Capital Resources</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td style="vertical-align: top"><a href="#I_022"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development, patents and licenses, etc.</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td style="vertical-align: top"><a href="#I_023"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trend information</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.</span></td>
    <td style="vertical-align: top"><a href="#I_024"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Critical Accounting Estimates</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 6.</span></td>
    <td style="vertical-align: top"><a href="#I_025"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES.</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="vertical-align: top"><a href="#I_026"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors and Senior Management.</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="vertical-align: top"><a href="#I_027"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation.</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">77</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td style="vertical-align: top"><a href="#I_028"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Board Practices</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">78</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td style="vertical-align: top"><a href="#I_029"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employees</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">92</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.</span></td>
    <td style="vertical-align: top"><a href="#I_030"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share Ownership</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">93</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F</span></td>
    <td style="vertical-align: top"><a href="#I_031"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosure of a registrant&#8217;s action to recover erroneously awarded compensation</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">94</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 7.</span></td>
    <td style="vertical-align: top"><a href="#I_032"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">94</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="vertical-align: top"><a href="#I_033"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Major Shareholders</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">94</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="vertical-align: top"><a href="#I_034"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related Party Transactions</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">95</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td style="vertical-align: top"><a href="#I_035"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interests of Experts and Counsel</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">96</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 8.</span></td>
    <td style="vertical-align: top"><a href="#I_036"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FINANCIAL INFORMATION</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">96</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="vertical-align: top"><a href="#I_037"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statements and Other Financial Information</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">96</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="vertical-align: top"><a href="#I_038"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant Changes</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">98</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 9.</span></td>
    <td style="vertical-align: top"><a href="#I_039"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THE OFFER AND LISTING</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">98</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="vertical-align: top"><a href="#I_040"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offer and Listing Details</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">98</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="vertical-align: top"><a href="#I_041"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plan of Distribution</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">98</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td style="vertical-align: top"><a href="#I_042"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Markets</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">98</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td style="vertical-align: top"><a href="#I_043"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling Shareholders</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">98</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.</span></td>
    <td style="vertical-align: top"><a href="#I_044"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dilution</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">98</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F.</span></td>
    <td style="vertical-align: top"><a href="#I_045"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenses of the Issue</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">98</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 10.</span></td>
    <td style="vertical-align: top"><a href="#I_046"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ADDITIONAL INFORMATION</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">98</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td style="vertical-align: top"><a href="#I_047"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share Capital</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">98</span></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td style="vertical-align: top"><a href="#I_048"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Memorandum and Articles of Association</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">98</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td style="vertical-align: top"><a href="#I_049"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Material Contracts</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 3; Options: NewSection --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
<tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.</span></td>
    <td style="vertical-align: top; width: 82%"><a href="#I_050"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exchange Controls</span></a></td>
    <td style="vertical-align: bottom; text-align: center; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99</span></td></tr>
<tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.</span></td>
    <td style="vertical-align: top"><a href="#I_051"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxation</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F.</span></td>
    <td style="vertical-align: top"><a href="#I_052"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends and Paying Agents</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">106</span></td></tr>
<tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">G.</span></td>
    <td style="vertical-align: top"><a href="#I_053"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statement by Experts</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">106</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">H.</span></td>
    <td style="vertical-align: top"><a href="#I_054"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Documents on Display</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">107</span></td></tr>
<tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">I.</span></td>
    <td style="vertical-align: top"><a href="#I_055"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiary Information</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">107</span></td></tr>
<tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">J.</span></td>
    <td style="vertical-align: top"><a href="#I_056"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual Report to Security Holders</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">107</span></td></tr>

<tr style="vertical-align: top; ">
    <td style="width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 11.</span></td>
    <td style="width: 82%"><a href="#I_057"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></a></td>
    <td style="width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">107</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 12.</span></td>
    <td><a href="#I_058"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">108</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</span></td>
    <td><a href="#I_059"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Debt Securities</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">108</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</span></td>
    <td><a href="#I_060"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants and rights</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">108</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.</span></td>
    <td><a href="#I_061"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other Securities</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">108</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART II</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 13.</span></td>
    <td><a href="#I_064"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">109</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 14.</span></td>
    <td><a href="#I_065"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">109</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 15.</span></td>
    <td><a href="#I_066"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONTROLS AND PROCEDURES</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">109</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16.</span></td>
    <td><a href="#I_067"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[RESERVED]</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">110</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16A.</span></td>
    <td><a href="#I_068"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AUDIT COMMITTEE FINANCIAL EXPERT</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">110</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16B.</span></td>
    <td><a href="#I_069"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CODE OF ETHICS</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">110</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16C.</span></td>
    <td><a href="#I_070"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">110</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16D.</span></td>
    <td><a href="#I_071"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">111</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16E.</span></td>
    <td><a href="#I_072"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">111</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16F.</span></td>
    <td><a href="#I_073"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CHANGE IN REGISTRANT&#8217;S CERTIFYING ACCOUNTANT</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">111</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16G.</span></td>
    <td><a href="#I_074"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CORPORATE GOVERNANCE</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">111</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16H.</span></td>
    <td><a href="#I_075"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MINE SAFETY DISCLOSURE</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">114</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16I</span></td>
    <td><a href="#I_076"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">114</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16J</span></td>
    <td><a href="#I_077"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">INSIDER TRADING POLICIES</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">114</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16K</span></td>
    <td><a href="#I_078"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CYBERSECURITY</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">114</span></td></tr>
  <tr style="vertical-align: top; ">
    <td colspan="3" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART III</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 17.</span></td>
    <td><a href="#I_080"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FINANCIAL STATEMENTS</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">115</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 18.</span></td>
    <td><a href="#I_081"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FINANCIAL STATEMENTS</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">115</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 19.</span></td>
    <td><a href="#I_082"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXHIBITS</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">115</span></td></tr>
  <tr style="vertical-align: top; ">
    <td colspan="2"><a href="#I_083"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SIGNATURES</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">116</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 4 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;<img alt="" src="image_001.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Inspira
Technologies Oxy B.H.N. Ltd. </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="I_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><b>INTRODUCTION</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a specialty medical
device company engaged in the research, development, manufacturing, and marketing of proprietary life support technologies. We aim for
our technology to supersede mechanical ventilators and revolutionize the global mechanical ventilation market.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;<img alt="" src="image_002.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;<img alt="" src="image_003.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 5 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;<img alt="" src="image_004.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_005.jpg"/><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>Targeting
to Revolutionize Life Support</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
are a specialty medical device company engaged in the research, development, manufacturing, and marketing of proprietary life support
technology with a vision to supersede traditional mechanical ventilators, or mechanical ventilation, which is the standard of care today
for the treatment of acute respiratory failure. Mechanical ventilation may elevate risks, increase the cost of care, extend hospital
stays, raise infection rates, lead to ventilator dependence and heighten mortality. Using our state-of-the-art life support technology,
our goal is to set a new standard of care and provide patients with acute respiratory failure with an opportunity to preserve natural
breathing and avoid intubation, induced coma and risks associated with the use of mechanical ventilation. As part of our strategy to
reach this goal, and in parallel to pursuing regulatory approvals, we are actively working to establish collaborations with strategic
partners, leading hospitals, medical device companies and distributors both for endorsement and early clinical adoption. We intend to
target intensive care units, or ICUs, general medical units, operating theaters, and small urban and rural hospitals, with the goal of
increasing access to our solutions to markets with millions of potential users. We expect these activities to support our strategy plan
to reach market penetration and adoption of our life support technology.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 6 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
are developing the following products:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>The
INSPIRA<sup>TM</sup> ART</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
INSPIRA ART system, which is an augmented life support respiratory technology, also known as the INSPIRA ART500, is our flagship product
The INSPIRA ART system aims to monitor and oxygenate blood to boost patient saturation levels, within minutes, while the patient is awake,
without the need for an invasive mechanical ventilator.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;<img alt="" src="image_006.jpg" style="height: 306px; width: 750px"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
INSPIRA ART is a potential alternative treatment for up to 20 million patients each year who are taken to ICUs and require mechanical
ventilators. Mortality rates are highest for patients undergoing prolonged mechanical ventilation and may exceed 50%. As
opposed to treating patients by forcing oxygen through their lungs in a procedure that requires intubation and medically induced coma,
the INSPIRA ART system is designed to deliver oxygen directly into the blood to elevate and stabilize declining oxygen saturation levels
within minutes, while performing blood parameter measurements in real-time without requiring intubation and induced coma. Our objective
is to enable patient-treatment without resorting to mechanical ventilation, with the potential to reduce associated legacy risks, complications
and high costs. This may allow for the treatment of larger patient populations even beyond ICU settings.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
technology is designed to continuously monitor the patient&#8217;s blood parameters in real-time, while enriching small volumes of blood
with oxygen and simultaneously removing carbon dioxide. Boosting oxygen saturation levels in minutes may allow patients to be awake,
potentially making the treatment suitable in the future to migrate from ICUs to emergency rooms, medical units, emergency medical services
and smaller rural hospitals with no ICUs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: center; width: 50%"><img alt="" src="image_007.jpg"/></td>
  <td style="width: 50%"><span style="font-family: Times New Roman, Times, Serif"><b>Patient treated awake and without mechanical ventilation.
  <br/>
  <br/>
  Oxygen is delivered straight into the blood, with simultaneous carbon dioxide removal.<br/>
  <br/>
  Blood parameters measured continuously and in real-time.</b></span></td></tr>
</table><div>

</div><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
INSPIRA ART is being designed with the intent of treating those on life support as a result of acute respiratory failure, while awake,
for longer than six hours, or prolonged life support, with extracorporeal circulation and physiologic gas exchange involving oxygenation
and carbon dioxide removal from the patient&#8217;s blood. The INSPIRA ART is being designed to potentially eliminate the need for invasive
mechanical ventilation, targeting acute respiratory failure patients in ICUs and potentially in general medical units. The Company believes
that the INSPIRA ART may enable treatment of patients without the need for induced coma, intubation or weaning, all of which are associated
with incurring the risk of lung infections and lung injury that may prolong hospital admission. The INSPIRA ART, which is in the development
phase and has not yet been tested in humans, will likely be submitted to the U.S. Food and Drug Administration, or the FDA, for
regulatory approval via the pre-market approval, or PMA, application or De Novo regulatory pathways. The Company aims to receive FDA
regulatory approval through its submission of the INSPIRA ART through the 510(k) regulatory pathway as part of its multi-step approach
in anticipation of a De Novo or PMA in connection with future clinical study results.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 7 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->v<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>The
INSPIRA<sup>TM</sup> ART100 </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
INSPIRA ART100 system, previously referred to as the ALICE, Liby, INSPIRA ART (Gen1) or ECLS system, is also referred to as a device
or system. The INSPIRA ART100 is an FDA-cleared advanced form of life support system, better known by the medical industry as a cardiopulmonary
bypass system, or CPB, designed for use in surgical procedures requiring cardiopulmonary bypass for six hours or less. The INSPIRA ART100
utilizes a technique that circulates, adds oxygen to and removes carbon dioxide from blood, with the enriched blood being circulated
back to the patient. The device takes over the function of the heart and/or lungs in critical care patients undergoing life-saving procedures.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May 2024, we received 510(k)
class II regulatory clearance from the FDA for the INSPIRA ART100 system. In July 2024, we received an Israeli Medical Equipment Division
Ministry of Health, or AMAR, regulatory approval for extra-corporeal membrane oxygenation, or ECMO, and cardiopulmonary bypass procedure.
In December 2024, our first devices were shipped for deployment to Westchester Medical Center in Valhalla, New York, as part of an evaluation
and collaboration for the INSPIRA ART.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: center; width: 50%"><span style="font-family: Times New Roman, Times, Serif"><img alt="" src="image_008.jpg"/>&#160;</span></td>
  <td style="text-align: center; width: 50%"><img alt="" src="image_009.jpg"/></td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
INSPIRA&#8482; ART100 system includes software that navigates the physician through the setup process and provides alerts while offering
potential troubleshooting solutions. The system has a compact design, with extended battery life to support intra-hospital patient transfers
between hospitals and is compatible with various disposable parts, allowing for customization of tubing and oxygenators, which simplifies
purchasing and inventory management.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 8 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->vi<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>The
HYLA<sup>TM</sup> Blood Sensor</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
HYLA blood sensor, described herein as the HYLA or HYLA blood sensor, is being designed to perform real-time sampling and analysis of
key blood parameter measurements, without the need for blood draws. The HYLA is being designed to measure, in real-time, thousands of
blood samples to be made accessible to physicians during a single ICU treatment or operating room procedure. The HYLA is being developed
in its first configuration, HYLA 1, and is currently undergoing a clinical evaluation in patients undergoing open heart surgery, with
a view to being submitted for 510(k) clearance in the second half of 2025.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_010.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
HYLA blood sensor is being designed to provide continuous, real-time monitoring of blood key parameters that can indicate oxygen deficiencies,
without the need to take intermittent blood draws. Designed for patients undergoing medical procedures or needing frequent monitoring,
this technology can detect sudden changes in medical conditions by tracking vital blood indicators.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Currently,
the HYLA is undergoing clinical evaluation at Sheba Hospital in Israel, where it is being tested on six patients during open-heart
procedures. The device is being developed to capture thousands of blood parameter measurements during a single procedure, with the
data simultaneously validated against traditional blood analyzers and equipment.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
are developing the HYLA as both an integrated component of our INSPIRA ART100 and INSPIRA ART systems, and as a standalone device. This
versatility may expand our market offering across multiple critical care applications and market segments.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
development process combines in-house laboratory testing with hospital collaborations for clinical research. This comprehensive approach
may allow for better validation of the technology in real-world medical settings, refinement of the sensor&#8217;s accuracy against industry
standards, and optimization of the disposable components for practical clinical use.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
have a goal to set a new standard of care in various areas of patient care. As part of our strategy to reach these goals, and in parallel
to pursuing regulatory approvals, we are actively working to establish collaborations with strategic partners and globally ranked health
centers to provide endorsement and clinical adoption for regional deployments of our products and technologies. We plan to target ICUs,
general medical units, operating theaters, and small urban and rural hospitals, with the goal of making our solutions more accessible
to millions of patients.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
are an Israeli corporation based in Ra&#8217;anana, Israel, and were incorporated in Israel in 2018 under the name Clearx Medical Ltd.
On April 10, 2018, our name was changed to Insense Medical Ltd. On July 30, 2020, our name was further changed to our current name, Inspira
Technologies Oxy B.H.N. Ltd. Our principal executive offices are located at 2 Ha-Tidhar St., Ra&#8217;anana, 4366504 Israel. Our telephone
number in Israel is +972 996 644 88. Our website address is&#160;<i>www.inspira-technologies.com</i>. The information contained on, or
that can be accessed through, our website is not part of this annual report. We have included our website address in this annual report
solely as an inactive textual reference.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 9 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->vii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="I_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><b>CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Certain
information included or incorporated by reference in this annual report on Form 20-F may be deemed to be &#8220;forward-looking statements&#8221;
within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements
are often characterized by the use of forward-looking terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221;
&#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;believe,&#8221; &#8220;predict,&#8221; &#8220;should,&#8221;
&#8220;intend,&#8221; &#8220;project&#8221; or other similar words, but are not the only way these statements are identified.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">These
forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, statements
that contain projections of results of operations or of financial condition, expected capital needs and expenses, statements relating
to the research, development, completion and use of our products, and all statements (other than statements of historical facts) that
address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Forward-looking
statements are not guarantees of future performance and are subject to risks and uncertainties. We have based these forward-looking statements
on assumptions and assessments made by our management in light of their experience and their perception of historical trends, current
conditions, expected future developments and other factors they believe to be appropriate.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Important
factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking
statements include, among other things:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our planned level of revenues
    and capital expenditures;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our available cash and
    our ability to obtain additional funding;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our ability to market and
    sell our products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our expectation regarding
    the sufficiency of our existing cash and cash equivalents to fund our current operations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our ability to advance
    the development of our products and future potential and product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our ability to commercialize
    our products and future potential product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our assessment of the potential
    of our products and future potential product candidates to treat certain indications;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our planned level of capital
    expenditures and liquidity;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our plans to continue to
    invest in research and development to develop technology for new products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our ability to maintain
    our relationships with suppliers, manufacturers, distributors and other partners;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anticipated actions of
    the FDA, state regulators, if any, or other similar foreign regulatory agencies, including approval to conduct clinical trials, the
    timing and scope of those trials and the prospects for regulatory approval or clearance of, or other regulatory action with respect
    to our products or services;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The regulatory environment
    and changes in the health policies and regimes in the countries in which we intend to operate, including the impact of any changes
    in regulation and legislation that could affect the medical device industry;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 10 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->viii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our ability to meet our
    expectations regarding the commercial supply of our products and future product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our ability to retain key
    office holders;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our ability to internally
    develop new inventions and intellectual property;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The overall global economic
    environment;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The impact of competition
    and new technologies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The possible impacts of
    cybersecurity incidents on our business and operations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General market, political
    and economic conditions in the countries in which we operate, including those related to the multi-front war risk that Israel faces;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The impact of competition
    and new technologies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our ability to internally
    develop new inventions and intellectual property;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in our strategy;
    and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Litigation.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Readers
are urged to carefully review and consider the various disclosures made throughout this annual report on Form 20-F which are designed
to advise interested parties of the risks and factors that may affect our business, financial condition, results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">You
should not put undue reliance on any forward-looking statements. Any forward-looking statements in this annual report on Form 20-F are
made as of the date hereof, and we undertake no obligation to publicly update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise, except as required by law.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition, the sections of this annual report on Form 20-F entitled &#8220;Introduction&#8221; and &#8220;Item 4. Information on the Company&#8221;
contain information obtained from independent industry sources and other sources that we have not independently verified.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">Unless
otherwise indicated, all references to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our&#8221; and &#8220;Inspira&#8221; refer
to Inspira Technologies Oxy B.H.N. Ltd. References to &#8220;U.S. dollars, &#8220;dollars,&#8221; and &#8220;$&#8221; are to currency
of the United States of America, and references to &#8220;NIS&#8221; are to New Israeli Shekels.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">Beginning
with the year ended December 31, 2023, we transitioned from preparing and reporting our financial statements in accordance with the International
Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards Board, or IASB, to preparing and reporting
our financial statements in accordance with generally accepted accounting principles in the United States, or U.S. GAAP, which may cause
our financial results to differ from results, or impact the comparability to our financial statements, prepared in accordance with IFRS.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">Notwithstanding
the foregoing, we have retroactively converted the historical financial statements that were prepared in accordance with IFRS and included
in this report to present such financial statements in accordance with U.S. GAAP.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">All
trademarks or trade names referred to in this Form 20-F are the property of their respective owners. Solely for convenience, the trademarks
and trade names in this annual report on Form 20-F are referred to without the &#174; and &#8482; symbols, but such references should
not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights
thereto. We do not intend the use or display of other companies&#8217; trademarks and trade names to imply a relationship with, or endorsement
or sponsorship of us by, any other companies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">This
Form 20-F contains various depictions and illustrations of the various products we are developing. These illustrations are representative
of the current expected designs for our products and are subject to change.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 11 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ix<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="I_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Summary
Risk Factors</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
risk factors described below are a summary of the principal risk factors associated with an investment in us. These are not the only
risks we face. You should carefully consider these risk factors, together with the risk factors set forth in Item 3D. of this annual
report on Form 20-F and the other reports and documents filed by us with the SEC.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our financial statements
    for the year ended December 31, 2024, contain an explanatory paragraph regarding substantial doubt about our ability to continue
    as a going concern. This going concern assessment may prevent us from obtaining new financing on reasonable terms, if at all, and
    imperil our ability to continue operating as a going concern;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our principal shareholders,
    officers and directors currently beneficially own approximately 18.01% of our securities and may therefore be able to exert control
    over matters submitted to our shareholders for approval;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have a limited operating
    history, and we have incurred significant operating losses since our inception and anticipate that we will incur continued losses
    for the foreseeable future.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify"><span>On March 10, 2025, we
received a written notice, or the Notice, from Nasdaq indicating that we were not in compliance with the minimum bid price requirement
for continued listing set forth in Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of
$1.00 per share. Under Nasdaq Listing Rule 5810(c)(3)(A), we were granted a period of 180 calendar days to regain compliance with the
minimum bid price requirement. No assurance can be given that we will remain eligible to be listed on Nasdaq. Any delisting could adversely
affect our ability to obtain financing for the continuation of our operations and could result in the loss of confidence by investors,
customers and employees.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have not generated any
    revenue from product sales and may never be profitable.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We will need to raise substantial
    additional funding, which may not be available on acceptable terms, if at all. Failure to obtain funding on acceptable terms and
    on a timely basis may require us to curtail, delay or discontinue our product development efforts or other operations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are highly dependent
    on the successful development, marketing and sale of our products and on receiving the required regulatory approvals for such products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our success depends on
    our ability to generate demand for our products, develop and commercialize new products and generate revenues and identify new markets
    for our technology;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical device development
    is costly and involves continual technological change, which may render certain of our current or future products obsolete;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our customer acquisition
    strategy may not succeed;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are dependent upon third-party
    service providers. If such third-party service providers fail to maintain a high quality of service, the functionality of our products
    could be impaired, which in turn may adversely affect our products, business, operating results and reputation;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may be exposed to foreign
    currency exchange rate fluctuations, which could adversely affect our results of operations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We manage our business
    through a small number of employees and key consultants;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may need to expand our
    company but we may experience difficulties in recruiting needed additional employees and consultants, which could disrupt our operations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 12 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->x<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">International expansion
    of our business exposes us to business, regulatory, political, operational, financial and economic risk associated with doing business
    outside of the United States, or U.S., or Israel;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If third-party payors do
    not provide adequate coverage and reimbursement for the use of our products or services or any future product candidates, our revenue
    will be negatively impacted;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our products and operations
    are subject to extensive government regulation and oversight both in the U.S. and abroad and our failure to comply with applicable
    requirements could harm our business;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may not receive, or
    may be delayed in receiving, the necessary clearances or approvals for our products and failure to timely obtain necessary clearances
    or approvals for our products would adversely affect our ability to grow our business;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure to comply with
    post-marketing regulatory requirements could subject us to enforcement actions, including substantial penalties, and might require
    us to recall or withdraw a product from the market;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our products may cause
    or contribute to adverse medical events or be subject to failures or malfunctions that we are required to report to the FDA, and
    if we fail to do so, we would be subject to sanctions that could harm our reputation, business, financial condition and results of
    operations. The discovery of serious safety issues with our products, or a recall of our products either voluntarily or at the direction
    of the FDA or another governmental authority, could have a negative impact on us;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Healthcare legislative
    and regulatory reform measures may have a material adverse effect on our business and results of operations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legislative or regulatory
    reforms in the U.S. or the European Union, or the EU, may make it more difficult and costly for us to obtain regulatory clearances
    or approvals for our products or to manufacture, market or distribute our products after clearance or approval is obtained;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we are unable to obtain
    and maintain effective patent rights for our products and services, we may not be able to compete effectively in our markets. If
    we are unable to protect the confidentiality of our trade secrets or know-how, such proprietary information may be used by others
    to compete against us;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may be subject, directly
    or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws and health information privacy and security
    laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our business and operations
    might be adversely affected by security breaches, including any cybersecurity incidents; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potential political, economic
    and military instability in Israel, where our headquarters, members of our management team and our research and development facilities
    are located, may adversely affect our results of operations.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 13 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->xi<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="I_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>PART
I</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="I_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>ITEM
1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="I_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>ITEM
2. <span style="text-transform: uppercase">OFFER STATISTICS AND EXPECTED TIMETABLE</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="I_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>ITEM
3. KEY INFORMATION</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="I_008"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
<tr style="vertical-align: top; text-align: left">
  <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>A. </b></span></td>
  <td>[Reserved]</td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="I_084"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td><td style="text-align: justify"><b>Capitalization and Indebtedness.</b></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="I_085"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td><td style="text-align: justify"><b>Reasons for the Offer and Use of Proceeds.</b></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Not
applicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="I_011"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.
Risk Factors</b></span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">You
should carefully consider the risks and uncertainties described below, together with all of the other information in this annual report
on Form 20-F. If any of these risks actually occurs, our business and financial condition could suffer, and the price of our securities
could decline.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Risks
Related to Our Business and Industry</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
are highly dependent on the successful development, marketing and sale of our products and on receiving the required regulatory approvals.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
products, focused on the treatment of respiratory failure, are the basis of our business. As a result, the success of our business plan
is highly dependent on our ability to develop, manufacture and commercialize our products, and our failure to do so could cause our business
to fail. Successful commercialization of medical devices is a complex and uncertain process, dependent on the efforts of management,
manufacturers, local operators, integrators, medical professionals, third-party payors, as well as general economic conditions, among
other factors. Any factor that adversely impacts the development and commercialization of our products, will have a negative impact on
our business, financial condition, results of operations and prospects. We have limited experience in commercializing our products and
we may face several challenges with respect to our commercialization efforts, including, among others, that:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may not have adequate
    financial or other resources to complete the development of our products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may not be able to manufacture
    our products in commercial quantities, at an adequate quality or at an acceptable cost;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may not be able to establish
    adequate sales, marketing and distribution channels;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 14; Options: NewSection --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">healthcare professionals
    and patients may not accept our products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may not be aware of
    possible complications from the continued use of our products since we have limited clinical experience with respect to the actual
    use of our products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may not be able to compete
    with existing solutions for respiratory failure;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">technological breakthroughs
    in the respiratory support solutions may reduce the demand for our products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">third-party payors may
    not agree to reimburse patients for any or all of the purchase price of our products, which may adversely affect patients&#8217;
    willingness to use our products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may face third-party
    claims of intellectual property infringement; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may fail to obtain or
    maintain regulatory clearance or approvals in our target markets or may face adverse regulatory or legal actions even if regulatory
    approval is obtained.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">If
we are unable to meet any one or more of these challenges successfully, our ability to effectively commercialize our products and services
could be limited, which in turn could have a material adverse effect on our business, financial condition and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
success depends upon market acceptance of our products, our ability to develop and commercialize new products and generate revenues and
our ability to identify new markets for our technology. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
have developed, and are engaged in the development of, respiratory support technology. Our success will depend on the approval and acceptance
of our products and any future products in the healthcare market. We are faced with the risk that the marketplace will not be receptive
to our products or any future products over competing products and that we will be unable to compete effectively. Factors that could
affect our ability to successfully commercialize our current and any potential future products:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the challenges of developing
    (or acquiring externally developed) technology solutions that are adequate and competitive in meeting the requirements of next-generation
    design challenges; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the dependence upon referrals
    from physicians for the sale of our products and provision of our service.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">We
cannot assure that our products or any future products will gain broad market acceptance. If the market for our products fails to develop
or develops more slowly than expected, our business and operating results would be materially and adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>If
we fail to maintain existing strategic relationships with Innovimed, Glo-Med, our other distributors, or are unable to identify additional
distributors of our products or any future products and technologies, our revenues may decrease.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
currently expect to record revenue through our strategic relationships and distribution agreements with Innovimed Sp. z o.o, or Innovimed,
Bepex Ltd., or Bepex, Anita T&#233;cnica S.L, or WAAS Group, Glo-Med Networks Inc., or Glo-Med, and CIO MED GROUP, CORP, or CIO MED
GROUP, as well as other distributors for the deployment of our products. If our relationships with our distributors are terminated or
impaired for any reason and we are unable to replace these relationships with other means of distribution, we could suffer a material
decrease in revenues.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 15 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
may need, or decide it is otherwise advantageous to us, to obtain the assistance of additional distributors to market and distribute
our future products and technologies, as well as to market and distribute our INSPIRA ART system, INSPIRA ART100 system, HYLA blood sensors,
and Inspira disposable devices to existing or new markets or geographical areas. We may not be able to find additional distributors who
will agree to and are able to successfully market and distribute our systems and technologies on commercially reasonable terms, if at
all. If we are unable to establish additional distribution relationships on favorable terms, our revenues may decline. In addition, our
distributors may choose to favor the products of our competitors over ours and give preference to them.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to our agreements with the aforementioned distributors, we will be responsible for obtaining and maintaining any and all regulatory approvals
for our products. If we are unable to obtain or maintain such approvals, or if the parties to the distribution agreement fail to purchase
the agreed upon products at the agreed upon pricing, it may adversely impact our relationships with these distributors, and we may never
realize any revenues from these agreements ships as a result.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Medical
device development is costly and involves continual technological change which may render our current or future products obsolete.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
market for medical device technologies and products is characterized by factors such as rapid technological change, medical advances,
changing consumer requirements, short device lifecycles, changing regulatory requirements and evolving industry standards. Any one of
these factors could reduce the demand for our devices or require substantial resources and expenditures for, among other things, research,
design and development, to avoid technological or market obsolescence.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
success will depend on our ability to enhance our current technology and develop or acquire new technologies to keep pace with technological
developments and evolving industry standards, while responding to changes in customer needs. A failure to adequately develop or acquire
device enhancements or new devices that will address changing technologies and customer requirements adequately, or to introduce such
devices on a timely basis, may have a material adverse effect on our business, financial condition and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
might have insufficient financial resources to improve our products, advance technologies and develop new devices at competitive prices.
Technological advances by one or more competitors or future entrants into the field may result in our present services or devices becoming
non-competitive or obsolete, which may decrease revenues and profits and adversely affect our business and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
may encounter significant competition across our product lines and in each market in which we will sell our products and services from
various companies, some of which may have greater financial and marketing resources than we do. Our competitors may include any companies
engaged in the research, development, manufacture, and marketing of respiratory support solutions and technologies, as well as a wide
range of medical device companies that sell a single or limited number of competitive products and services or participate in only a
specific market segment.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
customer acquisition strategy may not succeed and although we have executed distribution agreements with various parties in various geographic
region, we may never realize any revenues from such agreements</i>.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
business will be dependent upon success in our customer acquisition strategy. To date, we have executed various distribution agreements
in various geographic regions which are subject to regulatory approvals. If we do not obtain regulatory approval, or if the parties to
the distribution agreement fail to purchase the agreed upon products at the agreed upon pricing, we may not realize any revenues from
such agreements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition, if we fail to maintain a high quality of device technology, we may fail to retain or add new customers. If we fail, our revenue,
financial results and business may be significantly harmed. Our future success depends upon expanding our commercial operations in the
U.S., Israel and Europe, as well as entering additional markets to commercialize our products and any future products. We believe that
our expanded growth will depend on the further development, regulatory approval and commercialization of our products. If we fail to
expand the use of our products in a timely manner, we may not be able to expand our markets or to grow our revenue, and our business
may be adversely impacted. If people do not perceive our products to be useful and reliable, we may not be able to attract or retain
new customers. A decrease in costumer growth could render less attractive to developers, which may have a material and adverse impact
on our revenue, business, financial condition and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 16 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
business and operations would suffer in the event of computer system failures, cyber-attacks or a deficiency in our cybersecurity.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">Despite
the implementation of security measures intended to secure our data against impermissible access and to preserve the integrity and confidentiality
of our data, our internal computer systems, and those of third parties on which we rely, are vulnerable to damage from computer viruses,
malware, natural disasters, terrorism, war, telecommunication and electrical failures, cyber-attacks or cyber-intrusions, attachments
to emails, persons inside our organization, or persons with access to systems inside our organization. The risk of a security breach
or disruption, particularly through cyber-attacks or cyber intrusion, including by computer hackers, foreign governments, and cyber terrorists,
has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased.
If such an event were to occur and cause interruptions to our operations, it could result in a material disruption of our drug development
programs. For example, the loss of clinical trial data from completed or ongoing or planned clinical trials could result in delays in
our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption
or security breach was to result in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary
information, we could incur material legal claims and liability, including under data privacy laws such as the General Data Protection
Regulation, or the GDPR, damage to our reputation, and the further development of our drug candidates could be delayed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
are dependent upon third-party manufacturers and suppliers, which makes us vulnerable to potential supply shortages and problems, increased
costs and quality or compliance issues, any of which could harm our business.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
products are comprised of multiple components. We are planning to sell an assembled product as well as its disposable respiratory support
unit. The components of the assembled product and the disposable unit consist of both proprietary and off the shelf components. Proprietary
components will be manufactured on our behalf at good manufacturing practices, or GMP, approved production plant to adhere to regulatory
requirements, whereas off the shelf components will be sourced and manufactured by GMP suppliers. GMP sub-contractors will assemble proprietary
and off the shelf components together to create our products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Therefore,
we rely on third parties to manufacture and supply us with proprietary custom components. Although we rely on a number of suppliers who
provide us materials and components as well as manufacture and assemble certain components of our products, we do not rely on single-source
suppliers. Our suppliers may encounter problems during manufacturing for a variety of reasons, including, for example, failure to follow
specific protocols and procedures, failure to comply with applicable legal and regulatory requirements, equipment malfunction and environmental
factors, failure to properly conduct their own business affairs, and infringement of third-party intellectual property rights, any of
which could delay or impede their ability to meet our requirements. Our reliance on these third-party suppliers also subjects us to other
risks that could harm our business, including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we are not currently a
    major customer of many of our suppliers, and these suppliers may therefore prioritize other customers&#8217; needs;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may not be able to obtain
    an adequate supply in a timely manner or on commercially reasonable terms;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our suppliers, especially
    new suppliers, may make errors in manufacturing that could negatively affect the efficacy or safety of our products or cause delays
    in shipment;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may have difficulty
    locating and qualifying alternative suppliers;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">switching components or
    suppliers may require product redesign and possibly submission to the FDA or other similar foreign regulatory agencies, which could
    impede or delay our commercial activities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 17 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">one or more of our suppliers
    may be unwilling or unable to supply components of our products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the occurrence of a fire,
    natural disaster or other catastrophe impacting one or more of our suppliers may affect their ability to deliver products to us in
    a timely manner; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our suppliers may encounter
    financial or other business hardships unrelated to our demand, which could inhibit their ability to fulfill our orders and meet our
    requirements.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
may not be able to quickly establish additional or alternative suppliers, if necessary, in part because we may need to undertake additional
activities to establish such suppliers as required by the regulatory approval process. Any interruption or delay in obtaining products
from our third-party suppliers, or our inability to obtain products from qualified alternate sources at acceptable prices in a timely
manner, could impair our ability to meet the demand of our customers and cause them to switch to competing products. Given our reliance
on certain suppliers, we may be susceptible to supply shortages while looking for alternate suppliers.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
have limited manufacturing history on which to assess the prospects for our business and we anticipate that we will incur significant
losses once we initiate our in-house manufacturing until we are able to successfully commercialize our products globally.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">If
our future manufacturing operation or any current or future contracted manufacturing operations become unreliable or unavailable, we
may not be able to proceed with our intended business operations and our entire business plan could fail. There is no assurance that
our manufacturing operation or any third-party manufacturers will be able to meet commercialized scale production requirements in a timely
manner or in accordance with applicable standards.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
may not be able to replace our manufacturing capabilities in a timely manner.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">If
our future manufacturing facility or any current or future contracted manufacturing operations suffer any type of prolonged interruption,
whether caused by regulator action, equipment failure, critical facility services (such as water purification, clean steam generation
or building management and monitoring system), fire, natural disaster or any other event that causes the cessation of manufacturing activities,
we may be exposed to long-term loss of sales and profits. There are limited facilities which are capable of contract manufacturing some
of our products and product candidates. Replacement of our current manufacturing capabilities may have a material adverse effect on our
business and financial condition.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
are dependent upon third-party service providers. If such third-party service providers fail to maintain a high quality of service, the
utility of our products could be impaired, which could adversely affect the penetration of our products, our business, operating results
and reputation. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
success of certain services and products that we provide are dependent upon third-party service providers. Such service providers include
manufacturers of proprietary custom components for our products. As we expand our commercial activities, an increased burden will be
placed upon the quality of such third-party providers. If third-party providers fail to maintain a high quality of service, our products,
business, reputation and operating results could be adversely affected. In addition, poor quality of service by third-party service providers
could result in liability claims and litigation against us for damages or injuries.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 18 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Non-U.S.
governments often impose strict price controls, which may adversely affect our future profitability.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">We
may be subject to rules and regulations in the U.S. and non-U.S. jurisdictions relating to our products or any future products. In some
countries, including countries of the EU, each of which has developed its own rules and regulations, pricing may be subject to governmental
control under certain circumstances. In these countries, pricing negotiations with governmental agencies can take considerable time after
the receipt of marketing approval for a medical device candidate. To obtain reimbursement or pricing approval in some countries, we may
be required to conduct a clinical trial that compares the cost-effectiveness of our product to other available products.<b>&#160;</b>If
reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, we may be
unable to achieve or sustain profitability.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif"><b><i>We
manage our business through a small number of employees and key consultants.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">As
of March 3, 2025, we had 38 full-time employees (including our senior management team), seven part-time employees, and two additional
independent contractors and consultants. Our future growth and success depend to a large extent on the continued services of members
of our current management including, in particular, Dagi Ben-Noon, our chief executive Officer, and Joe Hayon, our president. Any of
our employees and consultants may leave our company at any time, subject to certain notice periods. The loss of the services of any of
our executive officers or any key employees or consultants would adversely affect our ability to execute our business plan and harm our
operating results. Our operational success will substantially depend on the continued employment of senior executives, technical staff
and other key personnel. The loss of key personnel may have an adverse effect on our operations and financial performance.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif"><b><i>We
may need to expand our organization and we may experience difficulties in recruiting needed additional employees and consultants, which
could disrupt our operations.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">As
our development and commercialization plans and strategies develop and because we are leanly staffed, we may need additional managerial,
operational, sales, marketing, financial, legal and other resources. The competition for qualified personnel in the medical device industry
is intense. Due to this intense competition, we may be unable to attract and retain qualified personnel necessary for the development
of our business or to recruit suitable replacement personnel.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
management may need to divert its attention away from our day-to-day activities and devote a substantial amount of time to managing these
growth activities. We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure,
operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our expected
growth could require significant capital expenditures and may divert financial resources from other projects, such as the development
of additional medical device products. If our management is unable to effectively manage our growth, our expenses may increase more than
expected, our ability to generate and/or grow revenue could be reduced and we may not be able to implement our business strategy. Our
future financial performance and our ability to commercialize medical device products and services and compete effectively will depend,
in part, on our ability to effectively manage any future growth.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>International
expansion of our business exposes us to business, regulatory, political, operational, financial and economic risks associated with doing
business outside of the U.S. or Israel.</i></b>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Other
than our headquarters and other operations which are located in Israel (as further described below), our business strategy incorporates
significant international expansion, particularly in anticipated expansion of regulatory approvals of our products. Doing business internationally
involves a number of risks, including but not limited to:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">multiple, conflicting and
    changing laws and regulations such as privacy regulations, tax laws, export and import restrictions, employment laws, regulatory
    requirements and other governmental approvals, permits and licenses;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure by us to obtain
    regulatory approvals for the use of our products and services in various countries;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additional potentially
    relevant third-party patent rights;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 19 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">complexities and difficulties
    in obtaining protection and enforcing our intellectual property;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties in staffing
    and managing foreign operations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">complexities associated
    with managing multiple regulatory, governmental and reimbursement regimes;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#8239;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limits in our ability to
    penetrate international markets;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">financial risks, such as
    longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and
    payment for our products and exposure to foreign currency exchange rate fluctuations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">natural disasters, political
    and economic instability, including wars, terrorism and political unrest, outbreak of disease, boycotts, curtailment of trade and
    other business restrictions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">certain expenses including,
    among others, expenses for travel, translation and insurance; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory and compliance
    risks that relate to maintaining accurate information and control over sales and activities that may fall within the purview of the
    U.S. Foreign Corrupt Practices Act, its books and records provisions or its anti-bribery provisions.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">Any
of these factors could significantly harm our future international expansion and operations and, consequently, our results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif"><b><i>We
face intense competition, and we may be unable to effectively compete in our industry.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
market participants in the ICU and the acute respiratory care space include Boston Scientific Corporation (NYSE: BSX), ResMed Inc., (NYSE:
RMD), Masimo Corporation (Nasdaq: MASI), Becton, Dickinson and Company (NYSE: BDX), Chart Industries, Inc. (Nasdaq: GTLS), Philips Healthcare,
Medtronic plc (NYSE: MDT), Fisher &amp; Paykel Healthcare Corporation Limited, Dr&#228;gerwerk AG &amp; Co. KGaA, Dr&#228;gerwerk AG,
Hamilton Medical AG, Smiths Medical Inc. (acquired by ICU Medical Inc.), Siemens Healthineers AG ADR (OTCMKTS: SMMNY), Baxter International
(NYSE: BAX), Getinge AB (OTCMKTS: GNGBY), GE HealthCare, Terumo Corporation (TYO: 4543, Nikkei 225 Component), LivaNova PLC (Nasdaq:
LIVN), Fresenius SE &amp; Co. KGaA (OTCMKTS: FSNUY), Johnson &amp; Johnson (NYSE: JNJ), Zoll Medical Corporation (TYO: 3407 ), Resuscitec
GmbH, Spectrum Medical Limited, Abiomed, Inc. (Nasdaq: ABMD), Abbott Laboratories (NYSE: ABT), DataMed s.r.l, Chalice Medical Ltd., APMTD
Global Limited, Eurosets s.r.l. and Braile Biomedica. These companies have either developed or acquired respiratory care devices and
solutions, such as ventilators, ECMO devices and blood sensors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
aforementioned companies, have substantially greater brand recognition, research and development, and regulatory capabilities, as well
as financial, technical, manufacturing, marketing and human resources than we do and significantly greater experience and infrastructure
in the research and development of medical devices, obtaining FDA and other regulatory clearances of those devices and commercializing
those devices around the world. Further, some of these companies hold significant market share. Their dominant market position and significant
control over the market could significantly limit our ability to introduce or effectively market and generate sales of our products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Many
of our competitors have long histories and strong reputations within the industry. They have significantly greater brand recognition,
financial and human resources than we do. They also have more experience and capabilities in researching and developing testing devices,
obtaining and maintaining regulatory clearances and other requirements, manufacturing and marketing those products than we do. There
is a significant risk that we may be unable to overcome the advantages held by our competition, and our inability to do so could lead
to the failure of our business. In addition, we may be unable to develop additional products in the future or to keep pace with developments
and innovations in the market and lose market share to our competitors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 20 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Competition
in the medical devices and more specifically respiratory support technologies and solutions markets is intense, which can lead to, among
other things, price reductions, longer selling cycles, lower product margins, loss of market share and additional working capital requirements.
To succeed, we must, among other critical matters, gain consumer acceptance for our products, as compared to other solutions currently
available in the market for the treatment of respiratory failure and potential future medical devices incorporating our principal technology
or offering other advanced respiratory support solutions. If our competitors offer significant discounts on certain products and solutions,
we may need to lower our prices or offer other favorable terms in order to compete successfully. Moreover, any broad-based changes to
our prices and pricing policies could make it difficult to generate revenues or cause our revenues to decline. Moreover, if our competitors
develop and commercialize products and solutions that are more effective or desirable than products and solutions that we may develop,
we may not convince our customers to use our products and solutions. Any such changes would likely reduce our commercial opportunity
and revenue potential and could materially adversely impact our operating results.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>If
third-party payors do not provide adequate coverage and reimbursement for the use of our products or any future products, our revenue
will be negatively impacted.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
products are not yet approved for third-party payor coverage or reimbursement. Such reimbursement may vary based on the particular device
used in providing services and is based on the identity of the third-party. Our ability to obtain and maintain a leading position in
the medical device market, and specifically in the respiratory care market, depends on our relationships with private third parties.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">We
expect to engage with private third parties to allow our customers to receive reimbursement from insurance companies for our products.
The loss of a significant number of private third-party contracts may have an adverse effect on our revenues, which could have an adverse
effect on our business, financial condition and results of operations. Over the past few years, reimbursement rates from certain third
parties have declined, in some cases significantly. There can be no assurance that this trend will not continue or apply on more third
parties.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition, private third parties may not reimburse any new products offered by us or reimburse those new products at commercially viable
rates. The failure to receive reimbursement at adequate levels for our existing or future products may adversely affect demand for those
products, our revenues and expected growth. This could have an adverse effect on our business, financial condition and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
may be subject to litigation for a variety of claims, which could adversely affect our results of operations, harm our reputation or
otherwise negatively impact our business.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
may be subject to litigation for a variety of claims arising from our normal business activities. These may include claims, suits, and
proceedings involving labor and employment, wage and hour, commercial and other matters. The outcome of any litigation, regardless of
its merits, is inherently uncertain. Any claims and lawsuits, and the disposition of such claims and lawsuits, could be time-consuming
and expensive to resolve, divert management attention and resources, and lead to attempts on the part of other parties to pursue similar
claims. Any adverse determination related to litigation could adversely affect our results of operations, harm our reputation or otherwise
negatively impact our business. In addition, depending on the nature and timing of any such dispute, a resolution of a legal matter could
materially affect our future operating results, our cash flows or both.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 21 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif"><b><i>We
could become subject to product liability, warranty or similar claims and product recalls that could be expensive, divert management&#8217;s
attention and harm our business reputation and financial results.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
business exposes us to an inherent risk of potential product liability, warranty or similar claims and product recalls. The medical device
industry has historically been litigious, and we face financial exposure to product liability, warranty or similar claims if the use
of any of our products were to cause or contribute to injury or death. There is also the possibility that defects in the design or manufacture
of any of our products might necessitate a product recall. Although we maintain product liability insurance, the coverage limits of these
policies may not be adequate to cover future claims. In the future, we may be unable to maintain product liability insurance on acceptable
terms or at reasonable costs and such insurance may not provide us with adequate coverage against potential liabilities. A product liability
claim, regardless of merit or ultimate outcome, or any product recall could result in substantial costs to us, damage to our reputation,
customer dissatisfaction and frustration and a substantial diversion of management attention. A successful claim brought against us in
excess of, or outside of, our insurance coverage could have a material adverse effect on our business, financial condition and results
of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
business may be impacted by changes in general economic conditions.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
business is subject to risks arising from changes in domestic and global economic conditions, including adverse economic conditions in
markets in which we operate, which may harm our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Disruption
to the global economy could also result in a number of follow-on effects on our business, including a possible slow-down resulting from
lower customer expenditures; inability of customers to pay for products, solutions or services on time, if at all; more restrictive export
regulations which could limit our potential customer base; negative impact on our liquidity, financial condition and share price, which
may impact our ability to raise capital in the market, obtain financing and secure other sources of funding in the future on terms favorable
to us.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition, the occurrence of catastrophic events, such as hurricanes, storms, earthquakes, tsunamis, floods, epidemics and other catastrophes
that adversely affect the business climate in any of our markets could have a material adverse effect on our business, financial condition
and results of operations. Some of our operations are located in areas that have been in the past, and may be in the future, susceptible
to such occurrences.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Unstable
market and economic conditions may have serious adverse consequences on our business, financial condition and share price.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
global economy, including credit and financial markets, has experienced extreme volatility and disruptions, including severely diminished
liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates, increases
in inflation rates and uncertainty about economic stability. Any such volatility and disruptions may have adverse consequences on us
or the third parties on whom we rely. If the equity and credit markets deteriorate, including as a result of political unrest or war,
it may make any necessary debt or equity financing more difficult to obtain in a timely manner or on favorable terms, more costly or
more dilutive. Further, inflation can adversely affect us by increasing our costs. Increased cost of living around the world has caused
and may cause increased costs, such as higher wages, increase direct service costs, increased freight costs and costs of components,
and higher manufacturing costs. Any significant increases in inflation and related increase in interest rates could have a material adverse
effect on our business, results of operations and financial condition.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><!-- Field: Page; Sequence: 22 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
incur significant increased costs as a result of the listing of our securities for trading on Nasdaq. Our management is required to devote
substantial time to new compliance initiatives as well as compliance with ongoing U.S. requirements.</i></b>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">As
a public company in the U.S., we incur additional significant accounting, legal and other expenses that we did not incur prior to being
a public company in the U.S. We also incur costs associated with corporate governance requirements of the SEC, as well as requirements
under Section 404 and other provisions of the Sarbanes-Oxley Act. These rules and regulations increase our legal and financial compliance
costs, introduce new costs such as investor relations, stock exchange listing fees and shareholder reporting, and make some activities
more time consuming and costly. The implementation and testing of such processes and systems may require us to hire outside consultants
and incur other significant costs. Any future changes in the laws and regulations affecting public companies in the U.S., including Section
404 and other provisions of the Sarbanes-Oxley Act, and the rules and regulations adopted by the SEC, for so long as they apply to us,
will result in increased costs to us as we respond to such changes. These laws, rules and regulations could make it more difficult or
more costly for us to obtain certain types of insurance, including director and officer liability insurance, and we may be forced to
accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. The impact of these
requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our
board committees, or as executive officers.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
could fail to maintain the listing of our securities on Nasdaq, which could seriously harm the liquidity of our shares and our ability
to raise capital.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Companies trading on Nasdaq,
such as our Company, must be reporting issuers under Section&#160;12 of the Exchange Act, and must meet the listing requirements in order
to maintain the listing of its shares on the Nasdaq Capital Market. If we do not meet these requirements, the market liquidity for our
securities could be severely adversely affected by limiting the ability of broker-dealers to sell our securities and the ability of shareholders
to sell their securities in the secondary market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 10, 2025, we received
a written notice, or the Notice, from Nasdaq indicating that we are not in compliance with the minimum bid price requirement for continued
listing set forth in Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share.
Under Nasdaq Listing Rule 5810(c)(3)(A), we were granted a period of 180 calendar days to regain compliance with the minimum bid price
requirement, or until September 8, 2025. There is a risk that we could be subject to additional notices of delisting for failure to comply
with Nasdaq Listing Rule 5550(a)(2) or other Nasdaq Listing Rules and no assurance can be given that we will remain eligible to be listed
on Nasdaq. If we do not regain compliance with Nasdaq Listing Rule 5550(a)(2), our Ordinary Shares will be subject to delisting. A delisting
from Nasdaq would likely result in a reduction in some or all of the following, each of which could have a material adverse effect on
shareholders:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the
                                            liquidity of our Ordinary Shares;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the
                                            market price of our Ordinary Shares;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the
                                            availability of information concerning the trading prices and volume of our Ordinary Shares;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our
                                            ability to obtain financing or complete a strategic transaction;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the
                                            number of institutional and other investors that will consider investing in our Ordinary
                                            Shares; and</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the
                                            number of market markers or broker-dealers for our Ordinary Shares.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">We
intend to monitor the closing bid price of our Ordinary Shares and may, if appropriate, consider implementing available options to regain
compliance with the minimum bid price rule under the Nasdaq Listing Rules, including initiating a reverse stock split.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 23 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>If
we are not able to attract and retain highly skilled managerial, scientific, technical and marketing personnel, we may not be able to
implement our business model successfully.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-family: Times New Roman, Times, Serif">Our
success depends in part on our continued ability to attract, retain and motivate highly qualified management, clinical and scientific
personnel. We are highly dependent upon our senior management as well as other employees, consultants and scientific and medical collaborators.
Our management team must be able to act decisively to apply and adapt our business model in the rapidly changing markets in which we
will compete. In addition, we will rely upon technical and scientific employees or third-party contractors to effectively establish,
manage and grow our business. Consequently, we believe that our future viability will depend largely on our ability to attract and retain
highly skilled managerial, sales, scientific and technical personnel. In order to do so, we may need to pay higher compensation or fees
to our employees or consultants than currently expected and such higher compensation payments may have a negative effect on our operating
results. Competition for experienced, high-quality personnel in the medical device field is intense. We may not be able to hire or retain
the necessary personnel to implement our business strategy. Our failure to hire and retain quality personnel on acceptable terms could
impair our ability to develop new products and services and manage our business effectively.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>If
we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute our shareholders, cause
us to incur debt or assume contingent liabilities, and subject us to other risks.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
may evaluate various acquisition opportunities and strategic partnerships, including licensing or acquiring complementary products, intellectual
property rights, technologies or businesses. Any potential acquisition or strategic partnership may entail numerous risks, including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increased operating expenses
    and cash requirements;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the assumption of additional
    indebtedness or contingent liabilities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the issuance of our equity
    securities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.3pt"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">assimilation of operations,
    intellectual property and products of an acquired company, including difficulties associated with integrating new personnel;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the diversion of our management&#8217;s
    attention from our existing product programs and initiatives in pursuing such a strategic merger or acquisition;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">retention of key employees,
    the loss of key personnel and uncertainties in our ability to maintain key business relationships;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">risks and uncertainties
    associated with the other party to such a transaction, including the prospects of that party and their existing products or product
    candidates and marketing approvals; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our inability to generate
    revenue from acquired technology and/or products sufficient to meet our objectives in undertaking the acquisition or even to offset
    the associated acquisition and maintenance costs.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
are subject to certain U.S. and foreign anticorruption, anti-money laundering, export control, sanctions and other trade laws and regulations.
We can face serious consequences for violations.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Among
other matters, U.S. and foreign anticorruption, anti-money laundering, export control, sanctions and other trade laws and regulations,
which are collectively referred to as Trade Laws, prohibit companies and their employees, agents, clinical research organizations, legal
counsel, accountants, consultants, contractors and other partners from authorizing, promising, offering, providing, soliciting or receiving,
directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector.
Violations of Trade Laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment,
tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. We have direct or indirect interactions
with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. We also
expect our non-U.S. activities to increase over time. We plan to engage third parties for clinical trials and/or to obtain necessary
permits, licenses, patent registrations and other regulatory approvals, and we can be held liable for the corrupt or other illegal activities
of our personnel, agents or partners, even if we do not explicitly authorize or have prior knowledge of such activities.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 24 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
business and operations might be adversely affected by security breaches, including any cybersecurity incidents.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
depend on the efficient and uninterrupted operation of our computer and communications systems, and those of our consultants, contractors
and vendors, which we use for, among other things, sensitive company data, including our intellectual property, financial data and other
proprietary business information.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">While
certain of our operations have business continuity and disaster recovery plans and other security measures intended to prevent and minimize
the impact of IT-related interruptions, our IT infrastructure and the IT infrastructure of our consultants, contractors and vendors are
vulnerable to damage from cyberattacks, computer viruses, unauthorized access, electrical failures and natural disasters or other catastrophic
events. We could experience failures in our information systems and computer servers, which could result in an interruption of our normal
business operations and require substantial expenditure of financial and administrative resources to remedy. System failures, accidents
or security breaches can cause interruptions in our operations and can result in a material disruption of our product development activities
and other business operations. The loss of data from completed or future studies or clinical trials could result in delays in our research,
development or regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that
any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of
confidential or proprietary information, we could incur regulatory investigations and redresses, penalties and liabilities and the development
of our products could be delayed or otherwise adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Even
though we believe we carry commercially reasonable business interruption and liability insurance, we may suffer losses as a result of
business interruptions that exceed the coverage available under our insurance policies or for which we do not have coverage. For example,
we are not insured against terrorist or cyber-attacks. Any natural disaster or catastrophic event could have a significant negative impact
on our operations and financial results. Moreover, any such event could delay the development of our products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Changes
in laws or regulations relating to data protection, or any actual or perceived failure by us to comply with such laws and regulations
or our privacy policies, could materially and adversely affect our business or could lead to government enforcement actions and significant
penalties against us, and adversely impact our operating results.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
expect to receive health information and other highly sensitive or confidential information and data of patients and other third parties
(e.g., healthcare providers who refer patients for scans), which we expect to compile and analyze. Collection and use of this data might
raise privacy and data protection concerns, which could negatively impact our business. There are numerous federal, state and international
laws and regulations regarding privacy, data protection, information security, and the collection, storing, sharing, use, processing,
transfer, disclosure, and protection of personal information and other data, and the scope of such laws and regulations may change, be
subject to differing interpretations, and may be inconsistent among countries and regions we intend to operate in (e.g., the U.S., the
EU and Israel), or conflict with other laws and regulations. The regulatory framework for privacy and data protection worldwide is, and
is likely to remain for the foreseeable future, uncertain and complex, and this or other actual or alleged obligations may be interpreted
and applied in a manner that we may not anticipate or that is inconsistent from one jurisdiction to another and may conflict with other
rules or practices including ours. Further, any significant change to applicable laws, regulations, or industry practices regarding the
collection, use, retention, security, or disclosure of data, or their interpretation, or any changes regarding the manner in which the
consent of relevant users for the collection, use, retention, or disclosure of such data must be obtained, could increase our costs and
require us to modify our services and candidate products, possibly in a material manner, which we may be unable to complete, and may
limit our ability to store and process patients&#8217; data or develop new services and features.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
particular, we will be subject to U.S. data protection laws and regulations (i.e., laws and regulations that address privacy and data
security) at both the federal and state levels. The legislative and regulatory landscape for data protection continues to evolve, and
in recent years there has been an increasing focus on privacy and data security issues. Numerous federal and state laws, including state
data breach notification laws, state health information privacy laws, and federal and state consumer protection laws, govern the collection,
use, and disclosure of health-related and other personal information. Failure to comply with such laws and regulations could result in
government enforcement actions and create liability for us (including the imposition of significant civil or criminal penalties), private
litigation and/or adverse publicity that could negatively affect our business. For instance, California enacted the California Consumer
Privacy Act, or the CCPA, on June 28, 2018, which took effect on January 1, 2020. The CCPA creates individual privacy rights for California
consumers and increases the privacy and security obligations of entities handling certain personal data. The CCPA provides for civil
penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation.
The CCPA may increase our compliance costs and potential liability, and many similar laws have been proposed at the federal level and
in other states.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 25 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition, we expect to obtain health information that is subject to privacy and security requirements under the Health Information Technology
for Economic and Clinical Health, or HITECH, and its implementing regulations. The Privacy Standards and Security Standards under the
federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, establish a set of standards for the protection of individually
identifiable health information by health plans, health care clearinghouses and certain health care providers, referred to as Covered
Entities, and the business associates with whom Covered Entities enter into service relationships pursuant to which individually identifiable
health information may be exchanged. Notably, whereas HIPAA previously directly regulated only Covered Entities, HITECH makes certain
of HIPAA&#8217;s privacy and security standards also directly applicable to Covered Entities&#8217; business associates. As a result,
both Covered Entities and business associates are now subject to significant civil and criminal penalties for failure to comply with
Privacy Standards and Security Standards. As part of our normal operations, we expect to collect, process and retain personal identifying
information regarding patients, including as a business associate of Covered Entities, so we expect to be subject to HIPAA, including
changes implemented through HITECH, and we could be subject to criminal penalties if we knowingly obtain or disclose individually identifiable
health information in a manner that is not authorized or permitted by HIPAA. A data breach affecting sensitive personal information,
including health information, also could result in significant legal and financial exposure and reputational damages that could potentially
have an adverse effect on our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">HIPAA
requires Covered Entities (like many of our potential customers) and business associates, like us, to develop and maintain policies and
procedures with respect to protected health information that is used or disclosed, including the adoption of administrative, physical
and technical safeguards to protect such information. HITECH expands the notification requirement for breaches of patient-identifiable
health information, restricts certain disclosures and sales of patient-identifiable health information and provides for civil monetary
penalties for HIPAA violations. HITECH also increased the civil and criminal penalties that may be imposed against Covered Entities and
business associates and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts
to enforce HIPAA and its implementing regulations and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions.
Additionally, certain states have adopted comparable privacy and security laws and regulations, some of which may be more stringent than
HIPAA.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Internationally,
many jurisdictions have or are considering enacting privacy or data protection laws or regulations relating to the collection, use, storage,
transfer, disclosure and/or other processing of personal data, as well as certification requirements for the hosting of health data specifically.
Such laws and regulations may include data hosting, data residency or data localization requirements (which generally require that certain
types of data collected within a certain country be stored and processed within that country), data export restrictions, international
transfer laws (which prohibit or impose conditions upon the transfer of such data from one country to another), or may require companies
to implement privacy or data protection and security policies, enable users to access, correct and delete personal data stored or maintained
by such companies, inform individuals of security breaches that affect their personal data or obtain individuals&#8217; consent to use
their personal data. For example, European legislators adopted the EU&#8217;s GDPR which became effective on May 25, 2018, and are now
in the process of finalizing the ePrivacy Regulation to replace the European ePrivacy Directive (Directive 2002/58/EC as amended by Directive
2009/136/EC). The GDPR, supplemented by national laws and further implemented through binding guidance from the European Data Protection
Board, imposes more stringent EU data protection requirements and provides for significant penalties for noncompliance.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Virtually
every jurisdiction in which we expect to operate has established its own data security and privacy legal framework with which we must,
and our target customers will need to, comply, including the rules and regulation mentioned above. We may also need to comply with varying
and possibly conflicting privacy laws and regulations in other jurisdictions. As a result, we could face regulatory actions, including
significant fines or penalties, adverse publicity and possible loss of business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">While
we are preparing to implement various measures intended to enable us to comply with applicable privacy or data protection laws, regulations
and contractual obligations, these measures may not always be effective and do not guarantee compliance. Any failure or perceived failure
by us to comply with our contractual or legal obligations or regulatory requirements relating to privacy, data protection, or information
security may result in governmental investigations or enforcement actions, litigation, claims, or public statements against us by consumer
advocacy groups or others and could result in significant liability, cause our customers, partners or patients to lose trust in us, and
otherwise materially and adversely affect our reputation and business. Furthermore, the costs of compliance with, and other burdens imposed
by, the laws, regulations, and policies that are applicable to the businesses of our customers or partners may limit the adoption and
use of, and reduce the overall demand for, our products and services. Additionally, if third parties we work with violate applicable
laws, regulations, or agreements, such violations may put the data we have received at risk, could result in governmental investigations
or enforcement actions, fines, litigation, claims, or public statements against us by consumer advocacy groups or others and could result
in significant liability, cause our customers, partners or patients to lose trust in us, and otherwise materially and adversely affect
our reputation and business. Further, public scrutiny of, or complaints about, technology companies or their data handling or data protection
practices, even if unrelated to our business, industry or operations, may lead to increased scrutiny of technology companies, including
us, and may cause government agencies to enact additional regulatory requirements, or to modify their enforcement or investigation activities,
which may increase our costs and risks.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 26 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to Our Financial Condition and
Capital Requirements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Our financial statements
for the year ended December 31, 2024, contained an explanatory paragraph regarding substantial doubt about our ability to continue as
a going concern. This going concern opinion could prevent us from obtaining new financing on reasonable terms or at all and risk our ability
to continue operating as a going concern.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span>To
date, the Company has not generated significant revenues from its activities and has incurred substantial operating losses. </span>In
part because we have incurred losses in each year since our inception, our audited financial statements for the period ended December
31, 2024 contain an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern. These events and
conditions, along with other matters, indicated that a material uncertainty existed as of December 31, 2024, that raises substantial doubt
on our ability to continue as a going concern. The financial statements for the year ended December 31, 2024 have been prepared assuming
that we will continue as a going concern. <span>Management expects the Company to continue to generate
substantial operating losses and to continue to fund its operations primarily through the utilization of its current financial resources,
sales of its products, and through additional raises of capital. </span>As of December 31, 2024, we incurred accumulated losses of approximately
$67 million. A going concern assessment could materially limit our ability to raise additional funds through the issuance of equity or
debt securities or otherwise in the future. Further financial statements may also include an explanatory paragraph with respect to our
ability to continue as a going concern. Until we can generate significant recurring revenues, we expect to satisfy our future cash needs
through existing cash, debt or equity financing. We expect to require additional financing to fund our operations in the near future.
We cannot be certain that additional funding will be available to us on acceptable terms, if at all. If funds are not available, we may
be required to delay, reduce the scope of, or eliminate research or development plans for, or commercialization efforts with respect to
our products and it risks our ability to continue operating as a going concern.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our principal shareholders, officers and
directors currently beneficially own 18.01% of our Ordinary Shares. They may therefore be able to exert control over matters submitted
to our shareholders for approval.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 3, 2025, our principal
shareholders, officers and directors beneficially own approximately 18.01% of our Ordinary Shares. As a result, these shareholders, if
they acted in concert, could influence matters requiring approval by our shareholders, including the election of directors and the approval
of mergers or other business combination transactions. The interests of these shareholders may not always coincide with our interests
or the interests of other shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have a limited operating history, have
incurred significant operating losses since our inception and anticipate that we will incur continued losses for the foreseeable future.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a specialty medical
device company with a limited operating history. To date, we have focused almost exclusively on developing our INSPIRA ART system, INSPIRA
ART100 system followed by our HYLA Blood Sensor, VORTX device and Inspira disposables. We have funded our operations to date primarily
through our initial public offering, or IPO, convertible loans and royalty-bearing grants that we received from the Israel Innovation
Authority, or the IIA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have only a limited operating
history upon which you can evaluate our business and prospects. In addition, we have limited experience and have not yet demonstrated
an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving
fields, particularly in the medical device industry. To date, we have not generated any revenue from the sale of our products (see &#8220;Item
5. Operating and Financial Review and Prospects&#8221; for additional information). We have incurred losses in each year since our inception,
including net losses of approximately $11 million and $11.3 million for the years ended December 31, 2024 and 2023, respectively. As of
December, 2024, we had an accumulated deficit of approximately $67 million. Substantially all of our operating losses resulted from costs
incurred in connection with our development of our products and from general and administrative costs associated with our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect our research and
development expenses to increase in connection with our planned expanded studies. Having obtained marketing approval for one of our products,
if we obtain marketing approval for additional products which are currently under development, we will likely incur significant sales,
marketing and outsourced manufacturing expenses, as well as continued research and development expenses and costs associated with operating
as a public company. As a result, we expect to continue to incur significant and increasing operating losses for the foreseeable future.
Because of the numerous risks and uncertainties associated with developing a medical device, we are unable to predict the extent of any
future losses or when we will become profitable, if at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 27 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect to continue to incur
significant losses until and even when we are able to commercialize our products, which we may not be successful in achieving. We anticipate
that our expenses will increase substantially if and as we:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">continue the research and development of our products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">seek regulatory and marketing approvals for our products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">establish a sales, marketing, and distribution infrastructure to commercialize our products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">seek to identify, assess, acquire, license, and/or develop other product candidates and subsequent generations of our current product candidate;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">seek to maintain, protect, and expand our intellectual property portfolio;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">seek to attract and retain skilled personnel;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">create additional infrastructure to support our operations as a public company and our product candidate development and planned future commercialization efforts; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">experience any delays or encounter issues with respect to any of the above, including, but not limited to, failed studies, complex results, safety issues or other regulatory challenges that require longer follow-up of existing studies or additional supportive studies in order to pursue marketing approval.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
amount of our future operating losses will depend, in part, on the rate of our future expenditures. Even though we obtained regulatory
approval to market one of our products and even if we obtain regulatory approval to market the rest of our products or any future product
candidates<sub>,</sub> our future revenue will depend upon the size of any markets in which our products or any future product candidates
receive approval and our ability to achieve sufficient market acceptance, pricing, reimbursement from third-party payors for our products
or any future product candidates. Further, the operating losses that we incur may fluctuate significantly from quarter to quarter and
year to year, such that a period-to-period comparison of our results of operations may not be a good indication of our future performance.
Other unanticipated costs may also arise.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have not generated any revenue from product
sales and may never be profitable.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Although
we have received marketing authorization for one of our products from the FDA and from AMAR, we have never generated any revenue from
product sales. Our ability to generate revenue and achieve profitability depends on our ability, alone or with strategic collaboration
partners, to successfully complete the development of, and obtain the regulatory and marketing approvals necessary to commercialize all
our products or any future product candidates. We do not know when, or if, we will generate any such revenue. Our ability to generate
future revenue from product sales will depend heavily on our success in many areas, including but not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">complete research and development of our products and any future product candidates in a timely and successful manner;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">obtain regulatory and marketing approval for any product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">maintain and enhance a commercially viable, sustainable, scalable, reproducible and transferable manufacturing process for our products and any future product candidates that is compliant with current good manufacturing practices, or cGMPs;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">establish and maintain supply and, if applicable, manufacturing relationships with third parties that can provide, in both amount and quality, adequate products to support development and the market demand for our products and any future product candidates, if and when approved;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">identify, assess, acquire and/or develop new product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">launch and commercialize any product candidates for which we obtain regulatory and marketing approval, either directly by establishing a sales force, marketing and distribution infrastructure, and/or with collaborators or distributors;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">accurately identify demand for our products or any future product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">expose and educate physicians and other medical professionals to use our products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 28 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">obtain market acceptance, if and when approved, of our products and any future product candidates from the medical community and third-party payors;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">ensure our product candidates are approved for reimbursement from governmental agencies, health care providers and insurers in jurisdictions where they have been approved for marketing;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">address any competing technological and market developments that impact our products and any future product candidates or their prospective usage by medical professionals;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">negotiate favorable terms in any collaboration, licensing or other arrangements into which we may enter and perform our obligations under such collaborations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">maintain, protect and expand our portfolio of intellectual property rights, including patents, patent applications, trade secrets and know-how;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">avoid and defend against third-party interference or infringement claims;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">attract, hire and retain qualified personnel; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">locate and lease or acquire suitable facilities to support our clinical development, manufacturing facilities and commercial expansion.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Even
though we obtained marketing approval for our of our products and even if all our product candidates are approved for marketing and sale,
we anticipate incurring significant incremental costs associated with commercializing such product and product candidates. Our expenses
could increase beyond expectations if we are required by the FDA, or other regulatory agencies, domestic or foreign, to change our manufacturing
processes or assays or to perform studies in addition to those that we currently anticipate. Even if we are successful in obtaining regulatory
approvals to market all our products or any future product candidates, our revenue earned from such product candidates will be dependent
in part upon the size of the markets in the territories for which we gain regulatory approval for such products, the accepted price for
such products, our ability to obtain reimbursement for such products at any price, whether we own the commercial rights for that territory
in which such products have been approved and the expenses associated with manufacturing and marketing such products for such markets.
Therefore, we may not generate significant revenue from the sale of such products, even if approved. Further, if we are not able to generate
significant revenue from the sale of our approved products, we may be forced to curtail or cease our operations. Due to the numerous risks
and uncertainties involved in product development, it is difficult to predict the timing or amount of increased expenses, or when, or
if, we will be able to achieve or maintain profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>We will need to
raise substantial additional funding, which may not be available on acceptable terms, or at all. Failure to obtain funding on acceptable
terms and on a timely basis may require us to curtail, delay or discontinue our product development efforts or other operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2024, our
cash and cash equivalents, short-term deposits and long-term deposits were approximately $5.8 million, not including restricted cash of
$90 thousand, and we had a working capital of approximately $5.0 million and an accumulated deficit of approximately $67 million. Based
upon our currently expected level of operating expenditures, we expect that our existing cash and cash equivalent will only be sufficient
to fund operations through the next six months. We expect that we will require substantial additional capital to operate and to commercialize
our products and we need to expect to seek additional funds to enable us to fund our operations for the text twelve months. Our future
funding requirements will depend on many factors, including but not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">the progress, results and costs
of our ongoing and planned studies and, if applicable, clinical trials of products and any future product candidates;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the cost, timing and outcomes of regulatory review of products and any future product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the costs of maintaining our own commercial-scale cGMP manufacturing facility, including costs related to obtaining and maintaining regulatory compliance, and/or engaging third-party manufacturers therefor;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 29 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the scope, progress, results and costs of product development, testing, manufacturing, preclinical development and, if applicable, clinical trials for any other product candidates that we may develop or otherwise obtain in the future;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the cost of our future activities, including establishing sales, marketing and distribution capabilities for any product candidates in any particular geography where we receive marketing approval for such product candidates</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the terms and timing of any collaborative, licensing and other arrangements that we may establish;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the level of revenue, if any, received from commercial sales of any product candidates for which we receive marketing approval.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any additional fundraising
efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize
our products and any future product candidates. In addition, future financing may not be available in sufficient amounts or on terms acceptable
to us, if at all. Moreover, the terms of any financing may adversely affect the holdings or the rights of holders of our securities and
the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price
of our securities to decline. The incurrence of indebtedness could result in increased fixed payment obligations, and we may be required
to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to
acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct
our business. We could also be required to seek funds through arrangements with collaborative partners or otherwise at an earlier stage
than otherwise would be desirable, and we may be required to relinquish rights to some of our technologies or product candidates or otherwise
agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating results and prospects. Even
if we believe that we have sufficient funds for our current or future operating plans, we may seek additional capital if market conditions
are favorable or if we have specific strategic considerations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are unable to obtain
funding on a timely basis, we may be required to significantly curtail, delay or discontinue one or more of our research or development
programs or the development or commercialization, if any, of our products or any other product candidates or be unable to expand our operations
or otherwise capitalize on our business opportunities, as desired, which could materially affect our business, financial condition and
results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Raising additional capital would cause dilution
to our existing shareholders, and may adversely affect the rights of existing shareholders.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may seek additional capital
through a combination of private and public equity offerings, debt financings and collaborations and strategic and licensing arrangements.
To the extent that we raise additional capital through the issuance of equity or otherwise including through convertible debt securities,
your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights
as a shareholder. Future sales of our Ordinary Shares or of securities convertible into our Ordinary Shares, or the perception that such
sales may occur, could cause immediate dilution and adversely affect the market price of our Ordinary Shares and tradable warrants, or
Warrants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 30 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "><b>Risks Related to Product
Development and Regulatory Approval</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our product candidates and operations are
subject to extensive government regulation and oversight both in the U.S. and abroad and our failure to comply with applicable requirements
could harm our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect our products and
any future products we develop to be regulated by the FDA as medical devices. Our product candidates are subject to extensive regulation
in the U.S. and elsewhere, including by the FDA and its foreign counterparts, the U.S. Department of Justice, or the DOJ, and the U.S.
Health and Human Services-Office of the Inspector General, or the HHS. The FDA and foreign regulatory agencies regulate, among other things,
with respect to medical devices: design, development and manufacturing; testing, labeling, content and language of instructions for use
and storage; clinical trials; product safety; establishment registration and device listing; marketing, sales and distribution; pre-market
clearance and approval; conformity assessment procedures; record keeping procedures; advertising and promotion; recalls and field safety
corrective actions; post-market surveillance, including reporting of deaths or serious injuries and malfunctions that, if they were to
occur, could lead to death or serious injury; post-market approval studies; and product import and export.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The regulations our product
candidate is subject to are complex and have tended to become more stringent over time. Regulatory changes could result in restrictions
on our ability to carry on or expand our operations, higher than anticipated costs or lower than anticipated sales for any approved product.
Failure to comply with applicable regulations could jeopardize our ability to sell our future products, if cleared or approved, and result
in enforcement actions such as: warning or untitled letters; fines; injunctions; consent decrees; civil penalties; customer notifications;
termination of distribution; recalls or seizures of products; administrative detention of medical devices believed to be adulterated or
misbranded; delays in the introduction of products into the market; operating restrictions; total or partial suspension of production;
refusal to grant future clearances or approvals for new products, new intended uses or modifications to our products; withdrawals or suspensions
of current approvals, resulting in prohibitions on sales of our products; and in the most serious cases, criminal prosecution or penalties.
The occurrence of any of these events would have a material adverse effect on our business, financial condition and results of operations
and could result in shareholders losing their entire investment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not receive, or may be delayed in
receiving, the necessary clearances or approvals for our products and failure to timely obtain necessary clearances or approvals for our
products would adversely affect our ability to grow our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the U.S., before we can
market a new medical device, or a new use of, new claim for or significant modification to an existing product, we must first receive
either clearance under Section 510(k) of the Federal Food, Drug, and Cosmetic Act, or the FDCA, and/or PMA from the FDA, unless an exemption
applies. In the 510(k) clearance process, before a device may be marketed, the FDA must determine that a proposed device is &#8220;substantially
equivalent&#8221; to a legally-marketed &#8220;predicate&#8221; device, which includes a device that has been previously cleared through
the 510(k) process, a device that was legally marketed prior to May 28, 1976 (pre-amendments device), a device that was originally on
the U.S. market pursuant to an approved PMA and later down-classified, or a 510(k)-exempt device. To be &#8220;substantially equivalent,&#8221;
the proposed device must have the same intended use as the predicate device, and either have the same technological characteristics as
the predicate device or have different technological characteristics and not raise different questions of safety or effectiveness than
the predicate device. Clinical data are sometimes required to support substantial equivalence. In the process of obtaining PMA approval,
the FDA must determine that a proposed device is safe and effective for its intended use based, in part, on extensive data, including,
but not limited to, technical, pre-clinical, clinical trial, manufacturing and labeling data. The PMA process is typically required for
devices that are deemed to pose the greatest risk, such as life-sustaining, life-supporting or implantable devices.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Modifications to products
that are approved through a PMA application generally require FDA approval. Similarly, certain modifications made to products cleared
through a 510(k) may require a new 510(k) clearance. Both the PMA approval and the 510(k) clearance process can be expensive, lengthy
and uncertain. The FDA&#8217;s 510(k) clearance process usually takes from three to twelve months but can last longer. The process of
obtaining a PMA is much more costly and uncertain than the 510(k) clearance process and generally takes from one to three years, or even
longer, from the time the application is submitted to the FDA. In addition, a PMA generally requires the performance of one or more clinical
trials. The FDA may not approve or clear any device which we may seek to have approved or cleared. Any delay or failure to obtain necessary
regulatory clearances or approvals could harm our business. Furthermore, even if we are granted regulatory clearances or approvals, they
may include significant limitations on the indicated uses for the device or other restrictions or requirements, which may limit the market
for the device.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 31 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the U.S., we expect to
take a multi-step approach to the regulatory clearance process. As a first step, we intend to submit a Q-Submission, or Q-Sub, application
to the FDA for our advanced INSPIRA ART (Gen 2) device and may also choose to do so, for the VORTX device. The pre-IDE program was established
in 1995, to provide sponsors a mechanism to obtain FDA feedback on future Investigational Device Exemption, or IDE, applications prior
to their submission. An IDE allows an investigational device to be used in order to collect safety and effectiveness data required to
support a premarket approval application or a premarket notification submission to Food and Drug Administration. Over time, the pre-IDE
program evolved to include feedback on PMAs, Humanitarian Device Exemptions, or HDEs, De Novo requests, and 510(k) submissions, as well
as to address whether a clinical study requires submission of an IDE. To capture this evolution, the HHS 2012 Commitment Letter to Congress
regarding the Medical Device User Fee Amendments of 2012 (MDUFA III) included FDA&#8217;s commitment to institute a structured process
for managing these interactions, referring to them as Pre-Submissions, or Pre-Subs. The Q-Submission Guidance, published on June 2, 2023,
named &#8220;Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program&#8221; implemented the broader
Q-Program, which includes Pre-Subs, as well as additional opportunities to engage with the FDA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Early interaction with the
FDA on planned non-clinical and clinical studies, risk determination, and careful consideration of the FDA&#8217;s feedback may improve
the quality of subsequent submissions, shorten total review times, and facilitate the development process for new devices. The FDA believes
that interactions provided within Pre-Subs are likely to contribute to a more transparent review process for the FDA and the submitter.
We intend to align and update our regulatory and clinical plans based on the FDA&#8217;s feedback as part of this Q-sub process.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We submitted a 510(k) application
for our INSPIRA ART100 system in September 2023. In May 2024, we received 510(k) class II regulatory clearance. Even with this clearance,
any modification to our INSPIRA ART100 system that has not been previously cleared may require us to submit a new 510(k) premarket notification
and obtain clearance, or submit a PMA and obtain FDA approval prior to implementing the change. Specifically, any modification to a 510(k)-cleared
device that could significantly affect its safety or effectiveness, or that would constitute a major change in its intended use, design
or manufacture, requires a new 510(k) clearance or, possibly, approval of a PMA. The FDA requires every manufacturer to make this determination
in the first instance, but the FDA may review any manufacturer&#8217;s decision. The FDA may not agree with our decisions regarding whether
new clearances or approvals are necessary. We may make modifications or add additional features in the future that we believe do not require
a new 510(k) clearance or approval of a PMA. If the FDA disagrees with our determination and requires us to submit new 510(k) notifications
or PMA applications for modifications to our previously cleared products for which we have concluded that new clearances or approvals
are unnecessary, we may be required to cease marketing or to recall the modified product until we obtain clearance or approval, and we
may be subject to significant regulatory fines or penalties. If the FDA requires us to go through a lengthier, more rigorous examination
for future products or modifications to existing products than we had expected, product introductions or modifications could be delayed
or canceled, which could adversely affect our ability to grow our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 32 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA can delay, limit or
deny clearance or approval of a medical device for many reasons, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">our inability to demonstrate to the satisfaction of the FDA or the applicable regulatory entity or notified body that our product candidates are safe or effective for their intended uses;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: justify">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the disagreement of the FDA or the applicable foreign regulatory body with the design or the interpretation of data from pre-clinical studies or clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: justify">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">serious and unexpected adverse effects experienced by participants in our clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: justify">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the data from our pre-clinical studies and clinical trials may be insufficient to support clearance or approval, where required;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: justify">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">our inability to demonstrate that the clinical and other benefits of the device outweigh the risks;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: justify">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the manufacturing process or facilities we use may not meet applicable requirements; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: justify">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">the potential for approval policies or regulations of the FDA or applicable foreign regulatory bodies to change significantly in a manner rendering our clinical data or regulatory filings insufficient for clearance or approval.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to sell our products
in member countries of the European Economic Area, or EEA, our products must comply with the General Safety and Performance Requirements
of the EU Medical Devices Regulation (Regulation (EU) 2017/745). Compliance with these requirements is a prerequisite to be able to affix
the Conformit&#233; Europ&#233;ene, or CE, mark to our products, without which they cannot be sold or marketed in the EEA. To demonstrate
compliance with the general safety and performance requirements we must undergo a conformity assessment procedure, which varies according
to the type of medical device and its classification. Except for low-risk medical devices (Class I non-sterile, non-measuring devices),
where the manufacturer can issue a European Community, or EC, Declaration of Conformity based on a self-assessment of the conformity of
its products with the general safety and performance requirements of the EU Medical Devices Regulation, a conformity assessment procedure
requires the intervention of an organization accredited by a member state of the EEA to conduct conformity assessments, or a Notified
Body. Depending on the relevant conformity assessment procedure, the Notified Body would typically audit and examine the technical file
and the quality system for the manufacture, design and final inspection of our devices. The Notified Body issues a certificate of conformity
following successful completion of a conformity assessment procedure conducted in relation to the medical device and its manufacturer
and their conformity with the general safety and performance requirements. This certificate entitles the manufacturer to affix the CE
mark to its medical devices after having prepared and signed a related EC Declaration of Conformity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Some of our products may also
need to comply with the following European Directives in order to be sold in the EEA:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">ROHS Directive 2011/65/EU of the European Parliament and of the Council of June 8, 2011 on the restriction of the use of certain hazardous substances in electrical and electronic equipment, as amended by (EU) 2017/2102.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 53.85pt; text-align: justify; text-indent: -17.85pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">WEEE Directive 2012/19/EU of the European Parliament and of the Council of July 4, 2012 on waste electrical and electronic equipment.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 53.85pt; text-align: justify; text-indent: -17.85pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">RED Directive 2014/53/EU of the European Parliament and of the Council of April 16, 2014 on the harmonization of the laws of the Member States relating to the making available on the market of radio equipment and repealing Directive 1999/5/EC Text with EEA relevance. Applicable as of June 13, 2016.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 53.85pt; text-align: justify; text-indent: -17.85pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Machinery Directive 2006/42/EC of the European Parliament and of the Council of May 17, 2006 on machinery, and amending Directive 95/16/EC</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">Regulation (EU) 2016/679 of the European Parliament and of the Council of April 27, 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (GDPR)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our products may be required
to comply with additional EU Directives.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 33 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a general rule, demonstration
of conformity of medical devices and their manufacturers with the general safety and performance requirements and essential requirements
must be based, among other things, on the evaluation of clinical data supporting the safety and performance of the products during normal
conditions of use. Specifically, a manufacturer must demonstrate that the device achieves its intended performance during normal conditions
of use, that the known and foreseeable risks, and any adverse events, are minimized and acceptable when weighed against the benefits of
its intended performance, and that any claims made about the performance and safety of the device are supported by suitable evidence.
If we fail to remain in compliance with applicable European laws, regulations and directives, we will be unable to continue to affix the
CE mark to our products, which would prevent us from selling them within the EEA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Failure to comply with post-marketing regulatory
requirements could subject us to enforcement actions, including substantial penalties, and might require us to recall or withdraw a product
from the market.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we receive regulatory clearance
or approval of the products or other future products, we will remain subject to ongoing and pervasive regulatory requirements governing,
among other things, the manufacture, marketing, advertising, medical device reporting, sale, promotion, import, export, registration,
and listing of devices. For example, we are required to submit periodic reports to the FDA as a condition of 510(k) clearance. These reports
include information about failures and certain adverse events associated with the device after its clearance. Failure to submit such reports,
or failure to submit the reports in a timely manner, could result in enforcement action by the FDA. Following its review of the periodic
reports, the FDA might ask for additional information or initiate further investigation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The regulations to which we
are subject are complex and have become more stringent over time. Regulatory changes could result in restrictions on our ability to continue
or expand our operations, higher than anticipated costs, or lower than anticipated sales. Even after we have obtained the proper regulatory
clearance to market a device, we have ongoing responsibilities under FDA regulations and applicable foreign laws and regulations. The
FDA, state and foreign regulatory authorities have broad enforcement powers. Our failure to comply with applicable regulatory requirements
could result in enforcement action by the FDA, state or foreign regulatory authorities, which may include any of the following sanctions:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">untitled letters or warning letters;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: justify">&#160;</td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">fines, injunctions, consent decrees and civil penalties;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">recalls, termination of distribution, administrative detention, or seizure of our products;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">customer notifications or repair, replacement or refunds;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">operating restrictions or partial suspension or total shutdown of production;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">delays in or refusal to grant our requests for future clearances or approvals or foreign marketing authorizations of new products, new intended uses, or modifications to existing products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">withdrawals or suspensions of product clearances or approvals, resulting in prohibitions on sales of our products;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">FDA refusal to issue certificates to foreign governments needed to export products for sale in other countries; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">criminal prosecution.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any of these sanctions could
result in higher than anticipated costs or lower than anticipated sales and have a material adverse effect on our reputation, business,
financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the FDA or state
or foreign authorities may change their clearance and approval policies, adopt additional regulations or revise existing regulations,
or take other actions, which may prevent or delay clearance or approval of our future products under development on a timely basis. Such
policy or regulatory changes could impose additional requirements upon us that could delay our ability to obtain new clearances or approvals,
increase the costs of compliance or restrict our ability to maintain any approvals we are able to obtain.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 34 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our products must be manufactured in accordance
with federal, state and foreign regulations, and we could be forced to recall our devices or terminate production if we fail to comply
with these regulations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The methods used in, and the
facilities used for, the manufacture of our products must comply with the Quality System Regulation, or ISO 13485 standard requirements,
as basic reference for requirements to establish a Quality Management System for the company, which is a complex regulatory scheme that
covers the procedures and documentation of the design, testing, production, process controls, quality assurance, labeling, packaging,
handling, storage, distribution, installation, servicing and shipping of medical devices. As manufacturers of electron radiation-emitting
products, we are also responsible for compliance with the radiological health regulations and certain radiation safety performance standards.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, we are required
to verify that our suppliers maintain facilities, procedures and operations that comply with our quality standards and applicable regulatory
requirements. The FDA enforces the Quality System (QS) Regulation, or QSR through periodic announced or unannounced inspections of medical
device manufacturing facilities, which may include the facilities of subcontractors. Our products are also subject to similar state regulations
and various laws and regulations of foreign countries governing manufacturing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our third-party manufacturers
may not take the necessary steps to comply with applicable regulations, which could cause delays in the delivery of our products. In addition,
failure to comply with applicable FDA or state or foreign requirements or later discovery of previously unknown problems with our products
or manufacturing processes could result in, among other things: warning letters or untitled letters; fines, injunctions or civil penalties;
suspension or withdrawal of approvals; seizures or recalls of our products; total or partial suspension of production or distribution;
administrative or judicially imposed sanctions; the FDA&#8217;s refusal to grant pending or future clearances or approvals for our products;
clinical holds; refusal to permit the import or export of our products; and criminal prosecution of us, our suppliers or our employees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any of these actions could
significantly and negatively affect supply of our products. If any of these events occurs, our reputation could be harmed, we could be
exposed to product liability claims and we could lose customers and experience reduced sales and increased costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The misuse or off-label use of our products
may harm our reputation in the marketplace and result in injuries that lead to product liability suits or result in costly investigations,
fines or sanctions by regulatory bodies if we are deemed to have engaged in the promotion of these uses, any of which could be costly
to our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Advertising and promotion
of our future products that obtains approval in the U.S. may be heavily scrutinized by the FDA, the DOJ, HHS, state attorneys general,
members of Congress, and the public. In addition, advertising and promotion of any future product that obtains approval outside of the
U.S. will be heavily scrutinized by comparable foreign regulatory authorities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect that, if cleared
or approved, our products will be cleared by the requisite regulatory authorities for specific indications. We expect to train our marketing
personnel and direct sales force to not promote our devices for uses outside of the FDA-approved indications for use, or any other regulatory
authority approved indications for use in a relevant territory, known as &#8220;off-label uses.&#8221; We cannot, however, prevent a physician
from using our devices off-label, when in the physician&#8217;s independent professional medical judgment, he or she deems it appropriate.
There may be increased risk of injury to patients if physicians attempt to use our devices off-label. Furthermore, the use of our devices
for indications other than those approved by the FDA or approved by any foreign regulatory body may not effectively treat such conditions,
which could harm our reputation in the marketplace among healthcare providers and patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 35 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the FDA or any state or
foreign regulatory body determines that our promotional materials or training constitute promotion of an off-label use, it could request
that we modify our training or promotional materials or subject us to regulatory or enforcement actions, including the issuance or imposition
of an untitled letter, which is used for violators that do not necessitate a warning letter, injunction, seizure, civil fine or criminal
penalties. It is also possible that other federal, state or foreign enforcement authorities might take action under other regulatory authority,
such as false claims laws, if they consider our business activities to constitute promotion of an off-label use, which could result in
significant penalties, including, but not limited to, criminal, civil and administrative penalties, damages, fines, disgorgement, exclusion
from participation in government healthcare programs and the curtailment of our operations. We may become subject to such actions and,
if we are not successful in defending against such actions, those actions may have a material adverse effect on our business, financial
condition and results of operations. Equivalent laws and potential consequences exist in foreign jurisdictions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, if our products
are cleared or approved, healthcare providers may misuse our products or use improper techniques if they are not adequately trained, potentially
leading to injury and an increased risk of product liability. If our devices are misused or used with improper technique, we may become
subject to costly litigation by our customers or their patients. As described above, product liability claims could divert management&#8217;s
attention from our core business, be expensive to defend and result in sizeable damage awards against us that may not be covered by insurance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our products may cause or contribute to
adverse medical events or be subject to failures or malfunctions that we are required to report to the FDA, or any other regulatory authority
in a relevant territory, and if we fail to do so, we would be subject to sanctions that could harm our reputation, business, financial
condition and results of operations. The discovery of serious safety issues with our products, or a recall of our products either voluntarily
or at the direction of the FDA or another governmental authority, could have a negative impact on us.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our products or our other
future products receive clearance or approval, we will be subject to the FDA&#8217;s medical device reporting regulations and similar
foreign regulations, which require us to report to the FDA when we receive or become aware of information that reasonably suggests that
one or more of our products may have caused or contributed to a death or serious injury or malfunctioned in a way that, if the malfunction
were to recur, could cause or contribute to a death or serious injury. The timing of our obligation to report is triggered by the date
we become aware of the adverse event as well as the nature of the event. We may fail to report adverse events of which we become aware
within the prescribed timeframe. We may also fail to recognize that we have become aware of a reportable adverse event, especially if
it is not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of the product.
If we fail to comply with our reporting obligations, the FDA or other regulatory bodies could take action, including warning letters,
untitled letters, administrative actions, criminal prosecution, imposition of civil monetary penalties, revocation of our device clearance
or approval, seizure of our products or delay in clearance or approval of future products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA and foreign regulatory
bodies have the authority to require the recall of commercialized products in the event of material deficiencies or defects in design
or manufacture of a product or in the event that a product poses an unacceptable risk to health. Generally, a regulator&#8217;s authority
to require a recall must be based on a finding that there is reasonable probability that the device could cause serious injury or death.
We may also choose to voluntarily recall a product if any material deficiency is found. A government-mandated or voluntary recall by us
could occur as a result of an unacceptable risk to health, component failures, malfunctions, manufacturing defects, labeling or design
deficiencies, packaging defects or other deficiencies or failures to comply with applicable regulations. Product defects or other errors
may occur in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Depending on the corrective
action we take to redress a product&#8217;s deficiencies or defects, the FDA and any other regulatory authority may require, or we may
decide, that we will need to obtain new clearances or approvals for the device before we may market or distribute the corrected device.
Seeking such clearances or approvals may delay our ability to replace the recalled devices in a timely manner. Moreover, if we do not
adequately address problems associated with our devices, we may face additional regulatory enforcement action, including FDA warning letters,
product seizure, injunctions, administrative penalties or civil or criminal fines.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Companies are required to
maintain certain records of recalls and corrections, even if they are not reportable to the FDA. We may initiate voluntary withdrawals
or corrections for our products in the future that we determine do not require notification of the FDA or to any other regulatory authority
in a relevant territory. If the FDA or any other regulatory authority in a relevant territory, disagrees with our determinations, it could
require us to report those actions as recalls and we may be subject to enforcement action. A future recall announcement could harm our
reputation with customers, potentially lead to product liability claims against us and negatively affect our sales. Any corrective action,
whether voluntary or involuntary, as well as defending ourselves in a lawsuit, will require the dedication of our time and capital, distract
management from operating our business and may harm our reputation and financial results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 36 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>We may be subject,
directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws and health information privacy and security
laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many federal state and foreign
healthcare laws and regulations apply to medical devices. We may be subject to certain federal and state regulations, including the federal
healthcare programs&#8217; Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully soliciting, offering, receiving,
or paying any remuneration, directly or indirectly, in cash or in kind, to induce or reward purchasing, ordering or arranging for or recommending
the purchase or order of any item or service for which payment may be made, in whole or in part, under a federal healthcare program such
as Medicare and Medicaid; HIPAA, which imposes criminal and civil liability for knowingly and willfully executing, or attempting to execute,
a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or
making any materially false statement in connection with the delivery of, or payment for, healthcare benefits, items or services; the
federal Civil Monetary Penalties Law, which authorizes the imposition of substantial civil monetary penalties against an entity that engages
in activities including, among others (1) knowingly presenting, or causing to be presented, a claim for services not provided as claimed
or that is otherwise false or fraudulent in any way; (2) arranging for or contracting with an individual or entity that is excluded from
participation in federal healthcare programs to provide items or services reimbursable by a federal healthcare program; (3) violations
of the federal Anti-Kickback Statute; or (4) failing to report and return a known overpayment; the federal False Statements Statute, which
prohibits knowingly and willfully falsifying, concealing, or covering up a material fact or making any materially false, fictitious or
fraudulent statement or representation, or making or using any false writing or document knowing the same to contain any materially false,
fictitious or fraudulent statement or entry, in connection with the delivery of or payment for healthcare benefits, items, or services;
the federal civil False Claims Act, or the FCA, which prohibits, among other things, knowingly presenting, or causing to be presented
claims for payment of government funds that are false or fraudulent, or knowingly making, using or causing to be made or used a false
record or statement material to such a false or fraudulent claim, or knowingly concealing or knowingly and improperly avoiding, decreasing,
or concealing an obligation to pay money to the federal government; and other federal and state false claims laws. The FCA prohibits anyone
from knowingly presenting, conspiring to present, making a false statement in order to present, or causing to be presented, for payment
to federal programs (including Medicare and Medicaid) claims for items or services that are false or fraudulent, claims for items or services
not provided as claimed, or claims for medically unnecessary items or services. This law also prohibits anyone from knowingly underpaying
an obligation owed to a federal program. Increasingly, U.S. federal agencies are requiring nonmonetary remedial measures, such as corporate
integrity agreements in FCA settlements. The DOJ announced in 2016 its intent to follow the &#8220;Yates Memo,&#8221; taking a far more
aggressive approach in pursuing individuals as FCA defendants in addition to corporations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The majority of states also
have statutes similar to the federal Anti-Kickback Statute and false claims laws that apply to items and services reimbursed under Medicaid
and other state programs, or, in several states, that apply regardless of whether the payer is a government entity or a private commercial
entity. The Federal Open Payments, or Physician Payments Sunshine Act, program requires manufacturers of products for which payment is
available under Medicare, Medicaid or the State Children&#8217;s Health Insurance Program, to track and report annually to the federal
government (for disclosure to the public) certain payments and other transfers of value made to physicians and teaching hospitals as well
as disclosure of payments and other transfers of value provided to physicians and teaching hospitals, and ownership and investment interests
held by physicians and other healthcare providers and their immediate family members and applicable group purchasing organizations. Our
failure to appropriately track and report payments to the government could result in civil fines and penalties, which could adversely
affect the results of our operations. In addition, several U.S. states and localities have enacted legislation requiring medical device
companies to establish marketing compliance programs, file periodic reports with the state, and/or make periodic public disclosures on
sales, marketing, pricing, clinical trials, and other activities. Other state laws prohibit certain marketing-related activities including
the provision of gifts, meals or other items to certain healthcare providers. Many of these laws and regulations contain ambiguous requirements
that government officials have not yet clarified. Given the lack of clarity in the laws and their implementation, our reporting actions
could be subject to the penalty provisions of the pertinent federal and state laws and regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "></p><div>

</div><!-- Field: Page; Sequence: 37 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The medical device industry
has been under heightened scrutiny as the subject of government investigations and enforcement actions involving manufacturers who allegedly
offered unlawful inducements to potential or existing customers in an attempt to procure their business, including arrangements with physician
consultants. If our operations or arrangements are found to be in violation of such governmental regulations, we may be subject to civil
and criminal penalties, damages, fines, exclusion from the Medicare and Medicaid programs and the curtailment of our operations. All of
these penalties could adversely affect our ability to operate our business and our financial results.<b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we do not obtain and maintain international
regulatory registrations, clearances or approvals for our products, we will be unable to market and sell our products outside of the U.S.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Sales of our products outside
of the U.S. are subject to foreign regulatory requirements that vary widely from country to country. Approval procedures vary among countries
and can involve additional testing. The time required to obtain approval outside of the U.S. may differ substantially from that required
to obtain FDA approval. While the regulations of some countries may not impose barriers to marketing and selling our products or only
require notification, others require that we obtain the clearance or approval of a specified regulatory body. Complying with foreign regulatory
requirements, including obtaining registrations, clearances or approvals, can be expensive and time-consuming, and we may not receive
regulatory clearances or approvals in each country in which we plan to market our products, or we may be unable to do so on a timely basis.
The time required to obtain registrations, clearances or approvals, if required by other countries, may be longer than that required for
FDA clearance or approval, and requirements for such registrations, clearances or approvals may significantly differ from FDA requirements.
If we modify our products, we may need to apply for additional regulatory clearances or approvals before we are permitted to sell the
modified product. In addition, we may not continue to meet the quality and safety standards required to maintain the authorizations that
we have received. If we are unable to maintain our authorizations in a particular country, we will no longer be able to sell the applicable
product in that country.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Regulatory clearance or approval
by the FDA does not ensure registration, clearance or approval by regulatory authorities in other countries, and registration, clearance
or approval by one or more foreign regulatory authorities does not ensure registration, clearance or approval by regulatory authorities
in other foreign countries or by the FDA. However, a failure or delay in obtaining registration or regulatory clearance or approval in
one country may have a negative effect on the regulatory process in others.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Legislative or regulatory reforms in the
U.S. or the EU may make it more difficult and costly for us to obtain regulatory clearances or approvals for our products or to manufacture,
market or distribute our products after clearance or approval is obtained.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, legislation
is drafted and introduced in Congress that could significantly change the statutory provisions governing the regulation of medical devices.
In addition, the FDA may change its clearance and approval policies, adopt additional regulations or revise existing regulations, or take
other actions, which may prevent or delay approval or clearance of our future products under development or impact our ability to modify
our currently cleared products on a timely basis. Over the last several years, the FDA has proposed reforms to its 510(k) clearance process,
and such proposals could include increased requirements for clinical data and a longer review period, or could make it more difficult
for manufacturers to utilize the 510(k) clearance process for their products. For example, in November 2018, FDA officials announced forthcoming
steps that the FDA intends to take to modernize the premarket notification pathway under Section 510(k) of the FDCA. Among other things,
the FDA announced that it planned to develop proposals to drive manufacturers utilizing the 510(k) pathway toward the use of newer predicates.
These proposals included plans to potentially sunset certain older devices that were used as predicates under the 510(k) clearance pathway,
and to potentially publish a list of devices that have been cleared on the basis of demonstrated substantial equivalence to predicate
devices that are more than 10 years old. In May 2019, the FDA solicited public feedback on these proposals. The FDA requested public feedback
on whether it should consider certain actions that might require new authority, such as whether to sunset certain older devices that were
used as predicates under the 510(k) clearance pathway. These proposals have not yet been finalized or adopted, and the FDA may work with
Congress to implement such proposals through legislation. Accordingly, it is unclear the extent to which any proposals, if adopted, could
impose additional regulatory requirements on us that could delay our ability to obtain new 510(k) clearances, increase the costs of compliance,
or restrict our ability to maintain our current clearances, or otherwise create competition that may negatively affect our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 38 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2019, the FDA
finalized guidance describing an optional &#8220;safety and performance based&#8221; premarket review pathway for manufacturers of &#8220;certain,
well-understood device types&#8221; to demonstrate substantial equivalence under the 510(k) clearance pathway by showing that such device
meets objective safety and performance criteria established by the FDA, thereby obviating the need for manufacturers to compare the safety
and performance of their medical devices to specific predicate devices in the clearance process. The FDA has developed and maintains a
list device types appropriate for the &#8220;safety and performance based&#8221; pathway and will continue to develop product-specific
guidance documents that identify the performance criteria for each such device type, as well as the testing methods recommended in the
guidance documents, where feasible. The FDA may establish performance criteria for classes of devices for which we or our competitors
seek or currently have received clearance, and it is unclear the extent to which such performance standards, if established, could impact
our ability to obtain new 510(k) clearances or otherwise create competition that may negatively affect our business. In September 2023,
the FDA introduced draft guidance regarding best practices for selecting a device in 510(k) submissions to enhance the predictability,
consistency, and transparency of the 510(k) Program. The recommendations focus on characteristics of the predicate, including selecting
a predicate device that was cleared using well-established methods, meets or exceeds expected safety and performance, is without unmitigated
use-related or design-related safety issues, and is without an associated design-related recall. According to the FDA, these practices
will encourage the evolution of safer and more effective medical devices in the 510(k) program over time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Similarly, particular common
specifications, or sets of technical and/or clinical requirements (other than a standard) that provide a means of complying with the legal
obligations applicable to a device, process or system, are issued by the EU&#8217;s competent authorities and are mandatory as part of
the CE certification process. The EU competent authorities may establish performance criteria for classes of devices for which we or our
competitors seek or currently have received certification and it is unclear the extent to which such performance standards, if established,
could impact our ability to obtain new CE certifications or otherwise create competition that may negatively affect our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, FDA or any other
relevant regulatory authority, regulations and guidance are often revised or reinterpreted by the FDA or any other regulatory authority,
in ways that may significantly affect our business and our products. Any new statutes, regulations or revisions or reinterpretations of
existing regulations may impose additional costs or lengthen review times of any future products or make it more difficult to obtain clearance
or approval for, manufacture, market or distribute our products. We cannot determine what effect changes in regulations, statutes, legal
interpretation or policies, when and if promulgated, enacted or adopted may have on our business in the future. Such changes could, among
other things, require: additional testing prior to obtaining clearance or approval; changes to manufacturing methods; recall, replacement
or discontinuance of our products; or additional record keeping.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA&#8217;s and other
regulatory authorities&#8217; policies may change, and additional government regulations may be promulgated that could prevent, limit
or delay regulatory clearance or approval of our future products. We cannot predict the likelihood, nature or extent of government regulation
that may arise from future legislation or administrative action, either in the U.S. or abroad. For example, certain policies of the Trump
administration, as well as decisions by the U.S.&#8217; legislative or judicial branches may impact our business and industry.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 27, 2020, the U.S.
Supreme Court reversed a Federal Circuit decision that previously upheld Congress&#8217; denial of $12 billion in &#8220;risk corridor&#8221;
funding. Congress may consider additional legislation to repeal, or repeal and replace, other elements of the Patient Protection and Affordable
Care Act, as amended by the Health Care and Education Reconciliation Act, or the PPACA, On June 17, 2021, the U.S. Supreme Court dismissed
a challenge on procedural grounds that argued that the PPACA is unconstitutional in its entirety because the individual mandate was repealed
by Congress. Thus, the PPACA will remain in effect in its current form. Prior to the U.S. Supreme Court ruling, on January 28, 2021, President
Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through
the PPACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies
and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that
include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid
or the PPACA. In addition, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022, or the IRA, into law, which
among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in PPACA marketplaces through plan
year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering
the beneficiary maximum out-of-pocket cost through a newly established manufacturer discount program. It is possible that the PPACA will
be subject to judicial or Congressional challenges in the future. It is unclear how such challenges and any potential future healthcare
reform measures of the Trump administration will impact the PPACA and our business. We continue to evaluate the PPACA and its possible
repeal and replacement, as the extent to which any such changes may impact our business or financial condition remains uncertain. If we
are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able
to maintain regulatory compliance, we may lose any marketing approval or clearance that we may have obtained and we may not achieve or
sustain profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 39 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the EU, similar political,
economic and regulatory developments may affect our ability to profitably commercialize any of our product candidates, if approved. In
addition to continuing pressure on prices and cost containment measures, legislative developments at the EU or member state level may
result in significant additional requirements or obstacles that may increase our operating costs. The delivery of healthcare in the EU,
including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter
for national, rather than EU, law and policy. National governments and health service providers have different priorities and approaches
to the delivery of health care and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary
constraints in most EU member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service
providers. Coupled with ever-increasing EU and national regulatory burdens on those wishing to develop and market products, this could
prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to
commercialize any products for which we obtain marketing approval. Political, economic and regulatory developments may further complicate
pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU
member states, and parallel trade, i.e., arbitrage between low-priced and high-priced member states, can further reduce prices. There
can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable
reimbursement and pricing arrangements for any products, if approved in those countries. In international markets, reimbursement and healthcare
payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 5, 2017, the European
Parliament passed the Medical Devices Regulation (Regulation 2017/745), which became effective on May 26, 2021 and repeals and replaces
the EU Medical Devices Directive. Unlike directives, which must be implemented into the national laws of the EEA member states, the regulations
would be directly applicable, i.e., without the need for adoption of EEA member state laws implementing them, in all EEA member states
and are intended to eliminate current differences in the regulation of medical devices among EEA member States. The Medical Devices Regulation,
among other things, is intended to establish a uniform, transparent, predictable and sustainable regulatory framework across the EEA for
medical devices and ensure a high level of safety and health while supporting innovation. Among other things, the Medical Devices Regulation:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Strengthen the rules on placing devices on the market and reinforce surveillance once they are available;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Establish explicit provisions on manufacturers&#8217; responsibilities for follow-up regarding the quality, performance and safety of devices placed on the market;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Improve the traceability of medical devices throughout the supply chain to the end-user or patient through a unique identification number;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Set up a central database to provide patients, healthcare professionals and the public with comprehensive information on products available in the EU; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Strengthened rules for the assessment of certain high-risk devices, which may have to undergo an additional check by experts before they are placed on the market.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 40 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These modifications may have
an effect on the way we conduct our business in the EEA. We expect that these and other healthcare reform measures that may be adopted
in the future, may result in more rigorous coverage criteria and lower reimbursement, and in additional downward pressure on the price
that we receive for any approved product. Any reduction in reimbursement from Medicare or other government-funded programs may result
in a similar reduction in payments from private payors. Further, there is no guarantee that we can use existing reimbursement codes or
receive reimbursement at all. The implementation of cost containment measures or other healthcare reforms may prevent us from being able
to generate revenue, attain profitability or commercialize our drugs, once marketing approval is obtained. We cannot predict what healthcare
reform initiatives may be adopted in the future. However, it is possible that there will be further legislation or regulation that could
harm the business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Healthcare legislative and regulatory reform
measures may have a material adverse effect on our business and results of operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our industry is highly regulated
and changes in law may adversely impact our business, operations or financial results. The Patient Protection and Affordable Care Act,
as amended by the Health Care and Education Reconciliation Act, or the PPACA, is a sweeping measure intended to, among other things, expand
healthcare coverage within the U.S., primarily through the imposition of health insurance mandates on employers and individuals and expansion
of the Medicaid program. Several provisions of the law may affect us and increase certain of our costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, other legislative
changes have been adopted since the PPACA was enacted. These changes include aggregate reductions in Medicare payments to providers of
2% per fiscal year, which went into effect on April 1, 2013. These reductions went into effect in April 2013 and, due to subsequent legislative
amendments to the statute, will remain in effect until 2031.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2013, President
Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, further reduced Medicare payments to several
types of providers and increased the statute of limitations period for the government to recover overpayments to providers from three
to five years. These and new laws may result in additional reductions in Medicare and other healthcare funding, which could have a material
adverse effect on our customers and, accordingly, our financial operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We anticipate that the PPACA,
as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and an additional
downward pressure on the reimbursement our customers may receive for our products. Further, there have been, and there may continue to
be, judicial and Congressional challenges to certain aspects of the PPACA. For example, the U.S. Tax Cuts and Jobs Act of 2017, or TCJA,
includes a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the PPACA on certain
individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual
mandate.&#8221; On June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the PPACA is unconstitutional
in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Further, prior to the U.S. Supreme Court ruling,
on January 28, 2021, President Biden issued an executive order to initiate a special enrollment period from February 26, 2021 through
August 15, 2021 for purposes of obtaining health insurance coverage through the PPACA marketplace. The executive order also instructed
certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among
others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary
barriers to obtaining access to health insurance coverage through Medicaid or the PPACA. In addition, on August 16, 2022, President Biden
signed the Inflation Reduction Act of 2022, or the IRA, into law, which among other things, extends enhanced subsidies for individuals
purchasing health insurance coverage in PPACA marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221;
under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost through a newly
established manufacturer discount program. Additional legislative and regulatory changes and judicial challenges to the PPACA, its implementing
regulations and guidance and its policies, remain possible. However, it remains unclear how any new legislation, regulation or challenges
in court might affect the prices we may obtain for any of our products for which regulatory approval is obtained. Any reduction in reimbursement
from Medicare and other government programs may result in a similar reduction in payments from private payers. The implementation of cost
containment measures or other healthcare reforms may prevent us from being able to generate significant revenue, attain profitability
or commercialize our products in scale.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 41 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the delivery
of healthcare in the EU, including the establishment and operation of health services, is almost exclusively a matter for national, rather
than EU, law and policy. National governments and health service providers have different priorities and approaches to the delivery of
health care and the pricing and reimbursement of products in that context. Coupled with ever-increasing EU and national regulatory burdens
on those wishing to develop and market products, this could prevent or delay marketing approval of our products or any future product
candidates, restrict or regulate post-approval activities and affect our ability to commercialize any products for which we obtain marketing
approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are currently unable to
predict what additional legislation or regulation, if any, relating to the health care industry may be enacted in the future or what effect
recently enacted federal legislation or any such additional legislation or regulation would have on our business. The pendency or approval
of such proposals or reforms could result in a decrease in the price of our securities or limit our ability to raise capital or to enter
into collaboration agreements for the further development and potential commercialization of our products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Inadequate funding for the FDA and other
government agencies and/or potentially shifting priorities under the new administration could hinder their ability to hire, retain or
deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, cleared, approved or commercialized
in a timely manner or at all, or otherwise prevent those agencies from performing normal business functions on which the operation of
our business may rely, which could negatively impact our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The ability of the FDA to
review and clear or approve new products, provide feedback on clinical trials and development programs, meet with sponsors and otherwise
review regulatory submissions can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory,
and policy changes, the FDA&#8217;s ability to hire and retain key personnel and accept the payment of user fees, and other events that
may otherwise affect the FDA&#8217;s ability to perform routine functions. Average review times at the FDA have fluctuated in recent years
as a result. In addition, government funding of other government agencies that fund research and development activities is subject to
the political process, which is inherently fluid and unpredictable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Disruptions at the FDA and
other agencies may also increase the time necessary for new medical devices or modifications to cleared or approved medical devices to
be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, the&#160;Trump&#160;administration
has discussed several changes to the reach and oversight of the FDA, which could affect its relationship with the pharmaceutical industry,
transparency in decision making and ultimately the cost and availability of prescription drugs. Additionally, over the last several years,
the U.S. government has shut down multiple times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA and
other government employees and stop critical activities. If funding for the FDA is reduced, FDA priorities change, or a prolonged government
shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, including
our future-planned NDA submission for INSPIRA ART, which could have a material adverse effect on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Environmental, social and corporate governance
(ESG) issues, including those related to climate change and sustainability, may have an adverse effect on our business, financial condition
and results of operations and damage our reputation.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is an increasing focus
from certain investors, customers, consumers, employees and other stakeholders concerning ESG matters. Additionally, public interest and
legislative pressure related to public companies&#8217; ESG practices continue to grow. If our ESG practices fail to meet regulatory requirements
or investor, customer, consumer, employee or other stakeholders&#8217; evolving expectations and standards for responsible corporate citizenship
in areas including environmental stewardship, support for local communities, Board of Director and employee diversity, human capital management,
employee health and safety practices, product quality, supply chain management, corporate governance and transparency, our reputation,
brand and employee retention may be negatively impacted, and our customers and suppliers may be unwilling to continue to do business with
us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Customers, consumers, investors
and other stakeholders are increasingly focusing on environmental issues, including climate change, energy and water use, plastic waste
and other sustainability concerns. Concern over climate change may result in new or increased legal and regulatory requirements to reduce
or mitigate impacts to the environment. Changing customer and consumer preferences or increased regulatory requirements may result in
increased demands or requirements regarding plastics and packaging materials, including single-use and non-recyclable plastic products
and packaging, other components of our products and their environmental impact on sustainability, or increased customer and consumer concerns
or perceptions (whether accurate or inaccurate) regarding the effects of substances present in certain of our products. Complying with
these demands or requirements could cause us to incur additional manufacturing, operating or product development costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we do not adapt to or comply
with new regulations, or fail to meet evolving investor, industry or stakeholder expectations and concerns regarding ESG issues, investors
may reconsider their capital investment in our Company, and customers and consumers may choose to stop purchasing our products, which
could have a material adverse effect on our reputation, business or financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 42 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "><b>Risks Related to Our
Intellectual Property</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are unable to obtain and maintain
effective patent rights for our products and services, we may not be able to compete effectively in our markets. If we are unable to protect
the confidentiality of our trade secrets or know-how, such proprietary information may be used by others to compete against us.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our success and future revenue
growth will depend, in part, on our ability to protect our patent rights. In addition to the protection afforded by any patents that may
be granted, historically, we have relied on trade secret protection and confidentiality agreements with our employees, consultants, and
contractors to protect proprietary know-how that is not patentable or that we elect not to patent, processes that are not easily known,
knowable or easily ascertainable, and for which patent infringement is difficult to monitor and enforce and any other elements of our
product candidate discovery and development processes that involve proprietary know-how, information or technology that is not covered
by patents. However, agreements may be breached, trade secrets may be difficult to protect, and we may not receive adequate remedies for
any breach. In addition, our trade secrets and intellectual property may otherwise become known or be independently discovered by competitors
or other unauthorized third parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is no guarantee that
the patent applications that we submitted with regards to our technologies will result in patent registration. In the event of failure
to complete patent registration, our developments will not be proprietary, which might allow other entities to manufacture our products
or design our services and compete with them.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, there is no assurance
that all potentially relevant prior art relating to our patent applications has been found, which can invalidate a patent or prevent a
patent from issuing from a pending patent application. Even if patents do successfully issue, and even if such patents cover our products
or services, third parties may challenge their validity, enforceability, or scope, which may result in such patents being narrowed, found
unenforceable or invalidated. Furthermore, even if they are unchallenged, our patent applications and any future patents may not adequately
protect our intellectual property, products or services and provide exclusivity for our new products or services or prevent others from
designing around our claims. Furthermore, there is no guarantee that third parties will not infringe or misappropriate our patents or
similar proprietary rights. In addition, there can be no assurance that we will not have to pursue litigation against other parties to
assert its rights.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Any
of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we cannot obtain and maintain
effective patent rights for our products and services, we may not be able to compete effectively, and our business and results of operations
would be harmed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot provide any assurances
that our trade secrets and other confidential proprietary information will not be disclosed in violation of our confidentiality agreements
or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information
and techniques. Also, misappropriation or unauthorized and unavoidable disclosure of our trade secrets and intellectual property could
impair our competitive position and may have a material adverse effect on our business. Additionally, if the steps taken to maintain our
trade secrets and intellectual property are deemed inadequate, we may have insufficient recourse against third parties for misappropriating
any trade secret.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 43 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Intellectual property rights of third parties
could adversely affect our ability to commercialize our products and services, and we might be required to litigate or obtain licenses
from third parties in order to develop or market our product candidates. Such litigation or licenses could be costly or not available
on commercially reasonable terms.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is inherently difficult
to conclusively assess our freedom to operate without infringing on third-party rights. Our competitive position may be adversely affected
if existing patents or patents resulting from patent applications issued to third parties or other third-party intellectual property rights
are held to cover our products or services or elements thereof, or our manufacturing or uses relevant to our development plans. In such
cases, we may not be in a position to develop or commercialize products or services or our product candidates (and any relevant services)
unless we successfully pursue litigation to nullify or invalidate the third-party intellectual property right concerned or enter into
a license agreement with the intellectual property right holder, if available on commercially reasonable terms. There may also be pending
patent applications that if they result in issued patents, could be alleged to be infringed by our new products or services. If such an
infringement claim should be brought and be successful, we may be required to pay substantial damages, be forced to abandon our new products
or services or seek a license from any patent holders. No assurances can be given that a license will be available on commercially reasonable
terms, if at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is also possible that we
have failed to identify relevant third-party patents or applications. For example, U.S. patent applications filed before November 29,
2000 and certain U.S. patent applications filed after that date that will not be filed outside the U.S. remain confidential until patents
issue. Patent applications in the U.S. and elsewhere are published approximately 18 months after the earliest filing for which priority
is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering our
new products or services could have been filed by others without our knowledge. Additionally, pending patent applications which have been
published can, subject to certain limitations, be later amended in a manner that could cover our services, our new products or the use
of our new products. Third-party intellectual property right holders may also actively bring infringement claims against us. We cannot
guarantee that we will be able to successfully settle or otherwise resolve such infringement claims. If we are unable to successfully
settle future claims on terms acceptable to us, we may be required to engage in or continue costly, unpredictable and time-consuming litigation
and may be prevented from or experience substantial delays in pursuing the development of and/or marketing our new products or services.
If we fail in any such dispute, in addition to being forced to pay damages, we may be temporarily or permanently prohibited from commercializing
our new products or services that are held to be infringing. We might, if possible, also be forced to redesign our new products so that
we no longer infringe the third-party intellectual property rights. Any of these events, even if we were ultimately to prevail, could
require us to divert substantial financial and management resources that we would otherwise be able to devote to our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Third-party claims of intellectual property
infringement may prevent or delay our development and commercialization efforts.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our commercial success depends
in part on our avoiding infringement of the patents and proprietary rights of third parties. Numerous U.S. and foreign issued patents
and pending patent applications, which are owned by third parties, exist in the fields in which we are developing new products and services.
If our business expands and more patents are issued, the risk increases that our products and services may be subject to claims of infringement
of the patent rights of third parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Third parties may assert that
we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims
to materials, designs or methods of manufacture related to the use or manufacture of our products or services. There may be currently
pending patent applications or continued patent applications that may later result in issued patents that our products or services may
infringe. In addition, third parties may obtain patents or services in the future and claim that use of our technologies infringes upon
these patents.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If any third-party patents
were held by a court of competent jurisdiction to cover aspects of our processes for designs, or methods of use, the holders of any such
patents may be able to block our ability to develop and commercialize the applicable product candidate unless we obtain a license or until
such patent expires or is finally determined to be invalid or unenforceable. In either case, such a license may not be available on commercially
reasonable terms or at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Parties making claims against
us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one
or more of our products or services. Defense of these claims, regardless of their merit, would involve substantial litigation expense
and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against
us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties,
redesign our infringing products or services, or obtain one or more licenses from third parties, which may be impossible or require substantial
time and monetary expenditure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 44 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Patent policy and rule changes could increase
the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of any issued patents.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Changes
in either the patent laws or interpretation of the patent laws in the U.S. and other countries may diminish the value of any patents that
may issue from our patent applications or narrow the scope of our patent protection. The laws of foreign countries may not protect our
rights to the same extent as the laws of the U.S. Publications of discoveries in the scientific literature often lag behind the actual
discoveries, and patent applications in the U.S. and other jurisdictions are typically not published until 18 months after filing, or
in some cases not at all. We therefore cannot be certain that we were the first to file the invention claimed in our owned and licensed
patent or pending applications, or that we or our licensor were the first to file for patent protection of such inventions. Assuming all
other requirements for patentability are met, in the U.S. prior to March 15, 2013, the first to make the claimed invention without undue
delay in filing, is entitled to the patent, while generally outside the U.S., the first to file a patent application is entitled to the
patent. After March 15, 2013, under the Leahy-Smith America Invents Act, or the Leahy-Smith Act, enacted on September 16, 2011, the U.S.
has moved to a first to file system. The Leahy-Smith Act also includes a number of significant changes that affect the way patent applications
will be prosecuted and may also affect patent litigation. In general, the Leahy-Smith Act and its implementation could increase the uncertainties
and costs surrounding the prosecution of our patent applications and the enforcement or defense of any issued patents, all of which could
have a material adverse effect on our business and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be involved in lawsuits to protect
or enforce our intellectual property, which could be expensive, time consuming, and unsuccessful. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Competitors may infringe our
intellectual property. If we were to initiate legal proceedings against a third-party to enforce a patent covering one of our new products
or services, the defendant could counterclaim that the patent covering our product candidate is invalid and/or unenforceable. In patent
litigation in the U.S., defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge
could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, or non-enablement.
Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant
information from the U.S. Patent and Trademark Office, or USPTO, or made a misleading statement, during prosecution. Under the Leahy-Smith
Act, the validity of U.S. patents may also be challenged in post-grant proceedings before the USPTO. The outcome following legal assertions
of invalidity and unenforceability is unpredictable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Derivation proceedings initiated
by third parties or brought by us may be necessary to determine the priority of inventions and/or their scope with respect to our patent
or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology or to
attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license
on commercially reasonable terms. Our defense of litigation or interference proceedings may fail and, even if successful, may result in
substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation could have
a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs,
license necessary technology from third parties, or enter into development partnerships that would help us bring our new products or services
to market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, because of the
substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential
information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results
of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative,
it could have a material adverse effect on the price of our securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 45 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be subject to claims challenging
the inventorship of our intellectual property.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may be subject to claims
that former employees, collaborators or other third parties have an interest in, or right to compensation, with respect to our current
patent and patent applications, future patents or other intellectual property as an inventor or co-inventor. For example, we may have
inventorship disputes arise from conflicting obligations of consultants or others who are involved in developing our products or services.
Litigation may be necessary to defend against these and other claims challenging inventorship or claiming the right to compensation. If
we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such
as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our
business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction
to management and other employees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not be able to protect our intellectual
property rights throughout the world.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Filing, prosecuting, and defending
patents on products and services, as well as monitoring their infringement in all countries throughout the world would be prohibitively
expensive, and our intellectual property rights in some countries can be less extensive than those in the U.S. In addition, the laws of
some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the U.S.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Competitors may use our technologies
develop their own products or services in jurisdictions where we have not obtained patent protection to and may export infringing products
or services to territories where we have patent protection, but where patents are not enforced as strictly as they are in the U.S. These
products or services may compete with our products or services. Future patents or other intellectual property rights may not be effective
or sufficient to prevent them from competing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many companies have encountered
significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries,
particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection,
which could make it difficult for us to stop the marketing of competing products or services in violation of our proprietary rights generally.
Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert
our efforts and attention from other aspects of our business, could put our future patents at risk of being invalidated or interpreted
narrowly, put the issuance of our patent applications at risk, and could provoke third parties to assert claims against us. We may not
prevail in any lawsuits that we initiate, and any damages or other remedies that we may be awarded, may not be commercially meaningful.
Accordingly, our efforts to monitor and enforce our intellectual property rights around the world may be inadequate to obtain a significant
commercial advantage from the intellectual property that we develop or license.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 46 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risks Related to Ownership of our Securities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The market price of our securities is likely
to continue to be highly volatile, and you may not be able to resell your Ordinary Shares at or above the price that you paid.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since we completed our IPO
in July 2021, the trading price of our Ordinary Shares and Warrants have been volatile and is likely to continue to be volatile. The stock
market in general, and the market for medical device companies in particular, has experienced extreme volatility that has often been unrelated
to the operating performance of particular companies, which has resulted in decreased share prices for many companies notwithstanding
the lack of a fundamental change in their underlying business models or prospects. Broad market and industry factors, including potentially
worsening economic conditions, inflation and other adverse effects, may negatively affect the market price of our securities, regardless
of our actual operating performance. As a result of this volatility, you may not be able to sell your securities at or above the price
you paid. The following factors, in addition to other risk factors described in this section, may have a significant impact on the market
price of our securities:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt; ">Inability to obtain the approvals necessary to commence further clinical trials;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Unsatisfactory results of clinical trials; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Announcements of regulatory approval or the failure to obtain it, or specific label indications or patient populations for its use, or changes or delays in the regulatory review process; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Announcements of innovations or new products by us or our competitors; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Adverse actions taken by regulatory authorities with respect to our clinical trials, manufacturing supply chain or sales and marketing activities; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Any adverse changes to our relationship with manufacturers or suppliers; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Any intellectual property infringement actions in which we may become involved; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Achievement of expected product sales and profitability or our failure to meet expectations; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Our commencement of, or involvement in, litigation; </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;&#160;&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Any major changes in our board of directors or management; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Our ability to recruit and retain qualified regulatory, research and development personnel; </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Legislation in the U.S. relating to the sale or pricing of medical devices; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The depth of the trading market in our Ordinary Shares and Warrants; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Economic weakness, including inflation, or political instability in particular foreign economies and markets; </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Business interruptions resulting from a local or worldwide pandemic or other health epidemic, geopolitical actions, including war and terrorism, or natural disasters; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The granting or exercise of employee share options or other equity awards; and </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Changes in investors and securities analysts&#8217; perception of the business risks and conditions of our business. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the stock market
in general, and Nasdaq in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate
to the operating performance of small companies. Broad market and industry factors may negatively affect the market price of our Ordinary
Shares and Warrants, regardless of our actual operating performance. Further, a systemic decline in the financial markets and related
factors beyond our control may cause our share price to decline rapidly and unexpectedly.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Future sales of our Ordinary Shares could
reduce the market price of our securities.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Substantial sales of our Ordinary
Shares on Nasdaq may cause the market price of our securities to decline. Sales by us or our security holders of substantial amounts of
our Ordinary Shares, or the perception that these sales may occur in the future, could cause a reduction in the market price of our securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The issuance of any additional
Ordinary Shares or any securities that are exercisable for or convertible into Ordinary Shares, may have an adverse effect on the market
price of our Ordinary Shares and will have a dilutive effect on our existing shareholders and holders of Ordinary Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 47 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our principal shareholders, officers and
directors currently beneficially own 18.01% of our Ordinary Shares. They may therefore be able to exert control over matters submitted
to our shareholders for approval.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 3, 2025, our principal
shareholders, officers and directors beneficially own approximately 18.01% of our Ordinary Shares. As a result, these shareholders, if
they acted together, could influence matters requiring approval by our shareholders, including the election of directors and the approval
of mergers or other business combination transactions. The interests of these shareholders may not always coincide with our interests
or the interests of other shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have never paid cash dividends on our
share capital, and we do not anticipate paying any cash dividends in the foreseeable future.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have never declared or
paid cash dividends, and we do not anticipate paying cash dividends in the foreseeable future. Therefore, you should not rely on an investment
in our securities as a source for any future dividend income. Our board of directors has complete discretion as to whether to distribute
dividends. Even if our board of directors decides to declare and pay dividends, the timing, amount and form of future dividends, if any,
will depend on our future results of operations and cash flow, our capital requirements and surplus, the amount of distributions, if any,
received by us from our subsidiaries, our financial condition, contractual restrictions and other factors deemed relevant by our board
of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The JOBS Act will allow us to postpone the
date by which we must comply with some of the laws and regulations intended to protect investors and to reduce the amount of information
we provide in our reports filed with the SEC, which could undermine investor confidence in our company and adversely affect the market
price of our securities.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For so long as we remain an
&#8220;emerging growth company&#8221; as defined in the JOBS Act, we take advantage of certain exemptions from various requirements that
are applicable to public companies that are not &#8220;emerging growth companies&#8221; including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the provisions of the Sarbanes-Oxley Act requiring that our independent registered public accounting firm provide an attestation report on the effectiveness of our internal control over financial reporting; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">any rules that may be adopted by the Public Company Accounting Oversight Board requiring mandatory audit firm rotation or a supplement to the auditor&#8217;s report on the financial statements.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to take advantage
of these exemptions until we are no longer an &#8220;emerging growth company.&#8221; We will remain an emerging growth company until the
earlier of (1) the last day of the fiscal year (a) following the fifth anniversary of the date of the completion of our IPO, (b) in which
we have total annual gross revenue of at least $1.235 billion, or (c) in which we are deemed to be a large accelerated filer, as defined
in the rule under the Exchange Act, and (2) the date on which we have issued more than $1.0 billion in non-convertible debt during the
prior three-year period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot predict if investors
will find our securities less attractive because we may rely on these exemptions. If some investors find our securities less attractive
as a result, there may be a less active trading market for our securities, and our market prices may be more volatile and may decline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>As a &#8220;foreign private issuer&#8221;
we are permitted, and intend, to follow certain home country corporate governance practices instead of otherwise applicable SEC and Nasdaq
requirements, which may result in less protection than is accorded to investors under rules applicable to domestic U.S. issuers.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our status as a foreign private
issuer also exempts us from compliance with certain SEC laws and regulations and certain regulations of Nasdaq, including the proxy rules,
the short-swing profits recapture rules, and certain governance requirements such as independent director oversight of the nomination
of directors and executive compensation. In addition, we are not required under the Exchange Act to file current reports and financial
statements with the SEC as frequently or as promptly as U.S. domestic companies whose securities are registered under the Exchange Act,
and we are generally exempt from filing quarterly reports with the SEC. Also, although the Israeli Companies Law, 5759-1999 and the regulations
promulged thereunder, or the Companies Law, requires us to disclose the annual compensation of our five most highly compensated senior
officers on an individual basis (rather than on an aggregate basis), this disclosure will not be as extensive as that required of a U.S.
domestic issuer. Furthermore, as a foreign private issuer, we are also not subject to the requirements of Regulation FD (Fair Disclosure)
promulgated under the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 48 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These exemptions and leniencies
will reduce the frequency and scope of information and protections to which you are entitled as an investor.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The determination of foreign
private issuer status is made annually on the last business day of an issuer&#8217;s most recently completed second fiscal quarter and,
accordingly, the next determination will be made with respect to us on June 30, 2025. In the future, we would lose our foreign private
issuer status if a majority of our shareholders, directors or management are U.S. citizens or residents and we fail to meet additional
requirements necessary to avoid loss of foreign private issuer status. The regulatory and compliance costs to us under U.S. securities
laws as a U.S. domestic registrant may be significantly higher.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be a &#8220;passive foreign investment
company,&#8221; or PFIC, for U.S. federal income tax purposes in the current taxable year or may become one in any subsequent taxable
year. There generally would be negative tax consequences for U.S. taxpayers that are holders of the securities if we are or were to become
a PFIC.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on the projected composition
of our income and valuation of our assets, we do not expect that we will be treated as a PFIC for 2024 and we do not expect to become
a PFIC in the future, although there can be no assurance in this regard. The determination of whether we are a PFIC is made on an annual
basis and will depend on the composition of our income and assets from time to time. We will be treated as a PFIC for U.S. federal income
tax purposes in any taxable year in which either (1) at least 75% of our gross income is &#8220;passive income&#8221; or (2) on average
at least 50% of our assets by value produce passive income or are held for the production of passive income. Passive income for this purpose
generally includes, among other things, certain dividends, interest, royalties, rents and gains from commodities and securities transactions
and from the sale or exchange of property that gives rise to passive income. Passive income also includes amounts derived by reason of
the temporary investment of funds, including those raised in a public offering. In determining whether a non-U.S. corporation is a PFIC,
a proportionate share of the income and assets of each corporation in which it owns, directly or indirectly, at least a 25% interest (by
value) is taken into account. The tests for determining PFIC status are applied annually, and it is difficult to make accurate projections
of future income and assets which are relevant to this determination. In addition, our PFIC status may depend in part on the market value
of the securities. Accordingly, there can be no assurance that we currently are not or will not become a PFIC in the future. If we are
a PFIC in any taxable year during which a U.S. taxpayer holds the securities, such U.S. taxpayer would be subject to certain adverse U.S.
federal income tax rules. In particular, if the U.S. taxpayer did not make an election to treat us as a &#8220;qualified electing fund&#8221;,
or QEF, or make a &#8220;mark-to-market&#8221; election, then &#8220;excess distributions&#8221; to the U.S. taxpayer, and any gain realized
on the sale or other disposition of our securities by the U.S. taxpayer: (1) would be allocated ratably over the U.S. taxpayer&#8217;s
holding period for our securities; (2) the amount allocated to the current taxable year and any period prior to the first day of the first
taxable year in which we were a PFIC would be taxed as ordinary income; and (3) the amount allocated to each of the other taxable years
would be subject to tax at the highest rate of tax in effect for the applicable class of taxpayer for that year, and an interest charge
for the deemed deferral benefit would be imposed with respect to the resulting tax attributable to each such other taxable year. In addition,
if the U.S. Internal Revenue Service, or the IRS, determines that we are a PFIC for a year with respect to which we have determined that
we were not a PFIC, it may be too late for a U.S. taxpayer to make a timely QEF or mark-to-market election. U.S. taxpayers that have held
our securities during a period when we were a PFIC will be subject to the foregoing rules, even if we cease to be a PFIC in subsequent
years, subject to exceptions for U.S. taxpayer who made a timely QEF or mark-to-market election. A U.S. taxpayer can make a QEF election
by completing the relevant portions of and filing IRS Form 8621 in accordance with the instructions thereto. We do not intend to notify
U.S. taxpayers that hold our securities if we believe we will be treated as a PFIC for any taxable year in order to enable U.S. taxpayers
to consider whether to make a QEF election. In addition, we do not intend to furnish such U.S. taxpayers annually with information needed
in order to complete IRS Form 8621 and to make and maintain a valid QEF election for any year in which we or any of our subsidiaries are
a PFIC. U.S. taxpayers that hold our securities are strongly urged to consult their tax advisors about the PFIC rules, including tax return
filing requirements and the eligibility, manner, and consequences to them of making a QEF or mark-to-market election with respect to our
securities in the event that we are a PFIC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be subject to securities litigation,
which is expensive and could divert management attention.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the past, companies that
have experienced volatility in the market price of their shares have been subject to securities class action litigation. We may be the
target of this type of litigation in the future. Litigation of this type could result in substantial costs and diversion of management&#8217;s
attention and resources, which could seriously hurt our business. Any adverse determination in litigation could also subject us to significant
liabilities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 49 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If securities or industry analysts do not
publish or cease publishing research or reports about us, our business or our market, or if they adversely change their recommendations
or publish negative reports regarding our business or our securities, our share price and trading volume could decline.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The trading market for our
securities will be influenced by the research and reports that industry or securities analysts may publish about us, our business, our
market or our competitors. We do not have any control over these analysts and we cannot provide any assurance that analysts will cover
us or provide favorable coverage. If any of the analysts who may cover us adversely change their recommendation regarding our securities,
or provide more favorable relative recommendations about our competitors, the price of our securities would likely decline. If any analyst
who may cover us were to cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial
markets, which in turn could cause the price of our securities or trading volume to decline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>You may experience future dilution as a
result of future equity offerings.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to raise additional
capital, we may in the future offer additional Ordinary Shares or other securities convertible into or exchangeable for Ordinary Shares
at prices that may not be the same as the price per share in this offering. We may sell shares or other securities in any other offering
at a price per share that is less than the price per share paid by investors in this offering, and investors purchasing shares or other
securities in the future could have rights superior to existing shareholders. The price per share at which we sell additional Ordinary
Shares, or securities convertible or exchangeable into Ordinary Shares, in future transactions may be higher or lower than the price per
share paid by investors in this offering.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may need additional financing in the
future. We may be unable to obtain additional financing or if we obtain financing it may not be on terms favorable to us. You may lose
your entire investment.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on our current plans,
we believe our existing cash and cash equivalents will be sufficient to fund our operating expense and capital requirements for the next
six months. We expect that we will require substantial additional capital to operate and to commercialize our products and we expect to
seek additional funds to enable us to fund our operations for the next twelve months. We may be unable to obtain additional funds through
financing activities, and if we obtain financing it may not be on terms favorable to us. If we are unable to obtain additional funds on
terms favorable to us, we may be required to cease or reduce our operating activities. If we must cease or reduce our operating activities,
you may lose your entire investment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have never paid cash dividends on our
share capital, and we do not anticipate paying any cash dividends in the foreseeable future.</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have never declared or
paid cash dividends, and we do not anticipate paying cash dividends in the foreseeable future. Therefore, you should not rely on an investment
in Ordinary Shares as a source for any future dividend income.&#160;Our board of directors has complete discretion as to whether to distribute
dividends. Even if our board of directors decides to declare and pay dividends, the timing, amount and form of future dividends, if any,
will depend on our future results of operations and cash flow, our capital requirements and surplus, the amount of distributions, if any,
received by us from our subsidiaries, our financial condition, contractual restrictions and other factors deemed relevant by our board
of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 50 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "><b>Risks Related to Israeli
Law and Our Operations in Israel</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; "><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Our principal executive
offices, most of our research and development activities and other significant operations are located in Israel, and, therefore, our results
may be adversely affected by political, economic and military instability in Israel, including the recent attack by Hamas and other terrorist
organizations from the Gaza Strip and Israel&#8217;s war against them.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Our
executive offices, corporate headquarters and principal research and development facilities are located in Israel. In addition, all of
our officers and directors are residents of Israel. Accordingly, political, economic and military and security conditions in Israel and
the surrounding region may directly affect our business. Any conflicts, political instability, terrorism, cyberattacks or any other hostilities
involving Israel or the interruption or curtailment of trade between Israel and its present trading partners could adversely affect our
operations. Ongoing and revived hostilities in the Middle East or other Israeli political or economic factors, could harm our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">In
October 2023, Hamas terrorists infiltrated Israel&#8217;s border with the Gaza Strip and conducted a series of attacks on civilian and
military targets. Following the attack, Israel&#8217;s security cabinet declared war against Hamas and a military campaign commenced in
the Gaza Strip. As of March 3, 2025, whether the ceasefire between Hamas and Israel will continue for the foreseeable future is subject
to further negotiations and diplomatic efforts. Other regional hostilities, since October 7, 2023, concurrently became more pronounced.
This includes and has included a northern front war between Israel and Hezbollah, which as of March 3, 2025 is subject to a ceasefire
between Israel and Lebanon, hostilities between Israel and Iran, which have included Iranian strikes against Israel in April 2024 and
October 2024, and subsequent retaliation by Israel to both instances, and a continued conflict between Israel and the Houthi Movement
in Yemen.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
vicissitudes of the multi-front conflict are difficult to predict, as are such conflict&#8217;s economic implications on the Company&#8217;s
business and operations and on Israel&#8217;s economy in general. The potential deterioration of Israel&#8217;s economy, as a direct and
indirect result of these events, may have a material adverse effect on the Company and its ability to effectively conduct its operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">In
connection with the current multi-front conflict, Israeli military reservists have been called up to perform military service, four of
our employees have been called up. One employee is engaged in reserve duty as of March 3, 2025. There can be no guarantee that other employees
will not be called up again. Not any of the employees called up holds a key position in our Company. Additional employees may be called
up, for service, and such persons may be absent for an extended period of time. As a result, our operations may be disrupted by such absences,
which in turn may materially and adversely affect our business, prospects, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
State of Israel and Israeli companies have been the subject of boycotts, divestment and sanctions in the past from state and non-state
actors. These actions could expand in number and scope and may have an adverse impact on our operating results, financial condition or
the expansion of our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
Israeli government has pursued extensive changes to Israel&#8217;s judicial system. In response to the foregoing developments, individuals,
organizations and institutions, both within and outside of Israel, have voiced concerns that the proposed changes may negatively impact
the business environment in Israel due in part to the reluctance of foreign investors to invest or transact business in Israel, increased
volatility in foreign exchange rates involving the Israeli new shekel, downgrades in the credit rating of Israel, increased volatility
in securities markets, and other changes in macroeconomic conditions. To the extent that any reaction to judicial reform affect the Israeli
economy, they may have an adverse effect on our business, our results of operations and our ability to raise additional funds, if deemed
necessary by our management and board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "></p><div>

</div><!-- Field: Page; Sequence: 51 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The termination or reduction of tax and
other incentives that the Israeli government provides to Israeli companies may increase our costs and taxes.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Israeli government currently
provides tax and capital investment incentives to Israeli companies, as well as grant and loan programs relating to research and development
and marketing and export activities. In recent years, the Israeli government has reduced the benefits available under these programs and
the Israeli governmental authorities may in the future further reduce or eliminate the benefits of these programs. We may take advantage
of these benefits and programs in the future; however, there can be no assurance that such benefits and programs will be available to
us. If we qualify for such benefits and programs and fail to meet the conditions thereof, the benefits could be canceled and we could
be required to refund any benefits we might already have enjoyed and become subject to penalties. Additionally, if we qualify for such
benefits and programs and they are subsequently terminated or reduced, it could have an adverse effect on our financial condition and
results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be required to pay monetary remuneration
to our Israeli employees for their inventions, even if the rights to such inventions have been duly assigned to us. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We enter into agreements with
our Israeli employees pursuant to which such individuals agree that any inventions created in the scope of their employment are either
owned exclusively by us or are assigned to us, depending on the jurisdiction, without the employee retaining any rights. A portion of
our intellectual property has been developed by our Israeli employees during their employment for us. Under the Israeli Patent Law, 5727-1967,
or the Patent Law, inventions conceived by an employee during the course of his or her employment and within the scope of said employment
are considered &#8220;service inventions.&#8221; Service inventions belong to the employer by default, absent a specific agreement between
the employee and employer otherwise. The Patent Law also provides that if there is no agreement regarding the remuneration for the service
inventions, even if the ownership rights were assigned to the employer, the Israeli Compensation and Royalties Committee, or the Committee,
a body constituted under the Patent Law, shall determine whether the employee is entitled to remuneration for these inventions. The Committee
has not yet determined the method for calculating this Committee-enforced remuneration. While it has previously been held that an employee
may waive his or her rights to remuneration in writing, orally or by conduct, litigation is pending in the Israeli labor court is questioning
whether such waiver under an employment agreement is enforceable. Although our Israeli employees have agreed that we exclusively own any
rights related to their inventions, we may face claims demanding remuneration in consideration for employees&#8217; service inventions.
As a result, we could be required to pay additional remuneration or royalties to our current and/or former employees, or be forced to
litigate such claims, which could negatively affect our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>We received Israeli
government grants for certain of our research and development activities, the terms of which may require us to pay royalties and to satisfy
specified conditions in order to manufacture products and transfer technologies outside of Israel. If we fail to satisfy these conditions,
we may be required to pay penalties and refund grants previously received.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our research and development
efforts have been financed in part through royalty-bearing and non-royalty-bearing grants in an aggregate amount of $1,095,000 that we
received from the IIA as of December 31, 2024. With respect to the royalty-bearing grants we are committed to pay royalties at a rate
of 3% on sales proceeds from our products up to the total amount of grants received, linked to the U.S. dollar and bearing interest. For
IIA grants approved by the IIA prior to January 1, 2024 but which are outstanding thereafter, as of January 1, 2024 the annual interest
is calculated at a rate based on the 12-month Secured Overnight Financing Rate, or SOFR, as published by the CME Group or any authorized
body of the Federal Reserve on the first trading day of each year, or at an alternative rate published by the Bank of Israel plus 0.71513%;
and, for grants approved on or following January 1, 2024 the annual interest will be the higher of (i)12 month SOFR, plus 1%, or (ii)
a fixed annual interest rate of 4%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Regardless of any royalty
payment, we are further required to comply with the requirements of the Israeli Encouragement of Industrial Research and Development Law,
5744-1984, as amended, and related regulations, or the Research Law, with respect to those past grants. When a company develops know-how,
technology or products using IIA grants, the terms of these grants and the Research Law restrict the transfer of such know-how, and the
transfer of manufacturing or manufacturing rights of such products, technologies or know-how outside of Israel, without the prior approval
of the IIA. Therefore, the discretionary approval of an IIA committee would be required for any transfer to third parties inside or outside
of Israel of know-how or manufacturing or manufacturing rights related to those aspects of such technologies. We may not receive those
approvals. Furthermore, the IIA may impose certain conditions on any arrangement under which it permits us to transfer technology or development
out of Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "></p><div>

</div><!-- Field: Page; Sequence: 52 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not be able to enforce covenants
not-to-compete under current Israeli law that might result in added competition for our products.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have non-competition agreements
with all of our employees, all of which are governed by Israeli law. These agreements prohibit our employees from competing with or working
for our competitors, generally during their employment and for up to 12 months after termination of their employment. However, Israeli
courts are reluctant to enforce non-compete undertakings of former employees and tend, if at all, to enforce those provisions for relatively
brief periods of time in restricted geographical areas, and only when the employee has obtained unique value to the employer specific
to that employer&#8217;s business and not just regarding the professional development of the employee. If we are not able to enforce non-compete
covenants, we may be faced with added competition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Provisions of Israeli
law and our amended and restated articles of association may delay, prevent or otherwise impede a merger with, or an acquisition of, us,
which could prevent a change of control, even when the terms of such a transaction are favorable to us and our shareholders.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Israeli
corporate law regulates mergers, requires tender offers for acquisitions of shares above specified thresholds, requires special approvals
for transactions involving directors, officers or significant shareholders and regulates other matters that may be relevant to such types
of transactions. For example, a merger may not be consummated unless at least 50 days have passed from the date on which a merger proposal
is filed by each merging company with the Israel Registrar of Companies and at least 30 days have passed from the date on which the shareholders
of both merging companies have approved the merger. In addition, a majority of each class of securities of the target company must approve
a merger. Moreover, a tender offer for all of a company&#8217;s issued and outstanding shares can only be completed if the acquirer receives
positive responses from the holders of at least 95% of the issued share capital. Completion of the tender offer also requires approval
of a majority of the offerees that do not have a personal interest in the tender offer, unless, following consummation of the tender offer,
the acquirer would hold at least 98% of our outstanding shares. Furthermore, the shareholders, including those who indicated their acceptance
of the tender offer, may, at any time within six months following the completion of the tender offer, claim that the consideration for
the acquisition of the shares does not reflect their fair market value, and petition an Israeli court to alter the consideration for the
acquisition accordingly, unless the acquirer stipulated in its tender offer that a shareholder that accepts the offer may not seek such
appraisal rights, and the acquirer or the company published all required information with respect to the tender offer prior to the tender
offer&#8217;s response date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Furthermore,
Israeli tax considerations may make potential transactions unappealing to us or to our shareholders whose country of residence does not
have a tax treaty with Israel exempting such shareholders from Israeli tax. For example, Israeli tax law does not recognize tax-free share
exchanges to the same extent as U.S. tax law. With respect to mergers, Israeli tax law allows for tax deferral in certain circumstances
but makes the deferral contingent on the fulfillment of a number of conditions, including, in some cases, a holding period of two years
from the date of the transaction during which sales and dispositions of shares of the participating companies are subject to certain restrictions.
Moreover, with respect to certain share swap transactions, the tax deferral is limited in time, and when such time expires, the tax becomes
payable even if no disposition of the shares has occurred. These provisions could delay, prevent or impede an acquisition of us or our
merger with another company, even if such an acquisition or merger would be beneficial to us or to our shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>It may be difficult
to enforce a judgment of a U.S. court against us and our executive officers and directors in Israel or the U.S., to assert U.S. securities
laws claims in Israel or to serve process on our executive officers and directors and these experts.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">We
were incorporated in Israel. Substantially all of our executive officers and directors reside outside of the U.S., and all of our assets
and most of the assets of these persons are located outside of the U.S. Therefore, a judgment obtained against us, or any of these persons,
including a judgment based on the civil liability provisions of the U.S. federal securities laws, may not be collectible in the U.S. and
may not be enforced by an Israeli court. It also may be difficult for you to effect service of process on these persons in the U.S. or
to assert U.S. securities law claims in original actions instituted in Israel. Additionally, it may be difficult for an investor, or any
other person or entity, to initiate an action with respect to U.S. securities laws in Israel. Israeli courts may refuse to hear a claim
based on an alleged violation of U.S. securities laws reasoning that Israel is not the most appropriate forum in which to bring such a
claim. In addition, even if an Israeli court agrees to hear a claim, it may determine that Israeli law and not U.S. law is applicable
to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must be proven as a fact by expert witnesses,
which can be a time consuming and costly process. Certain matters of procedure will also be governed by Israeli law. There is little binding
case law in Israel that addresses the matters described above. As a result of the difficulty associated with enforcing a judgment against
us in Israel, you may not be able to collect any damages awarded by either a U.S. or foreign court.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>


</div><!-- Field: Page; Sequence: 53 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Your rights and
responsibilities as a shareholder will be governed in key respects by Israeli laws, which differs in some material respects from the rights
and responsibilities of shareholders of U.S. companies.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
rights and responsibilities of the holders of our securities are governed by our amended and restated articles of association and by Israeli
law. These rights and responsibilities differ in some material respects from the rights and responsibilities of shareholders in U.S. companies.
In particular, a shareholder of an Israeli company has a duty to act in good faith and in a customary manner in exercising its rights
and performing its obligations towards the company and other shareholders, and to refrain from abusing its power in such company, including,
among other things, in voting at a general meeting of shareholders on matters such as amendments to a company&#8217;s amended and restated
articles of association, increases in a company&#8217;s authorized share capital, mergers and acquisitions and related party transactions
requiring shareholder approval, as well as a general duty to refrain from discriminating against other shareholders. In addition, a shareholder
who is aware that it possesses the power to determine the outcome of a vote at a meeting of the shareholders or to appoint or prevent
the appointment of a director or executive officer in the company has a duty of fairness toward the company. There is limited case law
available to assist us in understanding the nature of these duties or the implications of these provisions. These provisions may be interpreted
to impose additional obligations and liabilities on holders of our securities that are not typically imposed on shareholders of U.S. companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="I_012"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 4. <span style="text-transform: uppercase">INFORMATION ON THE
COMPANY</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="I_013"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt"><b>A.</b></span></td>
    <td><span style="font-size: 10pt"><b>History and Development of the Company.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.5pt; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">We
are an Israeli corporation based in Ra&#8217;anana, Israel and were incorporated in Israel in 2018 under the name Clearx Medical Ltd.
On April 10, 2018, our name was changed to Insense Medical Ltd. and on July 30, 2020, our name was changed to our current name, Inspira
Technologies Oxy B.H.N. Ltd. On July 16, 2021, our Ordinary Shares and the Warrants issued in our IPO began trading on Nasdaq under the
symbols &#8220;IINN&#8221; and &#8220;IINNW&#8221;, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Our
principal executive offices are located at 2 Ha-Tidhar St., Ra&#8217;anana, 4366504 Israel. Our telephone number in Israel is +972 996
644 88. Our website address is <i>www.inspira-technologies.com</i>. The information contained on our website or available through our
website is not incorporated by reference into and should not be considered a part of this annual report on Form 20-F, and the reference
to our website in this annual report on Form 20-F is an inactive textual reference only. Puglisi &amp; Associates is our agent in the
U.S., and its address is 850 Library Avenue, Suite 204, Newark, Delaware 19711.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.5pt; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are an &#8220;emerging
growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act of 1933, as amended, or the Securities Act, as modified by
the JOBS Act. As such, we are eligible to, and intend to, take advantage of certain exemptions from various reporting requirements applicable
to other public companies that are not &#8220;emerging growth companies&#8221; such as not being required to comply with the auditor attestation
requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act. We could remain an &#8220;emerging growth
company&#8221; for up to five years, or until the earliest of (a)&#160;the last day of the first fiscal year in which our annual gross
revenues exceeds $1.235&#160;billion, (b)&#160;the date that we become a &#8220;large accelerated filer&#8221; as defined in Rule&#160;12b-2
under the Exchange Act, which would occur if the market value of our Ordinary Shares that are held by non-affiliates exceeds $700&#160;million
as of the last business day of our most recently completed second fiscal quarter, or (c)&#160;the date on which we have issued more than
$1&#160;billion in nonconvertible debt during the preceding three-year period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a foreign private issuer
as defined by the rules under the Securities Act and the Exchange Act. Our status as a foreign private issuer also exempts us from compliance
with certain laws and regulations of the SEC and certain regulations of the Nasdaq Capital Market, including the proxy rules, the short-swing
profits recapture rules, and certain governance requirements such as independent director oversight of the nomination of directors and
executive compensation. In addition, we are not required to file annual, quarterly and current reports and financial statements with the
SEC as frequently or as promptly as U.S. domestic companies registered under the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the years ended December
31, 2024, 2023, and 2022 our capital expenditures were $164,000, $206,000, and $263,000, respectively. Our current capital expenditures
are primarily for computers, research and development equipment and office improvements substantially all in Israel, and we expect to
finance these expenditures primarily from cash on hand.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 54 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="I_014"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; font-size: 10pt"><span style="font-size: 10pt"><b>B.</b></span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt"><b>Business Overview.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Overview</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a specialty medical
device company engaged in the research, development, manufacturing, and marketing of proprietary life support technologies. We aim for
our technology to supersede and revolutionize the global mechanical ventilation market.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_011.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_012.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 55 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_013.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;<img alt="" src="image_014.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 56 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Mechanical Ventilation &#8211; Major Disadvantages</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Up to an estimated 20 million
patients each year in ICUs end up being treated on invasive mechanical ventilators, while mortality rates of patients undergoing prolonged
mechanical ventilation may reach above 50%. Patients are often put on mechanical ventilators when they cannot breathe for themselves and
experience acute respiratory failure, and require assisted breathing using a machine. Patients are placed under heavy sedation or coma
with a tube placed in the throat. The ventilator pushes oxygen-rich air into the lungs to get oxygen into the blood and to body organs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: center; width: 48%; font-size: 10pt"><img alt="" src="image_015.jpg" style="height: 293px; width: 288px"/></td>
    <td style="text-align: left; width: 52%; font-size: 10pt; vertical-align: middle"><p style="margin-top: 0; margin-bottom: 0">&#160;</p>
                                            <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roan, Times, Serif; font-size: 10pt"><b>Patient under heavy sedation&#160;(Coma)</b></span></p>
                                            <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">with tube pushed down their throat&#160;</span></p>
                                            <p style="margin-top: 0; margin-bottom: 0">&#160;</p>
                                            <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ventilator forces oxygen-rich air into the lungs</b> to get oxygen into the blood and to body organs</span></p>
                                            <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
                                            <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Patients can often experience legacy complications:</b> delirium, lung infections and injury or possible death. &#160;</span></p></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Mechanical Ventilation &#8211; Associated Medical Complications</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Patients can often experience
complications associated with the use mechanical ventilators, such as increased risk, costs of care, extended lengths of stay, frequent
incidence of infections, ventilator dependence and high mortality rates. Associated complications may include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify"><b>Bacterial Infections: </b>The tube in the patient&#8217;s
airways can bring bacteria into the lungs, causing infections like pneumonia.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify"><b>Lung Damage: </b>The pressure from the ventilator can damage
patient lungs.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify"><b>Collapsed Lung</b>: If part of patient lung is weak, it
might develop a hole, causing the lungs to collapse.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify"><b>Heart and blood flow changes</b>: Can decrease patient
blood pressure or raise patient heart rate, with less oxygen reaching the blood (decreased perfusion).</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify"><b>Prolonged Ventilation</b>: The tube from the mouth is replaced
with a tube inserted through a small cut (incision) in the patient neck.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify"><b>Prolonging the dying process</b>: If a patient is unlikely
to recover from its condition, mechanical ventilation may prolong the dying process. This can cause unnecessary suffering.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 57 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_016.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Our
novel technology could potentially assist those ICU patients who are placed on mechanical ventilators. To overcome the risks and
medical complication typically associated with mechanical ventilation, which requires intubation and placing patients into a
medically induced coma, the INSPIRA ART is designed to treat the patients while allowing patients to be awake. The INSPIRA ART
targets to boost oxygen saturation levels to 95% or higher in minutes with small volumes of blood, with the HYLA blood sensor
technology monitoring the patient&#8217;s blood parameters for the rapid detection of life-threatening medical conditions. Our
adaptive technology is designed to continuously monitor the patient&#8217;s blood parameters in real-time, enriching small volumes
of blood with oxygen and simultaneously removing carbon dioxide. Boosting oxygen saturation levels in minutes may allow patients to
be awake, potentially making the treatment suitable in the future to migrate from ICUs to emergency rooms, medical units, emergency
medical services and smaller rural hospitals.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_017.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">INSPIRA ART is designed to enable the
following features:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span><b>&#9679;</b></span></td><td style="text-align: justify"><b>Patient treated awake and without Mechanical Ventilation.
</b>No coma; no tube in the throat; potentially reduces hospital overnight stays.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span><b>&#9679;</b></span></td><td style="text-align: justify"><b>Oxygen is delivered straight into the blood, with carbon
dioxide removed</b>. No lung infection; no lung injury.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span><b>&#9679;</b></span></td><td style="text-align: justify"><b>Blood parameters measured continuously and in real-time</b>.
Early detection of changes; provides decision-making assistance data.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 58 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>Disruptive Blood Oxygenation Technology</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Designed to boost oxygen saturation levels in minutes, while patient
is awake</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
<tr style="vertical-align: top"><td style="text-align: left; width: 53%; font-size: 10pt"><img alt="" src="image_028.jpg"/></td>
    <td style="width: 47%; font-size: 10pt"><p style="margin-top: 0; margin-bottom: 0">&#160;</p>
                                            <p style="margin-top: 0; margin-bottom: 0">&#160;</p>
                                            <p style="text-align: justify; text-indent: -0.25in; margin-left: 0.25in; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;&#160;&#160;&#160;&#160;</span><span style="font-size: 10pt">HYLA&#8482; blood sensor technology is designed to continuously test and monitor patient&#8217;s blood and key parameters for oxygen deficiencies in real-time. </span></p>
                                            <p style="margin-top: 0; margin-bottom: 0">&#160;</p>
                                            <p style="text-align: justify; text-indent: -0.25in; margin-left: 0.25in; margin-top: 0; margin-bottom: 0">&#9679;&#160;&#160;&#160;&#160;<span style="font-size: 10pt">VORTX&#8482;
blood oxygenation technology is designed to target saturation levels, dissolve oxygen into the blood and remove carbon dioxide.</span></p>
                                            <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">&#160;</span></p>
                                            <p style="text-align: justify; text-indent: -0.25in; margin-left: 0.25in; margin-top: 0; margin-bottom: 0">&#9679;&#160;&#160;Designed to elevate patient saturation level as HYLA blood sensor technology continues to monitor the patient&#8217;s medical
condition, providing early alerts and decision-support data.</p></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>INSPIRA ART &#8211; Targeted Advantages </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our lead product candidate,
the INSPIRA ART system, is a form of life support designed to provide adaptive blood oxygenation while continuously measuring the patient&#8217;s
blood parameters in real-time, delivering needed oxygen volume straight into the blood to elevate and stabilize declining oxygen saturation
levels while the patient remains awake, mobile, and breathing spontaneously with their compromised lungs. The INSPIRA ART is being designed
to enable a patient&#8217;s body and vital organs to receive the necessary amount of oxygen. We intend for our INSPIRA ART system to be
a low-cost, high-volume solution for critical care patients requiring advanced respiratory support. It is intended to provide an alternative
to mechanical ventilation, so that patients with respiratory failure will be able to recover from their lung condition without being subjected
to the risk of developing the various common complications brought on by intubation and mechanical ventilation. Our goal is to support
healthcare systems by providing a practical and portable solution facilitating the treatment of respiratory failure, without the need
for mechanical ventilation, and with the ability to deploy INSPIRA ART systems in and outside of ICUs to an ambulatory treatment that
can be administered in all hospital wards as well as in ambulances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 59 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although our INSPIRA ART system
remains in development, has not been tested in humans, and is not cleared or approved by the FDA or other foreign regulatory bodies, we
believe that our INSPIRA ART has potential competitive advantages over FDA-approved treatments, which are discussed in the table below.
Subject to regulatory clearances, we believe that our product will enable small medical teams to perform a simple bedside procedure, inserting
our dual lumen cannula into the jugular vein. The INSPIRA ART is being designed to enable patients to be treated while awake and breath
spontaneously, which may also result in potentially reducing the need or time of weaning off the INSPIRA ART. Accordingly, our INSPIRA
ART system has the potential to minimize patients&#8217; lengths of stay and costs in the ICU, rehabilitation period in the hospital,
and re-admissions compared to mechanical ventilation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; "><img alt="" src="image_018.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While our INSPIRA ART system
could potentially have unique advantages in comparison to currently available solutions used to provide life support, there are numerous
potential risks that might be associated with the use of our INSPIRA ART system. Such risks may include low blood flow that could be associated
with generation of thrombi, mechanical damage to the superior vena cava, generation of a systemic inflammatory response due to bio-compatibility
issues, allergic reactions to catheter or its components, decreased venous returns, local venous bleeding following the extraction of
our INSPIRA ART system or erroneous puncture of an artery during the insertion of our product. Additionally, any foreign material in a
body increases the risk of infections and the patient&#8217;s membrane might be clogged for a short period of time. Finally, an individual
patient&#8217;s requirements for gas exchange might significantly differ from the average, which means that the use of our INSPIRA ART
system might not meet minimum requirements for blood saturation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">One of the main advantages
of our INSPIRA ART system is that there is no anticipated need for an induced coma because there is no intubation involved, and the treated
patient stays awake. Our INSPIRA ART system has yet to be tested in humans and, as such, these claims of a potential advantage in humans
are unproven and speculative.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 60 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">We have developed and continue to develop the
following technologies:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>The INSPIRA ART100</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The INSPIRA ART100 system
utilizes a technique that circulated the patient&#8217;s blood, adding oxygen to the blood and removes carbon dioxide, with the enriched
blood being circulated back to the patient, taking over the functionality of the heart and/or lungs in critical care patients undergoing
life-saving procedures.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Designed in collaboration
with leading U.S. clinicians, the INSPIRA ART100 cardiopulmonary bypass system revolutionizes extracorporeal blood circulation by combining
cutting-edge technology with intuitive design to optimize patient care during crucial times.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The INSPIRA ART100 is
planned to be integrated with the HYLA, a continuous blood monitoring technology designed to potentially detect real-time changes in
patient condition. The HYLA is undergoing clinical evaluations at Sheba Hospital in six patients undergoing open-heart procedures,
in preparation of our FDA submission of the first configuration of the HYLA&#8482; in the second half of 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The delivered INSPIRA ART100
systems will be distributed to sales targets across hospitals in the U.S., with a view to collaborating with such hospital. We believe
that the delivery of the INSPIRA&#160;ART100 in the U.S. market serves our goal is to introduce physicians and perfusionists to our technology
and brand via initial deployments at leading hospitals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The INSPIRA ART100 system&#8217;s
design and advanced capabilities provide a comprehensive platform of efficiency, compatibility and performance, enabling medical technologies
companies to refine and optimize the products for improved patient care. The system features advanced software that navigates the physician
through the setup process, provides alerts while offering potential troubleshooting solutions. The system has a compact design, with extended
battery life to support intra patient transfer in hospitals and is has been uniquely designed to compatible with various disposable parts,
allowing for flexible customization of tubing and oxygenators, which simplifies purchasing and inventory management.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
<tr style="vertical-align: top; text-align: left">
  <td style="width: 50%">&#160;<img alt="" src="image_019.jpg"/></td>
  <td style="text-align: center; width: 50%; vertical-align: middle">&#160;<img alt="" src="image_020.jpg"/></td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The INSPIRA ART100 has received
FDA 510(k) regulatory clearance for use in an extracorporeal perfusion circuit to pump blood during short-duration cardiopulmonary bypass
procedures lasting 6 hours or less.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In April 2024, we announced
a program to explore the applicable use of the INSPIRA ART100 for an artificial womb for neonates in need of respiratory support.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 61 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In April 2024, we announced
that we had signed a collaboration term sheet with Beilinson Hospital for the evaluation of the INSPIRA ART100, under which Beilinson
Hospital would provide us with access to the internally logged data and diagnostics from the use of it.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2025, we announced
that we were preparing for a potential ramp-up of the INSPIRA ART100 in light of the outbreak of human metapneumovirus in China.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2025, we further
announced that we had modified the INSPIRA ART100 to integrate a given hospital&#8217;s established procedures and safety practices and
to include system-activated alarm troubleshooting uniquely designed to provide valuable direction when time is of the essence and user
anxiety is running high. We also integrated a prominent screen with advanced software that displays information in an accessible and visible
manner during complicated and challenging care situations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt"><b>Inspira Proprietary software is being
designed to offer on-screen patient monitoring with in-depth clinical insights</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 50%; font-size: 10pt; text-align: justify"><p style="text-indent: 0.5in; margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">Our proprietary software that would offer on-screen patient monitoring with in-depth clinical insights is still being developed for testing.</span></p>
                                                                 <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">&#160;</span></p>
                                                                 <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt"><b>In-Depth Incident Analysis </b></span></p>
                                                                 <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">&#160;</span></p>
                                                                 <p style="text-indent: 0.5in; margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">Designed to enable thorough investigation of procedural events, promoting continuous learning and driving quality improvements within your team.</span></p></td>
    <td style="width: 50%; font-size: 10pt; text-align: center"><img alt="" src="image_021.jpg"/></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 50%; font-size: 10pt; text-align: justify"><p style="margin-top: 0; margin-bottom: 0"><b>Alarm Troubleshooting
                                            Tips</b></p>
                                                                 <p style="margin-top: 0; margin-bottom: 0">&#160;</p>
                                                                 <p style="text-indent: 0.5in; margin-top: 0; margin-bottom: 0">Designed to support quick
response times and helps reduce users&#8217; level of anxiety*.</p>
                                                                 <p style="margin-top: 0; margin-bottom: 0">&#160;</p>
                                                                 <p style="text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt">* Includes recommended steps adopted
                                                                 from &#8220;Extracorporeal Life Support: The ELSO Red Book&#8221;, 6th edition, chapter 7 - Circuit Malfunction and Crisis
                                                                 Management.</span></p></td>
    <td style="width: 50%; font-size: 10pt; text-align: center"><img alt="" src="image_022.jpg"/></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 62 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 50%; font-size: 10pt; text-align: justify"><b>On-screen procedure overview</b>
                                                                 <p style="margin-top: 0; margin-bottom: 0">&#160;</p>
                                                                 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Hospital-Customizable Checklists</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="text-indent: 0.5in; margin-top: 0; margin-bottom: 0">Designed to upload institutional procedures to ensure every step aligns
with practice routines and is executed precisely.</p>

                                                                 <p style="margin-top: 0; margin-bottom: 0"></p></td>
    <td style="width: 50%; font-size: 10pt; text-align: center"><img alt="" src="image_023.jpg"/></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 50%; font-size: 10pt; text-align: justify">
                                                                 <p style="margin-top: 0; margin-bottom: 0">&#160;</p>
                                                                 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Comprehensive Procedure Overview</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are designing a system that delivers a complete report, including
parameters trends and alarms, to enhance team communication and facilitate smooth information sharing.</p>

                                                                 <p style="margin-top: 0; margin-bottom: 0"></p></td>
    <td style="width: 50%; font-size: 10pt; text-align: center"><img alt="" src="image_024.jpg"/></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b>HYLA Blood Sensor</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_025.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 63 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">The HYLA is being designed
to continuously test and monitor blood and key parameters, including for oxygen deficiencies in real-time without the need to take intermittent
blood draws. The HYLA is designed to perform real-time analysis of blood gases for patients undergoing medical procedures or requiring
more frequent patient monitoring. The HYLA is designed to enable the measurement and tracking of blood oxygen levels and other key indicators
that may reflect sudden changes in medical conditions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">The HYLA is
currently being tested as part of the development strategy in a clinical evaluation study in a group of six patients undergoing
open-heart procedures at Sheba Hospital in Israel. The HYLA is designed to measure and accumulate thousands of sampled blood
parameter measurements during medical procedures, with the data being simultaneously validated against other types of blood tests
and equipment currently in use.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">The clinical evaluation validated
thousands of real-time samples from a single procedure without the need for blood draws. &#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">The HYLA may expand our market
offering across critical care applications and multiple market segments, designed for both integration and standalone use. The product
is being developed as an integrated component of the INSPIRA ART100 and INSPIRA ART systems.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">In developing the blood sensor
line, we use in-house lab testing as well as hospital collaborations for the purpose of clinical research and development. This approach
has enabled us to define the blood sensor&#8217;s disposable materials and methods. We also plan to offer a standalone version of the
HYLA blood sensor.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">In February 2025, we announced that we had integrated
the new oxygenation indicator into the HYLA, designed to enable the continuous monitoring of tissue oxygenation and early hypoxia detection.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-size: 10pt"><b>VORTX
Orbiting Blood Oxygenation Delivery System</b></span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">The VORTX represents a groundbreaking
advancement in blood oxygenation technology, having received the first U.S. patent approval for an orbiting blood oxygenation delivery
system. This innovation is comprised of 16 claims found to be novel. The VORTX technology is designed to enrich small volumes of blood
with oxygen while simultaneously removing carbon dioxide, achieving saturation levels of 95% or higher.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">The VORTX aims to oxygenate
blood without fiber membranes that exist in current blood oxygenators, known to cause harmful turbulence, friction, and sheer forces,
which result in significant damage to blood components and cells. Unlike the natural laminar blood flow in blood vessels inside the body,
in existing fiber oxygenators, the blood is &#8220;forced&#8221; to flow in a harmful turbulent flow through many layers of fibers while
experiencing friction and sheer forces with the fiber walls. Additionally, since the fiber fabric is a significant resistor to blood flow,
high-pressure differences between the oxygenator inlet and outlet are formed, resulting in significant damage to the various blood components,
including, high hemolysis (the breakdown of red cells), damage to white blood cells, activation of the inflammatory system in the body,
activation of the immune system, and blood clotting. In September 2024, we received an additional U.S. patent allowance
for the VORTX. In January 2025, we unveiled the modular configuration for the VORTX.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">We believe that the VORTX
is another game-changing core technology that will be part of the INSPIRA ART system and has the potential to revolutionize the medical
landscape.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 64 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt"><b>Dual Lumen Cannula</b></span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><img alt="" src="image_026.jpg"/>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">The proprietary
dual lumen cannula design is subject to a patent comprised of 16 novel and unique claims, offering a novel approach to intravascular access
and manipulation. The key innovation lies in the cannula&#8217;s ability to intravascularly convert from a single-lumen to a dual-lumen
configuration after initial insertion, all through the same incision point. This design eliminates the traditional need for multiple incisions
when changing or adding cannulas, potentially reducing patient risk, complications and infection points.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">Our cannula <sub>&#160;</sub>has
numerous proprietary characteristics that makes it superior in comparison to existing commercial cannulas, such as small diameter 16-21Fr
(depending on flow rate required) that allows the lumen to be injected directly into a patient&#8217;s jugular vein while the patient
is awake and breathing spontaneously, short length that eliminates the need for positioning that requires fluoroscopy or other imaging
and simplicity of cannulation and application. The cannula has the potential to as an essential tool in a wide range of medical settings
a dual-lumen cannula is often used for the simultaneous venous drainage and reinfusion of blood during processes such as ECMO in ICUs.
The cannula device may potentially allow for fast action and reduced risk, complications and additional infection points.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-size: 10pt"><b>Disposables</b></span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in">We are also progressing
in our plan to launch single-use disposables to be used during the blood oxygenation procedure, currently in development, for our INSPIRA
ART system, with the design potentially suitable for use with the INSPIRA ART100. The disposables are intended to be compatible with various
other life support machines, tapping into the disposable perfusion systems market. The disposables, anticipated to be submitted to the
FDA for marketing clearance in 2025 for the disposable blood flow technology and in 2026 for the disposable blood oxygenation technology,
are a single-use product designed to be used for efficient blood circulation, blood oxygenation and carbon dioxide removal. The disposables
have the potential to become a recurring revenue model. We are focusing on making the disposables compatible with other medical devices
such as certain types of cardio-pulmonary bypass machines. In October 2024, we announced that we are developing a new disposable kit,
or the Kit, with a built-in performance monitoring mechanism. The Kit is being developed as a single-use product designed to identify
and alert users on changes in the performance of a key disposable used during operations and treatment. The Kit is designed
to support improved safety during the procedure</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.2pt; text-align: justify; text-indent: 21.8pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 65 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>INSPIRA Cardi-ART</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2024, we introduced
plans to develop the INSPIRA Cardi-ART, which aims to provide oxygen to the brain during cardiac arrest. The INSPIRA Cardi-ART is
being designed for fast emergency response during cardio-pulmonary resuscitations in and outside of hospitals, allowing for the delivery
of oxygenated blood throughout the body to reduce damage to the heart and brain during cardiac arrest. It is being designed to monitor
key vital parameters using the groundbreaking HYLA blood sensor technology. The INSPIRA Cardi-ART, being designed as part of the ART system,
offers quick hemodynamic support in the case of cardiac failure as it drains blood, exchanges gases, and then returns the blood to the
arterial system to maintain systemic perfusion. The technique has been used in other procedures that have been recommended in medical
guidelines as set out by the American Heart Association. We plan to complete the regulatory submission of the INSPIRA Cardi-ART by early
2026.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Clinical Studies and Expected Regulatory Strategy</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Our
regulatory strategy is to submit certain key technologies and key components for 510(k) pathway clearance based on the assumption that
we do not currently expect to require human trials for FDA clearance. This strategy both provides verification and validation testing
as well as anticipated FDA clearance of key elements that may be integrated as important technologies in our INSPIR ART system, or other
product candidates. Taking this approach is expected to potentially reduce risk certain factors in the planned pivotal clinical studies
for the INSPIRA ART system with a view to submitting an application for regulatory clearance from the FDA Approval through an expected
PMA or De Novo regulatory pathway.&#160;&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">In
January 2022, we listed a component of our INSPIRA ART and INSPIRA ART100 systems on the FDA Class I 510(k) exempt list. The component
is intended to reduce the potential complications associated with jugular vein cannula movement, occurring during a change of a patient&#8217;s
posture in bed and/or during transportation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2023, we announced
the first in-human study of a patient undergoing open-heart surgery in the HYLA research clinical study at Sheba Medical Center in Israel.
The HYLA research clinical study is a first in-human study designed to compare parameters measured by the non-invasive HYLA sensor to
a standard blood gas analyzer that requires blood draw from the patient. Continued data collection will further support the final product
design and part of the development process.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">In
July 2023, we announced that we received&#160;International Organization for Standardization, or ISO, 13485:2016 Standard Certification,
which is the international standard for quality management systems within the medical device industry, and a requirement for EU regulatory
approval. The ISO certification encompasses key aspects, including design, development, manufacturing, distribution and sales of extracorporeal
and blood monitoring devices and respiratory care devices.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">In
May 2024, we received 510(k) class II regulatory clearance from the FDA for the INSPIRA ART100 system. The INSPIRA ART100 System is FDA
510(k)-cleared for use in an extracorporeal perfusion circuit to pump blood during short-duration cardiopulmonary bypass procedures lasting
6 hours or less. The system has been deployed to the U.S. as part of a clinical evaluation agreement through our distributor, Glo-Med.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Milestones Achieved in 2024 and early 2025
include:</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="padding: 0pt; width: 0.5in; text-align: justify; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; width: 0.25in; text-align: justify; text-indent: 0pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-size: 10pt">We delivered INSPIRA ART100 systems to our distributor in the U.S. for deployment. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-size: 10pt">We expanded the HYLA measured parameters for rapid detection of serious medical conditions. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-size: 10pt">We collaborated with Westchester Medical Center to evaluate INSPIRA ART100 functionality and performance in clinical scenarios.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-size: 10pt">We secured a second U.S. patent
    approval for VORTX, the orbiting blood oxygenation delivery system.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="padding: 0pt; text-align: justify; text-indent: 0pt"><span style="font-size: 10pt">We were approached by a medical company to evaluate the INSPIRA ART100, with results exceeding 100% of the standard value for gas transfer at maximum flow, as indicated in the product&#8217;s specification when integrated with the INSPIRA&#8482; ART100 system. </span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 66 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">We received AMAR certification for the INSPIRA ART100 system. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">We received FDA 510(k) clearance for the INSPIRA ART100.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#9679;</td>
    <td style="text-align: justify">We started production of the INSPIRA ART100 in May 2024.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">We and Ennocure MedTech Ltd. collaboratively conducted an in-vitro study, showing up to 100% prevention of bacterial growth that may cause bloodstream infections.</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">We received a first U.S. patent approval for an orbiting blood oxygenation delivery system.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#9679; </td>
    <td style="text-align: justify">We announced plans to launch and target a single-use disposable blood oxygenation kit for the disposable perfusion market.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#9679;</td>
    <td style="text-align: justify">We showcased our technology at Arab Health 2025 in Dubai in January 2025.</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While we intend to execute
strategic distribution agreements, there is no guarantee any sales will occur pursuant to those existing agreements, and agreements that
may be executed in the future. The pre-conditional distribution agreements are for a period of up to seven years and subject to completion
of development, and the required regulatory approvals or clearances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.9pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Targeted Milestones (2025-2026):</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.9pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are targeting strategic
collaborations with leading hospitals and medical device companies as part of the company&#8217;s business strategy to develop the market
with the INSPIRA ART100, HYLA Blood Sensor and INSPIRA ART Disposables (Kits compatible with the INSPIRA ART100) in preparation of the
INSPIRA ART system being targeting to replace the need for mechanical ventilators.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.9pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt; ">HYLA Compatible with INSPIRA ART100 - planned FDA submission for regulatory clearance (</span><span style="font-size: 10pt">second half of 2025<span>)</span></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt; ">INSPIRA ART100 - First in-patient use in U.S. </span><span style="font-size: 10pt">(first half of 2025)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt; ">INSPIRA
ART 100 - First reported revenue </span><span style="font-size: 10pt">(first half of 2025).</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt; ">INSPIRA
ART - Additional U.S. hospital deployments </span><span style="font-size: 10pt">(first half of 2025) <span>INSPIR
ART &#8211; Business Development Event (2025)</span></span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt; ">INSPIRA
ART - Business development event (2025) INSPIR ART, Blood Flow Disposable &#8211; Planned FDA submission for clearance (H2-2025)</span><span style="font-size: 10pt">.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt; ">INSPIRA
ART - Blood flow disposable - planned FDA submission for clearance (</span><span style="font-size: 10pt">second half of 2025<span>)
INSPIR ART &#8211; Business Development Event (2025).</span></span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>INSPIRA
ART &#8211; Potential patent grant for blood flow technology (</span>second half of 2025<span>)</span>.</p></td>
    </tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    </tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>INSPIRA
ART - </span>Planned submission for clearance in preparation of filing for pilot study <span>(</span>first
half of 202<span>6)</span>&#160;</p></td>
    </tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    </tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt; ">INSPIRA ART - Blood oxygenation
    disposable</span><span style="font-size: 10pt"> <span>- Planned FDA submission for clearance
    (</span>second half of 2026<span>)</span></span></td>
    </tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 67 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>INSPIRA ART</b> - <b>Market Opportunity</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The World Health Organization
estimates that in 2017, over 400 million people globally were affected by respiratory insufficiency. Approximately 20 million patients
annually are admitted to ICUs, requiring acute respiratory care. The respiratory care devices market size is expected to reach $29.86
billion in 2025, from $16.09 billion in 2019. The major factors influencing this growth include the high prevalence of respiratory
diseases, the rapid growth of the aging population, the high prevalence of smoking, rising urbanization and pollution levels, the increasing
incidence of pre-term births and lifestyle changes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>Go To Market Strategy</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Our
go-to-market strategy is based upon providing affordable products, based on a razor-blade business model based on disposables and software
licensing to maximize our market reach while enhancing affordability and accessibility to medical care worldwide. We focus on this effort
comprehensively, understanding a multidisciplinary marketing and business approach is necessary to achieve our goals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; "><img alt="" src="image_027.jpg"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; "><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>Our go-to-market strategy includes, but
is not limited to:</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b><i>Pursuing world-wide regulatory approvals</i></b><i>: </i>we plan to pursue regulatory approvals in North America, Europe, Asia, Central America, South America, and Africa. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b><i>Collaborating with leading medical centers and health organizations</i></b>: we are working with leading medical centers and health organizations as part of our strategy toward reaching regional deployment of our products. This also includes collaborations with top ranked hospitals to expose our INSPIRA ART systems to physicians and the healthcare industry. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b><i>Identifying potential customer profiles</i></b>: we will be targeting leading medical centers, group purchasing organizations and medical device companies with a need for updated or revolutionary life support solutions. We believe that due to many recalls within the perfusionist market, and a lack of innovation in the sector, we are identifying potential customers searching for a different experience and result.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b><i>Strategic partners</i></b>: we have entered into agreements with medical device companies, manufacturers, distributors. We intend to target similar agreements with distributors in additional territories across the globe, including the U.S., Europe, and Asia.&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b><i>Investing in marketing and public relations to increase awareness of our solution</i></b>: in order to drive market demand for the INSPIRA ART, we are introducing the INSPIRA ART100, to be followed by disposables and the HYLA Blood Sensor (also to be integrated with the INSPIRA ART100). We hope to introduce the industry, as we have in conferences such as the 2024 Annual Extracorporeal Life Support Organization conference&#160;&#160;, to the caliber of technology and devices that we plan to offer. To-date, the INSPIRA ART 100 system has received FDA 510(k) clearance and the INSPIRA ART system is currently in development. The systems have not been used or tested in humans.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b><i>Garnering appropriate reimbursement and insurance coverage</i></b>: it is paramount for us to receive reimbursement and insurance coverage to enable hospitals and medical centers to provide treatment utilizing our products. With intensive care becoming increasingly expensive, the INSPIRA ART may provide treatment at significantly reduced cost and without compromising quality of care to patients. We are working on a health economics model as part of the reimbursement strategy. Our goal is to publish medical literature to provide the Centers for Medicare and Medicaid Services actual data, presented by us together with top-ranking hospitals.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "></p><div>

</div><!-- Field: Page; Sequence: 68 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>Working on Collaborations </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">In
December 2022, we entered into an exclusive OEM agreement with Terumo Cardiovascular. The agreement provides for the manufacture of a
disposable flow mechanism that may be distributed with our INSPIRA ART systems.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>&#160;&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, in November 2023,
we entered into a collaboration agreement with Ennocure, a pioneer in the development of bioelectronic wound dressing, for the development
of a proprietary bio-electronic treatment to prevent associated bloodstream infections in ICU patients. The aim of the collaboration is
to research the prevention of growth of bacteria that often results from cannula insertion and is associated with bloodstream infection
(sepsis). Once developed, we plan to combine the bio-electronic novel physical stimulation technology, as a preemptive measure for potentially
at-risk patients, providing a cost-competitive solution to reduce complications. It is estimated that 250,000 bloodstream infections related
to intravenous lines occur worldwide each year, leading to prolonged hospital stays and increasing healthcare costs. In April 2024, we
announced positive results from our collaborative development which showed a 75% reduction in bacterial growth four hours after the application
of the treatment and a 100% reduction within 24 hours. The in vitro study was carried out at the Hebrew University of Jerusalem and involved
testing bioelectric patches in an in vitro environment. As part of the in vitro study, bacteria were cultured and spread on agar in petri
dishes. The bioelectric patch was then applied to the agar plate and activated for a pre-specified duration. Following the procedure,
the agar plates were transferred to an incubation chamber for 24 hours and thereafter examined.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2025, we announced our collaboration
with Zriha Medical Ltd to establish a dedicated production line for a crucial component of our innovative respiratory support system.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>Working to Establish Distribution Partners
Around the World</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">We
seek to enter into strategic distribution agreements internationally to collaborate with local distribution networks to form a platform
for implementation of our go-to-market strategy. Distribution companies with which we have already entered into such agreements include
Innovimed (covering all European countries), Bepex, WAAS Group (covering Spain and Portugal), Glo-Med (covering Texas, New Jersey, New
York, Florida, North Carolina, South Carolina and Gulf States) and CIO MED GROUP (covering Central America). The agreements are for a
period of three to seven years and are conditional on the completion of product development and receipt of regulatory approvals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While we intend to execute
strategic distribution agreements, there is no guarantee any sales will occur pursuant to those existing agreements, and agreements that
may be executed in the future. The pre-conditional distribution agreements are for a period of up to seven years and subject to completion
of development, and the required regulatory approvals or clearances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In October 2021, we entered
into an exclusive distribution agreement with WAAS Group, one of Spain&#8217;s leading distributors and technical service providers of
medical equipment and supplies. According to the agreement, WAAS Group is committed to purchase a minimum of 1,040 INSPIRA ART systems
and 35,360 disposable units for deployment at hospitals and medical centers within a seven-year period, subject to regulatory approval
for the sale and marketing of the INSPIRA ART systems in Spain and Portugal.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">In
December 2021, we entered into an exclusive summary distribution agreement with Innovimed, a master distributor specializing in state-of-the-art
medical solutions in Eastern Europe, Middle East and Africa. The agreement has an initial term of 7 years, subject to completion of product
development and regulatory approval. The parties will collaborate on the marketing and deployment of the INSPIRA ART system. In order
to maintain exclusivity in the territory, Innovimed has committed to purchase minimum orders of 1,552 INSPIRA ART systems and 59,040 disposable
units for deployment at hospitals and medical centers, subject to regulatory approvals for the sale and marketing of the INSPIRA ART systems
in Poland, Czech Republic and Slovakia. In August 2023, we entered into an agreement expansion with Innovimed to collaborate towards clinical
trials for Inspira ART respiratory systems, which covers any European country.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 69 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2022, we entered
into an exclusive summary distribution agreement with Glo-Med, a U.S company that aims to meet the continuously growing demand for innovative
medical devices and related products, for distribution across six states in the U.S. (Texas, New Jersey, New York, Florida, North Carolina,
and South Carolina). The summary distribution agreement will be followed by a more comprehensive agreement. The agreement entered with
Glo-Med has an initial term of seven years, subject to the completion of product development and relevant regulatory approval. The parties
will collaborate on the marketing and deployment of the INSPIRA ART. Pursuant to the agreement, and in order to maintain exclusivity in
the territory, Glo-Med has committed to purchase a minimum order of 2,121 INSPIRA ART systems and 131,413 disposable units for deployment
at hospitals and medical centers over a period of seven years, subject to regulatory approvals for the sale and marketing of the INSPIRA
ART systems in the six states in the U.S. Pursuant to the agreement with Glo-med, Inspira shipped five systems to hospitals in the U.S.,
including a cardiothoracic surgery division at a leading hospital in New York.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In April 2022, we entered
into a summary distribution agreement with Bepex that includes the potential future deployment of our INSPIRA ART systems, designed to
prevent the need for invasive mechanical ventilation. Bepex is a leading Israeli medical technology company that imports, markets and
services medical equipment for global medical device companies such as Hamilton (mechanical ventilators) and LivaNova (ECMO systems).
As part of the collaboration with Bepex, the first systems are slated for deployment at the largest medical centers in Israel. The summary
distribution agreement with Bepex is expected to be followed by a more comprehensive agreement. The agreement has an initial term of seven
years, subject to the completion of product development and relevant regulatory approvals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2022, we entered into
an exclusive summary distribution agreement with Glo-Med, for the distribution of the HYLA blood sensor device and disposable units across
six states in the U.S. (Texas, New Jersey, New York, Florida, North Carlina and South Carolina). The summary distribution agreement will
be followed by a more comprehensive agreement. The agreement has an initial term of three years, subject to completion of product development
and regulatory approvals. The parties will collaborate on the marketing and deployment of the HYLA blood sensor. Pursuant to the agreement,
and in order to maintain exclusivity in the territory, Glo-Med has committed to purchase a minimum order of 3,889 HYLA blood sensors and
264,873 disposable units for deployment at hospitals and medical centers, subject to regulatory approvals for the sale and marketing of
the HYLA blood sensor device in the six states within the U.S.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2022, we entered
into an exclusive summary distribution agreement for the HYLA blood sensor with Innovimed. The summary distribution agreement would be
followed by a more comprehensive definitive agreement. The agreement has an initial term of five years, subject to the completion of product
development and the receipt of regulatory approvals. The parties will collaborate on the marketing and deployment of the HYLA blood sensor.
In order to maintain exclusivity in the territory, Innovimed has committed to purchase a minimum order of 1,364 HYLA blood sensors and
128,511 disposable units for deployment in hospital units and operating theaters in Poland, Czech Republic and Slovakia.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In October 2023, we entered
into an exclusive summary distribution agreement for the INSPIRA ART systems and disposable kits with CIO MED GROUP in Central America.
The Agreement to potentially generate $28 million, mainly in recurring revenues from disposable kits over five years, subject to the receipt
of regulatory approval.&#160;In addition to the INSPIRA ART100 system intended for patients undergoing CPB procedures, the Agreement also
includes both the flagship INSPIRA&#160;ART systems and HYLA&#160;Blood Sensor Technology, as well as disposable kits to be used with
these Inspira Technologies devices in the procedures.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2024, we entered
into a summary distribution agreement to enter Gulf States with Glo-Med for deployment of 531 INSPIRA ART systems. The agreement will
potentially provide Inspira Technologies with $32.6 million over a 5-year period, subject to regulatory approvals. Under such Agreement,
Glo-Med shall be designated as the Company&#8217;s distributor in Saudi Arabia, United Arab Emirates and Bahrain. We believe that Saudi
Arabia&#8217;s dual strategy to invest $65 billion and further privatize its healthcare sector, or Vision 2030, signals that the Territory
is a burgeoning market for medical innovation. The summary distribution agreement will be followed by a more comprehensive agreement.
Under the Agreement, Glo-Med shall undertake the role of Territory wholesale distributor, involving the promotion, marketing and sale
of the INSPIRA ART system, the INSPIRA ART system Disposable Kit, the INSPIRA ART100 System and the INSPIRA ART100 Disposable Kit, to
approved customers in the Territory. Glo-Med shall be the exclusive Territory distributor provided that it meets the minimum purchase
targets amounting to 531 INSPIRA ART systems and 8,794 disposable units from when the relevant regulatory approvals for the devices in
the Territory are granted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2024, we announced
that we had received the first ever purchase order for five INSPIRA ART100 systems in the U.S. from Glo-Med, which included an option
for the additional purchase of 20 units. In December 2024, we announced that the units were shipped and delivered in fulfillment of the
purchase order.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In October 2024, we entered
into a distribution agreement with Glo-Med to use its distribution facility as a support center for the deployment of the INSPIRA ART100
in the U.S.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 70 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While we intend to execute
on strategic distribution agreements, there is no guarantee any sales will occur pursuant to those existing agreements, and agreements
that may be executed in the future. The pre-conditional distribution agreements are for a period of up to seven year and subject to completion
of development, and the required regulatory approvals or clearances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>Third-Party Reimbursement</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 3, 2025, we do
not have any third-party reimbursement agreements. We aim to use existing CPT Codes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>Intellectual Property
</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We seek patent protection
as well as other effective intellectual property rights for our products and technologies in the U.S. and internationally. Our policy
is to pursue, maintain and defend intellectual property rights developed internally and to protect the technology, inventions and improvements
that are commercially important to the development of our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our intellectual property
portfolio consists of seven patent families that include four granted patents, three in the USA and one in Israel; four International
Patent Applications (PCT), three of which are exhausted, and nineteen pending patent applications that include six U.S. utility and one
US provisional patent applications, three European patent applications and nine additional national phase filings (two in Republic of
Korea, two in Israel, two in Japan and one application in each of Australia, Brazil and Canada.) Our portfolio also includes four registered
Israeli trademarks for &#8216;INSPIRA&#8217; text and logo, for &#8216;INSPIRA ART&#8217;, and for our slogan &#8216;INSPIRA. BREATHING
EMPOWERED.&#8217;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Extracorporeal oxygenation system (Initiation
Module)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A novel automated self-priming
module designed for the INSPIRA ART system, this unique innovative operating module further expands the INSPIRA ART system advancement
to potentially ensure patient safety with a proprietary built-in self-automated priming module aimed to ensure an emboli-free connection
to the patient&#8217;s vascular system, thereby potentially reducing risks of the formation of clots that reduces blood flow. The patent
consists of nine distinct claims, all deemed novel with inventive merit and practical applicability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>A blood-gas exchange device and methods of
use</b> - Orbiting blood oxygenation delivery system (VORTX)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This innovation has 16 claims
found to be novel and is designed to oxygenate blood without fiber membranes, and we believe it is expected to revolutionize the medical
landscape. The current fiber technologies used for blood oxygenation cause substantial damage to the patient&#8217;s blood cells. Unlike
the natural laminar blood flow in blood vessels inside the body, in existing fiber oxygenators, the blood is &#8220;forced&#8221; to flow
in a harmful turbulent flow through many layers of fibers while experiencing friction and shear forces within the fiber walls. Since the
fiber fabric is a significant resistor to blood flow, high-pressure differences are formed and cause significant damage to the various
blood components, including, high hemolysis, damage to white blood cells, activation of the inflammatory system in the body, activation
of the immune system, and blood clotting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Dual lumen cannula and methods of use</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The granted U.S. patent approval
includes 20 claims. Inspira&#8217;s convertible dual lumen cannula device uniquely intravascularly converts a single-lumen cannula into
a dual lumen cannula after initial insertion, thus allowing for the same incision point to potentially have multiple uses. The convertible
dual lumen cannula is designed to allow for switching from a single lumen to a dual lumen cannula, and vice versa, without the need for
new incisions required when changing or adding additional cannulas. Inspira&#8217;s convertible dual lumen is designed to potentially
allow for fast action and reduced risk, complications and additional infection points.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Cannula fixation device</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The component is intended
to reduce the potential complications associated with jugular vein cannula movement, occurring during a change of a patient&#8217;s posture
in bed and/or during transportation. The component can also be potentially utilized in the treatment of thousands of patients being treated
each year by through ECMO. This component is expected to allow the medical staff a safer mobilization for the awake cannulated patients
within and between hospitals and medical centers. A patent was granted in Israel for this device.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 71 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table comprises
our technology patents:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="border-bottom: black 1.5pt solid; text-align: left; vertical-align: bottom; width: 23%"><span style="font-size: 10pt"><b>Application;
    Publication No.</b></span></td>
    <td style="text-align: center; width: 1%; vertical-align: bottom"><b>&#160;</b></td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 39%; text-align: center"><span style="font-size: 10pt"><b>Title</b></span></td>
    <td style="text-align: center; width: 1%; vertical-align: bottom"><b>&#160;</b></td>
    <td style="white-space: nowrap; border-bottom: black 1.5pt solid; vertical-align: bottom; width: 15%; text-align: center"><span style="font-size: 10pt"><b>Effective
    Filing&#160;Date</b></span></td>
    <td style="text-align: center; width: 1%; vertical-align: bottom"><b>&#160;</b></td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 20%; text-align: center"><span style="font-size: 10pt"><b>Status</b></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">IL 286271</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">A Cannula Fixation Device</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">10 Sep 2021</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">GRANTED</span></td></tr>
  <tr>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">PCT/IL2022/050902</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">A Cannula Fixation Device</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">18 Aug 2022</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">EXHAUSTED</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">EP 22856981.0; 4185347</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">A Cannula Fixation Device</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">18 Aug 2022</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">PENDING</span></td></tr>
  <tr>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">US 17/931,134</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">A Cannula Fixation Device</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">11 Sep 2022</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">PENDING</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">EP 21891360.6; 4199990</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">Dual Lumen Cannula and Methods of Use</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">10 Nov 2021</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">PENDING</span></td></tr>
  <tr>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">IL 302851</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">Dual Lumen Cannula and Methods of Use</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">10 Nov 2021</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">PENDING</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">JP 2023550749; 2023548436</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">Dual Lumen Cannula and Methods of Use</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">10 Nov 2021</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">PENDING</span></td></tr>
  <tr>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">KR 10-2023-7019401; 20230107622</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">Dual Lumen Cannula and Methods of Use</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">10 Nov 2021</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">PENDING</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">US 11,541,159</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">Dual Lumen Cannula and Methods of Use</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">10 Nov 2021</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">GRANTED</span></td></tr>
  <tr>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">US 18/062,610; 2023/0095678</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">Transformable Dual Lumen Cannula into a Single Lumen Cannula and Methods of Use</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">10 Nov 2021</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">PENDING</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">AU 2021390218</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">Extracorporeal Oxygenation System for Low Flow Rates and Methods of Use</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; white-space: nowrap; text-align: center"><span style="font-size: 10pt">1 Dec 2021</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">PENDING</span></td></tr>
  <tr>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">BR 112023010627-3</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">Extracorporeal Oxygenation System for Low Flow Rates and Methods of Use</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; white-space: nowrap; text-align: center"><span style="font-size: 10pt">1 Dec 2021</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">PENDING</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">CA 3200492</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">Extracorporeal Oxygenation System for Low Flow Rates and Methods of Use</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; white-space: nowrap; text-align: center"><span style="font-size: 10pt">1 Dec 2021</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">PENDING</span></td></tr>
  <tr>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: center; white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: center; vertical-align: top">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">EP 21900219.3; 4228717</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">Extracorporeal Oxygenation System for Low Flow Rates and Methods of Use</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; white-space: nowrap; text-align: center"><span style="font-size: 10pt">1 Dec 2021</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">PENDING</span></td></tr>
  <tr>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">IL 303362</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">Extracorporeal Oxygenation System for Low Flow Rates and Methods of Use</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; white-space: nowrap; text-align: center"><span style="font-size: 10pt">1 Dec 2021</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">PENDING</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">JP 2023533325; 2023552754</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">Extracorporeal Oxygenation System for Low Flow Rates and Methods of Use</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; white-space: nowrap; text-align: center"><span style="font-size: 10pt">1 Dec 2021</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">PENDING</span></td></tr>
  <tr>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">KR 10-2023-7022195; 20230118594</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">Extracorporeal Oxygenation System for Low Flow Rates and Methods of Use</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; white-space: nowrap; text-align: center"><span style="font-size: 10pt">1 Dec 2021</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">PENDING</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">US 11,793,919</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">Extracorporeal Oxygenation System for Low Flow Rates and Methods of Use</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; white-space: nowrap; text-align: center"><span style="font-size: 10pt">1 Dec 2021</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">GRANTED</span></td></tr>
  <tr>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">US 18/216,565; 2023/0338634</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">Extracorporeal Oxygenation System for Low Flow Rates and Methods of Use</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; white-space: nowrap; text-align: center"><span style="font-size: 10pt">1 Dec 2021</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">PENDING</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">US 11,938,257 (18/235,515)</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">A Blood-Gas Exchange Device and Methods of Use</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">18 Aug 2023</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">GRANTED</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">US 18/896,656</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">A Blood-Gas Exchange Device and Methods of Use</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">18 Aug 2023</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">PENDING</span></td></tr>
  <tr>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">US 18/434,809</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">Automated Monitoring of Extracorporeal Support Patient Care and Interactive User Interface Therefor</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">7 Jan 2024</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">PENDING</span></td></tr>
  <tr>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">US 18/747,453</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">A Blood-Gas Exchange Device and Methods of Use</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">19 Jun 2024</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">PENDING</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">US 63/686,724</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="text-align: left; vertical-align: top"><span style="font-size: 10pt">A Patch for Blood Stream Infection Prevention and Method of Use</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">23 Aug 2024</span></td>
    <td style="text-align: left; vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">FILED</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 72 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also rely on trade secrets,
know-how, and continuing innovation to develop and maintain our competitive position. We cannot be certain that patents will be granted
with respect to any of our pending patent applications or with respect to any patent applications filed by us in the future, nor can we
be sure that any of our existing patents or any patents granted to us in the future will be commercially useful in protecting our technology.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our success depends, in part,
on an intellectual property portfolio that supports future revenue streams and erects barriers to our competitors. We are maintaining
and building our patent portfolio through filing new patent applications, prosecuting existing applications, and licensing and acquiring
new patents and patent applications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Despite these measures, any
of our intellectual property and proprietary rights could be challenged, invalidated, circumvented, infringed or misappropriated. Intellectual
property and proprietary rights may not be sufficient to permit us to take advantage of current market trends or otherwise to provide
competitive one. For more information, see &#8220;Item 3.D. - Risk Factors-Risks Related to our Intellectual Property.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>Research and Development and Governmental
Grants</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We maintain an active internal
research and development process, which also includes clinical activities and regulatory affairs. Our research and development team consists
of 36 people as of December 31, 2024. We incurred approximately $6.4 million and $7.4 million in research and development
and related expenses during the years ended December 31, 2024 and 2023, respectively. The decrease in research and development expenses
is primarily attributable to <span>decreases in salary and related expenses and IIA grant participation
that was deducted from development expenses.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our research and development
efforts have been financed in part through grants in an aggregate amount of approximately $1,095 that we received from the IIA as of December
31, 2024. We received these grants for the development of a blood oxygenation system with the goal of providing life support through direct
blood oxygenation and elevation of the oxygen saturation level while removing carbon dioxide. These grants have no repayment obligation,
however, once we reach commercialization stage, we will be required to pay royalties for each grant at a rate of 3% of our revenues up
to the total amount of grants received plus interest. Following the full payment of such royalties, there is no further liability for
royalty payment. Nonetheless, the restrictions under the Innovation Law will continue to apply even after our company has repaid the full
amount of royalty payable pursuant to the grants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>Production and Manufacturing Activities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our INSPIRA ART and INSPIRA
ART100 systems are comprised of a number of components. We are planning to sell an assembled product (system) as well as a disposable
unit to be used per patient treatment for both the blood oxygenation and blood monitoring. The components of the assembled product and
the disposable unit consist of both proprietary and off the shelf components. Proprietary components will be manufactured on our behalf
at GMP approved production plant to adhere to regulatory requirements, whereas off the shelf components will be sourced by Inspira team.
GMP sub-contractors will assemble proprietary and off the shelf components together to create our INSPIRA ART and or INSPIRA ART100 systems.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">In
December 2022, we entered into a strategic OEM agreement with Terumo Cardiovascular. The agreement provides for the manufacture of a flow
mechanism that is intended to be integrated into our products for use in the extracorporeal circulation of the blood during the oxygenation
process. This may also include integration into the INSPIRA ART and or INSPIRA ART100 systems.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">In
addition, we have entered into discussions relating to additional contracted manufacturing and distribution agreements with leading turnkey
OEM vendors that provide end-to-end solutions. The outsourcing of the supply chain management, such as manufacturing, logistics, shipping
and after-market support, reduces capital expenditure, lead times and costs, while providing us with flexibility and agility.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "></p><div>

</div><!-- Field: Page; Sequence: 73 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">In
December 2022, we announced that our INSPIRA ART100 system is being contract manufactured by an end-to-end solution provider that offers
New Product Introduction, NPI, services to mass production capabilities for leading medical electronic device companies. This includes
full turn-key manufacturing, full system integration, including Printed Circuit Board, or PCB, manufacturing, assembly services, testing
and packaging in facilities that meet GMP compliance. The INSPIRA ART100 system underwent verification and validation prior to its submission
to the FDA. Having received FDA clearance, the INSPIRA ART100 system production line will be extended for low-rate initial production,
which is an important operational stage in developing infrastructure to support serial manufacturing, quality control and shipping. Additional
units are expected to be assembled for the targeted future first deployments of the INSPIRA ART100 systems in the U.S. and Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>Competition</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
medical device industry is characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products.
There are many medical device companies, biotechnology companies, public and private universities and research organizations actively
engaged in the research and development of products that may be similar to our products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
market participants in the ICU and the acute respiratory care space include Boston Scientific Corporation (NYSE: BSX), ResMed Inc., (NYSE:
RMD), Masimo Corporation (Nasdaq: MASI), Becton, Dickinson and Company (NYSE: BDX), Chart Industries, Inc. (Nasdaq: GTLS), Philips Healthcare,
Medtronic plc (NYSE: MDT), Fisher &amp; Paykel Healthcare Corporation Limited, Dr&#228;gerwerk AG &amp; Co. KGaA, Dr&#228;gerwerk AG,
Hamilton Medical AG, Smiths Medical Inc. (acquired by ICU Medical Inc.), Siemens Healthineers AG ADR (Nasdaq: SMMNY), Baxter International
(NYSE: BAX), Getinge AB (OTCMKTS: GNGBY), GE Healthcare, Terumo Corporation (TYO: 4543, Nikkei 225 Component), LivaNova PLC (Nasdaq: LIVN),
Fresenius SE &amp; Co. KGaA (OTCMKTS: FSNUY), Johnson &amp; Johnson (NYSE: JNJ), Zoll Medical Corporation (TYO: 3407 ), Resuscitec GmbH,
Spectrum Medical Limited, Abiomed, Inc. (Nasdaq: ABMD), Abbott Laboratories (NYSE: ABT), DataMed s.r.l, Chalice Medical Ltd., APMTD Global
Limited, Eurosets s.r.l. and Braile Biomedica. These companies have either developed or acquired respiratory care devices and solutions,
such as ventilators, ECMO devices and blood sensors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
aforementioned companies, have substantially greater brand recognition, R&amp;D, and regulatory capabilities and financial, technical,
manufacturing, marketing and human resources than we do and significantly greater experience and infrastructure in the research and development
of medical devices, obtaining the FDA and other regulatory clearances of those devices and commercializing those devices around the world.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>Government Regulation
and Product Approval </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our products and our operations
are subject to regulation by numerous worldwide regulatory bodies including the FDA and comparable international regulatory agencies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our products are subject to
regulation as medical devices under the FDCA, as implemented and enforced by the FDA. The FDA regulates the development, design, non-clinical
and clinical research, manufacturing, safety, efficacy, labeling, packaging, storage, installation, servicing, recordkeeping, premarket
clearance or approval, import, export, adverse event reporting, advertising, promotion, marketing and distribution, and import and export
of medical devices to ensure that medical devices distributed domestically are safe and effective for their intended uses and otherwise
meet the requirements of the FDCA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to U.S. regulations,
we are subject to a variety of regulations in the EEA, governing clinical trials and the commercial sales and distribution of our products.
Whether or not we have or are required to obtain FDA clearance or approval for a product, we will be required to obtain authorization
before commencing clinical trials and to obtain marketing authorization or approval of our products under the comparable regulatory authorities
of countries outside of the U.S. before we can commence clinical trials or commercialize our products in those countries. The approval
process varies from country to country and the time may be longer or shorter than that required for FDA clearance or approval. Medical
devices are generally subject to varying levels of regulatory control based on risk level of the device.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 74 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>FDA Premarket Clearance
and Approval Requirements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless an exemption applies,
each medical device commercially distributed in the U.S. requires FDA clearance of a 510(k) premarket notification, granting of a de novo
request, or approval of an application for premarket approval, or PMA. Under the FDCA, medical devices are classified into one of three
classes-Class I, Class II or Class III-depending on the degree of risk associated with each medical device and the extent of regulatory
controls needed to ensure its safety and effectiveness. Class I includes devices with the lowest risk to the patient and are those for
which safety and effectiveness can be assured by adherence to the FDA&#8217;s General Controls for medical devices, which include compliance
with the applicable portions of the QSR, facility registration and product listing, reporting of adverse medical events, and truthful
and non-misleading labeling. Class II devices are subject to the FDA&#8217;s General Controls, and special controls as deemed necessary
by the FDA to ensure the safety and effectiveness of the device. These special controls can include performance standards, post-market
surveillance, patient registries and FDA guidance documents. While most Class I devices are exempt from the 510(k) premarket notification
requirement, manufacturers of most Class II devices are required to submit to the FDA a premarket notification under Section 510(k) of
the FDCA requesting permission to commercially distribute the device. The FDA&#8217;s permission to commercially distribute a device subject
to a 510(k) premarket notification is generally known as 510(k) clearance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>The 510(k) Process</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the 510(k) process,
the manufacturer must submit to the FDA a premarket notification demonstrating that the device is &#8220;substantially equivalent&#8221;
to either a device that was legally marketed prior to May 28, 1976, the date upon which the Medical Device Amendments of 1976 were enacted,
and for which PMA is not required, a device that has been reclassified from Class III to Class II or Class I, or another commercially
available device that was cleared through the 510(k) process. To be &#8220;substantially equivalent,&#8221; the proposed device must have
the same intended use as the predicate device, and either have the same technological characteristics as the predicate device or have
different technological characteristics and not raise different questions of safety or effectiveness than the predicate device. Clinical
data is sometimes required to support substantial equivalence.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After a 510(k) premarket notification
is submitted, the FDA determines whether to accept it for substantive review. If it lacks necessary information for substantive review,
the FDA will refuse to accept the 510(k) notification. If it is accepted for filing, the FDA begins a substantive review. By statute,
the FDA is required to complete its review of a 510(k) notification within 90 days of receiving the 510(k) notification. As a practical
matter, clearance often takes longer, and clearance is never assured. Although many 510(k) premarket notifications are cleared without
clinical data, the FDA may require further information, including clinical data, to make a determination regarding substantial equivalence,
which may significantly prolong the review process.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;If the FDA agrees that
the device is substantially equivalent to a predicate device currently on the market, it will grant 510(k) clearance to commercially market
the device. If the FDA determines that the device is &#8220;not substantially equivalent&#8221; to a previously cleared device, the device
is automatically designated under the FDCA as a Class III device. The device sponsor must then fulfill more rigorous PMA requirements
or can request a risk-based classification determination for the device in accordance with the de novo process, which is a route to market
for novel medical devices that are low to moderate risk and are not substantially equivalent to a predicate device.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After a device receives 510(k)
marketing clearance, any modification that could significantly affect its safety or effectiveness, or that would constitute a major change
or modification in its intended use, will require a new 510(k) marketing clearance or, depending on the modification, a de novo grant
or PMA approval. The FDA requires each manufacturer to determine whether the proposed change requires submission of a 510(k) (or a PMA)
in the first instance, but the FDA can review any such decision and disagree with a manufacturer&#8217;s determination. Many minor modifications
today are accomplished by a manufacturer documenting the change in an internal letter-to-file. The FDA can review these letters to file
during an inspection. If the FDA disagrees with a manufacturer&#8217;s determination, the FDA can require the manufacturer to cease marketing
and/or request the recall of the modified device until 510(k) clearance, de novo grant or PMA approval is obtained. In these circumstances,
we may be subject to significant regulatory fines or penalties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 75 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>De Novo Classification</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Medical device types that
the FDA has not previously classified as Class I, II or III are automatically classified under the FDCA into Class III regardless of the
level of risk they pose. The Food and Drug Administration Modernization Act of 1997 established a route to market for low to moderate
risk medical devices that are automatically placed into Class III due to the absence of a predicate device, called the &#8220;Request
for Evaluation of Automatic Class III Designation,&#8221; or the de novo classification procedure. This procedure allows a manufacturer
whose novel device is automatically classified into Class III to request down-classification of its medical device into Class I or Class
II on the basis that the device presents low or moderate risk, rather than requiring the submission and approval of a PMA application.
Prior to the enactment of the Food and Drug Administration Safety and Innovation Act of 2012, or FDASIA, a medical device could be eligible
for de novo classification only if the manufacturer first submitted a 510(k) premarket notification and received a determination from
the FDA that the device was not substantially equivalent to a legally marketed predicate device. FDASIA streamlined the de novo classification
pathway by permitting manufacturers to request de novo classification directly without first submitting a 510(k) premarket notification
to the FDA and receiving a not substantially equivalent determination. Under FDASIA, the FDA is required to classify the device within
120 days following receipt of the de novo application. If the manufacturer seeks reclassification into Class II, the manufacturer must
include a draft proposal for special controls that are necessary to provide a reasonable assurance of the safety and effectiveness of
the medical device. In addition, the FDA may reject the request if it identifies a legally marketed predicate device that would be appropriate
for a 510(k) notification, determines that the device is not low to moderate risk, or that general controls would be inadequate to control
the risks and special controls cannot be developed. After a device receives de novo classification, any modification that could significantly
affect its safety or efficacy, or that would constitute a major change or modification in its intended use, will require a new 510(k)
clearance or, depending on the modification, another de novo petition or even PMA approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Clinical Trials</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Clinical trials are almost
always required to support a PMA and are sometimes required to support a 510(k) submission. All clinical investigations of investigational
devices to determine safety and effectiveness must be conducted in accordance with the FDA&#8217;s Investigational Device Exemption, or
IDE, regulations which govern investigational device labeling, prohibit promotion of the investigational device, and specify an array
of recordkeeping, reporting and monitoring responsibilities of study sponsors and study investigators. If the device presents a &#8220;significant
risk&#8221; to human health, as defined by the FDA, the FDA requires the device sponsor to submit an IDE application to the FDA, which
must become effective prior to commencing human clinical trials. A significant risk device is one that presents a potential for serious
risk to the health, safety or welfare of a patient and either is implanted, used in supporting or sustaining human life, substantially
important in diagnosing, curing, mitigating or treating disease or otherwise preventing impairment of human health, or otherwise presents
a potential for serious risk to a subject. An IDE application must be supported by appropriate data, such as animal and laboratory test
results, showing that it is safe to test the device in humans and that the testing protocol is scientifically sound. The IDE will automatically
become effective 30 days after receipt by the FDA unless the FDA notifies the company that the investigation may not begin. If the FDA
determines that there are deficiencies or other concerns with an IDE for which it requires modification, the FDA may permit a clinical
trial to proceed under a conditional approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the study must
be approved by, and conducted under the oversight of, an Institutional Review Board, or IRB. The IRB is responsible for the initial and
continuing review of the study and may pose additional requirements for the conduct of the study. If an IDE application is allowed to
go into effect by the FDA and the study approved by the reviewing IRB(s), human clinical trials may begin at a specific number of investigational
sites with a specific number of subjects as set forth in the study protocol. If the device presents a non-significant risk to the patient,
a sponsor may begin the clinical trial after obtaining approval for the trial by one or more IRBs without separate review from the FDA,
but must still follow abbreviated IDE requirements, such as monitoring the investigation, ensuring that the investigators obtain informed
consent, and labeling and record-keeping requirements. Acceptance of an IDE application for review does not guarantee that the FDA will
allow the IDE to become effective and, if it does become effective, the FDA may or may not determine that the data derived from the trials
support the safety and effectiveness of the device or warrant the continuation of clinical trials. An IDE supplement must be submitted
to, and allowed to go into effect by, the FDA before a sponsor or investigator may make a change to the investigational plan that may
affect its scientific soundness, study plan or the rights, safety or welfare of human subjects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During a study, the sponsor
is required to comply with the applicable FDA requirements, including, for example, trial monitoring, selecting clinical investigators
and providing them with the investigational plan, ensuring IRB review, adverse event reporting, record keeping and prohibitions on the
promotion of investigational devices or on making safety or effectiveness claims for them. The clinical investigators in the clinical
study are also subject to FDA regulations and must obtain patient informed consent, follow the investigational plan and study protocol,
control the disposition of the investigational device, and comply with all reporting and recordkeeping requirements. Additionally, after
a trial begins, we, the FDA or the IRB could suspend or terminate a clinical trial at any time for various reasons, including a belief
that the risks to study subjects outweigh the anticipated benefits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 76 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; "><b><i>Post-market
Regulation</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After a device is cleared
or approved for marketing, numerous and extensive regulatory requirements may continue to apply. These include but are not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">Annual and updated establishment
registration and device listing with the FDA;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 0.5in; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">QSR requirements, which require manufacturers to follow stringent design, testing, control, documentation, complaint handling and other quality assurance procedures during all aspects of the design and manufacturing process;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 0.5in; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Advertising and promotion requirements;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 0.5in; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Restrictions on sale, distribution or use of a device;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 0.5in; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Labeling and marketing regulations, which require that promotion is truthful, not misleading, and provides adequate directions for use and that all claims are substantiated, and also prohibit the promotion of products for unapproved or &#8220;off-label&#8221; uses and impose other restrictions on labeling;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 0.5in; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The federal Physician Sunshine Act and various state and foreign laws on reporting remunerative relationships with health care customers;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 0.5in; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The federal Anti-Kickback Statute (and similar state laws) prohibiting, among other things, soliciting, receiving, offering or providing remuneration intended to induce the purchase or recommendation of an item or service reimbursable under a federal healthcare program, such as Medicare or Medicaid. A person or entity does not have to have actual knowledge of this statute or specific intent to violate it to have committed a violation;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The federal False Claims Act (and similar state laws) prohibiting, among other things, knowingly presenting, or causing to be presented, claims for payment or approval to the federal government that are false or fraudulent, knowingly making a false statement material to an obligation to pay or transmit money or property to the federal government or knowingly concealing, or knowingly and improperly avoiding or decreasing, an obligation to pay or transmit money to the federal government. The government may assert that a claim that includes items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the false claims statute;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 0.5in; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Clearance or approval of product modifications to legally marketed devices that could significantly affect safety or effectiveness or that would constitute a major change in intended use;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 0.5in; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Medical device reporting regulations, which require that a manufacturer report to the FDA if a device it markets may have caused or contributed to a death or serious injury, or has malfunctioned and the device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 0.5in; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Correction, removal and recall reporting regulations, which require that manufacturers report to the FDA field corrections and product recalls or removals if undertaken to reduce a risk to health posed by the device or to remedy a violation of the FDCA that may present a risk to health;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 0.5in; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Complying with the federal law and regulations requiring Unique Device Identifiers on devices and also requiring the submission of certain information about each device to the FDA&#8217;s Global Unique Device Identification Database;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 0.5in; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The FDA&#8217;s recall authority, whereby the agency can order device manufacturers to recall from the market a product that is in violation of governing laws and regulations if there is a reasonable probability that the use of the device would cause a serious, adverse health consequence or death; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 0.5in; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Post-market surveillance activities and regulations, which apply when deemed by the FDA to be necessary to protect the public health or to provide additional safety and effectiveness data for the device.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA has broad regulatory
compliance and enforcement powers. If the FDA determines that we failed to comply with applicable regulatory requirements, it can take
a variety of compliance or enforcement actions, which may result in any of the following sanctions:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 0.5in; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Warning letters, untitled letters, fines, injunctions, consent decrees and civil penalties;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 77 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 0.5in; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Recalls, withdrawals, or administrative detention or seizure of our products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 0.5in; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Operating restrictions or partial suspension or total shutdown of production;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 0.5in; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Refusing or delaying requests for 510(k) marketing clearance or PMA approvals of new products or modified products;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 0.5in; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Withdrawing 510(k) clearances or PMA approvals that have already been granted;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 0.5in; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Refusal to grant export or import approvals for our products; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 0.5in; text-align: justify">&#160;</td>
    <td style="white-space: nowrap; width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Criminal prosecution.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the EU, we will be required
to comply with the new Medical Device Regulation, or the MDR. The MDR was published in May 2017 with a 3-year transition period, which
has been extended. The CE Mark required to sell medical devices in the EU is affixed following conformity assessment and either approval
from the appointed independent Notified Body or through self-certification by the manufacturer for particular class I devices. The selected
pathway to CE marking is based on product risk classification. CE Marking indicates conformity to the applicable General Safety and Performance
Requirements for the MDR. The MDR change multiple aspects of the existing regulatory framework for CE marking, such as increased clinical
evidence requirements and other new requirements, including Unique Device Identification as well as many other post-market obligations.
MDR also significantly modifies and increases the compliance requirements for the industry and will require significant investment over
the next few years to implement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are also required to comply
with the regulations of every other country where we commercialize products before we can launch or maintain new products on the market.
Many countries that previously did not have medical device regulations, or had minimal regulations, are now introducing them. For example,
India is in the process of expanding its current regulations to include all medical device categories while many countries in the Middle
East and Southeast Asia are introducing new regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA and other worldwide
regulatory agencies and competent authorities actively monitor compliance to local laws and regulations through review and inspection
of design and manufacturing practices, record-keeping, reporting of adverse events, labeling and promotional practices. The FDA can ban
certain medical devices, detain or seize adulterated or misbranded medical devices, order repair, replacement or refund of these devices
and require notification of health professionals and others with regard to medical devices that present unreasonable risks of substantial
harm to the public health. The FDA may also enjoin and restrain a company for certain violations of the FDCA and the Safe Medical Devices
Act pertaining to medical devices or initiate action for criminal prosecution of such violations. Regulatory agencies and authorities
in the countries where we do business can halt production in or distribution within their respective country or otherwise take action
in accordance with local laws and regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">International sales of medical
devices manufactured in the U.S. that are not approved by the FDA for use in the U.S., or that are banned or deviate from lawful performance
standards, are subject to FDA export requirements. Additionally, exported devices are subject to the regulatory requirements of each country
to which the device is exported. Some countries do not have medical device regulations, but in most foreign countries, medical devices
are regulated. Frequently, regulatory approval may first be obtained in a foreign country prior to application in the U.S. due to differing
regulatory requirements; however, other countries, such as China, for example, require approval in the country of origin first.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Most countries outside of
the U.S. require that product approvals be recertified on a regular basis, generally every five years. The recertification process requires
that we evaluate any device changes and any new regulations or standards relevant to the device and, where needed, conduct appropriate
testing to document continued compliance. Where recertification applications are required, they must be approved in order to continue
selling our products in those countries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 78 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Regulatory Clearances</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2024, we received from
the FDA 510(k) regulatory clearance for the INSPIRA ART100 system. We also received confirmation that the INSPIRA ART device was placed
on the FDA Class I 510(k) exempt list.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2024, we received AMAR
certification for the INSPIRA ART100 system and for the INSPIRA ART.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Expected Regulatory Filings</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To date, our systems have
not been tested in humans and any future testing in humans will be subject to the request of the appropriate regulators, including the
FDA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are taking a multi-step
approach to the regulatory clearance process. In January 2022, we listed a component of the INSPIRA ART system and the INSPIRA ART100
system on the FDA Class I 510(k) exempt list. The component is intended to reduce the potential complications associated with jugular
vein cannula movement, occurring during a change of a patient&#8217;s posture in bed and/or during transportation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2025, we plan to apply
for 510(k) regulatory clearance for the INSPIRA ART100 incorporating the HYLA blood sensor and also apply for 510(k) regulatory clearance
for our centrifugal pump.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As part of our strategy to
bring our device to market and streamline reimbursement coding and clinical adoption of the INSPIRA ART system that offers a new intent
of use, we will collaborate with top ranking hospitals to perform a human observational study focused on (pending approvals): (i) proving
that the INSPIRA ART system can prevent patient deterioration resulting in the need for invasive mechanical ventilation; and (ii) assisting
in weaning patients off mechanical ventilation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><div><a id="I_015"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-size: 10pt"><b>C.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Organizational Structure. </b>&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">We
are an Israeli corporation based in Ra&#8217;anana, Israel and were incorporated in Israel in 2018 under the name Clearx Medical Ltd.
On April 10, 2018, our name was changed to Insense Medical Ltd. and on July 30, 2020, our name was changed to our current name, Inspira
Technologies Oxy B.H.N. Ltd. Our principal executive offices are located at 2 Ha-Tidhar St., Ra&#8217;anana, 4366504 Israel. Our telephone
number in Israel is +972 996 644 88. Our website address is www.inspira-technologies.com. The information contained on our website or
available through our website is not incorporated by reference into and should not be considered a part of this Annual Report, and the
reference to our website in this Annual Report is an inactive textual reference only. The SEC also maintains an Internet website that
contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. Our
filings with the SEC will also be available to the public through the SEC&#8217;s website at www.sec.gov.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Currently, we do not have any subsidiaries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><div>

</div><div><a id="I_016"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt"><b>D.</b></span></td>
    <td><span style="font-size: 10pt"><b>Property, Plant and Equipment. </b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our main business activities
are conducted in Israel. Our offices, research and development and manufacturing facilities are located at Melisron (Millennium Building),
2 Ha-Tidhar St., Ra&#8217;anana 4366504, Israel, where we occupy approximately 670 square meters. Our lease ends in August 2027. Our monthly
rent payment is approximately NIS 67,000 (approximately $18,100).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="I_017"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 4A. UNRESOLVED STAFF COMMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 79 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="I_018"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 5. <span style="text-transform: uppercase">OPERATING AND FINANCIAL
REVIEW AND PROSPECTS</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="I_020"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt"><b>A.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Operating Results.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><i>The
following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial
statements and the related notes included elsewhere in this annual report on Form 20-F. The discussion below contains forward-looking
statements that are based upon our current expectations and are subject to uncertainty and changes in circumstances. Actual results may
differ materially from these expectations due to inaccurate assumptions and known or unknown risks and uncertainties, including those
identified in &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221; and under &#8220;Risk Factors&#8221; elsewhere in this
annual report on Form 20-F. </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Overview</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since our inception in 2018,
we have incurred operating losses. Our operating loss for the years ended December 31, 2024 and 2023 were approximately $11.3 million
and $12.1 million, respectively; and our net loss for the same periods were $11 million and $11.3 million. As of December 31, 2024, we
had an accumulated deficit of $67 million. We expect to continue to incur significant expenses and operating losses for the foreseeable
future, and our losses may fluctuate significantly from year to year. We anticipate that our expenses will increase significantly in connection
with our ongoing activities, as we:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Continue clinical development of our products;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">File new applications seeking regulatory approval for the products pursuant to FDA&#8217;s Section 510(K) or other regulatory pathway in the U.S.;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Continue to invest in the preclinical research and development of any future product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Establish a commercial infrastructure to support the marketing, sale and distribution of the products if they receive regulatory approval;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Hire additional research and development and general and administrative personnel to support our operations;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Maintain, expand and protect our intellectual property portfolio; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Continue to incur costs associated with operating as a public company.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not have any product
candidates approved for sale and have not generated any revenue from product sales.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 16, 2021, we closed
our IPO whereby we sold 2,909,091 Ordinary Shares and 3,345,455 tradable warrants (inclusive of 436,364 tradable warrants pursuant to
the exercise of an overallotment option granted to the underwriters). The aggregate gross proceeds received by us from the IPO were $16
million, before underwriting discounts and other offering costs. Prior to our IPO, we financed our operations primarily through convertible
debt, as well as grants from the IIA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Current Outlook</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">We
have financed our operations to date primarily through proceeds from sales of our Ordinary Shares, convertible notes and loans and from
grants from the IIA. We have incurred losses and generated negative cash flows from operations since inception in 2018. Since inception,
we have not generated significant revenues and we do not expect to generate significant revenues in the near future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">As
of December 31, 2024, our cash and cash equivalents and cash deposits were $5.8 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">We
expect that our existing cash and cash equivalents as of December 31, 2024 will enable us to fund our operating expenses and capital expenditure
requirements for the next six months. We expect that we will require substantial additional capital to operate and to commercialize our
products and we expect to seek additional funds to enable us to fund our operations for the next twelve months.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "></p><div>

</div><!-- Field: Page; Sequence: 80 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Our
operating plans may change as a result of many factors that may currently be unknown to us, and we may need to seek additional funds sooner
than planned. Our future capital requirements will depend on many factors, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top; ">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the progress and costs of our research and development activities;</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the costs of manufacturing our products;</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the costs of filing, prosecuting, enforcing and defending patent claims and other intellectual property rights;</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the potential costs of contracting with third parties to provide marketing and distribution services for us or for building such capacities internally; and</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the magnitude of our general and administrative expenses.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Liquidity or Going Concern</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Until we can generate significant
recurring revenues, we expect to satisfy our future cash needs through debt and/or equity financings. We cannot be certain that additional
funding will be available to us on acceptable terms, if at all. This may raise substantial doubt about our ability to continue as a going
concern.&#160;The financial statements do not include any adjustments that might result from the outcome of this uncertainty. If funds
are not available, we may be required to delay, reduce the scope of, or eliminate research or development plans for, or commercialization
efforts with respect to our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Operating Expenses</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Our
current operating expenses consist of three components - research and development expenses, general and administrative expenses and marketing
expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>Revenue</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To date, we have not generated
any significant revenue, and we do not expect to generate significant revenue within the next year at least.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Research and Development Expenses, net</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Our
research and development expenses consist primarily of salaries and related personnel expenses, share-based compensation expenses, materials
costs consultants and other third parties who support the developments of our products and other related research and development expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span>The
following tables discloses the breakdown of research and development expenses:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended<br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic">U.S. dollars in thousands</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Share based compensation</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">801</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">663</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,392</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Salary and related expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,079</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,429</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,458</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Subcontractors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">340</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">304</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">850</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Materials and related expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">812</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,365</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,081</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">IIA participation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(286</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">371</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">291</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">188</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">206</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">268</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">214</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">6,323</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">7,320</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">8,183</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">We
expect that our research and development expenses will materially increase as we continue to develop our products and recruit additional
research and development employees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "></p><div>

</div><!-- Field: Page; Sequence: 81 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>General and Administrative Expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">General
and administrative expenses consist primarily of salaries and related expenses, share based compensation, professional service fees for
accounting and booking, legal fees, facilities, travel expenses and other general and administrative expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
following tables discloses the breakdown of general and administrative expenses:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-style: italic">Unaudited</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended<br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic">U.S. dollars in thousands</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Share-based compensation</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">716</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">675</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,984</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,758</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,432</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Related funds raising expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">260</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Directors&#8217; fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">239</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">241</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">239</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Salary and related expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">808</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">766</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">716</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Insurance expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">196</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">300</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">557</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Office maintenance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">135</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">129</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">102</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">117</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">115</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">104</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Travel abroad</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">104</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">100</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">105</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">112</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">45</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">68</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">4,185</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">4,063</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,375</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>Comparison of the
Years Ended December 31, 2024, 2023 and 2022</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Results of Operations</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
following tables summarizes our results of operations for the years ended December 31, 2024, 2023 and 2022:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended <br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic">U.S. dollars in thousands</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Research and development expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">6,323</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7,320</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">8,183</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,185</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,063</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,375</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Sales and Marketing expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">754</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">746</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,328</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Other expenses (income)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,267</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,133</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,893</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Interest Income from deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(172</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(318</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(192</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Financial expenses (income), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(42</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(529</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">275</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,053</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,286</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,976</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Loss attributable to holders of Ordinary Shares</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">11,053</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">11,286</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">14,976</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Research and Development Expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Our research and development expenses for the year ended December 31,
2024, amounted to $6,323,000, a decrease of $997,000, or 13.6%, compared to $7,320,000 for the year ended December 31, 2023. The decrease
was primarily attributable to the reflection of the exchange rate on salary and related expenses and an IIA grant deducted from the research
and development expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "></p><div>

</div><!-- Field: Page; Sequence: 82 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>General and administrative expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Our
general and administrative expenses totaled $4,185,000 for year ended December 31, 2024, an increase of $122,000, or 3%, compared to $4,063,000
for the year ended December 31, 2023. The increase was primarily attributable to an increase in professional fees, salary and related
expenses and share based compensation, which was offset by a decrease in expenses related to fund raising which were all allocated to
equity this year based their terms and accounting principles.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Sales and marketing
expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Marketing
expenses for the year ended December 31, 2024, amounted to $754,000 representing an increase of $8,000, or 1%, compared to $746,000 for
the year ended December 31, 2023. The increase is attributable to an increase in salary and related expenses and share based compensation
that is offset by professional fees paid for projects related to digital marketing and media materials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Operating loss</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">As
a result of the foregoing, our operating loss for the year ended December 31, 2024, amounted to $11,267,000 representing a decrease of
$866,000, or 7%, compared to $12,133,000 for the year ended December 31, 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Financial expenses (income)</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Financial income consists
of deposit interest, revaluation of financial liabilities presented at fair value and foreign currency changes reflections.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We recognized interest income
from deposits in amount of $172,000 and financial income <span>of $42,000 as a result of the revaluation
of financial labilities. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Total net loss</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span>As
a result of the foregoing, our total net loss for the year ended December 31, 2024, amounted to $11,053,000 representing a decrease of
$233,000, or 2%, compared to a loss of $11,286,000 for the year ended December 31, 2023.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="I_021"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt"><b>B.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Liquidity and Capital Resources</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Overview </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2024, we
had $<span>5.8 million </span>in cash, cash equivalents and cash deposits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The table below presents our
cash flows for the year ended December 31, 2024 and December 31, 2023:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>&#160;</i></b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended<br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic">U.S. dollars in thousands</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Net cash used in operating activities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(9,374</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(9,691</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(9,209</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net cash provided by (used in) investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,488</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,594</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,383</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net cash provided by financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,902</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,453</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Effect of exchange rate changes on cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">55</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(65</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(438</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net increase (decrease) in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,644</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(16,592</td><td style="text-align: left">)</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "></p><div>

</div><!-- Field: Page; Sequence: 83 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Operating Activities</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since our incorporation, we
have had ongoing losses and incurred negative cash flows from operating activities. For example, in the year ended December 31, 2024,
we had operating losses of $11,267,000. We have mainly financed our activities in the year ended December 31, 2024 through offerings of
our securities. There are no assurances however, that we will be successful in obtaining the level of financing needed for our operations
or that such financing will be available on terms acceptable to us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Net
cash used in operating activities of $9,374,000 during the year ended December 31, 2024 and net cash used in operating activities of $9,691,000
during the year ended December 31, 2023 was primarily used for payment of salaries and related personnel expenses, materials expenses,
subcontractors, travel and office maintenance. In addition, cash flows from operating activities are impacted by changes in operating
assets and liabilities, which include trade account payables and financial liabilities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Investing Activities</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used in investing
activities of $1,488,000 during the year ended December 31, 2024 consisted of $164,000 used for purchasing property and equipment, and
$1,652,000 representing the proceeds from sale of short-term deposits. Net cash provided by investing activities of $4,594,000 during
the year ended December 31, 2023, consisted of $206,000 used for purchasing property and equipment, and $4,800,000 representing the proceeds
from sale of short-term deposits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Financing Activities </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash provided by financing
activities of $7,902,000 <span>during the year ended December 31, 2024</span>, consisted of the issuance
of ordinary shares, pre-funded warrants and ordinary warrants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash provided by financing
activities of $3,453,000 <span>during the year ended December 31, 2023</span>, consisted mainly of $2,128,000
from issuance of Ordinary Shares and $1,750,000 from issuance of warrants to purchase Ordinary Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span>No
cash was provided by or used in financing activities during the year ended December 31, 2022</span>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">We
have an effective Form F-3 registration statement (File No. 333-266748), filed under the Securities Act of 1933, with the SEC using a
&#8220;shelf&#8221; registration process. Under this shelf registration process, we may, from time to time, sell our Ordinary Shares and
warrants to purchase Ordinary Shares, and units of two or more of such securities in one or more offerings up to a total dollar amount
of $50,000,000.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">On
April 4, 2023, we entered into a sales agreement with Roth Capital Partners, LLC, or Roth, pursuant to which we were able to offer and
sell, from time to time, through Roth, our Ordinary Shares, no par value per share. The Ordinary Shares were to be offered and sold pursuant
to our Registration Statement on&#160;Form F-3&#160;(File No. 333-266748), and a prospectus supplement to the Registration Statement,
filed on April 4, 2023 with the SEC. On October 23, 2023, notice was provided to Roth to terminate the sales agreement, effective immediately.
Under the sales agreement, we sold approximately $26,000 of Ordinary Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">On
December 26, 2023, we entered into a securities purchase agreement whereby we sold: (i) 1,375,000 Ordinary Shares at a purchase price
of $1.28 per share; (ii) pre-funded warrants to purchase up to 1,656,250 Ordinary Shares at a purchase price of $1.28, less $0.001 per
pre-funded warrant; and (iii) private warrants to purchase up to 3,031,250 Ordinary Shares at an exercise price of $1.28 per share. The
pre-funded warrants were exercised subsequent to the transaction in full and, as a result, we issued 1,656,250 additional Ordinary Shares
for such exercise. The gross proceeds in connection with this offering were $3.88 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">On
March 28, 2024, we entered into a purchase agreement with certain investors providing for the issuance, in a registered direct offering,
of an aggregate of 1,339,285 of our Ordinary Shares at a price per share of $1.232. The Company raised approximately $1.65 million in
proceeds from this registered direct offering.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">On
June 14, 2024, we entered into a purchase agreement with a single investor providing for the issuance, in a registered direct offering,
of (i) 941,541 Ordinary Shares at a purchase price of $1.30 per share and (ii) pre-funded warrants to purchase up to 1,709,760 Ordinary
Shares at a purchase price of $1.30, less $0.001 per pre-funded warrant. We received approximately $3.4 million in gross proceeds.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; "></p><div>

</div><!-- Field: Page; Sequence: 84 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">On
December 27, 2024, we entered into securities purchase agreements for private placement financing with certain accredited investors, pursuant
to which the investors agreed to purchase (i) 3,950,343 of our Ordinary Shares at a purchase price of $0.70 per share, (ii) pre-funded
warrants to purchase up to 658,372 ordinary shares at a purchase price of $0.70, less $0.001 per pre-funded warrant. In addition, the
purchasers of such Ordinary Shares or pre-funded warrants received warrants to purchase up to 4,608,715 Ordinary Shares at an exercise
price of $1.10 per share. We received approximately $3.2 million in gross proceeds. In addition, we entered into a placement agency agreement
with Dawson James Securities, Inc., who served as placement agent in the offering, dated December 27, 2024, pursuant to which we agreed
to pay the placement agent a cash placement fee equal to: (a) 8.0% of the gross proceeds received in the offering from certain investors
introduced by the placement agent and 4.0% of the gross proceeds received by us from the exercise of warrants by such investors, (b) 4.0%
of the gross proceeds received in the offering from certain investors introduced by us and 4.0% of the gross proceeds received by us from
the exercise of warrants by such investors, and (c) 0% of the gross proceeds received in the offering from certain other investors and
0% of the gross proceeds received by us from the exercise of warrants by such investors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><div><a id="I_022"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt"><b>5.C</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Research and development, patents and licenses, etc.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For a description of our research
and development programs and the amounts that we have incurred over the last two years pursuant to those programs, please see &#8220;Item
5. Operating and Financial Review and Prospects- A. Operating Results- Operating Expenses- Research and Development Expenses, net&#8221;
and &#8220;Item 5. Operating and Financial Review and Prospects- A. Operating Results- Comparison of the year ended December 31, 2024
to the year ended December 31, 2022- Research and Development Expenses.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="I_023"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: left; width: 0.5in"><span style="font-size: 10pt"><b>5.D</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Trend Information</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="I_024"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt"><b>E.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Critical Accounting Estimates</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We describe our significant
accounting policies more fully in Note 2 to our financial statements for the year ended December 31, 2024. We believe that the accounting
policies below are critical in order to fully understand and evaluate our financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We prepare our financial statements
in accordance with <span>U.S. GAAP</span>. At the time of the preparation of the financial statements,
our management is required to use estimates, evaluations, and assumptions which affect the application of the accounting policy and the
amounts reported for assets, obligations, and expenses. Any estimates and assumptions are continually reviewed. The changes to the accounting
estimates are credited during the period in which the change to the estimate is made. The preparation of financial statements requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities in relation with stock-based compensation
expense, fair value financial liabilities, recognition, measurement, and disclosure of contingent liabilities, Interest rate used for
lease liability measurement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 85 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="I_025"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 6. <span style="text-transform: uppercase">DIRECTORS,
SENIOR MANAGEMENT AND EMPLOYEES</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="I_026"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-size: 10pt"><b>A.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Directors and Senior Management.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
information regarding our executive officers, key employees and directors as of the date of this annual report on Form 20-F&#160;:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; width: 33%"><span style="font-size: 10pt"><b>Name</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 5%; text-align: center"><span style="font-size: 10pt"><b>Age</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 60%"><span style="font-size: 10pt"><b>Position</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Dagi Ben-Noon</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">48</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chief Executive Officer, Director</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Joe Hayon&#160;</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">51</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">President and Director</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Yafit Tehila</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">44</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chief Financial Officer</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Avi Shabtai</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">51</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chief Operations Officer and VP of Research and Development</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Daniella Yeheskely Hayon </span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">51</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chief Technology Officer</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Lior Amit <sup>(1) (2) (3)</sup></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">58</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Tal Parnes <sup>(1) (2) (3)</sup></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">56</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chairman of the Board of Directors</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">Limor Rozen <sup>(1) (2) (3)</sup></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">51</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Director </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top; ">
    <td style="width: 0.25in"><span style="font-size: 10pt">(1)</span></td>
    <td><span style="font-size: 10pt">Member of the Compensation Committee</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">(2)</span></td>
    <td><span style="font-size: 10pt">Member of the Audit Committee and Financial Statement Examination Committee</span></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt">(3)</span></td>
    <td><span style="font-size: 10pt">Independent Director (as defined under Nasdaq rules)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt; ">In
January 2025, Prof. Benad Goldwasser announced that he retired from his position as member and chairman of our board of directors due
to personal reasons.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>Dagi Ben-Noon, Chief
Executive Officer, Director</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Mr. Dagi Ben-Noon</i> has
served as our Chief Executive Officer since June 2020 and as a director since March 2020. Prior to that, Mr. Ben-Noon served as our Chief
Operations Officer from March 2018 to June 2020. Mr. Ben-Noon founded our company together with Dr. Udi Nussinovitch and Mr. Joe Hayon
in February 2018. Mr. Ben-Noon has over 15 years of experience in product development from idea inception to illustration, design, manufacturing
and product launch. Mr. Ben-Noon co-founded Nano Dimension Ltd. (Nasdaq: NNDN) and served as the company&#8217;s chief operating officer
and director from July 2012 to October 2017. As Nano Dimension Ltd.&#8217;s chief operating officer, Mr. Ben-Noon was in charge of the
company&#8217;s research and development, operations, production, quality and information technology. Mr. Ben-Noon has a BSc in Mechanical
Engineering from the Ben-Gurion University of the Negev in Beer Sheva, Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>Joe Hayon, President
and Director</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Mr. Joe Hayon</i> has served
as our President since August 2022 and as a Director since November 2020. Mr. Hayon served as a President and Chief Financial Officer
from June 2020 to August 2022. Prior to that, Mr. Hayon served as our Chief Executive Officer from March 2018 to June 2020. Mr. Hayon
founded our company together with Dr. Udi Nussinovitch and Mr. Dagi Ben-Noon in July 2017. Mr. Hayon has over 20 years of experience in
managerial roles. From 2001 to 2005, Mr. Hayon worked as a treasurer and cost accountant at Sanmina Ltd. (formerly known as Elscint).
From 2006 to 2007, Mr. Hayon worked as chief financial officer for Arazim Group. He worked for Plasan Sasa Ltd. from 2007 to 2018 as the
company&#8217;s chief information officer and group controller. Mr. Hayon has a B.A. in Business and Economics and an MBA with a major
in Marketing and Finance, both from the University of Manchester, as well as a Business Management Diploma from Damelin College.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 86 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Yafit Tehila, Chief Financial Officer</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Ms. Yafit Tehila </i>has
served as our Chief Financial Officer since August 2022. Prior to becoming our CFO, Ms. Tehila served as our Vice President of Finance
and Legal since February 2021. Ms. Tehila served as Director of Finance at Nano Dimension Ltd. (NASDAQ: NNDM) from November 2020 through
February 2021 and Financial Controller from February 2016 through November 2020. Ms. Tehila served as Financial Controller at Migdal Capital
Markets from August 2010 through November 2016. Ms. Tehila received has a B.A. in Accounting, Economics and business management from Tel
Aviv University.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>Avi Shabtai, Chief
Operations Officer and Vice President of Research and Development</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Mr. Avi Shabtai</i> has
served as our Chief Operations Officer since July 2020 and as our Vice President of Research and Development since June 2019. Mr. Shabtai&#8217;s
expertise lies in engineering, testing, quality management, regulation, risk management and production across a product&#8217;s life cycle
from concept to production. He has over 25 years of experience in management of high-tech companies, particularly in their research and
development and operations departments, including roles of vice president of research and development and vice president of quality and
engineering. From July 2015 to March 2018, Mr. Shabtai worked as vice president of research and development at Nano Dimension Ltd. (Nasdaq:
NNDN). Prior to that, Mr. Shabtai worked as vice president of research and development at ZutaCore from April 2018 to May 2019. Mr. Shabtai
is qualified as software quality engineer by the ALD College and the Israeli Standard Institute.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Daniella Yeheskely -Hayon, PhD, MBA, Chief
Technology Officer.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Dr. Daniella Yeheskely-Hayon
</i>has served as our Chief Technology Officer since January 2022. Dr. Yeheskely-Hayon has comprehensive project management experience
in biomedical engineering as well as in key roles within medical device companies. Since June 2016, Dr. Yeheskely-Hayon has served as
the director of research and development and chief of operations at O2Cure Ltd., a medical device company that specializes in the development
of long-term oxygenators and respiratory assist devices for hospitals. From October 2009 to May 2016, Dr. Yeheskely-Hayon served as a
senior research associate at the Technion Department of Biomedical Engineering. Dr. Yeheskely-Hayon holds a PhD in Biology from the Technion
Institute, Israel and an MBA from ONO academic college.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>Tal Parnes, Director,
Chairman of the Board of Directors </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Mr. Tal Parnes</i> has
served as chairman of our board of directors since February 1, 2025, and <span>has served on our board
of directors since July 16, 2021. Mr. Parnes co-founded and served as a chief executive officer and president of Zuta-Core Ltd. from 2016
to 2020. Prior to that, Mr. Parnes co-founded and served as a chief executive officer of HQL Pharmaceuticals Ltd. from 2010 to 2015. Mr.
Parnes also served as chief operating officer of Silynx Communications Inc. from 2007 to 2009, served as a vice president of operations
of Wavion Inc. from 2005 to 2006 and vice president of operations of Atrica Ltd. from 2002 to 2004. Between 1999 to 2001, Mr. Parnes also
served as a chief financial officer and business development director of Printlife Ltd. Mr. Parnes holds a B.A. in Economics and History
from Tel Aviv University.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>Lior Amit, Director</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><i>Mr.
Lior Amit&#160;</i>has served on our board of directors since August 1, 2021. Since 2014, Mr. Amit has served as a private financial advisor
for both high net worth individuals and companies and serves as a director at Capital link , Nirplex and Ronimar LTD. Mr. Amit was the
CFO of the BBR Saatchi &amp; Saatchi advertising group in Israel from 1996 to 2013, helping to turn it into a leading local advertising
company including advertising agencies, media operations and digital and content, growing from 40 employees to 250 employees. Mr. Amit
holds a Master of Business Administration ((Finance and Insurance) and a B.A. in Economics and Accounting from the Tel Aviv University.
Mr. Amit is a Certified Public accountant in Israel and holds an advisor license with the Israeli Securities Authority.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 87 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>Limor Rozen, Director
</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span><i>Mrs.
Limor Rozen</i> has served on our board of directors since July 2021. Mrs Rozen is the co-founder of&#160;Wellfield Technologies Inc.
(TSXV: WFLD.V), a&#160;public company&#160;established in 2018, where she has played a key role in its growth and strategic direction.
Mrs. Rozen has been working a senior consultant at Vecon Ltd. from 2019. Prior to that, Mrs. Rozen was co-founded and served as a chief
executive officer and general manager of zzoo from 2017 to 2020. From 2012 to 2017, Mrs. Rozen served as a chief operating officer of
365 Technologies Ltd. Mrs. Rozen also served as VP of product and customer projects of Collarity in Palo Alto, California from 2006 to
2011, served as senior team leader at Right Order</span>, Inc.<span>, San Jose, California from 2000 to
2006 and as a team leader at Comverse Technology, Inc between 1999 to 2004. Mrs. Rozen holds an MBA with specialization in Technology
Management from University of Phoenix, Phoenix, Arizona, and a B.A. in Computer Science from Bar-Ilan University. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Scientific Advisory Board</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have a Scientific Advisory
Board of several active physicians and experts in the fields of respiratory disease, pulmonary diseases, cardiac disease and laboratory
animal science. The Scientific Advisory Board consults and assists us in the aforementioned fields by conducting clinical research and
participating in pre-clinical studies. The members of our Scientific Advisory Board receive compensation in the form of cash payments
or option grants. All members of the Scientific Advisory Board provided us with their consent to be named in this annual report on Form
20-F and any materials related hereto.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><i>Dr.
Avraham Abutbul, M.D.,</i> has held numerous positions at the Hadassah Medical Center in Jerusalem, Israel, since 2008. Currently, Dr.
Abutbul has served a senior physician the Hadassah Medical Center&#8217;s Medical Intensive Care Unit and its Pulmonology Institute since
2017, in addition to leading the Hadassah Medical Center&#8217;s nationwide research of chronic obstructive pulmonary disease. Prior to
his current roles, Dr. Abutbul completed fellowship at the Institute of Pulmonology in 2016 and the General Intensive Care Unit in 2014.
Dr. Abutbul also completed residency at the Department of Internal Medicine in 2012. Dr. Abutbul is a lecturer at the Hebrew University
of Jerusalem, Israel and at the Hadassah Medical School, Jerusalem, Israel. Dr. Abutbul received his B.Med.Sc. from the Ruth and Bruce
Rappaport Faculty of Medicine in Haifa, Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><i>Professor
Daniel Brodie</i> is the Section Chief for Critical Care within the Division of Pulmonary, Allergy and Critical Care Medicine, the Director
of the Adult ECMO Program and the Director of the Center for Acute Respiratory Failure at the Columbia University/New York-Presbyterian
Hospital. Prof. Brodie is the President-elect of the Extracorporeal Life Support Organization (ELSO) and the chairman of the Executive
Committee of the International ECMO Network (ECMONet), two leading international organizations spearheading scientific knowledge in the
field of extracorporeal life support. He is currently on the Steering Committee of numerous ongoing and upcoming clinical trials in the
field. In addition, Prof. Brodie serves as a member of the National Heart, Lung, and Blood Institute&#8217;s (NHLBI) Protocol Review Committee
for the Prevention and Early Treatment of Acute Lung Injury (PETAL) Network. Prof. Brodie has served as a reviewer in influential scientific
journals, including the New England Journal of medicine, Lancet and JAMA. Prof Brodie has authored more than 300 peer-reviewed publications
and book chapters and has delivered nearly 400 invited lectures throughout the world.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Prof. Eddy Fan</i> is an
associate professor in the Interdepartmental Division of Critical Care Medicine and the Institute of Health Policy, Management and Evaluation
at the University of Toronto and a staff intensivist at the University Health Network/Mount Sinai Hospital in Toronto, Ontario. Prof.
Fan currently is the medical director of the extracorporeal life support program at the Toronto General Hospital. Dr. Fan received an
undergraduate degree from the University of Toronto, his medical degree from the University of Western Ontario and a doctorate in clinical
investigation from Johns Hopkins University. Among his most significant publications are: (1) &#8220;An Official American Thoracic Society/European
Society of Intensive Care Medicine/Society of Critical Care Medicine Clinical Practice Guideline: Mechanical Ventilation in Adult Patients
with Acute Respiratory Distress Syndrome&#8221; in the American Journal of Respiratory and Critical Care Medicine; (2) &#8220;Veno-venous
extracorporeal membrane oxygenation for acute respiratory failure: a clinical review from an international group of experts.&#8221; in
Intensive Care Medicine; and (3) Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in
intensive care units in 50 countries&#8221; published in JAMA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 88 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Dr. Orit Cohen Jacob</i>
is veterinary surgeon with a unique certified specialty in laboratory animal medicine. Dr. Jacob held numerous positions at the Israel
Institute for Biological Research in Ness Ziona, Israel, for 16 years, while leading the establishment of the biggest pre-clinical animal
facility and laboratories in Israel. At the Israel Institute for Biological Research, Dr. Jacob founded a GMP stable facility, for anti-serum
production for the State of Israel. Dr. Jacob participated as a surgeon and advisor, in her field of expertise, in a wide variety of research
studies, related to homeland security from 1999 to 2015. Dr. Jacob was a member of the national animal experimentation council of the
ministry of health, and head of the national ethics committee for animal experimentations from 2013 to 2018. Currently, Dr. Jacob is the
co-owner and chief executive officer of SeruMed GMP Ltd., which has been the sole manufacturer and provider of the anti-venom serum against
viper and echis snakes to the Ministry of Health of Israel since 2016. Furthermore, Dr. Jacob is the owner of BioSphera Consulting Ltd.,
through which she has been providing knowledge to bio-tech companies in all aspects of pre-clinical research, facility establishment,
GMP regulations, ethics and science since 2016.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Dr. Stefan Ledot</i> is
an expert in various clinical fields including critical care medicine, anesthesia, extracorporeal support and echocardiography. During
his career, he has undertaken a large number of educational duties, including advanced cardiovascular life support (ACLS) instruction,
critical care module for physiotherapists instruction, critical care module nursing school instruction, among others. Dr. Ledot is a highly
appreciated speaker in the critical care space. Dr. Ledot completed his accreditation for transesophageal echocardiography (TOE) from
the European Association of Cardiovascular Imaging and holds a European Diploma in Intensive Care. Dr. Ledot has served as a senior clinician
in critical care and anesthetics at Royal Brompton &amp; Harefield Hospitals in the United Kingdom and became the director of the ECMO
service and critical care. The Royal Brompton ECMO service is one of the largest in Europe and has been recognized as a center of excellence.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Dr. Yael Lichter </i>is
Director of the Medical Intensive Care Unit at Tel Aviv Sourasky Medical Center, where she completed her residency training in Internal
Medicine and Intensive Care. She also serves as Treasurer of the Israeli ECMO Society. Dr. Lichter served as a Captain in the IDF Medical
Corps, as a field doctor in combat units. She completed her medical training at the Tel Aviv University the Sackler Faculty of Medicine.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Dr. Sharon Marx</i> obtained
a PhD in physical organic chemistry from the Hebrew University, Jerusalem in 1996. Since 1996, Dr. Marx has worked at the Israel Institute
for Biological Research in the physical chemistry department. Dr. Marx was a fellow at the Israel Institute for Biological Researchand
is currently serving as the physical chemistry department head. From 2008 to 2010, Dr. Marx was an Assistant Professor (on sabbatical)
at the University of Pennsylvania and developed biocompatible fuel cells while there. Her research interests include sensor and biosensors
development, chemical sensor networks, molecularly imprinted polymers, chemiresistors, sensors for gas phase (air pollution and toxic
materials) and sensors for water quality.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Dr. Dekel Stavi, </i>medical
director, has considerable experience in leading Extracorporeal Life Support programs, and treating cardio and hemato-oncology patients
in the ICU. Prior to joining Critical Care at the University of Toronto, he served as a senior intensive care physician at the Tel Aviv
Sourasky Medical Center in Israel where he initiated its institutional ECMO program. Dr. Stavi&#8217;s notable publications include &#8220;Outcomes
of prolonged mechanical ventilation in patients who underwent bedside percutaneous dilatation tracheostomy in intermediate care units
- a single center study&#8221; and &#8220;Outcome and survival following tracheostomy in patients &#8805; 85 years old.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Dr. Dan Gorfil </i>is a
distinguished specialist in cardiac surgery and intensive care medicine. Dr. Gorfil is both the head of the Cardiothoracic Surgery Intensive
Care Unit and the ECMO program at the Department of Cardiothoracic Surgery at Rabin Medical Center, Israel. Dr. Gorfil&#8217;s expertise
is expected to significantly contribute to the deployment of the INSPIRA ART100.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 89 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Family Relationships</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are no family relationships
between any members of our executive management and our directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Arrangements for
Election of Directors and Members of Management</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">There
are no arrangements or understandings with major shareholders, customers, suppliers or others pursuant to which any of our executive management
or our directors were selected. See &#8220;Item 7.B. - Related Party Transactions&#8221; for additional information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="I_027"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-size: 10pt"><b>B.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Compensation</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table presents
all compensation paid by us to our five most highly compensated officers for the year ended December 31, 2024. The table does not include
any amounts we paid to reimburse any of such persons for costs incurred in providing us with services during this period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All amounts reported in the
tables below reflect the cost to the Company, in U.S. dollars, for the year ended December 31, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Amounts paid in NIS are translated
into U.S. dollars at the rate of NIS 3.699 = U.S. $1.00, based on the average representative rate of exchange between the NIS and the
U.S. dollar as reported by the Bank of Israel during such period of time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Salary,<br/> bonuses<br/> and</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Related</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Benefits</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pension,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Retirement</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>and Other</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Similar</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Benefits</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share<br/> Based<br/> Compensation</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-size: 10pt">Dagi Ben-Non, <i>Chief Executive Officer</i></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">314,412</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">21,022</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">470,653</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Joe Hayon, <i>President and Director</i></span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">316,376</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">21,022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">470,653</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Yafit Tehila, <i>Chief Financial Officer</i></span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">199,850</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">40,662</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">107,625</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Avi Shabtai, <i>Chief Operations Officer and VP of Research and Development</i></span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">245,115</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">55,776</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">147,582</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Daniella Yeheskely-Hayon, <i>Chief Technology Officer</i></span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">173,516</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">37,898</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">75,910</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For so long as we qualify
as a foreign private issuer, we will not be required to comply with the proxy rules applicable to U.S. domestic companies regarding disclosure
of the compensation of certain executive officers on an individual basis. Pursuant to the Companies Law, as a public company we are required
to disclose the annual compensation of our five most highly compensated officers on an individual basis. This disclosure will not be as
extensive as that required of a U.S. domestic issuer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><!-- Field: Page; Sequence: 90 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Employment Agreements
with Executive Officers </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have entered into written
employment agreements with each of our executive officers. All of these agreements contain customary provisions regarding noncompetition,
confidentiality of information and assignment of inventions. However, the enforceability of the noncompetition provisions may be limited
under applicable law. In addition, we entered into indemnification agreements, with each executive officer and director pursuant to which
we indemnify each of them up to a certain amount and to the extent that these liabilities are not covered by directors and officers insurance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">For
a description of the terms of our options and option plans, see &#8220;Item 6.E. Share Ownership-Equity Incentive Plan.<span style="font-variant: small-caps">&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span style="font-variant: small-caps">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b><i>Directors&#8217; Service Contracts</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other than with respect to
our directors that are also executive officers, we do not have written agreements with any director providing for benefits upon the termination
of his employment with our company. In our first annual general meeting as a public company, which took place in December 2021, we instituted
a yearly fixed fee in the amount of $40,000 for each of our currently serving directors who are not also executive officers (including
the current Chairman of our board of directors). However, on February 20, 2025, the Company&#8217;s compensation committee and board
of directors approved an increase in the yearly fixed fee of Mr. Tal Parnes, the Company&#8217;s chairman of the board of directors,
to $80,000, and an increase to the yearly fixed fee of Mrs. Limor Rozen and Mr. Lior Amit, the Company&#8217;s non-executive directors,
to $46,000, subject to the approval of the Company&#8217;s shareholders, which was not yet convened.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="I_028"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b>C.</b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><b>Board Practices. </b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Introduction</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors consists
of six members. We believe that Limor Rozen, Lior Amit, and Tal Parnes are &#8220;independent&#8221; for purposes of the Nasdaq rules.
Our amended and restated articles of association provide that the number of board of directors&#8217; members shall be set by the general
meeting of the shareholders provided that it will consist of not less than three (3) and not more than twelve (12). Pursuant to the Companies
Law, the management of our business is vested in our board of directors. Our board of directors may exercise all powers and may take all
actions that are not specifically granted to our shareholders or to management. Our executive officers are responsible for our day-to-day
management and have individual responsibilities established by our board of directors. Pursuant to the Companies Law, our Chief Executive
Officer is appointed by, and serves at the discretion of, our board of directors, subject to the employment agreement that we have entered
into with him. All other executive officers are appointed by our Chief Executive Officer. According to the Companies Law, their terms
of employment are subject to the approval of the board of directors&#8217; compensation committee and of the board of directors (and in
some cases are also subject to shareholders approval) and are subject to the terms of any applicable employment agreements that we may
enter into with them.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each director, except external
directors, if applicable, that may be required to be appointed under the Companies Law under certain circumstances, will hold office until
the next annual general meeting of our shareholders following his or her appointment, or until he or she resigns or unless he or she is
removed by a majority vote of our shareholders at a general meeting of our shareholders or upon the occurrence of certain events, in accordance
with the Companies Law and/or our amended and restated articles of association.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, under certain
circumstances, our amended and restated articles of association allow our board of directors to appoint directors to fill vacancies on
our board of directors or in addition to the acting directors (subject to the limitation set forth in our articles of association on
the number of directors), until the next annual general meeting or special general meeting in which directors term may be terminated.
External directors, if applicable, may be elected for up to two additional three-year terms after their initial three-year term under
the circumstances described below, with certain exceptions as described in &#8220;External Directors&#8221; below, and may be removed
from office only under the limited circumstances set forth in the Companies Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 91 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, any
shareholder holding at least one percent of our outstanding voting power may suggest nominating a director in an Annual General Meeting
of the shareholders. However, any such shareholder may make such a suggestion only if a written and timely notice of such shareholder&#8217;s
intent to make such nomination has been given to our board of directors, in accordance with the provisions of our amended and restated
articles of association and the Companies Law. Any such notice must include certain information, including the consent of the proposed
director nominee to serve as our director if elected, and a declaration that the nominee signed declaring that he or she possesses the
requisite skills and has the availability to carry out his or her duties. Additionally, the nominee must provide details of such skills,
and demonstrate an absence of any limitation under the Companies Law that may prevent his or her election, and affirm that all of the
required election-information is provided to us, pursuant to the Companies Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">However, under the Companies
Law regulations (exemptions applicable for Israeli companies whose shares are listed outside of Israel, 5760-2000 (the &#8220;<b>Exemptions
Regulations</b>&#8221;), one or more shareholders may request the company&#8217;s board of directors to include an appointment of a candidate
for a position on the board of directors or the termination of a board member, as an item on the agenda of a future general meeting (if
the company sees fit), provided that the shareholder hold at least five percent (5%) of the voting rights of the company, instead of one
percent (1%) as required in the past.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli law, we
are required to hold an annual general meeting of our shareholders once every calendar year, at such time and place which shall be determined
by our board of directors, that must be no later than 15 months after the date of the previous annual general meeting. All meetings other
than the annual general meeting of shareholders are referred to as special general meetings. Our board of directors may call special meetings
whenever it sees fit and upon the request of: (a) any two of our directors or such number of directors equal to one quarter of the directors
then at office; and/or (b) one or more shareholders holding, in the aggregate, (i) 5% or more of our outstanding issued shares and 1%
of our outstanding voting power or (ii) 5% or more of our outstanding voting power, or the Non Exempted Holding. However, under the Exemptions
Regulations, the board of directors of an Israeli company whose shares are listed outside of Israel, shall convene a special meeting at
the request of: (i) one or more shareholders holding at least ten percent (10%) of the issued and outstanding share capital instead of
five (5%) in the past, and at least one percent (1%) of the voting rights in the company, or (ii) one or more shareholders holding at
least ten percent (10%) of the voting rights in the company, unless the applicable law incorporated in the country in which the Company
is listed for trade, establishes a right to demand convening of such a meeting for those holding less than ten percent (10%) of the voting
rights in the company (in which case, the Non Exempted Holding shall apply).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, our
board of directors must determine the minimum number of directors who are required to have accounting and financial expertise. In determining
the number of directors required to have such expertise, our board of directors must consider, among other things, the type and size of
the company and the scope and complexity of its operations. Our board of directors has determined that the minimum number of directors
of our company who are required to have accounting and financial expertise is one.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The board of directors must
elect one director to serve as the chairman of the board of directors to preside at the meetings of the board of directors, and may also
remove that director as chairman. Pursuant to the Companies Law, neither the chief executive officer nor any of his or her relatives is
permitted to serve as the chairman of the board of directors, and a company may not vest the chairman or any of his or her relatives with
the chief executive officer&#8217;s authorities. In addition, a person who reports, directly or indirectly, to the chief executive officer
may not serve as the chairman of the board of directors; the chairman may not be vested with authorities of a person who reports, directly
or indirectly, to the chief executive officer; and the chairman may not serve in any other position in the company or a controlled company,
but he or she may serve as a director or chairman of a controlled company. However, the Companies Law permits a company&#8217;s shareholders
to determine, for a period not exceeding three years from each such determination, that the chairman or his or her relative may serve
as chief executive officer or be vested with the chief executive officer&#8217;s authorities, and that the chief executive officer or
his or her relative may serve as chairman or be vested with the chairman&#8217;s authorities. Such determination of a company&#8217;s
shareholders requires either: (1) the approval of at least a majority of the shares of those shareholders present and voting on the matter
(other than controlling shareholders and those having a personal interest in the determination) (shares held by abstaining shareholders
shall not be considered); or (2) that the total number of shares opposing such determination does not exceed 2% of the total voting power
in the company. Currently, we have a separate chairman and chief executive officer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 92 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The board of directors may,
subject to the provisions of the Companies Law, delegate some of its powers to committees of the board, and it may, from time to time,
revoke such delegation or alter the composition of any such committees, subject to certain limitations. Unless otherwise expressly provided
by the board of directors, the committees shall not be empowered to further delegate such powers. The composition and duties of our audit
committee, financial statement examination committee and compensation committee are described below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The board of directors oversees
how management monitors compliance with our risk management policies and procedures, and reviews the adequacy of the risk management framework
in relation to the risks faced by us. The board of directors is assisted in its oversight role by an internal auditor. The internal auditor
undertakes both regular and ad hoc reviews of risk management controls and procedures, the results of which are reported to our audit
committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>External Directors</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Under
the Companies Law, except as provided below, companies incorporated under the laws of the State of Israel that are publicly traded, including
Israeli companies with shares listed on the Nasdaq, are required to appoint at least two external directors who meet the qualification
requirements set forth in the Companies Law. The definitions of an external director under the Companies Law and independent director
under Nasdaq rules are similar such that it would generally be expected that our two external directors will also comply with the independence
requirement under Nasdaq rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under regulations promulgated
pursuant to the Companies Law, a company with no controlling shareholder whose shares are listed for trading on specified exchanges outside
of Israel, including Nasdaq, may adopt exemptions from various corporate governance requirements of the Companies Law, so long as such
company satisfies the requirements of applicable foreign country laws and regulations, including applicable stock exchange rules, that
apply to companies organized in that country and relating to the appointment of independent directors and the composition of audit and
compensation committees. Such exemptions include an exemption from the requirement to appoint external directors and the requirement that
an external director be a member of certain committees, as well as exemption from limitations on directors&#8217; compensation. We do
not currently have a controlling shareholder and we use this exemption from the requirement described herein.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Independent Directors Under the Companies
Law</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An &#8220;independent director&#8221;
under the Companies Law is either an external director or a director who meets the same non-affiliation criteria as an external director
(except for (i) the requirement that the director be an Israeli resident (which does not apply to companies such as ours whose securities
have been offered outside of Israel or are listed outside of Israel) and (ii) the requirement for accounting and financial expertise or
professional qualifications), as determined by the audit committee, and who has not served as a director of the company for more than
nine consecutive years. For these purposes, ceasing to serve as a director for a period of two years or less would not be deemed to sever
the consecutive nature of such director&#8217;s service.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the Exemptions
Regulations, a director in a public company whose shares are listed for trading on specified exchanges outside of Israel, including on
the Nasdaq Capital Market, who qualifies as an independent director under the relevant non-Israeli rules and who meets certain non-affiliation
criteria, which are less stringent than those applicable to independent directors as set forth above, would be deemed an &#8220;independent&#8221;
director pursuant to the Companies Law provided: (i) he or she has not served as a director for more than nine consecutive years; (ii)
he or she has been approved as such by the audit committee; and (iii) his or her remuneration shall be in accordance with the Companies
Law and the regulations promulgated thereunder. For these purposes, ceasing to serve as a director for a period of two years or less would
not be deemed to sever the consecutive nature of such director&#8217;s service.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, pursuant to these
regulations, such company may reappoint a person as an independent director for additional terms, beyond nine years, which do not exceed
three years each, if each of the audit committee and the board of directors determine, in that order, that in light of the independent
director&#8217;s expertise and special contribution to the board of directors and its committees, the reappointment for an additional
term is in the company&#8217;s best interest.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 93 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Alternate Directors</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Our
amended and restated articles of association provide, as allowed by the Companies Law, that any director may, subject to the conditions
set thereto including approval of the nominee by our board of directors, appoint a person as an alternate to act in his place, to remove
the alternate and appoint another in his place and to appoint an alternate in place of an alternate whose office is vacated for any reason
whatsoever. Under the Companies Law, a person who is not qualified to be appointed as a director, a person who is already serving as a
director or a person who is already serving as an alternate director for another director, may not be appointed as an alternate director.
Nevertheless, a director who is already serving as a director may be appointed as an alternate director for a member of a committee of
the board of directors so long as he or she is not already serving as a member of such committee, and if the alternate director is to
replace an external director, he or she is required to be an external director and to have either &#8220;financial and accounting expertise&#8221;
or &#8220;professional expertise,&#8221; depending on the qualifications of the external director he or she is replacing. A person who
does not have the requisite &#8220;financial and accounting experience&#8221; or the &#8220;professional expertise,&#8221; depending on
the qualifications of the external director he or she is replacing, may not be appointed as an alternate director for an external director.
A person who is not qualified to be appointed as an independent director, pursuant to the Companies Law, may not be appointed as an alternate
director of an independent director qualified as such under the Companies Law. Unless the appointing director limits the time or scope
of the appointment, the appointment is effective for all purposes until the appointing director ceases to be a director or terminates
the appointment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Committees of the Board of Directors </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors has
established two standing statutory committees, the audit committee and the compensation committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Audit Committee</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, the
board of directors of any public company must establish an audit committee. The audit committee must be comprised of at least three directors,
including all of the external directors, if applicable, (one of whom must serve as chair of the committee). The audit committee may not
include the chairman of the board; a director employed by the company or by a controlling shareholder of the company or by an entity controlled
by a controlling shareholder; a controlling shareholder or a relative of a controlling shareholder; a director employed by or providing
services on a regular basis to the company, to a controlling shareholder or to an entity controlled by a controlling shareholder, or a
director who derives most of his or her income from a controlling shareholder. In addition, a majority of the members of the audit committee
of a publicly traded company must be independent directors under the Companies Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">However, under the Exemptions
Regulations, a company with no controlling shareholder might be exempted from certain obligations mentioned above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our audit committee is comprised
of Lior Amit, Limor Rozen and Tal Parnes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, our
audit committee is responsible for, among other things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">(i)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">determining whether there are deficiencies in the business management practices of our company, and making recommendations to the board of directors to improve such practices; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">(ii)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">determining whether to approve certain related party transactions (including transactions in which an office holder has a personal interest and whether such transaction is extraordinary or material under Companies Law) and establishing the approval process for certain transactions with a controlling shareholder or in which a controlling shareholder has a personal interest; (see &#8220;Item 6.C. Directors, Senior Management and Employees-Board Practices-Approval of Related Party Transactions under Israeli law&#8221;); </span></td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 94 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in"><span style="font-size: 10pt">(iii)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">determining the approval process for transactions that are &#8220;non-negligible&#8221; (i.e., transactions with a controlling shareholder that are classified by the audit committee as non-negligible, even though they are not deemed extraordinary transactions), as well as determining which types of transactions would require the approval of the audit committee, optionally based on criteria which may be determined annually in advance by the audit committee;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">(iv)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">examining our internal controls and internal auditor&#8217;s performance, including whether the internal auditor has sufficient resources and tools to dispose of its responsibilities; </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">(v)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">examining the scope of our auditor&#8217;s work and compensation and submitting a recommendation with respect thereto to our board of directors or shareholders, depending on which of them is considering the appointment of our auditor;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">(vi)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">establishing procedures for the handling of employees&#8217; complaints as to deficiencies in the management of our business and the protection to be provided to such employees; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">(vii)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">where the board of directors approves the working plan of the internal auditor, examining such working plan before its submission to the board of directors and proposing amendments thereto.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our audit committee may not
conduct any discussions or approve any actions requiring its approval (see &#8220;Item 6.C. Directors, Senior Management and Employees-Board
Practices-Approval of Related Party Transactions under Israeli law&#8221;); unless at the time of the approval a majority of the committee&#8217;s
members are present, which majority consists of independent directors under the Companies Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors has
adopted an audit committee charter setting forth, among others, the responsibilities of the audit committee consistent with the rules
of the SEC and Nasdaq rules (in addition to the requirements for such committee under the Companies Law), including, among others, the
following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">oversight of our independent registered public accounting firm and recommending the engagement, compensation or termination of engagement of our independent registered public accounting firm to the board of directors in accordance with Israeli law;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">recommending the engagement or termination of the person filling the office of our internal auditor, reviewing the services provided by our internal auditor and reviewing effectiveness of our system of internal control over financial reporting;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">recommending the terms of audit and non-audit services provided by the independent registered public accounting firm for pre-approval by our board of directors; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">reviewing and monitoring, if applicable, legal matters with significant impact, finding of regulatory authorities&#8217; findings, receive reports regarding irregularities and legal compliance, acting according to &#8220;whistleblower policy&#8221; and recommend to our board of directors if so required.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 95 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Nasdaq Stock Market Requirements for Audit
Committee</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Nasdaq rules, we
are required to maintain an audit committee consisting of at least three members, all of whom are independent and are financially literate
and one of whom has accounting or related financial management expertise.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As noted above, the members
of our audit committee include Lior Amit, Tal Parnes and Limor Rozen. Mr. Amit serves as the chairman of our audit committee. All members
of our audit committee meet the requirements for financial literacy, and are each &#8220;independent&#8221;, as both terms are defined
under the Nasdaq rules. Our board of directors has determined that each member of our audit committee is an audit committee financial
expert as defined by the SEC rules and has the requisite financial experience as defined by the Nasdaq rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, our
audit committee also carries out the duties of a financial statement examination committee. As such, the audit committee is responsible
to discuss and provide recommendations to its board of directors (including the report of any deficiency found) with respect to the following
issues: (i) estimations and assessments made in connection with the preparation of financial statements; (ii) internal controls related
to the financial statements; (iii) completeness and propriety of the disclosure in the financial statements; (iv) the accounting policies
adopted and the accounting treatments implemented in material matters of the company; and (v) value evaluations, including the assumptions
and assessments on which evaluations are based and the supporting data in the financial statements. Our independent registered public
accounting firm and our internal auditor are invited to attend all meetings of our financial statements examination committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Compensation Committee</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, the
board of directors of any public company must establish a compensation committee. The compensation committee must be comprised of at least
three directors, including all of the external directors (if applicable), who if applicable must constitute a majority of the members
of the compensation committee. Each compensation committee member that is not an external director must be a director whose compensation
does not exceed an amount that may be paid to an external director. The compensation committee is subject to the same Companies Law restrictions
as the audit committee as to: (a) who may not be a member of the committee; and (b) who may not be present during committee deliberations
as described above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">However, under the Exemptions
Regulations, a company with no controlling shareholder might be exempted from certain obligations mentioned above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our compensation committee,
acting pursuant to a written charter, consists of Lior Amit, Limor Rozen and Tal Parnes. Tal Parnes serves as the chairman of our compensation
committee. Our compensation committee complies with the provisions of the Companies Law, the regulations promulgated thereunder, and our
amended and restated articles of association, on all aspects referring to its independence, authorities and practice. Our compensation
committee follows home country practice as opposed to complying with the compensation committee membership and charter requirements prescribed
under the Nasdaq rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our compensation committee
reviews and recommends to our board of directors (and in accordance with the provisions of our amended and restated compensation policy):
with respect to our executive officers&#8217; and directors&#8217;: (1) annual base compensation; (2) annual incentive bonus, including
the specific goals and amounts; (3) equity compensation; (4) employment agreements, severance arrangements, and change in control agreements
and provisions; (5) retirement grants and/or retirement bonuses; and (6) any other benefits, compensation, compensation policies or arrangements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 96 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The duties of the compensation
committee include the recommendation to the company&#8217;s board of directors of a policy regarding the terms of engagement of office
holders, to which we refer as a compensation policy. Every three years (or following five years from its initial public offering), such
policy must be adopted by the company&#8217;s board of directors, after considering the recommendations of the compensation committee.
The compensation policy is then brought for approval by our shareholders, which requires a special majority (see &#8220;Item 6.C. Directors,
Senior Management and Employees-Board Practices-Approval of Related Party Transactions under Israeli law&#8221;). Under the Companies
Law, and under certain conditions, the board of directors may adopt the compensation policy if it is not approved by the shareholders,
provided that after the shareholders oppose the approval of such policy, the compensation committee and the board of directors revisit
the matter and determine that adopting the compensation policy is in our best interests.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 17, 2021, a general
meeting of our shareholders approved the adoption of a compensation policy for our officers and directors for a period of five years,
or the compensation policy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The compensation policy serves
as the basis for decisions concerning the financial terms of employment or engagement of executive officers and directors, including exemption,
insurance, indemnification or any monetary payment or obligation of payment in respect of employment or engagement. The compensation policy
relates to certain factors, including advancement of our objectives, our business and long-term strategy and creation of appropriate incentives
for executives. It also considers, among other things, our risk management, size and the nature of our operations. The compensation policy
further considers the following additional factors:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the education, skills, expertise and accomplishments of the relevant director or executive;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the director&#8217;s or executive&#8217;s roles and responsibilities and prior compensation agreements with him or her;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the relationship between the cost of the terms of service of an office holder and the average median compensation of the other employees of the company (including those employed through manpower companies), including the impact of disparities in salary upon work relationships in our company;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the possibility of reducing variable compensation at the discretion of the board of directors; and the possibility of setting a limit on the exercise value of non-cash variable compensation; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">as to severance compensation, the period of service of the director or executive, the terms of his or her compensation during such service period, our performance during that period of service, the person&#8217;s contribution towards the achievement of our goals and the maximization of our profits, and the circumstances under which the person is leaving the company.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The compensation policy also
includes the following principles:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">with the exception of office holders who report directly to the chief executive officer, the link between variable compensation and long-term performance and measurable criteria;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the relationship between variable and fixed compensation, and the ceiling for the value of variable compensation at the time of its grant;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the conditions under which a director or executive are required to repay compensation paid to him or her if it was later shown that the data upon which such compensation was based was inaccurate and was required to be restated in the company&#8217;s financial statements;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the minimum holding or vesting period for variable, equity-based compensation; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">maximum limits for severance compensation.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 97 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The compensation policy also
considers appropriate incentives from a long-term perspective.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The compensation committee
is responsible for: (1) recommending the compensation policy to a company&#8217;s board of directors for its approval (and subsequent
approval by the shareholders); and (2) duties related to the compensation policy and to the compensation of a company&#8217;s office holders,
including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">recommending whether a compensation policy should continue in effect, if the then-current policy has a term of greater than three years (approval of either a new compensation policy or the continuation of an existing compensation policy must in any case occur every three years);</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">recommending to the board of directors periodic updates to the compensation policy;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">assessing implementation of the compensation policy;</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">administering the Company&#8217;s clawback policy;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">determining whether the terms of compensation of certain office holders need not be brought to approval of the shareholders; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">determining whether to approve the terms of compensation of office holders that require the committee&#8217;s approval.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our compensation policy is
designed to promote our long-term goals, work plan and policy, retain, motivate and incentivize our directors and executive officers,
while considering the risks that our activities involve, our size, the nature and scope of our activities and the contribution of an officer
to the achievement of our goals and maximization of profits, and align the interests of our directors and executive officers with our
long-term performance. To that end, a portion of an executive officer compensation package is targeted to reflect our short and long-term
goals, as well as the executive officer&#8217;s individual performance. On the other hand, our compensation policy includes measures designed
to reduce the executive officer&#8217;s incentives to take excessive risks that may harm us in the long-term, such as limits on the value
of cash bonuses and equity-based compensation, limitations on the ratio between the variable and the total compensation of an executive
officer and minimum vesting periods for equity-based compensation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our compensation policy also
addresses our executive officer&#8217;s individual characteristics (such as his or her respective position, education, scope of responsibilities
and contribution to the attainment of our goals) as the basis for compensation variation among our executive officers, and considers the
internal ratios between compensation of our executive officers and directors and other employees. For example, the compensation that may
be granted to an executive officer may include base salary, annual bonuses, equity-based compensation, benefits and retirement and termination
of service arrangements. All cash bonuses are limited to a maximum amount linked to the executive officer&#8217;s base salary. In addition,
our compensation policy provides for maximum permitted ratios between the total variable (cash bonuses and equity-based compensation)
and non-variable (base salary) compensation components, in accordance with an officer&#8217;s respective position with the company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An annual cash bonus may be
awarded to executive officers upon the attainment of pre-set periodic objectives and individual targets. The annual cash bonus that may
be granted to subordinate officeholders may be based entirely on a discretionary evaluation. Our Chief Executive Officer will be entitled
to recommend performance objectives to such executive officers, and such performance objectives will be approved by our compensation committee
(and, if required by law, by our board of directors).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The performance measurable
objectives of our chairman and Chief Executive Officer are determined annually by our compensation committee and board of directors. A
less significant portion of the chairman&#8217;s and/or the Chief Executive Officer&#8217;s annual cash bonus may be based on a discretionary
evaluation of the chairman&#8217;s or the Chief Executive Officer&#8217;s respective overall performance by the compensation committee
and the board of directors based on quantitative and qualitative criteria.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 98 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The equity-based compensation
under our compensation policy for our executive officers (including members of our board of directors) is designed in a manner consistent
with the underlying objectives in determining the base salary and the annual cash bonus, with its main objectives being to enhance the
alignment between the executive officers&#8217; interests with our long-term interests and those of our shareholders and to strengthen
the retention and the motivation of executive officers in the long term. Our compensation policy provides for executive officer compensation
in the form of share options or other equity-based awards, such as restricted shares and phantom, options, in accordance with our equity
incentive plan then in place. Share options granted to executive officers are subject to vesting periods in order to promote long-term
retention of the awarded executive officers. The equity-based compensation is granted from time to time and be individually determined
and awarded according to the performance, educational background, prior business experience, qualifications, role and the personal responsibilities
of the executive officer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, our compensation
policy contains compensation recovery provisions which allows us under certain conditions to recover bonuses paid in excess, enables our
Chief Executive Officer to approve an immaterial change in the terms of employment of an executive officer (provided that the changes
of the terms of employment are in accordance our compensation policy) and allows us to exempt, indemnify and insure our executive officers
and directors subject to certain limitations set forth thereto.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our compensation policy also
provides for compensation to the members of our board of directors either: (i) in accordance with the amounts provided in the Companies
Regulations (Rules Regarding the Compensation and Expenses of an External Director) of 2000, as amended by the Companies Regulations
(Relief for Public Companies Traded in Stock Exchange Outside of Israel) of 2000, as such regulations may be amended from time to time;
or (ii) in accordance with the amounts determined in our compensation policy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Nasdaq Requirements for Compensation Committee</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Nasdaq rules, we
are required to maintain a compensation committee consisting of at least two members, each of whom are independent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As noted above, the members
of our compensation committee include Mr. Parnes, Mr. Amit, and Mrs. Rozen, each of whom is &#8220;independent&#8221;, as such term is
defined in under Nasdaq rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Internal Auditor </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, the
board of directors of an Israeli public company must appoint an internal auditor nominated by the audit committee. Our internal auditor
Chaim Yechezkely, CPA (Isr) who has been serving as our internal auditor since October 2021, is a Certified Public Accountant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The role of the internal auditor
is to examine, among other things, whether a company&#8217;s actions comply with the law and proper business procedure. The audit committee
is required to oversee the activities, and to assess the performance of the internal auditor as well as to review the internal auditor&#8217;s
work plan. An internal auditor may not be an interested party or office holder, or a relative of any interested party or office holder,
and may not be a member of the company&#8217;s independent accounting firm or its representative. The Companies Law defines an interested
party as a holder of 5% or more of the outstanding shares or voting rights of a company, any person or entity that has the right to appoint
at least one director or the general manager of the company or any person who serves as a director or as the general manager of a company.
Our internal auditor is not an interested party in the Company and not our employee, but partner of a firm which specializes in internal
auditing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Remuneration of Directors</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, remuneration
of directors is subject to the approval of the compensation committee, thereafter by the board of directors and thereafter, unless exempted
under the regulations promulgated under the Companies Law, by the general meeting of the shareholders. In case the remuneration of the
directors is in accordance with regulations applicable to remuneration of the external directors then such remuneration shall be exempt
from the approval of the general meeting. Where the director is also a controlling shareholder, the requirements for approval of transactions
with controlling shareholders apply. In our 2021 general meeting of shareholders, we instituted a yearly fixed fee in the amount of $40,000
for all of our currently serving non-executive directors, including the chairman of our board of directors. However, on February 20, 2025, the Company&#8217;s compensation committee and board of directors approved an
increase in the yearly fixed fee of Mr. Tal Parnes, the Company&#8217;s chairman of the board of directors, to $80,000, and an increase
to the yearly fixed fee of Mrs. Limor Rozen and Mr. Lior Amit, the Company&#8217;s non-executive directors, to $46,000, subject to the
approval of the Company&#8217;s shareholders, which was not yet convened.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Page; Sequence: 99 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Fiduciary Duties of Office Holders</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law imposes
a duty of care and a duty of loyalty on all office holders of a company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The duty of care requires
an office holder to act with the level of care with which a reasonable office holder in the same position would have acted under the same
circumstances. The duty of care of an office holder includes a duty to use reasonable means to obtain:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">information on the profitability of a given action brought for his approval or performed by him by virtue of his position; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">all other important information pertaining to these actions.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The duty of loyalty of an
office holder requires an office holder to act in good faith and for the benefit of the company, and includes a duty to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">refrain from any conflict of interest between the performance of his duties in the company and his performance of his other duties or personal affairs;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">refrain from any action that is competitive with the company&#8217;s business;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">refrain from exploiting any business opportunity of the company to receive a personal gain for himself or others; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">disclose to the company any information or documents relating to the company&#8217;s affairs which the office holder has received due to his position as an office holder.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Insurance</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, a
company may obtain insurance for any of its office holders against the following liabilities incurred due to acts he or she performed
as an office holder, if and to the extent provided for in the company&#8217;s articles of association:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">breach of his or her duty of care to the company or to another person, to the extent such a breach arises out of the negligent conduct of the office holder;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">a breach of his or her duty of loyalty to the company, provided that the office holder acted in good faith and had reasonable cause to assume that his or her act would not prejudice the company&#8217;s interests; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">a financial liability imposed upon him or her in favor of another person.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently have directors&#8217;
and officers&#8217; liability insurance, providing total coverage of $5 million for the benefit of the Company and all of our directors
and officers, in respect of which we paid a twelve-month premium of approximately $160,000, which expires in July 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 100 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Indemnification</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law, and the
Israeli Securities Law, 5728-1968, or the Securities Law, provide that a company may indemnify an office holder against the following
liabilities and expenses incurred for acts performed by him or her as an office holder, either pursuant to an undertaking made in advance
of an event or following an event, provided its articles of association include a provision authorizing such indemnification:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">a financial liability imposed on him or her in favor of another person by any judgment concerning an act performed in his or her capacity as an office holder, including a settlement or arbitrator&#8217;s award approved by a court;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">reasonable litigation expenses, including attorneys&#8217; fees, expended by the office holder (a) as a result of an investigation or proceeding instituted against him or her by an authority authorized to conduct such investigation or proceeding, provided that (1) no indictment (as defined in the Companies Law) was filed against such office holder as a result of such investigation or proceeding; and (2) no financial liability as a substitute for the criminal proceeding (as defined in the Companies Law) was imposed upon him or her as a result of such investigation or proceeding, or, if such financial liability was imposed, it was imposed with respect to an offense that does not require proof of criminal intent; or (b) in connection with a monetary sanction;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">reasonable litigation expenses, including attorneys&#8217; fees, expended by the office holder or imposed on him or her by a court (1) in proceedings that the company institutes, or that another person institutes on the company&#8217;s behalf, against him or her; (2) in a criminal proceedings of which he or she was acquitted; or (3) as a result of a conviction for a crime that does not require proof of criminal intent; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">expenses incurred by an office holder in connection with an Administrative Procedure under the Securities Law, including reasonable litigation expenses and reasonable attorneys&#8217; fees. An &#8220;Administrative Procedure&#8221; is defined as a procedure pursuant to chapters H3 (Monetary Sanction by the Israeli Securities Authority), H4 (Administrative Enforcement Procedures of the Administrative Enforcement Committee) or I1 (Arrangement to prevent Procedures or Interruption of procedures subject to conditions) to the Securities Law.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law also permits
a company to undertake in advance to indemnify an office holder, provided that if such indemnification relates to financial liability
imposed on him or her, as described above, then the undertaking should be limited and shall detail the following foreseen events and amount
or criterion:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">to events that in the opinion of the board of directors can be foreseen based on the company&#8217;s activities at the time that the undertaking to indemnify is made; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">in amount or criterion determined by the board of directors, at the time of the giving of such undertaking to indemnify, to be reasonable under the circumstances.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We entered into indemnification
agreements with all of our directors and with all members of our senior management. Each such indemnification agreement provides the office
holder with indemnification permitted under applicable law and up to a certain amount, and to the extent that these liabilities are not
covered by directors and officers insurance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 101 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Exemption</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span>Under
the Companies Law, an Israeli company may not exempt an office holder from liability for a breach of his or her duty of loyalty, but may
exempt in advance an office holder from his or her liability to the company, in whole or in part, for damages caused to the company as
a result of a breach of his or her duty of care (other than in relation to distributions), but only if a provision authorizing such exemption
is included in its articles of association. Our amended and restated articles of association provide that we may exempt, in whole or in
part, any office holder from liability to us for damages caused to the company as a result of a breach of his or her duty of care, but
prohibit an exemption from liability arising from a company&#8217;s transaction in which our controlling shareholder or officer has a
personal interest. Subject to the aforesaid limitations, under the indemnification agreements, we exempt and release our office holders
from any and all liability to us related to any breach by them of their duty of care to us to the fullest extent permitted by law.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Limitations</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span>The
Companies Law provides that the Company may not exempt or indemnify an office holder nor enter into an insurance contract that would provide
coverage for any liability incurred as a result of any of the following: (1) a breach by the office holder of his or her duty of loyalty
unless (in the case of indemnity or insurance only, but not exemption) the office holder acted in good faith and had a reasonable basis
to believe that the act would not prejudice us; (2) a breach by the office holder of his or her duty of care if the breach was carried
out intentionally or recklessly (as opposed to merely negligently); (3) any act or omission committed with the intent to derive an illegal
personal benefit; or (4) any fine, monetary sanction, penalty or forfeit levied against the office holder.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><span>Under
the Companies Law, exemption, indemnification and insurance of office holders in a public company must be approved by the compensation
committee and the board of (and, with respect to directors and the chief executive officer, by the shareholders). However, under regulations
promulgated under the Companies Law, the insurance of office holders shall not require shareholders&#8217; approval and may be approved
by only the compensation committee (and, in case a controlling shareholder is an office holder, the board of directors as well), if the
engagement terms are determined in accordance with the company&#8217;s compensation policy that was approved by the shareholders by the
same special majority required to approve a compensation policy, provided that the insurance policy is on market terms and the insurance
policy is not likely to materially impact the company&#8217;s profitability, assets or obligations. &#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our amended and restated articles
of association permit us to exempt (subject to the aforesaid limitation), indemnify and insure our office holders to the fullest extent
permitted or to be permitted by the Companies Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The foregoing descriptions
summarize the material aspects and practices of our board of directors. For additional details, we also refer you to the full text of
the Companies Law, as well as of our amended and restated articles of association, which is an exhibit to this annual report on Form 20-F.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are no service contracts
between us, on the one hand, and our directors in their capacity as directors, on the other hand, providing for benefits upon termination
of service.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Approval of Related Party Transactions under
Israeli Law</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>General</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Under
the Companies Law, we may approve an action by an office holder from which the office holder would otherwise have to refrain, as described
above, if:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the office holder acts in good faith and the act or its approval does not cause harm to the company; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the office holder disclosed the nature of his or her interest in the transaction (including any significant fact or document) to the company at a reasonable time before the company&#8217;s approval of such matter.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 102 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Disclosure of Personal Interests of an Office
Holder</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
Companies Law requires that an office holder disclose to the company, promptly, and, in any event, not later than the board meeting at
which the transaction is first discussed, any direct or indirect personal interest that he or she may have and all related material information
known to him or her relating to any existing or proposed transaction by the company. If the transaction is an extraordinary transaction,
the office holder must also disclose any personal interest held by:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the office holder&#8217;s relatives; or</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">any corporation in which the office holder or his or her relatives holds 5% or more of the shares or voting rights, serves as a director or general manager or has the right to appoint at least one director or the general manager.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">An
office holder is not, however, obliged to disclose a personal interest if it derives solely from the personal interest of his or her relative
in a transaction that is not considered an extraordinary transaction. Under the Companies Law, an extraordinary transaction is a transaction:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">not in the ordinary course of business;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">not on market terms; or</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">that is likely to have a material effect on the company&#8217;s profitability, assets or liabilities.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
Companies Law does not specify to whom within us nor the manner in which required disclosures are to be made. We require our office holders
to make such disclosures to our board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Under
the Companies Law, once an office holder complies with the above disclosure requirement, the board of directors may approve a transaction
between the company and an office holder, or a third party in which an office holder has a personal interest, unless the articles of association
provide otherwise and provided that the transaction is in the company&#8217;s interest. If the transaction is an extraordinary transaction
in which an office holder has a personal interest, first the audit committee and then the board of directors, in that order, must approve
the transaction. Under specific circumstances, shareholder approval may also be required. Generally, a person who has a personal interest
in a matter which is considered at a meeting of the board of directors or the audit committee may not be present at such a meeting unless
the chairman of the audit committee or board of directors (as applicable) determines that he or she should be present in order to present
the transaction that is subject to approval. A director who has a personal interest in a transaction, which is considered at a meeting
of the board of directors or the audit committee, may not be present at this meeting or vote on this matter, unless a majority of members
of the board of directors or the audit committee, as the case may be, has a personal interest. If a majority of the board of directors
has a personal interest, then shareholder approval is generally also required.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Disclosure of Personal Interests of a Controlling
Shareholder</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Under
the Companies Law, the disclosure requirements that apply to an office holder also apply to a controlling shareholder of a public company.
Extraordinary transactions with a controlling shareholder or in which a controlling shareholder has a personal interest, including a private
placement in which a controlling shareholder has a personal interest, as well as transactions for the provision of services whether directly
or indirectly by a controlling shareholder or his or her relative, or a company such controlling shareholder controls, and transactions
concerning the terms of engagement and compensation of a controlling shareholder or a controlling shareholder&#8217;s relative, whether
as an office holder or an employee, require the approval of the audit committee or the compensation committee, as the case may be, the
board of directors and a majority of the shares voted by the shareholders of the company participating and voting on the matter in a shareholders&#8217;
meeting. In addition, the shareholder approval must fulfill one of the following requirements:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">at least a majority of the shares held by shareholders who have no personal interest in the transaction and are voting at the meeting must be voted in favor of approving the transaction, excluding abstentions; or</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the shares voted by shareholders who have no personal interest in the transaction who vote against the transaction represent no more than 2% of the voting rights in the company.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 103 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, any extraordinary
transaction with a controlling shareholder or in which a controlling shareholder has a personal interest with a term of more than three
years requires the aforementioned approval every three years; however, such transactions can be approved for a longer term, provided that
the audit committee determines that such longer term is reasonable under the circumstances. In addition, under Companies Law regulations,
subject to certain terms, such transactions can be extended or approved after three years only by the audit committee and the board of
directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
Companies Law requires that every shareholder that participates, in person, by proxy or by voting instrument, in a vote regarding a transaction
with a controlling shareholder, must indicate in advance or in the ballot whether or not that shareholder has a personal interest in the
vote in question. Failure to so indicate will result in the invalidation of that shareholder&#8217;s vote.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
term &#8220;controlling shareholder&#8221; is defined in the Companies Law as a shareholder with the ability to direct the activities
of the company, other than by virtue of being an office holder. A shareholder is presumed to be a controlling shareholder if the shareholder
holds 50% or more of the voting rights in a company or has the right to appoint 50% or more of the directors of the company or its general
manager. In the context of a transaction involving a shareholder of the company, a controlling shareholder also includes a shareholder
who holds 25% or more of the voting rights in the company if no other shareholder holds more than 50% of the voting rights in the company.
For this purpose, the holdings of all shareholders who have a personal interest in the same transaction will be aggregated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Approval of the Compensation of Directors and
Executive Officers</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The compensation of, or an
undertaking to indemnify, insure or exempt, an office holder who is not a director requires the approval of our compensation committee,
followed by the approval of the company&#8217;s board of directors, and, if such compensation arrangement or an undertaking to indemnify,
insure or exempt is inconsistent with our compensation policy, or if the said office holder is the chief executive officer of the company
(subject to a number of specific exceptions), then such arrangement is subject to the approval of our shareholders, subject to a special
majority requirement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Directors</i>. Under the
Companies Law, the compensation of our directors requires the approval of our compensation committee, the subsequent approval of the board
of directors and, unless exempted under the regulations promulgated under the Companies Law, the approval of the general meeting of our
shareholders. If the compensation of our directors is inconsistent with our stated compensation policy, then, provided that those provisions
that must be included in the compensation policy according to the Companies Law have been considered by the compensation committee and
board of directors, shareholder approval by a special majority will be required.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Executive officers other
than the chief executive officer.</i> The Companies Law requires the approval of the compensation of a public company&#8217;s executive
officers (other than the chief executive officer) in the following order: (i) the compensation committee, (ii) the company&#8217;s board
of directors, and (iii) only if such compensation arrangement is inconsistent with the company&#8217;s stated compensation policy, the
company&#8217;s shareholders by a special majority. However, if the shareholders of the company do not approve a compensation arrangement
with an executive officer that is inconsistent with the company&#8217;s stated compensation policy, the compensation committee and board
of directors may override the shareholders&#8217; decision if each of the compensation committee and the board of directors reconvene
and provide detailed reasons for their decision (including a discussion regarding the shareholders&#8217; decision).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Chief executive officer.</i>
Under the Companies Law, the compensation of a public company&#8217;s chief executive officer is required to be approved by: (i) the company&#8217;s
compensation committee; (ii) the company&#8217;s board of directors, and (iii) the company&#8217;s shareholders by a special majority.
However, if the shareholders of the company do not approve the compensation arrangement with the chief executive officer, the compensation
committee and board of directors may override the shareholders&#8217; decision if each of the compensation committee and the board of
directors reviewed and reapproved the terms of the compensation, considering that the shareholders did not approve the terms of compensation,
and provides detailed reasons for their decision. In addition, the compensation committee may exempt the engagement terms of a candidate
to serve as the chief executive officer from shareholders&#8217; approval, if the compensation committee determines that the compensation
arrangement is consistent with the company&#8217;s stated compensation policy, that the chief executive officer did not have a prior business
relationship or affiliation with the company or a controlling shareholder of the company, and that subjecting the approval to a shareholder
vote would impede the company&#8217;s ability to attain the candidate to serve as the company&#8217;s chief executive officer (and provide
detailed reasons for the latter).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 104 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The approval of each of the
compensation committee and the board of directors, with regard to the office holders and directors above, should be in accordance with
the company&#8217;s stated compensation policy; however, under special circumstances, the compensation committee and the board of directors
may approve compensation terms of a chief executive officer that are inconsistent with the company&#8217;s compensation policy provided
that they have considered those provisions that must be included in the compensation policy according to the Companies Law and that shareholder
approval was obtained by a special majority requirement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Duties of Shareholders</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Under
the Companies Law, a shareholder has a duty to refrain from abusing his power in the company and to act in good faith and in an acceptable
manner in exercising his rights and performing his obligations toward the company and other shareholders, including, among other things,
in voting at general meetings of shareholders (and at shareholder class meetings) on the following matters:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">amendment of the articles of association;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">increase in the company&#8217;s authorized share capital;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">merger; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the approval of related party transactions and acts of office holders that require shareholder approval.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">A
shareholder also has a general duty to refrain from oppressing other shareholders. The remedies generally available upon a breach of contract
will also apply to a breach of the above-mentioned duties, and in the event of oppression of other shareholders, additional remedies are
available to the injured shareholder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">In
addition, any controlling shareholder, any shareholder that knows that its vote can determine the outcome of a shareholder vote and any
shareholder that, under a company&#8217;s articles of association, has the power to appoint or prevent the appointment of an office holder,
or has another power with respect to a company, is under a duty to act with fairness towards the company. The Companies Law does not describe
the substance of this duty except to state that the remedies generally available upon a breach of contract will also apply in the event
of a breach of the duty to act with fairness, taking the shareholder&#8217;s position in the company into account.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><div><a id="I_029"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt"><b>D.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Employees.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 31, 2022, we had
32 full-time employees and five part-time employees. On December 31, 2023, we had 37 full time employees (including our senior management
team), five part-time employees, and three independent contractors. On December 31, 2024, we had 39 full-time employees, seven part-time
employees and two independent contractors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2024, we
had five members of senior management who are full-time employees. In addition, we had 33 full-time employees in Israel, seven part-time
employees and one full-time employee in France.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None of our employees located
in Israel are represented by labor unions or covered by collective bargaining agreements. However, in Israel, we are subject to certain
Israeli labor laws, regulations and national labor court precedent rulings, as well as certain provisions of collective bargaining agreements
applicable to us by virtue of extension orders issued in accordance with relevant labor laws by the Israeli and Industry of Economy and
which apply such agreement provisions to our employees even though they are not part of a union that has signed a collective bargaining
agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All of our employment and
consulting agreements include employees&#8217; and consultants&#8217; undertakings with respect to non-competition and assignment to us
of intellectual property rights developed in the course of employment and confidentiality. The enforceability of such provisions is limited
by Israeli law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "></p><div>

</div><!-- Field: Page; Sequence: 105 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><div><a id="I_030"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-size: 10pt"><b>E.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Share Ownership. </b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See &#8220;Item 7.A. Major
Shareholders&#8221; below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Equity Incentive Plan </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Our
2019 Equity Incentive Plan, or the 2019 Plan, was adopted by our board of directors on December 2019 (although no options were granted
until April 20, 2020) and amended on September 14, 2021. The 2019 Plan provides for the grant of options to our directors, employees,
officers, consultants and service providers who are our employees, officers, directors or consultants, as well as those of our affiliated
companies. In September 2021, our board of directors approved an amendment to the 2019 Plan to provide for the grant of restricted share
units, or RSUs. As of March 3, 2025, the total number of Ordinary Shares reserved for the exercise of options under our 2019 Plan was
7,178,569. The shares subject to our 2019 Plan may be either authorized but unissued Ordinary Shares or reacquired Ordinary Shares, subject
to applicable laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Our
2019 Plan is administered by the committee, consisting of our board of directors, regarding the granting of options and the terms of option
grants, including exercise price, method of payment, vesting schedule, acceleration of vesting and the other matters necessary in the
administration of this plan. Eligible employees, officers and directors, as well as those of our affiliated companies, would qualify for
provisions of Section 102 of the Israeli Income Tax Ordinance of 1961 (New Version), or the Tax Ordinance. Section 102 of the Tax Ordinance
allows employees, directors and officers who are not controlling shareholders and are considered Israeli residents to receive favorable
tax treatment for compensation in the form of shares or options. Section 102 includes two alternatives for tax treatment involving the
issuance of options or shares to a trustee for the benefit of the grantees and also includes an additional alternative for the issuance
of options or shares directly to the grantee. Section 102(b)(2) of the Ordinance, the most favorable tax treatment for the grantee, permits
the issuance to a trustee under the &#8220;capital gain track.&#8221; However, under this track we are not allowed to deduct an expense
with respect to the issuance of the options or shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Our
consultants and those of our affiliated companies and our employees, directors and/or officers and those of our affiliated companies who
are controlling shareholders prior to and/or after the issuance of Ordinary Shares underlying the options may only be granted options
under section 3(i) of the Tax Ordinance, which does not provide for similar tax benefits. In addition, the committee may, in its sole
discretion, grant restricted shares to our service providers, subject to terms and conditions of our 2019 Plan and the applicable restricted
shares agreement between the service provider and us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">As
a default, our 2019 Plan provides that upon termination of a service provider&#8217;s engagement for any reason, other than in the event
of death, disability or cause, all unvested options will terminate and the underlying Ordinary Shares will revert to our 2019 Plan, and
all vested options will generally be exercisable for 90 days following such termination, subject to the terms of the 2019 Plan and the
governing option agreement. Notwithstanding the foregoing, in the event the engagement is terminated for cause (including, inter alia,
due to dishonesty toward us or our affiliate, substantial malfeasance or nonfeasance of duty and conduct substantially prejudicial to
our or our affiliate&#8217;s business; or any substantial breach by the optionee of his or her service agreement) all options granted
to such service provider, whether vested or unvested, will not be exercisable and will terminate on the date of the termination of his
service agreement. If a service provider&#8217;s engagement with us is terminated six months following any exercise, payment or delivery
pursuant to an option or restricted share, the service provider shall pay to us the amount of any gain realized or payment received as
a result of the rescinded exercise, payment or delivery. Upon termination of a service agreement due to death or disability, all the options
vested at the time of termination and within 60 days after the date of such termination, will generally be exercisable for 12 months,
or such other period as determined by the plan administrator, subject to the terms of the 2019 Plan and the governing option agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">If
we are party to a merger, acquisition, reorganization or consolidation in which we are not the surviving entity or the sale, transfer,
exchange or other disposition of all or substantially all of our shares or assets, outstanding options and shares acquired under the 2019
Plan will be subject to the agreement of merger or consolidation, which will provide for one or more of the following: (i) the assumption
of such options by the surviving corporation or its parent, (ii) the substitution by the surviving corporation or its parent of new options,
or (iii) in the event that the successor entity neither assumes nor substitutes all outstanding options, then the option shall terminate
as of the date of a merger, acquisition, reorganization or consolidation in which we are not the surviving entity or the sale, transfer,
exchange or other disposition of all or substantially all of our shares or assets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 106 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="I_031"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="font-size: 10pt"><b>F.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Disclosure of a Registrant&#8217;s Action to Recover Erroneously Awarded Compensation.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not Applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="I_032"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 7. <span style="text-transform: uppercase">MAJOR
SHAREHOLDERS AND RELATED PARTY TRANSACTIONS</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="I_033"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-size: 10pt"><b>A.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Major Shareholders. </b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
following table sets forth information regarding beneficial ownership of our Ordinary Shares as of March 3, 2025 by:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">each person, or group of affiliated persons, known to us to be the beneficial owner of 5% or more of our outstanding Ordinary Shares;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">each of our directors and executive officers; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">all of our directors and executive officers as a group.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Beneficial
ownership is determined in accordance with the rules of the SEC and includes voting or investment power with respect to Ordinary Shares.
Ordinary Shares issuable under share options or warrants that are exercisable within 60 days after March 3, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Except
as indicated in footnotes to this table, we believe that the shareholders named in this table have sole voting and investment power with
respect to all shares shown to be beneficially owned by them, based on information provided to us by such shareholders. Unless otherwise
noted below, each beneficial owner&#8217;s address is: c/o Inspira Technologies Oxy B.H.N. Ltd., 2 Ha-Tidhar St., Ra&#8217;anana, 4366504
Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">No. of<br/> Shares<br/> Beneficially<br/> Owned</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Percentage<br/> Owned</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Holders of 5% or more of our voting securities:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Directors and Officers:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 10pt">Dagi Ben-Noon <sup>(1) *</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,671,064</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">6.49</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 10pt">Joe Hayon <sup>(2) *</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,972,908</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.66</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 10pt">Avi Shabtai <sup>(3)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">532,479</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.07</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 10pt">Yafit Tehila <sup>(4)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">215,277</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.84</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 10pt">Daniella Yeheskely Hayon <sup>(5)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">115,833</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.45</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 10pt">Tal Parnes <sup>(6) *</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">51,901</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.2</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 10pt">Limor Rozen <sup>(7) *</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">47,200</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.18</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 10pt">Lior Amit <sup>(8)*</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,166</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.06</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">All Executive Officers and Directors and holder of 5% or more of our voting securities, as a group (8 persons)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,621,763</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">17.95</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">*</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Indicates director of the Company.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">No. of shares beneficially owned consists of 326,739 Ordinary Shares, (ii) 1,213,833 Ordinary Shares vested pursuant to issued and outstanding RSUs, (iii) 57,159 Ordinary Shares issuable upon the exercise of options within 60 days at an exercise price of NIS 0.37 (approximately $0.12) per share and (iv) 73,333 Ordinary Shares vested within 60 days pursuant to issued and outstanding RSUs. Mr. Ben-Noon&#8217;s options expire on April 20, 2030.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 107 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">No. of shares beneficially owned consists of (i) 626,739 Ordinary Shares, (ii) 1,213,833 Ordinary Shares vested pursuant to issued and outstanding RSUs, and (iii) 57,159 Ordinary Shares issuable upon the exercise of options within 60 days. </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Includes (i) 415,268 Ordinary Shares vested pursuant to issued and outstanding RSUs, (ii) options to purchase 95,239 Ordinary Shares that are exercisable within 60 days, at an exercise price of NIS 0.37 (approximately $0.12) per share, and (iii) 21,972 Ordinary Shares vested within 60 days pursuant to issued and outstanding RSUs. Mr. Shabtai&#8217;s options expire on April 20, 2030.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Includes (i) 186,960 Ordinary Shares vested pursuant to issued and outstanding RSUs, (ii) options to purchase 13,605 Ordinary Shares that are exercisable within 60 days, at an exercise price of NIS 0.37 (approximately $0.12) per share and (iii) 14,722 Ordinary Shares vested within 60 days pursuant to issued and outstanding RSUs. Ms. Tehila&#8217;s options expire on March 16, 2031.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(5)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Includes (i) 106,666 Ordinary Shares vested pursuant to issued and outstanding RSUs and (ii) 9,167 Ordinary Shares vested within 60 days pursuant to issued and outstanding RSUs.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(6)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Includes (i) 39,999 Ordinary Shares vested pursuant to issued and outstanding RSUs, (ii) options to purchase 9,402 Ordinary Shares that are exercisable within 60 days, at an exercise price of NIS 0.37 (approximately $0.12) per share and (iii) 2,500 Ordinary Shares vested within 60 days pursuant to issued and outstanding RSUs. Mr. Parnes&#8217;s options expire on April 20, 2030.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(7) </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Includes (i) 39,999 Ordinary Shares vested pursuant to issued and outstanding RSUs, (ii) options to purchase 4,701 Ordinary Shares that are exercisable within 60 days, at an exercise price of NIS 0.37 (approximately $0.12) per share and (iii) 2,500 Ordinary Shares vested within 60 days pursuant to issued and outstanding RSUs. Mrs. Rozen&#8217;s options expire on April 20, 2030.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-size: 10pt">(8)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Includes (i) 39,999 Ordinary Shares vested pursuant to issued and outstanding RSUs (ii) 2,500 Ordinary Shares vested within 60 days pursuant to issued and outstanding RSUs. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;<b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Changes in Percentage Ownership by Major
Shareholders</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2024, there was a decrease in the beneficial ownership of Joe Hayon from 10.02% to 7.66% and a decrease in the beneficial ownership
of Dagi Ben Noon from 8.15% to 6.49%. As of December 31, 2024, Armistice Capital, LLC is no longer a beneficial owner of 5% or more of
the outstanding share capital of the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2023, there was: (i) an increase in the beneficial ownership of Armistice Capital, LLC to 9.89%, (ii) a decrease in the beneficial
ownership of Joe Hayon from 11.86% to 10.02%, and (iii) a decrease in the beneficial ownership of Dagi Ben Noon from 11.86% to 8.15%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2022, there was no significant change in the percentage ownership held by any major shareholders, other than decreases in the relative
percentage of ownership as a result of our IPO in July 2021 and the vesting of RSUs granted in December 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Record Holders</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 3, 2025, there
were 26 shareholders of record of our Ordinary Shares, which were located in Israel. We are not controlled by another corporation, by
any foreign government or by any natural or legal persons except as set forth herein, and there are no arrangements known to us which
would result in a change in control of our company at a subsequent date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><div><a id="I_034"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-size: 10pt"><b>B.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Related Party Transactions.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See &#8220;Item 6.B. Compensation&#8221;
for compensation to our directors and officers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Employment and Service Agreements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">We
have entered into written employment agreements with each of our executive officers. All of these agreements contain customary provisions
regarding noncompetition, confidentiality of information and assignment of inventions. However, the enforceability of the noncompetition
provisions may be limited under applicable law. In addition, we have entered into agreements with each executive officer and director
pursuant to which we have agreed to indemnify each of them up to a certain amount and to the extent that these liabilities are not covered
by directors and officers insurance. Some members of our senior management are eligible for bonuses each year. The bonuses are payable
upon meeting objectives and targets that are set by our Chief Executive Officer and approved annually by our board of directors that also
set the bonus targets for our Chief Executive Officer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "></p><div>

</div><!-- Field: Page; Sequence: 108 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">On
November 2, 2021, our board of directors approved and recommended to the shareholders of the Company to approve, the adoption of a compensation
policy for a period of five (5) years, which was approved by our shareholders in a meeting that took place on December 17, 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Options/RSUs </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Since
our inception, we have granted options to purchase our Ordinary Shares and RSUs to our officers and certain of our directors. Such option
agreements may contain acceleration provisions upon certain merger, acquisition, or change of control transactions. We describe our option
plans under &#8220;Item 6.E. Directors, Senior Management and Employees-Share Ownership-Equity Incentive Plan.&#8221; If the relationship
between us and an executive officer or a director is terminated, except for cause (as defined in the various option plan agreements),
options that are vested will generally remain exercisable for three months after such termination.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Shareholders Loans</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">When
we considered pursuing an initial public offering on the ASX, we focused on an intravenous oxygenation device. As the development of this
product did not progress as planned, we progressed with developing our INSPIRA ART product ahead of plans, reducing the time to market
by approximately two years, and decided to pursue an initial public offering on Nasdaq rather than the ASX. On November 27, 2020, we entered
into an agreement, or the Termination Agreement, with IML, the Founders and Newburyport to terminate the IPO Deed, the Deed of Variation
and the 2019 CLA, or the Previous Agreements. Pursuant to the Termination Agreement, we agreed to convert the loan amount and the interest
accrued under the 2019 CLA as of November 27, 2020, into 676,061 of our Ordinary Shares, at price per share of AUD 5.15 (approximately
$3.45) or AUD 5.88 (approximately $3.91), and to issue to Newburyport or its affiliates 80,273 of our Ordinary Shares as promoter shares,
and options to purchase 28,572 of our Ordinary Shares, to Daniel Goldstein, who promoted our contract with IML, at an exercise price of
NIS 0.37 (approximately $0.12 per share). We also issued 169,016 warrants to IML, exercisable upon our IPO on the Nasdaq Capital Market.
IML&#8217;s warrants are exercisable for three years. IML purchased its shares and distributed its holdings of our shares as a dividend
to its shareholders following our IPO on the Nasdaq Capital Market. Each party to the Termination Agreement agreed to release each other
party to the Termination Agreement from all the claims related to the IPO Deed, Deed of Variation and CLA. In addition, we agreed to hire
Newburyport and Peter Marks, another affiliate of IML, as our business developers, to identify, introduce and promote us to potential
investors, and to pay cash commission in the amount of 7% from the net proceeds received from an investment consummated within 12 months
of our introduction to the investor by Newburyport or Peter Marks. As of November 28, 2021, we have paid Newburyport and Peter Marks AUD
403,000 (approximately $321,000) each, as cash commission for investor introductions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><div><a id="I_035"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-size: 10pt"><b>C.</b></span></td>
    <td><span style="font-size: 10pt"><b>Interests of Experts and Counsel.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="I_036"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 8. <span style="text-transform: uppercase">FINANCIAL
INFORMATION.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="I_037"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-size: 10pt"><b>A.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Statements and Other Financial Information.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See &#8220;Item 18. Financial
Statements.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>Legal Proceedings</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, we may
be involved in various claims and legal proceedings relating to claims arising out of our operations. Regardless of outcome, litigation
can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors. We are
not currently party to, and our property is not the subject of, any material legal proceedings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 109 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 4, 2022, Exchange
filed a complaint in the Federal Court for the Southern District of New York against us and our Chief Financial Officer, Joe Hayon, in
connection with a contract between the parties pursuant to which Exchange provided certain consultancy services to us in preparation for
our IPO. The precise damages sought are unclear, however Exchange is seeking approximately $250,000 plus 75,000 Ordinary Shares or the
cash equivalent. On July 1, 2022, we filed a motion to dismiss for failure to state a claim upon relief can be granted based on the language
of the written contract between the parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 8, 2023, the court
issued an order granting our motion in part and denying it in part. Specifically, the court dismissed all claims against Joe Hayon and
he is no longer a party in the action. The court also dismissed the breach of contract action (Count I) to the extent it was based improper
termination or frustration. The Court also dismissed Count IV (Quantum Merit on the written agreement), Count VI (Breach of Implied Covenant
of Good Faith) and Count VII (Fraud in the Inducement). The court allowed Count 1 (breach of written agreement based on alleged anticipatory
repudiation), Count II (breach of alleged oral agreement), Count III (Promissory Estoppel to the extent based on alleged oral agreement)
and Count V (Quantum Meruit based on alleged oral agreement) to survive the pleading or early dismissal stage. We will continue to defend
ourselves vigorously with respect to this matter. In July 2023, following a confidential settlement agreement reached between the parties,
this matter was voluntarily dismissed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 12, 2021, we terminated
our employment agreement with Dr. Udi Nussinovitch, who is one of our founders and who served as our Chief Scientific Officer since March
2018. On February 24, 2022, we sued Mr. Nussinovitch for breach good faith and his fiduciary duties as a shareholder and former officer
of the Company. On November 9, 2022, Mr. Nussinovitch filed a statement of claim against us, as well as a statement of claim with the
regional labor court in Tel Aviv on November 8, 2022. Mr. Nussinovitch alleged certain deficiencies in our <span>Extraordinary
General Meeting of Shareholders held on Friday, December 17, 2021, resulting from his status as a minority shareholder. In addition, with
respect to the labor dispute, Mr. </span>Nussinovitch is seeking renumeration and the issuance of Ordinary Shares. On July 19, 2023, a
partial hearing about the labor dispute was held, in which the parties were required by the court to file their positions on a stay of
the proceeding pending the decision on the case initiated by Mr. Nussinovitch in the District Court. On January 21, 2024, a partial hearing
about the civil case was held. During the hearing, the court suggested the parties consider the possibility of resolving the case through
an out-of-court arrangement or mediation. The parties agreed to a mediation process which did not succeed. On January 7, 2025, Mr. Nussinovitch
filed a motion to amend his Statement of Claim, requesting to modify the requested relief. Instead of the original remedies sought, Mr.
Nussinovitch now requests that the Company or Mr. Ben Noon and Mr. Hayon purchase all of his rights and shares in the Company at their
average value from the date of the Company's IPO until the date of the general meeting held on December 17, 2021. On January 13, 2025,
a pretrial hearing was held. The court denied Mr. Nussinovitch&#8217;s motion to amend and instructed him to notify whether he wishes
to withdraw his original claim or maintain it. As of March 3, 2025, Mr. Nussinovitch has not yet provided his response.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span>We
</span>strongly disagree with the claims and believe we have meritorious defenses and will vigorously defend itself against the claims.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Dividends</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have never declared or
paid any cash dividends on our Ordinary Shares and do not anticipate paying any cash dividends in the foreseeable future. Payment of cash
dividends, if any, in the future will be at the discretion of our board of directors and will depend on then-existing conditions, including
our financial condition, operating results, contractual restrictions, capital requirements, business prospects and other factors our board
of directors may deem relevant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law imposes
further restrictions on our ability to declare and pay dividends. Under the Companies Law, we may declare and pay dividends only if, upon
the determination of our board of directors, there is no reasonable concern that the distribution will prevent us from being able to meet
the terms of our existing and foreseeable obligations as they become due. Under the Companies Law, the distribution amount is further
limited to the greater of retained earnings or earnings generated over the two most recent years legally available for distribution according
to our then last reviewed or audited financial statements, provided that the end of the period to which the financial statements relate
is not more than six months prior to the date of distribution. In the event that we do not meet such earnings criteria, we may seek the
approval of a court in order to distribute a dividend. The court may approve our request if it is convinced that there is no reasonable
concern that the payment of a dividend will prevent us from satisfying our existing and foreseeable obligations as they become due.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 110 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Payment of dividends may be
subject to Israeli withholding taxes. See &#8220;Item 10.E. Taxation&#8221;, for additional information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><div><a id="I_038"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-size: 10pt"><b>B.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Significant Changes.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No significant change, other
than as otherwise described in this annual report on Form 20-F, has occurred in our operations since the date of our financial statements
included in this annual report on Form 20-F.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;&#160;</p><div>

</div><div><a id="I_039"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 9. <span style="text-transform: uppercase">THE
OFFER AND LISTING</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="I_040"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-size: 10pt"><b>A.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Offer and Listing Details.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since July 16, 2021, our Ordinary
Shares and Warrants have been traded on the Nasdaq Capital Market under the symbols &#8220;IINN&#8221; and &#8220;IINNW&#8221;, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="I_041"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-size: 10pt"><b>B.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Plan of Distribution.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="I_042"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-size: 10pt"><b>C.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Markets.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Ordinary Shares and Warrants
trade on the Nasdaq Capital Market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="I_043"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-size: 10pt"><b>D.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Selling Shareholders.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="I_044"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify"><span style="font-size: 10pt"><b>E.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Dilution.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="I_045"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-size: 10pt"><b>F.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Expenses of the Issue.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="I_046"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 10. <span style="text-transform: uppercase">ADDITIONAL
INFORMATION</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="I_047"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-size: 10pt"><b>A.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Share Capital.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="I_048"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-size: 10pt"><b>B.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Memorandum and Articles of Association.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A copy of our amended and
restated articles of association is attached as Exhibit 1.1 to this annual report on Form 20-F. The information called for by this Item
is set forth in Exhibit 2(d) to this annual report on Form 20-F and is incorporated by reference into this annual report on Form 20-F.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 111 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="I_049"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-size: 10pt"><b>C.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Material Contracts. </b>&#160;&#160;&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">We
have not entered into any material contract within the two years prior to the date of this Annual Report, other than contracts entered
into in the ordinary course of business, as otherwise described herein in &#8220;Item 4.A. History and Development of the Company&#8221;
above, &#8220;Item 4.B. Business Overview&#8221; above, &#8220;Item 6.C Board Practices - Indemnification,&#8221; &#8220;Item 6.E Share
Ownership - Equity Incentive Plan,&#8221; &#8220;Item 7.A. Major Shareholders,&#8221; or &#8220;Item 7.B. Related Party Transactions,&#8221;
above, or as otherwise described below:&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9679;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Securities Purchase Agreement by and between the Company and certain signatories thereto, dated March 28, 2024. See Item 5.A &#8220;<i>Operating and Financial Review and Prospects</i>&#8221; for more information about this document.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities Purchase Agreement by and between
the Company and certain signatories thereto, dated June 14, 2024. See Item 5.A &#8220;<i>Operating and Financial Review and Prospects</i>&#8221;
for more information about this document.&#160;</p></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Securities Purchase Agreement by and between the Company and certain signatories thereto, dated December 24, 2024. See Item 5.A &#8220;<i>Operating and Financial Review and Prospects</i>&#8221; for more information about this document.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><div><a id="I_050"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-size: 10pt"><b>D.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Exchange Controls.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are currently no Israeli
currency control restrictions on payments of dividends or other distributions with respect to our securities or the proceeds from the
sale of the shares, except for the obligation of Israeli residents to file reports with the Bank of Israel regarding certain transactions.
However, legislation remains in effect pursuant to which currency controls can be imposed by administrative action at any time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The ownership or voting of
our securities by non-residents of Israel, except with respect to citizens of countries that are in a state of war with Israel, is not
restricted in any way by our memorandum of association or amended and restated articles of association or by the laws of the State of
Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><div><a id="I_051"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-size: 10pt"><b>E.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Taxation.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
following is a description of the material Israeli income tax consequences of the ownership of our securities. The following also contains
a description of material relevant provisions of the current Israeli income tax structure applicable to companies in Israel, with reference
to its effect on us. To the extent that the discussion is based on new tax legislation which has not been subject to judicial or administrative
interpretation, there can be no assurance that the tax authorities will accept the views expressed in the discussion in question. The
discussion is not intended, and should not be taken, as legal or professional tax advice and is not exhaustive of all possible tax considerations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
following description is not intended to constitute a complete analysis of all tax consequences relating to the ownership or disposition
of our securities. Shareholders should consult their own tax advisors concerning the tax consequences of their particular situation, as
well as any tax consequences that may arise under the laws of any state, local, foreign or other taxing jurisdiction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>General Corporate Tax Structure in Israel</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Israeli
companies are generally subject to corporate tax. As of January 2016, the corporate tax rate was 25%. As of January 1, 2017, the corporate
tax rate was reduced to 24% and as of January 1, 2018, the corporate tax rate is 23%. However, the effective tax rate payable by a company
that derives income from a Preferred Enterprise (as discussed below) may be considerably less. Capital gains derived by an Israeli company
are generally subject to the prevailing corporate tax rate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Capital
gains derived by an Israeli resident company are subject to tax at the prevailing corporate tax rate. Under Israeli tax legislation, a
corporation will be considered as an &#8220;Israeli resident company&#8221; if it meets one of the following: (i) it was incorporated
in Israel; or (ii) the control and management of its business are exercised in Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Law for the Encouragement of Industry (Taxes),
5729-1969</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
Law for the Encouragement of Industry (Taxes), 5729-1969, generally referred to as the Industry Encouragement Law, provides several tax
benefits for &#8220;Industrial Companies.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
Industry Encouragement Law defines an &#8220;Industrial Company&#8221; as an Israeli resident-company, of which 90% or more of its income
in any tax year, other than income from defense loans, is derived from an &#8220;Industrial Enterprise&#8221; owned by it. An &#8220;Industrial
Enterprise&#8221; is defined as an enterprise whose principal activity in a given tax year is industrial production.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "></p><div>

</div><!-- Field: Page; Sequence: 112 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
following corporate tax benefits, among others, are available to Industrial Companies:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">amortization of the cost of purchased a patent, rights to use a patent, and know-how, which are used for the development or advancement of the company, over an eight-year period, commencing on the year in which such rights were first exercised;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">under limited conditions, an election to file consolidated tax returns with related Israeli Industrial Companies; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">expenses related to a public offering are deductible in equal amounts over three years.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Eligibility
for benefits under the Industry Encouragement Law is not contingent upon approval of any governmental authority.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Tax Benefits and Grants for Research and
Development</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Under
the Israeli Encouragement of Research, Development and Industrial Initiative Technology Law, 5744-1984, as amended, and related regulations,
or the Research Law, research and development programs which meet specified criteria and are approved by the IIA are eligible for grants
of up to 50% of the project&#8217;s expenditure, as determined by the research committee, in exchange for the payment of royalties from
the revenues generated from the sale of products and related services developed, in whole or in part pursuant to, or as a result of, a
research and development program funded by the IIA. The royalties are generally at a range of 3.0% to 5.0% of revenues until the entire
IIA grant is repaid, together with an annual interest. As of January 1, 2024, annual interest on IIA grants approved by the IIA prior
to January 1, 2024, but which are outstanding thereafter, will be calculated at a rate based on the 12-month secured overnight financing
rate, or SOFR, or at an alternative rate published by the Bank of Israel plus 0.71513%; and, for grants approved on or following January
1, 2024 the annual interest will be the higher of (i) the 12 month SOFR, plus 1%, or (ii) a fixed annual interest rate of 4%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
terms of the Research Law also require that the manufacture of products developed with government grants be performed in Israel. The transfer
of manufacturing activity outside Israel may be subject to the prior approval of the IIA. Under the regulations of the Research Law, assuming
we receive approval from the Chief Scientist to manufacture our IIA-funded products outside Israel, we may be required to pay increased
royalties. The increase in royalties depends upon the manufacturing volume that is performed outside of Israel as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">Manufacturing Volume Outside of Israel</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Royalties to <br/> the Chief <br/> Scientist<br/> as a <br/> Percentage <br/> of Grant</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify">Up to 50%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">120</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Between 50% and 90%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">150</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">90% and more</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">300</td><td style="text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">If
the manufacturing is performed outside of Israel by us, the rate of royalties payable by us on revenues from the sale of products manufactured
outside of Israel will increase by 1% over the regular rates. If the manufacturing is performed outside of Israel by a third party, the
rate of royalties payable by us on those revenues will be equal to the ratio obtained by dividing the amount of the grants received from
the IIA and our total investment in the project that was funded by these grants. The transfer of no more than 10% of the manufacturing
capacity in the aggregate outside of Israel is exempt under the Research Law from obtaining the prior approval of the IIA. A company requesting
funds from the IIA also has the option of declaring in its IIA grant application an intention to perform part of its manufacturing outside
Israel, thus avoiding the need to obtain additional approval. On January 6, 2011, the Research Law was amended to clarify that the potential
increased royalties specified in the table above will apply even in those cases where the IIA approval for transfer of manufacturing outside
of Israel is not required, namely when the volume of the transferred manufacturing capacity is less than 10% of total capacity or when
the company received an advance approval to manufacture abroad in the framework of its IIA grant application. For applications to manufacture
abroad submitted to the IIA after October 25, 2023, the maximum increased liability is up to 150% of the IIA grants, plus interest accrued
thereon, instead of 300%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "></p><div>

</div><!-- Field: Page; Sequence: 113 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
know-how developed within the framework of the Chief Scientist plan may not be transferred to third parties outside Israel without the
prior approval of a governmental committee charted under the Research Law. The approval, however, is not required for the export of any
products developed using grants received from the Chief Scientist. The IIA approval to transfer know-how created, in whole or in part,
in connection with an IIA-funded project to third party outside Israel where the transferring company remains an operating Israeli entity
is subject to payment of a redemption fee to the IIA calculated according to a formula provided under the Research Law that is based,
in general, on the ratio between the aggregate IIA grants to the company&#8217;s aggregate investments in the project that was funded
by these IIA grants, multiplied by the transaction consideration. The transfer of such know-how to a party outside Israel where the transferring
company ceases to exist as an Israeli entity is subject to a redemption fee formula that is based, in general, on the ratio between the
aggregate IIA grants to the total financial investments in the company, multiplied by the transaction consideration. According to the
January 2011 amendment, the redemption fee in case of transfer of know-how to a party outside Israel will be based on the ratio between
the aggregate IIA grants received by the company and the company&#8217;s aggregate R&amp;D expenses, multiplied by the transaction consideration.
According to regulations promulgated following the 2011 amendment, the maximum amount payable to the IIA in case of transfer of know how
outside Israel shall not exceed 6 times the value of the grants received plus interest, and in the event that the receiver of the grants
ceases to be an Israeli corporation such payment shall not exceed six times the value of the grants received plus interest, with a possibility
to reduce such payment to up to three times the value of the grants received plus interest if the R&amp;D activity remains in Israel for
a period of three years after payment to the IIA and maintain at least 75% of the research and development employees the Company had for
the six months before the know-how was transferred, subject to additional conditions specified in the regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Transfer
of know-how within Israel is subject to an undertaking of the recipient Israeli entity to comply with the provisions of the Research Law
and related regulations, including the restrictions on the transfer of know-how and the obligation to pay royalties, as further described
in the Research Law and related regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">These
restrictions may impair our ability to outsource manufacturing, engage in change of control transactions or otherwise transfer our know-how
outside Israel and may require us to obtain the approval of the IIA for certain actions and transactions and pay additional royalties
to the IIA. In particular, any change of control and any change of ownership of our securities that would make a non-Israeli citizen or
resident an &#8220;interested party,&#8221; as defined in the Research Law, requires a prior written notice to the IIA in addition to
any payment that may be required of us for transfer of manufacturing or know-how outside Israel. If we fail to comply with the Research
Law, we may be subject to criminal charges or to mandatory repayment of grants received by us (together with interest and penalties).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Tax Benefits for Research and Development</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Israeli
tax law allows, under certain conditions, a tax deduction for expenditures, including capital expenditures, for the year in which they
are incurred. Expenditures are deemed related to scientific research and development projects, if:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The expenditures are approved by the relevant Israeli government ministry, determined by the field of research;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The research and development must be for the promotion of the company; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">The research and development is carried out by or on behalf of the company seeking such tax deduction.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
amount of such deductible expenses is reduced by the sum of any funds received through government grants for the finance of such scientific
research and development projects. No deduction under these research and development deduction rules is allowed if such deduction is related
to an expense invested in an asset depreciable under the general depreciation rules of the income Tax Ordinance, 1961. Expenditures not
so approved are deductible in equal amounts over three years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 114 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">From
time to time, we may apply the Office of the Chief Scientist for approval to allow a tax deduction for all research and development expenses
during the year incurred. There can be no assurance that such application will be accepted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Law for the Encouragement of Capital Investments,
5719-1959</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
Law for the Encouragement of Capital Investments, 5719-1959, generally referred to as the Investment Law, provides certain incentives
for capital investments in production facilities (or other eligible assets).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Tax Benefits</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
Investment Law grants tax benefits for income generated by a &#8220;Preferred Company&#8221; through its &#8220;Preferred Enterprise&#8221;
(as such terms are defined in the Investment Law) The definition of a Preferred Company includes a company incorporated in Israel that
is not fully owned by a governmental entity, and that has, among other things, Preferred Enterprise status and is controlled and managed
from Israel. A Preferred Company is entitled to a reduced corporate tax rate of 16% with respect to its income derived by its Preferred
Enterprise, unless the Preferred Enterprise is located in a specified development zone, in which case the rate will be 7.5%.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Dividends
paid out of income attributed to a Preferred Enterprise are generally subject to withholding tax at source at the rate of 20% or such
lower rate as may be provided in an applicable tax treaty. However, if such dividends are paid to an Israeli company, no tax is required
to be withheld.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Taxation of our Shareholders</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Capital
Gains Taxes Applicable to Non-Israeli Resident Shareholders. A non-Israeli resident who derives capital gains from the sale of shares
in an Israeli resident company will be exempt from Israeli tax so long as the shares were not held through a permanent establishment that
the non-resident maintains in Israel. However, non-Israeli corporations will not be entitled to the foregoing exemption if Israeli residents:
(i) have a controlling interest of 25% or more in such non-Israeli corporation or (ii) are the beneficiaries of, or are entitled to, 25%
or more of the revenues or profits of such non-Israeli corporation, whether directly or indirectly.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Additionally,
a sale of securities by a non-Israeli resident may be exempt from Israeli capital gains tax under the provisions of an applicable tax
treaty. For example, under Convention Between the Government of the United States of America and the Government of the State of Israel
with respect to Taxes on Income, as amended, or the United States-Israel Tax Treaty, the sale, exchange or other disposition of shares
by a shareholder who is a U.S. resident (for purposes of the treaty) holding the shares as a capital asset and is entitled to claim the
benefits afforded to such a resident by the U.S.-Israel Tax Treaty, or a Treaty U.S. Resident, is generally exempt from Israeli capital
gains tax unless: (i) the capital gain arising from such sale, exchange or disposition is attributed to real estate located in Israel;
(ii) the capital gain arising from such sale, exchange or disposition is attributed to royalties; (iii) the capital gain arising from
the such sale, exchange or disposition is attributed to a permanent establishment in Israel, under certain terms; (iv) such Treaty U.S.
Resident holds, directly or indirectly, shares representing 10% or more of the voting capital during any part of the 12-month period preceding
the disposition, subject to certain conditions; or (v) such Treaty U.S. Resident is an individual and was present in Israel for 183 days
or more during the relevant taxable year.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">In
some instances where our shareholders may be liable for Israeli tax on the sale of their securities, the payment of the consideration
may be subject to the withholding of Israeli tax at source. Shareholders may be required to demonstrate that they are exempt from tax
on their capital gains in order to avoid withholding at source at the time of sale.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 115 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Taxation
of Non-Israeli Shareholders on Receipt of Dividends. Non-Israeli residents are generally subject to Israeli income tax on the receipt
of dividends paid on our securities at the rate of 25% (before a surtax at a rate of up to 5% on income above a certain threshold), which
tax will be withheld at source, unless relief is provided in a treaty between Israel and the shareholder&#8217;s country of residence.
With respect to a person who is a &#8220;substantial shareholder&#8221; at the time of receiving the dividend or on any time during the
preceding twelve months, the applicable tax rate is 30% (before a surtax at a rate of up to 5% on income above a certain threshold). A
&#8220;substantial shareholder&#8221; is generally a person who alone or together with such person&#8217;s relative or another person
who collaborates with such person on a permanent basis, holds, directly or indirectly, at least 10% of any of the &#8220;means of control&#8221;
of the corporation. &#8220;Means of control&#8221; generally include the right to vote, receive profits, nominate a director or an executive
officer, receive assets upon liquidation, or order someone who holds any of the aforesaid rights how to act, regardless of the source
of such right. However, a distribution of dividends to non-Israeli residents is subject to withholding tax at source at a rate of 20%
if the dividend is distributed from income attributed to a Preferred Enterprise, unless a reduced tax rate is provided under an applicable
tax treaty. For example, under the United States-Israel Tax Treaty, the maximum rate of tax withheld at source in Israel on dividends
paid to a holder of our securities who is a Treaty U.S. Resident is 25%. However, generally, the maximum rate of withholding tax on dividends,
not generated by a Preferred Enterprise, that are paid to a U.S. corporation holding 10% or more of the outstanding voting capital throughout
the tax year in which the dividend is distributed as well as during the previous tax year, is 12.5%, provided that not more than 25% of
the gross income for such preceding year consists of certain types of dividends and interest. Notwithstanding the foregoing, dividends
distributed from income attributed to a Preferred Enterprise are not entitled to such reduction under the tax treaty but are subject to
a withholding tax rate of 15% for a shareholder that is a U.S. corporation, provided that the condition related to our gross income for
the previous year (as set forth in the previous sentence) is met. If the dividend is attributable partly to income derived from a Preferred
Enterprise, and partly to other sources of income, the withholding rate will be a blended rate reflecting the relative portions of the
two types of income. We cannot assure you that we will designate the profits that we may distribute in a way that will reduce shareholders&#8217;
tax liability.<b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>U.S. FEDERAL INCOME TAX CONSIDERATIONS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THE FOLLOWING SUMMARY IS INCLUDED
HEREIN FOR GENERAL INFORMATION AND IS NOT INTENDED TO BE, AND SHOULD NOT BE CONSIDERED TO BE, LEGAL OR TAX ADVICE. EACH U.S. HOLDER SHOULD
CONSULT WITH HIS OR HER OWN TAX ADVISOR AS TO THE PARTICULAR U.S. FEDERAL INCOME TAX CONSEQUENCES OF THE PURCHASE, OWNERSHIP AND SALE
OF ORDINARY SHARES INCLUDING THE EFFECTS OF APPLICABLE STATE, LOCAL, FOREIGN OR OTHER TAX LAWS AND POSSIBLE CHANGES IN THE TAX LAWS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the limitations
described in the next two paragraphs, the following discussion summarizes the material U.S. federal income tax consequences to a &#8220;U.S.
Holder&#8221; arising from the purchase, ownership and sale of the Ordinary Shares, the Warrants, and the Ordinary Shares issued or issuable
upon exercise of the Warrants, collectively, the &#8220;securities&#8221;. For this purpose, a &#8220;U.S. Holder&#8221; is a holder of
securities that is: (1) an individual citizen or resident of the U.S, including an alien individual who is a lawful permanent resident
of the U.S. or meets the substantial presence residency test under U.S. federal income tax laws; (2) a corporation (or entity treated
as a corporation for U.S. federal income tax purposes) or a partnership (other than a partnership that is not treated as a U.S. person
under any applicable U.S. Treasury regulations) created or organized under the laws of the U.S. or the District of Columbia or any political
subdivision thereof; (3) an estate, the income of which is includable in gross income for U.S. federal income tax purposes regardless
of source; (4) a trust if a court within the U.S. is able to exercise primary supervision over the administration of the trust and one
or more U.S. persons have authority to control all substantial decisions of the trust; or (5) a trust that has a valid election in effect
to be treated as a U.S. person to the extent provided in U.S. Treasury regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This summary is for general
information purposes only and does not purport to be a comprehensive description of all of the U.S. federal income tax considerations
that may be relevant to a decision to purchase our securities. This summary generally considers only U.S. Holders that will own our securities
as capital assets. Except to the limited extent discussed below, this summary does not consider the U.S. federal tax consequences to a
person that is not a U.S. Holder, nor does it describe the rules applicable to determine a taxpayer&#8217;s status as a U.S. Holder. This
summary is based on the provisions of the Internal Revenue Code of 1986, as amended, or the Code, final, temporary and proposed U.S. Treasury
regulations promulgated thereunder, administrative and judicial interpretations thereof, and the U.S./Israel Income Tax Treaty, all as
in effect as of the date hereof and all of which are subject to change, possibly on a retroactive basis, and all of which are open to
differing interpretations. We will not seek a ruling from the IRS with regard to the U.S. federal income tax treatment of an investment
in our securities by U.S. Holders and, therefore, can provide no assurances that the IRS will agree with the conclusions set forth below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 116 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This discussion does not address
all of the aspects of U.S. federal income taxation that may be relevant to a particular U.S. holder based on such holder&#8217;s particular
circumstances and in particular does not discuss any estate, gift, generation-skipping transfer, state, local, excise or foreign tax considerations.
In addition, this discussion does not address the U.S. federal income tax treatment of a U.S. Holder who is: (1) a bank, life insurance
company, regulated investment company, or other financial institution or &#8220;financial services entity;&#8221; (2) a broker or dealer
in securities or foreign currency; (3) a person who acquired our securities in connection with employment or other performance of services;
(4) a U.S. Holder that is subject to the U.S. alternative minimum tax; (5) a U.S. Holder that holds our securities as a hedge or as part
of a hedging, straddle, conversion or constructive sale transaction or other risk-reduction transaction for U.S. federal income tax purposes;
(6) a tax-exempt entity; (7) real estate investment trusts or grantor trusts; (8) a U.S. Holder that expatriates out of the U.S. or a
former long-term resident of the U.S.; or (9) a person having a functional currency other than the U.S. dollar. This discussion does not
address the U.S. federal income tax treatment of a U.S. Holder that owns, directly or constructively, at any time, securities representing
10% or more of our voting power. Additionally, the U.S. federal income tax treatment of partnerships (or other pass-through entities)
or persons who hold securities through a partnership or other pass-through entity are not addressed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each prospective investor
is advised to consult his or her own tax adviser for the specific tax consequences to that investor of purchasing, holding or disposing
of our securities, including the effects of applicable state, local, foreign or other tax laws and possible changes in the tax laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span><b><i>Exercise
or Expiry of Warrants</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No gain or loss will be realized
on the exercise of a Warrant. When a Warrant is exercised, the U.S. Holder&#8217;s cost of the common share acquired thereby will be equal
to the U.S. Holder&#8217;s adjusted cost basis of the Warrant plus the exercise price paid for the common share. The expiry of an unexercised
Warrant will generally give rise to a capital loss equal to the adjusted cost basis to the U.S. Holder of the expired Warrant. The holding
period of the common share acquired thru the exercise of a Warrant includes the holding period of the Warrant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Taxation of Dividends
Paid on Ordinary Shares</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not intend to pay dividends
in the foreseeable future. In the event that we do pay dividends, and subject to the discussion under the heading &#8220;Passive Foreign
Investment Companies&#8221; below and the discussion of &#8220;qualified dividend income&#8221; below, a U.S. Holder, other than certain
U.S. Holders that are U.S. corporations, will be required to include in gross income as ordinary income the amount of any distribution
paid on securities (including the amount of any Israeli tax withheld on the date of the distribution), to the extent that such distribution
does not exceed our current and accumulated earnings and profits, as determined for U.S. federal income tax purposes. The amount of a
distribution which exceeds our earnings and profits will be treated first as a non-taxable return of capital, reducing the U.S. Holder&#8217;s
tax basis for the securities to the extent thereof, and then capital gain. We do not expect to maintain calculations of our earnings and
profits under U.S. federal income tax principles and, therefore, U.S. Holders should expect that the entire amount of any distribution
generally will be reported as dividend income.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, preferential tax
rates for &#8220;qualified dividend income&#8221; and long-term capital gains are applicable for U.S. Holders that are individuals, estates
or trusts. For this purpose, &#8220;qualified dividend income&#8221; means, inter alia, dividends received from a &#8220;qualified foreign
corporation.&#8221; A &#8220;qualified foreign corporation&#8221; is a corporation that is entitled to the benefits of a comprehensive
tax treaty with the U.S. which includes an exchange of information program. The IRS has stated that the Israel/U.S. Tax Treaty satisfies
this requirement and we believe we are eligible for the benefits of that treaty.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "></p><div>

</div><!-- Field: Page; Sequence: 117 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, our dividends
will be qualified dividend income if our securities are readily tradable on the Nasdaq Capital Market or another established securities
market in the U.S. Dividends will not qualify for the preferential rate if we are treated, in the year the dividend is paid or in the
prior year, as a PFIC, as described below under &#8220;Passive Foreign Investment Companies.&#8221; A U.S. Holder will not be entitled
to the preferential rate: (1) if the U.S. Holder has not held our securities for at least 61 days of the 121 day period beginning on the
date which is 60 days before the ex-dividend date, or (2) to the extent the U.S. Holder is under an obligation to make related payments
on substantially similar property. Any days during which the U.S. Holder has diminished its risk of loss on our securities are not counted
towards meeting the 61-day holding period. Finally, U.S. Holders who elect to treat the dividend income as &#8220;investment income&#8221;
pursuant to Code section 163(d)(4) will not be eligible for the preferential rate of taxation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The amount of a distribution
with respect to our securities will be measured by the amount of the fair market value of any property distributed, and for U.S. federal
income tax purposes, the amount of any Israeli taxes withheld therefrom. Cash distributions paid by us in NIS will be included in the
income of U.S. Holders at a U.S. dollar amount based upon the spot rate of exchange in effect on the date the dividend is includible in
the income of the U.S. Holder, and U.S. Holders will have a tax basis in such NIS for U.S. federal income tax purposes equal to such U.S.
dollar value. If the U.S. Holder subsequently converts the NIS into U.S. dollars or otherwise disposes of them, any subsequent gain or
loss in respect of such NIS arising from exchange rate fluctuations will be U.S. source ordinary exchange gain or loss.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Taxation of the
Disposition of Securities</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as provided under the
PFIC rules described below under &#8220;Passive Foreign Investment Companies,&#8221; upon the sale, exchange or other disposition of our
securities, a U.S. Holder will recognize capital gain or loss in an amount equal to the difference between such U.S. Holder&#8217;s tax
basis for the securities in U.S. dollars and the amount realized on the disposition in U.S. dollar (or its U.S. dollar equivalent determined
by reference to the spot rate of exchange on the date of disposition, if the amount realized is denominated in a foreign currency). The
gain or loss realized on the sale, exchange or other disposition of securities will be long-term capital gain or loss if the U.S. Holder
has a holding period of more than one year at the time of the disposition. Individuals who recognize long-term capital gains may be taxed
on such gains at reduced rates of tax. The deduction of capital losses is subject to various limitations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Passive Foreign
Investment Companies</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Special U.S. federal income
tax laws apply to U.S. taxpayers who own shares of a corporation that is a PFIC. We will be treated as a PFIC for U.S. federal income
tax purposes for any taxable year that either:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">75% or more of our gross income (including our pro rata share of gross income for any company, in which we are considered to own 25% or more of the shares by value), in a taxable year is passive; or</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">At least 50% of our assets, averaged over the year and generally determined based upon fair market value (including our pro rata share of the assets of any company in which we are considered to own 25% or more of the shares by value) are held for the production of, or produce, passive income.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For this purpose, passive
income generally consists of dividends, interest, rents, royalties, annuities and income from certain commodities transactions and from
notional principal contracts. Cash is treated as generating passive income.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that we will not
be a PFIC for the current taxable year, although we have not determined whether we will be a PFIC in the foreseeable future. The tests
for determining PFIC status are applied annually, and it is difficult to make accurate projections of future income and assets which are
relevant to this determination. In addition, our PFIC status may depend in part on the market value of our securities. Accordingly, there
can be no assurance that we currently are not or will not become a PFIC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we currently are or become
a PFIC, each U.S. Holder who has not elected to mark the shares to market (as discussed below), would, upon receipt of certain distributions
by us and upon disposition of our securities at a gain:&#160;(1) have such distribution or gain allocated ratably over the U.S. Holder&#8217;s
holding period for the securities, as the case may be; (2) the amount allocated to the current taxable year and any period prior to the
first day of the first taxable year in which we were a PFIC would be taxed as ordinary income; and (3) the amount allocated to each of
the other taxable years would be subject to tax at the highest rate of tax in effect for the applicable class of taxpayer for that year,
and an interest charge for the deemed deferral benefit would be imposed with respect to the resulting tax attributable to each such other
taxable year. In addition, when shares of a PFIC are acquired by reason of death from a decedent that was a U.S. Holder, the tax basis
of such shares would not receive a step-up to fair market value as of the date of the decedent&#8217;s death, but instead would be equal
to the decedent&#8217;s basis if lower, unless all gain were recognized by the decedent. Indirect investments in a PFIC may also be subject
to these special U.S. federal income tax rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; "></p><div>

</div><!-- Field: Page; Sequence: 118 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The PFIC rules described above
would not apply to a U.S. Holder who makes a QEF election for all taxable years that such U.S. Holder has held the securities while we
are a PFIC, provided that we comply with specified reporting requirements. Instead, each U.S. Holder who has made such a QEF election
is required for each taxable year that we are a PFIC to include in income such U.S. Holder&#8217;s pro rata share of our ordinary earnings
as ordinary income and such U.S. Holder&#8217;s pro rata share of our net capital gains as long-term capital gain, regardless of whether
we make any distributions of such earnings or gain. In general, a QEF election is effective only if we make available certain required
information. The QEF election is made on a shareholder-by-shareholder basis and generally may be revoked only with the consent of the
IRS. We do not intend to notify U.S. Holders if we believe we will be treated as a PFIC for any tax year. In addition, we do not intend
to furnish U.S. Holders annually with information needed in order to complete IRS Form 8621 and to make and maintain a valid QEF election
for any year in which we or any of our Subsidiaries are a PFIC. Therefore, the QEF election will not be available with respect to our
securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the PFIC rules
described above would not apply if we were a PFIC and a U.S. Holder made a mark-to-market election. A U.S. Holder of our securities which
are regularly traded on a qualifying exchange, including the Nasdaq Capital Market, can elect to mark the securities to market annually,
recognizing as ordinary income or loss each year an amount equal to the difference as of the close of the taxable year between the fair
market value of the securities and the U.S. Holder&#8217;s adjusted tax basis in the securities. Losses are allowed only to the extent
of net mark-to-market gain previously included income by the U.S. Holder under the election for prior taxable years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">U.S. Holders who hold our
securities during a period when we are a PFIC will be subject to the foregoing rules, even if we cease to be a PFIC. U.S. Holders are
strongly urged to consult their tax advisors about the PFIC rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>Tax on Net Investment
Income</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">U.S. Holders who are individuals,
estates or trusts will generally be required to pay a 3.8% Medicare tax on their net investment income (including dividends on and gains
from the sale or other disposition of our securities), or in the case of estates and trusts on their net investment income that is not
distributed to beneficiaries of the estate or trust. In each case, the 3.8% Medicare tax applies only to the extent the U.S. Holder&#8217;s
total adjusted income exceeds applicable thresholds.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Information Reporting
and Withholding</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A U.S. Holder may be subject
to backup withholding at a rate of 24% with respect to cash dividends and proceeds from a disposition of securities. In general, backup
withholding will apply only if a U.S. Holder fails to comply with specified identification procedures. Backup withholding will not apply
with respect to payments made to designated exempt recipients, such as corporations and tax-exempt organizations. Backup withholding is
not an additional tax and may be claimed as a credit against the U.S. federal income tax liability of a U.S. Holder, provided that the
required information is timely furnished to the IRS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A U.S. Holder with interests
in &#8220;specified foreign financial assets&#8221; (including, among other assets, our securities, unless such securities are held on
such U.S. Holder&#8217;s behalf through a financial institution) may be required to file an information report with the IRS if the aggregate
value of all such assets exceeds $50,000 on the last day of the taxable year or $75,000 at any time during the taxable year (or such higher
dollar amount as may be prescribed by applicable IRS guidance); and may be required to file a Report of Foreign Bank and Financial Accounts,
or FBAR, if the aggregate value of the foreign financial accounts exceeds $10,000 at any time during the calendar year. You should consult
your own tax advisor as to the possible obligation to file such information report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="I_052"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-size: 10pt"><b>F.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Dividends and Paying Agents.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="I_053"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-size: 10pt"><b>G.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Statement by Experts.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 119 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="I_054"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-size: 10pt"><b>H.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Documents on Display.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to the information
reporting requirements of the Exchange Act, applicable to foreign private issuers and under those requirements file reports with the SEC.
The SEC maintains an Internet website that contains reports and other information regarding issuers that file electronically with the
SEC. Our filings with the SEC are also available to the public through the SEC&#8217;s website at www.sec.gov.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a foreign private issuer,
we are exempt from the rules under the Exchange Act related to the furnishing and content of proxy statements, and our officers, directors
and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange
Act. In addition, we are not required under the Exchange Act to file annual, quarterly and current reports and financial statements with
the SEC as frequently or as promptly as U.S. domestic companies whose securities are registered under the Exchange Act. However, we file
with the SEC, within 120 days after the end of each fiscal year, or such applicable time as required by the SEC, an annual report on Form
20-F containing financial statements audited by an independent registered public accounting firm, and may submit to the SEC, on a Form
6-K, unaudited quarterly financial information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We maintain a corporate website
www.inspira-technologies.com. Information contained on, or that can be accessed through, our website and the other websites referenced
above do not constitute a part of this annual report on Form 20-F. We have included these website addresses in this annual report on Form
20-F solely as inactive textual references.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="I_055"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-size: 10pt"><b>I.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Subsidiary Information.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">Not
applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><div><a id="I_056"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-size: 10pt"><b>J.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Annual Report to Security Holders</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;&#160;</p><div>

</div><div><a id="I_057"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 11. <span style="text-transform: uppercase">QUANTITATIVE
AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the ordinary course of
our operations, we are exposed to certain market risks, primarily changes in foreign currency exchange rates and interest rates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Quantitative and Qualitative Disclosure About
Market Risk</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are exposed to market risks
in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse
changes in financial market prices and rates. Our current investment policy is to invest available cash in bank deposits with banks that
have a credit rating of at least A-minus. Accordingly, a substantial majority of our equivalents is held in deposits that bear interest.
Given the current low rates of interest we receive, we will not be adversely affected if such rates are reduced. Our market risk exposure
is primarily a result of NIS/U.S. dollar exchange rates, which is discussed in detail in the following paragraph.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "></p><div>

</div><!-- Field: Page; Sequence: 120 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Foreign Currency Exchange Risk</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We operate primarily in Israel,
and approximately 80% of our expenses are denominated in NIS. We are therefore exposed to market risk, which represents the risk of loss
that may impact our financial position due to adverse changes in financial market prices and rates. We are subject to fluctuations in
foreign currency rates in connection with these arrangements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently partially hedge
our foreign currency exchange rate risk to decrease the risk of financial exposure from fluctuations in the exchange rates of our principal
operating currencies. These measures, however, may not adequately protect us from the material adverse effects of such fluctuations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Interest Rate Risk</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not anticipate undertaking
any significant long-term borrowings. At present, our investments consist primarily of cash and cash equivalents, and short-term deposits.
The primary objective of our investment activities is to preserve principal while maximizing the income that we receive from our investments
without significantly increasing risk and loss. Our investments may be exposed to market risk due to fluctuation in interest rates, which
may affect our interest income and the fair market value of our investments, if any.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Impact of Inflation and Currency Fluctuations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Inflation generally affects
us by increasing our NIS-denominated expenses, including salaries and benefits, as well as facility rental costs and payment to local
suppliers. We do not believe that inflation had a material effect on our business, financial condition or results of operations during
the year ended December 31, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><div><a id="I_058"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 12. <span style="text-transform: uppercase">DESCRIPTION
OF SECURITIES OTHER THAN EQUITY SECURITIES</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="I_059"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-size: 10pt"><b>A.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Debt Securities.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="I_060"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-size: 10pt"><b>B.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Warrants and rights.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="I_061"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-size: 10pt"><b>C.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Other Securities.</b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="I_062"></a></div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify"><span style="font-size: 10pt"><b>D.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>American Depositary Shares. </b></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 121 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="I_063"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART II</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="I_064"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 13. DEFAULTS, DIVIDEND ARREARAGES AND
DELINQUENCIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="I_065"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 14. MATERIAL MODIFICATIONS TO THE RIGHTS
OF SECURITY HOLDERS AND USE OF PROCEEDS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2021, we completed
our IPO of Ordinary Shares and warrants pursuant to Registration Statement on Form F-1, as amended (Registration No. 333-253920), whereby
we sold 2,909,091 Ordinary Shares and 3,345,455 tradable warrants (inclusive of 436,364 tradable warrants pursuant to the exercise of
an overallotment option granted to the underwriters). All these Ordinary Shares and warrants were sold at a combined price of $5.50 per
unit, yielding an aggregate net proceeds received by us from the IPO were $14 million, after underwriting discounts and other offering
costs. We continue to use the proceeds from the exercise of warrants related to this offering, as described in the final prospectus filed
with the SEC on July 15, 2021, under File Nos. 333-253920 and 333-279276.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><div><a id="I_066"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 15. CONTROLS AND PROCEDURES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(a) Disclosure Controls and Procedures</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management, with the participation
of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures
(as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of December 31, 2024, or the Evaluation Date. Based
on such evaluation, those officers have concluded that, as of the Evaluation Date, our disclosure controls and procedures are effective
in recording, processing, summarizing and reporting, on a timely basis, information required to be included in periodic filings under
the Exchange Act and that such information is accumulated and communicated to management, including our principal executive and financial
officers, as appropriate to allow timely decisions regarding required disclosure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(b) Management&#8217;s Annual Report on Internal
Control over Financial Reporting</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management is responsible
for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule 13a-15(f) under the
Exchange Act. Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial
Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework and criteria
established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission
as of the end of the period covered by this report. Based on that evaluation, our management has concluded that our internal control over
financial reporting was effective as of December 31, 2024 at providing reasonable assurance regarding the reliability of financial reporting
and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(c) Attestation Report of the Registered Public
Accounting Firm</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This annual report does not
include an attestation report of our independent registered public accounting firm regarding internal control over financial reporting
due to an exemption for EGCs provided in the JOBS Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(d) Changes in Internal Control over Financial
Reporting</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2024, there were no changes in our internal control over financial reporting that have materially affected, or are reasonably likely
to materially affect, our internal control over financial reporting.</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 122 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="I_067"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 16. [RESERVED]</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="I_068"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16A. AUDIT COMMITTEE FINANCIAL EXPERT</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors has
determined that each member of our audit committee is an audit committee financial expert, as defined under the rules under the Exchange
Act, and is independent in accordance with applicable Exchange Act rules and Nasdaq rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="I_069"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16B. CODE OF ETHICS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have adopted a written
code of ethics that applies to our officers and employees, including our principal executive officer, principal financial officer, principal
controller and persons performing similar functions as well as our directors. Our Code of Business Conduct and Ethics is posted on our
website at www.icecure-medical.com. Information contained on, or that can be accessed through, our website does not constitute a part
of this annual report on Form 20-F and is not incorporated by reference herein. If we make any amendment to the Code of Business Conduct
and Ethics or grant any waivers, including any implicit waiver, from a provision of the code, we will disclose the nature of such amendment
or waiver on our website to the extent required by the rules and regulations of the SEC including the instructions to Item 16B of Form
20-F. We have not granted any waivers under our Code of Business Conduct and Ethics.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="I_070"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16C. PRINCIPAL ACCOUNTANT FEES AND SERVICES
</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Ziv Haft., Certified Public
Accountants, Isr., BDO member firm, an independent registered public accounting firm, has served as our principal independent registered
public accounting firm for each of the two years ended December 31, 2023 and 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table provides
information regarding fees paid by us to Ziv Haft and/or other BDO member firms for all services, including audit services, for the years
ended December 31, 2023 and 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended<br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 1.5pt"><span style="font-size: 10pt">Audit fees <sup>(1) </sup></span></td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">129.5</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">170</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Review of registration statements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16.5</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">17.1</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">146</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">187.1</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-size: 10pt">Includes professional services
rendered in connection with the audit of our annual financial statements and review of our interim financial statements.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "></p><div>

</div><!-- Field: Page; Sequence: 123 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Pre-Approval of Auditors&#8217; Compensation</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our audit committee has a
pre-approval policy for the engagement of our independent registered public accounting firm to perform certain audit and non-audit services.
Pursuant to this policy, which is designed to assure that such engagements do not impair the independence of our auditors, the audit committee
pre-approves annually a catalog of specific audit and non-audit services in the categories of audit services, audit-related services and
tax services that may be performed by our independent registered public accounting firm. If a type of service, that is to be provided
by our auditors, has not received such general pre-approval, it will require specific pre-approval by our audit committee. The policy
prohibits retention of the independent registered public accounting firm to perform the prohibited non-audit functions defined in applicable
SEC rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="I_071"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16D. EXEMPTIONS FROM THE LISTING STANDARDS
FOR AUDIT COMMITTEES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="I_072"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16E. PURCHASES OF EQUITY SECURITIES BY
THE ISSUER AND AFFILIATED PURCHASERS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="I_073"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16F. CHANGE IN REGISTRANT&#8217;S CERTIFYING
ACCOUNTANT</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="I_074"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16G. CORPORATE GOVERNANCE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under Nasdaq rules, we may
elect to follow certain corporate governance practices permitted under the Companies Law in lieu of compliance with corresponding corporate
governance requirements otherwise imposed by the Nasdaq rules for U.S. domestic issuers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with Israeli
law and practice and subject to the exemption set forth in Rule 5615 of the Nasdaq rules, we have elected to follow the provisions of
the Companies Law, rather than the Nasdaq rules, with respect to the following requirements:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><i>Quorum</i>. While the Nasdaq rules require that the quorum for purposes of any meeting of the holders of a listed company&#8217;s ordinary voting stock, as specified in the company&#8217;s bylaws, be no less than 33 1/3% of the company&#8217;s outstanding ordinary voting stock, under Israeli law, a company is entitled to determine in its articles of association the number of shareholders and percentage of holdings required for a quorum at a shareholders meeting. Our amended and restated articles of association provide that a quorum of two or more shareholders holding at least 25% of the voting rights in person or by proxy is required for commencement of business at a general meeting. However, the quorum set forth in our amended and restated articles of association with respect to an adjourned meeting consists of at least one shareholder present in person or by proxy.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><i>Nomination of our directors</i>. With the exception of directors elected by our board of directors and external directors (if applicable), our directors are generally elected by an annual meeting of our shareholders for a term of office that expires on the annual general meeting following their election or re-election. The nominations for directors, which are presented to our shareholders by our board of directors, are generally made by the board of directors itself, in accordance with the provisions of our amended and restated articles of association and the Companies Law. Nominations need not be made by a nominating committee of our board of directors consisting solely of independent directors, as required under the Nasdaq rules.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><i>Compensation of officers. </i>Israeli law and our amended and restated articles of association do not require that the independent members of our board of directors (or a compensation committee composed solely of independent members of our board of directors) determine an executive officer&#8217;s compensation, as is generally required under the Nasdaq rules with respect to the chief executive officer and all other executive officers. Instead, compensation of executive officers is determined and approved by our compensation committee and our board of directors, and in certain circumstances by our shareholders, either in consistency with our office holder compensation policy or, in special circumstances in deviation therefrom, taking into account certain considerations stated in the Companies Law. See &#8220;Item 6.C. Directors, Senior Management and Employees-Board Practices-Approval of Related Party Transactions under Israeli law&#8221; for additional information.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 124 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><i>Shareholder approval.</i> We will seek shareholder approval for all corporate actions requiring such approval under the requirements of the Companies Law, rather than seeking approval for corporation actions in accordance with Nasdaq Listing Rule 5635. In particular, under this Nasdaq rule, shareholder approval is generally required for: (i) an acquisition of shares/assets of another company that involves the issuance of 20% or more of the acquirer&#8217;s shares or voting rights or if a director, officer or 5% shareholder has greater than a 5% interest in the target company or the consideration to be received; (ii) the issuance of shares leading to a change of control; (iii) adoption/amendment of equity compensation arrangements (although under the provisions of the Companies Law there is no requirement for shareholder approval for the adoption/amendment of the equity compensation plan); and (iv) issuances of 20% or more of the shares or voting rights (including securities convertible into, or exercisable for, equity) of a listed company via a private placement (and/or via sales by directors/officers/5% shareholders) if such equity is issued (or sold) at below the greater of the book or market value of shares. By contrast, under the Companies Law, shareholder approval is required for, among other things: (i) transactions with directors concerning the terms of their service or indemnification, exemption and insurance for their service (or for any other position that they may hold at a company), for which approvals of the compensation committee, board of directors and shareholders are all required, (ii) extraordinary transactions with controlling shareholders of publicly held companies, which require the special approval, and (iii) terms of employment or other engagement of the controlling shareholder of us or such controlling shareholder&#8217;s relative, which require special approval. In addition, under the Companies Law, a merger requires approval of the shareholders of each of the merging companies.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><i>Approval of Related Party Transactions</i>. All related party transactions are approved in accordance with the requirements and procedures for approval of interested party acts and transaction as set forth in the Companies Law, which requires the approval of the audit committee, or the compensation committee, as the case may be, the board of directors and shareholders, as may be applicable, for specified transactions, rather than approval by the audit committee or other independent body of our board of directors as required under the Nasdaq rules. See &#8220;Item 6.C. Directors, Senior Management and Employees-Board Practices-Approval of Related Party Transactions under Israeli law&#8221; for additional information.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><i>Annual Shareholders Meeting. </i>As opposed to the Nasdaq Listing Rule 5620(a), which mandates that a listed company hold its annual shareholders meeting within one year of the company&#8217;s fiscal year-end, we are required, under the Companies Law, to hold an annual shareholders&#8217; meeting each calendar year and within 15 months of the last annual shareholders meeting.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><i>Distribution of periodic reports to shareholders; proxy solicitation.</i> As opposed to the Nasdaq rules, which require listed issuers to make such reports available to shareholders in one of a number of specific manners, Israeli law does not require us to distribute periodic reports directly to shareholders, and the generally accepted business practice in Israel is not to distribute such reports to shareholders but to make such reports available through a public website. In addition to making such reports available on a public website, we currently make our audited financial statements available to our shareholders at our offices and will only mail such reports to shareholders upon request. As a foreign private issuer, we are generally exempt from the SEC&#8217;s proxy solicitation rules.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Shareholder approval is generally
required for officer compensation in the event (i) approval by our Board of Directors and our compensation committee is not consistent
with our office holder compensation policy, or (ii) compensation required to be approved is that of our chief executive officer or an
executive officer who is also the controlling shareholder of our company (including an affiliate thereof). Such shareholder approval shall
require a majority vote of the shares present and voting at a shareholders meeting, provided either (i) such majority includes a majority
of the shares held by non-controlling shareholders who do not otherwise have a personal interest in the compensation arrangement that
are voted at the meeting, excluding for such purpose any abstentions disinterested majority, or (ii) the total shares held by non-controlling
and disinterested shareholders voted against the arrangement does not exceed 2% of the voting rights in our company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 125 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, approval of
the compensation of an executive officer who is also a director requires a simple majority vote of the shares present and voting at a
shareholders meeting, if consistent with our office holder compensation policy. Our compensation committee and board of directors may,
in special circumstances, approve the compensation of an executive officer (other than a director, a chief executive officer or a controlling
shareholder) or approve the compensation policy despite shareholders&#8217; objection, based on specified arguments and taking shareholders&#8217;
objection into account. Our compensation committee may further exempt an engagement with a nominee for the position of chief executive
officer, who meets the non-affiliation requirements set forth for an external director, from requiring shareholder approval, if such engagement
is consistent with our office holder compensation policy and our compensation committee determines based on specified arguments that presentation
of such engagement to shareholder approval is likely to prevent such engagement. To the extent that any such transaction with a controlling
shareholder is for a period exceeding three years, approval is required once every three years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A director or executive officer
may not be present when the board of directors of a company discusses or votes upon a transaction in which he or she has a personal interest,
except in case of ordinary transactions, unless the chairman of the board of directors determines that he or she should be present to
present the transaction that is subject to approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><i>Independent directors. </i>Israeli law does not require that a majority of the directors serving on our Board of Directors be &#8220;independent,&#8221; as defined under Nasdaq Listing Rule 5605(a)(2), and rather requires we have at least two external directors who meet the requirements of the Companies Law, as described above under &#8220;Item 6. C. Board Practices - External Directors.&#8221; Notwithstanding Israeli law, we believe that a majority of our directors are currently &#8220;independent&#8221; under the Nasdaq rules. We are required, however, to ensure that all members of our audit committee are &#8220;independent&#8221; under the applicable Nasdaq and SEC criteria for independence (as we cannot exempt ourselves from compliance with that SEC independence requirement, despite our status as a foreign private issuer), and we must also ensure that a majority of the members of our audit committee are &#8220;unaffiliated directors&#8221; as defined in the Companies Law. Furthermore, Israeli law does not require, nor do our independent directors conduct, regularly scheduled meetings at which only they are present, which Nasdaq rules otherwise require.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><i>Shareholder approval. </i>We will seek shareholder approval for all corporate actions requiring such approval under the requirements of the Companies Law, rather than seeking approval for corporation actions in accordance with Nasdaq Listing Rule 5635. In particular, under this Nasdaq rule, shareholder approval is generally required for: (i) an acquisition of shares/assets of another company that involves the issuance of 20% or more of the acquirer&#8217;s shares or voting rights or if a director, officer or 5% shareholder has greater than a 5% interest in the target company or the consideration to be received; (ii) the issuance of shares leading to a change of control; (iii) adoption/amendment of equity compensation arrangements (although under the provisions of the Companies Law there is no requirement for shareholder approval for the adoption/amendment of the equity compensation plan); and (iv) issuances of 20% or more of the shares or voting rights (including securities convertible into, or exercisable for, equity) of a listed company via a private placement (and/or via sales by directors/officers/5% shareholders) if such equity is issued (or sold) below a specified minimum price. By contrast, under the Companies Law, shareholder approval is required for, among other things: (i) transactions with directors concerning the terms of their service or indemnification, exemption and insurance for their service (or for any other position that they may hold at a company), for which approvals of the compensation committee, board of directors and shareholders are all required, subject to applicable relief, (ii) extraordinary transactions with controlling shareholders of publicly held companies, which require the special approval, and (iii) terms of employment or other engagement of the controlling shareholder of us or such controlling shareholder&#8217;s relative, which require special approval. In addition, under the Companies Law, a merger requires approval of the shareholders of each of the merging companies.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><i>Approval of Related Party Transactions</i>. All related party transactions are approved in accordance with the requirements and procedures for approval of interested party acts and transaction as set forth in the Companies Law, which requires the approval of the audit committee, or the compensation committee, as the case may be, the board of directors and shareholders, as may be applicable, for specified transactions, rather than approval by the audit committee or other independent body of our board of directors as required under the Nasdaq rules.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><i>Annual Shareholders Meeting.</i> As opposed to the Nasdaq Listing Rule 5620(a), which mandates that a listed company hold its annual shareholders meeting within one year of the company&#8217;s fiscal year-end, we are required, under the Companies Law, to hold an annual shareholders&#8217; meeting each calendar year and within 15 months of the last annual shareholders meeting.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 126 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="I_075"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16H. MINE SAFETY DISCLOSURE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="I_076"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16I. DISCLOSURE REGARDING FOREIGN JURISDICTIONS
THAT PREVENT INSPECTIONS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="I_077"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16J. INSIDER TRADING POLICIES.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have <ix:nonNumeric contextRef="c31" format="ixt:fixed-false" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" id="ixv-25450">adopted</ix:nonNumeric> an&#160;insider
trading policy governing the purchase, sale and other transactions in our securities that applies to our directors, senior management,
employees, consultants, contractors and other covered persons, including immediate family members and entities controlled by any of the
foregoing persons.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This policy prohibits, among
other things, insider trading and certain speculative transactions in our securities (including short sales, buying put and selling call
options and other hedging or derivative transactions in our securities) and establishes a regular blackout period schedule during which
directors, senior management, employees, and other covered persons may not trade in our securities, as well as certain pre-clearance procedures
that directors and officers of the Company, the Company&#8217;s subsidiaries and/or affiliates must observe prior to effecting any transaction
in our securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that the policy&#160;is
reasonably designed to promote compliance with applicable insider trading laws, rules and regulations, and listing standards applicable
to us. A copy of the policy&#160;is filed as Exhibit 11.1 to this Form 20-F.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="I_078"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 16K. CYBERSECURITY.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_1" escape="true" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" id="ixv-12820"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has
developed and maintained a cybersecurity risk management strategy, consisting of cybersecurity policies, procedures, compliance and
awareness programs to mitigate risk and to ensure compliance with security, availability and confidentiality trust principles. <ix:nonNumeric contextRef="c0" escape="true" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" id="ixv-25451">The
cybersecurity process has been <ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" id="ixv-25452">integrated</ix:nonNumeric> into the Company&#8217;s overall risk management system and process and is solely
internally managed.</ix:nonNumeric> <ix:nonNumeric contextRef="c0" escape="true" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" id="ixv-25453">Management is <ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" id="ixv-25454">responsible</ix:nonNumeric> for identifying risks that threaten achievement of the control activities stated in
the management&#8217;s description of the services organizations systems. The risk assessment occurs annually, or as business needs
change, and covers <ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" id="ixv-25455">identification</ix:nonNumeric> of risks that could act against the company&#8217;s objectives as well as specific risks related
to a compromise to the security of data.</ix:nonNumeric></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_2" id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The level of each identified
risk is determined by considering the impact of the risk itself and the likelihood of the risk materializing and high scoring risks are
actioned upon. Risks are analyzed to determine whether the risk meets company risk acceptance criteria to be accepted or whether a mitigation
plan will be applied. Mitigation plans include both the individual or department responsible for the plan and may include budget considerations.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" id="ixv-12830"><ix:continuation id="_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this report,
we are <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" id="ixv-25456">not</ix:nonNumeric> aware of any material risks from cybersecurity threats that have materially affected or are reasonably likely to materially
affect us, including our business strategy, results of operations or financial condition.</p></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_CybersecurityRiskBoardOfDirectorsOversightTextBlock-c0_cont_1" escape="true" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" id="ixv-12836"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Governance</b></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:continuation id="_CybersecurityRiskBoardOfDirectorsOversightTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" escape="true" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="ixv-12844"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><ix:nonNumeric contextRef="c0" escape="true" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="ixv-25457">Our Chief Executive Officer
and Chief Financial Officer oversee our cybersecurity risk management and mitigation efforts</ix:nonNumeric>. The board of directors receive prompt and
timely information regarding any cybersecurity incidents. Our Audit Committee periodically discusses cybersecurity.</p></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risk Management and Strategy</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_CybersecurityRiskRoleOfManagementTextBlock-c0_cont_1" escape="true" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" id="ixv-12855"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As part of the critical elements
of our overall risk management approach, our cybersecurity program is focused on the following key areas:</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskRoleOfManagementTextBlock-c0_cont_2" id="_CybersecurityRiskRoleOfManagementTextBlock-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Collaborative Approach: The Company has implemented a comprehensive, cross-functional approach to identifying, preventing and mitigating cybersecurity threats and incidents, while also implementing controls and procedures that provide for the prompt escalation of certain cybersecurity incidents so that decisions regarding the public disclosure and reporting of such incidents can be made by management in a timely manner.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  </table></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_CybersecurityRiskRoleOfManagementTextBlock-c0_cont_3" id="_CybersecurityRiskRoleOfManagementTextBlock-c0_cont_2"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Technical Safeguards: The Company deploys technical safeguards that are designed to protect the Company&#8217;s information systems from cybersecurity threats, including firewalls, intrusion prevention and detection systems, anti-malware functionality and access controls, which are evaluated and improved through vulnerability assessments and cybersecurity threat intelligence.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  </table></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="_CybersecurityRiskRoleOfManagementTextBlock-c0_cont_3"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Incident Response and Recovery Planning: The Company has established and maintains comprehensive incident response and recovery plans that fully address the Company&#8217;s response to a cybersecurity incident, and such plans are tested and evaluated on a regular basis.</span></td></tr>
  </table></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 127 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><div><a id="I_079"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART III</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="I_080"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 17. <span style="text-transform: uppercase">FINANCIAL
STATEMENTS</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have elected to provide
financial statements and related information pursuant to Item 18.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="I_081"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 18. <span style="text-transform: uppercase">FINANCIAL
STATEMENTS</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The financial statements and
the related notes required by this Item are included in this annual report on Form 20-F beginning on page F-1.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="I_082"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>ITEM 19. <span style="text-transform: uppercase">EXHIBITS
</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; width: 8%"><span style="font-size: 10pt"><b>Number</b></span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 91%; text-align: justify"><span style="font-size: 10pt"><b>Exhibit Description</b>&#160;</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt">1.1</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1837493/000121390021066318/ea152692ex99-1_inspiratech.htm"><span style="font-size: 10pt">Amended and Restated Articles of Association of Inspira Technologies Oxy B.H.N. Ltd. (filed as Exhibit 99.1 to Form 6-K (File No. 001-40303) filed on December 20, 2021 and incorporated herein by reference.)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">2.1*</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt"><a href="ea023322601ex2-1_inspira.htm">Description of Securities.</a> </span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt">4.1</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1837493/000121390021015150/ea137365ex10-1_inspiratech.htm"><span style="font-size: 10pt">Form of Indemnification Agreement (filed as Exhibit 10.1 to Form F-1 (File No. 333-253920) filed on March 12, 2021 and incorporated herein by reference.)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">4.2</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1837493/000121390025020699/ea023315301ex99-1_inspira.htm"><span style="font-size: 10pt">Amended and Restated Inspira
    Technologies Oxy B.H.N. Ltd. 2019 Equity Incentive Plan, (filed as Exhibit 99.1 to Form S-8 (File No. 333-285565) filed on March 5,
    2025, and incorporated herein by reference.)</span></a></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt">4.3</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1837493/000121390021066318/ea152692ex99-2_inspiratech.htm"><span style="font-size: 10pt">Inspira Technologies Oxy B.H.N. Ltd. Compensation Policy for Company&#8217;s Executives, (filed as Exhibit 99.2 to Form 6-K (File No. 001-4030) filed on December 20, 2021, and incorporated herein by reference.)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">4.4</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1837493/000121390021031503/ea140235ex4-2_inspiratech.htm"><span style="font-size: 10pt">Form of Warrant Agent Agreement (filed as Exhibit 4.2 to Form F-1 (File No. 333-253920) filed on July 1, 2021 and incorporated herein by reference.)</span></a></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt">4.5</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1837493/000121390021031503/ea140235ex4-4_inspiratech.htm"><span style="font-size: 10pt">Form of Warrant (filed as Exhibit 4.4 to Form F-1 (File No. 333-253920) filed on July 1, 2021 and incorporated herein by reference.)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">4.6</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1837493/000121390024025316/ea020216701ex4-6_inspira.htm"><span style="font-size: 10pt">Form of Amendment of Warrant Agreement by and between the Company and American Stock Transfer &amp; Trust Company, LLC, dated August 8, 2022 (filed as Exhibit 4.6 to Form 20-F, filed on March 25, 2024 and incorporated herein by reference.) </span></a></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt">4.7</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1837493/000121390021015150/ea137365ex10-7_inspiratech.htm"><span style="font-size: 10pt">Form of Simple Agreement for Future Equity (filed as Exhibit 10.7 to Form F-1 (File No. 333-253920) filed on July 1, 2021, and incorporated herein by reference.)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">4.8</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1837493/000121390021034372/ea143325ex10-8_inspiratec.htm"><span style="font-size: 10pt">Shareholder Loan Agreement, dated March 1, 2018, by and between the Company and Dagi Ben-Noon (filed as Exhibit 10.8 to form F-1 (File No. 333-253920) filed on July 1, 2021, and incorporated herein by reference.)</span></a></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-size: 10pt">4.9</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1837493/000121390021015150/ea137365ex10-8_inspiratech.htm"><span style="font-size: 10pt">Form of Convertible Loan Agreement (filed as Exhibit 10.9 to form F-1 (File No. 333-253920) filed on July 1, 2021, and incorporated herein by reference.)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">4.10</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1837493/000121390023098916/ea190727ex10-1_inspira.htm"><span style="font-size: 10pt">Form of Securities Purchase Agreement (filed as Exhibit 10.1 to the Report of Foreign Private Issuer on Form 6-K on December 27, 2023, and incorporated herein by reference.)</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">4.11</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1837493/000121390024041365/ea020565001ex4-7_inspira.htm"><span style="font-size: 10pt">Warrant to Purchase Ordinary Shares (filed as Exhibit 4.7 to Form F-1 on May 9, 2024, and incorporated herein by reference.)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top">4.12</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1837493/000121390024053164/ea020795901ex4-1_inspira.htm">Pre-Funded Ordinary Share Purchase Warrant (filed as Exhibit 4.1 to the Report of Foreign Private Issuer on Form 6-K on June 17, 2024, and incorporated herein by reference.)</a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">4.13</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1837493/000121390024053164/ea020795901ex10-1_inspira.htm"><span style="font-size: 10pt">Form of Securities Purchase Agreement (filed as Exhibit 10.1 to the Report of Foreign Private Issuer on Form 6-K on June 17, 2024, and incorporated herein by reference.)</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">4.14</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1837493/000121390024113079/ea022602101ex99-3_inspira.htm"><span style="font-size: 10pt">Form of Ordinary Share Purchase Warrant (filed as Exhibit 99.3 to the Report of Foreign Private Issuer on Form 6-K on December 27, 2024, and incorporated herein by reference.)</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">4.15</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1837493/000121390024113079/ea022602101ex99-2_inspira.htm">Pre-Funded Ordinary Share Purchase Warrant (filed as Exhibit 99.2 to the Report of Foreign Private Issuer on Form 6-K on December 27, 2024, and incorporated herein by reference.)</a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">4.16</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1837493/000121390024113079/ea022602101ex99-1_inspira.htm"><span style="font-size: 10pt">Securities Purchase Agreement (filed as Exhibit 99.1 to the Report of Foreign Private Issuer on Form 6-K on December 27, 2024, and incorporated herein by reference.)</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">11.1(b)*</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="ea023322601ex11-1b_inspira.htm">Insider Trading Policy.</a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">12.1*</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="ea023322601ex12-1_inspira.htm"><span style="font-size: 10pt">Certification of the Chief Executive Officer pursuant to rule 13a-14(a) of the Securities Exchange Act of 1934.</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">12.2*</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="ea023322601ex12-2_inspira.htm"><span style="font-size: 10pt">Certification of the Chief Financial Officer pursuant to rule 13a-14(a) of the Securities Exchange Act of 1934.</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">13.1%</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="ea023322601ex13-1_inspira.htm"><span style="font-size: 10pt">Certification of the Chief Executive Officer pursuant to 18 U.S.C. 1350.</span></a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">13.2%</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="ea023322601ex13-2_inspira.htm"><span style="font-size: 10pt">Certification of the Chief Financial Officer pursuant to 18 U.S.C. 1350.</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">15.1*</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-size: 10pt"><a href="ea023322601ex15-1_inspira.htm">Consent of Ziv Haft, a member firm of BDO, independent registered public accounting firm.</a></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">97.1</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1837493/000121390024025316/ea020216701ex97-1_inspira.htm"><span style="font-size: 10pt">Inspira Technologies Oxy B.H.N. Ltd. Clawback Policy (filed as Exhibit 97.1 to Form 20-F, filed on March 25, 2024, and incorporated herein by reference).</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">101*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">The following financial information from the Registrant&#8217;s Annual Report on Form 20-F for the year ended December 31, 2024, formatted in XBRL (eXtensible Business Reporting Language): (i) Balance sheets as of December 31, 2024, December 31, 2023 and December 31, 2022; (ii) Statements of Comprehensive Loss as of December 31, 2024, December 31, 2023 and December 31, 2022; (iii) Statement of Changes in Shareholders&#8217; Equity as of December 31, 2024, December 31, 2023 and December 31, 2022; (iv) Statements of Cash Flows as of December 31, 2024, December 31, 2023 and December 31, 2022; and (v) Notes to the financial statements.</span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><span style="font-size: 10pt">104*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-size: 10pt">*</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Filed herewith.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">%</span></td>
    <td><span style="font-size: 10pt">Furnished herewith.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 128 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="I_083"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The registrant hereby certifies
that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this
annual report on Form 20-F filed on its behalf.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-size: 10pt"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 36%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Date: March 10, 2025</span></td>
    <td><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap">/s/ <span style="font-size: 10pt">Dagi Ben-Noon</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom"><span style="font-size: 10pt">Dagi Ben-Noon</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chief Executive Officer</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 129; Options: NewSection; Value: 116 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b><span style="text-decoration:underline">INSPIRA
TECHNOLOGIES OXY B.H.N. LTD.</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b><span style="text-decoration:underline">TABLE
OF CONTENTS</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif"><a href="#a_001"><span style="font-size: 10pt">Report of Independent Registered Public Accounting Firm (BDO Ziv Haft; Tel-Aviv, Israel; PCAOB#<ix:nonNumeric contextRef="c0" name="dei:AuditorFirmId" id="ixv-25458">1185</ix:nonNumeric>)</span></a></span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr> <tr style="vertical-align: bottom; "> <td style="width: 89%"><span style="font-family: Times New Roman, Times, Serif"><a href="#a_002"><span style="font-size: 10pt">Statements of balance sheet</span></a></span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif"><a href="#a_003"><span style="font-size: 10pt">Statements of comprehensive loss</span></a></span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif"><a href="#a_004"><span style="font-size: 10pt">Statements of changes in shareholders&#8217; equity</span></a></span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif"><a href="#a_005"><span style="font-size: 10pt">Statements of cash flows</span></a></span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-8</span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif"><a href="#a_006"><span style="font-size: 10pt">Notes to the financial statements</span></a></span></td> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-10 &#8211; F-33</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">______________________</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">________________</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">____________</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">The
amounts are stated in thousands of U.S. dollars</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 130; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">To
The Board of Directors and Shareholders of Inspira Technologies Oxy B.H.N. Ltd.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Ha-Tidhar
Street 2, Ra&#8217;anana, Israel</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_AuditorOpinionTextBlock-c0_cont_1" escape="true" name="dei:AuditorOpinionTextBlock" id="ixv-13362"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Opinion
on the Financial Statements&#160;</i></b></span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation id="_AuditorOpinionTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
have audited the accompanying balance sheets of Inspira Technologies Oxy B.H.N. Ltd. (the &#8220;Company&#8221;) as of December 31, 2024
and 2023, the related statements of comprehensive loss, changes in shareholders&#8217; equity, and cash flows for each of the three years
in the period ended December 31, 2024, and the related notes (collectively, the &#8220;Financial Statements&#8221;). In our opinion,
the Financial Statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and
2023, and the results of its operations and its cash flows for each of the three years in the period ended December&#160;31, 2024, in
conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;).</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Going
Concern</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
accompanying Financial Statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note
1 to the Financial Statements, the Company is at its development stage, therefore, it has suffered recurring losses and negative cash
flows from operations since inception. As of December 31, 2024, the Company had incurred accumulated losses of $67 million. The Company&#8217;s
operations have been funded substantially through issuance of shares and warrants. Considering the above, the Company&#8217;s dependency
on external funding for its operations raises a substantial doubt about the Company&#8217;s ability to continue as a going concern. Management&#8217;s
evaluation of the events and conditions and management&#8217;s plans regarding these matters are described in Note 1. The Financial Statements
do not include any adjustments that might result from the outcome of these uncertainties.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;<b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Basis
for Opinion</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">These
Financial Statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these Financial
Statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United
States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and
the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the Financial Statements are free of material misstatement, whether due to error or fraud. The Company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits,
we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion
on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Our
audits included performing procedures to assess the risks of material misstatement of the Financial Statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the Financial Statements. Our audits also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the Financial Statements. We believe that our audits
provide a reasonable basis for our opinion.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr> <td style="vertical-align: bottom; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have served as the Company&#8217;s auditors since 2018.</span></td> <td style="vertical-align: top; width: 50%; text-align: center"/></tr> <tr style="vertical-align: bottom"> <td><ix:nonNumeric contextRef="c0" name="dei:AuditorLocation" id="ixv-13428"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel-Aviv, Israel</span></ix:nonNumeric></td> <td style="text-align: center">/s/ <ix:nonNumeric contextRef="c0" name="dei:AuditorName" id="ixv-13431"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ziv Haft</span></ix:nonNumeric></td></tr> <tr> <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 10, 2025</span></td> <td style="padding-left: 2.85pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certified Public Accountants (Isr.)</span></td></tr> <tr> <td style="vertical-align: bottom">&#160;</td> <td style="padding-left: 2.85pt; text-align: center">BDO Member Firm</td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 131; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>INSPIRA
TECHNOLOGIES OXY B.H.N. LTD.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>BALANCE
SHEETS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>(US
dollars in thousands)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December&#160;31,</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December&#160;31,</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Note</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">ASSETS</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Current
    Assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 66%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash
    and cash equivalents</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 9%; text-align: center"/><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-25459">5,111</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-25460">5,041</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Deposits</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">3</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepositsAssetsCurrent" scale="3" unitRef="usd" id="ixv-25461">668</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepositsAssetsCurrent" scale="3" unitRef="usd" id="ixv-25462">2,320</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other
    current assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">4</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-25463">587</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-25464">432</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Inventory</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">5</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" unitRef="usd" id="ixv-25465">444</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-1; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    current assets</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd" id="ixv-25466">6,810</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd" id="ixv-25467">7,793</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Non-Current
    Assets:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Right
    of use assets, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">9</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-25468">761</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-25469">1,011</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Property,
    plant and equipment, net</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">6</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-25470">499</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-25471">506</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    non-current assets</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="3" unitRef="usd" id="ixv-25472">1,260</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="3" unitRef="usd" id="ixv-25473">1,517</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total
    Assets</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-25474">8,070</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-25475">9,310</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">LIABILITIES
    AND SHAREHOLDERS&#8217; EQUITY</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Current
    Liabilities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Trade
    accounts payables</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" unitRef="usd" id="ixv-25476">154</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" unitRef="usd" id="ixv-25477">198</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other
    accounts payables</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">7</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" unitRef="usd" id="ixv-25478">1,364</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" unitRef="usd" id="ixv-25479">1,026</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Lease
    liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">9</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-25480">277</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-25481">290</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Financial
    liabilities at fair value</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">10</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-25482">1,575</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-25483">1,470</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    current liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-25484">3,370</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-25485">2,984</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Non-Current
    Liabilities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Lease
    liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">9</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-25486">378</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-25487">588</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    non- current liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" unitRef="usd" id="ixv-25488">378</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" unitRef="usd" id="ixv-25489">588</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">COMMITMENTS
    AND CONTINGENCIES</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">8</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-3"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Shareholders&#8217;
    Equity:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Ordinary shares, <span style="-sec-ix-hidden: hidden-fact-6"><span style="-sec-ix-hidden: hidden-fact-7">no</span></span> par value:<br/> <b>Authorized</b> <ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-25490"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-25491">100,000,000</ix:nonFraction></ix:nonFraction> ordinary shares as of December 31, 2024 and December 31, 2023;<br/> <b>Issued and outstanding </b><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-25492"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-25493">24,252,096</ix:nonFraction></ix:nonFraction> ordinary shares as of December 31, 2024 and <ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-25494"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-25495">15,652,176</ix:nonFraction></ix:nonFraction> shares as of December 31, 2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-4; font-family: Times New Roman, Times, Serif">-&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-5; font-family: Times New Roman, Times, Serif">-&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Share
    capital and additional paid in capital</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">11</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" unitRef="usd" id="ixv-25496">70,896</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" unitRef="usd" id="ixv-25497">61,259</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Accumulated
    losses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-25498">66,574</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" sign="-" unitRef="usd" id="ixv-25499">55,521</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    Shareholders&#8217; Equity</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-25500">4,322</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-25501">5,738</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total
    liabilities and Shareholders&#8217; Equity</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd" id="ixv-25502">8,070</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd" id="ixv-25503">9,310</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">These Financial
Statements were authorized by the Board of Directors on March 6, 2025.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>The accompanying
notes are an integral part of the Financial Statements.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 132; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><div><a id="a_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>INSPIRA
TECHNOLOGIES OXY B.H.N. LTD.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>STATEMENTS
OF COMPREHENSIVE LOSS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>(US
dollars in thousands except for loss per share)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Note</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 54%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and development expenses</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">12</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-25504">6,323</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-25505">7,320</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-25506">8,183</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">General and administrative expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">13</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-25507">4,185</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-25508">4,063</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-25509">5,375</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Sales and marketing expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">14</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="3" unitRef="usd" id="ixv-25510">754</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="3" unitRef="usd" id="ixv-25511">746</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="3" unitRef="usd" id="ixv-25512">1,328</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Other expenses (income)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" sign="-" unitRef="usd" id="ixv-25513">5</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" sign="-" unitRef="usd" id="ixv-25514">4</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" sign="-" unitRef="usd" id="ixv-25515">7</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Operating
    loss</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-25516">11,267</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-25517">12,133</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-25518">14,893</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Interest income from deposits</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeDepositsWithFinancialInstitutions" scale="3" unitRef="usd" id="ixv-25519">172</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeDepositsWithFinancialInstitutions" scale="3" unitRef="usd" id="ixv-25520">318</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeDepositsWithFinancialInstitutions" scale="3" unitRef="usd" id="ixv-25521">192</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Finance expenses (income),
    net</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">15</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" unitRef="usd" id="ixv-25522">42</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" unitRef="usd" id="ixv-25523">529</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" sign="-" unitRef="usd" id="ixv-25524">275</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Loss
    before tax</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-25525">11,053</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-25526">11,286</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-25527">14,976</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Taxes on income</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-8; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-9; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-10; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Total
    comprehensive and net loss</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-25528">11,053</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-25529">11,286</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-25530">14,976</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net loss per ordinary share,
    basic and diluted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-25531"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-25532">0.60</ix:nonFraction></ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-25533"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-25534">0.93</ix:nonFraction></ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-25535"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-25536">1.39</ix:nonFraction></ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-indent: -10pt; font-weight: bold; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Weighted
    average number of ordinary shares outstanding basic and diluted</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-25537"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-25538">18,515,545</ix:nonFraction></ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-25539"><ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-25540">12,095,477</ix:nonFraction></ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-25541"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-25542">10,794,594</ix:nonFraction></ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>The accompanying
notes are an integral part of the Financial Statements.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;&#160;</b></span></p><div>

</div><!-- Field: Page; Sequence: 133; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>INSPIRA
TECHNOLOGIES OXY B.H.N. LTD.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>STATEMENTS
OF CHANGES IN SHAREHOLDERS&#8217; EQUITY</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>(US
dollars in thousands)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><span style="text-decoration:underline">For
the year ended December 31, 2024:</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">&#160;<span style="font-family: Times New Roman, Times, Serif">Ordinary
    Share Capital</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number
    of shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Share&#160;capital<br/>
 and<br/>
Additional<br/>
 Paid in<br/>
 Capital</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Accumulated
    deficit</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 52%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Balance
    as of January&#160;1, 2024:</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c8" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-25543">15,652,176</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-25544">61,259</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-25545">55,521</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-25546">5,738</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Changes
    during the period:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issuance
    of ordinary shares, private warrants and pre-funded warrants, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c11" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-25547">6,231,169</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-25548">7,679</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-11; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-25549">7,679</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Exercise of options</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c11" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares" id="ixv-25550">19,048</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitRef="usd" id="ixv-25551">2</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-12; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitRef="usd" id="ixv-25552">2</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Exercise of June
    2024 pre-funded warrants into ordinary shares</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c11" decimals="INF" format="ixt:num-dot-decimal" name="iinn:ExerciseOfJune2024PrefundedWarrantsIntoOrdinarySharesinShares" scale="0" unitRef="shares" id="ixv-25553">1,709,760</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ExerciseOfJune2024PrefundedWarrantsIntoOrdinaryShares" scale="3" unitRef="usd" id="ixv-25554">2</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-13; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ExerciseOfJune2024PrefundedWarrantsIntoOrdinaryShares" scale="3" unitRef="usd" id="ixv-25555">2</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Restricted
    share unit (&#8220;RSU&#8221;)vesting</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c11" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" unitRef="shares" id="ixv-25556">594,943</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-14; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-15"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-16; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issuance
    of ordinary shares- advisor fees</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c11" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares" id="ixv-25557">45,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" unitRef="usd" id="ixv-25558">62</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-17; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" unitRef="usd" id="ixv-25559">62</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Share-based
    compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-25560">1,892</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-18; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-25561">1,892</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Comprehensive
    and net loss</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-19; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-25562">11,053</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-25563">11,053</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Balance
    as of December 31, 2024</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c14" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-25564">24,252,096</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c15" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-25565">70,896</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-25566">66,574</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-25567">4,322</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 134; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>INSPIRA
TECHNOLOGIES OXY B.H.N. LTD.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>STATEMENTS
OF CHANGES IN SHAREHOLDERS&#8217; EQUITY</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>(US
dollars in thousands)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;<b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><span style="text-decoration:underline">For
the year ended December 31, 2023:</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Ordinary
    Share Capital</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number
    of shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Share&#160;capital<br/>
 and&#160;<br/>
Additional<br/>
 Paid in<br/>
 Capital</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Accumulated
    deficit</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 52%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Balance
    as of January&#160;1, 2023:</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c17" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-25568">11,338,940</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c18" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-25569">57,866</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-25570">44,235</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-25571">13,631</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Changes
    during the period:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issuance
    of ordinary shares and private warrants, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c21" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-25572">3,031,250</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c22" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-25573">1,806</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-20; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-25574">1,806</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issuance
    of placement agent warrants (Note 11.3)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c22" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" unitRef="usd" id="ixv-25575">131</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-21; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" unitRef="usd" id="ixv-25576">131</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issuance
    of ordinary shares (pursuant to an at-the-market facility)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c21" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitRef="shares" id="ixv-25577">17,566</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c22" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" unitRef="usd" id="ixv-25578">26</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-22; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" unitRef="usd" id="ixv-25579">26</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Exercise of share
    based payments</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c21" decimals="INF" format="ixt:num-dot-decimal" name="iinn:StockIssuedDuringPeriodSharesStockOptionsExerciseOfShareBasedPayments" scale="0" unitRef="shares" id="ixv-25580">37,972</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c22" decimals="-3" format="ixt:num-dot-decimal" name="iinn:StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments" scale="3" unitRef="usd" id="ixv-25581">3</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-23; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="iinn:StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments" scale="3" unitRef="usd" id="ixv-25582">3</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">RSU
    vesting</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c21" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" unitRef="shares" id="ixv-25583">1,226,448</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-24; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-25; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Share-based
    compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c22" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-25584">1,427</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-26; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-25585">1,427</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Comprehensive
    and net loss</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-27; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c23" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-25586">11,286</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-25587">11,286</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: justify; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Balance
    as of December 31, 2023</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c8" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-25588">15,652,176</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-25589">61,259</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-25590">55,521</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-25591">5,738</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>The
accompanying notes are an integral part of the Financial Statements.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 135; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>INSPIRA
TECHNOLOGIES OXY B.H.N. LTD.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>STATEMENTS
OF CHANGES IN SHAREHOLDERS&#8217; EQUITY</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>(US
dollars in thousands)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><span style="text-decoration:underline">For
the year ended December 31, 2022:</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Ordinary
    Share Capital</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number
    of shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Share&#160;capital<br/>
 and<br/> Additional Paid in Capital</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Accumulated
    deficit</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Balance as of January&#160;1,
    2022:</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c24" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-25592">10,091,706</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-25593">52,987</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c26" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-25594">29,259</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-25595">23,728</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Changes during the period:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Exercise of share based payments</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c28" decimals="INF" format="ixt:num-dot-decimal" name="iinn:StockIssuedDuringPeriodSharesStockOptionsExerciseOfShareBasedPayments" scale="0" unitRef="shares" id="ixv-25596">7,030</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-28">*</div></td><td style="text-align: left"/><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-29; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-30; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">RSU vesting</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c28" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" unitRef="shares" id="ixv-25597">1,240,204</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-31; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-32; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-33; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Share-based compensation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c29" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-25598">4,879</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-34; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-25599">4,879</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Comprehensive and
    net loss</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-35; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c30" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-25600">14,976</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-25601">14,976</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Balance
    as of December 31, 2022</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c17" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-25602">11,338,940</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c18" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-25603">57,866</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-25604">44,235</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-25605">13,631</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">(*) <ix:footnote id="ix_0_footnote" xml:lang="en-US">Less
than thousand dollars</ix:footnote></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>The
accompanying notes are an integral part of the Financial Statements.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 136; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>INSPIRA
TECHNOLOGIES OXY B.H.N. LTD.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>STATEMENTS
OF CASH FLOW</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>(US
dollars in thousands)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended December 31</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">CASH
    FLOW FROM OPERATING ACTIVITIES:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net
    loss</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-25607">11,053</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-25608">11,286</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-25609">14,976</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Adjustments
    to reconcile net loss to net cash provided by operating activities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Depreciation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-25610">171</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-25611">111</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-25612">54</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Capital
    loss</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProvisionForOtherLosses" scale="3" unitRef="usd" id="ixv-25613">5</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-36; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-37; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Share
    based compensation expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-25614">1,892</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-25615">1,427</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-25616">4,879</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Share
    based compensation &#8211; placement agent warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-38; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" scale="3" unitRef="usd" id="ixv-25617">59</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-39; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Evaluation
    of financial liability at fair value</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" scale="3" sign="-" unitRef="usd" id="ixv-25618">47</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" scale="3" unitRef="usd" id="ixv-25619">306</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" scale="3" unitRef="usd" id="ixv-25620">108</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expiration
    of financial liability</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ExpirationOfFinancialLiability" scale="3" unitRef="usd" id="ixv-25621">11</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-40; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-41; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issuance
    cost</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-42; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCosts" scale="3" unitRef="usd" id="ixv-25622">205</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-43; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issuance
    of ordinary shares - advisor fees</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:IssuanceOfOrdinarySharesAdvisorFees" scale="3" unitRef="usd" id="ixv-25623">62</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-44; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-45; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Prepayments
    of lease liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" sign="-" unitRef="usd" id="ixv-25624">9</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" sign="-" unitRef="usd" id="ixv-25625">7</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" sign="-" unitRef="usd" id="ixv-25626">51</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Decrease
    (increase) in right of use assets, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInLeasingReceivables" scale="3" sign="-" unitRef="usd" id="ixv-25627">31</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInLeasingReceivables" scale="3" unitRef="usd" id="ixv-25628">5</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInLeasingReceivables" scale="3" unitRef="usd" id="ixv-25629">99</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Decrease
    (increase) in other current assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" scale="3" unitRef="usd" id="ixv-25630">84</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" scale="3" sign="-" unitRef="usd" id="ixv-25631">190</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" scale="3" sign="-" unitRef="usd" id="ixv-25632">99</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(Decrease)
    increase in trade accounts payables</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" sign="-" unitRef="usd" id="ixv-25633">44</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" unitRef="usd" id="ixv-25634">46</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" unitRef="usd" id="ixv-25635">59</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(Decrease)
    increase in other accounts payable</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" scale="3" unitRef="usd" id="ixv-25636">118</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" scale="3" sign="-" unitRef="usd" id="ixv-25637">190</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" scale="3" unitRef="usd" id="ixv-25638">496</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">(<span style="font-family: Times New Roman, Times, Serif">Increase)
    decrease in inventory</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" unitRef="usd" id="ixv-25639">444</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-46; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-47; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Unrealized
    foreign exchange (gain) loss</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" unitRef="usd" id="ixv-25640">55</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" sign="-" unitRef="usd" id="ixv-25641">65</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" sign="-" unitRef="usd" id="ixv-25642">438</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.375in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Net
    cash used in operating activities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-25643">9,374</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-25644">9,691</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-25645">9,209</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">CASH
    FLOW FROM INVESTING ACTIVITIES:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Purchase
    of property, plant, and equipment</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-25646">164</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-25647">206</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-25648">263</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Change
    in deposits, net</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForProceedsFromInvestments" scale="3" sign="-" unitRef="usd" id="ixv-25649">1,652</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForProceedsFromInvestments" scale="3" sign="-" unitRef="usd" id="ixv-25650">4,800</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForProceedsFromInvestments" scale="3" unitRef="usd" id="ixv-25651">7,120</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.375in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Net
    cash provided (used in) investing activities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" unitRef="usd" id="ixv-25652">1,488</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" unitRef="usd" id="ixv-25653">4,594</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" sign="-" unitRef="usd" id="ixv-25654">7,383</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">CASH
    FLOWS FROM FINANCING ACTIVITIES:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issuance
    of ordinary shares, pre-funded warrants and ordinary warrants, net</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="3" unitRef="usd" id="ixv-25655">7,898</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="3" unitRef="usd" id="ixv-25656">3,424</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-48; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Exercise
    of options</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" unitRef="usd" id="ixv-25657">2</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" unitRef="usd" id="ixv-25658">3</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-49; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Exercise
    of pre-funded warrants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromWarrantExercises" scale="3" unitRef="usd" id="ixv-25659">2</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-50; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-51; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issuance
    of ordinary shares (issuances pursuant to an at-the-market facility)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-52; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" unitRef="usd" id="ixv-25660">26</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-53; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.375in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Net
    cash provided by financing activities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" unitRef="usd" id="ixv-25661">7,902</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" unitRef="usd" id="ixv-25662">3,453</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-54; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Effect
    of exchange rate changes on cash and cash equivalents</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-25663">55</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" sign="-" unitRef="usd" id="ixv-25664">65</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" sign="-" unitRef="usd" id="ixv-25665">438</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net
    increase (decrease) in cash and cash equivalents and restricted cash</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" unitRef="usd" id="ixv-25666">16</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" sign="-" unitRef="usd" id="ixv-25667">1,644</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" sign="-" unitRef="usd" id="ixv-25668">16,592</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Cash,
    cash equivalents and restricted cash at the beginning of the period</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-25669">5,130</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-25670">6,839</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-25671">23,869</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Cash,
    cash equivalents and restricted cash at the end of the period</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-25672">5,201</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-25673">5,130</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-25674">6,839</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;&#160;</b></span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>The accompanying
notes are an integral part of the Financial Statements.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 137; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>INSPIRA
TECHNOLOGIES OXY B.H.N. LTD.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>STATEMENTS
OF CASH FLOW</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>(US
dollars in thousands)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><span style="text-decoration:underline">APPENDIX
A - RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH:</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The
following table provides a reconciliation of cash, cash equivalents and restricted cash reported on the balance sheet that sum to the
total of the same such amounts shown in the statement of cash flows.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash
    and cash equivalents</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-25675">5,111</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-25676">5,041</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-25677">6,783</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Restricted
    cash</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCash" scale="3" unitRef="usd" id="ixv-25678">90</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCash" scale="3" unitRef="usd" id="ixv-25679">89</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCash" scale="3" unitRef="usd" id="ixv-25680">56</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total
    cash, cash equivalents and restricted cash shown in the statement of cash flows</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-25681">5,201</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-25682">5,130</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-25683">6,839</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><span style="text-decoration:underline">APPENDIX
B &#8211; NON-CASH TRANSACTIONS:</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other
    receivable in connection to December private placement</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:OtherReceivableInConnectionToPrivatePlacement" scale="3" unitRef="usd" id="ixv-25684">70</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-55; font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-56; font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued
    issuance expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:AccruedIssuanceExpenses" scale="3" sign="-" unitRef="usd" id="ixv-25685">220</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: hidden-fact-57; font-family: Times New Roman, Times, Serif">-</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-58; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Financial
    liability- placement agent fee (Note 10-A)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:FinancialLiabilityPlacementAgentFee" scale="3" sign="-" unitRef="usd" id="ixv-25686">69</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-59; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-60; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Share
    based compensation- placement agent warrants against additional paid in capital (Note 11)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital" scale="3" sign="-" unitRef="usd" id="ixv-25687">254</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital" scale="3" sign="-" unitRef="usd" id="ixv-25688">73</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-61; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:NonCashTransactions" scale="3" sign="-" unitRef="usd" id="ixv-25689">473</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="iinn:NonCashTransactions" scale="3" sign="-" unitRef="usd" id="ixv-25690">73</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-62; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><span style="text-decoration:underline">APPENDIX
C - AMOUNT PAID DURING THE PERIOD:</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 64%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Interest paid</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" unitRef="usd" id="ixv-25691">72</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" unitRef="usd" id="ixv-25692">93</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" unitRef="usd" id="ixv-25693">106</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;&#160;</b></span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>The accompanying
notes are an integral part of the Financial Statements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 138; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_006"></a></div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>INSPIRA
TECHNOLOGIES OXY B.H.N. LTD.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>In
thousands $ (except share and per share data)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="ixv-17690"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 1
- GENERAL:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">1.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Inspira
                                            Technologies Oxy B.H.N. Ltd (the &#8220;Company&#8221;) was incorporated in Israel and commenced
                                            its operations on February 27, 2018. The Company operates in the medical technology industry
                                            in the field of respiratory support technology engaged in the research, development, manufacturing
                                            related activities, and go-to-market activities of proprietary products and technologies.
                                            The Company is developing the following products:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
                                            INSPIRA ART (Augmented Respiratory Technology), which is a respiratory support technology
                                            targeted toward utilizing blood monitoring and direct blood oxygenation to boost patient
                                            saturation levels within minutes while the patient is awake. The aim is to provide an alternative
                                            to invasive mechanical ventilation, associated with high risks, complications, high costs
                                            and high mortality rates.</span></td></tr><tr style="vertical-align: top">
<td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
                                   </table>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
                                            HYLA blood sensor, which is a non-invasive optical blood sensor designed to perform real-time
                                            and continuous blood parameter measurements, potentially reducing the need for intermittent
                                            blood samples from patients.</span></td></tr><tr style="vertical-align: top">
<td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
                                                                                                                              </table>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
                                            INSPIRA ART100 System, an advanced form of life support system, better known by the medical
                                            industry as a cardiopulmonary bypass system, has been designed for use in procedures requiring
                                            cardiopulmonary bypass for six hours or less.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company&#8217;s INSPIRA&#8482; ART100 system received U.S. Food and Drug Administration 510(k) regulatory clearance for cardiopulmonary
bypass procedures and Israeli Medical Equipment Division certification for extra-corporeal membrane oxygenation and cardiopulmonary bypass
procedures. The Company&#8217;s other products, including the INSPIRA&#8482; ART and HYLA&#8482; blood sensor, have not yet been tested
or used in humans and have not been approved by any regulatory entity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;  border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">2.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On April 1, 2024, the Company entered into a purchase agreement with two investors in a registered direct offering (the &#8220;2024 April Offering&#8221;), pursuant to which the Company issued an aggregate of <ix:nonFraction contextRef="c32" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-25694">1,339,285</ix:nonFraction> of the Company&#8217;s ordinary shares (&#8220;Ordinary Shares&#8221;) at a purchase price of $<ix:nonFraction contextRef="c33" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares" id="ixv-25695">1.232</ix:nonFraction> per share. The gross proceeds received by the Company from the 2024 April Offering were approximately $<ix:nonFraction contextRef="c32" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="3" unitRef="usd" id="ixv-25696">1,651</ix:nonFraction>. There were no issuance costs.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;  border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">3.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On June 14, 2024, the Company entered into a purchase agreement with an individual private investor in a registered direct offering (the &#8220;2024 June Offering&#8221;), pursuant to which the Company issued: (i) <ix:nonFraction contextRef="c34" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-25697">941,541</ix:nonFraction> Ordinary Shares at a purchase price of $<ix:nonFraction contextRef="c35" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares" id="ixv-25698">1.30</ix:nonFraction> per share and (ii) pre-funded warrants (&#8220;June Pre-Funded Warrants&#8221;) to purchase up to <ix:nonFraction contextRef="c36" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-25699">1,709,760</ix:nonFraction> Ordinary shares, at a purchase price of $<ix:nonFraction contextRef="c37" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares" id="ixv-25700">1.30</ix:nonFraction>, less $<ix:nonFraction contextRef="c38" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-25701">0.001</ix:nonFraction> per June Pre-Funded Warrant. The net proceeds received by the Company from the 2024 June Offering were approximately $<ix:nonFraction contextRef="c39" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="3" unitRef="usd" id="ixv-25702">3,102</ix:nonFraction>, after deducting offering costs in cash, which totaled in approximately $<ix:nonFraction contextRef="c39" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PartnersCapitalAccountPublicSaleOfUnitsNetOfOfferingCosts" scale="3" unitRef="usd" id="ixv-25703">343</ix:nonFraction>. In addition, the Company issued the placement agent in the 2024 June Offering (&#8220;June Placement Agent&#8221;) warrants equal to a total of <ix:nonFraction contextRef="c40" decimals="3" format="ixt:num-dot-decimal" name="iinn:PercentageOfOrdinaryShares" scale="-2" unitRef="pure" id="ixv-25704">7.0</ix:nonFraction>% of the aggregate number of Ordinary Shares sold in the transaction to purchase up to <ix:nonFraction contextRef="c40" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-25705">185,591</ix:nonFraction> Ordinary Shares (the &#8220;June Placement Agent Warrants&#8221;). The fair value of the June Placement Agent Warrants on the issuance date was $<ix:nonFraction contextRef="c40" decimals="-3" format="ixt:num-dot-decimal" name="iinn:PlacementAgentWarrantsFairValue" scale="3" unitRef="usd" id="ixv-25706">254</ix:nonFraction> and it was recorded as part of the issuance costs.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;  border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">4.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On December 27, 2024, the Company entered into a purchase agreement with several investors in a private placement financing (the &#8220;December Private Placement&#8221;), pursuant to which the Company issued (i) an aggregate of <ix:nonFraction contextRef="c41" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-25707">3,950,343</ix:nonFraction> of the Company&#8217;s Ordinary Shares at a purchase price of $<ix:nonFraction contextRef="c42" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares" id="ixv-25708">0.70</ix:nonFraction> per share, and (ii) pre-funded warrants (the &#8220;December Pre-Funded Warrants&#8221;) to purchase up to <ix:nonFraction contextRef="c43" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-25709">658,372</ix:nonFraction> Ordinary shares, at a purchase price of $<ix:nonFraction contextRef="c44" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares" id="ixv-25710">0.70</ix:nonFraction>, less $<ix:nonFraction contextRef="c45" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-25711">0.001</ix:nonFraction> per December Pre-Funded Warrant. In addition, pursuant to a certain securities purchase agreement, the Company issued warrants to the investors to purchase up to an aggregate of <ix:nonFraction contextRef="c46" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-25712">4,608,715</ix:nonFraction> Ordinary Shares at an exercise price of $<ix:nonFraction contextRef="c47" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:StockOptionExercisePriceIncrease" scale="0" unitRef="usdPershares" id="ixv-25713">1.10</ix:nonFraction> per share. The gross proceeds received by the Company from the December Private Placement were approximately $<ix:nonFraction contextRef="c41" decimals="-3" format="ixt:num-dot-decimal" name="iinn:AggregateProceedsReceived" scale="3" unitRef="usd" id="ixv-25714">3,228</ix:nonFraction>, before deducting placement agent commissions and additional offering costs which totaled in approximately $<ix:nonFraction contextRef="c48" decimals="-3" format="ixt:num-dot-decimal" name="iinn:AdditionalOfferingCosts" scale="3" unitRef="usd" id="ixv-25715">233</ix:nonFraction>. In addition, The Company agreed to pay fees of 4% from the funds that may be received in an event of the exercise of the Company&#8217;s private warrants issued in December 2024 Private Placement, which created a financial liability in amount of $<ix:nonFraction contextRef="c48" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" unitRef="usd" id="ixv-25716">69</ix:nonFraction> which is the total potential amount (Note 10-A).</span></td></tr></table></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; "></p><div>

</div><!-- Field: Page; Sequence: 139; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>INSPIRA
TECHNOLOGIES OXY B.H.N. LTD.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>In
thousands $ (except share and per share data)</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; "><span style="font-family: Times New Roman, Times, Serif"><b>NOTE
1 - GENERAL (CONT.):</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; "><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p><div>

</div><ix:continuation id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">5.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The accompanying financial statements (the &#8220;Financial Statements&#8221;)
have been prepared assuming that the Company will continue as a going concern. To date, the Company is in its development stage. Therefore,
the Company has suffered recurring losses from operations and negative cash flows from operations since inception. As of December 31,
2024, the Company had incurred accumulated losses of $<ix:nonFraction contextRef="c4" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" scale="6" unitRef="usd" id="ixv-25717">67</ix:nonFraction> million and expects to continue to fund its operations through fundings such
as issuance of convertible securities, Ordinary Shares and warrants and through Israeli governmental grants. There is no assurance that
such financing will be obtained. Considering the above, our dependence on external funding for our operations raises a substantial doubt
about our ability to continue as a going concern. The Financial Statements do not include any adjustments that might result from the outcome
of these uncertainties.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">6.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Our
                                            offices are located in Ra&#8217;anana, Israel. On October 7, 2023, Hamas terrorists infiltrated
                                            Israel&#8217;s southern border from the Gaza Strip and conducted a series of attacks on civilian
                                            and military targets. Following the attack, Israel declared war against Hamas and the Israeli
                                            military began to call-up reservists for an active duty. Other regional hostilities, since
                                            October 7, 2023, concurrently became more pronounced. This includes and has included a northern
                                            front war igniting between Israel and Hezbollah, which as of February 24, 2025 we are under
                                            a ceasefire, hostilities between Israel and Iran, which have included Iranian strikes against
                                            Israel in April 2024 and October 2024, and subsequent retaliation by Israel to both instances,
                                            and a continued conflict between Israel and the Houthi Movement in Yemen.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">As
of the date of these Financial Statements, these events have no material impact on the Company&#8217;s operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">7.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Although
                                            we do not currently conduct business in Russia and Ukraine, the escalation of geopolitical
                                            instability in Russia and Ukraine as well as currency fluctuations in the Russian Ruble has
                                            had a negative impact on worldwide markets. Such impact may negatively impact our supply
                                            chain, our operations and future growth prospects in that region.&#160;As a result of the
                                            crisis in Ukraine,&#160;both the U.S. and other countries have implemented sanctions against
                                            certain Russian individuals and entities. Our global operations expose us to risks that could
                                            adversely affect our business, financial condition, results of operations, cash flows or
                                            the market price of our securities, including the potential for increased tensions between
                                            Russia and other countries resulting from the current situation involving Russia and Ukraine,
                                            tariffs, economic sanctions and import-export restrictions imposed, and retaliatory actions,
                                            as well as the potential negative impact on our potential business and sales in the region.
                                            Current geopolitical instability in Russia and Ukraine and related sanctions by the U.S.
                                            and other governments against certain companies and individuals may hinder our ability to
                                            conduct business with potential customers and vendors in these countries.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">8.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">These
                                            Financial Statements were authorized by the Board of Directors on March 6, 2025.</span></td></tr></table></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 140; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>INSPIRA
TECHNOLOGIES OXY B.H.N. LTD.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>In
thousands $ (except share and per share data)</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="ixv-17881"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 2
</b>- <b>SIGNIFICANT ACCOUNTING POLICIES:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
accompanying Financial Statements have been prepared in conformity with the U.S. GAAP. The significant accounting policies followed in
the preparation of the Financial Statements are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_UseOfEstimates-c0_cont_1" escape="true" name="us-gaap:UseOfEstimates" id="ixv-17892"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>A.
Use of estimates:</b></span></p></ix:nonNumeric>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_UseOfEstimates-c0_cont_2" id="_UseOfEstimates-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
preparation of Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the Financial Statements,
and the reported amounts of expenses during the reporting period.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_UseOfEstimates-c0_cont_3" id="_UseOfEstimates-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif">Items
subject to such estimates and assumptions include:</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_UseOfEstimates-c0_cont_4" id="_UseOfEstimates-c0_cont_3"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">stock-based
                                            compensation expense;</span></td></tr><tr style="vertical-align: top">
<td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
                                                                                                                                                              </table></ix:continuation>

<ix:continuation continuedAt="_UseOfEstimates-c0_cont_5" id="_UseOfEstimates-c0_cont_4"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">fair
                                            value financial liabilities;</span></td></tr><tr style="vertical-align: top">
<td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
                                                                                                                                                              </table></ix:continuation>

<ix:continuation continuedAt="_UseOfEstimates-c0_cont_6" id="_UseOfEstimates-c0_cont_5"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">recognition,
                                            measurement, and disclosure of contingent liabilities;</span></td></tr><tr style="vertical-align: top">
<td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
                                                                                                                                                                                                </table></ix:continuation>

<ix:continuation continuedAt="_UseOfEstimates-c0_cont_7" id="_UseOfEstimates-c0_cont_6"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">Interest
                                            rate used for lease liability measurement.</span></td></tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_UseOfEstimates-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">As
of the date of issuance of the Financial Statements, the Company is not aware of any material specific events or circumstances that would
require it to update its estimates, judgments, or to revise the carrying values of its assets or liabilities. These estimates may change,
as new events occur and additional information is obtained, and are recognized in the Financial Statements as soon as they become known.
Actual results could differ from those estimates and any such differences may be material to the Company&#8217;s Financial Statements.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="ixv-17968"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>B.
<span>Foreign Currency</span></b></span></p></ix:nonNumeric>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:continuation continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_2" id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
currency of the primary economic environment in which the operations of the Company are conducted is the U.S. dollar (&#8220;USD&#8221;).
The Company&#8217;s funding and expected revenues are mostly in USD. Thus, the functional currency of the Company is in USD.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Transactions
and balances originally denominated in USD are presented at their original amounts. Balances in non-USD currencies are translated into
USD using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-USD transactions and other
items in the statements of income (indicated below), the following exchange rates are used: (i) for transactions &#8211; exchange rates
at transaction dates or average exchange rates; and (ii) for other items (derived from non-monetary balance sheet items such as depreciation
and amortization) &#8211; historical exchange rates. Currency transaction gains and losses are presented in financial expenses (income),
net as appropriate. The functional currency of the Company is USD.&#160;</span></p></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 141; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>INSPIRA
                                            TECHNOLOGIES OXY B.H.N. LTD.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>In
thousands $ (except share and per share data)</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE
2 - SIGNIFICANT ACCOUNTING POLICIES (CONT.):</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_2" id="_SignificantAccountingPoliciesTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="ixv-18029"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>C.
Property, Plant, and Equipment</b></span></p></ix:nonNumeric>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_2" id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Property
and equipment are stated at cost. Depreciation is computed based on the straight-line method, over the estimated useful life of the assets.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="iinn:ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock" id="ixv-18040"><ix:continuation continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_3" id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Annual
rates of depreciation are as follows:</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_3"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 90%"><span style="font-family: Times New Roman, Times, Serif">Computers</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c50" decimals="2" format="ixt:num-dot-decimal" name="iinn:AnnualDepreciationRatesOfPropertyPlantAndEquipment" scale="-2" unitRef="pure" id="ixv-25718">33</ix:nonFraction></span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">R&amp;D equipment</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c51" decimals="2" format="ixt:num-dot-decimal" name="iinn:AnnualDepreciationRatesOfPropertyPlantAndEquipment" scale="-2" unitRef="pure" id="ixv-25719">20</ix:nonFraction></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Furniture and office equipment</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c52" decimals="2" format="ixt:num-dot-decimal" name="iinn:AnnualDepreciationRatesOfPropertyPlantAndEquipment" scale="-2" unitRef="pure" id="ixv-25720">6</ix:nonFraction>-<ix:nonFraction contextRef="c53" decimals="2" format="ixt:num-dot-decimal" name="iinn:AnnualDepreciationRatesOfPropertyPlantAndEquipment" scale="-2" unitRef="pure" id="ixv-25721">15</ix:nonFraction></span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Leasehold Improvements</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c54" decimals="2" format="ixt:num-dot-decimal" name="iinn:AnnualDepreciationRatesOfPropertyPlantAndEquipment" scale="-2" unitRef="pure" id="ixv-25722">10</ix:nonFraction></span></td></tr>
  </table></ix:continuation></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif"><b>&#160;&#160;</b></span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_InventoryPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:InventoryPolicyTextBlock" id="ixv-18093"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>D.
Inventory</b></span></p></ix:nonNumeric>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_InventoryPolicyTextBlock-c0_cont_2" id="_InventoryPolicyTextBlock-c0_cont_1"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Inventories
are stated at the lower of cost or net realizable value. Inventory write-offs are provided to cover risks arising from slow-moving items,
technological obsolescence, excess inventories, discontinued products, and for market prices lower than cost, if any.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_InventoryPolicyTextBlock-c0_cont_3" id="_InventoryPolicyTextBlock-c0_cont_2"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The
Company periodically evaluates the quantities on hand relative to historical and projected sales volume (which is determined based on
an assumption of future demand and market conditions) and the age of the inventory. At the point of the loss recognition, a new lower
cost basis for that inventory has been established.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_InventoryPolicyTextBlock-c0_cont_3"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Cost
is determined for all types of inventory using the moving average cost method plus indirect costs.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock" id="ixv-18114"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>E.
Leases</b></span></p></ix:nonNumeric>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_2" id="_LesseeLeasesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company implemented Accounting Standards Update (&#8220;ASU&#8221;) 2016-02, Leases (Topic 842) (&#8220;ASU 2016-02&#8221;) using the
modified retrospective approach for all lease arrangements as of such date. The Company leases office space and vehicles under operating
leases.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_3" id="_LesseeLeasesPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Arrangements
meeting the definition of a lease are classified as operating or financing leases and are recorded on the balance sheet as both a right
of use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease
or the Company&#8217;s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and
the right of use asset is amortized over the lease term.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_4" id="_LesseeLeasesPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
lease liability was measured at the present value of the remaining lease payments, discounted using the Company&#8217;s incremental borrowing
rate. The weighted-average&#160;rate applied was <ix:nonFraction contextRef="c49" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure" id="ixv-25723">9.60</ix:nonFraction>%. Right-of-use&#160;assets were measured at an amount equal to the lease liability.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_LesseeLeasesPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">For
operating leases, interest on the lease liability and the amortization of the right of use asset result in straight-line&#160;rent expense
over the lease term. Variable lease expenses are recorded when incurred.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_ResearchAndDevelopmentExpensePolicy-c0_cont_1" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="ixv-18140"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>F.
Research and Development Costs.</b></span></p></ix:nonNumeric>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_ResearchAndDevelopmentExpensePolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">Research
and development expenses consist primarily of payroll, payroll related expenses, subcontractors, and materials. Costs are expensed as
incurred.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_GovernmentAssistancePolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:GovernmentAssistancePolicyTextBlock" id="ixv-18151"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>G.
Government Grants </b></span></p></ix:nonNumeric>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_GovernmentAssistancePolicyTextBlock-c0_cont_2" id="_GovernmentAssistancePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company receives royalty-bearing grants from the Israeli Innovation Authority (&#8220;IIA&#8221;) for approved research and development
projects Under Israeli law, royalties on the revenues derived from products and services developed using such grants, are payable to
the Israeli Government.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_GovernmentAssistancePolicyTextBlock-c0_cont_3" id="_GovernmentAssistancePolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
grants are linked to the exchange rate of the dollar to the New Israeli Shekel and bear interest of the Secured Overnight Financing Rate
(&#8220;SOFR&#8221;) per year (SOFR is a benchmark interest rate which replaced LIBOR).</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 142; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>INSPIRA
TECHNOLOGIES OXY B.H.N. LTD.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>In
thousands $ (except share and per share data)</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE
2 </b>- <b>SIGNIFICANT ACCOUNTING POLICIES (CONT.):</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_3" id="_SignificantAccountingPoliciesTextBlock-c0_cont_2"><ix:continuation id="_GovernmentAssistancePolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
amounts of grants received and recorded into income should be disclosed for each period presented. The research and development grants
are presented in the statement of operations as an offset to related research and development expenses. Companies are required to pay
royalties in connection with such grants at specified rates, up to the total dollar-linked amount of such grants. <span>research
and development (&#8220;R&amp;D&#8221;).&#160;The Company did not generate sales as of December 31, 2024; therefore, no liability was
recorded in these Financial Statements.</span></span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;<b>&#160;</b></span></p>

<ix:nonNumeric contextRef="c0" continuedAt="iinn_FinanceIncomeAndExpensesPolicyTextBlock-c0_cont_1" escape="true" name="iinn:FinanceIncomeAndExpensesPolicyTextBlock" id="ixv-18213"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>H.
Finance Income and Expenses.</b></span></p></ix:nonNumeric>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="iinn_FinanceIncomeAndExpensesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Finance
income is composed of interest on deposits and revaluation of financial liabilities at fair value, while finance expenses are composed
of the revaluation of certain financial liabilities at fair value, bank charges and net currency exchange rates differences.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock" id="ixv-18224"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>I.
Current Taxes</b></span></p></ix:nonNumeric>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:continuation id="_IncomeTaxPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">The
current tax liability is measured using the tax rates and tax laws that have been enacted or substantively enacted by the reporting date
as well as adjustments required in connection with the tax liability in respect of previous years. The Company has no tax liability due
to its carry forward losses.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="ixv-18236"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>J.
Share-Based Compensation.</b></span></p></ix:nonNumeric>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_2" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">Share-based
compensation expenses related to employees, directors and subcontractors&#8217; options or restricted share units (&#8220;RSU&#8221;)
which recognized based on their fair value, which is based on the fair value of the underlying Ordinary Shares as to the de-minimis exercise
price using the graded vesting method.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_3" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company recognizes compensation expense for grants of share-based awards to its employees based on the estimated fair value on the grant
date. Compensation cost for awards is recognized over the requisite service period, which approximates the vesting period. Share-based
compensation is included in research and development, selling and marketing and general and administrative expenses. Forfeitures of equity
grants are recognized as incurred.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">All
issuances of stock options or other equity instruments to non-employees as consideration for goods or services received by the Company
are accounted for based on the fair value of the equity instruments issued.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_DerivativesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:DerivativesPolicyTextBlock" id="ixv-18257"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>K.
Warrants and Pre-Funded Warrants</b></span></p></ix:nonNumeric>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_DerivativesPolicyTextBlock-c0_cont_2" id="_DerivativesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company issues warrants and pre-funded warrants as part of its financing activities or compensation arrangements. Warrants are derivative
financial instruments that entitle the holder to purchase a specified number of the Company&#8217;s Ordinary Shares at a predetermined
exercise price. Warrants and pre-funded warrants issued by the Company may have various terms, including expiration dates, exercise prices,
and conditions.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_DerivativesPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company classifies warrants as either equity or liabilities upon issuance, based on specific terms and conditions and in accordance with
Accounting Standard Codification (&#8220;ASC&#8221;) 815, Derivatives and Hedging. Warrants and pre-funded warrants are classified as
equity if they meet the criteria for equity classification outlined in ASC 815-40. Otherwise, warrants are classified as liabilities.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="iinn_SeverancePolicyTextBlock-c0_cont_1" escape="true" name="iinn:SeverancePolicyTextBlock" id="ixv-18273"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>L.
Severance</b></span></p></ix:nonNumeric>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="iinn_SeverancePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Israeli
labor law generally requires payment of severance pay upon dismissal of an employee or upon termination of employment in certain other
circumstances. The Company&#8217;s pension and severance pay liabilities are covered mainly by insurance policies. Pursuant to section
14 of the Israeli Severance Compensation Act, 1963 (&#8220;Section 14&#8221;), the Company&#8217;s employees are entitled to monthly
deposits, at a rate of <ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" unitRef="pure" id="ixv-25724">8.33</ix:nonFraction>% of their monthly salary, made in their name with insurance companies. Payments in accordance with Section
14 relieve the Company from any future severance payments in respect of those employees and, as such, the Company may only utilize the
insurance policies for the purpose of paying severance pay.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 143; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>INSPIRA
TECHNOLOGIES OXY B.H.N. LTD.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>In
thousands $ (except share and per share data)</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 2
</b>- <b>SIGNIFICANT ACCOUNTING POLICIES (CONT.):</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_4" id="_SignificantAccountingPoliciesTextBlock-c0_cont_3"><ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock" id="ixv-18323"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>M.
Basic and Diluted Loss Per Share</b></span></p></ix:nonNumeric>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_EarningsPerSharePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Basic
and diluted loss per share is calculated by dividing the loss attributable to equity holders of the Company by the weighted average number
of Ordinary Shares and pre-funded warrants outstanding during the financial year, adjusted for Ordinary Shares and pre-funded warrants
issued during the year, if applicable.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="ixv-18334"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>N.
Fair Value Measurements</b></span></p></ix:nonNumeric>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company measures and discloses fair value in accordance with the Financial Accounting Standards Board (&#8220;FASB&#8221;), ASC 820,
Fair Value Measurements and Disclosures (&#8220;ASC 820&#8221;). ASC 820 defines fair value, establishes a framework and gives guidance
regarding the methods used for measuring fair value, and expands disclosures about fair value measurements. Fair value is an exit price,
representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market
participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions
that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, there exists a three-tier
fair-value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Level
1 &#8211; unadjusted quoted prices are available in active markets for identical assets or liabilities that the Company has the ability
to access as of the measurement date.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; "><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Level
2 &#8211; pricing inputs are other than quoted prices in active markets that are directly observable for the asset or liability or indirectly
observable through corroboration with observable market data.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; "><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Level
3 &#8211; pricing inputs are unobservable for the non-financial asset or liability and only used when there is little, if any, market
activity for the non-financial asset or liability at the measurement date. The inputs into the determination of fair value require significant
management judgment or estimation. Level 3 inputs are considered as the lowest priority within the fair value hierarchy.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_6" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">This
hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining
fair value.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
fair value of cash is based on its demand value, which is equal to its carrying value. Additionally, the carrying value of all other
short-term monetary assets and liabilities are estimated to be equal to their fair value due to the short-term nature of these instruments.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_ConcentrationRiskCreditRisk-c0_cont_1" escape="true" name="us-gaap:ConcentrationRiskCreditRisk" id="ixv-18373"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>O.
Concentration of Credit Risk</b></span></p></ix:nonNumeric>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c0_cont_2" id="_ConcentrationRiskCreditRisk-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company maintains certain cash balances in a well-known Israeli banks and U.S based banks.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_ConcentrationRiskCreditRisk-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Part
of the Company&#8217;s operating expenses are denominated in New Israeli Shekel (&#8220;NIS&#8221;), and therefore, subject to foreign
currency risk.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 144; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>INSPIRA
TECHNOLOGIES OXY B.H.N. LTD.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>In
thousands $ (except share and per share data)</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;<b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 2
</b>- <b>SIGNIFICANT ACCOUNTING POLICIES (CONT.):</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_5" id="_SignificantAccountingPoliciesTextBlock-c0_cont_4"><ix:nonNumeric contextRef="c0" continuedAt="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="ixv-18429"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>P.
Cash and Cash Equivalent</b></span></p></ix:nonNumeric>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_2" id="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Cash
equivalents are highly liquid investments that are readily convertible into cash, typically with an original maturity of three months
or less from <span>the date of purchase that are not restricted as to withdrawal or use and are readily
convertible to known amounts of cash.</span></span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; ">&#160;</span></p>

<ix:continuation continuedAt="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_3" id="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; ">Restricted
cash consists of funds that are contractually restricted to bank guarantee due to rental agreements. The Company has presented restricted
cash separately from cash and cash equivalents in the balance sheets.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; ">&#160;</span></p>

<ix:continuation id="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Bank
deposits with maturities of more than three months, but less than one year, and which are not restricted are included in short-term deposits.
Such deposits are stated at cost which approximates market value. As of December 31, 2024 and December 31, 2023, the Company had short-term
deposits in the amounts of $<ix:nonFraction contextRef="c4" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShortTermInvestments" scale="6" unitRef="usd" id="ixv-25725">0.7</ix:nonFraction> million and $<ix:nonFraction contextRef="c5" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShortTermInvestments" scale="6" unitRef="usd" id="ixv-25726">2.3</ix:nonFraction> million, respectively.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_SegmentReportingPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="ixv-18452"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>Q.
Segment Information</b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>



<ix:continuation id="_SegmentReportingPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; ">The
Company has a single operating and reportable segment. The Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;), who is
the Chief Executive Officer, evaluates the performance of its business based on financial data consistent with the presentation in the
accompanying Financial Statements for the purposes of making operating decisions, assessing financial performance, and allocating resources.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="ixv-18465"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>R.
New accounting Pronouncements</b></span></p></ix:nonNumeric>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; "><b><i>Accounting
Standards Adopted in 2024</i></b></span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_3" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; ">In
March 2023, the FASB issued Accounting Standard Updated No. 2023-01 &#8220;Lease (Topic 842)&#8221;. Topic 842 requires that entities
determine whether a related party arrangement between entities under common control (hereinafter referred to as a common control arrangement)
is a lease. If the arrangement is determined to be a lease, an entity must classify and account for the lease on the same basis as an
arrangement with an unrelated party (on the basis of legally enforceable terms and conditions).That represents a change from the requirements
of Topic 840, Leases, which required that an entity classify and account for an arrangement on the basis of economic substance when those
terms and conditions were affected by the related party nature of the arrangement. The amendments in this Update affect all lessees that
are a party to a lease between entities under common control in which there are leasehold improvements. The amendments apply to all entities
(that is, public business entities, private companies, not-for-profit. The Company adopted ASU 2023-01 on January 1, 2024, its adoption
did not have a material impact on the Financial Statements and related disclosures.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_4" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; ">In
June 2022, the FASB issued ASU 2022-03, Fair Value Measurement (Topic 820), &#8220;Fair Value Measurement of Equity Securities Subject
to Contractual Sale Restrictions&#8221; which clarifies that contractual restrictions on equity security sales are not considered part
of the security unit of account and, therefore, are not considered in measuring fair value. In addition, the restrictions cannot be recognized
and measured as separate units of account. Disclosures on such restrictions are also required. The amendments are effective for Fiscal
years beginning after December 15, 2023, and interim periods within those fiscal years on a prospectively basis. The Company expects
that ASU 2022-03 will not have a material impact on its Financial Statements and related disclosures. </span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 145; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>INSPIRA
TECHNOLOGIES OXY B.H.N. LTD.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>In
thousands $ (except share and per share data)</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;<b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 2
</b>- <b>SIGNIFICANT ACCOUNTING POLICIES (CONT.):</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation id="_SignificantAccountingPoliciesTextBlock-c0_cont_5"><ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_5" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; ">In
November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This ASU expands
public entities&#8217; segment disclosures by requiring disclosure of significant segment expenses that are regularly provided to the
CODM and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment
items, and interim disclosures of a reportable segment&#8217;s profit or loss and assets. All disclosure requirements under ASU 2023-07
are also required for public entities with a single reportable segment. The ASU&#8217;s amendments are effective for all public entities
for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early
adoption permitted. We are currently evaluating the impact of this pronouncement on our Financial Statements.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_6" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; "><b><i>Accounting
Pronouncements Issued but Not Yet Adopted</i></b></span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_7" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; ">In
December 2023, the FASB issued ASU 2023-08, Intangibles&#8212;Goodwill and Other&#8212;Crypto Assets (Subtopic 350-60): Accounting for
and Disclosure of Crypto Assets, which addresses the accounting and disclosure requirements for certain crypto assets. This ASU requires
entities to subsequently measure certain crypto assets at fair value, with changes in fair value recorded in net income in each reporting
period. In addition, entities are required to provide additional disclosures about the holdings of certain crypto assets. The ASU&#8217;s
amendments are effective for all entities holding assets that meet certain scope criteria for fiscal years beginning after December 15,
2024, including interim periods within those years. Early adoption is permitted for both interim and annual periods. If an entity adopts
the amendments in an interim period, it must adopt them as of the beginning of the fiscal year that includes that interim period. We
do not expect this pronouncement to have a material impact on our Financial Statements.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; ">In
December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. Under this ASU, public
entities must annually (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling
items that meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than five percent of the amount
computed by multiplying pretax income or loss by the applicable statutory income tax rate). This ASU&#8217;s amendments are effective
for all entities that are subject to Topic 740, Income Taxes, for annual periods beginning after December 15, 2024, with early adoption
permitted. We are currently evaluating the impact of this pronouncement on our disclosures.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:DepositLiabilitiesDisclosuresTextBlock" id="ixv-18554"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif"><b>NOTE
3 &#8211; DEPOSITS:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif">The
Company&#8217;s deposits consist of short-term bank deposits with maturities of more than three months but less than one year. The deposits
bear annual interest. <span>Interest earned is recorded as finance income, net in the statement of operations
during the years for which the Company held short-term deposits.</span></span></p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">As
of December 31, 2024, the Company had a deposit in NIS at Bank Leumi in the amount of $<ix:nonFraction contextRef="c55" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Deposits" scale="3" unitRef="usd" id="ixv-25727">668</ix:nonFraction>, including interest that bore a fixed annual
interest of <ix:nonFraction contextRef="c56" decimals="5" format="ixt:num-dot-decimal" name="us-gaap:ShortTermDebtPercentageBearingFixedInterestRate" scale="-2" unitRef="pure" id="ixv-25728">4.108</ix:nonFraction>%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">As
of December 31, 2023, the Company had a deposit in USD at Bank Leumi in the amount of $<ix:nonFraction contextRef="c57" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Deposits" scale="3" unitRef="usd" id="ixv-25729">2,040</ix:nonFraction>, including interest that bore fixed annual
interest of <ix:nonFraction contextRef="c58" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShortTermDebtPercentageBearingFixedInterestRate" scale="-2" unitRef="pure" id="ixv-25730">6.18</ix:nonFraction>% and a deposit in NIS in the amount of $<ix:nonFraction contextRef="c59" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Deposits" scale="3" unitRef="usd" id="ixv-25731">280</ix:nonFraction> that bore fixed annual interest of <ix:nonFraction contextRef="c59" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShortTermDebtPercentageBearingFixedInterestRate" scale="-2" unitRef="pure" id="ixv-25732">4.85</ix:nonFraction>%.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 146; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>INSPIRA
TECHNOLOGIES OXY B.H.N. LTD.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>In
thousands $ (except share and per share data)</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.1pt; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:OtherCurrentAssetsTextBlock" id="ixv-18603"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif"><b>NOTE
4 - OTHER CURRENT ASSETS:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock" id="ixv-18610"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December&#160;31,<br/>
    2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December&#160;31,
    <br/> 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Prepaid expenses</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" unitRef="usd" id="ixv-25733">240</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" unitRef="usd" id="ixv-25734">176</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Institutions</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestBearingDepositsInBanks" scale="3" unitRef="usd" id="ixv-25735">183</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestBearingDepositsInBanks" scale="3" unitRef="usd" id="ixv-25736">164</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Restricted Cash</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashCurrent" scale="3" unitRef="usd" id="ixv-25737">90</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashCurrent" scale="3" unitRef="usd" id="ixv-25738">89</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Others</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" unitRef="usd" id="ixv-25739">74</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" unitRef="usd" id="ixv-25740">3</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-25741">587</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-25742">432</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:InventoryDisclosureTextBlock" id="ixv-18729"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 5
- INVENTORY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="ixv-18736"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December&#160;31,<br/>
    2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December&#160;31,
    <br/> 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Raw materials</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterials" scale="3" unitRef="usd" id="ixv-25743">96</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-63; font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Work in progress</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryWorkInProcess" scale="3" unitRef="usd" id="ixv-25744">55</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-64; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Finished good (*)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" id="ix_0_fact" name="us-gaap:InventoryFinishedGoods" scale="3" unitRef="usd">293</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-65; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" unitRef="usd" id="ixv-25746">444</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-66; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0"><b>(*) <ix:footnote id="ix_1_footnote" xml:lang="en-US">As of December 31, 2024, seven INSPIRA ART100 systems and
seven carts were in the course of being delivered to a distributor in the U.S.</ix:footnote> </b></p></ix:nonNumeric></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="ixv-18841"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 6
- PROPERTY AND EQUIPMENT, NET:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="ixv-18847"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">For the
year ended December 31, 2024:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Computers</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Leasehold<br/>
    improvements</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">R&amp;D<br/>
    equipment</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Furniture<br/>
    and office<br/> equipment</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Cost</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">At January 1, 2024</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c60" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-25748">172</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c61" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-25749">36</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c62" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-25750">381</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c63" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-25751">116</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-25752">705</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Additions</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c50" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="3" unitRef="usd" id="ixv-25753">10</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-67; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c64" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="3" unitRef="usd" id="ixv-25754">154</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-68; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="3" unitRef="usd" id="ixv-25755">164</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">At December 31, 2024</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c66" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-25756">182</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c67" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-25757">36</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c68" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-25758">535</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c69" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-25759">116</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-25760">869</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accumulated depreciation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">At January 1, 2024</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c60" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-25761">102</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c61" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-25762">8</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c62" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-25763">73</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c63" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-25764">16</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-25765">199</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Depreciation</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c50" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-25766">44</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c54" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-25767">4</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c64" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-25768">116</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c65" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-25769">7</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-25770">171</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">At December 31, 2024</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c66" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-25771">146</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c67" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-25772">12</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c68" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-25773">189</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c69" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-25774">23</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-25775">370</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Net book value:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">As of December 31, 2024</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c66" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-25776">36</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c67" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-25777">24</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c68" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-25778">346</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c69" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-25779">93</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-25780">499</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 147; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>INSPIRA
TECHNOLOGIES OXY B.H.N. LTD.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>In
thousands $ (except share and per share data)</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 6
- PROPERTY AND EQUIPMENT, NET (CONT.):</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation id="_PropertyPlantAndEquipmentTextBlock-c0_cont_1"><ix:continuation id="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">For the
year ended December 31, 2023:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Computers</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Leasehold<br/> improvements</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Development<br/> equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Furniture<br/> and office<br/> equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Cost</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-weight: bold">At January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c70" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-25781">121</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c71" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-25782">33</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c72" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-25783">229</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c73" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-25784">116</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-25785">499</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Additions</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c74" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="3" unitRef="usd" id="ixv-25786">51</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c75" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="3" unitRef="usd" id="ixv-25787">3</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c76" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="3" unitRef="usd" id="ixv-25788">152</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="3" unitRef="usd" id="ixv-25789">206</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-left: 9pt">At December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c60" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-25790">172</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c61" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-25791">36</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c62" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-25792">381</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c63" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-25793">116</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-25794">705</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Accumulated depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold">At January 1, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c70" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-25795">51</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c71" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-25796">4</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c72" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-25797">25</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c73" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-25798">8</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-25799">88</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c74" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-25800">51</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c75" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-25801">4</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c76" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-25802">48</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c77" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-25803">8</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-25804">111</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-left: 9pt">At December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c60" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-25805">102</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c61" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-25806">8</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c62" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-25807">73</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c63" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-25808">16</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-25809">199</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold">Net book value:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt">As of December 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c60" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-25810">70</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c61" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-25811">28</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c62" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-25812">308</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c63" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-25813">100</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-25814">506</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:continuation><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="ixv-19859"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 7
- OTHER ACCOUNTS PAYABLE:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="ixv-19866"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December&#160;31,<br/>
    2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December&#160;31,<br/>
    2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Employees&#8217; salaries and related
    liabilities</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent" scale="3" unitRef="usd" id="ixv-25815">414</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent" scale="3" unitRef="usd" id="ixv-25816">388</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Related parties</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="iinn:AccountsPayableToRelatedParties" scale="3" unitRef="usd" id="ixv-25817">421</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="iinn:AccountsPayableToRelatedParties" scale="3" unitRef="usd" id="ixv-25818">354</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" scale="3" unitRef="usd" id="ixv-25819">508</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" scale="3" unitRef="usd" id="ixv-25820">267</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent" scale="3" unitRef="usd" id="ixv-25821">21</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent" scale="3" unitRef="usd" id="ixv-25822">17</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" unitRef="usd" id="ixv-25823">1,364</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" unitRef="usd" id="ixv-25824">1,026</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="ixv-19999"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; "><b>NOTE
8 - COMMITMENTS AND CONTINGENCIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.&#160;Royalties
to the IIA:</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 57.4pt; text-indent: -0.7pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; ">In
September 2019, the IIA approved a grant to the Company for the development of intravenous blood oxygenation system for an aggregate
budget of NIS&#160;<ix:nonFraction contextRef="c78" decimals="-3" format="ixt:num-dot-decimal" name="iinn:AggregateBudget" scale="3" unitRef="ils" id="ixv-25825">4,880,603</ix:nonFraction> (approximately $<ix:nonFraction contextRef="c78" decimals="-3" format="ixt:num-dot-decimal" name="iinn:AggregateBudget" scale="3" unitRef="usd" id="ixv-25826">1,500</ix:nonFraction>). The IIA committed to fund&#160;<ix:nonFraction contextRef="c78" decimals="2" format="ixt:num-dot-decimal" name="iinn:PercentageOfApprovedBudget" scale="-2" unitRef="pure" id="ixv-25827">60</ix:nonFraction>% of the approved budget. Eventually the project
budget concluded in the aggregate amount of NIS <ix:nonFraction contextRef="c78" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ProjectBudgetAggregateAmount" scale="3" unitRef="ils" id="ixv-25828">4,623,142</ix:nonFraction> (approximately $<ix:nonFraction contextRef="c78" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ProjectBudgetAggregateAmount" scale="3" unitRef="usd" id="ixv-25829">1,333</ix:nonFraction>). The program is for the period beginning October 2019
through November 2020. From 2019 to 2021, the Company received total funds in the amount of NIS <ix:nonFraction contextRef="c79" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivables" scale="3" unitRef="ils" id="ixv-25830">2,773,885</ix:nonFraction> (approximately $<ix:nonFraction contextRef="c79" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivables" scale="3" unitRef="usd" id="ixv-25831">809</ix:nonFraction>) from the
IIA, which were recorded as IIA participation and were deducted from R&amp;D expenses. </span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 148; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>INSPIRA
                                            TECHNOLOGIES OXY B.H.N. LTD.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>In
thousands $ (except share and per share data)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; "><b>NOTE
8 - COMMITMENTS AND CONTINGENCIES</b></span><b> <span style="font-family: Times New Roman, Times, Serif">(CONT.):</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; ">In
October 2023, the IIA approved a grant to support another development project of the Company at an aggregate budget of NIS&#160;<ix:nonFraction contextRef="c80" decimals="-3" format="ixt:num-dot-decimal" name="iinn:AggregateBudget" scale="3" unitRef="ils" id="ixv-25832">3,850,869</ix:nonFraction>
(approximately $<ix:nonFraction contextRef="c80" decimals="-3" format="ixt:num-dot-decimal" name="iinn:AggregateBudget" scale="3" unitRef="usd" id="ixv-25833">1,062</ix:nonFraction>). The IIA committed to fund&#160;<ix:nonFraction contextRef="c80" decimals="2" format="ixt:num-dot-decimal" name="iinn:PercentageOfApprovedBudget" scale="-2" unitRef="pure" id="ixv-25834">40</ix:nonFraction>% of the approved budget. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; ">The
program is for the period beginning January 2024 through March 2025, and as of December 31, 2024, the Company received total funds in
the amount of NIS <ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivables" scale="3" unitRef="ils" id="ixv-25835">1,062,049</ix:nonFraction> (approximately $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivables" scale="3" unitRef="usd" id="ixv-25836">286</ix:nonFraction>) from the IIA, which were recorded as IIA participation and were deducted from the R&amp;D
expenses. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; ">According
to the agreements with the IIA, The Company will pay royalties of&#160;<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="iinn:RoyaltiesPercentage" scale="-2" unitRef="pure" id="ixv-25837">3</ix:nonFraction>% of future sales up to an amount equal to the accumulated grant
received linked to the U.S. dollar and bearing interest at an annual rate of SOFR. Repayment of the grants are contingent upon the successful
completion of the Company&#8217;s R&amp;D programs and generating sales. The Company has no obligation to repay these grants if the R&amp;D
programs fail, are unsuccessful or aborted or if no sales are generated. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; ">The
Company had not generated sales as of December 31, 2024; therefore, no liability was recorded in these Financial Statements. As of December
31, 2024, the maximum obligation with respect to the grants received from the IIA, contingent upon entitled future sales, is $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ContingentUponFutureSales" scale="3" unitRef="usd" id="ixv-25838">1,095</ix:nonFraction> plus
SOFR interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; ">The
Company has obligations regarding know-how, technology, or products, not to transfer the information, rights thereon and production rights
which derive from the research and development without the IIA Research Committee approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; ">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>B.
Legal Claims</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
the normal course of business, various legal claims and other contingent matters may arise. Management believes that any liability that
may arise from such matters would not have a material adverse effect on the Company&#8217;s results of operations or financial condition
as of and for the years ended December 31, 2024, and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
December 12, 2021, the Company terminated its employment agreement with Dr. Udi Nussinovitch, one of its founders who served as the Company&#8217;s
Chief Scientific Officer since March 2018. On February 24, 2022, the Company sued Mr. Nussinovitch for breach good faith and his fiduciary
duties as a shareholder and former officer of the Company. On November 9, 2022, Mr. Nussinovitch filed a Statement of Claim against the
Company,, as well as a Statement of Claim with the regional labor court in Tel Aviv, Israel on November 8, 2022. Mr. Nussinovitch alleged
certain deficiencies in the Company&#8217;s&#160;Extraordinary General Meeting of Shareholders held on Friday, December 17, 2021, resulting
from his status as a minority shareholder. In addition, with respect to the labor dispute, Mr.&#160;Nussinovitch is seeking renumeration
and the issuance of Ordinary Shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
July 19. 2023, a partial hearing about the labor dispute was held, in which the parties were required by the court to file their positions
on a stay of the proceeding pending the decision on the case initiated by Mr. Nussinovitch in the District Court. On January 21, 2024,
a partial hearing about the civil case was held. During the hearing, the court suggested the parties consider the possibility of resolving
the case through an out-of-court arrangement or mediation. The parties agreed to a mediation process which did not succeed. On
January 7, 2025,&#160;Mr. Nussinovitch&#160;filed a motion to amend his Statement of Claim, requesting to modify the requested relief.
Instead of the original remedies sought,&#160;Mr. Nussinovitch&#160;now requests that the Company or Mr. Ben Noon and Mr. Hayon purchase
all of his rights and shares in the Company at their average value from the date of the Company&#8217;s initial public offering until
the date of the general meeting held on December 17, 2021. On January 13, 2025, a pretrial hearing was held. The court denied Mr. Nussinovitch&#8217;s
motion to amend and instructed him to notify whether he wishes to withdraw his original claim or maintain it. As of the date of these
Financial Statements, Mr. Nussinovitch has not yet provided his response.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">As
of the date of these Financial Statements, the Company believes that the claims will result in no payments by the Company.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 149; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>INSPIRA
TECHNOLOGIES OXY B.H.N. LTD.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>In
thousands $ (except share and per share data)</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeOperatingLeasesTextBlock" id="ixv-20128"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; "><b>NOTE
9 &#8211; LEASE LIABILITIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Lease
Commitments &#8211; Operating Leases:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; ">In
September 2021, the Company entered into a lease agreement for its facilities in Ra&#8217;anana, Israel. The lease agreement is for a
period of 69 months commencing September 1, 2021, and the Company began to pay lease and related expenses after completing 3 months of
lease. The Company has the option to shorten the period and terminates the lease agreement after completing 45 months of rent by paying
an amount of NIS <ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRent" scale="3" unitRef="ils" id="ixv-25839">500,000</ix:nonFraction>, (approximately $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRent" scale="3" unitRef="usd" id="ixv-25840">153</ix:nonFraction>). This amount of reimbursement will be deducted monthly in NIS <ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:MonthlyDeductionFromTerminationFee" scale="3" unitRef="ils" id="ixv-25841">30,000</ix:nonFraction>, (approximately $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:MonthlyDeductionFromTerminationFee" scale="3" unitRef="usd" id="ixv-25842">9</ix:nonFraction>)
if the Company terminates the agreement after 45 months of rent. The Company is reasonably certain that it will not exercise the termination
option. The annual lease payment, including management fees, as of December 31, 2024, is approximately NIS <ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromLeasePayments" scale="3" unitRef="ils" id="ixv-25843">69,000</ix:nonFraction> ($<ix:nonFraction contextRef="c0" decimals="-2" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromLeasePayments" scale="3" sign="-" unitRef="usd" id="ixv-25844">17.5</ix:nonFraction>). As security
for the obligations under this lease agreement, the Company provided a bank guarantee in an amount equal to three monthly lease payments
plus the Israeli value added tax and an unlimited guarantee according to the terms specified in the contract. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; ">The
Company has various operating leases for vehicles that expire through 2027. The Company leases vehicles for approximately three-year
periods from multiple different leasing companies and from time to time increases or decreases the number of leased vehicles according
to its current needs. The leased vehicles are used by the Company&#8217;s headquarters staff and other employees whose employment agreements
include an obligation on the Company to provide a vehicle. The agreements with the leasing companies include termination options, allowing
for early cancellation by paying a penalty of <ix:nonNumeric contextRef="c0" name="iinn:PercentageForCarsLeaseAgreementCancellationPenalty" id="ixv-25845">up to 400%</ix:nonNumeric> of the monthly costs. The Company is reasonably certain that it will not exercise
this option or that the employee will bear the cost for early termination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; ">The
total expenses related to the leases were $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="3" unitRef="usd" id="ixv-25846">390</ix:nonFraction>&#160;for the year ended December 31, 2024, and $<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="3" unitRef="usd" id="ixv-25847">371</ix:nonFraction>&#160;for the year ended December 31,
2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; ">The
right-of-use asset and lease liability are initially measured at the present value of the lease payments, discounted using the interest
rate implicit in the lease or, if that rate cannot be readily determined, the Company&#8217;s incremental borrowing rate based on the
information available at the date of determining the present value of the lease payments. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; ">The
Company&#8217;s incremental borrowing rate is estimated to approximate the interest rate on similar terms and payments and in economic
environments where the leased asset is located.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; ">The
Company has various operating leases for vehicles that expire through 2027. <ix:nonNumeric contextRef="c0" continuedAt="iinn_ScheduleOfLesseeOperatingLeasesDisclosureTableTextBlock-c0_cont_1" escape="true" name="iinn:ScheduleOfLesseeOperatingLeasesDisclosureTableTextBlock" id="ixv-25848">Below is a summary of the Company&#8217;s operating right-of-use
assets and operating lease liabilities as of December 31, 2024, and 2023:</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>

<ix:continuation id="iinn_ScheduleOfLesseeOperatingLeasesDisclosureTableTextBlock-c0_cont_1"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>December&#160;31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>2024</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December&#160;31, <br/> 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating lease liabilities, current</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-25849">277</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-25850">290</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Operating lease liabilities long-term</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-25851">378</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-25852">588</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total operating lease liabilities</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" unitRef="usd" id="ixv-25853">655</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" unitRef="usd" id="ixv-25854">878</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Weighted Average of Remaining Lease Term</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonNumeric contextRef="c4" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="ixv-20286"><span style="font-family: Times New Roman, Times, Serif">2.52</span></ix:nonNumeric></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonNumeric contextRef="c5" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="ixv-20295"><span style="font-family: Times New Roman, Times, Serif">3.33</span></ix:nonNumeric></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Weighted-average discount rate - operating leases</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure" id="ixv-25855">9.92</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure" id="ixv-25856">9.6</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> </table></ix:continuation></ix:nonNumeric><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;<b>&#160;</b></span></p><div>

</div><!-- Field: Page; Sequence: 150; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>INSPIRA
                                            TECHNOLOGIES OXY B.H.N. LTD.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>In
thousands $ (except share and per share data)</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; "><b>NOTE
9 &#8211; LEASE LIABILITIES</b></span><b> <span style="font-family: Times New Roman, Times, Serif">(CONT.):</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="ixv-20361"><ix:continuation id="_LesseeOperatingLeasesTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Lease
payments for the Company&#8217;s right-of-use assets over the remaining lease periods as of December 31, 2024, are as follows:<span>&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; ">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year
    ended December&#160;31, </b></span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">U.S.&#160;dollars<br/>
    in&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" unitRef="usd" id="ixv-25857">326</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2026</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" unitRef="usd" id="ixv-25858">254</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2027</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" unitRef="usd" id="ixv-25859">154</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total undiscounted lease
    payment</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" unitRef="usd" id="ixv-25860">734</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less: Interest (*)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" id="ix_1_fact" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" unitRef="usd">79</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Present value of lease
    liabilities</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" unitRef="usd" id="ixv-25862">655</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">(*)
<ix:footnote id="ix_2_footnote" xml:lang="en-US">Future lease payments were discounted by&#160;<ix:nonFraction contextRef="c81" decimals="4" format="ixt:num-dot-decimal" name="iinn:PercentageOfFutureLeasePaymentsDiscounted" scale="-2" unitRef="pure" id="ixv-25864">7.98</ix:nonFraction>%-<ix:nonFraction contextRef="c82" decimals="4" format="ixt:num-dot-decimal" name="iinn:PercentageOfFutureLeasePaymentsDiscounted" scale="-2" unitRef="pure" id="ixv-25865">15.78</ix:nonFraction>% interest rate.</ix:footnote></span></p></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_FairValueDisclosuresTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueDisclosuresTextBlock" id="ixv-20475"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE
10 &#8211; FINACIAL LIABILITIES AT FAIR VALUE:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" id="ixv-20481"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>December&#160;31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>2024</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>December&#160;31,
                                            </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>2023</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Financial liability (A)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c87" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-25866">69</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c88" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-25867">11</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Private warrants (B)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c101" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-25868">1,506</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c102" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-25869">1,459</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-25870">1,575</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-25871">1,470</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><span style="font-size: 10pt"><b>A Financial Liability</b></span></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">1.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The Company agreed to pay fees of <ix:nonFraction contextRef="c83" decimals="2" format="ixt:num-dot-decimal" name="iinn:PercentageOfPayFees" scale="-2" unitRef="pure" id="ixv-25872">7</ix:nonFraction>% from funds that may be received in an event of exercise of the Company&#8217;s tradable warrants which created a financial liability. The financial liability was designated to be measured at fair value through profit or loss. As of December 31, 2023, the fair value of the financial liability was $<ix:nonFraction contextRef="c84" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" unitRef="usd" id="ixv-25873">11</ix:nonFraction>. Such agreement expired in July 2024 and as of December 31, 2024, the financial liability amounted to null.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">2.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The Company agreed to pay fees of <ix:nonFraction contextRef="c85" decimals="2" format="ixt:num-dot-decimal" name="iinn:PercentageOfPayFees" scale="-2" unitRef="pure" id="ixv-25874">4</ix:nonFraction>% from the funds that will be received in an event of exercise of part of the Company&#8217;s ordinary warrants that were issued in a certain December 2024 private placement which created a financial liability on the total potential amount which is $<ix:nonFraction contextRef="c86" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" unitRef="usd" id="ixv-25875">69</ix:nonFraction> as of December 31, 2024 (Note 10).</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
financial liability fair value as of December 31, 2024, and 2023 is $<ix:nonFraction contextRef="c87" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" unitRef="usd" id="ixv-25876">69</ix:nonFraction> and $<ix:nonFraction contextRef="c88" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" unitRef="usd" id="ixv-25877">11</ix:nonFraction> respectively.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 151; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>INSPIRA
                                            TECHNOLOGIES OXY B.H.N. LTD.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>In
thousands $ (except share and per share data)</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE
10 &#8211; FINACIAL LIABILITIES AT FAIR VALUE (CONT.):</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><ix:continuation id="_FairValueDisclosuresTextBlock-c0_cont_1"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B
Private warrants </b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
December 26, 2023, the Company entered into a certain securities purchase agreement (Note 11.3), pursuant to which it issued unregistered
warrants, to purchase up to an aggregate of <ix:nonFraction contextRef="c89" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" unitRef="shares" id="ixv-25878">3,031,250</ix:nonFraction> Ordinary Shares at an exercise of $<ix:nonFraction contextRef="c90" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-25879">1.28</ix:nonFraction> per share (the &#8220;Private Warrants&#8221;).
The Private Warrants were exercisable immediately upon issuance and will expire three and a half years following their issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Private Warrants include cashless exercise mechanism, according to the terms specified in the agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Private Warrants may create obligation to transfer cash to the investors at fundamental transactions within the Black Scholes option
pricing framework.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Therefore,
the Company accounts for the Private Warrants as financial liability instruments that are measured at fair value and recognized financial
expenses or income through profit and loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
company measured fair value by using Black-Scholes option pricing model;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
key inputs that were used in the private warrants fair value as of December 31, 2023, were:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">risk-free interest rate <ix:nonFraction contextRef="c91" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" unitRef="pure" id="ixv-25880">4.00</ix:nonFraction>%</span></td></tr><tr style="vertical-align: top">
<td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> </table>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">expected volatility <ix:nonFraction contextRef="c92" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" unitRef="pure" id="ixv-25881">66.63</ix:nonFraction>%</span></td></tr><tr style="vertical-align: top">
<td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> </table>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">expected dividend yield of <ix:nonFraction contextRef="c93" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" unitRef="pure" id="ixv-25882">0</ix:nonFraction>%</span></td></tr><tr style="vertical-align: top">
<td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> </table>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">expected term of warrants &#8211; <ix:nonFraction contextRef="c94" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" unitRef="pure" id="ixv-25883">3.5</ix:nonFraction> years.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
key inputs that were used in the private warrants fair value as of December 31, 2024, were:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">risk-free interest rate <ix:nonFraction contextRef="c95" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" unitRef="pure" id="ixv-25884">4.26</ix:nonFraction>%</span></td></tr><tr style="vertical-align: top">
<td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> </table>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">expected volatility <ix:nonFraction contextRef="c96" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" unitRef="pure" id="ixv-25885">88.61</ix:nonFraction>%</span></td></tr><tr style="vertical-align: top">
<td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> </table>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">expected dividend yield of <ix:nonFraction contextRef="c97" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" unitRef="pure" id="ixv-25886">0</ix:nonFraction>%</span></td></tr><tr style="vertical-align: top">
<td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> </table>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">expected term of warrants &#8211; <ix:nonFraction contextRef="c98" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" unitRef="pure" id="ixv-25887">2.5</ix:nonFraction> years.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
fair value of the Private Warrants as of December 31, 2024 and 2023 was $<ix:nonFraction contextRef="c99" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-25888">1,506</ix:nonFraction> and $<ix:nonFraction contextRef="c100" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-25889">1,459</ix:nonFraction> respectively.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c0_cont_1" escape="true" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock" id="ixv-20794"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 11
&#8211; SHAREHOLDERS&#8217; EQUITY:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>A.
Share capital:</b></span></p>



<p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>


<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfStockholdersEquityTableTextBlock" id="ixv-20806"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of shares as of<br/> December 31,&#160;2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of shares as of<br/> December 31,&#160;2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Authorized</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Issued
    and outstanding</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Authorized</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Issued
    and outstanding</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Ordinary shares</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c147" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-25890">100,000,000</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c147" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-25891"><ix:nonFraction contextRef="c147" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-25892">24,252,096</ix:nonFraction></ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c148" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-25893">100,000,000</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c148" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-25894"><ix:nonFraction contextRef="c148" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-25895">15,652,176</ix:nonFraction></ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;&#160;</b></span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">1.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">During the year ended December 31, 2022, the Company issued an aggregate amount of <ix:nonFraction contextRef="c103" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitRef="shares" id="ixv-25896">1,240,204</ix:nonFraction> Ordinary Shares in connection to vested RSUs and an additional <ix:nonFraction contextRef="c104" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" unitRef="shares" id="ixv-25897">7,030</ix:nonFraction> Ordinary Shares in connection to certain option exercises.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">2.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On April 4, 2023, the Company entered into a sales agreement (the &#8220;Sales Agreement&#8221;) with Roth Capital Partners, LLC, as sales agent, pursuant to which the Company could offer and sell, from time to time, through the sales agent, Ordinary Shares pursuant to an at-the-market facility (&#8220;ATM&#8221;). In 2023, the Company sold <ix:nonFraction contextRef="c105" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-25898">17,566</ix:nonFraction> Ordinary Shares under the ATM. On October 23, 2023, the Company terminated the Sales Agreement and the associated ATM, effective immediately.</span></td></tr></table></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 152; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>INSPIRA
TECHNOLOGIES OXY B.H.N. LTD.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>In
thousands $ (except share and per share data)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 11
- SHAREHOLDERS&#8217; EQUITY (CONT.):</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation continuedAt="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c0_cont_2" id="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">3.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On December 26, 2023, the Company entered into a securities purchase agreement (the &#8220;Purchase Agreement&#8221;) with an institutional investor in a registered direct offering (the &#8220;Registered Direct Offering&#8221;), pursuant to which the Company issued (i) <ix:nonFraction contextRef="c106" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-25899">1,375,000</ix:nonFraction> Ordinary Shares at a purchase price of $<ix:nonFraction contextRef="c107" decimals="2" format="ixt:num-dot-decimal" name="iinn:PurchasePricePerShare" scale="0" unitRef="usdPershares" id="ixv-25900">1.28</ix:nonFraction> per share, (ii) pre-funded warrants, to purchase up to <ix:nonFraction contextRef="c108" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-25901">1,656,250</ix:nonFraction> Ordinary Shares, at a purchase price of $<ix:nonFraction contextRef="c109" decimals="2" format="ixt:num-dot-decimal" name="iinn:PurchasePricePerShare" scale="0" unitRef="usdPershares" id="ixv-25902">1.28</ix:nonFraction>, less $<ix:nonFraction contextRef="c110" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-25903">0.001</ix:nonFraction> per pre-funded warrant and (iii) Private Warrants, to purchase up to an aggregate of <ix:nonFraction contextRef="c90" decimals="0" format="ixt:num-dot-decimal" name="iinn:ClassOfPrivateWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-25904">3,031,250</ix:nonFraction> Ordinary Shares at an exercise of $<ix:nonFraction contextRef="c90" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-25905">1.28</ix:nonFraction> per share (Note 10-B).</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company concluded that the Pre-Funded Warrants are not within the scope of ASC480. Further, applying ASC 815-40, the Company
concluded that the pre-funded warrants are indexed to the Company&#8217;s own stock and meet the conditions for equity classification,
and thus should be presented within equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">As
for the common warrants, the Company concluded that they should be classified as a liability under ASC 815-40, as they are not indexed
to the Company&#8217;s own stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
pre-funded warrants were exercised on the same day and the day after the transaction in full in an exercise price of $<ix:nonFraction contextRef="c111" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-25906">0.001</ix:nonFraction> per share
and the Company issued <ix:nonFraction contextRef="c112" decimals="0" format="ixt:num-dot-decimal" name="iinn:NumberofAdditionalOrdinaryShares" scale="0" unitRef="shares" id="ixv-25907">1,656,250</ix:nonFraction> additional Ordinary Shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
aggregate proceeds received by the Company from the Registered Direct Offering were approximately $<ix:nonFraction contextRef="c113" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" unitRef="usd" id="ixv-25908">3,424</ix:nonFraction>, after deducting underwriting
discounts and commissions and additional cash offering costs totaled in approximately $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredOfferingCosts" scale="3" unitRef="usd" id="ixv-25909">454</ix:nonFraction>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company issued the placement agent in the Registered Direct Offering a number of warrants equal to a total of <ix:nonFraction contextRef="c4" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ProductWarrantyLiquidationProceedsPercentage" scale="-2" unitRef="pure" id="ixv-25910">7.0</ix:nonFraction>% of the aggregate number
of Ordinary Shares sold in the transaction, total to <ix:nonFraction contextRef="c114" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-25911">212,188</ix:nonFraction> warrants to purchase up to <ix:nonFraction contextRef="c115" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-25912">212,188</ix:nonFraction> Ordinary Shares, were issued (the &#8220;Placement
Agent Warrants&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Placement Agent Warrants were substantially on the same terms as the Warrants issued to the investor in the offering, except an exercise
price of $<ix:nonFraction contextRef="c116" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares" id="ixv-25913">1.60</ix:nonFraction> per share. The Placement Agent Warrants were exercisable immediately upon issuance and will expire <ix:nonNumeric contextRef="c116" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="ixv-25914">five years</ix:nonNumeric> following
their issuance. The Company accounts for the Placement Agent Warrants as equity-classified instruments (as part of additional paid in
capital), based on an assessment of ASC 718. The fair value of the warrants at the issuance date was $<ix:nonFraction contextRef="c117" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" unitRef="usd" id="ixv-25915">131</ix:nonFraction>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Those
cash and non-cash issuance costs were accounted proportionally to issuance expenses and decrease of additional paid in capital, according
to the ratio of the liability versus equity in the Registered Direct offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">4.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">During the year ended December 31, 2023, the Company issued an aggregate amount of <ix:nonFraction contextRef="c118" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitRef="shares" id="ixv-25916">1,226,448</ix:nonFraction> Ordinary Shares in connection with vested RSUs and an additional <ix:nonFraction contextRef="c118" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" unitRef="shares" id="ixv-25917">37,972</ix:nonFraction> Ordinary Shares in connection with option exercises.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">5.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On April 1, 2024, the Company completed its 2024 April Offering, whereby the Company sold <ix:nonFraction contextRef="c119" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-25918">1,339,285</ix:nonFraction> Ordinary Shares at a purchase price of $<ix:nonFraction contextRef="c120" decimals="3" format="ixt:num-dot-decimal" name="iinn:PurchasePricePerShare" scale="0" unitRef="usdPershares" id="ixv-25919">1.232</ix:nonFraction> per share. The gross proceeds received by the Company from the 2024 April Offering were approximately $<ix:nonFraction contextRef="c119" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" unitRef="usd" id="ixv-25920">1,651</ix:nonFraction>.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">6.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On May 20, 2024, the Company issued warrant to purchase <ix:nonFraction contextRef="c121" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-25921">220,000</ix:nonFraction> Ordinary Shares to a service provider, at an exercise price of $<ix:nonFraction contextRef="c121" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-25922">2.25</ix:nonFraction> per share. These warrants are immediately exercisable and are due to expire <ix:nonNumeric contextRef="c121" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="ixv-25923">six months</ix:nonNumeric> from the initial issuance date. The Company accounting treatment for those warrants as equity-classified instruments (as part of additional paid in capital), based on an assessment of ASC 718. The fair value of the warrants at the issuance date was $<ix:nonFraction contextRef="c122" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" unitRef="usd" id="ixv-25924">125</ix:nonFraction>. The warrants were not exercised within the designated timeframe and expired on November 21, 2024.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">7.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On June 14, 2024, the Company completed its 2024 June Offering, whereby the Company sold: (i) <ix:nonFraction contextRef="c123" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-25925">941,541</ix:nonFraction> Ordinary Shares at a purchase price of $<ix:nonFraction contextRef="c124" decimals="2" format="ixt:num-dot-decimal" name="iinn:PurchasePricePerShare" scale="0" unitRef="usdPershares" id="ixv-25926">1.30</ix:nonFraction> per share, and (ii) June Pre-Funded Warrants to purchase up to <ix:nonFraction contextRef="c38" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-25927">1,709,760</ix:nonFraction> Ordinary Shares, at a purchase price of $<ix:nonFraction contextRef="c125" decimals="2" format="ixt:num-dot-decimal" name="iinn:PurchasePricePerShare" scale="0" unitRef="usdPershares" id="ixv-25928">1.30</ix:nonFraction>, less $<ix:nonFraction contextRef="c126" decimals="3" format="ixt:num-dot-decimal" name="iinn:PurchasePricePerShare" scale="0" unitRef="usdPershares" id="ixv-25929">0.001</ix:nonFraction> per June Pre-Funded Warrant. Each June Pre-Funded Warrant is exercisable for <ix:nonFraction contextRef="c127" decimals="0" format="ixt-sec:numwordsen" name="iinn:NumberOfSharesPerUnits" scale="0" unitRef="shares" id="ixv-25930">one</ix:nonFraction> Ordinary Share at an exercise price of $<ix:nonFraction contextRef="c38" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-25931">0.001</ix:nonFraction> per share. The June Pre-Funded Warrants are immediately exercisable and may be exercised at any time until all of the June Pre-Funded Warrants are exercised in full. As of December 31, 2024, all of the June Pre-Funded warrants were exercised, and the company issued <ix:nonFraction contextRef="c128" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-25932">1,709,760</ix:nonFraction> Ordinary Shares.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Net
proceeds received by the Company from the 2024 June Offering were approximately $<ix:nonFraction contextRef="c129" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" scale="3" unitRef="usd" id="ixv-25933">3,102</ix:nonFraction>, after deducting cash offering costs which
were approximately $<ix:nonFraction contextRef="c130" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredOfferingCosts" scale="3" unitRef="usd" id="ixv-25934">343</ix:nonFraction>.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 153; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>INSPIRA
TECHNOLOGIES OXY B.H.N. LTD.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>In
thousands $ (except share and per share data)</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 11
- SHAREHOLDERS&#8217; EQUITY (CONT.):</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation continuedAt="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c0_cont_3" id="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company also received $<ix:nonFraction contextRef="c131" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" unitRef="usd" id="ixv-25935">2</ix:nonFraction> from an exercise of the June Pre-Funded Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company concluded that the June Pre-Funded Warrants are not within the scope of ASC 480. Further, applying ASC 815-40, the Company concluded
that the June Pre-Funded Warrants are indexed to the Company&#8217;s own stock and meet the conditions for equity classification, and
thus should be presented within equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company issued the June Placement Agent in the agreement warrants equal to a total of <ix:nonFraction contextRef="c132" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ProductWarrantyLiquidationProceedsPercentage" scale="-2" unitRef="pure" id="ixv-25936">7.0</ix:nonFraction>% of the aggregate number of Ordinary Shares
sold in the transaction. A total to <ix:nonFraction contextRef="c132" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-25937">185,591</ix:nonFraction> warrants to purchase up to <ix:nonFraction contextRef="c133" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-25938">185,591</ix:nonFraction> Ordinary Shares were issued. The June Placement Agent
Warrants had an exercise price of $<ix:nonFraction contextRef="c134" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-25939">1.56</ix:nonFraction> per share. The June Placement Agent Warrants were exercisable immediately upon issuance and will
expire <ix:nonNumeric contextRef="c132" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="ixv-25940">four years</ix:nonNumeric> following their issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company accounting treatment for the June Placement Agent Warrants as equity-classified instruments (as part of additional paid in capital),
based on an assessment of ASC 718. The fair value of the June Placement Agent Warrants at the issuance date was $<ix:nonFraction contextRef="c132" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" unitRef="usd" id="ixv-25941">254</ix:nonFraction>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
cash and non-cash issuance costs were recorded against additional paid in capital, due to the classification of the Ordinary Shares and
the June Pre-Funded Warrants as equity instrument.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">8.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On June 30, 2024, the Company issued <ix:nonFraction contextRef="c135" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares" id="ixv-25942">45,000</ix:nonFraction> Ordinary Shares to an advisor in connection with a consulting service agreement.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">9.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On December 27, 2024, the Company completed its December Private Placement, whereby the Company sold (i) <ix:nonFraction contextRef="c136" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-25943">3,950,343</ix:nonFraction> Ordinary Shares and December Private Warrants to purchase up to <ix:nonFraction contextRef="c137" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-25944">3,950,343</ix:nonFraction> Ordinary Shares at a purchase price of $<ix:nonFraction contextRef="c138" decimals="2" format="ixt:num-dot-decimal" name="iinn:PurchasePricePerShare" scale="0" unitRef="usdPershares" id="ixv-25945">0.70</ix:nonFraction> per unit, and (ii) December Pre-Funded Warrants to purchase up to <ix:nonFraction contextRef="c45" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-25946">658,372</ix:nonFraction> Ordinary Shares and December Private Warrants to purchase up to <ix:nonFraction contextRef="c138" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-25947">658,372</ix:nonFraction> Ordinary Shares, at a purchase price of $<ix:nonFraction contextRef="c139" decimals="2" format="ixt:num-dot-decimal" name="iinn:PurchasePricePerShare" scale="0" unitRef="usdPershares" id="ixv-25948">0.70</ix:nonFraction>, less $<ix:nonFraction contextRef="c140" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-25949">0.001</ix:nonFraction> per unit with December Pre-Funded Warrant. Each December Pre-Funded Warrant is exercisable for <ix:nonFraction contextRef="c43" decimals="0" format="ixt-sec:numwordsen" name="iinn:NumberOfSharesPerUnits" scale="0" unitRef="shares" id="ixv-25950">one</ix:nonFraction> Ordinary Share at an exercise price of $<ix:nonFraction contextRef="c45" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-25951">0.001</ix:nonFraction> per share. Each December Private Warrant is exercisable for <ix:nonFraction contextRef="c141" decimals="0" format="ixt-sec:numwordsen" name="iinn:NumberOfSharesPerUnits" scale="0" unitRef="shares" id="ixv-25952">one</ix:nonFraction> Ordinary Share at an exercise price of $<ix:nonFraction contextRef="c137" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-25953">1.10</ix:nonFraction> per share. The December Private Warrants are immediately exercisable and may be exercised at any time until the end of June 2026. The December Pre-Funded Warrants are immediately exercisable and may be exercised at any time until all of the December Pre-Funded Warrants are exercised in full. As of December 31, 2024, none of the December Pre-Funded warrants or the December Private Warrants were exercised.</span></td></tr></table></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 154; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>INSPIRA
TECHNOLOGIES OXY B.H.N. LTD.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>In
thousands $ (except share and per share data)</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 11
- SHAREHOLDERS&#8217; EQUITY (CONT.):</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation continuedAt="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c0_cont_4" id="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company concluded that the December Private Warrants and December Pre-Funded Warrants are not within the scope of ASC 480. Further, applying
ASC 815-40, the Company concluded that the December Private Warrants and December Pre-Funded Warrants are indexed to the Company&#8217;s
own stock and meet the conditions for equity classification, and thus should be presented within equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
gross proceeds received by the Company from the December Private Offering were approximately $<ix:nonFraction contextRef="c142" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" unitRef="usd" id="ixv-25954">3,228</ix:nonFraction>, before deducting underwriting discounts
and commissions and additional cash offering costs totaled approximately $<ix:nonFraction contextRef="c143" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredOfferingCosts" scale="3" unitRef="usd" id="ixv-25955">233</ix:nonFraction>. In addition, the Company agreed to pay fees of <ix:nonFraction contextRef="c144" decimals="2" format="ixt:num-dot-decimal" name="iinn:PercentageOfPayFees" scale="-2" unitRef="pure" id="ixv-25956">4</ix:nonFraction>% from
the funds that may be received in an event of exercise of part of the Company&#8217;s private warrants issued in December 2024 Private
Placement which created a financial liability in amount of $<ix:nonFraction contextRef="c145" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" unitRef="usd" id="ixv-25957">69</ix:nonFraction> which is the total potential amount (Note 10-A).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
cash and non-cash issuance costs were recorded against additional paid in capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">10.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">During the year ended December 31, 2024, the Company issued an aggregate amount of <ix:nonFraction contextRef="c146" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitRef="shares" id="ixv-25958">594,943</ix:nonFraction> Ordinary Shares in connection with vested RSUs and an additional <ix:nonFraction contextRef="c146" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" unitRef="shares" id="ixv-25959">19,048</ix:nonFraction> Ordinary Shares in connection with option exercises.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>B.
Warrants reserves -</b>Composition and movements:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 21.8pt"/><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif">1.</span></td><td style="text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="ixv-21171"><span style="font-family: Times New Roman, Times, Serif">The following table reconciles the movement in warrants outstanding at the beginning and end of the period:</span></ix:nonNumeric></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:continuation id="_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock-c0_cont_1"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number of<br/> Warrants</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted-average exercise price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Weighted average remaining contractual term</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>(in years)</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; font-weight: bold; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance as of December 31, 2023</span></td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c149" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-25960">3,333,283</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c149" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-25961">5.47</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonNumeric contextRef="c150" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" id="ixv-21250"><span style="font-family: Times New Roman, Times, Serif">1.83</span></ix:nonNumeric></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issued</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c114" decimals="INF" format="ixt:num-dot-decimal" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsIssued" scale="0" unitRef="shares" id="ixv-25962">7,382,438</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c114" decimals="2" format="ixt:num-dot-decimal" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeighted-averageExercisePriceIssued" scale="0" unitRef="usdPershares" id="ixv-25963">1.22</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><ix:nonNumeric contextRef="c114" format="ixt-sec:duryear" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms" id="ixv-21305"><span style="font-family: Times New Roman, Times, Serif">1.93</span></ix:nonNumeric></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c114" decimals="INF" format="ixt:num-dot-decimal" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" scale="0" sign="-" unitRef="shares" id="ixv-25964">1,709,760</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c114" decimals="3" format="ixt:num-dot-decimal" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-25965">0.001</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-70; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Expired</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c114" decimals="INF" format="ixt:num-dot-decimal" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" scale="0" sign="-" unitRef="shares" id="ixv-25966">1,277,350</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c114" decimals="2" format="ixt:num-dot-decimal" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-25967">5.25</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonNumeric contextRef="c114" format="ixt-sec:duryear" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms" id="ixv-21360"><span style="font-family: Times New Roman, Times, Serif">0.54</span></ix:nonNumeric></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Balance as of December 31, 2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c151" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-25968">7,728,611</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c151" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-25969">4.14</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><ix:nonNumeric contextRef="c114" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" id="ixv-21388"><span style="font-family: Times New Roman, Times, Serif">1.63</span></ix:nonNumeric></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 21.8pt"/><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif">2.</span></td><td style="text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" id="ixv-21400"><span style="font-family: Times New Roman, Times, Serif">The following table summarizes information about the Company&#8217;s outstanding warrants as of December 31, 2024</span></ix:nonNumeric></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock-c0_cont_1"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Exercise Price</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Warrants<br/> outstanding</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>as of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>December 31, 2024</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Expiration date</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 41%; text-align: center; padding-left: 2pt"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c152" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" unitRef="usdPershares" id="ixv-25970">5.5</ix:nonFraction></span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c152" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" unitRef="shares" id="ixv-25971">1,640,455</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 40%; text-align: center; padding-left: 1.4pt"><ix:nonNumeric contextRef="c153" format="ixt:date-day-month-year" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" id="ixv-21444"><span style="font-family: Times New Roman, Times, Serif">15/07/2026</span></ix:nonNumeric></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: center; padding-left: 2pt"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c154" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" unitRef="usdPershares" id="ixv-25972">5.5</ix:nonFraction></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c154" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" unitRef="shares" id="ixv-25973">277,835</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: center; padding-left: 1.4pt"><ix:nonNumeric contextRef="c155" format="ixt:date-day-month-year" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" id="ixv-21460"><span style="font-family: Times New Roman, Times, Serif">15/07/2025</span></ix:nonNumeric></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-left: 2pt"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c156" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" unitRef="usdPershares" id="ixv-25974">6.875</ix:nonFraction></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c156" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" unitRef="shares" id="ixv-25975">145,455</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: center; padding-left: 1.4pt"><ix:nonNumeric contextRef="c157" format="ixt:date-day-month-year" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" id="ixv-21476"><span style="font-family: Times New Roman, Times, Serif">15/01/2027</span></ix:nonNumeric></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: center; padding-left: 2pt"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c158" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" unitRef="usdPershares" id="ixv-25976">1.6</ix:nonFraction></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c158" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" unitRef="shares" id="ixv-25977">212,188</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: center; padding-left: 1.4pt"><ix:nonNumeric contextRef="c159" format="ixt:date-day-month-year" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" id="ixv-21492"><span style="font-family: Times New Roman, Times, Serif">28/06/2027</span></ix:nonNumeric></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-left: 2pt"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c160" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" unitRef="usdPershares" id="ixv-25978">1.56</ix:nonFraction></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c160" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" unitRef="shares" id="ixv-25979">185,591</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: center; padding-left: 1.4pt"><ix:nonNumeric contextRef="c161" format="ixt:date-day-month-year" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" id="ixv-21508"><span style="font-family: Times New Roman, Times, Serif">18/06/2028</span></ix:nonNumeric></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: center; padding-left: 2pt"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c162" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" unitRef="usdPershares" id="ixv-25980">1.1</ix:nonFraction></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c162" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" unitRef="shares" id="ixv-25981">4,608,715</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: center; padding-left: 1.4pt"><ix:nonNumeric contextRef="c163" format="ixt:date-day-month-year" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" id="ixv-21524"><span style="font-family: Times New Roman, Times, Serif">30/06/2026</span></ix:nonNumeric></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-left: 2pt"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c164" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" unitRef="usdPershares" id="ixv-25982">0.001</ix:nonFraction></span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c164" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" unitRef="shares" id="ixv-25983">658,372</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: center; padding-left: 1.4pt"><ix:nonNumeric contextRef="c165" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentExpirationDate" id="ixv-21540"><span style="font-family: Times New Roman, Times, Serif">Until fully exercised</span></ix:nonNumeric></td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: center; padding-left: 2pt"><span style="font-family: Times New Roman, Times, Serif">Balance as of December 31, 2024</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c151" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" unitRef="shares" id="ixv-25984">7,728,611</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: center; padding-left: 1.4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> </table></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 155; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>INSPIRA
TECHNOLOGIES OXY B.H.N. LTD.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>In
thousands $ (except share and per share data)</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 11
- SHAREHOLDERS&#8217; EQUITY (CONT.):</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation id="_ShareholdersEquityAndShareBasedPaymentsTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>C.
Loss per share:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="ixv-21603"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Loss
per share has been calculated using the weighted average number of Ordinary Shares and pre-funded warrants in issue during the relevant
financial periods, the weighted average number of equity shares in issue and profit for the period as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December&#160;31,<br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December&#160;31,<br/> 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December&#160;31,<br/> 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Loss
    for the period</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-25985">11,053</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-25986">11,286</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-25987">14,976</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Total number of Ordinary
    Shares</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-25988">24,252,096</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-25989">15,652,176</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c20" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-25990">11,338,940</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Weighted average number of Ordinary Shares
    and pre-funded warrants</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-25991">18,515,545</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-25992">12,095,477</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-25993">10,794,594</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Basic
    and diluted loss per share</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-25994"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-25995">0.60</ix:nonFraction></ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-25996"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-25997">0.93</ix:nonFraction></ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-25998"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-25999">1.39</ix:nonFraction></ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table></ix:nonNumeric></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" id="ixv-21797"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE
12 - RESEARCH AND DEVELOPMENT EXPENSES:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock" id="ixv-21804"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December&#160;31, <br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December&#160;31, <br/> 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December&#160;31, <br/> 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Salary
    and related expenses</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LaborAndRelatedExpense" scale="3" unitRef="usd" id="ixv-26000">4,079</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LaborAndRelatedExpense" scale="3" unitRef="usd" id="ixv-26001">4,429</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LaborAndRelatedExpense" scale="3" unitRef="usd" id="ixv-26002">3,458</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Materials
    and related expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLaborRelatedExpenses" scale="3" unitRef="usd" id="ixv-26003">812</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLaborRelatedExpenses" scale="3" unitRef="usd" id="ixv-26004">1,365</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLaborRelatedExpenses" scale="3" unitRef="usd" id="ixv-26005">1,082</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Share based payment</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="3" unitRef="usd" id="ixv-26006">801</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="3" unitRef="usd" id="ixv-26007">663</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="3" unitRef="usd" id="ixv-26008">2,392</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Depreciation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationNonproduction" scale="3" unitRef="usd" id="ixv-26009">371</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationNonproduction" scale="3" unitRef="usd" id="ixv-26010">291</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationNonproduction" scale="3" unitRef="usd" id="ixv-26011">188</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Subcontractors</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:Subcontractors" scale="3" unitRef="usd" id="ixv-26012">340</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="iinn:Subcontractors" scale="3" unitRef="usd" id="ixv-26013">304</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="iinn:Subcontractors" scale="3" unitRef="usd" id="ixv-26014">850</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">IIA
    participation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:IIAParticipation" scale="3" unitRef="usd" id="ixv-26015">286</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-71; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-72; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-26016">206</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-26017">268</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-26018">213</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-26019">6,323</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-26020">7,320</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-26021">8,183</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 156; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>INSPIRA
                                            TECHNOLOGIES OXY B.H.N. LTD.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>In
thousands $ (except share and per share data)</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="iinn:GeneralAndAdministrativeExpensesTextBlock" id="ixv-22106"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 13
- GENERAL AND ADMINISTRATIVE EXPENSES:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="iinn:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" id="ixv-22112"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December 31, <br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December 31, <br/> 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December 31, <br/> 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Professional fees</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c166" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="3" unitRef="usd" id="ixv-26022">1,758</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c167" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="3" unitRef="usd" id="ixv-26023">1,432</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c168" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="3" unitRef="usd" id="ixv-26024">1,500</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Salary and related expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c166" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OfficersCompensation" scale="3" unitRef="usd" id="ixv-26025">808</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c167" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OfficersCompensation" scale="3" unitRef="usd" id="ixv-26026">766</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c168" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OfficersCompensation" scale="3" unitRef="usd" id="ixv-26027">716</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Share-based payment</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c166" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-26028">716</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c167" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-26029">675</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c168" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-26030">1,984</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Director fees</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c166" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LegalFees" scale="3" unitRef="usd" id="ixv-26031">239</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c167" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LegalFees" scale="3" unitRef="usd" id="ixv-26032">241</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c168" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LegalFees" scale="3" unitRef="usd" id="ixv-26033">239</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Insurance expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c166" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralInsuranceExpense" scale="3" unitRef="usd" id="ixv-26034">196</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c167" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralInsuranceExpense" scale="3" unitRef="usd" id="ixv-26035">300</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c168" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralInsuranceExpense" scale="3" unitRef="usd" id="ixv-26036">557</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Office maintenance</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c166" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostMaintenance" scale="3" unitRef="usd" id="ixv-26037">135</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c167" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostMaintenance" scale="3" unitRef="usd" id="ixv-26038">129</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c168" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostMaintenance" scale="3" unitRef="usd" id="ixv-26039">102</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Depreciation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c166" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-26040">117</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c167" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-26041">115</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c168" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-26042">104</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Travel abroad</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c166" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TravelAndEntertainmentExpense" scale="3" unitRef="usd" id="ixv-26043">104</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c167" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TravelAndEntertainmentExpense" scale="3" unitRef="usd" id="ixv-26044">100</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c168" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TravelAndEntertainmentExpense" scale="3" unitRef="usd" id="ixv-26045">105</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Fundraising expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-73; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c167" decimals="-3" format="ixt:num-dot-decimal" name="iinn:FundraisingExpenses" scale="3" unitRef="usd" id="ixv-26046">260</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-74; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Others</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c166" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherGeneralExpense" scale="3" unitRef="usd" id="ixv-26047">112</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c167" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherGeneralExpense" scale="3" unitRef="usd" id="ixv-26048">45</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c168" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherGeneralExpense" scale="3" unitRef="usd" id="ixv-26049">68</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c166" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-26050">4,185</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c167" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-26051">4,063</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">,<ix:nonFraction contextRef="c168" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-26052">5375</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="iinn:SalesAndMarketingExpensesTextBlock" id="ixv-22465"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 14
- SALES AND MARKETING EXPENSES:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="iinn:ScheduleOfSalesAndMarketingExpensesTableTextBlock" id="ixv-22472"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December&#160;31, <br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December 31,<br/> 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December 31,<br/> 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Salary and related expenses</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OfficersCompensation" scale="3" unitRef="usd" id="ixv-26053">266</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OfficersCompensation" scale="3" unitRef="usd" id="ixv-26054">248</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OfficersCompensation" scale="3" unitRef="usd" id="ixv-26055">282</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Share-based payment</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold" scale="3" unitRef="usd" id="ixv-26056">250</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold" scale="3" unitRef="usd" id="ixv-26057">89</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold" scale="3" unitRef="usd" id="ixv-26058">503</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Professional fees</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="3" unitRef="usd" id="ixv-26059">187</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="3" unitRef="usd" id="ixv-26060">348</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="3" unitRef="usd" id="ixv-26061">527</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherSellingAndMarketingExpense" scale="3" unitRef="usd" id="ixv-26062">51</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherSellingAndMarketingExpense" scale="3" unitRef="usd" id="ixv-26063">61</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherSellingAndMarketingExpense" scale="3" unitRef="usd" id="ixv-26064">16</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="3" unitRef="usd" id="ixv-26065">754</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="3" unitRef="usd" id="ixv-26066">746</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="3" unitRef="usd" id="ixv-26067">1,328</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock" id="ixv-22662"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 15&#8211;
FINANCIAL (INCOME) AND EXPENSES:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="ixv-22669"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December 31, <br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December 31, <br/> 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December 31, <br/> 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Revaluation of financial liabilities
    at fair value through profit or loss</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss" scale="3" unitRef="usd" id="ixv-26068">36</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="iinn:RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss" scale="3" sign="-" unitRef="usd" id="ixv-26069">306</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="iinn:RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss" scale="3" sign="-" unitRef="usd" id="ixv-26070">108</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Foreign currency transaction income</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" sign="-" unitRef="usd" id="ixv-26071">77</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" sign="-" unitRef="usd" id="ixv-26072">233</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" unitRef="usd" id="ixv-26073">530</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Finance expense in respect of lease liability</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-75; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-76; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseInterestExpense" scale="3" unitRef="usd" id="ixv-26074">143</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Others</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashIncomeExpense" scale="3" sign="-" unitRef="usd" id="ixv-26075">1</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashIncomeExpense" scale="3" unitRef="usd" id="ixv-26076">10</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashIncomeExpense" scale="3" sign="-" unitRef="usd" id="ixv-26077">4</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total
    expenses (Income)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" unitRef="usd" id="ixv-26078">42</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" unitRef="usd" id="ixv-26079">529</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" sign="-" unitRef="usd" id="ixv-26080">275</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><!-- Field: Page; Sequence: 157; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>INSPIRA
                                            TECHNOLOGIES OXY B.H.N. LTD.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>In
thousands $ (except share and per share data)</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock" id="ixv-22894"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 16
- TAXES ON INCOME: </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>A.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Taxes
                                            on income:</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Israeli corporate tax rate was <ix:nonFraction contextRef="c169" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" unitRef="pure" id="ixv-26081"><ix:nonFraction contextRef="c170" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" unitRef="pure" id="ixv-26082">23</ix:nonFraction></ix:nonFraction>% in 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>B.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Net
                                            operating losses carry forwards</b>:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Carryforward
tax losses of the Company as of December 31, 2023, amounted to approximately $<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="3" unitRef="usd" id="ixv-26083">24,000</ix:nonFraction>; however, a full valuation allowance of $<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" unitRef="usd" id="ixv-26084">7,000</ix:nonFraction> was
recorded against the potential future tax benefits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Carryforward
tax losses of the Company as of December 31, 2024, amounted to approximately $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="3" unitRef="usd" id="ixv-26085">29,000</ix:nonFraction>; however, a full valuation allowance of $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" unitRef="usd" id="ixv-26086">8,000</ix:nonFraction> was
recorded against the potential future tax benefits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="ixv-22935"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
deferred tax assets and liabilities are composed of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December&#160;31, <br/>
2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December&#160;31, <br/>
2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Deferred tax assets:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net
    operating loss carryforward</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" unitRef="usd" id="ixv-26087">6,739</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" unitRef="usd" id="ixv-26088">5,519</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued
    expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="iinn:DeferredTaxAssetsAccruedExpenses" scale="3" unitRef="usd" id="ixv-26089">97</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="iinn:DeferredTaxAssetsAccruedExpenses" scale="3" unitRef="usd" id="ixv-26090">80</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">R&amp;D
    temporary differences</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" unitRef="usd" id="ixv-26091">1,218</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" unitRef="usd" id="ixv-26092">1,335</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Fund raising costs
    2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="iinn:DeferredTaxAssetsFundRaisingCost2023" scale="3" unitRef="usd" id="ixv-26093">35</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="iinn:DeferredTaxAssetsFundRaisingCost2023" scale="3" unitRef="usd" id="ixv-26094">70</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Operating
    lease liability</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="iinn:DeferredTaxLiabilitiesOperatingLeaseLiability" scale="3" sign="-" unitRef="usd" id="ixv-26095">8</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="iinn:DeferredTaxLiabilitiesOperatingLeaseLiability" scale="3" sign="-" unitRef="usd" id="ixv-26096">8</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total
    deferred tax assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" unitRef="usd" id="ixv-26097">8,097</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" unitRef="usd" id="ixv-26098">7,012</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Valuation
    allowance</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd" id="ixv-26099">8,097</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd" id="ixv-26100">7,012</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred
    tax liabilities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    deferred tax liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-77; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-78; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Net
    deferred taxes</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-79; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-80; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><ix:nonNumeric contextRef="c0" continuedAt="iinn_ScheduleOfTheoreticalTaxTableTextBlock-c0_cont_1" escape="true" name="iinn:ScheduleOfTheoreticalTaxTableTextBlock" id="ixv-23169"><span style="font-family: Times New Roman, Times, Serif"><b>C.</b></span></ix:nonNumeric></td><td style="text-align: justify"><ix:continuation continuedAt="iinn_ScheduleOfTheoreticalTaxTableTextBlock-c0_cont_2" id="iinn_ScheduleOfTheoreticalTaxTableTextBlock-c0_cont_1"><span style="font-family: Times New Roman, Times, Serif"><b>Theoretical tax:</b></span></ix:continuation></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:continuation id="iinn_ScheduleOfTheoreticalTaxTableTextBlock-c0_cont_2"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December&#160;31,<br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December&#160;31,<br/> 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December&#160;31,<br/> 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Loss before taxation</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-26101">11,053</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-26102">11,286</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-26103">14,976</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Theoretical tax credit at applicable statutory rate: <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-26104"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-26105"><ix:nonFraction contextRef="c7" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-26106">23</ix:nonFraction></ix:nonFraction></ix:nonFraction>%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:EffectiveIncomeTaxTheoreticalTaxCredit" scale="3" unitRef="usd" id="ixv-26107">2,542</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="iinn:EffectiveIncomeTaxTheoreticalTaxCredit" scale="3" unitRef="usd" id="ixv-26108">2,596</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="iinn:EffectiveIncomeTaxTheoreticalTaxCredit" scale="3" unitRef="usd" id="ixv-26109">3,444</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Non-allowable expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="3" unitRef="usd" id="ixv-26110">391</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="3" unitRef="usd" id="ixv-26111">244</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="3" unitRef="usd" id="ixv-26112">1,026</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Temporary
    differences and tax losses for which no Deferred Tax Asset is recognized</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized" scale="3" unitRef="usd" id="ixv-26113">2,151</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="iinn:TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized" scale="3" unitRef="usd" id="ixv-26114">2,352</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="iinn:TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized" scale="3" unitRef="usd" id="ixv-26115">2,418</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Income tax benefit</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-81; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-82; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-83; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 158; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>INSPIRA
                                            TECHNOLOGIES OXY B.H.N. LTD.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>In
thousands $ (except share and per share data)</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_1" escape="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="ixv-23399"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 17
&#8211; SHARE-BASED PAYMENT:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">1.&#160;
On March 24, 2022, the Company&#8217;s board of directors (&#8220;Board of directors&#8221;) approved a grant of <ix:nonFraction contextRef="c171" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" unitRef="shares" id="ixv-26116">536,141</ix:nonFraction> RSUs to employees
and a grant of <ix:nonFraction contextRef="c172" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" unitRef="shares" id="ixv-26117">22,500</ix:nonFraction> RSUs to the Company&#8217;s advisory board members and an additional consultant. The RSUs represent the right to
receive Ordinary Shares at a future time. <ix:nonFraction contextRef="c173" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" unitRef="shares" id="ixv-26118">555,500</ix:nonFraction> of the RSUs in this grant, vest over a period of <ix:nonNumeric contextRef="c174" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="ixv-26119">three years</ix:nonNumeric>, with a 1-year cliff period,
and <ix:nonFraction contextRef="c174" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" unitRef="shares" id="ixv-26120">3,141</ix:nonFraction> RSUs vested immediately on the grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">2.&#160;
On March 24, 2022, the Company&#8217;s Board of Directors approved a grant of <ix:nonFraction contextRef="c175" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" unitRef="shares" id="ixv-26121">29,400</ix:nonFraction> Ordinary Shares options to medical board members,
which are exercisable to <ix:nonFraction contextRef="c176" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-26122">29,400</ix:nonFraction> Ordinary Shares. The share options vesting period is up to <ix:nonNumeric contextRef="c177" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="ixv-26123">three years</ix:nonNumeric> from the grant date. The exercise
price per share was NIS <ix:nonFraction contextRef="c178" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-26124">10.84</ix:nonFraction> ($<ix:nonFraction contextRef="c178" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-26125">3.08</ix:nonFraction>). The contractual life of the options under the 2019 Equity Incentive Plan is <ix:nonNumeric contextRef="c179" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" id="ixv-26126">ten</ix:nonNumeric> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">3.&#160;
On April 6, 2022, the Company&#8217;s Board of Directors approved a grant of <ix:nonFraction contextRef="c180" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" unitRef="shares" id="ixv-26127">285,713</ix:nonFraction> fully vested RSUs to an officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">4.&#160;
On May 19, 2022, the Company&#8217;s Board of Directors approved a grant of <ix:nonFraction contextRef="c181" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" unitRef="shares" id="ixv-26128">30,000</ix:nonFraction> RSUs to an employee. The RSUs vest over a period of
<ix:nonNumeric contextRef="c182" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="ixv-26129">three years</ix:nonNumeric>, with a 1-year cliff period, commencing on the grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">5.&#160;
On November 22, 2022, the Company&#8217;s Board of Directors approved a grant of <ix:nonFraction contextRef="c183" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" unitRef="shares" id="ixv-26130">165,000</ix:nonFraction> RSUs to employees. The RSUs vest over a period
of <ix:nonNumeric contextRef="c184" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="ixv-26131">three years</ix:nonNumeric>, with a 1-year cliff period, commencing on the grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">6.&#160;
On January 22, 2024, the Company&#8217;s Board of Directors approved a grant of <ix:nonFraction contextRef="c185" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" unitRef="shares" id="ixv-26132">320,000</ix:nonFraction> RSUs to employees and a grant of options to purchase
<ix:nonFraction contextRef="c186" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" scale="0" unitRef="shares" id="ixv-26133">80,000</ix:nonFraction> shares to consultants. The RSUs represents the right to receive Ordinary Shares at a future time, <ix:nonFraction contextRef="c187" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" unitRef="shares" id="ixv-26134">245,000</ix:nonFraction> of which vest over a
period of <ix:nonNumeric contextRef="c186" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="ixv-26135">three years</ix:nonNumeric>, with a one-year cliff period and <ix:nonFraction contextRef="c188" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" scale="0" unitRef="shares" id="ixv-26136">70,000</ix:nonFraction> vesting immediately on the grant date. <ix:nonFraction contextRef="c189" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" unitRef="shares" id="ixv-26137">10,000</ix:nonFraction> of the options were vested
immediately on the grant date, <ix:nonFraction contextRef="c190" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" unitRef="shares" id="ixv-26138">25,000</ix:nonFraction> option vest over a period of <ix:nonNumeric contextRef="c191" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="ixv-26139">three years</ix:nonNumeric> and <ix:nonFraction contextRef="c192" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" unitRef="shares" id="ixv-26140">45,000</ix:nonFraction> option vests over a period of one year and
nine months. The RSUs designated to employees were granted under Section 102 of the Israeli Tax Ordinance, which enables the employee
to pay a <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="iinn:CapitalGainTaxRate" scale="-2" unitRef="pure" id="ixv-26141">25</ix:nonFraction>% capital gain tax upon exercise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">7.&#160;
On February 5, 2024, the Company&#8217;s Board of Directors approved a grant of <ix:nonFraction contextRef="c193" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-26142">2,277,000</ix:nonFraction> RSUs to officers, a grant of options to purchase
<ix:nonFraction contextRef="c194" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" scale="0" unitRef="shares" id="ixv-26143">30,000</ix:nonFraction> Ordinary Shares and <ix:nonFraction contextRef="c195" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" unitRef="shares" id="ixv-26144">90,000</ix:nonFraction> RSUs to directors. The RSUs and options represents the right to receive Ordinary Shares at a future
time and vest over a period of <ix:nonNumeric contextRef="c193" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="ixv-26145">three years</ix:nonNumeric>, with a one-year cliff. The RSUs designated to employees and directors were granted under
Section 102 of the Israeli Tax Ordinance, which enables the employee to pay a <ix:nonFraction contextRef="c196" decimals="2" format="ixt:num-dot-decimal" name="iinn:PercentageOfCapitalGainTax" scale="-2" unitRef="pure" id="ixv-26146">25</ix:nonFraction>% capital gain tax upon exercise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
fair value of all granted options was estimated by using the Black Scholes option pricing model, which was aimed to model the value of
the Company&#8217;s assets over time. The simulation approach was designed to take into account the terms and conditions of the share
options, as well as the capital structure of the Company and the volatility of its assets, on the date of grant based on certain assumptions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="ixv-23438"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
following inputs were used to measure the fair value of the option at grant date:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">March
    24, 2022</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">January
    22, 2024</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">February
    5, 2024</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif">(i)</span></td>
    <td style="width: 47%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Expected volatility</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 15%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c178" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-26147">52</ix:nonFraction>%</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 15%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c189" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-26148">144.83</ix:nonFraction>%</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 15%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c196" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-26149">143.98</ix:nonFraction>%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">(ii)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Dividend rate</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c178" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure" id="ixv-26150">0</ix:nonFraction>%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c189" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure" id="ixv-26151">0</ix:nonFraction>%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c196" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure" id="ixv-26152">0</ix:nonFraction>%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">(iii)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Expected term (vesting period)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three years</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three years</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="-sec-ix-hidden: hidden-fact-84; font-family: Times New Roman, Times, Serif">Three years</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">(iv)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Contractual life</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Ten years</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Ten years</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="-sec-ix-hidden: hidden-fact-85; font-family: Times New Roman, Times, Serif">Ten years</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">(v)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Free risk rate</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c200" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-26153">2.79</ix:nonFraction>%-<ix:nonFraction contextRef="c201" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-26154">2.80</ix:nonFraction>%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c202" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-26155">4.03</ix:nonFraction>%-<ix:nonFraction contextRef="c203" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-26156">4.07</ix:nonFraction>%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c196" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-26157">4.16</ix:nonFraction>%</span></td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 159; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>INSPIRA
                                            TECHNOLOGIES OXY B.H.N. LTD.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>In
thousands $ (except share and per share data)</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 17
&#8211; SHARE-BASED PAYMENT (CONT.):</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_2" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
fair value of all granted RSUs was the Company&#8217;s quote price at the grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">During the
year ended December 31, 2024, the Company recorded share-based payment expenses to employees, directors and subcontractors in the amount
of $<ix:nonFraction contextRef="c197" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-26158">1,767</ix:nonFraction>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">During the
year ended December 31, 2023, the Company recorded share-based payment expenses to employees, directors and subcontractors in the amount
of $<ix:nonFraction contextRef="c198" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-26159">1,427</ix:nonFraction>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">During the
year ended December 31, 2022, the Company recorded share-based payment expenses to employees, directors and subcontractors in the amount
of $<ix:nonFraction contextRef="c199" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-26160">4,879</ix:nonFraction>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="ixv-23605"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The options
to services providers and advisers outstanding as December 31, 2024, 2023 and 2022 were as&#160;follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>


<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December 31, 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December 31, 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December 31, 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number
    of <br/> options</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted
    <br/> average <br/> Exercise <br/> price NIS</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number
    of <br/> options</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted
    <br/> average <br/> Exercise <br/> price NIS</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number
    of<br/> options</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted
    <br/> average <br/> Exercise <br/> price NIS</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Outstanding at beginning of year</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c204" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-26161">105,111</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c204" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-26162">4.085</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c205" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-26163">114,512</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c205" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-26164">3.058</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c206" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-26165">87,833</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c206" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-26166">0.37</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Reclassified to employees and directors</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-86; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-87; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-88; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-89; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-90; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-91; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c207" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-26167">80,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c207" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-26168">3.779</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-92; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-93; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c209" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-26169">29,400</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c209" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-26170">10.84</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-94; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-95; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c208" decimals="INF" format="ixt:num-dot-decimal" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi" scale="0" unitRef="shares" id="ixv-26171">9,401</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c208" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-26172">0.367</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c209" decimals="INF" format="ixt:num-dot-decimal" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi" scale="0" sign="-" unitRef="shares" id="ixv-26173">2,721</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c209" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-26174">0.37</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-96; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-97; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-98; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-99; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-100; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-101; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 1.1pt"><span style="font-family: Times New Roman, Times, Serif">Options
    outstanding</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c210" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-26175">185,111</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c210" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-26176">3.359</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c204" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-26177">105,111</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c204" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-26178">4.085</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c205" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-26179">114,512</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c205" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-26180">3.058</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 1.1pt"><span style="font-family: Times New Roman, Times, Serif">Options
    exercisable</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c210" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-26181">162,154</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c210" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-26182">3.251</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c204" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-26183">94,242</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c204" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-26184">3.267</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c205" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-26185">82,257</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c205" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-26186">0.37</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 1.1pt"><span style="font-family: Times New Roman, Times, Serif">Share-based
    payment expenses</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c207" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-26187">66</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c208" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-26188">19</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c209" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-26189">54</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:nonNumeric>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="ixv-24136"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The RSUs
to services providers and advisers outstanding as of December 31, 2024, 2023 and 2022 were as&#160;follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>


<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December 31, <br/>
2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December 31, <br/>
2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December 31, <br/>
2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number
    of <br/>
RSUs</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number
    of <br/>
RSUs</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number
    of <br/>
RSUs</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Outstanding at beginning of year</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c218" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-26190">7,433</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c219" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-26191">18,266</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c220" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-26192">10,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-107; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-108; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c104" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" unitRef="shares" id="ixv-26193">22,500</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Vested</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c146" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" unitRef="shares" id="ixv-26194">7,433</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c221" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" unitRef="shares" id="ixv-26195">10,833</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c104" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" unitRef="shares" id="ixv-26196">14,234</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 1.1pt"><span style="font-family: Times New Roman, Times, Serif">RSUs
    outstanding</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-109; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c218" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-26197">7,433</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c219" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-26198">18,266</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 1.1pt"><span style="font-family: Times New Roman, Times, Serif">RSU&#8217;s
    Vested</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c146" decimals="INF" format="ixt:num-dot-decimal" name="iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested" scale="0" unitRef="shares" id="ixv-26199">32,500</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c221" decimals="INF" format="ixt:num-dot-decimal" name="iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested" scale="0" unitRef="shares" id="ixv-26200">25,067</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c104" decimals="INF" format="ixt:num-dot-decimal" name="iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested" scale="0" unitRef="shares" id="ixv-26201">14,234</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 1.1pt"><span style="font-family: Times New Roman, Times, Serif">Share-based
    payment expenses</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c146" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-26202">1</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c221" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-26203">9</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c104" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-26204">33</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:nonNumeric></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 160; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>INSPIRA
TECHNOLOGIES OXY B.H.N. LTD.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>In
thousands $ (except share and per share data)</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 17
- SHARE BASED PAYMENT (CONT.):</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_2"><ix:continuation id="_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The options
to employees and directors outstanding as of December 31, 2024, 2023 and 2022 were as&#160;follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>




<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December 31, 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December 31, 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December 31, 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number
    of <br/> options</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted
    <br/> average <br/> Exercise <br/> price NIS</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number
    of <br/> options</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted
    <br/> average <br/> Exercise <br/> price NIS</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number
    of <br/> options</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted
    <br/> average <br/> Exercise <br/> price NIS</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Outstanding at beginning of year</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c211" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-26205">357,689</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c211" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-26206">0.37</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c212" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-26207">386,260</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c212" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-26208">0.37</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c213" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-26209">448,120</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c213" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-26210">0.37</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c214" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-26211">30,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c214" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-26212">3.56</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-102; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-103; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-104; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c214" decimals="INF" format="ixt:num-dot-decimal" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi" scale="0" unitRef="shares" id="ixv-26213">19,048</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c214" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-26214">0.37</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c215" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-26215">0.37</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c216" decimals="INF" format="ixt:num-dot-decimal" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi" scale="0" unitRef="shares" id="ixv-26216">4,309</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c216" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-26217">0.37</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-105; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-106; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c215" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" unitRef="shares" id="ixv-26218">28,571</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c215" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-26219">0.37</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c216" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" unitRef="shares" id="ixv-26220">57,551</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c216" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-26221">0.37</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 1.1pt"><span style="font-family: Times New Roman, Times, Serif">Options
    outstanding</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c217" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-26222">368,641</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c217" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-26223">0.70</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c211" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-26224">357,689</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c211" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-26225">0.37</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c212" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-26226">386,260</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c212" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-26227">0.37</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 1.1pt"><span style="font-family: Times New Roman, Times, Serif">Options
    exercisable</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c217" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-26228">338,641</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c217" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-26229">0.45</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c211" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-26230">350,131</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c211" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-26231">0.37</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c212" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-26232">342,757</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c212" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="ilsPershares" id="ixv-26233">0.37</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 1.1pt"><span style="font-family: Times New Roman, Times, Serif">Share-based
    payment expenses</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c214" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-26234">17</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c215" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-26235">47</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c216" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-26236">174</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The RSUs
to employees and directors outstanding as of December 31, 2024, 2023 and 2022 were as&#160;follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December&#160;31, <br/>
    2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December&#160;31, <br/>
    2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December&#160;31, <br/>
    2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number
    of<br/>
 RSUs</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number
    of<br/>
 RSUs</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number
    of<br/>
 RSUs</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Outstanding at beginning of year</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-26237">445,140</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c20" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-26238">1,727,842</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c27" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-26239">2,002,587</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" unitRef="shares" id="ixv-26240">2,687,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-110; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" unitRef="shares" id="ixv-26241">1,016,854</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" unitRef="shares" id="ixv-26242">25,836</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" unitRef="shares" id="ixv-26243">67,087</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" unitRef="shares" id="ixv-26244">65,626</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Vested</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" unitRef="shares" id="ixv-26245">587,508</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" unitRef="shares" id="ixv-26246">1,215,615</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" unitRef="shares" id="ixv-26247">1,225,973</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 1.1pt"><span style="font-family: Times New Roman, Times, Serif">RSUs
    outstanding</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-26248">2,518,796</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-26249">445,140</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c20" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-26250">1,727,842</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 1.1pt"><span style="font-family: Times New Roman, Times, Serif">RSU&#8217;s
    Vested</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested" scale="0" unitRef="shares" id="ixv-26251">3,684,697</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" name="iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested" scale="0" unitRef="shares" id="ixv-26252">3,097,189</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested" scale="0" unitRef="shares" id="ixv-26253">1,881,574</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 1.1pt"><span style="font-family: Times New Roman, Times, Serif">Share-based
    payment expenses</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-26254">1,683</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-26255">1,352</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-26256">4,618</ix:nonFraction></span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 161; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>INSPIRA
                                            TECHNOLOGIES OXY B.H.N. LTD.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>NOTES
TO FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>In
thousands $ (except share and per share data)</b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="ixv-25157"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE
18 - RELATED PARTIES:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>The following
transactions arose with related parties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Transactions
and balances with related parties</span><b>:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td> <td style="text-align: justify"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfRelatedPartyTransactionsTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" id="ixv-25182"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Shareholders and other related parties&#8217; benefits</span></span></ix:nonNumeric></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_ScheduleOfRelatedPartyTransactionsTableTextBlock-c0_cont_2" id="_ScheduleOfRelatedPartyTransactionsTableTextBlock-c0_cont_1"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December&#160;31,
    <br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December&#160;31,
    <br/> 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December&#160;31,<br/>
    2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Salary and related expenses &#8211;
    officers and directors</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c223" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OfficersCompensation" scale="3" unitRef="usd" id="ixv-26257">1,710</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c224" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OfficersCompensation" scale="3" unitRef="usd" id="ixv-26258">1,761</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c225" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OfficersCompensation" scale="3" unitRef="usd" id="ixv-26259">1,923</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Share based payment &#8211; officers and directors</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c223" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-26260">1,376</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c224" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-26261">1,009</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c225" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-26262">3,745</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td> <td style="text-align: justify"><ix:continuation continuedAt="_ScheduleOfRelatedPartyTransactionsTableTextBlock-c0_cont_3" id="_ScheduleOfRelatedPartyTransactionsTableTextBlock-c0_cont_2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Balances with related parties</span></span></ix:continuation></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_ScheduleOfRelatedPartyTransactionsTableTextBlock-c0_cont_3"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Name</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Nature of transaction</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December&#160;31, <br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December&#160;31, <br/> 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 20%"><span style="font-family: Times New Roman, Times, Serif">Officers</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 55%; text-align: left"><ix:nonNumeric contextRef="c226" name="us-gaap:NatureOfCommonOwnershipOrManagementControlRelationships" id="ixv-25310"><span style="font-family: Times New Roman, Times, Serif">Salaries and related</span></ix:nonNumeric></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c226" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="3" sign="-" unitRef="usd" id="ixv-26263">381</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c227" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="3" sign="-" unitRef="usd" id="ixv-26264">314</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif">Directors</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><ix:nonNumeric contextRef="c228" name="us-gaap:NatureOfCommonOwnershipOrManagementControlRelationships" id="ixv-25334"><span style="font-family: Times New Roman, Times, Serif">Compensation for directors</span></ix:nonNumeric></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c228" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="3" sign="-" unitRef="usd" id="ixv-26265">40</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c229" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="3" sign="-" unitRef="usd" id="ixv-26266">40</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> </table></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:SubsequentEventsTextBlock" id="ixv-25356"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 19
- SUBSEQUENT EVENTS:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 17.85pt"/><td style="width: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">1.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Following the closing of the December Private Placement, $<ix:nonFraction contextRef="c230" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="3" unitRef="usd" id="ixv-26267">70</ix:nonFraction> was wired to the Company from one of the investors before the end of the year but was registered by the receiving bank in January 2025. As a result, $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromBankDebt" scale="3" unitRef="usd" id="ixv-26268">70</ix:nonFraction> were not included in the cash and cash equivalent as of December 31, 2024. The private offering fees and other related expenses in the amount of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="iinn:OfferingFeesAndOtherRelatedExpenses" scale="3" unitRef="usd" id="ixv-26269">220</ix:nonFraction> were paid by the Company after the end of the year.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">2.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">During January and February 2025, the Company received funds in the amount of NIS <ix:nonFraction contextRef="c231" decimals="0" format="ixt:num-dot-decimal" name="iinn:ProceedsFromReceivedFund" scale="0" unitRef="ils" id="ixv-26270">238,122</ix:nonFraction> (approximately $<ix:nonFraction contextRef="c232" decimals="-3" format="ixt:num-dot-decimal" name="iinn:ProceedsFromReceivedFund" scale="3" unitRef="usd" id="ixv-26271">66</ix:nonFraction>) from the IIA.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 17.85pt"/><td style="width: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">3.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On February 20, 2025, the Company&#8217;s Board of Directors approved a grant of <ix:nonFraction contextRef="c233" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-26272">676,000</ix:nonFraction> RSUs to employees and options to purchase an aggregate of <ix:nonFraction contextRef="c234" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" unitRef="shares" id="ixv-26273">50,000</ix:nonFraction> Ordinary Shares to service providers under the 2019 Equity Incentive Plan. <ix:nonFraction contextRef="c233" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" scale="0" unitRef="shares" id="ixv-26274">20,166</ix:nonFraction> RSUs are vested as of the date of these Financial Statements. <span style="-sec-ix-hidden: hidden-fact-111">None</span> of the total amount of the options are vested as of the date of these Financial Statements. The total grant fair value is approximately $<ix:nonFraction contextRef="c233" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="3" unitRef="usd" id="ixv-26275">656</ix:nonFraction> that will be registered as expenses in the upcoming vesting period of <ix:nonNumeric contextRef="c233" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="ixv-26276">three years</ix:nonNumeric>.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 17.85pt"/><td style="width: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">4.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On February 20, 2025, the Company&#8217;s Board of Directors approved a grant of <ix:nonFraction contextRef="c235" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-26277">550,000</ix:nonFraction> RSUs to certain of its executives. <span style="-sec-ix-hidden: hidden-fact-112">None</span> of the total amount of RSUs are vested as of the date of these Financial Statements. The total grant fair value is approximately $<ix:nonFraction contextRef="c235" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="3" unitRef="usd" id="ixv-26278">494</ix:nonFraction> that will be registered as expenses in the upcoming vesting period of <ix:nonNumeric contextRef="c235" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="ixv-26279">three years</ix:nonNumeric>.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">5.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On February 20, 2025, the Company&#8217;s Board of Directors approved a grant of <ix:nonFraction contextRef="c236" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-26280">1,810,000</ix:nonFraction> RSUs to certain of its executives. The approval is subject to shareholder approval. <span style="-sec-ix-hidden: hidden-fact-113">None</span> of the total amount of RSUs are vested as of the date of these Financial Statements. The total grant fair value is approximately $<ix:nonFraction contextRef="c236" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" unitRef="usd" id="ixv-26281">1.6</ix:nonFraction> million that will be registered as expenses in the upcoming vesting period of <ix:nonNumeric contextRef="c236" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="ixv-26282">three years</ix:nonNumeric>.</span></td></tr></table></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.7pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.7pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">F-33</span></p><div>














































</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="c0" id="hidden-fact-0" name="dei:DocumentAccountingStandard">U.S. GAAP</ix:nonNumeric>
<ix:nonFraction contextRef="c5" id="hidden-fact-1" name="us-gaap:InventoryNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-2" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-3" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-4" name="us-gaap:CommonStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-5" name="us-gaap:CommonStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-6" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-7" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-8" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-9" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-10" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-11" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-12" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-13" name="iinn:ExerciseOfJune2024PrefundedWarrantsIntoOrdinaryShares" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-14" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-15" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-16" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-17" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-18" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-19" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-20" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-21" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-22" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-23" name="iinn:StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-24" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-25" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-26" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-27" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c29" id="hidden-fact-28" name="iinn:StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c30" id="hidden-fact-29" name="iinn:StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-30" name="iinn:StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c29" id="hidden-fact-31" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c30" id="hidden-fact-32" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-33" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c30" id="hidden-fact-34" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c29" id="hidden-fact-35" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-36" name="us-gaap:ProvisionForOtherLosses" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-37" name="us-gaap:ProvisionForOtherLosses" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-38" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-39" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-40" name="iinn:ExpirationOfFinancialLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-41" name="iinn:ExpirationOfFinancialLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-42" name="us-gaap:AmortizationOfFinancingCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-43" name="us-gaap:AmortizationOfFinancingCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-44" name="iinn:IssuanceOfOrdinarySharesAdvisorFees" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-45" name="iinn:IssuanceOfOrdinarySharesAdvisorFees" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-46" name="us-gaap:IncreaseDecreaseInInventories" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-47" name="us-gaap:IncreaseDecreaseInInventories" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-48" name="us-gaap:ProceedsFromIssuanceOfWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-49" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-50" name="us-gaap:ProceedsFromWarrantExercises" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-51" name="us-gaap:ProceedsFromWarrantExercises" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-52" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-53" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-54" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-55" name="iinn:OtherReceivableInConnectionToPrivatePlacement" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-56" name="iinn:OtherReceivableInConnectionToPrivatePlacement" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-57" name="iinn:AccruedIssuanceExpenses" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-58" name="iinn:AccruedIssuanceExpenses" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-59" name="iinn:FinancialLiabilityPlacementAgentFee" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-60" name="iinn:FinancialLiabilityPlacementAgentFee" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-61" name="iinn:ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-62" name="iinn:NonCashTransactions" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-63" name="us-gaap:InventoryRawMaterials" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-64" name="us-gaap:InventoryWorkInProcess" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-65" name="us-gaap:InventoryFinishedGoods" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-66" name="us-gaap:InventoryNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c54" id="hidden-fact-67" name="us-gaap:PropertyPlantAndEquipmentAdditions" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c65" id="hidden-fact-68" name="us-gaap:PropertyPlantAndEquipmentAdditions" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c77" id="hidden-fact-69" name="us-gaap:PropertyPlantAndEquipmentAdditions" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c114" id="hidden-fact-70" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms" xsi:nil="true"></ix:nonNumeric>
<ix:nonFraction contextRef="c6" id="hidden-fact-71" name="iinn:IIAParticipation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-72" name="iinn:IIAParticipation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c166" id="hidden-fact-73" name="iinn:FundraisingExpenses" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c168" id="hidden-fact-74" name="iinn:FundraisingExpenses" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-75" name="us-gaap:FinanceLeaseInterestExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-76" name="us-gaap:FinanceLeaseInterestExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-77" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-78" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-79" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-80" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-81" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-82" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c7" id="hidden-fact-83" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c196" id="hidden-fact-84" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">P3Y</ix:nonNumeric>
<ix:nonNumeric contextRef="c196" id="hidden-fact-85" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife">P10Y</ix:nonNumeric>
<ix:nonFraction contextRef="c207" id="hidden-fact-86" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsReclassifiedToEmployeesAndDirectors" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c207" id="hidden-fact-87" name="iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceReclassifiedToEmployeesAndDirectors" unitRef="ilsPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c208" id="hidden-fact-88" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsReclassifiedToEmployeesAndDirectors" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c208" id="hidden-fact-89" name="iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceReclassifiedToEmployeesAndDirectors" unitRef="ilsPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c209" id="hidden-fact-90" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsReclassifiedToEmployeesAndDirectors" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c209" id="hidden-fact-91" name="iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceReclassifiedToEmployeesAndDirectors" unitRef="ilsPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c208" id="hidden-fact-92" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c208" id="hidden-fact-93" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="ilsPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c207" id="hidden-fact-94" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c207" id="hidden-fact-95" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="ilsPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c207" id="hidden-fact-96" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c207" id="hidden-fact-97" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="ilsPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c208" id="hidden-fact-98" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c208" id="hidden-fact-99" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="ilsPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c209" id="hidden-fact-100" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c209" id="hidden-fact-101" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="ilsPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c215" id="hidden-fact-102" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c215" id="hidden-fact-103" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="ilsPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c216" id="hidden-fact-104" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="ilsPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c214" id="hidden-fact-105" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c214" id="hidden-fact-106" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="ilsPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c146" id="hidden-fact-107" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c221" id="hidden-fact-108" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c222" id="hidden-fact-109" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-110" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c233" id="hidden-fact-111" name="iinn:RestrictedStockUnits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c235" id="hidden-fact-112" name="iinn:RestrictedStockUnits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c236" id="hidden-fact-113" name="iinn:RestrictedStockUnits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey" id="ixv-26399">0001837493</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag" id="ixv-26400">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalPeriodFocus" id="ixv-26401">FY</ix:nonNumeric>
<ix:nonNumeric contextRef="c178" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-26402">P3Y</ix:nonNumeric><!--From Schedule of Measure the Fair Value of the Option at Grant Date with text 'Three years'-->
<ix:nonNumeric contextRef="c189" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-26403">P3Y</ix:nonNumeric><!--From Schedule of Measure the Fair Value of the Option at Grant Date with text 'Three years'-->
<ix:nonNumeric contextRef="c178" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife" id="ixv-26404">P10Y</ix:nonNumeric><!--From Schedule of Measure the Fair Value of the Option at Grant Date with text 'Ten years'-->
<ix:nonNumeric contextRef="c189" name="iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife" id="ixv-26405">P10Y</ix:nonNumeric><!--From Schedule of Measure the Fair Value of the Option at Grant Date with text 'Ten years'-->
</ix:hidden>
<ix:references><link:schemaRef xlink:href="iinn-20241231.xsd" xlink:type="simple"/></ix:references>
<ix:resources xmlns="http://www.xbrl.org/2003/instance"><ix:relationship xmlns="" fromRefs="hidden-fact-28" toRefs="ix_0_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_0_fact hidden-fact-65" toRefs="ix_1_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_1_fact" toRefs="ix_2_footnote"/>
<xbrli:context xmlns="" id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">iinn:OrdinarySharesNoParValueMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">iinn:WarrantsToPurchaseOrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-10-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2024-04-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-06-14</xbrli:startDate>
    <xbrli:endDate>2024-06-14</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:PreFundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-14</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:PreFundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-06-14</xbrli:startDate>
    <xbrli:endDate>2024-06-14</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-14</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:JunePreFundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-14</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-06-14</xbrli:startDate>
    <xbrli:endDate>2024-06-14</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:JunePlacementAgentWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-06-14</xbrli:startDate>
    <xbrli:endDate>2024-06-14</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">iinn:DecemberPrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-12-27</xbrli:startDate>
    <xbrli:endDate>2024-12-27</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">iinn:DecemberPrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:DecemberPreFundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-12-27</xbrli:startDate>
    <xbrli:endDate>2024-12-27</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:PreFundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:DecemberPreFundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-12-27</xbrli:startDate>
    <xbrli:endDate>2024-12-27</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-12-27</xbrli:startDate>
    <xbrli:endDate>2024-12-27</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">iinn:BankLeumiMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">iinn:BankLeumiMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">iinn:RDEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">iinn:RDEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">iinn:RDEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">iinn:RDEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">iinn:RDEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-09-01</xbrli:startDate>
    <xbrli:endDate>2019-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-31</xbrli:startDate>
    <xbrli:endDate>2023-10-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">iinn:December2024PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">iinn:December2024PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">iinn:December2024PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">iinn:December2024PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c88">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c89">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-12-26</xbrli:startDate>
    <xbrli:endDate>2023-12-26</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c90">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:PrivateWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-26</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c91">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c92">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c93">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c94">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c95">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c96">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c97">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c98">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c99">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:PrivateWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c100">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:PrivateWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c101">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">iinn:PrivateWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c102">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">iinn:PrivateWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c103">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c104">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c105">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">iinn:RothCapitalPartnersLLCMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c106">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">iinn:RegisteredDirectOfferingMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-12-26</xbrli:startDate>
    <xbrli:endDate>2023-12-26</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c107">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-26</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c108">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:PreFundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-26</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c109">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:PreFundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-26</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c110">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:PreFundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-26</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c111">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:PreFundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c112">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:PreFundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c113">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">iinn:RegisteredDirectOfferingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c114">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c115">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:PlacementAgentWarrantsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c116">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:PlacementAgentWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c117">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:PlacementAgentWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrarGpi3WKEtaAw66u01Fz01dWXY8Co/0nt/EYPpxJQpmucNPntkKGDUIzqiVXTghuh97D+3HoPuNe26jHPIaw4lyMqYvKxFlhkbYBWIUcgKRgNZdvBJC1M0l0xZMZd9F+M0zfHyxoKPMqOYWCT/B42d+bXUalw9kCR7ECrTZgyIl6CQNUWcHwWg7YyEKbKXVQrc457FUG7zZJKYSUUC+IL4iKzuqc3lzwnQ2dokFxrCaevH4cZ3wAdRaitsTLXse0F0xvf4jN2RRHLlyM3FMFitrs00ViK9yaE=] CSR-->
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c118">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c119">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">iinn:TwoThousandTwentyFourAprilOfferingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2024-04-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c120">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">iinn:TwoThousandTwentyFourAprilOfferingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c121">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-05-20</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c122">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-05-20</xbrli:startDate>
    <xbrli:endDate>2024-05-20</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c123">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">iinn:TwoThousandTwentyFourJuneOfferingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-06-14</xbrli:startDate>
    <xbrli:endDate>2024-06-14</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c124">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">iinn:TwoThousandTwentyFourJuneOfferingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-14</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c125">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:JunePreFundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-14</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c126">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:JunePreFundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-14</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c127">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:JunePreFundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-06-14</xbrli:startDate>
    <xbrli:endDate>2024-06-14</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c128">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:JunePreFundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c129">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:TwoThousandTwentyFourJuneOfferingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c130">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:TwoThousandTwentyFourJuneOfferingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c131">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:JunePreFundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c132">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:JunePlacementAgentWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c133">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:JunePlacementAgentWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c134">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:JunePlacementAgentWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-14</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c135">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-06-30</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c136">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:DecemberPrivateWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-12-27</xbrli:startDate>
    <xbrli:endDate>2024-12-27</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c137">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:DecemberPrivateWarrantsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c138">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:DecemberPrivateWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c139">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:DecemberPrivateWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c140">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:DecemberPreFundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c141">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:DecemberPrivateWarrantsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-12-27</xbrli:startDate>
    <xbrli:endDate>2024-12-27</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c142">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c143">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">iinn:DecemberPrivateOfferingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c144">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">iinn:DecemberPrivateOfferingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c145">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">iinn:December2024PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c146">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c147">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c148">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c149">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c150">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-12-31</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c151">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c152">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">iinn:ExercisePrice55Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c153">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">iinn:ExercisePrice55Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c154">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">iinn:ExercisePrice55TwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c155">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">iinn:ExercisePrice55TwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c156">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">iinn:Exercise6875Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c157">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">iinn:Exercise6875Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c158">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">iinn:ExercisePriceOnePointSixMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c159">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">iinn:ExercisePriceOnePointSixMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c160">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">iinn:ExercisePrice156Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c161">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">iinn:ExercisePrice156Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c162">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">iinn:ExercisePriceOnePointOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c163">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">iinn:ExercisePriceOnePointOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c164">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">iinn:ExercisePrice0001Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c165">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">iinn:ExercisePrice0001Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c166">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c167">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c168">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c169">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c170">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c171">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-24</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c172">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">iinn:AdvisoryBoardMembersMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-24</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c173">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-24</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c174">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-03-24</xbrli:startDate>
    <xbrli:endDate>2022-03-24</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c175">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-24</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c176">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">iinn:MedicalBoardMembersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-24</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c177">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-03-24</xbrli:startDate>
    <xbrli:endDate>2022-03-24</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c178">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-03-24</xbrli:startDate>
    <xbrli:endDate>2022-03-24</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c179">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iinn:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-03-24</xbrli:startDate>
    <xbrli:endDate>2022-03-24</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c180">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-04-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c181">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-05-19</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c182">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-05-19</xbrli:startDate>
    <xbrli:endDate>2022-05-19</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c183">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-11-22</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c184">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-11-22</xbrli:startDate>
    <xbrli:endDate>2022-11-22</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c185">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-01-22</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c186">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-22</xbrli:startDate>
    <xbrli:endDate>2024-01-22</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c187">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-01-22</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c188">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-01-22</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c189">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-22</xbrli:startDate>
    <xbrli:endDate>2024-01-22</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c190">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-22</xbrli:startDate>
    <xbrli:endDate>2024-01-22</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c191">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-22</xbrli:startDate>
    <xbrli:endDate>2024-01-22</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c192">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c193">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-05</xbrli:startDate>
    <xbrli:endDate>2024-02-05</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c194">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-05</xbrli:startDate>
    <xbrli:endDate>2024-02-05</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c195">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c196">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-05</xbrli:startDate>
    <xbrli:endDate>2024-02-05</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c197">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">iinn:EmployeesDirectorsAndSubcontractorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c198">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">iinn:EmployeesDirectorsAndSubcontractorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c199">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">iinn:EmployeesDirectorsAndSubcontractorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c200">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-03-24</xbrli:startDate>
    <xbrli:endDate>2022-03-24</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c201">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-03-24</xbrli:startDate>
    <xbrli:endDate>2022-03-24</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c202">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-22</xbrli:startDate>
    <xbrli:endDate>2024-01-22</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c203">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-22</xbrli:startDate>
    <xbrli:endDate>2024-01-22</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c204">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:ServicesProvidersAndAdvisersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c205">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:ServicesProvidersAndAdvisersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c206">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:ServicesProvidersAndAdvisersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c207">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:ServicesProvidersAndAdvisersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c208">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:ServicesProvidersAndAdvisersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c209">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:ServicesProvidersAndAdvisersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c210">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:ServicesProvidersAndAdvisersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c211">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c212">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c213">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c214">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c215">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c216">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c217">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c218">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c219">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c220">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c221">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c222">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c223">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">iinn:OfficersAndDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c224">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">iinn:OfficersAndDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c225">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">iinn:OfficersAndDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c226">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c227">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c228">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c229">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c230">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">iinn:DecemberPrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c231">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-01-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c232">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-02-28</xbrli:startDate>
    <xbrli:endDate>2025-02-28</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c233">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-02-20</xbrli:startDate>
    <xbrli:endDate>2025-02-20</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c234">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iinn:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-02-20</xbrli:startDate>
    <xbrli:endDate>2025-02-20</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c235">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">iinn:ExecutivesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-02-20</xbrli:startDate>
    <xbrli:endDate>2025-02-20</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c236">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001837493</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-02-20</xbrli:startDate>
    <xbrli:endDate>2025-02-20</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:unit xmlns="" id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit xmlns="" id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="ils">
  <xbrli:measure>iso4217:ILS</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="ilsPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:ILS</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit></ix:resources></ix:header>

</div></div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>ea023322601ex2-1_inspira.htm
<DESCRIPTION>DESCRIPTION OF SECURITIES
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 2.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Description of Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following description
of the share capital of Inspira Technologies Oxy B.H.N. Ltd. (the &ldquo;Company&rdquo;, &ldquo;we&rdquo;, &ldquo;us&rdquo; or &ldquo;our&rdquo;),
provisions of the Company&rsquo;s amended and restated articles of association<FONT STYLE="background-color: white">, as they may be amended
and restated from time to time </FONT>(our &ldquo;Articles<FONT STYLE="background-color: white">&rdquo;), and Israeli law</FONT> are summaries
and do not purport to be complete, and is qualified in its entirety by reference to, the provisions of our Articles as well as the Israeli
law and any other documents referenced in the summary and from which the summary is derived.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 3, 2025, our authorized
share capital consisted of 100,000,000 Ordinary Shares, no par value (&ldquo;Ordinary Shares&rdquo;), of which 25,619,276 Ordinary Shares
were issued and outstanding as of such date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 3, 2025, we had
issued and outstanding warrants to purchase up to 1,640,455 of our Ordinary Shares issued in our initial public offering (the &ldquo;IPO
Warrants&rdquo;). Each IPO Warrant is exercisable for one Ordinary Share at an exercise price of $5.50 per share and expires five years
from the date of issuance, or July 16, 2026, and underwriter warrants to purchase up to an aggregate of 145,455 Ordinary Shares at an
exercise price of $6.875 per share, which expire five and half years from the date of issuance, or January 15, 2027, issued to Aegis Capital
in connection with our initial public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 3, 2025, we also
had issued and outstanding warrants to purchase up to 277,835 Ordinary Shares issued in connection with the termination of an investment
agreement, certain other Simple Agreements for Future Equity (&ldquo;SAFEs,&rdquo;) and a convertible loan, and their promoters in connection
with such SAFEs and convertible loan (the &ldquo;Pre-IPO Warrants&rdquo;). Each of the outstanding Pre-IPO Warrant is exercisable for
one Ordinary Share at an exercise price of $5.50 per share, and expire four years from the date of issuance, or July 15, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 3, 2025, we also
had issued and outstanding warrants to purchase up to an aggregate of 3,031,280 Ordinary Shares at an exercise price of $1.28 per share,
which expire three and a half years following their date of issuance, or June 28, 2027, issued to an institutional investor. In addition,
we had issued and outstanding placement agent warrants to purchase up to an aggregate of 212,188 Ordinary Shares at an exercise price
of $1.60 per share, which expire three and a half years following their date of issuance, or June 28, 2027, that the Company agreed to
issue to H.C. Wainwright &amp; Co., LLC, the placement agent, or its designees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 3, 2025, we had issued and outstanding placement agent
warrants to purchase up to an aggregate of 185,591 Ordinary Shares at an exercise price of $1.56 per share, which expire four years following
their date of issuance, or June 18, 2028, that the Company agreed to issue to Newbridge Securities Corporation, the placement agent, or
its designees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 3, 2025, we also
had issued and outstanding warrants to purchase up to an aggregate of 4,608,715 Ordinary Shares at an exercise price of $1.10 per share,
which expire eighteen (18) months from the date of issuance, or June 30, 2026, issued in a private placement financing with certain accredited
investors, on December 31, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 3, 2025, we also
had issued and outstanding pre-funded warrants to purchase up to an aggregate of 129,800 Ordinary Shares at an exercise price of $0.001
per share, which never expire, issued in a private placement financing with certain accredited investors, on December 31, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 3, 2025, we had
outstanding options to purchase up to an aggregate of 573,752 Ordinary Shares and 4,721,187 unvested Restricted Share Units issued to
certain employees, directors, consultants and service providers who are our employees, officers, directors or consultants under our Amended
and Restated 2019 Equity Incentive Plan (the &ldquo;Plan&rdquo;). A total of 1,810,000 of the unvested Restricted Share Units is subject
to the shareholders&rsquo; approval. An additional 245,255 Ordinary Shares are reserved for future issuance of options or other equity
awards under the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Name of Exchange on which Registered</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Ordinary Shares have been
listed on the Nasdaq Capital Market (&ldquo;Nasdaq&rdquo;) under the symbol &ldquo;IINN&rdquo; since July 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our IPO Warrants have been
listed on Nasdaq under the symbol &ldquo;IINNW&rdquo; since July 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Transfer of Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No transfer of shares may
be registered unless a proper writing or instrument of transfer (in any customary form or any other form satisfactory to the board of
directors (the &ldquo;Board of Directors&rdquo;)) has been submitted to the Company (or its transfer agent), together with any share certificate(s)
and such other evidence of title as the Board of Directors may reasonably require. The Board of Directors, may, from time to time, prescribe
a fee for the registration of a transfer, and may approve other methods of recognizing the transfer of shares in order to facilitate the
trading of the Company&rsquo;s shares on the Nasdaq or on any other stock exchange on which the Company&rsquo;s shares are then listed
for trading. The ownership or voting of our Ordinary Shares by non-residents of Israel is not restricted in any way by our Articles or
the laws of the State of Israel, except for ownership by nationals of certain countries that are, or have been, in a state of war with
Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Liability to Further Capital Calls</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Board of Directors may
make, from time to time, such calls as it may deem fit upon shareholders with respect to any sum unpaid with respect to shares held by
such shareholders which is not payable at a fixed time. Such shareholder has to pay the amount of every call so made upon him or her.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Election of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under our Articles, our Board
of Directors must consist of at least three (3) and not more than twelve (12) directors, including two external directors, if applicable,
which will be elected if and when required under the Companies Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other than external directors,
if applicable (who shall be elected and serve in office in strict accordance with the provisions of the Companies Law), and other than
directors elected by our Board of Directors (due to the number being less than the maximum amount, or due to a director&rsquo;s office
becoming vacant), directors of the Company shall be elected solely at an annual general meeting and shall serve in their office until
the next annual general meeting, or until they cease to serve in their office in accordance with the provisions of the Articles or any
law, whichever is earlier. Prior to every annual general meeting of the Company, and subject to clause 39 (a) and (f) of the Articles,
the Board of Directors (or a committee thereof) shall select, by a resolution adopted by a majority of the Board of Directors (or such
committee), a number of persons to be proposed to the shareholders for election as Directors at such annual general meeting.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, if a director&rsquo;s
office becomes vacant, the remaining serving directors may continue to act in any manner, provided that the number of the serving directors
shall not be less than three (3). If the number of serving directors is lower than their minimal one, the Board shall not be permitted
to act, they may only act in an emergency or to fill the office of director which has become vacant up to a number equal to the minimum
number provided for pursuant to the Articles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">External directors, if applicable,
are elected for an initial term of three years, and may be elected thereafter for up to two additional three-year terms under certain
circumstances, and may be removed from office pursuant to the terms of the Companies Law. Under certain circumstances, the term of office
for external directors for Israeli companies traded on certain foreign stock exchanges, including the Nasdaq Stock Market, may be extended
indefinitely in increments of additional three-year terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dividend Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board of Directors may
from time to time declare, and cause the Company to pay, such dividend as may appear to the Board of Directors to be justified by the
profits of the Company and as permitted by the Companies Law. The Board of Directors shall determine the time for payment of such dividends
and the record date for determining the shareholders entitled thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Companies
Law, the distribution amount is limited to the greater of retained earnings or earnings generated over the previous two years, according
to our then last reviewed or audited consolidated financial statements, provided that the date of the financial statements is not more
than six months prior to the date of the distribution, or we may distribute dividends that do not meet such criteria only with Israeli
court approval. In each case, we are only permitted to distribute a dividend if our Board of Directors and the court, if applicable, determines
that there is no reasonable concern that payment of the dividend will prevent us from satisfying our existing and foreseeable obligations
as they become due.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Shareholder Meetings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, we
are required to hold an annual general meeting of our shareholders once every calendar year that must be held no later than 15 months
after the date of the previous annual general meeting. All general meetings other than the annual meeting of shareholders are referred
to in our Articles as special meetings. Our Board of Directors may call special meetings whenever it sees fit, at such time and place,
within or outside of Israel, as it may determine. In addition, the Companies Law provides that our Board of Directors is required to convene
a special meeting upon the written request of (i) any two of our directors or one-quarter of the members of our Board of Directors or
(ii) one or more shareholders holding, in the aggregate, either (a) 5% or more of our outstanding issued shares and 1% or more of our
outstanding voting power or (b) 5% or more of our outstanding voting power (the &ldquo;Non Exempted Holding&rdquo;), However, under an
exemption applicable for Israeli companies whose shares are listed outside of Israel (the &ldquo;Exemption Regulations&rdquo;), the Board
of Directors shall convene a special meeting at the request of one or more shareholders holding at least ten percent (10%) of the issued
and outstanding share capital instead of five (5%) in the past, and at least one percent (1%) of the voting rights in the company, or
one or more shareholders holding at least ten percent (10%) of the voting rights in the company, provided that if the applicable law to
companies incorporated in the country which the company is listed for trade, establishes a right to demand convening of such a meeting
for those holding a percentage of holdings lower than ten percent (10%), then the Non Exempted Holding shall apply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, one
or more shareholders holding at least 1% of the voting rights at the general meeting may request that the Board of Directors include a
matter in the agenda of a general meeting to be convened in the future, provided that it is appropriate to discuss such a matter at the
general meeting. However, under the Exemption Regulations, one or more shareholders may request the Board of Directors to include a nomination
of a candidate for a position on the Board of Directors or the termination of a director, as an item on the agenda of a future general
meeting if they hold at least five percent (5%) of the voting rights of the company, instead of one percent (1%) as required in the past.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the provisions
of the Companies Law and the regulations promulgated thereunder, shareholders entitled to participate and vote at general meetings are
the shareholders of record on a date to be decided by the Board, which according to the Companies Law may be between four (4) and sixty
(60) days prior to the date of the meeting, as applicable according to the matters on the general meeting agenda. According to the Companies
Law, resolutions regarding the following matters must be passed at a general meeting of the Company&rsquo;s shareholders:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">amendments to the Company&rsquo;s Articles;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the exercise of the Board&rsquo;s powers by a general meeting if the Board&rsquo;s is unable to exercise its powers and the exercise of any of its powers is required for the Company&rsquo;s proper management;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">appointment or termination of the Company&rsquo;s auditors;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">appointment of directors (other than in the cases specified in the Company&rsquo;s Articles);</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approval of acts and transactions requiring general meeting approval pursuant to the provisions of the Companies Law and any other applicable law;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">increases or reductions of the Company&rsquo;s authorized share capital;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a merger (as such term is defined in the Companies Law); and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">dissolution of the Company by the court, voluntary dissolution, or by voluntary dissolution in an expedited procedure.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under our Articles, we are
not required to give notice to our registered shareholders pursuant to the Companies Law, unless otherwise required by law. The Companies
Law requires that a notice of any annual or special general meeting be provided 14 or 21 days (as applicable) prior to the meeting, and
if the agenda of the meeting includes certain matters prescribed under the Companies Law and the regulations promulgated thereafter, among
others, the appointment or removal of directors, the approval of transactions with office holders or interested or related parties, approval
of the Company&rsquo;s general manager to serve as the chairman of the Board of Directors or an approval of a merger, notice must be provided
at least 35 days prior to such meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Voting Rights</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Every shareholder shall have
one vote for each share held by him of record, on every resolution, without regard to whether the vote thereon is conducted by a show
of hands, by written ballot or by any other means.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Quorum Requirements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As permitted under the Companies
Law and as stated in the Company&rsquo;s Articles, the quorum required for the Company&rsquo;s general meetings consists of two or more
shareholders, present in person or by proxy and holding shares conferring in the aggregate at least twenty five percent (25%) of the voting
power of the Company. If within half an hour of the time set forth for the general meeting a quorum is not present, the general meeting
shall stand adjourned either (i) to the same day of the following week, at the same hour and in the same place (ii) to such other date,
time and place as prescribed in the notice to the shareholders and in such adjourned meeting or (iii) to such day and at such time and
place as the chairperson of the general meeting shall determine (which may be earlier or later than the date pursuant to clause (i) above).
If no quorum is present within half an hour of the time arranged, any number of shareholders participating in the meeting, shall constitute
a quorum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a special general meeting
was called following the request of a shareholder according to applicable law, and within half an hour a legal quorum has not been formed,
the meeting shall be canceled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Vote Requirements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Articles provide that
all resolutions of our shareholders require a simple majority vote, unless otherwise required by the Companies Law or by our Articles.
Under the Companies Law, each of (i) the approval of an extraordinary transaction with a controlling shareholder and (ii) the terms of
employment or other engagement of the controlling shareholder of the company or such controlling shareholder&rsquo;s relative (even if
not extraordinary) requires the approval described under &ldquo;<FONT STYLE="background-color: white">Item 6.</FONT>C. <FONT STYLE="background-color: white"><I>Directors,
Senior Management and Employees</I></FONT><I>&mdash;Board Practices&mdash; Fiduciary Duties of Office Holders</I> and Approval of Related
Party Transactions under Israeli Law &mdash; Disclosure of Personal Interests of an Office Holder.&rdquo; Certain transactions with respect
to remuneration of our office holders and directors require further approvals described under &ldquo;<FONT STYLE="background-color: white">Item
6. Directors, Senior Management and Employees</FONT>&mdash;C. Board Practices&mdash; Fiduciary Duties of Office Holders and Disclosure
of Personal Interests of an Office Holder.&rdquo; Another exception to the simple majority vote requirement is a resolution for the voluntary
winding up, or an approval of a scheme of arrangement or reorganization, of the company pursuant to Section 350 of the Companies Law,
which requires the approval of the court and the approval of the majority of the shareholders voting their shares, other than abstainees,
holding at least 75% of the voting rights represented at the meeting, in person, by proxy or by voting deed and voting on the resolution.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Access to Corporate Records</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Companies Law, shareholders
are entitled to have access to: minutes of the Company&rsquo;s general meetings; the Company&rsquo;s shareholders register and principal
shareholders register, articles of association and annual audited financial statements; and any document that the Company is required
by law to file publicly with the Israeli Companies Registrar or the Israel Securities Authority. These documents are publicly available
and may be found and inspected at the Israeli Registrar of Companies. In addition, shareholders may request to be provided with any document
related to an action or transaction requiring shareholder approval under the related party transaction provisions of the Companies Law.
The Company may deny this request if the Company believes it has not been made in good faith or if such denial is necessary to protect
the Company&rsquo;s interest or protect a trade secret or patent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Special or Class Rights; Modification of Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If at any time the share capital
of the Company is divided into different classes of shares, the rights attached to any class, unless otherwise provided by the Companies
Law or the Company&rsquo;s Articles, may be modified or cancelled by the Company by a resolution of the general meeting of the holders
of all shares as one class, without any required separate resolution of any class of shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The provisions of our Articles
relating to general meetings shall, mutatis mutandis, apply to any separate general meeting of the holders of the shares of a particular
class, it being clarified that the requisite quorum at any such separate general meeting shall be two or more shareholders present in
person or by proxy and holding not less than 15 percent of the issued shares of such class.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless otherwise provided
by Company&rsquo;s Articles, an increase in the authorized share capital, the creation of a new class of shares, an increase in the authorized
share capital of a class of shares, or the issuance of additional shares thereof out of the authorized and unissued share capital, shall
not be deemed to modify or derogate or cancel the rights attached to previously issued shares of such class or of any other class.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Acquisitions under Israeli Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Full Tender Offer</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If, as a result of an acquisition
of shares, the acquirer will hold more than 90% of an Israeli public company&rsquo;s outstanding shares or of certain class of shares,
the acquisition must be made by means of a tender offer for all of the outstanding shares, or for all of the outstanding shares of such
class, as applicable. In general, if less than 5% of the outstanding shares, or of applicable class, are not tendered in the tender offer
and more than half of the offerees who have no personal interest in the offer tendered their shares, all the shares that the acquirer
offered to purchase will be transferred to it by operation of law. However, a tender offer will also be accepted if the shareholders who
do not accept the offer hold less than 2% of the issued and outstanding share capital of the company or of the applicable class of shares.
Any shareholders that was an offeree in such tender offer, whether such shareholder accepted the tender offer or not, may request, by
petition to an Israeli court, (i) appraisal rights in connection with a full tender offer, and (ii) that the fair value should be paid
as determined by the court, for a period of six months following the acceptance of the offer. However, the acquirer is entitled to stipulate,
under certain conditions, that tendering shareholders will forfeit such appraisal rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Special Tender Offer</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law also provides
that, subject to certain exceptions, an acquisition of shares in an Israeli public company must be made by means of a &ldquo;special&rdquo;
tender offer if as a result of the acquisition (1) the purchaser would become a holder of 25% or more of the voting rights in the company,
unless there is already another holder of at least 25% or more of the voting rights in the company or (2) the purchaser would become a
holder of 45% or more of the voting rights in the company, unless there is already a holder of more than 45% of the voting rights in the
company. These requirements do not apply if, in general, the acquisition (1) was made in a private placement that received shareholders&rsquo;
approval, subject to certain conditions, (2) was from a holder of 25% or more of the voting rights in the company which resulted in the
acquirer becoming a holder of 25% or more of the voting rights in the company, or (3) was from a holder of more than 45% of the voting
rights in the company which resulted in the acquirer becoming a holder of more than 45% of the voting rights in the company. A &ldquo;special&rdquo;
tender offer must be extended to all shareholders. In general, a &ldquo;special&rdquo; tender offer may be consummated only if (1) at
least 5% of the voting power attached to the company&rsquo;s outstanding shares will be acquired by the offeror and (2) the offer is accepted
by a majority of the offerees who notified the company of their position in connection with such offer (excluding the offeror, controlling
shareholders, holders of 25% or more of the voting rights in the company or anyone on their behalf, or any person having a personal interest
in the acceptance of the tender offer). If a special tender offer is accepted, then the purchaser or any person or entity controlling
it or under common control with the purchaser or such controlling person or entity may not make a subsequent tender offer for the purchase
of shares of the target company and may not enter into a merger with the target company for a period of one year from the date of the
offer, unless the purchaser or such person or entity undertook to effect such an offer or merger in the initial special tender offer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">However, under the Exemption
Regulations, the aforesaid limitations regarding a special tender offer do not apply for an Israeli company whose shares are listed outside
of Israel, provided that if the applicable law as applicable to companies incorporated in the country which the company is listed for
trade, provide a restriction on the acquisition of control of any proportion of the company or that the acquisition of control of any
proportion requires the purchaser to also offer a purchase offer to shareholders from among the public.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Merger</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Companies Law includes
provisions that allow a merger transaction and requires that each company that is a party to the merger have the transaction approved
by its board of directors and, unless certain requirements described under the Companies Law are met, a vote of the majority of its shareholders,
and, in the case of the target company, also a majority vote of each class of its shares. For purposes of the shareholder vote of each
party, unless a court rules otherwise, the merger will not be deemed approved if shares representing a majority of the voting power present
at the shareholders meeting and which are not held by the other party to the merger (or by any person or group of persons acting in concert
who holds 25% or more of the voting power or the right to appoint 25% or more of the directors of the other party) vote against the merger.
If, however, the merger involves a merger with a company&rsquo;s own controlling shareholder or if the controlling shareholder has a personal
interest in the merger, then the merger is instead subject to the same Special Majority (as defined below) approval that governs all extraordinary
transactions with controlling shareholders. Upon the request of a creditor of either party to the proposed merger, the court may delay
or prevent the merger if it concludes that there exists a reasonable concern that as a result of the merger the surviving company will
be unable to satisfy the obligations of any of the parties to the merger, and may further give instructions to secure the rights of creditors.
If the transaction would have been approved by the shareholders of a merging company but for the separate approval of each class or the
exclusion of the votes of certain shareholders as provided above, a court may still approve the merger upon the petition of holders of
at least 25% of the voting rights of a company. For such petition to be granted, the court must find that the merger is fair and reasonable,
taking into account the value of the parties to the merger and the consideration offered to the shareholders. In addition, a merger may
not be completed unless at least (1) 50 days have passed from the time that the requisite proposals for approval of the merger were filed
with the Israeli Registrar of Companies by each merging company; and (2) 30 days have passed since the merger was approved by the shareholders
of each merging company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The term &ldquo;Special Majority&rdquo;
will be defined as described in section 275(a)(3) of the Companies Law as:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at least a majority of the shares held by shareholders who are not controlling shareholders and do not have personal interest in the merger have voted in favor of the proposal (shares held by abstaining shareholders shall not be considered); or</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the total number of shares voted against the merger does not exceed 2% of the aggregate voting rights of the company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Borrowing Powers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Companies
Law and our Articles, our Board of Directors may exercise all powers and take all actions that are not required under law or under our
Articles to be exercised or taken by a certain organ of the Company, including the power to borrow money for company purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Changes in Capital</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Articles enable us to
increase or reduce our authorized share capital. Any such changes are subject to the provisions of the Companies Law and must be approved
by a resolution duly adopted by our shareholders at a general meeting. In addition, transactions that have the effect of reducing capital,
such as the declaration and payment of dividends in the absence of sufficient retained earnings or profits, require the approval of both
our Board of Directors and an Israeli court.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>IPO Warrant Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The IPO Warrants were issued
in registered form pursuant to the warrant agent agreement dated July 13, 2021, by and between the Company and VStock Transfer, LLC, as
warrant agent (the &ldquo;Warrant Agreement&rdquo;). On August 8, 2022 the Company and American Stock Transfer &amp; Trust Company, LLC,
as a successor warrant agent, entered into an amendment to the Warrant Agreement (the &ldquo;Amendment to the Warrant Agreement&rdquo;).
You should review a copy of the Warrant Agreement, the Amendment to the Warrant Agreement and the form of IPO Warrant filed as exhibits
to our Annual Report on Form 20-F for the year ended December 31, 2024, for a complete description of the terms and conditions of the
Warrants, the Warrant Agreement and the Amendment to the Warrant Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Duration and Exercise Price Adjustments</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The IPO Warrants expire at
5:00 p.m., New York City time on July 16, 2026. The exercise price and number of Ordinary Shares issuable upon exercise is subject to
appropriate adjustments in the event of stock dividends, stock splits, reorganizations or other events affecting our Ordinary Shares and
the exercise price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Exercisability</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The IPO Warrants may be exercised
upon surrender of the warrant certificate on or prior to the expiration date at the offices of the warrant agent, with the exercise form
completed and executed as indicated, accompanied by full payment of the exercise price (or on a cashless basis, if applicable), by paying
in full, in lawful money of the United States by wire transfer to the warrant agent, for the number of Warrants being exercised. The warrant
holders do not have the rights or privileges of a shareholder of the Company and any voting rights until they exercise their IPO Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Fractional Shares</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No fractional shares will
be issued in connection with the exercise of an IPO Warrant. In lieu of fractional shares, we will pay the holder an amount in cash equal
to the fractional amount multiplied by the exercise price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Transferability</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to applicable laws,
each warrant may be transferred at the option of the holder upon surrender of the warrant to the Company or its designated agent together
with a written assignment substantially in the form attached to the warrant as an exhibit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Warrant Agent</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The warrant agent for the
IPO Warrants is Equinity&nbsp;Trust Company, LLC (formerly known as American Stock Transfer &amp; Trust Company, LLC) <FONT STYLE="background-color: white">Its
address</FONT> is 48 Wall Street, 23rd floor, New York, NY 10043.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Exchange Listing</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The IPO Warrants are listed
on Nasdaq under the symbol &ldquo;IINNW&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">8</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-11.1B
<SEQUENCE>3
<FILENAME>ea023322601ex11-1b_inspira.htm
<DESCRIPTION>INSIDER TRADING POLICY
<TEXT>
<html>
<head>
     <title></title>
</head>
<body style="font: 10pt Times New Roman, Times, Serif">

<p style="text-align: right; margin: 0"><b>Exhibit 11.1(b)</b></p>

<p style="margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>INSIDER TRADING POLICY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>AND GUIDELINES WITH RESPECT TO</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>CERTAIN TRANSACTIONS IN COMPANY SECURITIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Date: March 10, 2025</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Insider Trading Policy
(the &ldquo;<b>Policy</b>&rdquo;) provides guidelines to directors, officers, employees and other related persons of Inspira Technologies
Oxy B.H.N. Ltd., an Israeli company (the &ldquo;<b>Company</b>&rdquo;), with respect to transactions in the Company&rsquo;s securities.
The Company has adopted this Policy in order to ensure compliance with securities laws and to avoid even the appearance of improper conduct
by anyone associated with the Company. Failure to comply with these procedures could result in a serious violation of the securities laws
by you and/or the Company and can result in both civil penalties and criminal fines and imprisonment. We have all worked hard to establish
the Company&rsquo;s reputation for integrity and ethical conduct, and we are all responsible for preserving and enhancing this reputation.
The appearance of insider trading can cause a substantial loss of confidence in the Company and its shares on the part of the public and
the securities markets. This could result in an adverse impact on the Company and its shareholders. Accordingly, avoiding the appearance
of engaging in share transactions on the basis of material undisclosed information can be as important as avoiding a transaction actually
based on such information. The Company has appointed its VP Finance, or in his or her absence, the Company&rsquo;s Chief Executive Officer
(the &ldquo;<b>Compliance Officer</b>,&rdquo; as the case may be), as the Company&rsquo;s Insider Trading Compliance Officer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>I. <u>Applicability of Policy</u></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Policy applies to all
transactions in the Company&rsquo;s securities, including ordinary shares, American depositary shares, American depositary receipts, options
and any other securities the Company may issue from time to time, such as preferred shares, warrants, notes, and convertible debentures,
as well as to derivative securities relating to the Company&rsquo;s shares, whether or not issued by the Company, such as exchange-traded
options and debt securities. It applies to all officers of the Company, all members of the Company&rsquo;s Board of Directors, and all
employees of, and consultants and contractors to, the Company and its subsidiaries/branches who receive or have access to Material Nonpublic
Information (as defined below) regarding the Company (collectively, &ldquo;<b>Company Affiliated Persons</b>&rdquo;). Company Affiliated
Persons, members of their immediate families (which include spouse and minor children), members of their households, other family members
living with them or who are supported by them, are sometimes referred to in this Policy as &ldquo;<b>Insiders</b>&rdquo;. This Policy
also applies to any trust or other estate in which an Insider has a substantial beneficial interest or as to which he or she serves as
trustee or in a similar fiduciary capacity, and to any trust, corporation, partnership or other entity which the Insider controls, including
venture capital partnerships. This Policy also applies to any person who receives Material Nonpublic Information from any Insider.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any person who possesses
Material Nonpublic Information regarding the Company is an Insider for so long as the information is not publicly known. Any employee
can be an Insider from time to time and would at those times be subject to this Policy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Policy imposes additional
restrictions upon Insiders who have routine access to Material Nonpublic Information, referred to as &ldquo;<b>Access Insiders</b>.&rdquo;
Access Insiders are: (1) members of the board of directors, (2) the executive officers, (3) the controller, and (4) the investor relations
department of the Company. In addition, other employees of the Company who have routine access to Material Nonpublic Information as determined
by the Compliance Officer, who were notified that these additional restrictions apply to them shall also be Access Insiders until otherwise
determined by the Compliance Officer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the Company itself
must comply with securities laws applicable to its own securities trading activities, and must not engage in any transaction involving
a purchase or sale of its securities, including any offer to purchase or offer to sell or other disposition of its securities, when it
is in possession of Material Nonpublic Information concerning the Company, other than in compliance with applicable law, subject to the
policies and procedures adopted by the Company and the exceptions listed in Section XII of this Policy to the extent applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>II. <u>General Policy</u></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is the policy of the Company
to oppose the unauthorized disclosure of any nonpublic information acquired in the work-place and the misuse of Material Nonpublic Information
in securities trading.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>III. <u>Specific Policies</u></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><u>1. Trading
on Material Nonpublic Information</u>. </b>No Insider shall engage in any transaction involving a purchase or sale of the Company&rsquo;s
securities, including any offer to purchase or offer to sell or gift, or any other disposition of the Company&rsquo;s securities, during
any period commencing with the time that he or she first receives Material Nonpublic Information concerning the Company, and ending at
the close of business on the second Trading Day following the date of public disclosure of that information, or at such time as such nonpublic
information is no longer material. As used herein, the term &ldquo;<b>Trading Day</b>&rdquo; shall mean a day on which the Nasdaq Capital
Market is open for trading.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><u>2. Tipping</u>.
</b>No Insider shall disclose (sometimes called a &ldquo;<b>Tip</b>&rdquo;) Material Nonpublic Information to any other person (including
family members) where such information may be used by such person to his or her profit by trading in the securities of companies to which
such information relates, nor shall such Insider or related person make recommendations or express opinions on the basis of Material Nonpublic
Information as to trading in the Company&rsquo;s securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><u>3. Confidentiality
of Nonpublic Information</u>. </b>Nonpublic information relating to the Company is the property of the Company and the unauthorized disclosure
of such information is forbidden. In the event any officer, director or employee of the Company receives any inquiry from outside the
Company, such as a stock analyst, for information (particularly financial results and/or projections) that may be Material Nonpublic Information,
the inquiry should be referred to the Compliance Officer, and to the other appropriate Company officers, as provided for in the Disclosure
Policy of the Company, if any, as may be in place from time to time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>IV. <u>Potential Criminal and Civil Liability and/or Disciplinary
Action</u></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>1. <u>Liability
for Insider Trading</u>. </b>In the United States and many other countries, the personal consequences to an Insider of illegally trading
securities while in possession, or on the basis of, Material Nonpublic Information can be quite severe. In the United States there are
substantial civil penalties and criminal sanctions which may be assessed for insider trading. Civil penalties are a payment of a penalty
of up to three times the illicit windfall. In addition, Insiders may be subject to criminal fines of up to $5,000,000 and up to twenty
years in prison for engaging in transactions in the Company&rsquo;s securities at a time when they have knowledge of Material Nonpublic
Information regarding the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If you are located or engaged
in dealings outside the U.S., be aware that laws regarding insider trading and similar offenses differ from country to country. Employees
must abide by the laws in the country where located. However, you are required to comply with this Policy even if local law is less restrictive.
If a local law conflicts with this Policy, you must consult the Compliance Officer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If securities transactions
ever become the subject of scrutiny, they are likely to be viewed after-the-fact with the benefit of hindsight. As a result, before engaging
in any transaction an Insider should carefully consider how the transaction may be construed in the bright light of hindsight. If you
have any questions or uncertainties about this Policy or a proposed transaction, please ask the Compliance Officer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><u>2. Liability
for Tipping</u>. </b>Insiders may also be liable for improper transactions by any person (commonly referred to as a &ldquo;<b>Tippee&rdquo;</b>)
to whom they have disclosed Material Nonpublic Information or any person to whom the Tippee discloses such Material Nonpublic Information
regarding the Company or to whom they have made recommendations or expressed opinions on the basis of such information as to trading in
the Company&rsquo;s securities. The civil penalties and criminal sanctions for tipping by an Insider are the same as the ones for an Insider
conducting insider trading, even if the disclosing person did not profit from the trading. The U.S. Securities and Exchange Commission
(the &ldquo;<b>SEC</b>&rdquo;), the Financial Industry Regulatory Authority (&ldquo;<b>FINRA</b>&rdquo;) and the stock exchanges use sophisticated
electronic surveillance techniques to uncover insider trading.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><u>3. Possible
Disciplinary Actions</u>. </b>The seriousness of securities law violations is reflected in the penalties and criminal sanctions such violations
carry. These violations may also create negative publicity for the Company and a director&rsquo;s resignation may be sought, or an officer
or other employee will be subject to possible Company disciplinary action including ineligibility for future participation in the Company&rsquo;s
equity incentive plans or termination of employment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>V. <u>Individual Responsibility</u></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Every Company Affiliated
Person has the individual responsibility to comply with this Policy against insider trading, regardless of whether the Company has recommended
a trading window to that person or any other Insiders of the Company. The guidelines set forth in this Policy are not intended to provide
a conclusive solution for all circumstances, and appropriate judgment should be exercised in connection with any trade in the Company&rsquo;s
securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An Insider may, from time
to time, have to forego a proposed transaction in the Company&rsquo;s securities even if he or she planned to make the transaction before
learning of the Material Nonpublic Information and even though the Insider believes he or she may suffer an economic loss or forego anticipated
profit by waiting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>VI. <u>Applicability of Policy to Inside Information Regarding Other
Companies</u></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Policy and the guidelines
described herein also apply to Material Nonpublic Information relating to other companies, including the Company&rsquo;s customers, vendors
or suppliers (&ldquo;<b>Business Partners</b>&rdquo;), when that information is obtained in the course of employment with, or other services
performed on behalf of, the Company. Civil penalties and criminal sanctions, and termination of employment, may result from trading on
inside information regarding the Company&rsquo;s Business Partners. All employees should treat Material Nonpublic Information about the
Company&rsquo;s Business Partners with the same care required with respect to information related directly to the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><u>VII. Dissemination of
Company Information</u></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The prohibition of the disclosure
of Material Nonpublic Information applies to all contacts made within and outside the Company. Care should be taken to prevent the disclosure
of Material Nonpublic Information during all contact including phone calls and casual conversation. If in doubt about whether information
falls into the category of Material Nonpublic Information, then the information should not be disclosed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to disclosure to any
third party, any officer, director or employee of the Company who is aware of any Material Nonpublic Information concerning the Company
that has not been disclosed to the public should report the intention to disclose such information promptly to the Compliance Officer
and obtain approval to do so, or otherwise act in accordance with the Company&rsquo;s Disclosure Policy, if any, as may be in place from
time to time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><u>VIII. Definition of Material Nonpublic Information</u></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Material Nonpublic Information
is information which is material, and that has not been disclosed or otherwise made available to the general public by the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is not possible to define
all categories of material information. Generally, information should be regarded as material if a reasonable investor would consider
it important in making an investment decision regarding the purchase or sale of the Company&rsquo;s securities or the information, if
made public, would likely affect the market price of the Company&rsquo;s securities. Either positive or negative information may be material.
Information may be material even if it relates to future, speculative or contingent events and even if it is significant only when considered
in combination with publicly available information. Nonpublic information can be material even with respect to companies that do not have
publicly traded stock, such as those with outstanding bonds or bank loans.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While it may be difficult
under this standard to determine whether particular information is material, there are various categories of information that are particularly
sensitive and, as a general rule, should always be considered material. If any Insider has questions as to the materiality of information,
he or she should contact the Compliance Officer for clarification. Examples of informatio<font style="font-family: Times New Roman, Times, Serif">n
which is deemed to be material include:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#9679;</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">Financial
                                            results;</font></td>
</tr><tr style="vertical-align: top; text-align: justify">
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td></tr>
     </table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#9679;</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">Projections
                                            of future earnings or losses;</font></td>
</tr><tr style="vertical-align: top; text-align: justify">
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td></tr>
     </table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#9679;</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">News
                                            of a pending or proposed merger or acquisition;</font></td>
</tr><tr style="vertical-align: top; text-align: justify">
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td></tr>
     </table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#9679;</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">New
                                            product or project announcements of a significant nature;</font></td>
</tr><tr style="vertical-align: top; text-align: justify">
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td></tr>
     </table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#9679;</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">Expansion
                                            or curtailment of operations or the gain or loss of a substantial customer;</font></td>
</tr><tr style="vertical-align: top; text-align: justify">
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td></tr>
     </table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#9679;</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">Changes
                                            in control of the Company or major changes in senior management;</font></td>
</tr><tr style="vertical-align: top; text-align: justify">
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td></tr>
     </table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#9679;</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">Significant
                                            new joint ventures, alliances, or strategic partnerships or material developments in existing
                                            arrangements;</font></td>
</tr><tr style="vertical-align: top; text-align: justify">
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td></tr>
     </table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#9679;</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">Impending
                                            bankruptcy or financial liquidity problems;</font></td>
</tr><tr style="vertical-align: top; text-align: justify">
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td></tr>
     </table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#9679;</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">Cybersecurity
                                            risks and incidents;</font></td>
</tr><tr style="vertical-align: top; text-align: justify">
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td></tr>
     </table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#9679;</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">Significant
                                            product defects or modifications;</font></td>
</tr><tr style="vertical-align: top; text-align: justify">
<td><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td><td style="text-align: left"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td></tr>
     </table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#9679;</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">Significant
                                            pricing changes;</font></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#9679;</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">Events
regarding the Company&rsquo;s securities (e.g. stock splits, repurchases, or changes in dividend policy);</font></td>
</tr><tr style="vertical-align: top; text-align: justify">
<td>&nbsp;</td><td style="text-align: left">&nbsp;</td><td style="text-align: justify">&nbsp;</td></tr>
     </table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#9679;</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">Changes
in auditors or auditor notification that the Company may no longer rely on an audit report;</font></td>
</tr><tr style="vertical-align: top; text-align: justify">
<td>&nbsp;</td><td style="text-align: left">&nbsp;</td><td style="text-align: justify">&nbsp;</td></tr>
     </table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#9679;</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">A
significant purchase or sale of assets or disposition of a subsidiary or division;</font></td>
</tr><tr style="vertical-align: top; text-align: justify">
<td>&nbsp;</td><td style="text-align: left">&nbsp;</td><td style="text-align: justify">&nbsp;</td></tr>
     </table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#9679;</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">New
equity or debt offerings, significant borrowings, or other material financial transactions;</font></td>
</tr><tr style="vertical-align: top; text-align: justify">
<td>&nbsp;</td><td style="text-align: left">&nbsp;</td><td style="text-align: justify">&nbsp;</td></tr>
     </table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#9679;</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">Significant
litigation exposure due to actual or threatened litigation;</font></td>
</tr><tr style="vertical-align: top; text-align: justify">
<td>&nbsp;</td><td style="text-align: left">&nbsp;</td><td style="text-align: justify">&nbsp;</td></tr>
     </table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#9679;</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">Significant
actions by regulatory bodies;</font></td>
</tr><tr style="vertical-align: top; text-align: justify">
<td>&nbsp;</td><td style="text-align: left">&nbsp;</td><td style="text-align: justify">&nbsp;</td></tr>
     </table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#9679;</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">Receipt,
cancellation or deferral of significant purchase orders;</font></td>
</tr><tr style="vertical-align: top; text-align: justify">
<td>&nbsp;</td><td style="text-align: left">&nbsp;</td><td style="text-align: justify">&nbsp;</td></tr>
     </table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#9679;</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">Proposed
payment of a dividend; and</font></td>
</tr><tr style="vertical-align: top; text-align: justify">
<td>&nbsp;</td><td style="text-align: left">&nbsp;</td><td style="text-align: justify">&nbsp;</td></tr>
     </table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#9679;</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">Any
of the a</font>bove with respect to a subsidiary, or other affiliate of the Company.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Nonpublic information is information
that has not been previously disclosed to the general public and is otherwise not available to the general public. It is important to
note that information is not necessarily &ldquo;public information&rdquo; merely because it has been discussed in the press, which will
sometimes report rumors. You should presume that information is nonpublic unless you can point to its official release by the Company
in at least one of the following ways:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.75in; text-indent: -0.25in">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">1.</td><td style="text-align: justify">Information contained in publicly available documents filed with securities regulatory authorities (e.g.,
filings with the SEC);</td></tr><tr style="vertical-align: top">
<td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr>
                                </table>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">2.</td><td>Issuance of press releases; or</td></tr><tr style="vertical-align: top">
<td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr>
                                                                                                           </table>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">3.</td><td>Meetings with members of the press and the public.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><u>IX. Additional Circumstances
Where No Exceptions Apply</u></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are almost no exceptions
to the prohibition against insider trading. For example, absent a Qualified Plan (as defined below), it does not matter that the transactions
in question may have been planned before the Insider came into possession of the undisclosed material information, regardless of the economic
loss that the person may believe he or she might suffer as a consequence of not trading.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As noted above, the definition
of Insiders, to which this Policy applies, includes immediate family members of Company Affiliated Persons. Although immediate family
is narrowly defined, a Company Affiliated Person should be especially careful with respect to family members or to unrelated persons living
in the same household.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Finally, there are no limits
on the size of a transaction that will trigger insider trading liability; relatively small trades have in the past occasioned investigations
and lawsuits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><u>X. Trading Window</u></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The period beginning two weeks
before the end of the last month of each calendar quarter and ending two Trading Days following the date of public disclosure of the financial
results for that quarter, is a particularly sensitive period of time for transactions in the Company&rsquo;s shares from the perspective
of compliance with applicable securities laws. This sensitivity is due to the fact that directors, officers and certain other employees
will, during that period, often possess Material Nonpublic Information about the expected financial results for the quarter.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Accordingly, to ensure compliance
with this Policy and applicable federal and state securities laws, it is the Company&rsquo;s policy that all directors, officers and employees
refrain from conducting transactions involving the Company&rsquo;s securities other than during the period (the &ldquo;<b>Trading Window</b>&rdquo;)
commencing at the close of business on the second Trading Day following the date of public disclosure of the financial results for a particular
fiscal quarter or year and continuing until the day that is two weeks before the last day of the last month of the next fiscal quarter.
As a courtesy to the persons subject to this Policy, the Company may provide advance notice before the Trading Window opens.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, the Company
may also notify that directors, officers, selected employees and others are required to suspend trading because of developments known
to the Company and not yet disclosed to the public. In such event, such persons are advised not to engage in any transaction involving
the Company&rsquo;s securities during such period and should not disclose to others the fact of such suspension of trading.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The purpose behind the self-imposed
Trading Window period is to help establish a diligent effort to avoid any improper transaction. It should be noted, however, that even
during the Trading Window, any person possessing Material Nonpublic Information concerning the Company may not attempt to &ldquo;beat
the market&rdquo; by trading simultaneously with, or shortly after, the official release of Material Nonpublic Information. Although there
is no fixed period for how long it takes the market to absorb information, out of prudence a person aware of Material Nonpublic Information
should refrain from any trading activity for at least two full Trading Days following its official release, whether or not the Company
has recommended a suspension of trading to that person.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>NOTWITHSTANDING THESE TIMING
GUIDELINES, IT IS ILLEGAL FOR ANY PERSON TO TRADE WHILE IN POSSESSION OF MATERIAL NONPUBLIC INFORMATION, INCLUDING SITUATIONS IN WHICH
THE PERSON IS AWARE OF MAJOR DEVELOPMENTS THAT HAVE NOT YET BEEN PUBLICLY ANNOUNCED BY THE COMPANY. TRADING IN THE COMPANY&rsquo;S SECURITIES
DURING THE TRADING WINDOW SHOULD <u>NOT</u> BE CONSIDERED A &quot;SAFE HARBOR,&quot; AND ALL DIRECTORS, OFFICERS AND OTHER INSIDERS SHOULD
USE GOOD JUDGMENT AT ALL TIMES.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><u>XI. Inquiries</u></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All Insiders should review
this Policy carefully and contact the Compliance Officer if they have a concern that a contemplated transaction in the Company&rsquo;s
securities might not conform with this Policy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><u>XII. Certain Exceptions</u></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For purposes of this Policy,
the Company considers that the exercise of share options for cash under the Company&rsquo;s share option plans or the purchase of shares
under employee purchase plans in effect at the time of the adoption of this Policy and that may be adopted in the future (but <u>not</u>
the sale of any such shares) is exempt from this Policy, since the other party to the transaction is the Company itself and the price
does not vary with the market but is fixed by the terms of the option agreement or the plan. Accordingly, cashless exercises of options
are subject to the Policy when they involve the sale of shares into the public marketplace.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The restrictions set forth
in this Policy shall not apply to purchases or sales made pursuant to a Qualified Plan. For purposes of this exception, a &ldquo;<b>Qualified
Plan</b>&rdquo; is a written plan for purchasing or selling the Company&rsquo;s securities which meets each of the following requirements:
(a) the plan is adopted by the Insider during a Trading Window and when the Insider is not in possession of material non-public information;
(b) the plan is adhered to strictly by the Insider; (c) the plan either (i) specifies the amount of securities to be sold and the date
on which the securities are to be sold, (ii) includes a written formula or algorithm, or computer program, for determining the amount
of securities to be purchased or sold and the price at which and the date on which the securities are to be purchased or sold, or (iii)
does not permit the Insider to exercise any subsequent influence over how, when, or whether to effect sales; provided, in addition, that
any other person who, pursuant to the plan, does exercise such influence must not have been aware of the material nonpublic information
when doing so; (d) d) the plan includes a representation from the Insider adopting the plan that such Insider (i) is not aware of any
material nonpublic information about the Company or its securities and (ii) is adopting the plan in good faith and not as part of a plan
or scheme to evade the prohibitions of Rule 10b-5 under the Securities Exchange Act of 1934, as amended (the &ldquo;<b>Exchange Act</b>&rdquo;);
(e) the plan provides that trading under the plan cannot begin until the later of (i) 90 days after the adoption of the plan or (ii) two
business days following the disclosure of the Company&rsquo;s financial results in a Form 6-K or Form 20-F (such period being referred
to as the &ldquo;cooling-off period&rdquo;, but, in either case, not to exceed 120 days following the adoption of the plan, and provided
that if the Insider is not a director or officer of the Company, such cooling-off period shall be at least 30 days rather than the longer
periods set forth above); and (e) at the time it is adopted the plan conforms to all other requirements of Rule&nbsp;10b5-1 under the
Exchange Act as then in effect. Rule 10b5-1 provides an affirmative defense from insider trading liability under the U.S. federal securities
laws for trading plans that meet the above requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with Rule 10b5-1
under the Exchange Act, any change to the amount, price, or timing of the purchase or sale of securities underlying a Qualified Plan constitutes
termination of the Qualified Plan and the adoption of a new Qualified Plan, which triggers the cooling-off period described above. No
Insider may have more than one Qualified Plan for purchases or sales of securities on the open market during the same period. In addition,
no Insider may have more than one single-trade Qualified Plan during any 12-month period. A single-trade plan is one that has the practical
effect of requiring the purchase or sale of securities as a single transaction. With respect to overlapping Qualified Plans, an Insider
may have two separate plans provided (i) the later-commencing plan does not begin until all trades have been completed under the first
plan or the first plan expires without execution, and trading during the cooling-off period that would have applied if the later-commencing
plan was adopted on the date the earlier-commencing plan terminates and (ii) the separate plans satisfy all other conditions applicable
to Qualified Plans. With respect to overlapping Qualified Plans, an Insider may have separate plans for &ldquo;sell-to-cover&rdquo; transactions
in which an Insider instructs an agent to sell securities in order to satisfy tax withholding obligations at the time an equity award
vests. Any such additional plan must only authorize qualified &ldquo;sell-to-cover&rdquo; transactions. With respect to single-trade Qualified
Plans, an Insider may have a single-trade plan for &ldquo;sell-to-cover&rdquo; transactions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to the above requirements,
a Qualified Plan shall be signed and dated by the Insider, and submitted to the Compliance Officer at least two (2) trading days before
it is filed with the broker who executes it. The Company shall have the right, at all time, to suspend purchases or sales under a Qualified
Plan, for instance in the event that the Company needs to comply with requirements by underwriters for &ldquo;lock-up&rdquo; agreements
in connection with an underwritten public offering of the Company&rsquo;s securities. Any cancellation, suspension, expansion or other
modification of a Qualified Plan by the Insider who established it must: (1) be in writing, signed and dated by such Insider, (2) be submitted
to the Compliance Officer within two (2) trading days before the cancellation, suspension, expansion or other modification was reduced
to writing, and (3) be made during a Trading Window, and when the Insider who established it has no Nonpublic Material Information about
the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b></b></p>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>XIII. <u>Additional Information for Directors,
Officers and Certain Employees with Routine Access to Material Nonpublic information </u></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Policy imposes additional
restrictions upon Access Insiders, because of their routine access to Material Nonpublic Information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>1. <u>Preclearance of
Trades</u>. </b>The Company has determined that all Access Insiders should refrain from trading in the Company&rsquo;s securities,
even during the Trading Window, without first complying with the Company&rsquo;s &ldquo;preclearance&rdquo; process. Each Access
Insider should contact the Compliance Officer prior to commencing any trade, gift or other transaction in the Company&rsquo;s
securities. At the time of executing a trade in the Company&rsquo;s securities, such individuals will be responsible for verifying
that the Company has not imposed any restrictions on their ability to engage in transactions. If the individual has not completed
the transaction within ten Trading Days of notification of the intention to execute a transaction, then the individual must again
notify the Compliance Officer that he or she intends to execute a transaction and re-verify the nonexistence of any restrictions on
such trade. For the avoidance of doubt, this paragraph shall not apply to a Qualified Plan, after it has been set up.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Before each transaction in
the Company&rsquo;s securities by a Company each officer and director should contact the Compliance Officer regarding compliance with
Rule 144 under the U.S. Securities Act of 1933, as amended (&ldquo;<b>Rule 144</b>&rdquo;), which contains guidelines for the sale of
privately issued shares and sales by affiliates of the Company, if such sales are not covered by an effective registration statement,
to the extent applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>2. <u>Rule
144 and Section 16 Matters for Directors and Officers</u>. </b>Directors and principal officers of the Company must also comply with Rule
144, or another applicable exemption from registration. The practical effect of Rule 144 is that directors and officers who sell the Company&rsquo;s
securities may be required to comply with a number of requirements including holding period, volume limitation, manner of sale and SEC
filing requirements. The Company may provide separate memoranda and other appropriate materials to its directors and officers regarding
compliance with Rule 144. In addition, if the Company is no longer considered a &ldquo;foreign private issuer&rdquo;, the directors and
officers who transact in Company securities have to report such transactions through the filing of Form 4s with the U.S. Securities and
Exchange Commission. The Company will advise such persons if they are subject to the requirements of Form 4.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>XIV. <u>Specific Requirements</u></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><u>1. Speculative
Trading</u></b>. No Insider may engage in transactions of a speculative nature at any time. All Insiders are prohibited from short-selling
the Company&rsquo;s securities or engaging in transactions involving the Company&rsquo;s based derivative securities. A short sale, for
these purposes, means any transaction whereby one may benefit from a decline in the price of the Company&rsquo;s securities. &ldquo;<b>Derivative
Securities</b>&rdquo; are options, warrants, stock appreciation rights or similar rights whose value is derived from the value of an equity
security, such as the Company&rsquo;s ordinary shares. This prohibition includes, but is not limited to, trading in the Company&rsquo;s
based put and call option contracts, transacting in straddles, hedging or monetization transaction with respect to the Company&rsquo;s
securities, and the like. In addition, no Insider shall engage in a transaction with respect to securities of the Company if he or she
owns the security, but does not deliver it against such sale (a &ldquo;short sale against the box&rdquo;) within twenty days thereafter,
or does not within five days after such sale deposit it in the mails or other usual channels of transportation. The above does not derogate
from Insiders&rsquo; right to hold and exercise options or other derivative securities granted under the Company&rsquo;s employee share
option or equity incentive plans as long as such exercise is not prohibited by this Policy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b></b></p>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><u>2. Margin
Accounts and Pledges</u></b>. Securities held in a margin account may be sold by the broker without the consent of the owner thereof if
such owner fails to meet a margin call. Similarly, securities pledged as collateral for a loan may be sold if the owner thereof defaults
on the loan. In case of an owner who is subject to this Policy, these sales may occur at a time when such person is aware of material,
non-public information or otherwise not permitted to trade such securities. Therefore, this policy prohibits holding any Company securities
in a margin account or pledging any Company securities as collateral for a loan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><u>3.
Post-Termination Transactions</u>. </b>If an Insider is aware of Material Nonpublic Information at the time such Insider&rsquo;s
association with the Company is terminated, whether by the Insider or the Company, the Insider may not trade in Company securities
until such information is no longer material or until two Trading Days after such information has become public. In addition, if the
Company is not in a Trading Window at the time such association with the Company is terminated, the Insider may not trade in Company
securities until two Trading Days after the next announcement of quarterly earnings or of the material, non-public information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><u>4. Ad
hoc Restrictions</u>. </b>The Compliance Officer has the authority to impose restrictions on trading in the Company&rsquo;s securities
by appropriate individuals at any time. In such event, the Compliance Officer will notify the affected individuals, either personally,
by email or by voicemail, to inform them of the restrictions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><u>5. Open
Orders</u></b>. Any Insider who has placed a limit order or open instruction to buy or sell the Company&rsquo;s securities shall bear
responsibility for canceling such instructions immediately upon becoming in possession of Material Nonpublic Information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>XV. <u>Acknowledgement</u></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Please sign the attached acknowledgement form and
return it to the Compliance Officer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If you have any questions
with respect to this Policy, please contact the Company&rsquo;s Compliance Officer, at yafit@inspirao2.com.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><u>ACKNOWLEDGEMENT</u></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.15in 0pt 0.1in; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">I have received, read and understand
the Insider Trading Policy and Guidelines with Respect to Certain Transactions in Company Securities of Inspira Technologies Oxy B.H.N.
Ltd., a copy of which is attached hereto, and agree to comply with the provisions thereof.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="padding: 0pt; width: 60%; text-indent: 0pt"><font style="font-family: Times New Roman, Times, Serif">Date:</font></td>
  <td style="padding: 0pt; width: 40%; text-indent: 0pt"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="padding: 0pt; text-indent: 0pt"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
  <td style="padding: 0pt; border-bottom: Black 1.5pt solid; text-indent: 0pt"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="padding: 0pt; text-indent: 0pt"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
  <td style="padding: 0pt 0pt 0pt 0.625in; text-align: left; text-indent: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature&nbsp;
  </font></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="padding: 0pt; text-indent: 0pt"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
  <td style="padding: 0pt; border-bottom: Black 1.5pt solid; text-indent: 0pt"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="padding: 0pt; text-indent: 0pt"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
  <td style="padding: 0pt 0pt 0pt 0.625in; text-align: left; text-indent: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name</font></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="padding: 0pt; text-indent: 0pt"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
  <td style="padding: 0pt; border-bottom: Black 1.5pt solid; text-indent: 0pt"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="padding: 0pt; text-indent: 0pt"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
  <td style="padding: 0pt 0pt 0pt 0.625in; text-align: left; text-indent: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title</font></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&#160;</p>

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>4
<FILENAME>ea023322601ex12-1_inspira.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<html>
<head>
     <title></title>
</head>
<body style="font: 10pt Times New Roman, Times, Serif">

<p style="margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>Exhibit 12.1</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CERTIFICATION PURSUANT TO EXCHANGE ACT RULE
13a-14(a) or 15d-14(a)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Dagi Ben-Noon, certify that:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">1.</td><td style="text-align: justify">I have reviewed this annual report on Form 20&ndash;F of Inspira
Technologies Oxy B.H.N. Ltd. (the &ldquo;company&rdquo;);</td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">2.</td><td style="text-align: justify">Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under
which such statements were made, not misleading with respect to the period covered by this report;</td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">3.</td><td style="text-align: justify">Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material respects the financial condition, results of operations and cash
flows of the company as of, and for, the periods presented in this report;</td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">4.</td><td style="text-align: justify">The company&rsquo;s other certifying officer and I are responsible
for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal
control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:</td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">a)</td><td style="text-align: justify">Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company,
including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which
this report is being prepared;</td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">b)</td><td style="text-align: justify">Designed such internal control over financial reporting,
or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;</td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&nbsp;</td>
    <td style="width: 0.25in; font-size: 10pt">c)</td>
    <td style="font-size: 10pt; text-align: justify">Evaluated the effectiveness of the company&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&nbsp;</td>
    <td style="width: 0.25in; font-size: 10pt">d)</td>
    <td style="font-size: 10pt; text-align: justify">Disclosed in this report any change in the company&rsquo;s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company&rsquo;s internal control over financial reporting.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">5.</td><td style="text-align: justify">The company&rsquo;s other certifying officer and I have disclosed,
based on our most recent evaluation of internal control over financial reporting, to the company&rsquo;s auditors and the audit committee
of the company&rsquo;s board of directors (or persons performing the equivalent function):</td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&nbsp;</td>
    <td style="width: 0.25in; font-size: 10pt">a)</td>
    <td style="font-size: 10pt; text-align: justify">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company&rsquo;s ability to record, process, summarize and report financial information; and</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&nbsp;</td>
    <td style="width: 0.25in; font-size: 10pt">b)</td>
    <td style="text-align: justify; font-size: 10pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the company&rsquo;s internal control over financial reporting.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 60%; font-size: 10pt">Date: March 10, 2025</td>
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 40%; font-size: 10pt">/s/ Dagi Ben-Noon</td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap">&nbsp;</td>
    <td style="white-space: nowrap; font-size: 10pt">Dagi Ben-Noon</td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap">&nbsp;</td>
    <td style="white-space: nowrap; font-size: 10pt">Chief Executive Officer</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>5
<FILENAME>ea023322601ex12-2_inspira.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<html>
<head>
     <title></title>
</head>
<body style="font: 10pt Times New Roman, Times, Serif">

<p style="text-align: right; margin: 0"><b>Exhibit 12.2</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CERTIFICATION PURSUANT TO EXCHANGE ACT RULE
13a-14(a) or 15d-14(a)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Yafit Tehila, certify that:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">1.</td><td style="text-align: justify">I have reviewed this annual report on Form 20&ndash;F of Inspira
Technologies Oxy B.H.N. Ltd. (the &ldquo;company&rdquo;);</td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">2.</td><td style="text-align: justify">Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under
which such statements were made, not misleading with respect to the period covered by this report;</td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">3.</td><td style="text-align: justify">Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material respects the financial condition, results of operations and cash
flows of the company as of, and for, the periods presented in this report;</td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">4.</td><td style="text-align: justify">The company&rsquo;s other certifying officer and I are responsible
for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal
control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:</td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">a)</td><td style="text-align: justify">Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company,
including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which
this report is being prepared;</td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">b)</td><td style="text-align: justify">Designed such internal control over financial reporting,
or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;</td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">c)</td><td style="text-align: justify">Evaluated the effectiveness of the company&rsquo;s disclosure
controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such evaluation; and</td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">d)</td><td style="text-align: justify">Disclosed in this report any change in the company&rsquo;s
internal control over financial reporting that occurred during the period covered by the annual report that has materially affected,
or is reasonably likely to materially affect, the company&rsquo;s internal control over financial reporting.</td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">5.</td><td style="text-align: justify">The company&rsquo;s other certifying officer and I have disclosed,
based on our most recent evaluation of internal control over financial reporting, to the company&rsquo;s auditors and the audit committee
of the company&rsquo;s board of directors (or persons performing the equivalent function):</td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">a)</td><td style="text-align: justify">All significant deficiencies and material weaknesses in the
design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company&rsquo;s
ability to record, process, summarize and report financial information; and</td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">b)</td><td style="text-align: justify">Any fraud, whether or not material, that involves management
or other employees who have a significant role in the company&rsquo;s internal control over financial reporting.</td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; width: 60%; font-size: 10pt">Date: March 10, 2025</td>
    <td style="white-space: nowrap; width: 40%; border-bottom: black 1.5pt solid">/s/ Yafit Tehila</td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap">&nbsp;</td>
    <td style="white-space: nowrap; font-size: 10pt">Yafit Tehila </td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap">&nbsp;</td>
    <td style="white-space: nowrap; font-size: 10pt">Chief Financial Officer</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p>

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>6
<FILENAME>ea023322601ex13-1_inspira.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<html>
<head>
     <title></title>
</head>
<body style="font: 10pt Times New Roman, Times, Serif">

<p style="margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>Exhibit 13.1</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CERTIFICATION PURSUANT TO</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>18 U.S.C. Section 1350</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the filing
of the Annual Report on Form 20-F for the period ended December 31, 2024 (the &ldquo;Report&rdquo;) by Inspira Technologies Oxy B.H.N.
Ltd. (the &ldquo;company&rdquo;), the undersigned, as the Chief Executive Officer of the company, hereby certifies pursuant to 18 U.S.C.
Section 1350, that, to my knowledge:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1) the Report fully complies
with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2) the information contained
in the Report fairly presents, in all material respects, the financial condition and results of operations of the company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 60%; font-size: 10pt">Date: March 10, 2025</td>
    <td style="width: 40%; border-bottom: black 1.5pt solid; font-size: 10pt">/s/ Dagi Ben-Noon</td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="font-size: 10pt">Dagi Ben-Noon</td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="font-size: 10pt">Chief Executive Officer</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.2
<SEQUENCE>7
<FILENAME>ea023322601ex13-2_inspira.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<html>
<head>
     <title></title>
</head>
<body style="font: 10pt Times New Roman, Times, Serif">

<p style="margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>Exhibit 13.2</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CERTIFICATION PURSUANT TO</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>18 U.S.C. Section 1350</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the filing
of the Annual Report on Form 20-F for the period ended December 31, 2024 (the &ldquo;Report&rdquo;) by Inspira Technologies Oxy B.H.N.
Ltd. (the &ldquo;company&rdquo;), the undersigned, as the Chief Financial Officer of the company, hereby certifies pursuant to 18 U.S.C.
Section 1350, that, to my knowledge:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1) the Report fully complies
with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2) the information contained
in the Report fairly presents, in all material respects, the financial condition and results of operations of the company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 60%; font-size: 10pt">Date: March 10, 2025</td>
    <td style="border-bottom: black 1.5pt solid; width: 40%">/s/ Yafit Tehila</td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="font-size: 10pt">Yafit Tehila </td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="font-size: 10pt">Chief Financial Officer</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>8
<FILENAME>ea023322601ex15-1_inspira.htm
<DESCRIPTION>CONSENT OF ZIV HAFT, A MEMBER FIRM OF BDO, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 15.1</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: left; margin-top: 0; margin-bottom: 0"><IMG SRC="ex15-1_001.jpg" ALT=""></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</U></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Inspira Technologies Oxy B.H.N. Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2 Ha-Tidhar St.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Rananna 4366504, Israel</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We hereby consent to the incorporation by
reference in the Registration Statements on Form S-8&nbsp;(Nos. 333-259057, 333-277980 and 333-285565) and Form F-3 (Nos. 333-266748
and 333-284308) of Inspira Technologies Oxy B.H.N Ltd (&ldquo;the Company&rdquo;) of our report dated March 6, 2025, relating to the
financial statements of the Company which appears in this Annual Report on Form 20-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our report contains an explanatory paragraph regarding the Company&rsquo;s
ability to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top"><TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Ziv
    Haft</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certified Public Accountants (Isr.)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BDO Member Firm</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tel Aviv, Israel</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">March 10, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !0 .0# 2(  A$! Q$!_\0
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D?PJO"-SDGL,U9/3'4U+-*6MY$<F=WX44^< .H]%%%*YK8__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $1 CH# 2(  A$! Q$!_\0
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M9QQ]/?CN*T]F[7(YU>Q[117CVG>/M>M]%\=ZA,_VR32KLQ6L;(,1@R%<G'4
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MZN?3Z4_;5/YF+V%+^5'::5=:KJ&H+<G49CI_E [!(<LQ_I5Y;NZ2[DBDNIR
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M_LBV_OW'_?\ ;_&C^R+;^_<?]_V_QJ]11[:I_,P]A2_E11_LBV_OW'_?]O\
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MM(!3P/>@ "TUY%C(&"3Z"H;Z^BL8/,D.!V&>M<3<:W<W%R[%MD8/RX&2/QH
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M>V[_  KV3P"!_P (.IQSY4G_ *%45(*$G%'=A,0\1251JUR[11169U!1110
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M<LW8"N.\706_VB6YMD"1O@/&. 1V/UH#8ZGPO<1S^*-':,#F4D$="-AKV2O
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MRTN]N) UM'\O>1N%H&3V/A?78IC<!H51OF,;2?,?TP#2WGA"6\E8R(8<Y8R
M@X/ICO7=),HC4%@3@#BE0"1O:@1SEE9-967V=5DDCC7ECR35-B[8(23'NIKO
MXD2),A:I2:U8+(T;W$093@@N.#0.YQ:'! 88SZTD\D:#!^9CT ZUW"7%C=K@
M"*0'TVM69<Q6\$C&*%4/J!S0%SF[6&ZE?)0P0CJ2,$_05/\ 9Y3Q'<L7[9'!
MJT\I)Q3'8Q?,H XR2>U &,-3D5FCE7E3@^QJ>*XCE(PW/O61<.KW#N@P"V:C
M5RK9!Q0!O2H)(V4]2.:JZ??M;2M"^<9XS3;2]WD1R'GL:BOX&!\^([BO) H
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MZ7..#4QS@&JVTQL#GO3]S$\&L3860\<=:S[DL\38ZCDU=*LO)[U4F!SQWZT
M<-J>8[YR.01UJ.WG#VKH(SN1>N>I)JQK49CO2O8]*JQ?Z/'&H \V5@1GMZ?X
MT ,N%>:Z@LP2S\(6]R>E>J602VBCB1/D10@/3@<5YMH,:S^)('8_*A)3/K_C
MWKT/ (X(SGUH Z#:8]H8#YAD$,#7">+-AUI0  WE_-^?%='!<&+&3D9_*N'U
MJ\:YUF>4\A3M'N!0"(HX]K!>34C)M&,9/I44,ZG)/X4_[3&7W'!(]:!C]IVY
M#$9IC!L '!/N*D%T7!VH,9["F?: 4RR8^M &1=Z<-_G(HC;KD>M6;*]#'R;H
M!6Z!NQJ\TD<B 8)/TJK/9;AD+@#N: +Y+11/E3*N,@+UJE!<P7RD*,,/O1N.
M13(Y+B!]^\Y]<58*6MZRO)^YN!TE3O\ 6D PW5O:!;.[A,UID2)MZQMGM[5V
MVD:W::E"HC(R1QVKS^YL)(7!F)VGHX.585;M+=EGB>"7RWW [AW]J8'1Z_81
M/=13(RJS?ZQ/[WO3;>,#Y0O2A?M-T[2.=W;)_E5VVC6,C=PW>@1/##MBWLG'
MI6=<:G#;3,99""RD $?>QTQ[UIWMRL4 2/J?T'K7#:E*;N]B>-\Q1Y7\?7_/
MI0".UM9EEC1U/RL,BK0)4CWK*TI=FGP@]<9_6M(?,0!UH MHS%01G)J0,0!D
M&H8E(QO&/I4N65@0>* +>D,#XHT<?]-V_P#0&KU2O*M(;=XJTCI_KV_] :O5
M:UE\$?G^9C#XY?+\@HHHK,U"BBB@ HHHH **** "BBB@#D?$<@C\6Z.2P7,,
MP&3CTJSYS#IBL[QC:+?>(=+@< @PRG!_"N;N(]3L5807$A5?X'^<#^HJZKTC
MZ?JS.DDW+U_1&5XTO)(]6EV+\[;5'MFN<DN$601F4%AU]:L:MJ#WEXS70$<O
M'S Y&1_*N>C#N\]L6 ?>&23L?:N5O0ZX1N]34DF9TWK_ *L'&?6G6ZJTT;9^
MZ:A4^3)Y;],<@=*M01C8<>N:QD[ZG7!6T%U" PR)(%'SG@]@*]&\!3W+Z;*L
MI)@4CR\^O?'M7"7!V+#NB>12.,=*[GP=,_V::-TV MN09[54-Q5Y>ZTCK)!O
M4CL>.:\[U7PZMAJ#*JKY3_,G';TKT,'(K-UNT^U6995S)'\P_J*Z3SS@GT^-
M2, 'VQ3-3M+9-)F+1[1@9*KD]1T'>M%^HQ^=4]8?;I,W[H2_=RAR=W(XXH0@
MT>Q:6SC6\M8XY<D8" ';V) Z'':M3^S[6W5VCB4.#]['-4_#D833X@ER+A>2
M'&<#_9&><#ISS6M/Q&_^\/Y4 +:G_1T^E3"J]IS;I]!5I13 D4=*L*.*B0<B
MK"CB@8R,?/5M1Q5>-?GK*UCQ=IND!HPWVFY'_+*(]/J>@JHPE)V2$V8%X/\
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MJ3DTIN1_%(?^ K5.(QJO)%3 HPZ@CZT6"XYKB,?PNQ]S43W!V\1@?4YIY5"
M./SIODJ?3\Z+"N0//(!Q@4S[3,IZJ?J*GD1>HQ47E9/3-.P7#^T)U/\ JXR!
M[4AU6Y/ C 'M3O)YR,5*EG(X^53C\J5@N5_[09B/,$A_&I$O+,@;_.!]"*G.
MG2D_,J\CNPH&DOGYVC ^N:+!<:+NS)^5&8^[8IXO8A]RV7/N<T[^PXBN7G7\
M,4PZ-:(.)3GU#46"YI^';HS>+=)3RE3$S'C_ '&KV"O&_#5M'!XNTG8[']\P
MY.?X&KV2M)_#'Y_F9P^*7R_(****R-@HHHH **** "BBB@ HHHH X_Q/$)O%
M.DH<X,$W ./2D>WC5"K*?4!C@#'I[U3\>7+6NN:5*DA1O+E&X'![5D1Z]=0H
M"TBW"C^%V&X_1NQK6I545%/M^K)HTG+G:[_HA^JLJ3P1H<[BSYSG/X_C2VD(
MC!F?L.*=-=6VI75I)&%5&1F.YAE>V#[U).Z$X$B;5_VA4O48OF +Q]X_I4D
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MO0$T?P];\1V<4C=,R29_K5R(V=E&!!'! /2/&?SJWC8K9$^QONSB[3PQJEX
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%** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %$ G # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBWGO97B_[X+8(]C7;T4 9FJ^']-UFSM;2\M\P6LT<T*(Q0*R?=Z=AZ5IT44
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ML[N)9;>92CHW0BK%% &':>$M,M?M#$W5Q)/ ;=I+JY>5EB/5%+$[1]*MG0[
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M<XK4HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'T/(HU/3A?:2]E&RQ [=I(R!M((&,CCBL>+PB54E[S#-(TC*B'8"64\9)/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^'M"M].B.2@S(_\ ><]30,U:*** "BBB@ HHHH **** "BBB@ HHHH ****
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M+Y,-OGM_>;^GYUZU7.^!+5;3P3I:*,;X?,/U8Y_K714 %%%% !1110 4444
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M^<+WX8^*= T^[N]2@CM8[>18U8N&$I;IMQU%?7=>7?'&\,'ABP@!QYUUD_\
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M&Q'U7/\ 6NCJS%N[N%%%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M< ?A0!+1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,ETFIVTID R(T5\EF&1E1U([UU59^MZO#H>DS7\T;RB/:%CCQN=B0 !GODT
M>:7'ACQ='I^L7T=Q.VO0ZKYEI<1 *LT+HB/A"<!<9./5<UJ:9;:CX-\1ZM%;
MZ/JNHV3VENEK+&P<.Z(=VXLP()8\GWKKX_$NG/;W=TTA2UMHHYFF/W2KKD$8
MJ,^+]$558WH&0=WR'Y,9&&XX.01@T >?Z%X3\4S1ZKI?B"(BWUR!KAKA;@R_
M9KK=G..-HPPP!D92NIT_P&^G^((]1BUFZ^RQW+SI8?\ +)-R!<#G/;Z>U;$G
MB_08HY';4H2L9*M@YY&WCZ_.OYU%)XU\/11-*VHQ^6JJQ?!V_,,CGUP"?H*
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MXBTWQ%>ZZDEB7^SQ%)+=O,01HP5]VY3R3DKCM0!HKX2LTTV]L4FE2"[$*RA
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MS(X)/-",?E)VD<COU-7:QO$FF7>JV$4-HZ967=)')(T:RKM88++R,$AO^ T
M5/\ A%=,G\.W5EITKQ6]]$H65'W80<KM]@#Q^%.MO"FCB<2QO-*\<F9P9RPF
MD!W9D'\1!.>?:N>B\#ZW#:S1?VF7)M8X80MRR(NU$7!78?E!4GKSGH*CU'P_
MXB_X2"U^]<6S?.6AE*(CDX_(#!]\ 4 ;\/P_\/6]O+##:NHD503YA)!5RX89
M[[L<^P]*DNO#>A2026\TA4PE;AV\P!DPI&[T (SGBLB3P7K -ND.K2+!'('9
M%N&!W;$!<,5;G<K''^UUJ>S\(7RP:W'>2P.U_;F$.)78N<L0S9''WAP,]* -
MG3M!TN.=M1M'E=;A'*CS28P),%BH[9(!JO%X(T>*W\G%S(0NQ9))R750 % /
M;:!QZ5DGP;JAF:,7R);94$I-(&DCWQML(QA0JHR@@\[NU:.M>']2O;R9[*Y1
M(WM!#"S3.IMV!.2 !@[@0"<Y&.] $Q\%Z.Q)D6>17!,ZO,2MP<$;I/[QY/-/
MA\.:6VFWFG)=7$JW++).YN-\APH"\]AA0/PK(B\'ZD94EFO0@4_)"D\C+"I8
MED&<;AM.,D57B\$:HME%;_;(H5B@\M%AFD #A2%;.!W(- '0V_A+2K6Z-Q#'
M(I,B2[=_ =<8/KV&>>:B_P"$*TD.CJ;I'C0+$R3$&+!)RI]>3S[UEW'AKQ!-
M*P:\MY+>,G;&9Y%\\&7>0Y ^7CY>,TP^%?$/E&W?4DFA\OF3SW20ML"X^Z1@
M$=><^E '5:9H]GI"LMHC*'55;+$YVC /UJ_6;HB7\%BEK?QQ![=$C$D;9$I"
MC+ =AG(Y]*TJ "BBB@ HHHH **** "BBB@ HHHH **** "L>_P##5CJ%S<3R
M2741N8_+G2&8HLHQ@%@.X'0^PK8KCO$.B:Y)?WVHZ7<!7,<?V=#(2?,4KQC
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M'#/)M1LQXZ@9X1AR/XJL^ ['4[*SO/[4@ECGDE#;Y)=V_CG [8_6@#K:***
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
2HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %B D8# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^&)IU5)*^[_S9HR2)#$TLKJD:#+,QP /6L]?$&C,VT:I9Y/_ $V7_&H_$_\
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MA11161J%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MDZWJL^GFSMK.&.:\O9O*B$K%47"EBS$<X '04)7 UJ*Y+6?%EUHKVXN(+1F
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8[=ZP-+\%W=CY!EN8',>F3V1P&/S22%\Y/.,''K6GJ&@7-QX*@T>*6+[5!#
MJLV=C-'M//?!V_K1:-QW=BY+XFT:">*&6_C225590P(P&^[NX^7/;.*EO=3-
MGJ^G6112EV)2TA;&S8N:YW4?#6KWW]IVX>R6WU@1M=.=Q>!E558)Q\PPO&<8
M.:UM;T!M6DM56?RXHK>X@<]6Q)'L!'TZT6079/!XFT:YSY5_&?G1.01DN<+C
M(Y!/ (XI]SXATFS\SSKV,&.3RG5068/MW8P 3TY/I7-V7@J8Z3<VEW'!'<?9
M%MH;I+B64Y4[E;:QPH# ' I'\'7ZVNFW!FBN-0A>>2[Q+)"LSRX+%67D8V@
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MR#WK8;7]*26[C:\0&T4M.Q!VQ@8SEL8XR,C-<S)X5UF_MKA;V6PB=M/2RC$
M8CY7#;CGL0.G:I[[PMJ%W<ZND+V]K:7L4BM&KNRS.Q&'93PI !!QUS3M$5Y&
M_;:_I5XA:"\1U$33]"/W:G!;D=,]ZBG\4Z);3)%-J4*.ZHP!SPK_ '2>. ?4
M\5G:SH.IS7J7&F/: R:>]A*)]P" D$,N.N,'BL1_#VL3WFK:3 +5;6>PM+2:
MXF1L_*C!F3L?IV)%)) VSKM,\06.JZA?V5N7\ZRD\N0,A /3D$CWK)O/'5C#
M;ZDT"EI-/N4@F$H9%P64%LX[;OTK3TO3[RPUC4W<PO9W+K+&P)\P-M"D$=,<
M9S[UDW?AC4+B75H!);?9+R[BNT8YW J4W*1TQA.#[T+EN-WL;*^)-'>P:]6^
M0P++Y).UL[_[NW&<^V*O6=Y;ZA:1W5I,LL$@RKKT/;^=<EJO@Z[N]4NM1AGC
M+M?1W<4/F/'D+"(B"R\@]P171:%IJZ5I:6X@CA8NTCI'(SC<S$D[FY).>?>D
MTK: F[ZFE1114E!1110 4444 ,FB2>%X9!E'4JP]0:XK5/!,ZJ&T^59EC8/'
M'-C>A'(*MV-=Q13N!Y)J?Q2U?PO>?V=J>FI//MWAFS&<9[\8/3J*RM(^(-MJ
M/C2VN&LVCDNKQ 51LA04"9R<=^>E>N:UX=TGQ#;>1JEE'<*!A6(PR_1AR*\O
MC\ :3I'Q%LTMI+CR$N(V2)FS@[=W7KU%2[ >LZH,Z1>C_I@__H)KF_ TFZ*=
M./\ 5Q-^AKI]0&=-NAZPO_(UQ_@ Y>X_Z]X?_9J3W0';E02"0"1T]JS;+28X
MKE[J=%:<GY6SG K3HJ@,'QIIL6J^#]3M)B54PEPP[%?F'ZBL+X8: -!T[44^
MT><9)U.=NW&%_P#KUU6O\^'=1_Z]I/\ T$UG>$N+6['_ $V'_H(I=0(_&YQI
M-K_U]Q_UJ_X8.[PW9'_8/_H1JAXW&=*M!_T]I_(U>\*_\BS8_P"X?_0C2Z@;
M%%%%4 4444 %%%% !1110 4444 %%%% !116!XH6ZE;2+>WN;FW2>_5)WMV*
MMY>QR03V!('--*XF;]%><Z+)JT,EC<SWFISG^T+RU>.1B0T*+(4X_O?*N&[U
MG1ZOJTUOJ_V*YOHXI-/CDC_?23/#*90",LHPX4\J,CBJY"><]/%];-J#6 F4
MW21B5H^X0D@'\P:L5YMJT-[I/C5#%+?-IJV4*WMR&9Y]OFN1AO3.-V.0O2I;
M.?5;WQ1-!<ZBUN_VR:-[?SI07M\,$")MVCC:P?=GK]*.4.8]"1UD0,C!E/0@
MY!IU<5X(LR?A^;""ZNH[M4DB<N[;H),D8&>F.#Q6%:ZUXEO98<M>11ZEY=@G
MR$?9Y8BHEDSVW#S"#_LBCDU8^8],BN[><L(ID8J[1D _Q#J/J*2UO+>]A,MM
M*)(P[1EA_>4E2/P((K@)U>77--N]1N+V.*'6;R)71G4*""$!QV)XS[XJ;1+6
M]L;FPNH[J^ N-6NXIK=B?*$9:0CY>W(!S[T<HN8] HK@_$]]/%K6H1W-_J%H
ML=FK::MIN EE^;.<##'.T;3V-0:EKFIVB:G:W$UU'J$ILVMXXT8X!5/-VD#
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MJK+;"XLEOX('8S\P^8B#"+CD!FR>G6A)V$VKG<45RNF>,'U+6$@BL&-E+-)
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M/4[N]@GD\]M/7"FUFC"DJ 0,AP!D@GG!ZUC6>N:V/#%U?P7VH31?V2D[W%U
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MD268AR#O0 *1Z$;13'\,:5)I=QI[V^Z*XD:61BWSERVXMNZYS6Q11=A9" 8
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MLWZ?X4?\)MXC_P"@K-^G^%']FU.Z#^U*7\K_  />:*\&_P"$V\1_]!6;]/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MXQGFFQ:3),+AX[JU,%OM,DV\A0&SCMGMTQFCEIVW#FJ7V&:=<VUL)EN(R6=
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M76N+<%\0R8:R^R9DDW-]_=N)Q^E8]%%.,5'8F4G+5A1115$A1110 5L^$_\
MD:],_P"OA?YUC5L^$_\ D:],_P"OA?YUG4^"7H_R-*7\2/JOS/H"BBBODS[(
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH ^9J***^P/B0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *V?"?_(UZ9_U\+_.BBLZGP2]'^1I2_B1]5^9] 4445\F?9!1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
' %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $V FH# 2(  A$! Q$!_\0
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M@8R0,]* RL2 P)'7!Z4 +12!E+%0P)'49I20!D\"@ HI P894@CU%(70 DL
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M .QKG7\$),";+6+*<=E9MI-4KCP5K]K\R6C2#^]"X:BT@.M/Q#<?\PL?]_\
M_P"QI/\ A8K_ /0+'_?_ /\ L:\_E@U6R<B>*>/':1#_ %IJWTH^_$K?3BE[
MP'H#?$>4?=TI3];@C_V6E7XD?W]*9?<39'Z"N$2^A/WXW7Z<U*)[9\?O%![
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MF-"V"!S@9Q7.Z-\/M(NEG-S#*=K?+B4CBLYP<-SHH8FG73=-['3_ /#3#?\
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M+_Q7\.-IOCK4IK9!'!.RS8 XRPR3^>:];'B77IKNW;3[VR:Q_=D1%2791@$
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MR,Y73NMSEM1L&A##RRD8Y4'T^M<1?C-P0. M>\^+K!!H$)TV,RP&/8WG#.W
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MA&&X=JLF8I.QJP(T@LWU.90(E.V%#_RUD]O8=34VNST5HM#H_ :L]UJ#G.Q
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M<#/I3A&S"4KHTWD^U200[6;+9R#Z5U7VN".WC5T*C.>37E<7C"*TNO.BL][
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M!/A5NOAS2C];1/\ "N4^(VM:S8:@D6C_ -HI/' DT9BYBD/F %=H4[SC.<D
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M;WMC MHL*B)HGB7S"1MS@'/?BK/@#6]0U?Q'(]_K$S*\,K1VDA.)2)"-Z#8
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MT!FFU")(QU8YP/TI>17++L:U%<_'XX\,R_<UFV;Z$_X4Z/QKX;E?8FL6S-Z
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M="UCCG'%0RP*JFE<1YKXPTG?9BX1?FCZ_2N(73I;B,,I4>Q->HZ]=%TEMUC
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M>O/:NVTK7ETRV U"Z@2V!VJJ'>PST)[X_E7EDVIW%SO6=BR.5X))*@=@:IJ
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M4=96_ "JLM_;KT@)_P!]_P#"LIQ.PQO_ %JNUG*W4_K1S!8NW&L1Q@E8X%_
MM6!>ZY/)D(S*/]E M7&L'QTJM)I._P"\:.8+'"7MJPUH7X94'+OY@R"P'?Z]
M*Y^ZN8[JZ::.$1*P'R#H.*],FT&*9L-DBJW_  AFEE][V^X^[G^E4I*]V)Q/
M/Y'B-C'Y:-E6_>.3W[5$@>0XCC=S_LJ37JEOX>TZW^Y9PC_@ )JZMI#'P(P/
MPIJ=@Y3RJ+2=3G_U=C,?<C'\ZZSPGX5FCU 7NH1KNBYBBSGG^\?I77*(E[ ?
MA5F*558;>*3FV/E+J1GC)Q^%3K$IZU&C*P!S4HJ1CQ&!T(I3Q2 TI]L4 2V^
M?,!S6P"Q3D#ZUCP<.*U5E79B@3*5VN>Q/TJM'@'&*N7#<]*J;A0!)BFL@S1N
M II>@!KH6P,]*NPG" &J>_GD58C?B@"VIS7>Z-_R"+;_ '?ZUY\&'K7H&B_\
M@>V_W?ZU<-R67ZXGXM9_X5IJNW.<Q=/^NJUVU<3\6RJ_#352^[&8?NG!_P!:
ME:D/8^6Y)6!Y!_$5 TY\P'&5'4>M7)1<(JI(J(>JLQSD4QPSX9AR>VW"_G18
MBZ+6FV'F*]Z)HHE4]&.23]*=/(\L@9B&)X  JH80H#.-A/3!Z_E79_#SPV=3
MU?\ M&Y!>TM""N>0TG;\NM#3:L3*2CJ>@^"/#XT'1%,RC[;<X>8]U]%_#^=;
M.J:C'IMBT[D@] 0A;'O@=AUJP6 '4 >]<!XVUF^A22&":W2.6++$DB18P>?^
M^B*I+H<6LG=G$^(]0LKB[EO-/B9#)*?E?)++C[S9.02:R#-!'Y<A +;@?E;)
MS39)Y+VZ>]*^VTG@ #&![54E9G<E54#T'85KSM;'0H(Z<ZO:QV230(9E!P8V
MBQ@^N?\ /:K/]HVDFF-J*V?DN#LC]7/I[BEL/+MK1H8(RLSIPHZ?3-84GB'4
M+&](6..$QJ42/;D)GJ1[^]):.[1-KZ(S6)9BQZDY-(#4L5U;W%P!<;T+MDLH
MS]>*V3%HUMJT4L+7)ME7=LN8P"6[=.-M=/M(BLUT+=N@T_2(H("KW5SAF(Y^
M8_=7Z <FM%'BTZU$8PVU?E+-C<W4G^9K)M[FUN;]IIG1O+8[%S^)/XUJ_;%D
M$UP4@FA@&'&.%SZ'WKF:<G=CO9"3R2>7;S27!$4;9,0&,@^I]?\ &G/-#/<1
M+<63DR9**&W;AZ8/(K'NISJMUY3XM[907$H&[&.<=:LZ:%OYE47#O.C^7$^,
M;R3@8'IZUMRV5S,]FT1([/0[4A %$895QCD\U<BMYM08RR/Y4/>0_P A3K>U
M5+:%93F.) N!W(I[F>[(2)2$Z #H*R9DC;T%;.*1X[9/F"DLYZGI6[6'H6G2
MVDC2R'[RD8_*MRLI;GH4/@.:\<WM[8>'Q-88\[SE7D]L&O)-5OM?UBV,,Z*4
M'. PKU?Q^=OAP'_INO\ (UYJD@$>#P2:N.)J4XN$=/EK]Y3P]*4U4E&[1F:9
MIYMM)>WF4"20EF'7Z5S-U%MD93V-=K(^TURFJIMNY/0\USP?0Z)&!"PBN;R;
M_GE%M'U-8,\A>!SZN*T;F?9I\[#K//C\!6=!:SW-E>31H6C@VM(1_""< _G6
MU];F;*-(>E/VT^&+S9T3MGFA*[LA'N?@=&LO 5CLC:1F#-M'7EC5RXDDNB-\
M$D>WU0-FI/#\9A\-:?&.,0@X_6KC*34R5G8I-&7Y>RVV#/+9_P!4%K2C@8SQ
M2!EPJXQWJ*Z$0B'GJS*3Q@5"SHFM6D0R"4&!CMS7/53:5NZ-:=.-1M/31O[C
MRKQ^"WBJ_!))R,?E7&5VOQ &/%5\1_>7_P!!%<5WKH,33T6Y,-T4)^612I%4
M9)'W,H/ )%.M&V7*MV'-5W=G9CGJ<TA$D4H3*L,@U9A"ABZG/'2J&*579#D'
M% &AM"#>QQDU]6_"D ?#?2L'(VOS_P #-?)2W*R#;(/QKZR^$@ ^&>D '(VO
M_P"AF@9VU%%% !1110 4444 8GB\9\+W@_W/_0UKR;RAGO7K/BXX\,7A_P!S
M_P!#6O*=QK&>Y<=AOE#TI<$= *=G-'-04 +#J*4X[TTG%(6I /PH.:"]1[OK
M1NH&.+$U&V:<7 [4PO[4 0E03TQ2%!4IP332!GDTP&;>.M1,CYZY%3$X[9I,
MYH$0^6V.13T3GFG[0:>B"@"Q#\JX%6 YJL@P:DW<=:8$PD.:D5P:JAJD5@>]
M %Z+&:NA\+@UG0M@BKH;*C&*!,CG((XJKR#5F3W%56X- #PP[YI"U,S2$T .
MW'-3Q,&'/454SGO4T>>U,"Z/K7HFA_\ (%M?]S^M>;+D=Z](T+_D"6O^Y_6J
MAN2S1KC?BHGF?#K4T\I)<F+Y'. ?WJUV5<;\4W:/X=:FZ E@8L ?]=%K4A['
MS2+"))C^_2%A_ C9 ]B#226T^UI 8Y%[%3MS_2H+EMTYG=H(V_N%<_RJI+J,
M0!19995_N+\JYJC%)LO6%G<:A?164,1$\SA5!Z?7Z"O>-'TR#1=*@L8/NQKR
MW=F[D_4UQ7PVT$6]F=8N(=DLR[85)SM3U_&NZNKJ.TMI+B9@L<:EF)]*#FJR
MN[(YGQ;XKMK>PFL+&?-[(?+.."B]SS7FKQF:X<W#SSN4'.> >V35WQ(E[?:G
M<:BS(Q<9*1<^6O8''?%5$U&R=&MBLL".@69\?-)W/T%:Q?*AJ&A&FC%F. Z6
MY&%D_P">AZ' ^M20Z#%]JF.9##&VTD\;L=0/\:K2:A))=12IB-(,!4SV'3@U
MI0:Y!*\V6D,SY :49 'L*))HM-VT-2&_L=-<W'GR22HN(HI$(YQ7':A=/?W,
MUQ*%+R')..:U=;E0100L@DGV[C*&X /;:.AK%QN.*NG!6U)OU*Z1^4ZRK]X'
MBM)KW[0H^TQ%B!@,&YJK@$^PK0T:T6[U%!+GRD^9ACKZ"M/9Q6K!S9T%NT*+
M'<G2)"#&,AB!O]]O;Z]ZRKI#>7$KV]H]I;Q8")@L2WO_ /7KIC:VEKJ\>HRW
MLLJHH9HH2"!Z ]/RKI8]8\/Z@%BFOH4D?^"ZBV$Y[9(K#FY7H2>:2PW=N55&
MAE9EWD)\I [YKL/ VEPWNN64OV:7="AEEEDZ;NP%-\6:1H>C6<-Y;6R27,K8
MBCMYBZ,.Y*\\5WW@RS@TSP]!<2A5N+L"0H% (STX%4YW6A+T1TZ6@F&^1@D2
M]JF%Y#$/+M8=[=CCBF2WEC(BH&D=\?<44U<JOS8A3^Z/O&H(V-737F>5C-("
M<'Y!T'2M.LC2)4>5D1<  G)ZGI6O6<MSOH? <E\19!'X8#,>//7^35Y$+S<<
M@\5ZA\625\&@C/\ Q])T^C5XG'.P YK-HW3-_P"T9ZFL#79UCB>4GH,"K N\
M*23@ <FN/U[5_M4NV(YC0_+_ +1]:(K4;9F7ESN$4(Z1@Y^IKU+X/:)!J6EZ
M\MY$6@N8UMVR.Q!.17CPR6R>IKZ(^$%NT/@MKAACSYFV^X Q5LD\9\4^&KSP
MOK,MA=*2N=T,N.)4[$?UJGID:F1I&Z"OI?QGH>FZWX9N4U&$-Y$9>*0<-&V.
MH/\ 2OG74K#^Q%EMS,LKM@ATZ8(S_*JA*SN)K0]!M/B!H\>GVUNPN4,2!24
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MWKMQ\.[8?\O\O_? IZ_#^V7_ )?I?^^!3Y6%T<@C"O3O#_\ R K3_<_K6(/
MD _Y?9/^^!72V%H+&QBME8L(Q@,>]5%-,ELL5S'Q!?9X*OV]#'_Z&M=/69X@
MT9/$&B3Z9),T*S;<NHR1A@?Z59,E=-'SV+OWI#,C') #>HX/YBO3/^%.V?\
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MW[LX.?\ 4K_C3 \,M-.,C+YF?FYQ5NQT<W%ZRX.Q3R:]V7X$V*-N77+G./\
MGBO^-20?!.&W<M'XAN1GJ/LZ?XTI;^Z"\SR0:<EJ=L1*^M4KK3I'$DJ2.9-N
M$"8&3[U[M_PJ"T8?O-6G9O41 ?UIG_"G++_H+7'_ '[%)7*T/G6.VDB<F4%6
MZ8-2%:^@Y/@OITHP^ISG_MDM4W^ ^FL<C6;H#T\I:!'@V"#2'FO=S\!=./\
MS&[K_ORO^-)_PH/3O^@Y=?\ ?E?\:8'@4J54=>:^AF^ &G-_S'+K_ORO^-1'
M]GK33_S';O\ [\K_ (T"/![#2+K49/W,1*#JQX%?5_PQMFL_A]ID#J%9%8$#
M_>-8-E\&[*QM5@CU:<A>YB7_ !KO=$TM=%TF&P64RB+/SD8)R<TM0-"BBBF
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MZ.=)@TR*VDN=1O1:J;DML3*LV3MY_AK-F^&6BWT-V=2::]NKB%(1=2GYXE1
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
>HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %. S,# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH ***,T %%)N &<\>M&0* %HJ.2>*)=TCJJ^I-9=UXFTZVR!+YA'9: -BBL
M;3_%&F:C.($F\N8_=23C=]#WK9H **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /G3XM:NVH>-+BV
M#_):((1Z+W/ZFN(>XD0X$R@#@<U9\17+77B359I&R[W4I.?]XUF):I<":1Y7
MC6-OF*Q%P >YQTH$VEN/>_=?^6PJ$ZF^>)0:<VE6^R1WN+@!"!D6QQTSS^%4
MI(+%54VMY),Y;!5H=H QUSFK46WJ0YJUTRXM_,Q #9S4K2WNS<JDCVJSH]DL
MKJ&S@'%;7]E/'9*Q#C<V/<'U(KT:6#4E=GBU\SY)\J.0DU"Y7.!R.Q.*9:^(
MS:SN9X7;Y<!<#@_C5R]MQ(\BD*C+DY/>IO"_@FX\:W-S!!=1VSVT6_<Z%MV3
MA5XZ#/<\"N6I1Y'='?3Q"J1M(RUOWNM.FE;@JQ _*LBW?<XX.#P>*NVJE-*N
MD;&5D(./85!I8#WL$3?<E.QA['_.:Y3O':-J+Z;J*.&/E.=LB]B/7\*[R60,
MC+GJ*\S?@L.N"1FNVCGE,,9"G)13EC["@"+3W9[$QC_EE,R#Z'D5>CA)^\:H
MZ-GR+G/_ #W_ /9:U5H >B*N,#O7HWPB7/BFY/I:G_T(5YV.H^M>C_" 9\2W
MI]+3_P!F% 'L]%%% !1110 4444 %%%% !1110 45G7>MZ?9Y#SAG'\$?S&L
M.[\72ME;2!4']Z3D_E5*+9+DD=82%!+$ #J365=^(]-M,CSO-<?PQ#=^O2N*
MNK^ZO6S<7$DG^R3@#\.E536BI]R'4['0W7C&[9P;:"*- <X?+%AZ=L5M:5XE
ML]1VQN?L]P?X'/!/L>]<$>M,90W!%-P1*FSUJBO/=+\3WNF[8ILW-N.-K'YE
M'L?\:[33M7LM5CW6TH+#[T;<,OU%9.+1JI)EZBBBI*"BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y!U_Y/$6JKZ7,P_\
M>-2:1K\.DV]_;SQ&19F4JH[]FS[;<_C3/$XV^+=93TNYA_X\:RX+-;R6?<MP
M=O3R4#>O7/TJX2E&5X[F%>E3JTW&IM]QT=UXJTJXN+^,F?[-<*,[4"DMMP6Q
MGC/ KB;9L2#N,]*OW5GI]I(%N'U!-RA@&@"D]<]3]*S9'@2<"V:1TP.9  <]
M^E;.I*3]XYJ6%IT8-4GH[=;[:';Z/+B,.N!V/L:ZI[EI=-66,<@X:O/])OVB
M&70LC?>']:VGUV-8$B@WE<DOD8QQ7L4*D5&[/E\9A)SJZ+J9VJVX-S<%5(1%
MW8_2K7PT_LB34-4&LZE-91?9&57CG,603\W(ZX'.WO4%_=A[2Y*_QP_EDCBJ
M_@#Q79>%=5OI[^Q-TD]N8U50I.<YQ\P/#=#WKBQ32GH>U@XR=)IK:QSUL%&E
MW00DH)#M)[C'%0:1_P A.S_ZZK_.I[9P^FW;A0H:0D*.@R.E0:1_R%+/_KJO
M\Z\L]U%&3[S_ %-=FG^HB_ZYK_Z"*XR3[S_4UV:?ZB+_ *YK_P"@B@8W1_\
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M1@"Y3F=!_$/[X_K^== O^IB_ZYK_ .@BL+0\C53_ -<9?_0#6YG"1C_IFO\
M(4 6H?\ 5)]!7>?#VP$NJSWC#BVB"K_O/S_*N#MQN6-?7 KUOP';B+0I9\8,
M]RY_!?E'\C5P5V1-Z'48I,4M%=!@-HQ3J,4 ,Q2$4_%)0 RD-/(YIIH 8>:8
MW J0U&W) HL L*9YJTJTV->*F44Q@!3@M*!3P*!%2=>#67(9FF*0H"0,DL>!
MZ5M3+E34,5O@RG!&7Z^H %(#'34;B"41S6KG_;B&Y?Q]*U(IS*<X(%*\"],4
MY(]O:@9,&P*>DN.*C"TNVF(>QWG.*9*-L3&GJ,57OY&%NP0;G/"CU/:D,P7@
MFU:XGMHG,4$6%FG R<G^!??'4]JKRZ?%896U!5B,%F.XMCUKJ+>T2QL4MD.=
MN2S?WF/+,?J:SKBU,KFD!C0S>:IW#:Z_>7^OTJ2K;Z.H82 L''<53G#V['<I
M9?4=J L'>BD5E= RG*GN*6@0VHY84E0JZAE/4&IJ:12 T](\5:IHP6)RU_9C
MCRY&_>(/]ECU^A_.N_TC7M/UN$O939=?OPN-LB?5?\BO+",U'L*3)/$[Q3H<
MI+&VUE_&H<$]C13MN>TT5Y_H_CN>VVP:W&98^@NX5Y _VU'\Q^5=U:W=O>VZ
M7%K-'-"XRKQMD&LFFMS5-,FHHHI#"BBB@ HHHH **** "BBB@ HHHH ****
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M::)>KU_ [[2O$.E:T6%A>)*Z#+)@JP'K@U%<^*M$M&N5GOXU>V8)*NTY!.>
M,<]#TKE['0]>D\:6FL3:9;6$2C;,()1AA@C.,]>1^54M)T>RU?XD:T+Z$31P
ML[K&WW2=P'/KUI>PI7;OHE?2SZ[#^L5K)6U;MK==+W.YL_$>DW]ZMG;7J27#
MH)%3:PRI&<\CT.:EN-9T^UU*'3IKE5NY@#'%@DG/T&!T/6N(\96B>'=>T;7+
M2,1P1E89$08 "]!^*Y'X5+X=9?$/Q"U'60=]M:+Y<#8X/\((_ ,?QI?5X.'M
M$_=M^-[6']9FI^R:7-?\+7N>@T445PGH!1110 4444 %%%% !1110 4444 %
M%%% !1110!\W?M!1D>*8) OR_9XQGWRW^%>47ZJUX@8X!'7\37L_[04>+I'X
MY6$_K)7BE]()7CD&""N:!K<<EK;$DF<^P'^-1WD<2.IA! /\.<@57R/2IGMI
M$$196Q*,ISG-)1;=RY586M:PZWEVD5NVE^%QD\9]:Y[R9%E,>QO,'5<=*<DC
M '!Z=:VA-Q.&K1C41U,VHLVX)DD],<U@WDP(V ]\D^]5C</C@_K4+,S&JG5<
MC.CA539H:?\ \>EU^%4;;_6)]:NZ=_QZ7/X51MOOI]:P.XO:)_R%3_URE_\
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MC[B_R%8%@QCF9@<,R% ?0'@G\JVH+B*3<3C';/I0!J:?_P ?,'^\*]L\)_\
M(J:9_P!<!_,UX/IEP&O(54X.>U>[^$W#>%-+95*J8 0"<UI3W,ZFQMT4@-+6
MQB***3I29H 4U&:4G-,)Q3 0FLS6M'T[7K,V^I6ZRJ/N..'0^H-:!-0R-Q0-
M:'&I>:OX+VQZ@TNK:$#M2Y49FMQV#>H^OX&NQL[NVU"TCN[.>.>"0961#D'V
M]C[4VV =)%8!D?*LK#(8>A%<U>^&M1\/74FJ^%&S$QW7&F.<JX]5_P Y^M&Q
M6C.R5O6ID;-<_H'B:P\01%8MT%Y&/WMI+Q(A[X_O"MH$CK^=!+5BX#3Q5>-_
M6I@: )13Q4:FI%H ?2XI*<*0"$"DQ3J*!#:0]*<::30 UJK3AV>/:V%5LM[\
M<#\ZF8U"],9!(>M9EY]TUI25GW2Y&*!',N?^)S:CW8_^.FM+-9=T?*UBS<]#
M(5_,$5H T@9)FDS3<T9H$+129I<T@#K6]X._Y#8_W#_*L#-;_@[_ )#8_P!P
M_P J4MF5'<]!HHHKG.D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *SM7T+2M?M?LVJV$%
MW$.0)%R5/L>H_"M&B@#S:\^!W@ZY),,=[:G' BN"1_X]FN!\=_"2R\(:(-7L
M]3N9]LRQF*9%Z'/.17T/65XCT"T\3Z'<:5>EUBF (=#AD8'((_&@#Y.L;:*Z
MNA%-<+;Q[68R,,]!G&/4U>3PS-<#]U) YR>"" !U!)Z#(YQ7I=Y\!)P2;+Q!
M&P[+/;8_4-_2L&^^"_B^S5OLQL;Q <A8K@HQ]\, !^= ' 7^C_8659UB);.-
MAST.#6%J-HJ,C(<;L_*/;%=O>^$/%D&%N]&OG\OY0%82[?88)IMI\-?$6O\
ME2?9Q80J2"]W\I[=%ZT[,5T<"+.1D#+("".] LYBV"5QZU[EHGP>TVP99-1O
MYKQQUC50L9_/)KIKCX?>$;D'=HD49(QF"1T_D<57)(GG1\Y);^6IQU/7%.2*
M0Y*Y ]:^@4^%_A!.1:7F[MNN2P_+%4+KX8VD[8@N4@C]-FXX_E1R2'S(\BT3
M3[F]U".UMD+74_[J, =,\%C[ 9KZ.L;*.PL+>SB^Y!&L:_@,5F^'O".F>&E9
MK2-GN'&'GDY8CT'H*W*TA&QE.5QF*<#3L4TKZ5H0+2$>E)R*7.:0$;9%1,:F
M-0N*8$9-5YF^4U(YQFJDSX4\T@)].;=&W^\:U%'0]ZQ-'DRLP_NR?S K;0\5
M0SG_ !#X/M=:D%]:RFPU6/E+J+C<?]K'\_YUE6'BJ[TN\72?%4(MKKI'=X_=
M3#U..!]1Q]*[H<U6U+2K+6+)K34+=9H3TS]Y#ZJ>QI-=BD^C&J<@,AR",C!S
MQ[>M3QRYZUP4UEKG@0^9;%]4T$')0_ZR ?T_E]*Z;2=;T_7+7[197 ?'WEQA
MD/HP[?6E<35C?5N]2J:HI*4(#_G5E7SWIB+(-.%0JU2@T /HI,T9I (:C8TY
MC43&F QC43=*>33&H B>J<Z9!J\14+KF@1R6LV331DID.I#*1V(Y%%K="ZBW
MXVR+Q(G]T_X>E=!/;AP>*P+W39(9?M%M\L@X]F'H?:D,FS2U7@N%G4\%77AD
M/53_ (>]3?2@0ZBBB@ KH/!W_(;'^X?Y5S]=!X._Y#8_W#_*E+8<=ST&BBBN
M8Z0HHHH **** "BBB@ HHHH **** "BBB@ HHI&&Y2IZ$8XH \VU'XQV$6K7
M-AI&BZCK'V4D32VJ_*,=<<$D>_%=3IOC/2]0\'GQ._G6M@JL91,GSQ[6*D$#
M/<=J\<M)/%/P8UO49)-*^WZ)=R@M.N<$ G:=PSM;!/!'^-=3XTU>+QU\*+C6
MM"U&6RMK?<UY:E.9#QF-L'U(.><UNX+2VW<Q4WK??L>FZ/J]EKVE0:EITWG6
MDX)1]I7."0>#SU!J]7CWPJT?6;/P:-;;7YI+![*<0Z?M^6%PQPP.>ORGMWK"
M^'R^.O'5H+C_ (2F>VL]/N1EF=B\['#%6(/( ]>.>E2Z:UUV*4]M-SWZHKF5
MH+6:9(FE:-&81KU<@9P/<UYGXML;I]?N7U;XDKHEJY'V2SMY!&RKCJWS FJ7
MPK\6:MJ>G^)-.O\ 4FOSIRDVUX3DL/F&<]Q\H(SZTN32X^?6QVO@;Q5?>+-+
MN+N^T2?2GBF\M4E).\8!R,@'VZ5U->*^"?&6O)\(O$6MSW<U_?VDS"%YR7V9
M5.?H,DXKF]8U'6[#P/IWB6#X@7MQJ-\RB2R6?[N<Y 4'@K@ \"J=.\F3[2R/
M5OB#XXN_!USHD=M:0W U"=HG,I(V@%>F/]XUW%>#_%FUO[/1/!,$MY+=WZR2
M'S[@89G)0C=],@?A2^)'\;_#[6-&U>^\42ZC'>S[+BW.1$IXRH7.,8)P0!C%
M/V::5O,7.TW<]=UKQ9HOA^_L;+4[OR9[YML"[&;<<@=0..2.M;5?/GQBTK45
M\?Z-(VL2.E]*/LB%?^/3YD''////:O:_#&E:CHVBI9ZIJTFJ70=F-S(N"03P
M.IZ5$HI13N7&3<FC)\6>,-0\.ZSI-C::!<ZC'?/MDFB)Q%\P'93S@YYQ775Y
M5\4]>U;2?%OA&WT_4+BVAN;C$R1/@2#>@PP[\$_G6=XUUSQ4/B_:Z#H.JM;"
MZM514D.8D+!MS[>A( R/I34+I"Y[-GLU8S^*='C\3Q^'&NL:I)'YBP[&Y7!/
M7&.@/>O+-+O/%'@SXM:=X?U+Q!<:O::@@+><20-V[! ).""O8]*PM2\.:Y)\
M;ETQ/$LZ7\T32QW^P[HT*L0F,^G'6FJ:ZOH)U'T1]$T5Y)XXU[Q#9:EX<\#:
M3JK+J5W%&+G46&';G;GV^ZQ..:R?$4OBKX6:QI%ZWB:[UC3;N3RYX;LD],9
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M[];XP&\%H&(C\O&<8SC..<8QVJ_>?%:_3X/VNN1A%UB><V1?;\H<9)<#I]T
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M]J^L^+/"=SIUA-<P6MQNG= ,1C>AR?P!_*F:SX<UB?X\:3K45A,^FQ0JKW(
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#E+S_C\E_WS_,U#4]Y_Q^2_[Y_F:AKI6QSO<***4"F(*=BC%+0
ME+BC%+0 F*7%+BC% "4N*7%&* &$4A6I,4$4 0%<U&R9[59*TPK0!FSVVX'C
M@UP^O:,]D[7,2EK8GYP!_JS_ (5Z,R56FME<'C(/!!'!H \QT_4&L90C-^Z)
MX/I786E^'4<UCZWX4>/?-IR%XSRUMW'^Y[>U<[9ZI)I[['+-$#@YZK[$4#W/
M38YE8<\U:CN9 ,+(2/0\UR=CJT<R JX.:U8[P$?>H$;9EED&&E('H.*6,*@
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MJV"I VGG\*A,.X]*U] A$=]D#M_0U,MF5'='3T445S'0%%%% !1110 4444
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M5@*Z*^LA=)D<2#H?6L26UEA)#J1CO6\9)HPE&S(L4N*,?YS2XQ_];FK) "E
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M8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M ,4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
C!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "N 3 # 2(  A$! Q$!_\0
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MMYE>-)D;Y7&>*FA4O=!4CU.J\$+CQCIW_70_^@FO<Z\,\#R!O&&G#/.\\?\
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D!X4;?N-T#_P$_P"-=+118#(LM&-I<))YP(4YQMK7HHI@?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image_008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %/ -L# 2(  A$! Q$!_\0
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MHH **** "BBB@ HHHH **** "BBB@ HHHH ***KSWUI;.$GN88F/0.X!/YT
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MY)<6=W#B2.X8N$/4,N>AR*Y.9'NI_M2 %3@G/;ZU;DDO+RPE1+-@@',B\@4
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M_K@/$/\ R%8_^OL?SH [^BBB@"MJ/_(-N?\ KFW\JX_PT/\ BL)S_P!.A_\
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MP8!,@_7FL[PIX3U/1M:M=0FO$B$1RRPDEB.XS77R28;DY-+ QDE5  "?4X%
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>image_009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #E 7X# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%9N@ZW:>(=&M]3LGS%,N2,\HW=3[@UI4 %%%% !1110 4444 %%%% !1110
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M'GM5(AZ.YXI\F.F#_.I(Y(D?+1Y4\$9KN9)/AQ:3E3::C<*#V8__ %JB36O
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MWVG*'\5(_*JWBBW@OKO^T81B/4(Q/Q_#)T;]10!G7,:2V<=W$H!;AC[]0?\
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MI'Q&T:XW@(\WDO@]588_K7UY7R[X<TJ >)--,4?SBYC(.?\ :%?45 !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
F%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>image_010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "? 88# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?2_C[-+<+%+IIN 3R5&P@?K5G*>[45%;7$=W:PW,+;HI4#H?4$9%2T %%%%
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M\Q0$& W]X>_O1':6T+!HK>*-E!4%4 (!.2/SYJ7--;#46GN34445F:!1110
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M@"KJ5(89!R,<U\4>)_#&J>%-=GT_4[8Q,&)C<#Y)%SP5/<4 06>1@CBM19I
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 ?,OQ>N_.^(5ZN1B%%7]!7I/
MP)BV^"II<?ZRY;]/_P!=>,?$R[\WXA:\WI.5Z^G%>Z?!./9\-[5L??E<_P A
M_2L8+WY,[JTO]GIQ/1****V.$**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBF3-L@D?^ZI/Z4 ?%7B^Z-QXPUF3INNY._\
MM&OJ/X36WV7X9:,N.7C:3IC[S$U\DZE+Y^JWDN,;YF./J:^S/ ]M]D\"Z'!Q
ME+*/./\ =!J5NS:H_=BC?HHHJC$**** "BBB@ HHHH **** "BBB@ HHHH *
J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>image_011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $1 CH# 2(  A$! Q$!_\0
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MHE=5U1XX+%2H)#-@DX/H/U(J+X;>)=3UC3]3TG79@==TJX:&X8*!N4D[6
MZ@C@=AZU/(^7F*YE>QW=%>6>&?$]YX/\&2W_ (LNM2O9KO49([&%XB;B1>@
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M#@[NO_ :NK]GT_5F=+>7K^B.1FT(Q[1%,LN>N R[?SI5T"_*DQ*[8YPK'/\
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MM9=BMK>L(R&2)1MW$-NXVX]:3P[KEI<S>5N1V(YV9XJ.XT>&?0!/.C17,_\
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M [G&(V" PZ^M)/+'&,'YF/11UKN$N;*\7Y?*E'L5:LRYBM[>1_*A2,^JJ :
MN<W:PW<SY9#!".22,$_05-]FE)Q'=,7[;EX/L?2K;R$DC-,=C%\Z@#C))[4
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M$_*1D4X6K$ D\8H 2WO)8UVE<H>"K=*L00Q7$FRU8(['_5-T_"JWV::29(E
M)9@HSZUWVF:6EI:QQ+M9@.6VXR?6@0VWLRD*(278#EO4^M.G@54RQX'<]JTU
M0Q_>48'<5S'BPO>QBPAO)+-\A_,4?>]!GT^E %#49W:TE4OMR-JMWYK&L(49
MQ#O+1<;BO][L/QY%5(-'U5;U!JCR75N#@2QRDC'N.HKJXK*U^SF&V0(AYPO4
M'U^M %NW894+C;V ]*U+<989[5@0W,46];F:.%XSAMS #/\ ]?J/_K5K:?<P
M7!/V>[BE(_N.#0!K87 P>::3V.*<N$7=*RJH'+,<"L^;6]+B?!N Y':,;OUZ
M4 ;&C#'BG2".]PW_ * U>K5X]X;U6WO_ !9I,4"R#;,S$L /X&KV&M9?!'Y_
MF8P^.7R_(****S-0HHHH **** "BBB@ HHHH Y+Q$VWQ?HI/_/O<_P#LE4-8
MM&FA-Q;.8[A!D$=&]B*O>)/^1MT;I_Q[W/4?[E,9'/&>>V.]76VCZ?JS*EO+
MU_1'DOB"5)B9O+\N<<. .*P+>&6:5$150L?E)8 $UZMJWA%+UFD9@@;D@=3^
M-<S-X,,2'R)'!4[D.0P_.L539TJ:1RLC.4$OF!PIP<=JOVETHP#WJ^_A>=9)
M-C [V(V8[^F?6HH?"6IOTV1]<$OUQ^%92IR['1&JM[EZW F@"=0K?B*ZSP[;
MRQRB9W.P+@ ]JQ](\.W$!1[R6.4CJJ\?KW]Z[.UO80ZVTD:J0/D('!'_ .JK
MC2:U9G.K?0OH^XC%2;JAQ'G"Y'TI2VWG/%:\K1SW.4URT^RWQ8+B*7YACL>X
MK"U@RFP*P2B*0N"KLVT+CD\]N!UKO=4M/MUB8U ,BD,F?6N#U^.%+0I>I(%7
M)*H0&## 7KP.2.O%(9=\.&U?28I;2&2*-BQQ(<L6SR<_Q9/?O6A<?ZI_]X?T
MJ#2OMHL(AJ#1/<X^9HNF.WMG'IQ7/?$"_N]/T>W:TN'A>2YVL4."1MSB@1U=
M@/\ 1(O]T5;45RGP[OKK4/#+27<[32).R!FZA0!@5UHZT -D+1LDF[" _,*7
M4]3@T?3VN[D.R A0$&22>@J8(KKM89!ZBFW]A'JFF3V4G"S)M!_NGL?P.*<;
M7UV!GG.K^+-2U1'6(_9;7."D;?,<^IZ_E5/2K.RN;:9KJ"0Q+A6ECDP5/J /
MYUDW -M/)!/A9HV*.OH0<&K6EW,L5\C0SK"6X)?[I]C7JU*?[IJGH13=IKF.
ME\/>'HK/Q%;:O:WTDZ6\;*895&[!!Z,.,<UT/B"S_MV. AC"\.2 >0<X_P *
MPM-\J.60M"]O*<95&RGU':ME)R."<XKY_P"L5(2YD]3T_J].2U1Y_K,-W;3B
M&XA9>,Y'(;Z&L9Y98^#D@=":]6N9()8S'<0)+&>@85G/INCR#G3HC]2?\:[U
MF<91O-:G(\!)/W7H>?\ VEY( 0,'H:J-:WETVVUM9YVZXCC+?RKTJ*RTR ;8
MM/MU'NN?YUV_A^=/[$C2%%C$;LNU1@#G/]:%CHU?=2(GA)4E=L\,MOA_XHU)
M XTUX$/>X(0_EUKHT\):O9V:QRJ)3&!EP,8&/UQ7KWG;_9^A!]14,N61BO#=
M1GU'2G&M*.L3%P3W,OX96,NGWFJ03 ;_ "X6X.00=U>BUQOA+9_PD.K>7D+Y
M%O\ +_=^_P 5V5%9MR3?9?D315HM>;_,*Y7X@_\ (KG_ *^(O_0JZJN6^('/
MAC'_ $\1?^A44?XB_KN%;^&_Z['FR@(,]3FFF7#$]">E3..>@R/2JDO3!7O6
M)N(6!P2V:CD((/.:4QY!QVIJQ%LY- %*8A8F ]>:Y*]A-DJVK;2Y9I&*^_3]
M/YUUD\L=NQW-DC]*Q;BU$UVL[J9'.1M)X(% &38?+MVC]X\F%S6K!<>6S1RH
M4=6VD$@\]NGK59K6:PO1/;*PB4[F"\D#O@>E;-U9F>VF\J)/.QE=O 8]15)D
MM%"#552:2*.9HI WRN<;3[>WX\5O6&M[)/(O5\IB?ED_A)]#Z5Y]ECN.?F[A
MO6M6RU(I&MO<KYD!Z'JR?3V]JDJQZ5]H")D\^F.]2;T*@2 .QZJ>@KD;&^%A
M A9VGM]VZ-P<[1Z?_6K=LKZ&\3S(6SZ@\,/J* *&JZ))O:>R7<AY:%1C'^[_
M (5SKD[,9*<]^M=^)20 O6@Z?9.[M);Q-(P_>,5&3[4 <#%+CCDGWIYF4D@C
M&.N:ZB[\-6;#%N#&PPS$G(V]\"J[^%U>61HI_D*YB##.3Z&@9S\;EC]W Z<U
M91G9U4+EF. HKH(/#$"H'EE=GQT' ^E:-K:6]J0D,2@N,@CO0%RAI&DE9!/.
M )/X4]*Z..)0,$[35,$-ALD*3C/=35I':2/9(/F'&1ZTQ,F+ KA@-P_6O+?%
MVIM?W5Q'&P\NV8K&%[XZG_/I7=:[=[-.>W5P)I4* ]P#U-<)-H<87<LDQ;VQ
M2 YBQ\0ZC:S[/M3/%C.UAN('L>M=GHMUJ>JH'ET]88B/EE=]I(^F*Y^W\*>7
M?+<1W+@*<A'B!_7-=4ES/;*HV32_[J@?S- #+GPM'.68Z9;R$\DB7%9=B9;6
MY:/2[%596^=D&5!';/2M^+49IU9)(I8E]&P0P_"D&H8'EQ6D[;> -H4?K0!5
MFT[5=3D$E[<#_=8\+]%'%6(O#V!\US^25)]IU)I!LLD6/.,R2@'&?;VS^5:0
M;GJ: +7A+3DLO%VE,LI8F5A@KC^!J]KKQWPT<^+-)_Z[-_Z U>Q5K+X(_/\
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MV-,M\]U_K6HAKC_#FLK/-=:>_$EH01[J>E=1%+GO0!YKXJB:'Q \?VEIKAI
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MV+9VE]>RNT^R*WB!9DB?8\G+ ;=W YR>PJ&X\>Z5$L;6UM?WRO9+J&;6#=B
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M_?L4?\(AX>_Z ]I_W[%9ND>+;FX\/QWL^FW%](9IHO,TV/='*L;$>:NYAA6
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MGV(>#4-1N9=-34&:VM0N8CG+E=V%Z?=R?;-30^,Q<>*$T^*PG?3I-/CO4O@
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MA1112&%%%% !63XAT9M:L88X;@6]U;7$=U;RE-ZK(AR-RY&01D'D=:UJ*$[
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' 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>image_012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %& F\# 2(  A$! Q$!_\0
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M(T/Q%:Z]:WUQ;13(MG>36<@D !+QG#$8)X]*@\(^+]+\::*-3TMW"ABDD,H
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M$6D#4;8ZA+%YR6PD!=DZ[@/3 - &C1110 4444 %%%% !1110 4444 %%%%
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M'H;.>\63R;FZ2V+J,B,L"=S?[(QR>W6N:U'PMJ,FH:@HCFN;/4]GFB.^$ C
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M*** "BBB@ HHHH *,<Y[T44 %%%% !1BBB@ HHHH *,<YHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH44Z-X:3[3=*H^1IN"%].NP8_P!^O5M:O)-.T2]O(@ID@A:10PXR!GGD?SH
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MD *YP#[D<\5HRSQ0!3+(J!F"+N.,L>@'O7-OX2=M.2(W\CS(2!N 5/++[BF
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M8M2(9$Q+N9F,C%B<[CR N00O0D 'B@#IJ*YC3-!U*VO;&ZO+@7#P&16#3LV
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M,^.K#ZR?^BVKB+::.XC66)PR-T(KN?AB"?'5C@=!(3_W[:@#W^BBB@ HHHH
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M&Z>6%RK+$LI'.QEW _A72Y-Q:!@IC5/E9, #/)SQBL?0VC#NKNWS?P  ;O\
M@1(VGZ5NSEHK<J1<CK\LK!OR(H&9-YI5\T!G6SF:'&=X0D8K+M]/N;BX2-(C
MEB -Q 'ZUZDUW9IX6F6*Z@9UA(VB09Z>E<5I$D)UBU5I%QYB\ Y)YH ^LO!M
MB=-\&Z3:, &CMER!TR>?ZUN5%;1^3:PQ 8V(JX],"I:!!1110 4444 %%%%
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M77Z9')!I=I#+(DDD<2HSH,!B!@D#M18=RW1113 **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "J6K:1I^NZ;+I^J6D=U:2CYXY!Q[
M$>A]QS5VB@#P+XB^ O#'@[1;6'3[1VDO+LL7FDWLB*OW5/ID_7WK#TCX5:WK
M>EV=_I(M?LERN099=NP@D<\$GIVKJOCU>;;W1[?/W(I)?S./Z5Z/\.H?(^'N
MB(>OV<-^9)_K62_B/T1WU))82$;:MM^?1'#P? C3X_#EU%-=I<ZU.@"7$B'R
MH.03M4'.< C<<]>@KU+1M/\ [)T.PT[<&^RV\<.X# .U0,X_"KU%:G %%%%
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MVQUJ^+ZT-\UB+F$W:QB5H-XWA"<!MO7&>,UY,/A9KKZ8MK)=V8B^P:?:3P*
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MT'-;FCV-YIT)MI[I;B"-56%BN'[D[OS '4X7)))K2HH **** "BBB@ HHHH
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MQ+<MIE]J5Q:[H_MXM;2%&4%E+K&I))XR6R<]*Z&ZLK6^C6.[MH;A%;<JRH&
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M=HVEBV.!@_3I$<21JZD%6 ((.015<Z98-;_9VLK<P\#RS$NWCD<8]S^=6@
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M((.#ST/2J7]B:9]E2V%E$D*,K(J#;M(4*"".1\HQQVXJ^ %4 =!P* %HHHH
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M@%]"/+QN+':!E0_4\'Y2#2?V_I0A65KZ%58X&YL'.0.G7J10!I4444 %%%%
M!1110!F_V!I?_/FGYG_&@Z#I9ZV:'ZD_XUI44 9W]@Z7C'V1,>F3_C1_8.F=
M/LB?F?\ &M&B@#._L'2QC_1$XZ<GC]::WA[27!#V4; \'))_K6G10!F_V!I?
M_/FGYG_&E_L'3,Y^R+GZG_&M&B@#..A:8>MHOYG_ !H.@Z8>MHIQ[G_&M&B@
M!D420Q)%&H5$ 50.P%/HHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#%U^WTRZ:SAU*Z>'<Y$2@\,W'7((X[$]SZUG3Z'H=@V9;VX0R(RYX8,
M "&'W3DD9XZGWK9U71H-6>W:9B# 25& 0<XZY^@JDOA>-;:UMQ?7(2VB\N,#
M [@[NGWL@'- %.WM]%@E*6^LW:/,R@[6'S%AP2=O?CGU[YJ]'X5M(D"I=WH
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MMQ,9A=2AR2Q*QQC)+;B?N\'//U)]:WZ* "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
+ "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>image_013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %B D8# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M"GUV@XJO9RT2UTN1[6-FV[:V->BJMGJ5G?V7VRVN$>WP27S@+CKG/3\:S/\
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MH5.;5TM =2"?*WJ;%%%%0:!1110 4444 %%%% !1110 4444 %%%% !1110
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MOJ=C+9W2;X91AA^.0?S%'MH7M;3;Y?UJ'L9VO?6]_*_Y^0^2TMI3(9+>)S(
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MHHH&T:292N]"9C'A3TXP>*JQ-SV:BN+\&_$/3_%#PV8Q%?M&SM"&9RH![MM
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MMA;VCX^SH^?-8?WF[#/854Z?+>VVGY(FG54DD]W?\V:$DB0Q-)(ZI&@+,S'
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MBD>WU K;SQ^9A8G!.21TZ9]\K[UZO28UL%%%%(84444 %%%% !1110 4444
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M%V1X7O,''W/_ $-:Y)]%MFAM=8566Y0RP,5/#J3D;O7'-==XN_Y%:^_W5_\
M0A3/#2))I,B.H9?.;@CZ5+W*3:V.5N&,.EW4@ZK"Y'UP<5TGAFV\E=I',<2I
M^@']*9XFT^VBTM-BLI:9%QN.&YS@^O2M+P\!_8EL^!O927;NQR>2>],1J444
M4P"BBB@ HHHH **** "BBB@ HHHH *R=<TJ35)M)>-HPMG?I=.'[JJ../?+
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M&>Q&:Z^BCG8<J*ULU\TTWVJ.W2+Y?)\IRS'Y1NW9 _BSC';TJS114E!1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#D_$</V/58=11>5V2$_[A^;\U.*ZL$$ @Y!Z&LW7(%ELE<D*(Y 2QZ!3\
MIS[8.?PJ#2]9LEGCT26\C_M&&,?(>/-4<!E['@9XZ4 ;5<'IW'Q!N /^?N4?
M^0LUWE<':';\19QZWC?^DXJ7T Z[6O\ D ZC_P!>LO\ Z":P_!7^INO^V9_0
MUN:S_P @/4/^O:3_ -!-87@HGR[KTVQ']&H>Z N^)XHQ!:7KX MYP&)_NO\
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MW?)&^EQS(/M$D\D,WF@$$LHVN <%%X&*OD)YSU87ML=0:P$R_:EB$QB[A"2
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MM^Q?:(OM7E^;Y.\;]F<;MO7&>,UQ>_2_"7C&PMY7^S62:/\ 9H7920S"4<9
MZ]S]:R9)]1_MS_A,!I;?94U'ROM/F?/]B_U)'EXSC?F7]:.4.8]0HHHJ"PHH
MHH **** "BBB@ HHHH **** "N$OQGX@J?[LT/ZKBN[KBY0/^%AS9' $)_3%
M3(#K+[_D'W/_ %R;^1KC?A\#ON&SP;:#_P!FKM;H!K293T,;#]*XSX>K^YD?
ML;:$?^A4/= =Q12$A1R0![U%+=0P@%W'/3WJ@*^M;3H5^&. ;=__ $$U1\-+
MLCU!>,BZ.1Z?(M5?$]W+?>';^TM+<S2S1%%3(!;/UXKSWP7XTA\*7U[INNV-
MU:?:9_-5Y =R?*%P0>HXZC/6BVMQ7/1_&">9I]F/2[4_DK58\*?\BS9_1O\
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M.Q]:GHI-W&E8****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKP?\
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M***\T]0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#0TS54ENKF&3S+:[,GS+ZAL_>'7]/2H;?74A\(7>AFW8O<7"S";=PN-O&/\
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MS1]!4445\F?9!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?_H0K(K7\*_\C5I?_7U'_P"A"E)<M-KR?ZCA+FJI^:_0^@J***^4/L HHHH
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MQJ**<8J.Q,I.6K"BBBJ)"BBB@ K7\*_\C5I?_7U'_P"A"LBM?PK_ ,C5I?\
MU]1_^A"HJ?!+T?Y&E+XX^J_-'T%1117R1]D%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?,U%%%?8'Q(4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %:_A7_D:M+_Z^
MH_\ T(445%3X)>C_ "-*7QQ]5^:/H*BBBODC[(**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
E** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>image_014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $V FL# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MH^),G_0*7_O_ /\ V-.'Q'D/_,*7_O\ _P#V-<5LIP6D%SM1\17/_,+7_O\
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M936I2,KR32;&%:A@I/L]18JYG ,*<"P[5>^STGV?VHL.Y5#FGAS4_P!GH,
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MH-E;Z?+(DWD($$J=&_"IUJY<SF8Y8YJIWIIOJ2UV'"G TP&ES3$/S033<T4
M-8\5D:EK/C"RO$CT6.YDL1&#E;<. V3D9(^E;B*"PS7066IB*%8^P'%)RL4D
M<1I&LZ[JBW']NADDC=1$K1!.,<].O-:PZ5KZK=)>!<@$KT.*R<8IIW$U8444
ME(302-?<>(V"R'A6(S@]C59](UIS_IGB._8]"MOB(?U-3J?](B_WU_G71W:#
M<>*+B9X-XBC%KK6H0F25UCFQND8LY&!R3W-;7@GPW:ZGX;M[UY[I)G9P6CG9
M<@,<=#61XM(3Q7J;-]U;G)^@45V7PXP?!UJ1T,DI'TWFG+8"U_PAV/\ 5ZGJ
M2_2\?^M4=9TJ]T?1+ZZAUC55EA@:1"UUN&1Z@BNW0\5@>-#GPOJ?_7I)_2D@
M1Q_Q'=I--TAW.YGM'9B>Y(7)KTC3N-/ML(3^Y3G_ ("*\T^(A_XE.B_]>;?^
M@I7IFG$_V=:X_P">*?\ H(H>P%Y&DQ]P+]3706&?L:9Z\_S-<\"?6NAL/^/-
M/Q_F:<=Q%FLSQ!9QZAH5W:2LRQRJ Q4X.,CI6G7/>.;FYM/!>J7%GO\ M"1@
MQ[,YSN'3'-:6OH)NRN>=W'@:SCN;6&WO"EBW,C78)(/7;\O;WKKKSP_90:&&
MTPV,$T/S9B8@,/3D\&O./ >NZIK^K3P:A,\BPQ@@,Q.#G'0UZ7J%J(].944*
M6*C@8SR*3C9V9$*MUS1%MM CFT\K<BSGF9"/.$YX)'';M7GKVE_I>H-;13RA
MT?$CPN2 !WXZC%=AK'EZ=I%U=!""L;,=O7I7F_A_6)(;B.WF\R59& S$,R;N
MV/7Z5M2H.I%RCT'*IKJ>D^'];6+1[>:>Z3[26=#QAMH/&1V)_6NCM_L^LZ9?
M379$EODJ".P5021[YS7/_P#"-6L,,926W349TRRW+>6Q'J%]15KQ)/\ \(M\
M+[]R5\X0E/E.=SR';Q^=-QBJ:[G+!S=9IKW3BY-42'1KF]A=CB(D G:.> O'
M&?K7G.G>%+[6+C[5*ICB;Y@K=3[XKO\ 0=+6PT>.!R3+<-YTVXY^8C'Z 8 _
MQK5:X@M$\L'9G^$#YF^M<THW.Y2L<UI7PV2<3?ZPS8&S& ?RJZ/!0M[6YCO6
M,JE0J*5PT8'I[UT=A<J\LDD8.-N.>"3Z582\S^[N9#)$WW9&Y9?\^E3R(KG9
MX?K>F-I89'"G"Y++T8=JZ70+C_B6P"7:!(N3@].*ZR_TGSWN=)>.)3*&(D==
MVW RI'J.E<3'"MA8;WG"(>KL  I'2B,;.X2E=&E-+]H1+?:S!WQD&NI2YABL
ME5TVY(SD_P J\L7Q;#:W:RQVHE9. =Y4'WK=TWXBPSN(+W3S$A/#QONQ]0:V
ML9W.^C:WG.]9556]2#6-=KDW$2'(*C:?7%6K1K62!)<*T1Y4KT/O56\:.&7<
MF0G/)J0,W2]0?RE2420,_9C@'\?2CQ%IFF:OHMT_D6T=\D9>.Y8;1N'0L?3'
M%>?-XDUBQU!XXI5FMPQ&R;D<G)P>WI72Z;XFT;4E>"^NIM/:3@HX'EM[;\?S
MQ4ZE%3X4WFLGXA:'#-(XMO,.Y#@9&QB.*^K:\6\!Z1ID.LZ1/;);.R\K)L&_
M.#GYAUZU[35W3V)2?4Y_QOQX2O/JG_H:UY=:-7J'CCCPC>?5/_0UKRJU;I0,
MU U2QGG%55:IXVYI"/*/'%XTOB2<=0IVK^'%9VBW8\][27A91E?]ZM+QK;;-
M9E< 8+MR>V>:Y9QL42(Y# \'O04G;4ZUIG_U3Y\Q<*?<9ZTIVR-AOSK/M-0&
MHPJS$+<1\;JG\TY(8;7[C_"LY1N=M*I8V+B[*V,=O&W[L#IWS5%].OC:K="!
MV@;.&'-4VGZ#-:=C=S1VTBI,ZHRG< >,5DEW.V4KKW2U9A-)T[[:R;KB0?)G
M^$5S%Y<R7$Q=R22>];VHZREQ:QVPB4>6,;AU-8+MENU*XU%QWW.@\/Q"UT^2
MX/\ K)F"+]*]#T5,0 ^U>?V3J4M(!S@[J]'TI0ML#[5I \W%;A=G@URFKR^6
M<UU-X?E/-<7K\F U:,Y:?Q(Y6^.+ECG@\X%4KB^EE\F*1CY2_=C_ (5]<"ED
MGW$GW-0I:O=WT:)G"@9(J%=GIRE&.QT-CJ;:68;I?NHP7'J">:^C/!<R7&@+
M-&<J[[@?^ BOEW595#):QD$1_>(Z;O\ ZU?0GP<N6N? 49<Y,=PZ?D%K5*VA
MYTG=G?T444R0HHHH **** ,KQ+_R +G_ (#_ .A"O/%KT/Q)_P @"Y_X#_Z$
M*\\6HEN4AXJ1:C%/%2,D!IX-1@TX&@"933P]0 TX&@=R4MFFDTW-&:!#\T9I
MF:,T 29I0:CS2@T 3*U2K(158' R>!3@X894@@]P:0[DY<FHR:9NHS3!CLTA
M-)FFDT"&@_Z1%_OK_.NFNVY-<L3^_B_WU_G7271.302SP[Q7@^+]1'8W0_D*
M[+X<_P#(GVW_ %UE_P#0S7$>*WQXQU ?]/*_R6NT^'+9\'V^!_RUF_\ 0S3>
MP'9*U8'C)O\ BEM4_P"O23^E;>[%<_XP;/A;5?3[))_*I0(Y'XAN/[(T09Y^
MQ$X_X"E>G::?^);:_P#7%/\ T$5Y7\0R#I&A-W-B1_XZE>CZ?J=BFG6H>]ME
M(A0$&91_"/>F]AFSFNCT[_CQC_'^9KC3K.F#KJ-G_P!_U_QKKM'GBN=+AE@E
M26-MV'1@P/S'N*<1%ZF2J6C(7KD=\=Z?6?K=R;/1KF==P**/N]>H%:".7ELM
M)TW6<V5O"+E\M<20QA<\Y)8]^:VK9(-9@(CGP4(.-F#P>/PXKA_[1M/(V^:1
M&<&0/D.[9[GIBNST;4=$LK;8FHV[S-_K'S@9]!["A0D]4C.\5H0:]H5Q=Z3<
M1G:X*$%8P2Q!XX&.M<3X+\-'1=1GGN\B\5ML#,F!M[D9Z-7JB:I82 E+VW('
M_305!<7UK,#$\L31-W#@_P!:M2G&+BMF#Y=RC-=B<QAK"*X,>=LDP! ]2"1P
M*Y;XC26%WH]CIZ1Q+.][&SI&N0 @+8SZ$@5M75B@F*0SLRM\R@-D-_\ 7J*8
MJ;:*Q,<4\TF2#+&#Y2CO_A6:DUH7RIZG)._EG+G'\.:K6=M)+*\S)N9C\O.,
M+6GJMC'!/*DH2Z@:/"$<8/\ $1CO6<TY$(C3"QJ  H_3ZTKCL:$4R("%Q\O4
M+^M1O,C1NH8'<,C/<U4MB5#$].]49&E)41+D[?RS0%C3CU+[3JEL\GRB-%A7
M/7'OZ]:\3U[4Y;N^EA+%889&1(_<'&3[UZY#";=?,8[I$^<^B@<DDUX9>7:W
M6HW5P@PDLSNH]BQ-- /54?Y9,[3UP>:Z'53HSBTDTI#&[#]X@R H&,9'K]*Y
ME6SR.M7K4_.N>I-6B6>G>';DC11NY"R,%!]/\YJ34[H)8R,QQA<YJGI(:'1K
M<D##KO\ S.:N0PZ9K5K/;SM))<(#LME?R_-(_A#>IJ!GE[QM-*0BEG8Y  R:
MK7MIY$7^D7$<+$<Q]7_+M7;ZSX:\2+IHDL+3R8&;8UM:C$B'T8]6^N:PQ\--
M:BC$^K/#IL;#=B9MTA'^Z.GXF@9?^$>I7$/Q,T>V@N)UMYY"'CW_ "L-C'D?
MA7UO7RO\,M/TZS^)NCK$[3R)*0LAZ?<;L*^J*8'->/FV^#+YO0Q_^AK7CUO<
MX'6O7/B.VSP)J!]X_P#T8M>%P7!QUH$=&MW[U9CN_>N;%S[U8BNO>@#$\6*+
MJ^G0D9."">QQQ7!33*I*D\]"!79>(I0]Y-M/)4 UQ\]JL4F0.">](""":1+A
M)$W  \D>E;R7RO\ ))C(Z&L7I3XW4G;(#M]1VH+C)Q-LEG8!.1[GFK44Q2V<
M$X.P\?C6$MU]G9#&QE0==P[^E7Q>0W*@K&4_O '</\:5C=5"%[D[VYIOVC-)
M,(2QVL#[BJ^WGAA4<B-_;R.ET2X+ZB@SP!7J-E<[;8#->1Z 3]O+>E>B0W.V
M #--*QQUIN3U-"[N^#S7#^(+O(?FMNZNS@\UQFM72@MGGVJS..C,R(/(%"CU
MR36BNH0V-LZ0G?<-P7'\/T]ZPVNI'X'RK[4*::T-)3+ ?J37T;\#SGP'+_U^
MR?\ H*5\VJ<GV[U])? _)\ NV,!KV0CZ;4H,STFBBB@ HHHH **** ,KQ)_R
M +G_ (#_ .A"O/!7H?B3_D 7/_ ?_0A7G@J);E(<*>*8*<*D9(*<#3!3@: '
M9Q4%U=B")B/O8XI[&JERH=2#4RVT S[;Q2!.8;V':/\ GHG\R*WXIHYXA)$Z
MNAZ,IXKA=;2.V*?("S$E3Z57TO6);28>6Y5^Z'HP]QWKRXXN5*;A4U7<Q<^5
MV9Z'FEW5S:^,]+$[03^;!(IVME,@'\.?TK>AGBN(4FAD62-QE74Y!%>G&<9?
M"S5-/8FW4&0*.34+R! 23C'K7#>(?& D==/TM?M,DK[&8'"D=P#_ %Z4Y.RN
M#=C3UGQ#+<2_9K,XBS@O_?\ I[59T35)I)DM.KR9+S$] /0=/QKF)KM7N/+=
M45(R$#@D[FQR/H.GX4VUUUX[XV^C1&ZOF4J&1=RQCN?<]O2O$]I5>)7X^A@I
M/F/39;NWM\>=/%&3T#N!G\ZFS6%H6C&QB-Q>L)]0E.Z25_F*_P"R#_A6WFO;
MBVU=G0.S32:3-%4!&W^MC/\ MC^=:7B"3?9NH)!5U;(;'?']:R;TE;&Y920R
MQ.01U!"G!KRW5O$UWK.GZ:[:G(;F. )<1(63YO[Q[$GO0A,@\53$^+KW)^;S
MDS]=JUT?@GP[INI^&8;BYBD:4RR@E9G7HY[ BO/I99)+PR2R-(Y<99CDGI7>
M>!](GO?#4<T>L:A;*9I1Y4$@51ACST-5+81O:AX5T>TM9)5M)7*#(7SY#G_Q
MZO)8YS(DN^1P-S !V)XR:]<E\+32H5?7=7<'L;G_ .M7/ZOX#TO3=$O[I#<M
M-#;R2(6ER-P&>1CFI3 J^/Y&&C>'W#$'["<8[?*E=S8>$_#LUA;22:-:,[Q(
MS$J>25!)ZUP/CX@:%X=)&1]A.1_P%*[*PTKQ,UC;-!XEC1#$A57LE.T;1@9S
M1T&; \&^&QTT:S_[XKO= L[:PT6"VM(4A@3=MC08 RQ->:'3/&"]/$EFW^]8
MC^AKT;PQ'>1>'[9-0N([BZ&[?+&FQ6^8XP.W&*J.XC7HZT458BJ9+"1E0O;,
M78HH)4[B.H'J1W%5+B#08U,UQ'IR*'\LO($ W?W<GO[5Y3)X;U'5)M,A@AN+
M:[AOM7N;:<H5$<HE1XBQQPK$8]QFJ\T3W.@QZS>6$UOJHU"^N8--NM,>ZAG+
ME=T;@+\I)X5N.];*-MF9.7D>O_9="-S]E\G3S/C_ %.U-V,9^[UZ5!)9>&(5
M5I(-*17)52RQ@,0<$#Z&O/;#PIJ.O>.-2NY[&VTZ**YL+II7A)G0I"A,4+\
M+D%2<]NE9-QH&K7]KHL-OID+S+_;+;+ZT,D8+2948.-I/\)/ZT[7^T%_(]B_
ML_1[1XC]ELX7=L1_*JECZ#WI]U;Z7#&TUW%:QIT+RA0/S->/:K8:OKNF:7#H
M^DWTT.B:1#) ]P_E2171*L#@C]X5$6W _O?2NM\>3/K7@?1+U;655DO[2XFC
M>U:8Q+G+;XL98#G([]*APU6H^;<[ KHKM;18L6:Y#>0OR'S0!D[1WP.N*?\
MV)I7_0-M/^_*_P"%>/Z;:ZS9_P!DS:;IDS36MQJ\EG)]E:))MT(:-A&1^Z4L
M2H4_W?>K\6L>(QI]VVGWVMW-E]FM#>7-Q:GSK>5I,3^2I09PG. "!VINGV#G
M/4O[%TL# TZU_P"_*_X5!;Z9H-S;K=6]GI\L#C<LL<:%6'J".*\Y_M77 END
MFHZZF@-J4R1Z@EJ6NGC$0,8(V$[3)N )7G&#5M]/U%_@1:6<-I<F=88O/MD0
MK*T8E!D7;UR5SQWZ4N0?.=U;V&@7T$BVUMIUQ$?ED$2HZ_0XJM_P@WA/.?\
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M *%S2O\ P#C_ ,*W:*DHPO\ A"O"V,?\(YI6/^O./_"M2QT^RTRV%M86D%K
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M-_Z%7E-Y9/I5\]I)DM$03^.#7J'PQ?=X2![?:I<?F#3EL([BL/Q4/^*;U/\
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M;JYC,D?0, "1^H_.D!H4444 %%%% !1110!D^)?^0!=?\!_]"%>="O1?$O\
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M@I7S ;9]YS7TW\ 59?AW*&Z_;Y/_ $%*UE4<HV9*6IZE1116104444 %%%%
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MV 7*#('UK'AX<5K),HC [T"93NUR.A/TJK'@'&"*N7#=>/QS53<* ),>]-9
M:3<![4A>@!KJ6 &:N0$A #53?[5/&XQ0!;!S7=:#_P @:#_@7_H1K@@P]:[W
M0.=%@_X%_P"A&KAN2S2KE?B5G_A7>M;<Y\D=/]X5U5<I\2RJ_#K6BX8KY(SM
M.#]Y:U(9\HR2N#\P;\15=YSO4@9 ZCUJY*+E(PDBJ@)RCLP.1^%,??( SX)]
MDPI_&BQ%T6--L/M)>\$T,*IUWMD_E4ES*TAWNP('H,53,*JH>10F>A!Z_E76
M> _#9UK6UN;@%[&S(=P3D._\*_U-#3:L2Y):GH/@#P]_8NB_:KE,7MX [@]4
M3^%?ZGW/M72:A?+I]D]PP)(Z!5+$GZ#GW/L*ER*XCQGK%]!&4M)[:,31.H9B
MPD1!]]QVYZ#O^=4E;0XM9.[.'\4:E87MW<7MA&PD:0+N<$M, /F=LGC)Z 5@
MM+ (UD=5+D@X1R3FDEN)-0NOM6S[@"A#T  X JI,[.[%%0<=!@UHIM:(Z%!'
M3#5[86!E@0RE3B2)X003]:M0ZE9W.GRW[61A\D@*W=F] 1Z]Z;I)CM+51%&Z
M321Y"I_7W[_C6/<:]J.G7ZJ(HH?)R%CV97)ZM]:.MVB;)Z(S99&ED:1CRQR:
M9FI/M\=U<EKK<'E;)<#/)[XK8E@T2*^M7A:\-L!NE%S&!O(_NX_A)]:Z?:1%
MRM="U8!-.T0/'MDNKK&0O)QGY4^I/)_"M.#9I]J$<JYP69V) =SU_ G]![5D
MK=6M]J1::2-E1LJ@/5CR2 /R%:RW8N'ED1()8[=-[H1PH(/.>>>WX5S-.;NQ
MI\J$F>:6RCF:Y:*)7WE ,9'N3^/Z4LMQ#<20^?9/LE?;&%;)8>FT_P!*R;RY
M&JW"0!$@LV&?- W!<#/'(_6GV;PW#M&UU)*8#F*0#:6/08![Y-;<ME<SW/9/
M#,45OX?MW$>R,Y?9C')/2M*.*?4I"Y;RX1]Z1AP/8>M1Z;8F'2[2"=OEAC4/
MCNV.:M.\UR1% A$8X"K63,C7T*.R@N3';J7D(YE;J:Z&N?T/3)K:X\^4XXQB
MN@K*6YWT/@,/QA=75GX8NY[+'VA2FW)QU< _I7C^H:GXAU6V-O,%*'J X%>N
M^-#CPI>'W3_T,5Y5%( ASP3Q6D,34I1Y8:?)7^\MX>E.2G*-VC+T73GL[.X2
MX4"28X(SG %<_?0^7<.I[&NQD;'.:YG65Q=%A_$*YH.QT2.=BPFJM)V@B9_Q
MQ@?SK"GF,B7#?3^=:5Q-Y<.H2CJS+"/YG^595I:SW@NQ"A<10&9\=E4C)_6M
MKZW,V4:0\"GE:5(S)(J#N:5KZ"/9_AA$UKX(>54+O)<.^T=3P!6Y<32W(V/;
M2Q '.2JOG\*J^"HO(\(6:KP#N/ZULL":4E9M%)JQEK'Y<$H^;+$?\L0M78K=
MG2W*NH"<X(QG\*6X$8@/FJ63/0#-4[EXHI].5=RJQ^48]Q7/63<=-]/S-:5.
M-27*]#S[XG9;Q-M)./LZ ?C7GAZUZ+\3UQXDR.OV>//ZUYVW+D^]=!B7=)N6
MMK^-@>IP:CO'9;R=%^Z'.*A@S]H3ZTVXE,D\C \%C2$$<OEL=W(/6K,01G#J
M?PJ@!ZTH+*<J<4 :)7[TC''-?2GP+V_\(!*5.0;Z0_\ CJ5\Q)=!ALD&1ZU]
M,_ 4*/A]-M.0;^0_^.I0,]0HHHH **** "BBB@#$\7C/A>\'^Y_Z&M>3>2#Z
MUZSXN./#%X?]S_T-:\IW&L:FY<=AOE <XI0".@%.SFCFH*$!;N*<<=Z;G%(6
MI .PH.:4O^%1Y^M&[F@8XL34;9I2X':FE_:@"$KD\KBD*"I3@FFD#UI@,V\=
M:B9'SUR*F)QVS2;L]J!$/EG'(IR1\X-2;0:>B"@"Q#\JX%6 YQ55!@],5+NX
MZTP)A(U2*X-50WUJ16![T 7HL9JXKX&#6="V"*O!LJ.E F1S$$<<55Y!JS)[
MBJK<&@!X8=\TA84S=32: '[CFIXF##!ZCVJIG/>IH\TP+@QV->@^'O\ D!V_
M_ O_ $(UYRN1WKT;PY_R K;_ (%_Z$:J&Y+-2N8^(B;_  !K"^4DN8A\CG ;
MYAUKIZYCXB,R> -8902PA& !_M"M2'L?+QT^%)C^^CMV_P"><;YQ[8-$EM,=
MTBM'(GJ#M_\ K5!=,9)O.D:WB8?P,H8G\JIRZC"N56:60=T0;5JC%)LMVUO<
M7-W';10,+B9PD:]F/X5[OH.D0Z#H\-C$02HW2/C[[GJ?\]JX;X9Z"!&=<N(/
M+9@5MU)S@=V_I^=>B33I!"\LKA$12S,>P%!SU97=D<[XI\5VUA8W%G:S ZB_
M[M%Z;,]6S[?SKR]T,MR&NI+FX)CR3NS@=%R3VK2\4?:]6U2340Z,I3Y(X\EH
MX^V[T)K.AU*T5!;[9;<M'Y<TX7EP>H'H.U:Q?*@4-"-='))8!EM\$&8G[[@<
MJHZFI$\/Q_;)5!D\N+ 9CQD]2!_C5:>^::6(0@116_\ JU+'E?H:TX-?@DN)
M"[2M,PPK2C*CCKCBB2:*3?0T[>ZT[3Y$F>XFS$O[J)X^"V.!UY%<GJM])J=[
M-=3*I:3CE1E1Z?\ UZT]8E1;*")U6660;UDS@(O^Z._N<UAXW'%73@GN*_5%
M81;2)!U!R*TS?&XC5;F(R8! 8.<C\ZJXR<=A5O3+07FH1Q29\H?,^T=AV_'I
M6GLUU!S9T5FT?V>VN3I,C;8\%F8#S<=PO'';=6?>JM_=2?9;![.WB7)&-S%L
M]#]??TKH9[*R6_M;Z6]D9(U#-!;LH 4<X.<8Z=*Z>/Q!H%ZBI<WZ12-T6\AV
M_D2/ZUAS<KT)U/-GMKR$1%'@EEE&0J_*PQUYZ5TG@[3(M3U?3=UK*T@<S2RO
MRJ@?= _GGWJ_XIT3P]INDC48K:*29F"PK:SDK(WNO/&,YQ76^ ;2&S\/+J<Z
M+'/=\B,*%..W JG.ZT$]%<[%+7SA\Q"1+4XN[> >7;1>8W; ICWM@\*HS2,^
M/N(O6F("HSM%NGIU8U!GL:>G/.\^9I!TXC7MUK6K%TJ9#<LD:X'=CU/6MJLY
M;G=0^ YWQRX3PA>L>@*?^AK7B_VP,W!X'2O7_B22/ >HD9_Y9]/^NBUX'%,P
M P>*S:.A,Z#[1N[UC:S,JQ-*QX09IRW7')KE?$&L"X8PQ',:GDC^(_X4DM1M
MF1>71,20?[1D;ZFO1/@KIJ76M:G-/%OA%H8B&'#!S@C\@:\J)+.2W4U[O\$K
M9DT/4;MA@-*L2GUVC)_4UHR3S?QQX0N/"6MO 59K&8EK68]&7^Z?]H=#^=86
MG1A[@D_PU]4ZYI&GZWH,]EJ< EM]A?T9& ^\I[&OFS4=+70_,*SK*)$#QD=0
M#P ?>JA*SN%CM=)\=Z39:-;V$BW*O",%XP.>?K5\>/=$?'^DW:_6//\ 6O%V
M8YZTW>PZ,:EZNXCW*+QOH>1F_F([[HJN1^,= =E)OUR.FZ,\?I7@7G2?WC2^
M?+V<TK#N=]X]O;;4M8^TVDHEA:!55QW()S7 M]XUL0/YMA&W< J?KUK.2V=R
M21M7/>F!"IV MW/ J*K$L)!R*AQ2 ;24[%-H$(1FOIW]G[_DG4W_ &$)?_0$
MKYB-?3O[/W_).IO^PA+_ .@)0,]5HHHH **** "BBB@#$\7_ /(KWG_ /_0U
MKRA37JWB_P#Y%:]_X!_Z&M>3CFL9[EQV)-U&ZFY [T;AZU!0'!YYJ,T\D>M,
M/% !DT9II;ZTTM[T .)--RU)O%,)'K0!)SU)I?K40?CUIP<$XH ?U[?E4;96
MI001UIC+GO0 Q6R>14H=4&6.![U%M J1,#O0!8!I2 >M,##UH##UI@.(XX.*
M0!LTO6E% $\.[/WOPJ]$^!R:H)COS5M<'&#CZT 32.I'%4I,YR#4TC[0?EJL
M90U @W$4N[ZTS<*,T /!J9&JOOJ1#3 MH<=*]'\-G.@VQ_WO_0C7FBG%>E>&
M>?#]M_P+_P!"-5#<EFM7,_$*SFU#P%J]I!M\V6(*NX\?>%=-6/XI8)X:OF/0
M(/\ T(5J9R=DV?.6F?#G?/&U]>[T4AFBB7 8>F:[>;PYHUZH^TZ3:$@;1B,
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MC3U\ 6J_\ODG_? _QI\K"Z..1A7I7ADY\/VW_ O_ $(UE#P+;#_E\D_[X_\
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MNVKT>N9T/P=#HFHB\CO))6VE=K* .:Z:HD[LWI1<8V9PGQC ;X7:L"<#,/\
MZ-2OEM-0:S7;911Q/WFQND_ GI^%?8OBSPY%XL\-W6BS7#V\=P4S(@!(VL&Z
M'Z5PFE? ;PY83"6ZN+B^(Z+*,+^0/-(U/GC3M*U+6YV6VAEG9CEY">![LQKH
M8-#ATAPT\D<UPO3!^5#[>_O7T+J?PWL;[2'TZVNGL8FP,P1@8'TS7'-^SSIK
ML2?$%Z2?6%?\: /+I=0A3.^:-?\ @5)!X@CM91)!<L&']T'%>H_\,[:7_P!!
MZ[_[\K_C2C]GG31T\07@_P"V*_XT </>_$)+S0WL9+>5I&=&W @#Y3FN(UF\
M75;MK@1B)\8QNSFO;S^SQIIZ^(;W_ORO^--/[.NEG_F/WG_?E?\ &F!X5:V!
ME*&3(#'I[5:AT@S:AY2 [1U/I7O*? C3T8%=<NN!@?N5_P :DB^",$,OF)XA
MN03U_P!'3_&B7D"\SR,:7':8$9(;N15>XT]I7,GFR;E4E=A );MSZ5[D/A#:
ME<2ZO,Y]?) _K3?^%.V&?^0K<?\ ?L?XU"N5H?.BVLT4I,ZLK#UJ0K7T*_P9
MTZ1=KZG.1[Q#_&J<GP)TMCE=7NE'IY:G^M,1X(1BD)S7O!^ NFG_ )C=U_WY
M7_&D/P#TT_\ ,;NO^_*_XT >!2K5-UYKZ';X Z:P_P"0Y=_]^5_QJ(_L]Z63
M_P AV[_[\K_C3$>!6>F7.H2[+>(MZMV%?3OP6L)-.\#2P2*%;[:YX/7Y4JII
MOP6L--MS%'J]PV3G<8E_QKN?#F@IX=TQK*.X:<&0R;F7'4 8_2EJ!KT444P"
MBBB@ HHHH *\S7XG7D46A75SI\ L[LW#7TB%O]'CCN/)#CV!*D_C7IE<M8^
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
:4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>image_015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_015.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $E 2 # 2(  A$! Q$!_\0
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M#EX?5<?F: .:^'R,]S?R>RKG\Z[=MS*ZL<C%<E\/$ M+V7NT@7\A_P#7KM"
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M/^$9L?\ <K<]J!E20;KC'8"J3C[.SG=\O85;WCS)FZX.!5>-3--O.=B]/<T
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MS[>U49K6>6<O/A,'  Z4 48K?"C<./US6A9P.3T7'TZ4L:)(=R D X&>E7U
M1.GY4#$V@#:,XIQ4JIRV!VIJY=N*E^S[R-Q[T@(?,4KA2,^IZ5%+$)HRIG<
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M;Y@S9[#I2 CEO9KZ8_9D+'H<]ZTK/2$XGNL/)[C@5<MXHHD"1Q@ =ZL9D9N
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M)QS7066G6UB@6) #CECU/U-3R.$4D?\ ZZ!'$7%U+:7"@#R]AQ@<#'IBMII
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M^@KG[F_N=88HFZ&T[\X+#W/84 7;K6XE9E@"S9.-P/ _Q^E9C[4N64*%R=Y
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M6V1?U-<)?W+&9]S XXKU'P3C_A%[(  ?*Q/UR>M '1;#G/8]Z:]N&'3O5F)
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; %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>image_016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_016.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $5 IL# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MAIIOM_T+??'7U_ UQVI?\%M?!N@Z9?ZA?:I\=-2L+2R-Y=F\\=^#=-P/3/\
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MIB\/?\%GO%_A[Q%;S^,/#NC>*_"1N635]+L[0^'?$U@&4J#HR.62;:,X\Y7
M))&"3G]Y?A!\7? /QT^'7ACXH_#76[;Q%X/\7V"WVDWR;%)&V%7T[4XS/*8=
M6B;*RQO\R$$X>/:\W^91XD^.4\TOGP7'K97G7\\]>.?;%?TQ_P#!M9^TAXC\
M2:_^TI^SWKE]<7&@6ND>&?C-X/M+NYW&QU$ZNW@7QX@[KN*>!2>S%5&.10!_
M6;1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P"2H>%_IXI_]0S7JY[]G3_DM'PG_P"QPTNOSH_9S]"/B=_QZ>!?^RD> _\
MT]>'Z^R9_P#D)ZC_ -?>J5\7_%F[@T[2_"]]>S?9M/M/'G@.]O+N[_Y<-*_M
MK0.?IQD]L<]>GV/#>07EU<7UC/\ :;>ZO/MMG=6GIQV_^O\ G0!U'_+F/^X7
M_P"@FOZ;?^#;#_DX?]I>?_JBWA7]/&N?Z>GK[5_,5_R[C_K\TO\ ]/9K^G__
M (-K@?\ A?G[4$XX@_X4_P" _P _^$UU_P# \?F?>@#^PFBBB@"%57UQ[8 Y
M_45(6 X()_ ?_6_2O//&'Q'\"?#^#[3XP\4:)H2LH:.VN[Z-+ZZRO(33!^_?
M=V=8V[ E<\?(?C7]NOPW8-/9^!/#&H>(9PHVZGK@/A[3D?\ B/\ 9$G_ !4<
MJGG;FUC88SNK?#Y=C,:[8-.7JDU][:7W'-B,5AL+\<EIV2O^%_Z[/0^^@,^P
M[GL/_K^U>2>.?C1\+/ANNWQAXVTC2[X*0NG/<_;]5)R#M_L72A-<D_[1B4''
MWCTK\C_B!^TS\9_'44\-[XPN=$L+D;?[+\*Y\.Z>5R#@NY/BILG'+-U&>M?.
M,WG^;_G/O[9QBO?P_#4F[XV7*NT5J_F_TB>+B.(8VM@TI>NWG_P=3]+O'G_!
M0*V@$EE\./!MQ=LBX.N^,[H:=%D@9SHVC>=<.020K^>BL ,QCFOA[Q]^T-\8
M/B()K;Q#XXU/^S[A0HT#0&;P_IY"C +R:$S2.?[S.[,2<MDG->13]OP_K4$W
M^I/T'\J]G#99@L)9V3:V;U?R;7^74\+$YEC,7IMZ&=+-_P \/IG/\OY<?E6?
M--_D_P"?R&?4DU8G[?A_6L^O1//"?M^']:SYIOW7X?S_ *?J.E$_;\/ZUGUS
M@5Y^WX?UJM-_KC]1_.K-5Z#H,^SO-5T'5-/\1>'-5U+PWX@TR\^VZ1X@TF\_
MLW4K#H/^0YZ&OTO^ W_!2+6O#QT_PO\ M$Z5=:QI!86=M\3?#MHPU*Q WDMX
MUT(-MUN9BWS7/A!1/L!4>"U(5D_,^;_7'ZC^=048K+,'C/\ ?;KI=;_?;Y]@
MPV98S"']6O@OQMX-^(_AVR\4^!_$.C^+/#>IINLM7TBZCO\ 3YP.NUU."0<9
M4A6 () !!KKG&#]?R_\ KGUX'ZU_)UX ^(WQ$^#GB%O$_P +?&.I^$M688O;
M2S9M0\-Z[Z-K6BJ1X:UYQP592K*P#*P(!K]@O@%_P4E\!>.)+'PS\;H+'X4^
M+KD_8K?7Q>23_#C7;\D&39K+%Y/ QY<B#Q6_DA2!'XLN) J2?&8S(\7A4_JT
M5.*UV;:]4KMV2Z+9;::_7Y?G>$QFSL_P_KL?J115&&X@N(8)H91/!< ?9KBW
MP05(.#N&05P",X(X.0,5>KRCV0HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** (5.T\_3Z4YRHQN/';'7GWSSGV'_UVOC(/J!^M?S,_P#!9SX\_''X
M5_\ !2;_ ((>^"/AG\8/B3\/_ _Q9_:2UG1?BGX3\$^,]:\/^'/B7I7_  LW
M]F71&T+QUHF@9CU_P]'H&O\ B"/R_$KRV\9UTK$P *)U8' /,L0\*K:4ZE1W
M3>E.E*H[I-;J+6_KTOR8[$K!X1XK=1<=/5Z']-?/J/R/^-'/J/R/^-?P%?\
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MDI5HT6G!Q3C*+DYM:^[%O=:U_;,.;ZKR)2NXMWV]V_IL?UM(5R>1['T_P_\
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M+GTHHV\G [<GKT/TQ^?.::V<YQP?R_/CT_R*_E(_X+K?&S]K3XU?M2?LW_\
M!./]@OXP_$#X2_%;_A4?QI_:G^+GB/X:>+_&7AG4SI'@CPCK_P#PJGP=K.L^
M "?$R0>+_$_@C7?#, #D?\)7K_A$L6(P/O/_ (([_MK>(OVQ_P#@DSX-^*/B
M+Q1J.L_&3X9^!_'7PG^*/B"ZUM-1\2S?$+X7:-,FD^+M;U15!?Q!XL\,2>#?
M&TTC'<9?$/F-N"L%6*R;%X?*?[7?+)/E4H_:2DIN$GKI&?LYJ+Y;:+76P4<X
MPDL9]25TU>S]-UW=KW/W"PPZ;?\ OH9_3-&XX^ZI_'!_0"O\X7]GGX@?M ^-
M/^"57Q9_;]\8?\%H/VMOAG^TE\*O'/BRP\#?!G7_ -IW5M1\+_$/_A'UT!M"
MT27P)XC\2IXH\0:]XP.MZPB>299&D(+0B*.25/Z -!^!7[6?_!1O_@G'^S!^
MVA\0/VX_VO?V1?BYHO[*/BO7_&?A/]GKQ5-\//#?Q/U+2-6\0:_X?^)NOZ#H
MDGA=UU[Q?X?T#1O$EM''Y%M;P:\EO#$D<*@]F)X?6"E;$9G!)5'2D_95HVJ*
M$9)I*,>:#YDO:0;@M;O22CRX;/WB[?\ "94U5TN:#TUZVLMMG9_A?^GV/8>A
MR?3&,?A_]?I4M?QL_P#!O_\  G]J/]L+X1_##]N?XL_\%,/VZ==NO GQT\3:
M/K'P)UKXOZ[XE^%_CW2_!*Z-NT/64USQ!+)/H7B<:J6DA"H-K+B09X_LDSPQ
M],C\J\O,,#_9F+G@N93E3DX3:4HI3BDVO>WLI1UNUKN>CEN8+,L)'%J/*I)M
M+1[7[>C'4445R'HA1110 4444 %%%% !1110 4444 %%%% 'XA?\'%UM]K_X
M(_?M:M_T#8_A#?\ _?KXU_#M?Q_UOX=:_P MSQA>'_A ].G_ -&_X_/_ )?_
M -.W].*_U._^#A2Q%W_P1O\ VZB#S;^ O FH$>G]B?&CX>ZV/TA_SU/^4YXD
M,VI?#G1X+&"YN=0NO$@L[.TM/^0G?ZI_;6O_ .>?7CK0!S'AKX5?$SXJ17-]
MX(\+6^HZ/:79LKS5KH#3M-L#V_XGF1@'N>2 .AXKYX99[:>&6^LKBW^T6IN[
M-KFT!!TL$C*D?>4XR&Y!!'J*^JOB#X*_;*O+NX'C'X7_ !\TXZ79_8A:M\./
M&GAO3;#2@1H6/[$'AU1@@$$XS@G!!QCP;QEI_CFS;0&\9:5XUTPG2/[(T<>-
M++5U4:;H8)&BZ"-<"JGAU2WRJ %0Y4* "M=&)^IZ_4]OD>AF7]D?\P2?X?.Q
MKZEI>N^&Y28=,U#4M' TPV>K#2=7T[33_;FCKKFA!5!))!.X XRH+#(Z\[>>
M*K[_ )X?9KC_ +C7Z8Y_QS[FNXU/QCX-7P)X2T>QMA>:_IUXSZP;KP9HVE;/
M^)P?+U;1/&F@>)%\2:Z54*GE^)_",B1@;(B^P*>&TS7]*M/'%EXJU?PW'XMT
M*V\6?VWJ_A35-;U5%UO2QJXD_L76]<0KXC):,&-O$A.\NY7:91L*6*;2;>]N
MNWEOK;OY>:%G62Y0\W3P?5)O2UF]U\N^FS=K-&,3+J>IP0W+1VXN;L6GVR[N
MP+"RX!R3E\#^+<2W '!YQ[W\%;<67BCXC:6+BRNOL_@_5+/[5I]S_:-C? ZM
M$0VBD9#HP(,; \KAMHW<]G\</C/\'=6\)^ / GP(\ 7/@O3/"/C7QM\0KKQ'
MK*:6OC>_U#QLGAF+1O"X=60Z]H7PSC\.F/PCYB^;<?;+HS11M(,\3\$;A;SQ
M7X\NQ/)<W&H^#]5OKNZ<]-2;648%1P!N))(&,@@\Y!J(N[B[-:6\K6N_LQZV
MU22WT5F>EQ#DV$R'-99-@\VI\0[/GX1YGPI)NS?)+3F5VN:\;-7?QQ9A? #_
M )*MX6_Z^_$__J%Z_6!^SW_R63X4?]CAI?\ 6NG^ /\ R5;PA_U^^)O_ $RZ
M_76_ SPW8V_C#X9ZS]BTRW%GK7@:Z%W9W6MG4+W4=;?(_M<S?\4ZBD@X#!)
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M<W[USC=OW(M1BZ:T?N^[=7UBY.VFA679/'*O]T=M-;VU=V[[K6[_ "/YO/\
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M " .WM[]OPK_ &<_^"A=C_:7["/[9-A_S]?LP?'5?R^&?B/_ /7T/I7^,9K
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M7ZWZE9_Z+_D?_K_I^%?$_P 9M,MYK:XY_P _SX_7O0!\;Z#K%CKVEV^K6/\
MHQ_X\KRTN\XL-4[:(?;_ #TZZ'D>_P"O_P!:O+_!,PTWXC>,-#X^SZ]X;TOQ
M/[?VIH6M?V#[GKKA_GZ5[!Y'O^O_ -:N<YS/_P!;_G&,?GZ^_7\L^:'_ "?\
M_D<>H(K8FA_R?\_D<>H(JO-#_D_Y_(X]010!Q^L:#I6L6$^E:I8VVI:?=?\
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M^J2Z#XV\/>(]7UBVBTR25_)@\.Z5=IYB[(VWHL18+($^*OVS/!&K?"KX#_\
M!-:\\(MJZ?MP^ ]&^%_A+P)X<T&Q74O$FN:7H?A[PV_B#1-;T3:4GA\-Z]-H
M?AIW=E"#7_$J*) [&/[[+N#LCXTR7@K'SRO#\"Y]GW%O%O"#4:,Z>&J?4N#Z
M?%E.NJ.)JU:M&&#J0E1XIKJJHTZ<X54W4IQO^<8[C?./#[..,<KEF\^-\FR3
MA7A+C"E4XHJP57FXOXR_U4?"D*E.C3BY5H153A&G*G)N5Z=24E-U#]ZM8^//
MP)\-:AK]KK7QC^%VBS>$;G2M-\8VNK^/O"FG2>$]4OH9H=%TO7S+K*C1+VY_
MLW4O+M;OR99C!,\(D$$AKL/%?Q!^'OP[TJRO_&GC+PIX0T_5;IM)TO4?%/B'
M2/#MEJ.K3+QING2ZS/;PS32J"QA4M(ZD%$8'</P%_92^!/@S]JW_ ()G?M%1
M:=/<>(OVA_B/XS\1^._B!JNJ%7\22?&#P1J<WB+P7I,A*H\6A^*M%C1-NYXQ
M!XZ\2,A,L\BQ^2? SXN:A_P4!^(/_!.[]G^^%WJ5M^SWX;U3QM\=+6\MC)I=
M[/\ "G5(O#GAY]:1PT>M+XKT#0? S2#:T6/'TDS@EFQP1\*<OQ=;B!//JU"/
M 6(QM'BZ=;"TJ=7#*AP>^*,/7A3E":G2XJQ,)<,X.572O>C4TA4A&/I3\7LS
MI87(YQR&$WQ[#A67!\83;E+ZUQE_JOB*<8JR=3A;A*,>+ZJ7*K2Y.;E4F?T6
M^._C[\"_ASK=OH/Q*^,WPG\ >(9;<75EH7C;XA>"_#^KW"X'S1:;KNLV]Q!S
MTE1?+;G8^!N.O9?&'X4:YX,U#Q_IOQ(^'^H^ +%9/[5\;:=XS\/7_@ZTAC1/
M/EO=;^U?V"4C:2-9@\P*F2/.U6!;^9W6=*U+XH_%S_@H[X3\*?L^^#/VF];^
M(/Q1\5^#M ^,?C?QQX-\%>)O@QJKZKKRHFB:)XYD/B4:!X,RP7Q-X2;PM"__
M  @;%4=TAGB]#_;5^$>N?L^?L^?\$Y_@!;67@:^T;6_B*MQ\7+*25_#'PV\;
M^.PGP^ETF'QCK.A0QRCPZ[:YK'A:X\3,7D7PO WB^4(]J(XN^?A'E$<;DV3Q
MX@MG.?VJ8BFWPJX2H1X(?&-647&K.I0<7?A6G'B=4V\3[SC."=-\W_$9>(?J
M7&&</A)K)LAYN6<8<5*?.N-7P?&,VZ"C6_=)<5N7"JK/ZO:FI*?O']#'PO\
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MSM2I5H-8I0G4<4H*$9)3YH_'X;Q.XCR/&9MPSAO^,];XR?"'"O%4HTYPJ?\
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M[5?[)>E]..O_  N#X,_Y'_"&U^H'B2\\FTN/\^O7G\/S KJ/AB/.T;3IX/\
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M1R%RZ$?H]D^WY#_"KE1K12<G%*2NM'JD[7,/;Q?1_@3T445!N%%%% !1110
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ML??\$:_VR?V>/V2/VK/V$?&_[:/@3Q[^S/\ %+X"_'CX7? WPO:_"&/1]6\
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M2+M]+_;=_P""D'[2/Q/^(VC^.OA#_P %!/A-??"36_A1::!J&F^(/#OAC7-
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M+-<R/Q4$_G7U57YWB?\ >9^L_P#TIGZ-AO\ =EZ?I$****S.H**** "BBB@
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M,/!WC7_B0#\>!UKP?K>DZU?V_P"R!\1;O]I8Z'9OK>K_ +.?C:ZTCX<_MF>
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M^_\ ["A]/U/^-8]YX;@_YX6W?K[YQ_GZXXH ^3_%46AZE+<3_P!E7.B7'/\
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MG+R/?]?_ *U'D>_Z_P#UJ^B?^%)R_P#0;@_\ 1_C3O\ A2DG_0;MO_!5%_\
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M&T^REV&:WMD^TL"#NO2J%F')&2Q;&."-I[Y.]117P)]@%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
8 !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>image_017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_017.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "N 3 # 2(  A$! Q$!_\0
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MMYE>-)D;Y7&>*FA4O=!4CU.J\$+CQCIW_70_^@FO<Z\,\#R!O&&G#/.\\?\
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D!X4;?N-T#_P$_P"-=+118#(LM&-I<))YP(4YQMK7HHI@?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>image_018.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_018.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %" :$# 2(  A$! Q$!_\0
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MN1DH<J<#TS4HTJR!O"( /M@Q< $X?C'3UQ6KK4K:1_+R_P""8JC5OK+\_/\
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MNJ?\]+/_ +]M_C1MU3_GI9_]^V_QHL!=HJEMU3_GI9_]^V_QHVZI_P ]+/\
M[]M_C18"[15+;JG_ #TL_P#OVW^-&W5/^>EG_P!^V_QHL!=HJEMU3_GI9_\
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MHHHI#"BBB@"G]GOO^?Y?^_(_QH^SWW_/\O\ WY'^-7**=Q6*?V>^_P"?Y?\
MOR/\:/L]]_S_ "_]^1_C5RBBX6*?V>^_Y_E_[\C_ !H^SWW_ #_+_P!^1_C5
MRBBX6*?V>^_Y_E_[\C_&C[/??\_R_P#?D?XU<HHN%BG]GOO^?Y?^_(_QH^SW
MW_/\O_?D?XU<HHN%BG]GOO\ G^7_ +\C_&C[/??\_P O_?D?XU<HHN%BG]GO
MO^?Y?^_(_P :/L]]_P _R_\ ?D?XU<HHN%BG]GOO^?Y?^_(_QH^SWW_/\O\
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MK9VLL,<4ZLI\SS50KQG(^_GZ>]&I^)I8=6M+:RMIYRM\UK/"BKND/D-(,$G
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M(H 1_P#D/P?]>LG_ *$E7ZPWLKC^W(!_:=UG[-)SMC_O)_LU>^PW/_05NO\
MOB+_ .(H8%ZBJ/V&Y_Z"MU_WQ%_\11]AN?\ H*W7_?$7_P 10!>HJC]AN?\
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M/V&Y_P"@K=?]\1?_ !%'V&Y_Z"MU_P!\1?\ Q% %ZBJ/V&Y_Z"MU_P!\1?\
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M_P "I/\ XJKM4KVZ>TN+5B0+=W,<F1T)&5.?PQ^(JE=NQ+:2NP_LJV_O7/\
MX%2?_%4?V5;?WKG_ ,"I/_BJSK?5KN6(QN$6XFF0P8''E/R#]0H.?>IX==CG
MN BQ?NG=D1_,&<KGJ.PX/-6Z<D0JD&6O[*MO[US_ .!4G_Q5']E6W]ZY_P#
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MH_LJV_O7/_@5)_\ %5R\'C:>\M \<-M;RK%$LHF+L%N&9@8@$!+$;&Z5G_\
M"8W4FJ:/="/;)?6TL"PL[+"LHF";F)&0/E.,C/('>CED+F1W']E6W]ZY_P#
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MLJB)O.(5O+#-@D[>.!S[4D=S<"ZOOLUZLK-/;Q"?RP< \'V)I^Q9/MET.GI
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MGW&Z6>$*RNL\:'(4D;5R2<9!QUHY6/F1Z#17"2:[K$,TNGP:I;7;B[M(EOA
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M #\P_P#?8H^VVG_/S#_WV* )Z*@^VVG_ #\P_P#?8H^VVG_/S#_WV* *[_\
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MA_[[%'VVT_Y^8?\ OL4ACEMH$V;88UV$E<*!M)ZD>F:<D,43R/'$B-(<NRJ
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M_/S#_P!]BC[;:?\ /S#_ -]BC46@ZWM;>SA$-M!%!$.B1(%4?@*EJ#[;:?\
M/S#_ -]BC[;:?\_,/_?8I#)Z*B^TP?\ /:/_ +Z%% #?L5K_ ,^T/_?L4?8K
M7_GVA_[]BIZ0LH(!(!/0$]: (?L5K_S[0_\ ?L4?8K7_ )]H?^_8J>B@"#[%
M:_\ /M#_ -^Q1]BM?^?:'_OV*GZ4W>GF&/<-X&[;WQZT 1?8K7_GVA_[]BC[
M%:_\^T/_ '[%3T4 0?8K7_GVA_[]BC[%:_\ /M#_ -^Q4]% $'V*U_Y]H?\
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M::M?3);B-7"!&'<;>?UK5K*22>AI!MKW@HHHJ2PHHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
>HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>image_019.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_019.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %/ -L# 2(  A$! Q$!_\0
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MHH **** "BBB@ HHHH **** "BBB@ HHHH ***KSWUI;.$GN88F/0.X!/YT
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MY)<6=W#B2.X8N$/4,N>AR*Y.9'NI_M2 %3@G/;ZU;DDO+RPE1+-@@',B\@4
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M_K@/$/\ R%8_^OL?SH [^BBB@"MJ/_(-N?\ KFW\JX_PT/\ BL)S_P!.A_\
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MP8!,@_7FL[PIX3U/1M:M=0FO$B$1RRPDEB.XS77R28;DY-+ QDE5  "?4X%
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>image_020.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_020.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #E 7X# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%9N@ZW:>(=&M]3LGS%,N2,\HW=3[@UI4 %%%% !1110 4444 %%%% !1110
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M'GM5(AZ.YXI\F.F#_.I(Y(D?+1Y4\$9KN9)/AQ:3E3::C<*#V8__ %JB36O
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MWVG*'\5(_*JWBBW@OKO^T81B/4(Q/Q_#)T;]10!G7,:2V<=W$H!;AC[]0?\
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MI'Q&T:XW@(\WDO@]588_K7UY7R[X<TJ >)--,4?SBYC(.?\ :%?45 !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
F%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>image_021.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_021.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #Z 2P# 2(  A$! Q$!_\0
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M>)V#9U23D <*.U5:/<6I] ^6O]T4>6O]VOGX_$'Q023_ &H_+;ONCK_A0OQ
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M58G'9J#D'GK[TXN@P#"K''4DT7LRUN,_=G^^/R-'[O'5_P A3O,C_P">"_\
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MVX^P'[NW.\_G]:4_#?PN=V-/QDCHYXQ_C19=PN^QX#2CJ*]]_P"%;^%MP/\
M9P^_NQO/3T^E(/AOX7&W_B7YP".7/.>_X467<+L\#/4TE>^GX;>%R"/L!R5V
MYWG\_K0?AOX7.?\ B7XR1T<\8_QHLNX79X.@R%&<9.,GM6C+IT"0N5U2WD*
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M5:^B4\#^'(VW)I4(.2>G4$8(^E,'@/PR !_9,/ (Y]Z++N%V?/-*WWC7T*?
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MZT^@#R#_ (5YXW_Z#"?^!K_X4?\ "O/&_P#T&$_\#7_PKU^B@#R#_A7GC?\
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M "8%&!2T4 )@48%+10 F!1@4M% "8%&!2T4 )@48%+10 F!1@4M% !BBBB@
&HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>image_022.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_022.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #V 2@# 2(  A$! Q$!_\0
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M8O38:9+.OWP,+]37G$DCRR%W8LQ.230!W/\ PE6F_P!Z3_OFC_A*M._O2?\
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MTG_?-<)10!W?_"5:=_>D_P"^:N6>L6=\<03 M_=88-><4Z.1HI%=&*LIR"*
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MGRSSV$,URL:RR*&(CS@ \CK5F@!**6B@!**** "BBB@!:*** .FT1RME&/\
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MK7>?V78_\^T?Y4?V78_\^T?Y4 < =%TTIM-G$5QC!&>V*>FF6**P2UC 92C
M#JIZBN\_LNQ_Y]H_RH_LNQ_Y]H_RH XU%6-%1  J@  =A2UV/]EV/_/M'^5'
M]EV/_/M'^5 ''9HKL?[+L?\ GVC_ "H_LNQ_Y]H_RH XZBNQ_LNQ_P"?:/\
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M* $*@]0#]12;$_N+^5.HH ;Y4>2=BY)R3CK1L3^XOY4ZB@!  HP  /:EHHH
M**** "BBB@ HHHH **** *[?\?7X_P!!6Q:_=%8[?\?7X_T%;%K]T4 7****
M "BBB@"K>?ZK\?Z5FUI7G^J_'^E9M !1110 4444 5;N_L;1E2[N(HF8957/
M7Z5-&\,L:/&R,C#*$8Y'M574;&*]: 23",H6VCC+94K_ %K/M/"T=I?07$=S
M+MA.1%MXZ8XYXH T!?Z4S8%Q:DA_+QD?>]*ME8=W(CSGVS6$?#MF(2B7>UEF
M\Z:3J3AB0.N !DU)=^&H[N<SBYD1VF,Q('7(  Z]L?K0!J3SVEL@DF>%%9@
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MW*555]1R.XI\A\4LKJ5BY."%"XZ'H?3I[UTU% '/6J:K->V]K?*PAB99MX&
M0J@!>.OS5T-%% !1110 4444 %5K^![BSD2/'F##*#T)!R!5FB@#.:XLKM[>
M>2Y6%H6+>6[A&!QC!S_DU);-]JO9+M01"(_*C)&-_.2?I5IH8G;<\4;-ZLH)
MI] !1110!7;_ (^OQ_H*V+7[HK';_CZ_'^@K8M?NB@"Y1110 4444 5;S_5?
MC_2LVM*\_P!5^/\ 2LV@ HHHH **** (9#<_:H1&L1MR&\TL3N![8K+U*35D
MU,-9<VL4.]U*YWGG@=R>G<5>OM4M-.*BYDVLXRHQR>0/YD5*U]:QLZ/<PJR#
M+J7 *_7TH YP:MK[.DALOEV%A$L9&2 _4GUPO'O3I-7\0- 3'8QH=N0RQL?4
M]#],8]ZZ#^T+3./M<.<X_P!8.OI1_:-GC=]L@Q@'/F#H> : ,V_U'5;>Z(MK
M..2 -&H9E;OR3QV[?C6<NJZ^L1B%HQ=06,CQ$G[_ $]#Q72)?6LCE$NHF8'&
M X)SZ4LM[;0,RRW$:,J[RK. 0/6@#G7U;7)HT460A+3 %D1B0N1QSTX[\BNI
M/4XJE;:M97</FQW"A/\ ;.W^=!U:P"3N+I'$"AI-AW;0>G2@"Y16=#KFGSMM
MBF8GRVE&4895>O4=1Z4^+6-/EB63[5$@;H)&"D_@: +U%4H]6L))#&+J,.#C
M:S8/4C^8-327MI"[))<PHRX+!G (STS0!/14#WMHDAC>YA5P0"I< @FH3JU@
M)0GVJ+D$[@XVC'J>U %VBH#?6@?9]JAW9 V[QG)Z"H?[7L/M?V;[5'YNXH03
MC##J/K0!=HJG/JEE!'%(TZ,DDGE*5((W4LNIV4-NTYN8V11G*L#GZ?D: +=%
M5K;4;.\4-;W,4@)P,-SGTQ^!JS0 4444 %%%% !1110!7;_CZ_'^@K8M?NBL
M=O\ CZ_'^@K8M?NB@"Y1110 4444 5;S_5?C_2LVM*\_U7X_TK-H **** "B
MBB@"E>Z7;WTT4LQ;=%]W!_VE;^:BJEWX;L+V>6:0R"21MQ*L.OR__$BGZMI,
MNI21-%=M;[$93M&<Y'UK._X168(V-1DWD8SR0!QQU]J +1\+:?MC3?+LC8E5
M)4@9ZCI3?^$3L?+V>?<@; APX&0#GTH@\.RQ70FDOVEVOO"D'!.&P3SSC(_*
MMU P10Y!;') P": ,4^&K>-K0VTK1&V#[6(R23T)]<'FI+WP[::A="YGEG,@
M0*,,,#'?IUK7HH P(O"EJJE9)Y2N[*A<#Y>P/K5F'P]9P6T\ >9HYT5'#,.0
M.G:M:B@#-&AV8N?.4,F(3"J)@*JD8/:JW_"+:=C!\T\8Y(]_;_:-;=% &)_P
MB]B @62=0I!X89)#%ASCCJ>E32^'[*>_-W(9"_F"3;GY0P(/_LHK5HH R;SP
M]97LK2R;P[2>82,==NW'TJI'X1LQ;^7)/.9"-K.K!<C/3'I70T4 8@\+V >)
MM\V(FW*I((' ![>PJ6X\/65S-/))YA,S%V (P"<9Q^5:U% &5'X?LXK-;56D
MV+(90V0#D@CKCWJL/"5@%1?-N"%ZY8?,<DY/'^T:WJ* ,BU\/VUIJ45W&[8B
M1E5#ZDYS^&3CZUKT44 %%%% !1110 4444 5V_X^OQ_H*V+7[HK';_CZ_'^@
MK8M?NB@"Y1110 4444 5;S_5?C_2LVM*\_U7X_TK-H **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH KM_Q]?C_05L6OW16.W_'U^/\ 05L6OW10!<HHHH **** *MY_JOQ_I6;6
ME>?ZK\?Z5FT %%%% !1110 4444 %%%% !1110 445#=W'V6UDFV[BHX7U).
M /S- $V":7!]#6?]@WQE[VXE=\9;#[47Z =JHP2:1<NBH]R-X)0NS*& &<@^
ME &]@^AHP?0US;7^AJJLTMT-Y 0$L"^<X*\\C@U9LAIE_-+';O<%H20Q,A'(
M./6@#:HJC&9+.[C@>5Y89LB,N<LK 9()[C&:O4 %%%% !1110 4444 %%%%
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M &#]D?\ R*/LC_Y%;WD#TH\@>E &#]D?U_2C[(_K^E;WD#TH\@>E &#]D?\
MR*/LC_Y%;WD#TH\@>E &#]D?_(H^R/Z_I6]Y ]*/('I0!@_9']?TH^R/_D5O
M>0/2CR!Z4 8/V1_\BC[(_P#D5O>0/2CR!Z4 8/V1_P#(IRV1)Y%;GD#TI1"!
MVH HV]KLQQ6@B[12A *=0 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
)44 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>image_023.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_023.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #V 2@# 2(  A$! Q$!_\0
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MHHH S]6_X]1_O5A5NZM_QZC_ 'JPJ "BBB@">U^\WTJ'6K!=1TF6%FO!M'F
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ML"/_ %_Y5OVOW10!;[44=J* "BBB@#/U;_CU'^]6%6[JW_'J/]ZL*@ HHHH
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M(QL'?K4BV=LJA1;QX"A.5!X'050;4KX1[_[*DQC@;^<YZ8Q3_M]Z86/]FN)
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MW[7[HK C_P!?^5;]K]T4 6^U%':B@ HHHH S]6_X]1_O5A5NZM_QZC_>K"H
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M_P WINI_V6+(Z_G63%X<6+7O[3$[_>9MG8DJ%_IG'K6E=V NI5D\YHV52H(
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M%B&<9^;+>_;_ /70!;35K%_*Q<+^]!*9[X.#^IH&K6.XK]I0,#C!ZY]*J/\
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M!@_99/[S?G1]ED_O-^=;WD#TH\@>E &#]ED_O-^='V63^\WYUO>0/2CR!Z4
M8/V63^\WYFC[+)_>;\S6]Y ]*/('I0!@_99/[S?G1]ED_O-^=;WD#TH\@>E
M&!]ED_O-^=+]ED_O-^=;WD#TH\@>E &#]ED_O-^='V63^\WYUO>0/2CR!Z4
M8/V63^\WYT?99/[S?G6]Y ]*/('I0!@_99/[S?G1]ED_O-^=;WD#TH\@>E &
M#]ED_O-^='V63^\WYUO>0/2CR!Z4 8/V63^\WYT?99/[S?G6]Y ]*/('I0!@
M_9I?[S?F::]DTBE7RRGJ&YKH/('I1Y ]* .?^PGTH^PGT-=!Y ]*/('I0!S_
M -A-/6Q)/(K=\@>E*(0.U %"WM=N.*T$7 Q2A .U. H 6BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
:*** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>image_024.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_024.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #P 2 # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ JI-J,$+;2Q8CTINI3F"V^7@N<9
MKGR23DT ;G]KP?W7_2C^UX/[K_I6'10!N?VO#_=?]*/[7@_NO^E8=% &Y_:\
M/]U_TH_M>#^Z_P"E8=% &Y_:\']U_P!*/[7A_NO^E8=% &Y_:\']U_TH_M>'
M^Z_Z5AT4 ;G]KP_W7_2C^UX/[K_I6'10!N?VO!_=?]*/[7@_NO\ I6'10!N?
MVO!_=?\ 2C^UX/[K_I6'10!N?VO!_=?]*/[7@_NO^E8=% &Y_:\']U_TH_M>
M#^Z_Z5AT4 ;G]KP?W7_2C^UX/[K_ *5AT4 ;G]KP?W7_ $H_M>#^Z_Z5AT4
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M;./ZT 35+"Y63'TJO%*DREHVW ,5S[CK4T?^M'X4 ;]JV5%6QTJE:?=%7>U
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MI6GW15WM0 4444 9>L_ZF/\ WC_*L.66.%-\C!5K<UG_ %,?^\?Y5S.IV/\
M:%J8=Q7((.#C@U=-1<DI.R)DVEH689HYTWQ,&7U%/WJ3@,,YQC-4='TT:58)
M;*Q*HH49.3@# YJK/X>BFO);I;J:.21BV%QA2<9Q]0H!HJ**DU%W01;:U-C(
MW;<C/7%+62NB%)C*M]-OV! 2,G&0>?4\8IR:.8;=TCNI2[1[-[DGTY_3]34%
M&IWQWHR,D9Y%91T7E2+V?(&#Z'IVS[<?6D&B%)(FCNY05(#DGEEXR,^^/U-
M&MGG'>BLFXT1IY)G^WSH9&+#&/EXQ@?Y[5(-'43"47,VX=B<@_K0!?,L:G!D
M0'T+"GCD9%4;K2;6[E,DB#E6R ."QQ\Q]3Q43Z09)2QNY50!0JIP1A0/Z9H
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M$'H:?'_K1^%5K:V6V#A69MQR2?IBK,?^M_*@#=M/NBKO:J5I]T5=[4 %%%%
M&7K/^IC_ -X_RK&K9UG_ %,?^\?Y5RFM7=Q9V#26T9>3L!W]JNG!SDHHF4N5
M79I45GZ/=37EDLDZ,K$ X;J,CH?I4=QJ%W:WDRO LL  *%%((^IYSU]**D'"
M3BPC+F5T:E%8YUR1(5EDL9$5E+#<>0 ,\\<4O]LSL,1V#EMI;YB0!@9YX[]J
M@HUZ*Q?[<F)W+8OL&?7)^[[<#YOT-3C4[B2WF=;-D*J&4MD@],G'MG/X&@#3
MHK(.KW$2Y:T,ZE@JR1 J&'K@]*;)K%SG$=DQ! YP3@[L$'WQS^'6@#9HK'.J
MW<L$Y@L\2H!L#9.X[B#Z?7KWI3JMW&I$EBQ*OL)' /OWX]\F@#7HK'76;C$9
M;3Y")&PI&1Q[Y'6KUA=/=P-*\?E_.54<],#U_&@"U1110 4444 %%%% !111
M0 4444 %%%% !15>YFEBV^6@8GL>Y]/;_P"M5?[9<F'<(D# GD@X^M &A15!
M[R<8VQ#E03E3QGJ?P]*=+<7016BA5CY>Y@?6@"[3X_\ 6C\*JVTTDRN9(S'@
MX /7%6H_];^5 &[:?=%7>U4K3[HJZ.E !1110!EZS_J8_P#>/\JQ&"L,. 0>
MQK;UG_4Q_P"\?Y5@7-U#:0F6=@J#N:J*;=H[B;26I(NQ1A< #L*7>/[WZU%;
M7,-W")86#(>A%#75LC%6FC#*"2"PR .OY4I)IV>X)IK0E+ C!((HWC^]^M-C
MEBE4-&Z,K#((/6EWH'";EW$$@9YXI#';Q_>_6DWC^]^M&5QG(IHEB9V0.A9?
MO*",CZT .WC^]^M&\?WOUIOF1[RF]=PZC--,\"N%,L88D #(R30!)O'][]:-
MX_O?K2;TW;=R[ASC-*"I. 03[4 &\?WOUHW _P 7ZTOX44 )N7U%&Y?44M&/
M:@!-P]11N'J*6B@!-R^HHW+ZBE_"B@!-R^HHW+ZBEH_"@!-P]11N7U%+1^%
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M7CGI5F#Q#I]Q*(HY&WLNX;EP#^-$I.3YF"22LB=M+MFD@=5*>004"G@8)/\
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M/\//7W;\JO6,MW*TINHO* QM7'Y\]_K0!<HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **CG\SRCY1P_&.,]ZJN]]B,!.-OSD 9S["@"]15%GO>,*<[1G
M"C\?Q]*=+]M**8B%81Y.1U:@"Y3X_P#6_E56V,[*YG4*<_*!V%6H_P#6C\*
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7TJ[10!36U4=JF2(+4U% " 4M%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>image_025.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_025.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "? 88# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?2_C[-+<+%+IIN 3R5&P@?K5G*>[45%;7$=W:PW,+;HI4#H?4$9%2T %%%%
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M\Q0$& W]X>_O1':6T+!HK>*-E!4%4 (!.2/SYJ7--;#46GN34445F:!1110
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M@"KJ5(89!R,<U\4>)_#&J>%-=GT_4[8Q,&)C<#Y)%SP5/<4 06>1@CBM19I
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 ?,OQ>N_.^(5ZN1B%%7]!7I/
MP)BV^"II<?ZRY;]/_P!=>,?$R[\WXA:\WI.5Z^G%>Z?!./9\-[5L??E<_P A
M_2L8+WY,[JTO]GIQ/1****V.$**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBF3-L@D?^ZI/Z4 ?%7B^Z-QXPUF3INNY._\
MM&OJ/X36WV7X9:,N.7C:3IC[S$U\DZE+Y^JWDN,;YF./J:^S/ ]M]D\"Z'!Q
ME+*/./\ =!J5NS:H_=BC?HHHJC$**** "BBB@ HHHH **** "BBB@ HHHH *
J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>image_026.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_026.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "@ 5$# 2(  A$! Q$!_\0
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M1110 4444 %%%% !1110!'L%(8Q4M)B@"(I4,EK%)]Z,?4<&K=(10!CS6$J
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M'8#)KJ9X$F7##Z'TKR7XH^&-2>*;5+=UDMEC D!^]'C R/;I0(EO/BQ::?J
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MBECGC62)PZ,,@@T^@84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %)2T4 -*AAS5=XBIRM6:* .1\3>#M*\46K1W4")<=4F Y!KSN
MVM_$GPWO6\M)[NQ(X"G.WG QV9?;KS7MSQ!AQP:IW-M'/"T%S&LD3=0:!&=X
M=\76>O(B<1W!'W>Q..0/0^U=%7 W7@("_2]T_4)HF1E<1GJQ#;L9SCVSBNBM
M-:>%S!J"E64XWD8/3TI@;E%-1UD0.C!E89!'>G4AA1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1BBB@!*0J".13J* (?*VG(Z>E17%G#=*!*O(Y##@C\:
MMTTK0!SYAO='??$^^WQEC@GH>_/''\JU++5+>]7 /ER9QY;D9Z9_D15LC.01
MD'J#6->Z$K[I;%E@D))("]<^A[>M,1N45@VFJW%M<)9WD;M(V2,]57(&3Z]1
M^?>MZD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!",TF,4
MZB@"-HXW=79%9U^Z2.14E&** "BBB@ HHHH **** "BBB@ HHHH **** "BB
0B@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>image_027.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_027.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $& G # 2(  A$! Q$!_\0
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M"K<PLQZ 2 FG9BNB>BCK12&%%%% !1110 4444 %%%% !1110 4444 %%%%
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MR64Q2HS @A?O?*01CMWS1RL7,CL**XQ?'CR6]Q<Q:1+);JI:%PY&_$@3#$J
MI.<CD_A6O9:W=2ZV=,O;.&TE$0<?ORWFG SY?R@,!G!.00>U'*T/F1N4445(
MPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KGO&0;^QH65
MID"7<+-)#'O9%#C+ 8/0>U=#133LQ-7/-;C6/$/E6ZQWLD-HSS_9[V>)@TN&
M CWA8V[;N"%R!70>);^\MFL5>[N+2V>"1I)[2$N3,-NQ,8. <L>G.,5U5%/F
M\A<IYE=Z3J&H?:+J]-VEU.]@)42-2!_> ^4\#J1T%3PZGXC>+5#]L\N>.-U^
MS+"Q:)A( A4; N-ONV>M=L-9LVOI+1&9Y$\O<4&5^<L%Y'^XV?2K?VF#87\^
M/:"03O&!CK5<WD+E\SBI;O7K;Q0+%+XF.(H(5N%;_24VY8Y5-N<\9W#&.GJ[
MPI<7-[X@2YN;B\GF_L[%QY]OY:PREQNC4X'3TYZ9SS7:F6-71#(@9_N@L,M]
M*:;F!5<M-& APQ+#Y3[^E+FTV'8X:?6M4;6]1C@NKFWA$=PI^T0EA"R$!' 5
M.AYQ@L2.2*U$U6Y_X0B.[<7RS%O+:3@N!OV[\[?NXYSMSCMFM]-2M7U&6Q\S
M$T<<<ASP&#[MN/4_(:+34K:\@\Z-]JF:2$;_ )261RA _%30WY!;S.%BU#Q'
M=:6LGVR[BD@L9Y@4@'[YTE(CSE><KCC )K9\0NAU#0[O5('?2U20SJ(V=4F*
MKL+* 3C[XZ=2*ZIY8X\;W5<]-QQFF_:(=KMYT>V,X<[A\OU]*.;R"QYP-&NM
M3-M;6UJ([&>2\-L+M'Q#$VW:P'4<Y*@XX/:M"S6'3_%U[;WLZR*L4:KYUF[R
M2A8L$K(#M'?(P:[CSHMRKYJ;F^Z-PR?I44-Y!-&C[PF_.%?Y3QGM^%',Q<IR
M/@NWNH+F[COX[E))($:Q:3)\JUR=D9..'7/(//(]*H6VM>)Y;^&TD2X57D73
MVD\C[LJ,&>;./NE"1GIE?>N\;4;-);>)KF+?<DB$;OOD#)Q4HGA(<B5#L.&P
MP^4^_I1S=;#MYG *^NZ3ILLNGO<2O,EXR6\D0VQ,),J5XSG!)YSFI+.YUR\%
MG"NK2M;RRSYG@C)=56,$*Q>-?XNAQWQ7>+-&ZAED1E)P"&!!-!EC5RC2(& W
M$%AG'K]*.;R#E.)U>>[O/"_AB]O#<03_ &B&:YEAA)>+]T^YMN#C\N,U3?Q!
MK=M8,9)+MS-9-]B?[*=\KB4@,0!PQ0J<'%>A--$@)>1% ZY8#'>D,\0*@RH-
MV-N6'.>F*.;R#E\SBY+SQ#%<RW4$UQ,QNKB".U:$>7M$19#G&?O <YQSBLNU
M:XO;\W"37U\<61,EQ;&/#B4EE'RC@'KZ>M>D^=%O9/,3>HW%=PR!ZU"NHV;W
MWV);F,W.SS/+#<[<XS^='-Y"Y?,\_L]7\1M87$]S?%3F(7<:0N9;7,F'908P
M,!<\#=TS6MHD=\OA+67LI;C[2UY<S6\LL6UY?FR#MP/O8QT[UTRZI;,]X@+[
MK1ML@V]3MW?+Z\4Z'4[*X,ZQW,>ZW($REL&,D @'TX(H;\@2\SA/[9\0ZC;7
MT<EO.D,MK/?QAK?_ )9&-ECA((Y;<,D=>:62TO)-0U&W-U>AY+VQEC'EY$2?
M+EDR,#!R/;'(KT4$$ @Y![T4<WD/E,KP_)=M82QWDDDLD-Q)$LDB[6= WRD\
M 'CN*U:**AE!1110 57O_P#D'7/_ %R?^1JQ5>__ .0=<_\ 7)_Y&G'="ELR
M2#_CWB_W!_*I*C@_X]XO]P?RJ2A[@MBG->R)>?9HK9I6$8D)#   DCO]*/M-
MW_T#V_[^K_C35_Y#LO\ U[)_Z$U7JIV70E7=]2HMS=%@#8LH)Y/FKQ6/XZU)
MM,\)W;QL5DFQ"I';=U_3-='7#?%//_"-0>GVD?\ H+5KATI5HIKJ8XEN%&33
MZ'C]:%MJ?V:S6W\D2!7:3#'@,0NUOJ,56LQ"UY&+@@1$\Y.!^/M6DL-EL)E2
MT5LMYP25OD&T;=G/)SG/6OI)M;-'RT$]TP_M>WDE6:>.4R1A]N,'>60+R?8C
M-(NJPNT.\2#82,'!4 E3G]*F":5)<2A8(0$F*1#S" ZX^\<GGGW%1?9=/$AD
M,L#0A ,*Y!+[QG ZXVUG[O9FOO\ =$PURW@GEVQ27"M*S[I<# + X'MQ65?W
M*W,J%-Q5$V@NH#'G//)]:M>=I\BHK6D48;<'='8E0#P0">N/S]JGNETN&.8Q
M0Q.P3]U^\)#9(P2 >N,^GTIJT7LQ2YI+=%/1=0DTK6;2]C.#%("?<=Q^6:^B
M58,H8=",BOF<=:^CM+W?V39[\[O(3.?7:*\[,XKW9'IY5)^]'T)9[2WN7A>:
M)7:!_,C)_A;!&1^!-4Y]!TRX'SVJAO-:;<A*MO;ACD<\CK6)X[4&VT@N(O*%
M^ID,R%XP-C_> [=*I7=WJ@:8Z7?&"TMH+0P1P6RF-S([*_49P!@XSQ@5Y23L
M>RV=/_PCVE?;!=?8D\X'<&R>NW;G&<9V\9]*4>']*#JPLHP1'''@9QM0@H,>
MV!BN.U'5_$%J4LUNY%BCN;B(WTBJI8J%,8;Y"O.X] ,X[&G7FLZW;VU_<W%Y
M,I6[@M8XK> #AE1G9,J26^]C@X[@T^5]Q778Z^X\/Z7=$-+9H6$K3;@2#N;[
MQR/7 R*CC\,Z-$\C)81@R*58<XP6#$ 9P!N /'>N.CUG7RVG0IJB.6B#B:3:
M%EE,K!HVPG)50!@;3DYJW/J?B&U$]U#--<O*U\D=LT*[4\LGRR,#)/'<\T<K
M[A==CKVTFQ?41?F "YXRZL1NQTR!P<>],U#0]-U2:.:\M4EEC!57R0=IZC(Z
MCVKE+C6=0M;>S.GZG/J$=_FSBFEA4&.X."&X49 &_MCY:G\6QW4.NZ5J-N)Y
M'TVVFN2L8/[P QAUP."2A; ]:5G?<+HZ+^P=,\^>7[*H,ZLLBACM;(P3MSC)
M'&:6YT;2Y5+SVT8"^6Q<G&WR\[#GMC)_.N$\_5K*74=5B$R3ZBEI+*Q_Y81-
M)(.,@@%4VYX..XI-8U+5IM"FMKW49%5["5H'MH/,%VVXC:QV]0N/N[<YST%/
ME?<.9=CN4T'2<3A+5"DK9=-Q*YSNX7.!S@\4S4-!TVY^T3R@PR2H4:<.05!Q
MNQGA20 "17-_VA=VVIM;RW,NGV3W4G[^& $NX2+:A^4]<MSU.,9XK/U#5]0U
M$ZO:#[4]J]M(WES(,QNDJ@ !5&W(.<$DXP:.5]PNCTH!44+T X%+7'^-A%#/
M97I$5S<0*_EV$\3.MQDKPI ^63@8/N>W-9LFN>(3>ZLPF$#01W!2T90S!53,
M;*NW).<$DL0>F*2C=#<K'H5(&##*D$>HKC9[S7+&[TZQ^U3W!U..,+<&%?W,
M@.Z4G P!LSC/<"JFEZI?K<6UO//+9QB-WMHH[<!;J3SI 5;Y>, +TQ][.:7*
M',=]37=8T+NP51U). *\[M-9U^;2+NXFU**)P(S(CX#Q/N.Y%.S"9' W!L$9
M[UH>*[B:_P#">F-&C0O/)')YM[&2L1"EAYRJ.03QV&33Y=0YM#M00RAE(((R
M".]+7+^!;U;C0S;):3VL=H_EI'< B0C&=QR!P26QCC %=14M6=AIW04444AA
M1110 4444 %%%% !1110 4444 %%%% !535;66]TF\M8)/+EFA9$?T)&!TJW
M10!PECX5U!+D3FPL;%/-LV,-O,2&$0D#$G:.3O&*HMH.H6-QH]JVDVEU"D\Y
MCMI)!M">4!^\<)@G/0E>GO7I-%7SLGE1P$?@_5(ECA:.UG=H[94NVE.^R\LY
M(C!!)'IR/>IT\.:M"EQ##9V)LI+I9?)F99)&7+%OG*>I7&02!GGI7<44<[#E
M1YW_ ,(;JOV:V@>ULI)?L-K;F[:8E[9HY'9BGR\\,,<CIZ58O/!]]/,K2HMS
M"WVA2BW'E-'OG:0.I*GG:PSC!!'6N\HHYV'*C#U?0SJ>L:9<NL30VL4X/F<E
M7<*%8#H<8-<U;>#;N+2I8);,/<A(U\Q+T!961]P<KY>,YYPV<Y(KT&BDI- X
MIGGJZ%J=WK,D<EE9">,63/?+\GDE!EA$N.AQC@CK5^/PK>1K//Y-C+=BS>&W
M:8;U5VD=NA'0A@*[.BGS,.5'!VOA*_AFAG:TM R7LLJ+Y@)A5XPNY2$ R&&[
M  ^M,A\&W\EG]GEL[&V"VT=O(L4A879$BL9'^4=@>#D_,>:[^BCG8<J.0M]&
M:/QPT4*!-*@1;T1JN%6<J8P!VQM7.!T/UHUCP[?WVK:E+:)!%%>V3V\DLK[B
MQ*87:-N4P>O)!]*Z^BES,.5' :CI>K2W\-U=Z5:3/<ZE$ZVAG+IM2VD4[FVX
M'/3C'2J'_"+:D;EM-^PVDTATZ-1,\A"VA:>5@(SMYVC'H>!7IU%/G8N5'!3>
M$=3E>>/RK7S-]S)_:!D/FSB16"HPV\ ;@#R1\HP*U+#PU_9FN:;=P6%D8X[$
M6TKC"O&XYW#CYL\CJ#74T4N9CY4<=>>&-0DU_4M0C:&6*[B>)(Y'(\DF/ D7
MC@DC:?;'/8UI_"5T$U%%T^V=KAX)HYDF",'2-5(8%""-RD\YSGM7=44<S#E1
M6T^.:'3K:*Y\KSTC59/)7";L<[1V%6:**DH**** "BBB@ JO?_\ (.N?^N3_
M ,C5BJ]__P @ZY_ZY/\ R-..Z%+9DD'_ ![Q?[@_E4E1P?\ 'O%_N#^524/<
M%L45_P"0[+_U[)_Z$U7JHK_R'9?^O9/_ $)JO4Y=!1Z^H5SOCC3&U3PI=QQJ
M6EBQ,@'<KU_3-=%00",$9!IPFX24ET%4@IP<7U/F:CBNN\<^%9-#U%KJWC)T
M^=LH1TC8_P )_I7(U]53J1J14H['R%2G*G)PENC4DTF)F8V\[M$G^M,D>TH,
M9!QW!Z?6IO[ 5IIT2Z.VW9EE+Q;#Q_=R>>M9OVZ?[.T._*MMW$\D@<@9]!Z4
M2WUU-.9GGDWDELACQGKCTJ;3[CYJ?8M7>DK:VKS)<B8HV&"*, 9P"3G^F*S:
MD>XFD4J\TC*>2&8D5&!DX%7%-+4B33>B-#0].DU76K2RC!/FR -CLO<_EFOH
MA0%4*.@&!7"_#SPJ^EVQU2]CVW4ZXC1ARB>_N:[NO!Q]95*G+'9'T67T'3I\
MTMV4=4U>PT>*&34+@0I-*L*%E)!<]!P./J>*'U>PCUB+2&N%%]+$9DAP<E!Q
MG/05G^)]$;78["WVJT"7&Z;)P0FQER/<$BN</A+7KF%;BYGB34Y;>XADF1_N
MC8$B [\@$GT+&N))6/0;=SO&G@$)E,L?EC^+<,?G6;]HTKQ!9(75GM]B7*2,
M&C SG#!^,'KT.17,1^%[V."W<Z:)XA,6FL)I8U0DQ[0ZA1MX//J>O6F0>%-5
MMH+</;0W,4,5HLEJ9?EF\L.&7GC@LIYX.*++N*[[':0K8:59&* 1QPQ(TNQ3
MDXZEO4_6HI]<L+;3+;4)))/(N2@AV1,[.6&5 503FN6F\/:O<:Q%,MC:VT$:
MLJ")E^5#"R["V-Q^8]/NX%:EWI6H1^'-#A@MUGN;":"22(2!<A!@X)XHLAW9
MJP76E:M%#?(\<@MY"$9\J8I,8(*G!#<XP1GFKTDR11/(QX0'..3],>M</J'A
MC5;Q_MDL,;>?<R336<;J=H:-44Y<;2PVYSVSQTJ8^%M12\:"-MVFFW\X"23+
M_:A%Y0!]1@[B?7%%EW"[['91SQ2A,,,N@<*W#8/MUH\Z'R3*)$\I027W#  Z
M\UPZ^&=5%M?VXMXOM4]NJPZAYH#0@1*ICZ9QD'IQSGK6GIGAZ5?#FJ6#QO:2
M7R,FUF0JA,>W("# 'ZGK2LNX79L6&N6&IAS;/)L10^^2%XU9?[RE@ P]Q5[S
M8@%.],-C!R.<]*Y:[M-:U#2;6VN-+A46DL3R0?: 5NE7(91Q@+T/S=<8(K+;
MP9>7$%P)[6$*UI.MO!YF1;N\@954^P[CIGBG9!=G>^;%M+F1-H)R=PP,=:/-
MB#*"Z;G'RC(RP]O6N#U/0I;&^@2'38[BTEU".1+4-A6Q 0Q/;DCOP>]1GPOK
MJPZ="(;<B!HY%=67=!B;>R;B-V AVC;C/.:.5=PYGV.]FNH88I9&;<(EW,J#
M<V/H.:>)(R^S<N\#)7/('TKB)_"%V+27[-!$ES/%?I,X?!D\URT0)[X'Y4J>
M%K[^UK^6[2:<2O,Z313)&71TP(R<;N.PZ @&BR[A=]CMT:.1-R,K*>ZG(-.Z
M]:R/#=I>6.C);WD44;H[;%C55PF?EW!?EW>N.*UZEE(****0!1110 4444 %
M%%% !1110 4444 %%%% !1110 44R66.")I9I%CC7DLQP!55-6T^1=R7L##U
M#B@"[159=0LV^[=1'Z,*<+RV/_+=/SH GHJ'[7;_ //>/_OH4JW,#MM6>-F]
M PH EHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "J]__ ,@ZY_ZY/_(U8JO?_P#(.N?^N3_R-..Z%+9DD'_'O%_N#^525'!_
MQ[Q?[@_E4E#W!;%%?^0[+_U[)_Z$U7JHK_R'9?\ KV3_ -":KU.704>OJ%%%
M%240W5K!>VTEM<Q++#(,,C#((KS'Q!\,9XG:?17\V+KY$APR_0]Z]4HK>CB*
ME%WBSGKX:G65IH^<[S2=0L'*75E/"0<?.A _.J85F.%!)]!7TNRJPPP!'H13
M!;P@Y$,8/LHKT%F>FL?Q/->5*^D_P/ ]-\*ZUJK@6UA+M/\ '(NU1^)KTKPQ
M\/+32'6[U!ENKL<JN/D0_P!37;45S5L=4J*RT1U4,OI4GS/5A1117">@%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.X2X#FWMV 0'G.[J1UK$U/2J*** "BBB@ HHHH **** "BBB@ HHHH ****
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M>/S)I%C3<%W,<#). /Q) J2@ HJ"UO;6^C>2TN(YT1RC-&VX!AU%3T %%%%
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MG]*9_:]QZ)^5']KW']U/RH W.M%95MJVYPLRA0>XK5H **** "BBB@ JO?\
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M7$4)D.U!(X7<?09ZTW)]A**[GGUY<ZYI%G CSZA,;E+,MYKX9I#N\U%8#Y>
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MVYKKM+O;=YULU<&=59V4=AQ6?XMTZ^T36=6OK+39Y[:[5;@R1+E8W (?=Z=
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MBBB@ HHHH **** "BBB@ HHHH *K:@,Z;=#_ *8O_(U9J"]YL+C_ *Y-_(T
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ML[A$! R?>@"6BJL&I65S&LD-S&Z,.&SQUQCZYXQ4QN(0')FC 0X8[A\OU]*
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MEI!JM[-,ZPM%&@V[8,N'RO'S<A?O9Z8H]T>IHMXQTI8D8"Y>1FD0PQP,SJ4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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8% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>image_028.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_028.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #V 4\# 2(  A$! Q$!_\0
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MHHH **** "BBB@ HHHH **** "BBB@ HHZ=:0D#J0,],GK0 M%%)GZ_D?\*
M%HI"<>OX G^0_P#KT9]B?R_J10 M%1":)E5EDC8,Q1")$(9P2"JD,06&#D D
MC!XS35N;=E=A/"5B+K(PEC(C:,XD60AB$*' <,05/#8H GHKQSQ9^T!\'/!#
M21>(_'^@65RBN1:17$E]=NT9VLBPV,5P0Q<A%+%5+'!85\]C_@H=^SA!KB:/
MJGB&^TZ"641+K)L)I],A)<INNU41ZBBXV,/LEA>GE@P79E@#[GHK'\/^(="\
M5Z-IWB+PSJ^G:]H.KVRW>F:OI-Y!?Z=?6SDJ);:ZMGDAE4.KQN%;='*CQ2!9
M$=1L4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%?%7[='[=WP4_8%^$1^)_P 6[V:_U/6+J;1_A]\/M(GMT\3^
M/?$$4:2S6FG"XW1:?H^E0RQ7?B/Q%=QM8Z-9R0(([W5;_2-)U( ^U:I7VI6.
MF0O<7UU#;1( 2TTBH.0Y4?,1R_EN$SC<PV@EN*_C3B_X+M?M*?%;5+[Q-JSZ
M-\.? -^\RZ!X"\$)!979T_S(C;76J^+M0M-1\47%Z4B^:73[[0K.X6>>3^S(
M%EAM;/C+[_@I1X7NKM]1N/A3H.HZ@V6>^U/Q;X^N[IV9F=BTL7B>VR"[-(R@
M8,C,2"30!_8;JWQ?\-0%K>RU*P$QX$MUJ.GVFT&+.5CNI=YDCG.QT:!HW1&V
M3 N&3FIOBE;0B6ZU#Q+H=M TADB>:YT6.WMD91B**:<N3&O+!Y99)3D@N5P%
M_CZO/^"EFER\-\'_ (8W 4_(NJVWB#6U7([G5_$-X6X[/N7CD9K*?_@IK?6X
MQIGPN^#FF="IM/ .CEL\@'=,DK9'0')(P#CM0*WF?V"Q?&[P!)*C/\4/ [2P
M^8SHOBSP>DC[F7F6.WGCF8PE<0[-C(7<,7XVYUU^T5\&-+U$76J?%WP]:W!M
MWLS#)XFO7T\*7$C.;:W:33!<@C:EYM^T*F468(2#_'\__!4OX@19^Q^&OAA;
M$$D,OPW\'S,,G/#7.DS-D=<YZCI5&7_@JU\;XB38ZAX8TPD#']F>"_"-C@^H
M^SZ.F<< =QZT!;S_ *_K^NI_8U<?M-? N>Q=9/BEX8U.VECVNFCZY<WMV\?<
M*FCN=1!(QDJ Q&0Q(9@7V7[6?P*NRT?_  F<V_[K"?PAXZ5) O&$DE\-F!U;
MHI67:Y._+%B3_&;=?\%8/VDYE*Q_$6^M%P<+9V^GVB@8Z#[+;1 #KP,=0.>*
MX;Q+_P %8/VE='TC4M6;XM^*XDL[625(8-9N;=99<!+>(^3*A59)G57*X(7<
M1R!0%C^SSX@?MV?LY?#'2QKOCGQ!JGA_PU#*$/B36=!FT70(F4'YUU#79=,B
MVQKNYC#.!D*O8TG_ ."@W[*$MB;K0?BEX8\5:@ZB0^'?#?B'PG=^))24#*B:
M9<>(+,SSLIP($F:;/RE W%?Y6GQI_;7^(O[1O[1'A7Q9^TY\4OB'\0O"^F>(
MH->;PY?ZSJ.OV-OIND2FYTG3;'0+[48M+BCOKZVMI+B)1&PL(9(TWG:LOWYX
M'^-7PW^,6E3Z_P##SQ-I^OP6<YBU*W1)++6M$NRS#[/J^D7<<&HZ9.75A&\L
M"P3,I-O/*!F@&[?\-_7]:']S_P 1O^"MGPZTG4I_"WA70-2T#Q*8II+33?B)
MIUUH&KW<$+$&\TG3Y=EAJUL!@F72]2U2.-64S;-RY_.WXN_\%&OB3XR:Y@D\
M2W<-DY?%G:3"SM$!S@?9[<QQD <?,K'/>OP'\,_&7^VM"G^%'Q;U74]5^'>L
M*8-(\4F1KSQ?\(/$+(4T3Q_X/U&=FNE'A^_:WO=3T9YC:ZII$5YISH8IWB?Q
M#P)^T3KVNZ%K&C^+[NU?QKX#\0:IX(\736$Y>PO-6T:62%-6L'WYETO7[-(M
M9TB<D^=97&PL\MM*[ )W/UJ\;?M&ZMK;7)U'5GN5DR72683*<YY99&()'8D$
MCJ#DU\Q:_P#&Z:TDV-J$DME,PBB,LK2S6LYSL1IF9FDM9^$C:9B\%P8XO,>.
M91%\+:_\8F8R@7)).>-Y]^F'S_.O'-9^(USJ4<UN)7(F5T)#M\I92 _WNJ-A
MU(Z,!T.*!G].W_!)[_@I%J/PP^/OACX!^//$#W'PG^,>MVWAK3H[^X,D'A'X
M@:M(EGX9U6Q:0E;2TUS46M?#^MQ!H;8QWMGJMS)C1HT?^PJO\GCPIXC\4G6=
M UG2[J\L-8T_4=,U&QO8&9+FQU&TN89[>ZC=2RQRP7,:S1X8@,H&3S7^JO\
M#SQ&_C'P!X&\721&&3Q5X/\ #/B-X2<F)]<T6RU-HB>,F-KHIG':@#L****
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M6@FN'T[[4P6+7?#4B+_Q,[2\B+W,ME9AH-01?M-D%OEG@?\ 1NR))7 R20%
MY)/ 4#W8G '<FOVE_P""-G[!&D_MM_M$ZO-\0O ?A?Q#\#_A1!X-U'XA^(];
M\/6VHZU=:IX:\;Z=XZT'P)X4\1R(+K0K;Q=XAT :5XOM[":,ZQX&MO$-L9%F
MNK>5.4ZC^E7_ ((;_L)_\,O_ +.</QD\=Z.+/XR?M :7I6N307<"IJ'@_P"&
M)CCO?"'A<J=S6EYK*/'XIU^%&B8O<:'IU];07NA.B_N)341(T2.-%CCC54CC
M10B(B *J(J@*JJH 50      *=0 4444 %%%% !1110 4444 %%%% !1110
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MS?R<2#<K?:&P<9!P*Z6R^(^MV/C2V\?P:UJW_"2V*HMI>7MI8ZA\L<)@6*X
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M;-;V*SPIJ-Q;F>V"!XUNA&GF31M;R_OK2[B0&1H',D<D:O)!,ZHRKZY7P_\
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M037=%FGW8!)&I:#!:18/4?;W _O'%?[47[6G["'[)'[<WA2T\(?M2_ _P?\
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MXZO@7]@[]KW]N/[5X'_9<^ OQ#^)^LZ/XE\-+X@U73]#O=*\,^$S%;^*$?\
MX2CQ-J\=CIFA3(]]9.D%Y/%=.K/)%"WE2$?O!^Q__P &@G[8/B)M-US]J_\
M:!^'/P4T6[F2ZUCP/X+T\?%'QCD%7,5QJ,$VE^%4>4!5NY;/79IFVM$)&!$R
M_P"B+%!!!YGDPQ0^=*\\WE1I'YL\F-\TFP#?*^U=\C9=L#).!4M '\V=Q_P:
ML_\ !+/5/!^B:+J>B_&?3?&%C:V\>M^/O!'Q8\1>'KGQ!>0H$ENSX3UR7QCX
M/T6*Y($DEII.D0(LA=DE ;:/G"]_X-!OV,3J4MWI'[4/[4MCI[7+20Z+=O\
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M34HM='&46M=;-I_Q\?LZ?";_ (*>?\$D_C1=Z1X(G\?_ +57[!&@1KXJ\6>
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MUL='T^PNK5IK+5M:E+W5U<^1Z9^QM\4_VN/VAO\ @KKIGP&_89L/B+\>)/\
M@H]\8='^&G[?>H_M-:?\$[[]D?64\4:7KL/D>%].U9/B'XE/A]/MNMM_PB.C
MZG#J,FO/H\XGMX9H#K3X;I2I1KU<?*A0EAL/6=>K0I4:<9UZU"C.+CB<1AZR
MI8?VZG.;A*=>,?\ 8UB'.$(YSS^JJDJ-/!1K5HXBO25&E6JU:DH4:5:K!J5"
MA7I.I7]BXPBIQA1E+_:O8*$IO^]&74M.A%R9K^RB%F8A>&6Z@C%J9_\ 4"Y+
M2#R#-D>4)=IDS\F:DM;RTOHS-975M>0AS&9;6>*XC#@*Q0O$SJ'"LI*YR RD
MC!&?X/\ _@H-9ZI:Z1_P<C:1K%S/XKU:S^+/_!&+1M7F)&F?\);JD%CX:L-9
M($3K;Z;_ ,)5?)=><498K5=0!D(CC&/=_P!GSXQZ9_P3L_:1_P""C'QLTG]F
MBU_X)S>$?V=OV*/ .F7'_!/"Y^+L_P 8+[]HK]HGXG^/FMO@E\<O!YT.6]\'
MZAX?N=0N_#_P>U76?AWJNKR:;J&JR6.K-;Z@VN6UI/\ JTY89U:6*=2NX494
M:*I4U&K*M0RJK&GKB/K%YSS6%.-2&'G1IJDZF*J8>-2+5+B!1Q"IU<,J=%2J
MQJU?:5'*FJ5;,Z<IZ4?86C#+9U)0E7A5FZJAAH5Y0DG_ &F0W%O<>;Y$\,_D
M3/;S>3*DGDW$>/,@EV,WES1[EWQ/AUW#<HR*FK^,/_@F5)\;/V8OV@KS]EG]
MI#X4_M1? K1O^"H_P&\4VGCWXB?M$_V)IT'B#_@I/IFF^,O$?Q-\3?"K6/AU
MXZU6YT;PAX]\"^*/L^DKJ%YX+\5ZEXC\(>&X]-M+.ZD6.V_9OP5_P3"^/O@7
MXV_!#X@Z'^W%\3(/A=\,-2^!GB#Q9\%);SQUJF@?$#Q+\)_AC8?#SQ%JE]J^
MN?$#5=1CL/B%/J_Q'\1:[X;N1>:)>:YKWAC6=6M]5U3PC8W+\6,RBA@JTZ53
M,:2@Z/ML+6]C.I3Q45"<9J$L/5KPA)8JE4PZ4IR23I5*CI^T=.'7A,SK8NE&
MI3P%3F57V6(I.M"$\-)R@XN4:].C*<7AZL*[<81;:J4X*;ASR_9N>X@MHS+<
MSPV\095,L\B11AG8(BEY&50SNP51G+,0H!) J&[U"PL!&;Z^L[(2EA$;NYAM
MA(4V[Q&9G3>5W+NVYV[ESC(S_+G_ ,%Q_%GB[]K_ ./?P^_X)X?#CX2_M(?&
M[X?_  E^'GB/]HC]IS3?V6;7PQ/XX\.?$7QGX/\ &'@_]D&RU;4/%?C'P/H]
MEI?AOQFVH?%?Q'H<VKW%UKNFV/AG[+IY\N2\M/SQ_:7^.VN?M^VO_!#/2_C#
M^S!+^U5\>_ ?Q$_;H_9T_:J_8]U_QMHWPLU7Q1\?/@G\+OAKI'BO3/%'BGQ'
MJ.G>'_"FJR_V9I'QEBM]0U"*VE%Q'H5K)--*83T83AV>(H8.O/$*G'$1KU:]
M.*HNIAJ$<-BL1A*LU4Q5-)8M8.M!2KK#TJ7-0DZM2-7W<,3GL*-;%4(4'-T)
M4:5&<G55/$5GB,/0Q5./L\/4;>%>*I2:HNO4J<M:*IP=/WO[EI]7TFV2"2YU
M/3K>.ZC$UM)/>VT27$1"L)8&DE59HRKH0\992&4@X89FM+ZROT:6QO+6]C1_
M+>2TN(KA%? ;8SPNZJ^UE;:2#@@XP17\(VI_LO? [XN?\$0_^"@7[0?COX4>
M']'\0_ SXX?M!+^RO\"]<\;>/O&GCC_@GGHS^./ACX7\1_ *^O?$;Z+<:5KE
MOK/AZX\42:&VFWFAVNFZ_IE]IDABU*XAB_K$_P""9_[,'P"_9D_9&^$%E\!/
MAAX?^&-I\4OAM\+/BAX_M_#[:FR>)O'NN_#+PG#JWB74#JE_J$HO[V*UMXY1
M"\, $2[858L3AF.4X? 8>=18NM6K0Q]3 .F\-3A3YZ6'P^*G)U5B:DFE2Q,(
M>Y"<)5H5'3J3P[HUJN^ S.OC:\*;PU*E2G@J>-YU7J3J<M2O7PT8JFZ$%=U,
M/.?O2A.-*=-3IPKJK2I_?]%%%>$>P%%%% "$ \&H)(E=61U5XR""K $8(P<@
M_P QV]*L44 ?/OQL_9[^%_QW\!Z]\-OBEX#\-_$?P!XCM9[?6/!OBK3X-0TZ
M3SXVC:[TR20&XTG5(0V^TU&PFM[NVE"O',-H!_'G2OA'^VE_P3!U.[U+]F/6
M/%7[7'[%EO*UU?\ [+OQ!UK[;\8_@I9OYOGGX6^/]7EFO-6\$Z:6:[_L6_CU
M"XBCE^6.&"P4WG] I0'IP?T/^?Y=JR=0TBVU#:TH,,ZY\JYB(6:,\<A@0"/5
M6R#GUZM.WFNJ>S_R(E!2V;C+I);K_->3/$_V;OVF_A=^U'X%'C7X;ZJS36-T
M^D^*O"VH[;?Q)X/U^".*2ZT?7-/)$D,B+-')!<!1%/'(%807<5U9VWT+7@^K
M?!?P_P#;)-=\-P67@GQBKWEQ#XH\,Z=;:4=1O+Q(_-E\1VFG1V::NTTMM;?:
MKN5UU*XBA%M)=S63S6DD=G\6;SP5>VN@?&".VT26\NKBWTGQA""/#FJQ1"W2
MU:\NUBBM+&]O)7F5(@+9MZ1QS:?8-/;+<.R=W'U<>J]/YDO+7NNH<SC93\ES
M_9;\_P"5OS]WM+H>^45'#-%<113P2QSP3QI-#-"ZR1312*'CEBD0LDD<B,'1
MT8JZD,I((-25)84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!2N--TZ[NK*^NK"RN;[36G;3KRXM8)KK3VN8Q%<M97$D;36K7$0$4Y@>,RQ
M@)(648JL- T(:8=$&BZ2-&+;SI TVS&F%_M/VW<;#R?LF[[9_I>[RL_:?W^?
M-^>M:BG=Z:O3;5Z==-=-6]K;ON[JR[+7?1:^NFOS.=F\(>$KGQ!;>+;CPOX=
MG\56=N]I:>)IM$TR7Q!:VL@59+:VUI[9M2@MW5$#PQ7*QL%4,I"C&I9Z9ING
MO>26&GV-C)J-T]]J$EG:06SWU[* )+R\>&-&N;J0 ![B<O*X #.<"KU%#;>C
M;:222;;22=TDFVDDVVELFVTDVV%DM4DG>]TDG=Z-Z):M:-[M:-M:&+/X;\.W
M1U$W6@Z+<G5Y+275C/I=C,=3ET_!L)-1,D#&]DLBJFT>Y\UK; \DI@4M]X<\
M/:G>1:CJ6A:-J&H6\<,4%]?:78W=Y#%;W/VR".*YN())XXX+L"ZA1'58[D>>
M@67YJV:*.:7\TOO?9+OV27HDMDDBR[+[EZ]N[;]6WNW>G=Z=I]^UH]]8V=X]
MA=)?6+W=M#<-97L2ND=Y:-,CFVNHTD=4N(2DJ*[JK@,0;E%%+]-O+T[#_7<I
MP:=I]M=WM_;6-G;WVI?9_P"T;V"U@BN[_P"QQM%:?;;F-%FNOLL3O';^>\GD
M1NR1;58@TD\.>'H[T:E'H.C)J*WEQJ*WZ:78K>KJ%Y EM=WPNE@$XO+JVBCM
M[BZ$GGSP1I%*[1HJC9HIW?=[6W>W;?;RV\A679=]EOWVW\]_,QV\.^'WAU2W
M?0M':#7)C<ZU VF630ZQ<,J*9]4B,!34)BL<:F6[69RJ("V%4#4BBB@BC@@C
MCAAAC2*&&)%CBBBC4)'''&@")&B *B* JJ J@  5)10VWNV_5M]$NK?1)>B2
MV22+);)+T276_;NV_5M[ML****0PHHHH **** "BBB@!I16X(!![$9'/7\\]
M^G:L/6?#NDZ]IUUI&L:=9:MI%[&T5WINHV\=W;3(RD#]W*& D4G,<J[98F/F
M12*X!K>HH XWP3X*T7P)I<^C^'QJ$.ER79N;:PO;V:[@TN(6UO:1:?I<<O\
MQZ:=;P6L2Q0@O(\AEN+B6:YFEE?LJ**&V]7J^XDDE9:);(****!A1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
I%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>ex15-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex15-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  R &X# 2(  A$! Q$!_\0
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MXN9_0OVH?^#E;1/%?A75/A_^Q/\ !GX@WWQ*\36L^D:+XZ\?:?IL::!/?1-
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M6I5E(8,K#PUE2" 5(.0>>>"/Z-O^%/?"K_HFW@C_ ,)?0O\ Y H_X4]\*O\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>38
<FILENAME>iinn-20241231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Mar 10 18:58:48 UTC 2025 -->
<xs:schema elementFormDefault="qualified" xmlns:iinn="http://www.inspiratechnologies.com/20241231" xmlns:srt-types="http://fasb.org/srt-types/2024" targetNamespace="http://www.inspiratechnologies.com/20241231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="iinn-20241231_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="iinn-20241231_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="iinn-20241231_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="iinn-20241231_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet" id="iinn_r_ConsolidatedBalanceSheet">
        <link:definition>995301 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet_Parentheticals" id="iinn_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>995302 - Statement - Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement" id="iinn_r_ConsolidatedIncomeStatement">
        <link:definition>995303 - Statement - Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3" id="iinn_r_ShareholdersEquityType2or3">
        <link:definition>995304 - Statement - Statements of Changes in Shareholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ConsolidatedCashFlow" id="iinn_r_ConsolidatedCashFlow">
        <link:definition>995305 - Statement - Statements of Cash Flow</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/General" id="iinn_r_General">
        <link:definition>995306 - Disclosure - General</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/SignificantAccountingPolicies" id="iinn_r_SignificantAccountingPolicies">
        <link:definition>995307 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/Deposits" id="iinn_r_Deposits">
        <link:definition>995308 - Disclosure - Deposits</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/OtherCurrentAssets" id="iinn_r_OtherCurrentAssets">
        <link:definition>995309 - Disclosure - Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/Inventory" id="iinn_r_Inventory">
        <link:definition>995310 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/PropertyandEquipmentNet" id="iinn_r_PropertyandEquipmentNet">
        <link:definition>995311 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/OtherAccountsPayable" id="iinn_r_OtherAccountsPayable">
        <link:definition>995312 - Disclosure - Other Accounts Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/CommitmentsandContingencies" id="iinn_r_CommitmentsandContingencies">
        <link:definition>995313 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/LeaseLiabilities" id="iinn_r_LeaseLiabilities">
        <link:definition>995314 - Disclosure - Lease Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValue" id="iinn_r_FinacialLiabilitiesatFairValue">
        <link:definition>995315 - Disclosure - Finacial Liabilities at Fair Value</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ShareholdersEquity" id="iinn_r_ShareholdersEquity">
        <link:definition>995316 - Disclosure - Shareholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ResearchandDevelopmentExpenses" id="iinn_r_ResearchandDevelopmentExpenses">
        <link:definition>995317 - Disclosure - Research and Development Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/GeneralandAdministrativeExpenses" id="iinn_r_GeneralandAdministrativeExpenses">
        <link:definition>995318 - Disclosure - General and Administrative Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/SalesandMarketingExpenses" id="iinn_r_SalesandMarketingExpenses">
        <link:definition>995319 - Disclosure - Sales and Marketing Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/FinancialIncomeandExpenses" id="iinn_r_FinancialIncomeandExpenses">
        <link:definition>995320 - Disclosure - Financial (Income) and Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/TaxesonIncome" id="iinn_r_TaxesonIncome">
        <link:definition>995321 - Disclosure - Taxes on Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ShareBasedPayment" id="iinn_r_ShareBasedPayment">
        <link:definition>995322 - Disclosure - Share-Based Payment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/RelatedParties" id="iinn_r_RelatedParties">
        <link:definition>995323 - Disclosure - Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/SubsequentEvents" id="iinn_r_SubsequentEvents">
        <link:definition>995324 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy" id="iinn_r_AccountingPoliciesByPolicy">
        <link:definition>996000 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/SignificantAccountingPoliciesTables" id="iinn_r_SignificantAccountingPoliciesTables">
        <link:definition>996001 - Disclosure - Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/OtherCurrentAssetsTables" id="iinn_r_OtherCurrentAssetsTables">
        <link:definition>996002 - Disclosure - Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/InventoryTables" id="iinn_r_InventoryTables">
        <link:definition>996003 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/PropertyandEquipmentNetTables" id="iinn_r_PropertyandEquipmentNetTables">
        <link:definition>996004 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/OtherAccountsPayableTables" id="iinn_r_OtherAccountsPayableTables">
        <link:definition>996005 - Disclosure - Other Accounts Payable (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/LeaseLiabilitiesTables" id="iinn_r_LeaseLiabilitiesTables">
        <link:definition>996006 - Disclosure - Lease Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueTables" id="iinn_r_FinacialLiabilitiesatFairValueTables">
        <link:definition>996007 - Disclosure - Finacial Liabilities at Fair Value (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ShareholdersEquityTables" id="iinn_r_ShareholdersEquityTables">
        <link:definition>996008 - Disclosure - Shareholders&#8217; Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ResearchandDevelopmentExpensesTables" id="iinn_r_ResearchandDevelopmentExpensesTables">
        <link:definition>996009 - Disclosure - Research and Development Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/GeneralandAdministrativeExpensesTables" id="iinn_r_GeneralandAdministrativeExpensesTables">
        <link:definition>996010 - Disclosure - General and Administrative Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/SalesandMarketingExpensesTables" id="iinn_r_SalesandMarketingExpensesTables">
        <link:definition>996011 - Disclosure - Sales and Marketing Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/FinancialIncomeandExpensesTables" id="iinn_r_FinancialIncomeandExpensesTables">
        <link:definition>996012 - Disclosure - Financial (Income) and Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/TaxesonIncomeTables" id="iinn_r_TaxesonIncomeTables">
        <link:definition>996013 - Disclosure - Taxes on Income (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ShareBasedPaymentTables" id="iinn_r_ShareBasedPaymentTables">
        <link:definition>996014 - Disclosure - Share-Based Payment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/RelatedPartiesTables" id="iinn_r_RelatedPartiesTables">
        <link:definition>996015 - Disclosure - Related Parties (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/GeneralDetails" id="iinn_r_GeneralDetails">
        <link:definition>996016 - Disclosure - General (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/SignificantAccountingPoliciesDetails" id="iinn_r_SignificantAccountingPoliciesDetails">
        <link:definition>996017 - Disclosure - Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable" id="iinn_r_ScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable">
        <link:definition>996018 - Disclosure - Significant Accounting Policies - Schedule of Depreciation on Straight-Line Method, Over the Estimated Useful Life of the Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/DepositsDetails" id="iinn_r_DepositsDetails">
        <link:definition>996019 - Disclosure - Deposits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofOtherCurrentAssetsTable" id="iinn_r_ScheduleofOtherCurrentAssetsTable">
        <link:definition>996020 - Disclosure - Other Current Assets - Schedule of Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofInventoryTable" id="iinn_r_ScheduleofInventoryTable">
        <link:definition>996021 - Disclosure - Inventory - Schedule of Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofPropertyandEquipmentNetTable" id="iinn_r_ScheduleofPropertyandEquipmentNetTable">
        <link:definition>996022 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofOtherAccountsPayableTable" id="iinn_r_ScheduleofOtherAccountsPayableTable">
        <link:definition>996023 - Disclosure - Other Accounts Payable - Schedule of Other Accounts Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrarGpi3WKEtaAw66u01Fz01dWXY8Co/0nt/EYPpxJQpmucNPntkKGDUIzqiVXTghuh97D+3HoPuNe26jHPIaw4lyMqYvKxFlhkbYBWIUcgKRgNZdvBJC1M0l0xZMZd9F+M0zfHyxoKPMqOYWCT/B42d+bXUalw9kCR7ECrTZgyIl6CQNUWcHwWg7YyEKbKXVQrc457FUG7zZJKYSUUC+IL4iKzuqc3lzwnQ2dokFxrCaevH4cZ3wAdRaitsTLXse0F0xvf4jN2RRDPJRiH3UMzqJGVjARxUjs8=] CSR-->
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/CommitmentsandContingenciesDetails" id="iinn_r_CommitmentsandContingenciesDetails">
        <link:definition>996024 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/LeaseLiabilitiesDetails" id="iinn_r_LeaseLiabilitiesDetails">
        <link:definition>996025 - Disclosure - Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofOperatingRightofUseAssetsandOperatingLeaseLiabilitiesTable" id="iinn_r_ScheduleofOperatingRightofUseAssetsandOperatingLeaseLiabilitiesTable">
        <link:definition>996026 - Disclosure - Lease Liabilities - Schedule of Operating Right-of-Use Assets and Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofRightofUseAssetsOvertheRemainingLeasePeriodsTable" id="iinn_r_ScheduleofRightofUseAssetsOvertheRemainingLeasePeriodsTable">
        <link:definition>996027 - Disclosure - Lease Liabilities - Schedule of Right-of-Use Assets Over the Remaining Lease Periods (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails" id="iinn_r_FinacialLiabilitiesatFairValueDetails">
        <link:definition>996028 - Disclosure - Finacial Liabilities at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofFinancialLiabilityTable" id="iinn_r_ScheduleofFinancialLiabilityTable">
        <link:definition>996029 - Disclosure - Finacial Liabilities at Fair Value - Schedule of Financial Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ShareholdersEquityDetails" id="iinn_r_ShareholdersEquityDetails">
        <link:definition>996030 - Disclosure - Shareholders&#8217; Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofShareCapitalTable" id="iinn_r_ScheduleofShareCapitalTable">
        <link:definition>996031 - Disclosure - Shareholders&#8217; Equity - Schedule of Share Capital (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofMovementinWarrantsOutstandingTable" id="iinn_r_ScheduleofMovementinWarrantsOutstandingTable">
        <link:definition>996032 - Disclosure - Shareholders&#8217; Equity - Schedule of Movement in Warrants Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofInformationabouttheCompanysOutstandingWarrantsTable" id="iinn_r_ScheduleofInformationabouttheCompanysOutstandingWarrantsTable">
        <link:definition>996033 - Disclosure - Shareholders&#8217; Equity - Schedule of Information about the Company&#8217;s Outstanding Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofLossPerShareCalculatedUsingtheWeightedAverageNumberofOrdinarySharesandPreFundedWarrantsTable" id="iinn_r_ScheduleofLossPerShareCalculatedUsingtheWeightedAverageNumberofOrdinarySharesandPreFundedWarrantsTable">
        <link:definition>996034 - Disclosure - Shareholders&#8217; Equity - Schedule of Loss Per Share Calculated Using the Weighted Average Number of Ordinary Shares and Pre-Funded Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofResearchandDevelopmentExpensesTable" id="iinn_r_ScheduleofResearchandDevelopmentExpensesTable">
        <link:definition>996035 - Disclosure - Research and Development Expenses - Schedule of Research and Development Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable" id="iinn_r_ScheduleofGeneralandAdministrativeExpensesTable">
        <link:definition>996036 - Disclosure - General and Administrative Expenses - Schedule of General and Administrative Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofSalesandMarketingExpensesTable" id="iinn_r_ScheduleofSalesandMarketingExpensesTable">
        <link:definition>996037 - Disclosure - Sales and Marketing Expenses - Schedule of Sales and Marketing Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofFinancialIncomeandExpensesTable" id="iinn_r_ScheduleofFinancialIncomeandExpensesTable">
        <link:definition>996038 - Disclosure - Financial (Income) and Expenses - Schedule of Financial (Income) and Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/TaxesonIncomeDetails" id="iinn_r_TaxesonIncomeDetails">
        <link:definition>996039 - Disclosure - Taxes on Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable" id="iinn_r_ScheduleofDeferredTaxAssetsandLiabilitiesTable">
        <link:definition>996040 - Disclosure - Taxes on Income - Schedule of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofTheoreticalTaxTable" id="iinn_r_ScheduleofTheoreticalTaxTable">
        <link:definition>996041 - Disclosure - Taxes on Income - Schedule of Theoretical Tax (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofTheoreticalTaxTable_Parentheticals" id="iinn_r_ScheduleofTheoreticalTaxTable_Parentheticals">
        <link:definition>996042 - Disclosure - Taxes on Income - Schedule of Theoretical Tax (Parentheticals) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails" id="iinn_r_ShareBasedPaymentDetails">
        <link:definition>996043 - Disclosure - Share-Based Payment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofMeasuretheFairValueoftheOptionatGrantDateTable" id="iinn_r_ScheduleofMeasuretheFairValueoftheOptionatGrantDateTable">
        <link:definition>996044 - Disclosure - Share-Based Payment - Schedule of Measure the Fair Value of the Option at Grant Date (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable" id="iinn_r_ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable">
        <link:definition>996045 - Disclosure - Share-Based Payment - Schedule of Options to Services Providers and Advisers Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable" id="iinn_r_ScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable">
        <link:definition>996046 - Disclosure - Share-Based Payment - Schedule of RSUs to Services Providers and Advisers Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/ScheduleofShareholdersandOtherRelatedPartiesBenefitsTable" id="iinn_r_ScheduleofShareholdersandOtherRelatedPartiesBenefitsTable">
        <link:definition>996047 - Disclosure - Related Parties - Schedule of Shareholders and Other Related Parties&#8217; Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/SubsequentEventsDetails" id="iinn_r_SubsequentEventsDetails">
        <link:definition>996048 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inspiratechnologies.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2024" schemaLocation="https://xbrl.sec.gov/sic/2024/sic-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/cyd-af/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-af-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd-sub/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei-sub/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-sub-2024.xsd"/>
  <xs:element name="ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsAbstract"/>
  <xs:element name="ScheduleOfPropertyAndEquipmentNetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfPropertyAndEquipmentNetAbstract"/>
  <xs:element name="ScheduleOfFinancialLiabilityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfFinancialLiabilityAbstract"/>
  <xs:element name="ScheduleOfMovementInWarrantsOutstandingAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfMovementInWarrantsOutstandingAbstract"/>
  <xs:element name="ScheduleOfInformationAboutTheCompanySOutstandingWarrantsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfInformationAboutTheCompanySOutstandingWarrantsAbstract"/>
  <xs:element name="ScheduleOfGeneralAndAdministrativeExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfGeneralAndAdministrativeExpensesAbstract"/>
  <xs:element name="ScheduleOfFinancialIncomeAndExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfFinancialIncomeAndExpensesAbstract"/>
  <xs:element name="ScheduleOfMeasureTheFairValueOfTheOptionAtGrantDateAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfMeasureTheFairValueOfTheOptionAtGrantDateAbstract"/>
  <xs:element name="ScheduleOfOptionsToServicesProvidersAndAdvisersOutstandingAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfOptionsToServicesProvidersAndAdvisersOutstandingAbstract"/>
  <xs:element name="ScheduleOfRsusToServicesProvidersAndAdvisersOutstandingAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfRsusToServicesProvidersAndAdvisersOutstandingAbstract"/>
  <xs:element name="ScheduleOfShareholdersAndOtherRelatedPartiesBenefitsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfShareholdersAndOtherRelatedPartiesBenefitsAbstract"/>
  <xs:element name="ChangesDuringThePeriodAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ChangesDuringThePeriodAbstract"/>
  <xs:element name="ChangesDuringThePeriodAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ChangesDuringThePeriodAbstract0"/>
  <xs:element name="ChangesDuringThePeriodAbstract1" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ChangesDuringThePeriodAbstract1"/>
  <xs:element name="NetBookValueAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_NetBookValueAbstract"/>
  <xs:element name="NetBookValueAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_NetBookValueAbstract0"/>
  <xs:element name="ExerciseOfJune2024PrefundedWarrantsIntoOrdinaryShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinaryShares"/>
  <xs:element name="ExerciseOfJune2024PrefundedWarrantsIntoOrdinarySharesinShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinarySharesinShares"/>
  <xs:element name="StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments"/>
  <xs:element name="StockIssuedDuringPeriodSharesStockOptionsExerciseOfShareBasedPayments" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_StockIssuedDuringPeriodSharesStockOptionsExerciseOfShareBasedPayments"/>
  <xs:element name="ExpirationOfFinancialLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_ExpirationOfFinancialLiability"/>
  <xs:element name="IssuanceOfOrdinarySharesAdvisorFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_IssuanceOfOrdinarySharesAdvisorFees"/>
  <xs:element name="OtherReceivableInConnectionToPrivatePlacement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_OtherReceivableInConnectionToPrivatePlacement"/>
  <xs:element name="AccruedIssuanceExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_AccruedIssuanceExpenses"/>
  <xs:element name="FinancialLiabilityPlacementAgentFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_FinancialLiabilityPlacementAgentFee"/>
  <xs:element name="ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital"/>
  <xs:element name="NonCashTransactions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_NonCashTransactions"/>
  <xs:element name="GeneralAndAdministrativeExpensesTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_GeneralAndAdministrativeExpensesTextBlock"/>
  <xs:element name="SalesAndMarketingExpensesTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_SalesAndMarketingExpensesTextBlock"/>
  <xs:element name="FinanceIncomeAndExpensesPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_FinanceIncomeAndExpensesPolicyTextBlock"/>
  <xs:element name="SeverancePolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_SeverancePolicyTextBlock"/>
  <xs:element name="ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock"/>
  <xs:element name="ScheduleOfLesseeOperatingLeasesDisclosureTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfLesseeOperatingLeasesDisclosureTableTextBlock"/>
  <xs:element name="ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock"/>
  <xs:element name="ScheduleOfSalesAndMarketingExpensesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock"/>
  <xs:element name="ScheduleOfTheoreticalTaxTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfTheoreticalTaxTableTextBlock"/>
  <xs:element name="SignificantAccountingPoliciesScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_SignificantAccountingPoliciesScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsDetailsTable"/>
  <xs:element name="AnnualDepreciationRatesOfPropertyPlantAndEquipment" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment"/>
  <xs:element name="AccountsPayableToRelatedParties" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_AccountsPayableToRelatedParties"/>
  <xs:element name="FinacialLiabilitiesatFairValueScheduleofFinancialLiabilityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_FinacialLiabilitiesatFairValueScheduleofFinancialLiabilityDetailsTable"/>
  <xs:element name="ShareholdersEquityScheduleofShareCapitalDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_ShareholdersEquityScheduleofShareCapitalDetailsTable"/>
  <xs:element name="ShareholdersEquityScheduleofShareCapitalDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ShareholdersEquityScheduleofShareCapitalDetailsLineItems"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsIssued"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeighted-averageExercisePriceIssued" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeighted-averageExercisePriceIssued"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentExpirationDate" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ShareBasedCompensationArrangementByShareBasedPaymentExpirationDate"/>
  <xs:element name="Subcontractors" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_Subcontractors"/>
  <xs:element name="IIAParticipation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_IIAParticipation"/>
  <xs:element name="GeneralandAdministrativeExpensesScheduleofGeneralandAdministrativeExpensesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_GeneralandAdministrativeExpensesScheduleofGeneralandAdministrativeExpensesDetailsTable"/>
  <xs:element name="FundraisingExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_FundraisingExpenses"/>
  <xs:element name="RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss"/>
  <xs:element name="DeferredTaxAssetsAccruedExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_DeferredTaxAssetsAccruedExpenses"/>
  <xs:element name="DeferredTaxAssetsFundRaisingCost2023" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_DeferredTaxAssetsFundRaisingCost2023"/>
  <xs:element name="DeferredTaxLiabilitiesOperatingLeaseLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_DeferredTaxLiabilitiesOperatingLeaseLiability"/>
  <xs:element name="EffectiveIncomeTaxTheoreticalTaxCredit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_EffectiveIncomeTaxTheoreticalTaxCredit"/>
  <xs:element name="TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized"/>
  <xs:element name="ShareBasedPaymentScheduleofMeasuretheFairValueoftheOptionatGrantDateDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_ShareBasedPaymentScheduleofMeasuretheFairValueoftheOptionatGrantDateDetailsTable"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife"/>
  <xs:element name="ShareBasedPaymentScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_ShareBasedPaymentScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsTable"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsReclassifiedToEmployeesAndDirectors" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsReclassifiedToEmployeesAndDirectors"/>
  <xs:element name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceReclassifiedToEmployeesAndDirectors" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceReclassifiedToEmployeesAndDirectors"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi"/>
  <xs:element name="ShareBasedPaymentScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_ShareBasedPaymentScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsTable"/>
  <xs:element name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested"/>
  <xs:element name="GeneralDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_GeneralDetailsTable"/>
  <xs:element name="PercentageOfOrdinaryShares" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_PercentageOfOrdinaryShares"/>
  <xs:element name="PlacementAgentWarrantsFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_PlacementAgentWarrantsFairValue"/>
  <xs:element name="AggregateProceedsReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_AggregateProceedsReceived"/>
  <xs:element name="AdditionalOfferingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_AdditionalOfferingCosts"/>
  <xs:element name="SignificantAccountingPoliciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_SignificantAccountingPoliciesDetailsTable"/>
  <xs:element name="DepositsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_DepositsDetailsTable"/>
  <xs:element name="CommitmentsandContingenciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_CommitmentsandContingenciesDetailsTable"/>
  <xs:element name="AggregateBudget" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_AggregateBudget"/>
  <xs:element name="PercentageOfApprovedBudget" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_PercentageOfApprovedBudget"/>
  <xs:element name="ProjectBudgetAggregateAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_ProjectBudgetAggregateAmount"/>
  <xs:element name="RoyaltiesPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_RoyaltiesPercentage"/>
  <xs:element name="ContingentUponFutureSales" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_ContingentUponFutureSales"/>
  <xs:element name="LeaseLiabilitiesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_LeaseLiabilitiesDetailsTable"/>
  <xs:element name="MonthlyDeductionFromTerminationFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_MonthlyDeductionFromTerminationFee"/>
  <xs:element name="PercentageOfFutureLeasePaymentsDiscounted" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="iinn_PercentageOfFutureLeasePaymentsDiscounted"/>
  <xs:element name="PercentageForCarsLeaseAgreementCancellationPenalty" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_PercentageForCarsLeaseAgreementCancellationPenalty"/>
  <xs:element name="FinacialLiabilitiesatFairValueDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_FinacialLiabilitiesatFairValueDetailsTable"/>
  <xs:element name="PercentageOfPayFees" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_PercentageOfPayFees"/>
  <xs:element name="ShareholdersEquityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_ShareholdersEquityDetailsTable"/>
  <xs:element name="PurchasePricePerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="iinn_PurchasePricePerShare"/>
  <xs:element name="ClassOfPrivateWarrantOrRightOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="iinn_ClassOfPrivateWarrantOrRightOutstanding"/>
  <xs:element name="NumberofAdditionalOrdinaryShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_NumberofAdditionalOrdinaryShares"/>
  <xs:element name="NumberOfSharesPerUnits" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_NumberOfSharesPerUnits"/>
  <xs:element name="TaxesonIncomeDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_TaxesonIncomeDetailsTable"/>
  <xs:element name="ShareBasedPaymentDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_ShareBasedPaymentDetailsTable"/>
  <xs:element name="CapitalGainTaxRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_CapitalGainTaxRate"/>
  <xs:element name="PercentageOfCapitalGainTax" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_PercentageOfCapitalGainTax"/>
  <xs:element name="SubsequentEventsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="iinn_SubsequentEventsDetailsTable"/>
  <xs:element name="OfferingFeesAndOtherRelatedExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_OfferingFeesAndOtherRelatedExpenses"/>
  <xs:element name="ProceedsFromReceivedFund" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="iinn_ProceedsFromReceivedFund"/>
  <xs:element name="RestrictedStockUnits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="iinn_RestrictedStockUnits"/>
  <xs:element name="AdvisoryBoardMembersMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_AdvisoryBoardMembersMember"/>
  <xs:element name="BankLeumiMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_BankLeumiMember"/>
  <xs:element name="December2024PrivatePlacementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_December2024PrivatePlacementMember"/>
  <xs:element name="DecemberPreFundedWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_DecemberPreFundedWarrantsMember"/>
  <xs:element name="DecemberPrivateOfferingMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_DecemberPrivateOfferingMember"/>
  <xs:element name="DecemberPrivatePlacementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_DecemberPrivatePlacementMember"/>
  <xs:element name="DecemberPrivateWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_DecemberPrivateWarrantsMember"/>
  <xs:element name="EmployeesAndDirectorsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_EmployeesAndDirectorsMember"/>
  <xs:element name="EmployeesDirectorsAndSubcontractorsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_EmployeesDirectorsAndSubcontractorsMember"/>
  <xs:element name="ExecutivesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ExecutivesMember"/>
  <xs:element name="Exercise6875Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_Exercise6875Member"/>
  <xs:element name="ExercisePrice0001Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ExercisePrice0001Member"/>
  <xs:element name="ExercisePrice156Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ExercisePrice156Member"/>
  <xs:element name="ExercisePrice55Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ExercisePrice55Member"/>
  <xs:element name="ExercisePrice55TwoMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ExercisePrice55TwoMember"/>
  <xs:element name="ExercisePriceOnePointOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ExercisePriceOnePointOneMember"/>
  <xs:element name="ExercisePriceOnePointSixMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ExercisePriceOnePointSixMember"/>
  <xs:element name="JunePlacementAgentWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_JunePlacementAgentWarrantsMember"/>
  <xs:element name="JunePreFundedWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_JunePreFundedWarrantsMember"/>
  <xs:element name="MedicalBoardMembersMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_MedicalBoardMembersMember"/>
  <xs:element name="OfficersAndDirectorsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_OfficersAndDirectorsMember"/>
  <xs:element name="OrdinarySharesNoParValueMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_OrdinarySharesNoParValueMember"/>
  <xs:element name="PlacementAgentWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_PlacementAgentWarrantsMember"/>
  <xs:element name="PreFundedWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_PreFundedWarrantsMember"/>
  <xs:element name="PrivateWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_PrivateWarrantsMember"/>
  <xs:element name="RDEquipmentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_RDEquipmentMember"/>
  <xs:element name="RegisteredDirectOfferingMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_RegisteredDirectOfferingMember"/>
  <xs:element name="RothCapitalPartnersLLCMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_RothCapitalPartnersLLCMember"/>
  <xs:element name="ServicesProvidersAndAdvisersMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ServicesProvidersAndAdvisersMember"/>
  <xs:element name="TwoThousandNineteenEquityIncentivePlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_TwoThousandNineteenEquityIncentivePlanMember"/>
  <xs:element name="TwoThousandTwentyFourAprilOfferingMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_TwoThousandTwentyFourAprilOfferingMember"/>
  <xs:element name="TwoThousandTwentyFourJuneOfferingMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_TwoThousandTwentyFourJuneOfferingMember"/>
  <xs:element name="WarrantsToPurchaseOrdinarySharesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_WarrantsToPurchaseOrdinarySharesMember"/>
  <xs:element name="ScheduleOfGeneralAndAdministrativeExpensesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfGeneralAndAdministrativeExpensesLineItems"/>
  <xs:element name="ScheduleOfTheoreticalTaxAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_ScheduleOfTheoreticalTaxAbstract"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="iinn_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>39
<FILENAME>iinn-20241231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Mar 10 18:58:49 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ConsolidatedBalanceSheet" roleURI="http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ConsolidatedIncomeStatement" roleURI="http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ConsolidatedCashFlow" roleURI="http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ScheduleofOtherCurrentAssetsTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofOtherCurrentAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ScheduleofInventoryTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofInventoryTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ScheduleofOtherAccountsPayableTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofOtherAccountsPayableTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ScheduleofOperatingRightofUseAssetsandOperatingLeaseLiabilitiesTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofOperatingRightofUseAssetsandOperatingLeaseLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ScheduleofRightofUseAssetsOvertheRemainingLeasePeriodsTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofRightofUseAssetsOvertheRemainingLeasePeriodsTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ScheduleofResearchandDevelopmentExpensesTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofResearchandDevelopmentExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ScheduleofGeneralandAdministrativeExpensesTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ScheduleofSalesandMarketingExpensesTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofSalesandMarketingExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ScheduleofDeferredTaxAssetsandLiabilitiesTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable"/>
  <calculationLink xlink:role="http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="3" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="4" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_SellingAndMarketingExpense" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeDepositsWithFinancialInstitutions"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.inspiratechnologies.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForOtherLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForOtherLosses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProvisionForOtherLosses" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="iinn_IssuanceOfOrdinarySharesAdvisorFees" xlink:href="iinn-20241231.xsd#iinn_IssuanceOfOrdinarySharesAdvisorFees"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="iinn_IssuanceOfOrdinarySharesAdvisorFees" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable" order="10" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_FairValueOptionChangesInFairValueGainLoss1" order="11" weight="-1"/>
    <loc xlink:type="locator" xlink:label="iinn_ExpirationOfFinancialLiability" xlink:href="iinn-20241231.xsd#iinn_ExpirationOfFinancialLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="iinn_ExpirationOfFinancialLiability" order="12" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInLeasingReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInLeasingReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInLeasingReceivables" order="13" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="14" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="15" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" order="16" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsForProceedsFromInvestments" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrarGpi3WKEtaAw66u01Fz01dWXY8Co/0nt/EYPpxJQpmucNPntkKGDUIzqiVXTghuh97D+3HoPuNe26jHPIaw4lyMqYvKxFlhkbYBWIUcgKRgNZdvBJC1M0l0xZMZd9F+M0zfHyxoKPMqOYWCT/B42d+bXUalw9kCR7ECrTZgyIl6CQNUWcHwWg7YyEKbKXVQrc457FUG7zZJKYSUUC+IL4iKzuqc3lzwnQ2dokFxrCaevH4cZ3wAdRaitsTLXse0F0xvf4jN2RROPYRDWnFVsCFxPB+a+CAW0=] CSR-->
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCash" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.inspiratechnologies.com/role/ScheduleofOtherCurrentAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestBearingDepositsInBanks" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestBearingDepositsInBanks"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_InterestBearingDepositsInBanks" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_RestrictedCashCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="4" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.inspiratechnologies.com/role/ScheduleofInventoryTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterials"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryRawMaterials" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcess"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcess" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoods"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoods" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.inspiratechnologies.com/role/ScheduleofOtherAccountsPayableTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="iinn_AccountsPayableToRelatedParties" xlink:href="iinn-20241231.xsd#iinn_AccountsPayableToRelatedParties"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="iinn_AccountsPayableToRelatedParties" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" order="4" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.inspiratechnologies.com/role/ScheduleofOperatingRightofUseAssetsandOperatingLeaseLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.inspiratechnologies.com/role/ScheduleofRightofUseAssetsOvertheRemainingLeasePeriodsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.inspiratechnologies.com/role/ScheduleofResearchandDevelopmentExpensesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LaborAndRelatedExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LaborAndRelatedExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_LaborAndRelatedExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLaborRelatedExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLaborRelatedExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherLaborRelatedExpenses" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationNonproduction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationNonproduction"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_DepreciationNonproduction" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="iinn_Subcontractors" xlink:href="iinn-20241231.xsd#iinn_Subcontractors"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="iinn_Subcontractors" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="iinn_IIAParticipation" xlink:href="iinn-20241231.xsd#iinn_IIAParticipation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="iinn_IIAParticipation" order="7" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalFees"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_ProfessionalFees" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficersCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficersCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_OfficersCompensation" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LegalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalFees"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_LegalFees" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralInsuranceExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralInsuranceExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralInsuranceExpense" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostMaintenance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostMaintenance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_CostMaintenance" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_Depreciation" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TravelAndEntertainmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TravelAndEntertainmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_TravelAndEntertainmentExpense" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="iinn_FundraisingExpenses" xlink:href="iinn-20241231.xsd#iinn_FundraisingExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="iinn_FundraisingExpenses" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherGeneralExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralExpense" order="10" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.inspiratechnologies.com/role/ScheduleofSalesandMarketingExpensesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficersCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficersCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_OfficersCompensation" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalFees"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_ProfessionalFees" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherSellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherSellingAndMarketingExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_OtherSellingAndMarketingExpense" order="4" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.inspiratechnologies.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="iinn_DeferredTaxAssetsAccruedExpenses" xlink:href="iinn-20241231.xsd#iinn_DeferredTaxAssetsAccruedExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="iinn_DeferredTaxAssetsAccruedExpenses" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="iinn_DeferredTaxAssetsFundRaisingCost2023" xlink:href="iinn-20241231.xsd#iinn_DeferredTaxAssetsFundRaisingCost2023"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="iinn_DeferredTaxAssetsFundRaisingCost2023" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="iinn_DeferredTaxLiabilitiesOperatingLeaseLiability" xlink:href="iinn-20241231.xsd#iinn_DeferredTaxLiabilitiesOperatingLeaseLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="iinn_DeferredTaxLiabilitiesOperatingLeaseLiability" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxAssetsGross" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="1" weight="-1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>40
<FILENAME>iinn-20241231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Mar 10 18:58:49 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ConsolidatedBalanceSheet" roleURI="http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ConsolidatedIncomeStatement" roleURI="http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ShareholdersEquityType2or3" roleURI="http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ConsolidatedCashFlow" roleURI="http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_General" roleURI="http://www.inspiratechnologies.com/role/General"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_SignificantAccountingPolicies" roleURI="http://www.inspiratechnologies.com/role/SignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_Deposits" roleURI="http://www.inspiratechnologies.com/role/Deposits"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_OtherCurrentAssets" roleURI="http://www.inspiratechnologies.com/role/OtherCurrentAssets"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_Inventory" roleURI="http://www.inspiratechnologies.com/role/Inventory"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_PropertyandEquipmentNet" roleURI="http://www.inspiratechnologies.com/role/PropertyandEquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_OtherAccountsPayable" roleURI="http://www.inspiratechnologies.com/role/OtherAccountsPayable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_CommitmentsandContingencies" roleURI="http://www.inspiratechnologies.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_LeaseLiabilities" roleURI="http://www.inspiratechnologies.com/role/LeaseLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_FinacialLiabilitiesatFairValue" roleURI="http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValue"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ShareholdersEquity" roleURI="http://www.inspiratechnologies.com/role/ShareholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ResearchandDevelopmentExpenses" roleURI="http://www.inspiratechnologies.com/role/ResearchandDevelopmentExpenses"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_GeneralandAdministrativeExpenses" roleURI="http://www.inspiratechnologies.com/role/GeneralandAdministrativeExpenses"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_SalesandMarketingExpenses" roleURI="http://www.inspiratechnologies.com/role/SalesandMarketingExpenses"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_FinancialIncomeandExpenses" roleURI="http://www.inspiratechnologies.com/role/FinancialIncomeandExpenses"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_TaxesonIncome" roleURI="http://www.inspiratechnologies.com/role/TaxesonIncome"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ShareBasedPayment" roleURI="http://www.inspiratechnologies.com/role/ShareBasedPayment"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_RelatedParties" roleURI="http://www.inspiratechnologies.com/role/RelatedParties"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_SubsequentEvents" roleURI="http://www.inspiratechnologies.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_AccountingPoliciesByPolicy" roleURI="http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_SignificantAccountingPoliciesTables" roleURI="http://www.inspiratechnologies.com/role/SignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_OtherCurrentAssetsTables" roleURI="http://www.inspiratechnologies.com/role/OtherCurrentAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_InventoryTables" roleURI="http://www.inspiratechnologies.com/role/InventoryTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_PropertyandEquipmentNetTables" roleURI="http://www.inspiratechnologies.com/role/PropertyandEquipmentNetTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_OtherAccountsPayableTables" roleURI="http://www.inspiratechnologies.com/role/OtherAccountsPayableTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_LeaseLiabilitiesTables" roleURI="http://www.inspiratechnologies.com/role/LeaseLiabilitiesTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_FinacialLiabilitiesatFairValueTables" roleURI="http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ShareholdersEquityTables" roleURI="http://www.inspiratechnologies.com/role/ShareholdersEquityTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ResearchandDevelopmentExpensesTables" roleURI="http://www.inspiratechnologies.com/role/ResearchandDevelopmentExpensesTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_GeneralandAdministrativeExpensesTables" roleURI="http://www.inspiratechnologies.com/role/GeneralandAdministrativeExpensesTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_SalesandMarketingExpensesTables" roleURI="http://www.inspiratechnologies.com/role/SalesandMarketingExpensesTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_FinancialIncomeandExpensesTables" roleURI="http://www.inspiratechnologies.com/role/FinancialIncomeandExpensesTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_TaxesonIncomeTables" roleURI="http://www.inspiratechnologies.com/role/TaxesonIncomeTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ShareBasedPaymentTables" roleURI="http://www.inspiratechnologies.com/role/ShareBasedPaymentTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_RelatedPartiesTables" roleURI="http://www.inspiratechnologies.com/role/RelatedPartiesTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ScheduleofOtherCurrentAssetsTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofOtherCurrentAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ScheduleofInventoryTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofInventoryTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ScheduleofPropertyandEquipmentNetTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofPropertyandEquipmentNetTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ScheduleofOtherAccountsPayableTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofOtherAccountsPayableTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ScheduleofOperatingRightofUseAssetsandOperatingLeaseLiabilitiesTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofOperatingRightofUseAssetsandOperatingLeaseLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ScheduleofRightofUseAssetsOvertheRemainingLeasePeriodsTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofRightofUseAssetsOvertheRemainingLeasePeriodsTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ScheduleofFinancialLiabilityTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofFinancialLiabilityTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ScheduleofShareCapitalTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofShareCapitalTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ScheduleofMovementinWarrantsOutstandingTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofMovementinWarrantsOutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ScheduleofInformationabouttheCompanysOutstandingWarrantsTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofInformationabouttheCompanysOutstandingWarrantsTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ScheduleofLossPerShareCalculatedUsingtheWeightedAverageNumberofOrdinarySharesandPreFundedWarrantsTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofLossPerShareCalculatedUsingtheWeightedAverageNumberofOrdinarySharesandPreFundedWarrantsTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ScheduleofResearchandDevelopmentExpensesTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofResearchandDevelopmentExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ScheduleofGeneralandAdministrativeExpensesTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ScheduleofSalesandMarketingExpensesTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofSalesandMarketingExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ScheduleofFinancialIncomeandExpensesTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofFinancialIncomeandExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ScheduleofDeferredTaxAssetsandLiabilitiesTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ScheduleofTheoreticalTaxTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofTheoreticalTaxTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ScheduleofTheoreticalTaxTable_Parentheticals" roleURI="http://www.inspiratechnologies.com/role/ScheduleofTheoreticalTaxTable_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ScheduleofMeasuretheFairValueoftheOptionatGrantDateTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofMeasuretheFairValueoftheOptionatGrantDateTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ScheduleofShareholdersandOtherRelatedPartiesBenefitsTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofShareholdersandOtherRelatedPartiesBenefitsTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_GeneralDetails" roleURI="http://www.inspiratechnologies.com/role/GeneralDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_SignificantAccountingPoliciesDetails" roleURI="http://www.inspiratechnologies.com/role/SignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_DepositsDetails" roleURI="http://www.inspiratechnologies.com/role/DepositsDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_CommitmentsandContingenciesDetails" roleURI="http://www.inspiratechnologies.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_LeaseLiabilitiesDetails" roleURI="http://www.inspiratechnologies.com/role/LeaseLiabilitiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_FinacialLiabilitiesatFairValueDetails" roleURI="http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ShareholdersEquityDetails" roleURI="http://www.inspiratechnologies.com/role/ShareholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_TaxesonIncomeDetails" roleURI="http://www.inspiratechnologies.com/role/TaxesonIncomeDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ShareBasedPaymentDetails" roleURI="http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_SubsequentEventsDetails" roleURI="http://www.inspiratechnologies.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#DocumentAndEntityInformation" roleURI="http://www.inspiratechnologies.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_DepositsAssetsCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_InventoryNet" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsNoncurrent" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Assets" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccountsPayableTradeCurrent" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccountsPayableOtherCurrent" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockValue" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquity" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="21" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_SellingAndMarketingExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeDepositsWithFinancialInstitutions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="13" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinarySharesinShares" xlink:href="iinn-20241231.xsd#iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinarySharesinShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinarySharesinShares" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinaryShares" xlink:href="iinn-20241231.xsd#iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinaryShares" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_StockIssuedDuringPeriodSharesStockOptionsExerciseOfShareBasedPayments" xlink:href="iinn-20241231.xsd#iinn_StockIssuedDuringPeriodSharesStockOptionsExerciseOfShareBasedPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="iinn_StockIssuedDuringPeriodSharesStockOptionsExerciseOfShareBasedPayments" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments" xlink:href="iinn-20241231.xsd#iinn_StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="iinn_StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments" order="18" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_Depreciation" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForOtherLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForOtherLosses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProvisionForOtherLosses" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_FairValueOptionChangesInFairValueGainLoss1" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ExpirationOfFinancialLiability" xlink:href="iinn-20241231.xsd#iinn_ExpirationOfFinancialLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="iinn_ExpirationOfFinancialLiability" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_IssuanceOfOrdinarySharesAdvisorFees" xlink:href="iinn-20241231.xsd#iinn_IssuanceOfOrdinarySharesAdvisorFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="iinn_IssuanceOfOrdinarySharesAdvisorFees" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInLeasingReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInLeasingReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInLeasingReceivables" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_PaymentsForProceedsFromInvestments" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_RestrictedCash" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_OtherReceivableInConnectionToPrivatePlacement" xlink:href="iinn-20241231.xsd#iinn_OtherReceivableInConnectionToPrivatePlacement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="iinn_OtherReceivableInConnectionToPrivatePlacement" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_AccruedIssuanceExpenses" xlink:href="iinn-20241231.xsd#iinn_AccruedIssuanceExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="iinn_AccruedIssuanceExpenses" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_FinancialLiabilityPlacementAgentFee" xlink:href="iinn-20241231.xsd#iinn_FinancialLiabilityPlacementAgentFee"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="iinn_FinancialLiabilityPlacementAgentFee" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital" xlink:href="iinn-20241231.xsd#iinn_ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="iinn_ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_NonCashTransactions" xlink:href="iinn-20241231.xsd#iinn_NonCashTransactions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="iinn_NonCashTransactions" order="35" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_InterestPaidNet" order="36" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/General" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/SignificantAccountingPolicies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/Deposits" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositLiabilitiesDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositLiabilitiesDisclosuresTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DepositsAbstract" xlink:to="us-gaap_DepositLiabilitiesDisclosuresTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/OtherCurrentAssets" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherCurrentAssetsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/Inventory" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/PropertyandEquipmentNet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/OtherAccountsPayable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrentAndNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/CommitmentsandContingencies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/LeaseLiabilities" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValue" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/ShareholdersEquity" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/ResearchandDevelopmentExpenses" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/GeneralandAdministrativeExpenses" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="iinn_GeneralAndAdministrativeExpensesTextBlock" xlink:href="iinn-20241231.xsd#iinn_GeneralAndAdministrativeExpensesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="iinn_GeneralAndAdministrativeExpensesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/SalesandMarketingExpenses" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="iinn_SalesAndMarketingExpensesTextBlock" xlink:href="iinn-20241231.xsd#iinn_SalesAndMarketingExpensesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SellingAndMarketingExpenseAbstract" xlink:to="iinn_SalesAndMarketingExpensesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/FinancialIncomeandExpenses" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/TaxesonIncome" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/ShareBasedPayment" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/RelatedParties" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/SubsequentEvents" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GovernmentAssistancePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistancePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GovernmentAssistancePolicyTextBlock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_FinanceIncomeAndExpensesPolicyTextBlock" xlink:href="iinn-20241231.xsd#iinn_FinanceIncomeAndExpensesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="iinn_FinanceIncomeAndExpensesPolicyTextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DerivativesPolicyTextBlock" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_SeverancePolicyTextBlock" xlink:href="iinn-20241231.xsd#iinn_SeverancePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="iinn_SeverancePolicyTextBlock" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="17" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/SignificantAccountingPoliciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock" xlink:href="iinn-20241231.xsd#iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/OtherCurrentAssetsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/InventoryTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/PropertyandEquipmentNetTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/OtherAccountsPayableTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrentAndNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableCurrentAndNoncurrentAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/LeaseLiabilitiesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfLesseeOperatingLeasesDisclosureTableTextBlock" xlink:href="iinn-20241231.xsd#iinn_ScheduleOfLesseeOperatingLeasesDisclosureTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="iinn_ScheduleOfLesseeOperatingLeasesDisclosureTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/ShareholdersEquityTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/ResearchandDevelopmentExpensesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/GeneralandAdministrativeExpensesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" xlink:href="iinn-20241231.xsd#iinn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="iinn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/SalesandMarketingExpensesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock" xlink:href="iinn-20241231.xsd#iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SellingAndMarketingExpenseAbstract" xlink:to="iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/FinancialIncomeandExpensesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/TaxesonIncomeTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfTheoreticalTaxTableTextBlock" xlink:href="iinn-20241231.xsd#iinn_ScheduleOfTheoreticalTaxTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="iinn_ScheduleOfTheoreticalTaxTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/ShareBasedPaymentTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/RelatedPartiesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/ScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_SignificantAccountingPoliciesScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsDetailsTable" xlink:href="iinn-20241231.xsd#iinn_SignificantAccountingPoliciesScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="iinn_SignificantAccountingPoliciesScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_SignificantAccountingPoliciesScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsDetailsTable" xlink:to="srt_RangeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_SignificantAccountingPoliciesScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment" xlink:href="iinn-20241231.xsd#iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/ScheduleofOtherCurrentAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestBearingDepositsInBanks" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestBearingDepositsInBanks"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_InterestBearingDepositsInBanks" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/ScheduleofInventoryTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterials"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryRawMaterials" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcess"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryWorkInProcess" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoods"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryFinishedGoods" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryNet" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/ScheduleofPropertyandEquipmentNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_RDEquipmentMember" xlink:href="iinn-20241231.xsd#iinn_RDEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="iinn_RDEquipmentMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAdditions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAdditions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentAdditions" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_Depreciation" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/ScheduleofOtherAccountsPayableTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_AccountsPayableToRelatedParties" xlink:href="iinn-20241231.xsd#iinn_AccountsPayableToRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract" xlink:to="iinn_AccountsPayableToRelatedParties" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract" xlink:to="us-gaap_AccountsPayableOtherCurrent" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/ScheduleofOperatingRightofUseAssetsandOperatingLeaseLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/ScheduleofRightofUseAssetsOvertheRemainingLeasePeriodsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/ScheduleofFinancialLiabilityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativesFairValueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_FinacialLiabilitiesatFairValueScheduleofFinancialLiabilityDetailsTable" xlink:href="iinn-20241231.xsd#iinn_FinacialLiabilitiesatFairValueScheduleofFinancialLiabilityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="iinn_FinacialLiabilitiesatFairValueScheduleofFinancialLiabilityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_FinacialLiabilitiesatFairValueScheduleofFinancialLiabilityDetailsTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_PrivateWarrantsMember" xlink:href="iinn-20241231.xsd#iinn_PrivateWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="iinn_PrivateWarrantsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/ScheduleofShareCapitalTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="iinn_ShareholdersEquityScheduleofShareCapitalDetailsLineItems" xlink:href="iinn-20241231.xsd#iinn_ShareholdersEquityScheduleofShareCapitalDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareholdersEquityScheduleofShareCapitalDetailsTable" xlink:href="iinn-20241231.xsd#iinn_ShareholdersEquityScheduleofShareCapitalDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="iinn_ShareholdersEquityScheduleofShareCapitalDetailsLineItems" xlink:to="iinn_ShareholdersEquityScheduleofShareCapitalDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_ShareholdersEquityScheduleofShareCapitalDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareholdersEquityScheduleofShareCapitalDetailsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareholdersEquityScheduleofShareCapitalDetailsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ShareholdersEquityScheduleofShareCapitalDetailsLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/ScheduleofMovementinWarrantsOutstandingTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsIssued" xlink:href="iinn-20241231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsIssued" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeighted-averageExercisePriceIssued" xlink:href="iinn-20241231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeighted-averageExercisePriceIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeighted-averageExercisePriceIssued" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms" xlink:href="iinn-20241231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:href="iinn-20241231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue" xlink:href="iinn-20241231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms" xlink:href="iinn-20241231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:href="iinn-20241231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue" xlink:href="iinn-20241231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms" xlink:href="iinn-20241231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/ScheduleofInformationabouttheCompanysOutstandingWarrantsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ExercisePrice55Member" xlink:href="iinn-20241231.xsd#iinn_ExercisePrice55Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="iinn_ExercisePrice55Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ExercisePrice55TwoMember" xlink:href="iinn-20241231.xsd#iinn_ExercisePrice55TwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="iinn_ExercisePrice55TwoMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_Exercise6875Member" xlink:href="iinn-20241231.xsd#iinn_Exercise6875Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="iinn_Exercise6875Member" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ExercisePriceOnePointSixMember" xlink:href="iinn-20241231.xsd#iinn_ExercisePriceOnePointSixMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="iinn_ExercisePriceOnePointSixMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ExercisePrice156Member" xlink:href="iinn-20241231.xsd#iinn_ExercisePrice156Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="iinn_ExercisePrice156Member" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ExercisePriceOnePointOneMember" xlink:href="iinn-20241231.xsd#iinn_ExercisePriceOnePointOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="iinn_ExercisePriceOnePointOneMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ExercisePrice0001Member" xlink:href="iinn-20241231.xsd#iinn_ExercisePrice0001Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="iinn_ExercisePrice0001Member" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentExpirationDate" xlink:href="iinn-20241231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentExpirationDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentExpirationDate" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/ScheduleofLossPerShareCalculatedUsingtheWeightedAverageNumberofOrdinarySharesandPreFundedWarrantsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/ScheduleofResearchandDevelopmentExpensesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LaborAndRelatedExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LaborAndRelatedExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_LaborAndRelatedExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLaborRelatedExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLaborRelatedExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_OtherLaborRelatedExpenses" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationNonproduction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationNonproduction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_DepreciationNonproduction" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_Subcontractors" xlink:href="iinn-20241231.xsd#iinn_Subcontractors"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="iinn_Subcontractors" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_IIAParticipation" xlink:href="iinn-20241231.xsd#iinn_IIAParticipation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="iinn_IIAParticipation" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfGeneralAndAdministrativeExpensesLineItems" xlink:href="iinn-20241231.xsd#iinn_ScheduleOfGeneralAndAdministrativeExpensesLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_GeneralandAdministrativeExpensesScheduleofGeneralandAdministrativeExpensesDetailsTable" xlink:href="iinn-20241231.xsd#iinn_GeneralandAdministrativeExpensesScheduleofGeneralandAdministrativeExpensesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="iinn_ScheduleOfGeneralAndAdministrativeExpensesLineItems" xlink:to="iinn_GeneralandAdministrativeExpensesScheduleofGeneralandAdministrativeExpensesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_GeneralandAdministrativeExpensesScheduleofGeneralandAdministrativeExpensesDetailsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10" xbrldt:closed="true"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrarGpi3WKEtaAw66u01Fz01dWXY8Co/0nt/EYPpxJQpmucNPntkKGDUIzqiVXTghuh97D+3HoPuNe26jHPIaw4lyMqYvKxFlhkbYBWIUcgKRgNZdvBJC1M0l0xZMZd9F+M0zfHyxoKPMqOYWCT/B42d+bXUalw9kCR7ECrTZgyIl6CQNUWcHwWg7YyEKbKXVQrc457FUG7zZJKYSUUC+IL4iKzuqc3lzwnQ2dokFxrCaevH4cZ3wAdRaitsTLXse0F0xvf4jN2RRFCAe3UGQgIs+ycypspvViQ=] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfGeneralAndAdministrativeExpensesLineItems" xlink:to="us-gaap_ProfessionalFees" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficersCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficersCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfGeneralAndAdministrativeExpensesLineItems" xlink:to="us-gaap_OfficersCompensation" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfGeneralAndAdministrativeExpensesLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LegalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfGeneralAndAdministrativeExpensesLineItems" xlink:to="us-gaap_LegalFees" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralInsuranceExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralInsuranceExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfGeneralAndAdministrativeExpensesLineItems" xlink:to="us-gaap_GeneralInsuranceExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostMaintenance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostMaintenance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfGeneralAndAdministrativeExpensesLineItems" xlink:to="us-gaap_CostMaintenance" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfGeneralAndAdministrativeExpensesLineItems" xlink:to="us-gaap_Depreciation" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TravelAndEntertainmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TravelAndEntertainmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfGeneralAndAdministrativeExpensesLineItems" xlink:to="us-gaap_TravelAndEntertainmentExpense" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_FundraisingExpenses" xlink:href="iinn-20241231.xsd#iinn_FundraisingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfGeneralAndAdministrativeExpensesLineItems" xlink:to="iinn_FundraisingExpenses" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherGeneralExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfGeneralAndAdministrativeExpensesLineItems" xlink:to="us-gaap_OtherGeneralExpense" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfGeneralAndAdministrativeExpensesLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/ScheduleofSalesandMarketingExpensesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficersCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficersCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SellingAndMarketingExpenseAbstract" xlink:to="us-gaap_OfficersCompensation" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SellingAndMarketingExpenseAbstract" xlink:to="us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SellingAndMarketingExpenseAbstract" xlink:to="us-gaap_ProfessionalFees" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherSellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherSellingAndMarketingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SellingAndMarketingExpenseAbstract" xlink:to="us-gaap_OtherSellingAndMarketingExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SellingAndMarketingExpenseAbstract" xlink:to="us-gaap_SellingAndMarketingExpense" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/ScheduleofFinancialIncomeandExpensesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfFinancialIncomeAndExpensesAbstract" xlink:href="iinn-20241231.xsd#iinn_ScheduleOfFinancialIncomeAndExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="iinn_RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:href="iinn-20241231.xsd#iinn_RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfFinancialIncomeAndExpensesAbstract" xlink:to="iinn_RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfFinancialIncomeAndExpensesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfFinancialIncomeAndExpensesAbstract" xlink:to="us-gaap_FinanceLeaseInterestExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfFinancialIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfFinancialIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_DeferredTaxAssetsAccruedExpenses" xlink:href="iinn-20241231.xsd#iinn_DeferredTaxAssetsAccruedExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="iinn_DeferredTaxAssetsAccruedExpenses" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_DeferredTaxAssetsFundRaisingCost2023" xlink:href="iinn-20241231.xsd#iinn_DeferredTaxAssetsFundRaisingCost2023"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="iinn_DeferredTaxAssetsFundRaisingCost2023" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_DeferredTaxLiabilitiesOperatingLeaseLiability" xlink:href="iinn-20241231.xsd#iinn_DeferredTaxLiabilitiesOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="iinn_DeferredTaxLiabilitiesOperatingLeaseLiability" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/ScheduleofTheoreticalTaxTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfTheoreticalTaxAbstract" xlink:href="iinn-20241231.xsd#iinn_ScheduleOfTheoreticalTaxAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfTheoreticalTaxAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_EffectiveIncomeTaxTheoreticalTaxCredit" xlink:href="iinn-20241231.xsd#iinn_EffectiveIncomeTaxTheoreticalTaxCredit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfTheoreticalTaxAbstract" xlink:to="iinn_EffectiveIncomeTaxTheoreticalTaxCredit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfTheoreticalTaxAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized" xlink:href="iinn-20241231.xsd#iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfTheoreticalTaxAbstract" xlink:to="iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfTheoreticalTaxAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/ScheduleofTheoreticalTaxTable_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfTheoreticalTaxAbstract" xlink:href="iinn-20241231.xsd#iinn_ScheduleOfTheoreticalTaxAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="iinn_ScheduleOfTheoreticalTaxAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/ScheduleofMeasuretheFairValueoftheOptionatGrantDateTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedPaymentScheduleofMeasuretheFairValueoftheOptionatGrantDateDetailsTable" xlink:href="iinn-20241231.xsd#iinn_ShareBasedPaymentScheduleofMeasuretheFairValueoftheOptionatGrantDateDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="iinn_ShareBasedPaymentScheduleofMeasuretheFairValueoftheOptionatGrantDateDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_ShareBasedPaymentScheduleofMeasuretheFairValueoftheOptionatGrantDateDetailsTable" xlink:to="srt_RangeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife" xlink:href="iinn-20241231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedPaymentScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsTable" xlink:href="iinn-20241231.xsd#iinn_ShareBasedPaymentScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="iinn_ShareBasedPaymentScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_ShareBasedPaymentScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ServicesProvidersAndAdvisersMember" xlink:href="iinn-20241231.xsd#iinn_ServicesProvidersAndAdvisersMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="iinn_ServicesProvidersAndAdvisersMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_EmployeesAndDirectorsMember" xlink:href="iinn-20241231.xsd#iinn_EmployeesAndDirectorsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="iinn_EmployeesAndDirectorsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsReclassifiedToEmployeesAndDirectors" xlink:href="iinn-20241231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsReclassifiedToEmployeesAndDirectors"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsReclassifiedToEmployeesAndDirectors" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceReclassifiedToEmployeesAndDirectors" xlink:href="iinn-20241231.xsd#iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceReclassifiedToEmployeesAndDirectors"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceReclassifiedToEmployeesAndDirectors" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi" xlink:href="iinn-20241231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="12" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/ScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedPaymentScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsTable" xlink:href="iinn-20241231.xsd#iinn_ShareBasedPaymentScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="iinn_ShareBasedPaymentScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_ShareBasedPaymentScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested" xlink:href="iinn-20241231.xsd#iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/ScheduleofShareholdersandOtherRelatedPartiesBenefitsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_TitleOfIndividualAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_OfficersAndDirectorsMember" xlink:href="iinn-20241231.xsd#iinn_OfficersAndDirectorsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="iinn_OfficersAndDirectorsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OfficerMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OfficerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_OfficerMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficersCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficersCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OfficersCompensation" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NatureOfCommonOwnershipOrManagementControlRelationships" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfCommonOwnershipOrManagementControlRelationships"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_NatureOfCommonOwnershipOrManagementControlRelationships" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/GeneralDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PublicUtilitiesGeneralDisclosuresLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PublicUtilitiesGeneralDisclosuresLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_GeneralDetailsTable" xlink:href="iinn-20241231.xsd#iinn_GeneralDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PublicUtilitiesGeneralDisclosuresLineItems" xlink:to="iinn_GeneralDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_GeneralDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_GeneralDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_GeneralDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_DecemberPrivatePlacementMember" xlink:href="iinn-20241231.xsd#iinn_DecemberPrivatePlacementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="iinn_DecemberPrivatePlacementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_PreFundedWarrantsMember" xlink:href="iinn-20241231.xsd#iinn_PreFundedWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="iinn_PreFundedWarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_JunePreFundedWarrantsMember" xlink:href="iinn-20241231.xsd#iinn_JunePreFundedWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="iinn_JunePreFundedWarrantsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_JunePlacementAgentWarrantsMember" xlink:href="iinn-20241231.xsd#iinn_JunePlacementAgentWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="iinn_JunePlacementAgentWarrantsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_DecemberPreFundedWarrantsMember" xlink:href="iinn-20241231.xsd#iinn_DecemberPreFundedWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="iinn_DecemberPreFundedWarrantsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_WarrantMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PublicUtilitiesGeneralDisclosuresLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PublicUtilitiesGeneralDisclosuresLineItems" xlink:to="us-gaap_SharePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PublicUtilitiesGeneralDisclosuresLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PublicUtilitiesGeneralDisclosuresLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PartnersCapitalAccountPublicSaleOfUnitsNetOfOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PartnersCapitalAccountPublicSaleOfUnitsNetOfOfferingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PublicUtilitiesGeneralDisclosuresLineItems" xlink:to="us-gaap_PartnersCapitalAccountPublicSaleOfUnitsNetOfOfferingCosts" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_PercentageOfOrdinaryShares" xlink:href="iinn-20241231.xsd#iinn_PercentageOfOrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PublicUtilitiesGeneralDisclosuresLineItems" xlink:to="iinn_PercentageOfOrdinaryShares" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_PlacementAgentWarrantsFairValue" xlink:href="iinn-20241231.xsd#iinn_PlacementAgentWarrantsFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PublicUtilitiesGeneralDisclosuresLineItems" xlink:to="iinn_PlacementAgentWarrantsFairValue" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionExercisePriceIncrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PublicUtilitiesGeneralDisclosuresLineItems" xlink:to="us-gaap_StockOptionExercisePriceIncrease" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_AggregateProceedsReceived" xlink:href="iinn-20241231.xsd#iinn_AggregateProceedsReceived"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PublicUtilitiesGeneralDisclosuresLineItems" xlink:to="iinn_AggregateProceedsReceived" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_AdditionalOfferingCosts" xlink:href="iinn-20241231.xsd#iinn_AdditionalOfferingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PublicUtilitiesGeneralDisclosuresLineItems" xlink:to="iinn_AdditionalOfferingCosts" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PublicUtilitiesGeneralDisclosuresLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PublicUtilitiesGeneralDisclosuresLineItems" xlink:to="us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/SignificantAccountingPoliciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatutoryAccountingPracticesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatutoryAccountingPracticesLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_SignificantAccountingPoliciesDetailsTable" xlink:href="iinn-20241231.xsd#iinn_SignificantAccountingPoliciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatutoryAccountingPracticesLineItems" xlink:to="iinn_SignificantAccountingPoliciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_SignificantAccountingPoliciesDetailsTable" xlink:to="srt_RangeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_WeightedAverageMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_WeightedAverageMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_WeightedAverageMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatutoryAccountingPracticesLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatutoryAccountingPracticesLineItems" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatutoryAccountingPracticesLineItems" xlink:to="us-gaap_ShortTermInvestments" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/DepositsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DepositLiabilityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositLiabilityLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_DepositsDetailsTable" xlink:href="iinn-20241231.xsd#iinn_DepositsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DepositLiabilityLineItems" xlink:to="iinn_DepositsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_DepositsDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_DepositsDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_BankLeumiMember" xlink:href="iinn-20241231.xsd#iinn_BankLeumiMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="iinn_BankLeumiMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_IL" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_IL"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_IL" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Deposits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Deposits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DepositLiabilityLineItems" xlink:to="us-gaap_Deposits" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtPercentageBearingFixedInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DepositLiabilityLineItems" xlink:to="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_CommitmentsandContingenciesDetailsTable" xlink:href="iinn-20241231.xsd#iinn_CommitmentsandContingenciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="iinn_CommitmentsandContingenciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_AggregateBudget" xlink:href="iinn-20241231.xsd#iinn_AggregateBudget"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="iinn_AggregateBudget" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_PercentageOfApprovedBudget" xlink:href="iinn-20241231.xsd#iinn_PercentageOfApprovedBudget"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="iinn_PercentageOfApprovedBudget" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ProjectBudgetAggregateAmount" xlink:href="iinn-20241231.xsd#iinn_ProjectBudgetAggregateAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="iinn_ProjectBudgetAggregateAmount" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherReceivables" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_RoyaltiesPercentage" xlink:href="iinn-20241231.xsd#iinn_RoyaltiesPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="iinn_RoyaltiesPercentage" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ContingentUponFutureSales" xlink:href="iinn-20241231.xsd#iinn_ContingentUponFutureSales"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="iinn_ContingentUponFutureSales" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/LeaseLiabilitiesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_LeaseLiabilitiesDetailsTable" xlink:href="iinn-20241231.xsd#iinn_LeaseLiabilitiesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="iinn_LeaseLiabilitiesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_LeaseLiabilitiesDetailsTable" xlink:to="srt_RangeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_PaymentsForRent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_MonthlyDeductionFromTerminationFee" xlink:href="iinn-20241231.xsd#iinn_MonthlyDeductionFromTerminationFee"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="iinn_MonthlyDeductionFromTerminationFee" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLeasePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_ProceedsFromLeasePayments" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_PercentageOfFutureLeasePaymentsDiscounted" xlink:href="iinn-20241231.xsd#iinn_PercentageOfFutureLeasePaymentsDiscounted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="iinn_PercentageOfFutureLeasePaymentsDiscounted" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_PercentageForCarsLeaseAgreementCancellationPenalty" xlink:href="iinn-20241231.xsd#iinn_PercentageForCarsLeaseAgreementCancellationPenalty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="iinn_PercentageForCarsLeaseAgreementCancellationPenalty" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_FinacialLiabilitiesatFairValueDetailsTable" xlink:href="iinn-20241231.xsd#iinn_FinacialLiabilitiesatFairValueDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="iinn_FinacialLiabilitiesatFairValueDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_FinacialLiabilitiesatFairValueDetailsTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_FinacialLiabilitiesatFairValueDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_FinacialLiabilitiesatFairValueDetailsTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_FinacialLiabilitiesatFairValueDetailsTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_FinacialLiabilitiesatFairValueDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_PrivateWarrantsMember" xlink:href="iinn-20241231.xsd#iinn_PrivateWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="iinn_PrivateWarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_December2024PrivatePlacementMember" xlink:href="iinn-20241231.xsd#iinn_December2024PrivatePlacementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="iinn_December2024PrivatePlacementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_PercentageOfPayFees" xlink:href="iinn-20241231.xsd#iinn_PercentageOfPayFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="iinn_PercentageOfPayFees" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityMeasurementInput"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/ShareholdersEquityDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareholdersEquityDetailsTable" xlink:href="iinn-20241231.xsd#iinn_ShareholdersEquityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="iinn_ShareholdersEquityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_ShareholdersEquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_ShareholdersEquityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_ShareholdersEquityDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_ShareholdersEquityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_ShareholdersEquityDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_ShareholdersEquityDetailsTable" xlink:to="srt_RangeAxis" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_ShareholdersEquityDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_TwoThousandTwentyFourAprilOfferingMember" xlink:href="iinn-20241231.xsd#iinn_TwoThousandTwentyFourAprilOfferingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="iinn_TwoThousandTwentyFourAprilOfferingMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_TwoThousandTwentyFourJuneOfferingMember" xlink:href="iinn-20241231.xsd#iinn_TwoThousandTwentyFourJuneOfferingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="iinn_TwoThousandTwentyFourJuneOfferingMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_DecemberPrivateOfferingMember" xlink:href="iinn-20241231.xsd#iinn_DecemberPrivateOfferingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="iinn_DecemberPrivateOfferingMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_December2024PrivatePlacementMember" xlink:href="iinn-20241231.xsd#iinn_December2024PrivatePlacementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="iinn_December2024PrivatePlacementMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_PreFundedWarrantsMember" xlink:href="iinn-20241231.xsd#iinn_PreFundedWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="iinn_PreFundedWarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_PrivateWarrantsMember" xlink:href="iinn-20241231.xsd#iinn_PrivateWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="iinn_PrivateWarrantsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_WarrantMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_PlacementAgentWarrantsMember" xlink:href="iinn-20241231.xsd#iinn_PlacementAgentWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="iinn_PlacementAgentWarrantsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_JunePreFundedWarrantsMember" xlink:href="iinn-20241231.xsd#iinn_JunePreFundedWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="iinn_JunePreFundedWarrantsMember" order="4" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="iinn_TwoThousandTwentyFourJuneOfferingMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_JunePlacementAgentWarrantsMember" xlink:href="iinn-20241231.xsd#iinn_JunePlacementAgentWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="iinn_JunePlacementAgentWarrantsMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_DecemberPrivateWarrantsMember" xlink:href="iinn-20241231.xsd#iinn_DecemberPrivateWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="iinn_DecemberPrivateWarrantsMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_DecemberPreFundedWarrantsMember" xlink:href="iinn-20241231.xsd#iinn_DecemberPreFundedWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="iinn_DecemberPreFundedWarrantsMember" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_RothCapitalPartnersLLCMember" xlink:href="iinn-20241231.xsd#iinn_RothCapitalPartnersLLCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="iinn_RothCapitalPartnersLLCMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_RegisteredDirectOfferingMember" xlink:href="iinn-20241231.xsd#iinn_RegisteredDirectOfferingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="iinn_RegisteredDirectOfferingMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_PurchasePricePerShare" xlink:href="iinn-20241231.xsd#iinn_PurchasePricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="iinn_PurchasePricePerShare" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ClassOfPrivateWarrantOrRightOutstanding" xlink:href="iinn-20241231.xsd#iinn_ClassOfPrivateWarrantOrRightOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="iinn_ClassOfPrivateWarrantOrRightOutstanding" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_NumberofAdditionalOrdinaryShares" xlink:href="iinn-20241231.xsd#iinn_NumberofAdditionalOrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="iinn_NumberofAdditionalOrdinaryShares" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredOfferingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_DeferredOfferingCosts" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProductWarrantyLiquidationProceedsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductWarrantyLiquidationProceedsPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ProductWarrantyLiquidationProceedsPercentage" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_NumberOfSharesPerUnits" xlink:href="iinn-20241231.xsd#iinn_NumberOfSharesPerUnits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="iinn_NumberOfSharesPerUnits" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_PercentageOfPayFees" xlink:href="iinn-20241231.xsd#iinn_PercentageOfPayFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="iinn_PercentageOfPayFees" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" order="21" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/TaxesonIncomeDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_TaxesonIncomeDetailsTable" xlink:href="iinn-20241231.xsd#iinn_TaxesonIncomeDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="iinn_TaxesonIncomeDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_TaxesonIncomeDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_IL" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_IL"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_IL" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_DeferredTaxAssetsNet" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedPaymentDetailsTable" xlink:href="iinn-20241231.xsd#iinn_ShareBasedPaymentDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="iinn_ShareBasedPaymentDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_ShareBasedPaymentDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_ShareBasedPaymentDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_ShareBasedPaymentDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_ShareBasedPaymentDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockOptionMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_TwoThousandNineteenEquityIncentivePlanMember" xlink:href="iinn-20241231.xsd#iinn_TwoThousandNineteenEquityIncentivePlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="iinn_TwoThousandNineteenEquityIncentivePlanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_BoardOfDirectorsChairmanMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_BoardOfDirectorsChairmanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_AdvisoryBoardMembersMember" xlink:href="iinn-20241231.xsd#iinn_AdvisoryBoardMembersMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="iinn_AdvisoryBoardMembersMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_MedicalBoardMembersMember" xlink:href="iinn-20241231.xsd#iinn_MedicalBoardMembersMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="iinn_MedicalBoardMembersMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OfficerMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OfficerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_OfficerMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_EmployeesDirectorsAndSubcontractorsMember" xlink:href="iinn-20241231.xsd#iinn_EmployeesDirectorsAndSubcontractorsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="iinn_EmployeesDirectorsAndSubcontractorsMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_CapitalGainTaxRate" xlink:href="iinn-20241231.xsd#iinn_CapitalGainTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="iinn_CapitalGainTaxRate" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_PercentageOfCapitalGainTax" xlink:href="iinn-20241231.xsd#iinn_PercentageOfCapitalGainTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="iinn_PercentageOfCapitalGainTax" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/SubsequentEventsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <loc xlink:type="locator" xlink:label="iinn_SubsequentEventsDetailsTable" xlink:href="iinn-20241231.xsd#iinn_SubsequentEventsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="iinn_SubsequentEventsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_SubsequentEventsDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="iinn_SubsequentEventsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_TwoThousandNineteenEquityIncentivePlanMember" xlink:href="iinn-20241231.xsd#iinn_TwoThousandNineteenEquityIncentivePlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="iinn_TwoThousandNineteenEquityIncentivePlanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ExecutivesMember" xlink:href="iinn-20241231.xsd#iinn_ExecutivesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="iinn_ExecutivesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_DecemberPrivatePlacementMember" xlink:href="iinn-20241231.xsd#iinn_DecemberPrivatePlacementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="iinn_DecemberPrivatePlacementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromBankDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromBankDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromBankDebt" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_OfferingFeesAndOtherRelatedExpenses" xlink:href="iinn-20241231.xsd#iinn_OfferingFeesAndOtherRelatedExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="iinn_OfferingFeesAndOtherRelatedExpenses" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_ProceedsFromReceivedFund" xlink:href="iinn-20241231.xsd#iinn_ProceedsFromReceivedFund"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="iinn_ProceedsFromReceivedFund" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_RestrictedStockUnits" xlink:href="iinn-20241231.xsd#iinn_RestrictedStockUnits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="iinn_RestrictedStockUnits" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.inspiratechnologies.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain_0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_OrdinarySharesNoParValueMember" xlink:href="iinn-20241231.xsd#iinn_OrdinarySharesNoParValueMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="iinn_OrdinarySharesNoParValueMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="iinn_WarrantsToPurchaseOrdinarySharesMember" xlink:href="iinn-20241231.xsd#iinn_WarrantsToPurchaseOrdinarySharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="iinn_WarrantsToPurchaseOrdinarySharesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_AddressTypeDomain" xlink:to="dei_BusinessContactMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentRegistrationStatement" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentRegistrationStatement" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentShellCompanyReport" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelName" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_NoTradingSymbolFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_NoTradingSymbolFlag" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAccountingStandard" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAccountingStandard" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorOpinionTextBlock" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorOpinionTextBlock" order="35" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" order="36" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" order="37" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>41
<FILENAME>iinn-20241231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Mar 10 18:58:49 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Total non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total non- current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Shareholders&#8217; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and Shareholders&#8217; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss before tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0" xml:lang="en-US">Loss before taxation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Total comprehensive and net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Comprehensive and net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_NetIncomeLoss_lbl1" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLoss_lbl2" xml:lang="en-US">Loss for the period (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl2"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash at the beginning of the period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Cash, cash equivalents and restricted cash at the end of the period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Total cash, cash equivalents and restricted cash shown in the statement of cash flows</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">General [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Significant Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAbstract_lbl" xml:lang="en-US">Deposits [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAbstract" xlink:to="us-gaap_DepositsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xml:lang="en-US">Other Current Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl0" xml:lang="en-US">Other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">Inventory [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl0" xml:lang="en-US">Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl" xml:lang="en-US">Property and Equipment, Net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Cost, Beginning Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl0" xml:lang="en-US">Cost, Ending Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated depreciation, Beginning Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Accumulated depreciation, Ending Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Net book value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Property, plant and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrentAndNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrentAbstract_lbl" xml:lang="en-US">Other Accounts Payable [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Schedule of Other Accounts Payable [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl0" xml:lang="en-US">Other accounts payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract_lbl" xml:lang="en-US">Lease Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US">Schedule of Operating Right-of-Use Assets and Operating Lease Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Total operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl0" xml:lang="en-US">Present value of lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_lbl" xml:lang="en-US">Schedule of Right-of-Use Assets Over the Remaining Lease Periods [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total undiscounted lease payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_lbl" xml:lang="en-US">Finacial Liabilities at Fair Value [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xml:lang="en-US">Liability Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueByLiabilityClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Shareholders&#8217; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Shareholders&apos; Equity (Deficit) [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Shareholders&#8217; Equity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xml:lang="en-US">Schedule of Share Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Outstanding at ending of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl0" xml:lang="en-US">Outstanding at beginning of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average exercise price, ending Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xml:lang="en-US">Schedule of Loss Per Share Calculated Using the Weighted Average Number of Ordinary Shares and Pre-Funded Warrants [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentAbstract_lbl" xml:lang="en-US">Research and Development Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ResearchAndDevelopmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract_lbl" xml:lang="en-US">Schedule of Research and Development Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract_lbl" xml:lang="en-US">General and Administrative Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Statement of Income Location, Balance [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingAndMarketingExpenseAbstract_lbl" xml:lang="en-US">Sales and Marketing Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpenseAbstract" xlink:to="us-gaap_SellingAndMarketingExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_SellingAndMarketingExpense_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_SellingAndMarketingExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingAndMarketingExpense_lbl0" xml:lang="en-US">Sales and marketing expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_SellingAndMarketingExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xml:lang="en-US">Financial (Income) and Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfFinancialIncomeAndExpensesAbstract" xlink:href="iinn-20241231.xsd#iinn_ScheduleOfFinancialIncomeAndExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfFinancialIncomeAndExpensesAbstract_lbl" xml:lang="en-US">Schedule of Financial (Income) and Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfFinancialIncomeAndExpensesAbstract" xlink:to="iinn_ScheduleOfFinancialIncomeAndExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Total expenses (Income)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl0" xml:lang="en-US">Finance expenses (income), net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Taxes on Income [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US">Total deferred tax liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Net deferred taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfTheoreticalTaxAbstract" xlink:href="iinn-20241231.xsd#iinn_ScheduleOfTheoreticalTaxAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfTheoreticalTaxAbstract_lbl" xml:lang="en-US">Schedule of Theoretical Tax [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfTheoreticalTaxAbstract" xlink:to="iinn_ScheduleOfTheoreticalTaxAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_lbl" xml:lang="en-US">Share-Based Payment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of options, Outstanding at beginning of year (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0" xml:lang="en-US">Number of options, Options outstanding (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average Exercise price, Outstanding at beginning of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted average Exercise price, Options outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Parties [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title and Position [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepositsAssetsCurrent_lbl" xml:lang="en-US">Deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">Non-Current Assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right of use assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Trade accounts payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Operating lease liabilities, current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_lbl" xml:lang="en-US">Financial liabilities at fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_lbl0" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_lbl1" xml:lang="en-US">Derivative Liability, Current (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Non-Current Liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0" xml:lang="en-US">Operating lease liabilities long-term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Ordinary shares, no par value: Authorized 100,000,000 ordinary shares as of December 31, 2024 and December 31, 2023; Issued and outstanding 24,252,096 ordinary shares as of December 31, 2024 and 15,652,176 shares as of December 31, 2023</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Ordinary shares, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Ordinary shares, Authorized ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Ordinary shares, Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Ordinary shares, Issued ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Ordinary shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Ordinary shares, outstanding shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Ordinary shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl1" xml:lang="en-US">Total number of Ordinary Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Share capital and additional paid in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net loss per ordinary share, basic (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl0" xml:lang="en-US">Basic loss per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net loss per ordinary share, diluted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl0" xml:lang="en-US">Diluted loss per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average number of ordinary shares outstanding basic (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0" xml:lang="en-US">Weighted average number of Ordinary Shares and pre-funded warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average number of ordinary shares outstanding diluted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ChangesDuringThePeriodAbstract" xlink:href="iinn-20241231.xsd#iinn_ChangesDuringThePeriodAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ChangesDuringThePeriodAbstract_lbl" xml:lang="en-US">Changes during the period:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ChangesDuringThePeriodAbstract" xlink:to="iinn_ChangesDuringThePeriodAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of ordinary shares, private warrants and pre-funded warrants, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of ordinary shares, private warrants and pre-funded warrants, net (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1" xml:lang="en-US">Issued shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Exercise of options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercise of options (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinaryShares" xlink:href="iinn-20241231.xsd#iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinaryShares_lbl" xml:lang="en-US">Exercise of June 2024 pre-funded warrants into ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinaryShares" xlink:to="iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinaryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinarySharesinShares" xlink:href="iinn-20241231.xsd#iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinarySharesinShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinarySharesinShares_lbl" xml:lang="en-US">Exercise of June 2024 pre-funded warrants into ordinary shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinarySharesinShares" xlink:to="iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinarySharesinShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Restricted share unit (&#8220;RSU&#8221;)vesting</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Restricted share unit (&#8220;RSU&#8221;)vesting (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Issuance of ordinary shares- advisor fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Issuance of ordinary shares- advisor fees (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl0" xml:lang="en-US">Ordinary shares issued for consulting service agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ChangesDuringThePeriodAbstract0" xlink:href="iinn-20241231.xsd#iinn_ChangesDuringThePeriodAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ChangesDuringThePeriodAbstract0_lbl" xml:lang="en-US">Changes during the period:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ChangesDuringThePeriodAbstract0" xlink:to="iinn_ChangesDuringThePeriodAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US">Issuance of placement agent warrants (Note 11.3)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Issuance of ordinary shares (pursuant to an at-the-market facility)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Issuance of ordinary shares (pursuant to an at-the-market facility) (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0" xml:lang="en-US">Issued an aggregate shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments" xlink:href="iinn-20241231.xsd#iinn_StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments_lbl" xml:lang="en-US">Exercise of share based payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments" xlink:to="iinn_StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_StockIssuedDuringPeriodSharesStockOptionsExerciseOfShareBasedPayments" xlink:href="iinn-20241231.xsd#iinn_StockIssuedDuringPeriodSharesStockOptionsExerciseOfShareBasedPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_StockIssuedDuringPeriodSharesStockOptionsExerciseOfShareBasedPayments_lbl" xml:lang="en-US">Exercise of share based payments (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_StockIssuedDuringPeriodSharesStockOptionsExerciseOfShareBasedPayments" xlink:to="iinn_StockIssuedDuringPeriodSharesStockOptionsExerciseOfShareBasedPayments_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ChangesDuringThePeriodAbstract1" xlink:href="iinn-20241231.xsd#iinn_ChangesDuringThePeriodAbstract1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ChangesDuringThePeriodAbstract1_lbl" xml:lang="en-US">Changes during the period:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ChangesDuringThePeriodAbstract1" xlink:to="iinn_ChangesDuringThePeriodAbstract1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOW FROM OPERATING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash provided by operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForOtherLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForOtherLosses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProvisionForOtherLosses_lbl" xml:lang="en-US">Capital loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForOtherLosses" xlink:to="us-gaap_ProvisionForOtherLosses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share based compensation expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl0" xml:lang="en-US">Share based payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US">Share based compensation &#8211; placement agent warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US">Issuance cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_IssuanceOfOrdinarySharesAdvisorFees" xlink:href="iinn-20241231.xsd#iinn_IssuanceOfOrdinarySharesAdvisorFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_IssuanceOfOrdinarySharesAdvisorFees_lbl" xml:lang="en-US">Issuance of ordinary shares - advisor fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_IssuanceOfOrdinarySharesAdvisorFees" xlink:to="iinn_IssuanceOfOrdinarySharesAdvisorFees_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Prepayments of lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xml:lang="en-US">(Decrease) increase in trade accounts payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable_lbl" xml:lang="en-US">(Decrease) increase in other accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOW FROM INVESTING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided (used in) investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Issuance of ordinary shares, pre-funded warrants and ordinary warrants, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Exercise of options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Exercise of pre-funded warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Issuance of ordinary shares (issuances pursuant to an at-the-market facility)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0" xml:lang="en-US">Gross proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents and restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCash_lbl" xml:lang="en-US">Restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_OtherReceivableInConnectionToPrivatePlacement" xlink:href="iinn-20241231.xsd#iinn_OtherReceivableInConnectionToPrivatePlacement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_OtherReceivableInConnectionToPrivatePlacement_lbl" xml:lang="en-US">Other receivable in connection to December private placement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_OtherReceivableInConnectionToPrivatePlacement" xlink:to="iinn_OtherReceivableInConnectionToPrivatePlacement_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_AccruedIssuanceExpenses" xlink:href="iinn-20241231.xsd#iinn_AccruedIssuanceExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_AccruedIssuanceExpenses_lbl" xml:lang="en-US">Accrued issuance expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AccruedIssuanceExpenses" xlink:to="iinn_AccruedIssuanceExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_FinancialLiabilityPlacementAgentFee" xlink:href="iinn-20241231.xsd#iinn_FinancialLiabilityPlacementAgentFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_FinancialLiabilityPlacementAgentFee_lbl" xml:lang="en-US">Financial liability- placement agent fee (Note 10-A)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinancialLiabilityPlacementAgentFee" xlink:to="iinn_FinancialLiabilityPlacementAgentFee_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital" xlink:href="iinn-20241231.xsd#iinn_ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital_lbl" xml:lang="en-US">Share based compensation- placement agent warrants against additional paid in capital (Note 11)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital" xlink:to="iinn_ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_NonCashTransactions" xlink:href="iinn-20241231.xsd#iinn_NonCashTransactions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_NonCashTransactions_lbl" xml:lang="en-US">Total non cash transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NonCashTransactions" xlink:to="iinn_NonCashTransactions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet_lbl" xml:lang="en-US">Other expenses (income)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeDepositsWithFinancialInstitutions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestIncomeDepositsWithFinancialInstitutions_lbl" xml:lang="en-US">Interest income from deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" xlink:to="us-gaap_InterestIncomeDepositsWithFinancialInstitutions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Taxes on income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Income tax benefit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FairValueOptionChangesInFairValueGainLoss1_lbl" xml:lang="en-US">Evaluation of financial liability at fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:to="us-gaap_FairValueOptionChangesInFairValueGainLoss1_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ExpirationOfFinancialLiability" xlink:href="iinn-20241231.xsd#iinn_ExpirationOfFinancialLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="iinn_ExpirationOfFinancialLiability_lbl" xml:lang="en-US">Expiration of financial liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExpirationOfFinancialLiability" xlink:to="iinn_ExpirationOfFinancialLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInLeasingReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInLeasingReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInLeasingReceivables_lbl" xml:lang="en-US">Decrease (increase) in right of use assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInLeasingReceivables" xlink:to="us-gaap_IncreaseDecreaseInLeasingReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xml:lang="en-US">Decrease (increase) in other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">(Increase) decrease in inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xml:lang="en-US">Unrealized foreign exchange (gain) loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property, plant, and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForProceedsFromInvestments_lbl" xml:lang="en-US">Change in deposits, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromInvestments" xlink:to="us-gaap_PaymentsForProceedsFromInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_BusinessContactMember_lbl" xml:lang="en-US">Business Contact</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_OrdinarySharesNoParValueMember" xlink:href="iinn-20241231.xsd#iinn_OrdinarySharesNoParValueMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_OrdinarySharesNoParValueMember_lbl" xml:lang="en-US">Ordinary Shares, no par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_OrdinarySharesNoParValueMember" xlink:to="iinn_OrdinarySharesNoParValueMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_WarrantsToPurchaseOrdinarySharesMember" xlink:href="iinn-20241231.xsd#iinn_WarrantsToPurchaseOrdinarySharesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_WarrantsToPurchaseOrdinarySharesMember_lbl" xml:lang="en-US">Warrants to purchase Ordinary Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_WarrantsToPurchaseOrdinarySharesMember" xlink:to="iinn_WarrantsToPurchaseOrdinarySharesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Ordinary Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Ordinary Shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_CommonStockMember_lbl1" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Share capital and Additional Paid in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">GENERAL</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock" xlink:href="iinn-20241231.xsd#iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of Depreciation on Straight-Line Method, Over the Estimated Useful Life of the Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock" xlink:to="iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment" xlink:href="iinn-20241231.xsd#iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Annual depreciation rates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment" xlink:to="iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositLiabilitiesDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositLiabilitiesDisclosuresTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepositLiabilitiesDisclosuresTextBlock_lbl" xml:lang="en-US">DEPOSITS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositLiabilitiesDisclosuresTextBlock" xlink:to="us-gaap_DepositLiabilitiesDisclosuresTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl" xml:lang="en-US">OTHER CURRENT ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of Other Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestBearingDepositsInBanks" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestBearingDepositsInBanks"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestBearingDepositsInBanks_lbl" xml:lang="en-US">Institutions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestBearingDepositsInBanks" xlink:to="us-gaap_InterestBearingDepositsInBanks_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xml:lang="en-US">Restricted Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Others</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">INVENTORY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterials"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryRawMaterials_lbl" xml:lang="en-US">Raw materials</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcess"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xml:lang="en-US">Work in progress</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoods"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US">Finished good</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT, NET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of Property and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGrossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGrossAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGrossAbstract_lbl" xml:lang="en-US">Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGrossAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentGrossAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAdditions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAdditions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentAdditions_lbl" xml:lang="en-US">Additions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAdditions" xlink:to="us-gaap_PropertyPlantAndEquipmentAdditions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Accumulated depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_NetBookValueAbstract" xlink:href="iinn-20241231.xsd#iinn_NetBookValueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_NetBookValueAbstract_lbl" xml:lang="en-US">Net book value:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NetBookValueAbstract" xlink:to="iinn_NetBookValueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_NetBookValueAbstract0" xlink:href="iinn-20241231.xsd#iinn_NetBookValueAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_NetBookValueAbstract0_lbl" xml:lang="en-US">Net book value:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NetBookValueAbstract0" xlink:to="iinn_NetBookValueAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">OTHER ACCOUNTS PAYABLE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Other Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Employees&#8217; salaries and related liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_AccountsPayableToRelatedParties" xlink:href="iinn-20241231.xsd#iinn_AccountsPayableToRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_AccountsPayableToRelatedParties_lbl" xml:lang="en-US">Related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AccountsPayableToRelatedParties" xlink:to="iinn_AccountsPayableToRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">LEASE LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfLesseeOperatingLeasesDisclosureTableTextBlock" xlink:href="iinn-20241231.xsd#iinn_ScheduleOfLesseeOperatingLeasesDisclosureTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ScheduleOfLesseeOperatingLeasesDisclosureTableTextBlock_lbl" xml:lang="en-US">Schedule of Operating Right-of-Use Assets and Operating Lease Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfLesseeOperatingLeasesDisclosureTableTextBlock" xlink:to="iinn_ScheduleOfLesseeOperatingLeasesDisclosureTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted Average of Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted-average discount rate - operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0" xml:lang="en-US">Lease liability, weighted-average discount rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Right-of-Use Assets Over the Remaining Lease Periods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">FINACIAL LIABILITIES AT FAIR VALUE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" xml:lang="en-US">Schedule of Financial Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:to="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">SHAREHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockholdersEquityTableTextBlock_lbl" xml:lang="en-US">Schedule of Share Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of Movement in Warrants Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Weighted average remaining contractual term (in years), ending Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsIssued" xlink:href="iinn-20241231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsIssued_lbl" xml:lang="en-US">Number of Warrants, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsIssued" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeighted-averageExercisePriceIssued" xlink:href="iinn-20241231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeighted-averageExercisePriceIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeighted-averageExercisePriceIssued_lbl" xml:lang="en-US">Weighted-average exercise price, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeighted-averageExercisePriceIssued" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeighted-averageExercisePriceIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms" xlink:href="iinn-20241231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Weighted average remaining contractual term (in years), Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:href="iinn-20241231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_lbl" xml:lang="en-US">Number of Warrants, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue" xlink:href="iinn-20241231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average exercise price, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms" xlink:href="iinn-20241231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Weighted average remaining contractual term (in years), Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:href="iinn-20241231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_lbl" xml:lang="en-US">Number of Warrants, Expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue" xlink:href="iinn-20241231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average exercise price, Expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms" xlink:href="iinn-20241231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Weighted average remaining contractual term (in years), Expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US">Schedule of Information about the Company&#8217;s Outstanding Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xml:lang="en-US">Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Warrants outstanding (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl" xml:lang="en-US">Expiration date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentExpirationDate" xlink:href="iinn-20241231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentExpirationDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentExpirationDate_lbl" xml:lang="en-US">Expiration date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentExpirationDate" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentExpirationDate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of Loss Per Share Calculated Using the Weighted Average Number of Ordinary Shares and Pre-Funded Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl" xml:lang="en-US">RESEARCH AND DEVELOPMENT EXPENSES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock_lbl" xml:lang="en-US">Schedule of Research and Development Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LaborAndRelatedExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LaborAndRelatedExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LaborAndRelatedExpense_lbl" xml:lang="en-US">Salary and related expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LaborAndRelatedExpense" xlink:to="us-gaap_LaborAndRelatedExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLaborRelatedExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLaborRelatedExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLaborRelatedExpenses_lbl" xml:lang="en-US">Materials and related expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLaborRelatedExpenses" xlink:to="us-gaap_OtherLaborRelatedExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_lbl" xml:lang="en-US">Share based payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:to="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationNonproduction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationNonproduction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationNonproduction_lbl" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationNonproduction" xlink:to="us-gaap_DepreciationNonproduction_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_Subcontractors" xlink:href="iinn-20241231.xsd#iinn_Subcontractors"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_Subcontractors_lbl" xml:lang="en-US">Subcontractors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_Subcontractors" xlink:to="iinn_Subcontractors_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_GeneralAndAdministrativeExpensesTextBlock" xlink:href="iinn-20241231.xsd#iinn_GeneralAndAdministrativeExpensesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_GeneralAndAdministrativeExpensesTextBlock_lbl" xml:lang="en-US">GENERAL AND ADMINISTRATIVE EXPENSES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_GeneralAndAdministrativeExpensesTextBlock" xlink:to="iinn_GeneralAndAdministrativeExpensesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" xlink:href="iinn-20241231.xsd#iinn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock_lbl" xml:lang="en-US">Schedule of General and Administrative Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" xlink:to="iinn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfessionalFees_lbl" xml:lang="en-US">Professional fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficersCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficersCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OfficersCompensation_lbl" xml:lang="en-US">Salary and related expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficersCompensation" xlink:to="us-gaap_OfficersCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Share-based payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl0" xml:lang="en-US">Number of options, Share-based payment expenses (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl1" xml:lang="en-US">Number of RSUs, Share-based payment expenses (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl2" xml:lang="en-US">Share-based payment expenses (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl2"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LegalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LegalFees_lbl" xml:lang="en-US">Director fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralInsuranceExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralInsuranceExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralInsuranceExpense_lbl" xml:lang="en-US">Insurance expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralInsuranceExpense" xlink:to="us-gaap_GeneralInsuranceExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostMaintenance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostMaintenance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostMaintenance_lbl" xml:lang="en-US">Office maintenance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostMaintenance" xlink:to="us-gaap_CostMaintenance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TravelAndEntertainmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TravelAndEntertainmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TravelAndEntertainmentExpense_lbl" xml:lang="en-US">Travel abroad</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TravelAndEntertainmentExpense" xlink:to="us-gaap_TravelAndEntertainmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_FundraisingExpenses" xlink:href="iinn-20241231.xsd#iinn_FundraisingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_FundraisingExpenses_lbl" xml:lang="en-US">Fundraising expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FundraisingExpenses" xlink:to="iinn_FundraisingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherGeneralExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherGeneralExpense_lbl" xml:lang="en-US">Others</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralExpense" xlink:to="us-gaap_OtherGeneralExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_SalesAndMarketingExpensesTextBlock" xlink:href="iinn-20241231.xsd#iinn_SalesAndMarketingExpensesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_SalesAndMarketingExpensesTextBlock_lbl" xml:lang="en-US">SALES AND MARKETING EXPENSES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SalesAndMarketingExpensesTextBlock" xlink:to="iinn_SalesAndMarketingExpensesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock" xlink:href="iinn-20241231.xsd#iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock_lbl" xml:lang="en-US">Schedule of Sales and Marketing Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock" xlink:to="iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold_lbl" xml:lang="en-US">Share-based payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold" xlink:to="us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherSellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherSellingAndMarketingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherSellingAndMarketingExpense_lbl" xml:lang="en-US">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherSellingAndMarketingExpense" xlink:to="us-gaap_OtherSellingAndMarketingExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock_lbl" xml:lang="en-US">FINANCIAL (INCOME) AND EXPENSES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:to="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of Financial (Income) and Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:href="iinn-20241231.xsd#iinn_RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss_lbl" xml:lang="en-US">Revaluation of financial liabilities at fair value through profit or loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:to="iinn_RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">Foreign currency transaction income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xml:lang="en-US">Others</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">TAXES ON INCOME</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xml:lang="en-US">Deferred tax assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforward</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_DeferredTaxAssetsAccruedExpenses" xlink:href="iinn-20241231.xsd#iinn_DeferredTaxAssetsAccruedExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_DeferredTaxAssetsAccruedExpenses_lbl" xml:lang="en-US">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DeferredTaxAssetsAccruedExpenses" xlink:to="iinn_DeferredTaxAssetsAccruedExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">R&amp;D temporary differences</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_DeferredTaxAssetsFundRaisingCost2023" xlink:href="iinn-20241231.xsd#iinn_DeferredTaxAssetsFundRaisingCost2023"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_DeferredTaxAssetsFundRaisingCost2023_lbl" xml:lang="en-US">Fund raising costs 2023</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DeferredTaxAssetsFundRaisingCost2023" xlink:to="iinn_DeferredTaxAssetsFundRaisingCost2023_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US">Deferred tax liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfTheoreticalTaxTableTextBlock" xlink:href="iinn-20241231.xsd#iinn_ScheduleOfTheoreticalTaxTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ScheduleOfTheoreticalTaxTableTextBlock_lbl" xml:lang="en-US">Schedule of Theoretical Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfTheoreticalTaxTableTextBlock" xlink:to="iinn_ScheduleOfTheoreticalTaxTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Theoretical tax credit at applicable statutory rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">SHARE-BASED PAYMENT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Measure the Fair Value of the Option at Grant Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term (vesting period)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife" xlink:href="iinn-20241231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife_lbl" xml:lang="en-US">Contractual life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Free risk rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Options to Services Providers and Advisers Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsReclassifiedToEmployeesAndDirectors" xlink:href="iinn-20241231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsReclassifiedToEmployeesAndDirectors"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsReclassifiedToEmployeesAndDirectors_lbl" xml:lang="en-US">Number of options, Reclassified to employees and directors (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsReclassifiedToEmployeesAndDirectors" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsReclassifiedToEmployeesAndDirectors_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceReclassifiedToEmployeesAndDirectors" xlink:href="iinn-20241231.xsd#iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceReclassifiedToEmployeesAndDirectors"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceReclassifiedToEmployeesAndDirectors_lbl" xml:lang="en-US">Weighted average Exercise price, Reclassified to employees and directors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceReclassifiedToEmployeesAndDirectors" xlink:to="iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceReclassifiedToEmployeesAndDirectors_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of options, Granted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0" xml:lang="en-US">Grant shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" xml:lang="en-US">Number of shares granted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average Exercise price, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi" xlink:href="iinn-20241231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi_lbl" xml:lang="en-US">Number of options, Exercised (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average Exercise price, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Exercise price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of options, Forfeited (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average Exercise price, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of options, Options exercisable (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0" xml:lang="en-US">Exercisable ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average Exercise price, Options exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of RSUs to Services Providers and Advisers Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of RSUs, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Number of RSUs, Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested" xlink:href="iinn-20241231.xsd#iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested_lbl" xml:lang="en-US">Number of RSUs, RSU&#8217;s Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested" xlink:to="iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Number of RSUs, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Shareholders and Other Related Parties&#8217; Benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NatureOfCommonOwnershipOrManagementControlRelationships" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfCommonOwnershipOrManagementControlRelationships"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NatureOfCommonOwnershipOrManagementControlRelationships_lbl" xml:lang="en-US">Nature of transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfCommonOwnershipOrManagementControlRelationships" xlink:to="us-gaap_NatureOfCommonOwnershipOrManagementControlRelationships_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xml:lang="en-US">Balance with related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_IIAParticipation" xlink:href="iinn-20241231.xsd#iinn_IIAParticipation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="iinn_IIAParticipation_lbl" xml:lang="en-US">IIA participation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_IIAParticipation" xlink:to="iinn_IIAParticipation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xml:lang="en-US">Finance expense in respect of lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_DeferredTaxLiabilitiesOperatingLeaseLiability" xlink:href="iinn-20241231.xsd#iinn_DeferredTaxLiabilitiesOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="iinn_DeferredTaxLiabilitiesOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DeferredTaxLiabilitiesOperatingLeaseLiability" xlink:to="iinn_DeferredTaxLiabilitiesOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_EffectiveIncomeTaxTheoreticalTaxCredit" xlink:href="iinn-20241231.xsd#iinn_EffectiveIncomeTaxTheoreticalTaxCredit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="iinn_EffectiveIncomeTaxTheoreticalTaxCredit_lbl" xml:lang="en-US">Theoretical tax credit at applicable statutory rate: 23%</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_EffectiveIncomeTaxTheoreticalTaxCredit" xlink:to="iinn_EffectiveIncomeTaxTheoreticalTaxCredit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl" xml:lang="en-US">Non-allowable expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized" xlink:href="iinn-20241231.xsd#iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized_lbl" xml:lang="en-US">Temporary differences and tax losses for which no Deferred Tax Asset is recognized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized" xlink:to="iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computers [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">R&amp;D equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and office equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl0" xml:lang="en-US">Leasehold improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_RDEquipmentMember" xlink:href="iinn-20241231.xsd#iinn_RDEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_RDEquipmentMember_lbl" xml:lang="en-US">R&amp;D equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RDEquipmentMember" xlink:to="iinn_RDEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_lbl" xml:lang="en-US">Financial liability [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:to="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_PrivateWarrantsMember" xlink:href="iinn-20241231.xsd#iinn_PrivateWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_PrivateWarrantsMember_lbl" xml:lang="en-US">Private warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PrivateWarrantsMember" xlink:to="iinn_PrivateWarrantsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="iinn_PrivateWarrantsMember_lbl0" xml:lang="en-US">Private Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PrivateWarrantsMember" xlink:to="iinn_PrivateWarrantsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantMember_lbl0" xml:lang="en-US">Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_ExercisePrice55Member" xlink:href="iinn-20241231.xsd#iinn_ExercisePrice55Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ExercisePrice55Member_lbl" xml:lang="en-US">5.5 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExercisePrice55Member" xlink:to="iinn_ExercisePrice55Member_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ExercisePrice55TwoMember" xlink:href="iinn-20241231.xsd#iinn_ExercisePrice55TwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ExercisePrice55TwoMember_lbl" xml:lang="en-US">5.5 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExercisePrice55TwoMember" xlink:to="iinn_ExercisePrice55TwoMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_Exercise6875Member" xlink:href="iinn-20241231.xsd#iinn_Exercise6875Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_Exercise6875Member_lbl" xml:lang="en-US">6.875 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_Exercise6875Member" xlink:to="iinn_Exercise6875Member_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ExercisePriceOnePointSixMember" xlink:href="iinn-20241231.xsd#iinn_ExercisePriceOnePointSixMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ExercisePriceOnePointSixMember_lbl" xml:lang="en-US">1.6 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExercisePriceOnePointSixMember" xlink:to="iinn_ExercisePriceOnePointSixMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ExercisePrice156Member" xlink:href="iinn-20241231.xsd#iinn_ExercisePrice156Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ExercisePrice156Member_lbl" xml:lang="en-US">1.56	[Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExercisePrice156Member" xlink:to="iinn_ExercisePrice156Member_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ExercisePriceOnePointOneMember" xlink:href="iinn-20241231.xsd#iinn_ExercisePriceOnePointOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ExercisePriceOnePointOneMember_lbl" xml:lang="en-US">1.1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExercisePriceOnePointOneMember" xlink:to="iinn_ExercisePriceOnePointOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ExercisePrice0001Member" xlink:href="iinn-20241231.xsd#iinn_ExercisePrice0001Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ExercisePrice0001Member_lbl" xml:lang="en-US">0.001 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExercisePrice0001Member" xlink:to="iinn_ExercisePrice0001Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ServicesProvidersAndAdvisersMember" xlink:href="iinn-20241231.xsd#iinn_ServicesProvidersAndAdvisersMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ServicesProvidersAndAdvisersMember_lbl" xml:lang="en-US">Services Providers and Advisers [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ServicesProvidersAndAdvisersMember" xlink:to="iinn_ServicesProvidersAndAdvisersMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_EmployeesAndDirectorsMember" xlink:href="iinn-20241231.xsd#iinn_EmployeesAndDirectorsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_EmployeesAndDirectorsMember_lbl" xml:lang="en-US">Employees and Directors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_EmployeesAndDirectorsMember" xlink:to="iinn_EmployeesAndDirectorsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">RSUs [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl0" xml:lang="en-US">Vested RSUs [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_OfficersAndDirectorsMember" xlink:href="iinn-20241231.xsd#iinn_OfficersAndDirectorsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_OfficersAndDirectorsMember_lbl" xml:lang="en-US">Officers and Directors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_OfficersAndDirectorsMember" xlink:to="iinn_OfficersAndDirectorsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_OfficerMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OfficerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_OfficerMember_lbl" xml:lang="en-US">Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OfficerMember" xlink:to="srt_OfficerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US">Director [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="srt_DirectorMember_lbl0" xml:lang="en-US">Directors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xml:lang="en-US">Short-Term Debt, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US">Financial Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xml:lang="en-US">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board of Directors Oversight [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Role of Management [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Purchase price of per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Net proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Pre funded warrant, per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0" xml:lang="en-US">Exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1" xml:lang="en-US">Exercise price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PartnersCapitalAccountPublicSaleOfUnitsNetOfOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PartnersCapitalAccountPublicSaleOfUnitsNetOfOfferingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PartnersCapitalAccountPublicSaleOfUnitsNetOfOfferingCosts_lbl" xml:lang="en-US">Additional offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PartnersCapitalAccountPublicSaleOfUnitsNetOfOfferingCosts" xlink:to="us-gaap_PartnersCapitalAccountPublicSaleOfUnitsNetOfOfferingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_PercentageOfOrdinaryShares" xlink:href="iinn-20241231.xsd#iinn_PercentageOfOrdinaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_PercentageOfOrdinaryShares_lbl" xml:lang="en-US">Percentage of ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PercentageOfOrdinaryShares" xlink:to="iinn_PercentageOfOrdinaryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_PlacementAgentWarrantsFairValue" xlink:href="iinn-20241231.xsd#iinn_PlacementAgentWarrantsFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_PlacementAgentWarrantsFairValue_lbl" xml:lang="en-US">Placement agent warrants fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PlacementAgentWarrantsFairValue" xlink:to="iinn_PlacementAgentWarrantsFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionExercisePriceIncrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionExercisePriceIncrease_lbl" xml:lang="en-US">Exercise price of per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionExercisePriceIncrease" xlink:to="us-gaap_StockOptionExercisePriceIncrease_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_AggregateProceedsReceived" xlink:href="iinn-20241231.xsd#iinn_AggregateProceedsReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_AggregateProceedsReceived_lbl" xml:lang="en-US">Gross proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AggregateProceedsReceived" xlink:to="iinn_AggregateProceedsReceived_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_AdditionalOfferingCosts" xlink:href="iinn-20241231.xsd#iinn_AdditionalOfferingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_AdditionalOfferingCosts_lbl" xml:lang="en-US">Additional offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AdditionalOfferingCosts" xlink:to="iinn_AdditionalOfferingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xml:lang="en-US">Financial liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl0" xml:lang="en-US">Financial liability fair value (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax_lbl" xml:lang="en-US">Incurred accumulated losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" xlink:to="us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xml:lang="en-US">Employees monthly deposits rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermInvestments_lbl" xml:lang="en-US">Short-term deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Deposits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Deposits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Deposits_lbl" xml:lang="en-US">Deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Deposits" xlink:to="us-gaap_Deposits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtPercentageBearingFixedInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate_lbl" xml:lang="en-US">Fixed annual interest percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" xlink:to="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_AggregateBudget" xlink:href="iinn-20241231.xsd#iinn_AggregateBudget"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_AggregateBudget_lbl" xml:lang="en-US">Aggregate budget</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AggregateBudget" xlink:to="iinn_AggregateBudget_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_PercentageOfApprovedBudget" xlink:href="iinn-20241231.xsd#iinn_PercentageOfApprovedBudget"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_PercentageOfApprovedBudget_lbl" xml:lang="en-US">Percentage of approved budget</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PercentageOfApprovedBudget" xlink:to="iinn_PercentageOfApprovedBudget_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ProjectBudgetAggregateAmount" xlink:href="iinn-20241231.xsd#iinn_ProjectBudgetAggregateAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ProjectBudgetAggregateAmount_lbl" xml:lang="en-US">Project budget aggregate amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ProjectBudgetAggregateAmount" xlink:to="iinn_ProjectBudgetAggregateAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherReceivables_lbl" xml:lang="en-US">Total funds received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_RoyaltiesPercentage" xlink:href="iinn-20241231.xsd#iinn_RoyaltiesPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_RoyaltiesPercentage_lbl" xml:lang="en-US">Percentage of royalties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RoyaltiesPercentage" xlink:to="iinn_RoyaltiesPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ContingentUponFutureSales" xlink:href="iinn-20241231.xsd#iinn_ContingentUponFutureSales"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ContingentUponFutureSales_lbl" xml:lang="en-US">Contingent upon future sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ContingentUponFutureSales" xlink:to="iinn_ContingentUponFutureSales_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForRent_lbl" xml:lang="en-US">Rent termination penalty</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_MonthlyDeductionFromTerminationFee" xlink:href="iinn-20241231.xsd#iinn_MonthlyDeductionFromTerminationFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_MonthlyDeductionFromTerminationFee_lbl" xml:lang="en-US">Monthly deduction from termination fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_MonthlyDeductionFromTerminationFee" xlink:to="iinn_MonthlyDeductionFromTerminationFee_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLeasePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromLeasePayments_lbl" xml:lang="en-US">Lease payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLeasePayments" xlink:to="us-gaap_ProceedsFromLeasePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Lease expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_PercentageOfFutureLeasePaymentsDiscounted" xlink:href="iinn-20241231.xsd#iinn_PercentageOfFutureLeasePaymentsDiscounted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_PercentageOfFutureLeasePaymentsDiscounted_lbl" xml:lang="en-US">Percentage of future lease payments discounted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PercentageOfFutureLeasePaymentsDiscounted" xlink:to="iinn_PercentageOfFutureLeasePaymentsDiscounted_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_PercentageForCarsLeaseAgreementCancellationPenalty" xlink:href="iinn-20241231.xsd#iinn_PercentageForCarsLeaseAgreementCancellationPenalty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_PercentageForCarsLeaseAgreementCancellationPenalty_lbl" xml:lang="en-US">Percentage for car lease agreement cancellation penalty</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PercentageForCarsLeaseAgreementCancellationPenalty" xlink:to="iinn_PercentageForCarsLeaseAgreementCancellationPenalty_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_PercentageOfPayFees" xlink:href="iinn-20241231.xsd#iinn_PercentageOfPayFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_PercentageOfPayFees_lbl" xml:lang="en-US">Percentage of pay fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PercentageOfPayFees" xlink:to="iinn_PercentageOfPayFees_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xml:lang="en-US">Aggregate purchase (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityMeasurementInput"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput_lbl" xml:lang="en-US">Fair value of private warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilityMeasurementInput" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Options exercise shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl0" xml:lang="en-US">Vested options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Sale of stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_PurchasePricePerShare" xlink:href="iinn-20241231.xsd#iinn_PurchasePricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_PurchasePricePerShare_lbl" xml:lang="en-US">Purchase price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PurchasePricePerShare" xlink:to="iinn_PurchasePricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Pre funded warrant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ClassOfPrivateWarrantOrRightOutstanding" xlink:href="iinn-20241231.xsd#iinn_ClassOfPrivateWarrantOrRightOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ClassOfPrivateWarrantOrRightOutstanding_lbl" xml:lang="en-US">Private warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ClassOfPrivateWarrantOrRightOutstanding" xlink:to="iinn_ClassOfPrivateWarrantOrRightOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_NumberofAdditionalOrdinaryShares" xlink:href="iinn-20241231.xsd#iinn_NumberofAdditionalOrdinaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_NumberofAdditionalOrdinaryShares_lbl" xml:lang="en-US">Number of additional shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NumberofAdditionalOrdinaryShares" xlink:to="iinn_NumberofAdditionalOrdinaryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredOfferingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US">Offering cost (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProductWarrantyLiquidationProceedsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductWarrantyLiquidationProceedsPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProductWarrantyLiquidationProceedsPercentage_lbl" xml:lang="en-US">Percentage of agreement warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductWarrantyLiquidationProceedsPercentage" xlink:to="us-gaap_ProductWarrantyLiquidationProceedsPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Purchase of warrant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Warrants expire, term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Fair value of the warrant (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_NumberOfSharesPerUnits" xlink:href="iinn-20241231.xsd#iinn_NumberOfSharesPerUnits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_NumberOfSharesPerUnits_lbl" xml:lang="en-US">Number of shares per units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NumberOfSharesPerUnits" xlink:to="iinn_NumberOfSharesPerUnits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xml:lang="en-US">Net proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US">Exercise amount of warrants (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Corporate tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Carryforward tax losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Grant shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Vesting period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl" xml:lang="en-US">Option term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xml:lang="en-US">Option to purchase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US">Vested shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_CapitalGainTaxRate" xlink:href="iinn-20241231.xsd#iinn_CapitalGainTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_CapitalGainTaxRate_lbl" xml:lang="en-US">Capital gain tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_CapitalGainTaxRate" xlink:to="iinn_CapitalGainTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_PercentageOfCapitalGainTax" xlink:href="iinn-20241231.xsd#iinn_PercentageOfCapitalGainTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_PercentageOfCapitalGainTax_lbl" xml:lang="en-US">Percentage of capital gain tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PercentageOfCapitalGainTax" xlink:to="iinn_PercentageOfCapitalGainTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Proceeds from private placement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromBankDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromBankDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromBankDebt_lbl" xml:lang="en-US">Receiving bank</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromBankDebt" xlink:to="us-gaap_ProceedsFromBankDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_OfferingFeesAndOtherRelatedExpenses" xlink:href="iinn-20241231.xsd#iinn_OfferingFeesAndOtherRelatedExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_OfferingFeesAndOtherRelatedExpenses_lbl" xml:lang="en-US">Offering fees and other related expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_OfferingFeesAndOtherRelatedExpenses" xlink:to="iinn_OfferingFeesAndOtherRelatedExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ProceedsFromReceivedFund" xlink:href="iinn-20241231.xsd#iinn_ProceedsFromReceivedFund"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ProceedsFromReceivedFund_lbl" xml:lang="en-US">Received fund</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ProceedsFromReceivedFund" xlink:to="iinn_ProceedsFromReceivedFund_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US">Number of grant shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_lbl" xml:lang="en-US">Vested shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_RestrictedStockUnits" xlink:href="iinn-20241231.xsd#iinn_RestrictedStockUnits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_RestrictedStockUnits_lbl" xml:lang="en-US">Restricted stock units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RestrictedStockUnits" xlink:to="iinn_RestrictedStockUnits_lbl"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrarGpi3WKEtaAw66u01Fz01dWXY8Co/0nt/EYPpxJQpmucNPntkKGDUIzqiVXTghuh97D+3HoPuNe26jHPIaw4lyMqYvKxFlhkbYBWIUcgKRgNZdvBJC1M0l0xZMZd9F+M0zfHyxoKPMqOYWCT/B42d+bXUalw9kCR7ECrTZgyIl6CQNUWcHwWg7YyEKbKXVQrc457FUG7zZJKYSUUC+IL4iKzuqc3lzwnQ2dokFxrCaevH4cZ3wAdRaitsTLXse0F0xvf4jN2RRLJaldIZ9GAqrcdzGD0FDFM=] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xml:lang="en-US">Total grant fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xml:lang="en-US">Vesting period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Foreign Currency</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GovernmentAssistancePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistancePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GovernmentAssistancePolicyTextBlock_lbl" xml:lang="en-US">Government Grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentAssistancePolicyTextBlock" xlink:to="us-gaap_GovernmentAssistancePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_FinanceIncomeAndExpensesPolicyTextBlock" xlink:href="iinn-20241231.xsd#iinn_FinanceIncomeAndExpensesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_FinanceIncomeAndExpensesPolicyTextBlock_lbl" xml:lang="en-US">Finance Income and Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinanceIncomeAndExpensesPolicyTextBlock" xlink:to="iinn_FinanceIncomeAndExpensesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Current Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xml:lang="en-US">Warrants and Pre-Funded Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_SeverancePolicyTextBlock" xlink:href="iinn-20241231.xsd#iinn_SeverancePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_SeverancePolicyTextBlock_lbl" xml:lang="en-US">Severance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SeverancePolicyTextBlock" xlink:to="iinn_SeverancePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Basic and Diluted Loss Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of Credit Risk</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_PreFundedWarrantsMember" xlink:href="iinn-20241231.xsd#iinn_PreFundedWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_PreFundedWarrantsMember_lbl" xml:lang="en-US">Pre-Funded Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PreFundedWarrantsMember" xlink:to="iinn_PreFundedWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_JunePreFundedWarrantsMember" xlink:href="iinn-20241231.xsd#iinn_JunePreFundedWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_JunePreFundedWarrantsMember_lbl" xml:lang="en-US">June Pre-Funded Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_JunePreFundedWarrantsMember" xlink:to="iinn_JunePreFundedWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_JunePlacementAgentWarrantsMember" xlink:href="iinn-20241231.xsd#iinn_JunePlacementAgentWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_JunePlacementAgentWarrantsMember_lbl" xml:lang="en-US">June Placement Agent Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_JunePlacementAgentWarrantsMember" xlink:to="iinn_JunePlacementAgentWarrantsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="iinn_JunePlacementAgentWarrantsMember_lbl0" xml:lang="en-US">Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_JunePlacementAgentWarrantsMember" xlink:to="iinn_JunePlacementAgentWarrantsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_DecemberPrivatePlacementMember" xlink:href="iinn-20241231.xsd#iinn_DecemberPrivatePlacementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_DecemberPrivatePlacementMember_lbl" xml:lang="en-US">December Private Placement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DecemberPrivatePlacementMember" xlink:to="iinn_DecemberPrivatePlacementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_DecemberPreFundedWarrantsMember" xlink:href="iinn-20241231.xsd#iinn_DecemberPreFundedWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_DecemberPreFundedWarrantsMember_lbl" xml:lang="en-US">December Pre-Funded Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DecemberPreFundedWarrantsMember" xlink:to="iinn_DecemberPreFundedWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_WeightedAverageMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_WeightedAverageMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_WeightedAverageMember_lbl" xml:lang="en-US">Weighted Average [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_WeightedAverageMember" xlink:to="srt_WeightedAverageMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_BankLeumiMember" xlink:href="iinn-20241231.xsd#iinn_BankLeumiMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_BankLeumiMember_lbl" xml:lang="en-US">Bank Leumi [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_BankLeumiMember" xlink:to="iinn_BankLeumiMember_lbl"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_US_lbl" xml:lang="en-US">Israel [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="country_US_lbl0" xml:lang="en-US">USD [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl0"/>
    <loc xlink:type="locator" xlink:label="country_IL" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_IL"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_IL_lbl" xml:lang="en-US">Israel [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_IL" xlink:to="country_IL_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_December2024PrivatePlacementMember" xlink:href="iinn-20241231.xsd#iinn_December2024PrivatePlacementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_December2024PrivatePlacementMember_lbl" xml:lang="en-US">December 2024 Private Placement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_December2024PrivatePlacementMember" xlink:to="iinn_December2024PrivatePlacementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Risk-free Interest Rate [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl0" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Expected Volatility [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl0" xml:lang="en-US">Measurement Input, Price Volatility [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xml:lang="en-US">Expected Dividend Yield [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl0" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US">Expected Term of Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_RothCapitalPartnersLLCMember" xlink:href="iinn-20241231.xsd#iinn_RothCapitalPartnersLLCMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_RothCapitalPartnersLLCMember_lbl" xml:lang="en-US">Roth Capital Partners, LLC [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RothCapitalPartnersLLCMember" xlink:to="iinn_RothCapitalPartnersLLCMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_RegisteredDirectOfferingMember" xlink:href="iinn-20241231.xsd#iinn_RegisteredDirectOfferingMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_RegisteredDirectOfferingMember_lbl" xml:lang="en-US">Registered Direct Offering [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RegisteredDirectOfferingMember" xlink:to="iinn_RegisteredDirectOfferingMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_PlacementAgentWarrantsMember" xlink:href="iinn-20241231.xsd#iinn_PlacementAgentWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_PlacementAgentWarrantsMember_lbl" xml:lang="en-US">Placement Agent Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PlacementAgentWarrantsMember" xlink:to="iinn_PlacementAgentWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_TwoThousandTwentyFourAprilOfferingMember" xlink:href="iinn-20241231.xsd#iinn_TwoThousandTwentyFourAprilOfferingMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_TwoThousandTwentyFourAprilOfferingMember_lbl" xml:lang="en-US">2024 April Offering [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TwoThousandTwentyFourAprilOfferingMember" xlink:to="iinn_TwoThousandTwentyFourAprilOfferingMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_TwoThousandTwentyFourJuneOfferingMember" xlink:href="iinn-20241231.xsd#iinn_TwoThousandTwentyFourJuneOfferingMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_TwoThousandTwentyFourJuneOfferingMember_lbl" xml:lang="en-US">2024 June Offering [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TwoThousandTwentyFourJuneOfferingMember" xlink:to="iinn_TwoThousandTwentyFourJuneOfferingMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_DecemberPrivateWarrantsMember" xlink:href="iinn-20241231.xsd#iinn_DecemberPrivateWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_DecemberPrivateWarrantsMember_lbl" xml:lang="en-US">December Private Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DecemberPrivateWarrantsMember" xlink:to="iinn_DecemberPrivateWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">IPO [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_DecemberPrivateOfferingMember" xlink:href="iinn-20241231.xsd#iinn_DecemberPrivateOfferingMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_DecemberPrivateOfferingMember_lbl" xml:lang="en-US">December Private Offering [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DecemberPrivateOfferingMember" xlink:to="iinn_DecemberPrivateOfferingMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_BoardOfDirectorsChairmanMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl" xml:lang="en-US">Board of Directors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_BoardOfDirectorsChairmanMember" xlink:to="srt_BoardOfDirectorsChairmanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_AdvisoryBoardMembersMember" xlink:href="iinn-20241231.xsd#iinn_AdvisoryBoardMembersMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_AdvisoryBoardMembersMember_lbl" xml:lang="en-US">Advisory Board Members [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AdvisoryBoardMembersMember" xlink:to="iinn_AdvisoryBoardMembersMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_MedicalBoardMembersMember" xlink:href="iinn-20241231.xsd#iinn_MedicalBoardMembersMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_MedicalBoardMembersMember_lbl" xml:lang="en-US">Medical Board Members [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_MedicalBoardMembersMember" xlink:to="iinn_MedicalBoardMembersMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Share Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_TwoThousandNineteenEquityIncentivePlanMember" xlink:href="iinn-20241231.xsd#iinn_TwoThousandNineteenEquityIncentivePlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_TwoThousandNineteenEquityIncentivePlanMember_lbl" xml:lang="en-US">2019 Equity Incentive Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TwoThousandNineteenEquityIncentivePlanMember" xlink:to="iinn_TwoThousandNineteenEquityIncentivePlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockMember_lbl" xml:lang="en-US">Employee Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_EmployeesDirectorsAndSubcontractorsMember" xlink:href="iinn-20241231.xsd#iinn_EmployeesDirectorsAndSubcontractorsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_EmployeesDirectorsAndSubcontractorsMember_lbl" xml:lang="en-US">Employees, Directors and Subcontractors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_EmployeesDirectorsAndSubcontractorsMember" xlink:to="iinn_EmployeesDirectorsAndSubcontractorsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ExecutivesMember" xlink:href="iinn-20241231.xsd#iinn_ExecutivesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="iinn_ExecutivesMember_lbl" xml:lang="en-US">Executives [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExecutivesMember" xlink:to="iinn_ExecutivesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_SignificantAccountingPoliciesScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsDetailsTable" xlink:href="iinn-20241231.xsd#iinn_SignificantAccountingPoliciesScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_SignificantAccountingPoliciesScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsDetailsTable_lbl" xml:lang="en-US">Significant Accounting Policies - Schedule of Depreciation on Straight-Line Method, Over the Estimated Useful Life of the Assets (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SignificantAccountingPoliciesScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsDetailsTable" xlink:to="iinn_SignificantAccountingPoliciesScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Schedule of Depreciation on Straight-Line Method, Over the Estimated Useful Life of the Assets [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl0" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xml:lang="en-US">Fair Value by Liability Class [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_FinacialLiabilitiesatFairValueScheduleofFinancialLiabilityDetailsTable" xlink:href="iinn-20241231.xsd#iinn_FinacialLiabilitiesatFairValueScheduleofFinancialLiabilityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_FinacialLiabilitiesatFairValueScheduleofFinancialLiabilityDetailsTable_lbl" xml:lang="en-US">Finacial Liabilities at Fair Value - Schedule of Financial Liability (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinacialLiabilitiesatFairValueScheduleofFinancialLiabilityDetailsTable" xlink:to="iinn_FinacialLiabilitiesatFairValueScheduleofFinancialLiabilityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativesFairValueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativesFairValueLineItems_lbl" xml:lang="en-US">Schedule of Financial Liability [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="us-gaap_DerivativesFairValueLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareholdersEquityScheduleofShareCapitalDetailsTable" xlink:href="iinn-20241231.xsd#iinn_ShareholdersEquityScheduleofShareCapitalDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareholdersEquityScheduleofShareCapitalDetailsTable_lbl" xml:lang="en-US">Shareholders&#8217; Equity - Schedule of Share Capital (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareholdersEquityScheduleofShareCapitalDetailsTable" xlink:to="iinn_ShareholdersEquityScheduleofShareCapitalDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareholdersEquityScheduleofShareCapitalDetailsLineItems" xlink:href="iinn-20241231.xsd#iinn_ShareholdersEquityScheduleofShareCapitalDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareholdersEquityScheduleofShareCapitalDetailsLineItems_lbl" xml:lang="en-US">Shareholders&#8217; Equity - Schedule of Share Capital (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareholdersEquityScheduleofShareCapitalDetailsLineItems" xlink:to="iinn_ShareholdersEquityScheduleofShareCapitalDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xml:lang="en-US">Exercise Price Range [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Statement of Income Location, Balance [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_GeneralandAdministrativeExpensesScheduleofGeneralandAdministrativeExpensesDetailsTable" xlink:href="iinn-20241231.xsd#iinn_GeneralandAdministrativeExpensesScheduleofGeneralandAdministrativeExpensesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_GeneralandAdministrativeExpensesScheduleofGeneralandAdministrativeExpensesDetailsTable_lbl" xml:lang="en-US">General and Administrative Expenses - Schedule of General and Administrative Expenses (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_GeneralandAdministrativeExpensesScheduleofGeneralandAdministrativeExpensesDetailsTable" xlink:to="iinn_GeneralandAdministrativeExpensesScheduleofGeneralandAdministrativeExpensesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfGeneralAndAdministrativeExpensesLineItems" xlink:href="iinn-20241231.xsd#iinn_ScheduleOfGeneralAndAdministrativeExpensesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfGeneralAndAdministrativeExpensesLineItems_lbl" xml:lang="en-US">Schedule of General and Administrative Expenses [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfGeneralAndAdministrativeExpensesLineItems" xlink:to="iinn_ScheduleOfGeneralAndAdministrativeExpensesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedPaymentScheduleofMeasuretheFairValueoftheOptionatGrantDateDetailsTable" xlink:href="iinn-20241231.xsd#iinn_ShareBasedPaymentScheduleofMeasuretheFairValueoftheOptionatGrantDateDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedPaymentScheduleofMeasuretheFairValueoftheOptionatGrantDateDetailsTable_lbl" xml:lang="en-US">Share-Based Payment - Schedule of Measure the Fair Value of the Option at Grant Date (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedPaymentScheduleofMeasuretheFairValueoftheOptionatGrantDateDetailsTable" xlink:to="iinn_ShareBasedPaymentScheduleofMeasuretheFairValueoftheOptionatGrantDateDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Award Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedPaymentScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsTable" xlink:href="iinn-20241231.xsd#iinn_ShareBasedPaymentScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedPaymentScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsTable_lbl" xml:lang="en-US">Share-Based Payment - Schedule of Options to Services Providers and Advisers Outstanding (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedPaymentScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsTable" xlink:to="iinn_ShareBasedPaymentScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedPaymentScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsTable" xlink:href="iinn-20241231.xsd#iinn_ShareBasedPaymentScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedPaymentScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsTable_lbl" xml:lang="en-US">Share-Based Payment - Schedule of RSUs to Services Providers and Advisers Outstanding (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedPaymentScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsTable" xlink:to="iinn_ShareBasedPaymentScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Title and Position [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Related Party Transaction [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_GeneralDetailsTable" xlink:href="iinn-20241231.xsd#iinn_GeneralDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_GeneralDetailsTable_lbl" xml:lang="en-US">General (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_GeneralDetailsTable" xlink:to="iinn_GeneralDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PublicUtilitiesGeneralDisclosuresLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PublicUtilitiesGeneralDisclosuresLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PublicUtilitiesGeneralDisclosuresLineItems_lbl" xml:lang="en-US">General [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PublicUtilitiesGeneralDisclosuresLineItems" xlink:to="us-gaap_PublicUtilitiesGeneralDisclosuresLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_SignificantAccountingPoliciesDetailsTable" xlink:href="iinn-20241231.xsd#iinn_SignificantAccountingPoliciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_SignificantAccountingPoliciesDetailsTable_lbl" xml:lang="en-US">Significant Accounting Policies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SignificantAccountingPoliciesDetailsTable" xlink:to="iinn_SignificantAccountingPoliciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatutoryAccountingPracticesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatutoryAccountingPracticesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatutoryAccountingPracticesLineItems_lbl" xml:lang="en-US">Significant Accounting Policies [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatutoryAccountingPracticesLineItems" xlink:to="us-gaap_StatutoryAccountingPracticesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xml:lang="en-US">Short-Term Debt, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ShortTermDebtTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Geographical [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_DepositsDetailsTable" xlink:href="iinn-20241231.xsd#iinn_DepositsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_DepositsDetailsTable_lbl" xml:lang="en-US">Deposits (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DepositsDetailsTable" xlink:to="iinn_DepositsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositLiabilityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositLiabilityLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositLiabilityLineItems_lbl" xml:lang="en-US">Deposits [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositLiabilityLineItems" xlink:to="us-gaap_DepositLiabilityLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_CommitmentsandContingenciesDetailsTable" xlink:href="iinn-20241231.xsd#iinn_CommitmentsandContingenciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_CommitmentsandContingenciesDetailsTable_lbl" xml:lang="en-US">Commitments and Contingencies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_CommitmentsandContingenciesDetailsTable" xlink:to="iinn_CommitmentsandContingenciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xml:lang="en-US">Commitments and Contingencies [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_LeaseLiabilitiesDetailsTable" xlink:href="iinn-20241231.xsd#iinn_LeaseLiabilitiesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_LeaseLiabilitiesDetailsTable_lbl" xml:lang="en-US">Lease Liabilities (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_LeaseLiabilitiesDetailsTable" xlink:to="iinn_LeaseLiabilitiesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US">Lease Liabilities [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US">Financial Instruments [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xml:lang="en-US">Measurement Input Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_FinacialLiabilitiesatFairValueDetailsTable" xlink:href="iinn-20241231.xsd#iinn_FinacialLiabilitiesatFairValueDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_FinacialLiabilitiesatFairValueDetailsTable_lbl" xml:lang="en-US">Finacial Liabilities at Fair Value (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinacialLiabilitiesatFairValueDetailsTable" xlink:to="iinn_FinacialLiabilitiesatFairValueDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US">Finacial Liabilities at Fair Value [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related and Nonrelated Parties [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareholdersEquityDetailsTable" xlink:href="iinn-20241231.xsd#iinn_ShareholdersEquityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareholdersEquityDetailsTable_lbl" xml:lang="en-US">Shareholders&#8217; Equity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareholdersEquityDetailsTable" xlink:to="iinn_ShareholdersEquityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Shareholders&#8217; Equity [Line Item]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_TaxesonIncomeDetailsTable" xlink:href="iinn-20241231.xsd#iinn_TaxesonIncomeDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_TaxesonIncomeDetailsTable_lbl" xml:lang="en-US">Taxes on Income (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TaxesonIncomeDetailsTable" xlink:to="iinn_TaxesonIncomeDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl" xml:lang="en-US">Taxes on Income [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_ShareBasedPaymentDetailsTable" xlink:href="iinn-20241231.xsd#iinn_ShareBasedPaymentDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedPaymentDetailsTable_lbl" xml:lang="en-US">Share-Based Payment (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedPaymentDetailsTable" xlink:to="iinn_ShareBasedPaymentDetailsTable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl0" xml:lang="en-US">Share-Based Payment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="iinn_SubsequentEventsDetailsTable" xlink:href="iinn-20241231.xsd#iinn_SubsequentEventsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_SubsequentEventsDetailsTable_lbl" xml:lang="en-US">Subsequent Events (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SubsequentEventsDetailsTable" xlink:to="iinn_SubsequentEventsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Events [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_AccountsPayableToRelatedParties_lbl0" xml:lang="en-US">Amount of accounts payable to related parties, due after one year or beyond the normal operating cycle, if longer.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AccountsPayableToRelatedParties" xlink:to="iinn_AccountsPayableToRelatedParties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_AccruedIssuanceExpenses_lbl0" xml:lang="en-US">Amount of accrued issuance expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AccruedIssuanceExpenses" xlink:to="iinn_AccruedIssuanceExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_AdditionalOfferingCosts_lbl0" xml:lang="en-US">Amount of additional offering costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AdditionalOfferingCosts" xlink:to="iinn_AdditionalOfferingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_AggregateBudget_lbl0" xml:lang="en-US">The amount of aggregate budget.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AggregateBudget" xlink:to="iinn_AggregateBudget_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_AggregateProceedsReceived_lbl0" xml:lang="en-US">Represent the amount of aggregate proceeds received.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AggregateProceedsReceived" xlink:to="iinn_AggregateProceedsReceived_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Percentage of annual depreciation rates of property, plant and equipment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment" xlink:to="iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_CapitalGainTaxRate_lbl0" xml:lang="en-US">Capital gain tax rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_CapitalGainTaxRate" xlink:to="iinn_CapitalGainTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ClassOfPrivateWarrantOrRightOutstanding_lbl0" xml:lang="en-US">Represent the number of private warrant or right outstanding.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ClassOfPrivateWarrantOrRightOutstanding" xlink:to="iinn_ClassOfPrivateWarrantOrRightOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ContingentUponFutureSales_lbl0" xml:lang="en-US">The amount of contingent upon future sales.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ContingentUponFutureSales" xlink:to="iinn_ContingentUponFutureSales_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_DeferredTaxAssetsAccruedExpenses_lbl0" xml:lang="en-US">Represents amount of deferred tax accrued expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DeferredTaxAssetsAccruedExpenses" xlink:to="iinn_DeferredTaxAssetsAccruedExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_DeferredTaxAssetsFundRaisingCost2023_lbl0" xml:lang="en-US">Fund raising costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DeferredTaxAssetsFundRaisingCost2023" xlink:to="iinn_DeferredTaxAssetsFundRaisingCost2023_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_DeferredTaxLiabilitiesOperatingLeaseLiability_lbl0" xml:lang="en-US">Operating lease liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DeferredTaxLiabilitiesOperatingLeaseLiability" xlink:to="iinn_DeferredTaxLiabilitiesOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_EffectiveIncomeTaxTheoreticalTaxCredit_lbl0" xml:lang="en-US">Represents amount of theoretical tax credit.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_EffectiveIncomeTaxTheoreticalTaxCredit" xlink:to="iinn_EffectiveIncomeTaxTheoreticalTaxCredit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinaryShares_lbl0" xml:lang="en-US">The amount of exercise of june 2024 pre-funded warrants into ordinary shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinaryShares" xlink:to="iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinaryShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinarySharesinShares_lbl0" xml:lang="en-US">Number of exercise of June 2024 pre-funded warrants into ordinary shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinarySharesinShares" xlink:to="iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinarySharesinShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ExpirationOfFinancialLiability_lbl0" xml:lang="en-US">Amount of expiration of financial liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExpirationOfFinancialLiability" xlink:to="iinn_ExpirationOfFinancialLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_FinanceIncomeAndExpensesPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for finance income and expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinanceIncomeAndExpensesPolicyTextBlock" xlink:to="iinn_FinanceIncomeAndExpensesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_FinancialLiabilityPlacementAgentFee_lbl0" xml:lang="en-US">Amount of financial liability placement agent fee.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinancialLiabilityPlacementAgentFee" xlink:to="iinn_FinancialLiabilityPlacementAgentFee_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_FundraisingExpenses_lbl0" xml:lang="en-US">The amount of fundraising expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FundraisingExpenses" xlink:to="iinn_FundraisingExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_GeneralAndAdministrativeExpensesTextBlock_lbl0" xml:lang="en-US">The entire disclosure for general and administrative expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_GeneralAndAdministrativeExpensesTextBlock" xlink:to="iinn_GeneralAndAdministrativeExpensesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_IIAParticipation_lbl0" xml:lang="en-US">The expenses of IIA participation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_IIAParticipation" xlink:to="iinn_IIAParticipation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_IssuanceOfOrdinarySharesAdvisorFees_lbl0" xml:lang="en-US">Amount of issuance of ordinary shares advisor fees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_IssuanceOfOrdinarySharesAdvisorFees" xlink:to="iinn_IssuanceOfOrdinarySharesAdvisorFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_MonthlyDeductionFromTerminationFee_lbl0" xml:lang="en-US">Represent the value of monthly deduction from termination fee.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_MonthlyDeductionFromTerminationFee" xlink:to="iinn_MonthlyDeductionFromTerminationFee_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_NonCashTransactions_lbl0" xml:lang="en-US">The total amount of non cash transactions.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NonCashTransactions" xlink:to="iinn_NonCashTransactions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_NumberOfSharesPerUnits_lbl0" xml:lang="en-US">Number of shares per units.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NumberOfSharesPerUnits" xlink:to="iinn_NumberOfSharesPerUnits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_NumberofAdditionalOrdinaryShares_lbl0" xml:lang="en-US">Number of additional ordinary shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NumberofAdditionalOrdinaryShares" xlink:to="iinn_NumberofAdditionalOrdinaryShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_OfferingFeesAndOtherRelatedExpenses_lbl0" xml:lang="en-US">Amount of offering fees and other related expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_OfferingFeesAndOtherRelatedExpenses" xlink:to="iinn_OfferingFeesAndOtherRelatedExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_OtherReceivableInConnectionToPrivatePlacement_lbl0" xml:lang="en-US">Amount of other receivable in connection to private placement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_OtherReceivableInConnectionToPrivatePlacement" xlink:to="iinn_OtherReceivableInConnectionToPrivatePlacement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_PercentageForCarsLeaseAgreementCancellationPenalty_lbl0" xml:lang="en-US">Represent the description of percentage for car lease agreement cancellation penalty.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PercentageForCarsLeaseAgreementCancellationPenalty" xlink:to="iinn_PercentageForCarsLeaseAgreementCancellationPenalty_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_PercentageOfApprovedBudget_lbl0" xml:lang="en-US">Percentage of approved budget.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PercentageOfApprovedBudget" xlink:to="iinn_PercentageOfApprovedBudget_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_PercentageOfCapitalGainTax_lbl0" xml:lang="en-US">Percentage of capital gain tax.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PercentageOfCapitalGainTax" xlink:to="iinn_PercentageOfCapitalGainTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_PercentageOfFutureLeasePaymentsDiscounted_lbl0" xml:lang="en-US">Percentage of future lease payments discounted.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PercentageOfFutureLeasePaymentsDiscounted" xlink:to="iinn_PercentageOfFutureLeasePaymentsDiscounted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_PercentageOfOrdinaryShares_lbl0" xml:lang="en-US">Percentage of ordinary shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PercentageOfOrdinaryShares" xlink:to="iinn_PercentageOfOrdinaryShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_PercentageOfPayFees_lbl0" xml:lang="en-US">Percentage of pay fees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PercentageOfPayFees" xlink:to="iinn_PercentageOfPayFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_PlacementAgentWarrantsFairValue_lbl0" xml:lang="en-US">Represent the amount of fair value for the placement agent warrant.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PlacementAgentWarrantsFairValue" xlink:to="iinn_PlacementAgentWarrantsFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ProceedsFromReceivedFund_lbl0" xml:lang="en-US">Amount of proceeds from received fund.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ProceedsFromReceivedFund" xlink:to="iinn_ProceedsFromReceivedFund_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ProjectBudgetAggregateAmount_lbl0" xml:lang="en-US">The amount of project budget aggregate amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ProjectBudgetAggregateAmount" xlink:to="iinn_ProjectBudgetAggregateAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_PurchasePricePerShare_lbl0" xml:lang="en-US">Purchase price per share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PurchasePricePerShare" xlink:to="iinn_PurchasePricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_RestrictedStockUnits_lbl0" xml:lang="en-US">Amount of restricted stock units.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RestrictedStockUnits" xlink:to="iinn_RestrictedStockUnits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss_lbl0" xml:lang="en-US">The amount of revaluation of financial liabilities at fair value through profit or loss.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:to="iinn_RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_RoyaltiesPercentage_lbl0" xml:lang="en-US">Percentage of royalties.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RoyaltiesPercentage" xlink:to="iinn_RoyaltiesPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_SalesAndMarketingExpensesTextBlock_lbl0" xml:lang="en-US">Disclosure of sales and marketing expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SalesAndMarketingExpensesTextBlock" xlink:to="iinn_SalesAndMarketingExpensesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of depreciation on straight-line method, over the estimated useful life of the assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock" xlink:to="iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of general and administrative expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" xlink:to="iinn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ScheduleOfLesseeOperatingLeasesDisclosureTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of lessee operating leases.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfLesseeOperatingLeasesDisclosureTableTextBlock" xlink:to="iinn_ScheduleOfLesseeOperatingLeasesDisclosureTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of sales and marketing expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock" xlink:to="iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ScheduleOfTheoreticalTaxTableTextBlock_lbl0" xml:lang="en-US">Disclosure of theoretical tax.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfTheoreticalTaxTableTextBlock" xlink:to="iinn_ScheduleOfTheoreticalTaxTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_SeverancePolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for severance.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SeverancePolicyTextBlock" xlink:to="iinn_SeverancePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_lbl0" xml:lang="en-US">Number of warrants, exercised.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Weighted-average exercise price, exercised.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms_lbl0" xml:lang="en-US">Weighted average remaining contractual term, exercised.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_lbl0" xml:lang="en-US">Number of warrants, expired.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Weighted-average exercise price, expired.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms_lbl0" xml:lang="en-US">Weighted average remaining contractual term, expired.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms_lbl0" xml:lang="en-US">Weighted average remaining contractual term, issued.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsIssued_lbl0" xml:lang="en-US">Number of warrants, issued.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsIssued" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeighted-averageExercisePriceIssued_lbl0" xml:lang="en-US">Per share or unit weighted-average fair value of other than option under share-based payment arrangement. Excludes share and unit options.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeighted-averageExercisePriceIssued" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeighted-averageExercisePriceIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife_lbl0" xml:lang="en-US">Contractual life of award under share-based payment arrangement, in &apos;PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos; represents reported fact of one year, five months, and thirteen days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsReclassifiedToEmployeesAndDirectors_lbl0" xml:lang="en-US">The number of options, reclassified to employees and directors.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsReclassifiedToEmployeesAndDirectors" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsReclassifiedToEmployeesAndDirectors_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi_lbl0" xml:lang="en-US">Number of share options (or share units) exercised during the current period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentExpirationDate_lbl0" xml:lang="en-US">Date the equity-based award expires.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentExpirationDate" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentExpirationDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested_lbl0" xml:lang="en-US">Number of RSUs vested under share based payment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested" xlink:to="iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceReclassifiedToEmployeesAndDirectors_lbl0" xml:lang="en-US">Per share price of weighted average exercise price, reclassified to employees and directors.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceReclassifiedToEmployeesAndDirectors" xlink:to="iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceReclassifiedToEmployeesAndDirectors_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital_lbl0" xml:lang="en-US">The amount of share based compensation-placement agent warrants against additional paid in capital.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital" xlink:to="iinn_ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_StockIssuedDuringPeriodSharesStockOptionsExerciseOfShareBasedPayments_lbl0" xml:lang="en-US">Number of shares exercise of share based payments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_StockIssuedDuringPeriodSharesStockOptionsExerciseOfShareBasedPayments" xlink:to="iinn_StockIssuedDuringPeriodSharesStockOptionsExerciseOfShareBasedPayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments_lbl0" xml:lang="en-US">Exercise of share based payments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments" xlink:to="iinn_StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_Subcontractors_lbl0" xml:lang="en-US">Subcontractors.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_Subcontractors" xlink:to="iinn_Subcontractors_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized_lbl0" xml:lang="en-US">Temporary differences and tax losses for which no Deferred Tax Asset is recognized.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized" xlink:to="iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Contractual Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_MonthlyDeductionFromTerminationFee_lbl1" xml:lang="en-US">Monthly Deduction From Termination Fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_MonthlyDeductionFromTerminationFee" xlink:to="iinn_MonthlyDeductionFromTerminationFee_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl1" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl0" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl0" xml:lang="en-US">Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Role of Management [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ClassOfPrivateWarrantOrRightOutstanding_lbl1" xml:lang="en-US">Class Of Private Warrant Or Right Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ClassOfPrivateWarrantOrRightOutstanding" xlink:to="iinn_ClassOfPrivateWarrantOrRightOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_SalesAndMarketingExpensesTextBlock_lbl1" xml:lang="en-US">Sales And Marketing Expenses Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SalesAndMarketingExpensesTextBlock" xlink:to="iinn_SalesAndMarketingExpensesTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl0" xml:lang="en-US">Unrealized Gain (Loss), Foreign Currency Transaction, before Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsReclassifiedToEmployeesAndDirectors_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Number Of Options Reclassified To Employees And Directors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsReclassifiedToEmployeesAndDirectors" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsReclassifiedToEmployeesAndDirectors_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl1" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl1" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ExercisePrice0001Member_lbl0" xml:lang="en-US">Exercise Price0001 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExercisePrice0001Member" xlink:to="iinn_ExercisePrice0001Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl0" xml:lang="en-US">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl0" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ExpirationOfFinancialLiability_lbl1" xml:lang="en-US">Expiration Of Financial Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExpirationOfFinancialLiability" xlink:to="iinn_ExpirationOfFinancialLiability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfLesseeOperatingLeasesDisclosureTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Lessee Operating Leases Disclosure Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfLesseeOperatingLeasesDisclosureTableTextBlock" xlink:to="iinn_ScheduleOfLesseeOperatingLeasesDisclosureTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeDepositsWithFinancialInstitutions_lbl0" xml:lang="en-US">Interest Income, Deposits with Financial Institutions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" xlink:to="us-gaap_InterestIncomeDepositsWithFinancialInstitutions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl2" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsIssued_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Warrants Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsIssued" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_TwoThousandNineteenEquityIncentivePlanMember_lbl0" xml:lang="en-US">Two Thousand Nineteen Equity Incentive Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TwoThousandNineteenEquityIncentivePlanMember" xlink:to="iinn_TwoThousandNineteenEquityIncentivePlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ContingentUponFutureSales_lbl1" xml:lang="en-US">Contingent Upon Future Sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ContingentUponFutureSales" xlink:to="iinn_ContingentUponFutureSales_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput_lbl0" xml:lang="en-US">Derivative Liability, Measurement Input</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilityMeasurementInput" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_lbl0" xml:lang="en-US">Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_PercentageOfApprovedBudget_lbl1" xml:lang="en-US">Percentage Of Approved Budget</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PercentageOfApprovedBudget" xlink:to="iinn_PercentageOfApprovedBudget_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_TwoThousandTwentyFourJuneOfferingMember_lbl0" xml:lang="en-US">Two Thousand Twenty Four June Offering Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TwoThousandTwentyFourJuneOfferingMember" xlink:to="iinn_TwoThousandTwentyFourJuneOfferingMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl0" xml:lang="en-US">Board of Directors Chairman [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_BoardOfDirectorsChairmanMember" xlink:to="srt_BoardOfDirectorsChairmanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationNonproduction_lbl0" xml:lang="en-US">Depreciation, Nonproduction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationNonproduction" xlink:to="us-gaap_DepreciationNonproduction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl0" xml:lang="en-US">Warrants and Rights Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable_lbl0" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLeasePayments_lbl0" xml:lang="en-US">Proceeds from Lease Payment, Operating Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLeasePayments" xlink:to="us-gaap_ProceedsFromLeasePayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Trade</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl0" xml:lang="en-US">Accounts Payable, Trade, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ChangesDuringThePeriodAbstract_lbl0" xml:lang="en-US">Changes During The Period Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ChangesDuringThePeriodAbstract" xlink:to="iinn_ChangesDuringThePeriodAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_GeneralAndAdministrativeExpensesTextBlock_lbl1" xml:lang="en-US">General And Administrative Expenses Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_GeneralAndAdministrativeExpensesTextBlock" xlink:to="iinn_GeneralAndAdministrativeExpensesTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ExercisePriceOnePointOneMember_lbl0" xml:lang="en-US">Exercise Price One Point One Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExercisePriceOnePointOneMember" xlink:to="iinn_ExercisePriceOnePointOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl0" xml:lang="en-US">Prepaid Expense, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_BankLeumiMember_lbl0" xml:lang="en-US">Bank Leumi Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_BankLeumiMember" xlink:to="iinn_BankLeumiMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl0" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl0" xml:lang="en-US">Schedule of Stockholders&apos; Equity Note, Warrants or Rights [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl2" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_NetBookValueAbstract_lbl0" xml:lang="en-US">Net Book Value Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NetBookValueAbstract" xlink:to="iinn_NetBookValueAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment_lbl1" xml:lang="en-US">Annual Depreciation Rates Of Property Plant And Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment" xlink:to="iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl0" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expired Weighted Average Remaining Contractual Terms</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoods_lbl0" xml:lang="en-US">Inventory, Finished Goods, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl0" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet_lbl0" xml:lang="en-US">Other Operating Income (Expense), Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_AggregateBudget_lbl1" xml:lang="en-US">Aggregate Budget</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AggregateBudget" xlink:to="iinn_AggregateBudget_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss_lbl1" xml:lang="en-US">Revaluation Of Financial Liabilities At Fair Value Through Profit Or Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:to="iinn_RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl0" xml:lang="en-US">Deferred Tax Assets, Gross [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl0" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_OfficersAndDirectorsMember_lbl0" xml:lang="en-US">Officers And Directors Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_OfficersAndDirectorsMember" xlink:to="iinn_OfficersAndDirectorsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl0" xml:lang="en-US">Inventory Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_NonCashTransactions_lbl1" xml:lang="en-US">Non Cash Transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NonCashTransactions" xlink:to="iinn_NonCashTransactions_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_OrdinarySharesNoParValueMember_lbl0" xml:lang="en-US">Ordinary Shares No Par Value Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_OrdinarySharesNoParValueMember" xlink:to="iinn_OrdinarySharesNoParValueMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock_lbl0" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl0" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expired Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl1" xml:lang="en-US">UNITED STATES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl1" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate_lbl0" xml:lang="en-US">Short-Term Debt, Percentage Bearing Fixed Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" xlink:to="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_PercentageOfOrdinaryShares_lbl1" xml:lang="en-US">Percentage Of Ordinary Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PercentageOfOrdinaryShares" xlink:to="iinn_PercentageOfOrdinaryShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl1" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl0" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeighted-averageExercisePriceIssued_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted-average Exercise Price Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeighted-averageExercisePriceIssued" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeighted-averageExercisePriceIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl0" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_PercentageOfCapitalGainTax_lbl1" xml:lang="en-US">Percentage Of Capital Gain Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PercentageOfCapitalGainTax" xlink:to="iinn_PercentageOfCapitalGainTax_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCash_lbl0" xml:lang="en-US">Restricted Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGrossAbstract_lbl0" xml:lang="en-US">Property, Plant and Equipment, Gross [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGrossAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentGrossAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_OfferingFeesAndOtherRelatedExpenses_lbl1" xml:lang="en-US">Offering Fees And Other Related Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_OfferingFeesAndOtherRelatedExpenses" xlink:to="iinn_OfferingFeesAndOtherRelatedExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_EmployeesAndDirectorsMember_lbl0" xml:lang="en-US">Employees And Directors Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_EmployeesAndDirectorsMember" xlink:to="iinn_EmployeesAndDirectorsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfShareholdersAndOtherRelatedPartiesBenefitsAbstract" xlink:href="iinn-20241231.xsd#iinn_ScheduleOfShareholdersAndOtherRelatedPartiesBenefitsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfShareholdersAndOtherRelatedPartiesBenefitsAbstract_lbl" xml:lang="en-US">Schedule Of Shareholders And Other Related Parties Benefits Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfShareholdersAndOtherRelatedPartiesBenefitsAbstract" xlink:to="iinn_ScheduleOfShareholdersAndOtherRelatedPartiesBenefitsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl0" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_RDEquipmentMember_lbl0" xml:lang="en-US">RDEquipment Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RDEquipmentMember" xlink:to="iinn_RDEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_SeverancePolicyTextBlock_lbl1" xml:lang="en-US">Severance Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_SeverancePolicyTextBlock" xlink:to="iinn_SeverancePolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock_lbl0" xml:lang="en-US">Other Nonoperating Income and Expense [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:to="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_DeferredTaxAssetsAccruedExpenses_lbl1" xml:lang="en-US">Deferred Tax Assets Accrued Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DeferredTaxAssetsAccruedExpenses" xlink:to="iinn_DeferredTaxAssetsAccruedExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_AdvisoryBoardMembersMember_lbl0" xml:lang="en-US">Advisory Board Members Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AdvisoryBoardMembersMember" xlink:to="iinn_AdvisoryBoardMembersMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_NetBookValueAbstract0_lbl0" xml:lang="en-US">Net Book Value Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NetBookValueAbstract0" xlink:to="iinn_NetBookValueAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Deposits_lbl0" xml:lang="en-US">Deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Deposits" xlink:to="us-gaap_Deposits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl0" xml:lang="en-US">Issuance of Stock and Warrants for Services or Claims</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromBankDebt_lbl0" xml:lang="en-US">Proceeds from Bank Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromBankDebt" xlink:to="us-gaap_ProceedsFromBankDebt_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfRsusToServicesProvidersAndAdvisersOutstandingAbstract" xlink:href="iinn-20241231.xsd#iinn_ScheduleOfRsusToServicesProvidersAndAdvisersOutstandingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfRsusToServicesProvidersAndAdvisersOutstandingAbstract_lbl" xml:lang="en-US">Schedule Of Rsus To Services Providers And Advisers Outstanding Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfRsusToServicesProvidersAndAdvisersOutstandingAbstract" xlink:to="iinn_ScheduleOfRsusToServicesProvidersAndAdvisersOutstandingAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl0" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_RothCapitalPartnersLLCMember_lbl0" xml:lang="en-US">Roth Capital Partners LLCMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RothCapitalPartnersLLCMember" xlink:to="iinn_RothCapitalPartnersLLCMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_JunePlacementAgentWarrantsMember_lbl1" xml:lang="en-US">June Placement Agent Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_JunePlacementAgentWarrantsMember" xlink:to="iinn_JunePlacementAgentWarrantsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expired In Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_WeightedAverageMember_lbl0" xml:lang="en-US">Weighted Average [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_WeightedAverageMember" xlink:to="srt_WeightedAverageMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl0" xml:lang="en-US">Equity Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_PercentageOfPayFees_lbl1" xml:lang="en-US">Percentage Of Pay Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PercentageOfPayFees" xlink:to="iinn_PercentageOfPayFees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl1" xml:lang="en-US">Stock Issued During Period, Shares, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_WarrantsToPurchaseOrdinarySharesMember_lbl0" xml:lang="en-US">Warrants To Purchase Ordinary Shares Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_WarrantsToPurchaseOrdinarySharesMember" xlink:to="iinn_WarrantsToPurchaseOrdinarySharesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_December2024PrivatePlacementMember_lbl0" xml:lang="en-US">December2024 Private Placement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_December2024PrivatePlacementMember" xlink:to="iinn_December2024PrivatePlacementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US">Equity, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfCommonOwnershipOrManagementControlRelationships_lbl0" xml:lang="en-US">Nature of Common Ownership or Management Control Relationships</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfCommonOwnershipOrManagementControlRelationships" xlink:to="us-gaap_NatureOfCommonOwnershipOrManagementControlRelationships_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinarySharesinShares_lbl1" xml:lang="en-US">Exercise Of June2024 Prefunded Warrants Into Ordinary Sharesin Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinarySharesinShares" xlink:to="iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinarySharesinShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl1" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl0" xml:lang="en-US">Computer Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl0" xml:lang="en-US">Furniture and Fixtures [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_PrivateWarrantsMember_lbl1" xml:lang="en-US">Private Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PrivateWarrantsMember" xlink:to="iinn_PrivateWarrantsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Sales And Marketing Expenses Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock" xlink:to="iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_DecemberPrivateWarrantsMember_lbl0" xml:lang="en-US">December Private Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DecemberPrivateWarrantsMember" xlink:to="iinn_DecemberPrivateWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_NumberOfSharesPerUnits_lbl1" xml:lang="en-US">Number Of Shares Per Units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NumberOfSharesPerUnits" xlink:to="iinn_NumberOfSharesPerUnits_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_EmployeesDirectorsAndSubcontractorsMember_lbl0" xml:lang="en-US">Employees Directors And Subcontractors Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_EmployeesDirectorsAndSubcontractorsMember" xlink:to="iinn_EmployeesDirectorsAndSubcontractorsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_FundraisingExpenses_lbl1" xml:lang="en-US">Fundraising Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FundraisingExpenses" xlink:to="iinn_FundraisingExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl0" xml:lang="en-US">Fair Value Adjustment of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_Exercise6875Member_lbl0" xml:lang="en-US">Exercise6875 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_Exercise6875Member" xlink:to="iinn_Exercise6875Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_DecemberPrivatePlacementMember_lbl0" xml:lang="en-US">December Private Placement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DecemberPrivatePlacementMember" xlink:to="iinn_DecemberPrivatePlacementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_AccruedIssuanceExpenses_lbl1" xml:lang="en-US">Accrued Issuance Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AccruedIssuanceExpenses" xlink:to="iinn_AccruedIssuanceExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_AggregateProceedsReceived_lbl1" xml:lang="en-US">Aggregate Proceeds Received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AggregateProceedsReceived" xlink:to="iinn_AggregateProceedsReceived_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ProceedsFromReceivedFund_lbl1" xml:lang="en-US">Proceeds From Received Fund</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ProceedsFromReceivedFund" xlink:to="iinn_ProceedsFromReceivedFund_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl1" xml:lang="en-US">Accounts Payable, Other, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl1" xml:lang="en-US">Director [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl0" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl0" xml:lang="en-US">Proceeds from Warrant Exercises</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentExpirationDate_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Expiration Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentExpirationDate" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentExpirationDate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl0" xml:lang="en-US">Other Current Assets [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestBearingDepositsInBanks_lbl0" xml:lang="en-US">Interest-Bearing Deposits in Banks and Other Financial Institutions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestBearingDepositsInBanks" xlink:to="us-gaap_InterestBearingDepositsInBanks_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl0" xml:lang="en-US">Deferred Tax Liabilities, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl0" xml:lang="en-US">Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl0" xml:lang="en-US">Research, Development, and Computer Software Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl0" xml:lang="en-US">Finance Lease, Interest Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_AdditionalOfferingCosts_lbl1" xml:lang="en-US">Additional Offering Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AdditionalOfferingCosts" xlink:to="iinn_AdditionalOfferingCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Other Current Assets [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_IssuanceOfOrdinarySharesAdvisorFees_lbl1" xml:lang="en-US">Issuance Of Ordinary Shares Advisor Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_IssuanceOfOrdinarySharesAdvisorFees" xlink:to="iinn_IssuanceOfOrdinarySharesAdvisorFees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested_lbl1" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award Options Number Of RSUs Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested" xlink:to="iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl1" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ProjectBudgetAggregateAmount_lbl1" xml:lang="en-US">Project Budget Aggregate Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ProjectBudgetAggregateAmount" xlink:to="iinn_ProjectBudgetAggregateAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_StockIssuedDuringPeriodSharesStockOptionsExerciseOfShareBasedPayments_lbl1" xml:lang="en-US">Stock Issued During Period Shares Stock Options Exercise Of Share Based Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_StockIssuedDuringPeriodSharesStockOptionsExerciseOfShareBasedPayments" xlink:to="iinn_StockIssuedDuringPeriodSharesStockOptionsExerciseOfShareBasedPayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl1" xml:lang="en-US">Inventory, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_lbl0" xml:lang="en-US">Other Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRent_lbl0" xml:lang="en-US">Payments for Rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl0" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_RegisteredDirectOfferingMember_lbl0" xml:lang="en-US">Registered Direct Offering Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RegisteredDirectOfferingMember" xlink:to="iinn_RegisteredDirectOfferingMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashCurrent_lbl0" xml:lang="en-US">Restricted Cash, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl0" xml:lang="en-US">Proceeds from Issuance of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl0" xml:lang="en-US">Amortization of Debt Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_lbl0" xml:lang="en-US">Derivative Financial Instruments, Liabilities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:to="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivables_lbl0" xml:lang="en-US">Other Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_RestrictedStockUnits_lbl1" xml:lang="en-US">Restricted Stock Units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RestrictedStockUnits" xlink:to="iinn_RestrictedStockUnits_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForOtherLosses_lbl0" xml:lang="en-US">Provision for Other Losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForOtherLosses" xlink:to="us-gaap_ProvisionForOtherLosses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl0" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl0" xml:lang="en-US">Shareholders&apos; Equity and Share-Based Payments [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentAbstract_lbl0" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl0" xml:lang="en-US">IPO [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OfficerMember_lbl0" xml:lang="en-US">Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OfficerMember" xlink:to="srt_OfficerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_MedicalBoardMembersMember_lbl0" xml:lang="en-US">Medical Board Members Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_MedicalBoardMembersMember" xlink:to="iinn_MedicalBoardMembersMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_NumberofAdditionalOrdinaryShares_lbl1" xml:lang="en-US">Numberof Additional Ordinary Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_NumberofAdditionalOrdinaryShares" xlink:to="iinn_NumberofAdditionalOrdinaryShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfInformationAboutTheCompanySOutstandingWarrantsAbstract" xlink:href="iinn-20241231.xsd#iinn_ScheduleOfInformationAboutTheCompanySOutstandingWarrantsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfInformationAboutTheCompanySOutstandingWarrantsAbstract_lbl" xml:lang="en-US">Schedule Of Information About The Company SOutstanding Warrants Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfInformationAboutTheCompanySOutstandingWarrantsAbstract" xlink:to="iinn_ScheduleOfInformationAboutTheCompanySOutstandingWarrantsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl1" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ExercisePrice55Member_lbl0" xml:lang="en-US">Exercise Price55 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExercisePrice55Member" xlink:to="iinn_ExercisePrice55Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0" xml:lang="en-US">Research and Development Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ExercisePriceOnePointSixMember_lbl0" xml:lang="en-US">Exercise Price One Point Six Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExercisePriceOnePointSixMember" xlink:to="iinn_ExercisePriceOnePointSixMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Leases [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_DeferredTaxAssetsFundRaisingCost2023_lbl1" xml:lang="en-US">Deferred Tax Assets Fund Raising Cost2023</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DeferredTaxAssetsFundRaisingCost2023" xlink:to="iinn_DeferredTaxAssetsFundRaisingCost2023_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterials_lbl0" xml:lang="en-US">Inventory, Raw Materials, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ChangesDuringThePeriodAbstract1_lbl0" xml:lang="en-US">Changes During The Period Abstract1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ChangesDuringThePeriodAbstract1" xlink:to="iinn_ChangesDuringThePeriodAbstract1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ExecutivesMember_lbl0" xml:lang="en-US">Executives Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExecutivesMember" xlink:to="iinn_ExecutivesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ChangesDuringThePeriodAbstract0_lbl0" xml:lang="en-US">Changes During The Period Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ChangesDuringThePeriodAbstract0" xlink:to="iinn_ChangesDuringThePeriodAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl1" xml:lang="en-US">Earnings Per Share, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl0" xml:lang="en-US">Liabilities, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl0" xml:lang="en-US">Other Noncash Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl1" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl0" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralInsuranceExpense_lbl0" xml:lang="en-US">General Insurance Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralInsuranceExpense" xlink:to="us-gaap_GeneralInsuranceExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAdditions_lbl0" xml:lang="en-US">Property, Plant and Equipment, Additions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAdditions" xlink:to="us-gaap_PropertyPlantAndEquipmentAdditions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinaryShares_lbl1" xml:lang="en-US">Exercise Of June2024 Prefunded Warrants Into Ordinary Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinaryShares" xlink:to="iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinaryShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Other Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments_lbl1" xml:lang="en-US">Stock Issued During Period Value Stock Options Exercise Of Share Based Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments" xlink:to="iinn_StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositLiabilitiesDisclosuresTextBlock_lbl0" xml:lang="en-US">Deposit Liabilities Disclosures [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositLiabilitiesDisclosuresTextBlock" xlink:to="us-gaap_DepositLiabilitiesDisclosuresTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfFinancialLiabilityAbstract" xlink:href="iinn-20241231.xsd#iinn_ScheduleOfFinancialLiabilityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfFinancialLiabilityAbstract_lbl" xml:lang="en-US">Schedule Of Financial Liability Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfFinancialLiabilityAbstract" xlink:to="iinn_ScheduleOfFinancialLiabilityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityTableTextBlock_lbl0" xml:lang="en-US">Schedule of Stockholders Equity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_Subcontractors_lbl1" xml:lang="en-US">Subcontractors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_Subcontractors" xlink:to="iinn_Subcontractors_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl1" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl2" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_PercentageForCarsLeaseAgreementCancellationPenalty_lbl1" xml:lang="en-US">Percentage For Cars Lease Agreement Cancellation Penalty</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PercentageForCarsLeaseAgreementCancellationPenalty" xlink:to="iinn_PercentageForCarsLeaseAgreementCancellationPenalty_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl0" xml:lang="en-US">Increase (Decrease) in Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_lbl2" xml:lang="en-US">Derivative Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ExercisePrice55TwoMember_lbl0" xml:lang="en-US">Exercise Price55 Two Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExercisePrice55TwoMember" xlink:to="iinn_ExercisePrice55TwoMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl0" xml:lang="en-US">Gain (Loss), Foreign Currency Transaction, before Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_DecemberPrivateOfferingMember_lbl0" xml:lang="en-US">December Private Offering Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DecemberPrivateOfferingMember" xlink:to="iinn_DecemberPrivateOfferingMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ServicesProvidersAndAdvisersMember_lbl0" xml:lang="en-US">Services Providers And Advisers Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ServicesProvidersAndAdvisersMember" xlink:to="iinn_ServicesProvidersAndAdvisersMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl0" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl0" xml:lang="en-US">Inventory, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_DecemberPreFundedWarrantsMember_lbl0" xml:lang="en-US">December Pre Funded Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DecemberPreFundedWarrantsMember" xlink:to="iinn_DecemberPreFundedWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Accelerated Vesting, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_PercentageOfFutureLeasePaymentsDiscounted_lbl1" xml:lang="en-US">Percentage Of Future Lease Payments Discounted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PercentageOfFutureLeasePaymentsDiscounted" xlink:to="iinn_PercentageOfFutureLeasePaymentsDiscounted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl0" xml:lang="en-US">Warrants and Rights Outstanding, Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalFees_lbl0" xml:lang="en-US">Professional Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Expense, after Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:to="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl0" xml:lang="en-US">Deferred Tax Asset, In-Process Research and Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInLeasingReceivables_lbl0" xml:lang="en-US">Increase (Decrease) in Leasing Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInLeasingReceivables" xlink:to="us-gaap_IncreaseDecreaseInLeasingReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionExercisePriceIncrease_lbl0" xml:lang="en-US">Stock Option, Exercise Price, Increase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionExercisePriceIncrease" xlink:to="us-gaap_StockOptionExercisePriceIncrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfMeasureTheFairValueOfTheOptionAtGrantDateAbstract" xlink:href="iinn-20241231.xsd#iinn_ScheduleOfMeasureTheFairValueOfTheOptionAtGrantDateAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfMeasureTheFairValueOfTheOptionAtGrantDateAbstract_lbl" xml:lang="en-US">Schedule Of Measure The Fair Value Of The Option At Grant Date Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfMeasureTheFairValueOfTheOptionAtGrantDateAbstract" xlink:to="iinn_ScheduleOfMeasureTheFairValueOfTheOptionAtGrantDateAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl1" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_lbl0" xml:lang="en-US">Employee-related Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_IIAParticipation_lbl1" xml:lang="en-US">IIAParticipation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_IIAParticipation" xlink:to="iinn_IIAParticipation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl0" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl0" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl1" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl1" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_CapitalGainTaxRate_lbl1" xml:lang="en-US">Capital Gain Tax Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_CapitalGainTaxRate" xlink:to="iinn_CapitalGainTaxRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl0" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingAndMarketingExpense_lbl1" xml:lang="en-US">Selling and Marketing Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_SellingAndMarketingExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised Weighted Average Remaining Contractual Terms</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl1" xml:lang="en-US">Operating Lease, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl0" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherSellingAndMarketingExpense_lbl0" xml:lang="en-US">Other Selling and Marketing Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherSellingAndMarketingExpense" xlink:to="us-gaap_OtherSellingAndMarketingExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceReclassifiedToEmployeesAndDirectors_lbl1" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award Weighted Average Exercise Price Reclassified To Employees And Directors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceReclassifiedToEmployeesAndDirectors" xlink:to="iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceReclassifiedToEmployeesAndDirectors_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForProceedsFromInvestments_lbl0" xml:lang="en-US">Payments for (Proceeds from) Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromInvestments" xlink:to="us-gaap_PaymentsForProceedsFromInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_JunePreFundedWarrantsMember_lbl0" xml:lang="en-US">June Pre Funded Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_JunePreFundedWarrantsMember" xlink:to="iinn_JunePreFundedWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl0" xml:lang="en-US">Sale of Stock, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl2" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ExercisePrice156Member_lbl0" xml:lang="en-US">Exercise Price156 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ExercisePrice156Member" xlink:to="iinn_ExercisePrice156Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GovernmentAssistancePolicyTextBlock_lbl0" xml:lang="en-US">Government Assistance [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentAssistancePolicyTextBlock" xlink:to="us-gaap_GovernmentAssistancePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LaborAndRelatedExpense_lbl0" xml:lang="en-US">Labor and Related Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LaborAndRelatedExpense" xlink:to="us-gaap_LaborAndRelatedExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl1" xml:lang="en-US">Measurement Input, Price Volatility [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl0" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax_lbl0" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), after Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" xlink:to="us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl0" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl0" xml:lang="en-US">Other Prepaid Expense, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl1" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl1" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl0" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostMaintenance_lbl0" xml:lang="en-US">Cost, Maintenance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostMaintenance" xlink:to="us-gaap_CostMaintenance_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfMovementInWarrantsOutstandingAbstract" xlink:href="iinn-20241231.xsd#iinn_ScheduleOfMovementInWarrantsOutstandingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfMovementInWarrantsOutstandingAbstract_lbl" xml:lang="en-US">Schedule Of Movement In Warrants Outstanding Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfMovementInWarrantsOutstandingAbstract" xlink:to="iinn_ScheduleOfMovementInWarrantsOutstandingAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_lbl0" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl0" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_RoyaltiesPercentage_lbl1" xml:lang="en-US">Royalties Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_RoyaltiesPercentage" xlink:to="iinn_RoyaltiesPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockMember_lbl0" xml:lang="en-US">Employee Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl1" xml:lang="en-US">Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_PlacementAgentWarrantsMember_lbl0" xml:lang="en-US">Placement Agent Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PlacementAgentWarrantsMember" xlink:to="iinn_PlacementAgentWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_PlacementAgentWarrantsFairValue_lbl1" xml:lang="en-US">Placement Agent Warrants Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PlacementAgentWarrantsFairValue" xlink:to="iinn_PlacementAgentWarrantsFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LegalFees_lbl0" xml:lang="en-US">Legal Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl0" xml:lang="en-US">Stock Repurchased During Period, Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl0" xml:lang="en-US">General and Administrative Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl0" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfOptionsToServicesProvidersAndAdvisersOutstandingAbstract" xlink:href="iinn-20241231.xsd#iinn_ScheduleOfOptionsToServicesProvidersAndAdvisersOutstandingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfOptionsToServicesProvidersAndAdvisersOutstandingAbstract_lbl" xml:lang="en-US">Schedule Of Options To Services Providers And Advisers Outstanding Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfOptionsToServicesProvidersAndAdvisersOutstandingAbstract" xlink:to="iinn_ScheduleOfOptionsToServicesProvidersAndAdvisersOutstandingAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Depreciation On Straight Line Method Over The Estimated Useful Life Of The Assets Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock" xlink:to="iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl0" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherGeneralExpense_lbl0" xml:lang="en-US">Other General Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralExpense" xlink:to="us-gaap_OtherGeneralExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_DeferredTaxLiabilitiesOperatingLeaseLiability_lbl1" xml:lang="en-US">Deferred Tax Liabilities Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_DeferredTaxLiabilitiesOperatingLeaseLiability" xlink:to="iinn_DeferredTaxLiabilitiesOperatingLeaseLiability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl0" xml:lang="en-US">Share Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Issued Weighted Average Remaining Contractual Terms</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductWarrantyLiquidationProceedsPercentage_lbl0" xml:lang="en-US">Product Warranty, Liquidation Proceeds, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductWarrantyLiquidationProceedsPercentage" xlink:to="us-gaap_ProductWarrantyLiquidationProceedsPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_FinancialLiabilityPlacementAgentFee_lbl1" xml:lang="en-US">Financial Liability Placement Agent Fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinancialLiabilityPlacementAgentFee" xlink:to="iinn_FinancialLiabilityPlacementAgentFee_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl1" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PartnersCapitalAccountPublicSaleOfUnitsNetOfOfferingCosts_lbl0" xml:lang="en-US">Partners&apos; Capital Account, Public Sale of Units Net of Offering Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PartnersCapitalAccountPublicSaleOfUnitsNetOfOfferingCosts" xlink:to="us-gaap_PartnersCapitalAccountPublicSaleOfUnitsNetOfOfferingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl1" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_PreFundedWarrantsMember_lbl0" xml:lang="en-US">Pre Funded Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PreFundedWarrantsMember" xlink:to="iinn_PreFundedWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl0" xml:lang="en-US">Cybersecurity Risk Board of Directors Oversight [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock_lbl1" xml:lang="en-US">Schedule Of General And Administrative Expenses Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" xlink:to="iinn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLaborRelatedExpenses_lbl0" xml:lang="en-US">Other Labor-related Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLaborRelatedExpenses" xlink:to="us-gaap_OtherLaborRelatedExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl0" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Number Of Options Exercisedi</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi" xlink:to="iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl1" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_EffectiveIncomeTaxTheoreticalTaxCredit_lbl1" xml:lang="en-US">Effective Income Tax Theoretical Tax Credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_EffectiveIncomeTaxTheoreticalTaxCredit" xlink:to="iinn_EffectiveIncomeTaxTheoreticalTaxCredit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl0" xml:lang="en-US">Proceeds from Issuance of Private Placement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOptionChangesInFairValueGainLoss1_lbl0" xml:lang="en-US">Fair Value, Option, Changes in Fair Value, Gain (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:to="us-gaap_FairValueOptionChangesInFairValueGainLoss1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl0" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfTheoreticalTaxTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Theoretical Tax Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfTheoreticalTaxTableTextBlock" xlink:to="iinn_ScheduleOfTheoreticalTaxTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl0" xml:lang="en-US">Operating Lease, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl1" xml:lang="en-US">Financial Liabilities Fair Value Disclosure</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl0" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_TwoThousandTwentyFourAprilOfferingMember_lbl0" xml:lang="en-US">Two Thousand Twenty Four April Offering Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TwoThousandTwentyFourAprilOfferingMember" xlink:to="iinn_TwoThousandTwentyFourAprilOfferingMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcess_lbl0" xml:lang="en-US">Inventory, Work in Process, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermInvestments_lbl0" xml:lang="en-US">Short-Term Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_AccountsPayableToRelatedParties_lbl1" xml:lang="en-US">Accounts Payable To Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_AccountsPayableToRelatedParties" xlink:to="iinn_AccountsPayableToRelatedParties_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl0" xml:lang="en-US">Proceeds from Debt, Net of Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_IL_lbl0" xml:lang="en-US">ISRAEL</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_IL" xlink:to="country_IL_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl1" xml:lang="en-US">Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl0" xml:lang="en-US">Measurement Input, Expected Term [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl0" xml:lang="en-US">Schedule of Derivative Liabilities at Fair Value [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:to="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficersCompensation_lbl0" xml:lang="en-US">Salary and Wage, Officer, Excluding Cost of Good and Service Sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficersCompensation" xlink:to="us-gaap_OfficersCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Terms of Award</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital_lbl1" xml:lang="en-US">Share Based Compensationplacement Agent Warrants Against Additional Paid In Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital" xlink:to="iinn_ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital_lbl1"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfGeneralAndAdministrativeExpensesAbstract" xlink:href="iinn-20241231.xsd#iinn_ScheduleOfGeneralAndAdministrativeExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfGeneralAndAdministrativeExpensesAbstract_lbl" xml:lang="en-US">Schedule Of General And Administrative Expenses Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfGeneralAndAdministrativeExpensesAbstract" xlink:to="iinn_ScheduleOfGeneralAndAdministrativeExpensesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_OtherReceivableInConnectionToPrivatePlacement_lbl1" xml:lang="en-US">Other Receivable In Connection To Private Placement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_OtherReceivableInConnectionToPrivatePlacement" xlink:to="iinn_OtherReceivableInConnectionToPrivatePlacement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl2" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized_lbl1" xml:lang="en-US">Temporary Differences And Tax Losses For Which No Deferred Tax Asset Is Recognized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized" xlink:to="iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized_lbl1"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfPropertyAndEquipmentNetAbstract" xlink:href="iinn-20241231.xsd#iinn_ScheduleOfPropertyAndEquipmentNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfPropertyAndEquipmentNetAbstract_lbl" xml:lang="en-US">Schedule Of Property And Equipment Net Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfPropertyAndEquipmentNetAbstract" xlink:to="iinn_ScheduleOfPropertyAndEquipmentNetAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_FinanceIncomeAndExpensesPolicyTextBlock_lbl1" xml:lang="en-US">Finance Income And Expenses Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_FinanceIncomeAndExpensesPolicyTextBlock" xlink:to="iinn_FinanceIncomeAndExpensesPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TravelAndEntertainmentExpense_lbl0" xml:lang="en-US">Travel and Entertainment Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TravelAndEntertainmentExpense" xlink:to="us-gaap_TravelAndEntertainmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_PurchasePricePerShare_lbl1" xml:lang="en-US">Purchase Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_PurchasePricePerShare" xlink:to="iinn_PurchasePricePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredOfferingCosts_lbl0" xml:lang="en-US">Deferred Offering Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsCurrent_lbl0" xml:lang="en-US">Deposits Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsAbstract" xlink:href="iinn-20241231.xsd#iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsAbstract_lbl" xml:lang="en-US">Schedule Of Depreciation On Straight Line Method Over The Estimated Useful Life Of The Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsAbstract" xlink:to="iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Other Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl0" xml:lang="en-US">Assets, Noncurrent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold_lbl0" xml:lang="en-US">Compensation Expense, Excluding Cost of Good and Service Sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold" xlink:to="us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>42
<FILENAME>iinn-20241231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Mon Mar 10 18:58:49 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ConsolidatedBalanceSheet" roleURI="http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ConsolidatedIncomeStatement" roleURI="http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ShareholdersEquityType2or3" roleURI="http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ConsolidatedCashFlow" roleURI="http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_General" roleURI="http://www.inspiratechnologies.com/role/General"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_SignificantAccountingPolicies" roleURI="http://www.inspiratechnologies.com/role/SignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_Deposits" roleURI="http://www.inspiratechnologies.com/role/Deposits"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_OtherCurrentAssets" roleURI="http://www.inspiratechnologies.com/role/OtherCurrentAssets"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_Inventory" roleURI="http://www.inspiratechnologies.com/role/Inventory"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_PropertyandEquipmentNet" roleURI="http://www.inspiratechnologies.com/role/PropertyandEquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_OtherAccountsPayable" roleURI="http://www.inspiratechnologies.com/role/OtherAccountsPayable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_CommitmentsandContingencies" roleURI="http://www.inspiratechnologies.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_LeaseLiabilities" roleURI="http://www.inspiratechnologies.com/role/LeaseLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_FinacialLiabilitiesatFairValue" roleURI="http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValue"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ShareholdersEquity" roleURI="http://www.inspiratechnologies.com/role/ShareholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ResearchandDevelopmentExpenses" roleURI="http://www.inspiratechnologies.com/role/ResearchandDevelopmentExpenses"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_GeneralandAdministrativeExpenses" roleURI="http://www.inspiratechnologies.com/role/GeneralandAdministrativeExpenses"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_SalesandMarketingExpenses" roleURI="http://www.inspiratechnologies.com/role/SalesandMarketingExpenses"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_FinancialIncomeandExpenses" roleURI="http://www.inspiratechnologies.com/role/FinancialIncomeandExpenses"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_TaxesonIncome" roleURI="http://www.inspiratechnologies.com/role/TaxesonIncome"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ShareBasedPayment" roleURI="http://www.inspiratechnologies.com/role/ShareBasedPayment"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_RelatedParties" roleURI="http://www.inspiratechnologies.com/role/RelatedParties"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_SubsequentEvents" roleURI="http://www.inspiratechnologies.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_AccountingPoliciesByPolicy" roleURI="http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_SignificantAccountingPoliciesTables" roleURI="http://www.inspiratechnologies.com/role/SignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_OtherCurrentAssetsTables" roleURI="http://www.inspiratechnologies.com/role/OtherCurrentAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_InventoryTables" roleURI="http://www.inspiratechnologies.com/role/InventoryTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_PropertyandEquipmentNetTables" roleURI="http://www.inspiratechnologies.com/role/PropertyandEquipmentNetTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_OtherAccountsPayableTables" roleURI="http://www.inspiratechnologies.com/role/OtherAccountsPayableTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_LeaseLiabilitiesTables" roleURI="http://www.inspiratechnologies.com/role/LeaseLiabilitiesTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_FinacialLiabilitiesatFairValueTables" roleURI="http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ShareholdersEquityTables" roleURI="http://www.inspiratechnologies.com/role/ShareholdersEquityTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ResearchandDevelopmentExpensesTables" roleURI="http://www.inspiratechnologies.com/role/ResearchandDevelopmentExpensesTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_GeneralandAdministrativeExpensesTables" roleURI="http://www.inspiratechnologies.com/role/GeneralandAdministrativeExpensesTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_SalesandMarketingExpensesTables" roleURI="http://www.inspiratechnologies.com/role/SalesandMarketingExpensesTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_FinancialIncomeandExpensesTables" roleURI="http://www.inspiratechnologies.com/role/FinancialIncomeandExpensesTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_TaxesonIncomeTables" roleURI="http://www.inspiratechnologies.com/role/TaxesonIncomeTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ShareBasedPaymentTables" roleURI="http://www.inspiratechnologies.com/role/ShareBasedPaymentTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_RelatedPartiesTables" roleURI="http://www.inspiratechnologies.com/role/RelatedPartiesTables"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ScheduleofOtherCurrentAssetsTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofOtherCurrentAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ScheduleofInventoryTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofInventoryTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ScheduleofPropertyandEquipmentNetTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofPropertyandEquipmentNetTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ScheduleofOtherAccountsPayableTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofOtherAccountsPayableTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ScheduleofOperatingRightofUseAssetsandOperatingLeaseLiabilitiesTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofOperatingRightofUseAssetsandOperatingLeaseLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ScheduleofRightofUseAssetsOvertheRemainingLeasePeriodsTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofRightofUseAssetsOvertheRemainingLeasePeriodsTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ScheduleofFinancialLiabilityTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofFinancialLiabilityTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ScheduleofShareCapitalTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofShareCapitalTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ScheduleofMovementinWarrantsOutstandingTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofMovementinWarrantsOutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ScheduleofInformationabouttheCompanysOutstandingWarrantsTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofInformationabouttheCompanysOutstandingWarrantsTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ScheduleofLossPerShareCalculatedUsingtheWeightedAverageNumberofOrdinarySharesandPreFundedWarrantsTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofLossPerShareCalculatedUsingtheWeightedAverageNumberofOrdinarySharesandPreFundedWarrantsTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ScheduleofResearchandDevelopmentExpensesTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofResearchandDevelopmentExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ScheduleofGeneralandAdministrativeExpensesTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ScheduleofSalesandMarketingExpensesTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofSalesandMarketingExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ScheduleofFinancialIncomeandExpensesTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofFinancialIncomeandExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ScheduleofDeferredTaxAssetsandLiabilitiesTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ScheduleofTheoreticalTaxTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofTheoreticalTaxTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ScheduleofTheoreticalTaxTable_Parentheticals" roleURI="http://www.inspiratechnologies.com/role/ScheduleofTheoreticalTaxTable_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ScheduleofMeasuretheFairValueoftheOptionatGrantDateTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofMeasuretheFairValueoftheOptionatGrantDateTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ScheduleofShareholdersandOtherRelatedPartiesBenefitsTable" roleURI="http://www.inspiratechnologies.com/role/ScheduleofShareholdersandOtherRelatedPartiesBenefitsTable"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_GeneralDetails" roleURI="http://www.inspiratechnologies.com/role/GeneralDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_SignificantAccountingPoliciesDetails" roleURI="http://www.inspiratechnologies.com/role/SignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_DepositsDetails" roleURI="http://www.inspiratechnologies.com/role/DepositsDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_CommitmentsandContingenciesDetails" roleURI="http://www.inspiratechnologies.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_LeaseLiabilitiesDetails" roleURI="http://www.inspiratechnologies.com/role/LeaseLiabilitiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_FinacialLiabilitiesatFairValueDetails" roleURI="http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ShareholdersEquityDetails" roleURI="http://www.inspiratechnologies.com/role/ShareholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_TaxesonIncomeDetails" roleURI="http://www.inspiratechnologies.com/role/TaxesonIncomeDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_ShareBasedPaymentDetails" roleURI="http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails"/>
  <roleRef xlink:type="simple" xlink:href="iinn-20241231.xsd#iinn_r_SubsequentEventsDetails" roleURI="http://www.inspiratechnologies.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#cover" roleURI="http://xbrl.sec.gov/dei/role/document/Cover"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#ai" roleURI="http://xbrl.sec.gov/dei/role/document/AuditInformation"/>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DepositsAssetsCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_Assets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableTradeCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableOtherCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_SellingAndMarketingExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="us-gaap_OperatingIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeDepositsWithFinancialInstitutions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="3.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ChangesDuringThePeriodAbstract" xlink:href="iinn-20241231.xsd#iinn_ChangesDuringThePeriodAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ChangesDuringThePeriodAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringThePeriodAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringThePeriodAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringThePeriodAbstract" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringThePeriodAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringThePeriodAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments" xlink:href="iinn-20241231.xsd#iinn_StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringThePeriodAbstract" xlink:to="StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExerciseOfShareBasedPayments" xlink:href="iinn-20241231.xsd#iinn_StockIssuedDuringPeriodSharesStockOptionsExerciseOfShareBasedPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringThePeriodAbstract" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExerciseOfShareBasedPayments" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringThePeriodAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringThePeriodAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExerciseOfJune2024PrefundedWarrantsIntoOrdinaryShares" xlink:href="iinn-20241231.xsd#iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringThePeriodAbstract" xlink:to="ExerciseOfJune2024PrefundedWarrantsIntoOrdinaryShares" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExerciseOfJune2024PrefundedWarrantsIntoOrdinarySharesinShares" xlink:href="iinn-20241231.xsd#iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinarySharesinShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringThePeriodAbstract" xlink:to="ExerciseOfJune2024PrefundedWarrantsIntoOrdinarySharesinShares" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringThePeriodAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringThePeriodAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringThePeriodAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringThePeriodAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringThePeriodAbstract" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringThePeriodAbstract" xlink:to="us-gaap_NetIncomeLoss" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringThePeriodAbstract" xlink:to="us-gaap_StockholdersEquity_0" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesDuringThePeriodAbstract" xlink:to="us-gaap_SharesOutstanding_0" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForOtherLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForOtherLosses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProvisionForOtherLosses" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueOptionChangesInFairValueGainLoss1" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ExpirationOfFinancialLiability" xlink:href="iinn-20241231.xsd#iinn_ExpirationOfFinancialLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ExpirationOfFinancialLiability" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfOrdinarySharesAdvisorFees" xlink:href="iinn-20241231.xsd#iinn_IssuanceOfOrdinarySharesAdvisorFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="IssuanceOfOrdinarySharesAdvisorFees" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInLeasingReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInLeasingReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInLeasingReceivables" order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="13.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" order="14.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsForProceedsFromInvestments" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_RestrictedCash" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherReceivableInConnectionToPrivatePlacement" xlink:href="iinn-20241231.xsd#iinn_OtherReceivableInConnectionToPrivatePlacement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="OtherReceivableInConnectionToPrivatePlacement" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccruedIssuanceExpenses" xlink:href="iinn-20241231.xsd#iinn_AccruedIssuanceExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="AccruedIssuanceExpenses" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinancialLiabilityPlacementAgentFee" xlink:href="iinn-20241231.xsd#iinn_FinancialLiabilityPlacementAgentFee"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="FinancialLiabilityPlacementAgentFee" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital" xlink:href="iinn-20241231.xsd#iinn_ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NonCashTransactions" xlink:href="iinn-20241231.xsd#iinn_NonCashTransactions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="NonCashTransactions" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_InterestPaidNet" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/General" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/SignificantAccountingPolicies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/Deposits" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositLiabilitiesDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositLiabilitiesDisclosuresTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DepositsAbstract" xlink:to="us-gaap_DepositLiabilitiesDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/OtherCurrentAssets" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherCurrentAssetsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/Inventory" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/PropertyandEquipmentNet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/OtherAccountsPayable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrentAndNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/CommitmentsandContingencies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/LeaseLiabilities" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValue" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/ShareholdersEquity" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/ResearchandDevelopmentExpenses" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/GeneralandAdministrativeExpenses" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="GeneralAndAdministrativeExpensesTextBlock" xlink:href="iinn-20241231.xsd#iinn_GeneralAndAdministrativeExpensesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="GeneralAndAdministrativeExpensesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/SalesandMarketingExpenses" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="SalesAndMarketingExpensesTextBlock" xlink:href="iinn-20241231.xsd#iinn_SalesAndMarketingExpensesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SellingAndMarketingExpenseAbstract" xlink:to="SalesAndMarketingExpensesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/FinancialIncomeandExpenses" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/TaxesonIncome" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/ShareBasedPayment" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/RelatedParties" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/SubsequentEvents" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GovernmentAssistancePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistancePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GovernmentAssistancePolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinanceIncomeAndExpensesPolicyTextBlock" xlink:href="iinn-20241231.xsd#iinn_FinanceIncomeAndExpensesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="FinanceIncomeAndExpensesPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DerivativesPolicyTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeverancePolicyTextBlock" xlink:href="iinn-20241231.xsd#iinn_SeverancePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="SeverancePolicyTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/SignificantAccountingPoliciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock" xlink:href="iinn-20241231.xsd#iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/OtherCurrentAssetsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/InventoryTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/PropertyandEquipmentNetTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/OtherAccountsPayableTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrentAndNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableCurrentAndNoncurrentAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/LeaseLiabilitiesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfLesseeOperatingLeasesDisclosureTableTextBlock" xlink:href="iinn-20241231.xsd#iinn_ScheduleOfLesseeOperatingLeasesDisclosureTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="ScheduleOfLesseeOperatingLeasesDisclosureTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/ShareholdersEquityTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/ResearchandDevelopmentExpensesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/GeneralandAdministrativeExpensesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" xlink:href="iinn-20241231.xsd#iinn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/SalesandMarketingExpensesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfSalesAndMarketingExpensesTableTextBlock" xlink:href="iinn-20241231.xsd#iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SellingAndMarketingExpenseAbstract" xlink:to="ScheduleOfSalesAndMarketingExpensesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/FinancialIncomeandExpensesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/TaxesonIncomeTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfTheoreticalTaxTableTextBlock" xlink:href="iinn-20241231.xsd#iinn_ScheduleOfTheoreticalTaxTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="ScheduleOfTheoreticalTaxTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/ShareBasedPaymentTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/RelatedPartiesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/ScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsAbstract" xlink:href="iinn-20241231.xsd#iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="SignificantAccountingPoliciesScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsDetailsTable" xlink:href="iinn-20241231.xsd#iinn_SignificantAccountingPoliciesScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsAbstract" xlink:to="SignificantAccountingPoliciesScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsDetailsTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AnnualDepreciationRatesOfPropertyPlantAndEquipment" xlink:href="iinn-20241231.xsd#iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="AnnualDepreciationRatesOfPropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/ScheduleofOtherCurrentAssetsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestBearingDepositsInBanks" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestBearingDepositsInBanks"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_InterestBearingDepositsInBanks" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/ScheduleofInventoryTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterials"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryRawMaterials" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcess"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryWorkInProcess" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoods"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryFinishedGoods" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/ScheduleofPropertyandEquipmentNetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyAndEquipmentNetAbstract" xlink:href="iinn-20241231.xsd#iinn_ScheduleOfPropertyAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentNetAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="RDEquipmentMember" xlink:href="iinn-20241231.xsd#iinn_RDEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="RDEquipmentMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAdditions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAdditions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentAdditions" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_Depreciation" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/ScheduleofOtherAccountsPayableTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccountsPayableToRelatedParties" xlink:href="iinn-20241231.xsd#iinn_AccountsPayableToRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract" xlink:to="AccountsPayableToRelatedParties" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract" xlink:to="us-gaap_AccountsPayableOtherCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/ScheduleofOperatingRightofUseAssetsandOperatingLeaseLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/ScheduleofRightofUseAssetsOvertheRemainingLeasePeriodsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/ScheduleofFinancialLiabilityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfFinancialLiabilityAbstract" xlink:href="iinn-20241231.xsd#iinn_ScheduleOfFinancialLiabilityAbstract"/>
    <loc xlink:type="locator" xlink:label="FinacialLiabilitiesatFairValueScheduleofFinancialLiabilityDetailsTable" xlink:href="iinn-20241231.xsd#iinn_FinacialLiabilitiesatFairValueScheduleofFinancialLiabilityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativesFairValueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialLiabilityAbstract" xlink:to="FinacialLiabilitiesatFairValueScheduleofFinancialLiabilityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinacialLiabilitiesatFairValueScheduleofFinancialLiabilityDetailsTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrivateWarrantsMember" xlink:href="iinn-20241231.xsd#iinn_PrivateWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="PrivateWarrantsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinacialLiabilitiesatFairValueScheduleofFinancialLiabilityDetailsTable" xlink:to="us-gaap_DerivativesFairValueLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/ScheduleofShareCapitalTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityScheduleofShareCapitalDetailsTable" xlink:href="iinn-20241231.xsd#iinn_ShareholdersEquityScheduleofShareCapitalDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityScheduleofShareCapitalDetailsLineItems" xlink:href="iinn-20241231.xsd#iinn_ShareholdersEquityScheduleofShareCapitalDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="ShareholdersEquityScheduleofShareCapitalDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityScheduleofShareCapitalDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityScheduleofShareCapitalDetailsTable" xlink:to="ShareholdersEquityScheduleofShareCapitalDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityScheduleofShareCapitalDetailsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityScheduleofShareCapitalDetailsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityScheduleofShareCapitalDetailsLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/ScheduleofMovementinWarrantsOutstandingTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfMovementInWarrantsOutstandingAbstract" xlink:href="iinn-20241231.xsd#iinn_ScheduleOfMovementInWarrantsOutstandingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMovementInWarrantsOutstandingAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_WarrantMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsIssued" xlink:href="iinn-20241231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsIssued" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeighted-averageExercisePriceIssued" xlink:href="iinn-20241231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeighted-averageExercisePriceIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeighted-averageExercisePriceIssued" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms" xlink:href="iinn-20241231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:href="iinn-20241231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue" xlink:href="iinn-20241231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms" xlink:href="iinn-20241231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:href="iinn-20241231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue" xlink:href="iinn-20241231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms" xlink:href="iinn-20241231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/ScheduleofInformationabouttheCompanysOutstandingWarrantsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfInformationAboutTheCompanySOutstandingWarrantsAbstract" xlink:href="iinn-20241231.xsd#iinn_ScheduleOfInformationAboutTheCompanySOutstandingWarrantsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInformationAboutTheCompanySOutstandingWarrantsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ExercisePrice55Member" xlink:href="iinn-20241231.xsd#iinn_ExercisePrice55Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePrice55Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePrice55TwoMember" xlink:href="iinn-20241231.xsd#iinn_ExercisePrice55TwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePrice55TwoMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="Exercise6875Member" xlink:href="iinn-20241231.xsd#iinn_Exercise6875Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="Exercise6875Member" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceOnePointSixMember" xlink:href="iinn-20241231.xsd#iinn_ExercisePriceOnePointSixMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceOnePointSixMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePrice156Member" xlink:href="iinn-20241231.xsd#iinn_ExercisePrice156Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePrice156Member" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceOnePointOneMember" xlink:href="iinn-20241231.xsd#iinn_ExercisePriceOnePointOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceOnePointOneMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePrice0001Member" xlink:href="iinn-20241231.xsd#iinn_ExercisePrice0001Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePrice0001Member" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_WarrantMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrarGpi3WKEtaAw66u01Fz01dWXY8Co/0nt/EYPpxJQpmucNPntkKGDUIzqiVXTghuh97D+3HoPuNe26jHPIaw4lyMqYvKxFlhkbYBWIUcgKRgNZdvBJC1M0l0xZMZd9F+M0zfHyxoKPMqOYWCT/B42d+bXUalw9kCR7ECrTZgyIl6CQNUWcHwWg7YyEKbKXVQrc457FUG7zZJKYSUUC+IL4iKzuqc3lzwnQ2dokFxrCaevH4cZ3wAdRaitsTLXse0F0xvf4jN2RRB/Es4GBrN6DFIGUHP+xHVo=] CSR-->
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentExpirationDate" xlink:href="iinn-20241231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentExpirationDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentExpirationDate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/ScheduleofLossPerShareCalculatedUsingtheWeightedAverageNumberofOrdinarySharesandPreFundedWarrantsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_CommonStockSharesOutstanding" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/ScheduleofResearchandDevelopmentExpensesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LaborAndRelatedExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LaborAndRelatedExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_LaborAndRelatedExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLaborRelatedExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLaborRelatedExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_OtherLaborRelatedExpenses" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationNonproduction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationNonproduction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_DepreciationNonproduction" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="Subcontractors" xlink:href="iinn-20241231.xsd#iinn_Subcontractors"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="Subcontractors" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IIAParticipation" xlink:href="iinn-20241231.xsd#iinn_IIAParticipation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="IIAParticipation" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfGeneralAndAdministrativeExpensesAbstract" xlink:href="iinn-20241231.xsd#iinn_ScheduleOfGeneralAndAdministrativeExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="GeneralandAdministrativeExpensesScheduleofGeneralandAdministrativeExpensesDetailsTable" xlink:href="iinn-20241231.xsd#iinn_GeneralandAdministrativeExpensesScheduleofGeneralandAdministrativeExpensesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfGeneralAndAdministrativeExpensesLineItems" xlink:href="iinn-20241231.xsd#iinn_ScheduleOfGeneralAndAdministrativeExpensesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfGeneralAndAdministrativeExpensesAbstract" xlink:to="GeneralandAdministrativeExpensesScheduleofGeneralandAdministrativeExpensesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralandAdministrativeExpensesScheduleofGeneralandAdministrativeExpensesDetailsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralandAdministrativeExpensesScheduleofGeneralandAdministrativeExpensesDetailsTable" xlink:to="ScheduleOfGeneralAndAdministrativeExpensesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfGeneralAndAdministrativeExpensesLineItems" xlink:to="us-gaap_ProfessionalFees" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficersCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficersCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfGeneralAndAdministrativeExpensesLineItems" xlink:to="us-gaap_OfficersCompensation" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfGeneralAndAdministrativeExpensesLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LegalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfGeneralAndAdministrativeExpensesLineItems" xlink:to="us-gaap_LegalFees" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralInsuranceExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralInsuranceExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfGeneralAndAdministrativeExpensesLineItems" xlink:to="us-gaap_GeneralInsuranceExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostMaintenance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostMaintenance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfGeneralAndAdministrativeExpensesLineItems" xlink:to="us-gaap_CostMaintenance" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfGeneralAndAdministrativeExpensesLineItems" xlink:to="us-gaap_Depreciation" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TravelAndEntertainmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TravelAndEntertainmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfGeneralAndAdministrativeExpensesLineItems" xlink:to="us-gaap_TravelAndEntertainmentExpense" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FundraisingExpenses" xlink:href="iinn-20241231.xsd#iinn_FundraisingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfGeneralAndAdministrativeExpensesLineItems" xlink:to="FundraisingExpenses" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherGeneralExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfGeneralAndAdministrativeExpensesLineItems" xlink:to="us-gaap_OtherGeneralExpense" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherGeneralExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/ScheduleofSalesandMarketingExpensesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficersCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficersCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SellingAndMarketingExpenseAbstract" xlink:to="us-gaap_OfficersCompensation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SellingAndMarketingExpenseAbstract" xlink:to="us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SellingAndMarketingExpenseAbstract" xlink:to="us-gaap_ProfessionalFees" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherSellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherSellingAndMarketingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SellingAndMarketingExpenseAbstract" xlink:to="us-gaap_OtherSellingAndMarketingExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SellingAndMarketingExpenseAbstract" xlink:to="us-gaap_SellingAndMarketingExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/ScheduleofFinancialIncomeandExpensesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfFinancialIncomeAndExpensesAbstract" xlink:href="iinn-20241231.xsd#iinn_ScheduleOfFinancialIncomeAndExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:href="iinn-20241231.xsd#iinn_RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialIncomeAndExpensesAbstract" xlink:to="RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialIncomeAndExpensesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialIncomeAndExpensesAbstract" xlink:to="us-gaap_FinanceLeaseInterestExpense" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsAccruedExpenses" xlink:href="iinn-20241231.xsd#iinn_DeferredTaxAssetsAccruedExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="DeferredTaxAssetsAccruedExpenses" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsFundRaisingCost2023" xlink:href="iinn-20241231.xsd#iinn_DeferredTaxAssetsFundRaisingCost2023"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="DeferredTaxAssetsFundRaisingCost2023" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxLiabilitiesOperatingLeaseLiability" xlink:href="iinn-20241231.xsd#iinn_DeferredTaxLiabilitiesOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="DeferredTaxLiabilitiesOperatingLeaseLiability" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/ScheduleofTheoreticalTaxTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfTheoreticalTaxAbstract" xlink:href="iinn-20241231.xsd#iinn_ScheduleOfTheoreticalTaxAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTheoreticalTaxAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EffectiveIncomeTaxTheoreticalTaxCredit" xlink:href="iinn-20241231.xsd#iinn_EffectiveIncomeTaxTheoreticalTaxCredit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTheoreticalTaxAbstract" xlink:to="EffectiveIncomeTaxTheoreticalTaxCredit" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTheoreticalTaxAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized" xlink:href="iinn-20241231.xsd#iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTheoreticalTaxAbstract" xlink:to="TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTheoreticalTaxAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/ScheduleofTheoreticalTaxTable_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfTheoreticalTaxAbstract" xlink:href="iinn-20241231.xsd#iinn_ScheduleOfTheoreticalTaxAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTheoreticalTaxAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/ScheduleofMeasuretheFairValueoftheOptionatGrantDateTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfMeasureTheFairValueOfTheOptionAtGrantDateAbstract" xlink:href="iinn-20241231.xsd#iinn_ScheduleOfMeasureTheFairValueOfTheOptionAtGrantDateAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentScheduleofMeasuretheFairValueoftheOptionatGrantDateDetailsTable" xlink:href="iinn-20241231.xsd#iinn_ShareBasedPaymentScheduleofMeasuretheFairValueoftheOptionatGrantDateDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMeasureTheFairValueOfTheOptionAtGrantDateAbstract" xlink:to="ShareBasedPaymentScheduleofMeasuretheFairValueoftheOptionatGrantDateDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentScheduleofMeasuretheFairValueoftheOptionatGrantDateDetailsTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentScheduleofMeasuretheFairValueoftheOptionatGrantDateDetailsTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife" xlink:href="iinn-20241231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfOptionsToServicesProvidersAndAdvisersOutstandingAbstract" xlink:href="iinn-20241231.xsd#iinn_ScheduleOfOptionsToServicesProvidersAndAdvisersOutstandingAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsTable" xlink:href="iinn-20241231.xsd#iinn_ShareBasedPaymentScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOptionsToServicesProvidersAndAdvisersOutstandingAbstract" xlink:to="ShareBasedPaymentScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ServicesProvidersAndAdvisersMember" xlink:href="iinn-20241231.xsd#iinn_ServicesProvidersAndAdvisersMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="ServicesProvidersAndAdvisersMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EmployeesAndDirectorsMember" xlink:href="iinn-20241231.xsd#iinn_EmployeesAndDirectorsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="EmployeesAndDirectorsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsReclassifiedToEmployeesAndDirectors" xlink:href="iinn-20241231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsReclassifiedToEmployeesAndDirectors"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsReclassifiedToEmployeesAndDirectors" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceReclassifiedToEmployeesAndDirectors" xlink:href="iinn-20241231.xsd#iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceReclassifiedToEmployeesAndDirectors"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceReclassifiedToEmployeesAndDirectors" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi" xlink:href="iinn-20241231.xsd#iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/ScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfRsusToServicesProvidersAndAdvisersOutstandingAbstract" xlink:href="iinn-20241231.xsd#iinn_ScheduleOfRsusToServicesProvidersAndAdvisersOutstandingAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsTable" xlink:href="iinn-20241231.xsd#iinn_ShareBasedPaymentScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRsusToServicesProvidersAndAdvisersOutstandingAbstract" xlink:to="ShareBasedPaymentScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested" xlink:href="iinn-20241231.xsd#iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/ScheduleofShareholdersandOtherRelatedPartiesBenefitsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfShareholdersAndOtherRelatedPartiesBenefitsAbstract" xlink:href="iinn-20241231.xsd#iinn_ScheduleOfShareholdersAndOtherRelatedPartiesBenefitsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareholdersAndOtherRelatedPartiesBenefitsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_TitleOfIndividualAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="OfficersAndDirectorsMember" xlink:href="iinn-20241231.xsd#iinn_OfficersAndDirectorsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="OfficersAndDirectorsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_OfficerMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OfficerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_OfficerMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_DirectorMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficersCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficersCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OfficersCompensation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NatureOfCommonOwnershipOrManagementControlRelationships" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfCommonOwnershipOrManagementControlRelationships"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_NatureOfCommonOwnershipOrManagementControlRelationships" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NatureOfCommonOwnershipOrManagementControlRelationships_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfCommonOwnershipOrManagementControlRelationships"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/GeneralDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="GeneralDetailsTable" xlink:href="iinn-20241231.xsd#iinn_GeneralDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PublicUtilitiesGeneralDisclosuresLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PublicUtilitiesGeneralDisclosuresLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="GeneralDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="DecemberPrivatePlacementMember" xlink:href="iinn-20241231.xsd#iinn_DecemberPrivatePlacementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="DecemberPrivatePlacementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PreFundedWarrantsMember" xlink:href="iinn-20241231.xsd#iinn_PreFundedWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="PreFundedWarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="JunePreFundedWarrantsMember" xlink:href="iinn-20241231.xsd#iinn_JunePreFundedWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="JunePreFundedWarrantsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="JunePlacementAgentWarrantsMember" xlink:href="iinn-20241231.xsd#iinn_JunePlacementAgentWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="JunePlacementAgentWarrantsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DecemberPreFundedWarrantsMember" xlink:href="iinn-20241231.xsd#iinn_DecemberPreFundedWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="DecemberPreFundedWarrantsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_WarrantMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralDetailsTable" xlink:to="us-gaap_PublicUtilitiesGeneralDisclosuresLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesGeneralDisclosuresLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesGeneralDisclosuresLineItems" xlink:to="us-gaap_SharePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesGeneralDisclosuresLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesGeneralDisclosuresLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PartnersCapitalAccountPublicSaleOfUnitsNetOfOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PartnersCapitalAccountPublicSaleOfUnitsNetOfOfferingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesGeneralDisclosuresLineItems" xlink:to="us-gaap_PartnersCapitalAccountPublicSaleOfUnitsNetOfOfferingCosts" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfOrdinaryShares" xlink:href="iinn-20241231.xsd#iinn_PercentageOfOrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesGeneralDisclosuresLineItems" xlink:to="PercentageOfOrdinaryShares" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PlacementAgentWarrantsFairValue" xlink:href="iinn-20241231.xsd#iinn_PlacementAgentWarrantsFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesGeneralDisclosuresLineItems" xlink:to="PlacementAgentWarrantsFairValue" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionExercisePriceIncrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesGeneralDisclosuresLineItems" xlink:to="us-gaap_StockOptionExercisePriceIncrease" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateProceedsReceived" xlink:href="iinn-20241231.xsd#iinn_AggregateProceedsReceived"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesGeneralDisclosuresLineItems" xlink:to="AggregateProceedsReceived" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionalOfferingCosts" xlink:href="iinn-20241231.xsd#iinn_AdditionalOfferingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesGeneralDisclosuresLineItems" xlink:to="AdditionalOfferingCosts" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesGeneralDisclosuresLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PublicUtilitiesGeneralDisclosuresLineItems" xlink:to="us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/SignificantAccountingPoliciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="SignificantAccountingPoliciesDetailsTable" xlink:href="iinn-20241231.xsd#iinn_SignificantAccountingPoliciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatutoryAccountingPracticesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatutoryAccountingPracticesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="SignificantAccountingPoliciesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_WeightedAverageMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_WeightedAverageMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_WeightedAverageMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_StatutoryAccountingPracticesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatutoryAccountingPracticesLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatutoryAccountingPracticesLineItems" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatutoryAccountingPracticesLineItems" xlink:to="us-gaap_ShortTermInvestments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/DepositsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositsAbstract"/>
    <loc xlink:type="locator" xlink:label="DepositsDetailsTable" xlink:href="iinn-20241231.xsd#iinn_DepositsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositLiabilityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepositLiabilityLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DepositsAbstract" xlink:to="DepositsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DepositsDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="BankLeumiMember" xlink:href="iinn-20241231.xsd#iinn_BankLeumiMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="BankLeumiMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DepositsDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_US" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="country_IL" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_IL"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_IL" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DepositsDetailsTable" xlink:to="us-gaap_DepositLiabilityLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Deposits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Deposits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DepositLiabilityLineItems" xlink:to="us-gaap_Deposits" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtPercentageBearingFixedInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DepositLiabilityLineItems" xlink:to="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="CommitmentsandContingenciesDetailsTable" xlink:href="iinn-20241231.xsd#iinn_CommitmentsandContingenciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="CommitmentsandContingenciesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_OtherCommitmentsLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AggregateBudget" xlink:href="iinn-20241231.xsd#iinn_AggregateBudget"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="AggregateBudget" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfApprovedBudget" xlink:href="iinn-20241231.xsd#iinn_PercentageOfApprovedBudget"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="PercentageOfApprovedBudget" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProjectBudgetAggregateAmount" xlink:href="iinn-20241231.xsd#iinn_ProjectBudgetAggregateAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="ProjectBudgetAggregateAmount" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherReceivables" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RoyaltiesPercentage" xlink:href="iinn-20241231.xsd#iinn_RoyaltiesPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="RoyaltiesPercentage" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ContingentUponFutureSales" xlink:href="iinn-20241231.xsd#iinn_ContingentUponFutureSales"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="ContingentUponFutureSales" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/LeaseLiabilitiesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <loc xlink:type="locator" xlink:label="LeaseLiabilitiesDetailsTable" xlink:href="iinn-20241231.xsd#iinn_LeaseLiabilitiesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="LeaseLiabilitiesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeaseLiabilitiesDetailsTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeaseLiabilitiesDetailsTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_PaymentsForRent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MonthlyDeductionFromTerminationFee" xlink:href="iinn-20241231.xsd#iinn_MonthlyDeductionFromTerminationFee"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="MonthlyDeductionFromTerminationFee" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLeasePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_ProceedsFromLeasePayments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfFutureLeasePaymentsDiscounted" xlink:href="iinn-20241231.xsd#iinn_PercentageOfFutureLeasePaymentsDiscounted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="PercentageOfFutureLeasePaymentsDiscounted" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageForCarsLeaseAgreementCancellationPenalty" xlink:href="iinn-20241231.xsd#iinn_PercentageForCarsLeaseAgreementCancellationPenalty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="PercentageForCarsLeaseAgreementCancellationPenalty" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="FinacialLiabilitiesatFairValueDetailsTable" xlink:href="iinn-20241231.xsd#iinn_FinacialLiabilitiesatFairValueDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:to="FinacialLiabilitiesatFairValueDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinacialLiabilitiesatFairValueDetailsTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExpectedTermMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinacialLiabilitiesatFairValueDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinacialLiabilitiesatFairValueDetailsTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="December2024PrivatePlacementMember" xlink:href="iinn-20241231.xsd#iinn_December2024PrivatePlacementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="December2024PrivatePlacementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinacialLiabilitiesatFairValueDetailsTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinacialLiabilitiesatFairValueDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PrivateWarrantsMember" xlink:href="iinn-20241231.xsd#iinn_PrivateWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="PrivateWarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinacialLiabilitiesatFairValueDetailsTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="PercentageOfPayFees" xlink:href="iinn-20241231.xsd#iinn_PercentageOfPayFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="PercentageOfPayFees" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityMeasurementInput"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/ShareholdersEquityDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDetailsTable" xlink:href="iinn-20241231.xsd#iinn_ShareholdersEquityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="ShareholdersEquityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TwoThousandTwentyFourAprilOfferingMember" xlink:href="iinn-20241231.xsd#iinn_TwoThousandTwentyFourAprilOfferingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="TwoThousandTwentyFourAprilOfferingMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TwoThousandTwentyFourJuneOfferingMember" xlink:href="iinn-20241231.xsd#iinn_TwoThousandTwentyFourJuneOfferingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="TwoThousandTwentyFourJuneOfferingMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_IPOMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DecemberPrivateOfferingMember" xlink:href="iinn-20241231.xsd#iinn_DecemberPrivateOfferingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="DecemberPrivateOfferingMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="December2024PrivatePlacementMember" xlink:href="iinn-20241231.xsd#iinn_December2024PrivatePlacementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="December2024PrivatePlacementMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="RegisteredDirectOfferingMember" xlink:href="iinn-20241231.xsd#iinn_RegisteredDirectOfferingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="RegisteredDirectOfferingMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="RothCapitalPartnersLLCMember" xlink:href="iinn-20241231.xsd#iinn_RothCapitalPartnersLLCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RothCapitalPartnersLLCMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="srt_RangeAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PreFundedWarrantsMember" xlink:href="iinn-20241231.xsd#iinn_PreFundedWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="PreFundedWarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrivateWarrantsMember" xlink:href="iinn-20241231.xsd#iinn_PrivateWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="PrivateWarrantsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_WarrantMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PlacementAgentWarrantsMember" xlink:href="iinn-20241231.xsd#iinn_PlacementAgentWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="PlacementAgentWarrantsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="JunePreFundedWarrantsMember" xlink:href="iinn-20241231.xsd#iinn_JunePreFundedWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="JunePreFundedWarrantsMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TwoThousandTwentyFourJuneOfferingMember_0" xlink:href="iinn-20241231.xsd#iinn_TwoThousandTwentyFourJuneOfferingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="TwoThousandTwentyFourJuneOfferingMember_0" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="JunePlacementAgentWarrantsMember" xlink:href="iinn-20241231.xsd#iinn_JunePlacementAgentWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="JunePlacementAgentWarrantsMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DecemberPrivateWarrantsMember" xlink:href="iinn-20241231.xsd#iinn_DecemberPrivateWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="DecemberPrivateWarrantsMember" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DecemberPreFundedWarrantsMember" xlink:href="iinn-20241231.xsd#iinn_DecemberPreFundedWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="DecemberPreFundedWarrantsMember" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="PurchasePricePerShare" xlink:href="iinn-20241231.xsd#iinn_PurchasePricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="PurchasePricePerShare" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="ClassOfPrivateWarrantOrRightOutstanding" xlink:href="iinn-20241231.xsd#iinn_ClassOfPrivateWarrantOrRightOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ClassOfPrivateWarrantOrRightOutstanding" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberofAdditionalOrdinaryShares" xlink:href="iinn-20241231.xsd#iinn_NumberofAdditionalOrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="NumberofAdditionalOrdinaryShares" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredOfferingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_DeferredOfferingCosts" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProductWarrantyLiquidationProceedsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductWarrantyLiquidationProceedsPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ProductWarrantyLiquidationProceedsPercentage" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfSharesPerUnits" xlink:href="iinn-20241231.xsd#iinn_NumberOfSharesPerUnits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="NumberOfSharesPerUnits" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfPayFees" xlink:href="iinn-20241231.xsd#iinn_PercentageOfPayFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="PercentageOfPayFees" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/TaxesonIncomeDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="TaxesonIncomeDetailsTable" xlink:href="iinn-20241231.xsd#iinn_TaxesonIncomeDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="TaxesonIncomeDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesonIncomeDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="country_IL" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_IL"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_IL" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesonIncomeDetailsTable" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_DeferredTaxAssetsNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentDetailsTable" xlink:href="iinn-20241231.xsd#iinn_ShareBasedPaymentDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="ShareBasedPaymentDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_EmployeeStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TwoThousandNineteenEquityIncentivePlanMember" xlink:href="iinn-20241231.xsd#iinn_TwoThousandNineteenEquityIncentivePlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwoThousandNineteenEquityIncentivePlanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_BoardOfDirectorsChairmanMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_BoardOfDirectorsChairmanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdvisoryBoardMembersMember" xlink:href="iinn-20241231.xsd#iinn_AdvisoryBoardMembersMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="AdvisoryBoardMembersMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MedicalBoardMembersMember" xlink:href="iinn-20241231.xsd#iinn_MedicalBoardMembersMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="MedicalBoardMembersMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_OfficerMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OfficerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_OfficerMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_DirectorMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="EmployeesDirectorsAndSubcontractorsMember" xlink:href="iinn-20241231.xsd#iinn_EmployeesDirectorsAndSubcontractorsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="EmployeesDirectorsAndSubcontractorsMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_StockOptionMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentDetailsTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CapitalGainTaxRate" xlink:href="iinn-20241231.xsd#iinn_CapitalGainTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="CapitalGainTaxRate" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfCapitalGainTax" xlink:href="iinn-20241231.xsd#iinn_PercentageOfCapitalGainTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="PercentageOfCapitalGainTax" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.inspiratechnologies.com/role/SubsequentEventsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsTable" xlink:href="iinn-20241231.xsd#iinn_SubsequentEventsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="SubsequentEventsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="DecemberPrivatePlacementMember" xlink:href="iinn-20241231.xsd#iinn_DecemberPrivatePlacementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="DecemberPrivatePlacementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_EmployeeStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TwoThousandNineteenEquityIncentivePlanMember" xlink:href="iinn-20241231.xsd#iinn_TwoThousandNineteenEquityIncentivePlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwoThousandNineteenEquityIncentivePlanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ExecutivesMember" xlink:href="iinn-20241231.xsd#iinn_ExecutivesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="ExecutivesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromBankDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromBankDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromBankDebt" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OfferingFeesAndOtherRelatedExpenses" xlink:href="iinn-20241231.xsd#iinn_OfferingFeesAndOtherRelatedExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="OfferingFeesAndOtherRelatedExpenses" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProceedsFromReceivedFund" xlink:href="iinn-20241231.xsd#iinn_ProceedsFromReceivedFund"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="ProceedsFromReceivedFund" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RestrictedStockUnits" xlink:href="iinn-20241231.xsd#iinn_RestrictedStockUnits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="RestrictedStockUnits" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/dei/role/document/Cover" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitiesTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntitiesTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="11.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesTable" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="12.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityListingsTable" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityListingsTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityListingsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="13.0"/>
    <loc xlink:type="locator" xlink:label="dei_NameChangeEventTable" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NameChangeEventTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_NameChangeEventTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="14.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="OrdinarySharesNoParValueMember" xlink:href="iinn-20241231.xsd#iinn_OrdinarySharesNoParValueMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="OrdinarySharesNoParValueMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsToPurchaseOrdinarySharesMember" xlink:href="iinn-20241231.xsd#iinn_WarrantsToPurchaseOrdinarySharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="WarrantsToPurchaseOrdinarySharesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain"/>
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/dei/role/document/AuditInformation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorTable" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_AuditorTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="OrdinarySharesNoParValueMember" xlink:href="iinn-20241231.xsd#iinn_OrdinarySharesNoParValueMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="OrdinarySharesNoParValueMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsToPurchaseOrdinarySharesMember" xlink:href="iinn-20241231.xsd#iinn_WarrantsToPurchaseOrdinarySharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="WarrantsToPurchaseOrdinarySharesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorTable_0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_AuditorTable_0" xlink:to="dei_EntityAddressesAddressTypeAxis" order="11.0"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_BusinessContactMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094596615344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentRegistrationStatement', window );">Document Registration Statement</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAccountingStandard', window );">Document Accounting Standard</a></td>
<td class="text">U.S. GAAP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">INSPIRA
TECHNOLOGIES OXY B.H.N. LTD.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001837493<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">L3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityContactPersonnelLineItems', window );"><strong>Entity Contact Personnel [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2
Ha-Tidhar St<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Ra&#8217;anana<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">4366504<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">24,252,096<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=iinn_OrdinarySharesNoParValueMember', window );">Ordinary Shares, no par value</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary Shares, no par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_NoTradingSymbolFlag', window );">No Trading Symbol Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=iinn_WarrantsToPurchaseOrdinarySharesMember', window );">Warrants to purchase Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Warrants to purchase Ordinary Shares<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IINNW<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityContactPersonnelLineItems', window );"><strong>Entity Contact Personnel [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Dagi
Ben-Noon<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2
Ha-Tidhar St.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Ra&#8217;anana<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">4366504<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPhoneFaxNumbersLineItems', window );"><strong>Entity Phone Fax Numbers [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">+972<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">4.6230333<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:accountingStandardItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a registration statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityContactPersonnelLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityContactPersonnelLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPhoneFaxNumbersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPhoneFaxNumbersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_NoTradingSymbolFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a security having no trading symbol.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_NoTradingSymbolFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:trueItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=iinn_OrdinarySharesNoParValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=iinn_OrdinarySharesNoParValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=iinn_WarrantsToPurchaseOrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=iinn_WarrantsToPurchaseOrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094693180432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorTable', window );"><strong>Auditor [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ziv Haft<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">1185<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Tel-Aviv, Israel<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorOpinionTextBlock', window );">Auditor Opinion [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Opinion
on the Financial Statements&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
have audited the accompanying balance sheets of Inspira Technologies Oxy B.H.N. Ltd. (the &#8220;Company&#8221;) as of December 31, 2024
and 2023, the related statements of comprehensive loss, changes in shareholders&#8217; equity, and cash flows for each of the three years
in the period ended December 31, 2024, and the related notes (collectively, the &#8220;Financial Statements&#8221;). In our opinion,
the Financial Statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and
2023, and the results of its operations and its cash flows for each of the three years in the period ended December&#160;31, 2024, in
conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;).</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorOpinionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X<br> -Number 210<br> -Section 2<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorOpinionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094594871472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 5,111<span></span>
</td>
<td class="nump">$ 5,041<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsCurrent', window );">Deposits</a></td>
<td class="nump">668<span></span>
</td>
<td class="nump">2,320<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">587<span></span>
</td>
<td class="nump">432<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">444<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">6,810<span></span>
</td>
<td class="nump">7,793<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use assets, net</a></td>
<td class="nump">761<span></span>
</td>
<td class="nump">1,011<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">499<span></span>
</td>
<td class="nump">506<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">1,260<span></span>
</td>
<td class="nump">1,517<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">8,070<span></span>
</td>
<td class="nump">9,310<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade accounts payables</a></td>
<td class="nump">154<span></span>
</td>
<td class="nump">198<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other accounts payables</a></td>
<td class="nump">1,364<span></span>
</td>
<td class="nump">1,026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities</a></td>
<td class="nump">277<span></span>
</td>
<td class="nump">290<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Financial liabilities at fair value</a></td>
<td class="nump">1,575<span></span>
</td>
<td class="nump">1,470<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">3,370<span></span>
</td>
<td class="nump">2,984<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities</a></td>
<td class="nump">378<span></span>
</td>
<td class="nump">588<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non- current liabilities</a></td>
<td class="nump">378<span></span>
</td>
<td class="nump">588<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary shares, no par value: Authorized 100,000,000 ordinary shares as of December 31, 2024 and December 31, 2023; Issued and outstanding 24,252,096 ordinary shares as of December 31, 2024 and 15,652,176 shares as of December 31, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Share capital and additional paid in capital</a></td>
<td class="nump">70,896<span></span>
</td>
<td class="nump">61,259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated losses</a></td>
<td class="num">(66,574)<span></span>
</td>
<td class="num">(55,521)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Shareholders&#8217; Equity</a></td>
<td class="nump">4,322<span></span>
</td>
<td class="nump">5,738<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and Shareholders&#8217; Equity</a></td>
<td class="nump">$ 8,070<span></span>
</td>
<td class="nump">$ 9,310<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094693155632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value (in Dollars per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, Authorized ordinary shares</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, Issued ordinary shares</a></td>
<td class="nump">24,252,096<span></span>
</td>
<td class="nump">15,652,176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, outstanding shares</a></td>
<td class="nump">24,252,096<span></span>
</td>
<td class="nump">15,652,176<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094595692560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">$ 6,323<span></span>
</td>
<td class="nump">$ 7,320<span></span>
</td>
<td class="nump">$ 8,183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">4,185<span></span>
</td>
<td class="nump">4,063<span></span>
</td>
<td class="nump">5,375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing expenses</a></td>
<td class="nump">754<span></span>
</td>
<td class="nump">746<span></span>
</td>
<td class="nump">1,328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other expenses (income)</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="nump">11,267<span></span>
</td>
<td class="nump">12,133<span></span>
</td>
<td class="nump">14,893<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeDepositsWithFinancialInstitutions', window );">Interest income from deposits</a></td>
<td class="num">(172)<span></span>
</td>
<td class="num">(318)<span></span>
</td>
<td class="num">(192)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Finance expenses (income), net</a></td>
<td class="num">(42)<span></span>
</td>
<td class="num">(529)<span></span>
</td>
<td class="nump">275<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before tax</a></td>
<td class="nump">11,053<span></span>
</td>
<td class="nump">11,286<span></span>
</td>
<td class="nump">14,976<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Taxes on income</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Total comprehensive and net loss</a></td>
<td class="nump">$ 11,053<span></span>
</td>
<td class="nump">$ 11,286<span></span>
</td>
<td class="nump">$ 14,976<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per ordinary share, basic (in Dollars per share)</a></td>
<td class="num">$ (0.6)<span></span>
</td>
<td class="num">$ (0.93)<span></span>
</td>
<td class="num">$ (1.39)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per ordinary share, diluted (in Dollars per share)</a></td>
<td class="num">$ (0.6)<span></span>
</td>
<td class="num">$ (0.93)<span></span>
</td>
<td class="num">$ (1.39)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of ordinary shares outstanding basic (in Shares)</a></td>
<td class="nump">18,515,545<span></span>
</td>
<td class="nump">12,095,477<span></span>
</td>
<td class="nump">10,794,594<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of ordinary shares outstanding diluted (in Shares)</a></td>
<td class="nump">18,515,545<span></span>
</td>
<td class="nump">12,095,477<span></span>
</td>
<td class="nump">10,794,594<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeDepositsWithFinancialInstitutions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest income derived from funds deposited with both domestic and foreign financial institutions including funds in money market and other accounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph a<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph b<br> -Subparagraph (1)<br> -Publisher SEC<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeDepositsWithFinancialInstitutions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094594446784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Changes in Shareholders&#8217; Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Ordinary Share</div></th>
<th class="th" colspan="2"><div>Share capital and Additional Paid in Capital</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,987<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (29,259)<span></span>
</td>
<td class="nump">$ 23,728<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2021</a></td>
<td class="nump">10,091,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ChangesDuringThePeriodAbstract', window );"><strong>Changes during the period:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments', window );">Exercise of share based payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_StockIssuedDuringPeriodSharesStockOptionsExerciseOfShareBasedPayments', window );">Exercise of share based payments (in Shares)</a></td>
<td class="nump">7,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted share unit (&#8220;RSU&#8221;)vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted share unit (&#8220;RSU&#8221;)vesting (in Shares)</a></td>
<td class="nump">1,240,204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,879<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="nump">4,879<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Comprehensive and net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(14,976)<span></span>
</td>
<td class="num">(14,976)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,866<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(44,235)<span></span>
</td>
<td class="nump">13,631<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2022</a></td>
<td class="nump">11,338,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ChangesDuringThePeriodAbstract', window );"><strong>Changes during the period:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of ordinary shares, private warrants and pre-funded warrants, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,806<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,806<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of ordinary shares, private warrants and pre-funded warrants, net (in Shares)</a></td>
<td class="nump">3,031,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of placement agent warrants (Note 11.3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="nump">131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of ordinary shares (pursuant to an at-the-market facility)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of ordinary shares (pursuant to an at-the-market facility) (in Shares)</a></td>
<td class="nump">17,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments', window );">Exercise of share based payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_StockIssuedDuringPeriodSharesStockOptionsExerciseOfShareBasedPayments', window );">Exercise of share based payments (in Shares)</a></td>
<td class="nump">37,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted share unit (&#8220;RSU&#8221;)vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted share unit (&#8220;RSU&#8221;)vesting (in Shares)</a></td>
<td class="nump">1,226,448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,427<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,427<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Comprehensive and net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(11,286)<span></span>
</td>
<td class="num">(11,286)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,259<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(55,521)<span></span>
</td>
<td class="nump">5,738<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2023</a></td>
<td class="nump">15,652,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ChangesDuringThePeriodAbstract', window );"><strong>Changes during the period:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of ordinary shares, private warrants and pre-funded warrants, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,679<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="nump">7,679<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of ordinary shares, private warrants and pre-funded warrants, net (in Shares)</a></td>
<td class="nump">6,231,169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options (in Shares)</a></td>
<td class="nump">19,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinaryShares', window );">Exercise of June 2024 pre-funded warrants into ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinarySharesinShares', window );">Exercise of June 2024 pre-funded warrants into ordinary shares (in Shares)</a></td>
<td class="nump">1,709,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted share unit (&#8220;RSU&#8221;)vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted share unit (&#8220;RSU&#8221;)vesting (in Shares)</a></td>
<td class="nump">594,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of ordinary shares- advisor fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of ordinary shares- advisor fees (in Shares)</a></td>
<td class="nump">45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,892<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,892<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Comprehensive and net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(11,053)<span></span>
</td>
<td class="num">(11,053)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,896<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (66,574)<span></span>
</td>
<td class="nump">$ 4,322<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2024</a></td>
<td class="nump">24,252,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Less
than thousand dollars</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ChangesDuringThePeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ChangesDuringThePeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of exercise of june 2024 pre-funded warrants into ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinarySharesinShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of exercise of June 2024 pre-funded warrants into ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinarySharesinShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_StockIssuedDuringPeriodSharesStockOptionsExerciseOfShareBasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares exercise of share based payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_StockIssuedDuringPeriodSharesStockOptionsExerciseOfShareBasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise of share based payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for restricted stock unit under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094589109728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flow - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOW FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (11,053)<span></span>
</td>
<td class="num">$ (11,286)<span></span>
</td>
<td class="num">$ (14,976)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">171<span></span>
</td>
<td class="nump">111<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForOtherLosses', window );">Capital loss</a></td>
<td class="nump">5<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation expenses</a></td>
<td class="nump">1,892<span></span>
</td>
<td class="nump">1,427<span></span>
</td>
<td class="nump">4,879<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Share based compensation &#8211; placement agent warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1', window );">Evaluation of financial liability at fair value</a></td>
<td class="nump">47<span></span>
</td>
<td class="num">(306)<span></span>
</td>
<td class="num">(108)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ExpirationOfFinancialLiability', window );">Expiration of financial liability</a></td>
<td class="num">(11)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Issuance cost</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">205<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_IssuanceOfOrdinarySharesAdvisorFees', window );">Issuance of ordinary shares - advisor fees</a></td>
<td class="nump">62<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Prepayments of lease liabilities</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="num">(51)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInLeasingReceivables', window );">Decrease (increase) in right of use assets, net</a></td>
<td class="nump">31<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="num">(99)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Decrease (increase) in other current assets</a></td>
<td class="num">(84)<span></span>
</td>
<td class="nump">190<span></span>
</td>
<td class="nump">99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">(Decrease) increase in trade accounts payables</a></td>
<td class="num">(44)<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable', window );">(Decrease) increase in other accounts payable</a></td>
<td class="nump">118<span></span>
</td>
<td class="num">(190)<span></span>
</td>
<td class="nump">496<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">(Increase) decrease in inventory</a></td>
<td class="num">(444)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Unrealized foreign exchange (gain) loss</a></td>
<td class="num">(55)<span></span>
</td>
<td class="nump">65<span></span>
</td>
<td class="nump">438<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(9,374)<span></span>
</td>
<td class="num">(9,691)<span></span>
</td>
<td class="num">(9,209)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOW FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property, plant, and equipment</a></td>
<td class="num">(164)<span></span>
</td>
<td class="num">(206)<span></span>
</td>
<td class="num">(263)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromInvestments', window );">Change in deposits, net</a></td>
<td class="nump">1,652<span></span>
</td>
<td class="nump">4,800<span></span>
</td>
<td class="num">(7,120)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided (used in) investing activities</a></td>
<td class="nump">1,488<span></span>
</td>
<td class="nump">4,594<span></span>
</td>
<td class="num">(7,383)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Issuance of ordinary shares, pre-funded warrants and ordinary warrants, net</a></td>
<td class="nump">7,898<span></span>
</td>
<td class="nump">3,424<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Exercise of options</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Exercise of pre-funded warrants</a></td>
<td class="nump">2<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of ordinary shares (issuances pursuant to an at-the-market facility)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">7,902<span></span>
</td>
<td class="nump">3,453<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="nump">55<span></span>
</td>
<td class="num">(65)<span></span>
</td>
<td class="num">(438)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents and restricted cash</a></td>
<td class="nump">16<span></span>
</td>
<td class="num">(1,644)<span></span>
</td>
<td class="num">(16,592)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at the beginning of the period</a></td>
<td class="nump">5,130<span></span>
</td>
<td class="nump">6,839<span></span>
</td>
<td class="nump">23,869<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at the end of the period</a></td>
<td class="nump">5,201<span></span>
</td>
<td class="nump">5,130<span></span>
</td>
<td class="nump">6,839<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">5,111<span></span>
</td>
<td class="nump">5,041<span></span>
</td>
<td class="nump">6,783<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">90<span></span>
</td>
<td class="nump">89<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Total cash, cash equivalents and restricted cash shown in the statement of cash flows</a></td>
<td class="nump">5,201<span></span>
</td>
<td class="nump">5,130<span></span>
</td>
<td class="nump">6,839<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong></strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_OtherReceivableInConnectionToPrivatePlacement', window );">Other receivable in connection to December private placement</a></td>
<td class="nump">70<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AccruedIssuanceExpenses', window );">Accrued issuance expenses</a></td>
<td class="num">(220)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FinancialLiabilityPlacementAgentFee', window );">Financial liability- placement agent fee (Note 10-A)</a></td>
<td class="num">(69)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital', window );">Share based compensation- placement agent warrants against additional paid in capital (Note 11)</a></td>
<td class="num">(254)<span></span>
</td>
<td class="num">(73)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_NonCashTransactions', window );">Total non cash transactions</a></td>
<td class="num">(473)<span></span>
</td>
<td class="num">(73)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">$ 72<span></span>
</td>
<td class="nump">$ 93<span></span>
</td>
<td class="nump">$ 106<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_AccruedIssuanceExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued issuance expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_AccruedIssuanceExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ExpirationOfFinancialLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expiration of financial liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ExpirationOfFinancialLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_FinancialLiabilityPlacementAgentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of financial liability placement agent fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_FinancialLiabilityPlacementAgentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_IssuanceOfOrdinarySharesAdvisorFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of issuance of ordinary shares advisor fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_IssuanceOfOrdinarySharesAdvisorFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_NonCashTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of non cash transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_NonCashTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_OtherReceivableInConnectionToPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other receivable in connection to private placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_OtherReceivableInConnectionToPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of share based compensation-placement agent warrants against additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOptionChangesInFairValueGainLoss1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInLeasingReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from lessees arising from lease agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInLeasingReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash paid (received) associated with the acquisition or disposal of all investments, including securities and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForOtherLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to other loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForOtherLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094593136560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>General [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">GENERAL</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 1
- GENERAL:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">1.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Inspira
                                            Technologies Oxy B.H.N. Ltd (the &#8220;Company&#8221;) was incorporated in Israel and commenced
                                            its operations on February 27, 2018. The Company operates in the medical technology industry
                                            in the field of respiratory support technology engaged in the research, development, manufacturing
                                            related activities, and go-to-market activities of proprietary products and technologies.
                                            The Company is developing the following products:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
                                            INSPIRA ART (Augmented Respiratory Technology), which is a respiratory support technology
                                            targeted toward utilizing blood monitoring and direct blood oxygenation to boost patient
                                            saturation levels within minutes while the patient is awake. The aim is to provide an alternative
                                            to invasive mechanical ventilation, associated with high risks, complications, high costs
                                            and high mortality rates.</span></td></tr><tr style="vertical-align: top">
<td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
                                   </table>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
                                            HYLA blood sensor, which is a non-invasive optical blood sensor designed to perform real-time
                                            and continuous blood parameter measurements, potentially reducing the need for intermittent
                                            blood samples from patients.</span></td></tr><tr style="vertical-align: top">
<td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
                                                                                                                              </table>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
                                            INSPIRA ART100 System, an advanced form of life support system, better known by the medical
                                            industry as a cardiopulmonary bypass system, has been designed for use in procedures requiring
                                            cardiopulmonary bypass for six hours or less.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company&#8217;s INSPIRA&#8482; ART100 system received U.S. Food and Drug Administration 510(k) regulatory clearance for cardiopulmonary
bypass procedures and Israeli Medical Equipment Division certification for extra-corporeal membrane oxygenation and cardiopulmonary bypass
procedures. The Company&#8217;s other products, including the INSPIRA&#8482; ART and HYLA&#8482; blood sensor, have not yet been tested
or used in humans and have not been approved by any regulatory entity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;  border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">2.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On April 1, 2024, the Company entered into a purchase agreement with two investors in a registered direct offering (the &#8220;2024 April Offering&#8221;), pursuant to which the Company issued an aggregate of 1,339,285 of the Company&#8217;s ordinary shares (&#8220;Ordinary Shares&#8221;) at a purchase price of $1.232 per share. The gross proceeds received by the Company from the 2024 April Offering were approximately $1,651. There were no issuance costs.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;  border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">3.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On June 14, 2024, the Company entered into a purchase agreement with an individual private investor in a registered direct offering (the &#8220;2024 June Offering&#8221;), pursuant to which the Company issued: (i) 941,541 Ordinary Shares at a purchase price of $1.30 per share and (ii) pre-funded warrants (&#8220;June Pre-Funded Warrants&#8221;) to purchase up to 1,709,760 Ordinary shares, at a purchase price of $1.30, less $0.001 per June Pre-Funded Warrant. The net proceeds received by the Company from the 2024 June Offering were approximately $3,102, after deducting offering costs in cash, which totaled in approximately $343. In addition, the Company issued the placement agent in the 2024 June Offering (&#8220;June Placement Agent&#8221;) warrants equal to a total of 7.0% of the aggregate number of Ordinary Shares sold in the transaction to purchase up to 185,591 Ordinary Shares (the &#8220;June Placement Agent Warrants&#8221;). The fair value of the June Placement Agent Warrants on the issuance date was $254 and it was recorded as part of the issuance costs.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;  border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">4.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On December 27, 2024, the Company entered into a purchase agreement with several investors in a private placement financing (the &#8220;December Private Placement&#8221;), pursuant to which the Company issued (i) an aggregate of 3,950,343 of the Company&#8217;s Ordinary Shares at a purchase price of $0.70 per share, and (ii) pre-funded warrants (the &#8220;December Pre-Funded Warrants&#8221;) to purchase up to 658,372 Ordinary shares, at a purchase price of $0.70, less $0.001 per December Pre-Funded Warrant. In addition, pursuant to a certain securities purchase agreement, the Company issued warrants to the investors to purchase up to an aggregate of 4,608,715 Ordinary Shares at an exercise price of $1.10 per share. The gross proceeds received by the Company from the December Private Placement were approximately $3,228, before deducting placement agent commissions and additional offering costs which totaled in approximately $233. In addition, The Company agreed to pay fees of 4% from the funds that may be received in an event of the exercise of the Company&#8217;s private warrants issued in December 2024 Private Placement, which created a financial liability in amount of $69 which is the total potential amount (Note 10-A).</span></td></tr></table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">5.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The accompanying financial statements (the &#8220;Financial Statements&#8221;)
have been prepared assuming that the Company will continue as a going concern. To date, the Company is in its development stage. Therefore,
the Company has suffered recurring losses from operations and negative cash flows from operations since inception. As of December 31,
2024, the Company had incurred accumulated losses of $67 million and expects to continue to fund its operations through fundings such
as issuance of convertible securities, Ordinary Shares and warrants and through Israeli governmental grants. There is no assurance that
such financing will be obtained. Considering the above, our dependence on external funding for our operations raises a substantial doubt
about our ability to continue as a going concern. The Financial Statements do not include any adjustments that might result from the outcome
of these uncertainties.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">6.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Our
                                            offices are located in Ra&#8217;anana, Israel. On October 7, 2023, Hamas terrorists infiltrated
                                            Israel&#8217;s southern border from the Gaza Strip and conducted a series of attacks on civilian
                                            and military targets. Following the attack, Israel declared war against Hamas and the Israeli
                                            military began to call-up reservists for an active duty. Other regional hostilities, since
                                            October 7, 2023, concurrently became more pronounced. This includes and has included a northern
                                            front war igniting between Israel and Hezbollah, which as of February 24, 2025 we are under
                                            a ceasefire, hostilities between Israel and Iran, which have included Iranian strikes against
                                            Israel in April 2024 and October 2024, and subsequent retaliation by Israel to both instances,
                                            and a continued conflict between Israel and the Houthi Movement in Yemen.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">As
of the date of these Financial Statements, these events have no material impact on the Company&#8217;s operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">7.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Although
                                            we do not currently conduct business in Russia and Ukraine, the escalation of geopolitical
                                            instability in Russia and Ukraine as well as currency fluctuations in the Russian Ruble has
                                            had a negative impact on worldwide markets. Such impact may negatively impact our supply
                                            chain, our operations and future growth prospects in that region.&#160;As a result of the
                                            crisis in Ukraine,&#160;both the U.S. and other countries have implemented sanctions against
                                            certain Russian individuals and entities. Our global operations expose us to risks that could
                                            adversely affect our business, financial condition, results of operations, cash flows or
                                            the market price of our securities, including the potential for increased tensions between
                                            Russia and other countries resulting from the current situation involving Russia and Ukraine,
                                            tariffs, economic sanctions and import-export restrictions imposed, and retaliatory actions,
                                            as well as the potential negative impact on our potential business and sales in the region.
                                            Current geopolitical instability in Russia and Ukraine and related sanctions by the U.S.
                                            and other governments against certain companies and individuals may hinder our ability to
                                            conduct business with potential customers and vendors in these countries.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">8.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">These
                                            Financial Statements were authorized by the Board of Directors on March 6, 2025.</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094593157104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 2
</b>- <b>SIGNIFICANT ACCOUNTING POLICIES:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
accompanying Financial Statements have been prepared in conformity with the U.S. GAAP. The significant accounting policies followed in
the preparation of the Financial Statements are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>A.
Use of estimates:</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
preparation of Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the Financial Statements,
and the reported amounts of expenses during the reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif">Items
subject to such estimates and assumptions include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">stock-based
                                            compensation expense;</span></td></tr><tr style="vertical-align: top">
<td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
                                                                                                                                                              </table>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">fair
                                            value financial liabilities;</span></td></tr><tr style="vertical-align: top">
<td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
                                                                                                                                                              </table>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">recognition,
                                            measurement, and disclosure of contingent liabilities;</span></td></tr><tr style="vertical-align: top">
<td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
                                                                                                                                                                                                </table>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">Interest
                                            rate used for lease liability measurement.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">As
of the date of issuance of the Financial Statements, the Company is not aware of any material specific events or circumstances that would
require it to update its estimates, judgments, or to revise the carrying values of its assets or liabilities. These estimates may change,
as new events occur and additional information is obtained, and are recognized in the Financial Statements as soon as they become known.
Actual results could differ from those estimates and any such differences may be material to the Company&#8217;s Financial Statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>B.
<span>Foreign Currency</span></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
currency of the primary economic environment in which the operations of the Company are conducted is the U.S. dollar (&#8220;USD&#8221;).
The Company&#8217;s funding and expected revenues are mostly in USD. Thus, the functional currency of the Company is in USD.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Transactions
and balances originally denominated in USD are presented at their original amounts. Balances in non-USD currencies are translated into
USD using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-USD transactions and other
items in the statements of income (indicated below), the following exchange rates are used: (i) for transactions &#8211; exchange rates
at transaction dates or average exchange rates; and (ii) for other items (derived from non-monetary balance sheet items such as depreciation
and amortization) &#8211; historical exchange rates. Currency transaction gains and losses are presented in financial expenses (income),
net as appropriate. The functional currency of the Company is USD.&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>C.
Property, Plant, and Equipment</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Property
and equipment are stated at cost. Depreciation is computed based on the straight-line method, over the estimated useful life of the assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Annual
rates of depreciation are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 90%"><span style="font-family: Times New Roman, Times, Serif">Computers</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">33</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">R&amp;D equipment</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">20</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Furniture and office equipment</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">6-15</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Leasehold Improvements</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">10</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif"><b>&#160;&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>D.
Inventory</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Inventories
are stated at the lower of cost or net realizable value. Inventory write-offs are provided to cover risks arising from slow-moving items,
technological obsolescence, excess inventories, discontinued products, and for market prices lower than cost, if any.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The
Company periodically evaluates the quantities on hand relative to historical and projected sales volume (which is determined based on
an assumption of future demand and market conditions) and the age of the inventory. At the point of the loss recognition, a new lower
cost basis for that inventory has been established.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Cost
is determined for all types of inventory using the moving average cost method plus indirect costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>E.
Leases</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company implemented Accounting Standards Update (&#8220;ASU&#8221;) 2016-02, Leases (Topic 842) (&#8220;ASU 2016-02&#8221;) using the
modified retrospective approach for all lease arrangements as of such date. The Company leases office space and vehicles under operating
leases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Arrangements
meeting the definition of a lease are classified as operating or financing leases and are recorded on the balance sheet as both a right
of use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease
or the Company&#8217;s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and
the right of use asset is amortized over the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
lease liability was measured at the present value of the remaining lease payments, discounted using the Company&#8217;s incremental borrowing
rate. The weighted-average&#160;rate applied was 9.60%. Right-of-use&#160;assets were measured at an amount equal to the lease liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">For
operating leases, interest on the lease liability and the amortization of the right of use asset result in straight-line&#160;rent expense
over the lease term. Variable lease expenses are recorded when incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>F.
Research and Development Costs.</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">Research
and development expenses consist primarily of payroll, payroll related expenses, subcontractors, and materials. Costs are expensed as
incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>G.
Government Grants </b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company receives royalty-bearing grants from the Israeli Innovation Authority (&#8220;IIA&#8221;) for approved research and development
projects Under Israeli law, royalties on the revenues derived from products and services developed using such grants, are payable to
the Israeli Government.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
grants are linked to the exchange rate of the dollar to the New Israeli Shekel and bear interest of the Secured Overnight Financing Rate
(&#8220;SOFR&#8221;) per year (SOFR is a benchmark interest rate which replaced LIBOR).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
amounts of grants received and recorded into income should be disclosed for each period presented. The research and development grants
are presented in the statement of operations as an offset to related research and development expenses. Companies are required to pay
royalties in connection with such grants at specified rates, up to the total dollar-linked amount of such grants. <span>research
and development (&#8220;R&amp;D&#8221;).&#160;The Company did not generate sales as of December 31, 2024; therefore, no liability was
recorded in these Financial Statements.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;<b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>H.
Finance Income and Expenses.</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Finance
income is composed of interest on deposits and revaluation of financial liabilities at fair value, while finance expenses are composed
of the revaluation of certain financial liabilities at fair value, bank charges and net currency exchange rates differences.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>I.
Current Taxes</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">The
current tax liability is measured using the tax rates and tax laws that have been enacted or substantively enacted by the reporting date
as well as adjustments required in connection with the tax liability in respect of previous years. The Company has no tax liability due
to its carry forward losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>J.
Share-Based Compensation.</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">Share-based
compensation expenses related to employees, directors and subcontractors&#8217; options or restricted share units (&#8220;RSU&#8221;)
which recognized based on their fair value, which is based on the fair value of the underlying Ordinary Shares as to the de-minimis exercise
price using the graded vesting method.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company recognizes compensation expense for grants of share-based awards to its employees based on the estimated fair value on the grant
date. Compensation cost for awards is recognized over the requisite service period, which approximates the vesting period. Share-based
compensation is included in research and development, selling and marketing and general and administrative expenses. Forfeitures of equity
grants are recognized as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">All
issuances of stock options or other equity instruments to non-employees as consideration for goods or services received by the Company
are accounted for based on the fair value of the equity instruments issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>K.
Warrants and Pre-Funded Warrants</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company issues warrants and pre-funded warrants as part of its financing activities or compensation arrangements. Warrants are derivative
financial instruments that entitle the holder to purchase a specified number of the Company&#8217;s Ordinary Shares at a predetermined
exercise price. Warrants and pre-funded warrants issued by the Company may have various terms, including expiration dates, exercise prices,
and conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company classifies warrants as either equity or liabilities upon issuance, based on specific terms and conditions and in accordance with
Accounting Standard Codification (&#8220;ASC&#8221;) 815, Derivatives and Hedging. Warrants and pre-funded warrants are classified as
equity if they meet the criteria for equity classification outlined in ASC 815-40. Otherwise, warrants are classified as liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>L.
Severance</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Israeli
labor law generally requires payment of severance pay upon dismissal of an employee or upon termination of employment in certain other
circumstances. The Company&#8217;s pension and severance pay liabilities are covered mainly by insurance policies. Pursuant to section
14 of the Israeli Severance Compensation Act, 1963 (&#8220;Section 14&#8221;), the Company&#8217;s employees are entitled to monthly
deposits, at a rate of 8.33% of their monthly salary, made in their name with insurance companies. Payments in accordance with Section
14 relieve the Company from any future severance payments in respect of those employees and, as such, the Company may only utilize the
insurance policies for the purpose of paying severance pay.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>M.
Basic and Diluted Loss Per Share</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Basic
and diluted loss per share is calculated by dividing the loss attributable to equity holders of the Company by the weighted average number
of Ordinary Shares and pre-funded warrants outstanding during the financial year, adjusted for Ordinary Shares and pre-funded warrants
issued during the year, if applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>N.
Fair Value Measurements</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company measures and discloses fair value in accordance with the Financial Accounting Standards Board (&#8220;FASB&#8221;), ASC 820,
Fair Value Measurements and Disclosures (&#8220;ASC 820&#8221;). ASC 820 defines fair value, establishes a framework and gives guidance
regarding the methods used for measuring fair value, and expands disclosures about fair value measurements. Fair value is an exit price,
representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market
participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions
that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, there exists a three-tier
fair-value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Level
1 &#8211; unadjusted quoted prices are available in active markets for identical assets or liabilities that the Company has the ability
to access as of the measurement date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; "><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Level
2 &#8211; pricing inputs are other than quoted prices in active markets that are directly observable for the asset or liability or indirectly
observable through corroboration with observable market data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; "><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Level
3 &#8211; pricing inputs are unobservable for the non-financial asset or liability and only used when there is little, if any, market
activity for the non-financial asset or liability at the measurement date. The inputs into the determination of fair value require significant
management judgment or estimation. Level 3 inputs are considered as the lowest priority within the fair value hierarchy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">This
hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining
fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
fair value of cash is based on its demand value, which is equal to its carrying value. Additionally, the carrying value of all other
short-term monetary assets and liabilities are estimated to be equal to their fair value due to the short-term nature of these instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>O.
Concentration of Credit Risk</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company maintains certain cash balances in a well-known Israeli banks and U.S based banks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Part
of the Company&#8217;s operating expenses are denominated in New Israeli Shekel (&#8220;NIS&#8221;), and therefore, subject to foreign
currency risk.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>P.
Cash and Cash Equivalent</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Cash
equivalents are highly liquid investments that are readily convertible into cash, typically with an original maturity of three months
or less from <span>the date of purchase that are not restricted as to withdrawal or use and are readily
convertible to known amounts of cash.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; ">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; ">Restricted
cash consists of funds that are contractually restricted to bank guarantee due to rental agreements. The Company has presented restricted
cash separately from cash and cash equivalents in the balance sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; ">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Bank
deposits with maturities of more than three months, but less than one year, and which are not restricted are included in short-term deposits.
Such deposits are stated at cost which approximates market value. As of December 31, 2024 and December 31, 2023, the Company had short-term
deposits in the amounts of $0.7 million and $2.3 million, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>Q.
Segment Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; ">The
Company has a single operating and reportable segment. The Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;), who is
the Chief Executive Officer, evaluates the performance of its business based on financial data consistent with the presentation in the
accompanying Financial Statements for the purposes of making operating decisions, assessing financial performance, and allocating resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>R.
New accounting Pronouncements</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; "><b><i>Accounting
Standards Adopted in 2024</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; ">In
March 2023, the FASB issued Accounting Standard Updated No. 2023-01 &#8220;Lease (Topic 842)&#8221;. Topic 842 requires that entities
determine whether a related party arrangement between entities under common control (hereinafter referred to as a common control arrangement)
is a lease. If the arrangement is determined to be a lease, an entity must classify and account for the lease on the same basis as an
arrangement with an unrelated party (on the basis of legally enforceable terms and conditions).That represents a change from the requirements
of Topic 840, Leases, which required that an entity classify and account for an arrangement on the basis of economic substance when those
terms and conditions were affected by the related party nature of the arrangement. The amendments in this Update affect all lessees that
are a party to a lease between entities under common control in which there are leasehold improvements. The amendments apply to all entities
(that is, public business entities, private companies, not-for-profit. The Company adopted ASU 2023-01 on January 1, 2024, its adoption
did not have a material impact on the Financial Statements and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; ">In
June 2022, the FASB issued ASU 2022-03, Fair Value Measurement (Topic 820), &#8220;Fair Value Measurement of Equity Securities Subject
to Contractual Sale Restrictions&#8221; which clarifies that contractual restrictions on equity security sales are not considered part
of the security unit of account and, therefore, are not considered in measuring fair value. In addition, the restrictions cannot be recognized
and measured as separate units of account. Disclosures on such restrictions are also required. The amendments are effective for Fiscal
years beginning after December 15, 2023, and interim periods within those fiscal years on a prospectively basis. The Company expects
that ASU 2022-03 will not have a material impact on its Financial Statements and related disclosures. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; ">In
November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This ASU expands
public entities&#8217; segment disclosures by requiring disclosure of significant segment expenses that are regularly provided to the
CODM and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment
items, and interim disclosures of a reportable segment&#8217;s profit or loss and assets. All disclosure requirements under ASU 2023-07
are also required for public entities with a single reportable segment. The ASU&#8217;s amendments are effective for all public entities
for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early
adoption permitted. We are currently evaluating the impact of this pronouncement on our Financial Statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; "><b><i>Accounting
Pronouncements Issued but Not Yet Adopted</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; ">In
December 2023, the FASB issued ASU 2023-08, Intangibles&#8212;Goodwill and Other&#8212;Crypto Assets (Subtopic 350-60): Accounting for
and Disclosure of Crypto Assets, which addresses the accounting and disclosure requirements for certain crypto assets. This ASU requires
entities to subsequently measure certain crypto assets at fair value, with changes in fair value recorded in net income in each reporting
period. In addition, entities are required to provide additional disclosures about the holdings of certain crypto assets. The ASU&#8217;s
amendments are effective for all entities holding assets that meet certain scope criteria for fiscal years beginning after December 15,
2024, including interim periods within those years. Early adoption is permitted for both interim and annual periods. If an entity adopts
the amendments in an interim period, it must adopt them as of the beginning of the fiscal year that includes that interim period. We
do not expect this pronouncement to have a material impact on our Financial Statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; ">In
December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. Under this ASU, public
entities must annually (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling
items that meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than five percent of the amount
computed by multiplying pretax income or loss by the applicable statutory income tax rate). This ASU&#8217;s amendments are effective
for all entities that are subject to Topic 740, Income Taxes, for annual periods beginning after December 15, 2024, with early adoption
permitted. We are currently evaluating the impact of this pronouncement on our disclosures.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094693276848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deposits<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAbstract', window );"><strong>Deposits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositLiabilitiesDisclosuresTextBlock', window );">DEPOSITS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif"><b>NOTE
3 &#8211; DEPOSITS:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif">The
Company&#8217;s deposits consist of short-term bank deposits with maturities of more than three months but less than one year. The deposits
bear annual interest. <span>Interest earned is recorded as finance income, net in the statement of operations
during the years for which the Company held short-term deposits.</span></span></p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">As
of December 31, 2024, the Company had a deposit in NIS at Bank Leumi in the amount of $668, including interest that bore a fixed annual
interest of 4.108%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">As
of December 31, 2023, the Company had a deposit in USD at Bank Leumi in the amount of $2,040, including interest that bore fixed annual
interest of 6.18% and a deposit in NIS in the amount of $280 that bore fixed annual interest of 4.85%.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositLiabilitiesDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for deposit liabilities including data and tables. It may include a description of the entity's deposit liabilities, the aggregate amount of time deposits (including certificates of deposit) in denominations of $100,000 or more at the balance sheet date; the aggregate amount of any demand deposits that have been reclassified as loan balances, such as overdrafts, at the balance sheet date; deposits that are received on terms other than those in the normal course of business, the amount of accrued interest on deposit liabilities; securities, mortgage loans or other financial instruments that serve as collateral for deposits; for time deposits having a remaining term of more than one year, the aggregate amount of maturities for each of the five years following the balance sheet date; and the weighted average interest rate for all deposit liabilities held by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478353/942-405-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1406<br> -Paragraph e<br> -Publisher SEC<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1406<br> -Publisher SEC<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositLiabilitiesDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094693264080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Other Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">OTHER CURRENT ASSETS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif"><b>NOTE
4 - OTHER CURRENT ASSETS:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December&#160;31,<br/>
    2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December&#160;31,
    <br/> 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Prepaid expenses</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">240</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">176</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Institutions</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">183</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">164</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Restricted Cash</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">90</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">89</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Others</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">74</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">587</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">432</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094693266464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 5
- INVENTORY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December&#160;31,<br/>
    2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December&#160;31,
    <br/> 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Raw materials</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">96</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-63; font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Work in progress</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">55</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-64; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Finished good (*)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">293</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-65; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">444</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-66; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0"><b>(*) As of December 31, 2024, seven INSPIRA ART100 systems and
seven carts were in the course of being delivered to a distributor in the U.S. </b></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094699695648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT, NET</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 6
- PROPERTY AND EQUIPMENT, NET:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">For the
year ended December 31, 2024:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Computers</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Leasehold<br/>
    improvements</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">R&amp;D<br/>
    equipment</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Furniture<br/>
    and office<br/> equipment</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Cost</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">At January 1, 2024</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">172</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">36</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">381</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">116</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">705</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Additions</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">10</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-67; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">154</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-68; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">164</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">At December 31, 2024</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">182</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">36</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">535</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">116</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">869</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accumulated depreciation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">At January 1, 2024</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">102</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">8</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">73</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">16</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">199</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Depreciation</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">44</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">116</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">171</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">At December 31, 2024</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">146</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">12</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">189</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">23</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">370</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Net book value:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">As of December 31, 2024</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">36</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">24</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">346</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">93</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">499</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">For the
year ended December 31, 2023:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Computers</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Leasehold<br/> improvements</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Development<br/> equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Furniture<br/> and office<br/> equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Cost</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-weight: bold">At January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">121</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">33</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">229</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">116</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">499</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Additions</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">51</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">152</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">206</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-left: 9pt">At December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">172</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">381</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">116</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">705</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Accumulated depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold">At January 1, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">51</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">88</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">51</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">48</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">111</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-left: 9pt">At December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">102</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">73</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">199</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold">Net book value:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt">As of December 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">70</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">28</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">308</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">506</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094693208864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Accounts Payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrentAbstract', window );"><strong>Other Accounts Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">OTHER ACCOUNTS PAYABLE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 7
- OTHER ACCOUNTS PAYABLE:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December&#160;31,<br/>
    2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December&#160;31,<br/>
    2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Employees&#8217; salaries and related
    liabilities</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">414</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">388</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Related parties</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">421</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">354</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">508</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">267</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">21</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">17</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,364</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,026</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094693108000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; "><b>NOTE
8 - COMMITMENTS AND CONTINGENCIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.&#160;Royalties
to the IIA:</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 57.4pt; text-indent: -0.7pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; ">In
September 2019, the IIA approved a grant to the Company for the development of intravenous blood oxygenation system for an aggregate
budget of NIS&#160;4,880,603 (approximately $1,500). The IIA committed to fund&#160;60% of the approved budget. Eventually the project
budget concluded in the aggregate amount of NIS 4,623,142 (approximately $1,333). The program is for the period beginning October 2019
through November 2020. From 2019 to 2021, the Company received total funds in the amount of NIS 2,773,885 (approximately $809) from the
IIA, which were recorded as IIA participation and were deducted from R&amp;D expenses. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; ">In
October 2023, the IIA approved a grant to support another development project of the Company at an aggregate budget of NIS&#160;3,850,869
(approximately $1,062). The IIA committed to fund&#160;40% of the approved budget. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; ">The
program is for the period beginning January 2024 through March 2025, and as of December 31, 2024, the Company received total funds in
the amount of NIS 1,062,049 (approximately $286) from the IIA, which were recorded as IIA participation and were deducted from the R&amp;D
expenses. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; ">According
to the agreements with the IIA, The Company will pay royalties of&#160;3% of future sales up to an amount equal to the accumulated grant
received linked to the U.S. dollar and bearing interest at an annual rate of SOFR. Repayment of the grants are contingent upon the successful
completion of the Company&#8217;s R&amp;D programs and generating sales. The Company has no obligation to repay these grants if the R&amp;D
programs fail, are unsuccessful or aborted or if no sales are generated. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; ">The
Company had not generated sales as of December 31, 2024; therefore, no liability was recorded in these Financial Statements. As of December
31, 2024, the maximum obligation with respect to the grants received from the IIA, contingent upon entitled future sales, is $1,095 plus
SOFR interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; ">The
Company has obligations regarding know-how, technology, or products, not to transfer the information, rights thereon and production rights
which derive from the research and development without the IIA Research Committee approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; ">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>B.
Legal Claims</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
the normal course of business, various legal claims and other contingent matters may arise. Management believes that any liability that
may arise from such matters would not have a material adverse effect on the Company&#8217;s results of operations or financial condition
as of and for the years ended December 31, 2024, and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
December 12, 2021, the Company terminated its employment agreement with Dr. Udi Nussinovitch, one of its founders who served as the Company&#8217;s
Chief Scientific Officer since March 2018. On February 24, 2022, the Company sued Mr. Nussinovitch for breach good faith and his fiduciary
duties as a shareholder and former officer of the Company. On November 9, 2022, Mr. Nussinovitch filed a Statement of Claim against the
Company,, as well as a Statement of Claim with the regional labor court in Tel Aviv, Israel on November 8, 2022. Mr. Nussinovitch alleged
certain deficiencies in the Company&#8217;s&#160;Extraordinary General Meeting of Shareholders held on Friday, December 17, 2021, resulting
from his status as a minority shareholder. In addition, with respect to the labor dispute, Mr.&#160;Nussinovitch is seeking renumeration
and the issuance of Ordinary Shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
July 19. 2023, a partial hearing about the labor dispute was held, in which the parties were required by the court to file their positions
on a stay of the proceeding pending the decision on the case initiated by Mr. Nussinovitch in the District Court. On January 21, 2024,
a partial hearing about the civil case was held. During the hearing, the court suggested the parties consider the possibility of resolving
the case through an out-of-court arrangement or mediation. The parties agreed to a mediation process which did not succeed. On
January 7, 2025,&#160;Mr. Nussinovitch&#160;filed a motion to amend his Statement of Claim, requesting to modify the requested relief.
Instead of the original remedies sought,&#160;Mr. Nussinovitch&#160;now requests that the Company or Mr. Ben Noon and Mr. Hayon purchase
all of his rights and shares in the Company at their average value from the date of the Company&#8217;s initial public offering until
the date of the general meeting held on December 17, 2021. On January 13, 2025, a pretrial hearing was held. The court denied Mr. Nussinovitch&#8217;s
motion to amend and instructed him to notify whether he wishes to withdraw his original claim or maintain it. As of the date of these
Financial Statements, Mr. Nussinovitch has not yet provided his response.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">As
of the date of these Financial Statements, the Company believes that the claims will result in no payments by the Company.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094593121616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityAbstract', window );"><strong>Lease Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASE LIABILITIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; "><b>NOTE
9 &#8211; LEASE LIABILITIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Lease
Commitments &#8211; Operating Leases:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; ">In
September 2021, the Company entered into a lease agreement for its facilities in Ra&#8217;anana, Israel. The lease agreement is for a
period of 69 months commencing September 1, 2021, and the Company began to pay lease and related expenses after completing 3 months of
lease. The Company has the option to shorten the period and terminates the lease agreement after completing 45 months of rent by paying
an amount of NIS 500,000, (approximately $153). This amount of reimbursement will be deducted monthly in NIS 30,000, (approximately $9)
if the Company terminates the agreement after 45 months of rent. The Company is reasonably certain that it will not exercise the termination
option. The annual lease payment, including management fees, as of December 31, 2024, is approximately NIS 69,000 ($17.5). As security
for the obligations under this lease agreement, the Company provided a bank guarantee in an amount equal to three monthly lease payments
plus the Israeli value added tax and an unlimited guarantee according to the terms specified in the contract. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; ">The
Company has various operating leases for vehicles that expire through 2027. The Company leases vehicles for approximately three-year
periods from multiple different leasing companies and from time to time increases or decreases the number of leased vehicles according
to its current needs. The leased vehicles are used by the Company&#8217;s headquarters staff and other employees whose employment agreements
include an obligation on the Company to provide a vehicle. The agreements with the leasing companies include termination options, allowing
for early cancellation by paying a penalty of up to 400% of the monthly costs. The Company is reasonably certain that it will not exercise
this option or that the employee will bear the cost for early termination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; ">The
total expenses related to the leases were $390&#160;for the year ended December 31, 2024, and $371&#160;for the year ended December 31,
2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; ">The
right-of-use asset and lease liability are initially measured at the present value of the lease payments, discounted using the interest
rate implicit in the lease or, if that rate cannot be readily determined, the Company&#8217;s incremental borrowing rate based on the
information available at the date of determining the present value of the lease payments. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; ">The
Company&#8217;s incremental borrowing rate is estimated to approximate the interest rate on similar terms and payments and in economic
environments where the leased asset is located.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; ">The
Company has various operating leases for vehicles that expire through 2027. Below is a summary of the Company&#8217;s operating right-of-use
assets and operating lease liabilities as of December 31, 2024, and 2023:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>December&#160;31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>2024</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December&#160;31, <br/> 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating lease liabilities, current</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">277</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">290</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Operating lease liabilities long-term</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">378</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">588</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total operating lease liabilities</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">655</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">878</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Weighted Average of Remaining Lease Term</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2.52</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.33</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Weighted-average discount rate - operating leases</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9.92</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9.6</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Lease
payments for the Company&#8217;s right-of-use assets over the remaining lease periods as of December 31, 2024, are as follows:<span>&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; ">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year
    ended December&#160;31, </b></span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">U.S.&#160;dollars<br/>
    in&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">326</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2026</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">254</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2027</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">154</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total undiscounted lease
    payment</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">734</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less: Interest (*)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(79</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Present value of lease
    liabilities</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">655</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">(*)
Future lease payments were discounted by&#160;7.98%-15.78% interest rate.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094592781344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finacial Liabilities at Fair Value<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Finacial Liabilities at Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FINACIAL LIABILITIES AT FAIR VALUE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE
10 &#8211; FINACIAL LIABILITIES AT FAIR VALUE:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>December&#160;31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>2024</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>December&#160;31,
                                            </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>2023</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Financial liability (A)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">69</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Private warrants (B)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,506</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,459</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,575</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,470</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><span style="font-size: 10pt"><b>A Financial Liability</b></span></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">1.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The Company agreed to pay fees of 7% from funds that may be received in an event of exercise of the Company&#8217;s tradable warrants which created a financial liability. The financial liability was designated to be measured at fair value through profit or loss. As of December 31, 2023, the fair value of the financial liability was $11. Such agreement expired in July 2024 and as of December 31, 2024, the financial liability amounted to null.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">2.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The Company agreed to pay fees of 4% from the funds that will be received in an event of exercise of part of the Company&#8217;s ordinary warrants that were issued in a certain December 2024 private placement which created a financial liability on the total potential amount which is $69 as of December 31, 2024 (Note 10).</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
financial liability fair value as of December 31, 2024, and 2023 is $69 and $11 respectively.</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B
Private warrants </b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
December 26, 2023, the Company entered into a certain securities purchase agreement (Note 11.3), pursuant to which it issued unregistered
warrants, to purchase up to an aggregate of 3,031,250 Ordinary Shares at an exercise of $1.28 per share (the &#8220;Private Warrants&#8221;).
The Private Warrants were exercisable immediately upon issuance and will expire three and a half years following their issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Private Warrants include cashless exercise mechanism, according to the terms specified in the agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Private Warrants may create obligation to transfer cash to the investors at fundamental transactions within the Black Scholes option
pricing framework.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Therefore,
the Company accounts for the Private Warrants as financial liability instruments that are measured at fair value and recognized financial
expenses or income through profit and loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
company measured fair value by using Black-Scholes option pricing model;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
key inputs that were used in the private warrants fair value as of December 31, 2023, were:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">risk-free interest rate 4.00%</span></td></tr><tr style="vertical-align: top">
<td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> </table>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">expected volatility 66.63%</span></td></tr><tr style="vertical-align: top">
<td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> </table>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">expected dividend yield of 0%</span></td></tr><tr style="vertical-align: top">
<td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> </table>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">expected term of warrants &#8211; 3.5 years.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
key inputs that were used in the private warrants fair value as of December 31, 2024, were:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">risk-free interest rate 4.26%</span></td></tr><tr style="vertical-align: top">
<td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> </table>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">expected volatility 88.61%</span></td></tr><tr style="vertical-align: top">
<td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> </table>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">expected dividend yield of 0%</span></td></tr><tr style="vertical-align: top">
<td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> </table>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">expected term of warrants &#8211; 2.5 years.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
fair value of the Private Warrants as of December 31, 2024 and 2023 was $1,506 and $1,459 respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094701538368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Shareholders&#8217; Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">SHAREHOLDERS&#8217; EQUITY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 11
&#8211; SHAREHOLDERS&#8217; EQUITY:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>A.
Share capital:</b></span></p>



<p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>


<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of shares as of<br/> December 31,&#160;2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of shares as of<br/> December 31,&#160;2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Authorized</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Issued
    and outstanding</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Authorized</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Issued
    and outstanding</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Ordinary shares</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">100,000,000</span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">24,252,096</span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">100,000,000</span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">15,652,176</span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;&#160;</b></span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">1.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">During the year ended December 31, 2022, the Company issued an aggregate amount of 1,240,204 Ordinary Shares in connection to vested RSUs and an additional 7,030 Ordinary Shares in connection to certain option exercises.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">2.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On April 4, 2023, the Company entered into a sales agreement (the &#8220;Sales Agreement&#8221;) with Roth Capital Partners, LLC, as sales agent, pursuant to which the Company could offer and sell, from time to time, through the sales agent, Ordinary Shares pursuant to an at-the-market facility (&#8220;ATM&#8221;). In 2023, the Company sold 17,566 Ordinary Shares under the ATM. On October 23, 2023, the Company terminated the Sales Agreement and the associated ATM, effective immediately.</span></td></tr></table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">3.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On December 26, 2023, the Company entered into a securities purchase agreement (the &#8220;Purchase Agreement&#8221;) with an institutional investor in a registered direct offering (the &#8220;Registered Direct Offering&#8221;), pursuant to which the Company issued (i) 1,375,000 Ordinary Shares at a purchase price of $1.28 per share, (ii) pre-funded warrants, to purchase up to 1,656,250 Ordinary Shares, at a purchase price of $1.28, less $0.001 per pre-funded warrant and (iii) Private Warrants, to purchase up to an aggregate of 3,031,250 Ordinary Shares at an exercise of $1.28 per share (Note 10-B).</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company concluded that the Pre-Funded Warrants are not within the scope of ASC480. Further, applying ASC 815-40, the Company
concluded that the pre-funded warrants are indexed to the Company&#8217;s own stock and meet the conditions for equity classification,
and thus should be presented within equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">As
for the common warrants, the Company concluded that they should be classified as a liability under ASC 815-40, as they are not indexed
to the Company&#8217;s own stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
pre-funded warrants were exercised on the same day and the day after the transaction in full in an exercise price of $0.001 per share
and the Company issued 1,656,250 additional Ordinary Shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
aggregate proceeds received by the Company from the Registered Direct Offering were approximately $3,424, after deducting underwriting
discounts and commissions and additional cash offering costs totaled in approximately $454.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company issued the placement agent in the Registered Direct Offering a number of warrants equal to a total of 7.0% of the aggregate number
of Ordinary Shares sold in the transaction, total to 212,188 warrants to purchase up to 212,188 Ordinary Shares, were issued (the &#8220;Placement
Agent Warrants&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Placement Agent Warrants were substantially on the same terms as the Warrants issued to the investor in the offering, except an exercise
price of $1.60 per share. The Placement Agent Warrants were exercisable immediately upon issuance and will expire five years following
their issuance. The Company accounts for the Placement Agent Warrants as equity-classified instruments (as part of additional paid in
capital), based on an assessment of ASC 718. The fair value of the warrants at the issuance date was $131.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Those
cash and non-cash issuance costs were accounted proportionally to issuance expenses and decrease of additional paid in capital, according
to the ratio of the liability versus equity in the Registered Direct offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">4.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">During the year ended December 31, 2023, the Company issued an aggregate amount of 1,226,448 Ordinary Shares in connection with vested RSUs and an additional 37,972 Ordinary Shares in connection with option exercises.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">5.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On April 1, 2024, the Company completed its 2024 April Offering, whereby the Company sold 1,339,285 Ordinary Shares at a purchase price of $1.232 per share. The gross proceeds received by the Company from the 2024 April Offering were approximately $1,651.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">6.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On May 20, 2024, the Company issued warrant to purchase 220,000 Ordinary Shares to a service provider, at an exercise price of $2.25 per share. These warrants are immediately exercisable and are due to expire six months from the initial issuance date. The Company accounting treatment for those warrants as equity-classified instruments (as part of additional paid in capital), based on an assessment of ASC 718. The fair value of the warrants at the issuance date was $125. The warrants were not exercised within the designated timeframe and expired on November 21, 2024.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">7.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On June 14, 2024, the Company completed its 2024 June Offering, whereby the Company sold: (i) 941,541 Ordinary Shares at a purchase price of $1.30 per share, and (ii) June Pre-Funded Warrants to purchase up to 1,709,760 Ordinary Shares, at a purchase price of $1.30, less $0.001 per June Pre-Funded Warrant. Each June Pre-Funded Warrant is exercisable for one Ordinary Share at an exercise price of $0.001 per share. The June Pre-Funded Warrants are immediately exercisable and may be exercised at any time until all of the June Pre-Funded Warrants are exercised in full. As of December 31, 2024, all of the June Pre-Funded warrants were exercised, and the company issued 1,709,760 Ordinary Shares.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Net
proceeds received by the Company from the 2024 June Offering were approximately $3,102, after deducting cash offering costs which
were approximately $343.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company also received $2 from an exercise of the June Pre-Funded Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company concluded that the June Pre-Funded Warrants are not within the scope of ASC 480. Further, applying ASC 815-40, the Company concluded
that the June Pre-Funded Warrants are indexed to the Company&#8217;s own stock and meet the conditions for equity classification, and
thus should be presented within equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company issued the June Placement Agent in the agreement warrants equal to a total of 7.0% of the aggregate number of Ordinary Shares
sold in the transaction. A total to 185,591 warrants to purchase up to 185,591 Ordinary Shares were issued. The June Placement Agent
Warrants had an exercise price of $1.56 per share. The June Placement Agent Warrants were exercisable immediately upon issuance and will
expire four years following their issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company accounting treatment for the June Placement Agent Warrants as equity-classified instruments (as part of additional paid in capital),
based on an assessment of ASC 718. The fair value of the June Placement Agent Warrants at the issuance date was $254.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
cash and non-cash issuance costs were recorded against additional paid in capital, due to the classification of the Ordinary Shares and
the June Pre-Funded Warrants as equity instrument.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">8.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On June 30, 2024, the Company issued 45,000 Ordinary Shares to an advisor in connection with a consulting service agreement.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">9.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On December 27, 2024, the Company completed its December Private Placement, whereby the Company sold (i) 3,950,343 Ordinary Shares and December Private Warrants to purchase up to 3,950,343 Ordinary Shares at a purchase price of $0.70 per unit, and (ii) December Pre-Funded Warrants to purchase up to 658,372 Ordinary Shares and December Private Warrants to purchase up to 658,372 Ordinary Shares, at a purchase price of $0.70, less $0.001 per unit with December Pre-Funded Warrant. Each December Pre-Funded Warrant is exercisable for one Ordinary Share at an exercise price of $0.001 per share. Each December Private Warrant is exercisable for one Ordinary Share at an exercise price of $1.10 per share. The December Private Warrants are immediately exercisable and may be exercised at any time until the end of June 2026. The December Pre-Funded Warrants are immediately exercisable and may be exercised at any time until all of the December Pre-Funded Warrants are exercised in full. As of December 31, 2024, none of the December Pre-Funded warrants or the December Private Warrants were exercised.</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company concluded that the December Private Warrants and December Pre-Funded Warrants are not within the scope of ASC 480. Further, applying
ASC 815-40, the Company concluded that the December Private Warrants and December Pre-Funded Warrants are indexed to the Company&#8217;s
own stock and meet the conditions for equity classification, and thus should be presented within equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
gross proceeds received by the Company from the December Private Offering were approximately $3,228, before deducting underwriting discounts
and commissions and additional cash offering costs totaled approximately $233. In addition, the Company agreed to pay fees of 4% from
the funds that may be received in an event of exercise of part of the Company&#8217;s private warrants issued in December 2024 Private
Placement which created a financial liability in amount of $69 which is the total potential amount (Note 10-A).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
cash and non-cash issuance costs were recorded against additional paid in capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">10.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">During the year ended December 31, 2024, the Company issued an aggregate amount of 594,943 Ordinary Shares in connection with vested RSUs and an additional 19,048 Ordinary Shares in connection with option exercises.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>B.
Warrants reserves -</b>Composition and movements:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 21.8pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif">1.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The following table reconciles the movement in warrants outstanding at the beginning and end of the period:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.8pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number of<br/> Warrants</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted-average exercise price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Weighted average remaining contractual term</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>(in years)</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; font-weight: bold; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance as of December 31, 2023</span></td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,333,283</span></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5.47</span></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1.83</span></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issued</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,382,438</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1.22</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1.93</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,709,760</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.001</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-70; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Expired</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,277,350</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5.25</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.54</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Balance as of December 31, 2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,728,611</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4.14</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1.63</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 21.8pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif">2.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The following table summarizes information about the Company&#8217;s outstanding warrants as of December 31, 2024</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Exercise Price</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Warrants<br/> outstanding</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>as of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>December 31, 2024</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Expiration date</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 41%; text-align: center; padding-left: 2pt"><span style="font-family: Times New Roman, Times, Serif">5.5</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,640,455</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 40%; text-align: center; padding-left: 1.4pt"><span style="font-family: Times New Roman, Times, Serif">15/07/2026</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: center; padding-left: 2pt"><span style="font-family: Times New Roman, Times, Serif">5.5</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">277,835</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: center; padding-left: 1.4pt"><span style="font-family: Times New Roman, Times, Serif">15/07/2025</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-left: 2pt"><span style="font-family: Times New Roman, Times, Serif">6.875</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">145,455</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: center; padding-left: 1.4pt"><span style="font-family: Times New Roman, Times, Serif">15/01/2027</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: center; padding-left: 2pt"><span style="font-family: Times New Roman, Times, Serif">1.6</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">212,188</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: center; padding-left: 1.4pt"><span style="font-family: Times New Roman, Times, Serif">28/06/2027</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-left: 2pt"><span style="font-family: Times New Roman, Times, Serif">1.56</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">185,591</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: center; padding-left: 1.4pt"><span style="font-family: Times New Roman, Times, Serif">18/06/2028</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: center; padding-left: 2pt"><span style="font-family: Times New Roman, Times, Serif">1.1</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,608,715</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: center; padding-left: 1.4pt"><span style="font-family: Times New Roman, Times, Serif">30/06/2026</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-left: 2pt"><span style="font-family: Times New Roman, Times, Serif">0.001</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">658,372</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: center; padding-left: 1.4pt"><span style="font-family: Times New Roman, Times, Serif">Until fully exercised</span></td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: center; padding-left: 2pt"><span style="font-family: Times New Roman, Times, Serif">Balance as of December 31, 2024</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,728,611</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: center; padding-left: 1.4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>C.
Loss per share:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Loss
per share has been calculated using the weighted average number of Ordinary Shares and pre-funded warrants in issue during the relevant
financial periods, the weighted average number of equity shares in issue and profit for the period as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December&#160;31,<br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December&#160;31,<br/> 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December&#160;31,<br/> 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Loss
    for the period</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,053</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,286</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">14,976</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Total number of Ordinary
    Shares</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">24,252,096</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">15,652,176</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,338,940</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Weighted average number of Ordinary Shares
    and pre-funded warrants</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,515,545</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,095,477</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,794,594</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Basic
    and diluted loss per share</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(0.60</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(0.93</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1.39</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094593066768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Development Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock', window );">RESEARCH AND DEVELOPMENT EXPENSES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE
12 - RESEARCH AND DEVELOPMENT EXPENSES:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December&#160;31, <br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December&#160;31, <br/> 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December&#160;31, <br/> 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Salary
    and related expenses</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,079</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,429</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,458</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Materials
    and related expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">812</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,365</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,082</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Share based payment</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">801</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">663</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,392</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Depreciation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">371</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">291</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">188</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Subcontractors</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">340</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">304</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">850</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">IIA
    participation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(286</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-71; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-72; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">206</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">268</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">213</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,323</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,320</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,183</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/985-20/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094592775392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General and Administrative Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and Administrative Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_GeneralAndAdministrativeExpensesTextBlock', window );">GENERAL AND ADMINISTRATIVE EXPENSES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 13
- GENERAL AND ADMINISTRATIVE EXPENSES:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December 31, <br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December 31, <br/> 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December 31, <br/> 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Professional fees</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,758</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,432</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,500</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Salary and related expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">808</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">766</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">716</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Share-based payment</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">716</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">675</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,984</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Director fees</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">239</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">241</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">239</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Insurance expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">196</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">300</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">557</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Office maintenance</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">135</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">129</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">102</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Depreciation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">117</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">115</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">104</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Travel abroad</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">104</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">100</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">105</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Fundraising expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-73; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">260</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-74; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Others</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">112</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">45</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">68</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,185</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,063</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">,5375</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_GeneralAndAdministrativeExpensesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for general and administrative expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_GeneralAndAdministrativeExpensesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094693149920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sales and Marketing Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpenseAbstract', window );"><strong>Sales and Marketing Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SalesAndMarketingExpensesTextBlock', window );">SALES AND MARKETING EXPENSES:</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 14
- SALES AND MARKETING EXPENSES:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December&#160;31, <br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December 31,<br/> 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December 31,<br/> 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Salary and related expenses</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">266</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">248</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">282</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Share-based payment</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">250</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">89</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">503</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Professional fees</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">187</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">348</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">527</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">51</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">61</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">16</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">754</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">746</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,328</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_SalesAndMarketingExpensesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of sales and marketing expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_SalesAndMarketingExpensesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094593132272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial (Income) and Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Financial (Income) and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock', window );">FINANCIAL (INCOME) AND EXPENSES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 15&#8211;
FINANCIAL (INCOME) AND EXPENSES:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December 31, <br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December 31, <br/> 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December 31, <br/> 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Revaluation of financial liabilities
    at fair value through profit or loss</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">36</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(306</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(108</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Foreign currency transaction income</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(77</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(233</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">530</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Finance expense in respect of lease liability</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-75; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-76; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(143</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Others</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(4</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total
    expenses (Income)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(42</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(529</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">275</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the components of non-operating income or non-operating expense, including, but not limited to, amounts earned from dividends, interest on securities, gain (loss) on securities sold, equity earnings of unconsolidated affiliates, gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094595882896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Taxes on Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">TAXES ON INCOME</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 16
- TAXES ON INCOME: </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>A.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Taxes
                                            on income:</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Israeli corporate tax rate was 23% in 2024 and 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>B.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Net
                                            operating losses carry forwards</b>:</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Carryforward
tax losses of the Company as of December 31, 2023, amounted to approximately $24,000; however, a full valuation allowance of $7,000 was
recorded against the potential future tax benefits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Carryforward
tax losses of the Company as of December 31, 2024, amounted to approximately $29,000; however, a full valuation allowance of $8,000 was
recorded against the potential future tax benefits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
deferred tax assets and liabilities are composed of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December&#160;31, <br/>
2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December&#160;31, <br/>
2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Deferred tax assets:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net
    operating loss carryforward</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,739</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,519</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued
    expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">97</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">80</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">R&amp;D
    temporary differences</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,218</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,335</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Fund raising costs
    2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">35</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">70</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Operating
    lease liability</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total
    deferred tax assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,097</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,012</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Valuation
    allowance</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(8,097</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(7,012</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred
    tax liabilities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    deferred tax liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-77; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-78; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Net
    deferred taxes</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-79; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-80; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>C.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>Theoretical tax:</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December&#160;31,<br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December&#160;31,<br/> 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December&#160;31,<br/> 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Loss before taxation</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(11,053</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(11,286</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(14,976</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Theoretical tax credit at applicable statutory rate: 23%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,542</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,596</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,444</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Non-allowable expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(391</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(244</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,026</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Temporary
    differences and tax losses for which no Deferred Tax Asset is recognized</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,151</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,352</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,418</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Income tax benefit</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-81; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-82; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-83; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094693280000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract', window );"><strong>Share-Based Payment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">SHARE-BASED PAYMENT</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 17
&#8211; SHARE-BASED PAYMENT:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">1.&#160;
On March 24, 2022, the Company&#8217;s board of directors (&#8220;Board of directors&#8221;) approved a grant of 536,141 RSUs to employees
and a grant of 22,500 RSUs to the Company&#8217;s advisory board members and an additional consultant. The RSUs represent the right to
receive Ordinary Shares at a future time. 555,500 of the RSUs in this grant, vest over a period of three years, with a 1-year cliff period,
and 3,141 RSUs vested immediately on the grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">2.&#160;
On March 24, 2022, the Company&#8217;s Board of Directors approved a grant of 29,400 Ordinary Shares options to medical board members,
which are exercisable to 29,400 Ordinary Shares. The share options vesting period is up to three years from the grant date. The exercise
price per share was NIS 10.84 ($3.08). The contractual life of the options under the 2019 Equity Incentive Plan is ten years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">3.&#160;
On April 6, 2022, the Company&#8217;s Board of Directors approved a grant of 285,713 fully vested RSUs to an officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">4.&#160;
On May 19, 2022, the Company&#8217;s Board of Directors approved a grant of 30,000 RSUs to an employee. The RSUs vest over a period of
three years, with a 1-year cliff period, commencing on the grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">5.&#160;
On November 22, 2022, the Company&#8217;s Board of Directors approved a grant of 165,000 RSUs to employees. The RSUs vest over a period
of three years, with a 1-year cliff period, commencing on the grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">6.&#160;
On January 22, 2024, the Company&#8217;s Board of Directors approved a grant of 320,000 RSUs to employees and a grant of options to purchase
80,000 shares to consultants. The RSUs represents the right to receive Ordinary Shares at a future time, 245,000 of which vest over a
period of three years, with a one-year cliff period and 70,000 vesting immediately on the grant date. 10,000 of the options were vested
immediately on the grant date, 25,000 option vest over a period of three years and 45,000 option vests over a period of one year and
nine months. The RSUs designated to employees were granted under Section 102 of the Israeli Tax Ordinance, which enables the employee
to pay a 25% capital gain tax upon exercise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">7.&#160;
On February 5, 2024, the Company&#8217;s Board of Directors approved a grant of 2,277,000 RSUs to officers, a grant of options to purchase
30,000 Ordinary Shares and 90,000 RSUs to directors. The RSUs and options represents the right to receive Ordinary Shares at a future
time and vest over a period of three years, with a one-year cliff. The RSUs designated to employees and directors were granted under
Section 102 of the Israeli Tax Ordinance, which enables the employee to pay a 25% capital gain tax upon exercise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
fair value of all granted options was estimated by using the Black Scholes option pricing model, which was aimed to model the value of
the Company&#8217;s assets over time. The simulation approach was designed to take into account the terms and conditions of the share
options, as well as the capital structure of the Company and the volatility of its assets, on the date of grant based on certain assumptions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
following inputs were used to measure the fair value of the option at grant date:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">March
    24, 2022</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">January
    22, 2024</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">February
    5, 2024</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif">(i)</span></td>
    <td style="width: 47%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Expected volatility</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 15%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">52%</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 15%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">144.83%</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 15%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">143.98%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">(ii)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Dividend rate</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">0%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">0%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">0%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">(iii)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Expected term (vesting period)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three years</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three years</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="-sec-ix-hidden: hidden-fact-84; font-family: Times New Roman, Times, Serif">Three years</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">(iv)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Contractual life</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Ten years</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Ten years</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="-sec-ix-hidden: hidden-fact-85; font-family: Times New Roman, Times, Serif">Ten years</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">(v)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Free risk rate</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">2.79%-2.80%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">4.03%-4.07%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">4.16%</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
fair value of all granted RSUs was the Company&#8217;s quote price at the grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">During the
year ended December 31, 2024, the Company recorded share-based payment expenses to employees, directors and subcontractors in the amount
of $1,767.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">During the
year ended December 31, 2023, the Company recorded share-based payment expenses to employees, directors and subcontractors in the amount
of $1,427.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">During the
year ended December 31, 2022, the Company recorded share-based payment expenses to employees, directors and subcontractors in the amount
of $4,879.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The options
to services providers and advisers outstanding as December 31, 2024, 2023 and 2022 were as&#160;follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>


<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December 31, 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December 31, 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December 31, 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number
    of <br/> options</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted
    <br/> average <br/> Exercise <br/> price NIS</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number
    of <br/> options</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted
    <br/> average <br/> Exercise <br/> price NIS</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number
    of<br/> options</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted
    <br/> average <br/> Exercise <br/> price NIS</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Outstanding at beginning of year</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">105,111</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4.085</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">114,512</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.058</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">87,833</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.37</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Reclassified to employees and directors</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-86; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-87; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-88; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-89; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-90; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-91; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">80,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.779</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-92; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-93; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">29,400</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">10.84</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-94; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-95; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,401</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.367</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,721</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.37</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-96; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-97; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-98; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-99; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-100; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-101; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 1.1pt"><span style="font-family: Times New Roman, Times, Serif">Options
    outstanding</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">185,111</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.359</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">105,111</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4.085</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">114,512</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.058</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 1.1pt"><span style="font-family: Times New Roman, Times, Serif">Options
    exercisable</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">162,154</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.251</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">94,242</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.267</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">82,257</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.37</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 1.1pt"><span style="font-family: Times New Roman, Times, Serif">Share-based
    payment expenses</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">66</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">19</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">54</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The RSUs
to services providers and advisers outstanding as of December 31, 2024, 2023 and 2022 were as&#160;follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>


<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December 31, <br/>
2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December 31, <br/>
2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December 31, <br/>
2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number
    of <br/>
RSUs</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number
    of <br/>
RSUs</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number
    of <br/>
RSUs</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Outstanding at beginning of year</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,433</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,266</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-107; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-108; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">22,500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Vested</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,433</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,833</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">14,234</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 1.1pt"><span style="font-family: Times New Roman, Times, Serif">RSUs
    outstanding</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-109; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,433</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,266</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 1.1pt"><span style="font-family: Times New Roman, Times, Serif">RSU&#8217;s
    Vested</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">32,500</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">25,067</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">14,234</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 1.1pt"><span style="font-family: Times New Roman, Times, Serif">Share-based
    payment expenses</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">33</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The options
to employees and directors outstanding as of December 31, 2024, 2023 and 2022 were as&#160;follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>




<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December 31, 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December 31, 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December 31, 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number
    of <br/> options</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted
    <br/> average <br/> Exercise <br/> price NIS</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number
    of <br/> options</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted
    <br/> average <br/> Exercise <br/> price NIS</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number
    of <br/> options</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted
    <br/> average <br/> Exercise <br/> price NIS</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Outstanding at beginning of year</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">357,689</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.37</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">386,260</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.37</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">448,120</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.37</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">30,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.56</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-102; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-103; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-104; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">19,048</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.37</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.37</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,309</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.37</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-105; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-106; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">28,571</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.37</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">57,551</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.37</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 1.1pt"><span style="font-family: Times New Roman, Times, Serif">Options
    outstanding</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">368,641</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.70</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">357,689</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.37</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">386,260</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.37</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 1.1pt"><span style="font-family: Times New Roman, Times, Serif">Options
    exercisable</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">338,641</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.45</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">350,131</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.37</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">342,757</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.37</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 1.1pt"><span style="font-family: Times New Roman, Times, Serif">Share-based
    payment expenses</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">17</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">47</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">174</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The RSUs
to employees and directors outstanding as of December 31, 2024, 2023 and 2022 were as&#160;follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December&#160;31, <br/>
    2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December&#160;31, <br/>
    2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December&#160;31, <br/>
    2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number
    of<br/>
 RSUs</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number
    of<br/>
 RSUs</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number
    of<br/>
 RSUs</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Outstanding at beginning of year</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">445,140</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,727,842</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,002,587</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,687,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-110; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,016,854</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">25,836</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">67,087</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">65,626</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Vested</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">587,508</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,215,615</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,225,973</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 1.1pt"><span style="font-family: Times New Roman, Times, Serif">RSUs
    outstanding</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,518,796</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">445,140</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,727,842</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 1.1pt"><span style="font-family: Times New Roman, Times, Serif">RSU&#8217;s
    Vested</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,684,697</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,097,189</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,881,574</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 1.1pt"><span style="font-family: Times New Roman, Times, Serif">Share-based
    payment expenses</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,683</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,352</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,618</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094592726928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Parties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE
18 - RELATED PARTIES:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>The following
transactions arose with related parties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">Transactions
and balances with related parties</span><b>:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Shareholders and other related parties&#8217; benefits</span></span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December&#160;31,
    <br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December&#160;31,
    <br/> 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December&#160;31,<br/>
    2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Salary and related expenses &#8211;
    officers and directors</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,710</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,761</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,923</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Share based payment &#8211; officers and directors</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,376</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,009</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,745</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Balances with related parties</span></span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Name</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Nature of transaction</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December&#160;31, <br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December&#160;31, <br/> 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 20%"><span style="font-family: Times New Roman, Times, Serif">Officers</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 55%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Salaries and related</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(381</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(314</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif">Directors</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Compensation for directors</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(40</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(40</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094693156384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>NOTE 19
- SUBSEQUENT EVENTS:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 17.85pt"></td><td style="width: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">1.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Following the closing of the December Private Placement, $70 was wired to the Company from one of the investors before the end of the year but was registered by the receiving bank in January 2025. As a result, $70 were not included in the cash and cash equivalent as of December 31, 2024. The private offering fees and other related expenses in the amount of $220 were paid by the Company after the end of the year.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">2.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">During January and February 2025, the Company received funds in the amount of NIS 238,122 (approximately $66) from the IIA.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 17.85pt"></td><td style="width: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">3.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On February 20, 2025, the Company&#8217;s Board of Directors approved a grant of 676,000 RSUs to employees and options to purchase an aggregate of 50,000 Ordinary Shares to service providers under the 2019 Equity Incentive Plan. 20,166 RSUs are vested as of the date of these Financial Statements. <span style="-sec-ix-hidden: hidden-fact-111">None</span> of the total amount of the options are vested as of the date of these Financial Statements. The total grant fair value is approximately $656 that will be registered as expenses in the upcoming vesting period of three years.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 17.85pt"></td><td style="width: 17.85pt"><span style="font-family: Times New Roman, Times, Serif">4.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On February 20, 2025, the Company&#8217;s Board of Directors approved a grant of 550,000 RSUs to certain of its executives. <span style="-sec-ix-hidden: hidden-fact-112">None</span> of the total amount of RSUs are vested as of the date of these Financial Statements. The total grant fair value is approximately $494 that will be registered as expenses in the upcoming vesting period of three years.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">5.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On February 20, 2025, the Company&#8217;s Board of Directors approved a grant of 1,810,000 RSUs to certain of its executives. The approval is subject to shareholder approval. <span style="-sec-ix-hidden: hidden-fact-113">None</span> of the total amount of RSUs are vested as of the date of these Financial Statements. The total grant fair value is approximately $1.6 million that will be registered as expenses in the upcoming vesting period of three years.</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094700373728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (11,053)<span></span>
</td>
<td class="num">$ (11,286)<span></span>
</td>
<td class="num">$ (14,976)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094693203296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094594396672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text">The
cybersecurity process has been integrated into the Company&#8217;s overall risk management system and process and is solely
internally managed.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text">Management is responsible for identifying risks that threaten achievement of the control activities stated in
the management&#8217;s description of the services organizations systems. The risk assessment occurs annually, or as business needs
change, and covers identification of risks that could act against the company&#8217;s objectives as well as specific risks related
to a compromise to the security of data.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this report,
we are not aware of any material risks from cybersecurity threats that have materially affected or are reasonably likely to materially
affect us, including our business strategy, results of operations or financial condition.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Governance</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Chief Executive Officer
and Chief Financial Officer oversee our cybersecurity risk management and mitigation efforts. The board of directors receive prompt and
timely information regarding any cybersecurity incidents. Our Audit Committee periodically discusses cybersecurity.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">Our Chief Executive Officer
and Chief Financial Officer oversee our cybersecurity risk management and mitigation efforts<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Chief Executive Officer
and Chief Financial Officer oversee our cybersecurity risk management and mitigation efforts. The board of directors receive prompt and
timely information regarding any cybersecurity incidents. Our Audit Committee periodically discusses cybersecurity.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has
developed and maintained a cybersecurity risk management strategy, consisting of cybersecurity policies, procedures, compliance and
awareness programs to mitigate risk and to ensure compliance with security, availability and confidentiality trust principles. The
cybersecurity process has been integrated into the Company&#8217;s overall risk management system and process and is solely
internally managed. Management is responsible for identifying risks that threaten achievement of the control activities stated in
the management&#8217;s description of the services organizations systems. The risk assessment occurs annually, or as business needs
change, and covers identification of risks that could act against the company&#8217;s objectives as well as specific risks related
to a compromise to the security of data.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The level of each identified
risk is determined by considering the impact of the risk itself and the likelihood of the risk materializing and high scoring risks are
actioned upon. Risks are analyzed to determine whether the risk meets company risk acceptance criteria to be accepted or whether a mitigation
plan will be applied. Mitigation plans include both the individual or department responsible for the plan and may include budget considerations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this report,
we are not aware of any material risks from cybersecurity threats that have materially affected or are reasonably likely to materially
affect us, including our business strategy, results of operations or financial condition.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As part of the critical elements
of our overall risk management approach, our cybersecurity program is focused on the following key areas:</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Collaborative Approach: The Company has implemented a comprehensive, cross-functional approach to identifying, preventing and mitigating cybersecurity threats and incidents, while also implementing controls and procedures that provide for the prompt escalation of certain cybersecurity incidents so that decisions regarding the public disclosure and reporting of such incidents can be made by management in a timely manner.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Technical Safeguards: The Company deploys technical safeguards that are designed to protect the Company&#8217;s information systems from cybersecurity threats, including firewalls, intrusion prevention and detection systems, anti-malware functionality and access controls, which are evaluated and improved through vulnerability assessments and cybersecurity threat intelligence.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Incident Response and Recovery Planning: The Company has established and maintains comprehensive incident response and recovery plans that fully address the Company&#8217;s response to a cybersecurity incident, and such plans are tested and evaluated on a regular basis.</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094596328480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>A.
Use of estimates:</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
preparation of Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the Financial Statements,
and the reported amounts of expenses during the reporting period.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif">Items
subject to such estimates and assumptions include:</span></p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">stock-based
                                            compensation expense;</span></td></tr><tr style="vertical-align: top">
<td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
                                                                                                                                                              </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">fair
                                            value financial liabilities;</span></td></tr><tr style="vertical-align: top">
<td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
                                                                                                                                                              </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">recognition,
                                            measurement, and disclosure of contingent liabilities;</span></td></tr><tr style="vertical-align: top">
<td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
                                                                                                                                                                                                </table><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td><span style="font-family: Times New Roman, Times, Serif">Interest
                                            rate used for lease liability measurement.</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">As
of the date of issuance of the Financial Statements, the Company is not aware of any material specific events or circumstances that would
require it to update its estimates, judgments, or to revise the carrying values of its assets or liabilities. These estimates may change,
as new events occur and additional information is obtained, and are recognized in the Financial Statements as soon as they become known.
Actual results could differ from those estimates and any such differences may be material to the Company&#8217;s Financial Statements.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>B.
<span>Foreign Currency</span></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
currency of the primary economic environment in which the operations of the Company are conducted is the U.S. dollar (&#8220;USD&#8221;).
The Company&#8217;s funding and expected revenues are mostly in USD. Thus, the functional currency of the Company is in USD.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Transactions
and balances originally denominated in USD are presented at their original amounts. Balances in non-USD currencies are translated into
USD using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-USD transactions and other
items in the statements of income (indicated below), the following exchange rates are used: (i) for transactions &#8211; exchange rates
at transaction dates or average exchange rates; and (ii) for other items (derived from non-monetary balance sheet items such as depreciation
and amortization) &#8211; historical exchange rates. Currency transaction gains and losses are presented in financial expenses (income),
net as appropriate. The functional currency of the Company is USD.&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant, and Equipment</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>C.
Property, Plant, and Equipment</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Property
and equipment are stated at cost. Depreciation is computed based on the straight-line method, over the estimated useful life of the assets.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Annual
rates of depreciation are as follows:</span></p><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 90%"><span style="font-family: Times New Roman, Times, Serif">Computers</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">33</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">R&amp;D equipment</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">20</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Furniture and office equipment</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">6-15</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Leasehold Improvements</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">10</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>D.
Inventory</b></span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Inventories
are stated at the lower of cost or net realizable value. Inventory write-offs are provided to cover risks arising from slow-moving items,
technological obsolescence, excess inventories, discontinued products, and for market prices lower than cost, if any.</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The
Company periodically evaluates the quantities on hand relative to historical and projected sales volume (which is determined based on
an assumption of future demand and market conditions) and the age of the inventory. At the point of the loss recognition, a new lower
cost basis for that inventory has been established.</span></p><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Cost
is determined for all types of inventory using the moving average cost method plus indirect costs.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>E.
Leases</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company implemented Accounting Standards Update (&#8220;ASU&#8221;) 2016-02, Leases (Topic 842) (&#8220;ASU 2016-02&#8221;) using the
modified retrospective approach for all lease arrangements as of such date. The Company leases office space and vehicles under operating
leases.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Arrangements
meeting the definition of a lease are classified as operating or financing leases and are recorded on the balance sheet as both a right
of use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease
or the Company&#8217;s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and
the right of use asset is amortized over the lease term.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
lease liability was measured at the present value of the remaining lease payments, discounted using the Company&#8217;s incremental borrowing
rate. The weighted-average&#160;rate applied was 9.60%. Right-of-use&#160;assets were measured at an amount equal to the lease liability.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">For
operating leases, interest on the lease liability and the amortization of the right of use asset result in straight-line&#160;rent expense
over the lease term. Variable lease expenses are recorded when incurred.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>F.
Research and Development Costs.</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">Research
and development expenses consist primarily of payroll, payroll related expenses, subcontractors, and materials. Costs are expensed as
incurred.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistancePolicyTextBlock', window );">Government Grants</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>G.
Government Grants </b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company receives royalty-bearing grants from the Israeli Innovation Authority (&#8220;IIA&#8221;) for approved research and development
projects Under Israeli law, royalties on the revenues derived from products and services developed using such grants, are payable to
the Israeli Government.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
grants are linked to the exchange rate of the dollar to the New Israeli Shekel and bear interest of the Secured Overnight Financing Rate
(&#8220;SOFR&#8221;) per year (SOFR is a benchmark interest rate which replaced LIBOR).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
amounts of grants received and recorded into income should be disclosed for each period presented. The research and development grants
are presented in the statement of operations as an offset to related research and development expenses. Companies are required to pay
royalties in connection with such grants at specified rates, up to the total dollar-linked amount of such grants. <span>research
and development (&#8220;R&amp;D&#8221;).&#160;The Company did not generate sales as of December 31, 2024; therefore, no liability was
recorded in these Financial Statements.</span></span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FinanceIncomeAndExpensesPolicyTextBlock', window );">Finance Income and Expenses</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>H.
Finance Income and Expenses.</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Finance
income is composed of interest on deposits and revaluation of financial liabilities at fair value, while finance expenses are composed
of the revaluation of certain financial liabilities at fair value, bank charges and net currency exchange rates differences.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Current Taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>I.
Current Taxes</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">The
current tax liability is measured using the tax rates and tax laws that have been enacted or substantively enacted by the reporting date
as well as adjustments required in connection with the tax liability in respect of previous years. The Company has no tax liability due
to its carry forward losses.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>J.
Share-Based Compensation.</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif">Share-based
compensation expenses related to employees, directors and subcontractors&#8217; options or restricted share units (&#8220;RSU&#8221;)
which recognized based on their fair value, which is based on the fair value of the underlying Ordinary Shares as to the de-minimis exercise
price using the graded vesting method.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company recognizes compensation expense for grants of share-based awards to its employees based on the estimated fair value on the grant
date. Compensation cost for awards is recognized over the requisite service period, which approximates the vesting period. Share-based
compensation is included in research and development, selling and marketing and general and administrative expenses. Forfeitures of equity
grants are recognized as incurred.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">All
issuances of stock options or other equity instruments to non-employees as consideration for goods or services received by the Company
are accounted for based on the fair value of the equity instruments issued.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Warrants and Pre-Funded Warrants</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>K.
Warrants and Pre-Funded Warrants</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company issues warrants and pre-funded warrants as part of its financing activities or compensation arrangements. Warrants are derivative
financial instruments that entitle the holder to purchase a specified number of the Company&#8217;s Ordinary Shares at a predetermined
exercise price. Warrants and pre-funded warrants issued by the Company may have various terms, including expiration dates, exercise prices,
and conditions.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company classifies warrants as either equity or liabilities upon issuance, based on specific terms and conditions and in accordance with
Accounting Standard Codification (&#8220;ASC&#8221;) 815, Derivatives and Hedging. Warrants and pre-funded warrants are classified as
equity if they meet the criteria for equity classification outlined in ASC 815-40. Otherwise, warrants are classified as liabilities.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_SeverancePolicyTextBlock', window );">Severance</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>L.
Severance</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Israeli
labor law generally requires payment of severance pay upon dismissal of an employee or upon termination of employment in certain other
circumstances. The Company&#8217;s pension and severance pay liabilities are covered mainly by insurance policies. Pursuant to section
14 of the Israeli Severance Compensation Act, 1963 (&#8220;Section 14&#8221;), the Company&#8217;s employees are entitled to monthly
deposits, at a rate of 8.33% of their monthly salary, made in their name with insurance companies. Payments in accordance with Section
14 relieve the Company from any future severance payments in respect of those employees and, as such, the Company may only utilize the
insurance policies for the purpose of paying severance pay.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Loss Per Share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>M.
Basic and Diluted Loss Per Share</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Basic
and diluted loss per share is calculated by dividing the loss attributable to equity holders of the Company by the weighted average number
of Ordinary Shares and pre-funded warrants outstanding during the financial year, adjusted for Ordinary Shares and pre-funded warrants
issued during the year, if applicable.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>N.
Fair Value Measurements</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company measures and discloses fair value in accordance with the Financial Accounting Standards Board (&#8220;FASB&#8221;), ASC 820,
Fair Value Measurements and Disclosures (&#8220;ASC 820&#8221;). ASC 820 defines fair value, establishes a framework and gives guidance
regarding the methods used for measuring fair value, and expands disclosures about fair value measurements. Fair value is an exit price,
representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market
participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions
that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, there exists a three-tier
fair-value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Level
1 &#8211; unadjusted quoted prices are available in active markets for identical assets or liabilities that the Company has the ability
to access as of the measurement date.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Level
2 &#8211; pricing inputs are other than quoted prices in active markets that are directly observable for the asset or liability or indirectly
observable through corroboration with observable market data.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Level
3 &#8211; pricing inputs are unobservable for the non-financial asset or liability and only used when there is little, if any, market
activity for the non-financial asset or liability at the measurement date. The inputs into the determination of fair value require significant
management judgment or estimation. Level 3 inputs are considered as the lowest priority within the fair value hierarchy.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">This
hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining
fair value.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
fair value of cash is based on its demand value, which is equal to its carrying value. Additionally, the carrying value of all other
short-term monetary assets and liabilities are estimated to be equal to their fair value due to the short-term nature of these instruments.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>O.
Concentration of Credit Risk</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
Company maintains certain cash balances in a well-known Israeli banks and U.S based banks.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Part
of the Company&#8217;s operating expenses are denominated in New Israeli Shekel (&#8220;NIS&#8221;), and therefore, subject to foreign
currency risk.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalent</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>P.
Cash and Cash Equivalent</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Cash
equivalents are highly liquid investments that are readily convertible into cash, typically with an original maturity of three months
or less from <span>the date of purchase that are not restricted as to withdrawal or use and are readily
convertible to known amounts of cash.</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; ">Restricted
cash consists of funds that are contractually restricted to bank guarantee due to rental agreements. The Company has presented restricted
cash separately from cash and cash equivalents in the balance sheets.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Bank
deposits with maturities of more than three months, but less than one year, and which are not restricted are included in short-term deposits.
Such deposits are stated at cost which approximates market value. As of December 31, 2024 and December 31, 2023, the Company had short-term
deposits in the amounts of $0.7 million and $2.3 million, respectively.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>Q.
Segment Information</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; ">The
Company has a single operating and reportable segment. The Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;), who is
the Chief Executive Officer, evaluates the performance of its business based on financial data consistent with the presentation in the
accompanying Financial Statements for the purposes of making operating decisions, assessing financial performance, and allocating resources.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New accounting Pronouncements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>R.
New accounting Pronouncements</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; "><b><i>Accounting
Standards Adopted in 2024</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; ">In
March 2023, the FASB issued Accounting Standard Updated No. 2023-01 &#8220;Lease (Topic 842)&#8221;. Topic 842 requires that entities
determine whether a related party arrangement between entities under common control (hereinafter referred to as a common control arrangement)
is a lease. If the arrangement is determined to be a lease, an entity must classify and account for the lease on the same basis as an
arrangement with an unrelated party (on the basis of legally enforceable terms and conditions).That represents a change from the requirements
of Topic 840, Leases, which required that an entity classify and account for an arrangement on the basis of economic substance when those
terms and conditions were affected by the related party nature of the arrangement. The amendments in this Update affect all lessees that
are a party to a lease between entities under common control in which there are leasehold improvements. The amendments apply to all entities
(that is, public business entities, private companies, not-for-profit. The Company adopted ASU 2023-01 on January 1, 2024, its adoption
did not have a material impact on the Financial Statements and related disclosures.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; ">In
June 2022, the FASB issued ASU 2022-03, Fair Value Measurement (Topic 820), &#8220;Fair Value Measurement of Equity Securities Subject
to Contractual Sale Restrictions&#8221; which clarifies that contractual restrictions on equity security sales are not considered part
of the security unit of account and, therefore, are not considered in measuring fair value. In addition, the restrictions cannot be recognized
and measured as separate units of account. Disclosures on such restrictions are also required. The amendments are effective for Fiscal
years beginning after December 15, 2023, and interim periods within those fiscal years on a prospectively basis. The Company expects
that ASU 2022-03 will not have a material impact on its Financial Statements and related disclosures. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; ">In
November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This ASU expands
public entities&#8217; segment disclosures by requiring disclosure of significant segment expenses that are regularly provided to the
CODM and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment
items, and interim disclosures of a reportable segment&#8217;s profit or loss and assets. All disclosure requirements under ASU 2023-07
are also required for public entities with a single reportable segment. The ASU&#8217;s amendments are effective for all public entities
for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early
adoption permitted. We are currently evaluating the impact of this pronouncement on our Financial Statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; "><b><i>Accounting
Pronouncements Issued but Not Yet Adopted</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; ">In
December 2023, the FASB issued ASU 2023-08, Intangibles&#8212;Goodwill and Other&#8212;Crypto Assets (Subtopic 350-60): Accounting for
and Disclosure of Crypto Assets, which addresses the accounting and disclosure requirements for certain crypto assets. This ASU requires
entities to subsequently measure certain crypto assets at fair value, with changes in fair value recorded in net income in each reporting
period. In addition, entities are required to provide additional disclosures about the holdings of certain crypto assets. The ASU&#8217;s
amendments are effective for all entities holding assets that meet certain scope criteria for fiscal years beginning after December 15,
2024, including interim periods within those years. Early adoption is permitted for both interim and annual periods. If an entity adopts
the amendments in an interim period, it must adopt them as of the beginning of the fiscal year that includes that interim period. We
do not expect this pronouncement to have a material impact on our Financial Statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; ">In
December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. Under this ASU, public
entities must annually (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling
items that meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than five percent of the amount
computed by multiplying pretax income or loss by the applicable statutory income tax rate). This ASU&#8217;s amendments are effective
for all entities that are subject to Topic 740, Income Taxes, for annual periods beginning after December 15, 2024, with early adoption
permitted. We are currently evaluating the impact of this pronouncement on our disclosures.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_FinanceIncomeAndExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finance income and expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_FinanceIncomeAndExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_SeverancePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for severance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_SeverancePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistancePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for government assistance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483507/832-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483507/832-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistancePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094599975792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock', window );">Schedule of Depreciation on Straight-Line Method, Over the Estimated Useful Life of the Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Annual
rates of depreciation are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 90%"><span style="font-family: Times New Roman, Times, Serif">Computers</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">33</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">R&amp;D equipment</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">20</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Furniture and office equipment</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">6-15</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Leasehold Improvements</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">10</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of depreciation on straight-line method, over the estimated useful life of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094693274368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Other Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Schedule of Other Current Assets</a></td>
<td class="text"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December&#160;31,<br/>
    2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December&#160;31,
    <br/> 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Prepaid expenses</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">240</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">176</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Institutions</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">183</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">164</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Restricted Cash</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">90</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">89</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Others</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">74</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">587</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">432</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094593140736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December&#160;31,<br/>
    2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December&#160;31,
    <br/> 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Raw materials</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">96</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-63; font-family: Times New Roman, Times, Serif">-</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Work in progress</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">55</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-64; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Finished good (*)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">293</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-65; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">444</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-66; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0"><b>(*) As of December 31, 2024, seven INSPIRA ART100 systems and
seven carts were in the course of being delivered to a distributor in the U.S. </b></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094592794784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property and Equipment, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">For the
year ended December 31, 2024:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Computers</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Leasehold<br/>
    improvements</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">R&amp;D<br/>
    equipment</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Furniture<br/>
    and office<br/> equipment</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Cost</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">At January 1, 2024</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">172</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">36</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">381</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">116</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">705</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Additions</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">10</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-67; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">154</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-68; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">164</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">At December 31, 2024</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">182</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">36</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">535</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">116</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">869</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accumulated depreciation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">At January 1, 2024</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">102</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">8</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">73</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">16</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">199</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Depreciation</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">44</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">116</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">171</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">At December 31, 2024</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">146</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">12</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">189</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">23</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">370</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Net book value:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">As of December 31, 2024</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">36</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">24</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">346</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">93</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">499</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><span style="text-decoration:underline">For the
year ended December 31, 2023:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Computers</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Leasehold<br/> improvements</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Development<br/> equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Furniture<br/> and office<br/> equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Cost</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-weight: bold">At January 1, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">121</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">33</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">229</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">116</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">499</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Additions</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">51</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">152</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">206</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-left: 9pt">At December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">172</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">381</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">116</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">705</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Accumulated depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold">At January 1, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">51</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">88</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">51</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">48</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">111</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-left: 9pt">At December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">102</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">73</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">199</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold">Net book value:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt">As of December 31, 2023</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">70</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">28</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">308</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">506</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094693258560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Accounts Payable (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrentAbstract', window );"><strong>Other Accounts Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Other Accounts Payable</a></td>
<td class="text"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December&#160;31,<br/>
    2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December&#160;31,<br/>
    2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Employees&#8217; salaries and related
    liabilities</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">414</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">388</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Related parties</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">421</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">354</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">508</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">267</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">21</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">17</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,364</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,026</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094693309184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityAbstract', window );"><strong>Lease Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ScheduleOfLesseeOperatingLeasesDisclosureTableTextBlock', window );">Schedule of Operating Right-of-Use Assets and Operating Lease Liabilities</a></td>
<td class="text">Below is a summary of the Company&#8217;s operating right-of-use
assets and operating lease liabilities as of December 31, 2024, and 2023:<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>December&#160;31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>2024</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December&#160;31, <br/> 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating lease liabilities, current</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">277</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">290</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Operating lease liabilities long-term</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">378</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">588</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total operating lease liabilities</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">655</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">878</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Weighted Average of Remaining Lease Term</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2.52</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.33</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Weighted-average discount rate - operating leases</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9.92</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9.6</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Right-of-Use Assets Over the Remaining Lease Periods</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Lease
payments for the Company&#8217;s right-of-use assets over the remaining lease periods as of December 31, 2024, are as follows:<span>&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; ">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year
    ended December&#160;31, </b></span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">U.S.&#160;dollars<br/>
    in&#160;thousands</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">326</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2026</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">254</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2027</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">154</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total undiscounted lease
    payment</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">734</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less: Interest (*)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(79</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Present value of lease
    liabilities</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">655</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">(*)
Future lease payments were discounted by&#160;7.98%-15.78% interest rate.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ScheduleOfLesseeOperatingLeasesDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ScheduleOfLesseeOperatingLeasesDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094701535168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finacial Liabilities at Fair Value (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Finacial Liabilities at Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock', window );">Schedule of Financial Liability</a></td>
<td class="text"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>December&#160;31,</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>2024</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>December&#160;31,
                                            </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>2023</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Financial liability (A)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">69</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Private warrants (B)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,506</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,459</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,575</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,470</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative liabilities at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094693139376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders&#8217; Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' Equity (Deficit) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityTableTextBlock', window );">Schedule of Share Capital</a></td>
<td class="text"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of shares as of<br/> December 31,&#160;2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number
    of shares as of<br/> December 31,&#160;2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Authorized</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Issued
    and outstanding</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Authorized</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Issued
    and outstanding</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Ordinary shares</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">100,000,000</span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">24,252,096</span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">100,000,000</span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">15,652,176</span></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Movement in Warrants Outstanding</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif">The following table reconciles the movement in warrants outstanding at the beginning and end of the period:</span><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number of<br/> Warrants</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted-average exercise price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Weighted average remaining contractual term</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>(in years)</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; font-weight: bold; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Balance as of December 31, 2023</span></td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,333,283</span></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5.47</span></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1.83</span></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Issued</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,382,438</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1.22</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1.93</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,709,760</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.001</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-70; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Expired</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,277,350</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5.25</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.54</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Balance as of December 31, 2024</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,728,611</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4.14</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1.63</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Schedule of Information about the Company&#8217;s Outstanding Warrants</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif">The following table summarizes information about the Company&#8217;s outstanding warrants as of December 31, 2024</span><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Exercise Price</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Warrants<br/> outstanding</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>as of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>December 31, 2024</b></span></p></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Expiration date</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 41%; text-align: center; padding-left: 2pt"><span style="font-family: Times New Roman, Times, Serif">5.5</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,640,455</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 40%; text-align: center; padding-left: 1.4pt"><span style="font-family: Times New Roman, Times, Serif">15/07/2026</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: center; padding-left: 2pt"><span style="font-family: Times New Roman, Times, Serif">5.5</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">277,835</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: center; padding-left: 1.4pt"><span style="font-family: Times New Roman, Times, Serif">15/07/2025</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-left: 2pt"><span style="font-family: Times New Roman, Times, Serif">6.875</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">145,455</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: center; padding-left: 1.4pt"><span style="font-family: Times New Roman, Times, Serif">15/01/2027</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: center; padding-left: 2pt"><span style="font-family: Times New Roman, Times, Serif">1.6</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">212,188</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: center; padding-left: 1.4pt"><span style="font-family: Times New Roman, Times, Serif">28/06/2027</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-left: 2pt"><span style="font-family: Times New Roman, Times, Serif">1.56</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">185,591</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: center; padding-left: 1.4pt"><span style="font-family: Times New Roman, Times, Serif">18/06/2028</span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: center; padding-left: 2pt"><span style="font-family: Times New Roman, Times, Serif">1.1</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,608,715</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: center; padding-left: 1.4pt"><span style="font-family: Times New Roman, Times, Serif">30/06/2026</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center; padding-left: 2pt"><span style="font-family: Times New Roman, Times, Serif">0.001</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">658,372</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: center; padding-left: 1.4pt"><span style="font-family: Times New Roman, Times, Serif">Until fully exercised</span></td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; text-align: center; padding-left: 2pt"><span style="font-family: Times New Roman, Times, Serif">Balance as of December 31, 2024</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,728,611</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: center; padding-left: 1.4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Loss Per Share Calculated Using the Weighted Average Number of Ordinary Shares and Pre-Funded Warrants</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Loss
per share has been calculated using the weighted average number of Ordinary Shares and pre-funded warrants in issue during the relevant
financial periods, the weighted average number of equity shares in issue and profit for the period as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December&#160;31,<br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December&#160;31,<br/> 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December&#160;31,<br/> 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Loss
    for the period</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,053</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,286</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">14,976</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Total number of Ordinary
    Shares</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">24,252,096</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">15,652,176</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,338,940</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Weighted average number of Ordinary Shares
    and pre-funded warrants</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,515,545</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,095,477</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,794,594</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Basic
    and diluted loss per share</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(0.60</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(0.93</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1.39</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094593071664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Development Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock', window );">Schedule of Research and Development Expenses</a></td>
<td class="text"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December&#160;31, <br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December&#160;31, <br/> 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December&#160;31, <br/> 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Salary
    and related expenses</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,079</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,429</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,458</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Materials
    and related expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">812</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,365</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,082</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Share based payment</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">801</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">663</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,392</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Depreciation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">371</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">291</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">188</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Subcontractors</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">340</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">304</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">850</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">IIA
    participation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(286</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-71; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-72; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">206</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">268</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">213</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,323</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,320</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,183</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements. Include also the amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others. Aggregation of similar arrangements by type may be appropriate. Include also the amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others. Aggregation of similar arrangements by type may be appropriate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094703761952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General and Administrative Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and Administrative Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock', window );">Schedule of General and Administrative Expenses</a></td>
<td class="text"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December 31, <br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December 31, <br/> 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December 31, <br/> 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Professional fees</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,758</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,432</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,500</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Salary and related expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">808</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">766</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">716</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Share-based payment</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">716</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">675</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,984</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Director fees</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">239</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">241</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">239</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Insurance expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">196</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">300</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">557</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Office maintenance</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">135</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">129</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">102</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Depreciation</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">117</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">115</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">104</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Travel abroad</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">104</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">100</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">105</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Fundraising expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-73; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">260</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-74; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Others</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">112</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">45</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">68</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,185</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,063</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">,5375</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of general and administrative expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094693282224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sales and Marketing Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpenseAbstract', window );"><strong>Sales and Marketing Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock', window );">Schedule of Sales and Marketing Expenses</a></td>
<td class="text"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December&#160;31, <br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December 31,<br/> 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December 31,<br/> 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Salary and related expenses</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">266</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">248</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">282</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Share-based payment</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">250</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">89</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">503</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Professional fees</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">187</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">348</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">527</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">51</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">61</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">16</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">754</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">746</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,328</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of sales and marketing expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094693264576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial (Income) and Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Financial (Income) and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Schedule of Financial (Income) and Expenses</a></td>
<td class="text"><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December 31, <br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December 31, <br/> 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December 31, <br/> 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Revaluation of financial liabilities
    at fair value through profit or loss</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">36</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(306</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(108</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Foreign currency transaction income</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(77</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(233</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">530</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Finance expense in respect of lease liability</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-75; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-76; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(143</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Others</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(4</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total
    expenses (Income)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(42</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(529</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">275</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094593044976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Taxes on Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
deferred tax assets and liabilities are composed of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December&#160;31, <br/>
2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December&#160;31, <br/>
2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Deferred tax assets:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net
    operating loss carryforward</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,739</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,519</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued
    expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">97</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">80</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">R&amp;D
    temporary differences</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,218</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,335</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif">Fund raising costs
    2023</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">35</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">70</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Operating
    lease liability</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total
    deferred tax assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,097</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,012</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Valuation
    allowance</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(8,097</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(7,012</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred
    tax liabilities:</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total
    deferred tax liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-77; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-78; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Net
    deferred taxes</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-79; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-80; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ScheduleOfTheoreticalTaxTableTextBlock', window );">Schedule of Theoretical Tax</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif"><b>C.</b></span><span style="font-family: Times New Roman, Times, Serif"><b>Theoretical tax:</b></span><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December&#160;31,<br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December&#160;31,<br/> 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December&#160;31,<br/> 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Loss before taxation</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(11,053</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(11,286</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(14,976</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Theoretical tax credit at applicable statutory rate: 23%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,542</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,596</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,444</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Non-allowable expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(391</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(244</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,026</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Temporary
    differences and tax losses for which no Deferred Tax Asset is recognized</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,151</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,352</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,418</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Income tax benefit</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-81; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-82; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-83; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ScheduleOfTheoreticalTaxTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of theoretical tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ScheduleOfTheoreticalTaxTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094693303120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract', window );"><strong>Share-Based Payment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Measure the Fair Value of the Option at Grant Date</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
following inputs were used to measure the fair value of the option at grant date:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">March
    24, 2022</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">January
    22, 2024</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">February
    5, 2024</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif">(i)</span></td>
    <td style="width: 47%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Expected volatility</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 15%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">52%</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 15%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">144.83%</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 15%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">143.98%</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">(ii)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Dividend rate</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">0%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">0%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">0%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">(iii)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Expected term (vesting period)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three years</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Three years</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="-sec-ix-hidden: hidden-fact-84; font-family: Times New Roman, Times, Serif">Three years</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">(iv)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Contractual life</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Ten years</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Ten years</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="-sec-ix-hidden: hidden-fact-85; font-family: Times New Roman, Times, Serif">Ten years</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">(v)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Free risk rate</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">2.79%-2.80%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">4.03%-4.07%</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">4.16%</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Options to Services Providers and Advisers Outstanding</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The options
to services providers and advisers outstanding as December 31, 2024, 2023 and 2022 were as&#160;follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>


<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December 31, 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December 31, 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December 31, 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number
    of <br/> options</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted
    <br/> average <br/> Exercise <br/> price NIS</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number
    of <br/> options</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted
    <br/> average <br/> Exercise <br/> price NIS</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number
    of<br/> options</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted
    <br/> average <br/> Exercise <br/> price NIS</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Outstanding at beginning of year</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">105,111</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4.085</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">114,512</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.058</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">87,833</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.37</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Reclassified to employees and directors</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-86; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-87; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-88; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-89; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-90; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-91; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">80,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.779</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-92; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-93; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">29,400</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">10.84</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-94; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-95; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,401</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.367</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,721</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.37</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-96; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-97; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-98; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-99; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-100; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-101; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 1.1pt"><span style="font-family: Times New Roman, Times, Serif">Options
    outstanding</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">185,111</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.359</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">105,111</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4.085</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">114,512</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.058</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 1.1pt"><span style="font-family: Times New Roman, Times, Serif">Options
    exercisable</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">162,154</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.251</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">94,242</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.267</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">82,257</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.37</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 1.1pt"><span style="font-family: Times New Roman, Times, Serif">Share-based
    payment expenses</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">66</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">19</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">54</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The options
to employees and directors outstanding as of December 31, 2024, 2023 and 2022 were as&#160;follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>




<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December 31, 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December 31, 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December 31, 2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number
    of <br/> options</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted
    <br/> average <br/> Exercise <br/> price NIS</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number
    of <br/> options</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted
    <br/> average <br/> Exercise <br/> price NIS</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number
    of <br/> options</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted
    <br/> average <br/> Exercise <br/> price NIS</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Outstanding at beginning of year</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">357,689</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.37</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">386,260</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.37</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">448,120</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.37</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">30,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.56</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-102; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-103; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-104; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">19,048</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.37</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.37</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,309</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.37</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-105; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-106; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">28,571</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.37</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">57,551</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.37</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 1.1pt"><span style="font-family: Times New Roman, Times, Serif">Options
    outstanding</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">368,641</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.70</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">357,689</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.37</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">386,260</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.37</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 1.1pt"><span style="font-family: Times New Roman, Times, Serif">Options
    exercisable</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">338,641</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.45</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">350,131</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.37</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">342,757</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">0.37</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 1.1pt"><span style="font-family: Times New Roman, Times, Serif">Share-based
    payment expenses</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">17</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">47</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">174</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of RSUs to Services Providers and Advisers Outstanding</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The RSUs
to services providers and advisers outstanding as of December 31, 2024, 2023 and 2022 were as&#160;follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>


<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December 31, <br/>
2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December 31, <br/>
2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December 31, <br/>
2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number
    of <br/>
RSUs</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number
    of <br/>
RSUs</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number
    of <br/>
RSUs</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Outstanding at beginning of year</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,433</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,266</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-107; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-108; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">22,500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Vested</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,433</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,833</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">14,234</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 1.1pt"><span style="font-family: Times New Roman, Times, Serif">RSUs
    outstanding</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-109; font-family: Times New Roman, Times, Serif">-</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,433</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,266</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 1.1pt"><span style="font-family: Times New Roman, Times, Serif">RSU&#8217;s
    Vested</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">32,500</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">25,067</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">14,234</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 1.1pt"><span style="font-family: Times New Roman, Times, Serif">Share-based
    payment expenses</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">33</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The RSUs
to employees and directors outstanding as of December 31, 2024, 2023 and 2022 were as&#160;follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December&#160;31, <br/>
    2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December&#160;31, <br/>
    2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Year
    ended<br/> December&#160;31, <br/>
    2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number
    of<br/>
 RSUs</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number
    of<br/>
 RSUs</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number
    of<br/>
 RSUs</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Outstanding at beginning of year</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">445,140</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,727,842</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,002,587</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,687,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-110; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,016,854</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">25,836</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">67,087</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">65,626</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Vested</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">587,508</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,215,615</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,225,973</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 1.1pt"><span style="font-family: Times New Roman, Times, Serif">RSUs
    outstanding</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,518,796</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">445,140</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,727,842</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 1.1pt"><span style="font-family: Times New Roman, Times, Serif">RSU&#8217;s
    Vested</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,684,697</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,097,189</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,881,574</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 1.1pt"><span style="font-family: Times New Roman, Times, Serif">Share-based
    payment expenses</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,683</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,352</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,618</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094593172576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Parties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of Shareholders and Other Related Parties&#8217; Benefits</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Shareholders and other related parties&#8217; benefits</span></span><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December&#160;31,
    <br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December&#160;31,
    <br/> 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December&#160;31,<br/>
    2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Salary and related expenses &#8211;
    officers and directors</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,710</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,761</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,923</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Share based payment &#8211; officers and directors</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,376</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,009</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,745</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Balances with related parties</span></span><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Name</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Nature of transaction</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December&#160;31, <br/> 2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">December&#160;31, <br/> 2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 20%"><span style="font-family: Times New Roman, Times, Serif">Officers</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 55%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Salaries and related</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(381</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(314</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif">Directors</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Compensation for directors</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(40</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(40</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094596333200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 27, 2024</div></th>
<th class="th"><div>Jun. 14, 2024</div></th>
<th class="th"><div>Apr. 01, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PublicUtilitiesGeneralDisclosuresLineItems', window );"><strong>General [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,339,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Purchase price of per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="nump">$ 1.232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,102<span></span>
</td>
<td class="nump">$ 1,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PartnersCapitalAccountPublicSaleOfUnitsNetOfOfferingCosts', window );">Additional offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionExercisePriceIncrease', window );">Exercise price of per share</a></td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AdditionalOfferingCosts', window );">Additional offering costs</a></td>
<td class="nump">$ 233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liability</a></td>
<td class="nump">$ 69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax', window );">Incurred accumulated losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=iinn_PreFundedWarrantsMember', window );">Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PublicUtilitiesGeneralDisclosuresLineItems', window );"><strong>General [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,709,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Purchase price of per share</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Pre funded warrant, per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=iinn_JunePreFundedWarrantsMember', window );">June Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PublicUtilitiesGeneralDisclosuresLineItems', window );"><strong>General [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,709,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Pre funded warrant, per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=iinn_JunePlacementAgentWarrantsMember', window );">June Placement Agent Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PublicUtilitiesGeneralDisclosuresLineItems', window );"><strong>General [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Pre funded warrant, per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_PercentageOfOrdinaryShares', window );">Percentage of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_PlacementAgentWarrantsFairValue', window );">Placement agent warrants fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=iinn_DecemberPreFundedWarrantsMember', window );">December Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PublicUtilitiesGeneralDisclosuresLineItems', window );"><strong>General [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Ordinary shares</a></td>
<td class="nump">658,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Pre funded warrant, per share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PublicUtilitiesGeneralDisclosuresLineItems', window );"><strong>General [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Ordinary shares</a></td>
<td class="nump">4,608,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PublicUtilitiesGeneralDisclosuresLineItems', window );"><strong>General [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">941,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,231,169<span></span>
</td>
<td class="nump">3,031,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=iinn_DecemberPrivatePlacementMember', window );">December Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PublicUtilitiesGeneralDisclosuresLineItems', window );"><strong>General [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Ordinary shares</a></td>
<td class="nump">3,950,343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Purchase price of per share</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AggregateProceedsReceived', window );">Gross proceeds</a></td>
<td class="nump">$ 3,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_AdditionalOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of additional offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_AdditionalOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_AggregateProceedsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of aggregate proceeds received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_AggregateProceedsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_PercentageOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_PercentageOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_PlacementAgentWarrantsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of fair value for the placement agent warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_PlacementAgentWarrantsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PartnersCapitalAccountPublicSaleOfUnitsNetOfOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after offering cost, from issuance of new unit of limited partnership interest in public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 4.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-5<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PartnersCapitalAccountPublicSaleOfUnitsNetOfOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesGeneralDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesGeneralDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionExercisePriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share increase in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionExercisePriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=iinn_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=iinn_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=iinn_JunePreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=iinn_JunePreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=iinn_JunePlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=iinn_JunePlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=iinn_DecemberPreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=iinn_DecemberPreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=iinn_DecemberPrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=iinn_DecemberPrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094597172992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatutoryAccountingPracticesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Lease liability, weighted-average discount rate</a></td>
<td class="nump">9.92%<span></span>
</td>
<td class="nump">9.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Employees monthly deposits rate</a></td>
<td class="nump">8.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term deposits</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 2.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatutoryAccountingPracticesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Lease liability, weighted-average discount rate</a></td>
<td class="nump">9.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatutoryAccountingPracticesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatutoryAccountingPracticesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094594496768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Schedule of Depreciation on Straight-Line Method, Over the Estimated Useful Life of the Assets (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Depreciation on Straight-Line Method, Over the Estimated Useful Life of the Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment', window );">Annual depreciation rates</a></td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">R&amp;D equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Depreciation on Straight-Line Method, Over the Estimated Useful Life of the Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment', window );">Annual depreciation rates</a></td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Depreciation on Straight-Line Method, Over the Estimated Useful Life of the Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment', window );">Annual depreciation rates</a></td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Furniture and office equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Depreciation on Straight-Line Method, Over the Estimated Useful Life of the Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment', window );">Annual depreciation rates</a></td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Furniture and office equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Depreciation on Straight-Line Method, Over the Estimated Useful Life of the Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment', window );">Annual depreciation rates</a></td>
<td class="nump">15.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of annual depreciation rates of property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094596193232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Deposits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">USD [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositLiabilityLineItems', window );"><strong>Deposits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtPercentageBearingFixedInterestRate', window );">Fixed annual interest percentage</a></td>
<td class="nump">4.108%<span></span>
</td>
<td class="nump">6.18%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IL', window );">Israel [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositLiabilityLineItems', window );"><strong>Deposits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Deposits', window );">Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 280<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtPercentageBearingFixedInterestRate', window );">Fixed annual interest percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.85%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=iinn_BankLeumiMember', window );">Bank Leumi [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositLiabilityLineItems', window );"><strong>Deposits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Deposits', window );">Deposit</a></td>
<td class="nump">$ 668<span></span>
</td>
<td class="nump">$ 2,040<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositLiabilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1406<br> -Paragraph a<br> -Subparagraph (2)<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1406<br> -Paragraph a<br> -Subparagraph (1)<br> -Publisher SEC<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1406<br> -Paragraph a<br> -Subparagraph (5)<br> -Publisher SEC<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1406<br> -Paragraph c<br> -Publisher SEC<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1406<br> -Paragraph a<br> -Subparagraph (3)<br> -Publisher SEC<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1406<br> -Paragraph a<br> -Subparagraph (4)<br> -Publisher SEC<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositLiabilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Deposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate of all deposit liabilities held by the entity, including foreign and domestic, interest and noninterest bearing; may include demand deposits, saving deposits, Negotiable Order of Withdrawal (NOW) and time deposits among others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Deposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtPercentageBearingFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying amount of short-term borrowings outstanding as of the balance sheet date which accrues interest at a set, unchanging rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtPercentageBearingFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=iinn_BankLeumiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=iinn_BankLeumiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094594303488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Current Assets - Schedule of Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Other Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">$ 240<span></span>
</td>
<td class="nump">$ 176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestBearingDepositsInBanks', window );">Institutions</a></td>
<td class="nump">183<span></span>
</td>
<td class="nump">164<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted Cash</a></td>
<td class="nump">90<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Others</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Total</a></td>
<td class="nump">$ 587<span></span>
</td>
<td class="nump">$ 432<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestBearingDepositsInBanks">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For banks and other depository institutions (including Federal Reserve Banks, if applicable): Interest-bearing deposits in other financial institutions for relatively short periods of time including, for example, certificates of deposits, which are presented separately from cash on the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477263/942-210-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestBearingDepositsInBanks</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094702487648">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Inventory - Schedule of Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 96<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in progress</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">55<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished good</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">293<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 444<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">As of December 31, 2024, seven INSPIRA ART100 systems and
seven carts were in the course of being delivered to a distributor in the U.S.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094596200288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost, Beginning Balance</a></td>
<td class="nump">$ 705<span></span>
</td>
<td class="nump">$ 499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation, Beginning Balance</a></td>
<td class="nump">199<span></span>
</td>
<td class="nump">88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net book value</a></td>
<td class="nump">499<span></span>
</td>
<td class="nump">506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Additions</a></td>
<td class="nump">164<span></span>
</td>
<td class="nump">206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost, Ending Balance</a></td>
<td class="nump">869<span></span>
</td>
<td class="nump">705<span></span>
</td>
<td class="nump">$ 499<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">171<span></span>
</td>
<td class="nump">111<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation, Ending Balance</a></td>
<td class="nump">370<span></span>
</td>
<td class="nump">199<span></span>
</td>
<td class="nump">88<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost, Beginning Balance</a></td>
<td class="nump">172<span></span>
</td>
<td class="nump">121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation, Beginning Balance</a></td>
<td class="nump">102<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net book value</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Additions</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost, Ending Balance</a></td>
<td class="nump">182<span></span>
</td>
<td class="nump">172<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation, Ending Balance</a></td>
<td class="nump">146<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost, Beginning Balance</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation, Beginning Balance</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net book value</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Additions</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost, Ending Balance</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation, Ending Balance</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=iinn_RDEquipmentMember', window );">R&amp;D equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost, Beginning Balance</a></td>
<td class="nump">381<span></span>
</td>
<td class="nump">229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation, Beginning Balance</a></td>
<td class="nump">73<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net book value</a></td>
<td class="nump">346<span></span>
</td>
<td class="nump">308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Additions</a></td>
<td class="nump">154<span></span>
</td>
<td class="nump">152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost, Ending Balance</a></td>
<td class="nump">535<span></span>
</td>
<td class="nump">381<span></span>
</td>
<td class="nump">229<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">116<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation, Ending Balance</a></td>
<td class="nump">189<span></span>
</td>
<td class="nump">73<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and office equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost, Beginning Balance</a></td>
<td class="nump">116<span></span>
</td>
<td class="nump">116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation, Beginning Balance</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net book value</a></td>
<td class="nump">93<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Additions</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost, Ending Balance</a></td>
<td class="nump">116<span></span>
</td>
<td class="nump">116<span></span>
</td>
<td class="nump">116<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation, Ending Balance</a></td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=iinn_RDEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=iinn_RDEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094595514928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Accounts Payable - Schedule of Other Accounts Payable (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract', window );"><strong>Schedule of Other Accounts Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent', window );">Employees&#8217; salaries and related liabilities</a></td>
<td class="nump">$ 414<span></span>
</td>
<td class="nump">$ 388<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AccountsPayableToRelatedParties', window );">Related parties</a></td>
<td class="nump">421<span></span>
</td>
<td class="nump">354<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued expenses</a></td>
<td class="nump">508<span></span>
</td>
<td class="nump">267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent', window );">Other</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Total</a></td>
<td class="nump">$ 1,364<span></span>
</td>
<td class="nump">$ 1,026<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_AccountsPayableToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accounts payable to related parties, due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_AccountsPayableToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094592791760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br> &#8362; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2023 </div>
<div>ILS (&#8362;)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>ILS (&#8362;)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>ILS (&#8362;)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>ILS (&#8362;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_AggregateBudget', window );">Aggregate budget</a></td>
<td class="nump">$ 1,062<span></span>
</td>
<td class="nump">&#8362; 3,850,869<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="nump">&#8362; 4,880,603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_PercentageOfApprovedBudget', window );">Percentage of approved budget</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ProjectBudgetAggregateAmount', window );">Project budget aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,333<span></span>
</td>
<td class="nump">&#8362; 4,623,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Total funds received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 286<span></span>
</td>
<td class="nump">&#8362; 1,062,049<span></span>
</td>
<td class="nump">&#8362; 2,773,885<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_RoyaltiesPercentage', window );">Percentage of royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ContingentUponFutureSales', window );">Contingent upon future sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_AggregateBudget">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of aggregate budget.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_AggregateBudget</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ContingentUponFutureSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contingent upon future sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ContingentUponFutureSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_PercentageOfApprovedBudget">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of approved budget.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_PercentageOfApprovedBudget</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ProjectBudgetAggregateAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of project budget aggregate amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ProjectBudgetAggregateAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_RoyaltiesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_RoyaltiesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094595551696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Liabilities (Details)<br> &#8362; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>ILS (&#8362;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Rent termination penalty</a></td>
<td class="nump">$ 153,000<span></span>
</td>
<td class="nump">&#8362; 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_MonthlyDeductionFromTerminationFee', window );">Monthly deduction from termination fee</a></td>
<td class="nump">9,000<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLeasePayments', window );">Lease payment</a></td>
<td class="num">(17,500)<span></span>
</td>
<td class="nump">&#8362; 69,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Lease expenses</a></td>
<td class="nump">$ 390,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 371,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_PercentageForCarsLeaseAgreementCancellationPenalty', window );">Percentage for car lease agreement cancellation penalty</a></td>
<td class="text">up to 400%<span></span>
</td>
<td class="text">up to 400%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_PercentageOfFutureLeasePaymentsDiscounted', window );">Percentage of future lease payments discounted</a></td>
<td class="nump">7.98%<span></span>
</td>
<td class="nump">7.98%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lease Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_PercentageOfFutureLeasePaymentsDiscounted', window );">Percentage of future lease payments discounted</a></td>
<td class="nump">15.78%<span></span>
</td>
<td class="nump">15.78%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_MonthlyDeductionFromTerminationFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the value of monthly deduction from termination fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_MonthlyDeductionFromTerminationFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_PercentageForCarsLeaseAgreementCancellationPenalty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the description of percentage for car lease agreement cancellation penalty.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_PercentageForCarsLeaseAgreementCancellationPenalty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_PercentageOfFutureLeasePaymentsDiscounted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of future lease payments discounted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_PercentageOfFutureLeasePaymentsDiscounted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from lease payment, classified as operating activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479016/842-30-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479016/842-30-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094693190880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Lease Liabilities - Schedule of Operating Right-of-Use Assets and Operating Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Schedule of Operating Right-of-Use Assets and Operating Lease Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">$ 277<span></span>
</td>
<td class="nump">$ 290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities long-term</a></td>
<td class="nump">378<span></span>
</td>
<td class="nump">588<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 655<span></span>
</td>
<td class="nump">$ 878<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted Average of Remaining Lease Term</a></td>
<td class="text">2 years 6 months 7 days<span></span>
</td>
<td class="text">3 years 3 months 29 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate - operating leases</a></td>
<td class="nump">9.92%<span></span>
</td>
<td class="nump">9.60%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094594407840">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Lease Liabilities - Schedule of Right-of-Use Assets Over the Remaining Lease Periods (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>Schedule of Right-of-Use Assets Over the Remaining Lease Periods [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(79)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 655<span></span>
</td>
<td class="nump">$ 878<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Future lease payments were discounted by&#160;7.98%-15.78% interest rate.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094594366112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finacial Liabilities at Fair Value (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 26, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 27, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Finacial Liabilities at Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liability fair value (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative Liability, Current (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,575<span></span>
</td>
<td class="nump">$ 1,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=iinn_PrivateWarrantsMember', window );">Private Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Finacial Liabilities at Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative Liability, Current (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,506<span></span>
</td>
<td class="nump">1,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember', window );">Financial liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Finacial Liabilities at Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liability fair value (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative Liability, Current (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=iinn_December2024PrivatePlacementMember', window );">December 2024 Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Finacial Liabilities at Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_PercentageOfPayFees', window );">Percentage of pay fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liability fair value (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Finacial Liabilities at Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Aggregate purchase (in Shares) | shares</a></td>
<td class="nump">3,031,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Finacial Liabilities at Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Fair value of private warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.26<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Finacial Liabilities at Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Fair value of private warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88.61<span></span>
</td>
<td class="nump">66.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Finacial Liabilities at Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Fair value of private warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected Term of Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Finacial Liabilities at Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Fair value of private warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
<td class="nump">3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_PercentageOfPayFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of pay fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_PercentageOfPayFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=iinn_PrivateWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=iinn_PrivateWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=iinn_December2024PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=iinn_December2024PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094596622144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Finacial Liabilities at Fair Value - Schedule of Financial Liability (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Schedule of Financial Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 1,575<span></span>
</td>
<td class="nump">$ 1,470<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember', window );">Financial liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Schedule of Financial Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">69<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=iinn_PrivateWarrantsMember', window );">Private warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Schedule of Financial Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 1,506<span></span>
</td>
<td class="nump">$ 1,459<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=iinn_PrivateWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=iinn_PrivateWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094584114176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders&#8217; Equity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 27, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 14, 2024</div></th>
<th class="th"><div>May 20, 2024</div></th>
<th class="th"><div>Apr. 01, 2024</div></th>
<th class="th"><div>Jan. 22, 2024</div></th>
<th class="th"><div>Dec. 26, 2023</div></th>
<th class="th"><div>Mar. 24, 2022</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Shareholders&#8217; Equity [Line Item]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Options exercise shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,339,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_PurchasePricePerShare', window );">Purchase price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Offering cost (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantyLiquidationProceedsPercentage', window );">Percentage of agreement warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Ordinary shares issued for consulting service agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liability fair value (in Dollars)</a></td>
<td class="nump">$ 69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=iinn_PreFundedWarrantsMember', window );">Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Shareholders&#8217; Equity [Line Item]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,709,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Pre funded warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,656,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_NumberofAdditionalOrdinaryShares', window );">Number of additional shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,656,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=iinn_PrivateWarrantsMember', window );">Private Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Shareholders&#8217; Equity [Line Item]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ClassOfPrivateWarrantOrRightOutstanding', window );">Private warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,031,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Shareholders&#8217; Equity [Line Item]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">212,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issued shares</a></td>
<td class="nump">4,608,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=iinn_PlacementAgentWarrantsMember', window );">Placement Agent Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Shareholders&#8217; Equity [Line Item]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants expire, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of the warrant (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=iinn_JunePreFundedWarrantsMember', window );">June Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Shareholders&#8217; Equity [Line Item]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,709,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,709,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_NumberOfSharesPerUnits', window );">Number of shares per units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Exercise amount of warrants (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=iinn_TwoThousandTwentyFourJuneOfferingMember', window );">2024 June Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Shareholders&#8217; Equity [Line Item]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Offering cost (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Net proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=iinn_JunePlacementAgentWarrantsMember', window );">June Placement Agent Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Shareholders&#8217; Equity [Line Item]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductWarrantyLiquidationProceedsPercentage', window );">Percentage of agreement warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants expire, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Exercise amount of warrants (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=iinn_DecemberPrivateWarrantsMember', window );">December Private Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Shareholders&#8217; Equity [Line Item]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock</a></td>
<td class="nump">3,950,343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_PurchasePricePerShare', window );">Purchase price per share (in Dollars per share)</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrant</a></td>
<td class="nump">658,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=iinn_DecemberPreFundedWarrantsMember', window );">December Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Shareholders&#8217; Equity [Line Item]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issued shares</a></td>
<td class="nump">658,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrant</a></td>
<td class="nump">658,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_NumberOfSharesPerUnits', window );">Number of shares per units</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Shareholders&#8217; Equity [Line Item]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_PurchasePricePerShare', window );">Purchase price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | June Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Shareholders&#8217; Equity [Line Item]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_PurchasePricePerShare', window );">Purchase price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | December Private Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Shareholders&#8217; Equity [Line Item]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_PurchasePricePerShare', window );">Purchase price per share (in Dollars per share)</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Shareholders&#8217; Equity [Line Item]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | June Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Shareholders&#8217; Equity [Line Item]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_PurchasePricePerShare', window );">Purchase price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | December Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Shareholders&#8217; Equity [Line Item]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in Dollars per share)</a></td>
<td class="nump">0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Vested RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Shareholders&#8217; Equity [Line Item]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issued an aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">594,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Options exercise shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,141<span></span>
</td>
<td class="nump">19,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,030<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=iinn_RegisteredDirectOfferingMember', window );">Registered Direct Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Shareholders&#8217; Equity [Line Item]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Ordinary Shares [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Shareholders&#8217; Equity [Line Item]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants expire, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of the warrant (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Ordinary Shares [Member] | Placement Agent Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Shareholders&#8217; Equity [Line Item]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">212,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Ordinary Shares [Member] | December Private Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Shareholders&#8217; Equity [Line Item]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in Dollars per share)</a></td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase of warrant</a></td>
<td class="nump">3,950,343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_NumberOfSharesPerUnits', window );">Number of shares per units</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Ordinary Shares [Member] | Roth Capital Partners, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Shareholders&#8217; Equity [Line Item]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Ordinary Shares [Member] | Vested RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Shareholders&#8217; Equity [Line Item]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issued an aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,226,448<span></span>
</td>
<td class="nump">1,240,204<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Options exercise shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Ordinary Shares [Member] | Registered Direct Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Shareholders&#8217; Equity [Line Item]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=iinn_TwoThousandTwentyFourAprilOfferingMember', window );">2024 April Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Shareholders&#8217; Equity [Line Item]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,339,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_PurchasePricePerShare', window );">Purchase price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=iinn_TwoThousandTwentyFourJuneOfferingMember', window );">2024 June Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Shareholders&#8217; Equity [Line Item]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">941,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_PurchasePricePerShare', window );">Purchase price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Shareholders&#8217; Equity [Line Item]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=iinn_DecemberPrivateOfferingMember', window );">December Private Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Shareholders&#8217; Equity [Line Item]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Offering cost (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_PercentageOfPayFees', window );">Percentage of pay fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=iinn_December2024PrivatePlacementMember', window );">December 2024 Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Shareholders&#8217; Equity [Line Item]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liability fair value (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ClassOfPrivateWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the number of private warrant or right outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ClassOfPrivateWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_NumberOfSharesPerUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares per units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_NumberOfSharesPerUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_NumberofAdditionalOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_NumberofAdditionalOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_PercentageOfPayFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of pay fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_PercentageOfPayFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_PurchasePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_PurchasePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480341/340-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyLiquidationProceedsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of proceeds from liquidation of asset held as collateral or by third party expected to cover maximum potential future payment for product warranty. Includes, but is not limited to, separately price extended warranty, product maintenance contract, and warranty obligation incurred in connection with agreed upon specification.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyLiquidationProceedsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=iinn_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=iinn_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=iinn_PrivateWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=iinn_PrivateWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=iinn_PlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=iinn_PlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=iinn_JunePreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=iinn_JunePreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=iinn_TwoThousandTwentyFourJuneOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=iinn_TwoThousandTwentyFourJuneOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=iinn_JunePlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=iinn_JunePlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=iinn_DecemberPrivateWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=iinn_DecemberPrivateWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=iinn_DecemberPreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=iinn_DecemberPreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=iinn_RegisteredDirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=iinn_RegisteredDirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=iinn_RothCapitalPartnersLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=iinn_RothCapitalPartnersLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=iinn_TwoThousandTwentyFourAprilOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=iinn_TwoThousandTwentyFourAprilOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=iinn_TwoThousandTwentyFourJuneOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=iinn_TwoThousandTwentyFourJuneOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=iinn_DecemberPrivateOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=iinn_DecemberPrivateOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=iinn_December2024PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=iinn_December2024PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094593123472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Shareholders&#8217; Equity - Schedule of Share Capital (Details) - Ordinary Shares [Member] - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareholdersEquityScheduleofShareCapitalDetailsLineItems', window );"><strong>Shareholders&#8217; Equity - Schedule of Share Capital (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, Authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, Issued</a></td>
<td class="nump">24,252,096<span></span>
</td>
<td class="nump">15,652,176<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, Outstanding</a></td>
<td class="nump">24,252,096<span></span>
</td>
<td class="nump">15,652,176<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ShareholdersEquityScheduleofShareCapitalDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ShareholdersEquityScheduleofShareCapitalDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094594461312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders&#8217; Equity - Schedule of Movement in Warrants Outstanding (Details) - Warrant [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at ending of year</a></td>
<td class="nump">3,333,283<span></span>
</td>
<td class="nump">7,728,611<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average exercise price, ending Balance</a></td>
<td class="nump">$ 5.47<span></span>
</td>
<td class="nump">$ 4.14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted average remaining contractual term (in years), ending Balance</a></td>
<td class="text">1 year 9 months 29 days<span></span>
</td>
<td class="text">1 year 7 months 17 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsIssued', window );">Number of Warrants, Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,382,438<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeighted-averageExercisePriceIssued', window );">Weighted-average exercise price, Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms', window );">Weighted average remaining contractual term (in years), Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 11 months 4 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod', window );">Number of Warrants, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,709,760)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue', window );">Weighted-average exercise price, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms', window );">Weighted average remaining contractual term (in years), Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod', window );">Number of Warrants, Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,277,350)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue', window );">Weighted-average exercise price, Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms', window );">Weighted average remaining contractual term (in years), Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months 14 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants, exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term, exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants, expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term, expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term, issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants, issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeighted-averageExercisePriceIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of other than option under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeighted-averageExercisePriceIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094594433216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders&#8217; Equity - Schedule of Information about the Company&#8217;s Outstanding Warrants (Details) - Warrant [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Warrants outstanding (in Shares)</a></td>
<td class="nump">7,728,611<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=iinn_ExercisePrice55Member', window );">5.5 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 5.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Warrants outstanding (in Shares)</a></td>
<td class="nump">1,640,455<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiration date</a></td>
<td class="text">Jul. 15,  2026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=iinn_ExercisePrice55TwoMember', window );">5.5 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 5.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Warrants outstanding (in Shares)</a></td>
<td class="nump">277,835<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiration date</a></td>
<td class="text">Jul. 15,  2025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=iinn_Exercise6875Member', window );">6.875 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 6.875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Warrants outstanding (in Shares)</a></td>
<td class="nump">145,455<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiration date</a></td>
<td class="text">Jan. 15,  2027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=iinn_ExercisePriceOnePointSixMember', window );">1.6 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 1.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Warrants outstanding (in Shares)</a></td>
<td class="nump">212,188<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiration date</a></td>
<td class="text">Jun. 28,  2027<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=iinn_ExercisePrice156Member', window );">1.56 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 1.56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Warrants outstanding (in Shares)</a></td>
<td class="nump">185,591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiration date</a></td>
<td class="text">Jun. 18,  2028<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=iinn_ExercisePriceOnePointOneMember', window );">1.1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 1.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Warrants outstanding (in Shares)</a></td>
<td class="nump">4,608,715<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiration date</a></td>
<td class="text">Jun. 30,  2026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=iinn_ExercisePrice0001Member', window );">0.001 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Warrants outstanding (in Shares)</a></td>
<td class="nump">658,372<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentExpirationDate', window );">Expiration date</a></td>
<td class="text">Until fully exercised<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the equity-based award expires.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ShareBasedCompensationArrangementByShareBasedPaymentExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the equity-based award expires, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=iinn_ExercisePrice55Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=iinn_ExercisePrice55Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=iinn_ExercisePrice55TwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=iinn_ExercisePrice55TwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=iinn_Exercise6875Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=iinn_Exercise6875Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=iinn_ExercisePriceOnePointSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=iinn_ExercisePriceOnePointSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=iinn_ExercisePrice156Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=iinn_ExercisePrice156Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=iinn_ExercisePriceOnePointOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=iinn_ExercisePriceOnePointOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=iinn_ExercisePrice0001Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=iinn_ExercisePrice0001Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094693255200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders&#8217; Equity - Schedule of Loss Per Share Calculated Using the Weighted Average Number of Ordinary Shares and Pre-Funded Warrants (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Schedule of Loss Per Share Calculated Using the Weighted Average Number of Ordinary Shares and Pre-Funded Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Loss for the period (in Dollars)</a></td>
<td class="nump">$ 11,053<span></span>
</td>
<td class="nump">$ 11,286<span></span>
</td>
<td class="nump">$ 14,976<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Total number of Ordinary Shares</a></td>
<td class="nump">24,252,096<span></span>
</td>
<td class="nump">15,652,176<span></span>
</td>
<td class="nump">11,338,940<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of Ordinary Shares and pre-funded warrants</a></td>
<td class="nump">18,515,545<span></span>
</td>
<td class="nump">12,095,477<span></span>
</td>
<td class="nump">10,794,594<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic loss per share (in Dollars per share)</a></td>
<td class="num">$ (0.6)<span></span>
</td>
<td class="num">$ (0.93)<span></span>
</td>
<td class="num">$ (1.39)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted loss per share (in Dollars per share)</a></td>
<td class="num">$ (0.6)<span></span>
</td>
<td class="num">$ (0.93)<span></span>
</td>
<td class="num">$ (1.39)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094594472304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Development Expenses - Schedule of Research and Development Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Schedule of Research and Development Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Salary and related expenses</a></td>
<td class="nump">$ 4,079<span></span>
</td>
<td class="nump">$ 4,429<span></span>
</td>
<td class="nump">$ 3,458<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLaborRelatedExpenses', window );">Materials and related expenses</a></td>
<td class="nump">812<span></span>
</td>
<td class="nump">1,365<span></span>
</td>
<td class="nump">1,082<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Share based payment</a></td>
<td class="nump">801<span></span>
</td>
<td class="nump">663<span></span>
</td>
<td class="nump">2,392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationNonproduction', window );">Depreciation</a></td>
<td class="nump">371<span></span>
</td>
<td class="nump">291<span></span>
</td>
<td class="nump">188<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_Subcontractors', window );">Subcontractors</a></td>
<td class="nump">340<span></span>
</td>
<td class="nump">304<span></span>
</td>
<td class="nump">850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_IIAParticipation', window );">IIA participation</a></td>
<td class="num">(286)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Other</a></td>
<td class="nump">206<span></span>
</td>
<td class="nump">268<span></span>
</td>
<td class="nump">213<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total</a></td>
<td class="nump">$ 6,323<span></span>
</td>
<td class="nump">$ 7,320<span></span>
</td>
<td class="nump">$ 8,183<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_IIAParticipation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expenses of IIA participation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_IIAParticipation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_Subcontractors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Subcontractors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_Subcontractors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of expense for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationNonproduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense recognized in the current period that allocates the cost of nonproduction tangible assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationNonproduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLaborRelatedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of labor-related expenses classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLaborRelatedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094595894240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General and Administrative Expenses - Schedule of General and Administrative Expenses (Details) - General and Administrative Expense [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ScheduleOfGeneralAndAdministrativeExpensesLineItems', window );"><strong>Schedule of General and Administrative Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional fees</a></td>
<td class="nump">$ 1,758<span></span>
</td>
<td class="nump">$ 1,432<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Salary and related expenses</a></td>
<td class="nump">808<span></span>
</td>
<td class="nump">766<span></span>
</td>
<td class="nump">716<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment</a></td>
<td class="nump">716<span></span>
</td>
<td class="nump">675<span></span>
</td>
<td class="nump">1,984<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Director fees</a></td>
<td class="nump">239<span></span>
</td>
<td class="nump">241<span></span>
</td>
<td class="nump">239<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralInsuranceExpense', window );">Insurance expenses</a></td>
<td class="nump">196<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">557<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostMaintenance', window );">Office maintenance</a></td>
<td class="nump">135<span></span>
</td>
<td class="nump">129<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">117<span></span>
</td>
<td class="nump">115<span></span>
</td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TravelAndEntertainmentExpense', window );">Travel abroad</a></td>
<td class="nump">104<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_FundraisingExpenses', window );">Fundraising expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">260<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralExpense', window );">Others</a></td>
<td class="nump">112<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total</a></td>
<td class="nump">$ 4,185<span></span>
</td>
<td class="nump">$ 4,063<span></span>
</td>
<td class="nump">$ 5,375<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_FundraisingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of fundraising expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_FundraisingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ScheduleOfGeneralAndAdministrativeExpensesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ScheduleOfGeneralAndAdministrativeExpensesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostMaintenance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of maintenance incurred and directly related to good produced and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostMaintenance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralInsuranceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense in the period incurred with respect to protection provided by insurance entities against risks other than risks associated with production (which are allocated to cost of sales).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralInsuranceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general expenses not normally included in Other Operating Costs and Expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TravelAndEntertainmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses incurred for travel and entertainment during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TravelAndEntertainmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094703755536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sales and Marketing Expenses - Schedule of Sales and Marketing Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpenseAbstract', window );"><strong>Sales and Marketing Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Salary and related expenses</a></td>
<td class="nump">$ 266<span></span>
</td>
<td class="nump">$ 248<span></span>
</td>
<td class="nump">$ 282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold', window );">Share-based payment</a></td>
<td class="nump">250<span></span>
</td>
<td class="nump">89<span></span>
</td>
<td class="nump">503<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional fees</a></td>
<td class="nump">187<span></span>
</td>
<td class="nump">348<span></span>
</td>
<td class="nump">527<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherSellingAndMarketingExpense', window );">Other</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Total</a></td>
<td class="nump">$ 754<span></span>
</td>
<td class="nump">$ 746<span></span>
</td>
<td class="nump">$ 1,328<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit. Other employee benefit expense includes, but is not limited to, service component of net periodic benefit cost for defined benefit plan. Excludes compensation cost in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of selling and marketing expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094593401296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial (Income) and Expenses - Schedule of Financial (Income) and Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ScheduleOfFinancialIncomeAndExpensesAbstract', window );"><strong>Schedule of Financial (Income) and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss', window );">Revaluation of financial liabilities at fair value through profit or loss</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="num">$ (306)<span></span>
</td>
<td class="num">$ (108)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency transaction income</a></td>
<td class="num">(77)<span></span>
</td>
<td class="num">(233)<span></span>
</td>
<td class="nump">530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Finance expense in respect of lease liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(143)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Others</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total expenses (Income)</a></td>
<td class="num">$ (42)<span></span>
</td>
<td class="num">$ (529)<span></span>
</td>
<td class="nump">$ 275<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revaluation of financial liabilities at fair value through profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ScheduleOfFinancialIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ScheduleOfFinancialIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094693151712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Taxes on Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Carryforward tax losses</a></td>
<td class="nump">$ 29,000<span></span>
</td>
<td class="nump">$ 24,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Valuation allowance</a></td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IL', window );">Israel [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Taxes on Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Corporate tax rate</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094596054224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Taxes on Income - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforward</a></td>
<td class="nump">$ 6,739<span></span>
</td>
<td class="nump">$ 5,519<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_DeferredTaxAssetsAccruedExpenses', window );">Accrued expenses</a></td>
<td class="nump">97<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">R&amp;D temporary differences</a></td>
<td class="nump">1,218<span></span>
</td>
<td class="nump">1,335<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_DeferredTaxAssetsFundRaisingCost2023', window );">Fund raising costs 2023</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_DeferredTaxLiabilitiesOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">8,097<span></span>
</td>
<td class="nump">7,012<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(8,097)<span></span>
</td>
<td class="num">(7,012)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_DeferredTaxAssetsAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents amount of deferred tax accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_DeferredTaxAssetsAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_DeferredTaxAssetsFundRaisingCost2023">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fund raising costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_DeferredTaxAssetsFundRaisingCost2023</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_DeferredTaxLiabilitiesOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_DeferredTaxLiabilitiesOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094693165808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income - Schedule of Theoretical Tax (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ScheduleOfTheoreticalTaxAbstract', window );"><strong>Schedule of Theoretical Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before taxation</a></td>
<td class="num">$ (11,053)<span></span>
</td>
<td class="num">$ (11,286)<span></span>
</td>
<td class="num">$ (14,976)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_EffectiveIncomeTaxTheoreticalTaxCredit', window );">Theoretical tax credit at applicable statutory rate: 23%</a></td>
<td class="num">(2,542)<span></span>
</td>
<td class="num">(2,596)<span></span>
</td>
<td class="num">(3,444)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense', window );">Non-allowable expenses</a></td>
<td class="num">(391)<span></span>
</td>
<td class="num">(244)<span></span>
</td>
<td class="num">(1,026)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized', window );">Temporary differences and tax losses for which no Deferred Tax Asset is recognized</a></td>
<td class="num">(2,151)<span></span>
</td>
<td class="num">(2,352)<span></span>
</td>
<td class="num">(2,418)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_EffectiveIncomeTaxTheoreticalTaxCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents amount of theoretical tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_EffectiveIncomeTaxTheoreticalTaxCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ScheduleOfTheoreticalTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ScheduleOfTheoreticalTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary differences and tax losses for which no Deferred Tax Asset is recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094693225696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income - Schedule of Theoretical Tax (Parentheticals) (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ScheduleOfTheoreticalTaxAbstract', window );"><strong>Schedule of Theoretical Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Theoretical tax credit at applicable statutory rate</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ScheduleOfTheoreticalTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ScheduleOfTheoreticalTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094582559440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 05, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 22, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 22, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 19, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 24, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 24, 2022 </div>
<div>&#8362; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 06, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Payment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercise price per share | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.08<span></span>
</td>
<td class="nump">&#8362; 10.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Vested shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_CapitalGainTaxRate', window );">Capital gain tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_PercentageOfCapitalGainTax', window );">Percentage of capital gain tax</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment expenses (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,683<span></span>
</td>
<td class="nump">$ 1,352<span></span>
</td>
<td class="nump">$ 4,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Payment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Grant shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">165,000<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">555,500<span></span>
</td>
<td class="nump">555,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,141<span></span>
</td>
<td class="nump">3,141<span></span>
</td>
<td class="nump">19,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment expenses (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Share Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Payment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember', window );">Board of Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Payment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Grant shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,400<span></span>
</td>
<td class="nump">29,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember', window );">Board of Directors [Member] | RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Payment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Grant shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">536,141<span></span>
</td>
<td class="nump">536,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285,713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=iinn_AdvisoryBoardMembersMember', window );">Advisory Board Members [Member] | RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Payment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Grant shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,500<span></span>
</td>
<td class="nump">22,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=iinn_MedicalBoardMembersMember', window );">Medical Board Members [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Payment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,400<span></span>
</td>
<td class="nump">29,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_OfficerMember', window );">Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Payment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Grant shares</a></td>
<td class="nump">2,277,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_OfficerMember', window );">Officer [Member] | Share Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Payment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Option to purchase</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Payment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Grant shares</a></td>
<td class="nump">90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=iinn_EmployeesDirectorsAndSubcontractorsMember', window );">Employees, Directors and Subcontractors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Payment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment expenses (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,767<span></span>
</td>
<td class="nump">$ 1,427<span></span>
</td>
<td class="nump">$ 4,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=iinn_TwoThousandNineteenEquityIncentivePlanMember', window );">2019 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Payment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward', window );">Option term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">ten<span></span>
</td>
<td class="text">ten<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employee Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Payment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Grant shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">320,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Option to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employee Stock [Member] | RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Payment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Grant shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">245,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_CapitalGainTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capital gain tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_CapitalGainTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_PercentageOfCapitalGainTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of capital gain tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_PercentageOfCapitalGainTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares purchased for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=iinn_AdvisoryBoardMembersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=iinn_AdvisoryBoardMembersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=iinn_MedicalBoardMembersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=iinn_MedicalBoardMembersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_OfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_OfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=iinn_EmployeesDirectorsAndSubcontractorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=iinn_EmployeesDirectorsAndSubcontractorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=iinn_TwoThousandNineteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=iinn_TwoThousandNineteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094594006112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Share-Based Payment - Schedule of Measure the Fair Value of the Option at Grant Date (Details)<br></strong></div></th>
<th class="th"><div>Feb. 05, 2024</div></th>
<th class="th"><div>Jan. 22, 2024</div></th>
<th class="th"><div>Mar. 24, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">143.98%<span></span>
</td>
<td class="nump">144.83%<span></span>
</td>
<td class="nump">52.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (vesting period)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife', window );">Contractual life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Free risk rate</a></td>
<td class="nump">4.16%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Free risk rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.03%<span></span>
</td>
<td class="nump">2.79%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Free risk rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.07%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual life of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094594037424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment - Schedule of Options to Services Providers and Advisers Outstanding (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="6">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>&#8362; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>&#8362; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>&#8362; / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=iinn_ServicesProvidersAndAdvisersMember', window );">Services Providers and Advisers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, Outstanding at beginning of year (in Shares) | shares</a></td>
<td class="nump">105,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average Exercise price, Outstanding at beginning of year | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 4.085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 3.058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsReclassifiedToEmployeesAndDirectors', window );">Number of options, Reclassified to employees and directors (in Shares) | shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceReclassifiedToEmployeesAndDirectors', window );">Weighted average Exercise price, Reclassified to employees and directors | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options, Granted (in Shares) | shares</a></td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average Exercise price, Granted | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.84<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi', window );">Number of options, Exercised (in Shares) | shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,721)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average Exercise price, Exercised | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of options, Forfeited (in Shares) | shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average Exercise price, Forfeited | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, Options outstanding (in Shares) | shares</a></td>
<td class="nump">185,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average Exercise price, Options outstanding | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 3.359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 4.085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 3.058<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options, Options exercisable (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,257<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average Exercise price, Options exercisable | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 3.251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 3.267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Number of options, Share-based payment expenses (in Dollars) | $</a></td>
<td class="nump">$ 66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=iinn_EmployeesAndDirectorsMember', window );">Employees and Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, Outstanding at beginning of year (in Shares) | shares</a></td>
<td class="nump">357,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">386,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">448,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average Exercise price, Outstanding at beginning of year | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options, Granted (in Shares) | shares</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average Exercise price, Granted | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi', window );">Number of options, Exercised (in Shares) | shares</a></td>
<td class="nump">19,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average Exercise price, Exercised | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of options, Forfeited (in Shares) | shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average Exercise price, Forfeited | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, Options outstanding (in Shares) | shares</a></td>
<td class="nump">368,641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">357,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">386,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average Exercise price, Options outstanding | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options, Options exercisable (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">338,641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">342,757<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average Exercise price, Options exercisable | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Number of options, Share-based payment expenses (in Dollars) | $</a></td>
<td class="nump">$ 17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsReclassifiedToEmployeesAndDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of options, reclassified to employees and directors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsReclassifiedToEmployeesAndDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceReclassifiedToEmployeesAndDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share price of weighted average exercise price, reclassified to employees and directors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceReclassifiedToEmployeesAndDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=iinn_ServicesProvidersAndAdvisersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=iinn_ServicesProvidersAndAdvisersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=iinn_EmployeesAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=iinn_EmployeesAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094582500800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment - Schedule of RSUs to Services Providers and Advisers Outstanding (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at beginning of year</a></td>
<td class="nump">445,140<span></span>
</td>
<td class="nump">1,727,842<span></span>
</td>
<td class="nump">2,002,587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of RSUs, Granted</a></td>
<td class="nump">2,687,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,016,854<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of RSUs, Forfeited</a></td>
<td class="nump">25,836<span></span>
</td>
<td class="nump">67,087<span></span>
</td>
<td class="nump">65,626<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of RSUs, Vested</a></td>
<td class="nump">587,508<span></span>
</td>
<td class="nump">1,215,615<span></span>
</td>
<td class="nump">1,225,973<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at ending of year</a></td>
<td class="nump">2,518,796<span></span>
</td>
<td class="nump">445,140<span></span>
</td>
<td class="nump">1,727,842<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested', window );">Number of RSUs, RSU&#8217;s Vested</a></td>
<td class="nump">3,684,697<span></span>
</td>
<td class="nump">3,097,189<span></span>
</td>
<td class="nump">1,881,574<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Number of RSUs, Share-based payment expenses (in Dollars)</a></td>
<td class="nump">$ 1,683<span></span>
</td>
<td class="nump">$ 1,352<span></span>
</td>
<td class="nump">$ 4,618<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at beginning of year</a></td>
<td class="nump">7,433<span></span>
</td>
<td class="nump">18,266<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of RSUs, Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">22,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of RSUs, Vested</a></td>
<td class="nump">7,433<span></span>
</td>
<td class="nump">10,833<span></span>
</td>
<td class="nump">14,234<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at ending of year</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">7,433<span></span>
</td>
<td class="nump">18,266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested', window );">Number of RSUs, RSU&#8217;s Vested</a></td>
<td class="nump">32,500<span></span>
</td>
<td class="nump">25,067<span></span>
</td>
<td class="nump">14,234<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Number of RSUs, Share-based payment expenses (in Dollars)</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of RSUs vested under share based payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094593404832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties - Schedule of Shareholders and Other Related Parties&#8217; Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=iinn_OfficersAndDirectorsMember', window );">Officers and Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Salary and related expenses</a></td>
<td class="nump">$ 1,710<span></span>
</td>
<td class="nump">$ 1,761<span></span>
</td>
<td class="nump">$ 1,923<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based payment</a></td>
<td class="nump">$ 1,376<span></span>
</td>
<td class="nump">1,009<span></span>
</td>
<td class="nump">$ 3,745<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_OfficerMember', window );">Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfCommonOwnershipOrManagementControlRelationships', window );">Nature of transaction</a></td>
<td class="text">Salaries and related<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Balance with related parties</a></td>
<td class="num">$ (381)<span></span>
</td>
<td class="num">(314)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfCommonOwnershipOrManagementControlRelationships', window );">Nature of transaction</a></td>
<td class="text">Compensation for directors<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Balance with related parties</a></td>
<td class="num">$ (40)<span></span>
</td>
<td class="num">$ (40)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfCommonOwnershipOrManagementControlRelationships">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents a description of the nature of common ownership or management control relationships with other entities, regardless of there being transactions between the entities, when the existence of that control could result in operating results or financial position of the reporting entity significantly different from that which would have been obtained if the entities' were autonomous.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfCommonOwnershipOrManagementControlRelationships</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=iinn_OfficersAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=iinn_OfficersAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_OfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_OfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46094594025648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 28, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 20, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 01, 2025 </div>
<div>ILS (&#8362;)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromBankDebt', window );">Receiving bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_OfferingFeesAndOtherRelatedExpenses', window );">Offering fees and other related expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_ProceedsFromReceivedFund', window );">Received fund</a></td>
<td class="nump">$ 66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 238,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares granted (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,810,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_RestrictedStockUnits', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total grant fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Executives [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares granted (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_RestrictedStockUnits', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total grant fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=iinn_TwoThousandNineteenEquityIncentivePlanMember', window );">2019 Equity Incentive Plan [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Number of grant shares (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=iinn_DecemberPrivatePlacementMember', window );">December Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employee Stock [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares granted (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">676,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber', window );">Vested shares (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_iinn_RestrictedStockUnits', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total grant fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_OfferingFeesAndOtherRelatedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of offering fees and other related expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_OfferingFeesAndOtherRelatedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_ProceedsFromReceivedFund">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of proceeds from received fund.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_ProceedsFromReceivedFund</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iinn_RestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iinn_RestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iinn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromBankDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from bank borrowing during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromBankDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares for which recognition of cost was accelerated for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=iinn_ExecutivesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=iinn_ExecutivesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=iinn_TwoThousandNineteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=iinn_TwoThousandNineteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=iinn_DecemberPrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=iinn_DecemberPrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>122
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$
MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7<K_WUE[O)I#-ZG7TZSFN4
M?VFK :?MNYO/D_QSZ.2?IY/734+.<+PL"?'[(UMAAR=N.Q-R.AQG0GS/]O:1
MI24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG LR+7E$8D19_(
M+;KD$3BU20TR$S\(G8:8:E < J0),9:AAOBTQJP1X!-]M[X(R-^-B/>K;YH]
M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M
MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZ<TT#PE"\D^DJ1CVFS(Z=T)LWH
M,QK!1J\;=8=HTCQZ_@7YG#4*')$;'0)G&[-&(81IN_ >KR2.FJW"$2M"/F(9
M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+
MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T
M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
M" "<BVI:&ON'?# '  #9)   &    'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;+6:VW+;-A"&[_,4&&4FTTXCB01)V4YMS<B*E6CJR*[E)$TSO8!)6.*$)%0
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M=;DA:K_ M8%ZOV9,OMSH,^']_P 6_P%02P,$%     @ G(MJ6J"->'V0 @
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MNT(\T,.OT CR%5]""ZY_T:'&AKZ%DAT7M&R,I0=E7M7_Y+D)Q(D!#@8,G,;
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MMTN4]\++'XJOBYO2#UPIOBH>EY2D5!@!_7W!]3C8_C 55+?S3_\/4$L#!!0
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M%B=VO.4A%CQ8BQF52*X7]V?Y34)QIU?I,+<F2F=^\O!8A*X,01:77(H5:)1
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M;V!XP@71%+8DW]?HC@]*4(H_737&S&EN(C-!4L,IC@(I50&#U^ HV61:-LR
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M+0H]O4UG:]YZ.-G^(.,"C4=Q<G.A [O)\=,91D$'^OR,RU4B"WD;U4GH:0K
M56U%.Y%IGS!.3&TOJ<%XAB!+CPR):6BG4GD8Y^IH'<RM09W.<ZGDRJ45G+^G
MZ7R0?R8%Q&J:12)WQ3&EJ:YD1A![!RT>A4'(61S>"*,*2YG)4@G<R7PQN;,P
MVTS$-S?TQKBTH2* 5V5[>^@\&2;OBZ5WRJFL)H L/5\B%L3?5JLQ(=5Q)%1?
M0Y/Y3+BL6J]<)^GF9%:JSV^SSO1%%"<#EDV<RZZ3N>P=ZJB%)0>"H.A!#V4&
M%SI9#_,&LHMQ+SPRHYKBAAB*W50:M>@/H9%#G+>HI[';%!HM9+157!T<_+UH
M!\+.FKIF\GY3)1=Z61C[X+N98GS5!RP5953U_K>0PKBT3=\ZHU&%-OO[@-B
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MOSW4SH'.MTK9;N,"]#_2Q?]02P,$%     @ G(MJ6H3YG\)F @  0@4  !D
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M<FMS:&5E=',O<VAE970Q,RYX;6R555V/TSH0?>^O& 6))]@D=II^T%;J;HL
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M(@J3H.-KSM71, >TDS;Y U!+ P04    " "<BVI:7_JC*+P)  "=%P  &0
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MF51@W);Q9+N&,''ILBXWP\,L1);G)"D-(9H8=739KI37:<4''0PMVZ!F2FI
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M1$G2GN]BC$GS-B%!F<9R$YG/D*X\QH> 2UPP-.6R7RW\18X4E"ZMM[^@:GN
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M](9%PPMH/M%TW-0?O,'J53S\!U!+ P04    " "<BVI:1N0A $<-   .+@
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M+[)'\-@;CRS/(>]*@9J*!2//C K",#()Q!5#FZO8\FTUXCI?KFCV3+@RAE
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MU7<T76.,G61+>=52LE<H/0834>E,05REF/Y-X)"^O4BV$WG%3C*.,3D'W^L
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M[NGX+N!;B5MQ, ==R8JQ![VXSJ:FK05AA:G4#%0-3WB)5:6)E(S'':<YI-3
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MM G-"=Y5;TWD1.&2\F0UK0JRLZ-GOD$#%)Z;(E,Y#EJ60-U2*ZL!+BN ^#L
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M&.IT^U<6$55UK S%2U.1-EQA?3/#%'\H(+0#KB><J]K0&S2_J/ O4$L#!!0
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M?%-\9&K#J;$*S,@U]$_&'JCFG6XF1E;N;5Q+0R^M&^;T:8/*;B![)J7I)C9
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M*)VK:Z5JO-6]UI"L,DJP9%+IBEGFZE<!7 >H_15C<FOH!/W/)_X'4$L#!!0
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M=/':=;Z.PQ0#J_K0P'MEW3B$9>?^/Z!]@CMOE+*'P!>8_VC53U!+ P04
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M!JX6T4-21++EJ&$N58--L<O*=0$$!FF#(X$;\SB796]9/JJ*> 4',PT[8A0
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M]^#D6/3#[C5?!PC@DA/(A41(5DI>"DBU8.BF*\R+.':RF!X40>=6)#>V;=O
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M+0N<Q>O.@"-GL-_*#/U)5HBUX%LAK.IP@G\638^YESCV&=\>KWB80/FY0&K
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M:N=@SS=*T<%P%_3#,O\#4$L#!!0    ( )R+:EHDMT%/E0(  ),%   9
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M6=,W6G @'Y[LHC_.0X.7V-"PW .N/&#R#F"<D'LI3*W)G:B@^A<@1'8]Q>1
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MV](^>:A<@#U?2VEVADO0/Z+I/U!+ P04    " "<BVI:3(2 61$%   H#0
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M?"/,@]Q^PET\?<N72J&;$;:M;Q2[D&ZTD>4.3 K*HFIG_K)[AP- XK\!8#L
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M&;03P/VI4G8]<0ZZ&_GH+U!+ P04    " "<BVI:5,1S)L0"  !B!@  &0
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M"LI-L.\+*<W]P"W0];>SWU!+ P04    " "<BVI:1,^)1\H"  #6"P  &0
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M[48UWL!U@)I?,2:?![JU:UKYZ"]02P,$%     @ G(MJ6BU/!\:6 @  :P<
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M"%P'J/=KQN3S1#?<_GQ-_P)02P,$%     @ G(MJ6E;P; <, P  ^P@  !D
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M_9W(0M2DO1G5RV!JB'X" $?9MPJ-LU^8"+MIB)I$1XV_-6TB1Y];X5#ZIJK
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M)MU?6M^_$<FNO,9]EPB11.7++?=\GA8"^?M-DHBG-\47U/]U8/4_4$L#!!0
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M!6D"\/M:"/W:,6=U=S7'_P!02P,$%     @ G(MJ6O$@<J@;!   V!4  !D
M  !X;"]W;W)K<VAE971S+W-H965T-30N>&ULK9A=CYLX%(;_BD6K:BI5PV>
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MU4<^$*9 WU]RKAXGYE11'R+COU!+ P04    " "<BVI:8^>W+ L:   .UP$
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M6O >"UH;0K44U02J2513J*91S:":1;4,U1RE^<FM^D7=<RU[U$4+1ZB6HII
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M:A;5,E1SE.:GM"H6]8ZL>K0*Z>H4-+_;]/SRN[)X/C$-+8@=)EO'$JT7H9I
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M7:(G99HH3P"Q)7I@6U#+)U&<H6?*.<VD0'_E4DB:17&V0N]N0=(X$>]58#4
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M^D$ 7 /4^RUC\FFA#^A_8L3_ 5!+ P04    " "<BVI:S.I)R/4#  #B#@
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MD^4W_B@+X.8(>(8L<X<[.0;YHTP<8\+9F7T\U'4\7=@?F"25T>UQ#?;Q;'@
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M.D!6-UKDY1GL7F@\T967:SQT@S0!^'XIA'Z^,<>ZYA@?_0%02P,$%     @
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MS!62([EA21\9T#:!UA=*X69B"PR?K?094$L#!!0    ( )R+:EJ=%MCS?PP
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MVX/=CH0CIPO0I0M1+4*UN.$5L4[[0[,N!JN;>MV\8.F;%PYWU>B!UAL[VIV
M:AZJ"53S42VP=EL/G-W>IA"=:81J,:6IN:G;'BQ]V\.'\5-:9/F+L3HQ6IWZ
MM#PG0OLA4,U%-0_5!*KYJ!:@6HAJ$:K%E*;FK^Z'L/A^" OMAT U%]4\5!.H
MYJ-:@&HAJD6H%E.:&KBZ'\+2%]P/GA.AW1"HYJ*:AVIBK2E']M;NIW..FRQ
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MH%J(:A&JQ92F!J[NR7"T)>A-B5CFT\9LH>T7J.:BFH=JXL"K7LI98X:^952
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M\XM.=29YFY5E-EW^^""3L<P7$U3_?Y=EY>N#Q0R>L_S+<G4N_P]02P,$%
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M\DQIM1*9A"F[5$O84J1K>DL-$)\$)/+S"3B'\Q_(*!?2* _(*!_(*"Z@G&U
M.>>5D*[AU:V22(U1K20G@(G._PC2*!?(* _2*/]\H[C@&FR#:Z!:K7RVNBW"
MK6LU&NQ/PAK[UUIK2,U0K34G@ EK#:11WOYY( .C?1Y\($K.V5AK!"#MO%JR
M<7ZW6B%G4RT6-1JVN#6 ;0]:ZPY05O<4-&$Y #7+WYP,@UO$7SB&>'6"=S1
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MO5Q1[EX_659[=@:5!@6,>-">F4%U/P%CN\;X4(S\'5"-[$?DLI_+=01&VXZ
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MB">=AV(>:(NVA4JBAZ3MY.^'E!19"RU8 P/S8HO2N8<\]W(YX/A V4^^(42
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M/J=EOE"D^>->&@OCI'EQ;%67Y<RN^R%N)"WV/^[8_S#EXE]02P,$%     @
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M"^HM!'HKZJT$>BOJK01Z*^JM!'KK9+.$0&]%O95 ;T6]E4!O1;V50&]%O95
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M>+FWW!Y_77Z=1 E75YSK^XKA^2]02P,$%     @ G(MJ6BXH"M@5 @  _"P
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M^T^.GY_UX+KQ)9_-?WJ^_@U02P$"% ,4    " "<BVI:!T%-8H$   "Q
M$               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    (
M )R+:EIXB<M7[P   "L"   1              "  :\   !D;V-0<F]P<R]C
M;W)E+GAM;%!+ 0(4 Q0    ( )R+:EJ97)PC$ 8  )PG   3
M  "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ G(MJ6AK[
MAWPP!P  V20  !@              ("!#@@  'AL+W=O<FMS:&5E=',O<VAE
M970Q+GAM;%!+ 0(4 Q0    ( )R+:EH%IK#YP0,  &D)   8
M  " @70/  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " "<
MBVI:;Z.,0&P%   /&   &               @(%K$P  >&PO=V]R:W-H965T
M<R]S:&5E=#,N>&UL4$L! A0#%     @ G(MJ6J"->'V0 @  F@<  !@
M         ("!#1D  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0
M   ( )R+:EK<:!0^IP0  "H2   8              " @=,;  !X;"]W;W)K
M<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " "<BVI:DF6C=6D(  #Q/@
M&               @(&P(   >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L!
M A0#%     @ G(MJ6HHFV.]""0  J2\  !@              ("!3RD  'AL
M+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( )R+:EJ+JR74I T
M !0C   8              " @<<R  !X;"]W;W)K<VAE971S+W-H965T."YX
M;6Q02P$"% ,4    " "<BVI:^F.G"O<:  !+3   &               @(&A
M0   >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ G(MJ6B:'
M"- E P  5 <  !D              ("!SEL  'AL+W=O<FMS:&5E=',O<VAE
M970Q,"YX;6Q02P$"% ,4    " "<BVI:A/F?PF8"  !"!0  &0
M    @($J7P  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    (
M )R+:EJ7<I6YF (  )$%   9              " @<=A  !X;"]W;W)K<VAE
M971S+W-H965T,3(N>&UL4$L! A0#%     @ G(MJ6C>'>8@_ P  T0<  !D
M             ("!EF0  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"
M% ,4    " "<BVI:4BWFMH "  !U!0  &0              @($,:   >&PO
M=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( )R+:EI?^J,HO D
M )T7   9              " @<-J  !X;"]W;W)K<VAE971S+W-H965T,34N
M>&UL4$L! A0#%     @ G(MJ6EB5@0=(!P  %1(  !D              ("!
MMG0  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " "<BVI:
M,\9 M^@%   A#P  &0              @($U?   >&PO=V]R:W-H965T<R]S
M:&5E=#$W+GAM;%!+ 0(4 Q0    ( )R+:EI&Y"$ 1PT   XN   9
M      " @52"  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%
M  @ G(MJ6HFIYB;9 @  &@8  !D              ("!TH\  'AL+W=O<FMS
M:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " "<BVI:^_L&308#  !G!@
M&0              @('BD@  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+
M 0(4 Q0    ( )R+:EJU0RJYB (  (\%   9              " @1^6  !X
M;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ G(MJ6A<J0-[7
M @  (P8  !D              ("!WI@  'AL+W=O<FMS:&5E=',O<VAE970R
M,BYX;6Q02P$"% ,4    " "<BVI:?_OU#UL$  #M"0  &0
M@('LFP  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( )R+
M:EK/ A66&PD  $P<   9              " @7Z@  !X;"]W;W)K<VAE971S
M+W-H965T,C0N>&UL4$L! A0#%     @ G(MJ6BCU#=+K @  K@8  !D
M         ("!T*D  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4
M    " "<BVI:8&_+=@P$   X"0  &0              @('RK   >&PO=V]R
M:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( )R+:EH .ZHD80(  (@&
M   9              " @36Q  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL
M4$L! A0#%     @ G(MJ6F4;>340 @  W00  !D              ("!S;,
M 'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " "<BVI:'*BY
M0(<(  !N'@  &0              @($4M@  >&PO=V]R:W-H965T<R]S:&5E
M=#(Y+GAM;%!+ 0(4 Q0    ( )R+:EKW4R.6]!L  +94   9
M  " @=*^  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @
MG(MJ6O,BT3R6 @  C04  !D              ("!_=H  'AL+W=O<FMS:&5E
M=',O<VAE970S,2YX;6Q02P$"% ,4    " "<BVI:&%S2\%H"   X!0  &0
M            @('*W0  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4
M Q0    ( )R+:EHDMT%/E0(  ),%   9              " @5O@  !X;"]W
M;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ G(MJ6IQE=?@N P
MP <  !D              ("!)^,  'AL+W=O<FMS:&5E=',O<VAE970S-"YX
M;6Q02P$"% ,4    " "<BVI:F=33^7 "  !I!0  &0              @(&,
MY@  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( )R+:EK9
M[DE*@0,  )4(   9              " @3/I  !X;"]W;W)K<VAE971S+W-H
M965T,S8N>&UL4$L! A0#%     @ G(MJ6OZ3_'); @  4 4  !D
M     ("!Z^P  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( )R+:EKJ\>NON (   @&   9              "
M@83]  !X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ G(MJ
M6C!7.V?' P  F@@  !D              ("!<P ! 'AL+W=O<FMS:&5E=',O
M<VAE970T,RYX;6Q02P$"% ,4    " "<BVI:?%-&U(H%  "=#P  &0
M        @(%Q! $ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0
M   ( )R+:EI4Q',FQ (  &(&   9              " @3(* 0!X;"]W;W)K
M<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ G(MJ6GSFZ2U^!P  &TH
M !D              ("!+0T! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q0
M2P$"% ,4    " "<BVI:U<6X!?("   ?"@  &0              @('B% $
M>&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( )R+:EI]0*$;
M5P,  .L.   9              " @0L8 0!X;"]W;W)K<VAE971S+W-H965T
M-#@N>&UL4$L! A0#%     @ G(MJ6D3/B4?* @  U@L  !D
M ("!F1L! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4    " "<
MBVI:+4\'QI8"  !K!P  &0              @(&:'@$ >&PO=V]R:W-H965T
M<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( )R+:EI6\&P'# ,  /L(   9
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M970U-2YX;6Q02P$"% ,4    " "<BVI:[U"_$_ "  "J"   &0
M    @('W-@$ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    (
M )R+:EJX>NU;/P,  *T*   9              " @1XZ 0!X;"]W;W)K<VAE
M971S+W-H965T-3<N>&UL4$L! A0#%     @ G(MJ6N+YKY-,!@  R#(  !D
M             ("!E#T! 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q02P$"
M% ,4    " "<BVI:Z'"_O;D"  !0"@  &0              @($71 $ >&PO
M=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( )R+:EICY[<L"QH
M  [7 0 9              " @0=' 0!X;"]W;W)K<VAE971S+W-H965T-C N
M>&UL4$L! A0#%     @ G(MJ6N"P>EQQ @  R@8  !D              ("!
M26$! 'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q02P$"% ,4    " "<BVI:
M_OS)\@($  !.$   &0              @('Q8P$ >&PO=V]R:W-H965T<R]S
M:&5E=#8R+GAM;%!+ 0(4 Q0    ( )R+:EI]W$ZOJ@0  %L;   9
M      " @2IH 0!X;"]W;W)K<VAE971S+W-H965T-C,N>&UL4$L! A0#%
M  @ G(MJ6B@[;46. P  (@L  !D              ("!"VT! 'AL+W=O<FMS
M:&5E=',O<VAE970V-"YX;6Q02P$"% ,4    " "<BVI:'03([8<#  !N#
M&0              @('0< $ >&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+
M 0(4 Q0    ( )R+:EK,ZDG(]0,  .(.   9              " @8YT 0!X
M;"]W;W)K<VAE971S+W-H965T-C8N>&UL4$L! A0#%     @ G(MJ6I7.)9$)
M P  K@D  !D              ("!NG@! 'AL+W=O<FMS:&5E=',O<VAE970V
M-RYX;6Q02P$"% ,4    " "<BVI:Z2/Q"DX#  !\"@  &0
M@('Z>P$ >&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;%!+ 0(4 Q0    ( )R+
M:EHVYS@/P@(  ,D(   9              " @7]_ 0!X;"]W;W)K<VAE971S
M+W-H965T-CDN>&UL4$L! A0#%     @ G(MJ6H/WO^Y6 P  T@L  !D
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M=#<T+GAM;%!+ 0(4 Q0    ( )R+:EK2JO_83P@  (Q'   9
M  " @=R< 0!X;"]W;W)K<VAE971S+W-H965T-S4N>&UL4$L! A0#%     @
MG(MJ6BZB_&F@!   <Q0  !D              ("!8J4! 'AL+W=O<FMS:&5E
M=',O<VAE970W-BYX;6Q02P$"% ,4    " "<BVI:Q(>63-P#  !S$@  &0
M            @($YJ@$ >&PO=V]R:W-H965T<R]S:&5E=#<W+GAM;%!+ 0(4
M Q0    ( )R+:EJIGW'@#P8  !8Q   9              " @4RN 0!X;"]W
M;W)K<VAE971S+W-H965T-S@N>&UL4$L! A0#%     @ G(MJ6LJI/SN< P
MFQH   T              ( !DK0! 'AL+W-T>6QE<RYX;6Q02P$"% ,4
M" "<BVI:EXJ[',     3 @  "P              @ %9N $ 7W)E;',O+G)E
M;'-02P$"% ,4    " "<BVI:E/F#4+<%   <,P  #P              @ %"
MN0$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ G(MJ6GH$ UU< @  (2X
M !H              ( !)K\! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS
M4$L! A0#%     @ G(MJ6BXH"M@5 @  _"P  !,              ( !NL$!
J %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     %8 5@"1%P   ,0!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>237</ContextCount>
  <ElementCount>366</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>65</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995100 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/dei/role/document/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995300 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/dei/role/document/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995301 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>995302 - Statement - Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>995303 - Statement - Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>995304 - Statement - Statements of Changes in Shareholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Statements of Changes in Shareholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995305 - Statement - Statements of Cash Flow</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Statements of Cash Flow</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995306 - Disclosure - General</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/General</Role>
      <ShortName>General</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995307 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/SignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995308 - Disclosure - Deposits</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/Deposits</Role>
      <ShortName>Deposits</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995309 - Disclosure - Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/OtherCurrentAssets</Role>
      <ShortName>Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995310 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995311 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/PropertyandEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995312 - Disclosure - Other Accounts Payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/OtherAccountsPayable</Role>
      <ShortName>Other Accounts Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995313 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995314 - Disclosure - Lease Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/LeaseLiabilities</Role>
      <ShortName>Lease Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995315 - Disclosure - Finacial Liabilities at Fair Value</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValue</Role>
      <ShortName>Finacial Liabilities at Fair Value</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995316 - Disclosure - Shareholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ShareholdersEquity</Role>
      <ShortName>Shareholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995317 - Disclosure - Research and Development Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ResearchandDevelopmentExpenses</Role>
      <ShortName>Research and Development Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995318 - Disclosure - General and Administrative Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/GeneralandAdministrativeExpenses</Role>
      <ShortName>General and Administrative Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995319 - Disclosure - Sales and Marketing Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/SalesandMarketingExpenses</Role>
      <ShortName>Sales and Marketing Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995320 - Disclosure - Financial (Income) and Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/FinancialIncomeandExpenses</Role>
      <ShortName>Financial (Income) and Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995321 - Disclosure - Taxes on Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/TaxesonIncome</Role>
      <ShortName>Taxes on Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995322 - Disclosure - Share-Based Payment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ShareBasedPayment</Role>
      <ShortName>Share-Based Payment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995323 - Disclosure - Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/RelatedParties</Role>
      <ShortName>Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995324 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>996000 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>996001 - Disclosure - Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/SignificantAccountingPoliciesTables</Role>
      <ShortName>Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>996002 - Disclosure - Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/OtherCurrentAssetsTables</Role>
      <ShortName>Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/OtherCurrentAssets</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>996003 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/Inventory</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>996004 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/PropertyandEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/PropertyandEquipmentNet</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>996005 - Disclosure - Other Accounts Payable (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/OtherAccountsPayableTables</Role>
      <ShortName>Other Accounts Payable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/OtherAccountsPayable</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>996006 - Disclosure - Lease Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/LeaseLiabilitiesTables</Role>
      <ShortName>Lease Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/LeaseLiabilities</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>996007 - Disclosure - Finacial Liabilities at Fair Value (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueTables</Role>
      <ShortName>Finacial Liabilities at Fair Value (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValue</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>996008 - Disclosure - Shareholders??? Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ShareholdersEquityTables</Role>
      <ShortName>Shareholders??? Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/ShareholdersEquity</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>996009 - Disclosure - Research and Development Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ResearchandDevelopmentExpensesTables</Role>
      <ShortName>Research and Development Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/ResearchandDevelopmentExpenses</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>996010 - Disclosure - General and Administrative Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/GeneralandAdministrativeExpensesTables</Role>
      <ShortName>General and Administrative Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/GeneralandAdministrativeExpenses</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>996011 - Disclosure - Sales and Marketing Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/SalesandMarketingExpensesTables</Role>
      <ShortName>Sales and Marketing Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/SalesandMarketingExpenses</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>996012 - Disclosure - Financial (Income) and Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/FinancialIncomeandExpensesTables</Role>
      <ShortName>Financial (Income) and Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/FinancialIncomeandExpenses</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>996013 - Disclosure - Taxes on Income (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/TaxesonIncomeTables</Role>
      <ShortName>Taxes on Income (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/TaxesonIncome</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>996014 - Disclosure - Share-Based Payment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ShareBasedPaymentTables</Role>
      <ShortName>Share-Based Payment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/ShareBasedPayment</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>996015 - Disclosure - Related Parties (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/RelatedPartiesTables</Role>
      <ShortName>Related Parties (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/RelatedParties</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>996016 - Disclosure - General (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/GeneralDetails</Role>
      <ShortName>General (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/GeneralandAdministrativeExpensesTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>996017 - Disclosure - Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/SignificantAccountingPoliciesDetails</Role>
      <ShortName>Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>996018 - Disclosure - Significant Accounting Policies - Schedule of Depreciation on Straight-Line Method, Over the Estimated Useful Life of the Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable</Role>
      <ShortName>Significant Accounting Policies - Schedule of Depreciation on Straight-Line Method, Over the Estimated Useful Life of the Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>996019 - Disclosure - Deposits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/DepositsDetails</Role>
      <ShortName>Deposits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/Deposits</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>996020 - Disclosure - Other Current Assets - Schedule of Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofOtherCurrentAssetsTable</Role>
      <ShortName>Other Current Assets - Schedule of Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>996021 - Disclosure - Inventory - Schedule of Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofInventoryTable</Role>
      <ShortName>Inventory - Schedule of Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>996022 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofPropertyandEquipmentNetTable</Role>
      <ShortName>Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>996023 - Disclosure - Other Accounts Payable - Schedule of Other Accounts Payable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofOtherAccountsPayableTable</Role>
      <ShortName>Other Accounts Payable - Schedule of Other Accounts Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>996024 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/CommitmentsandContingencies</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>996025 - Disclosure - Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/LeaseLiabilitiesDetails</Role>
      <ShortName>Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/LeaseLiabilitiesTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>996026 - Disclosure - Lease Liabilities - Schedule of Operating Right-of-Use Assets and Operating Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofOperatingRightofUseAssetsandOperatingLeaseLiabilitiesTable</Role>
      <ShortName>Lease Liabilities - Schedule of Operating Right-of-Use Assets and Operating Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>996027 - Disclosure - Lease Liabilities - Schedule of Right-of-Use Assets Over the Remaining Lease Periods (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofRightofUseAssetsOvertheRemainingLeasePeriodsTable</Role>
      <ShortName>Lease Liabilities - Schedule of Right-of-Use Assets Over the Remaining Lease Periods (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>996028 - Disclosure - Finacial Liabilities at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails</Role>
      <ShortName>Finacial Liabilities at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>996029 - Disclosure - Finacial Liabilities at Fair Value - Schedule of Financial Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofFinancialLiabilityTable</Role>
      <ShortName>Finacial Liabilities at Fair Value - Schedule of Financial Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>996030 - Disclosure - Shareholders??? Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ShareholdersEquityDetails</Role>
      <ShortName>Shareholders??? Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/ShareholdersEquityTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>996031 - Disclosure - Shareholders??? Equity - Schedule of Share Capital (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofShareCapitalTable</Role>
      <ShortName>Shareholders??? Equity - Schedule of Share Capital (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>996032 - Disclosure - Shareholders??? Equity - Schedule of Movement in Warrants Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofMovementinWarrantsOutstandingTable</Role>
      <ShortName>Shareholders??? Equity - Schedule of Movement in Warrants Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>996033 - Disclosure - Shareholders??? Equity - Schedule of Information about the Company???s Outstanding Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofInformationabouttheCompanysOutstandingWarrantsTable</Role>
      <ShortName>Shareholders??? Equity - Schedule of Information about the Company???s Outstanding Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>996034 - Disclosure - Shareholders??? Equity - Schedule of Loss Per Share Calculated Using the Weighted Average Number of Ordinary Shares and Pre-Funded Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofLossPerShareCalculatedUsingtheWeightedAverageNumberofOrdinarySharesandPreFundedWarrantsTable</Role>
      <ShortName>Shareholders??? Equity - Schedule of Loss Per Share Calculated Using the Weighted Average Number of Ordinary Shares and Pre-Funded Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>996035 - Disclosure - Research and Development Expenses - Schedule of Research and Development Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofResearchandDevelopmentExpensesTable</Role>
      <ShortName>Research and Development Expenses - Schedule of Research and Development Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>996036 - Disclosure - General and Administrative Expenses - Schedule of General and Administrative Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable</Role>
      <ShortName>General and Administrative Expenses - Schedule of General and Administrative Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>996037 - Disclosure - Sales and Marketing Expenses - Schedule of Sales and Marketing Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofSalesandMarketingExpensesTable</Role>
      <ShortName>Sales and Marketing Expenses - Schedule of Sales and Marketing Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>996038 - Disclosure - Financial (Income) and Expenses - Schedule of Financial (Income) and Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofFinancialIncomeandExpensesTable</Role>
      <ShortName>Financial (Income) and Expenses - Schedule of Financial (Income) and Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/FinancialIncomeandExpensesTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>996039 - Disclosure - Taxes on Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/TaxesonIncomeDetails</Role>
      <ShortName>Taxes on Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/TaxesonIncomeTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>996040 - Disclosure - Taxes on Income - Schedule of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable</Role>
      <ShortName>Taxes on Income - Schedule of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>996041 - Disclosure - Taxes on Income - Schedule of Theoretical Tax (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofTheoreticalTaxTable</Role>
      <ShortName>Taxes on Income - Schedule of Theoretical Tax (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>996042 - Disclosure - Taxes on Income - Schedule of Theoretical Tax (Parentheticals) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofTheoreticalTaxTable_Parentheticals</Role>
      <ShortName>Taxes on Income - Schedule of Theoretical Tax (Parentheticals) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>996043 - Disclosure - Share-Based Payment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails</Role>
      <ShortName>Share-Based Payment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/ShareBasedPaymentTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>996044 - Disclosure - Share-Based Payment - Schedule of Measure the Fair Value of the Option at Grant Date (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofMeasuretheFairValueoftheOptionatGrantDateTable</Role>
      <ShortName>Share-Based Payment - Schedule of Measure the Fair Value of the Option at Grant Date (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>996045 - Disclosure - Share-Based Payment - Schedule of Options to Services Providers and Advisers Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable</Role>
      <ShortName>Share-Based Payment - Schedule of Options to Services Providers and Advisers Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>996046 - Disclosure - Share-Based Payment - Schedule of RSUs to Services Providers and Advisers Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable</Role>
      <ShortName>Share-Based Payment - Schedule of RSUs to Services Providers and Advisers Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>996047 - Disclosure - Related Parties - Schedule of Shareholders and Other Related Parties??? Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/ScheduleofShareholdersandOtherRelatedPartiesBenefitsTable</Role>
      <ShortName>Related Parties - Schedule of Shareholders and Other Related Parties??? Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="ea0233226-20f_inspira.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>996048 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inspiratechnologies.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inspiratechnologies.com/role/SubsequentEvents</ParentRole>
      <Position>78</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="20-F" isDefinitelyFs="true" isUsgaap="true" original="ea0233226-20f_inspira.htm">ea0233226-20f_inspira.htm</File>
    <File>iinn-20241231.xsd</File>
    <File>iinn-20241231_cal.xml</File>
    <File>iinn-20241231_def.xml</File>
    <File>iinn-20241231_lab.xml</File>
    <File>iinn-20241231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
    <File>image_002.jpg</File>
    <File>image_003.jpg</File>
    <File>image_004.jpg</File>
    <File>image_005.jpg</File>
    <File>image_006.jpg</File>
    <File>image_007.jpg</File>
    <File>image_008.jpg</File>
    <File>image_009.jpg</File>
    <File>image_010.jpg</File>
    <File>image_011.jpg</File>
    <File>image_012.jpg</File>
    <File>image_013.jpg</File>
    <File>image_014.jpg</File>
    <File>image_015.jpg</File>
    <File>image_016.jpg</File>
    <File>image_017.jpg</File>
    <File>image_018.jpg</File>
    <File>image_019.jpg</File>
    <File>image_020.jpg</File>
    <File>image_021.jpg</File>
    <File>image_022.jpg</File>
    <File>image_023.jpg</File>
    <File>image_024.jpg</File>
    <File>image_025.jpg</File>
    <File>image_026.jpg</File>
    <File>image_027.jpg</File>
    <File>image_028.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="865">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="12">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="47">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="1">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>129
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0233226-20f_inspira.htm": {
   "nsprefix": "iinn",
   "nsuri": "http://www.inspiratechnologies.com/20241231",
   "dts": {
    "inline": {
     "local": [
      "ea0233226-20f_inspira.htm"
     ]
    },
    "schema": {
     "local": [
      "iinn-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024_def.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024_lab.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024_pre.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-sub-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/sic/2024/sic-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "iinn-20241231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "iinn-20241231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "iinn-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "iinn-20241231_pre.xml"
     ]
    }
   },
   "keyStandard": 298,
   "keyCustom": 68,
   "axisStandard": 19,
   "axisCustom": 0,
   "memberStandard": 28,
   "memberCustom": 33,
   "hidden": {
    "total": 121,
    "http://www.inspiratechnologies.com/20241231": 35,
    "http://fasb.org/us-gaap/2024": 82,
    "http://xbrl.sec.gov/dei/2024": 4
   },
   "contextCount": 237,
   "entityCount": 1,
   "segmentCount": 65,
   "elementCount": 780,
   "unitCount": 6,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 865,
    "http://xbrl.sec.gov/dei/2024": 47,
    "http://xbrl.sec.gov/cyd/2024": 12,
    "http://xbrl.sec.gov/ecd/2024": 1
   },
   "report": {
    "R1": {
     "role": "http://xbrl.sec.gov/dei/role/document/Cover",
     "longName": "995100 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://xbrl.sec.gov/dei/role/document/AuditInformation",
     "longName": "995300 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet",
     "longName": "995301 - Statement - Balance Sheets",
     "shortName": "Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:DepositsAssetsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet_Parentheticals",
     "longName": "995302 - Statement - Balance Sheets (Parentheticals)",
     "shortName": "Balance Sheets (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement",
     "longName": "995303 - Statement - Statements of Comprehensive Loss",
     "shortName": "Statements of Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3",
     "longName": "995304 - Statement - Statements of Changes in Shareholders\u2019 Equity",
     "shortName": "Statements of Changes in Shareholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c25",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c25",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow",
     "longName": "995305 - Statement - Statements of Cash Flow",
     "shortName": "Statements of Cash Flow",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ProvisionForOtherLosses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.inspiratechnologies.com/role/General",
     "longName": "995306 - Disclosure - General",
     "shortName": "General",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.inspiratechnologies.com/role/SignificantAccountingPolicies",
     "longName": "995307 - Disclosure - Significant Accounting Policies",
     "shortName": "Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.inspiratechnologies.com/role/Deposits",
     "longName": "995308 - Disclosure - Deposits",
     "shortName": "Deposits",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DepositLiabilitiesDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DepositLiabilitiesDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.inspiratechnologies.com/role/OtherCurrentAssets",
     "longName": "995309 - Disclosure - Other Current Assets",
     "shortName": "Other Current Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.inspiratechnologies.com/role/Inventory",
     "longName": "995310 - Disclosure - Inventory",
     "shortName": "Inventory",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.inspiratechnologies.com/role/PropertyandEquipmentNet",
     "longName": "995311 - Disclosure - Property and Equipment, Net",
     "shortName": "Property and Equipment, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.inspiratechnologies.com/role/OtherAccountsPayable",
     "longName": "995312 - Disclosure - Other Accounts Payable",
     "shortName": "Other Accounts Payable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.inspiratechnologies.com/role/CommitmentsandContingencies",
     "longName": "995313 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.inspiratechnologies.com/role/LeaseLiabilities",
     "longName": "995314 - Disclosure - Lease Liabilities",
     "shortName": "Lease Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValue",
     "longName": "995315 - Disclosure - Finacial Liabilities at Fair Value",
     "shortName": "Finacial Liabilities at Fair Value",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.inspiratechnologies.com/role/ShareholdersEquity",
     "longName": "995316 - Disclosure - Shareholders\u2019 Equity",
     "shortName": "Shareholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.inspiratechnologies.com/role/ResearchandDevelopmentExpenses",
     "longName": "995317 - Disclosure - Research and Development Expenses",
     "shortName": "Research and Development Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.inspiratechnologies.com/role/GeneralandAdministrativeExpenses",
     "longName": "995318 - Disclosure - General and Administrative Expenses",
     "shortName": "General and Administrative Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "iinn:GeneralAndAdministrativeExpensesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "iinn:GeneralAndAdministrativeExpensesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.inspiratechnologies.com/role/SalesandMarketingExpenses",
     "longName": "995319 - Disclosure - Sales and Marketing Expenses",
     "shortName": "Sales and Marketing Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "iinn:SalesAndMarketingExpensesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "iinn:SalesAndMarketingExpensesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.inspiratechnologies.com/role/FinancialIncomeandExpenses",
     "longName": "995320 - Disclosure - Financial (Income) and Expenses",
     "shortName": "Financial (Income) and Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.inspiratechnologies.com/role/TaxesonIncome",
     "longName": "995321 - Disclosure - Taxes on Income",
     "shortName": "Taxes on Income",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.inspiratechnologies.com/role/ShareBasedPayment",
     "longName": "995322 - Disclosure - Share-Based Payment",
     "shortName": "Share-Based Payment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.inspiratechnologies.com/role/RelatedParties",
     "longName": "995323 - Disclosure - Related Parties",
     "shortName": "Related Parties",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.inspiratechnologies.com/role/SubsequentEvents",
     "longName": "995324 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R28": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c31",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c31",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy",
     "longName": "996000 - Disclosure - Accounting Policies, by Policy (Policies)",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.inspiratechnologies.com/role/SignificantAccountingPoliciesTables",
     "longName": "996001 - Disclosure - Significant Accounting Policies (Tables)",
     "shortName": "Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "iinn:ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "iinn:ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.inspiratechnologies.com/role/OtherCurrentAssetsTables",
     "longName": "996002 - Disclosure - Other Current Assets (Tables)",
     "shortName": "Other Current Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.inspiratechnologies.com/role/InventoryTables",
     "longName": "996003 - Disclosure - Inventory (Tables)",
     "shortName": "Inventory (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.inspiratechnologies.com/role/PropertyandEquipmentNetTables",
     "longName": "996004 - Disclosure - Property and Equipment, Net (Tables)",
     "shortName": "Property and Equipment, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.inspiratechnologies.com/role/OtherAccountsPayableTables",
     "longName": "996005 - Disclosure - Other Accounts Payable (Tables)",
     "shortName": "Other Accounts Payable (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.inspiratechnologies.com/role/LeaseLiabilitiesTables",
     "longName": "996006 - Disclosure - Lease Liabilities (Tables)",
     "shortName": "Lease Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "iinn:ScheduleOfLesseeOperatingLeasesDisclosureTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "iinn:ScheduleOfLesseeOperatingLeasesDisclosureTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueTables",
     "longName": "996007 - Disclosure - Finacial Liabilities at Fair Value (Tables)",
     "shortName": "Finacial Liabilities at Fair Value (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.inspiratechnologies.com/role/ShareholdersEquityTables",
     "longName": "996008 - Disclosure - Shareholders\u2019 Equity (Tables)",
     "shortName": "Shareholders\u2019 Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.inspiratechnologies.com/role/ResearchandDevelopmentExpensesTables",
     "longName": "996009 - Disclosure - Research and Development Expenses (Tables)",
     "shortName": "Research and Development Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.inspiratechnologies.com/role/GeneralandAdministrativeExpensesTables",
     "longName": "996010 - Disclosure - General and Administrative Expenses (Tables)",
     "shortName": "General and Administrative Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "iinn:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "iinn:GeneralAndAdministrativeExpensesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "iinn:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "iinn:GeneralAndAdministrativeExpensesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.inspiratechnologies.com/role/SalesandMarketingExpensesTables",
     "longName": "996011 - Disclosure - Sales and Marketing Expenses (Tables)",
     "shortName": "Sales and Marketing Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "iinn:ScheduleOfSalesAndMarketingExpensesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "iinn:SalesAndMarketingExpensesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "iinn:ScheduleOfSalesAndMarketingExpensesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "iinn:SalesAndMarketingExpensesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.inspiratechnologies.com/role/FinancialIncomeandExpensesTables",
     "longName": "996012 - Disclosure - Financial (Income) and Expenses (Tables)",
     "shortName": "Financial (Income) and Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.inspiratechnologies.com/role/TaxesonIncomeTables",
     "longName": "996013 - Disclosure - Taxes on Income (Tables)",
     "shortName": "Taxes on Income (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.inspiratechnologies.com/role/ShareBasedPaymentTables",
     "longName": "996014 - Disclosure - Share-Based Payment (Tables)",
     "shortName": "Share-Based Payment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.inspiratechnologies.com/role/RelatedPartiesTables",
     "longName": "996015 - Disclosure - Related Parties (Tables)",
     "shortName": "Related Parties (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.inspiratechnologies.com/role/GeneralDetails",
     "longName": "996016 - Disclosure - General (Details)",
     "shortName": "General (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c32",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c37",
      "name": "us-gaap:SharePrice",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.inspiratechnologies.com/role/SignificantAccountingPoliciesDetails",
     "longName": "996017 - Disclosure - Significant Accounting Policies (Details)",
     "shortName": "Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.inspiratechnologies.com/role/ScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable",
     "longName": "996018 - Disclosure - Significant Accounting Policies - Schedule of Depreciation on Straight-Line Method, Over the Estimated Useful Life of the Assets (Details)",
     "shortName": "Significant Accounting Policies - Schedule of Depreciation on Straight-Line Method, Over the Estimated Useful Life of the Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c50",
      "name": "iinn:AnnualDepreciationRatesOfPropertyPlantAndEquipment",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "iinn:ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c50",
      "name": "iinn:AnnualDepreciationRatesOfPropertyPlantAndEquipment",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "iinn:ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.inspiratechnologies.com/role/DepositsDetails",
     "longName": "996019 - Disclosure - Deposits (Details)",
     "shortName": "Deposits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c56",
      "name": "us-gaap:ShortTermDebtPercentageBearingFixedInterestRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DepositLiabilitiesDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c56",
      "name": "us-gaap:ShortTermDebtPercentageBearingFixedInterestRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DepositLiabilitiesDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.inspiratechnologies.com/role/ScheduleofOtherCurrentAssetsTable",
     "longName": "996020 - Disclosure - Other Current Assets - Schedule of Other Current Assets (Details)",
     "shortName": "Other Current Assets - Schedule of Other Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.inspiratechnologies.com/role/ScheduleofInventoryTable",
     "longName": "996021 - Disclosure - Inventory - Schedule of Inventory (Details)",
     "shortName": "Inventory - Schedule of Inventory (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.inspiratechnologies.com/role/ScheduleofPropertyandEquipmentNetTable",
     "longName": "996022 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)",
     "shortName": "Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentAdditions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.inspiratechnologies.com/role/ScheduleofOtherAccountsPayableTable",
     "longName": "996023 - Disclosure - Other Accounts Payable - Schedule of Other Accounts Payable (Details)",
     "shortName": "Other Accounts Payable - Schedule of Other Accounts Payable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.inspiratechnologies.com/role/CommitmentsandContingenciesDetails",
     "longName": "996024 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c80",
      "name": "iinn:AggregateBudget",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c80",
      "name": "iinn:AggregateBudget",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.inspiratechnologies.com/role/LeaseLiabilitiesDetails",
     "longName": "996025 - Disclosure - Lease Liabilities (Details)",
     "shortName": "Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PaymentsForRent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PaymentsForRent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.inspiratechnologies.com/role/ScheduleofOperatingRightofUseAssetsandOperatingLeaseLiabilitiesTable",
     "longName": "996026 - Disclosure - Lease Liabilities - Schedule of Operating Right-of-Use Assets and Operating Lease Liabilities (Details)",
     "shortName": "Lease Liabilities - Schedule of Operating Right-of-Use Assets and Operating Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.inspiratechnologies.com/role/ScheduleofRightofUseAssetsOvertheRemainingLeasePeriodsTable",
     "longName": "996027 - Disclosure - Lease Liabilities - Schedule of Right-of-Use Assets Over the Remaining Lease Periods (Details)",
     "shortName": "Lease Liabilities - Schedule of Right-of-Use Assets Over the Remaining Lease Periods (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails",
     "longName": "996028 - Disclosure - Finacial Liabilities at Fair Value (Details)",
     "shortName": "Finacial Liabilities at Fair Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c48",
      "name": "us-gaap:FinancialLiabilitiesFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c99",
      "name": "us-gaap:DerivativeLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.inspiratechnologies.com/role/ScheduleofFinancialLiabilityTable",
     "longName": "996029 - Disclosure - Finacial Liabilities at Fair Value - Schedule of Financial Liability (Details)",
     "shortName": "Finacial Liabilities at Fair Value - Schedule of Financial Liability (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:DerivativeLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c101",
      "name": "us-gaap:DerivativeLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.inspiratechnologies.com/role/ShareholdersEquityDetails",
     "longName": "996030 - Disclosure - Shareholders\u2019 Equity (Details)",
     "shortName": "Shareholders\u2019 Equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c189",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c107",
      "name": "iinn:PurchasePricePerShare",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.inspiratechnologies.com/role/ScheduleofShareCapitalTable",
     "longName": "996031 - Disclosure - Shareholders\u2019 Equity - Schedule of Share Capital (Details)",
     "shortName": "Shareholders\u2019 Equity - Schedule of Share Capital (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c147",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c147",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
       "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.inspiratechnologies.com/role/ScheduleofMovementinWarrantsOutstandingTable",
     "longName": "996032 - Disclosure - Shareholders\u2019 Equity - Schedule of Movement in Warrants Outstanding (Details)",
     "shortName": "Shareholders\u2019 Equity - Schedule of Movement in Warrants Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c149",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c149",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.inspiratechnologies.com/role/ScheduleofInformationabouttheCompanysOutstandingWarrantsTable",
     "longName": "996033 - Disclosure - Shareholders\u2019 Equity - Schedule of Information about the Company\u2019s Outstanding Warrants (Details)",
     "shortName": "Shareholders\u2019 Equity - Schedule of Information about the Company\u2019s Outstanding Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c151",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c151",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.inspiratechnologies.com/role/ScheduleofLossPerShareCalculatedUsingtheWeightedAverageNumberofOrdinarySharesandPreFundedWarrantsTable",
     "longName": "996034 - Disclosure - Shareholders\u2019 Equity - Schedule of Loss Per Share Calculated Using the Weighted Average Number of Ordinary Shares and Pre-Funded Warrants (Details)",
     "shortName": "Shareholders\u2019 Equity - Schedule of Loss Per Share Calculated Using the Weighted Average Number of Ordinary Shares and Pre-Funded Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.inspiratechnologies.com/role/ScheduleofResearchandDevelopmentExpensesTable",
     "longName": "996035 - Disclosure - Research and Development Expenses - Schedule of Research and Development Expenses (Details)",
     "shortName": "Research and Development Expenses - Schedule of Research and Development Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LaborAndRelatedExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock",
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:LaborAndRelatedExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock",
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable",
     "longName": "996036 - Disclosure - General and Administrative Expenses - Schedule of General and Administrative Expenses (Details)",
     "shortName": "General and Administrative Expenses - Schedule of General and Administrative Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c166",
      "name": "us-gaap:ProfessionalFees",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "iinn:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock",
       "iinn:GeneralAndAdministrativeExpensesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c166",
      "name": "us-gaap:ProfessionalFees",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "iinn:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock",
       "iinn:GeneralAndAdministrativeExpensesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.inspiratechnologies.com/role/ScheduleofSalesandMarketingExpensesTable",
     "longName": "996037 - Disclosure - Sales and Marketing Expenses - Schedule of Sales and Marketing Expenses (Details)",
     "shortName": "Sales and Marketing Expenses - Schedule of Sales and Marketing Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OfficersCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "iinn:ScheduleOfSalesAndMarketingExpensesTableTextBlock",
       "iinn:SalesAndMarketingExpensesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OfficersCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "iinn:ScheduleOfSalesAndMarketingExpensesTableTextBlock",
       "iinn:SalesAndMarketingExpensesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.inspiratechnologies.com/role/ScheduleofFinancialIncomeandExpensesTable",
     "longName": "996038 - Disclosure - Financial (Income) and Expenses - Schedule of Financial (Income) and Expenses (Details)",
     "shortName": "Financial (Income) and Expenses - Schedule of Financial (Income) and Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "iinn:RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "iinn:RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.inspiratechnologies.com/role/TaxesonIncomeDetails",
     "longName": "996039 - Disclosure - Taxes on Income (Details)",
     "shortName": "Taxes on Income (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.inspiratechnologies.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable",
     "longName": "996040 - Disclosure - Taxes on Income - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "shortName": "Taxes on Income - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.inspiratechnologies.com/role/ScheduleofTheoreticalTaxTable",
     "longName": "996041 - Disclosure - Taxes on Income - Schedule of Theoretical Tax (Details)",
     "shortName": "Taxes on Income - Schedule of Theoretical Tax (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "iinn:EffectiveIncomeTaxTheoreticalTaxCredit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.inspiratechnologies.com/role/ScheduleofTheoreticalTaxTable_Parentheticals",
     "longName": "996042 - Disclosure - Taxes on Income - Schedule of Theoretical Tax (Parentheticals) (Details)",
     "shortName": "Taxes on Income - Schedule of Theoretical Tax (Parentheticals) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails",
     "longName": "996043 - Disclosure - Share-Based Payment (Details)",
     "shortName": "Share-Based Payment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c189",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c178",
      "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.inspiratechnologies.com/role/ScheduleofMeasuretheFairValueoftheOptionatGrantDateTable",
     "longName": "996044 - Disclosure - Share-Based Payment - Schedule of Measure the Fair Value of the Option at Grant Date (Details)",
     "shortName": "Share-Based Payment - Schedule of Measure the Fair Value of the Option at Grant Date (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c196",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c196",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.inspiratechnologies.com/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable",
     "longName": "996045 - Disclosure - Share-Based Payment - Schedule of Options to Services Providers and Advisers Outstanding (Details)",
     "shortName": "Share-Based Payment - Schedule of Options to Services Providers and Advisers Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c204",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c206",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.inspiratechnologies.com/role/ScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable",
     "longName": "996046 - Disclosure - Share-Based Payment - Schedule of RSUs to Services Providers and Advisers Outstanding (Details)",
     "shortName": "Share-Based Payment - Schedule of RSUs to Services Providers and Advisers Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c27",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.inspiratechnologies.com/role/ScheduleofShareholdersandOtherRelatedPartiesBenefitsTable",
     "longName": "996047 - Disclosure - Related Parties - Schedule of Shareholders and Other Related Parties\u2019 Benefits (Details)",
     "shortName": "Related Parties - Schedule of Shareholders and Other Related Parties\u2019 Benefits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c223",
      "name": "us-gaap:OfficersCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c223",
      "name": "us-gaap:OfficersCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.inspiratechnologies.com/role/SubsequentEventsDetails",
     "longName": "996048 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ProceedsFromBankDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ProceedsFromBankDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0233226-20f_inspira.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/OtherAccountsPayable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OTHER ACCOUNTS PAYABLE",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r47",
      "r50",
      "r926"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesNoncurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Other Accounts Payable [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrentAndNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrentAndNoncurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accounts Payable [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableOtherCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableOtherCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.inspiratechnologies.com/role/ScheduleofOtherAccountsPayableTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet",
      "http://www.inspiratechnologies.com/role/ScheduleofOtherAccountsPayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Other accounts payables",
        "label": "Accounts Payable, Other, Current",
        "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "iinn_AccountsPayableToRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "AccountsPayableToRelatedParties",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofOtherAccountsPayableTable": {
       "parentTag": "us-gaap_AccountsPayableOtherCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofOtherAccountsPayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related parties",
        "documentation": "Amount of accounts payable to related parties, due after one year or beyond the normal operating cycle, if longer.",
        "label": "Accounts Payable To Related Parties"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableTradeCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade accounts payables",
        "label": "Accounts Payable, Trade, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r45"
     ]
    },
    "iinn_AccruedIssuanceExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "AccruedIssuanceExpenses",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued issuance expenses",
        "documentation": "Amount of accrued issuance expenses.",
        "label": "Accrued Issuance Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofOtherAccountsPayableTable": {
       "parentTag": "us-gaap_AccountsPayableOtherCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofOtherAccountsPayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Accrued Liabilities",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Accumulated depreciation, Beginning Balance",
        "periodEndLabel": "Accumulated depreciation, Ending Balance",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r133",
      "r519"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated losses",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r64",
      "r139",
      "r515",
      "r534",
      "r535"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "iinn_AdditionalOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "AdditionalOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional offering costs",
        "documentation": "Amount of additional offering costs.",
        "label": "Additional Offering Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share capital and additional paid in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share capital and Additional Paid in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r549",
      "r867",
      "r868",
      "r869",
      "r870",
      "r933",
      "r998"
     ]
    },
    "dei_AdditionalSecurities462b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AdditionalSecurities462b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities. 462(b)"
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "dei_AdditionalSecurities462bFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AdditionalSecurities462bFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities, 462(b), File Number"
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "dei_AdditionalSecuritiesEffective413b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AdditionalSecuritiesEffective413b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities Effective, 413(b)"
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for restricted stock unit under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of placement agent warrants (Note 11.3)",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r28",
      "r82"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash provided by operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_AdvisoryBoardMembersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "AdvisoryBoardMembersMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advisory Board Members [Member]",
        "label": "Advisory Board Members Member"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_AggregateBudget": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "AggregateBudget",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate budget",
        "documentation": "The amount of aggregate budget.",
        "label": "Aggregate Budget"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_AggregateProceedsReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "AggregateProceedsReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross proceeds",
        "documentation": "Represent the amount of aggregate proceeds received.",
        "label": "Aggregate Proceeds Received"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r734",
      "r745",
      "r761",
      "r796"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r737",
      "r748",
      "r764",
      "r799"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r738",
      "r749",
      "r765",
      "r791",
      "r800",
      "r804",
      "r812"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable",
      "http://www.inspiratechnologies.com/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable",
      "http://www.inspiratechnologies.com/role/ScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable",
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment",
        "verboseLabel": "Number of options, Share-based payment expenses (in Dollars)",
        "netLabel": "Number of RSUs, Share-based payment expenses (in Dollars)",
        "label": "Share-based payment expenses (in Dollars)",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r320",
      "r328"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpenseNetOfTax",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofResearchandDevelopmentExpensesTable": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofResearchandDevelopmentExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based payment",
        "label": "Share-Based Payment Arrangement, Expense, after Tax",
        "documentation": "Amount, after tax, of expense for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfFinancingCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance cost",
        "label": "Amortization of Debt Issuance Costs",
        "documentation": "Amount of amortization expense attributable to debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r273",
      "r863",
      "r945"
     ]
    },
    "iinn_AnnualDepreciationRatesOfPropertyPlantAndEquipment": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "AnnualDepreciationRatesOfPropertyPlantAndEquipment",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual depreciation rates",
        "documentation": "Percentage of annual depreciation rates of property, plant and equipment.",
        "label": "Annual Depreciation Rates Of Property Plant And Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": {
     "xbrltype": "dateOrAsapItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Approximate Date of Commencement of Proposed Sale to Public",
        "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r104",
      "r134",
      "r162",
      "r189",
      "r193",
      "r202",
      "r203",
      "r238",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r368",
      "r370",
      "r401",
      "r511",
      "r585",
      "r662",
      "r663",
      "r683",
      "r705",
      "r893",
      "r894",
      "r950"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r144",
      "r162",
      "r238",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r368",
      "r370",
      "r401",
      "r683",
      "r893",
      "r894",
      "r950"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Assets",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current assets",
        "label": "Assets, Noncurrent",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r238",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r368",
      "r370",
      "r401",
      "r893",
      "r894",
      "r950"
     ]
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Current Assets:",
        "label": "Assets, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r718",
      "r721",
      "r741"
     ]
    },
    "dei_AuditorLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r718",
      "r721",
      "r741"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r718",
      "r721",
      "r741"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "dei_AuditorTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable",
      "http://www.inspiratechnologies.com/role/ScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable",
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r292",
      "r293",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "iinn_BankLeumiMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "BankLeumiMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/DepositsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bank Leumi [Member]",
        "label": "Bank Leumi Member"
       }
      }
     },
     "auth_ref": []
    },
    "srt_BoardOfDirectorsChairmanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "BoardOfDirectorsChairmanMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Board of Directors [Member]",
        "label": "Board of Directors Chairman [Member]"
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Contact",
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r721",
      "r741"
     ]
    },
    "iinn_CapitalGainTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "CapitalGainTaxRate",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital gain tax rate",
        "documentation": "Capital gain tax rate.",
        "label": "Capital Gain Tax Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet",
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r131",
      "r654"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalent",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, cash equivalents and restricted cash at the beginning of the period",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at the end of the period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r73",
      "r160"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash and cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r73"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r782"
     ]
    },
    "iinn_ChangesDuringThePeriodAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "ChangesDuringThePeriodAbstract",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes during the period:",
        "label": "Changes During The Period Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ClassOfPrivateWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "ClassOfPrivateWarrantOrRightOutstanding",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private warrants",
        "documentation": "Represent the number of private warrant or right outstanding.",
        "label": "Class Of Private Warrant Or Right Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDetails",
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r135",
      "r136",
      "r137",
      "r162",
      "r181",
      "r182",
      "r184",
      "r186",
      "r191",
      "r192",
      "r238",
      "r264",
      "r266",
      "r267",
      "r268",
      "r271",
      "r272",
      "r275",
      "r276",
      "r277",
      "r278",
      "r280",
      "r401",
      "r541",
      "r542",
      "r543",
      "r544",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r573",
      "r595",
      "r618",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r843",
      "r865",
      "r871"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails",
      "http://www.inspiratechnologies.com/role/GeneralDetails",
      "http://www.inspiratechnologies.com/role/ScheduleofInformationabouttheCompanysOutstandingWarrantsTable",
      "http://www.inspiratechnologies.com/role/ScheduleofMovementinWarrantsOutstandingTable",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails",
      "http://www.inspiratechnologies.com/role/GeneralDetails",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails",
      "http://www.inspiratechnologies.com/role/GeneralDetails",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre funded warrant, per share",
        "verboseLabel": "Exercise price (in Dollars per share)",
        "netLabel": "Exercise price per share (in Dollars per share)",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r281"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders\u2019 Equity [Line Item]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase of warrant",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r281"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre funded warrant",
        "label": "Class of Warrant or Right, Outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofMovementinWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COMMITMENTS AND CONTINGENCIES",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r94",
      "r513",
      "r572"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COMMITMENTS AND CONTINGENCIES",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r258",
      "r259",
      "r639",
      "r886",
      "r891"
     ]
    },
    "iinn_CommitmentsandContingenciesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "CommitmentsandContingenciesDetailsTable",
     "presentation": [
      "http://www.inspiratechnologies.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails",
      "http://www.inspiratechnologies.com/role/GeneralDetails",
      "http://www.inspiratechnologies.com/role/ScheduleofShareCapitalTable",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDetails",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary Share",
        "verboseLabel": "Ordinary Shares [Member]",
        "netLabel": "Common Stock [Member]",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r695",
      "r696",
      "r697",
      "r699",
      "r700",
      "r701",
      "r702",
      "r867",
      "r868",
      "r870",
      "r933",
      "r993",
      "r998"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, par value (in Dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.inspiratechnologies.com/role/ScheduleofShareCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, Authorized ordinary shares",
        "verboseLabel": "Ordinary shares, Authorized",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r573"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.inspiratechnologies.com/role/ScheduleofShareCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, Issued ordinary shares",
        "verboseLabel": "Ordinary shares, Issued",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.inspiratechnologies.com/role/ScheduleofLossPerShareCalculatedUsingtheWeightedAverageNumberofOrdinarySharesandPreFundedWarrantsTable",
      "http://www.inspiratechnologies.com/role/ScheduleofShareCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, outstanding shares",
        "verboseLabel": "Ordinary shares, Outstanding",
        "netLabel": "Total number of Ordinary Shares",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r56",
      "r573",
      "r591",
      "r998",
      "r999"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, no par value: Authorized 100,000,000 ordinary shares as of December 31, 2024 and December 31, 2023; Issued and outstanding 24,252,096 ordinary shares as of December 31, 2024 and 15,652,176 shares as of December 31, 2023",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r514",
      "r683"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationExpenseExcludingCostOfGoodAndServiceSold",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofSalesandMarketingExpensesTable": {
       "parentTag": "us-gaap_SellingAndMarketingExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofSalesandMarketingExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment",
        "label": "Compensation Expense, Excluding Cost of Good and Service Sold",
        "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit. Other employee benefit expense includes, but is not limited to, service component of net periodic benefit cost for defined benefit plan. Excludes compensation cost in cost of good and service sold."
       }
      }
     },
     "auth_ref": [
      "r662",
      "r860"
     ]
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable",
      "http://www.inspiratechnologies.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computers [Member]",
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of Credit Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r109"
     ]
    },
    "dei_ContactPersonnelEmailAddress": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelEmailAddress",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Email Address",
        "documentation": "Email address of contact personnel."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelFaxNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelFaxNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Fax Number",
        "documentation": "Fax Number of contact personnel."
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Description",
        "documentation": "The description of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Name",
        "documentation": "The name of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Number",
        "documentation": "The SEC Document Number of the contained file."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContainedFileInformationFileType": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContainedFileInformationFileType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contained File Information, File Type",
        "documentation": "The type or format of the contained file (usually XBRL but may be used for other types such as HTML, Word, PDF, GIF/JPG, etc.)."
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ContingentUponFutureSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "ContingentUponFutureSales",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent upon future sales",
        "documentation": "The amount of contingent upon future sales.",
        "label": "Contingent Upon Future Sales"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostMaintenance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostMaintenance",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office maintenance",
        "label": "Cost, Maintenance",
        "documentation": "Cost of maintenance incurred and directly related to good produced and service rendered."
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]",
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r728",
      "r822"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Board of Directors Oversight [Text Block]",
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r728",
      "r822"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]",
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r730",
      "r824"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]",
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r730",
      "r824"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]",
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r724",
      "r818"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Management Processes Integrated [Flag]",
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r725",
      "r819"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Management Processes Integrated [Text Block]",
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r725",
      "r819"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r723",
      "r817"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r723",
      "r817"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r723",
      "r817"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]",
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r727",
      "r821"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]",
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r727",
      "r821"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]",
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r728",
      "r822"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Role of Management [Text Block]",
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r729",
      "r823"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]",
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r726",
      "r820"
     ]
    },
    "iinn_December2024PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "December2024PrivatePlacementMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "December 2024 Private Placement [Member]",
        "label": "December2024 Private Placement Member"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_DecemberPreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "DecemberPreFundedWarrantsMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/GeneralDetails",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "December Pre-Funded Warrants [Member]",
        "label": "December Pre Funded Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_DecemberPrivateOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "DecemberPrivateOfferingMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "December Private Offering [Member]",
        "label": "December Private Offering Member"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_DecemberPrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "DecemberPrivatePlacementMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/GeneralDetails",
      "http://www.inspiratechnologies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "December Private Placement [Member]",
        "label": "December Private Placement Member"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_DecemberPrivateWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "DecemberPrivateWarrantsMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "December Private Warrants [Member]",
        "label": "December Private Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r53",
      "r92",
      "r346"
     ]
    },
    "us-gaap_DeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offering cost (in Dollars)",
        "label": "Deferred Offering Costs",
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "iinn_DeferredTaxAssetsAccruedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "DeferredTaxAssetsAccruedExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "documentation": "Represents amount of deferred tax accrued expenses.",
        "label": "Deferred Tax Assets Accrued Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_DeferredTaxAssetsFundRaisingCost2023": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "DeferredTaxAssetsFundRaisingCost2023",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fund raising costs 2023",
        "documentation": "Fund raising costs.",
        "label": "Deferred Tax Assets Fund Raising Cost2023"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGrossAbstract",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets:",
        "label": "Deferred Tax Assets, Gross [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "R&amp;D temporary differences",
        "label": "Deferred Tax Asset, In-Process Research and Development",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred taxes",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/TaxesonIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforward",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities:",
        "label": "Deferred Tax Liabilities, Gross [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_DeferredTaxLiabilitiesOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "DeferredTaxLiabilitiesOperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Operating lease liability",
        "documentation": "Operating lease liability.",
        "label": "Deferred Tax Liabilities Operating Lease Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incurred accumulated losses",
        "label": "Accumulated Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), after Tax",
        "documentation": "Amount, after tax, of accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r284"
     ]
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "presentation": [
      "http://www.inspiratechnologies.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employees monthly deposits rate",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DelayedOrContinuousOffering": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DelayedOrContinuousOffering",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Delayed or Continuous Offering"
       }
      }
     },
     "auth_ref": [
      "r753",
      "r754",
      "r768"
     ]
    },
    "us-gaap_DepositLiabilitiesDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepositLiabilitiesDisclosuresTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/Deposits"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "DEPOSITS",
        "label": "Deposit Liabilities Disclosures [Text Block]",
        "documentation": "The entire disclosure for deposit liabilities including data and tables. It may include a description of the entity's deposit liabilities, the aggregate amount of time deposits (including certificates of deposit) in denominations of $100,000 or more at the balance sheet date; the aggregate amount of any demand deposits that have been reclassified as loan balances, such as overdrafts, at the balance sheet date; deposits that are received on terms other than those in the normal course of business, the amount of accrued interest on deposit liabilities; securities, mortgage loans or other financial instruments that serve as collateral for deposits; for time deposits having a remaining term of more than one year, the aggregate amount of maturities for each of the five years following the balance sheet date; and the weighted average interest rate for all deposit liabilities held by the entity."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r91",
      "r124",
      "r125"
     ]
    },
    "us-gaap_DepositLiabilityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepositLiabilityLineItems",
     "presentation": [
      "http://www.inspiratechnologies.com/role/DepositsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deposits [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r123"
     ]
    },
    "us-gaap_Deposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Deposits",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/DepositsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deposit",
        "label": "Deposits",
        "documentation": "The aggregate of all deposit liabilities held by the entity, including foreign and domestic, interest and noninterest bearing; may include demand deposits, saving deposits, Negotiable Order of Withdrawal (NOW) and time deposits among others."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_DepositsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepositsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Deposits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepositsAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepositsAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deposits",
        "label": "Deposits Assets, Current",
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter."
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "iinn_DepositsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "DepositsDetailsTable",
     "presentation": [
      "http://www.inspiratechnologies.com/role/DepositsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deposits (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow",
      "http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable",
      "http://www.inspiratechnologies.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r26"
     ]
    },
    "us-gaap_DepreciationNonproduction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationNonproduction",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofResearchandDevelopmentExpensesTable": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofResearchandDevelopmentExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Depreciation, Nonproduction",
        "documentation": "The expense recognized in the current period that allocates the cost of nonproduction tangible assets over their useful lives."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r26"
     ]
    },
    "us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeFinancialInstrumentsLiabilitiesMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails",
      "http://www.inspiratechnologies.com/role/ScheduleofFinancialLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liability [Member]",
        "label": "Derivative Financial Instruments, Liabilities [Member]",
        "documentation": "This item represents derivative instrument obligations meeting the definition of a liability which are reported as of the balance sheet date. Derivative instrument obligations are generally measured at fair value, and adjustments to the carrying amount of hedged items reflect changes in their fair value (that is, losses) that are attributable to the risk being hedged and that arise while the hedge is in effect."
       }
      }
     },
     "auth_ref": [
      "r394"
     ]
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet",
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails",
      "http://www.inspiratechnologies.com/role/ScheduleofFinancialLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liabilities at fair value",
        "verboseLabel": "Total",
        "netLabel": "Derivative Liability, Current (in Dollars)",
        "label": "Derivative Liability, Current",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "us-gaap_DerivativeLiabilityMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilityMeasurementInput",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of private warrants",
        "label": "Derivative Liability, Measurement Input",
        "documentation": "Value of input used to measure derivative liability."
       }
      }
     },
     "auth_ref": [
      "r382",
      "r383",
      "r384"
     ]
    },
    "us-gaap_DerivativesFairValueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativesFairValueLineItems",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofFinancialLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Financial Liability [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativesPolicyTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants and Pre-Funded Warrants",
        "label": "Derivatives, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r35",
      "r36",
      "r37",
      "r38",
      "r164",
      "r178"
     ]
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "DirectorMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofShareholdersandOtherRelatedPartiesBenefitsTable",
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Director [Member]",
        "verboseLabel": "Directors [Member]",
        "label": "Director [Member]"
       }
      }
     },
     "auth_ref": [
      "r878",
      "r994"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedPayment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SHARE-BASED PAYMENT",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r290",
      "r321",
      "r322",
      "r323",
      "r670"
     ]
    },
    "dei_DividendOrInterestReinvestmentPlanOnly": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DividendOrInterestReinvestmentPlanOnly",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend or Interest Reinvestment Plan Only"
       }
      }
     },
     "auth_ref": [
      "r753",
      "r754",
      "r768"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r718",
      "r721",
      "r741"
     ]
    },
    "dei_DocumentCopyrightInformation": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentCopyrightInformation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Copyright Information",
        "documentation": "The copyright information for the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentCreationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentCreationDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Creation Date",
        "documentation": "The date the document was made available and submitted, in YYYY-MM-DD format. The date of submission, date of acceptance by the recipient, and the document effective date are all potentially different."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Description",
        "documentation": "The description of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document [Domain]",
        "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentEffectiveDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentEffectiveDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Effective Date",
        "documentation": "The date when a document, upon receipt and acceptance, becomes officially effective, in YYYY-MM-DD format. Usually it is a system-assigned date time value, but it may be declared by the submitter in some cases."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r718",
      "r721",
      "r741",
      "r792"
     ]
    },
    "dei_DocumentFinStmtRestatementRecoveryAnalysisFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtRestatementRecoveryAnalysisFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Restatement Recovery Analysis [Flag]",
        "documentation": "Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to \u00a7240.10D-1(b)."
       }
      }
     },
     "auth_ref": [
      "r718",
      "r721",
      "r741",
      "r792"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationDocumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationDocumentAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information, Document [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Text Block]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Name",
        "documentation": "Name of the document as assigned by the filer, corresponding to SEC document naming convention standards. Examples appear in the &lt;FILENAME> field of EDGAR filings, such as 'htm_25911.htm', 'exhibit1.htm', 'v105727_8k.txt'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "dei_DocumentSubtitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentSubtitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Subtitle",
        "documentation": "The subtitle given to the document resource by the creator or publisher. An example is 'A New Period of Growth'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentSynopsis": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentSynopsis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Synopsis",
        "documentation": "A synopsis or description of the document provided by the creator or publisher. Examples are 'This is the 2006 annual report for Company. During this period we saw revenue grow by 10% and earnings per share grow by 15% over the prior period'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTitle": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Title",
        "documentation": "The name or title given to the document resource by the creator or publisher. An example is '2002 Annual Report'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentVersion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentVersion",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Version",
        "documentation": "The version identifier of the document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r710"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r781"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement",
      "http://www.inspiratechnologies.com/role/ScheduleofLossPerShareCalculatedUsingtheWeightedAverageNumberofOrdinarySharesandPreFundedWarrantsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per ordinary share, basic (in Dollars per share)",
        "verboseLabel": "Basic loss per share (in Dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r179",
      "r181",
      "r184",
      "r185",
      "r186",
      "r188",
      "r364",
      "r367",
      "r380",
      "r381",
      "r508",
      "r525",
      "r658"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement",
      "http://www.inspiratechnologies.com/role/ScheduleofLossPerShareCalculatedUsingtheWeightedAverageNumberofOrdinarySharesandPreFundedWarrantsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per ordinary share, diluted (in Dollars per share)",
        "verboseLabel": "Diluted loss per share (in Dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r181",
      "r184",
      "r185",
      "r186",
      "r188",
      "r364",
      "r367",
      "r380",
      "r381",
      "r508",
      "r525",
      "r658"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic and Diluted Loss Per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r187"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r407"
     ]
    },
    "dei_EffectiveAfter60Days486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveAfter60Days486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective after 60 Days, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://www.inspiratechnologies.com/role/TaxesonIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r671"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofTheoreticalTaxTable_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Theoretical tax credit at applicable statutory rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r337",
      "r355",
      "r671"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationLineItems",
     "presentation": [
      "http://www.inspiratechnologies.com/role/TaxesonIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes on Income [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r338",
      "r671"
     ]
    },
    "iinn_EffectiveIncomeTaxTheoreticalTaxCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "EffectiveIncomeTaxTheoreticalTaxCredit",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofTheoreticalTaxTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Theoretical tax credit at applicable statutory rate: 23%",
        "documentation": "Represents amount of theoretical tax credit.",
        "label": "Effective Income Tax Theoretical Tax Credit"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EffectiveOnDate486a": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "dei_EffectiveOnDate486b": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "dei_EffectiveOnSetDate486a": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnSetDate486a",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(a)"
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "dei_EffectiveOnSetDate486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveOnSetDate486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "dei_EffectiveUponFiling462e": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveUponFiling462e",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Upon Filing, 462(e)"
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "dei_EffectiveUponFiling486b": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveUponFiling486b",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective upon Filing, 486(b)"
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "dei_EffectiveWhenDeclaredSection8c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EffectiveWhenDeclaredSection8c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective when Declared, Section 8(c)"
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofOtherAccountsPayableTable": {
       "parentTag": "us-gaap_AccountsPayableOtherCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofOtherAccountsPayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employees\u2019 salaries and related liabilities",
        "label": "Employee-related Liabilities",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r960"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails",
      "http://www.inspiratechnologies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock [Member]",
        "label": "Employee Stock [Member]",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "iinn_EmployeesAndDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "EmployeesAndDirectorsMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employees and Directors [Member]",
        "label": "Employees And Directors Member"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_EmployeesDirectorsAndSubcontractorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "EmployeesDirectorsAndSubcontractorsMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employees, Directors and Subcontractors [Member]",
        "label": "Employees Directors And Subcontractors Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitiesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entities [Table]",
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAccountingStandard": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAccountingStandard",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Accounting Standard",
        "documentation": "The standardized abbreviation of the accounting standard used by the entity. This can either be US GAAP as promulgated by the FASB or IFRS as promulgated by the IASB. Example: 'US GAAP', 'IFRS'. This is distinct from the Document Accounting Standard element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Description",
        "documentation": "Description of the kind of address for the entity, if needed to distinguish more finely among mailing, principal, legal, accounting, contact or other addresses."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses [Table]",
        "documentation": "Container of address information for the entity"
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r713"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityContactPersonnelLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityContactPersonnelLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Contact Personnel [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "dei_EntityHomeCountryISOCode": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityHomeCountryISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Home Country ISO Code",
        "documentation": "ISO 3166-1 alpha-2 country code for the Entity's home country. If home country is different from country of legal incorporation, then also provide country of legal incorporation in the 'Entity Incorporation, State Country Code' element."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationDateOfIncorporation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, Date of Incorporation",
        "documentation": "Date when an entity was incorporated"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information, Former Legal or Registered Name",
        "documentation": "Former Legal or Registered Name of an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInformationLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "dei_EntityInvCompanyType": {
     "xbrltype": "invCompanyType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInvCompanyType",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Inv Company Type",
        "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product)."
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "dei_EntityLegalForm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityLegalForm",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Legal Form",
        "documentation": "The details of the entity's legal form. Examples are partnership, limited liability company, trust, etc."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDepositoryReceiptRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingDepositoryReceiptRatio",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Depository Receipt Ratio",
        "documentation": "The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Description",
        "documentation": "Description of the kind of listing the entity has on the exchange, if necessary to further describe different instruments that are already distinguished by Entity, Exchange and Security."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingForeign": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingForeign",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Foreign",
        "documentation": "Yes or No value indicating whether this is a listing that is a foreign listing or depository receipt."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingParValuePerShare",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Par Value Per Share",
        "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingPrimary": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingPrimary",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Primary",
        "documentation": "Yes or No value indicating whether a listing of an instrument on an exchange is primary for the entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingSecurityTradingCurrency": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingSecurityTradingCurrency",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listing, Security Trading Currency",
        "documentation": "The three character ISO 4217 code for the currency in which the security is quoted. Example: 'USD'"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsExchangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingsExchangeAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings, Exchange [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingsLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingsTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Listings [Table]",
        "documentation": "Container for exchange listing information for an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityNumberOfEmployees": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityNumberOfEmployees",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Number of Employees",
        "documentation": "Number of persons employed by the Entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPhoneFaxNumbersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPhoneFaxNumbersLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Phone Fax Numbers [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "dei_EntityReportingCurrencyISOCode": {
     "xbrltype": "currencyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityReportingCurrencyISOCode",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Reporting Currency ISO Code",
        "documentation": "The three character ISO 4217 code for the currency used for reporting purposes. Example: 'USD'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r709"
     ]
    },
    "dei_EntityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Text Block]",
        "documentation": "Container to serve as parent of six Entity related Table concepts."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders\u2019 Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails",
      "http://www.inspiratechnologies.com/role/GeneralDetails",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r126",
      "r149",
      "r150",
      "r151",
      "r165",
      "r166",
      "r167",
      "r169",
      "r174",
      "r176",
      "r178",
      "r190",
      "r239",
      "r240",
      "r254",
      "r282",
      "r353",
      "r354",
      "r361",
      "r362",
      "r363",
      "r365",
      "r366",
      "r367",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r379",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r417",
      "r419",
      "r433",
      "r523",
      "r531",
      "r532",
      "r533",
      "r549",
      "r618"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r734",
      "r745",
      "r761",
      "r796"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r731",
      "r742",
      "r758",
      "r793"
     ]
    },
    "dei_ExchangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ExchangeDomain",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange [Domain]",
        "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "iinn_ExecutivesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "ExecutivesMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executives [Member]",
        "label": "Executives Member"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_Exercise6875Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "Exercise6875Member",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofInformationabouttheCompanysOutstandingWarrantsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "6.875 [Member]",
        "label": "Exercise6875 Member"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinaryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "ExerciseOfJune2024PrefundedWarrantsIntoOrdinaryShares",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of June 2024 pre-funded warrants into ordinary shares",
        "documentation": "The amount of exercise of june 2024 pre-funded warrants into ordinary shares.",
        "label": "Exercise Of June2024 Prefunded Warrants Into Ordinary Shares"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ExerciseOfJune2024PrefundedWarrantsIntoOrdinarySharesinShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "ExerciseOfJune2024PrefundedWarrantsIntoOrdinarySharesinShares",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of June 2024 pre-funded warrants into ordinary shares (in Shares)",
        "documentation": "Number of exercise of June 2024 pre-funded warrants into ordinary shares.",
        "label": "Exercise Of June2024 Prefunded Warrants Into Ordinary Sharesin Shares"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ExercisePrice0001Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "ExercisePrice0001Member",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofInformationabouttheCompanysOutstandingWarrantsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "0.001 [Member]",
        "label": "Exercise Price0001 Member"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ExercisePrice156Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "ExercisePrice156Member",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofInformationabouttheCompanysOutstandingWarrantsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1.56\t[Member]",
        "label": "Exercise Price156 Member"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ExercisePrice55Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "ExercisePrice55Member",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofInformationabouttheCompanysOutstandingWarrantsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "5.5 [Member]",
        "label": "Exercise Price55 Member"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ExercisePrice55TwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "ExercisePrice55TwoMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofInformationabouttheCompanysOutstandingWarrantsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "5.5 [Member]",
        "label": "Exercise Price55 Two Member"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ExercisePriceOnePointOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "ExercisePriceOnePointOneMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofInformationabouttheCompanysOutstandingWarrantsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1.1 [Member]",
        "label": "Exercise Price One Point One Member"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ExercisePriceOnePointSixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "ExercisePriceOnePointSixMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofInformationabouttheCompanysOutstandingWarrantsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1.6 [Member]",
        "label": "Exercise Price One Point Six Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ExhibitsOnly462d": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ExhibitsOnly462d",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d)"
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "dei_ExhibitsOnly462dFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ExhibitsOnly462dFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d), File Number"
       }
      }
     },
     "auth_ref": [
      "r837"
     ]
    },
    "iinn_ExpirationOfFinancialLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "ExpirationOfFinancialLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Expiration of financial liability",
        "documentation": "Amount of expiration of financial liability.",
        "label": "Expiration Of Financial Liability"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of the warrant (in Dollars)",
        "label": "Fair Value Adjustment of Warrants",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r5"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finacial Liabilities at Fair Value [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r382",
      "r383",
      "r384",
      "r675"
     ]
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByLiabilityClassAxis",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails",
      "http://www.inspiratechnologies.com/role/ScheduleofFinancialLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability Class [Axis]",
        "documentation": "Information by class of liability."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r394"
     ]
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FINACIAL LIABILITIES AT FAIR VALUE",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r389",
      "r391",
      "r392",
      "r393",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r507",
      "r672",
      "r676"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails",
      "http://www.inspiratechnologies.com/role/ScheduleofFinancialLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value by Liability Class [Domain]",
        "documentation": "Represents classes of liabilities measured and disclosed at fair value."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r394"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueOptionChangesInFairValueGainLoss1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOptionChangesInFairValueGainLoss1",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Evaluation of financial liability at fair value",
        "label": "Fair Value, Option, Changes in Fair Value, Gain (Loss)",
        "documentation": "For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "iinn_FinacialLiabilitiesatFairValueDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "FinacialLiabilitiesatFairValueDetailsTable",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finacial Liabilities at Fair Value (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_FinacialLiabilitiesatFairValueScheduleofFinancialLiabilityDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "FinacialLiabilitiesatFairValueScheduleofFinancialLiabilityDetailsTable",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofFinancialLiabilityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finacial Liabilities at Fair Value - Schedule of Financial Liability (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_FinanceIncomeAndExpensesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "FinanceIncomeAndExpensesPolicyTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Income and Expenses",
        "documentation": "Disclosure of accounting policy for finance income and expenses.",
        "label": "Finance Income And Expenses Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofFinancialIncomeandExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Finance expense in respect of lease liability",
        "label": "Finance Lease, Interest Expense",
        "documentation": "Amount of interest expense on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r422",
      "r425",
      "r682"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r274",
      "r279",
      "r378",
      "r400",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r524",
      "r666",
      "r672",
      "r673",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r684",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r879",
      "r880",
      "r881",
      "r882",
      "r934",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941"
     ]
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails",
      "http://www.inspiratechnologies.com/role/GeneralDetails",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liability",
        "verboseLabel": "Financial liability fair value (in Dollars)",
        "label": "Financial Liabilities Fair Value Disclosure",
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities."
       }
      }
     },
     "auth_ref": [
      "r935",
      "r936",
      "r940"
     ]
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialLiabilitiesFairValueDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Finacial Liabilities at Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_FinancialLiabilityPlacementAgentFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "FinancialLiabilityPlacementAgentFee",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liability- placement agent fee (Note 10-A)",
        "documentation": "Amount of financial liability placement agent fee.",
        "label": "Financial Liability Placement Agent Fee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofFinancialIncomeandExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency transaction income",
        "label": "Gain (Loss), Foreign Currency Transaction, before Tax",
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r404",
      "r405",
      "r406",
      "r615"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unrealized foreign exchange (gain) loss",
        "label": "Unrealized Gain (Loss), Foreign Currency Transaction, before Tax",
        "documentation": "Amount, before tax, of unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r593",
      "r703",
      "r943",
      "r944",
      "r997"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Currency",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r402"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r738",
      "r749",
      "r765",
      "r800"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r738",
      "r749",
      "r765",
      "r800"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r738",
      "r749",
      "r765",
      "r800"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r738",
      "r749",
      "r765",
      "r800"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r738",
      "r749",
      "r765",
      "r800"
     ]
    },
    "dei_FormerAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "FormerAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Address [Member]",
        "documentation": "Former address for entity"
       }
      }
     },
     "auth_ref": [
      "r720",
      "r752"
     ]
    },
    "dei_FormerFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "FormerFiscalYearEndDate",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Fiscal Year End Date",
        "documentation": "Former end date of previous fiscal years"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "iinn_FundraisingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "FundraisingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fundraising expenses",
        "documentation": "The amount of fundraising expenses.",
        "label": "Fundraising Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable",
      "http://www.inspiratechnologies.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and office equipment [Member]",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      },
      "http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement",
      "http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "General and administrative expenses",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r597"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and Administrative Expense [Member]",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "iinn_GeneralAndAdministrativeExpensesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "GeneralAndAdministrativeExpensesTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/GeneralandAdministrativeExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GENERAL AND ADMINISTRATIVE EXPENSES",
        "documentation": "The entire disclosure for general and administrative expenses.",
        "label": "General And Administrative Expenses Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_GeneralDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "GeneralDetailsTable",
     "presentation": [
      "http://www.inspiratechnologies.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralInsuranceExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralInsuranceExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insurance expenses",
        "label": "General Insurance Expense",
        "documentation": "The expense in the period incurred with respect to protection provided by insurance entities against risks other than risks associated with production (which are allocated to cost of sales)."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "iinn_GeneralandAdministrativeExpensesScheduleofGeneralandAdministrativeExpensesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "GeneralandAdministrativeExpensesScheduleofGeneralandAdministrativeExpensesDetailsTable",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expenses - Schedule of General and Administrative Expenses (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GovernmentAssistancePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GovernmentAssistancePolicyTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government Grants",
        "label": "Government Assistance [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for government assistance."
       }
      }
     },
     "auth_ref": [
      "r415",
      "r416"
     ]
    },
    "iinn_IIAParticipation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "IIAParticipation",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofResearchandDevelopmentExpensesTable": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofResearchandDevelopmentExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "IIA participation",
        "documentation": "The expenses of IIA participation.",
        "label": "IIAParticipation"
       }
      }
     },
     "auth_ref": []
    },
    "country_IL": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "IL",
     "presentation": [
      "http://www.inspiratechnologies.com/role/DepositsDetails",
      "http://www.inspiratechnologies.com/role/TaxesonIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Israel [Member]",
        "label": "ISRAEL"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IPOMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IPO [Member]",
        "label": "IPO [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r718",
      "r721",
      "r741"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement",
      "http://www.inspiratechnologies.com/role/ScheduleofTheoreticalTaxTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Loss before tax",
        "terseLabel": "Loss before taxation",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r100",
      "r103",
      "r509",
      "r521",
      "r659",
      "r662",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r256",
      "r257",
      "r386",
      "r390",
      "r394",
      "r528",
      "r530",
      "r602",
      "r652",
      "r674",
      "r965"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes on Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/TaxesonIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TAXES ON INCOME",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r333",
      "r337",
      "r341",
      "r342",
      "r343",
      "r344",
      "r350",
      "r356",
      "r358",
      "r359",
      "r360",
      "r545",
      "r671"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement",
      "http://www.inspiratechnologies.com/role/ScheduleofTheoreticalTaxTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Taxes on income",
        "terseLabel": "Income tax benefit",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r115",
      "r177",
      "r178",
      "r189",
      "r194",
      "r203",
      "r336",
      "r337",
      "r357",
      "r526",
      "r671"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r334",
      "r335",
      "r344",
      "r345",
      "r349",
      "r352",
      "r540"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationNondeductibleExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofTheoreticalTaxTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Non-allowable expenses",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r340",
      "r930"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(Decrease) increase in trade accounts payables",
        "label": "Increase (Decrease) in Accounts Payable, Trade",
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "(Increase) decrease in inventory",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInLeasingReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInLeasingReceivables",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Decrease (increase) in right of use assets, net",
        "label": "Increase (Decrease) in Leasing Receivables",
        "documentation": "The increase (decrease) during the reporting period in the amount due from lessees arising from lease agreements."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepayments of lease liabilities",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r844",
      "r862"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(Decrease) increase in other accounts payable",
        "label": "Increase (Decrease) in Other Accounts Payable",
        "documentation": "Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherCurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Decrease (increase) in other current assets",
        "label": "Increase (Decrease) in Other Current Assets",
        "documentation": "Amount of increase (decrease) in current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r862"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r738",
      "r749",
      "r765",
      "r791",
      "r800",
      "r804",
      "r812"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r722",
      "r816"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r722",
      "r816"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r722",
      "r816"
     ]
    },
    "us-gaap_InterestBearingDepositsInBanks": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestBearingDepositsInBanks",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofOtherCurrentAssetsTable": {
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofOtherCurrentAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Institutions",
        "label": "Interest-Bearing Deposits in Banks and Other Financial Institutions",
        "documentation": "For banks and other depository institutions (including Federal Reserve Banks, if applicable): Interest-bearing deposits in other financial institutions for relatively short periods of time including, for example, certificates of deposits, which are presented separately from cash on the balance sheet."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r95"
     ]
    },
    "us-gaap_InterestIncomeDepositsWithFinancialInstitutions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestIncomeDepositsWithFinancialInstitutions",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest income from deposits",
        "label": "Interest Income, Deposits with Financial Institutions",
        "documentation": "Interest income derived from funds deposited with both domestic and foreign financial institutions including funds in money market and other accounts."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r116",
      "r117"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest paid",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r158",
      "r159"
     ]
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/Inventory"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INVENTORY",
        "label": "Inventory Disclosure [Text Block]",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r249"
     ]
    },
    "us-gaap_InventoryFinishedGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryFinishedGoods",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofInventoryTable": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofInventoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finished good",
        "label": "Inventory, Finished Goods, Gross",
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r854"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.inspiratechnologies.com/role/ScheduleofInventoryTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet",
      "http://www.inspiratechnologies.com/role/ScheduleofInventoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Inventory",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r655",
      "r683"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory",
        "label": "Inventory, Policy [Policy Text Block]",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r130",
      "r140",
      "r249",
      "r250",
      "r251",
      "r475",
      "r657"
     ]
    },
    "us-gaap_InventoryRawMaterials": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryRawMaterials",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofInventoryTable": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofInventoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Raw materials",
        "label": "Inventory, Raw Materials, Gross",
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "us-gaap_InventoryWorkInProcess": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryWorkInProcess",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofInventoryTable": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofInventoryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Work in progress",
        "label": "Inventory, Work in Process, Gross",
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r855"
     ]
    },
    "dei_InvestmentCompanyActFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyActFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act File Number"
       }
      }
     },
     "auth_ref": [
      "r754",
      "r755",
      "r756",
      "r757"
     ]
    },
    "dei_InvestmentCompanyActRegistration": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyActRegistration",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act Registration"
       }
      }
     },
     "auth_ref": [
      "r770"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyRegistrationAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment"
       }
      }
     },
     "auth_ref": [
      "r770"
     ]
    },
    "dei_InvestmentCompanyRegistrationAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "InvestmentCompanyRegistrationAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment Number"
       }
      }
     },
     "auth_ref": [
      "r770"
     ]
    },
    "iinn_IssuanceOfOrdinarySharesAdvisorFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "IssuanceOfOrdinarySharesAdvisorFees",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of ordinary shares - advisor fees",
        "documentation": "Amount of issuance of ordinary shares advisor fees.",
        "label": "Issuance Of Ordinary Shares Advisor Fees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based compensation \u2013 placement agent warrants",
        "label": "Issuance of Stock and Warrants for Services or Claims",
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "iinn_JunePlacementAgentWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "JunePlacementAgentWarrantsMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/GeneralDetails",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "June Placement Agent Warrants [Member]",
        "verboseLabel": "Warrants [Member]",
        "label": "June Placement Agent Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_JunePreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "JunePreFundedWarrantsMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/GeneralDetails",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "June Pre-Funded Warrants [Member]",
        "label": "June Pre Funded Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LaborAndRelatedExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LaborAndRelatedExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofResearchandDevelopmentExpensesTable": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofResearchandDevelopmentExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Salary and related expenses",
        "label": "Labor and Related Expense",
        "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit."
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "us-gaap_LeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Operating Right-of-Use Assets and Operating Lease Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_LeaseLiabilitiesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "LeaseLiabilitiesDetailsTable",
     "presentation": [
      "http://www.inspiratechnologies.com/role/LeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Liabilities (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable",
      "http://www.inspiratechnologies.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold Improvements [Member]",
        "verboseLabel": "Leasehold improvements [Member]",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r429"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityIdentifier": {
     "xbrltype": "legalEntityIdentifierItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityIdentifier",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity Identifier",
        "documentation": "A globally unique ISO 17442 value to identify entities, commonly abbreviated as LEI."
       }
      }
     },
     "auth_ref": [
      "r706"
     ]
    },
    "us-gaap_LegalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LegalFees",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Director fees",
        "label": "Legal Fees",
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings."
       }
      }
     },
     "auth_ref": [
      "r845"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.inspiratechnologies.com/role/LeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Liabilities [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r424",
      "r430"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/LeaseLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Right-of-Use Assets Over the Remaining Lease Periods",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofRightofUseAssetsOvertheRemainingLeasePeriodsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofRightofUseAssetsOvertheRemainingLeasePeriodsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total undiscounted lease payment",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofRightofUseAssetsOvertheRemainingLeasePeriodsTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofRightofUseAssetsOvertheRemainingLeasePeriodsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofRightofUseAssetsOvertheRemainingLeasePeriodsTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofRightofUseAssetsOvertheRemainingLeasePeriodsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofRightofUseAssetsOvertheRemainingLeasePeriodsTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofRightofUseAssetsOvertheRemainingLeasePeriodsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofRightofUseAssetsOvertheRemainingLeasePeriodsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/LeaseLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LEASE LIABILITIES",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and Shareholders\u2019 Equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r96",
      "r516",
      "r683",
      "r866",
      "r883",
      "r942"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES AND SHAREHOLDERS\u2019 EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r129",
      "r162",
      "r238",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r369",
      "r370",
      "r371",
      "r401",
      "r683",
      "r893",
      "r950",
      "r951"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non- current liabilities",
        "label": "Liabilities, Noncurrent",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r49",
      "r50",
      "r51",
      "r54",
      "r162",
      "r238",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r369",
      "r370",
      "r371",
      "r401",
      "r893",
      "r950",
      "r951"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Current Liabilities:",
        "label": "Liabilities, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/LeaseLiabilitiesDetails",
      "http://www.inspiratechnologies.com/role/ScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable",
      "http://www.inspiratechnologies.com/role/ScheduleofMeasuretheFairValueoftheOptionatGrantDateTable",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum [Member]",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r260",
      "r261",
      "r262",
      "r263",
      "r286",
      "r329",
      "r384",
      "r474",
      "r527",
      "r529",
      "r536",
      "r564",
      "r565",
      "r624",
      "r626",
      "r628",
      "r629",
      "r631",
      "r649",
      "r650",
      "r665",
      "r667",
      "r669",
      "r675",
      "r676",
      "r680",
      "r681",
      "r693",
      "r895",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected Dividend Yield [Member]",
        "verboseLabel": "Measurement Input, Expected Dividend Rate [Member]",
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r937",
      "r938",
      "r939"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected Term of Warrants [Member]",
        "label": "Measurement Input, Expected Term [Member]",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r937",
      "r938",
      "r939"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected Volatility [Member]",
        "verboseLabel": "Measurement Input, Price Volatility [Member]",
        "label": "Measurement Input, Price Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r675",
      "r937",
      "r938",
      "r939"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free Interest Rate [Member]",
        "verboseLabel": "Measurement Input, Risk Free Interest Rate [Member]",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r937",
      "r938",
      "r939"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r382",
      "r383",
      "r384",
      "r675"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r382",
      "r383",
      "r384",
      "r675"
     ]
    },
    "iinn_MedicalBoardMembersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "MedicalBoardMembersMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medical Board Members [Member]",
        "label": "Medical Board Members Member"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/LeaseLiabilitiesDetails",
      "http://www.inspiratechnologies.com/role/ScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable",
      "http://www.inspiratechnologies.com/role/ScheduleofMeasuretheFairValueoftheOptionatGrantDateTable",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum [Member]",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r260",
      "r261",
      "r262",
      "r263",
      "r286",
      "r329",
      "r384",
      "r474",
      "r527",
      "r529",
      "r536",
      "r564",
      "r565",
      "r624",
      "r626",
      "r628",
      "r629",
      "r631",
      "r649",
      "r650",
      "r665",
      "r667",
      "r669",
      "r675",
      "r676",
      "r680",
      "r693",
      "r895",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "iinn_MonthlyDeductionFromTerminationFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "MonthlyDeductionFromTerminationFee",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/LeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Monthly deduction from termination fee",
        "documentation": "Represent the value of monthly deduction from termination fee.",
        "label": "Monthly Deduction From Termination Fee"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "dei_NameChangeEventDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NameChangeEventDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event Date [Axis]",
        "documentation": "For a sequence of name change event related facts, use this typed dimension to distinguish them. The axis members are restricted to be a valid for xml schema 'date' or 'datetime' data type."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NameChangeEventLineItems",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Line Items]",
        "documentation": "Line items represent concepts included in a table. Name change event line item concepts are used for information qualified by domain members of axes in the Name Change Event table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NameChangeEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NameChangeEventTable",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Change Event [Table]",
        "documentation": "For a set of related facts in a sequence of name change events, use this table when the events occurred within a single reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "us-gaap_NatureOfCommonOwnershipOrManagementControlRelationships": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NatureOfCommonOwnershipOrManagementControlRelationships",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofShareholdersandOtherRelatedPartiesBenefitsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nature of transaction",
        "label": "Nature of Common Ownership or Management Control Relationships",
        "documentation": "This element represents a description of the nature of common ownership or management control relationships with other entities, regardless of there being transactions between the entities, when the existence of that control could result in operating results or financial position of the reporting entity significantly different from that which would have been obtained if the entities' were autonomous."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided (used in) investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOW FROM INVESTING ACTIVITIES:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r74",
      "r75"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOW FROM OPERATING ACTIVITIES:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow",
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement",
      "http://www.inspiratechnologies.com/role/ScheduleofLossPerShareCalculatedUsingtheWeightedAverageNumberofOrdinarySharesandPreFundedWarrantsTable",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total comprehensive and net loss",
        "verboseLabel": "Comprehensive and net loss",
        "netLabel": "Net loss",
        "negatedLabel": "Loss for the period (in Dollars)",
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r75",
      "r101",
      "r127",
      "r146",
      "r147",
      "r151",
      "r162",
      "r168",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r177",
      "r178",
      "r183",
      "r238",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r364",
      "r367",
      "r381",
      "r401",
      "r522",
      "r594",
      "r616",
      "r617",
      "r703",
      "r893"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Loss Per Share Calculated Using the Weighted Average Number of Ordinary Shares and Pre-Funded Warrants [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NewEffectiveDateForPreviousFiling": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NewEffectiveDateForPreviousFiling",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Effective Date for Previous Filing"
       }
      }
     },
     "auth_ref": [
      "r754",
      "r755",
      "r756",
      "r757"
     ]
    },
    "dei_NoSubstantiveChanges462c": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoSubstantiveChanges462c",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c)"
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "dei_NoSubstantiveChanges462cFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoSubstantiveChanges462cFileNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c), File Number"
       }
      }
     },
     "auth_ref": [
      "r836"
     ]
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "iinn_NonCashTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "NonCashTransactions",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total non cash transactions",
        "documentation": "The total amount of non cash transactions.",
        "label": "Non Cash Transactions"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r738",
      "r749",
      "r765",
      "r791",
      "r800"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r774"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "",
        "label": "Noncash Investing and Financing Items [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_NumberOfSharesPerUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "NumberOfSharesPerUnits",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares per units",
        "documentation": "Number of shares per units.",
        "label": "Number Of Shares Per Units"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_NumberofAdditionalOrdinaryShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "NumberofAdditionalOrdinaryShares",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of additional shares",
        "documentation": "Number of additional ordinary shares.",
        "label": "Numberof Additional Ordinary Shares"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_OfferingFeesAndOtherRelatedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "OfferingFeesAndOtherRelatedExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offering fees and other related expenses",
        "documentation": "Amount of offering fees and other related expenses.",
        "label": "Offering Fees And Other Related Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "srt_OfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "OfficerMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofShareholdersandOtherRelatedPartiesBenefitsTable",
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Officer [Member]",
        "label": "Officer [Member]"
       }
      }
     },
     "auth_ref": [
      "r207",
      "r994"
     ]
    },
    "iinn_OfficersAndDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "OfficersAndDirectorsMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofShareholdersandOtherRelatedPartiesBenefitsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Officers and Directors [Member]",
        "label": "Officers And Directors Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OfficersCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OfficersCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofSalesandMarketingExpensesTable": {
       "parentTag": "us-gaap_SellingAndMarketingExpense",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable",
      "http://www.inspiratechnologies.com/role/ScheduleofSalesandMarketingExpensesTable",
      "http://www.inspiratechnologies.com/role/ScheduleofShareholdersandOtherRelatedPartiesBenefitsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Salary and related expenses",
        "label": "Salary and Wage, Officer, Excluding Cost of Good and Service Sold",
        "documentation": "Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold."
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Operating loss",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r659",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/LeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease expenses",
        "label": "Operating Lease, Expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r946"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofOperatingRightofUseAssetsandOperatingLeaseLiabilitiesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofOperatingRightofUseAssetsandOperatingLeaseLiabilitiesTable",
      "http://www.inspiratechnologies.com/role/ScheduleofRightofUseAssetsOvertheRemainingLeasePeriodsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating lease liabilities",
        "terseLabel": "Present value of lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofOperatingRightofUseAssetsandOperatingLeaseLiabilitiesTable": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet",
      "http://www.inspiratechnologies.com/role/ScheduleofOperatingRightofUseAssetsandOperatingLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "verboseLabel": "Operating lease liabilities, current",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.inspiratechnologies.com/role/ScheduleofOperatingRightofUseAssetsandOperatingLeaseLiabilitiesTable": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet",
      "http://www.inspiratechnologies.com/role/ScheduleofOperatingRightofUseAssetsandOperatingLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "verboseLabel": "Operating lease liabilities long-term",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right of use assets, net",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofOperatingRightofUseAssetsandOperatingLeaseLiabilitiesTable",
      "http://www.inspiratechnologies.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average discount rate - operating leases",
        "verboseLabel": "Lease liability, weighted-average discount rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r427",
      "r682"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofOperatingRightofUseAssetsandOperatingLeaseLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average of Remaining Lease Term",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r426",
      "r682"
     ]
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasesFutureMinimumPaymentsDueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Right-of-Use Assets Over the Remaining Lease Periods [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/TaxesonIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carryforward tax losses",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "iinn_OrdinarySharesNoParValueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "OrdinarySharesNoParValueMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary Shares, no par value",
        "label": "Ordinary Shares No Par Value Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "General [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/General"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GENERAL",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r89",
      "r537",
      "r538"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofOtherAccountsPayableTable": {
       "parentTag": "us-gaap_AccountsPayableOtherCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofOtherAccountsPayableTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Accrued Liabilities",
        "documentation": "Amount of expenses incurred but not yet paid classified as other."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "dei_OtherAddressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherAddressMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Address [Member]",
        "documentation": "Other address for entity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.inspiratechnologies.com/role/ScheduleofOtherCurrentAssetsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet",
      "http://www.inspiratechnologies.com/role/ScheduleofOtherCurrentAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Other current assets",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r683"
     ]
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://www.inspiratechnologies.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCurrentAssetsTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/OtherCurrentAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OTHER CURRENT ASSETS",
        "label": "Other Current Assets [Text Block]",
        "documentation": "The entire disclosure for other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherGeneralExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherGeneralExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Others",
        "label": "Other General Expense",
        "documentation": "Amount of general expenses not normally included in Other Operating Costs and Expenses."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r662"
     ]
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherIncomeAndExpensesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial (Income) and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLaborRelatedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLaborRelatedExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofResearchandDevelopmentExpensesTable": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofResearchandDevelopmentExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Materials and related expenses",
        "label": "Other Labor-related Expenses",
        "documentation": "Amount of labor-related expenses classified as other."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNoncashIncomeExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofFinancialIncomeandExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Others",
        "label": "Other Noncash Income (Expense)",
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeAndExpenseTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinancialIncomeandExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FINANCIAL (INCOME) AND EXPENSES",
        "label": "Other Nonoperating Income and Expense [Text Block]",
        "documentation": "The entire disclosure for the components of non-operating income or non-operating expense, including, but not limited to, amounts earned from dividends, interest on securities, gain (loss) on securities sold, equity earnings of unconsolidated affiliates, gain (loss) on sales of business, interest expense and other miscellaneous income or expense items."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r154"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement",
      "http://www.inspiratechnologies.com/role/ScheduleofFinancialIncomeandExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total expenses (Income)",
        "negatedLabel": "Finance expenses (income), net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherOperatingIncomeExpenseNet",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other expenses (income)",
        "label": "Other Operating Income (Expense), Net",
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofOtherCurrentAssetsTable": {
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofOtherCurrentAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Others",
        "label": "Other Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r857",
      "r884"
     ]
    },
    "iinn_OtherReceivableInConnectionToPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "OtherReceivableInConnectionToPrivatePlacement",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other receivable in connection to December private placement",
        "documentation": "Amount of other receivable in connection to private placement.",
        "label": "Other Receivable In Connection To Private Placement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherReceivables",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total funds received",
        "label": "Other Receivables",
        "documentation": "Amount due from parties in nontrade transactions, classified as other."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r580",
      "r663",
      "r963"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofResearchandDevelopmentExpensesTable": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofResearchandDevelopmentExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Research and Development Expense",
        "documentation": "Amount of other research and development expense."
       }
      }
     },
     "auth_ref": [
      "r927"
     ]
    },
    "us-gaap_OtherSellingAndMarketingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherSellingAndMarketingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofSalesandMarketingExpensesTable": {
       "parentTag": "us-gaap_SellingAndMarketingExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofSalesandMarketingExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Selling and Marketing Expense",
        "documentation": "Amount of selling and marketing expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r736",
      "r747",
      "r763",
      "r798"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r739",
      "r750",
      "r766",
      "r801"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r739",
      "r750",
      "r766",
      "r801"
     ]
    },
    "dei_ParentEntityLegalName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ParentEntityLegalName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Parent Entity Legal Name",
        "documentation": "If the entity which the financial information concerns is a subsidiary of another company, then provide to full legal name of the parent entity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PartnersCapitalAccountPublicSaleOfUnitsNetOfOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PartnersCapitalAccountPublicSaleOfUnitsNetOfOfferingCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional offering costs",
        "label": "Partners' Capital Account, Public Sale of Units Net of Offering Costs",
        "documentation": "Amount, after offering cost, from issuance of new unit of limited partnership interest in public offering."
       }
      }
     },
     "auth_ref": [
      "r896",
      "r897"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r772"
     ]
    },
    "us-gaap_PaymentsForProceedsFromInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForProceedsFromInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in deposits, net",
        "label": "Payments for (Proceeds from) Investments",
        "documentation": "The net cash paid (received) associated with the acquisition or disposal of all investments, including securities and other assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRent",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/LeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rent termination penalty",
        "label": "Payments for Rent",
        "documentation": "Cash payments to lessor's for use of assets under operating leases."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of property, plant, and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r782"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r782"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r774"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "iinn_PercentageForCarsLeaseAgreementCancellationPenalty": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "PercentageForCarsLeaseAgreementCancellationPenalty",
     "presentation": [
      "http://www.inspiratechnologies.com/role/LeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage for car lease agreement cancellation penalty",
        "documentation": "Represent the description of percentage for car lease agreement cancellation penalty.",
        "label": "Percentage For Cars Lease Agreement Cancellation Penalty"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_PercentageOfApprovedBudget": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "PercentageOfApprovedBudget",
     "presentation": [
      "http://www.inspiratechnologies.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of approved budget",
        "documentation": "Percentage of approved budget.",
        "label": "Percentage Of Approved Budget"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_PercentageOfCapitalGainTax": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "PercentageOfCapitalGainTax",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of capital gain tax",
        "documentation": "Percentage of capital gain tax.",
        "label": "Percentage Of Capital Gain Tax"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_PercentageOfFutureLeasePaymentsDiscounted": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "PercentageOfFutureLeasePaymentsDiscounted",
     "presentation": [
      "http://www.inspiratechnologies.com/role/LeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of future lease payments discounted",
        "documentation": "Percentage of future lease payments discounted.",
        "label": "Percentage Of Future Lease Payments Discounted"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_PercentageOfOrdinaryShares": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "PercentageOfOrdinaryShares",
     "presentation": [
      "http://www.inspiratechnologies.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of ordinary shares",
        "documentation": "Percentage of ordinary shares.",
        "label": "Percentage Of Ordinary Shares"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_PercentageOfPayFees": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "PercentageOfPayFees",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of pay fees",
        "documentation": "Percentage of pay fees.",
        "label": "Percentage Of Pay Fees"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PhoneFaxNumberDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PhoneFaxNumberDescription",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Phone Fax Number Description",
        "documentation": "Description of Phone or Fax Number"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_PlacementAgentWarrantsFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "PlacementAgentWarrantsFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Placement agent warrants fair value",
        "documentation": "Represent the amount of fair value for the placement agent warrant.",
        "label": "Placement Agent Warrants Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_PlacementAgentWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "PlacementAgentWarrantsMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Placement Agent Warrants [Member]",
        "label": "Placement Agent Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails",
      "http://www.inspiratechnologies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails",
      "http://www.inspiratechnologies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r774"
     ]
    },
    "dei_PostEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PostEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "dei_PostEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PostEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "dei_PreEffectiveAmendment": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreEffectiveAmendment",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment"
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "dei_PreEffectiveAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreEffectiveAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment Number",
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective."
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "iinn_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/GeneralDetails",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-Funded Warrants [Member]",
        "label": "Pre Funded Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Current Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofOtherCurrentAssetsTable": {
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofOtherCurrentAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses",
        "label": "Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r252",
      "r253",
      "r656"
     ]
    },
    "iinn_PrivateWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "PrivateWarrantsMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails",
      "http://www.inspiratechnologies.com/role/ScheduleofFinancialLiabilityTable",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private warrants [Member]",
        "verboseLabel": "Private Warrants [Member]",
        "label": "Private Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromBankDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromBankDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receiving bank",
        "label": "Proceeds from Bank Debt",
        "documentation": "The cash inflow from bank borrowing during the year."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromDebtNetOfIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds (in Dollars)",
        "label": "Proceeds from Debt, Net of Issuance Costs",
        "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination."
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds",
        "label": "Proceeds from Issuance Initial Public Offering",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of ordinary shares (issuances pursuant to an at-the-market facility)",
        "verboseLabel": "Gross proceeds (in Dollars)",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from private placement",
        "label": "Proceeds from Issuance of Private Placement",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of ordinary shares, pre-funded warrants and ordinary warrants, net",
        "label": "Proceeds from Issuance of Warrants",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromLeasePayments",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/LeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease payment",
        "label": "Proceeds from Lease Payment, Operating Activity",
        "documentation": "Amount of cash inflow from lease payment, classified as operating activity."
       }
      }
     },
     "auth_ref": [
      "r431",
      "r432"
     ]
    },
    "iinn_ProceedsFromReceivedFund": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "ProceedsFromReceivedFund",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Received fund",
        "documentation": "Amount of proceeds from received fund.",
        "label": "Proceeds From Received Fund"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of options",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r12"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of pre-funded warrants",
        "label": "Proceeds from Warrant Exercises",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r861"
     ]
    },
    "us-gaap_ProductWarrantyLiquidationProceedsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductWarrantyLiquidationProceedsPercentage",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of agreement warrants",
        "label": "Product Warranty, Liquidation Proceeds, Percentage",
        "documentation": "Percentage of proceeds from liquidation of asset held as collateral or by third party expected to cover maximum potential future payment for product warranty. Includes, but is not limited to, separately price extended warranty, product maintenance contract, and warranty obligation incurred in connection with agreed upon specification."
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "us-gaap_ProfessionalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfessionalFees",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.inspiratechnologies.com/role/ScheduleofSalesandMarketingExpensesTable": {
       "parentTag": "us-gaap_SellingAndMarketingExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable",
      "http://www.inspiratechnologies.com/role/ScheduleofSalesandMarketingExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Professional fees",
        "label": "Professional Fees",
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer."
       }
      }
     },
     "auth_ref": [
      "r662",
      "r703",
      "r995",
      "r996"
     ]
    },
    "iinn_ProjectBudgetAggregateAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "ProjectBudgetAggregateAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Project budget aggregate amount",
        "documentation": "The amount of project budget aggregate amount.",
        "label": "Project Budget Aggregate Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAdditions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAdditions",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions",
        "label": "Property, Plant and Equipment, Additions",
        "documentation": "Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable",
      "http://www.inspiratechnologies.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r429"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/PropertyandEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PROPERTY AND EQUIPMENT, NET",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r110",
      "r113",
      "r114"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cost, Beginning Balance",
        "periodEndLabel": "Cost, Ending Balance",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r132",
      "r520"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable",
      "http://www.inspiratechnologies.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Depreciation on Straight-Line Method, Over the Estimated Useful Life of the Assets [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet",
      "http://www.inspiratechnologies.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Net book value",
        "terseLabel": "Property, plant and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r429",
      "r510",
      "r520",
      "r683"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant, and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r110",
      "r113",
      "r518"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/PropertyandEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment, Net",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r429"
     ]
    },
    "us-gaap_ProvisionForOtherLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProvisionForOtherLosses",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital loss",
        "label": "Provision for Other Losses",
        "documentation": "Amount of expense related to other loss."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r68",
      "r99"
     ]
    },
    "us-gaap_PublicUtilitiesGeneralDisclosuresLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PublicUtilitiesGeneralDisclosuresLineItems",
     "presentation": [
      "http://www.inspiratechnologies.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "iinn_PurchasePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "PurchasePricePerShare",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price per share (in Dollars per share)",
        "documentation": "Purchase price per share.",
        "label": "Purchase Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r772"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r772"
     ]
    },
    "iinn_RDEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "RDEquipmentMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "R&amp;D equipment [Member]",
        "label": "RDEquipment Member"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.inspiratechnologies.com/role/LeaseLiabilitiesDetails",
      "http://www.inspiratechnologies.com/role/ScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable",
      "http://www.inspiratechnologies.com/role/ScheduleofMeasuretheFairValueoftheOptionatGrantDateTable",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDetails",
      "http://www.inspiratechnologies.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r260",
      "r261",
      "r262",
      "r263",
      "r283",
      "r286",
      "r316",
      "r317",
      "r318",
      "r329",
      "r384",
      "r449",
      "r458",
      "r474",
      "r527",
      "r529",
      "r536",
      "r564",
      "r565",
      "r624",
      "r626",
      "r628",
      "r629",
      "r631",
      "r649",
      "r650",
      "r665",
      "r667",
      "r669",
      "r675",
      "r676",
      "r680",
      "r681",
      "r693",
      "r697",
      "r890",
      "r895",
      "r938",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/LeaseLiabilitiesDetails",
      "http://www.inspiratechnologies.com/role/ScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable",
      "http://www.inspiratechnologies.com/role/ScheduleofMeasuretheFairValueoftheOptionatGrantDateTable",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDetails",
      "http://www.inspiratechnologies.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r260",
      "r261",
      "r262",
      "r263",
      "r283",
      "r286",
      "r316",
      "r317",
      "r318",
      "r329",
      "r384",
      "r449",
      "r458",
      "r474",
      "r527",
      "r529",
      "r536",
      "r564",
      "r565",
      "r624",
      "r626",
      "r628",
      "r629",
      "r631",
      "r649",
      "r650",
      "r665",
      "r667",
      "r669",
      "r675",
      "r676",
      "r680",
      "r681",
      "r693",
      "r697",
      "r890",
      "r895",
      "r938",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r731",
      "r742",
      "r758",
      "r793"
     ]
    },
    "iinn_RegisteredDirectOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "RegisteredDirectOfferingMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Registered Direct Offering [Member]",
        "label": "Registered Direct Offering Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_RegistrationStatementAmendmentNumber": {
     "xbrltype": "sequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "RegistrationStatementAmendmentNumber",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration Statement Amendment Number",
        "documentation": "Amendment number to registration statement under the Investment Company Act of 1940."
       }
      }
     },
     "auth_ref": [
      "r707"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDetails",
      "http://www.inspiratechnologies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r285",
      "r437",
      "r438",
      "r512",
      "r517",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r590",
      "r592",
      "r623"
     ]
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofShareholdersandOtherRelatedPartiesBenefitsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance with related parties",
        "label": "Related Party Transaction, Amounts of Transaction",
        "documentation": "Amount of transactions with related party during the financial reporting period."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r437"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofShareholdersandOtherRelatedPartiesBenefitsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r598",
      "r599",
      "r602"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Parties [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDetails",
      "http://www.inspiratechnologies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r285",
      "r437",
      "r438",
      "r512",
      "r517",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r590",
      "r592",
      "r623",
      "r949"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/RelatedParties"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RELATED PARTIES",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r434",
      "r435",
      "r436",
      "r438",
      "r439",
      "r546",
      "r547",
      "r548",
      "r600",
      "r601",
      "r602",
      "r621",
      "r622"
     ]
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ResearchandDevelopmentExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Research and Development Expenses",
        "label": "Research and Development Arrangement, Contract to Perform for Others [Table Text Block]",
        "documentation": "Tabular disclosure of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements. Include also the amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others. Aggregation of similar arrangements by type may be appropriate. Include also the amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others. Aggregation of similar arrangements by type may be appropriate."
       }
      }
     },
     "auth_ref": [
      "r928",
      "r929"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.inspiratechnologies.com/role/ScheduleofResearchandDevelopmentExpensesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement",
      "http://www.inspiratechnologies.com/role/ScheduleofResearchandDevelopmentExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Research and development expenses",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r652",
      "r662",
      "r958"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Research and Development Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "R&amp;D equipment [Member]",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Costs",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ResearchandDevelopmentExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RESEARCH AND DEVELOPMENT EXPENSES",
        "label": "Research, Development, and Computer Software Disclosure [Text Block]",
        "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period."
       }
      }
     },
     "auth_ref": [
      "r332",
      "r651"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r732",
      "r743",
      "r759",
      "r794"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r733",
      "r744",
      "r760",
      "r795"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r740",
      "r751",
      "r767",
      "r802"
     ]
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r853",
      "r864",
      "r959",
      "r961"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total cash, cash equivalents and restricted cash shown in the statement of cash flows",
        "label": "Restricted Cash and Cash Equivalents, Current",
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r131",
      "r160"
     ]
    },
    "us-gaap_RestrictedCashCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofOtherCurrentAssetsTable": {
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofOtherCurrentAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Cash",
        "label": "Restricted Cash, Current",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r853",
      "r864"
     ]
    },
    "iinn_RestrictedStockUnits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "RestrictedStockUnits",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock units",
        "documentation": "Amount of restricted stock units.",
        "label": "Restricted Stock Units"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable",
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSUs [Member]",
        "verboseLabel": "Vested RSUs [Member]",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r165",
      "r166",
      "r167",
      "r169",
      "r174",
      "r176",
      "r178",
      "r239",
      "r240",
      "r254",
      "r353",
      "r354",
      "r361",
      "r362",
      "r363",
      "r365",
      "r366",
      "r367",
      "r372",
      "r374",
      "r375",
      "r377",
      "r379",
      "r417",
      "r419",
      "r531",
      "r533",
      "r549",
      "r998"
     ]
    },
    "iinn_RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofFinancialIncomeandExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revaluation of financial liabilities at fair value through profit or loss",
        "documentation": "The amount of revaluation of financial liabilities at fair value through profit or loss.",
        "label": "Revaluation Of Financial Liabilities At Fair Value Through Profit Or Loss"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_RothCapitalPartnersLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "RothCapitalPartnersLLCMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Roth Capital Partners, LLC [Member]",
        "label": "Roth Capital Partners LLCMember"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_RoyaltiesPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "RoyaltiesPercentage",
     "presentation": [
      "http://www.inspiratechnologies.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of royalties",
        "documentation": "Percentage of royalties.",
        "label": "Royalties Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.inspiratechnologies.com/role/GeneralDetails",
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDetails",
      "http://www.inspiratechnologies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Price per share (in Dollars per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "iinn_SalesAndMarketingExpensesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "SalesAndMarketingExpensesTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/SalesandMarketingExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SALES AND MARKETING EXPENSES:",
        "documentation": "Disclosure of sales and marketing expenses.",
        "label": "Sales And Marketing Expenses Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/OtherAccountsPayableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Accounts Payable",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/TaxesonIncomeTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Depreciation On Straight Line Method Over The Estimated Useful Life Of The Assets Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/SignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Depreciation on Straight-Line Method, Over the Estimated Useful Life of the Assets",
        "documentation": "Tabular disclosure of depreciation on straight-line method, over the estimated useful life of the assets.",
        "label": "Schedule Of Depreciation On Straight Line Method Over The Estimated Useful Life Of The Assets Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Financial Liability",
        "label": "Schedule of Derivative Liabilities at Fair Value [Table Text Block]",
        "documentation": "Tabular disclosure of derivative liabilities at fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Loss Per Share Calculated Using the Weighted Average Number of Ordinary Shares and Pre-Funded Warrants",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "iinn_ScheduleOfFinancialIncomeAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "ScheduleOfFinancialIncomeAndExpensesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Financial (Income) and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ScheduleOfFinancialLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "ScheduleOfFinancialLiabilityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Financial Liability Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ScheduleOfGeneralAndAdministrativeExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "ScheduleOfGeneralAndAdministrativeExpensesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of General And Administrative Expenses Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ScheduleOfGeneralAndAdministrativeExpensesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "ScheduleOfGeneralAndAdministrativeExpensesLineItems",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of General and Administrative Expenses [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/GeneralandAdministrativeExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of General and Administrative Expenses",
        "documentation": "Tabular disclosure of general and administrative expenses.",
        "label": "Schedule Of General And Administrative Expenses Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ScheduleOfInformationAboutTheCompanySOutstandingWarrantsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "ScheduleOfInformationAboutTheCompanySOutstandingWarrantsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Information About The Company SOutstanding Warrants Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/InventoryTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Inventory",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r61",
      "r62",
      "r63"
     ]
    },
    "iinn_ScheduleOfLesseeOperatingLeasesDisclosureTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "ScheduleOfLesseeOperatingLeasesDisclosureTableTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/LeaseLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Operating Right-of-Use Assets and Operating Lease Liabilities",
        "documentation": "Tabular disclosure of lessee operating leases.",
        "label": "Schedule Of Lessee Operating Leases Disclosure Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ScheduleOfMeasureTheFairValueOfTheOptionAtGrantDateAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "ScheduleOfMeasureTheFairValueOfTheOptionAtGrantDateAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Measure The Fair Value Of The Option At Grant Date Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ScheduleOfMovementInWarrantsOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "ScheduleOfMovementInWarrantsOutstandingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Movement In Warrants Outstanding Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ScheduleOfOptionsToServicesProvidersAndAdvisersOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "ScheduleOfOptionsToServicesProvidersAndAdvisersOutstandingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Options To Services Providers And Advisers Outstanding Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/OtherCurrentAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Current Assets",
        "label": "Schedule of Other Current Assets [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amounts of other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinancialIncomeandExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Financial (Income) and Expenses",
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items."
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ScheduleOfPropertyAndEquipmentNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "ScheduleOfPropertyAndEquipmentNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Property And Equipment Net Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofPropertyandEquipmentNetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r429"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofShareholdersandOtherRelatedPartiesBenefitsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r41",
      "r598",
      "r599",
      "r602"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/RelatedPartiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Shareholders and Other Related Parties\u2019 Benefits",
        "label": "Schedule of Related Party Transactions [Table Text Block]",
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates."
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ScheduleOfRsusToServicesProvidersAndAdvisersOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "ScheduleOfRsusToServicesProvidersAndAdvisersOutstandingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Rsus To Services Providers And Advisers Outstanding Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ScheduleOfSalesAndMarketingExpensesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "ScheduleOfSalesAndMarketingExpensesTableTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/SalesandMarketingExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Sales and Marketing Expenses",
        "documentation": "Tabular disclosure of sales and marketing expenses.",
        "label": "Schedule Of Sales And Marketing Expenses Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of RSUs to Services Providers and Advisers Outstanding",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofInformationabouttheCompanysOutstandingWarrantsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement by range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Information about the Company\u2019s Outstanding Warrants",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]",
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Options to Services Providers and Advisers Outstanding",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r11",
      "r84"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Measure the Fair Value of the Option at Grant Date",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "iinn_ScheduleOfShareholdersAndOtherRelatedPartiesBenefitsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "ScheduleOfShareholdersAndOtherRelatedPartiesBenefitsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Shareholders And Other Related Parties Benefits Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Movement in Warrants Outstanding",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockholdersEquityTableTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share Capital",
        "label": "Schedule of Stockholders Equity [Table Text Block]",
        "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "iinn_ScheduleOfTheoreticalTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "ScheduleOfTheoreticalTaxAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Theoretical Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ScheduleOfTheoreticalTaxTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "ScheduleOfTheoreticalTaxTableTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/TaxesonIncomeTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Theoretical Tax",
        "documentation": "Disclosure of theoretical tax.",
        "label": "Schedule Of Theoretical Tax Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r711"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.inspiratechnologies.com/role/DepositsDetails",
      "http://www.inspiratechnologies.com/role/TaxesonIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r205",
      "r206",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r561",
      "r562",
      "r563",
      "r625",
      "r627",
      "r630",
      "r632",
      "r638",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r653",
      "r668",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r694",
      "r697",
      "r898",
      "r964",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r204",
      "r205",
      "r660",
      "r661",
      "r664"
     ]
    },
    "us-gaap_SellingAndMarketingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingAndMarketingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 4.0
      },
      "http://www.inspiratechnologies.com/role/ScheduleofSalesandMarketingExpensesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement",
      "http://www.inspiratechnologies.com/role/ScheduleofSalesandMarketingExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Sales and marketing expenses",
        "label": "Selling and Marketing Expense",
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingAndMarketingExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingAndMarketingExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales and Marketing Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ServicesProvidersAndAdvisersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "ServicesProvidersAndAdvisersMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Services Providers and Advisers [Member]",
        "label": "Services Providers And Advisers Member"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_SeverancePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "SeverancePolicyTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Severance",
        "documentation": "Disclosure of accounting policy for severance.",
        "label": "Severance Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedArrangementsToObtainGoodsAndServicesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow",
      "http://www.inspiratechnologies.com/role/ScheduleofShareholdersandOtherRelatedPartiesBenefitsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based compensation expenses",
        "verboseLabel": "Share based payment",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "presentation": [
      "http://www.inspiratechnologies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period",
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r670"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r670"
     ]
    },
    "iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofMovementinWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Warrants, Exercised",
        "documentation": "Number of warrants, exercised.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofMovementinWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average exercise price, Exercised",
        "documentation": "Weighted-average exercise price, exercised.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised Weighted Average Grant Date Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofMovementinWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual term (in years), Exercised",
        "documentation": "Weighted average remaining contractual term, exercised.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised Weighted Average Remaining Contractual Terms"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofMovementinWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Warrants, Expired",
        "documentation": "Number of warrants, expired.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expired In Period"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofMovementinWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average exercise price, Expired",
        "documentation": "Weighted-average exercise price, expired.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expired Weighted Average Grant Date Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofMovementinWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual term (in years), Expired",
        "documentation": "Weighted average remaining contractual term, expired.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expired Weighted Average Remaining Contractual Terms"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of RSUs, Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of RSUs, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r306"
     ]
    },
    "iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofMovementinWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual term (in years), Issued",
        "documentation": "Weighted average remaining contractual term, issued.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Issued Weighted Average Remaining Contractual Terms"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofMovementinWarrantsOutstandingTable",
      "http://www.inspiratechnologies.com/role/ScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Outstanding at ending of year",
        "periodStartLabel": "Outstanding at beginning of year",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r304"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofMovementinWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted-average exercise price, ending Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r304"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofMovementinWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual term (in years), ending Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of RSUs, Vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r307"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total grant fair value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsIssued",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofMovementinWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Warrants, Issued",
        "documentation": "Number of warrants, issued.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Warrants Issued"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeighted-averageExercisePriceIssued": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeighted-averageExercisePriceIssued",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofMovementinWarrantsOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average exercise price, Issued",
        "documentation": "Per share or unit weighted-average fair value of other than option under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted-average Exercise Price Issued"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofInformationabouttheCompanysOutstandingWarrantsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration date",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date",
        "documentation": "Date the equity-based award expires, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofMeasuretheFairValueoftheOptionatGrantDateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractual life",
        "documentation": "Contractual life of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Contractual Life"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofMeasuretheFairValueoftheOptionatGrantDateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r317"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofMeasuretheFairValueoftheOptionatGrantDateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r316"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofMeasuretheFairValueoftheOptionatGrantDateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Free risk rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r318"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofInformationabouttheCompanysOutstandingWarrantsTable",
      "http://www.inspiratechnologies.com/role/ScheduleofMeasuretheFairValueoftheOptionatGrantDateTable",
      "http://www.inspiratechnologies.com/role/ScheduleofMovementinWarrantsOutstandingTable",
      "http://www.inspiratechnologies.com/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable",
      "http://www.inspiratechnologies.com/role/ScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable",
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-Based Payment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r289",
      "r291",
      "r292",
      "r293",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319"
     ]
    },
    "iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsReclassifiedToEmployeesAndDirectors": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsReclassifiedToEmployeesAndDirectors",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of options, Reclassified to employees and directors (in Shares)",
        "documentation": "The number of options, reclassified to employees and directors.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Options Reclassified To Employees And Directors"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grant shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable",
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of options, Options exercisable (in Shares)",
        "verboseLabel": "Exercisable ordinary shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r297"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average Exercise price, Options exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r297"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of options, Forfeited (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r301"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable",
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails",
      "http://www.inspiratechnologies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of options, Granted (in Shares)",
        "verboseLabel": "Grant shares",
        "netLabel": "Number of shares granted (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r299"
     ]
    },
    "iinn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of options, Exercised (in Shares)",
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Number Of Options Exercisedi"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of options, Outstanding at beginning of year (in Shares)",
        "periodEndLabel": "Number of options, Options outstanding (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r295",
      "r296"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average Exercise price, Outstanding at beginning of year",
        "periodEndLabel": "Weighted average Exercise price, Options outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r295",
      "r296"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "presentation": [
      "http://www.inspiratechnologies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of grant shares (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "documentation": "Number of shares issued under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option to purchase",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award",
        "documentation": "Number of shares purchased for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Terms of Award",
        "documentation": "Description of terms of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "iinn_ShareBasedCompensationArrangementByShareBasedPaymentExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentExpirationDate",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofInformationabouttheCompanysOutstandingWarrantsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration date",
        "documentation": "Date the equity-based award expires.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Expiration Date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable",
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r292",
      "r293",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable",
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average Exercise price, Exercised",
        "verboseLabel": "Exercise price per share",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r300"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average Exercise price, Forfeited",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r301"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average Exercise price, Granted",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r299"
     ]
    },
    "iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of RSUs, RSU\u2019s Vested",
        "documentation": "Number of RSUs vested under share based payment.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Number Of RSUs Vested"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceReclassifiedToEmployeesAndDirectors": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceReclassifiedToEmployeesAndDirectors",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average Exercise price, Reclassified to employees and directors",
        "documentation": "Per share price of weighted average exercise price, reclassified to employees and directors.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Weighted Average Exercise Price Reclassified To Employees And Directors"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r294",
      "r313",
      "r314",
      "r315",
      "r316",
      "r319",
      "r324",
      "r325",
      "r326",
      "r327"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofInformationabouttheCompanysOutstandingWarrantsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range [Axis]",
        "documentation": "Information by range of option prices pertaining to options granted."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofInformationabouttheCompanysOutstandingWarrantsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range [Domain]",
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofInformationabouttheCompanysOutstandingWarrantsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants outstanding (in Shares)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r86"
     ]
    },
    "iinn_ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based compensation- placement agent warrants against additional paid in capital (Note 11)",
        "documentation": "The amount of share based compensation-placement agent warrants against additional paid in capital.",
        "label": "Share Based Compensationplacement Agent Warrants Against Additional Paid In Capital"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ShareBasedPaymentDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "ShareBasedPaymentDetailsTable",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ShareBasedPaymentScheduleofMeasuretheFairValueoftheOptionatGrantDateDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "ShareBasedPaymentScheduleofMeasuretheFairValueoftheOptionatGrantDateDetailsTable",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofMeasuretheFairValueoftheOptionatGrantDateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment - Schedule of Measure the Fair Value of the Option at Grant Date (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ShareBasedPaymentScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "ShareBasedPaymentScheduleofOptionstoServicesProvidersandAdvisersOutstandingDetailsTable",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofOptionstoServicesProvidersandAdvisersOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment - Schedule of Options to Services Providers and Advisers Outstanding (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ShareBasedPaymentScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "ShareBasedPaymentScheduleofRSUstoServicesProvidersandAdvisersOutstandingDetailsTable",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofRSUstoServicesProvidersandAdvisersOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment - Schedule of RSUs to Services Providers and Advisers Outstanding (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharePrice",
     "presentation": [
      "http://www.inspiratechnologies.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price of per share",
        "label": "Share Price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber",
     "presentation": [
      "http://www.inspiratechnologies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested shares (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Accelerated Vesting, Number",
        "documentation": "Number of shares for which recognition of cost was accelerated for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofMeasuretheFairValueoftheOptionatGrantDateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term (vesting period)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r315"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares",
        "documentation": "Number of non-vested options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercise shares",
        "verboseLabel": "Vested options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "documentation": "Number of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofInformationabouttheCompanysOutstandingWarrantsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price",
        "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SHAREHOLDERS\u2019 EQUITY",
        "label": "Shareholders' Equity and Share-Based Payments [Text Block]",
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP)."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r83"
     ]
    },
    "iinn_ShareholdersEquityDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "ShareholdersEquityDetailsTable",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders\u2019 Equity (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ShareholdersEquityScheduleofShareCapitalDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "ShareholdersEquityScheduleofShareCapitalDetailsLineItems",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofShareCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders\u2019 Equity - Schedule of Share Capital (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_ShareholdersEquityScheduleofShareCapitalDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "ShareholdersEquityScheduleofShareCapitalDetailsTable",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofShareCapitalTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders\u2019 Equity - Schedule of Share Capital (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance (in Shares)",
        "periodEndLabel": "Balance (in Shares)",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtPercentageBearingFixedInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtPercentageBearingFixedInterestRate",
     "presentation": [
      "http://www.inspiratechnologies.com/role/DepositsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed annual interest percentage",
        "label": "Short-Term Debt, Percentage Bearing Fixed Interest Rate",
        "documentation": "The portion of the carrying amount of short-term borrowings outstanding as of the balance sheet date which accrues interest at a set, unchanging rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtTypeAxis",
     "presentation": [
      "http://www.inspiratechnologies.com/role/DepositsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Type [Axis]",
        "documentation": "Information by type of short-term debt arrangement."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r887",
      "r888",
      "r889"
     ]
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtTypeDomain",
     "presentation": [
      "http://www.inspiratechnologies.com/role/DepositsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Type [Domain]",
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r887",
      "r888",
      "r889"
     ]
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term deposits",
        "label": "Short-Term Investments",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r98",
      "r858"
     ]
    },
    "iinn_SignificantAccountingPoliciesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "SignificantAccountingPoliciesDetailsTable",
     "presentation": [
      "http://www.inspiratechnologies.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_SignificantAccountingPoliciesScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "SignificantAccountingPoliciesScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsDetailsTable",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofDepreciationonStraightLineMethodOvertheEstimatedUsefulLifeoftheAssetsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies - Schedule of Depreciation on Straight-Line Method, Over the Estimated Useful Life of the Assets (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/SignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r161"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r715"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofShareCapitalTable",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDetails",
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r135",
      "r136",
      "r137",
      "r162",
      "r181",
      "r182",
      "r184",
      "r186",
      "r191",
      "r192",
      "r238",
      "r264",
      "r266",
      "r267",
      "r268",
      "r271",
      "r272",
      "r275",
      "r276",
      "r277",
      "r278",
      "r280",
      "r401",
      "r541",
      "r542",
      "r543",
      "r544",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r573",
      "r595",
      "r618",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r843",
      "r865",
      "r871"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails",
      "http://www.inspiratechnologies.com/role/GeneralDetails",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r56",
      "r58",
      "r59",
      "r126",
      "r149",
      "r150",
      "r151",
      "r165",
      "r166",
      "r167",
      "r169",
      "r174",
      "r176",
      "r178",
      "r190",
      "r239",
      "r240",
      "r254",
      "r282",
      "r353",
      "r354",
      "r361",
      "r362",
      "r363",
      "r365",
      "r366",
      "r367",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r379",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r417",
      "r419",
      "r433",
      "r523",
      "r531",
      "r532",
      "r533",
      "r549",
      "r618"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.inspiratechnologies.com/role/DepositsDetails",
      "http://www.inspiratechnologies.com/role/TaxesonIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r205",
      "r206",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r561",
      "r562",
      "r563",
      "r625",
      "r627",
      "r630",
      "r632",
      "r638",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r653",
      "r668",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r694",
      "r697",
      "r898",
      "r964",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r166",
      "r167",
      "r190",
      "r419",
      "r476",
      "r539",
      "r560",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r573",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r581",
      "r582",
      "r583",
      "r584",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r592",
      "r596",
      "r597",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r618",
      "r698"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r166",
      "r167",
      "r190",
      "r207",
      "r419",
      "r476",
      "r539",
      "r560",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r573",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r581",
      "r582",
      "r583",
      "r584",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r592",
      "r596",
      "r597",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r618",
      "r698"
     ]
    },
    "us-gaap_StatutoryAccountingPracticesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatutoryAccountingPracticesLineItems",
     "presentation": [
      "http://www.inspiratechnologies.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r962"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r735",
      "r746",
      "r762",
      "r797"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDetails",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of ordinary shares- advisor fees (in Shares)",
        "verboseLabel": "Ordinary shares issued for consulting service agreement",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.inspiratechnologies.com/role/GeneralDetails",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDetails",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of ordinary shares, private warrants and pre-funded warrants, net (in Shares)",
        "verboseLabel": "Ordinary shares",
        "netLabel": "Issued shares",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r55",
      "r56",
      "r82",
      "r541",
      "r618",
      "r634"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesOther",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDetails",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of ordinary shares (pursuant to an at-the-market facility) (in Shares)",
        "verboseLabel": "Issued an aggregate shares",
        "label": "Stock Issued During Period, Shares, Other",
        "documentation": "Number of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted share unit (\u201cRSU\u201d)vesting (in Shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r82"
     ]
    },
    "iinn_StockIssuedDuringPeriodSharesStockOptionsExerciseOfShareBasedPayments": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExerciseOfShareBasedPayments",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of share based payments (in Shares)",
        "documentation": "Number of shares exercise of share based payments.",
        "label": "Stock Issued During Period Shares Stock Options Exercise Of Share Based Payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of options (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r55",
      "r56",
      "r82",
      "r300"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of ordinary shares- advisor fees",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of ordinary shares, private warrants and pre-funded warrants, net",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r55",
      "r56",
      "r82",
      "r549",
      "r618",
      "r634",
      "r704"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueOther",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of ordinary shares (pursuant to an at-the-market facility)",
        "label": "Stock Issued During Period, Value, Other",
        "documentation": "Value of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted share unit (\u201cRSU\u201d)vesting",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r55",
      "r56",
      "r82"
     ]
    },
    "iinn_StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of share based payments",
        "documentation": "Exercise of share based payments.",
        "label": "Stock Issued During Period Value Stock Options Exercise Of Share Based Payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of options",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r56",
      "r58",
      "r59",
      "r82"
     ]
    },
    "us-gaap_StockOptionExercisePriceIncrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockOptionExercisePriceIncrease",
     "presentation": [
      "http://www.inspiratechnologies.com/role/GeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price of per share",
        "label": "Stock Option, Exercise Price, Increase",
        "documentation": "Per share increase in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r281"
     ]
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockOptionMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Options [Member]",
        "label": "Equity Option [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockRepurchasedDuringPeriodShares",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate purchase (in Shares)",
        "label": "Stock Repurchased During Period, Shares",
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r55",
      "r56",
      "r82",
      "r544",
      "r618",
      "r636"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Shareholders\u2019 Equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r58",
      "r59",
      "r77",
      "r574",
      "r591",
      "r619",
      "r620",
      "r683",
      "r705",
      "r866",
      "r883",
      "r942",
      "r998"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity (Deficit) [Abstract]",
        "terseLabel": "Shareholders\u2019 Equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_Subcontractors": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "Subcontractors",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofResearchandDevelopmentExpensesTable": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofResearchandDevelopmentExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subcontractors",
        "documentation": "Subcontractors.",
        "label": "Subcontractors"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.inspiratechnologies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r414",
      "r441"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Member]",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r414",
      "r441"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.inspiratechnologies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r414",
      "r441"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.inspiratechnologies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r414",
      "r441"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_SubsequentEventsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "SubsequentEventsDetailsTable",
     "presentation": [
      "http://www.inspiratechnologies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.inspiratechnologies.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUBSEQUENT EVENTS",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r440",
      "r442"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.inspiratechnologies.com/role/GeneralDetails",
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDetails",
      "http://www.inspiratechnologies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "iinn_TaxesonIncomeDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "TaxesonIncomeDetailsTable",
     "presentation": [
      "http://www.inspiratechnologies.com/role/TaxesonIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes on Income (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofTheoreticalTaxTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Temporary differences and tax losses for which no Deferred Tax Asset is recognized",
        "documentation": "Temporary differences and tax losses for which no Deferred Tax Asset is recognized.",
        "label": "Temporary Differences And Tax Losses For Which No Deferred Tax Asset Is Recognized"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofShareholdersandOtherRelatedPartiesBenefitsTable",
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r878",
      "r948"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r782"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.inspiratechnologies.com/role/FinacialLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r274",
      "r279",
      "r378",
      "r400",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r524",
      "r672",
      "r673",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r684",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r879",
      "r880",
      "r881",
      "r882",
      "r934",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941"
     ]
    },
    "us-gaap_TravelAndEntertainmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TravelAndEntertainmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable": {
       "parentTag": "us-gaap_GeneralAndAdministrativeExpense",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.inspiratechnologies.com/role/ScheduleofGeneralandAdministrativeExpensesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Travel abroad",
        "label": "Travel and Entertainment Expense",
        "documentation": "Expenses incurred for travel and entertainment during the period."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "iinn_TwoThousandNineteenEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "TwoThousandNineteenEquityIncentivePlanMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareBasedPaymentDetails",
      "http://www.inspiratechnologies.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2019 Equity Incentive Plan [Member]",
        "label": "Two Thousand Nineteen Equity Incentive Plan Member"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_TwoThousandTwentyFourAprilOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "TwoThousandTwentyFourAprilOfferingMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 April Offering [Member]",
        "label": "Two Thousand Twenty Four April Offering Member"
       }
      }
     },
     "auth_ref": []
    },
    "iinn_TwoThousandTwentyFourJuneOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "TwoThousandTwentyFourJuneOfferingMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 June Offering [Member]",
        "label": "Two Thousand Twenty Four June Offering Member"
       }
      }
     },
     "auth_ref": []
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "US",
     "presentation": [
      "http://www.inspiratechnologies.com/role/DepositsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Israel [Member]",
        "verboseLabel": "USD [Member]",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.inspiratechnologies.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r25",
      "r107",
      "r108",
      "r111",
      "r112"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/GeneralDetails",
      "http://www.inspiratechnologies.com/role/ScheduleofInformationabouttheCompanysOutstandingWarrantsTable",
      "http://www.inspiratechnologies.com/role/ScheduleofMovementinWarrantsOutstandingTable",
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant [Member]",
        "verboseLabel": "Warrants [Member]",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r695",
      "r696",
      "r699",
      "r700",
      "r701",
      "r702"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise amount of warrants (in Dollars)",
        "label": "Warrants and Rights Outstanding",
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price."
       }
      }
     },
     "auth_ref": [
      "r937",
      "r938",
      "r939"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants expire, term",
        "label": "Warrants and Rights Outstanding, Term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r937",
      "r938",
      "r939"
     ]
    },
    "iinn_WarrantsToPurchaseOrdinarySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inspiratechnologies.com/20241231",
     "localname": "WarrantsToPurchaseOrdinarySharesMember",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants to purchase Ordinary Shares",
        "label": "Warrants To Purchase Ordinary Shares Member"
       }
      }
     },
     "auth_ref": []
    },
    "srt_WeightedAverageMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "WeightedAverageMember",
     "presentation": [
      "http://www.inspiratechnologies.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average [Member]",
        "label": "Weighted Average [Member]"
       }
      }
     },
     "auth_ref": [
      "r384",
      "r458",
      "r649",
      "r650",
      "r675",
      "r952",
      "r954",
      "r957"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average number of ordinary shares outstanding diluted (in Shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r186"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.inspiratechnologies.com/role/ConsolidatedIncomeStatement",
      "http://www.inspiratechnologies.com/role/ScheduleofLossPerShareCalculatedUsingtheWeightedAverageNumberofOrdinarySharesandPreFundedWarrantsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average number of ordinary shares outstanding basic (in Shares)",
        "verboseLabel": "Weighted average number of Ordinary Shares and pre-funded warrants",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r186"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478353/942-405-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477263/942-210-45-4"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "a",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "a",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "a",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "a",
   "Subparagraph": "(4)",
   "Publisher": "SEC"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "a",
   "Subparagraph": "(5)",
   "Publisher": "SEC"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "c",
   "Publisher": "SEC"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "e",
   "Publisher": "SEC"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Publisher": "SEC"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(n))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483507/832-10-50-3"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483507/832-10-50-5"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479016/842-30-45-5"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479016/842-30-45-7"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-6"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/985-20/tableOfContent"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "Global LEI Foundation"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "249",
   "Section": "308",
   "Subsection": "a"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Number": "249",
   "Section": "308"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form F-3"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-2"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-3"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-4"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-6"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form S-3"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Investment Company Act",
   "Number": "270"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "313"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "413",
   "Subsection": "b"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "b"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "c"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "d"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "462",
   "Subsection": "e"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "a"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "486",
   "Subsection": "b"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Section": "8",
   "Subsection": "c"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480341/340-10-S99-1"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-4"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 4.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-5"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>130
<FILENAME>0001213900-25-022325-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-25-022325-xbrl.zip
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M2F\/(C4+<(N\212'\3C@]:"'=G:++P0JWM_=>5T_LMWM[;T7^H[\@>ME]^[
MO5$81/*?'_O'Q>UI_?W%K2]20SAN"J2'0]S>VM[=VMFU7K(%,R^]R*S$3>_9
M>;FU_<9:3KCSVPTSQ9^'KI+F=I448Q^Y:DAWPL72RF=J:^RZL\4;]0_5FW&G
M5>W=]$OI=AR>7R$O/=I7+_A'^];@IEV,5.I&7CZWZ_"&F_]Y#"M1W%E=M:L]
MNG7G[=NW+^C7_%95=Q^\<N?%/T^.!]Y$3MVMA9&HX,>?6CX>%!#/4%!(U__@
M"/Q_OZ9!&LH/XM<7_!^.\^M4IJ[PXBB5$>QQ*J_3%_0@R:PM^4<67/[MV0'_
MOG4!&_/L!;SS!;_TUV'LSS_\Z@>70J7S4/[MV0CN? =2:Y:*BV JE3B55Z(?
M3]VHQ1=:8B"38/2,GL(WX3^_SLSS4S<9!]$[L0TWO)CIF\Q=*"&/ AF"?.QG
MH=PZ=\<2A:$] '[!5AK/X"6S]+W0%X9QFL93?>TJ\-,)#G/[/YXM#']+!?^6
M\"/>.(P37R;\MH^AZWT3NS S%8>!G_]HWLR_[YC?X<5JYD:E-X_<:1#.WWUO
M:?[ZEYU7V^]_?8'/?]!S7UB!%PM+4"Q4OIRXGUMN&(QA23W809GD"\(KM+@^
MJQMW=?MF/THDE;$NV\W%2=YA#K\./WPY[5UT#YW!1>>B._AUF #!.X/NP9=^
M[Z+7'8C.Z:'H_O/@<^?T4U<<G)V<] :#WMFIPW?^WAE\[IU^NC@[;8E#/*]?
M[K_]]<7PPV:ORA/9V:.S_HGS:W#]+HJCTVP*USV6?==I7X[^]LS;?B8B=PHO
M!IWEW6'LP3U12E)/!*" !->76[LO]W?>/OL )_/1KR]*K_K0[//*YO!>W&6G
M;]YA5HQP-TF9>C>,XW#HAF&<#N/K.@+HRW&@0*="96J0@BJ)%TL4L;N-:_?V
M]?[^^RI1./WNI][@HM^Y "$A2*B<=$\OQ/F7_N!+!_[CXDR =*%?=W:?#W\1
M9WWQ? S_'(F+SUUA29Y<ZG0.+O#GG;=[^YN^5T^$XH8?SOIKPOYWG8C9D2<P
MF17+@4X496[8E[,XJ;#_CF;_5XOLWSD]_=(Y%OWN^5E_"=?O(<OOO'SN-TR_
M.4?E49PXZ42*4: \-Q1SZ29"1K[TQ>W)[IT/A\G6%&Z8(+5M^>Y\"U^T):,Z
M^CN']\5^-_(/X;$R >[^"+77?;;\Q8,L2>"#1S2WKS"BVH_N/?MP*#TY'<I$
M[.U4*;_UO858G&#QO2.XHLI?VT>E:W=_4>FJ_KW)5+4VG-$<A\UQ^)WCD-S<
M 2K%=4?BR^4:,2C#IX,>G7W-L=@P_QI/I&'^9<P_F,@PQ("7&\WKV/_5<O8?
M?.X>'Z/G[+QS^O7)28"GP/]WF .0Q#10&#EUCH)0BM.X_>[VBF W2H-TC@_"
MO:!6EFGJ];,/V]L[6_O;>]M[C=IW7W/XL;TROK$H/85?BOUZNW\WR=L['9SW
M^AWGHGOP^?3L^.P3LOS9/[^*C^W/[=.V.+XX;)?D<I4<-I(.?@T^/.]>NU[J
MX#J+>"22?'V%JX2:22\8!6!D!I$(4B6\B9O )W^!^6\X"\#4#1<\@:F0;AR2
MQ]@I[>)?__)F=^?U>T6,!+N8QJ(;C<- 3=Z!K(1-GLW"P'.'H=S\=5@;J797
M-9"<_KB//ZA%27_L)K,DOM2)-64G"PO07N3%">A/173A@&\^B/V*O^7-LP\]
ME;@RK$J[IZ2F?GC^]RP)E!]XAGD">X5$G,#_C=TH^#?]O2Z2[VD8?G=CDQ]4
M'3J^GTBE]#_'021WRO2.85;GL[MU$?APS(E!6J7[=FM-:/XQUNT _O,LN8BO
MHM*J[6T_^]!W]3'C1O#_%QRSMP^!ESYX'JO4#?]/,%N03'L[SS[L[[UZ]7)[
MP3W[HR)32TH<0IVT-'/GN\J#V%TF'M>$2.YZ"EW(\)WSO]Z^WFWOMU_M@@VT
MM_<D9@8B7V\K2OM9 O(^F+FAD-?2R]+@$O7@4>!)U<CZAS/U=DKA(/@%C))S
MF:@XBF18-O5V]N]HZQVZX\#Y**.MTSB.GJ!1=[.$W_GQDW%OKWHRMA>$_)J(
MAL=8MV4GX_[=3L;E'[SA9'SYYT[&G96>C*]^AI/Q]M(,5RN1[N)FO7[V <_7
M!37SUJ\^CCTW/)_$49W_<@_L-^OD?H([ 2<Y'@TM!S9$SG 96J*[-76#4+B1
M_P),MR/74\$4'<,1+1!>%YITT=VE(PI"GSB"CYQU.?@;]Q9.90!J61*D@50.
M^[5D(GVTR]-8#*6PKLVR1&7HNH1?X"FRWSG'$;8:DV<Z7OIN]8M!D\;<]H?T
M9J7HLX.OA.',]:E4[!F8-S\\ ZLT(:\P\.(P=&=*PB3T?^4_P6 \^!;.^/K]
M,SA3TL1\\U(F:0#BR"P 4 C=X-]4'%!?T]!^650]Z 'N[<+XJI_@Q_[T&K\7
M=OT%+!:[4K%4!0E&NMY$>*&K5(F'4O^[L]([DD^+)I1/Y::9F$V_Q4?6<>D2
M%^<M!O/I, Z?5PRH9N&6+MRICKX0R<EK;^)&8[@0B:M) %<L$5==4?B?Y'ML
M"%.&*8X34-5\9.XX>2>2\?#Y[O9^:W?O36OWY<M?OL^JM?Q]DZ:R:VLJ6HC/
M=W:'Q&"6.??F[4I7<_CA+ $B<I.Y&("Q@O=&,5!6(B[=,),WVGNWH)[:9?@!
MZOLSRVCG4HZ":^EOI4DF[>4]C37O,>L=A>[86N$[!$?K5[C7.SU=SX5<Y2QO
MORL<?0&^7;26#.%W-5>7?1FHI@/YG[K*=_]8L-@.W%D AAY69G^3:6G!;\WZ
M]\#8>[=C[-WMO15OR.]N@C%-A?H=Z'JPH$J*"K>O)UG>=C5+7&POY9M[X.#?
MUW.M'HJ%]U;&POO;=V/A%Z3,+RE1W@AK9,U&>V>3<5PR&<5I',E-F?O&[A0P
MH]9W8=T3*0(E7-@JS/5$HR(>PB<Y)E^[:92V^6";MBD;]*],I<%H?H?A]B(?
M9'0JJ?I(>]%@F>,L16 (LO<4G;RY :,W(5 JDTF>@$26--_E::$(&^[%TVF,
MXXK!"'.5>=8+8R7-'S.)=4APZR6RK#.<TU67JN,T@3R45^?NR[EANZ\/T*/$
M938KG:#[SX0OO6#JANIOSWJG1V5+!6AERX_3+7W+8@CA@/9^@%O/NMM905//
M!)9F27)J95' 'V0Z*Q^].\\^[((9^W*WM?WVE3E^S7 _.+'1#E6-+=C2%&=5
ME;40\FB__;#[HR\&D2_QI=OMET'T\Y"8$3 (:>5-),@!^-PW$3#S6PFI="!<
MR3#<^A;%5_ MZ2J0\;Z6-+2;OAP%$>>K(F")V-]^:<1(<=3@^=!L\2-/X2L<
M^;IDXT<3]G\'&O@'DL! 4T"/"* L&'9!)X\7]/&\;'J#5V[3^'L$J@/P+I_4
MQ,61.;U1)<_+^O0=+6#>VTN$*$[ARA]9@-H\Z(,C#/;QBU2=HNCL[.%72^JB
M,>Q0+N U+.UIY,/FRH??XC"+4CCUL;(GJ2@,>^LC%S9L@Y_=C)&&V&#OX6U_
M9#+RT E3 (41&!P_X-=CI^WLUL227UF8:$O#-<_^U&R_BU16']HN%G[VH9C0
ML@D.$^E^VQI*T(IA/6:T/O9'7M5\!!?"GI*U+;?XN W8]AVLMI^;D.]L#9>/
MIJN)1*=%]7QZOO.+F(!6BH>2+]PPS$\F^\@:2GT#O#-W9]SNE')\4&G! B<S
M.0$SANSQG5U!:!M*/(>7H%]%96"7JTF,Q5O&GDXG;EH=\)6K%D]3>E@/_)<6
MI= \W^6)#:6$9<R&_X)A.W _W0H/X2CT>[!Z5]$@:)"N2L7;;>&[<]4<L9M[
MQ&K$EKYQSV$E405!!=-TU^6D?:"]?PIS>!*"%V43B*5ID")6M@Q!/"5QA+&F
M<"[DI4SFHH>'/KJ)+J4X=%-7'+'E4)++Q3ML4P(]"X[V+/3E../"2S'8NA#/
M<5E?O]_=VVWGKH> ZF9G6#<K5BNOG:J\YO'F8EBJ7QHA^\A3^$'!:I$E4J66
MLV7!^I)$]P+0A9:LXC06.1;&!B_<DQ90Y,L,83Q2N)X' HI1_9%GT9$9U5X5
ML-M;-3_$F-<L0-/"Z8W%.(FOTHGC<6YS&P8HV2_*7A:021B4V=U^O^S[]//.
M>W/;\AM0%=0W5;XN]-?UG8[QQ^[L#K=VZS3:)RVG-B]95W]J_S_NV=ZK9(F8
M3,^7*_YN37;(<3WQB^\-;>?^AU:5WO4CH?34>QY)YT>79^?-HRS/;7+AEF?"
MW3=5UW_K![$=2#N@/<!39AS7PSN0Q_- WU!H#7N[*TVR/:T[A_Y,)ME]4<>K
M']R+E7V]:X[!3WP,F@*C^R2-I>!I3!)F2#PB/2"+-+!<[_Z6OX88'BSKK=%+
M.?RVJ!P:]8R-2K!$9Y3!@Q!/H">ZD1>X(7Q,8\\K#*<#OX-:@:U@0 ^!-WQI
M#]KB4Z=S?OMXG8-F.1GC(#,P< <6:Z8DW05S9CAC*QZH#=\1YPG-PCE.@#Z.
M0X]@QO!+(B\#13+(C!M'FD64-$;I)&[B*])#]]\+1,<)X#-.;0[9WG.WUMW:
M_E%8B>^QY'4!9LHHRV4#;SF:8:,EKZ9"L4Z5KNC+W\NLKV539U$EVF[OPK*5
M[P_E*+W30A(UES2@^U)M+B;2264R-8;>C["=L1,3.9()I>TCXV8S! 3GK!T*
M>B"['>7OZ13O&1CV%1]C^ <C#"BB:N\XB/U@A&((.=D=H>.L,TN"4+S$G*Z=
MW;:]6@Z=0>4C:%T%^*:=-S_LJ-71,9,@@ML7P=]I*O$$PNW4^PY?<\=T(N59
MI913JO"2D=MR-)+D/HLTPDM YQ?00P3$A8([B4.!N:06[19IQAG(NB0_$?:W
M]ZWRX8&;#%UX[=;9=2CG%(=[OO.23L*#MGB]^PIKC7\Q%%UDF<-A,PSAU+ X
M9!0 1]F'+Z6G:Y; $;N9'Z1Z7 _L&]DP6KW'H-AI_"/=%;@T;^2&JE2;U_-&
M20=W,TXZ!4V72_3PT'^]M*G'1J_GIHFOD:.*1%%@S!\%&%BJ#ML2L%;)CA?T
MY2#RPLSG=%9^3$?61ZA$<Z9\G"1Z)/ \:OI)PH4N,SRBXTR%<R-7ZKZZ.M6V
MZ*H1#=)IVL5Q'.2C6Z3W-VNBY/Y$M'WST8RZ&=$@UEXP&17497C!HE<ZOO+H
M(Y[?5*(QAQ>YX5P%1-% PNBZNI1;V.'5)T-.1HIDH(,14/B)E,#\ZS8'Y.=\
M%9P-M$DKE)J 47F)?)D/09N.-L/JR.S^=GMG^W!K![BV_3AQLH;@J,H+Z(%)
MQ%*+:K3#3'%H6^M)R\5G65@&2DO+)QU8VH0IE![$(V0KN-Z:!#Z\_9W@?^%5
M7KJU_>P#JM(..I7TC)]TMM &3:'']A,*;3=T"EL]S_^R#''@V;)I7WKX!O.^
MR5I8CRF<H3;@-)OQ&+:'=K+1%ACO69YH2T<H'W"@B,U *9-X,NID,E+VQ1\9
MJ&C :3>8(0$EARV<H"* ?_%E3N4$-AY[S >.0?&_:H[41Y\"\:;3PQW;>6T$
MI^"_WVSXW#:-9TG9+)6U?:>0[::<,(6-KDQXKF&TI^8,Y/B?W<VL[!1YVS@!
M'ZA<#=,1M^P:J;JRM-O$#Y^5GK83(JSR-7J;KETK@ 9K:]MVB\HVLVPT]L4*
MKX4IK*^8O&<"^,'2Q-V'+TUL"@[__-;^:<_#_7;4O!]$),07[WP\[CIG1^+@
M[/2B>WHQP/%O%J[3)B1$ QW_FB::G(OTB=ID#_VEM_]1 KC[D4??[/[8L\R?
MUI<7Y,UP$;EVA7M8#ZB'/%Y#C2:KCY<T%T>W@)W-EP'NP)?][=GNLQN6$P;A
MBDF"&M=?>O]O>WMGE?/KG5[TSPZ_4#?8?&KNAQ_:KOO=@2 (EJSY71=R=Y7#
M/.A\P37L]+^*T[.+KNAW/W7ZA[W33^+HK/\[_.?6\=G9/_#OP47GHGO",FYU
M"WY)Z_1H1+E2W-/!EY,37,A^;_ /<=0YN#CKKW2MKN].27]"JM6-Q'I-S;[]
M:6#KQ>GL/5NNE:URZ\X[_0O1^R[#WDA8JQ-NP&=P6)2RX&XU@A)IOUSID Z!
M\7L77[&=]F&OWR7:AMN[I[VSOCCIG'8^D6P0G=-#T3G\K3?HKI;V5S>5G54>
MA0]($+MW)8B5%@^<'1UU^W0F] 87O8,!;7SWG^= &=U#<=$[Z9)JO%DD\"C[
MNG?7?7V]RB']H_M5]$[A[#_IK*]NM8$LW/G175[FUBEM_4JQQO^[+Y5,+J7_
M?S=KUQ]Z*S_>D6'?K+3'@X8MUTV/*1^[%_ERF$H?TZK;F[67:\S!!W?=]I4J
M9'W"TRS0FLY&(]TS[0O#,9\GL2>EKS9K_Q]Z4P_ON*D[*_5J] /U#1OAI7&R
M8?NVQGQ+2M;^7?=YI4X72\$2\'\7G[OBX.SDO'/Z=3UW?7]=V/6'M:CJ-J[4
MW_,Y4,"I<Y*ZA_)2AO',+F_24>,-V](UYN2[*EX[*U6\/F8J0 U+G,&7+P-Y
MM:8;O;LFO'M7_6EGI?K363)V(ZTTNZ$8I$GFI5DBUW,37[W:/&Z]LVJU4G\5
MJ,,S^.2\)<Y#:DR&0KO[1Q:0R-ZP77\<%>K.A^]*'55?3OO=P=GQ;]U#]$(>
M803^9.71J9^;@VG;7]YUUU?JHSH[[_9!;S[]1/[FH]YIY_2@USD6_>YOO>[O
M=/&\?S9 -_2Z$L+K-6'JN[+S[I_/]ZG;V!D"5&&I25^J+$S7U/Y=NGMKS,9W
M59MW5^KC. [@T/6#E,TFTW01-CW.$D^NZ;:_WEX3IKVK$KV[4C\&!@S<Q)O0
M5OJ%!=P2,S>51LL* ]@0A>^1J;>F_NC7RZRD->;KNRK8NRMUAEPD,L)Z)\ZL
M!ZMJPS;ZH7>O>]?=6VT4"5$TO'+-9U>E 6SEVLKD#619TJA?W77G5^H(^6XV
M3_?D_/CL:[<[6%?1O;<F''UGA7JE#H_# .% XH3/X(&,@C@1)SDLUZ9MYAHS
M]9WUZY7Z10XLU)9UW>1U,8'OK$VOU+?!R KGU%)B?2VA-YO'H'=6E%>*R-V=
MSL)X+M=U@]\^%05Y;Z7^*6I[+<ZN(IFH23!;T[W;P-/SZ(Z[O%+GU&&@L)]]
MEE *E5L';Z:[JZ>Q03 C_+5(,GR?>P4RO(*=MJ:TLK\F?$XVT>N[,OM*_5HG
MG;^#'33XW.EW/Y\='W;[G-[>[QYW,+L=BT6^BHM^YW30H0JT-0TU+-WB-18'
M=S6B]E;JU#IQ_P56$\G^21SZ<EW3\M:&F>]J"^VMU*O5ER$U/3EWDW0N",B?
MQ?>Z;N/+S6/8N]I0>ZNM4\,MD8HA>KO7F/+!#I #6#0EPS7=][5*]'ASUQU=
MJ1^KB/&O?5G2TFU<8_:]\WF[4N?5H,"(1:8E;#VKWT1OW:-+:\/(=SZ'5^K9
M&L!7J.-'E(H#:M6SK@?P!GJW2&:_O>M^K]3%A04-7"",9M,Q5@B??MJP'=\T
M0;R_VG2LO)SL.% 4#3Z4J1N$#=^NC8C>7ZGG"[.B46<^1']7,,S6^(Q=%XZ]
MJ^6SOUJ?E9M\D^N:-KF)_'G7J-'^:K&%9$@-93; %[4N_'G7 -+^2GU1AT&X
MB4)UC1GTZ*[[NU+/$SJ;,,O55'_VL+'"AFWVHY@N.]MWW<>5^ILZAX<]0L3;
M!(?3!G+MG>V<U3J<**ROJQ V;),WSF!9J4_I1$[C! S4;$IF:@>_'K+X[2@5
M>\$ZNPDWD&_O;.VLU,-TXL*6H$OX '[!C+EU58;?UN[TO70S_M/C7C?,][WW
MXFQ&8=IW^ '3OO/!@>!YMA&&',);3?I/(\?;JV'6X;VXF,]@-8[C*YG0Y]Z+
M4W<J>;U.8UR/H(3J;IZDE6I0Z->5#=8#47WUITT)>OT1_3!E'/?2(?1RI4[R
M[K5'P2P^A.)5.L?O:2WKCJ,-],R\7*GK^\*]7F==L7[+UEA3O*M?YN5*_>*'
MP67@R\CGC()S=XY>U,X8<PS6<\-WMFN2"!Z!23_==1M7Z__.>Q\.YR:Q:[/V
M;XTY]O-=MWJUGG+=G1YL^0CCD;/075,0O9WMFDJVQ_"CWG7_5NH)'V1#%?B!
MF\S7/V%KV0ZN,;/^_:Z;O5IW.;?1Y.[26!4#UGJ6(+S+YW4.4M;NN[WQM7;%
MXE[?BY;.89&;&X L-W%6ZA__KR\=[/O1N>C]UJ5D+KAP;/X^[ T.CL\&7_K=
M@>A\//MR(4XZ_7]T+Z@!SO?VW6J6]0A;7?*VUN[UCW#^RO>^OM='9:-7ZDX_
M[ X.^KUSAB0^$H/NP9=^[Z('.WMV\;G;%Q>?.Z>B^U]?L =,\>/W-OF^=_9[
M?O3O</&]A[4J.[92%_BA'*9&V@;?3ZA=RZUX)":KCV25-^O52EU%O[M)DL..
M)L%X\GWK92TW[%ZVHSZT5-F.E;I\N+#@9V*>FL9OW[OVXS3Q6'W;EC5N6T?9
MPP=\?=.G"LFOUJKN'G6^'%\,6J"V_8;MW Y%I]_O=OJ=3UTN;S[L'O=._^M+
M]_1@#4[V^KCI8T@GWK#Z!A*5#5NI&7W2N>CVL>[MY.RP=]0[H#RD@;@XHWX1
M_=ZGSQ<#2U7[*NQ2]2\#K,! +-R#;O=P,W?S41FT'O:XLM\KM:2Q@W3_['A@
M0(P/NH=H66WDUMWCQM2CYU4V9J4V\'_#+G3[OW4/O]L7[9[W8F<9"NWZLM&K
MV]A%KU9JR7:^'/8N" V^=W'1[5H@X=B>LG^QD9MXGUMT*VMHI:;KP=DA'4_=
MB\^]@\>6<)O(5;>QF%ZOU( ][_> B<Z!BSH'!V=?3B\ZIQ?BJ*M51Y2/O8-'
M/ZS6C[?JDU<J&[52T[;[S^[).:N*1_VS$U(6=04N-LHX/>ST#P?8W%U4!.6C
M;][W.E*M(1_6)[)4MG>EZ0SG7_H'GSN#+JG^"_Y8\?$K;7AO,/BBJZ\[1T>]
MXQ[C5NEGO]^9>RVW^CXWLCYGI;*1*TUH@)TX_00[=2KZW4_ GWT0J!ID;B .
M0$_I'7VE/B>YN-W(37M<_JS/8:ELZTK=+ =G_?.S/K";^'3V6[>/JN=WFZ"O
MY<;=Y[;4YYM4MF6USI3>:5<,.D==$)=%V/*Q-^9[^'QKR%&]6^S<:G',\]U"
M00G*"PI%4%^ZO4^GXN]P[@T.>P?:-?:Y<R'.^]W?$+J^=TI=H&Z#SKB6VWR?
MF_CW6VSB2ETHL!F]0XPB]SNT?^=GQ[TU\#)O(@/^XQ9[MU)_RL'7CZ Q:B?S
M1F[8&@2H-B]"58_(6VEIOU(70^&H SOUHGNK9H[W36_? ^1\:-%=C\U8V965
M^A.>S*X\*C?5X[-5]FVECH+N/S_W/O8V=*_J)/9N)='QS6KK"T"=[%RL0<!M
MIQY"LE0QO/:5DC<4]^XW=;PU=;Q-(>^:%_+^:9+00PFF8^&&Z=^>@=Z9>'][
M%DQAS?[?]O9.^U^S\;,7CSS(>ZEU7I_-*XULI?GF\.#P0R]2LR!QG0OI32)0
M+<8!/'!V/1<?VY_;IVUQG/IM8)OAATV9TW=V@/['%8'_MV<]).%G^K!<OZGH
MEV$'%X652.]$-IO)Q'.5Y)W#E)O#+P<,\;0I&_2]69GM>[#Y_"M3:3":ZXM!
MY$M\Z7;[91 ]^_"[%(BQY HUDXCBG<[%5/JH\CF^O S@E,-F.6XT%S(:@U#$
M)K*$H);H[L*M<FMA&%HV<KTT2X)HW**$ZBEA7V)A;SP2LR2>)8%,L?XL#$92
M*%@=*DZRV+,M<%C!%!2PQ(FSI/AQCD5,\(A,E/0E#!5K_*DUZB5\/@C=O*=B
M(B]CQO0#_8U&/ [C(=Q8\PSBE_ HV\5F//Q>K)U,OO%<JF>:[QRHNZL\4)MU
M7KK.>\TZKV8*/V(\O6R,ISKCJ;&>GA87K5Y:[3?2:C7KO'2%7YH57K=)/H%]
M>L I@/EP =\D;=H!3;A?4G*/49\>L#Z]+O;%S[Q;OTMGB6TE'M2V<BSSZ2I(
M)S"BRT#I/JF%,046JQ\@+=4;26!8M42<++&?6N)J$G@3$2B:@4IA=-@P&X;E
MX2*DL>_.'3C"Z><4CO24\(*PD:N7I31G=-/ 9^9BY 9AELBV.%EFJ\&2A?+2
MQ><"]0T&%D0>O%.QI>?%*C5?;@G84@E+-8D5X0@[,+8Y/)&X =P>1",-8 G?
MQKT+I>OCNA33ADV8220)V#!<\XG$"F$)PX"U!0)*YVWQ1=$>9!@X@?=LQ:,M
M&,B6"X9MO94[;Y%A.XYA:KAFL!$RA8V)@)@6%@^_"IN+4%F@_Z0!P>_P3BY;
M._US)&+Z<!8AZ =\98:TE5Q*$;E 1[ :J%VE$QP]?L6]C ,DPS0;ZFT%9L@\
M[IGKZOIH6'#A:A1?^(6^A,N>*6K,6T\@;=%1,/B$-H87"E><+'H'QN#A.V E
M<$68MH$9X'XW#&5((\\2E>$X$SG.0IZL.\-E<4/8MROMR(#-!)8!0H^3;W@W
M/"D5AF<"-6'<1="O:41Z"?4X L_!T6$':28"?-C0#%RJY5QT)>)0?=.7!;T/
M<$I/T',!7.W#WXR+A7<!3\/ O##@Q7']>,8K\SO2(1$IK$5* IXO*)@+DP!N
M(/-?[^ +_,=8PDB)47E8YG=@9I?D 6P(HO J7DL%]@'<E R!(F@3<>_MZ>6;
M2!09CQS-4$08GB<5T2CMFSYQZ ++'[V2(!1#^@%E49SBWN/(@-[8HR.O00ZF
M^!6E-XK*N[44(OXH$<8L=".'6CDC=?"G!+"B3'D#F6+U*AJR6L)N[8T^2=;H
M,/P1@_A58Q#7&,27C3W\LS/1'35*K15J,0]G31C&5_@7G(9P6J?JW4;/\@EL
M%!IJ$^E@FG.OW_D5SJ,/%R<P(_A7=+#*M;'.'GL*UO[@E@@U5ZF<6G8,JDK9
M&+4W4')+:H6M;UL:O0!-*A;?HO@*GF0[R/K R^WM%KX6E911Z([5))@9AG4N
MRO?JP6 ,C-4L,/#1$D&%)[Z>@_*'IL\PC&.R588Q&CS:,A"*-'O2B4(4%%J[
M W5Z&D09&3DPQY!-)?,0SO?*_29;#MX;9Z2F@34"4Q_1AT$AO71)'ZVU#1O]
MZF%<I:_(D6?&PZ;H.[&W_6IVG:.2OWZY/;M>K3OUS_@B&TI8#\&&K&W98T!5
M,@'Y@:Q<^&&0R;,9"I/=;6/(%;X&,L#F8+^"Y(C)SDY!5I#_",U1'7#_(PL2
M6SPXENNH+4Z,MX0]+?26"9 O6.?T]?QC&:Q#,HZU/A/&$7K&ED3MV0<V!]/2
M0U'U<OL_T,_@H--#29*--$5ZEWG_<([?\\AA0[(41%T29V.R?P.P(+-HK-#[
MX.+W/>FC.R6=N*F9HK(<)#P"-L+!N+>])2TGK9?JL"&^5$ !/$)?AK 7B1F,
M#U_P4GH7#G]BR7GC\R*+/G6'08AN7U^22Z&8SL(!X-3+_YE,,$$%G^1/H+ME
M*H$\8$:N@FDST#,\"8L8;J5 9L(<#[P6^&QE,>PE:(LS..WBX;\DN64<]G3!
MZ84]-O2&;!5$6+Q; ;%H[\U2?Z/Q6!2D3;X"_+KMG@KEV/7FQD^(?IL07D8>
M#(?<>4"#Y#$$&KU #Q32DXL:M:AU5X;HG\G)%;X^RT+M3X+%CL10SF-X+? %
MNO1P%JHY'!]Y"D"%MA.\PH >O DX(\X4<)U1M2SE2!=^JRJ7E#G#<)6,$E @
MD7C9Z881&AP<D X]3\QH6)4X.9AF8>I&D@< 7!=?XN.>FPQCE ?Q=>#+MOB(
M6MY-;"X*%K>(.)=[J"A*H^7E3(-3=K\94[*@=)4%W I'QR1&64IR$!@R&*,$
M%Z,DGK+X1YZ>@LR6$3):'$\M?ZEV3!:_FQ_0#1UXDIF0E@JXJN*79":/^)1I
MN.B^7'@W]CRZH7G1[<=:UPY)+>]Y5%MV8D\PE*/T&=>JW%#ZD7\7]((;@N.O
M\_0#+BA9Q,'FY^_@##C7IP7Q%T@=XD+B?G/F+8F:X'"&R8L/UK]GS/XDQ$AS
MD#[YS-$4J"@-^I2T)4Q%K+"X<<-V]2L?J[).JP1^65SJ0$TN!=LEUT8!VG]S
M3[V2D;%H8CP-MENA/C^4*+#S,RQ7A2AH1%I*KO8"=6%8+BI[,%RT"4#- K*X
M,01K#C5]:J!"1 HYGH\XF^ :A'6F(\.%MFY_2],@K$CB>G$"EX!6A!<D7F8I
M\;/)7 64_NN),8Q.FNY=000'Z&5Q[-$C=&;4$S(?2TM/;]3QRDKYXG)BL-$Z
M'H')X%3%$Z_D$C'^$&>9@IJ:3(T;HK3YX0P\E%M2]L?A>FVHC^=QH/,'AC!&
M4 &40V9*U>P@ XEU[I(F6PHE+[A\2J:,K>3#;U?2C3@'(<1@H?:94?PU5[Q9
MSPDB+TL2HUZ@$DXZ=$9V@PZ]\ZSUM7]EZ%3#:>"P-4GE&H%P_6F@%$5-*QMI
M>>ZTRF(E3SBS"28'D+X/U!7%*9BS*:P;6G]@@7+NQ20#]B-W&4PK#+YA''F(
MA#R<!FFJ[4EX\9?VH"V.4#[B"P^3;"PZ,*XH4#HR2>R =QX==EJ4Q5X3M!:7
M@<N$FL@M'=TTO]$+SD_@8;AB[!6\=BC%:7P9VT%PV,;)E3NOD(1Q'8(Q*='4
MAY'4#L+8OD!3/%%:W;Q/ND5&EI4L7NYL/__V2\TH4+*8*#^^$@^>8 L6>,:?
M=+V)@Z8UT+<7S%P3N77SB?&\<3?@G(ET;@:1DM9 \_BY2C-_KH58HQP^1GSW
M=1/?78SO-N'=GYZ'[BEJ"-;30Q8J-MMT.X4<M\4$#^$HOPR,'V<DDX25!AT-
M[!SW#KHM<1P,YZW2T?K\DXQV?L&SKWMP/,C?AIY[#"E67N7J)#0'[N=;%Y0A
M'!.',.'<W_)"Z>+CKG_I1A[K=U/2PVR;P'QU*%-T 7,<<SBGD1O=$Y5"4'+F
M/ S0P$'[GF7A-([<9.X,YS/0__(7P? .SC^V"L6:@@R4= D?A4W#-^8N=F6Y
ME"LO%OK%^'QN<N#K0ZE4W=R=+"7?. Z2_'X!2&'6*HWA@?OI^K[*8P"QCF*
M%2$7K&0R*FR3&A>%/7TP+_8+LA61O]]W$-/$J(Q:U^;!ZAQ"C*' ]R]EHCUL
MD9=:NM=$HAX%@WH16T$)#WNBX,)16F!=T 0W=4NYESJ HE>W49!6,X5>)$Y
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M'8H_-\!57[H8OB,$4FQ'J%LW)7*44<\$24T)*9D*CL? X,E;[9N],%94D4+
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MB ((A!\RD=G XNH8VB<3ZYL3/L6!<52 0P) HI&46Z\)\.U-7<#8"\(I'10
MYB<]-MM.7_ ;)IF5CMH MB/H[!KCWQF-0ONV*;88CE">5SIJT;Z-J("VVT=G
M/C!2"O70J@1A#[S@I3;P1/F7?L9:J%\CRZJ.!XT(<=8$D' YJSD[.Y6E*/)+
MB=-(^%DYQ, 70AJ88?=-TU[6Y>*\#%RL\;Z?#SKO<VBY^?;8<C-HN;E[;+GY
M4D_&;PL"DCF54+%Q: :/1IZ5!\@@I<*]%T.:]A@2<?A\/Z.OR:?\WVA8SG%
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M_O%UE'R(R<X/]6]A%+UYEIY;BSC96V(R^1S,@V[PJ4&#5"CY)QFXX<5!^0<
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M8+DH03ZWU9I:Y3$C2DXP1T=3Y].Z[(>>7RAQ%]#GEY 0X.@[]T_YQX?3EZS
M]!!_8-WQ5L7Q^W>.Q?%!<?S[8W'\4Y9S%0#<_24U1&0O(X3FA4QH>3R@^7T9
M 31GDC_[X ^KZ_0A=0$VZ/F!?KH4WNRUJ.MWLW\)F!CFM*=@.7+\* Y)E37]
MH2>CPV3,4N'^Y?35*>OR6=<6BS#O:1F[% !BVG-D'HOO":Y8.NB\<E\G3O+7
MZHP)S'N83G3C="(U!(2$Y%;2)>>"QH\=AA2D*%N-_S0QN#/8^T#KY:1L1(%P
MP]TOZ[Y$"3E!@9O;$QL4-WY1]V(F0_XH-2-=<KC48RK];'5RQU]IE2BG)W['
MX^=_C=X4?=[]S-13]+N?=WX+:.GQ<B?/*2\16ON>-DAH^.O\!3U>=;CFSS^_
MXM1?F#TD3SC1B!E6-J>\*P70<-BV*_BY;CBI<+#>?T242)V;0UKR!,#R, );
MO(=,.:5S\J6:K7ZZ]M[PCA0_,I3,TAMP_3O*&\&9]KXU&:,!PN6A&;]#4P\?
MQIJKGOD*CKB>>GYX[ZGBF1[&TD2>Q<%8%HU =RA/^&-N7OO G^<?D(H09?R0
MWH>Z4,%-!P+MM0S$GI<+ZN]X2*40[V5D;\IR$X8<R)_@-6ZKWI0&URW?VG_+
MQ]O\4$LRDO*:7K]TG; W%;Q<#RF/O)4']?+>793><1=*/M,^@VF-7-Y>E,5V
M!>>YIY%M.T)4$*U9& ]6+W>-R8(B7P&.,S3M;%N7N,9^;1:<@?:7'5UUGSY@
M &$(;/YATIE<K='Q+FPO_L<O-%TPK3!?KZQNZJW:C*,1J2?2:+6"!])B$B@M
M&S*(6VH37K :)0 Y9[%(MGT 2CJ)9I!1PNS4^AC<A3VN$-BLN!OG[.<^4N%9
M5]UT/HHH,<Y9P5"7U6AL'V7LV\NIOP>>;V3%ADVJI^ZG&QCGN)S\7O\J6Z^;
M%\B'I2_"Y0,S=3#TPGKQAP;P]VX[0V[)+!^T3F1(N%+/93HYG%KV^",%=XVT
MJWJ+46UK-(=MO>WP1V!)3L)#G)=&3S6E?.E*"V(DHK_.JXNJ]C%KXTT%#L[<
MRY+?W(YJ:\AJ\C?1,&ER&ZE24\V"8UK]9]>525<*:27_9=&=%V2226'+I0:6
M0%/I(FG^JWXE9*Z=#V'753_S2M-+XD,=C"OFUD?F?+^0?A$? "%[#)X?'JC-
M^./3HJVO8Q 8YM'VU/";7I#>V'7E<M=SN]HYA=1AC+/J]#YNJF(GS;@#O_WT
M+TJ+X%#MA(U@W2[BHF>2:8C+2(*XZ(K+0M8Z/!YZB;2J$.ZJ@%$&;M!U5M6L
M"A6O) EB]@K<E+Q@A,E3Q3LOT/D\[PC1Q+4O!IWP*0TRA'9USG.$8F&<2TSU
ME@LN1HE7^W9%F0-YX>EQH(ZS::GFL?E,FF?*.2VJ?9-,=B1(%UXLZ,1]N [M
M*<W]L>9_:F5= !<Y=[#ON=;G3QRZZV68+7P=;@/5B8M7'8$1!,!$0E)K$8SP
MC:_GHJ\_**M.XQ/.N_;R(X=1'S$I=J <%@.6/.-\#1A.BL:IAP5]E:IJ;KS'
M'\ WOV2E!A 8[TZ74%-8Y<;#RF.103:1:VS^4?TY[_H@@DZF=T2/F4D=7Y6L
M[1_<O7/KS6V-9WXJJ:A99S^UK3>GC[O=.1O51ZWWI(DHYHQN)"'.3X\?G87V
MH1?/SI)YJ[F_3\W$JOY1RS72N@Z>@ !4Z(-R]_AP0C 3EK+00$%.$:\IV7J-
M /'*9!7)R)9A"G+7TAR $&=X)^U__8\?[MV[\] T4==[%YNX\>>[#[&ZWA,X
MIS^?Z.WTR\QWX16N?EJWD^MSDG_OXV/C<59%SY0G&^H4] :AW@?_14H"SJQ&
M6(/T*I>$UN#G"LM V6SFWWGFU^?>#WEV]\?OO\MN4:A4>#6\8/ "7^;VU!7;
MKCHGFX3QJ"X$S)HLI['Q)( L<\'CH]WFF)$H1!?M97/B9;?OP:LFPLUO<\*;
M+_?U(3$\DZF], WUN2RODS;@9"NQX>Q6@S5E72;. &4D^&NR56&/$,7P:4B_
MGK+]>K>;B..\6J L ;'1N*GKT4OB,D2(4L)[N.8Z_O:P#:@IQ6_]>T=Q.1R+
MI825<-VA@OT)1FF87/')QSC-'H6FE&);<)*EI<.Z1F+!%-N%OLRR"(0EIPO)
MF=2Y?^0.A%Y";+A.!')O??;HM7C]]:V@Y2IV,>/>S0CXA,%LY$?FY,/$-!&]
MGXFA<S=F \AY#V@YT+!SHFF*84O.D*N-A9G3(K@1)V_HM74]_&ML]QNZ1+V/
M"TNL2^I^\_MWM#4^ZL"B;UH!C)UW)27!MJ#?L?"K97DBPQHY-\._V(3T0$=!
M>.WWJ^!J(>?8OJ8P_-G0LU>WQ84%#XHI5I1%8A7)+21,9N\X,Z<XV.R5%Z*Z
MZ.I]'J!S:4BQ)CY:<W=5X::*+0K<LN"PD1_:N=/LS^V6J\?V9(4DY"&[B/F%
M,Z7*XD:(LCG?KO8IH5-(/9(BO?O]P_[P%7=>P=.J;(LW<=B# L0LB0?(-^C^
M7M%OP2!#5>'7B<9PIOL8;T:<0.#C:CN&XLOTX_"DG&2X\IWI\W'WS',2) CQ
M*3WNWG^-2\D4)#E^OCSZ)*00F3;-" 7G;KSVD,J/*+8!@)9?921 O1:M*>6H
M   +4U*5XSA'&O/!&B:(V *41*^-8$^T9D+5#0"%?SX.^538]6M$07:&;PIN
M:CFB<@HQ@;-=X ?"@T-%$^4Y6X-.K4SI^A#+EXOL^NO#=]L["UBPONX 7,KY
M";9Y$NTKT4PTQ,IQ:."B&#41*T$6AXT[F+2&2R_XA2K7MRWJWST6]0=%_1^.
M1?U/4K)O$)D;6J_6D0FAQ!GE]T[Z;;EAW51X]2 V8$J)J3WRNI8"/(ZRZ=NX
M.KNQ[&>30?&?^,?)*_H1\SM@F/"+W!H@%VU.2/(4BPNZW2)[^O=7+YZ^/,O.
M7K[.;OW%*]M[MU7E!2 B(=GGJQ9>9NL#,7^F\J ?__OYR]?_-T9>'#V</'W\
M)!.$+"+ 4*CSKHRW%'=__/%!+GX.C=S)^HU7IS23TZ]8236)JE\;RX)'+\O%
MC,YUVV@V]RDR@=*QX$_S8W[P)YH*P(+X1TF6H^=X5E:EZG@ML8!DX>CSU&W2
M7B*M4 UNH:$M(LQ=STR6T#Y<D$#K@49823""$ OADPF8G 9,%-&4PW*9]2(0
M[L;/V/2_>0-Z",JKX-:46LG.3&J?WO"YEH%RC6!ILQ3.[ TN\W-R7P;LIEUX
M[Z/X0X-RM;>?WN-H1HO._M'/CY_X'QZ7V=_;BQ9O[)=1T*WBA,6G9ARR]P-K
M@@12&D &YFA/31$C*RHA&N_(O#KRV+1]2 #,BPUD9+OR_A>]U8XE0NKFV;T[
M=^]EC]JU/T8HWOP-=1FZ^2/OU='=R8NAHA'GG[-GDER3]_VE]Y_^R?N$9S$%
MXI\ E[WU[/$O/YUE3Y\^O:VKN$@<Y7F\+Q;:2]AV1U#4+ RN7:@J<$P@W2AQ
M3BE-+IV4FZB*L"R9.YIE>DVK^<)O["N[PI0_X]^)DVA51_87PG*B?@PH+!U4
MVN^_[KRK>0]$D/=SUQ3KF*9Z*7L*3?"3R@CM[[,217;^RV#9S"/]<?P4+U@*
M-?%%02D\JY(C%J!TRL[]XT0^.,J)Z1L&@:+_&FAM@GYGPL%S,EDRRIT=\P_L
MFGT"9NP)Q:16JL*".%*]_M]*?->T3<AW,!C:'DRT%%#R(21LI/>!"2VI*E>G
M?2TA*6Q.1U X\-[7"$20#L)4!6V<F_7PC;:I'@$9:=E(K5!(T[:\2%S0 +T5
MY;:&71L:"FHM,$"--**2RJ>D!.P95#O&7-)5$^0044M=O:%Z!_>,<5F6&8@Y
M@O.JN>DW1<<0%CRP?12+0D(V46+)[M3]T[H$V&>.>S? #'#W2C)Y.VP6NI@X
M$Z;QS^0.^-,#SG'LDE>D_SCQMP].RM=3?CL(=HN1?<C,6-=+_2WC9MV]<R?K
M]]ZG6Y/K\(K8U<&W2RH6.0%DV4&\&[NJ%S%S47BY>/ITTGL4>GLYNU4?_Y(#
M?3>L\!Q^LE!2X!;>Z;+"F(@YN*4F'S7MLR"5)-Y=?$JNFLLU-/]O?,#@&862
M1# 1:J89T'*:O9*&.DJF<+/AJ+ZEU0/-L=FR!:<GTMXQ*5A20OE "EW*5E3V
MX :"UICV=?$O2J;PV -JPATDIG/!V+G63D0H\^CL3.?Y_#USZ2O&J^H:D3]$
MBQ@56+B0UV)=2KS'PPW>B+^4:&_%2W(P0LX*[Q6EZK8FV22Z"TMMKAR4RL)O
M"'O9HQ05FD4AMB22^D%@%L4#$T_0<05S.J4$2GS-0:$5EVZ MTJSK"W:C9-^
M_+( -W/*?15:=+1]U,<^7'G'.KJ#^S&U"4^#H2-T#EZYM^]L$3R,F)#-2HZ6
MN6&" ')2'DT"G>5AR,KH,"?C#4)>$+E +\7BPV(]KM@"QRV;81,.]63R(('(
M%,%GF6%*@FQ9R/@D 0D2?JJ.8UNF5UL[G)W<TD#FTJD(074"A)7"8^Q&#?;@
MO#6Y?\Z)5Y3_A1GOJO,6LP_*7XMP=);M"%DVB2,:%MJY&*?<YLHLGD?,I %3
M35QQ'IN_ 0@AZ9C3:M7#/L]W@6,<$Y?9_7O'Q.4@<?GC,7'Y24KV8=@Q:3BJ
MM4%)".%&AE)SL[_*G*4P(QEPU9 #4/0(PD+Y_(LFSD<;\*;WPJH__4[\4Q.L
M4N],2/5.]%$?B*6*N<X2KJ(U.="8-B%)[-Y;N'Y9S >Y X6+C5'@9.4I/&!O
MG7TFZBYJ%_LX?>-0(Q$A2JR/KP%YU:78X&G*O[?<\ILMX14[_S92<M5GW],+
MO,W]/V6Q1)Y(/';M[CHL=A,M6)"UD&'D($^_B2S2AJ:&!N@^E0B *+#8(DVO
M<3T^;8LZ"M^7*WR*[F<\2Q@QE,+P>T0(756BI#=3EMQJ4_!0]G2:Z%%JOGBI
M@9X)>D0B_K$N25+"PB(NH7/5&'8L ^P\$'<S [.&^$?9^H)EZVHO#?,Y5Q&6
M9BCW9F53+BLNDUIDU6Y[Z2WF2OB-^C='U?0EBP\CXBPL.B [.SO-^A+PBI B
M7I?E-O7N(^SN,*'Q46:^&)G9M.A)%2;_6 AJZVHN?G'21IWXZ-?ZYX(&D.),
M6O:AR0,DL@W0G]38I,3<\Z0KHNW2S'(-#$1B2)=M-VU!CQ3)P-(%(%5HRPXP
M?(+*<Z$4]!L@+I!-?K(CFE<O/T_F;=.NJ8.L*PO4XIX\.<O3KD:TD]C&<;J"
M$&MDKR)NZX6!7+^T;"]ZTU\&T)9>V^HICKME?W[RRVW"!7W_S???/KA]2J C
MF8L5'J!/%1I!Q@'VPB_[:JN LS"[V$O4KX!$/%(RBO_U/^[=O_^0UX)_]N^$
M-7CTA =P#/N5<]S>FU\I"(#LP<N\L#;W;;W@UE)I Y/2F%]2 *R,V7?S\2LI
ME-UBX2R,/9W,*1U7:!L\;\'5=R7)AA8Q+@IFL)@3X0:1:4N::+O?E./F]<#D
MHGUD<P'%/?F5..%P/.OV\@0(EF'?^ZU'7'H'!*:GEBNBU*5_K,NB9U,FG[V=
M.W:(4V-7H@@#*C^J!P>Q)10:09+V++*/"#?GGS "9![%Q0B0C8+.R/+$+(X(
MIEFY=NGH;6,'[KOLS4WD/;]^QUS2T("TQT4D&2#JXNZ\:(0LE3:4>M"$!ZC0
MH]\#N*-/].3,\#!/WU^F3V=_E[R?^W.[V(.JIPPTLHS%K<L+J@U>*W?T:;U:
M]F=D=E!(BVU;A0^NE,ZDD)ZU,O:,D65@GAL+:1+<A0)^DOJ_9(R8%X:JU14S
M LG:<?G88)72QX.XD3ZA9AB6>2QA?%.W; GO*I/NR1=CF!9!*\(&7;<RN@^L
M*#!Q0G 6>)_I<VC/ABY)U=E;O8O(TBH0^,6\;\GT&_WX1*HVQ5\>/7&J*?%X
M Q50++?<U\EN*_$]E0RUI0T"!DA';3QY=/@0?Z$EU&FK_LJ0B$<C++!RIZ.A
MAP8Y2F30DH\K(4'J$\BU6JIHG;[HHM-QLDEZFY?/?WX518/<K+O??/?@&V^M
MAL[A"V+++P)OF?SYD7<F?<S)C&U>5?^0XQK1+H1N+_T&<RF$_LU5\9^B6U"*
M5GJ>YRR@)34"="$%PO]L&R$9EC& !$Y><QG)F[GH*-Z[>^?>APL)\/\/[I_^
M\.# )@Q.]LG=[_'9XP'X! [ /Y\\>9(>@'O?W/WQ'0^ 5\'?YMS#0!CPHB?3
M>;T@'T7U**HWT=5/'J>2^NTW#^Z_DZ2>;7STE=W]#K+ZK2IK:B9N0P@AWZJ+
MRQ##/.,HXM46%7[V44/7# %%T5,>IA7)906]3).SBD751K$7F*9_9# ZQ%>[
M^^.//W[CC="C[+5?)?9J*%J1*(. VF<Q(U7TP?K<O8\W^NYXH(X'Z@8'ZEDQ
M7_GXLMLGQ^K.=]]\>X^$[ZV/%74>W/T^QS5(^M=Z?0;6PE5))?W'!]_<_<[?
MZSA.\&N2NXGDYG??^!N_JR*_]SVK/=6X/D[<QOQ&0]!\2O67'<$+,Z$JILX
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MCHCY835QY?E72.XF3"9E$_GAV*? .>./KXF0L>-!LP8B7"I/'U-@AT=UR0U
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M@>-4<'TU.S<2H]NYF62*,+49R=!BWK5]'[:.B")&;P3^*WC4!=2Y.+\"/1-
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MNQ1MA)19BD46N*5L3[TSC,%H9;01C54O+S?/D><6Z E7O*!4Z[[5$XR]&^-
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M TV8*X=Q3T8I+[!WFAFGKUE8A6E>H6^9ID"TCL!@6@'LP6(7F84FAZ.Y(A<
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MJ.MN\6;1#\WJ$'^8ED/">YRU+FB0N$119L6F'0Q)M]=T#F;5VR/U- !M*5I
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M_6A])><IF;X3^"B^.["'8,=XJ!4]P$>/T0UEPCLD#7/:?0'AD$592@ #A,1
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M*WLOW"\.U<E.E\XNNDDCF0>)NGVY0LZK!=<.6$ VKETH78.X?5(=)/>0:I<
M!KH0O2M962$+;05WBJR[)R(PW&')NKW^W!(;G\0V7CV_@F*FI1YZ/MKCW(9'
M:TB2 QZW1A!(>N$LI"(D?(Y [-I2V]Y2,R+B 4"--LDLB3H\+/<F@\?&.J$X
M+EN.%85['*W_[*L\??B L3APN2Q"EQ3>4<#"J8ZC>]J[U6%803GJ-R]R/,;
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M_9+0CD./ ]!'F[L.X>^%&!4]A%MP2:#/\,LLL,JL\VPI?:.JV:[+<^_Z<^Z
MX!VFE]< /T<24B(/LX>NG9L"M)73+7^]3@39OW+IF>Z5G54J\P]&WV"2D]XM
M+Q>K<M'VC)Q.]!5H]X60JHY!(\3*6CH'J9U-JVO.K%SA8C>G?4AKW&NNB!BB
MV^8RA GKK@.!R0]IJ=1%=!'5YIY0_:7VNE#EA?(PW07!>\+[I438LJ6YHR2+
ME&<(WU_1N N@9<@>2W%>,!K'Z<N*$;!<HCR'=VF>6>.+'XOETH46WU)CBL]@
M*ZE(&!_*P.J$B2LY\VGB9C/(B;Q/W_'>[-L75?+2#91;/]10^' F!M*;19J"
M55%VS!DWL'[L!P;0[L!6TL[H8<\SH*1R1@+K.JW2A3M=J*49V\7O+@:!N<7Q
M7<2WQ[^;#9\A[$.W,ZJ\"R&NM<W![&=A&R^RC8N!SRI.P:%T7E1)_"(0:1A+
M1?B8<2U8[571A$T2[B;;18K5Q%O9YSX7-XZ:J;0B^*^$P;^X2Y6?U5UAXKME
ML2UKPOHNJ 6!:K)N*^&K;&3<7C"[:.;.;')J=:*_F,E<NR>R0B4+*BZA;KUM
MW"[J:42.D]=45 @M<R1_E/D_+-&_AJ>LZ,QTIH"&?<):?)__>TZTN6LM F?C
M<36OCX[Y,+3)Q!5_R.=917;?&HR)[[UH:,/P39FA4)^=/BE 4-H4;^CE9+7(
MCYWQ>>9.J=*WVMJM\F@F$;1OU6YR%V/S+)&G(1<A#'\->#:EA1>:)<W\<EAZ
M6S_U\+1.OJ_[;EVD/];GN69*_IO^=7<&[)X8J]?K/#DO%D7;%AU6HP Z-M3M
M<L3+SP\F2#!M-Z$P*3)5$C+UP'#RU[T]\0=(L4$SCW0P5(9U:N<!HA[Q!(<R
MSL'4U=!4\:7AK4K#K=0C:\!,H5[?H8#I$:W35Q"V)_8BL#"UA3,-. !&V !2
M'BFGI:1-TW!Y8DI![;EA?R^ *V,?FZH,2JI<[M2XXRN',W5XIKK1J2STW[;,
M3:W6F?=F_.E$9T-SCB,XH*N=ET/4./T6"YHE2<-/6NW(6K$/#%=8=9,G+T,>
M6!ZDE0E07YUE9^QD\Q.X7=1WNRESK7P4H;GUS#GX+B[,!2@@PLSZ (EE/0MO
M JM[G/Z$?+,':87'#M_D9M4L?9-3?"@MDR):(,O6G=>A2A2N(:$F7RKIM\S>
MX<>++;E[,S>DK2G'9W-XMYQ[9I8V.C>DUXN>%$0$D8[3H/ F5UH6+;G8'-LR
M8R%=F\Z#) 9%T0]TBY9[1!AB*)X[K=%8XOXYD7A5[/HX57P_-NN]V+)TLKSJ
MI+G3^@ZR*T.[1-A$'-^QM^)^-:]WB[KKT%OON0*PL-R,^/A0.S XP0#J1WR)
M2 #P7PG'+=A;5)^6GW(4D[_=,FXFK?K-G!F8A&9+27&'\ICN&,N"IF4H7,J*
MF%XR=0,W&+?3_H@H1KT7*^<>K!E='\Q-BBDG[WC;-R#!#KR."Q%*]_E*?Z;_
MUB\+)I:'DC1R&M0I1AUGXU91DQX!F&@I9)0 G]H$%J\3]P*=EG'@AM)I5+!-
M<%XE94+"BA=!\/.Z6+!7NG#O)#@TX1CAGF-]F8$$-R\UK!SO&.75>>%..HQ,
M2(\L^]R3*OB>99(85UW9F(>)4C>>#EC0H(!.A?O$&4!B\7!V/FYBTFMZ*A&*
M:>F7FA;I#%-IY=9+N\[?T 67]45U1EF00.=$KB2ZP0$.6HWO;1JHR%\WD#&/
MA0U)2!W/@JS_HJF]#QIR2\X>\#AA274*A@9AB2=(\$L)V=:-E>S1)+GW(#O5
MF=ROISL"?%]2<01]3? 4A_!*SYBRDMI>$KC1I+AGV_7<!<>%U@\XW+EI'>_D
M4,<;U/&^/-3Q[NGJMD)K$8%88Y36A5*#0EDVB92PJCI0._GS9^*PE6X+<ZY:
M7XUQW&R1I<M!FTV(2>3CI(E_/3V2/A&8A#'E&?'P$<.!9:=G8N1GK(%&4.HV
M/0/=))ACZXP8+VOWETTK+3%T[M9[2T )N[5T8FJ9P#FEI,L3H?4J+?0)+<:>
MU4*N&:/X.+$FI"IN19QG1<D(2J6S;O/PI%K-&5^2LBA]MZ[]V3YL'- 4KH('
M&^(8P![(XT?P&1N]J\=E[E/0"4_/E+K\K-'MOW(A\P4!OZ[DH4)(.GU%Q=2&
M0>KJ)$ UF8!IQP'U_JL [&1)4^%'A=H9GJ]>S>)162C=S8(>%:S TBE&'R0#
M?*=S>WJA(/)7(!@G^/^STMF!I?@[>?5;O9.K"<.623QO\XJ9[&PV@2J#Q>0;
M)_O?F!LM!1;LN?S5# *'IRL2A#:FIV&O2[8GQD_N78S_WNE=[=H@.-ZFKG+)
MK6WZ2H9(Y=)U<X>DD=1IB@:6KY(P2EEZ$+1PWPGUZ?=(X>C73)I@V4.N@6 3
M_"2T=3[&@^=7<'OC;*?BSEF3&]6+9'H*$$@+@Q^GR62@?=S+%PKQD)F#A3#Z
MB$GT=.0\IWP33_G,;)^)"_40MR_*ON6HEL&.PKD9S^-,<)D( ODFO[DPKUT6
MPB%';Z;$-#[)2G4B)D9$_(8E1'Q+0I>D>5LJRY?$'T-X24]Y24<8+RL^)#FA
M.#UX05,K?EU:U[0(_^6E&_2W/V<(+D6<X_2+HY.G3[Z8J>:Z_=0.,R4*%!<*
M[35YT7!_LFMDR-S@HT6I24-BV$=\DIJ(IJHEC'+X'A1,E5S)W5#H^22/:Q[*
M2\.]&GU$+24U>QUF6AIZ^&6^RI##E;QOEE)>E<!.8;EJD2Z)YA2.B5[)"R1Q
M>2<,&Q-\!/\*S70K.9K=N%1F6Y@N8TZ/!(OE"\CRWLD^\T2+N6G7Q58-%;.2
MF35L1R!VFYY;N11ZO5^4WI4^@L!4;M58Y"])YJ+*)<I#G'N*)$+L"FK765D&
MHK>HI!X7)$0/  ?\>!3::-XQXOYQ$MHN5'#8Y5W,*>?."'<[(3]<9.6B5V>4
M%JB_P%%.K%H+8)'#K9UKMB9=GT*R?81<80H8;$T0\XI!\J\"M-M%1KE LP7"
M 1*]&E%KD4M)8/&:B7EKK%"INLTB2IPV52,DVT?GT'EK$'@F7AKW+>=^M/0+
MZN[4T88YQ6,U,D_^F7EC^O6(J<!@D ](,C_"(CUM?-B'H5\O?:.4-:MN;9+]
M2V0$FH#G'!^YTLVSRA8@5BPVA! GD4].9,<#I^8A+!+_4))S32?L11+5<'QG
M^X0389):T:W)D_-;1'P*+?FY1_UK#0K(C2V(8?_,D=Y%2%(G,JU:G,:[QG1#
M)M\Z!1Y[]R?\>ZK3&&_.]QUH$M.$= @NV553-MKKHUJE*P,M9. S#S)UW,PG
M(O#T%S^UTK9'EK%=[1(Y(3AA;H" OM/<O7]/8+2^R>/./B2Q5\"@+M957=9G
M0$@-L_(:9VGP)#<6TQ=NBG;)/8ZO#VBD&(@P28;.6"\=Z(\2Q<H">GL3$8*S
M,HX]QV%YH(>6WDA9*[NCN;N29BVHOC?\NTQ ,= ,"WTX?SF9/7CZ>/;@P0,U
MH:$'QP.47[QX)L7Y;]QGJ H^/$&!_I$[IZ;88:<?0[HN%W+T+2=6/GE$5#2A
M',3#3\GE)29CJ-(MG)TW+4%^H3-2 =N,Y6W]R\EM]87H2*O>!*]$=$O*4GB%
M]6F5,)?@@4U"+R\7RK;D6 7Z&_K(,Q#_TVU""OQD8)R][ Q/..VY3HX3.&/9
MJA-M7/>@P]\"C,B:<OHP2=%Z)X*R"CI0I/\6E").3H_0<NO6J3L8W-])P;I"
M<N([WR?[B_L9SH57+[_[!8\@["OAS9[_^&WZGVZI;17K*RDH8IB&\R40BN^$
MB?L7P7%X*6MB8E;$KC R@Q28F8GIHG!=W+03XR_3UJ '</@D7V?5&U,QIUXR
MMYF^.'E\\O#3KQ)@_\DR#V>(3\L@IWR-$0XTK>O DK!*/RL^/SE-950Q8'B&
MDT]9%[DH/G<.Z:IXZ]GFPP65ROG1I^\M1W)Z7[K(?D&L 5*/FFF$Q$@DS@*0
M^?,2@B&?:=JJJ;5R%X!.0SE!ZY)^6Y$[JH4^6CK,157(.O6V]QMS8E.\D#S^
MXM$C%X]^^8C1;QM <69RH/&^,^J1/C3Q%T70,6;+IEYM #)XD9)KGU> 9S(,
M3LZ -GU3U1='Z]H]B3^O=\([):8.]"7!(@V\"SZO=2L(M-,^G6^*Y-^I=T!1
M,#F#_O[ZX\1^)7@90E<1_T&\;+V6/O-LX'LT_BY3Z ";S6#+RCLZ*U4%P;U\
MU/A+?PO]MFB=D%^(_!B-EIXX>2 W]ZO+4S![7PE*#LV2E010,^?';/2)DV"/
MW+_"^PR'9-\819$(K8Z,P55^\.R0^20]]S7C*..?)?JF[4"H4\\FU I XNX]
M5^-!ULS)DS4-00.P"S@\\SH>+/.LBJ=C9Q*+TWHPX!GS7N4!P7/3HOOIH>@^
M*+H_/13=_T2[8,B5).K#J@K!N1T0 U9T1B7N"T1ESK2$6AG5C$9(,5UP;,)%
MML"XG"V7(HE&G(::BK&QP8&1+I!SN.C0#E4HCB3P6+BS,8W@W-KO:.(8SHNP
M>VXFR&-)0\G%S<&ZF!==?,F@!<_E=MR;Q(CJAFCN$YW!B*DR:(?MJS<(SX7$
M@NJO.R>(HJP8$S(NSARGWVL)6],_2&AJ,R>C!CN[A,-HRJKMP-*ONIM1"HZ=
MJ9PB%:*Y@&K,S%Y,/$3*V;>>24G9/,M=,F^*?"6(\%8AX8*>AS?GIN,LIY+P
M=HTFQ8S@*(+^J\AM7@N6V">]*:?,E$=(GA?.K(H@W+!FH>6)!!^XI]=/0HN>
M[5"A+4_K<5!;<"^W<E_AG*;-E V@^):<">PP ]-AQCWQ9L1R,5$"5Q1K1N;A
M ^7Q#(G,G\,2\EY804*M 3_),8T"]CO.)9!@5BFMDVU;+Z3#C.7)RHSZE1L6
MCJA-Z8E<RQQZ+VZYGTF3)L?V)+CBW&NO.#6C2F9B<\QZP2P-HGO"WBL%)K]H
M?7C#/0V6U)#CQ9B9R[]KQ,KX,:8;T2CD#9IVR9<( Q'%$IP(4]?.-!YJ8:F4
MI)--D9E+G@>A3IJ[#9B&Y'2W=G]%_XRY&CXFDZ2A"LM/65[*@([V.-Q9Z*ZO
M8SH(.ZFRBO55&-6W(46%QE";SF.1/HZOG-,)A3_[($CWI?G;C%B<9F%9&T\&
M\C";3<8E1R0SC,@F);HD>TL:D3:#ND0FJ/(*>7)IAKN[X+9H2;J(CU7DR>@+
M(,.2'('/?$C<^8NH+",R?^[AB&CET2=Z>/TG0JG7#&V";I-N^!R^.\7GV;C,
M22\S9$I(K38VRT6J8)GE76;[+ZH<^K9@Q9-[))F_P8_.B:]Q3F?1,N55RJZ*
M3ZOX\PFZUTO?CZ!96%G%!%?#(3G/C1BY5+>Q\AODHA!WMPGWA(%DF_LG#(^'
MT3KV<_"4U5SI8WF.B(/N&'-7YL8UB=\,Y7R_FVPR)!Y@U.+I%[E6_2-N=.DZ
ML\G)HAK=;2:+>F82IW[)[WG"61(-%.=7(+@4QN!++S\[GH")U$4LHCY40"76
M<0+GB.X>?+EL0<)D5"I)IAZ1MO L%?0.G"<!@@323?/&#":Y;%9F7#8-L.%1
M03@,2E!=]*]&^@MY*_F<52G]$P5HT55&@;TQ]N&"SUX9'&S/C2W(H$\_!#)X
M]B$R2T$B]BN:/7>4;*7 X$:'4C_18F3 @9T?^1.&OPV+T-M,L(D"P$A+-RM:
M*FDC">9SC.'N=>/''A*/OA20!?+3921"-J5,&#UQI _)GR3XQ%L'WP=%!O$#
M[O^8=@_LWO.=9BKP[A=3*QVC;VPC>72&]Y6;7Y(@9=03H]D$H1 =V1?8P]#S
M;6"XA"MGD?M-D8C)HL> 8IZ<?G+RY6]=L,"TVW241U>'*3:O,3C2[0N2&V2V
MX:)V/L:_(?]YM"*T'ZZ;:".7*K(Q.[HT2+D82M7F. 8>ED*]<S6\,>F&7@CZ
MT_W)2W!2@E83M46SZ#="Z)!0,9'&G_>8_SX3/)S!,U=0=ND<"<^LDVD7)[O7
M6L</1A5LX2V!DQ=9BX@_'4BWDN6ZJ$7#=. ^K$(=01SR2 F82[?,)N(%:*T+
M*1=@R5XB 8U=#4$U#[6 +;/C<1*<@J$UT._SB=M>9-MHT4KQ)!I_DH#;%(KH
M=)M,Z$K7D!TC1ZG _&^+)C<78'QW2Z4L!"**D*OJH?2N.000@R^0[5IJ_L0D
M 52K9AA_:=0UC+%DTT$T)<1C[GO2 ,A6-:#W.)H:7*7QL9S621AX#A_^LHW]
M 5M.KZODXPG/^9&8U$1&O9%G8>.)WCH=TTKZ8H+3(9'9B$<L=++606<9:2-R
MY-U%<?W@25.8WRIT+?YQG7)Q'AB*5LF0KWX$.:!;D>V[^W3JO3DF?\T3X%J)
M"5CBZ(@C[E5@9"?0G$FE7C7&?/S94FB8:P1SX5JL/<_M2D*M"/>))>E#<X_P
M2U@ZNXG+VQJJ7;J:% QK=F:D5Z-;S)+@FYM+1( 4\&^E*BNXLP;./HPJNELM
M3K>>9W'P#:RZ:)V$WX+9*WS-PVD9*AXYS"Y&[3BD&NYDG,5$(NTY:#R$TSVG
MV3GQ(-OG(*]_W^[$J1\VIPO;W$JDM(C/@7@HLUE6@\Z@L?U1VA#M8=>ID@Y'
M?DITA!'">3?C%O>"B+[D!)ETHR<>OK7/%8UI*W#&5<]D FO(M//+)GXM .M3
MYD3[<E[4I0\G)V]%Z6M@B#F\4*XL]M60<:@U/^ <?%'E[C=!+I@8L1KO(F8)
M'F:0H-!S<!14H8;1#E_%CW^ DYN'XRJ5)L#Q4O2'HC6"[8GJVLO#K*+OK8C#
M4>6X_6]F&MEU>JX$_7?_:V1+YNP\Y"S6!&Y"))-@N6F&*44?J&"D2X^UNB7(
M5R AM;"6.UWTQ^ES\:,TM:8;8DEX4X"FL*7FEU>'N/_ &8'./?N\0 X@(:>3
M1\"?6!Q1+I<-GI>G6VZ\S-M%4\S).E'N,6+%47/B]\;.Y[*U(,"686"MQ,Z1
MPILA>%"=A4$%4TP0K.$RVV04&&076;.4S!T:?/3L9S1VSNQ_9'SN&Q[B.HB$
MAP=$0HQ(>/3@ T(D?&#.FU&T\WTOTK9*.9YB[JE^VT$:2Z&?WH Y6T 48'(H
MM@.#YALFR-KD[*TCB/;$=_Z'/F+FYTFD\A8_CT;$)H,LX8.$PA^MY^T.CB3,
MY.3(#5+O V''(6CAQE50(,-WMIJJP?IES\4+X_KK8N_;1>O"76ZP+I(7E:1/
M2$AS-EC6]<"]X<3JFJD=>^;1(4>!Z"+K&MWSW5IXG<CQ<7/CIK.AW%]5\>NX
MB,:=H2WK+;5V50M7H'Y2STMI'R-?B@[)-DKO&KKW*-\OS2_.H6P@[T3CE,U[
M?\<M5.N*2LDU):T1,EI)MJ'F2R%?)S%CUL0[KYG@@5+8@B@!38#P*\4;,'@[
M[$(*')BA+4P<.R@S32VJ9,^B"BQ.K8ST\&(>;I\.-(LDI\C!H2W,6I0RK8A=
ME.Q*.'\^4"OT!:6(32,,CZZ1:#* MF6""8RG!(KCN1Q5!,V'$(\MV'M2S<>.
M&!?;X/;Q3$/S)KC<B)7!IH LBYO4G*?43.6PB"19$/>R=<%)-,FG<9F&_QPR
M-QJ=L]SB((#W_%SCS438GZQH@(7A%6^_&3G!G&-4[S>QO!=HGN5DD;L5P$6V
M<R1UP\YRH1**NENK@.TZ'U#*&L(/B;HG$HT25*(PZ,:%EBV%B8P;-JV(=D.#
M:D6">MR]NL0$LT<OB)YNMR6,4JG(9$2'5QY^=R&IL?_$P_]D:;'\CT]>_'\/
M3DX)UIO]XQT]"IR6%Z^__3%]=)S^O=V"+!H7Q",RZMK9U;^E_=:96%HSG_SC
MQ4_?O?SEQV>O7[S\*77_[_7WWR;/7_[X\[.?_OOO?Z5+W*ZO,!0(NN9##_1*
MY#FO&.R'T6!WK+KM#-665F9U]A^?//CDYB]U42R[-7WUP:<^-J'8+MNVSB?7
M?_F/W)-2V$B#\/:K3\BW_GO7Z%TASNI6M"XFY\1_(NYWM]0OR0VG!HR>^JAU
MIIX?'</T[#@:HF[I+WCU;[\O*!.T&W6XB%U4$MOA#=S_-'BSOV*,WVV @/]]
M3.'>_<4N7Y+[9;TUXT=Q#A@L[$AP.4/]2R:'=U:Y_ZLE/^$2VILZIG^=/CCY
MTA 85%1A?%[F6?,V_9'HQ)WI_:%;'B<OE2O^Y,$,/V+"1'S_@N3G4*EDO:*J
MA?2H_;TRAO^3R&(>XA*G#_9?PO:6T^<SNNBV:++DM>WG>?EVEWY]_/WQ3\=\
MDY=R@Y,GN,$)WV"DNB>E_U_1?-)YC(X0+;_X^:4[D<Y(EUA:"-US_Y2UR^Q_
MPD E[6XSK\M6&3I>O/CI)Z7DH.N;/_\J?Y^I^PU<[;W+Q[PO49T)%2?Q=N(J
M@CO%3]/OLZ/7Q=)-8_JJ.YZ-EOVCAT^>/'[PR*>*J>&YR\M\NZZ=^R;%:+/\
MV_3_>OK%:?KTZ9/DR:-'Z9=?\D\N\KGS:W/- ]+W7%Q_<7%Q7/ J/(I:I)RK
M0 $R4W-8@ AE3KF>(44OO3#ER8/3)5W55#O5+TBV.=JV<^2YW6ZN%J*]#7+D
M(#LYCZAC,N[9AN$E5Y>[0YL<Y'+N>;XC M73!T??!2R,O[Q21OG'J:ZZ"+QI
M*@6 ?"#'?/-7]8D)YG:<_MR?E<[S2_]WMME^E3[3'"G&&,'QF1#ITAX+A2AP
MCX79^/+Q@_2'8M[0IG[F7&G"*KWJZ4E/'SR:T4K-FC<S=P"5[.&?//WBY.06
M=MSH9+E_VPP]&'*$B%'*!5:9G#7U11>B6&^_*->]*B01]8II_OE%3C_+/M>S
M_%7PL9\Q0_C)TX</X^95B0OBK^(KFWK)P-WY#G'0/U]^_8H^1%J=HE[?D>L.
MO;."HQ-9#%2/6.(_8^I X$RD7"! '2]U=IXU1 (A:Y=Y5:Q8:%0HD0(60< 6
M!A$2A1*#P4RCP2R8BX5&4R-XWJ'FQI.MQ5F_I+83$@-"%$_\;<-VXVA&'CES
MIQ.2-?/,Q7]'+]^6^4XGY?3!@],P$:.OH,&3T1[N%AES-4R_6V+R!/1FH>5E
M15M>J"GICU5'5![469$U99%SN=@M'7YD^J D:*:TYG>^9W_E@GMG-.A*H9P&
ML\"&QSU'2\D$;/F6Z'; RO"7D^/3AX_YXBXH+!'P?S8WMULR'26S] @?8J:O
M61+\%S#",F=32VCH9GH[_-*7.5_WY'1^=)H$U^E;I=W&$N=G9R +<#:*ZK4(
M2PU7AQZ*7VA@6IKOT'F2N4.Q9&/I7_R+!P_X83;\VDGFDY(88=\=(T,-'NJZ
M[81.%#(GBCINB3I[J7,@4G9,,[ 8#J6';E](@Y>X4!!7<D]?)7\YB>8#E/ZU
M.\XJ1"RTG9?YO+,4:EMZ)DDT-'E^A%7 ,+!;9/VY%Z;9E^J<,W2>=3*<36*6
MGA!2-#WE\\*B&QAA/<GM6F2?AHQ)+[6'Z;MQ'97M9NOUC[$^"H";8:34OJ)4
M;EH@+*CBU;?/N93K(7.CKX@__5R8=W_$IAB*6VZ;VCGX>&7%9CO;?=024)I8
M?$%)ZE9-MF6Y:/ZBO3/GWL$"&UE1-<HT'\0M1DY'2+P1*2FZ/>5AB:L^-/!%
M$"6C";DPA'*#Y*/I*;/&G\R,F+:9;CA11-'@AX\K89?UO*C([P9N23A+&'2:
M-,_"2L<(.B'=A(*B4SEG-D239@^V!OT<<!NG[=D'V[PVM2N_D\,2!UK*>76E
M'DJ4>D@EYFABW+].(QURPCT0W+4G8XX _"\G3QX1S]$L_<OI@R?\+_KI7TZ?
M/.3_BH)#;%E= U-715; [5_WCD7)3+TTG7TG[51[J,%H\6U]SRJ'690*;41Z
M#?)T S!9+';+-'>"U4F$(LH ]?QKFX>#'2'%=DK4NFO\J<SY35D4'ATP"P/,
MPLD'A%FX_?4ZR$ _^I RT(^^=!=(QWGCJ[+*7^_-2.__U9775->82,K.B_SB
M;I/2MYD<P/OI:]UE+>8>'-[>I9;>WVZ7;C@/G;B#L%B$VJD1 N3D%Y^9,WM@
MSF(*)3X!@UP#8Q'=2<>LZV6QHI:1+;)C(Q8EZMFCYKRZCTB,T!5,6%GNJX!,
M=%U"TPHM0>[1SLIZ#K@ .61(J8/6M=1&>7H<<Z;^T4&_] RX9NWR?3S$WXO-
M&74D_L<GSB0VB__XI"",I+.A)\>_;<\^^>N[7Y[O8J3NTT"=?L@#=7-;\IYG
MZ49NY^.#VSEP.T\/;N?]VH#OTE(]_) MU>]_AGW#]4B&ZUX\Y)VQH=W(@#XY
M&-"! 7UX,*#O.VN)2.['X/?_E_'[ 7TX^2K]D8A8TF^*UM=!V]N)^>Z%3_8O
M%!Q)P\-]B;F03A^D6OZB)GZD,3W=-]*7S_^%/"Y5*[D$VXER$@I3YQD4C"?"
M*Y!!74 *9>-BN@Q-I*RJ2Z&?W@PY<Y8O=N$@B>_DRV1OM,:2MFMAL'K\X--C
MDHWA*X&L?=7E5;KM ;"8?BA/3[:C5CI4ENF%UKD2KVS:O#S/M4)!131LW6S1
M=TP>5#09<'HDNM WN=),LRH$8X"IZ(2KTGLQ IY8?Q;NO_/!(V]+$-]Q[6"=
M9^>[U(6SF7;UNX@[$Y['M.OG_OM* K1NZJQC^$QX23<"[9H&^NWN+*^.&E!7
M%2*NA0)G3Y2'[C^(NXF_%3Z<E]11(&A^YHPG]>@[8PK8OU?^K"F\J;/'I_4^
MG<KJ[7-&'L,9T>NN<RJU_2T]??J0DH-RR=,OO]R^A<,RD>RSCU+FJ\[_ZO'I
M^$&^2H>OMRF6RS(?GS)RAHY/4#N9>);K_I\;W&&<KUQESJKM_A8MA/$ZF$IM
MRMZ<W(_\)I\]=VOJ\P$2^OV^VL0:'[T;%SMA07IP,Y%RN=!7L171B;KUE[HO
M*^(ZP^:6Q'\%NPJ"@JOL*BV-F]K6/]52NK.%\DZGT9^Z( Z$HV".]S(_RQ8"
MZ=$VG+]A)I=Y631%OYEA=@FDFB]"+TU1_=8WK/50NZ.?P3GNX#].1Z-T26'D
M W:QGX5>?@6U/[>#_-YYMN^!8W[ITDRB-3GB1B"K0@0>^USP -?AOD7GJA;M
MFYG(G1/J,R,?%LQHA-8H\^J,:!6IL;(C!BM%Q1!GC!"^N<_"-IA9QU,A00NN
MQY 8S]#]/[9+(GXWT60O^V7^MWNY)MZ1 WJM+-"4ESIP12_W0_<8@V1?=Y/S
M&"<^.04:>^@VTA ]??+%TZ_8J$W[EY9;_^ML(8W4+_S*^5M*FY]"%_@E$M)(
M:*@=M8D[8"^(#!?$)T \SN5:@W/7K>E,NHV#C2X+XCZL\GY35T5VS#XQC/#M
M6&#^W^/1H-U5;/,1+JT?Z%C^!J0N845MJ=^!D(V^7=]8*5I*S *C60]>0;>_
M/ Z+XHX6Q7.)XI<I+0]:%7\CXB;MZ['33ETQ%WGVAHBB$I8J$1@#<VKFP;!$
MN1--%!Q6S0>S:K[/:7V . 2!VJJL+Z2WLN4U])Q,1\ZNE*ZBA+_L30Z)@&1%
M^!QT9"PJ*%RGK*;'L2$RFKJX^$J?Z1V8FZ.G=O_/#\OL@UEF/VNFVT9,O+Z\
M-^3/K4W=NQ53H/T*N=\H'5Q4Q%K((@YHA<S2=D/0XT7?I9^1RX[%,W"NTBI?
MO#DLJ ]M0:D56>ZDGD(T@/[LR_SL%U1W(<^XW"4@B2%%GH:7'/6%>,+IV7[@
MW$[K->,[4CFB8(>=#DX26G+KS7U 0+^V)WXE]^WWM/SN;1+@9B7W+PXE]T')
M_=&AY'ZO=L"[A"P]N2W(TN_8II>"XXF5H7+&M+0P91'.4@$&]).!*8IU45X\
M_U>HAQ.[EBD+[RUC.QM;H]L._;A,1]>^X:JU@+:CY)JA;QIF$*=-O+;A>@F;
MHG(.1^:9]>@!8?/UR9E606].-%'5LE]PCB\3:=N?7OW\XI=GZ;-?7M,9M,Q)
M($KD=*E<;EV45L #F:J[^+\+U>Y%]B;GPK>Y;,)Z1/RE&F3;[&6W1+[%3U]2
M<(=O0..G4<EP(LHMJIX0"A@7]J,(4+YAT *<\UE(NW[_WS\\$X^=6%N(1CI,
M.N6;W$3Y?LPXJR4_<^&H,V.=ZG5A&K-ML01QVD*[)@D;?T2-O6[.0*X<)EB%
M(=#UEF3+;"L4$OXY!N/,PA-]W;>E?\;K/2":49T+U!7$*9-75/T"*YT=ID2'
M2?0A>?!!ME%L^K++JIQOW>2;&M)ABZR9D_Q$4;\MEFY"OZ990X/ OHDS\T1N
M"!:(71V)KHY9M.<V$'H4W0LWE&CE:_N"O<Y"53C0#DL2(,495-=8F810,$0P
M#A*_:D$:Z/6&6,YE)GHWD.X__>=^#PH7.1>+,%0D2M431Y_;_&A.I+33'DJM
M@_UG^__%_;'_M_4(5R:.+S&>>25L.'D2U+!6.?@&VUNHI!R2W'\\POL[;_EY
M"/4&'737B/HDG%-$'HP>-QH[XTN2[M.UV>.$;O83&%2RKTCKQM9?& SR560[
MFYR.\M:;+'@>%5*E5"2\@\3Y8<G=BR7W4O L+6 1YZ ](#5++(48Y2*.$I_O
MB9SO?.[G2[KU<>J68(RIP&*4/Q&NXK"N/I)U]?70V]SD&>72E['#*@37W@_%
M,DJ^S8CZ(W*9)6?_%=/E+HG7.^=4Z)'X@1R"@8%AF75W5QG^8M]2&[@;1SS>
MM^YPW/AY;I:G^O*0IQKDJ1X?\E3W?F]<@P/AFZ)M>HZVV7CQT<B1JF=:W5W*
MF/Q.\'>6F?E6;O"-B32NR*F$T%Q[/[1$RHSQ;_([:*^Y'UT"5_4(7 N3__ F
MS0&G7_I.Q0G@O_8;?#%YR?L$WO[#=[BV ?%WIU$/'LZ=0JGA,?$KC_]7+<>E
MQHC2D/_[?WWYZ,O3KZ)LY'6S@,26R>0<D@Z<3@72-TA99Y"S%%NPA-:H.\F*
M/$X5'J=_AHZ"6U\R5TWTI3/\7R]_>?W_RA0+V*0VI\W^>>9L^-A0ST@+Q#E.
MQ!>]MT.!0[5A@O:]P/YOH_O@?4RY/4IS-Q648-:B_'"2"+0]JC#$925LXAR9
MZ<M2^4KB8\KZ'!91')0C>,K*7*D2?:"D;#P2'MU) \,M]RK8'*HV*+S&'G%S
M\LSW *>'I@24,MU"S C75B_[!7$INN5#%+:S9%C,:W=MEY/2IE"D;K1LY2F=
MK%62F#SUY:JQ26/G,2Y6(2.PIYZ67%&NDFP5_;K*<^IS$+O'=:M].2R[3U'
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MR'!S*=\O;L=:J3K^6C?"R4)!UW0%*; ,)VBF:[-SWZ].:9]#MMXC$Q"YEBY
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MVO-_/(.K^3IV-6^TYUX76Z\K>:>&Y'?RT%QQV]]E(ZP5T%+8__3%XDWBFR>
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M;5EG!+)QL][UC#NWZ5-$5=!YS('ZH\,]Q5)I&2NM2=74>;#.=<T]O"A_FR^
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M*1<NGFE)TVMAGH%V9Q6H]:..0^WS,3&F^Z8GO4TV!"I>-5CTW40]>_^S!5U
MU5,"PRE84ER0REW6JXA^694\T)0"[D ::B+P6: [A8%D1!'5Y*N2.C;;?KDD
M>CS?KCDE3_J^4!EW(:'T>Y=_$CC!>",(YPP1+E+[J>"C##5D2C3574X\_Q5Y
M_N-F5_>-?BD?GS4U(_GVM+HFDZVNT]VR+]HFR\O]*TV6%\<7BT6_07\_U9W[
M-J/ @QXCHT!ER<LMQ"9V:;8*M!KO"4,J $2HD"C'JK)N',!0[A[BC*@U.UG#
MG3M>S'ZD@6[1,4F;C(<V3(9[W;Y]?ZP\]W+)3BTU/]A)-,W!$/*$"UB7.#>K
ML])P;8ZM<*#:$J,;:Z$<YB,V(62%\[=;YK=NI*\X\4V6TOH<4V)(8TI@?*/]
M4Q 7JF]+/MLH$9[L;TP+1_\,O-3\ .GG+;.RKE T9NL@O:>).=X]>TW+S%X>
MO>EI]_;@C>D>$Z3>=[4U[]6LOZB&Q/"1\KC;GSE Q=PW=D0[,D_+;*Z -4M4
M[BG,HUZ H$&^[9MMS<!ZO_&="78G!?'X0B/$GTDTZR3[0,2_V6*=4*,;^QT$
MYV62(G0I#Q_9PY1-_ZS2%LK2S)U]6+8!^$MD% $PFMGU1\FPT)F0C(13;F_-
MW*D^]$V7S'?YO-G3$A"!S<.F3-@:7T1R'-[_"^S'3/NQQ]LTP#&#NP0W)/%R
M1M?&,0P1FO5N6[\MLJ#D^2?>Z#<(THR(ZF6I*8A )2^;>8'M/!8=_$9Y*%[!
M3$YBHM^W:NY[.BXQ=I0@)RL&+@QXQ]42B0'RA:5A *Z@<P O$]DB@G; '[6?
MUY"^@."#V"PIS (7NC10N;FM=>K&%U<*D43I>&%3"[=5SV4#,D=M _$7MX].
MGBCYY(I>0^AYW-?52><WWJ\,QL1<0I3.6BS!0>8ZI@2$3-TP<+1!_"5=#Q'S
MESL"BAR?C-4AW>6?/OZ4@EOJY\AOT2;_&5TZGC',*1UQLCIRR4*HK[PJY@B9
MF))7"%7SMT6+92M!S&"%@53B355?,!,UJ%376;-9]67JYFC>ESF81U9N202A
M%6H*A'( ,>\GW-07R.8-)Z]A=1;Z+L^FS$TRSNMPA_B_JK)X(YI"6!JE<T\V
M194UEF':[[USZ@L"7P\8^N$]U,L=F)CPODCV8#2B]PQNAEOQ I+#2RP%_$;/
MJ;?*1N/0*=$UXZ4W1*I<9CLJH;GEB_L)FTGB7&\W^Y1>HB>1L1L-70A;^6$O
M,HQ&3-WL0J-%;KZTRN8-<5ZW")O"2+OQ=V].7EIM!FV60%&)C!N"<&9(ICDE
M'[R[@(S$.C?CY-Z]S#M5QL$_&] .;(A%EV>Y@ K[GHFVPD3#2:<IDFP<:SVE
M:V<M."7V&::'C.Z2EB/"15DAG\_,]=T(=SJ/^)0L"WK13/MI1 FN',.562H3
M/Z$29^[URD":Q#<I:U#+':?.:WJ5;]W'-!&^J=;;>FH5\W,7VWMB?:%#)%$_
M&EL:5QSU_O75>5Z4<G9L7,A$2A(Q95A\E3^O*_3[S>*O [D//QJ0$ZXXMW.6
M;?(C9!^Y9:&)F '9R16F,)M6FV" !A)Z2MHBXBR4="I+*I:4]5ADV]M(%[UG
M)^N2&]^LG/7H4,X:E+-.#N6L=[?:WQ$\XEIAVS4P%#<AFPH8KGV(BK_^8^J3
MT]$H72>&G$!1[*&GNCY>XAO21_H!^DC/61]I")A(@)BX%>2,+)GQ:%PJYWM[
MQ,V_!Q@PWP^B>#( 4=P>*_G]&<*K'NN>%K1-4W(R(1DF%)+45QPDSC+U&X>!
M/:)XID-@OFZ.]&>!/C'3[TC258E#L_.L7<"39#8#E+C<*Q?;7K4_Z6FYHNMS
M"Z64QY&XXR?VN5DCLAG=H(3\-!FXN+ISQ"^.UZ.!X/].8L<V6W4@8&2*4B]O
M [&>-"*5S(@IHF(]:N>2%3[=+"/JG$.*()6:TCV@]\Q]0<D7./1";0(:"N\R
M4G:&:<[E[:D'=DI+S<OX%NV;V4"(E7D914N''_4VZA0WW*_W,-5!/?RZ+_[N
MMD-HKW;_=MYWHAI74:>_FRQ"U;M'8/X?02&\H97;!2&ID>R6SQ2@&:\!R5J8
M99#[DJ8+LF#+0@K2)T^.3D^^:Y+/EODVKY@ O^*\  A71!YH^3D_!N(^7H!^
M]8,KF^5]A?X$A67=]A'5OM41'(M&(]092 *.9*)G(L+$4GN2%(KWAM\/V[K%
M'N$R4M;IZ[3N#?NZJ=M%O=T%Z4@ZC9 @I;P&*$D7PL(OX^BS'J:TR'9&IWDR
MIN)B(,A?Y$\UJU61D^7&&/I/[BZ*!&ASQ.?.IAG#$D09*3W3Y14KJ6GD;).6
MJMNU;+*"6A!%O\#MV5X+1Q%_HE#9YJU?)=\^__$EL!#/_]4>)_8%E_DY]7M0
M/=8:#BP,YH#-",D4$D3<:;O<:TE,AN$>&)7;*(^0PWK]OMO?53#YQM<5I_EA
M/@87ZJ;I%D $4&HE7DLB1');WZUYR,Y)];7,^@K\Q#CP*9D<*K@J:8IM:#3L
MQB4/([D:06\B)=R!K+S1(+5P(/8%[,YK^X+#0F52]5^.$09LI^SC@Z3(*,B3
MVMTT[W/"]M%*-;H96*RIXXLT3+9;SJ!*MM2R1'L&5Z6R9^S%Z&EFD3P:/PWD
M!CKY;RIU$YDL_!Q<@T40E$C6C2=E'+U!- ]A51U#NHS=&/K1D_T_VE,6@\A9
M9M>%2O/:PI,N#KJZLJ)W8]V/V<2]4$R(ZDU<A\K*T<@E$$X:'3IS:LJGAW0G
MLEMT7,1S!T./'&S.!/^<"E_TK1S\&Y:CZ08K9;@L>#GH<<5'0IOHX;%P/BX)
MY7DD&A/R'HUD4G0)(6W\<M'541IZ7+WG+B$/#,E0NS=3]J;H9HG,Y/_M_JV:
M!_.^*,D"6/)Y6ZP7U<YVPV/K?IKN@?1<->,@^G%&)^'F(XH90#%!8VM0HY@L
M\RQ0U:-0Q;R,-2ON_HTY,KW@=/2\%EOL">&5$%](\(R9\D;IENSQR:/CTSW-
M*0.3?'IR_.4@,W>+R?_?UZ?P^)#8'21V3P^)W6NNM+M7B].3_SD9WB-W_G^D
M8G%4C>S+73A3O.3,$FI/[4!8,!T-G"I4*%9!"3\'*G$4:'GB3/IMMG"GE7,J
MQ42/KDN8^+@E) 1/N8O>ST@_Q6H_ATO;@Y3*U^U"A.1;IO=$G1M  J*J5=V/
M61HI=5@Q'\C8*@9#B\22FU+,,F2541X$;U)<'??Z=)</Q(MNW @#0#V?Q D=
M@.? :IIF7G9-Z"XQBBD=P1Z-?[9GT&?#FP_:#XS+S=#BEFFD4-1?[JJ,Q+F#
MUHID$04\*B^[RHH2W0'(UB "]PJ#JO7<<I>,U_"M5'?;Q _B\4(BFSPZ[8AV
MP^4N"?_*ZX5[)YO?.Z@?!I&7EN7NV'&S# _D6L&!Q/<LDU/H;DG.^H(6"_@=
M6DI/T!(CN3J,FENNA)E(O\<R>"9*Z7B<7W,?2OG>;?J-D8(8:XJ--XN[$V"3
M"3GK'R;;['Y;^EQAR:^Z?ED(Q<:W;[><<?LEC.0KZ9AYSV;WJ_0>L%#30[SL
MF\0N--]0U#)1' 67/E@AXV/5IWSKG4%XD>$4+1,7#JTO,BMD,L]0UF"KX**;
M?K/EJ-'ML,0=/?\_>V_:W#:2K M_QZ] ].V^8<<+L;EH;<]T!"W);LU8MJYD
MC\_<+S= LDAB# (<@)"L_O5O;K4 !"7*;8J4Q1-Q>BP)2Z$J*RN7)Y\<I-1\
MW08 %"TA*U6*2@JO^(Q1X?@R]'?-&R0=8#Z#RA1,\ZEKG"V7T$!*5MAQI<"P
MY\#B76>[]!;<A/C9*I8J)5,$5^Z)B/IM@HH0P5*EB9,0"N]B5Z>:0*NG72?0
M&@.JJ\&B0^UZ.@A[9I(12:\T4923",.*9A&'81^1<<;%DH:.T^@ZI1( O9-R
MWDD&O%0#D*FTRY-0!+."NN%?6J?ZSC::MQ_GMZL!LCKG0\UN^,N\B_,NSLV)
M\M^GUZG[-!&SAEL<M!%[:R,&<99X#MBL318><B])[P>GX,8)K-$B5ZIM;"N\
M7.]@7+3C&*,49WK/JZ\*]C2]08+^^A4>(9AM)$UDLQR3J82^Y9C4[45+F1$=
M;)\(TRQLG;X.XHAQ%4H\@6,'E3R+-TUS;'-'$%/F;\?6P=K[Q[YPM'4?L_#@
M;DE:NSR1LW!.53\@2YVYEA(:]8[U1J2FN?K4G?T%K57S JSY[%8K););3851
M227=VH+4<XFM'9,/Z92E>A_O>P8A:6L'.]?AC_I&&U-;BE,'VK!+T@3FZ#HD
MMB%ZI3:T4T\7)&4#6_?-U>!_4B=K-]=FRQRM3I0I:_C'7#ZCFY]@E99NH(!(
M1ND;8:QN7@BA*:/B.Z=GY:)28LEO/2/#\2Z-*0YQ9T&05:-_>;QGW*-&$G0?
MLE&8Z*Z.>/!=B1#([^B(/[OZ$/BMSN[AWF_M9FO?7 .RS-V_^%*!V4>YVPM'
MWF-D"]^AF;=M TC?ML4E_FT'I:KSD_#E,!/9+?M8H19&NAL?>OK).68]7;XB
M?N/5![(HK#T%SCAN%TJ1HG$4YGARE[@8=*/.4DX'AER@34)Z-[#=>PUXGOKW
M8L_4$K6M9[':3I1:PNR25+7]T?H2%L<_;H8R7[^0GX=.T,?@V>4<[_.Q?K:$
MV59C(%I;H1QED#]="38_Q_L]?N,./5U"/(_2[-!U\:79H5=M=EAM.DL! &ZB
M;#)N#/IWPB3U3 SA*%.\M[1YBP:7$?<T"_RW<;H#A]JS$E!RW\\CF.U9BK&3
M+A6,*9UVW'7J03%U*;4DZK='C=;^:*R2,MHRBGDQV+HJ*&XFH89[;<'3EP:I
M?1<"N/(@OLM;/R]N0F].6VG$[FSK4J]W5&ZV!WO#KZ62^TN+^;V7;_W/>]+S
MLJ%RS#0A4F[&Y"':L7&<'0K;A--H8$OPB;A'<:%?#:_35J"W KT6@;;,)3I8
M]!DLBOX8*;2R:J0 @<!LF,WW8)8F%^Q.D</L8% P[&0""7V5(/(K;VQE?BOS
MZY#Y'$%K%,>%?X$.=JN/:00EQ@DJE.5Z^"68)[3[MI7MK6RO0[:I+[%.<7&X
M-70,CLD4B1A</3X?@1!H([,78(ZLKQ2%H=#/TB%0$T7#YS ^&*.T%/XG4BG,
MZWV-)L6$J14HI\?L1^RCSBS'F:G@P,B7#8Q1=9&3%:QBC^&VW</VJVK<9'[G
MW=.YSCBR2WCPSK4/P_CM;S%^%8Q?YT?&^"TA4T\U!E*KJ9:FK[_[;JGH^*NJ
M]1MJL#\[H=SN>?>R$J2_)U;[/4[[.P-HRW[D7[A^K>->]Y)C/-Y$\$VTOG;1
MOXMI]ZP7VRSGLC=\)GLCXY9/9#+4(/ID2T:8:><$36,3/O5I+M&:]B.A#Y,D
M1?\,@P\?57_LOYL-&B[#ZK7BJGF4 R:2@A/^.IIE*4,1J(B7P,C%%$U=,ENG
M5)^DY:;'-=!@%XVR]$97^B(0C5G=R+_+L11F8@M'%P8LYCY^><*2NG6!3\77
M_/VG]D];65E"=X??AS/R>WKNSUIWR(K[#]+O%BMB:B>D/I9P[&!.([E>?;%L
MS:)^B69U=9<V#2Z5HILP6T]ZE1]VB(->[C.4N7!+*C!:@'XBHOSCV9AK;>$@
M/REZ883_<&G_*FNVJ5WI'W$(GXGKXD877#-?![7(] 30'?4K^""-J6"B3P1S
MYGZ2^J,"3=^9POUX*P@B@LH11!3YS/.",-D(X$!F<\,+XCZ14%'F9P:I"\C;
MM.Z4"-"P0"BI9KQ7.R8EAFBK^A%KBDW$1F)"C>A^^*3/\8SW;\%^9R23PQ(D
M%2+P**Q(*@&II%#&T)&XT!U]CA"RQ7@&ZX)"M?8;1T+*\.A%</36CZ2'88H<
MX,D+W)0[6#SS\C'!)1LT-7>R0/#11> JO1>]2KL "FR";%&0U135"75_"7G(
M =R(2Z5<1*I$=DTDM8>E;2IW*CHJQ8C2Y&(!GT/@SS7PFVLBX=""^"_^&<WF
M*_GGG_L2]SWL<\R5.SZ<5U,C(:U\S.P1\AUL X&^6UHJKJ_'22(#GS;NNC?H
M&F)^WZT%Y>[A].NR'2C78?PCTHZD\[@B;I5 P(XIT<'@CE,)N+"HYH4>YYW?
M)#G#<1@/47Q1^]$-O[\TG_GM#D3=O#^FB5C[_O6L\=QROM%E!Z8D@M&NY/<M
MM70OV%%TE^[EZIN2EOF-[C0:MQRLR5HX6!UY(VXD5^"X'329A<QP\\VBUGA<
M/M>MI#T!2=MQ.ABP)C--I2S>-?]VF?/Y;.)7TAO)1FR]\E]K$_'$J68Z11N*
M3?JZXVPKM%NA):$UPN.6PBE'>)P2[4#\B#?(D6:]!B.(%XO--,<V^Z.]4Y+*
M.[]_JVFW0ELCM):JSXD)W^DG?#_GP',X"Y96P8TE=? *N@<\;2?V?B#*]\*<
MR#]6%7-S3N]NZ?B^,+7_DO(:8>36:?U:I:34 GRO_\JQ$_N-*W)AYW^W5E_U
ML==Q1]MT^OA;J'GF0V;#*-9<6],H3F><]Q933Z\S&8.>L\S\YWV]S"[<[9FM
M]?>*2Y@SQ4D]TCOL\;+4J2$KM[.4*40O6+R9]Q<'H\HSOPI[Z&GES1Z&X#W8
M(G@K"-[='QG!^W1W0(FEL\O\G'C<]'X_Y];D'XCNI$BBV6/2N4F3'O/9T>]K
M3]%AUOESFL4##3QP.4@\)#:;2-^'<,9U]:V#P$_AI/)WFTU_$L4Q4;"K%/NB
MC.*T1^QA7(,Q'#*U6.^VQ*@1)7DA=-W]VP9S=WVE]U"EOGTH![FQ]TQ2<!L$
M?.K DI9C_X1 LM;<I[Z@IAIE]@[.K2_B]##=ZK$A7X40#79G?^S_W#YJ'.Y[
M/1F6,*$'3&7Q<VN_T3SR2W]L'?$K)^%_B'14LZ8-XT)Z?!(-FP#OA): J3ZQ
MQR4"]4)JI,I=+<VX/3A4%5-;4K:>ZFOE*9(%I0X;_C2=&O+S!8_-)^D78DW)
M(J( +;*>Y9ZAXL4TYD:%TG,W$"*9/DR*</GWD8^;'X?(!="U$YB(;#;FS"WR
MV9,@:V[N9\401)O];>I_3'U1.FLAD-P</(#FC!RE<+;MZ%WGL$8RQ6,QY98.
MUQ&! 4")@+G T#4&/L,X#!ED")O@SQ1LB3B$'612_L3 ;Z\J=65 4$PZG-V
M"O!B4 !)+KEU*M9")8#(+!D>*P#NI*,2D.*^.Z;(5/IRDZS(MK@R]6:H:6Y0
MP6(O&F)LI88 S(.'Z@:?-?.H<Y<:XV@0W!LPV1F5F#$='?6>@@_I1],X(BH:
MVZ6!^(STM[ODCHG"8>'%V":'Z5'H\T9I&'_7[?C@AG4K88OYIE$L[)IW4.F:
MM^9AKGH;TRL^D'#4;E ^IG#W%<3(B'2KV!B*S\K'!3[]>#5E#O3D 4#Y>3S*
M7=&71PT4:&/W A&3J*5("^YP2ZX:>*$QAZ/??_/QAQM+;DVHR_K;T.)Z#QIT
MK(FR _^TR-*I"OQN'L%/2-R '>+-GZ_2PKT:E6<7>ZZ'VR*V)UD(P6)V; &%
M*&LNGM"<Q:1+V008L[>3.MZ.D<#?=#,<D-@OW_PT%Y^(1ZX#0[S!JG$R+;AM
MT$C0OB;;K>_1%H]P4U,[+:V'_3H():PL]KO[ BK9HB@)##U%K'*5I]>AGIJ.
M;W-PR4+= X?[#L!7];F/%?,];K?($]XB9](]B3U$PYL,CT@GW+9@&%&'.V<;
MZ'[W%H6Z8!\$U$!BBJH:O#UN>%7>#G=A>84.W$!:B^F " \(IWB=LB.*=FRI
M1UHN?\C)KNZIF.Q;"E4,"L4V?8*Q!WAG7*(S-54P43X30UI3F5(T$O:?T]96
M;LI5G[@613M$=TXG]G% ^F"=I0C!"\&>%X02^(JP?7*=A6T4C/MMU=6C["Q_
M)5OKRA29H,I/8/E+NX@Z@- ^H;H/=,9L,0?)_J*=X9+<TBYSZ %9[&W%BY2(
MY6"34^/FRBO<.XDBU:*N8& 9\>"B@]S/TIQ9@S&<IUP67DU&:&TLLI[ SFJ8
MWKN/ R5])FR;/ZQ7<)9<<]<,ZH-3BF1,BUX,&RE3L9P<U#&<PHX*^Q>#"L4X
MAS:KY RP^PT;9.#T4[U'AN3JXLH.U 2?7\-I8'6Z-+#2PEZM">&ND\,4>SUQ
M8+L:6S*LB*7*D1=DNNENS@OY?'2-"&WL,6PPW2T]-0T/'.;MW*@6:E:=T.G2
M=]H,X_5$A-NE +I_6F9$?H=GZ96<I27N<?LPMWU H%F+06HC["6),>=RPT\=
M4]=LY]J!HW9/8,6F.WBN!W-=02R3"'$EWTU*H:>YIF0&C.1%+6!=0N:<IPTC
M&+9_$[6XRJ4RCWC]OP\_W_9,7L^9_#;,X" FK3+E!O#<<3V:](HL9SYM;E*;
M%RQ8?<QKA2/EZ!+JJ4:\IFDAV*(BY]00B>A2SR,/+*$CJ+ZV3?N23@<\TX34
M!_461W^205UR"3]'E#R:<<R8(\W4E9:UJL[32"LDNFA^XU&C\;E7AFA%C!(B
M_Z&MI+N,]].</Q(U%S8IH[@UO)(,?MU*@/NUT6?K')YIAZM]:@K>B]^," YX
M1E\'[BN5?>4IUGYTP_\@@6SI.$7G1FY-*1@*MG4M9"#Z(^&!QS+=N)K,[YFQ
M5N$?(E3;F70# ,,+S;)P%@:8Y,(>\ZSX20S WL+V&=KWWD'?NU3"6*]!U@H\
M62U/^T,Q)8=;3$D%4[*WQ90LRDX\0@+DL]5/Q^4 VS-.VYXEW@F<=Q-I(,ZM
MP,K^+/;; #>1CJ(/I^=.SPI2CA]55DQ2[CF97H<Y-F?/V"2S5YIN>]I$=WQ?
MZH[A.:!U O>:UN*E/GK&T]4F]H*XY^/A$9SEW(A%I79<.@ 0< [EVJQO)_#F
MUK<<;JXNKV:L"I"2 OZNE&E>X);'(.]4E"IL096E"3AY-]AS%KPT3)XC&,7V
MSC4W>=P#C PX-:,>+%&ZXSS#FBUTS',)CM/_K9[)BGI^'7]R#!22Q6AB^03<
M[XURCXP^Z0G&U*TNGY:%X6AF+1;)=#BCQJ_,)$N0(=U^#@Q%M,,%;Q/--ZVK
M';GW(E?3/,K!2?R YX),E1H$KL,%=EDO2MC<J<Q7 BL=2[R?FD%%$P$+.=X<
MN9<X[0J;\I$3S2S_#+FVC2*]<+9#32+U1 8N>(,,QATT$L&_I\=H?]WIXU?J
MW*?[&&OHF73.:N\U@R8XB0L6DX(%V$B.W65P[A)L,\ ]=9FYQ8 P?,)T($5*
M8(+9;"#&:3)R,B<P->%M+C:]-J?=K A^' XX\;L@G+&O6R)Y#I53FO-WER0
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M$97)^S_O[QF&40IY%QG5'4XSA!X3<2EL(@>9KJE*8*S_XD!9N]EI!E35291
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M?W%Q_/&E?B*,B?UJE /U=1P6R%#()WX":SQ#^L*IXBXA,N[0?5II[)AMIIU
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M/TCD73DVL3Y]N2,L<2+@(B&' OE/%(IVA1N[4<&!I8:>T>P<6457FCU_;5O
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M*UP:BI-H,Y%(/7[0Y/<"A(V 45O[%/9J$:BL'V-C5@]UT]G%!]-D#_Z2I_'
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MP-1,+LGIM'8NT<6ZN<=.*+X0#)&P#,8INZ$WXS*:VQEY7BU&<AZB1WKO5__
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ME%1C4U-)/_V.D$DDM\G[6335O%FIP^\]QT<-.V^4A<+QB3N-,Q^Y@2128LI
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M#5M/&[8P[C2;"4B9*P<"/^W!I+KO-7U:_&YR:T<X-R:2WA1?6(0HKAE9B&K
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MDJ%(+HE5_OBUU_"-8IZ.!5P,<OKG4^6UF<?_*4K4['"&OB2MZKLDPB9+,RO
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MHVI >G#+.1X5&Y-0C ##DA/I>B49<"TQE+0/MJPK&;."C>]@78M[@WROQ5G
M0DU=9*ZFU"K+)*!]P8P71H;+9$I5)TR?4-7J![YD]@."L/QC=#:"?<0"^BJZ
MV0%XZOH6=D!6G\XWHJW>G)&%2,E@TET!T3ZYBZMA@5(@2?B=_='1R4GX/_RY
M/^^.=G:B\#RNF"F#,"Q8,'V!N%>Y[#&I6'U&\A7#9?!W-4&IC ,GPW&)P)D
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MXK>.U%BZ%3ED1'P=5#&"1CL:R=.D+"5$CUZ!VV$I\OILLUW,<+#N.]OU$!<
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MA@];Q-PJP<UP:KJDL''/IA,82EB"S"$ ZB0%G]WFIA6!3-VXL1(,]*GB5BP
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M.HHWE6B1@-*>\8':.)%_A&- 7A,< 6F32T1VO1[EQOWY'G"]XPU<KP77.]C
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M2GN,R2BN\;+($#%$%44P3N16*5",P.NI9[]I\J<NSL?%=Y9*K+82\-,&^WA
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MG10#G'=FC^EAX;&*VI;V=*^23[O$Z-FG+>-.<SWJ=N.$-C"($>;,YZSGGA+
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M==U@XO4 \2WE1Z7$D!0&,</_!$,@TL"UVN8W+?)L2:4.J_+_B1[@@'CE"#%
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M=8H9P@0>RH$>F&0@D2M&/\$?*0S8BX<Q5LV!/KZXY(S6=-0=)#',XY)Q;78
M*0*\DV^4:? ##HV=30I$C ?P[KT=^G<Y",KK'% D DY5>A4/8"<IG$XE$J;&
M ],3LG?#3(,KO;3 V 5M5S].!].<+M ";2I<4[S[.-J88[^\?HBW6,>F;TVK
M.HI4PW2F,.] P P*2+QI9UY\C8XY:F^=NBU8,CA$@2E2#>DBX%77<*EL(HID
M+($L>/ ,_YQ.]->U\&P,(HG5/(/!S'FV[CP^?C P1HZ<1UNP!8\-+I-R21_;
M#1H3I&/(!X"?3?%L^P)"W.6*=#32P-\+UPXHI-A>+V$<81*(5F$) T.)#)/
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MZ (>U/)5!.ZL0/./#=O2BM$EN,V6)O@':B.P+)XI=22C@([IIHRGQT0!]:K
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MQ[N55P5X-^6K+*Z&5LZI;#3ED*GE?!/M7P@K,ZP[HTN,<3ZYS+/I117X7;4
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M-:_O+BWJ8A<'8)+_UY>9:5#0]=H)S!7V<3<^ID1>S'IORN6X4LRY#YC*OLA
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MNH"3G<YGT(9;]%Q-HJYSOA(-'16;-:=OMO\7-0'1")&W<HJ5WB)A!/729FX
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M]+$CISP(5Z,4V.R4CAPUJJ.UQO!71!5WHL*]LKO"!HMX>+C<%UAA;!B?X*S
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MB/]EM^S*0%#E^N@I/)57S[QD/2HES2RGF3<6X])+;QPTD=C]X#1AW.U.A^*
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MJBZ^QL$/T@0;1#/RV_#NJ9YR)\=OXU*(EVXO_4#OX+U5@JR<(-M>)<A^\G-
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M$Y@Z*$9+4/T )WVPT[O(G[&Q+>3.#7N4%;C$4!B@'?@H[M+AYQ7TSR+.1S@
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M%7+(?4-$KY=2O:]MH4Q*(**:83GJW23F:OR.U<C^A9(G =SY&08SPVE^X5.
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MW2F!+DZX,I\3Y_0W2P@H?XNHUTJ"4 /6#)>);?TQDBXC^.R>W9NNNS>6"S7
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M]!+TY<F)9R<.Z3&'[%>)E4A$DA0Z8P>3C,ZYWWHEJ$D^D2P,QP=L2'01?VO
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M2Q4X2X4]Z3%#34^XCM,K2A)80<!?IT-48:! ^>^1=@4TC-"FGS.\T-($2;:
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M-!=^0R2TMX44[BF2.Y!7V#5#">+6Q%)/3KL@!1"A*UE1B.EPS')+8MHNG">
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M=_PX5%[ZW3-;%&(V:&;["6V(!N_KXYLJ3VXK#- ^,& ;E580'#J5/F=_9V8
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M\^5O:SH0\7Y!0V9\IAY4EHW/;@VG>W+5,!"O5IYMCC,="7AT,%JP(6^RA8U
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M15(AW7P::P&-SREF3D)BP10]2NUV@'//_)]L%I:*C8:?M3O]$5A\E_TU8>:
MP?.+A0OMWQ11JN6U;%;<2<*+WQS*L A#(%]8@($*?K?.T$MO-,E%X(T$R9ML
M>/[>S"^TWML8YMRT08X,+K0V2!>^.FT+EZ$8ONF3=Q<M$"ZOOS3+EJIO,_UG
MML] I,%SQ[3JX>%6%@P7ES2\."&Z!NQVZ<O#X\5Y!,0\&NS3/SI):/W/'$KG
MWS[IC2V-?A&$DLVHU>[>M>Z;J=[UY;=VY[;SM77=U3K_^4/[<O[MO'VNW?:N
M=LN,MC^E;J_9N^;)C)T;[;+S_>[^^MMUN]OZ][5VV^EVCVPZ9S^ZJ:$U&ND@
MT T31(8U<<"<=S3V:\#@E; [Z:1;&S.;QYA^/*89KA'\I#'"6T8CH;=27.ZT
M&3# U1D[P*.\3Q?:JS%TGW!VN0]Q% 3Q1!C, -Z%,_YUD8[D3@I<12?C=]U]
MG/#4@Z;]9'N<+J &O_U'.A] :XWGSI/>$?2$30?\!]-Y-S%F#MF0)UF$H\;C
M^5SGYG,8I^O.=\EAD13YF" 2O!*,L0UFAY0KY.^U@D1;#=-AI-I.BEJKJ36;
M+:.H)3.U"E)1Z^"BZKA5METC5^+AJMGOB6L=%XIW''$@+-ERZ<-6CVGNF</H
M; !# X;LA8VL,?J>-?9KS,SE<?.>8?UAIQJT>$O]PY;UXOPR6;37:>6W2\J5
M*LF2E=SIH6@NP:&HA\NF.;P*4'G-01GM1+24;E0R1502HYV('HXJ"F[;@%OE
ML' KIQM5@%OD W@%M^.&6_6P<*M@A%*^)A]W2Y+.L,61?64FL_TD\V?#-!P7
MRX"_L&6JS=$89/E#50DYB?S@)%J) !5LV^84I&+MW"H&^N=KD;N4JNQRB="3
M1,G8"GIJB)Y<)3+?5^B1"#U)=(:MH >3(3/%Z!V295$5-O&8;+-V#:PLSYYX
MUNV?#)N)'+\6,7O6I7;RGK2(+AN- $&PD[][:(JSB?,YL#3+D7/SE0"0"#9)
MU(>DL,D#;$JJIM$QPB:)WI 4-@5L4%\L1,[VE$5E6*\0;/]4GLI7^)J!=F90
M\0IY:I>H^@8J:SRI]D(8]WOJ\?(L@J&TF1NK.$LY7P1[1.HT<@5=R:";1(/:
M*G1+Z89$];$4=.6';A(M;JO0Q:-*J:&[6\?0FFC(:=605_BH)U,+/;KY]2B/
MU6FD3+F#JE[3^Q^+XL7<^16L3YTI5")O?^4&D @[B72?Q-BI8MQ<)E]41T_'
MB)U$RD=B[-3PO"%3JTN"'4EB5%HHC9GC:MQ/I#W8UC-0:6PYAJM4A%/>JJN+
MZ2;1$3Q,\:UZ)<#TN^$^^15&6J;C&NX$W^M$\P'78?M6(U>FW&'99X6C.#A*
MHB_L D>%7+I1S!_B)$'A* F.DN@..\$1MC:L'YX?[3=^9?M'-9P";/[ *D-C
M,9DKC4-Q'R=7^;(TTWVO_M/=Z47D0&U;IK70AQJ-[132C9)$];GE.5=6<-W)
M455"N.+A:B%R"RJ%U]/'ZVZ/IR+!=;VSJ%!*-PK10Y0E/Z"2X/@)_74T"%[#
M47/U7\JY=,+&W Y]2Y[[]\:VGB_AL88Y 90*_S"8;U\(8?RZGOZ+.=>_7%OW
M6I&W7/;L )?  =D6A25ZYF%,%E&F<ZQ<61)_LL+@WLZQY,&@.$NMJ9#J8\1@
M,I^6+!BLTKE:O2H)!H_=(4:DPGKYW \FC;VBXK:/VD3+.FR0-7YEGXSAD,$U
M_+\PN(&;K8E*=Q%'FI7)"E+XV#T^Z@H?"A\K\)'/'3% ]N9&F>IRM$W?2M!G
M;Q#N6DRYXB9S%P7[+EMQU5=O]PS@?7<I2^+[:3-WT^B_0BVNMT:UTWO?0$WB
M($H"U'I<EXX"ZOL&:A(O4@*@%G-Q_3X';/>X76?0D?I,U<G7/CR^D5^DW.^*
M&(H8LAT*;&3D)QAL6QCHU#//.YSAS?-X!&Q?=XP!+XUOC"8N&RKI<<)[)$;P
M:2&6IG>MVR8H7\X=L[L(KBL.)E_GRRW1^>!Z J,SK?SEXYCYR4;Z!3? IN,L
MI!NY\\JB@N@J_^.HH%^1!OK%.(Z# T*_A-!?F.VJH']4T*]* _UR'%?$ :&/
M85'GQ45AYR>=K35]J)3/^?X5PQPR[#N<Y=]M>FR58!E^I[>Q(0U9ATEC2W6
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M)*#-GH"&QHLH9&@.,:-/&UE.K#KF.ZW$M*Z<\($[/RX=R:ZTM"5UCO>U" H
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M651*-_*98K&>*=3*<_%%7OC(''\"KD;\C#]1.Q/+V/&^YZ/QO>VZ&Z8:+/.
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M%4">9?*Y>;T0H/V 3K0ANMY=G*<O%4C?X36+G2?O,,&U7'@;F=S[6PO==DT
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ME%,A1XM"CO(JY.@0J%=11G+$X*@HH_U&&<G14:6+3G<LE6>Z(LL<,RJ :0]
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MP1=0OA$J&[SIV-@0['W(C_6F7^UDZ(PNJ&MR*LQX7A>(M-7DWC]^]K0SM5=
MY0L)_>D>P=ID3 HHUQDR@9#VFQH39K1I%-"?H*FB@+>'='Z!?KW4@LH% ,8A
M!1_02@?E""[]0-):OIS10JM/#__&AK!FCQ&@/Y<VGO(TB0?>;1@SSWGO9"Q<
M91LZ/[SG%WEWBO%9$W=$Y5I@<C!&'%NVE#O7.KB"K[ M,BM>/-5[^43V2:R3
MX2[#[-CXJ2J\?\"2FZ<TEJJL9[^WYRE_ J>JFO@'O1'H+!^C%-'PJ9'>1Q:H
MOWHV\^C-.ZMPO!QV,IV\2>*7G$T.#><96"66J\-R<KX3 GDJ7< %N'].RW_W
MNOAZI[:\8^A4A_BI$PY?44#EA507RA@)CV:V" 35W6/H$S!,F Y5@G FXGH1
MZ'6NW4UL9/,40^3PXYA4ON2I*7ZV@/^F*2=)<^!FM'R]4O1Y>%><Z.1+'BO/
M+-1W0B8E)OAQ-8H<I<] OJ?16\H[2L]P7<C+:EB9VI_;/+/_"LN/H,EONK;1
MG^"ST<#_KO\RGB?/O,)J^$?GCMG78A(QD_U+Z4;M?$'E\@]BU<$(%HN  4R@
M%&: AD,F(I'@5QPY/S,+*#KP@KJ I%YACWEAK'4#$MM 6/;"II1#RDJB#[R:
MW13"_(>&#N7<)PO3P0-JFEA#A/=^S<SIG18"$99O9/R7WIN:1Z2H8\=0B<9P
M!Y%+2GE0X<&H1)$M##=>HDA1)8HL2A0IJ401:?:'2A21(XVBK1)%5*+(\N$F
M!Y=62,F5$S)5%G7G1\X[3! I;98@4DS':V=ZK=M8)@S5:')Y;GBHL>8Q83]!
ML2"KG^#[>>J+[L"248D<8T0-*6^Q\#-,BWN$3]E]$ ,+\G%*(AS/61&$HXK=
M ??':/&9XI$OQM +BJ&+=9>;E:*H@^>&Y <*SLR1@>?/]TKA^86A^0$#1H?/
M'28L\9):$Q=]#328X<3VQA2<=V"D948$<(H#VXC/3HG#A]!C^<.PYCY6ZAO@
M9-^;0_3/&]VPR8;ZSN-Q@VZ4&_*_R ^<XH1%60/.V^<IG!&W,[70G-[)T6Y\
M?'@GO9L@2SYN&CZX$B'KG,5X299..$AD@7\+&4V0J+>P:/87"T^@/(?E3;/[
M)7!5TO%.(9=9AD(AH6DL-+;0V17>Z"<G>D_B98VGAIT)M6/ ^B@/-NSH5\O^
MR6.VZ+3K<6+0I%(V>]1M7UKPF$D'RSJ*!B<T-BI#''H^M<'^-2;39!@:K-X'
MCA]>P.?0U,ZUF]#*4G8I^V6(YBD9&(A(3?7&(I(YZ1C\U<N%]0-_R)N,\?^F
MJ#\)@QWK!J]6 Q+">0 !J4_'^F,^JTW!IOP2X>'M,_<5,Q%X;%L*#_E!!QU[
M.:A\7?QYB(+C3<\%^3 ]*?$4$3X8OH\F$LKJG>_Y$6KXX:3H<J^_3'A(?"VP
M\"9,"1>/1^,%RQ!48L51ZJ'V'5YHE5_T*?3"#,]619I063SXTV8LZQH@\G&.
M63[')_@;PP3?O !$& $6NJ+@2MYN9 Q2GR,(!K@(0"?5"3HI?RUNS%]E# RX
MQ<#15%ZC<YC\A38Q?>7NKXGE4A,EBN C+\:+;HQ()R5&2W&C'/$<K@!5T^5=
M='A%XIDH MHB[DR6#K$.CG],S@'^C4V==%_+G=O*Q]+/)$:665),EC;&I(SQ
MJ1R3!1^3'L\4G J1R -4J7/7-$SG@4F@(Z\;95E@,=(^QJ42CKVSI7E>C']X
MC71&;ZG0/<!GK<GC$Q#-MJV^)0*C2-D(724D ;KZ%&+G<5?>&+$R%NSFB"VN
M0NS$7  [C*4.C.L%(*3&OG1&ZGCEM+G4-S".R'5'S&M:E_'4(1'=^!;C)<MT
MIEZ@'E"E$Y[8,Q.^$%(31("$Y@2>PA2LELX#*F&=AX\\;L+V4C P9TZCU=.*
MX=7R%!\>,>4U(.0EA7F93MQOQER4N*_M['?/'3!!.>E&K&R\$<L2;L3>D^&D
M?! $$3MAI0. C,KX8EZ=X9O,UW2X[811*)3-QJ,4^/T/TWM:H)=N]S8)]JH(
MT'G<F(SLO-T$@S(BB:6FTT\&NC.='HE1Y:*[XVP*I=]OP\\U1W$@FJ0VASQ
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M/83N1:Y'!62>]9\@/[PCG,O.U??@#.?UR=(,AYH+7]+]U[_88$)QEIV'!V/
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M!\3\+4-_WUG/&@.[KY4*'X7,!]W!^RH<1>M5N 4K.N4GQ&',*^5CZ'Y_"TR
M>PM7T_63]KS;>1L)K%+V+$AN6R/M#.-$0 (_P*/A80_,%HTH2>^9N3CT^(\I
MRN4;X6S.M18/:PF_WG#""7P\-%)<GZ',1AS6F_8,!/+*=?+H>\&O?8V";O'J
MDSM8=XVGZU'[S53XE9Y;=F).K\J9Y?F3\#Y03$;LD5Q>#'7_ >-))@OJJ7X\
M[R$!_,1+6A+>EXT\6'[[ 9' B>$]'A5S&8U([7A!JD&73_*_^2NP=/+Z5'5D
M;782#,9I/<.[1%.H ?/2%4#_2BTL#_N*B0SZPP.;;AL57JNI:-3P^[EN"\MO
M#I\#)QT,A6-=/);":-&=PP1Z><%Y\7"$E:!G-'3"._CB\1P,?!;=CG49-.-Y
M;%LO83]D:'18X8"_$ ;D[Z S6GL#:#*>]($'!1JR=TD&$QY><$)^.3]L30KL
MPK*S\+X'8UK+UW0A-)K='_Y6AQG\\_]G[UV;$T>R_.'W?(H<=GJCZA] (8&X
M5,T00?G2S3[5V&O3,].O.F1(;&W+B)&$JSR?_CDG4Q("!$CH#CD14UUE@Y29
MYW>N>2XJ"%?SG3@AHQJSQ]EGL?>?.R:5=8'&BEC6 %?'+:E3C]2!AC;W/#C)
M?)7%)8N.9FK)M./JI>(%7!V]]#\K4 : +SE +7$\RO4FZ*S@6GI/"\E-\#C=
M:OS@CX) N.$]41[!#W7"NH\\LQ"K2*_6=PGD405YZMY#H.!Q5)S#RR#P3-X-
MFW&C[Q;""_'RL1@+MPV+Q5_Y[DX3=@+"OIJEI2^YTOLTQ@E9:K\C5%EG3%]B
M9,!S]M1C@X8#8>Q4$=0<L>E;ZE1=X(.>_*-:6$<:;^@?-N1T[C^<Z5'KA34V
M^AE@D^\5TQ>^%S IJEN&IT5V!1Z6(C 9C#$"U!^W&H9,*VQ6'RP-H+A@H0NF
MZKWP-7;YYH8-;QZ.DNC5F8UCK8N^L _HG#V0#_]CQ?@@*XUU/)6KIDWIB.FL
M4]NIU?=!$AX,<OFP",1#BB0"B4ADS3J151&)K$&)K!V1R%H8_A")K,5(\Q2)
MK"*1522RYI7(>DHBJE(]EA![LD>EQ'7)BM>4PG')QAB20,-Z3[30"Q-T\7O\
M#MJ[+74],KG7_/B9C'P!#@QE/*PO'-UO7OO-7ZS%9R]P.H]5G""'&]MP)]LZ
MMY4;C<F>W-I]=D_G_8)-W%BCQONJ5Z;F2YY\7H%C!VX +EJ;\: ?7A[BQ:;C
M7#@9.XY7057FYN"FUIW ^(P/_A8>;V&],PS+8F%#I^<9'\%I34UMZ=;(LL)O
M<#LPS\:=B\B[UCB/JVC@0%B;?H[_"- A"[C47<_]V%@-#]>QLO &&8(SXSLT
M?TS0"6SYZ%[9<>;86K>(Y40SW:OG?9?-0SY[F"WPH#>(<;"M5U3PYQM.73PO
M,=*CVC6^0XJ8J;B1,7SDJV;;Z.#^DP?\>*TBMA%R[KO=]G>NISCG<<BE7WH0
M-C3*#/0?1:CL>'.2&(*]B')YY])O<TMDY,SI6]ED;-CD=VJ[EX%EO03,$#/=
MN)@I7C<21Y=[,NN8+N_5R&AAJXMG3,#G>E;^\K-AS%B8"T4FFU3G_.+*?%^"
M;ASRGB(?'E=/-M/Z+:59[Z#B]UTI@HBN;'8\Y?T@?$_P!EW/9B;>O#@=_M;/
M\'5OW=%.K.FEVW* /]55:IXYX5Y'5CS=A+U%5T\6BVN@9'9U=^"3,-]V8^P]
MBGU^C<9ND3;Z66$O61Z'75 <SP4:G34_]-D*R+_N[.Z-L*RW/'6]2V:%.!:)
M]U%5#VC*Z@X0Q3;HK&1BWZEL*-W*4:7KK<IYN'LJO'TI#D%TWV1-C>76.,30
M*K7BW#)Y(T0/1G+9\QKDAMEKGN[5K+7ZY:.A#3;@BC^(V3ML")?[3';ON[[(
M9,_A*6N;UX3J8FLU>!O&;W[9=_#H7WT-*-?[='[@.P5^;(XE:;G_\C\<#8?*
MS&#!91Y^#K(/@*+[(\\793G$D]VQ1E470G;W478S,3-1?\!C'1>LVPYRP=:?
MW'2]?F-&ONU(3/=Z>2TP.=@9]P#'?9 ^>NVTUQ-=IP"S9\/4J%<EP&Z+4"8"
M$'6-DPO9\(/\,4BF:>M49L:^WC=!8#+?QR=S5/)OG#FH89XGFT 'VV"WZA\T
M9^X[O\_W!LSY'D;XP_Q=MW &O4F1DW@=QQP?NN1#^;QD N:Z5=!'6SGY!Z\K
MW=:6.DLK79K4AF-U1+[K93E)"NN!!:R(8V4;YKO[4?P6GM3'M<HZZA)5=J2S
MY\CZVJ5X2-B$2,U)S_#+PFC^SCH3(&%_)W1&0"ZW82E/X#F01WLH^_6:U^9\
M6_=U\[%V8,ZKHB03?HH?YO2U0+V^N;]['$T>M\.816P1'G@YXX$DCU7Z<OX]
MX>$5;3EI\BPTM:XT8R62T4O>]E2\<<O2?5SE"6T=1\0P^X9:=L.I(!XY_T99
MPH9B6VO#&1O',\N%.N*QYAC2/#7"-65P>4Y>/K;2WYH1P]T"+_-J7=1&]5E@
MK=UN97$AB7P0BH4P7JJ#(<LBW*DYW*TN5-WC9ZW!1H_H9F$5)OE&5Z_:9J'A
M\3I#9;-@KQ5Q<B_'@5>DUSI4I <F8Z?3VRG2VW%>$.%,*S\9+(=PKOV@K@M2
M\3YQ;""QTO%O[,1"Q&OZ9#LCAM5G^A58!%9YB^MQ>?$!&"OL].%>==!N2,W=
M(_BI46QLEI=_ JIS-_CGM\?KF/S3S8Q_^M6!7&NVFU$YZ$3^Z9T^T3L=_FDU
M08 TI #VX3&*;;D8E9+]K"C9DH"2O5TZ[J$9"4^S?N%H)J/,ZRF'1=YV"5:I
M;^"+D:#7$0EZ00EZ79&@5QC^$ EZQ4A?$PEZV2;HL3^[#0EWFDZP++60&;O-
MO.*!2GX)&1@GZS23J9Q)($[6)G5R-_GEYH%<_?;P<(.9@(^/-\6+EIW<^.5@
MYY;I"YVM='HW#R <!M6#J2=A'B;/.9I275_B5</B^>]5>)NK!KDQ,#5T75U:
MH G=OWTAW[69_8*GU_PIBCAWG@C[QGE.>*(_OE11$?[--MVWLDYW8'6Z#,/E
M0]51E_8L,96%C[)G&P_B,Y_QG?KL"W&.9*WBT0Y*3F7"^]T]X<GB3_]>E:L'
M%A0D5D-8;*>NUW6S^;K!U_[;D_F)KYE7T <>9."I<9!L;"?1@Q2$C$1(OERD
M)@N?%(J2GVPSE$2 $X,3>C;![Y^AC#+,S\1\?OH@-]LUN=6KR8KR<2TUW&<Y
M@JO;^6F3"CJ=QT'$O4G9]%TW<W;/B;IB\Z=TP+?]ED2W>)#IG%?VMUYI(DCB
MZ,OPS?.B17(<>MUP<CDJ,UQ8!XP>.2 \=XSBF=-"@"P)D,6Y.(D!LG9U('4[
MA0-9>-F<A+TV6H"K9*_8)>;6SM-$=E9P+H6@=*/!3H38C8"/%GB9$C(0K@"8
M>[M].T,<2QK'+Z"3D?A+ CH=@$ZG70SHI&N8)KCV=9-P-AE!X#\?T;DF U(A
MDOKO5@?]T":F$)@% DP<@1D#,+WJH-<O!F!.L1$/1AQB+(\%1/<YXQE&A38#
MJGM#/-FY4M%64E@1R^@;P\WJ5P?=T-;%GG!85B03<"T$7.,(^)AP;3>K@]!N
M5"YH3==$#A'9;^,>W1_B_CZ3?BPNF1BVJH<\XG8>_ @O)3-C]:33G-EQWT**
MK3SX-6DD+I2J Z6W.SXE/$CRTQD"H9DC-+:^. &AF([9D@N,4%=/?&+Y![N9
MH<&9HL7H/Q6B0=;IN1PX$VF!Y8_K(K7 [(UNO+F<R37B4BIU,AK_XV8\N7OX
M/?ELF^+FVGB4<CAS?Z8-BV**3!N1H"$R;2Z/D"+3)N%,FP?UN]?40Z39%-S%
M\I0D4.U7EVCA;-A6== O7@*$P)C_G76+3NO:C_J+-IM1^ S_+ZQB:M<[+4=^
MA5Q3/6_2QKFW2'!E_S3,/[&H<6D:S]CP2US&Y2RZD""CQ;UI3($:X617NSI0
M=HLAQ?5M:H@Y*(C:R0BBHDB?)))+DC?4;[6%9H%O3)X-8T8^_+^/XA:KR+=8
MT20CEVU_-/] AMHK*%T(8&?,_8)R(/>+?8<EL)H,5@_*9"49F5SP2TYQA2DN
MB+(Q4L<TY-50ISIHMT].>1&7EZ7 YD'1VTE']&9_:YC$!.]T[I<"5O5)4IH_
M15W:TP ,:=8,:&X8]L*PJ6N*27^X/ZF2'Z_Z9UW%"R6@\6^/V"2+!#>9LRB(
M"^*TO"##AXG4;!+KW6(-7]7%K,(_,%5-VQDGZW17FAHKTV*]R9\H&R%"=>V-
MNK.$L2^I;6I/V+?5_<9OC<<&DS+N.@>$GU- 'Z# V][SN.O=;,)_;V)71OO]
M7L<9/8L9SMQ<8L/&@-M>WZ#U@S>249[IOY7LM9.8X)[ #7*G4B?W#W?W-P^3
MW\EP?$UN_O>WT3VV):F1\<TDA18.R4FE$+?)(1&0'-WW4#N)5MYQJ.W_(E,3
M,VQJJJ+U\9D-T=&U!:T.;OE<<#;7E- %-CW=$62?#S<D+08J2GC?'Q0MXG>F
MX@8YLQOD*]Y /5K5@KCTSY-DW]RA]>NL#?_T>D'(LA#RX;_5U^67ZS49J:M4
M!0W+0L/;E;G0;+!ZUU3$WF_&?*Y-^<\$5<M'U2@QS&(E3X6( <>R%JQM%&<%
MBB0#I*E?7(MS$><BSJ5PCSN?<\DDE[;MQ@224A]#F_R/NEBIYCMQ8BLBVS']
M&[].,U93L3UQOY]-(VQ^6@^[BX6N#Q/)M26'FY0SW/K504ND<E\*VN1\T:9@
MDX2>).!V(7!KY0PW"72I)*3;A< M7CO8^&B3JX-N,W1I0:%K9V)X+<Y09%$;
M$P?)J3@A'FG"P;D%PE/T.2Q*H4RW#(4RET&GY.RC>%WRDV%S[&:N%*2+[V7@
MYR"?]P2?%X5.B?%Y$;2Y<C'-NM._CA=E:">L))5KHB-I!J(84:! H$"@0*!
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MRD[?][W7P:;QQ/Y>E:L''ABD!8[;DE?&ZW(%G[5"EA4&9*B4;<O?J&K1%WC
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M0K-H YS(!5B)C&>>J*X!"R$G,OOKW:?,\$<5[VN< <%:>?$>^=U8Z5QQOJC
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MZ^172IG#A6[?^EPM\D)!RL"*;DUMIH*EL<9GU\4GER3HJC,IA02SX!Q6#ID
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M<]%Z_PHHI@/%2!GJY<!M*W_<1L^Q*L-M3NE3J<2YY)ABEG3GY%MMH2ZF&HY
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MI2?0GQ:R'>/)^B9/$I<G7XT9U0N^T[)0XT^*?+1<;=P9KJRU=EMN>S]'+UW
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M'8]GYK;B=,%/(3.WS9(V^DJS%I3+$*1,=T_FU 16J74@]Z\@T89V.]KYG)3
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M=6.*3!$\I\1AE3&U[^83]4<XCNF ?CX^2$O(V0)"*8Y^3@-*W>J@TPG=L4I
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MA)/WGE'WSOP&M T7S^A5!RU1ZG4^4/R0>(PW:2Q:L$]X^2%0]G&*<<ZH_"@
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MA59&EJE270,Q:2X-\#DIL=4?A/WENVJ1(Y.C^WY?5X[DZM[,YW2*8Z0]H?L
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M6Z8-N&?-F7*6!Q"87BU'0TP200\1U4:V3)T&OXC#'AQ7F!:NE-^Z!JS8=,T
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MA2[G'8;!#0PTJPZ#*1JA&,=Y(^Q^M];N-[765V @ Q8J'%$7:!ADDAW/T6[
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M801S'WXG>3!*)5LH6+\F&W[/K[4O7H"E:#8ZUS3S4!$IJ;2VI&)Q^^'D=]<
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MU%BRAEK#[5'8[)*C$R%'HW Y(D9@[5"$]XH9<.51#&CCA^WX$A50!K=#8;Y
M>:)B1"CHGX,)L"PTS/(76RZ*OG0L3/+5NJ%87ZA$43H*A?B%1%"6OFT#QPY(
ME/WJ_ @E=4+D2[$B12UBCMBP4,QRW0@WZX2(EZ*$B4@+G8C*.VMAHJN";I1J
MPJN&TO;%66[+@XAS'Q>UP R@B564YX5:[T;Z]MINF 1B-[,I9J)D#I0G5]H$
M:OI&X%\5>\N$+A]E_%8V<GL=AX83O^2Z!8HNV[8VT:"JS8M%;RI8;BYW!4?L
MI,U@#4_D,[:3/:.][2$WZL=%77D#]0^2/;&FV\DV;>Q\[H@2I].IF&VCGK%[
M +:-6(G1S6CP1(QMHYXQ#J-&NVTC,-T-+]'*HZ5!&C.F>9KP(J[4AHQ\G->L
MNX_I4F2:;B,;K_2?<\,YESR&EL9X:1XGO"AZ7],MYS?SM5Z:APWO_=G3?)>F
M-0$:.E3(7C6SS,/KHIXFO#MH7]-%/$Y9KA<59D+C<FK,%_4TH3%]E<P7D>L%
M/KR%B13[I7N>\*)PBBRXZY&%J(X0/+EU2[KGH;5RV?FT$02&P$<3+Q5XV@C.
M5."3ES:DA)OHYTE>O= 3;H1&)&"3ESBIIQ#7D9S2KCLWP0E13YE=74/(4T9M
MHN:3USNIG_+:-+S6=HLNZ5F/I:+ &NX60K89=VU*C6Q!LL[71.UBRF4G=U3N
M%L1R9(FTO92O+-LZA:W:@ET8#H3,&4#S"/K 4,'+)S /-N"3X("CQ_.\T)':
MC:X4FER(?ZL^A*2*8'FIRP_!6S1@A=^;R+H-(J8NXE]_T>'L4D.M%CV(7\+7
M[/5[";7>9<0<R>L3.^&YW1SGGM;$%2.GHM[_JUY'2YZYD3(%JJOC[IN?@6R[
M_F%QZ"X<OLVB1Z<7 CC9X7 4X,Y1S\YGS9GB'GG<?X]731;_NU[?J9%.=%PN
M0",2H1II9S2I$F>B;TTAC>AYOSPT HR@/G;.AR:=@\E,)<U258+NNNS:Z*G(
M0JL<@*$ N_=>UXSO;VTHP:,,]<2]X+\AUB:>FNJHG90@2L+Q"P[X^&UGCDZ.
MM;7'F0Y0N^B3]6LN;F*;K@7_YEX>=<.&R<9Q9F]/3IZ?GX]?[BW]V+0>3D2>
MET[0HF*T>,?K-VD%3BU??+6&#_B"\MGAO@>.Z;VNO?S-_STQ3<<P'235"A&[
MKNA]$UYOK1$Q6D$9N+:P>>VXEQ;PI=>N)8:OA32BO?4!N[H2@A%,+-AR'.=_
M"N TV<,O+5_45/3R1 ,6AZT)UA1N ^7XP7PZ.1M\6D^@FU_VQ(%7/=FX5^#^
M7O/>C?M#$UH.PF,/(:;."_#_Q456[W'^Y0//HJZ^)(AU25C=V7LG*,WRS@C7
M:RKKO:I!H;9\KN)4N%(->$#!(_#P_ELJ%.1EIFN*YGSVS@15-?A)M"T[6!#U
M514ZDXWV.^)?QM#]^B^:7>NASYRZMF; 5U$(@D#S+N1)%;I^SY?K9$.PRAE<
MI-#@J^81?I_R,S3CN]ANCNWM[4E:VP-[;=[(7CK:8?F5D)6WOE1AZR\VXXS-
M&__$O'4\[$3!@6"@408&$JO0*WV<"%TLWLE"%TW:="'EIXL6%;I8<RTIC6M)
M^;E6FSX5BFE4*.:GPDX5,I3'\*+1LVD@@M?+4A'MP7=7)MDEI6*B2+?Z]MNR
MS;>P\44QAA2\P76U37D+T#E.0+V0+;2/<'>-2)\9A0,P8TD1E>@R7Q /P/!E
MAV*R$2 =  +*C.!D6[]Q -8OOY3.D9P0F@=@P;(C>$&F;!V *0DIIO,T8_L
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MPE!%'7&U U6+%%46L;QAK$P'7-WBJ:JJP9TZZF?7NK %VV(O:[.^H8[<>Z0
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M3 )"6TRZ7@P>% :DX9"(&#@UW((Z(&K."6%,80-6K5)ZZ7F\]%Z"P"/Q(A"
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M=MR56=-_?\=\\+.PVINXZQ]GI-^]VA_>BN.U&B[6[;$[^E!%65A)[CDQ*]O
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M,>>4!MJ6YXO,9CR]*E/!*HLC/FY:,D>#/O_<.2A9.Q_8MS)0\^R2""H?R$T
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MQVDK[<>E^:19NK>9>OV"H)FVH9EKZ_[CDT5*=@.R%VHG])[1,I=V)][E<;%
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M-94T]G$%F18SB XW(B7=NK$9_%,OI-* \]AA;,&H((A18>A5GX#0;"X2FH>
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MV*[?)1YC>1N:HD[DK?$CL-+B:[L0%=H5':W1S++B')- '-H<6/>,)\X_MD4
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MJ&.YU305*T[#>=,Z$$R9&YAO4,C![.PI?^0IAR=>Z*-$0#<+F+,]N#\;W!'
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M+A;DF\YI>%>0;;=8;C9-MY#^!%!+ P04    " "<BVI:=R*)'IH#  #!#
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M-+I910[&K^%$XU_"@[:+HI^<MK>VMT?#08L7I1K44Z&JOTP4P2--W-I1X=)
M1O[QV^S[WO.=\/G>N+WO0%6[X?/Q"#2@YV# XS; ?GR"/X $\*]L"/R>(ENW
M6MMP8#91@\&4K36N.@)2F/(FHFNL2DHB2IRBT/DE4A1Y;R,T@5;SC'S&*,N<
M,<!PAO=R=S3D0>YXY&5@SZ_K_?YDO-_C[=$OQE8[23&N@?Z TZ1I0\$/M=UT
M!(N2H,(H/!BQ'T_LJ)NQ L;;Y%\ +4CAK(Y4S+,$ERKQ@$ M<?4J@<EJO1:F
M'._NA>,N]P=, '\"YM"E#TB8L1EJF#.YG80 T %$!JRF=0-&@"=$!E<($2[W
MT1%X T@6F/_W]&GP+M9)]"(X!=7F$&;\4F&8   +GCZ52.K+MR?_\*.>3\ML
M":^,EZ6![NDD*\ML\2+8Q]\F60X;8G][#2SR<P#*'BR@R)(X A#:<=1EZ2+K
MY3.8M0. 2:[5YZ<3#90"4"X):A>H_0Z8$-"OG=)!S3/$#:/C!]G .PN-?% +
M.H#'5\!U4\ ".I](,'Y"?V&I0;+=1=SD^PFICQT>[[D"3CL!]7(X2"0RPD&U
M#ZJ(U!?C1471]EF7UI/&3ZTGK69:Q7HQR1+K'3_Y\,%$98L8.2!YD$ \CAZ8
M@H"X=_U_W8@7I%^'SG_^>/B\LR-\#J@K9JA*S(1^[_>!_0"JB;/D@H_L0H&V
M,$%-P[ M()A$%P5I\AGJ_1C1(6TS)T]=3J%S4H[,<!NHS:?K8 KS9Q0B!RFT
MP _JF#O]4J@R+F8*];IU(+K2) -5!88;#FJ5SU747LOSX*UY;#C%)M!]062/
M"M@B+DOV8KB^C0WQ=%E8R5.Q&<)[%YH (YL$7Y7H+GK=00D%77*CV&3=DGSS
MHF"A_BK:5QF7B3;I!FTP*4D#I'(!:MXDP;^"<I;KK>"\\_40WP_;R1LAFGJ8
M##/1 $TPTQSPPSEYT_(ZS&&7R1YY!(#53BW@+V#-643V!4R;7:3QO\4EV44<
M&!?)B7MD >Q:G,2H8N/;H.GFBFV0[N07&<'G_Q2G=&@"J 7T']V2H=<,J,C#
M"CO.?&XX(%PP+(S9;)6"UCV/ESC=958*D%T1VLDZ2+/T*?P5-[4DM'#:""KU
MF+R2URJ_T/A*46:*EWF";B^$.5$KFPUT5HKIQ0.&N$P-1Y:"M19$A$"Q(4!?
M&K-J"LI-B:DT[*TCPQL^M'P^9%N[,). ND^$/!SP=/=!(!*7?A^K"=(=L8MW
M54YT8_2(-RI)[CG71E'?S5J&@X7ZK#L9!O&K*2('N5-<$B.(M%X$,_A'M82#
MYEJHS *!U)<P.GL/UICL!))@J>*H]5B.XAR, "#@X8"F\P>D8RQG:*G6%&1$
M.@8 KI!) YA;P5GC.V+GZ,L :/$(J06> EPX.IO6M"*PDV UD>95S&.2,D 3
M]X'@^W65XT0"W"X1W&_"_[UV\PB;Y7PL.@P4AG-. PQDTK%(#I9! G*WE%C<
MQ@Z'YY$8%QD)$ 5R::43X*8;H_&FZ[H"13BI2+*5JPR8-NA$Z*5QWYBA4$U
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M%_S,"17\Q@Z(>RX(?^_V%R.ILQEF/<M Y8B9:[Q\$@/U9 !2:!U< 7I47%G
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M+C&;'J,*5\MKS<U2SJ9,MY)TB/.#W=P+LS@NZYP29,\7*K?QP[H%A9G+6/C
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M])BX% F5U/:MD&NMG4P=-2FH\P4U1FP5ISW?ZZE.R[483YQ\[MDZU@D0UBX
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M%1:$K1G8MELDV*!;4G(@LL\I)J\"&7VM:V7SEDWG3]#CH*((>+WI38X@[AX
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M#YLMSV\>?1[,%N__FDT#ZV+@^=].WQ[>G-Q_=SY\&HXGP61O]_"/[CLX""Y
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MDNU+V"H9A]Z4SEJ=12;%+6+V"BY-ET; 5P/U]$+C@1).JF0>^C<SZ!T'?H
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M0(G@)E*7985:"M0.4.26U@!3Q0#J&J[HH"H:,-^9C7C"Q.%-:.)$8CES0KF
MLAW'H<D4PS'4=.*G[$TM-TC720[?'O;!0GPHG @]Y_ XIH9)*>5$91MZ_KHF
M9SY01\+M3CX32L>Z?"'!&3O/+&#%8LW#I':VBC&QU@HUN8$T&IE 32*@&?A=
M'E(!FUTH<?R\K6"U9'V+O]KSJ>+;$?$YDVT2@9V@Z_1Y=DILE-N\#?U993-K
M"&E31\MC^0IT=N*(7_2( ,M[SB5$N< :<0AE@D-K=UM;G;6M3;! X5CY!M0Q
MU8F@*^C]RANIXVS-JW.VY@G6)PHMUQ@EID"1C 6=7SG]U%@/JN3C43VXT5#T
M' 8?J BJA/$4=-@;"/)F1I/8:<<])D%S["1N^AP.$782)Y(O0?UR09H(,4+1
M %ZV2$VM>);\DI"@6C4S((:Z^ TUV5F::Y/8@@3,"<OU%BAP)<_%MHMW=\_=
M*\:X2<PE$3506YIN*(9IU4UX*TF&GG.JLF7M$VLC-CNU0C5B+6)&:UE$MWRP
MO*/;;??Z".I%[JHD87=FR9:W[-R3<&95O3TN0YD%IS8K&YQ6<4Y"PZ&2C1\/
MHA1%2P8__"QF>[,H;X=3.=,G*7LR+;>#T4PAI9PO!SJ=KUF%$'6)I K6%)3X
M;AX7./7:R[]KF$JHXWJ[]Q$E]LP)AB3JH.8+W[*R5G3.4=YF]'M)$KR3U[*)
MWAK11-B*$:C&PKLS#Z7@'8-+GL EQ=X88'@.B%ET(9.XG2PZ"P>DT-V&1QQO
MIU?:H$G737K*LSVT%E?JFGP/, ::H9-&T8-XIDA0;^.&"I2)\&0W$7;>&<]F
M<B;DV5'Y@YA=&A.$#>75JF![Z*3*VJB!=/&'(,*@"CY<AM/H*':TP9AI'3%_
M:RAM)X>R1@*]+I.Q&N$F]'LWSE'U..44LTO%I\G1Y%A<@HGI+LD+:/]WS5+O
M[DGQ*6=,W%PG@C<<(..3Z\CZ4<RL7A"8=6@D<TF9H 4?,>-2ZPAZ(F3Z/M",
M&/<19=]!6: _G9IL:MT$NRIB,K8)%&QM,FY/:>4:8Z"-H-[25I]? 46C>4M-
ML*8)@ N=9R0AV%6VMM':K>6_+Q?6O.!Z* 54C@/E1#@1110XN(DBQ]4A.&,K
M9LBD#I?>;08EJ,QHIQ:_S!D#\J<*9EB4NC(&]J8(='R>>P^WX_:\D#^5BBQ*
M714#&UK$J.C>;2)^D2(<*]_M>:*%\[#H*O:!L6TO58R","E&L]N%M+3N(082
MK:'K.P<:L4-57J$L.DI) EUD29-Q["I\)$AACNVT5>EY+"2R@%-/#Y+ W3HX
MT$=UZ8>I8,B]BT7TLDI\X-T,L4/T]ZRS)" XN#J9WIFXN*3O$$0)0MG:Q6%;
M;?TE(T%# '=R#$JH8QB?H7LI1(T[J[GG;8\[+.#TX\XZAZOI7'=91/P2;AC8
MCB:+(4+[%G)#F>1NM-I4-FLMRYXXT"\7$$N*+CS$B<;;U7FU%.IQ"!5X+<XZ
MFM-"7* L^UP ZB<2+4BCP T4[+Z=W54(T7BN<M:S*7_<WWX_^O./!VEJ+AZU
M#R?RZ_%L]+C4!A?F_.H8GQQ?[_\]Z"]U]7@FO5;5KT;%Z,&OK\<'+XN:=&-4
MGYK-_=YU9;8X;SQ69W(/ WPU50[NKR\-4)\?'9G56O.U6I/O'QX_-E"EJAF5
MR\?.=/'UVW1B2G<=S7BYOKH8M%Y_*-\?^J.Q.3XYOGAW\ 5US#NX?_3WETX+
MS _5Y>V/Q]GUHJF.7YX?S^]; VETW1W=/<FS\Z^-VFU5K2Z>;I_DD^:[V^KK
M\,MR@:X[MS_:C_>-?N7\<%]^]_PP .K\Y*71/;YLX/[3:-E2CQK?[@;WTI?Y
M_>CX<7EY_7S]\/T;E@X_'#<'5\>O3U^O'WN#0>-=Z^90N7XU?T@'ZNM<^[8O
MHY?F C< G'TYE)X.YG6Y"Q02'MX\Z+#:K"YFP\._[_:[W7;GL7MQKS6_ZXWF
MHG/^#KQKU.^K9W^6&KVN\W;-3]%_.,U:X#VNU%#?7=1=$K-A17*VGI(@W/O!
MVC?MAPS\<PJ7"TDU9>M@DV3-F7>! 2^'0RB)3I.V;'S>H5 ^6ODVC,:>J8@(
MK7X1&)5F1=Q'\XO J+&5>[M#RN/AWGIN]>V#I.BIJ_GK80=.TT^IO[BG']+.
MT'H-S[1=YCR')4 B/UF\,3C;XS\Q7GU;)]3[Z$PA'ZE(FOG!*5!DY[16-A:S
M,?*]8H"KDC=_8)(C_$BA?5;Q' ),.I1[XKBEG0/M):NSWQRPO./R>+I$,2;V
M1+9W(,NFB[ Q"M!%..1$W@:68E#=QE 5 E0 ,<)H"C_2LQ4/['^VE.]XB_)0
M44H#NV!^2]C""E#%C^\LC)SO;@GJPGQ8R4L+W\MNQ/T]PB\MS9H9%'ZBF0.2
M^_TI,?GW42/X%.T*IDEOT")CPA5"<F8*>$&*HH"/FG ONKVLB?U\,V?X_BE>
M-DEF_N5DJJ(EA%UH7:D<O)Z7)-"9/120$#S?IZ.B=5[O%TEY%>,RK-WQ_B:/
M'!LZ  =WPG#.#D25400IXI$A<.L P<+FMOM03-#<MQ,D[#]QN12XD\#U%]O7
M, ERT81,Q&HNEU6O10SN"J;U["5:/7M)7Q9GG[9]>\A<\%3L5@Y.AQR3%FSX
MO_)5L0@14SPM)BBC_/4@5 9:Q7GU85L#F7_\:L\@)N-P%TX 2=,<R^V5^.CQ
M*]U3*20/AY!#E;M1_$+X(G)LV/2=)R[$'6&Q/X?J#-XBS1B+GBY(;4:^+ZLD
M;!:>%U92$\\;/;.4_Q$"W)^CG%1WT?-^JF4+<J^(%OOD<1)T(FY> ]D;?KZ[
M+K:FM,WU#DPOND]? -;3%Q%>]6=YF21AGP+/"%M[ ZTIF&Q,YX#DOV\L6CQ/
MG^!P)=*5V7=:4B OBO 7E+@X>6=HB64)H4SPFE-=M?X.9?9%EV]/(&7R<F0R
M\%Q#RL0:)F56X!3C^EV_)%^<8B2;4L:W(WMQ"M?C0B@3=-6KM4[0,Y^M._B!
M1+X0;XW$]Y/<=[W&XY596\YUJJF=RC9CE1B !9$F"86<ZU33-/U6JVZMADG*
M% 3'(M[UJ?X?%<,'<"H<O AU_3J4K:03SD-M@/-06^0T79J^NJ//Z24^ #PD
M":1"G_4.WOXKXKROM_A<&WI,Q7PG27W\"+WNH#T<*A+$>H;7US,A\@YD4BC!
MIBIDK2"CI"&79"'_)9X4BL7E4_">\1LXRF0L>RLWWX@HA1)KE @\]^X8TM)T
M$],3]IDZO@!*$7L$ES'NBPQI7[K7C5N@:"3"H3""%?&77D!G$B"(EQ%L.D^1
MX=1$WK.R*6AGOM;$>$ A#>M]#$CN0N^[HX?$#")N=EES.%;AW$,$=9P7$1*G
MRDU3DS%0]+?WFN--%;%^5QB.^37GO$NPP6J$8U:&,T4^A,*H$$I3V),"6YF]
MZ $5TEV2_N?,,U@'W:DWYG_ERG&:>;1DL=-D(0N?C!QN=0$-C:O:0WJ*B9CK
M/#S60ZKH6QM3F9!SN)1,QG0DBSW__J^:&TPF#W=:4,Q%29:;VMI0'856(%TB
MB>.N>F[+UU_ (<08RGVP6)V.B'\>(ETZZD.\PN+?=.: I.X!@?+>-KB1<JT[
MB(8(SP$6?I(X"7+N<U#AVGI3[P2$"GC%VLI[ J#.4:9$Z5]D(3D[]F@-8G(A
M<BTC@+8ZW\]>[<VZ$T7!%[DG15(K8 \4NPG1>86N/:] @T(BPT&Z+L4J*%>W
MG[93,1D1L.;A1UMSV;%.&T8+$:/$O#/1Y*+$H2FX]I'^41(7NJ61T MZ#<AH
MB&-";;!V$R"97K1HZZRJ:)[!>DX<Q%UI>F'"A@[2+!:CSH46LJ).G^0^%2.D
M3:X9)?[2K2BTW7),;"I8$K$E#7F3B960?JK0\I_)$$JU_ =02P,$%     @
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MJC>1X!5YJK!+HY#],R\Q'_<AS-;DQU2AM3VV.IWKT6-:I'5E>2$;^'26$<8
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M$LH93Z9G:B4+[\422IW(&(6R Q..7;6A=D70%"T?>HP"R"#1LH]Z.H)E'1;
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MSL:RR=!1OE75O0.9TOX\E$4>@-"T"B,#OQ0VJ;<BVJ!*/N,=^B6Q%6VK+BU
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MN.NP<IS#=_3D/H8HS'JE[A.?U(@C>1!-.#!^Z-T9?EHN"GY@'CN4KMF9R6O
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MUJK3 :67&ET9R^5"@-X?0CJCVREBQ*#K<S9G6IP^\_Z(T$]SS33L^:@,)".
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M"S(HIVI][%$L<P$LP,F<N9Q+?35Y9/_/9)'+!A@%VAHXX'1UY"9K%U4N^WX
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M?SW: KX20(#[\W!NI[.9[Q(*IICJXXU1" VH@'?GX31*+0<&_<Z H],_3:"
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MQF%'=!PWPZ)1D*/S)LC5'N .* 8<F_;9 %&"#GKQ+=S5[(H=1V%(@L[F4..
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M!;\ '@2PVS5=JDX;<7+6P#L>'4MAKDO'EM?GG^;:%AL%1382NKH=-W;[878
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MW>3B$"[\/&_G!/@^5[<'=UQC,VZ\CVGT7:$-Q1UA7-ZEN%4/ (UU SY%Z_\
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M7^T;4WNWI9+BI5R3RDR5^M9&\;=,7]Q@YY%$6$DZ7[V+(@\7:(;Q'AT7'J+
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M%QWKXAE.E1VM0_]WP1@G3:3,&X1Z&&?IV*)SX%6]DSLVK'$#0@"LHAA\P"1
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MT?Y-_G&VGO-_5,NYUI6Q.(>*)NNU31([B &K:[0]QUB"1ZQKWBXYMG>3,,W
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MUP#=S+"".G$C[)@KFUFV0<3E5L3O"HQ;T=Z8>'L_B>(#H9!U)V-L<)H;?0+
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M6Z<VKRW,XI4>-C&8I'JXHV>A&VU@%;J//T9$!]GJ^+1,KAXN)YU/,]"))>L
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M-B^:0U_EI76]"[V%XR?Y.>#MV=LO6!+#GZ*=AWQ[?.*Q+@[*.+I%PAR\!;=
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MX,1+H=OD#?SDC>ATF\B(SA53K?0_%EKD,4 J+B"/<(940+;X$A=W=]6!;YV
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M\JW<K@F)OGG%E[Z[.2]M@NWVD7+&VVO/=_T533GYAG_VC7"I-_]E%M?/UU9
MO&A-(FI;;@B(>G5E$SLY9XKV0&XC]O,#@]43^^IJ;_X+2%!NUXP4:]]UF)4X
M_3VFT7;!%GGO!]]J8-RRV)M$MN')?&R%ZS/7_]J3OKME$CQ!L$R-J:N!6/Y-
M.";3E4>73-:]:&;;?NQ%[ 2X9GNW&5P=/K>N!Z5-)^31#VFD@^#NJV_@3.J<
MV8O@. ZXY9B%(=%"K&$10!3/O0U;UP^V&ICMOPO%O^O ?R1!M+4\AQN#1VZX
MKK2.(-%*T-S-A#F\MK;6/?^J'G^KR\#9%.:3/="(;S]DM& &C"L><^GTU+AM
M-3#;<T&8HW-!K7OJTD@/S]H2D(?)&?4LFUIN87TK.K-H\*OEQCHBT+$@G##4
M3UN0(QM2JVY(2*S 7C/Q.B$;XOJ)ZIX^/1(OU!*%C@7!3V\&9^8\4(^&$4.)
M;D@/W#N7A#OO+9=PE6;WK2^$*W4/K,5KP1&;JXS'=29U<[F9UT>X93%(N[&P
MGMBMUTN!:*!9_CZ@SB4:?<0LIL/.'\VK1WT-,-F\(2YWN-D-3/,TJ"P Y:W<
MQO<A^3WFUH0[0EJJ4ET"4M[JCO;1-OE)Q^JW+ :)<^L]8<%](_#;1[8JG&VJ
M>^S:B N7@I+AG0^OC6)U!3@Z"GQX;4S;UX.B:),_WX__S8M!:EW57=;&5[ 0
MV%'0[BEKHRVU+*B9JX>]M&V;:"DH@6YWH+7QEEH6DN9=SK3V3B07AG381!ZV
MOA1UK A]?VYVMWLI<.N28!:HY(1KX]NT"IA;6O7$^YF6AI5 K_M%U[R',6E8
M!C!N8J^)$[O$7YZ0QX P0>.O>KYWRS2=KM;1!?7()8G6OC/?, ]C34[#B#YP
MC.Y"LHS9N;)DWV6_+_AP.OPP@0:8V.V0$SBMO38L6A/2J.Z E5W:7GA7EH(G
M=IM3VPOSUH6-D%WH[/:7G,953=B'^2-/AV#GYPU72'_)%"\55T;&W=\:O>1^
MF]0':X25530R>W1#'BSF(&6H7). ^@[ [M6AP>OAS@/)"0Q@/$1K&F%9<M@?
M6X\TLMS^J-=7@PM5[X!<^ILDMX%ZGZP@L)A^S^.(9^'P=*7^>Y!8'EZ.SCV>
M.)4<[-:]'T=,CGE:E>5MB]!SA" .*'5XH#?A'287?A@R)<TDQ[5C-_5<&'B&
MU"?"E9PX,Z;;UHI<Q0_W)&"&+V#H6<$V^1:W=M<!.8L]ASAP)#**F &UD+A9
M]S.W$NN;.%NE[MF]=B8'P0#+VJ_?_2QQ^](F&-5Q&X<Y$P5KF[%-)V1)V-W#
M8??VG5\%ZL!) 3"SM\6:^$&:U\B@]]]*TWKPYV0#E/[9GTK+P^_IDOFI,8.Z
M)KO8<W)=GS\FQW/TD9\;)PQW -]&#909R4N!A9%_2X(-M4G([IP;R@/9B07>
MT)#]".K2Z4$T<T6ZO1MRYQK@3!P-Q=<*?C?EE_-R\.Z(G<%+"N&WJ<)2/=<Y
M1B%#*4G7#XG]YY6_>6-OG3><!/R'A!8)'8ZWS"ED'XD#=HF[H>&72\MCSB+W
MFV:>P^-W$5EM3VAHNS[7R_J^:T"2S2JO"V6T,D_IA$06U3*UE07 C&G;2[\^
MME++0AK)/!U9'^7J"H.DE.JC*[$HE(Q4XV#Z2(M6 CPPVI^F]5&76]=@T4@/
M912N!2?CI0<Z?50;EP'.YRT^T/4D:M-2IK+E>J J6$E=ZQI/<(?0] 1G/^Q/
M<-O?D*#C6.;?3#!T?#OF-&16C7_+*&(65<9J%CLT*@3^=FK^&)"0?2#YY07#
M)L.)?QN@^J^T:_(4$1X-^R81+P;;]>W2!UQ>.^D'^;=<ZYZX/WT3AZ]7EO7X
M>5?7-M]'!*[Y><<PG]WSN(T=M9!T:87W285EMEY*5^)&8?Z;/8&50+[1VTYZ
MYS>$>&7QC-D5=L^",KY68.=HL!]K$E N4<T^\>8QN2&_MM?4=?)O+P/_08]O
MD2\FD!\PZ__3-V]Y@3+;1AH\N4B)*D0SP3'B#G/RR;U>:O(K?X\VR;8JC)V
M(3"O64KK;*K1!9E;O%2378?X?[B_L+%<?FS,HF,K"+;,S<SJ=D"Y)P<S=P4P
M^2F0XB);)0D(QF8=)N?WG=*F@)G:# -?)258*"!/QK)W?5FFP[$T,\,@NQH
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M=S"TT0*PR;T2>QI#$6<6#7ZUW%@NW:AKC0DRJHLJ</4S^M>K=&)"Z;PX]^R
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M( $$"[0X #8=I+@:EL_=*%<E:C<,R-&2WD^$!XZ),]NPXQF0BLWKCI*> A+
MOKN-78T5SRK$T2J/C$L<K0L>?JGPCKN7'.L;'@M(PZG YZHR>.QKNY+S41K,
MHDQHW*2"[,J0M,>G]W'2W(W=&RZM)_H0/\P\+[;<XA]#AO?IPZ/K;XDA68'
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MP0XZ8;F=>_38*<PE)XBVA7< )E;%OQ@PV J <2X6ZK9<A99H-1M%5(Q8Z08
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M-")J=I,[IOCW#CI[P7R59?Z/KO9HCZ %#I?+SN0N!(G.S.X_Y3T'9CC@+>?
M,:+._5?B.;!*_:I2&CM5^]5M6FJP$>XZ6F<=\?Y!_K#R\N,I_#*F'8T>"_O
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M8+I2V.1B1IN\_3[9V.@+PLV?I3M])H+]N)GI7;\6>XF;W?FW?P)02P,$%
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M@W$%=Q"X/,X8R/X^[$]Q>$E:0\?(%.T$^Z0=1N$D%W*6U*[%K<-PEG'W#U1
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MO#/&FOHHR&$3IN+C%- W/"A;1W/42J[3J'I66P=!_8U.YV[W (C66S!F+7F
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M/VA-/?=EF^4U)=L>#8:DHV!A?U 5R6TO=YKI6<$KGL9+&R7#[<RS&>*[ <,
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MQ>5:V9V'!(2(/8>D]TK5/\*$B?/X#-@M;$].:L42C1&A7O4[5@,-6I2,4V<
MJUM*L^_N+"_"9]3OWEV\"'@@//D#X57^)KS( ^&3_A!>=I&KU-AW<O9X7\O:
M30Y%QT)^SE;"J*[N(W2<F$)D%(%N7-58CV-5U?1SV'[N"2V1:(@I6E@Y5+%A
M:9&B-^ZXN(;H'O#?/#'ZG;!+V/> AXP]>PAFQH..^"2UJV:WF#B"L%.K(A?]
M>U>J<.6'%IHIPV1DLB^CM@U>$7LXL,%*E^LT/L^C1<Y,XQ,+ 0%.J4S7?S(*
M^B>CK.\!?T/>M"IW0]WXES,[=WQ)>9#-W42GU"6%AJAMD6D00P7D<*L^A*):
M""W,@\_YHE-3DUL^W!+&,(-0*"9E=,=\9Q*Y 9XBB^#Q>4!H_X$@&@_@MR_]
M1\WB_>FE9NE:S!]M^WC^N#/W6(5,)XC/=3ZS$AHTE[D];F1]NWK.FS9CY,P-
M$N5*US:@&RA*P7I+W5OK%SE;D9N>KOZU(KHFTX1DB] X/8A9\=]G\8S;I.(I
M^;O7WLE:%(9N5\')%GFP5LH'5Y%G[P%+A%4RNGF\A4D\+M\9W DO2-(. R[=
M[SZ>-UUT4!X&0/YK"9H207@;'KRN'07![?= C]<&H_3UL\\D<_6RU[?EX.H%
M:K<Y%V4&I$J[Q37/8*WD?^].\/<:MD28E@6I1<!PLLXZ4\364EU&B,=6%\B"
MGYOV&W1]$JL1VDOT$N<F_D!7,@;GO4[8/;!K'(]33&;71DI.!0R)M73\(Z'7
M[V26+E_6_V88U.@:$7>'>_";$!13=Y?Y1!\XJ^[ZRKRK=$/[A^MWV> EK7R@
MK*#-, BR$!_=4IA+GQ<)_*!H;#?/<PB$9*ZM)R$D(0G9D1,S/#@P_9,F?3?!
ML']Y3ODO/#3+CI06+QN]2<6$E^?HZL%R$.(U:C^R5$\R8^A&^E' EX/3MW:)
M9GBJS 4+"RR^;G-RH6NFEV$KX9WAUIKG&S (E%FSB?DZ[HJX:07[(?I(>["#
M((E_+0O<$::FA?T_2,*29_6,YKJ%2U^>A%PLYU&&6FQ1L$YPG(8"&7S1*Z"A
MDK,+[01[,I(ZW<"[C7EH!=GOPK-K./@[5YZG_9^V6[0@@FM$;2;9""2F]P\L
ML=I$!GH9W5!..P60]K._C=:_R]T1WIN,M(KPJ-0:A<\7YMAI;K=3=7JXM9P#
MGLF)&6W H#B6OR4[-.WRY<W?R(?_8UU6+X3 ;+!\FT W41@0YR1JT<*F&H]'
MEBMR<8T\UN R&W.C:Y@$A@G7R3@ (UNQ*H>Y'1E=F1GL+2]*\S42'W")3'E0
M)-A#6<:QO0=XJ3W<N/]]HP&&],GY(NZ>\?#,Z,#7ZK2H.A>XMCV=]EF$O"Q8
M*T+5GU]RD,X^CU<SEQ=7<HUB[%Y<.N ZZ[3:+%CX&Q?2_XG+GV7: R[ZE[Z[
MMIJ:PP:H@6=Q/Q*4D1Q]'UT[@U,=W9UT^2G82L8=OE6%L7Q5@M\#S*NC1.6<
M?AR ))0CD\VP1O:8[P$\U].W,1SK1L[D?]MK_4_C_]SD7Z9/*=9!C<H6#?H(
M#+T0DVQWREXK2:F7@LBI3^4X0LKCL[2K>D>5R+CUF+-5>KL=LR7T*1I3?I['
M0)L: LJR;@KVC=84_N/^;U)9Q@P79PU&F:IKHJ9EM3;DPMUNVTJ>*PR-3>:U
MK#;P:T4/5#94?F*]FZ=/9&5I2T8EVTQM V;\UJ;SOP06%NG^CQS*?"@3(FU-
MIV@5]X!&YKK+,=6JBKK$X]GSD3U- 0A]P,4G6E!^\R-GGJ[2@E_B#0Z%"NX8
M4F"0DTWO#RDP1=>;-F;/5/2,?TE?W\V7OUDN<1!D](_,K?R9=UXA\<#=#YUI
M#V80N-Q2OA[U&BK1Z7#8,(7%5@\*PX0;9 B?5NX/$&B\BWI0LXC6LANYS!3W
MMJE9[:^O[-.YKOPM'59T8^0T)^#EMI05^H$DQ-JC@G'@[EW'_(P:^L0E*;$*
M)IM&BK"#MC%K3ZB<Z0:A4"!_@8D/]<<N+%2<TD)!+TQ1TG>GG :Z4DYB-P)'
MK/S7)H&K3X[WAJCV=J82I^,Z'-MC?[H,R"_.$\^845/8/WL>OUZYMP9.!7>\
M>NC7ZH.?L.T5%Z5>T5E]]R6KYL(EU\;GCU"%*6;U*ZTSVZ1B>FLL#HCUHR(\
M]O;5#,E' @+Y(WI5F9UM;(TP1$'9W5JJ%5"E,9<><X?UC U^9=>UFP7O? .)
MSEF++%9,+.(\PGX.WF=]J.-?J?I\HI/#'<5^J)0=#29Y4L-^&+40=M3-Z_6)
MBFB:2\5B#KT1V@3N)7XXA&:"(>I;&DK64'S][,)?(1;R/?K<,8R2XB$><(.W
M\B#%$X7J$]_GF&FBH35+Q]RK<P<6/Y:/X#$=H17C;L(!OTS?CS($JNVC+G1\
M)0(PDO=0]J;AA)Q>9UC$.AK,#[@4+2I;U:VBMQ@YL@ISM2#3Q]5+N 2UM3J8
M.ZQ<AD[#=A-HG=U@A8N%7'NA2UDZ$RXB/:ZY?"GTQR*VX_YSO3_D&H4R&!S1
M4'"EUBC!ZG((6R'VX@P\?4PH_HZ3FX:'?#=W\TF=SYZ?QEB7L%&T:!R>P9R'
M9NN6IADP]H4CT%'5&14;O7N0\<)O =\;69MX<K:B*,_A-K=R8W&YQ]XK(=IM
MY=@OAMF3+'DC@=B?[G@E%G&CXCF;:"/ XP'!UC!^$7((:*947/K11,Q/OZWG
M 7^TZ:S_& 5I:9W6=)ZT^\=13.AN2;K.4OI\Y[%.]^''*BE9^=>>D=U/0X(X
MJ,JX'UH1HQ>SMF_HCCI.@\\=>SH*I54Y.QL[@C^DQKS?:>8GC9]8'\_T**I
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M=UI=[3>$*Y;?\94<[V$1Q5UP&UPM*K^1!B;U.A>G.@J1#W##R*TCIU^Z.SA
M(66Z%:MT]9+E3DPM%EBRG%(D:X?6URW[<>6ACUU"%>\00NXRSA$O9.48:512
MH!N5MOA][>>SG],K-2?C[!&":S&51=,OB]:?GEA&_D2_@-<&?,AB<?DC__\V
MHO_OJ_0L!97-XAZ@E IC0Y3%K%EE2K8J?S>\2QC0GN0+]B::H$^AB\F*,?E,
MH@7NW1O1^.#MS9(T)JKJ"H4YTGK ,^ZF].17$N<=,-<<&.>/NDWKTB;S&&KI
M*DIA[88DT=JQ_2UL92T.SSM!]B^6< 9"!-_(]5>OBH+5MAH):T?M3W7VBM\[
ME.H\9VKKN"OC[IW1I_RZ[MWQ.I6GQ)L>]'9W*M@LI( LB_A9K/='AH';AU83
MK@)&6,$;^_#&BM<:JF4C[3)"E?.#''4:0=_,PFXV0\8N*HGK:GP; 5;48[,"
M)76)DPOP% =056>O?K4YL-LD&3K9?=B#Z57 JQ8,%V/UE2$:#\DUB1#!2<JR
M,(",THX7.GR/TAI94JFNC2'B2&/\F>/7S1+;?<Y7ZHT8X&[U0(!90[&<A(['
MW%99"%\9>IB&K(XE.L03,V&GK>S !?0_GS^O3D0V)<QJ!P'GE8WWS(56#YR?
MTBWYLU:H.%^H36#J/S&1IPXU@[0[?71'+@]9#Q2]?FA+GF3Y!-R)%=U-G7^W
M/A?+V[C*<O>YJ%RU&G1_7WYP%@SBD8G6J-=Y[\N+W:NU"6Q&IJBA4K\(^#ZP
M ,%7@F/*CB6I4Y?/\ /=P&R-'B$G"](AUYHA%$3\=YQU4T0[7'V4^WN]1V29
MCRV'JM]1?I+*A30BAMZ,@*9>-;+D*KT0+BLZG:TA:3/^=;:56(<6!-HO<OA>
M.78&;&S?(XNB!;Y]$8'!-,20EI-' &V]4':Y]+ E2@"MSU=/+%?K-57&.I."
MKA,J+<G6PK\7O(&([9YQ[(DHM1!N-<6Z.28KH83&!@9XN:*5$M) *A?7J8\;
M1RRYM]5T5+"&"S@MUCB>?D2GV4!!1%R.3B)60" X!VR4R GD8JKV+-YG7FHA
M^9&84,X!6JV$PLB9P9.<)V+PCK@4402??V 2E&=O(=F2@3 O1P8*_BY#5/;"
MMN;]BQ53$K4Z(:-F,BV^=,CF'NGCO-H?#2"I\E673ROH53(:#C-#[Z&K80GP
M 62].-W#>M+"R6B='MI'TE&,.^5DQ:+%HA;1JKGTM63CE$]#W,ZY>O(2*)Y'
M36&;;D =M>SD4C_*^AWRU>5"3 Y ?-V/AU7WA%:_DM<<GQ>:4ES-_)I@] +;
M/@Y-['EZ>]L?B^DU +)!VP^D*GU>TB!LN9682 EDO6-0$6<!+K8J$=3K#:,V
MPZ.KUPZKSP>M&XTOY"B?E(ZOUEUKM]H4YX)FQGG%#9=V$OW:/F 9X<PW%Q E
MT!*U^/,$Z^LO;P*]SEHZY72;LB]KN]3K*ZKT;.=<ZV6A"D4O9N, 6"DYM*>;
M*%A!89OM5;B7W58LV8,C?&FSXJ/?3%[O@H<6;L%*B]-B"^WCIT\55=3W+Q3'
MJ:NN76M;G'](&]DO- L;ASEV^74I9@GX!%:/[;,=S JYQ"/"7_>NR:+]&EB]
MK H3"U 4Y5D5++9CI1F/VF8)A"^JN;**O(BSY"C?+-G\MIIE8RW.4CIQ0%,9
MQA)O:*5\ON$"4"6A(M)_MBTH*"C&=-TM-FGR]-&6EP[BJ30C/?^6G4JF' ;I
MQJOV$/]?GZ32U&TII0X[!C92^ .='*@J:\?\WRXHV8S48V>YO=AWFZ^9=^04
MO(!?B1K_LOQR=LGQK2ZUMZ_;^/SPLYZ+61]/<AC/$%!P3[T%45RVK;LY1[[Y
MF:6;;?>[#[+H)X0F1F/F6JJJHGM$X6<<5 7V&+#M"VO-'XJ'D6RA.;'R<ECN
MX$&GL0H''6OZ,:,)/AY&$\^27&7O(5;.G261_/ ;>F'(CR@YWR-V]37=Y_1?
M/#;4N0FPEM? R:OD6S@AY6<_K%4:EFN)7XSMBK\YN1D5>-SI=/'!;I/D0/TJ
MP7!K1$W_PO\L.-2&7--Z\A7N-K<4F7-7Z:K,NROYLQZ^X?$*$&K*@UIG<J8'
M,0(*TW"M#@JGV\@$'BUN+")$XFG-%K\/K]D#@6B14PVV:M)N:'G] ]]WG UU
M;?+R=$+54:+H%^P6E637R.O<]U$(T80V$PU86F$S<;KFS?4G%"/VRIE=X<(*
M,SI)Q<@L8XE;5OD;[]?EF(C]%_M>CYKJ%?.5=]L3/Q+UR):A<E\%%@[@M.K"
M)P,S0@V/<'6V]@APV1JG0M?"34ZP=\DS0@ \BW7;C+\W8($MGX"S?SIUB=7-
M;^&A1\RW&C+)-H?&H. -X_EU-<CE0:0W[@'*Y64*O'TF>.SFGT=BTIUGV)[@
M'*<5@7]I&<B0]0NI=2]"^%64-&MJ:FM]!>E]]=RO>>EH$PS<PGGWJ8/.T,BM
M9]T_%;,69OO? TQYLY$>R;/B#'+S;#RZ\46C,DVU+4P/LR#+;1VN%W6!XZ^^
M3EU6C*X/+>-\]T+S#@4EBL ;.ND:]XE/$/8CHV:";2-8(32V"U2JR?HFO3R-
M:W!"#)7'P)4 S'6<$4B!0:KY":XG!^8;)YX<8!U!/Z%96*5_M^G;CA,WCM'5
M=+APHTL<0%VM5Q4O6B7L?RAI;L(;'!VCCJ,N*[5*<;8U_O;M R3(EBNV ])C
M*N.DHZV#VYCNY==L WE6_2+'H>6<C O=/=NV#G=X#HL+PD,$TMY,+D=D;_9>
M4=7,HWIZW8K53LG),- _.--XN%5_Z.6),RM-$$1RLY<P%-L+#KF8VUDLF+]4
M*V*M4()5/KYV^TZ^?\"Q;\>5TN Q%#>U6*O+!.::(4N9\F=G)];R<44?Q>S+
M;/QX)02Q5,^T3.9>1R-!2ZW(ROQYX6A3I5N9XXIU\:,] @E%AB:,C_8C$FV4
M$KX"7X6,N 61')/WBDA!:9$>_$;!.E\^^J,)W6JD&_+@+JZTIWO.S@<<@_>;
M;U**8DA7V&Z^C=CCU;-KX_.<("?C=1&.J\GQ$#-SN[ Q&W #ZR]W\76TGYTS
M8AE_%!S4CK(E]Z+VL#X'[O*1:!Z/;F^;6W]C#8DNI9/'PI:5Q8;^X8.;'$<&
M1%:%&<2NP(<C5FA:(RNNN<0Y0']SMDK.$CDARN*1,S^K>Z5%_$9/FUN.U@W$
M_7J/14CVG;&&,U)/RPW+1&YV=CLB3$54(G=;-S:ZP. VK%7/-4P!?Y%FPY?X
M*9[W-%/T</A145D0LU[U:(F:#,'GO_]-[-\O,XB?7)RF[\B>/='B_N"ZO;&[
MRE;U(W23R @I&C^=V%2"NK"U!8-MM0''7XG;V.I/@]MEQ3Z:'0T9V6SGYO2?
M$T9VM:T\GUX;S^'9RCJ@T9Z=UA686:,.9'\HD%2K-)2A=''^?.2T.OI;OS(E
M0+Y,QK!RZ2&\P'G!=\^K )E8SI =@U""J_@:M3YM"#N+T*ZN7G&YW..LCOK>
MH]5!ZV21*D-4<%>#>M4E;/W23>G)&1[8XSQ^'W]#&])NS&K5EZK!V+)F23L%
M^I-D/0,KMGGE"G8AGE0>64LO@AF.NSN1KJ^KL ?2;"8-Z!&46%U9\'YW'CF,
M=O.&\'X=IY;%&B#:CNZX^H9IF>"U$>K"C-X6W"%7FIW5@;;ZE55\:^ZV1F>&
MF_1'R"9<+ZEUM/%3@?6(#:I 4YUM))4T_WI,)2ZVO(BCHQS*E-(#I]@UG&)3
M4:/FB6SK7$WS6G))EJL8_?K>U %8506W;=':A,6S0+GMX28""4[G_K708$TU
MNT+M==J%BD 1L,]0A><#$M/.&?%5A^%?$U^(;:R/V9G]L),+Y_',W]_I6KC8
MT25ECW'-N71F8][>8 KAO$T5,OV2TTULLX;OT:4[E9Y5V67F7.O@E]C6=P]X
MC?-#SH#GUI!;B@%F]"$-3DN!ESBKQUE5*HJ9_91[BX(F ==R0_KYNFAJ35%1
MD%>_?NZZRQ#FDI1[%G]&;AO8(9.&+KT#2?:]EK$U]FH4<1A@)[')/7V^#V'%
M!X7F1G[HG8SNH#6OH@8UYZ$8;T[Q5<FP6XC0Q(6WM.WJBA56?<H86TDE9H[G
M?H*;0W84<CU6+["24"X0:B[L$H@BKNS<9J-N@8S,VO'EIU SL"CQP8 'C;3Y
M@#]N?U"14S%A\GE*)_1%3>A>%3>52F:&/5F$_)JQ^L!RE<X^N]U!+%/CW./U
M$D@5,PGBN+)*R%C6TQ3N.J[6W]$;)JN*;JC8I>8M2[E77)FU_%72*^*=:"G%
MP,Q<>2HX.7E4PI]#IZD<5O[];O;:L>'$RV_MB#*69J9.Q.UB$#S@>JK6WQ9#
M<D<QLCFRTG#];G9!Q=WMXO4.13/FX^>2/<L@^$/U6NC5?4R@)O]_'CG^/UXX
M]S/_#U!+ P04    " "<BVI:&RT&"35'  !93P  #0   &EM86=E7S P,RYJ
M<&?,N754'-'>+=@-!)>@P2$T!(*[.T$:@KN[NWOP)#@T 8*[6W!W=Y?@T#AI
MH'%+F-QOYKVWYLUWOW?OS)HU<WKM?[IJ5=6N<WZ_L_>NEY67;<!K>1FP#  (
M! ),_OX +VL *0 J,C(*\BM4%!04-#14=$P"+$P,#$P2/'P< @I2*DH*4G)R
M:EI6>FH:9A Y.0/?>V9V#FYN;BIZ 1%^3F%6+F[.?UP$B(J&AHF!28R%1<SY
MEOPMY[\]7GH N*C #P@NB$ :  (N$!$7^#( H ( @*^ _S$ _\< (B BO4)&
M045#Q_A[0N-K  (0$1$!"?'5*R2DOT<#_QX'(.&^PGO+(8&,KVJ*0N-*P!F2
MF(<*DJSM)52;O:#E,G,+14,G>D-,0DKWCI[A/2,W#R\?OX"@U =I&5DYL+RZ
MAJ:6MHZNGKF%I96UC:V=NX>GE[>/KU]8>,3G+U\CHR!)WY)34K^GI><7%!85
MEY26E=?5-S0V-;>TMO7U#PP.#8^,CLW-+RPN+:_\7-W9A>[M'QP>'9_ +Z^N
M;V[O[A\>_\$+"$ $_K?QG_+"_<L+ 0D)$0GE'[R "-[_. $7Z=5;#F0\"544
M4U=\&LX05 +)Q+S:7C00E]H%H9G;+#H1+?<.'?P?U/Z#V;]&+/3_%K/_3NQ_
M\%H%8"("_TX>(BY #'#WR) ?C/[_9T"?P95;*_?G?>F!C;T*^LN9!K(-%#OJ
MH.R"'/E?3"'PH.=OTX@O@&6%G-]OQ D"O*$B[OV4PG,%M1'5UXVUD(,_BP1$
MEXL]K)V7N6'QYH999[6$RV%GGK&,^Q:QE9O^ODF)=V#DUDZP5(#+;'(P]5$S
M(&SK+MK@3U?\Q22/@J>V,YH=? S40VM[QURR?QL;OQ>D@A498%UFFX/BL?6:
M+]6];+T?'8V.6((VG/5V6)PKO:Z+&-[6UZSJ<SWJ)>[,JB@J5E][W;.'XSK)
M%H$<3]^GB#QOR+MEUM80AZSP&6B0V'>U%554YL-ZVM>F.%6T4T.X=0S7&YC'
MT/_YX7: 86HK(YFBA1L8M/NNK,K6Z,V\Z."GIO2(25AG0WT_L0E?)H?*3Z@(
MEV)&/Z5 ?63)#WB_H0'U>M-="NZ#&]49I 4DFM_Z B"SYTN_ZWL!8-H=.R1N
M;ACKCOUH?<N7 J6OG@N2TK]\ ?1-+=#8.V93S0T$AWF2C7+EWFA28SZJO%*4
M'7[3%M];$8^_$I1[@IZA R ;3[18Z;$N'>%_7#S_*CA55GQ/-'6JV&FO/WKF
M:,95SO2:(M@\E&.S/L!RY]08(^!UURR,8B]NDVXB_J[0G)IY>!VB*+2;^"V
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MT:OR&.]UG+9-C"GZ]G.A%TV5;;J&H 8.N;KA1\-FKO6IN5;^82W:VXH%%>3
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M C8S_@4G@&QT#. 6O I<^W:I) ]M!-C4A%?.*W;6@HOD6 >8&,3?[,=JRKT
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MBH &7NH)56?6I)POEE1-T[.5EP%-(E^,_% V'R8[?OR"P5V[AH"G-LDIN]E
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M1>G^X+#?9.OZ-HI7X:S6D#/%2YA6G][S;_I0HF1A/:RZD->I+X4AX!52MS<
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MPG"TOG&^VQ'8EZJJ+7$7"QX;&"O^D=.7UL.K<U1Z%\PG=D!YCSYI$\B[3VU
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M-Y,OD1)=TA'.=?9>QS1!0;AH$,[?/&_9.@?LWUU\8J<W.UD9<N9([Z&XP_V
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MNZ.!$MBZ!07)-9\PW H7GW!=R^UYLF260-7&LF%F$>KQO3TT50!'4Y0]; &
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MVY-/)'?2/,V.[AG[984HM%GK^AM:GF*CIH&H=N]<*J13>]'3'L&XN%<F8.Q
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M[,_;_B.]9_B_$3S^[S*4QYG_ %!+ P04    " "<BVI:E'6F":Y^  !?@@
M#0   &EM86=E7S P-2YJ<&?4NV54'%VW+MI D* AP3VX!Y?@(;A#< L2H"%
M</?@VKB[2Q.D<8*[N[N[>T-?WN]\^]R]Q[ECCW//O[-JS!]5M6J.]<Q:\WGF
M'-4-FX>M ][)2LI( N#@X #?7P\ ; D@#D!!0D)&0D1!1D9^^Q8%%1T' QT-
M#9WP_0<L'%(B<C)2(A(2"FI6.@I*9BH2$GI>!F8V=BXN+G(Z?B$^#D%63BZ.
M?YS H;Q]BXZ&3H"!0<#QD>0CQ__O 6L'8*/ \<!;(L!1 N"QX1"PX6#= '(
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M%-ZKKDATF#?%DS/2$/8UNZ.>M,2_[%=&094J] __TDZ#*ZDYI&U(>7B_PH4
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M>&- TFB5^".<GC#>-#I=8\3T/B%L7^T$L)U[M:^%VG!6PMG&5+7+T5?[OE7
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M=X'MBY^_N[S*SX]5@&!SVR>RW]=";>@7LNT&35,5MAN7X&R9O-%?77S<I.!
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M1:HEPX?/4YG'?L;5$^7;#=XA')/\ ]P] \6LE2YN NAOOQS?(A1(79!KVT\
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M_YQ LK>#:5DSS55Q7J;4[5A8.NBLMU5$;HC!82UUD@Z)=7GQ@WXFAGU3WO$
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M;R9W31+9T[.Z9\O$1Q++#^ESPXS_XZ]1'"TR,  %6M8]ULMOIC&\5JSNK$M
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MR>+'EK7>7K*W=1UV0!:XVN$_:B8_Q5_0X&%\%.&CCO#MY2S8F3D%OOL=2<;
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M!4HEFCN*9?E_"#[0>%H[J*LG[8):Z>3VN=0$W6JZP2=C[5H%DJZ% XY&9K!
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MB\W/MX*/ZAS9MU_3(:]A#F#6!J*;_SQZ17#''N3X@P(<USM0(!B5U:^PE&^
MS@^,8%HK@^>/<F\ K\_<V(YD$P[FU1)O@" ;JW<N\<GWPE_V?ZMVE 3^\$W#
M-_1<_VHQ(F1Z27#7V+]\@ENZVO]527YL" O?([\4;MO&HP9'USMS^-<6WRW=
M%92G4-G__(FF(UE(9%EO%FV=04CC>W[&]U!A [J $*:)Z/J%Y W@]RY2%84K
M478*Q7VA'^ %;^N[=Z_PLJF"TO=B]"X.^B<>I8XE"=4&G=[%?]+Y7EMWFS>
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M0 Q(^H<VG6'C,"42;@ ^HL:G,OFF!P?=,FM3;MJLAG.S>[>9:(,O^KX;B6\
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MOC^+=/OLDU7:8_73-UK+$)Y\])ER ,S+I6M>##,,-EN_-O3*)+^&7E;&F+
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M6S/Y_>?-&[OOSGU3]5[-FWJ[ZSOG5)]=N^O;9^VUOK7.[N??SVO "T59!5D
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MMM5[6(ZL/ZI@W5N"A(MZ;36;*2+7O*_Y@J>5I$G7\U\%.-N.E J%])6'^%]
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M[*7($^Z\J$WQ2P,5Z&<>3J<*;IX_P582ZL9IIS'PO_&0' 3[>YRJ4CBU46R
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M'+CU]/VVTC7TMLQ'@Q2*4!ASQ!-WOLC$!'"\$GRTY= N%BQ1V&OD90-MO?*
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M>Z,.?S&>.+=!ALV9&%#B<B7Q\I93K3%!O9,L.IO'R5Q.U.L&C6J+S"3\O$#
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MWE&.IVPHT^G'Y5>W*UBJQW\F<O1?B[;]T=?*U]ZDK@PB$ZL47>N.:GD4DO@
MHZ/ZNH&5_<KNOCY=&P+NZU8TC7,=68K+:J;75I;X4 >%L]B7!F".4004:#F'
M?YGD%KDJO>]@;0IZV9D<Y,UZR%>1U."\L.RY=.()"?@P-SN>[5U'^' 8BOZ(
M8]CB'3UMH_E%RQRODW7"D]S649S5GG^NY'78L*-L.T)L<?%<!^+-7T\C<9@
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MB9F%E8T/_(I?0%!(ZK6TC*R<O(*&II:VSEM=/:B9N86EE;6-LXNKF[N'IU?
MY\"@X"\AH=$QL7'Q"8E)R5G9.;D_\O(+"BLJJ^#5-;6(NM:V]H[.KNZ>WI'1
ML?&)R:GIF:7EE=6U]8W-K>VCXY/3L_.+RZOKOW A 2A(_Y!_BXO@$1<R*BH*
M*L9?N)"0W?_:0("*1LN-3BBAAF'B2$3'\PF36#(JL[P%BYY7_1!DZC2,3<+
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M82PT; _J'IMI1DD64,GWE+T^=)\NJ[*TU+)^79)2O8^OH#D[G:SSV:[_*5=
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MUX<J_\651FFFR4-RE1["4;?KQ:JAU_S;6:STQHN7 /12/^"=&J3[_/'-&98
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MQ2$\,O+2HG+WQ,1%_]D$1$A$1$I"2G_K%KTH&Q.;Z+\M; MPFQ!8 06#0>P
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MY11?X-K_!^U?9/\SL)=_1?;?8/^':PH@!8/^'![X-@ %3B]XLT.(_Y]TOH:
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M>KDR.AO5XS"$!<@!R'A:Y39#T$<+<9'E;T^++XQ6LRL*>D*'3X1_;MN2N\0
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MB!R8-<T'UV?/>\_2G04MRH.-4,WFWQ[8N:B#!)C)#24&X%J8@A,RU'6>/8N
M$'T&J,-]!LF"6O>&FV/VTHRFIBZ4Y[?MPDDO#YPS)IIX' +'P[QS!G-G?WQ5
MN(J+,8R$032E?M%&OLF07?;=L5S"G"ZFOII]2QN_R#?.6#C1;[IR^5I(D?Y$
M^GC+D@I,J=[:W2@_NN8Q'Y/R,W9Q+MP&LUI&L_J!T\O1N!0]7>-""-O]RMS(
M7WU&L!B0?K"E]+'WI4/3B'O6@EV+!U0827P0;3X8UI/ZKHM,^76+0G9#5CC7
M]G??/)AWYV@4XY@EQY_[A=#^BU$%+^CRM?TS^;ZVYR*?GS%DT)Y4R T+A:/E
MQ/@2?!COF#<1L5X30O,"=4&AN+8LA!4*^PK)7/%]OZ>*9M^+X,WW?7R$W",K
M.=<AX-\'J[Q$L%\<\$9F':B?0?W+D7D!/W8SDAU.=90[T<-+#5&9V3)J'!BG
MX_YHCC&V=_F]#TZ0"+%N_0A(_S[-:CJI]5*'J..(R*2WC6 EP1B9VOICP&.8
MOSUHC<,5?!63D9&"T'KLK+WP+0)3FX=8J?\Z4G%;O=MP66JA1R*I;SK*3624
M&$C<376;\\$"FF_%XSXG513FY[@I:EM&;BDRQ\!A$\W5Z-:"R.U>>L-;@)?Z
M\0_Q,RQ@11&>:/@UEB2DZFYVT0E@S/4P'<_6O7>).=#]>*KQ<K][+ZI[Q2!W
MO,*.L]?7EU4^<V%0H=%92OSK)P$S\\CW/XW$6KFR>,#[N:CZFK3C!^LL]*E-
MRI+N+AYD]ZETWH.B6..]H%'VW)4I&S?CETU&@YKX/B:A;_K7")<YDQG8VB[M
M);@&C"6[9J4"X/WA<RLI+WR7..;*[$FB!@*>MBQ5%5?.H+KRZGM60GJXOB!E
M ;3'>B>3Z!>,TA*-N'$9S9OQ;-Z/=JR[=N=)"?.C4Q;C[?JF0C<^+BL?DLB+
MRG/T:]$W;6CU2AJ.N_NW_[SD9?A+)MUV*>U-QL:45^CN='OO/90?F9%VI &#
MXHJ7H&;%_CP7(Z&?"'!)U7F8[/.]S3-I1MF'Y/3SG>CPXK]+$1^X;HO$W3P8
MIW+C];/QV,@RZT68;9CDW,4A(YS6VT/<RMXXD. J.L6EZO3&]6[;XM3CM?65
MP66)R*V@/+NU%("B=X-+(5B%<,['<[& -U3TAMEYVBE.^=\MZ"6S)M-.%%'E
M-F3%K1,9%.V?\4MU%5E>E#HT_\KDB%FDL1O9LZCHDTZ ;19<IUW?"L [?PW;
MG\FM^O(YX=H@C0D/^08+R%YX[>+6U_K/J)#:XMR?^-%,(_"(H:R]\'*=*2CY
M!^!C*9.VI8T>.#FC7:_ W?JUVX56"SQ$>/7Q:P@^KUN=7<3S53AKO7:NV7]\
M)14,C.P*<CL:S6?7>&54M<S47(:>3W!]-L^B] \>'QR8Y$+UPTK;LY.3%>G-
M7PD+4]'<8'IN4.L45])QR/)&FYOUXF N#"(S.0?QA2XY-[Z%*U$Q<(@ HBI8
MJ>&FQ\?)2[_$:D\S.>W/,.70_E%/)3F#4^83F6C,KBW&* O7;M:Y.G&O4!$I
MNW;OZ&SQ7=YWLJ69ZJM",/>7\IJ30],A-SWOA,4&H>W+B<NT]9S9-PYO!T]S
MXQW ;X)>Z,;U'JV6;8S/:CC:T=NTA8TW2&"N(O=F$EL,PA3K+ +>BD+0(:)R
M8Z=7Q3OY-:Z"LVR =Y+N=/P[&:C%V,IPS7[<>\8,+R=#]-%QEV#OVAUQ4*@G
M8NWGP;E37H+Z+8.UT3BANK[>KL")I[5^L7%F]\1^^WS>=K7:,^\(+N8%1R#T
M7M!;L)Y05SQ'IR83MO/*72PVE)21/_:0@K'SA/1X_A"LC2;5C5KF?IP#:O!,
M!ZQ>'0SFPF'#Y5(AB5(I9_*&$= R1(#5O3-OS1#_UX]%U YCW_7(8 $'X]&_
M^SLP#H<;Q/ G<2>^IJJA%/)0HX=F.L]L_0CF.K-V_O P7GE817FK80%8%IZ7
MOI*&*BFR$'F7J4I%BI<0:4:/UMJJC+@I[T)F61H[H2T3VJ[.18_PEZAC[Q'
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M<-N5?X6;W#4[-SN$/6**!'XNW,V"K/]D4/.7S]7_[W\9@IW\#U!+ P04
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ME6V4$"G=+18+UR$J5@'I><'M7VA_DOT>6-"_1?:_8/_'A0?0@(#GP0,Q I0
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M4V05HN^2.N:A::V^Y/PDI+7+EB38!5GMF8<^A7!?9XI"Z/AAR^?3W-PP^#_
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M )R+:EK;3AUKZG(  &)W   -    :6UA9V5?,#$Q+FIP9[2[!5!<3]<^>)$
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MU7IU]X;PR8Z@F:[%W(.Y0(')6]Z:@MZ6<JFHKT^ 0[$82+].I K _%GZ &4
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MU70Z2-R4C)"QPW7$T._ VU8^:&;CJ!ZUW4QH_ 7FNG>V;$Z!@?;2P4E=/?:
M*FJG@.OQX;,W)%Q2>_D\L 8ST'O.6][>T6#SB>5%(;!6C/D[.:R*KI:W-5*@
M76[H&V9 -U;;_-OU71U4"W.?HJQLGPUW\(=]Q&! O ETY25;G0 7E^MN(#]%
MBMY<OH5^5_B7I%;_MZ3.KBRZIR<J#NNSIN<;M^Y9,MDB-8];0S5_RE#A6KL4
M@Q] ^#)5,SPFKY$@UD+<,WNM>/2HF1PVL"Y5_ N-N")L;6J#?WA(:IB03+'Q
M6(]VK-ZW6)\[T20+/K"#?-9 ^Z16QF=?YMU7Y,(UQM[?8HJ$'8>C@-T^),;(
MD-UGA%,JW\HWCO$I#[F6V/M7G&D4<7D;Y31]1I>9AZ';+"<KIR71JSWI34Z!
MXWA^3$$(8FJ6Q6A&XDJSMI)T=HO2WFH/$Z,^'7"OIN3;\ O3C^1GDD^O';7[
MN+@F! :H=OO_2J$XW:D@$2*%!\E6XA%Q<D8 =M72Y]F\?]=-9N!1>&C<)J5"
MHMX(<ZGT$ZQ#*\.$,61N5#PQ9?#@R-D=X?I](*ZCZ7UR(2)Y0I \IF_=+C%7
M8V2HZ6(NSGW.AH4%@I"8^!)Y&T>\IPP3^CB0##=*E+MCYN7GVCH&ME0:T*8P
MZK6AE[% H\4BM[OR>1222-OUC,XPV6C3D&!,5G+7_.>)D1M-L;6+WS#@C4AR
M8X[^G_ACHNJ:<S%LCRE3?6&[#\F7"CL(=P'"(FE0]<&_$HU'PB6*;Y?'V<)V
M8R094^ZDYQ:)QC?3.VWJHY.3PXQ./X>X\TX&L2/+3A"[UDX=I= :>\</E#-V
MZZ50B=C&2I9WRT".[5'SXF)\%9'/?R5DPH!08GQ.QOMS_S=0'O+^]@F(?7:S
M=/SI3=Y"M><G&( #)6M+WB?X@Q:NAON-@NO#%V&;V',?@IT=7;!EE^0=CB0?
MHIM#&5SES)W!AF L[MY1@ O#%RD)W@]4K3$M".O?$LAL% /OM>QC^FY,36*G
MKRO\RRS.^G?O(RA(VPS_J;;$%_W/:DO'D_BNZA\84"&7_9S00M^[>D&D^+#[
M%AIL<+H) ^Y17S+YZWV7IY06IMY-*-W>\C<.W'N-9+?8PH.18@=1PTE"S([%
M=RK-E0,HHJI*I>9B8H.;O\"O:3I0_F9(Q:X3%1!2=]X7C G2U\_-180DZB!S
MQ4037?;_H38A6HNX$?V^>D$PZW]$OOJ ,Q<GX^#$7()/ZQ,XS,KN/5?AP[JI
M-8O\_''Q11/I?"NMY8[I]P7AJ1+^MZ8F\GO)]U6?2JY54H-%YQY0TP"BSQHJ
MGY'<.!P@Q<^-]7(H$7QSB-D24OQE"#B#OP7 2,QETS,0_1*6WH7/&>C.BD)7
MG?CCJAN2\?.3NH0\-9]^Z'S&@:=A(3>@71+9%^;*V-W76S[MSM0!0N:T CO-
M5#,SS"4:'UXM^ O4EPQ'>E/N<G. 1#.9,ZD9&^&TMESY^@V2=ZDE2=QX<VQ9
ML?@NYX81)MJ\GE]9H<@W]VE(.EO9NSIZ4/>P&E^ZOL]%5_HPUDXGAW"/3Q&,
MH!C:Z35<XID^U#=2F8"^QWLB2>-Z-(0\6:T7/VVKN>V=1GK%FB!5DZV$9D'>
M7U'+MT\0\:I97X>[(H$5U'6D>!(D_/A@L="$9[8T=G[DZG0GJ)* Q%*&&.=
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MWU>J3,;)K>#S];NUQYB^P+<MH +>,B>1'%L$&3Q9?:Y9B<M8)ST9%4, 7;,
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MF;, #6BU3FZ=>3LD<;9Y*KD9#Z5*(UD2>WSJSM93#Y'3A6@FWKZE_CW8O\,
M1]04-*DQ=H++4_"IZ.WII[_'Q\?Z;?%E"]:.15$74F35=VX\N[>\.!*=!?16
MHDS!C5K^BOFZ-754&T24J4..:REDS\6!4S8WV,)+JM2,S1G2V2OD-<.6'?<2
M5U<YH-'IFG)WMR7_.'#=9*DIP7KS!)6'T2+!C8(P$^^F:@C$G'- W.P=/%<S
M&7#%4^SM7"F&(U*V..$UAU$L=],\G_5AA&/;?\V@/?;J%_;"PE!57TSA]A<4
ML%@R]4I534ZUPC?W/L\'2-PP.T(9H*MA_"MJ:R8P#('1FC IR@'P9=2K:NC<
M"&#91\<*OW):/<:  ;]XO/(]#>(66U1_DXMNKK=?(56HE9F=2>W>_^C>3!V^
M0'V?6\WS<@GX3^-GPQZ@/O<+DWLUVMI!Q#=XSP<F=XE!$@FI;C$Q3X523[$L
MBR.MK*U%7?W5F^W1R8SX$[0C'_F$=1GX#-+7_.TKJF$!HML^?*!FZTM-D (/
M5_JY,P8O\HS).$:^BQI"PVP=501;L[E[C+J&;6\R%U)3WVL*$[I9'<N]LEO?
M3"1"SLHN<Z[/F4-9/K >Y/BZ4G@KMBG2=G7H*IG.NU^SDZ.Z-41E:T(:.%6F
MV\=+ZL9?:GI://?*[M7,%_:!A%<4_&LW\*TD':I+;6GL28GVOST]#[/N;LIQ
MUHZT/GRZ8" UR7<7P4Q7K)8G#7O#92^>M<R8TP >7K8B,WDZ\+W;:3E5/SO0
MLD8O*:'TSV07P%+L:OTG7SMTR[:N9@:G4=^G/D3L"UT&^8KP4 ,47QC2,\NJ
MK-Z2Y'4LP#$VVN?].K$!W5.3>L\*F]7M<_GMR=]*I8A3WI-^<9%XTP1*'#:/
M]+8A==Z*0@2.CZ1)$6)^:13.L]C-+O"I\1E=FJ3GKP_,<M\%Z:,E;X42=>R>
M1%T ^\&CUN,]#M S:!)05_A,+GH+4FCD,9C^Z0$#EO&M0.PTR@-@5+ZB.&=&
M5U(ECLJH5CWE7HUH/Z]!B(]AP3Y<GL:C^@0,2%$F1WX<G5"7Q$FLDK#M;*$X
M]V9N/?*_T0#[B?SHO:&AZ"E[ZC6G/=()[3VFN\#]L3,=C.607"6*T&OI(Z$W
M6$AA05%4'L58:YJ6;!B8L2BWI>-]/&K"'2*A!?F^>!10,:%AC$WZJ+C,<R1_
M:!+#).&X5HZAW&"&*2XTF[8QSQD=KYVJY338C1E25<Q$M1%^M/WZ0Q(61H)(
M;3T:3E##;*,EJXF;J&L@#T1R49=I8E+"?4*=RLNA*_;N;K9].1(&F%=\KN"Z
M4W(1*97Z7Z0[UN=/]-1.;?OA#.IPB;KM1PD#!DI6KU?^*624;(M0^0\4S<.
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M<CK?RFEH_1(%?*609F*-C!3KQQ^H)0G5CUN@)%LCQCCFPGV6"$H"DCC$CY%
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M.U='N 7:G\DSQH1R)B7B4"!16;_TJFVL0^-V429+Y]/4+%\V,>!_CQH7HZ[
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M:S;-UYC*"+N4P5X8&W3'2*^2XV#1!!Z#G"][*DYL9?E@GMYL@8#X<2X[1FJ
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M4=%NE8KI/]EI3:Z06X7L2FZD=^:&7-LEXP@>H:CH.SIV*)WW\.J=X_F3%N
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M:?;0XN*F8L@J=-G"!+^"8#,=I)TIO?#5*CO*;NIU.LI.*T[3Y'Y^@+>^:RG
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M@47P$@L3$PN,_PJ'@(*4BI*"E)R<&L)&3TW#0DM.SL#/R,+!R</#0T4O*"K
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M#?NS86DVP5615_H5E3>.N ^=[83]TX>SBF8?POS9A$J1%Q2!/ZL6UZA%?8I
MM3G-CZ#^:]+'U6N:]?->57\DV.)&[YY"T0<0<,AL$HPT5_[J<\."V1QM0Y2:
MD,OQDN(O +]0(*0"1SE)!:6>L-?J&8"W-U=&] SX<.8;PE:V6B6?J\5QKU7<
MQ14P2SG7OG5*<+@.T0VL)\;57ZY23!5NBO@D(3>T6EA-@38D5@=LE'9^8D($
M)6_>>\G7XW%C)K?5:WUR9O)/C(D:RH5Y:8S/[=7'_VALY(9H3 V8P33$F8K
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M546YI,6JDDTV'LJTBS=KBH\#$G$M^?JFVNM@\_-O11]5'LA6X7E^:"N!+73
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MUH%WIUE8,W932ZV\+X1;!2_X&M F(6;!%)RQ$F19W^20R,FIK/G9'E.#?EN
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MF.OV_I/#24GE+K-0W%[D1!DKH4XALP^96$)M6\,L*VUK73)]XP][>=P]+<^
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M(ZT5#]F^A)<.>LSL1ZG(F'T:$D]$754'7_'RKN$/3/8)&12RMK+@#5^0R&N
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MX[=0O8'LG73A#W,3"=3Q)R"C'O:10O#NKY:17[Q40,N4@JKE^![ECK=8U9!
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M1;)8BO-5U%J?OJOE*=HGI_V':\*T%'*>3N!0RP5MNK%$F4A"].N60#.SWTH
MMX0GIK.K5>)7NC8IMC]UV0[7A?.,<*]L*5'G"\(__]R?HU(,5Z_QD>1NF;/X
MQ+13H2E8R1^P]2$G QTV87,+F9-)9OV.5\(D11(;G^H<^'=%OCAY.@_R0A]
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M] $5LB#_/T8(+ ^3R%B#=QHQ<(DQH$G$IN<9$T];?8)LE'"2_A3^2,T+-5!
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MN84R]+]9EK4C8YK91$0/*6CA(@;SR"M77'0J)2V71AZB\))__J"^3V(JQ#<
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M@Y&:.<2CX>G^CU=:ZX\D/YI2+GT#+8(M2C9QE&8!"I@K9R^J>6^TE[!V\7>
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M.%@F6\ ]"A-0X4<HDSZJV[9RM.CS7%NH*0&.Q#96E_K]:B,Y"Q9@Y&4VAI%
MMB$PW=U$_IB>>'QM,+KTT=7+SGU%BF.3T3/G(B0OEZ%]8%T2.ED@_. "H/I"
M7+]L()CZ[&,@=]?^NKD2 S^'-V!KU?IWL!<-F%CCB:.3BW,K48&ZHM4Z+B!)
MD!7]LE7P:C747D-:K@7T\_*))D-\8M&/\O#91$HDYG@0142[GZ!C,=M8T3N@
MD(Z47J"ZK0L\Z/^QP*%D(L>R-0:(Z+/"!X-K=&6JC7;6V3PR]=PP9]6J7IB
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MD2L\\3:OV?>W6.]SVMOQE#Q$$[_AY15"89;*B2WTY%Y<^M;2V>X!TIRG[HR
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MS_"&O*E/> 9HM30V-4<'7YY*8E11L?!U8H -,B);!#0YK<W&3!J:\5:EP<\
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M&=]@R.@%CKY(UG3#<Q.P9API$9+WR)C_;&B@=^OVVWW/E3P4UY"%+VG<3!G
M0F3CV-['7;3"U5 )XQ6HC;[VV*ZT.3#&;(O^02^^#4>T>3H3,'7RW"AL#TNB
M"";H6[KIN%"P25&0EO_.3:#K!H>0I>VQIK'&_:Q7J0DY:-^,3H^G#2F'Z38;
M=HT;@J$>+&]E,B\^1??^>/V0#S@"'O_"YJK7+R/OVR\H%ZDX$[K#2G-:V%H(
M3YY@DM!EC K@C5ZB]M#6?-0V[W5"YN"<E6 E,?R4<"J9DY-8;9#"/304!3\.
M;S&IIG[G\$K(@AIJ=<[VCVA?^4VR )>N6*60^;)TK3SOL(!*8'3_]H_ICBBM
M*+E=.[&KPK=GX*Y$Y4\N8PUJOX_R>QUWO_P>PNBORV-[714]*XQ%[U2Q(_U9
MTO@&I-MTAISVF"D<H*/;Y^?P\@G$]S) RPAIR['_8*'@)M!  *MA]C-7N15R
M+-?1"TJ*KDJDAR^V%BM036^L_5F!(L;H;SU$N-HK7+4)40J(/<5,<*R$<Y01
MMB-BD[8 M.#+J[S%FX$3M=KJ2(5)FH1KC[)W\92[)E(5_=NU,XO]S)-?>_54
M!KJ'H!V0BV;:;DT-'4S85+^SGQ-7&*J<T!HJI96.T#F?[15P[6RRU$;/HV-_
MA"CDO&=FX<H^.(E#?V/9F2B9O$^3&KQ)]N6*/)P_>E9%;_0!2!HQV]E_]0O\
M%M[,XZ0GC=ZGK0F(<H:G(WLYWTV!-X2-/#4J]C0N5GM-6>T2CR1!:+)H!6Y;
MU6"[GPC0&J?*"YHB&AJ47-.])]*)FL;0'1C<82P3^OI"* PMU?1MY1L4Q#P!
MDVI8VI<;#W>Y:2XM8Y"O< &Z4[=#3%6X [8H&^6R9[?R-\/I$MBCD;PE"Q-H
MBMG(C9>/S;.RJR["L0_CEI^F'!]X^'Y\444O/6.39XJ[JP;:EB++\JY66ZW2
MU?+WB^-&MZ!WKU <A3GXU\Y0PG8F7$'Y"_.+2APE**:S(KJ#._5B-,HYM4MF
MS4CD9==8IJYQFM1/G TJ?G03<9U(SX!K<(L=V^02R0LLGO7/._W W<#VPLPS
MT\$O7(N++Z&/K%DU<9(\-QW]9#)E.06TQ]$!*%S_W2*<[#<.ZLM-*BLF)G23
M[,I*$X?KYL*V<"[P:E+)+P$SKB<195>&V HL$?G1;R9TKBV\(R( @E,OVP1_
M</ ?LK5<_D7%6])S. /"K<^AH'JN9?#T!WX.:,\?\]18C[_8)D*A3>L%6ASH
M$E%RU,,5%+<O<PG=W U-OC^-7RBQNZJ<!PMJ[FR=>_ A9]!@F;J0)D2:%?T@
MW>>]8)YKXNAFE#J+87,8$"=!04FWUB5#U^<89K;=P)$(BOH9&R,+C/$$QLC2
MQB@XRVZB?YL$QBW,MSLEBEH@;ZQO0@RCV"S[(YU=>WA.Q2]+^AZLF'M#7>J9
M-Z*AQ7D?9V986:9PDX@KS7N0\:F<PQ&DF0*3* ,E'1UNBO9<29B8#E?V=S8_
M-]1&'O&^416E)ZB.2D(_"O#=;][MTHQ4K*V#3V9>;-5:+:"'E08GF;+_V.R(
M.:JC[ SWFM@R'H*>0W8?9'T]S0@AQK']GE>"'N:H?0SS2_4TN8[%&\W6,YTJ
MT./+Q/I6\\E\M)]%[^8@,EY&474T]1A^C1)A1EO1^VJ:6 W0;%#Y/HXU/'%,
M3VXRC?_%FYIDMMPHQ/#O !+J*$4L#D:T4?U9Z6 6V"O6*_K,IV[=[RSVS!V>
M[M+V.+C%]0Y:E]1&1A=*T6%_I8&-N.K;JWWKX76[_@WO&RS06=3-C!#IA4WP
MN$:']IF@;Z;N6A)8WW>7HD2"@EWIB)1"-H0%;"0.FK>CY5$!!\$@4B^?X3UI
M&BH.P0'&\,9)'T."0>&0+'W*#=N2XQPF!9AR9"*_7B.H90Q;9VX*)NLCO#;/
MC;Z+[6QCB9Y @\T" *2G5B*>Y1HO+68UC?M(?Q$B\[5V36B>LN4FL[%BM:WE
M'":ODA+7PZQG.&Q5+Y3<*?1>BW!6T0<I!^V=.(!)@JQ$<% &!8YZ/H1L C9?
M7N7W]>\(DT)R<W6:<X,<^SV=W88O2%B("7?A  SUA8".OQ5V80R;%?++7%R"
M!1@^70'G:7Z^4[LS]4NG0RQ.OEM!N.AC['Q0WR":^,(B/'2QU)O7%"4$::RM
M*BJGF7HAJ.F'7[F4-8@?QB#*L#^/<E;HBHDL^"CT[C%&3[>B3YN([S=*T5,<
M0CU6*ZC(:L=79!\]5%\1*-6WMSIY5F;1CEOC!@X L$E_37?@["OCN&AS7] [
M<5]/N34!OIX9N3$1]/=BN^:>\N$_+2O.4A"Z"Z[[F/"Z\'YLJ&F7^$BVU(ZF
MXH5VSDL993<3!N?<).D3/5XAMDTJN1JC\+6:;R(_-U(+"I]**J]ZO;)LS4?S
MY='PJ$X 1RM5Y5SWP@9SBX8+TD)^2TF<D?GYZ_H:)"G -:RI<GPG# %$R5[0
MP.)Z;IQ[4E5K\L*,(C!$? >)LL@Y8Y3[EQ=R-.'7K/;\=DX%#.V%(61/X/7=
M5'F^SW:,(O9I12$SO/T>CF(/VA-[NXP_QI,NX,?@^O9?K;I3?06F7-3^XT$3
MDH22-"Q72- $^$9>T>S;2!0;6O-XF;5F^#H3-$D&A$17H%Y2YB6?(YNWKPN_
M12 Z-HW/CM'6WHE/R_7$ R4"'^8-^"\)"%H#+CVHDTEP-W;HF2-^ZB:M*+'@
MA?<DB=*MN>QNDY\R*ELW>(;(2AXB\VUII36U![LMPI3JE^HH?F/K#$\)F?W<
MJU5=EB^0!#HJ432E?T9F.%Z4_K(4>Y@_D=&DU$!]^B4!;&><5G9LL"9%N>&=
MZ*DFM1AKL\L(:S&&/DPWLXI534BNS@]W-F^BU,58)2W/T>EMI4(!>TH"3U%P
MC>OA0IWOQP0ZQ$/9+&3'FP>+,UFQW0(O/P^^3.Z&#!*>L&,<Q"\XB)/L8]O5
M>+=GJGGPRIFFZG%O3\7T5'XO8TG;BE"'TTG1,H8@5/'WD9]IK)T^EDB-YZ8?
M[\C++GCDU*6E!>+3^6&P;YX5DAE.$#"3[VLTV@-XMN1>Q3EPM&0#L7MJ+,'0
MOJZ&T[(T=UQQFF5T8YJ!4^;.5]O,;Z).*)Y,_.)Q/#Y_"OM,5$0K:&$3![?Z
MT1'+XTS]:8U]D*J0MA0\+G?(%&YYB00+E*^NK$]8&.@!,4J5R,MW&LM;'&]7
M2?N@5198ZGPI9.SW1DEIF3_2EB<GG@N0GF7@WV>4^BM:L-T/37O8LD+)L_!3
M/\<H_H1^HRR>OQC#<IV)\,4PUPVOW&O=;I*FT#:SKLIEON@$C>6WU19,)/6[
M$PUH=#O&IL:T02X>1S'+QE%24;J+!1>Z0<&_>T2112/4SE""%7.=,8?+$W2/
M#"WK(-H&[/3G39G?%#41R;&PO?;ILI."HZ/SK/"DUT</FPVV5KF^O_W4E:[2
M?\OA24V_&-O?8UW2@CEI#GGI>?*[&Z&6HW3Q6P*N<^4<><769MVHSB_+K#^?
M?K],.' OJ\ =G06/'&1_19P9FHF$%CWY$L.70?1&^I!'GUY;:UD!_X(]:CN=
M+47IZ8/>W<6!3IR*&Z&40OZW(R97HL;:]'-N=T^%BCI[6F_3ROG)&-G>3ZDS
M[V'K"HKW!HU33.4@N'?H!I1^1AM7'IS4C];*E-1_OZH8/S>N(/NSBH.J4\ T
MV7<Y]N.3^G1_HQ/P38)).[P82RT$$.[2+>;S)H\[=K%:GZM<8 DV7P<23<Y&
M6[P[16:?) <EKV3%SVD3SU 237+ME>[ 99L&/=]'D^Q8".;VG,L*[5+LIWC@
M?;P'\A0DJGR@:-2IZG8ZV.G2JI2F?NAD\N,\T&?&=V:KXI]OPLM6$I0Y<*Z5
M_/X^2(\/:A8*^#K+1PTZ.]$T.[U.XXY83NGY\W+M]4Y HPZ]$(P2++4 !.(]
MR/1?P9-LN:>Y<6>ZJ&4P5-K:^)R0[;*488E!F+^]A*":1;O.&QATM2\.Z+8'
M)L'CV5+S_24^\@%YB_>/]/^A/I00ET%?<=9LJ+B WJ +<9_,!5"YS/&2@C%M
MR@?3@>7W'I[T2QM+HZ\+&VHQRT/0'3'-1PO6#C@BY4YC,GTA%Q9=IF/N!U][
M,XH#H5$K)N>2I 6=C[^ZL'NA\7)^KW[-"KAH<.H2A3!V>E/J'6O+)P*IBBF%
ML1B=()K&IB;PX,-W4Z3GGO:TMGWCO=R#-8Z< <19L?X.7=XO'"&5[[^!6+^%
M!/4] XP(#VSQ/$?: (C"7EBPW+^"/LWT/9P5FQ3$S2-&%[>@VJ%1@2ULF21*
MI]&52A3=TK3!ETDUC6DB\N!QO;[S@?O('_H9GN!E\>6^R[;+TF2Z1G3J(B]H
MDDV1]$MWZU%RSIS]S%"DJ&TGP?"US3GU 7J,WH;3D41/M]\<8AK2K[_A5*K;
M,RBQHR+6V5[\<E257W\4T;JR7.!%+8J\S,42 U6\H1F+1P1Z:>3B'W>;OBWX
MJ&X 8:.WS(KZY_[PE?W+O %'A*X\GCE?,O(OL(OPF?'!O%'*MK)0N52C ,8]
MN;6K9T (3T/-;XYY:PXM6/][R?,@".H!/#IRQE\H<KVLTF5%9**4>=L-7L_$
M0HW"X) 3(UW+F7QG4A>)Z,,V(83#!7<89-Y^"*L^PO7G877XZ3+JW%^VXL]Y
MPE5G+F4Y"]J$?]!>4/@]?RPRS.@3[A!T+1(_-LM;N%<%''U;R!Z;"IU"&,?_
M/$?J ' A2,HQ3/D1SI&Q^I%_] Q;!_[ND#W5M/)218R0KNC]G=0&GV-Z< 0U
M4:RK2>"<R5>B,"02(,*)<O,6>G2KXZ6!];O*$8QPV9/8Y/4O;PY^DY)?NPGX
MM@?(TE@!'8H4.8-[I"E(OZ9U[E-CMK-E%_.W%2O+57\$2F%$#$0YO2H'3);9
MG\#$[H(O9ZUE&-XY.0@[3@8^='M+!W/SP80Q2=]$5C?J5OS^'+D->0D>E\3'
M^!>1)=C=I*XSN2"T>;%R9_P64]6P;,2.11FL$H+JWZ'4X:^5#.+K);D.WY<Y
M&,XEEF]&\#!^3S "OVV>FJ=AB-'K0)/JK%C2Y7L&Y$F$G.95+2@\QKU MS'D
M6;&1IW&9R.HG[Y!:Z!;_: 1 '\$6<BF[AI2YL:@Y_*;$:ZZ?/;8K,[XHM=\.
MV+!,5/:8(8I0)F @^NV/__*/W0M,#_JA+TD[YPT\ \Q%S:>/R[>HG30,>>WX
M[CN]G@RF9U3DD[XQ\'T\S2NWL#=*H+((N4;-$P5#U^. 2@X3^);7&Y(,TN1&
MES2E;@D1+N/UC5"@'WM':&H%?=T1+;63%(<@E4XZ1&')2NN/$#[\IW4"8&Q_
M!JSSG]$^(KU[!K1H/M ] X)VNS(N\1.?;@U/RY7N>?)=;]*5KDM9M_V^GN!K
M!CX#.IPWE.[0Y)\!/N4W*L\ U-'OHK_H61_/6]>EK\&*!V?81SJ&?X2 N$)7
MCO(W:ME/>!FX?F.JAO?;?AV1APMILQM4"S6M\4\H32H&V'^G]$ K GP&_,QI
M_?V'5##5/$RPO$L49N7'^(#M4?)HHQXI/0ELB.&);SET+-<$C?E]/L3T:/W[
M).HSJ<)"N:A]WG(NGS@, $(KPEXRY =:5&"LS0<YSPB!6&79?9<+CY6M4>(P
MI9"%+?B*B5N4-\[5,98HZ8$0^Y>%L"5IMSX[&K1U%3?_TNB#V#[17$_%;*="
MRVKV>RB"Z&'ZJR?ITR*W%I[ZQ,\))[+)-GY+.1^C.!QC?'VEM_74UO85Q%T%
MBX8_!Z;,4WU@8,!@^'J)OW_J=Z/H(_L,$)?U.XE_!J")_G/I,XX]#1<N?Z%-
M>RR6OS5<\^[V7.U:15W9WUA5GP1Q*KWP5.W(9MI+#6C)P?7X?5W&^C>!_B]T
MJQG<#4/]K">>-&\(N.PQ#QJN?E570&S>?]<=:DQ^KQYZ]K5OZVRB.;OC"Q4E
MR>F#@+.BW?O^&*M(LN7Z]TUA_PYE0NW/#0\?[C42SUO;?D/^?0/*_H?]A/V?
M//SMW[(UC<1O#\;E*Q[?E&HS5*,W8M8)IHK.T3&@<;F):A"[7P4[+CD3U;-C
MU]9T64V34_^_^V>(F&=!& ^QOV-$ZG"PIY[I3W?7(+8_84>)4]ZR MSF.#8=
MU]*OJC=$T>=7;,:M23]:FM8T!+,>J7C1,WP(OJ/TE1Z;I>F6%.1>/75[4.P.
MBM54@F^4WU!J1H=OF?B+_Q(O5Y2I"?5Q+>]EF.OV* AHMXM[]<&69#//ZPLL
MI:2]U,_R5Z?F1,U6Z$H/TG(.R/9GQ:WLY4%[ILEG*]W<W^<M:1U:&K'N!^"F
MHW)0X!*VHWQTJD7RU7W!B?G9UXG%CFMGRR$)6#NL![],%GNRU%E5:V[Q1K1[
MT+JRGZ+Y5.8=-2?2P"EIG*.<QB3<X+@S':?G[NA+A&WY(V?0DK#TKOQ,LZ8R
M6&*@4T*!MC,!?C9L&>(TD])BRZI!(7A5YF=X.IW;VT7,%<'^4F4$9R<"ZZ.P
M_.;DUXR>5';VA AMFUVXHQ(ZG0V1N^MXZ;T[W_<+EZ_OH].Y^1?3.4\.5/-2
MN%[):2F0@AS?(B-2-C.VG)G!0JHS]5;V$FP0)E@^X2(IM)CJ83[RDSS!(GFJ
M/5:QL\+WG9-&?OX:W$WK867-)!E9M8OG2K5-I8YMSHAV53N>EJTM==U]Y/S!
M7A<[2+=^$1&LZ'R90UU,8/0!,>!5.\$>O"'=WT<?\[X&[ =FTC@K, +%L>G)
MZ3[ZZ_E*S"*4";2T%C;4F?*J1K5MX=1=)"_$:_(6U880%!19[VO.=&.$;PI-
MX*)\AEP>T<A,'KF$46&MZ@3Z%K<#A_D__2#^6F%![O+0VVSN03BBZ_D@B5^K
M,NII91\4(O/[Z4S> :6>@$I;(U;>OE?7\(3K+J<^*V7U=.+Z'HI'??DV8O!Q
M_78V6[^7>36HW%7!1@(V:5^R+05S_3; D1H95[@%77TJBEGL4N+]>@)+F+AL
MA8F[5!00=MI-P@NNMB;N.F%37HNN=;[J!B/ZK-5S%_J=4U]<<%%4D;PH4THH
M_#J>@-ZEHDH1I:7N4F.ZP=11RW_6MWSQH!_RG@Y!<VV*A=/OL>_'V^G"0VN;
M#,("3P$9,Q2WGJY7YW4M):7#P\>+\+1:H;NHUU[DLP6BW[B&R0QGK]Y8D8]I
M+91V$8X.%%> )B>W-R>YPPIEL4,?,'G@W&G-+9D63I5$<(4L2;ZUR!NBO8^.
M# K:5OD;_,9ZGQMG]86BNS5:@_VVK">> 0?[HH^O-"1M;C2?I$I9GUJRGP%C
MP?:?UQ*S'Z!>AN2^FCN1/PNR(+<TA__W%6K_8P,[J2"KQF50D''RK1+SD!-0
M5?Z^1C57Q1T4.[71TJ(X<'A3T-T_3XI[$P\<NQ06/"PC^Y0J-]IDHBC;1M$P
M-;PI&-IDQM)J@?<Q%JS-/%]% 0 $^&$$+E1F3YHV+C/_$#7'P#&M=XED#C\B
MX:/=D\K(AXW D=,<JJ1&>>/VD4F4\F>YOU7G6N3[]6JX>,O!-7Q+S\?).&\B
M95MGN<F6Y3_PLJW8+K2XS7ZS['WI-7G<I&U9JR%@EYC77)L!=DE4K%)HWC*S
MW10.-AK,6>D('<9MV<4Q(2&4*/.B7U!$O12)6RP5V)D0Y5 /SSL*SH[78_1S
M.:)%.=B3KLHY>O*C=K4N?@8D#LW,/N@6V)!&=(TM&^CJR $(.YQKC !>CJ,Z
M 8-Z\DJH^SKT<'.;?H*N3'_4B"90JUPN<J*G,]H@OO6'W4&-:/6<7OTB1=W3
M/'3TA+H0!$+39'8@B 9)AI;_LDWT$VDNFI53648F2ZXFBT7CHV+,;F_BXF5(
M!:<N<Y \>30)1^P:0A]EVY.+^,8!(Z:F^C37$8^6W0EH$<<3D0G#TWQO1!%+
MN#@M5J%!GJ=A$4^JB") KJ0/6V( 2VSKBRM+?AZ98%@D':=NQWBF&XU@&B_"
MPS. (1(D;?9HXRM_/=WR_AE0K*L4W6Q\AJ*&*T]9T:M<E?S^^]I"J.?Q*ZI=
M[KZH1NB88SKG+ '893 A%O0J6T1G,,E<C4PWGI^V-5=+ >W7XJHLS0?T^2K&
M7F 1ZO(D^64OS:R0>O?GO$5HXEO58I5WS+;F1B#BC1*M0:3FQZ99MJ2?4+%1
MW%1[Q%3S'%+]35W4+IN:WIV@"Z(A^L>CI.5('Y>=TKT&I.[EX;HD"4D&DE>X
M=+'F$Q_ (XZ]>B[%<9L6;A^-&8MI='YOL+2*9#+-P TMX*P_UL[':\LS^?H+
M(Z'4"DH:K;"*9%08NGIH?!QF#$#JU/%8E&$+#,YI!$J!](OKDV4)\+&+<32S
MQLJ6[=V;7C<797/T,T2TA[:C\-&@\/^R(9*"3,P\13>4&^BL/ ,F699NTJY$
M,3$YU67_@.'8H=I&#I_!?3)1#]='808R7]<WI\$K(>"YYNZ.H??+'9OVQ,\
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M\VUIZ(MH]2^E6W5K_:(RJ/T.Y(EJV70EZ+(<?PLT)H[*8*4MXU2GO%" C*I
M9P2KW^TC45KI2?&&]%)YYQN(Q,=+<BO246AS:JI.F[1 KU1Y#6OT<P[JH ")
M.I&'Z8(RDVD-&XWO3;$$K;+10&Q2VX%C/N/^S7*YMFR2/^:MC5+CWOC46IR\
M<-&^.[^XN(9NH_;=/THV9!"7%PMU-]4QV1#M&= WG?L,F)WRNWM= ID]+7^(
MT#%\])5^!F2BJ>K5+)S[%:RS6!?>EH_=H4'HRN-$VOYW;4#^7\=M\A\^%2+
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M=P\T3G /[N[N[MW3O^^<;^XY,W-GYLY_L^O9S].[:M>NO7:_M=ZUJ@JZ -T
MO)>3DI4"P,'! ;[!-@!T&2 !0$%"0D9"1$%&1G[[%@45'0<#'0T-G1#[ R8.
M*1$Y&2D1"0D%-2L=!24S%0D)/2\#\R=V+BXN<CI^83X.(59.+HY_!H%#>?L6
M'0V=  .#@.,CR4>._^4"[01@H<#QO+&%AZ,$O,&"@\>"@_8"R $ .$2X?Q7
M?Q:X-_ (B$C(*&]1T6 =P.\!;^#@X=\@P",B(B# COK!C@,0L!"Q/[*+(WU0
M,4:F=,;A^!Z?BT+UN;8+5W7R@IK3Q"7P+2H>/@$A$0TM'3T#(Q<W#R\?OX#$
M%TDI:1E9.35U#4TM;1U=4S-S"TLK:QN@JYN[AZ>7=]"/X)#0L/"(A,2?2<DI
MOU+3\O(+"HN*2TK+?M?5@QL:FYI;NGMZ^_H'!H>&IZ9G9N?F%Q:7-K>V=W;W
M]@\.CRZOKF]N[^X?'I_^P04'@(?[=_F_Q(4%P_4& 0$> ?D?7'!O//[I@(6
M^)$="5M<!=G8^0,EQW<4G,_QN;5=;ZDX52]P35PF4?&HN39I+O^!]B]D_^^
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M%J_?'WQYMTZFY)QA;>4,!=@3E1QX<\=T%/25V]2R[,XNL.HLQ+\?ZLZ!D/@
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MRS4&_XRYL2U+?= J70X*UHE!F=G]XW[K>)&?&G;Z88OKM]\H-=;KM@@R),C
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M ]S-!L-OQZ;C1).LY=50R\8EQD68#:19NK67:\UC[Q-X^2P=2T[XJOE"\-C
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M>I8N5SB6ENH^!0HC:)G]SLT*'S@KO+?C"Q#*0QFPOL]N?+Z:9>P=*%:ZPJG
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MU3* [K.WM=23:U=1JU$^8@F;^;BI@:BORRO+1Q<D8L]HMRV5V2DB@IOSK?=
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MK8GC#8ZR;!(L'X2H1J]XSWU +B_GI+)$',]\/B"1^=,Q_YB(0E2T!Y-CXC+
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MX\D";B1_ENS+:1KG6TRO+ )%/C;](.+T)^Q6I,\KYHF](>5-_ \['R\Z-V7
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M8Z<^&:"@:F7!6>WH2L$:A55@9% +SJN6S"9;F\KIU]K#M&XY-UI:>NKG6A9
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MFECG4+:P8O51_HWAF^G$%KLES31+G9Z$A)L39+&GS^,/LZY)T+-2)KC";,0
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M*U[ ILZ.L-=JO!NCZF)#I)QIJP.5*IJ05LP%JD>B#CQ-BKPEJAG.<N;%U]'
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M>PU2Y+4)$!\2$Q7&(S=).>#.;JU1U3EK+O$A@YUW1%RHTLKVCP1U:>C/ XN
M7<5ZIPS=DB/;#4%^-0>0P%H8<&!Z1EKF43#_W5)D6YVW6X/?AF,TKO.K67)T
M;LL,D?\#S+=^?W$)>8/^8@<ILX5_'#%ZV&+8BJBM<GV,Z5"0B6]OX>]-OZ07
MEC7L^,J<3 UL*[(5=1-5.5&,[7(@@F[C)LAQJ[*X-ZO)4<:]XT)N\.VUS='U
MM#>;QP9#:C]*D-7/S"U*%"XDKEDT[Z_L/-*#6KZF8\98*I.X#@M[,YP<'3(1
MWRN[</2?PX?RU;J"'ZVOED[X&_F-P=0/7K"=DPJ$_O.N=01AQOM,53G)WP_P
MENI]L7CP]^J*7$C DS6%$0S!9\VDL+!>+58/EU)!N&W*/T2S!<D8,Q>V>BH8
MN(3"123*KVOZ>6H6Q<^YUV*I<R/LBAQ^XQG'FP(@9WIS-7 @0DK0G78MN%=I
M3^AZHF$L A<WAL^S\!:<*#@"F/V0=M9&^JN2U;G#*%5NB?QT=KE=*@M?\57Y
M=AP$:8*$/S%.J4IZK]T3YQC'<CWT"<M8R_4X#ESX\0%IPSNEQ.*<N<WY[PDA
M;29/V_@D>A*-3]9LE_@:ILM8%YLC],WQF$[J/_\0];\/<TSD\#=7LJQ%RS%/
MCKE@?%8+BKGO_<>7H00OZJI?<28A#NDD^U&"P,B5+18\\WX&9F>WY*CM1TP8
M$PM]W,LP%(0^[M:B9?D*D#?3"^L$'=J_S0DFF^:-Q]H@3^>U6)P0O?MC_E8"
M*6AJ*SZJ"^;L.391]SSE%*@458YPM/G0G[LK06#<PO$-VD[J?S_U5JE^P<Y3
M'_I,0UDO7U][7F-W/2(Y8PJN@<[Y6E8=&W+']R!?!-CW!'-<E=V5Y_^S#NTG
M_;ZGSR_V)U+D$4/L-[8H%5E\67?RMHA^8?AX<6ND_S57!TU"70H-WL>;@!Z-
M)-FEY$A#H3KMJ!3" T)>QZR@4:2KL@-];A)/6AB7D&GZF-&1SN3>;(GB\0T]
M!,_018GU;S<3 P1;@L"DA4$P4P6#8.:-ON)6H<*A-^IL8QU'!H_!H?6S4=V/
MP0!9(4>G@WWYUT1)H6NTF#6..K]-<V/U*Q=EN=#OG>C/-_G<PK&0*=@BBSHB
M)*2:YK:S4"3;HL"+-F?\@TVOG.MW'),DYESH[NMM7;N(2#A +M-D+!PU </;
MB;E7-N?/R='UA(K5&J9=R'T)X:'C<NU=KI&:R'8U=@8]%M6BY:9.,?^3Q!^I
MEM%T8A"T5MRUQR9)$H^ 53UJDYQ(^J0J'*3UQX%ZTDVK=W)+YI>6B;\W,7/7
M[E6"F%@0J12^D0:AU FA=YSZT:I;C='LL/U#JVI^Y KUTG&9=^R4=MBNUW(?
M%7X4:FXI60(DR>F(QISP:A%FZO2+'CX!;0]67[.L:GG>M\XP'[8[9A5S^R;6
M;WD]&8H4J5O_I@?W)TC)&]L:N:*M+6_1N0Q*E8U7UN?J_ )$$ D5A#$=8H6B
M9ZI**A;GA 'LOO*LBL6/>_19" -7PNFTK^^[.?ZOYKL_<?M^?/198+JI9U?3
M^\S1,'K@7X__Q=MWSYU[?%$!I9-G#::*YU_%5L5P$RQT,CN1^&W*WG?WT4JF
M"DB@^"@FI2-C_+JFE$&=VLQ,G'[=#[A@RPTKZ!B_9@4#/TMOQ>4G3F4)-@0\
M99'_4,+KU\@^""+0(F4]%EO^UV\1"15>Y.7XO_W/<&+# +W7*"=,[V'__K7S
M/Q3EB/GX_0ZV3L$=E)IUC<_7YO-O(4BFE&N,D9&MT?=:SC"%Z\_);J,<V@0Q
MNHH\D?N;BUVBPX'LMX],JOJQ78?Y4WQ1Z7Q2$$HVVW[NHEYGZ>V:N"2^AI7@
M/\K7]@_W\;9<NA%LU ^,735"PCY_@MW -3L!^O -)V42V>+%\/IBQYN!^P&D
MY:,?M##O1K'R37<Q\GJ<:'H+WV$0#N,D_\@5+C6INCQ1;&V-))44U"#5KG30
M,(L.\2\4S\B[/ H++1V2L%C=U"/-/N&O6!4>KO&!;J@_",^O/?=?^%16WS%%
MO><Y"#_NXQW3Z9]A#DXM79EGPJV2Z<^[ZG.8J&\;PR)5?% =:YKO&'U BAL]
MW+%_W+#WONHQ6EF6]O5T<F,5&%A.K]Z7Y[,>DS!S^*VNOU':VO'WR97/ 7M>
M=VGO^GQ1LMC-S *L4"(\(SET\YQUZOL];_RP_,C59H^5"LO3PX0Y.IA\?_WS
M^GWUWB%C1&]#S(%&4L/0=A]IF9(L23@*H%]1.#=I=Y4?IS1541$\5J<C#0_]
M]HX=4"?K1!V+]4GKF'D@OIC<V3YH_-NQ=QOSO8"8+(5#K_73;&0IZ*%(<BGF
MV$7W8^8YX5G(DY/P/9L-VM&XG]'>=8H#-UIA0B_/@MC&'7&[2YF.;-&78#.+
M>5\BK:\&A5X9OCR(:;FTU\\5H>$YB2_ +-,[.[[C>PS$!?[$^*7>9Q5A-&1,
MT;Y&HD*)O#W-6<3!;A68[,HG<ZW '@[,09>8C/D<4F=^CFQ9W!2R05Y<4P%3
M#HC_U^!,"];0O%76?#L/)\?3].OK$<P)DH;KT0^"+9/V5E\-&KV?X60P+O?\
M9%DZ<-'T:8=W,Q>29F/%<K;*'XLVT _%OO45JJ;=JY7B_XSP+-B?<6GO"1\=
M[))8.(@D)73=]=,I9+ETOO7B%Y-N>ANKL.04K$X^3"Q]\BZNN\%=))./*=34
M*)*[2HGW$4,][^;D]LT(?N.GS.%FU,7=^ZN55"_PW+ <Z^V FD#>M[U?]VJY
MBGX8XFX>7TIF:6!H'R3%G2YD!$60HER.U.HE=4?>*[0O%2@%SQAE.&>Z/C.*
M/#)PM8L)BKK^)6GUS1AY9[><;,&3%^=^L;KU;.(<KGJ^N//\:0-:4Q>XM*_Y
MUDK@+%1,]U>;9$BVL5?<+%Q6DDQ@GUKLK%*+6X22@ .\[G!G>,6X4_BWE7K)
MML:9AA7S6H]">719M!Q)?<A[4!+2M\BL:6]Y Y!O$6=2HVA!N)2#+R-2[ =D
M@<AYB--$K!M7Q]6M7XJ\ZL3J3+K;"T"9D9N_^*M0O$A[A']Q@"$H=ETP,A+Q
MZS\X*_FS=3]("3SJ9.?I6E7RBL(1U*D$,D]<%@JFKRSMZPAM_>I8'2IP#T;8
M9?(P6J%=.RM%MX'7I%+Z+:V-S,;1%1/=2$'@>]40?NMGO_S0XOZXAONOC1C"
M\L'K$]X/B\&!@P0XL3^:E\?>J?GR#A3J[[V6DJ&^N$)3K(T#ISCC8(!I:)3<
M1B"6P(-JW<&0U,0Q9^E-+'U>@D78EUGW/C D<BW,K6<Y(B/>]8#(8&V$?<B)
MG_97T$-);J6S-.=BTL>Q+6.5D/=#.\[+VR&Y>_>E5HU\^7UI6L!9%ZI4FHD'
MKZ!GGTQW>UULU_/ZJ*UG--3$KC#\VT*%S<?QE=NP]6O<WK<)^M*$/(1'MVHZ
MTU.:"UM72]3)!2GI*(0\G'L75B.+9ZAID8^EE6O*.6%,)D#.*V7_3PHZ$Z<^
M1_X;D><2BR\IW</>*/".27S=QDJ5Y ^-V5A11(30#E1>5KF^N>:WAF9G?U]]
MLX$ITIP;V6\-A1R5VKEI%><0]I5M$@G*3[%UMM4#Z>%2&)%-!9J?2Q!F[7P$
M;<QS"$TS=&T<I99%.N%\'S++&6^_KGA/&G)Z?Z=D-I'=;D((.!QNYXZ;<\5'
M;9%=X?SBOMI:L1K3-S4S4ZL_:!* UB3IC'2C9IHY6*\R,20WL=[ZTW]YS(DZ
M%$],['M)B)6Q%!U=5JD7V&KRR_<Z''D'VQD7SZ)A2/:<AYU@+Y]YA3JG'<OW
M"*8!VAM>&)/7#"F31F-KX$JOK/9:H]7?I-'W;734'ZB:CNDGRF)M"#?UX;R7
MXGYJ9 ZI'F9NCN_3M.#F+9>] ,+G'RPKLCG1D 5DB^:6.3O, J=W5+!&.^@-
ML8PEG?;4*7_(3G,^7#@87[LLB-CCM*VO2\##E2$?C"E+U2LZO/]M'YYXHN\'
MIM257FL,]#1APN^DI17^#?KU9$V\^^X/9;LB5@])\LJ=&7LSM3]^%(4OJ*1V
MV3*R5APS5<"0 7ML9VL(,RB \-?UGEBQKW#Y(9W"0J/#K4T*%S/WI![U&"Z!
MENIP] O@YHSHQ\[D+3N9V]300-=]\Q&%[G[HFU.MP%H\!!VK-YTTZMIL-HQ9
M_"VV3@VB(/3B#5ZZ>HGN"_"K6N;'G_:.-6Z78O38L@B([1#QL3.B>Y3JD5PY
M"YJ2/+]&F'3P@14H^*]?.XGC:M+GKLJY/;#"&?Y\&^C(M<K"V0N*=%_] L#1
M6.<+:1S+65W0.!S<:SZ$$QG%HN@PY%IN&A!I&8:9N<YXV2:UN!QX<*OL?WRK
MB5E*&&=<P6MN,G7N".3[(JX^:$JRP">.?U:@A,UOHO^)EG24.HUV9O2MTPBO
M-*(K>:YPP=.4M4,,\2Y+)^-GB):F$L>?3TY"YPC4).R54I3AO#O\>QJ913>9
MF[[1$JH?'OXQ,S.#SSA$<ZAQG49JK&/-D$2Z)W:%<&Q^01P[KMJ0(VKP1ZGV
M887!PC8'9"!BT-L)UDJ3)WP:+N4%1H'=Y3STD;A;%%Z5VQG#9_8V[LYP&$3C
ME2D+K;A7,GNC"A9T^/UUN,"R*%R^77V,U$D0-4?-I4X#G>@3E.:+V^1U%_],
MO@YO)%-K&.'>2G"*%MT7Q'@?ME47IP4UKH9^-H7OKU 0%>WE\S@X$BO)FY#M
M6,/-64]U:%PWU%N4MW"AJ?]MSIO+KX^E9,VXQ\J92F*GJI/AEG!8=X=/@.\'
MD[3'(Q!$4I%7]_;&D)5N:ZUIL)']05%)_=7(]<M KZ0G/*Y0W;3:Q-U7BCW.
MU;%3-LN*.*6H3Q-F=:%U=_8P7<N"^+HMN$0EJ)['29RVU_(_7O;E7'7,(YCX
M&RRS-O1&F5^M>G.21!52HU2%PNC+T0/_ISX*K47^=I(+KX4M!2[WE=QOXBNO
M\AJGW[.X'J0BFRTZ.(O&.,V2A31X3_,QZJEZF#$,,-$]<7RR/I<R*Y  V$9,
MF 9K=HK-X9V.PFJY\_,4SO4:$CXT1^.:O(47([P!$_7YF%=;YA^N:];%%-L4
M+Y)R<3[)+$C_#?W13:U8O4%7M!.(R1'FRE>>7Y SN:"5G/W T8D]T!QJ1O4Z
M='I[:<CC>?/LDTWH>+YU;3TK&.)/'LZPJXLVA)@X]EJ/3S/;<S[P>Q](;\9.
M<$#,B1J8*ER""5\/J3:>TEIJ4_QF0L3\HUBM]>QLSJSQT@*)$:%#\WG0V&38
MZ.1)4+A'D<G[ZU1S?\B&/73GLL15J;B'R4\'8RK.PV]Z1'V6)EB08K%@H&[M
MUJ3?=R0C(YDGOZG]3SIM+"FM6E,"%/5BFWY@7\V$;HYX("?* OLZ=O'^T%ZH
MULBY(79%:XQFI$X:&T5H;NF]7+BI]T8Y^X[^6^+@6K=KYXX%Y7BTUJ?/PX5G
M#_41$C0R3/=W$=-QSVUE^/6^ZV_;Q\LO+P!I5<L,1\\457[0/5BK3IVGF'-5
MC.HCWL2^M;:U(VN&Z\.#1<8<U"PT)\XTAHV01Q!9*/C[%1._OO'@^>@H=+W>
MS;F2=2?Z6UK<^%?\) E6B<H4@W]S6.8&LJ@0+TH>^KYSX6Y!M)EF<59<QL5O
M6>Y@>V*7E[BP+9%THX _'9_F_*6/MF8W^Q<;PX#MYR0EJ3_!:=$U)<M<G<;S
M:Q7<+\#5_L-M,,.5O(QGN=ZB-4Z9,Z5T_:S]!W%?*9E?.7&%;Y_\](-+I/T,
M.K9M#*S=G2T+9>OJ8NF'UTV8:^S-^9W&C&Z5BZT385%QCG8TLE=:?Y:@ @W(
M0#_A*!2NQK*@N =<3&O7\+/&&A8^J>.9J//-W,;YE@H22%*-F-TT=40U65 ]
MR4(=R!^(?CY"X>'(B_KA Z+G35D)@S=/EIOI"U"QM:SR:*V)(T/%=AC(XZC@
M4B\RMB=;:@U6[7B AO<*Y$59\3Z4(/K)Y$JHA&DTBNDMMM\'X2FK094E\(#_
M3PIZF?\O4$L#!!0    ( )R+:EJ\&IL/[9D  $.G   -    :6UA9V5?,#$V
M+FIP9^RZ>5 33[LV/(B(BA 1D56BHJ(BH+(I2R+Z4U2$"(H("%%1$1 B A(P
M9!24':*BHB!$1439(K+)&EFC(D;9(J"$)"AK)&$) YE,OOR>YYSG//76>ZJ^
M>D_55]\?[U!-(-W3TW?W?=_7=76/]+MT$%AYY.#A@X"<G!QP1O8#2/N!_7__
M]S^Z_N[D?]J'G/0]H+I43GU1IKS<!F"1JIR\JIRT&4 #@)S"/QL _W')+9)?
MK+!$<>FRY4JR!N4K@45R\O*+%LLK*"Q>+*N-DM4#BU455JW?:;=$S?FLXH;@
MU;MNWGVV5']?28.ZRS?!1M-S5Z.7+5^CH:FEO6FSP9:MV\S,+2QW[[':_]>!
M@_:'#A\Y?L+UI-LI=P^?\Q<N^E[R\P\)#;L63HR(C+EU.S8N/B'Q7MK]!P_3
M'SW.>)[S(O=EWJO7^6]+R\HK*M]553<V-;>T,CY\_-31V=7=P_K>V\?A\H9^
M_1X>&1T33DW/S(KFH/F%O^V2 ^3_9?K_UBY5F5V+%B^67ZSXMUURB\+_;J"Z
M6&']SB6K[)P5SP:K;=AU<^GJ?7>?E30LTS=U$:B?N_IM^9J-9IQ-PK]-^X=E
M_^\,B_X_LNQ?AOV777W "GDYV>+)JP)8 $&V/$\$_F_YO^7_O-!W@P%T:"MK
MXK5X+13G!(4+U5KZJ/'UQOX]CE$7!#F</]D#ZX2.#^\/,B25Q7=\OMKL>98O
M_W:XN;.AS7#[Y7=F<@NV)V@FVPLYT[2\Z &5WT/Y%)B(D'3#:$W*X8@2>C#%
MVP1[@ 7+#[9C1J]EVGJWM>KI"S<EC'F* YH^V>Q8IG\S[>;W69IA%WVP(%LQ
MX[B-%%"WL0P+E@+GV:T>Z:!8RV8#B.JX@7WJS%->*=1E::RM=[BX1PHPW.9=
M*="AR[=</I=XG588S/0\>(ZX6[?B\-Q&\7+D*@T[6#2@&'OL#%00$LA_ :._
MQ2%49",8QW.?HPI.$8#]:W 4F&R/%8X.8I>,TG'SC[&,^?/R"ZY(5T5OC5ID
M5 .5:7L]] MH5:+\\;%EQ%%K'FU&"F@C9V1=EV+4=T9EHS5A'RE0Z8"-S2!4
M2I2BA"R6P)SACQ=XXI>,6%U GD7EDT*["HVVI_SJK16R8T)_H(Y*@<;*#XI:
M,[S^.ZBQ)A)]^CWYW&.S[&/3(<"-14&/>+8[5.P5M1CM3%M;+#-'UCPF%AN
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MV_/B8TZ[8Y#54N"&%,!"CC+CW@OGJ9$ TGA))NQONT8%\V_LD1PX=$IEJ8$
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M:U.O3]C8M^Z0<5AC*3&#F'WH9>W.H%BP&0T9S,76VET0^X,-7Z:9'*9J7U\
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M[0;E3?B(+88J 7/K-=W[28Y"ZLWZG7YO&EY":8V(M:"<TC)N#9H<?5/7'=9
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M38MHU,]O?UQT1<02T!.-;WIB?S]XB0IDV._H$47(G[H&AGBA, (F'(OE3Y]
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M&F\79__V"K(/-S;B\176,I>6H5F?M',[2:X-/[:-]^TB6:MLXQ9:K'JYF:W
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MX[H=Y]=@/L1,ABXCC=Y>2_?E!9;9K-MWMC[WQ!>S/ OB5[8*^A<2):$L:):
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M?]6J;9TOU>R@36PH1)&P:BG=EJ*?:?!YX?EZ0!4]B(1R>@<[HTEI#+U\I[Q
M_<L5ZPK)R84KE]0/7ZXK"IQT&WZ]SOKV0K>=H[>>'C_[T5DSRW_NS72WT! ?
MTW9I\)F6;?\<*]8]?8BKE;>J-(BF)*B5"V,<_T0+KEQF&8;X35\ZY5+ SV7$
M8?;'>;95%+PEJHBKB-8C%Y6C&G4'D"CXP:3X?#V8V)U;+S40+[HEVG*&N7C
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MFTRT!D<P)VMCK0GOM<6QQXMP?\O+P^RCI=^[>8D1<M*BCQ'5X&&H+\__D<<
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M*34>S, ;-*]U:]TJNA]5]QW)9TR?Z^V6"G9+1UNEL^04[ MW306N/"OQ%EN
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M% T/Q>Q9;1EL-YK?:W<M7SQU*/>$0MH^>?I9-,F]A?MRLM=#L.M&AU7,B))
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MZ*)H]L!95A:3K< ,.\7.)!0J.N@*OJT/=_>6!]$+L43*]:PN:XPFH>.Z"PN
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M0Q284P/R[J2$PF.)A].S"E>4CYM+=9=5T6J-A[\\JL8JCFD8A:DWJ7PHAIL
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MDL18(! T/WFL T1Z3VS&4O]JV>#QW/8+#9?'+AHF.RS,9!8PQR4T]'9\;?"
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M@.#+E7>,Q$M>%SV#B>,3 JD;.EN,_-=>PU,_40B^7.:*[$-+0/5X'.%T.5'
ME#.9)T=?U-MLX&=2XS8N2<FJ]@B *<E<.A*]'P:%[./-3,(BPO ?CD?$:CNK
MJ,3LR ;JBW-4!L=,[8WIR=!:U/3VLBOF+Y]"C[*)95Z#$TC8L<-PLE[R4<(B
M=V*)7:K'X5ZNDP_2ZWIPA-)(N3.F&+N>O,QG\'Z&;D2X[*U&5P+!*V]#+Y?9
MZ-R27=M<G*&=#,+E[SE#D&?YE&:4S19>,@.7P3X]WIF>=P]P0T_E*T9ES+>I
M<5%]DU'D#V+,>OK?ZOMTO]2L,$R<D?1,'O-]:JJ6M8@K;J]58W6,4.CU=IHK
MY1E7>F%CC:&[:?RMJ&SQMK[S!NB2P"9DJGE1,AE&P]Q.F?J(=-U)\7- "9N:
M=KLJAP(MCI@3;73(R;,Z%P-.WNI-Z[>DIR7EH'?]NGGKIM]4"GIL3/(^L)I<
M\\?3APH^1M$UK&BADG2[4J_^G"GGZ6F6I_4Z7&=7L3?BZ%!*LG/#$+*%A51E
MK23%10;IGO].9K<WB[8@MNY>@K'0$4ZH?(( RRF,]_2IX%J2_SV@73OPCC+I
M4B;6]H-&GD3JH070VJ4M]G+*"DCZ0/VDF*&-H 8?R^0M3 V8"WYD2(#))9&3
M-[K(B1#>KWOWJW-U*C'^!;Y3(I64'X.ZK)L+#1'OB;_,FEW^@#.NXOHT8Y9#
M2$N$]E?Y+&T6U2I%<D[IIZ6B3_@4IZ'^7CM;WR"FV /N7V:>F-1+8*_X0G0Y
M8U/='<5*DD#\'QPS(2+HJ9Z/K=P+W#-8\,NJ3 *9)/CZGHER&:JZD#H7[\H]
MU=ZY"KH')&DN(ON]\EKP!3>=) UGQ,8:E:,R9D3W__+61-T[[A[PI/GL_!XP
M6LE41LWRT>U@WZ0FT17(C.NP@]Q:XM+>!MLG55/N>9&J>6C4X+Z ")UN*;A#
M_>2#NKWUB=>_>Y-; 44DMNBANY7U.@_!ED&FPX1BKM0(XC@^U-Q(52+ZZ/.R
MO,44<^.:.R9)FHUI*3+/&WF]_+9?T^%>/H@2%]"F0>]3J;?C;]'8IW%)B9S^
MO,,7T1.:U'V$%/2DN1)?QWRC/EBJ+C'04.0FZ&D$44C?<7+R5/K(BU@"9BX2
M!2_9=I^9JP@'R1,==\<L_;<HA)?>(;FC95C^#KG;?><=25<#6:ZIJVQ]@C(7
M?8R44$KL@-GZ'28F;D%Z)R<W.;K*)E]=UA<[O22O@/@3<D'@YT->M\+Y/BL$
M/I7=WK,B@W:KS:K'=P8[B)).W7RGJ_4"3"=/-Z0>.RTCIDZBZ>]SK7<]B@B)
M2,F2:7;$F(8_Y1\2&ZTB:>?DF2^Q0YJ94Y(3,SJ^,S$ F RZ(Y$G:P#_X3KK
M1M]TFXW!@UZR_555U4F+ Q*4G"BX.;K032IYI)<S92-!J;GG0T)UUZ0N#2YK
M!SBNWOS%VDS\O(*4&2 F](>L ,@]]SR\O-._/A;MC*I8\AEZ:*&7('<\CB!7
M/)"/V4..2-MX*"UI;LROA2\>FNHGMY<4:QJ,&2MOTF8.FZ&7/H?=#S67R-!#
M8A'M>RB=I+Y/]#+6:OX1E1V?Z3;U^LXGX>XFZBAS[V+IY*;Y8MTG4C<C/.A_
M#3T./;2E_6FD.0U1T]@T1A]WYHM?@(S^%H#$#51^H2KUR[PZ( $:[MTO5$=^
M$BQ1 K9]%?U)E=OK+P$+WRO9ERG\E)+B%P$M-W!U6?]WTWMC$:V75KUZ)'6E
M<@_HH]K7^)7&N,<O1<&G4N#_1V3Z'].S8]Z]\PZYO<952V)"9TY9&&MULB!>
MLRYIK=C"3=O68"8JSDR53CFIIWZY?!7AH^U0=4:O41WLK#V3A!NM]2K5F8V5
MI/?F.U&7GL!%_MY;^CI9,59$)K.0@4XQ@,,=#^?VY%9\-YQ-C3@QK"<VV <U
MT.)1D2+U@'T.0(U4M!]W;>/*GD5RN7\T#Y1?I,!SS-94%--YOOD\P)PRA%F&
M]MHYWV3* ,R8<SS=MHSS=1P/BK3!P( TFEQ/5JFG$4M[Q.UP^;*':G >BC25
M),--\DPYH%^"$3M.YQ!FC.'S]PF]E)XJ'8R[L<0O8YO/AXLTF%#KXVQF# 1<
M=I792XO4[H88:UP88W&>=IA5.W(%*%<GHLFRQ,?B"'3W-&S,9SWR$9-[3;V@
M2S9Z:9@83WT/H"X;E*8(N]FQ@RU6M(DO/J_QY2D:+NXPE4[LOO3M=$,"-^U*
M%M*]Y[C]:&YW:LQ$(5R*)!JGE1?W^5.6>_$A JZ2\H_> ?!PP?S]/7T!UCV
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MB.GH)?$);S@G22W9D4#3O9T1(0R5Y!# Y9=F&6/%XKX?LS!\:5&9ITY9(F
MMOR*ZR2RM@&>9"I),"WK3E5_UV]G^D9S+;=?WFU?4=>\3 YNKG..*C% H9;
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M>N@D_)1]CE1]3'1\/*#W -BLAQ:A8%^YJ=Y3-ER=%LW5B321#(5():V=(K1
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M]P;19$K=D[V%G&;C/AR P_\$6#=^Q%XF.E,4J^ O>)G] 2FY7F*D$S=>4?+
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MP"G/Q![F?8;5!9NOXV8F55E3ZX]&)WWP2(IRL8M1@)%V_0F#GY]4:!7_:9,
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MT6J&&:/[[M.NWYD5_P$ R\20\KW0HZ<)=HEQ%+Q+#6FYEC8E:;E:"JSGD\-
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M-\9V0GBI6N'!)Z\^UG5]6[,@\4179ZL)I1^[P;*<C&5-L/,8%L1''RY\M>8
MOP8.H,4$LJN+& TSEA#;N&I75%:DGJ_R[8^Z:JV'2AS7V\*@/)_NXK.IHXE
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M?V#D]\#UJAR ZY\:POVIS6RPYL;KD?KZ]8C\[FX^FI,,*>E,"UJ#O/0*#CX
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M,WC!Q9J"IO0MT^&UC4<QL"DJK?N=YYP!E?&T(5'X_5U!_)5G28D[QJI80UA
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MU'*V(BEUBEC=B/+QRL, ^R0/GHK8MH\^=59BPW;-)O.3%B5/DCVD5Z2.%H?
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M-5N Z2V&F@@\(+=FA%.I.-RTOHXLDZ;EI=G XM)*;9=1VEJ?HZU:']!$)JC
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M-<PCIS^'/H@X_%'3=&M)7EME'.5-47F5G::/GS,=5M_OO:\>M;HZW/95W1
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MO2@;$YOHORUL"W";$%@!!8-![ #.;1#X-@C; 4   (0'^I> _Q0(!XR+AT]
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M;MU0@]##%A^N-#$9]A\-(+GWD'G*<]17+#DWRE\OE+' @B)S*DU[5FPP.>0
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MOPG=65/L0\@KG5*#_/YBU,2U><4S9)S@W]9;+L<?X,G@EMZFOCL4^ HB?&6
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M8&SMVN@J/^V[.9F4\/.,[1/=G5)?TZ=<3,D*7RQ8[YQ@M>+Q5\;EPT()9[Z
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MMVP!UB@PUN70C+UT"I^P%8390S<>EAI0\)(Z;W58;LV65+8%;Y!B6#>64J)
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MN E:)[JRRF>17Q:>RC,<R41?9M_(*2PPX(XO_99O3)7T4J[:"D9ET&HO UI
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MDM+W'ZIK:NOJ&QH_MW_YVM'9U=TS,OIM;'QB<@KQ?7%I>65U;7UC<V=W;_\
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M4\EQW?.AZI;>D&W\MD&R\AJ4B=3&@G7KT;C@Q$DC*MQ,(ZO)_LDP*G!XMRY
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MF9DG6P$5%WT'):D=_.8DTOLQ6N2NQYLF?&Y&QK*,-QC _H.??\!LY]W2%<"
MP3DVI8^VRG4M7OC;VO&WMPA\;E.Z[D>*^FZZP[)4 <DS[^:O\S4,B)'^D8'B
M4:="V3^!G884Y053Z7.':0/, %)-X9+' 6UQT;22AYMB>]>G$$1#N;RJ"=5K
MT2];BY94\+;?GH1TH*Y9"(0<29)B5PSFGX,EPINO>JT^X(5];?S*&Q9Q2VK
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M<C6MC\J6-WH,0092F *5'')H>=(3?:.K0Z8J#)I?)?N0C]TZ2\I3_<5VG#
M0F[3W^6/W3I;">T[@?1PGB5/9EI&2+TNN5JMX+FB/=W$N.?RPXX-P> 9& L&
M4/7;3!;\PN%7/"Z<*2C.NI:>\WZN2^Y=."MV)45M <#(L?%'-0X#5)N$1-W
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M_U9Q]?VGNIQNCNVR0X7-")=1+]<F8_HZUK(2MA:<C2;:S_]Q<VCBWI_-,6&
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MPQ*F,8@#4G%G>^CFP*FD_2L\?U/['B2Y>_D46HV1D'=3X8Y"]8U.X:A0"5T
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M4H+PBTH$_=J2,1SYE5:EZU67CX;35<ZEYEWD<8,<]2=UJ>X\BD'ILJR*:P<
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MMB.X;?89!DXCB9(.L8O_+O; 1RWL/4%:$[0:%?D)J!'EP? _ %!+ P04
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ME6V4$"G=+18+UR$J5@'I><'M7VA_DOT>6-"_1?:_8/_'A0?0@(#GP0,Q I0
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M4V05HN^2.N:A::V^Y/PDI+7+EB38!5GMF8<^A7!?9XI"Z/AAR^?3W-PP^#_
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MR)JE+#F%*,F2+6,_]-SEG_O'N?=X?Y_77Y_O\WV>U^?]?+<'MD< 41L+:PL
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M_" P.Q<WZ*^'P*&BH6%B8))@89& :,AI0/_;[>4G  \5#AG>$0&.%@"/!X>
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MA&@HS;EU2 9E3V(C@ -4U^%ZP<_@87MXF7 VBC05$Y'$R\312<6=M0?XZ5&
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MS53F3)X\\YB$MAR'M-P LVB22&[@L_#Z"\ 1RAR??ZPZQY@3+HG.F =D!&;
M#7##82UMM0>7I?"IEGWH!8WV^1L:K..$-7I@GUH=7'MZ>XV"CBXID,QN5WI
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MP%)-M=Z!J"T?OE4-^3(5;"-IL7$;T73A=VV)/"<VU\VY\UM?E:O4MTOSLU=
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MY:K1XQ8\/D[RC,]BG2F+GD:)[UW'O0"^U=N&RFODI.V;AMD3F$WN>CY9Z=E
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M)&8JH2\ ZH/L^\T70/]T^#]SD]&[JO/QXB\ RC-HDVB2G$KG/TC)1:(>PA=
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MS\K9F.T"G-3IW7</B5)1TH>P\NX(U_;)?[W54U'H#>!=*DB'\J,!AYZ*I+8
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M68.;Q KYB;B\IY+>Y&>!NK3=I*;GO^\._&L=!08VPH]8ZWS4""/Q^APC5P=
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MEZ#X@'*)AE1OH3Q['N2"HO*NEI 97_IL4;I<5J2L!=A#"C #/2!SHU2IZ71
MB9M):) ^H.PX'0\*F0.SH$$=Z!) F/3>^Y@.6P&/3HV/:#A-FIY=:.SD2W>,
M*]CWL#/85*XS.9"-(3T:6G9TFE?.-8+B\!A/LGG!F/\E5<%6'QG)P(8TS[@
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M*0:33CYX)9:/F0@7'7QFCFU\)C1OG%TK_&"O#5GY_\-O9OM^COX!4$L#!!0
M   ( )R+:EH]"6.:O%<  )%;   -    :6UA9V5?,#(X+FIP9Z2Z=U1301\M
M&@5$!*5(K]([2"]2;'0A]%ZD$T+O/4KO2)<N0NBA-P%!NH(4";TGH4@))(H0
M(83G=^];]_USWUOO>V_.VF>=<^8WL]8^,V?_9I\U-\LWVP J;74M=<"M6[<
MK_\=@)LUP(O_W/W_*O_IY/]O'[=NO@"H[P+.;P&);G$!;E/?(J*^=3,"X
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M788",JQL<JOY,[R5L1?Q^'G,..F""THJ($<LO"?*Y8FFW:$L,2FX*_ ]-D!
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MR/G+'N(4UD[,ET>A[4FV@VH]'UHZJ%:7I:E65Q-[&.9!4+XCL[Z/)7+NAOK
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MI.&?4-2R38]V=MH(CT9Q9#F'-$38(9X4I)=_W$23^S*LGH&1ET$5/KF9-C<
MV$S-#< %IGX#,,$!:]PMH>A-:(UMA"[V95?PQ1+-AJV-9BD]AE;[@D%*:E(J
ML>+??'-XKI[\8$%?)0W3YF!C?'%E\N%@V9)/U5#Y:+*? Z_0BU.K##E"C)Y
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M7BZ4T?LCWU/6N7%<"BW)_$HXV  N>K-OB):E$J2LI4A>XI:04^/?0-/#B"9
M_-U$<N]'"%:B9OQX:B9'O#GI@@0<_>--I,;*(Z&GWPX?^V:G1[6'7.>$P%%D
M D[DV-Y1\=W;1#I=PZ4 +FD7!%OB+>MW5/C1?"\$9=SROJ'\F'<V-US6=)R]
M (#FK[8._*!X?0,HOTZ##+:]E!O=2I='N1X?8#[[EIV&+-DX^)Z$<E@21H1Q
M1S> &!>7I"CQB% :)=_FZU(5&J%ZQ5I.O%DCZYME!1= F?_;0L*HP/]'\>_[
M)_MKIMRZUQ_^*.MQ\^0;18!PP8V,T/8L1F3:/T>6<1MDZM5V&MC3V=.-^3P/
M"E"9OC_Z&9WC]LM\4O &H.E.> S9/CI=D3P=WV3"B(^4T,^V#U"W"U.26FR0
MK( ]L:X(MKT!9-EM<[OUKT$:<B.JI+CAL4U:^!V#![4?#O(FJL(Q(Z1[D-+3
M45&O)=LET0X85SBXUVJ*?JK*3HCL1 3ZN?#D&E:M59&)WNL*_R1JD>T]<XNE
MWWEC=PP!2+)=A7N\S..22]<:#RS5W#6S/V5*2W"0KQ> +UM_;;42,0N:T_%6
M_KS;VMX)']M30&0)9D<P4&O"6%)Y6KKMWZG9$A8WC6;@Q\[&I#OJ_3&AJJ/<
M4-03CG/CCY"V= &BND4"NWL8;T)LA^ '^(G1>-#B;Q#]9>39\)6*53G+,Y+9
M;#0E3QIMRU=3K?3ON2X4T)?!' \BC%Q1=Y7(V#,AOLA@:KEE&$_R[@F->=^?
M\)?F2"*)F+A0)][X'UGJOCM8BBXJ4+->(%7/RWJ^]X[S(YD'".>')*U=I5/X
M8DTYX<CR9M]W/L+05EP&;!DWMS:. 5MVX7DZA5) H>$@QYJ(EJ'7YHV [K8T
MA/FWOVIM$O*.>8 E&--.6RV#D$4\.R7U&\/S0+=%GZ&QY'1G@=]CK N'9K9K
M=XOT8WD.9IQF"DO$A*'//T(3OTET5+R=+N&UHTP>>M[HJ&1<YT15\W.Z#AH#
MC<WQ6<GY"#6%:HJHL?AK\ZG%6G[I7A#UW%Y@1FD\O.Y<\>A;@45]1[/NG4X6
M>;!;U0L#6&N-?NVPRA_)=5%)9UJ'=AZT6Z]+FX$\W:URM/;<F(P',-N/E245
MEPRV9Y)ZMF("F^C A5'5%9N;N$F]@9;%._656^. \ -+?VEAXN!/$MJ[N:_
M3 #AVV_V!N+[G"Y)W^ =M\?@2G+U \F57>$V6G\>DNR]_Y&Y+\D[MZK6J<\
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M<W!I<F$N:'1M4$L! A0#%     @ G(MJ6EJPC= '!P  C"0  !T
M     ( !)?L# &5A,#(S,S(R-C Q97@Q,BTQ7VEN<W!I<F$N:'1M4$L! A0#
M%     @ G(MJ6J8!CX?V!@  ]2,  !T              ( !9P($ &5A,#(S
M,S(R-C Q97@Q,BTR7VEN<W!I<F$N:'1M4$L! A0#%     @ G(MJ6KO6LN,-
M P  O0H  !T              ( !F D$ &5A,#(S,S(R-C Q97@Q,RTQ7VEN
M<W!I<F$N:'1M4$L! A0#%     @ G(MJ6GG^,.P1 P  EPH  !T
M     ( !X P$ &5A,#(S,S(R-C Q97@Q,RTR7VEN<W!I<F$N:'1M4$L! A0#
M%     @ G(MJ6G<BB1Z: P  P0P  !T              ( !+! $ &5A,#(S
M,S(R-C Q97@Q-2TQ7VEN<W!I<F$N:'1M4$L! A0#%     @ G(MJ6E^_X_[4
M*0  'N(  !P              ( ! 10$ &5A,#(S,S(R-C Q97@R+3%?:6YS
M<&ER82YH=&U02P$"% ,4    " "<BVI:P-[$T&T8  !('P$ $0
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M,# R+FIP9U!+ 0(4 Q0    ( )R+:EH;+08)-4<  %E/   -
M  "  0,W!@!I;6%G95\P,#,N:G!G4$L! A0#%     @ G(MJ6F^#LO819P
MQ6X   T              ( !8WX& &EM86=E7S P-"YJ<&=02P$"% ,4
M" "<BVI:E'6F":Y^  !?@@  #0              @ &?Y08 :6UA9V5?,# U
M+FIP9U!+ 0(4 Q0    ( )R+:EK?E,<SS$,  %Q.   -              "
M 7AD!P!I;6%G95\P,#8N:G!G4$L! A0#%     @ G(MJ6C>2,OT)(P  AR0
M  T              ( !;Z@' &EM86=E7S P-RYJ<&=02P$"% ,4    " "<
MBVI:?NOHSJXD  "L)@  #0              @ &CRP< :6UA9V5?,# X+FIP
M9U!+ 0(4 Q0    ( )R+:EKJ3/%$01<  )(;   -              "  7SP
M!P!I;6%G95\P,#DN:G!G4$L! A0#%     @ G(MJ6BM4W4+R#@  &!(   T
M             ( !Z <( &EM86=E7S Q,"YJ<&=02P$"% ,4    " "<BVI:
MVTX=:^IR  !B=P  #0              @ $%%P@ :6UA9V5?,#$Q+FIP9U!+
M 0(4 Q0    ( )R+:EI B%*7[U4  !9>   -              "  1J*" !I
M;6%G95\P,3(N:G!G4$L! A0#%     @ G(MJ6GY!UNQ';P  )G<   T
M         ( !-. ( &EM86=E7S Q,RYJ<&=02P$"% ,4    " "<BVI:U7C[
MN&.$  ""B   #0              @ &F3PD :6UA9V5?,#$T+FIP9U!+ 0(4
M Q0    ( )R+:EI[8;K7I#,  *HT   -              "  334"0!I;6%G
M95\P,34N:G!G4$L! A0#%     @ G(MJ6KP:FP_MF0  0Z<   T
M     ( ! P@* &EM86=E7S Q-BYJ<&=02P$"% ,4    " "<BVI:-Y(R_0DC
M  "')   #0              @ $;H@H :6UA9V5?,#$W+FIP9U!+ 0(4 Q0
M   ( )R+:EJ<0$)8Q4T   I?   -              "  4_%"@!I;6%G95\P
M,3@N:G!G4$L! A0#%     @ G(MJ6G[KZ,ZN)   K"8   T
M ( !/Q,+ &EM86=E7S Q.2YJ<&=02P$"% ,4    " "<BVI:ZDSQ1$$7  "2
M&P  #0              @ $8. L :6UA9V5?,#(P+FIP9U!+ 0(4 Q0    (
M )R+:EJ3BXC$:Q\  &DD   -              "  81/"P!I;6%G95\P,C$N
M:G!G4$L! A0#%     @ G(MJ6NE OXT)%P  L!P   T              ( !
M&F\+ &EM86=E7S R,BYJ<&=02P$"% ,4    " "<BVI:4E_+.)D;  !R(
M#0              @ %.A@L :6UA9V5?,#(S+FIP9U!+ 0(4 Q0    ( )R+
M:EJPN!CW?A8  ,\:   -              "  1*B"P!I;6%G95\P,C0N:G!G
M4$L! A0#%     @ G(MJ6BM4W4+R#@  &!(   T              ( !N[@+
M &EM86=E7S R-2YJ<&=02P$"% ,4    " "<BVI:F#UTBH@'  "<"@  #0
M            @ '8QPL :6UA9V5?,#(V+FIP9U!+ 0(4 Q0    ( )R+:EIC
M$;*P*TP  !!3   -              "  8O/"P!I;6%G95\P,C<N:G!G4$L!
M A0#%     @ G(MJ6CT)8YJ\5P  D5L   T              ( !X1L, &EM
A86=E7S R."YJ<&=02P4&     "D *0 3"@  R',,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>ea0233226-20f_inspira_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2024"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iinn="http://www.inspiratechnologies.com/20241231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="iinn-20241231.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">iinn:OrdinarySharesNoParValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">iinn:WarrantsToPurchaseOrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-04-01</endDate>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <instant>2024-04-01</instant>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-14</startDate>
            <endDate>2024-06-14</endDate>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-14</instant>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-14</startDate>
            <endDate>2024-06-14</endDate>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <instant>2024-06-14</instant>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:JunePreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-14</instant>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <startDate>2024-06-14</startDate>
            <endDate>2024-06-14</endDate>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:JunePlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-14</startDate>
            <endDate>2024-06-14</endDate>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">iinn:DecemberPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-27</startDate>
            <endDate>2024-12-27</endDate>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">iinn:DecemberPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-27</instant>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:DecemberPreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-27</startDate>
            <endDate>2024-12-27</endDate>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-27</instant>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:DecemberPreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-27</instant>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-27</startDate>
            <endDate>2024-12-27</endDate>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <startDate>2024-12-27</startDate>
            <endDate>2024-12-27</endDate>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <instant>2024-12-27</instant>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">iinn:BankLeumiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">iinn:BankLeumiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">iinn:RDEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">iinn:RDEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">iinn:RDEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">iinn:RDEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">iinn:RDEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <startDate>2023-10-31</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">iinn:December2024PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">iinn:December2024PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">iinn:December2024PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">iinn:December2024PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-26</startDate>
            <endDate>2023-12-26</endDate>
        </period>
    </context>
    <context id="c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:PrivateWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-26</instant>
        </period>
    </context>
    <context id="c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:PrivateWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:PrivateWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">iinn:PrivateWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">iinn:PrivateWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">iinn:RothCapitalPartnersLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">iinn:RegisteredDirectOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-26</startDate>
            <endDate>2023-12-26</endDate>
        </period>
    </context>
    <context id="c107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <instant>2023-12-26</instant>
        </period>
    </context>
    <context id="c108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-26</instant>
        </period>
    </context>
    <context id="c109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-26</instant>
        </period>
    </context>
    <context id="c110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-26</instant>
        </period>
    </context>
    <context id="c111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">iinn:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:PlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:PlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:PlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">iinn:TwoThousandTwentyFourAprilOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-04-01</endDate>
        </period>
    </context>
    <context id="c120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">iinn:TwoThousandTwentyFourAprilOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-01</instant>
        </period>
    </context>
    <context id="c121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-20</instant>
        </period>
    </context>
    <context id="c122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-20</startDate>
            <endDate>2024-05-20</endDate>
        </period>
    </context>
    <context id="c123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">iinn:TwoThousandTwentyFourJuneOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-14</startDate>
            <endDate>2024-06-14</endDate>
        </period>
    </context>
    <context id="c124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">iinn:TwoThousandTwentyFourJuneOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-14</instant>
        </period>
    </context>
    <context id="c125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:JunePreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-14</instant>
        </period>
    </context>
    <context id="c126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:JunePreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-14</instant>
        </period>
    </context>
    <context id="c127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:JunePreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-14</startDate>
            <endDate>2024-06-14</endDate>
        </period>
    </context>
    <context id="c128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:JunePreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:TwoThousandTwentyFourJuneOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:TwoThousandTwentyFourJuneOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:JunePreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:JunePlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:JunePlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:JunePlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-14</instant>
        </period>
    </context>
    <context id="c135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <startDate>2024-06-30</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:DecemberPrivateWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-27</startDate>
            <endDate>2024-12-27</endDate>
        </period>
    </context>
    <context id="c137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:DecemberPrivateWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-27</instant>
        </period>
    </context>
    <context id="c138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:DecemberPrivateWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-27</instant>
        </period>
    </context>
    <context id="c139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:DecemberPrivateWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-27</instant>
        </period>
    </context>
    <context id="c140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:DecemberPreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-27</instant>
        </period>
    </context>
    <context id="c141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">iinn:DecemberPrivateWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-27</startDate>
            <endDate>2024-12-27</endDate>
        </period>
    </context>
    <context id="c142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">iinn:DecemberPrivateOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">iinn:DecemberPrivateOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">iinn:December2024PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-31</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">iinn:ExercisePrice55Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">iinn:ExercisePrice55Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">iinn:ExercisePrice55TwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">iinn:ExercisePrice55TwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">iinn:Exercise6875Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">iinn:Exercise6875Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">iinn:ExercisePriceOnePointSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">iinn:ExercisePriceOnePointSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">iinn:ExercisePrice156Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">iinn:ExercisePrice156Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">iinn:ExercisePriceOnePointOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">iinn:ExercisePriceOnePointOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">iinn:ExercisePrice0001Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">iinn:ExercisePrice0001Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-24</instant>
        </period>
    </context>
    <context id="c172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">iinn:AdvisoryBoardMembersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-24</instant>
        </period>
    </context>
    <context id="c173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-24</instant>
        </period>
    </context>
    <context id="c174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-24</startDate>
            <endDate>2022-03-24</endDate>
        </period>
    </context>
    <context id="c175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-24</instant>
        </period>
    </context>
    <context id="c176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">iinn:MedicalBoardMembersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-24</instant>
        </period>
    </context>
    <context id="c177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-24</startDate>
            <endDate>2022-03-24</endDate>
        </period>
    </context>
    <context id="c178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <startDate>2022-03-24</startDate>
            <endDate>2022-03-24</endDate>
        </period>
    </context>
    <context id="c179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iinn:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-24</startDate>
            <endDate>2022-03-24</endDate>
        </period>
    </context>
    <context id="c180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-06</instant>
        </period>
    </context>
    <context id="c181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-19</instant>
        </period>
    </context>
    <context id="c182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-19</startDate>
            <endDate>2022-05-19</endDate>
        </period>
    </context>
    <context id="c183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-22</instant>
        </period>
    </context>
    <context id="c184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-22</startDate>
            <endDate>2022-11-22</endDate>
        </period>
    </context>
    <context id="c185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-22</instant>
        </period>
    </context>
    <context id="c186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-22</startDate>
            <endDate>2024-01-22</endDate>
        </period>
    </context>
    <context id="c187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-22</instant>
        </period>
    </context>
    <context id="c188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <instant>2024-01-22</instant>
        </period>
    </context>
    <context id="c189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <startDate>2024-01-22</startDate>
            <endDate>2024-01-22</endDate>
        </period>
    </context>
    <context id="c190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-22</startDate>
            <endDate>2024-01-22</endDate>
        </period>
    </context>
    <context id="c191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-22</startDate>
            <endDate>2024-01-22</endDate>
        </period>
    </context>
    <context id="c192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-05</startDate>
            <endDate>2024-02-05</endDate>
        </period>
    </context>
    <context id="c194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-05</startDate>
            <endDate>2024-02-05</endDate>
        </period>
    </context>
    <context id="c195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-05</instant>
        </period>
    </context>
    <context id="c196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
        </entity>
        <period>
            <startDate>2024-02-05</startDate>
            <endDate>2024-02-05</endDate>
        </period>
    </context>
    <context id="c197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">iinn:EmployeesDirectorsAndSubcontractorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">iinn:EmployeesDirectorsAndSubcontractorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">iinn:EmployeesDirectorsAndSubcontractorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-24</startDate>
            <endDate>2022-03-24</endDate>
        </period>
    </context>
    <context id="c201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-24</startDate>
            <endDate>2022-03-24</endDate>
        </period>
    </context>
    <context id="c202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-22</startDate>
            <endDate>2024-01-22</endDate>
        </period>
    </context>
    <context id="c203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-22</startDate>
            <endDate>2024-01-22</endDate>
        </period>
    </context>
    <context id="c204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:ServicesProvidersAndAdvisersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:ServicesProvidersAndAdvisersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:ServicesProvidersAndAdvisersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:ServicesProvidersAndAdvisersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:ServicesProvidersAndAdvisersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:ServicesProvidersAndAdvisersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:ServicesProvidersAndAdvisersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">iinn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">iinn:OfficersAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">iinn:OfficersAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">iinn:OfficersAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">iinn:DecemberPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-01</endDate>
        </period>
    </context>
    <context id="c232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-28</startDate>
            <endDate>2025-02-28</endDate>
        </period>
    </context>
    <context id="c233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-20</startDate>
            <endDate>2025-02-20</endDate>
        </period>
    </context>
    <context id="c234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">iinn:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-20</startDate>
            <endDate>2025-02-20</endDate>
        </period>
    </context>
    <context id="c235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">iinn:ExecutivesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-20</startDate>
            <endDate>2025-02-20</endDate>
        </period>
    </context>
    <context id="c236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001837493</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-20</startDate>
            <endDate>2025-02-20</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="ils">
        <measure>iso4217:ILS</measure>
    </unit>
    <unit id="ilsPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:ILS</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:DocumentType contextRef="c0" id="ixv-25419">20-F</dei:DocumentType>
    <dei:DocumentRegistrationStatement contextRef="c0" id="ixv-25420">false</dei:DocumentRegistrationStatement>
    <dei:DocumentAnnualReport contextRef="c0" id="ixv-25421">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c0" id="ixv-25422">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c0" id="ixv-25423">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c0" id="ixv-25424">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="c0" id="ixv-25425">false</dei:DocumentTransitionReport>
    <dei:DocumentShellCompanyReport contextRef="c0" id="ixv-25426">false</dei:DocumentShellCompanyReport>
    <dei:EntityFileNumber contextRef="c0" id="ixv-25427">001-40303</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c0" id="ixv-94">INSPIRA TECHNOLOGIES OXY B.H.N. LTD.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0" id="ixv-25428">L3</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="c0" id="ixv-25429">2 Ha-Tidhar St</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c0" id="ixv-25430">Ra&#x2019;anana</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="c0" id="ixv-25431">4366504</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="c0" id="ixv-25432">IL</dei:EntityAddressCountry>
    <dei:ContactPersonnelName contextRef="c1" id="ixv-144">Dagi Ben-Noon</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1 contextRef="c1" id="ixv-25433">2 Ha-Tidhar St.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c1" id="ixv-25434">Ra&#x2019;anana</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="c1" id="ixv-25435">4366504</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="c1" id="ixv-25436">IL</dei:EntityAddressCountry>
    <dei:CityAreaCode contextRef="c1" id="ixv-25437">+972</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c1" id="ixv-25438">4.6230333</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c2" id="ixv-189">Ordinary Shares, no par value</dei:Security12bTitle>
    <dei:NoTradingSymbolFlag contextRef="c2" id="ixv-194">true</dei:NoTradingSymbolFlag>
    <dei:SecurityExchangeName contextRef="c2" id="ixv-25439">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c3" id="ixv-203">Warrants to purchase Ordinary Shares</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c3" id="ixv-208">IINNW</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c3" id="ixv-25440">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="c4"
      decimals="INF"
      id="ixv-25441"
      unitRef="shares">24252096</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c0" id="ixv-25442">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c0" id="ixv-25443">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c0" id="ixv-25444">No</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c0" id="ixv-25445">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c0" id="ixv-329">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany contextRef="c0" id="ixv-336">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="c0" id="ixv-25446">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="c0" id="ixv-25447">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c0" id="ixv-25448">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c0" id="ixv-25449">false</dei:EntityShellCompany>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="c31" id="ixv-25450">false</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="c0" id="ixv-12820">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The Company has
developed and maintained a cybersecurity risk management strategy, consisting of cybersecurity policies, procedures, compliance and
awareness programs to mitigate risk and to ensure compliance with security, availability and confidentiality trust principles. The
cybersecurity process has been integrated into the Company&#x2019;s overall risk management system and process and is solely
internally managed. Management is responsible for identifying risks that threaten achievement of the control activities stated in
the management&#x2019;s description of the services organizations systems. The risk assessment occurs annually, or as business needs
change, and covers identification of risks that could act against the company&#x2019;s objectives as well as specific risks related
to a compromise to the security of data.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;The level of each identified
risk is determined by considering the impact of the risk itself and the likelihood of the risk materializing and high scoring risks are
actioned upon. Risks are analyzed to determine whether the risk meets company risk acceptance criteria to be accepted or whether a mitigation
plan will be applied. Mitigation plans include both the individual or department responsible for the plan and may include budget considerations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;As of the date of this report,
we are not aware of any material risks from cybersecurity threats that have materially affected or are reasonably likely to materially
affect us, including our business strategy, results of operations or financial condition.&lt;/p&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock contextRef="c0" id="ixv-25451">The
cybersecurity process has been integrated into the Company&#x2019;s overall risk management system and process and is solely
internally managed.</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="c0" id="ixv-25452">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock contextRef="c0" id="ixv-25453">Management is responsible for identifying risks that threaten achievement of the control activities stated in
the management&#x2019;s description of the services organizations systems. The risk assessment occurs annually, or as business needs
change, and covers identification of risks that could act against the company&#x2019;s objectives as well as specific risks related
to a compromise to the security of data.</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag contextRef="c0" id="ixv-25454">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag contextRef="c0" id="ixv-25455">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock contextRef="c0" id="ixv-12830">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;As of the date of this report,
we are not aware of any material risks from cybersecurity threats that have materially affected or are reasonably likely to materially
affect us, including our business strategy, results of operations or financial condition.&lt;/p&gt;</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="c0" id="ixv-25456">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="c0" id="ixv-12836">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Governance&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Our Chief Executive Officer
and Chief Financial Officer oversee our cybersecurity risk management and mitigation efforts. The board of directors receive prompt and
timely information regarding any cybersecurity incidents. Our Audit Committee periodically discusses cybersecurity.&lt;/p&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c0" id="ixv-12844">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;Our Chief Executive Officer
and Chief Financial Officer oversee our cybersecurity risk management and mitigation efforts. The board of directors receive prompt and
timely information regarding any cybersecurity incidents. Our Audit Committee periodically discusses cybersecurity.&lt;/p&gt;</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c0" id="ixv-25457">Our Chief Executive Officer
and Chief Financial Officer oversee our cybersecurity risk management and mitigation efforts</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock contextRef="c0" id="ixv-12855">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;As part of the critical elements
of our overall risk management approach, our cybersecurity program is focused on the following key areas:&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Collaborative Approach: The Company has implemented a comprehensive, cross-functional approach to identifying, preventing and mitigating cybersecurity threats and incidents, while also implementing controls and procedures that provide for the prompt escalation of certain cybersecurity incidents so that decisions regarding the public disclosure and reporting of such incidents can be made by management in a timely manner.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Technical Safeguards: The Company deploys technical safeguards that are designed to protect the Company&#x2019;s information systems from cybersecurity threats, including firewalls, intrusion prevention and detection systems, anti-malware functionality and access controls, which are evaluated and improved through vulnerability assessments and cybersecurity threat intelligence.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Incident Response and Recovery Planning: The Company has established and maintains comprehensive incident response and recovery plans that fully address the Company&#x2019;s response to a cybersecurity incident, and such plans are tested and evaluated on a regular basis.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <dei:AuditorFirmId contextRef="c0" id="ixv-25458">1185</dei:AuditorFirmId>
    <dei:AuditorOpinionTextBlock contextRef="c0" id="ixv-13362">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Opinion
on the Financial Statements&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;We
have audited the accompanying balance sheets of Inspira Technologies Oxy B.H.N. Ltd. (the &#x201c;Company&#x201d;) as of December 31, 2024
and 2023, the related statements of comprehensive loss, changes in shareholders&#x2019; equity, and cash flows for each of the three years
in the period ended December 31, 2024, and the related notes (collectively, the &#x201c;Financial Statements&#x201d;). In our opinion,
the Financial Statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and
2023, and the results of its operations and its cash flows for each of the three years in the period ended December&#160;31, 2024, in
conformity with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;).&lt;/span&gt;&lt;/p&gt;</dei:AuditorOpinionTextBlock>
    <dei:AuditorLocation contextRef="c0" id="ixv-13428">Tel-Aviv, Israel</dei:AuditorLocation>
    <dei:AuditorName contextRef="c0" id="ixv-13431">Ziv Haft</dei:AuditorName>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c4" decimals="-3" id="ixv-25459" unitRef="usd">5111000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c5" decimals="-3" id="ixv-25460" unitRef="usd">5041000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:DepositsAssetsCurrent contextRef="c4" decimals="-3" id="ixv-25461" unitRef="usd">668000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:DepositsAssetsCurrent contextRef="c5" decimals="-3" id="ixv-25462" unitRef="usd">2320000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c4" decimals="-3" id="ixv-25463" unitRef="usd">587000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c5" decimals="-3" id="ixv-25464" unitRef="usd">432000</us-gaap:OtherAssetsCurrent>
    <us-gaap:InventoryNet contextRef="c4" decimals="-3" id="ixv-25465" unitRef="usd">444000</us-gaap:InventoryNet>
    <us-gaap:AssetsCurrent contextRef="c4" decimals="-3" id="ixv-25466" unitRef="usd">6810000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c5" decimals="-3" id="ixv-25467" unitRef="usd">7793000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c4" decimals="-3" id="ixv-25468" unitRef="usd">761000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c5" decimals="-3" id="ixv-25469" unitRef="usd">1011000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c4" decimals="-3" id="ixv-25470" unitRef="usd">499000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c5" decimals="-3" id="ixv-25471" unitRef="usd">506000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AssetsNoncurrent contextRef="c4" decimals="-3" id="ixv-25472" unitRef="usd">1260000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c5" decimals="-3" id="ixv-25473" unitRef="usd">1517000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets contextRef="c4" decimals="-3" id="ixv-25474" unitRef="usd">8070000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c5" decimals="-3" id="ixv-25475" unitRef="usd">9310000</us-gaap:Assets>
    <us-gaap:AccountsPayableTradeCurrent contextRef="c4" decimals="-3" id="ixv-25476" unitRef="usd">154000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent contextRef="c5" decimals="-3" id="ixv-25477" unitRef="usd">198000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableOtherCurrent contextRef="c4" decimals="-3" id="ixv-25478" unitRef="usd">1364000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent contextRef="c5" decimals="-3" id="ixv-25479" unitRef="usd">1026000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c4" decimals="-3" id="ixv-25480" unitRef="usd">277000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c5" decimals="-3" id="ixv-25481" unitRef="usd">290000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="c4" decimals="-3" id="ixv-25482" unitRef="usd">1575000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="c5" decimals="-3" id="ixv-25483" unitRef="usd">1470000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c4" decimals="-3" id="ixv-25484" unitRef="usd">3370000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c5" decimals="-3" id="ixv-25485" unitRef="usd">2984000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c4" decimals="-3" id="ixv-25486" unitRef="usd">378000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c5" decimals="-3" id="ixv-25487" unitRef="usd">588000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c4" decimals="-3" id="ixv-25488" unitRef="usd">378000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c5" decimals="-3" id="ixv-25489" unitRef="usd">588000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c4"
      decimals="INF"
      id="ixv-25490"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c5"
      decimals="INF"
      id="ixv-25491"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c4"
      decimals="INF"
      id="ixv-25492"
      unitRef="shares">24252096</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c4"
      decimals="INF"
      id="ixv-25493"
      unitRef="shares">24252096</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c5"
      decimals="INF"
      id="ixv-25494"
      unitRef="shares">15652176</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c5"
      decimals="INF"
      id="ixv-25495"
      unitRef="shares">15652176</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c4" decimals="-3" id="ixv-25496" unitRef="usd">70896000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c5" decimals="-3" id="ixv-25497" unitRef="usd">61259000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c4" decimals="-3" id="ixv-25498" unitRef="usd">-66574000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c5" decimals="-3" id="ixv-25499" unitRef="usd">-55521000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c4" decimals="-3" id="ixv-25500" unitRef="usd">4322000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c5" decimals="-3" id="ixv-25501" unitRef="usd">5738000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c4" decimals="-3" id="ixv-25502" unitRef="usd">8070000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c5" decimals="-3" id="ixv-25503" unitRef="usd">9310000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="-3" id="ixv-25504" unitRef="usd">6323000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c6" decimals="-3" id="ixv-25505" unitRef="usd">7320000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c7" decimals="-3" id="ixv-25506" unitRef="usd">8183000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c0" decimals="-3" id="ixv-25507" unitRef="usd">4185000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c6" decimals="-3" id="ixv-25508" unitRef="usd">4063000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c7" decimals="-3" id="ixv-25509" unitRef="usd">5375000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c0" decimals="-3" id="ixv-25510" unitRef="usd">754000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c6" decimals="-3" id="ixv-25511" unitRef="usd">746000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c7" decimals="-3" id="ixv-25512" unitRef="usd">1328000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c0" decimals="-3" id="ixv-25513" unitRef="usd">-5000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c6" decimals="-3" id="ixv-25514" unitRef="usd">-4000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c7" decimals="-3" id="ixv-25515" unitRef="usd">-7000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="-3" id="ixv-25516" unitRef="usd">-11267000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c6" decimals="-3" id="ixv-25517" unitRef="usd">-12133000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c7" decimals="-3" id="ixv-25518" unitRef="usd">-14893000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeDepositsWithFinancialInstitutions contextRef="c0" decimals="-3" id="ixv-25519" unitRef="usd">172000</us-gaap:InterestIncomeDepositsWithFinancialInstitutions>
    <us-gaap:InterestIncomeDepositsWithFinancialInstitutions contextRef="c6" decimals="-3" id="ixv-25520" unitRef="usd">318000</us-gaap:InterestIncomeDepositsWithFinancialInstitutions>
    <us-gaap:InterestIncomeDepositsWithFinancialInstitutions contextRef="c7" decimals="-3" id="ixv-25521" unitRef="usd">192000</us-gaap:InterestIncomeDepositsWithFinancialInstitutions>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c0" decimals="-3" id="ixv-25522" unitRef="usd">42000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c6" decimals="-3" id="ixv-25523" unitRef="usd">529000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c7" decimals="-3" id="ixv-25524" unitRef="usd">-275000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c0" decimals="-3" id="ixv-25525" unitRef="usd">-11053000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c6" decimals="-3" id="ixv-25526" unitRef="usd">-11286000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c7" decimals="-3" id="ixv-25527" unitRef="usd">-14976000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-25528" unitRef="usd">-11053000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c6" decimals="-3" id="ixv-25529" unitRef="usd">-11286000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c7" decimals="-3" id="ixv-25530" unitRef="usd">-14976000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="2"
      id="ixv-25531"
      unitRef="usdPershares">-0.6</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c0"
      decimals="2"
      id="ixv-25532"
      unitRef="usdPershares">-0.6</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c6"
      decimals="2"
      id="ixv-25533"
      unitRef="usdPershares">-0.93</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c6"
      decimals="2"
      id="ixv-25534"
      unitRef="usdPershares">-0.93</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c7"
      decimals="2"
      id="ixv-25535"
      unitRef="usdPershares">-1.39</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c7"
      decimals="2"
      id="ixv-25536"
      unitRef="usdPershares">-1.39</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c0"
      decimals="INF"
      id="ixv-25537"
      unitRef="shares">18515545</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c0"
      decimals="INF"
      id="ixv-25538"
      unitRef="shares">18515545</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c6"
      decimals="INF"
      id="ixv-25539"
      unitRef="shares">12095477</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c6"
      decimals="INF"
      id="ixv-25540"
      unitRef="shares">12095477</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c7"
      decimals="INF"
      id="ixv-25541"
      unitRef="shares">10794594</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c7"
      decimals="INF"
      id="ixv-25542"
      unitRef="shares">10794594</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="c8"
      decimals="INF"
      id="ixv-25543"
      unitRef="shares">15652176</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c9" decimals="-3" id="ixv-25544" unitRef="usd">61259000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c10" decimals="-3" id="ixv-25545" unitRef="usd">-55521000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c5" decimals="-3" id="ixv-25546" unitRef="usd">5738000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c11"
      decimals="INF"
      id="ixv-25547"
      unitRef="shares">6231169</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c12" decimals="-3" id="ixv-25548" unitRef="usd">7679000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c0" decimals="-3" id="ixv-25549" unitRef="usd">7679000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c11"
      decimals="INF"
      id="ixv-25550"
      unitRef="shares">19048</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c12" decimals="-3" id="ixv-25551" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c0" decimals="-3" id="ixv-25552" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <iinn:ExerciseOfJune2024PrefundedWarrantsIntoOrdinarySharesinShares
      contextRef="c11"
      decimals="INF"
      id="ixv-25553"
      unitRef="shares">1709760</iinn:ExerciseOfJune2024PrefundedWarrantsIntoOrdinarySharesinShares>
    <iinn:ExerciseOfJune2024PrefundedWarrantsIntoOrdinaryShares contextRef="c12" decimals="-3" id="ixv-25554" unitRef="usd">2000</iinn:ExerciseOfJune2024PrefundedWarrantsIntoOrdinaryShares>
    <iinn:ExerciseOfJune2024PrefundedWarrantsIntoOrdinaryShares contextRef="c0" decimals="-3" id="ixv-25555" unitRef="usd">2000</iinn:ExerciseOfJune2024PrefundedWarrantsIntoOrdinaryShares>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="c11"
      decimals="INF"
      id="ixv-25556"
      unitRef="shares">594943</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c11"
      decimals="INF"
      id="ixv-25557"
      unitRef="shares">45000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c12" decimals="-3" id="ixv-25558" unitRef="usd">62000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c0" decimals="-3" id="ixv-25559" unitRef="usd">62000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition contextRef="c12" decimals="-3" id="ixv-25560" unitRef="usd">1892000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition contextRef="c0" decimals="-3" id="ixv-25561" unitRef="usd">1892000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss contextRef="c13" decimals="-3" id="ixv-25562" unitRef="usd">-11053000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-25563" unitRef="usd">-11053000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c14"
      decimals="INF"
      id="ixv-25564"
      unitRef="shares">24252096</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c15" decimals="-3" id="ixv-25565" unitRef="usd">70896000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c16" decimals="-3" id="ixv-25566" unitRef="usd">-66574000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c4" decimals="-3" id="ixv-25567" unitRef="usd">4322000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c17"
      decimals="INF"
      id="ixv-25568"
      unitRef="shares">11338940</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c18" decimals="-3" id="ixv-25569" unitRef="usd">57866000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c19" decimals="-3" id="ixv-25570" unitRef="usd">-44235000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c20" decimals="-3" id="ixv-25571" unitRef="usd">13631000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c21"
      decimals="INF"
      id="ixv-25572"
      unitRef="shares">3031250</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c22" decimals="-3" id="ixv-25573" unitRef="usd">1806000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c6" decimals="-3" id="ixv-25574" unitRef="usd">1806000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c22" decimals="-3" id="ixv-25575" unitRef="usd">131000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c6" decimals="-3" id="ixv-25576" unitRef="usd">131000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="c21"
      decimals="INF"
      id="ixv-25577"
      unitRef="shares">17566</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c22" decimals="-3" id="ixv-25578" unitRef="usd">26000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c6" decimals="-3" id="ixv-25579" unitRef="usd">26000</us-gaap:StockIssuedDuringPeriodValueOther>
    <iinn:StockIssuedDuringPeriodSharesStockOptionsExerciseOfShareBasedPayments
      contextRef="c21"
      decimals="INF"
      id="ixv-25580"
      unitRef="shares">37972</iinn:StockIssuedDuringPeriodSharesStockOptionsExerciseOfShareBasedPayments>
    <iinn:StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments contextRef="c22" decimals="-3" id="ixv-25581" unitRef="usd">3000</iinn:StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments>
    <iinn:StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments contextRef="c6" decimals="-3" id="ixv-25582" unitRef="usd">3000</iinn:StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="c21"
      decimals="INF"
      id="ixv-25583"
      unitRef="shares">1226448</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition contextRef="c22" decimals="-3" id="ixv-25584" unitRef="usd">1427000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition contextRef="c6" decimals="-3" id="ixv-25585" unitRef="usd">1427000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss contextRef="c23" decimals="-3" id="ixv-25586" unitRef="usd">-11286000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c6" decimals="-3" id="ixv-25587" unitRef="usd">-11286000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c8"
      decimals="INF"
      id="ixv-25588"
      unitRef="shares">15652176</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c9" decimals="-3" id="ixv-25589" unitRef="usd">61259000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c10" decimals="-3" id="ixv-25590" unitRef="usd">-55521000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c5" decimals="-3" id="ixv-25591" unitRef="usd">5738000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c24"
      decimals="INF"
      id="ixv-25592"
      unitRef="shares">10091706</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c25" decimals="-3" id="ixv-25593" unitRef="usd">52987000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c26" decimals="-3" id="ixv-25594" unitRef="usd">-29259000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c27" decimals="-3" id="ixv-25595" unitRef="usd">23728000</us-gaap:StockholdersEquity>
    <iinn:StockIssuedDuringPeriodSharesStockOptionsExerciseOfShareBasedPayments
      contextRef="c28"
      decimals="INF"
      id="ixv-25596"
      unitRef="shares">7030</iinn:StockIssuedDuringPeriodSharesStockOptionsExerciseOfShareBasedPayments>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="c28"
      decimals="INF"
      id="ixv-25597"
      unitRef="shares">1240204</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition contextRef="c29" decimals="-3" id="ixv-25598" unitRef="usd">4879000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition contextRef="c7" decimals="-3" id="ixv-25599" unitRef="usd">4879000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss contextRef="c30" decimals="-3" id="ixv-25600" unitRef="usd">-14976000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c7" decimals="-3" id="ixv-25601" unitRef="usd">-14976000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c17"
      decimals="INF"
      id="ixv-25602"
      unitRef="shares">11338940</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c18" decimals="-3" id="ixv-25603" unitRef="usd">57866000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c19" decimals="-3" id="ixv-25604" unitRef="usd">-44235000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c20" decimals="-3" id="ixv-25605" unitRef="usd">13631000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-25607" unitRef="usd">-11053000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c6" decimals="-3" id="ixv-25608" unitRef="usd">-11286000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c7" decimals="-3" id="ixv-25609" unitRef="usd">-14976000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation contextRef="c0" decimals="-3" id="ixv-25610" unitRef="usd">171000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c6" decimals="-3" id="ixv-25611" unitRef="usd">111000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c7" decimals="-3" id="ixv-25612" unitRef="usd">54000</us-gaap:Depreciation>
    <us-gaap:ProvisionForOtherLosses contextRef="c0" decimals="-3" id="ixv-25613" unitRef="usd">5000</us-gaap:ProvisionForOtherLosses>
    <us-gaap:ShareBasedCompensation contextRef="c0" decimals="-3" id="ixv-25614" unitRef="usd">1892000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c6" decimals="-3" id="ixv-25615" unitRef="usd">1427000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c7" decimals="-3" id="ixv-25616" unitRef="usd">4879000</us-gaap:ShareBasedCompensation>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="c6" decimals="-3" id="ixv-25617" unitRef="usd">59000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1 contextRef="c0" decimals="-3" id="ixv-25618" unitRef="usd">-47000</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1 contextRef="c6" decimals="-3" id="ixv-25619" unitRef="usd">306000</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1 contextRef="c7" decimals="-3" id="ixv-25620" unitRef="usd">108000</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <iinn:ExpirationOfFinancialLiability contextRef="c0" decimals="-3" id="ixv-25621" unitRef="usd">11000</iinn:ExpirationOfFinancialLiability>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c6" decimals="-3" id="ixv-25622" unitRef="usd">205000</us-gaap:AmortizationOfFinancingCosts>
    <iinn:IssuanceOfOrdinarySharesAdvisorFees contextRef="c0" decimals="-3" id="ixv-25623" unitRef="usd">62000</iinn:IssuanceOfOrdinarySharesAdvisorFees>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c0" decimals="-3" id="ixv-25624" unitRef="usd">-9000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c6" decimals="-3" id="ixv-25625" unitRef="usd">-7000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c7" decimals="-3" id="ixv-25626" unitRef="usd">-51000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInLeasingReceivables contextRef="c0" decimals="-3" id="ixv-25627" unitRef="usd">-31000</us-gaap:IncreaseDecreaseInLeasingReceivables>
    <us-gaap:IncreaseDecreaseInLeasingReceivables contextRef="c6" decimals="-3" id="ixv-25628" unitRef="usd">5000</us-gaap:IncreaseDecreaseInLeasingReceivables>
    <us-gaap:IncreaseDecreaseInLeasingReceivables contextRef="c7" decimals="-3" id="ixv-25629" unitRef="usd">99000</us-gaap:IncreaseDecreaseInLeasingReceivables>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="c0" decimals="-3" id="ixv-25630" unitRef="usd">84000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="c6" decimals="-3" id="ixv-25631" unitRef="usd">-190000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="c7" decimals="-3" id="ixv-25632" unitRef="usd">-99000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="c0" decimals="-3" id="ixv-25633" unitRef="usd">-44000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="c6" decimals="-3" id="ixv-25634" unitRef="usd">46000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="c7" decimals="-3" id="ixv-25635" unitRef="usd">59000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable contextRef="c0" decimals="-3" id="ixv-25636" unitRef="usd">118000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable contextRef="c6" decimals="-3" id="ixv-25637" unitRef="usd">-190000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable contextRef="c7" decimals="-3" id="ixv-25638" unitRef="usd">496000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c0" decimals="-3" id="ixv-25639" unitRef="usd">444000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized contextRef="c0" decimals="-3" id="ixv-25640" unitRef="usd">55000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized contextRef="c6" decimals="-3" id="ixv-25641" unitRef="usd">-65000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized contextRef="c7" decimals="-3" id="ixv-25642" unitRef="usd">-438000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="-3" id="ixv-25643" unitRef="usd">-9374000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c6" decimals="-3" id="ixv-25644" unitRef="usd">-9691000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c7" decimals="-3" id="ixv-25645" unitRef="usd">-9209000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c0" decimals="-3" id="ixv-25646" unitRef="usd">164000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c6" decimals="-3" id="ixv-25647" unitRef="usd">206000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c7" decimals="-3" id="ixv-25648" unitRef="usd">263000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsForProceedsFromInvestments contextRef="c0" decimals="-3" id="ixv-25649" unitRef="usd">-1652000</us-gaap:PaymentsForProceedsFromInvestments>
    <us-gaap:PaymentsForProceedsFromInvestments contextRef="c6" decimals="-3" id="ixv-25650" unitRef="usd">-4800000</us-gaap:PaymentsForProceedsFromInvestments>
    <us-gaap:PaymentsForProceedsFromInvestments contextRef="c7" decimals="-3" id="ixv-25651" unitRef="usd">7120000</us-gaap:PaymentsForProceedsFromInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c0" decimals="-3" id="ixv-25652" unitRef="usd">1488000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c6" decimals="-3" id="ixv-25653" unitRef="usd">4594000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c7" decimals="-3" id="ixv-25654" unitRef="usd">-7383000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="c0" decimals="-3" id="ixv-25655" unitRef="usd">7898000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="c6" decimals="-3" id="ixv-25656" unitRef="usd">3424000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c0" decimals="-3" id="ixv-25657" unitRef="usd">2000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c6" decimals="-3" id="ixv-25658" unitRef="usd">3000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c0" decimals="-3" id="ixv-25659" unitRef="usd">2000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c6" decimals="-3" id="ixv-25660" unitRef="usd">26000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c0" decimals="-3" id="ixv-25661" unitRef="usd">7902000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c6" decimals="-3" id="ixv-25662" unitRef="usd">3453000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c0" decimals="-3" id="ixv-25663" unitRef="usd">55000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c6" decimals="-3" id="ixv-25664" unitRef="usd">-65000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c7" decimals="-3" id="ixv-25665" unitRef="usd">-438000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c0" decimals="-3" id="ixv-25666" unitRef="usd">16000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c6" decimals="-3" id="ixv-25667" unitRef="usd">-1644000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c7" decimals="-3" id="ixv-25668" unitRef="usd">-16592000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c5" decimals="-3" id="ixv-25669" unitRef="usd">5130000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c20" decimals="-3" id="ixv-25670" unitRef="usd">6839000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c27" decimals="-3" id="ixv-25671" unitRef="usd">23869000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c4" decimals="-3" id="ixv-25672" unitRef="usd">5201000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c5" decimals="-3" id="ixv-25673" unitRef="usd">5130000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c20" decimals="-3" id="ixv-25674" unitRef="usd">6839000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c4" decimals="-3" id="ixv-25675" unitRef="usd">5111000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c5" decimals="-3" id="ixv-25676" unitRef="usd">5041000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c20" decimals="-3" id="ixv-25677" unitRef="usd">6783000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash contextRef="c4" decimals="-3" id="ixv-25678" unitRef="usd">90000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="c5" decimals="-3" id="ixv-25679" unitRef="usd">89000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="c20" decimals="-3" id="ixv-25680" unitRef="usd">56000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="c4" decimals="-3" id="ixv-25681" unitRef="usd">5201000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="c5" decimals="-3" id="ixv-25682" unitRef="usd">5130000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="c20" decimals="-3" id="ixv-25683" unitRef="usd">6839000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <iinn:OtherReceivableInConnectionToPrivatePlacement contextRef="c0" decimals="-3" id="ixv-25684" unitRef="usd">70000</iinn:OtherReceivableInConnectionToPrivatePlacement>
    <iinn:AccruedIssuanceExpenses contextRef="c0" decimals="-3" id="ixv-25685" unitRef="usd">-220000</iinn:AccruedIssuanceExpenses>
    <iinn:FinancialLiabilityPlacementAgentFee contextRef="c0" decimals="-3" id="ixv-25686" unitRef="usd">-69000</iinn:FinancialLiabilityPlacementAgentFee>
    <iinn:ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital contextRef="c0" decimals="-3" id="ixv-25687" unitRef="usd">-254000</iinn:ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital>
    <iinn:ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital contextRef="c6" decimals="-3" id="ixv-25688" unitRef="usd">-73000</iinn:ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital>
    <iinn:NonCashTransactions contextRef="c0" decimals="-3" id="ixv-25689" unitRef="usd">-473000</iinn:NonCashTransactions>
    <iinn:NonCashTransactions contextRef="c6" decimals="-3" id="ixv-25690" unitRef="usd">-73000</iinn:NonCashTransactions>
    <us-gaap:InterestPaidNet contextRef="c0" decimals="-3" id="ixv-25691" unitRef="usd">72000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c6" decimals="-3" id="ixv-25692" unitRef="usd">93000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c7" decimals="-3" id="ixv-25693" unitRef="usd">106000</us-gaap:InterestPaidNet>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c0" id="ixv-17690">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE 1
- GENERAL:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Inspira
                                            Technologies Oxy B.H.N. Ltd (the &#x201c;Company&#x201d;) was incorporated in Israel and commenced
                                            its operations on February 27, 2018. The Company operates in the medical technology industry
                                            in the field of respiratory support technology engaged in the research, development, manufacturing
                                            related activities, and go-to-market activities of proprietary products and technologies.
                                            The Company is developing the following products:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
                                            INSPIRA ART (Augmented Respiratory Technology), which is a respiratory support technology
                                            targeted toward utilizing blood monitoring and direct blood oxygenation to boost patient
                                            saturation levels within minutes while the patient is awake. The aim is to provide an alternative
                                            to invasive mechanical ventilation, associated with high risks, complications, high costs
                                            and high mortality rates.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
                                   &lt;/table&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
                                            HYLA blood sensor, which is a non-invasive optical blood sensor designed to perform real-time
                                            and continuous blood parameter measurements, potentially reducing the need for intermittent
                                            blood samples from patients.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
                                                                                                                              &lt;/table&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
                                            INSPIRA ART100 System, an advanced form of life support system, better known by the medical
                                            industry as a cardiopulmonary bypass system, has been designed for use in procedures requiring
                                            cardiopulmonary bypass for six hours or less.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company&#x2019;s INSPIRA&#x2122; ART100 system received U.S. Food and Drug Administration 510(k) regulatory clearance for cardiopulmonary
bypass procedures and Israeli Medical Equipment Division certification for extra-corporeal membrane oxygenation and cardiopulmonary bypass
procedures. The Company&#x2019;s other products, including the INSPIRA&#x2122; ART and HYLA&#x2122; blood sensor, have not yet been tested
or used in humans and have not been approved by any regulatory entity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;  border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On April 1, 2024, the Company entered into a purchase agreement with two investors in a registered direct offering (the &#x201c;2024 April Offering&#x201d;), pursuant to which the Company issued an aggregate of 1,339,285 of the Company&#x2019;s ordinary shares (&#x201c;Ordinary Shares&#x201d;) at a purchase price of $1.232 per share. The gross proceeds received by the Company from the 2024 April Offering were approximately $1,651. There were no issuance costs.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;  border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On June 14, 2024, the Company entered into a purchase agreement with an individual private investor in a registered direct offering (the &#x201c;2024 June Offering&#x201d;), pursuant to which the Company issued: (i) 941,541 Ordinary Shares at a purchase price of $1.30 per share and (ii) pre-funded warrants (&#x201c;June Pre-Funded Warrants&#x201d;) to purchase up to 1,709,760 Ordinary shares, at a purchase price of $1.30, less $0.001 per June Pre-Funded Warrant. The net proceeds received by the Company from the 2024 June Offering were approximately $3,102, after deducting offering costs in cash, which totaled in approximately $343. In addition, the Company issued the placement agent in the 2024 June Offering (&#x201c;June Placement Agent&#x201d;) warrants equal to a total of 7.0% of the aggregate number of Ordinary Shares sold in the transaction to purchase up to 185,591 Ordinary Shares (the &#x201c;June Placement Agent Warrants&#x201d;). The fair value of the June Placement Agent Warrants on the issuance date was $254 and it was recorded as part of the issuance costs.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;  border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On December 27, 2024, the Company entered into a purchase agreement with several investors in a private placement financing (the &#x201c;December Private Placement&#x201d;), pursuant to which the Company issued (i) an aggregate of 3,950,343 of the Company&#x2019;s Ordinary Shares at a purchase price of $0.70 per share, and (ii) pre-funded warrants (the &#x201c;December Pre-Funded Warrants&#x201d;) to purchase up to 658,372 Ordinary shares, at a purchase price of $0.70, less $0.001 per December Pre-Funded Warrant. In addition, pursuant to a certain securities purchase agreement, the Company issued warrants to the investors to purchase up to an aggregate of 4,608,715 Ordinary Shares at an exercise price of $1.10 per share. The gross proceeds received by the Company from the December Private Placement were approximately $3,228, before deducting placement agent commissions and additional offering costs which totaled in approximately $233. In addition, The Company agreed to pay fees of 4% from the funds that may be received in an event of the exercise of the Company&#x2019;s private warrants issued in December 2024 Private Placement, which created a financial liability in amount of $69 which is the total potential amount (Note 10-A).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The accompanying financial statements (the &#x201c;Financial Statements&#x201d;)
have been prepared assuming that the Company will continue as a going concern. To date, the Company is in its development stage. Therefore,
the Company has suffered recurring losses from operations and negative cash flows from operations since inception. As of December 31,
2024, the Company had incurred accumulated losses of $67 million and expects to continue to fund its operations through fundings such
as issuance of convertible securities, Ordinary Shares and warrants and through Israeli governmental grants. There is no assurance that
such financing will be obtained. Considering the above, our dependence on external funding for our operations raises a substantial doubt
about our ability to continue as a going concern. The Financial Statements do not include any adjustments that might result from the outcome
of these uncertainties.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Our
                                            offices are located in Ra&#x2019;anana, Israel. On October 7, 2023, Hamas terrorists infiltrated
                                            Israel&#x2019;s southern border from the Gaza Strip and conducted a series of attacks on civilian
                                            and military targets. Following the attack, Israel declared war against Hamas and the Israeli
                                            military began to call-up reservists for an active duty. Other regional hostilities, since
                                            October 7, 2023, concurrently became more pronounced. This includes and has included a northern
                                            front war igniting between Israel and Hezbollah, which as of February 24, 2025 we are under
                                            a ceasefire, hostilities between Israel and Iran, which have included Iranian strikes against
                                            Israel in April 2024 and October 2024, and subsequent retaliation by Israel to both instances,
                                            and a continued conflict between Israel and the Houthi Movement in Yemen.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
of the date of these Financial Statements, these events have no material impact on the Company&#x2019;s operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Although
                                            we do not currently conduct business in Russia and Ukraine, the escalation of geopolitical
                                            instability in Russia and Ukraine as well as currency fluctuations in the Russian Ruble has
                                            had a negative impact on worldwide markets. Such impact may negatively impact our supply
                                            chain, our operations and future growth prospects in that region.&#160;As a result of the
                                            crisis in Ukraine,&#160;both the U.S. and other countries have implemented sanctions against
                                            certain Russian individuals and entities. Our global operations expose us to risks that could
                                            adversely affect our business, financial condition, results of operations, cash flows or
                                            the market price of our securities, including the potential for increased tensions between
                                            Russia and other countries resulting from the current situation involving Russia and Ukraine,
                                            tariffs, economic sanctions and import-export restrictions imposed, and retaliatory actions,
                                            as well as the potential negative impact on our potential business and sales in the region.
                                            Current geopolitical instability in Russia and Ukraine and related sanctions by the U.S.
                                            and other governments against certain companies and individuals may hinder our ability to
                                            conduct business with potential customers and vendors in these countries.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;These
                                            Financial Statements were authorized by the Board of Directors on March 6, 2025.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c32"
      decimals="0"
      id="ixv-25694"
      unitRef="shares">1339285</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="c33"
      decimals="3"
      id="ixv-25695"
      unitRef="usdPershares">1.232</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="c32" decimals="-3" id="ixv-25696" unitRef="usd">1651000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c34"
      decimals="0"
      id="ixv-25697"
      unitRef="shares">941541</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="c35"
      decimals="2"
      id="ixv-25698"
      unitRef="usdPershares">1.3</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c36"
      decimals="0"
      id="ixv-25699"
      unitRef="shares">1709760</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="c37"
      decimals="2"
      id="ixv-25700"
      unitRef="usdPershares">1.3</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c38"
      decimals="3"
      id="ixv-25701"
      unitRef="usdPershares">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="c39" decimals="-3" id="ixv-25702" unitRef="usd">3102000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:PartnersCapitalAccountPublicSaleOfUnitsNetOfOfferingCosts contextRef="c39" decimals="-3" id="ixv-25703" unitRef="usd">343000</us-gaap:PartnersCapitalAccountPublicSaleOfUnitsNetOfOfferingCosts>
    <iinn:PercentageOfOrdinaryShares contextRef="c40" decimals="3" id="ixv-25704" unitRef="pure">0.07</iinn:PercentageOfOrdinaryShares>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c40"
      decimals="0"
      id="ixv-25705"
      unitRef="shares">185591</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <iinn:PlacementAgentWarrantsFairValue contextRef="c40" decimals="-3" id="ixv-25706" unitRef="usd">254000</iinn:PlacementAgentWarrantsFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c41"
      decimals="0"
      id="ixv-25707"
      unitRef="shares">3950343</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="c42"
      decimals="2"
      id="ixv-25708"
      unitRef="usdPershares">0.7</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c43"
      decimals="0"
      id="ixv-25709"
      unitRef="shares">658372</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="c44"
      decimals="2"
      id="ixv-25710"
      unitRef="usdPershares">0.7</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c45"
      decimals="3"
      id="ixv-25711"
      unitRef="usdPershares">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c46"
      decimals="0"
      id="ixv-25712"
      unitRef="shares">4608715</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockOptionExercisePriceIncrease
      contextRef="c47"
      decimals="2"
      id="ixv-25713"
      unitRef="usdPershares">1.1</us-gaap:StockOptionExercisePriceIncrease>
    <iinn:AggregateProceedsReceived contextRef="c41" decimals="-3" id="ixv-25714" unitRef="usd">3228000</iinn:AggregateProceedsReceived>
    <iinn:AdditionalOfferingCosts contextRef="c48" decimals="-3" id="ixv-25715" unitRef="usd">233000</iinn:AdditionalOfferingCosts>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c48" decimals="-3" id="ixv-25716" unitRef="usd">69000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax contextRef="c4" decimals="-6" id="ixv-25717" unitRef="usd">67000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c0" id="ixv-17881">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE 2
&lt;/b&gt;- &lt;b&gt;SIGNIFICANT ACCOUNTING POLICIES:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
accompanying Financial Statements have been prepared in conformity with the U.S. GAAP. The significant accounting policies followed in
the preparation of the Financial Statements are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;A.
Use of estimates:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
preparation of Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the Financial Statements,
and the reported amounts of expenses during the reporting period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Items
subject to such estimates and assumptions include:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;stock-based
                                            compensation expense;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
                                                                                                                                                              &lt;/table&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;fair
                                            value financial liabilities;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
                                                                                                                                                              &lt;/table&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;recognition,
                                            measurement, and disclosure of contingent liabilities;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
                                                                                                                                                                                                &lt;/table&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Interest
                                            rate used for lease liability measurement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
of the date of issuance of the Financial Statements, the Company is not aware of any material specific events or circumstances that would
require it to update its estimates, judgments, or to revise the carrying values of its assets or liabilities. These estimates may change,
as new events occur and additional information is obtained, and are recognized in the Financial Statements as soon as they become known.
Actual results could differ from those estimates and any such differences may be material to the Company&#x2019;s Financial Statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;B.
&lt;span&gt;Foreign Currency&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
currency of the primary economic environment in which the operations of the Company are conducted is the U.S. dollar (&#x201c;USD&#x201d;).
The Company&#x2019;s funding and expected revenues are mostly in USD. Thus, the functional currency of the Company is in USD.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Transactions
and balances originally denominated in USD are presented at their original amounts. Balances in non-USD currencies are translated into
USD using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-USD transactions and other
items in the statements of income (indicated below), the following exchange rates are used: (i) for transactions &#x2013; exchange rates
at transaction dates or average exchange rates; and (ii) for other items (derived from non-monetary balance sheet items such as depreciation
and amortization) &#x2013; historical exchange rates. Currency transaction gains and losses are presented in financial expenses (income),
net as appropriate. The functional currency of the Company is USD.&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;C.
Property, Plant, and Equipment&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Property
and equipment are stated at cost. Depreciation is computed based on the straight-line method, over the estimated useful life of the assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Annual
rates of depreciation are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 90%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Computers&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;33&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;R&amp;amp;D equipment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Furniture and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6-15&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Leasehold Improvements&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;D.
Inventory&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Inventories
are stated at the lower of cost or net realizable value. Inventory write-offs are provided to cover risks arising from slow-moving items,
technological obsolescence, excess inventories, discontinued products, and for market prices lower than cost, if any.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company periodically evaluates the quantities on hand relative to historical and projected sales volume (which is determined based on
an assumption of future demand and market conditions) and the age of the inventory. At the point of the loss recognition, a new lower
cost basis for that inventory has been established.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cost
is determined for all types of inventory using the moving average cost method plus indirect costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;E.
Leases&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company implemented Accounting Standards Update (&#x201c;ASU&#x201d;) 2016-02, Leases (Topic 842) (&#x201c;ASU 2016-02&#x201d;) using the
modified retrospective approach for all lease arrangements as of such date. The Company leases office space and vehicles under operating
leases.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Arrangements
meeting the definition of a lease are classified as operating or financing leases and are recorded on the balance sheet as both a right
of use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease
or the Company&#x2019;s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and
the right of use asset is amortized over the lease term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
lease liability was measured at the present value of the remaining lease payments, discounted using the Company&#x2019;s incremental borrowing
rate. The weighted-average&#160;rate applied was 9.60%. Right-of-use&#160;assets were measured at an amount equal to the lease liability.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
operating leases, interest on the lease liability and the amortization of the right of use asset result in straight-line&#160;rent expense
over the lease term. Variable lease expenses are recorded when incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;F.
Research and Development Costs.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research
and development expenses consist primarily of payroll, payroll related expenses, subcontractors, and materials. Costs are expensed as
incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;G.
Government Grants &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company receives royalty-bearing grants from the Israeli Innovation Authority (&#x201c;IIA&#x201d;) for approved research and development
projects Under Israeli law, royalties on the revenues derived from products and services developed using such grants, are payable to
the Israeli Government.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
grants are linked to the exchange rate of the dollar to the New Israeli Shekel and bear interest of the Secured Overnight Financing Rate
(&#x201c;SOFR&#x201d;) per year (SOFR is a benchmark interest rate which replaced LIBOR).&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
amounts of grants received and recorded into income should be disclosed for each period presented. The research and development grants
are presented in the statement of operations as an offset to related research and development expenses. Companies are required to pay
royalties in connection with such grants at specified rates, up to the total dollar-linked amount of such grants. &lt;span&gt;research
and development (&#x201c;R&amp;amp;D&#x201d;).&#160;The Company did not generate sales as of December 31, 2024; therefore, no liability was
recorded in these Financial Statements.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;H.
Finance Income and Expenses.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Finance
income is composed of interest on deposits and revaluation of financial liabilities at fair value, while finance expenses are composed
of the revaluation of certain financial liabilities at fair value, bank charges and net currency exchange rates differences.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;I.
Current Taxes&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
current tax liability is measured using the tax rates and tax laws that have been enacted or substantively enacted by the reporting date
as well as adjustments required in connection with the tax liability in respect of previous years. The Company has no tax liability due
to its carry forward losses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;J.
Share-Based Compensation.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Share-based
compensation expenses related to employees, directors and subcontractors&#x2019; options or restricted share units (&#x201c;RSU&#x201d;)
which recognized based on their fair value, which is based on the fair value of the underlying Ordinary Shares as to the de-minimis exercise
price using the graded vesting method.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company recognizes compensation expense for grants of share-based awards to its employees based on the estimated fair value on the grant
date. Compensation cost for awards is recognized over the requisite service period, which approximates the vesting period. Share-based
compensation is included in research and development, selling and marketing and general and administrative expenses. Forfeitures of equity
grants are recognized as incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;All
issuances of stock options or other equity instruments to non-employees as consideration for goods or services received by the Company
are accounted for based on the fair value of the equity instruments issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;K.
Warrants and Pre-Funded Warrants&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company issues warrants and pre-funded warrants as part of its financing activities or compensation arrangements. Warrants are derivative
financial instruments that entitle the holder to purchase a specified number of the Company&#x2019;s Ordinary Shares at a predetermined
exercise price. Warrants and pre-funded warrants issued by the Company may have various terms, including expiration dates, exercise prices,
and conditions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company classifies warrants as either equity or liabilities upon issuance, based on specific terms and conditions and in accordance with
Accounting Standard Codification (&#x201c;ASC&#x201d;) 815, Derivatives and Hedging. Warrants and pre-funded warrants are classified as
equity if they meet the criteria for equity classification outlined in ASC 815-40. Otherwise, warrants are classified as liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;L.
Severance&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Israeli
labor law generally requires payment of severance pay upon dismissal of an employee or upon termination of employment in certain other
circumstances. The Company&#x2019;s pension and severance pay liabilities are covered mainly by insurance policies. Pursuant to section
14 of the Israeli Severance Compensation Act, 1963 (&#x201c;Section 14&#x201d;), the Company&#x2019;s employees are entitled to monthly
deposits, at a rate of 8.33% of their monthly salary, made in their name with insurance companies. Payments in accordance with Section
14 relieve the Company from any future severance payments in respect of those employees and, as such, the Company may only utilize the
insurance policies for the purpose of paying severance pay.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;M.
Basic and Diluted Loss Per Share&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Basic
and diluted loss per share is calculated by dividing the loss attributable to equity holders of the Company by the weighted average number
of Ordinary Shares and pre-funded warrants outstanding during the financial year, adjusted for Ordinary Shares and pre-funded warrants
issued during the year, if applicable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;N.
Fair Value Measurements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company measures and discloses fair value in accordance with the Financial Accounting Standards Board (&#x201c;FASB&#x201d;), ASC 820,
Fair Value Measurements and Disclosures (&#x201c;ASC 820&#x201d;). ASC 820 defines fair value, establishes a framework and gives guidance
regarding the methods used for measuring fair value, and expands disclosures about fair value measurements. Fair value is an exit price,
representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market
participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions
that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, there exists a three-tier
fair-value hierarchy, which prioritizes the inputs used in measuring fair value as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
1 &#x2013; unadjusted quoted prices are available in active markets for identical assets or liabilities that the Company has the ability
to access as of the measurement date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
2 &#x2013; pricing inputs are other than quoted prices in active markets that are directly observable for the asset or liability or indirectly
observable through corroboration with observable market data.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
3 &#x2013; pricing inputs are unobservable for the non-financial asset or liability and only used when there is little, if any, market
activity for the non-financial asset or liability at the measurement date. The inputs into the determination of fair value require significant
management judgment or estimation. Level 3 inputs are considered as the lowest priority within the fair value hierarchy.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;This
hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining
fair value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
fair value of cash is based on its demand value, which is equal to its carrying value. Additionally, the carrying value of all other
short-term monetary assets and liabilities are estimated to be equal to their fair value due to the short-term nature of these instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;O.
Concentration of Credit Risk&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company maintains certain cash balances in a well-known Israeli banks and U.S based banks.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Part
of the Company&#x2019;s operating expenses are denominated in New Israeli Shekel (&#x201c;NIS&#x201d;), and therefore, subject to foreign
currency risk.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;P.
Cash and Cash Equivalent&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cash
equivalents are highly liquid investments that are readily convertible into cash, typically with an original maturity of three months
or less from &lt;span&gt;the date of purchase that are not restricted as to withdrawal or use and are readily
convertible to known amounts of cash.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; "&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; "&gt;Restricted
cash consists of funds that are contractually restricted to bank guarantee due to rental agreements. The Company has presented restricted
cash separately from cash and cash equivalents in the balance sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; "&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Bank
deposits with maturities of more than three months, but less than one year, and which are not restricted are included in short-term deposits.
Such deposits are stated at cost which approximates market value. As of December 31, 2024 and December 31, 2023, the Company had short-term
deposits in the amounts of $0.7 million and $2.3 million, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Q.
Segment Information&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; "&gt;The
Company has a single operating and reportable segment. The Company&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;), who is
the Chief Executive Officer, evaluates the performance of its business based on financial data consistent with the presentation in the
accompanying Financial Statements for the purposes of making operating decisions, assessing financial performance, and allocating resources.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;R.
New accounting Pronouncements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; "&gt;&lt;b&gt;&lt;i&gt;Accounting
Standards Adopted in 2024&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; "&gt;In
March 2023, the FASB issued Accounting Standard Updated No. 2023-01 &#x201c;Lease (Topic 842)&#x201d;. Topic 842 requires that entities
determine whether a related party arrangement between entities under common control (hereinafter referred to as a common control arrangement)
is a lease. If the arrangement is determined to be a lease, an entity must classify and account for the lease on the same basis as an
arrangement with an unrelated party (on the basis of legally enforceable terms and conditions).That represents a change from the requirements
of Topic 840, Leases, which required that an entity classify and account for an arrangement on the basis of economic substance when those
terms and conditions were affected by the related party nature of the arrangement. The amendments in this Update affect all lessees that
are a party to a lease between entities under common control in which there are leasehold improvements. The amendments apply to all entities
(that is, public business entities, private companies, not-for-profit. The Company adopted ASU 2023-01 on January 1, 2024, its adoption
did not have a material impact on the Financial Statements and related disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; "&gt;In
June 2022, the FASB issued ASU 2022-03, Fair Value Measurement (Topic 820), &#x201c;Fair Value Measurement of Equity Securities Subject
to Contractual Sale Restrictions&#x201d; which clarifies that contractual restrictions on equity security sales are not considered part
of the security unit of account and, therefore, are not considered in measuring fair value. In addition, the restrictions cannot be recognized
and measured as separate units of account. Disclosures on such restrictions are also required. The amendments are effective for Fiscal
years beginning after December 15, 2023, and interim periods within those fiscal years on a prospectively basis. The Company expects
that ASU 2022-03 will not have a material impact on its Financial Statements and related disclosures. &lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; "&gt;In
November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This ASU expands
public entities&#x2019; segment disclosures by requiring disclosure of significant segment expenses that are regularly provided to the
CODM and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment
items, and interim disclosures of a reportable segment&#x2019;s profit or loss and assets. All disclosure requirements under ASU 2023-07
are also required for public entities with a single reportable segment. The ASU&#x2019;s amendments are effective for all public entities
for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early
adoption permitted. We are currently evaluating the impact of this pronouncement on our Financial Statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; "&gt;&lt;b&gt;&lt;i&gt;Accounting
Pronouncements Issued but Not Yet Adopted&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; "&gt;In
December 2023, the FASB issued ASU 2023-08, Intangibles&#x2014;Goodwill and Other&#x2014;Crypto Assets (Subtopic 350-60): Accounting for
and Disclosure of Crypto Assets, which addresses the accounting and disclosure requirements for certain crypto assets. This ASU requires
entities to subsequently measure certain crypto assets at fair value, with changes in fair value recorded in net income in each reporting
period. In addition, entities are required to provide additional disclosures about the holdings of certain crypto assets. The ASU&#x2019;s
amendments are effective for all entities holding assets that meet certain scope criteria for fiscal years beginning after December 15,
2024, including interim periods within those years. Early adoption is permitted for both interim and annual periods. If an entity adopts
the amendments in an interim period, it must adopt them as of the beginning of the fiscal year that includes that interim period. We
do not expect this pronouncement to have a material impact on our Financial Statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; "&gt;In
December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. Under this ASU, public
entities must annually (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling
items that meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than five percent of the amount
computed by multiplying pretax income or loss by the applicable statutory income tax rate). This ASU&#x2019;s amendments are effective
for all entities that are subject to Topic 740, Income Taxes, for annual periods beginning after December 15, 2024, with early adoption
permitted. We are currently evaluating the impact of this pronouncement on our disclosures.&lt;/span&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="c0" id="ixv-17892">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;A.
Use of estimates:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
preparation of Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the Financial Statements,
and the reported amounts of expenses during the reporting period.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Items
subject to such estimates and assumptions include:&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;stock-based
                                            compensation expense;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
                                                                                                                                                              &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;fair
                                            value financial liabilities;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
                                                                                                                                                              &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;recognition,
                                            measurement, and disclosure of contingent liabilities;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
                                                                                                                                                                                                &lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Interest
                                            rate used for lease liability measurement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
of the date of issuance of the Financial Statements, the Company is not aware of any material specific events or circumstances that would
require it to update its estimates, judgments, or to revise the carrying values of its assets or liabilities. These estimates may change,
as new events occur and additional information is obtained, and are recognized in the Financial Statements as soon as they become known.
Actual results could differ from those estimates and any such differences may be material to the Company&#x2019;s Financial Statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c0" id="ixv-17968">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;B.
&lt;span&gt;Foreign Currency&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
currency of the primary economic environment in which the operations of the Company are conducted is the U.S. dollar (&#x201c;USD&#x201d;).
The Company&#x2019;s funding and expected revenues are mostly in USD. Thus, the functional currency of the Company is in USD.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Transactions
and balances originally denominated in USD are presented at their original amounts. Balances in non-USD currencies are translated into
USD using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-USD transactions and other
items in the statements of income (indicated below), the following exchange rates are used: (i) for transactions &#x2013; exchange rates
at transaction dates or average exchange rates; and (ii) for other items (derived from non-monetary balance sheet items such as depreciation
and amortization) &#x2013; historical exchange rates. Currency transaction gains and losses are presented in financial expenses (income),
net as appropriate. The functional currency of the Company is USD.&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c0" id="ixv-18029">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;C.
Property, Plant, and Equipment&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Property
and equipment are stated at cost. Depreciation is computed based on the straight-line method, over the estimated useful life of the assets.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Annual
rates of depreciation are as follows:&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 90%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Computers&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;33&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;R&amp;amp;D equipment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Furniture and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6-15&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Leasehold Improvements&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <iinn:ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock contextRef="c0" id="ixv-18040">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Annual
rates of depreciation are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 90%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Computers&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;33&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;R&amp;amp;D equipment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Furniture and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6-15&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Leasehold Improvements&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</iinn:ScheduleOfDepreciationOnStraightLineMethodOverTheEstimatedUsefulLifeOfTheAssetsTableTextBlock>
    <iinn:AnnualDepreciationRatesOfPropertyPlantAndEquipment contextRef="c50" decimals="2" id="ixv-25718" unitRef="pure">0.33</iinn:AnnualDepreciationRatesOfPropertyPlantAndEquipment>
    <iinn:AnnualDepreciationRatesOfPropertyPlantAndEquipment contextRef="c51" decimals="2" id="ixv-25719" unitRef="pure">0.20</iinn:AnnualDepreciationRatesOfPropertyPlantAndEquipment>
    <iinn:AnnualDepreciationRatesOfPropertyPlantAndEquipment contextRef="c52" decimals="2" id="ixv-25720" unitRef="pure">0.06</iinn:AnnualDepreciationRatesOfPropertyPlantAndEquipment>
    <iinn:AnnualDepreciationRatesOfPropertyPlantAndEquipment contextRef="c53" decimals="2" id="ixv-25721" unitRef="pure">0.15</iinn:AnnualDepreciationRatesOfPropertyPlantAndEquipment>
    <iinn:AnnualDepreciationRatesOfPropertyPlantAndEquipment contextRef="c54" decimals="2" id="ixv-25722" unitRef="pure">0.10</iinn:AnnualDepreciationRatesOfPropertyPlantAndEquipment>
    <us-gaap:InventoryPolicyTextBlock contextRef="c0" id="ixv-18093">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;D.
Inventory&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Inventories
are stated at the lower of cost or net realizable value. Inventory write-offs are provided to cover risks arising from slow-moving items,
technological obsolescence, excess inventories, discontinued products, and for market prices lower than cost, if any.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company periodically evaluates the quantities on hand relative to historical and projected sales volume (which is determined based on
an assumption of future demand and market conditions) and the age of the inventory. At the point of the loss recognition, a new lower
cost basis for that inventory has been established.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cost
is determined for all types of inventory using the moving average cost method plus indirect costs.&lt;/span&gt;&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c0" id="ixv-18114">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;E.
Leases&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company implemented Accounting Standards Update (&#x201c;ASU&#x201d;) 2016-02, Leases (Topic 842) (&#x201c;ASU 2016-02&#x201d;) using the
modified retrospective approach for all lease arrangements as of such date. The Company leases office space and vehicles under operating
leases.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Arrangements
meeting the definition of a lease are classified as operating or financing leases and are recorded on the balance sheet as both a right
of use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease
or the Company&#x2019;s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and
the right of use asset is amortized over the lease term.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
lease liability was measured at the present value of the remaining lease payments, discounted using the Company&#x2019;s incremental borrowing
rate. The weighted-average&#160;rate applied was 9.60%. Right-of-use&#160;assets were measured at an amount equal to the lease liability.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
operating leases, interest on the lease liability and the amortization of the right of use asset result in straight-line&#160;rent expense
over the lease term. Variable lease expenses are recorded when incurred.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c49" decimals="4" id="ixv-25723" unitRef="pure">0.096</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c0" id="ixv-18140">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;F.
Research and Development Costs.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research
and development expenses consist primarily of payroll, payroll related expenses, subcontractors, and materials. Costs are expensed as
incurred.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:GovernmentAssistancePolicyTextBlock contextRef="c0" id="ixv-18151">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;G.
Government Grants &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company receives royalty-bearing grants from the Israeli Innovation Authority (&#x201c;IIA&#x201d;) for approved research and development
projects Under Israeli law, royalties on the revenues derived from products and services developed using such grants, are payable to
the Israeli Government.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
grants are linked to the exchange rate of the dollar to the New Israeli Shekel and bear interest of the Secured Overnight Financing Rate
(&#x201c;SOFR&#x201d;) per year (SOFR is a benchmark interest rate which replaced LIBOR).&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
amounts of grants received and recorded into income should be disclosed for each period presented. The research and development grants
are presented in the statement of operations as an offset to related research and development expenses. Companies are required to pay
royalties in connection with such grants at specified rates, up to the total dollar-linked amount of such grants. &lt;span&gt;research
and development (&#x201c;R&amp;amp;D&#x201d;).&#160;The Company did not generate sales as of December 31, 2024; therefore, no liability was
recorded in these Financial Statements.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;</us-gaap:GovernmentAssistancePolicyTextBlock>
    <iinn:FinanceIncomeAndExpensesPolicyTextBlock contextRef="c0" id="ixv-18213">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;H.
Finance Income and Expenses.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Finance
income is composed of interest on deposits and revaluation of financial liabilities at fair value, while finance expenses are composed
of the revaluation of certain financial liabilities at fair value, bank charges and net currency exchange rates differences.&lt;/span&gt;&lt;/p&gt;</iinn:FinanceIncomeAndExpensesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c0" id="ixv-18224">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;I.
Current Taxes&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
current tax liability is measured using the tax rates and tax laws that have been enacted or substantively enacted by the reporting date
as well as adjustments required in connection with the tax liability in respect of previous years. The Company has no tax liability due
to its carry forward losses.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c0" id="ixv-18236">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;J.
Share-Based Compensation.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Share-based
compensation expenses related to employees, directors and subcontractors&#x2019; options or restricted share units (&#x201c;RSU&#x201d;)
which recognized based on their fair value, which is based on the fair value of the underlying Ordinary Shares as to the de-minimis exercise
price using the graded vesting method.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company recognizes compensation expense for grants of share-based awards to its employees based on the estimated fair value on the grant
date. Compensation cost for awards is recognized over the requisite service period, which approximates the vesting period. Share-based
compensation is included in research and development, selling and marketing and general and administrative expenses. Forfeitures of equity
grants are recognized as incurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;All
issuances of stock options or other equity instruments to non-employees as consideration for goods or services received by the Company
are accounted for based on the fair value of the equity instruments issued.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:DerivativesPolicyTextBlock contextRef="c0" id="ixv-18257">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;K.
Warrants and Pre-Funded Warrants&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company issues warrants and pre-funded warrants as part of its financing activities or compensation arrangements. Warrants are derivative
financial instruments that entitle the holder to purchase a specified number of the Company&#x2019;s Ordinary Shares at a predetermined
exercise price. Warrants and pre-funded warrants issued by the Company may have various terms, including expiration dates, exercise prices,
and conditions.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company classifies warrants as either equity or liabilities upon issuance, based on specific terms and conditions and in accordance with
Accounting Standard Codification (&#x201c;ASC&#x201d;) 815, Derivatives and Hedging. Warrants and pre-funded warrants are classified as
equity if they meet the criteria for equity classification outlined in ASC 815-40. Otherwise, warrants are classified as liabilities.&lt;/span&gt;&lt;/p&gt;</us-gaap:DerivativesPolicyTextBlock>
    <iinn:SeverancePolicyTextBlock contextRef="c0" id="ixv-18273">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;L.
Severance&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Israeli
labor law generally requires payment of severance pay upon dismissal of an employee or upon termination of employment in certain other
circumstances. The Company&#x2019;s pension and severance pay liabilities are covered mainly by insurance policies. Pursuant to section
14 of the Israeli Severance Compensation Act, 1963 (&#x201c;Section 14&#x201d;), the Company&#x2019;s employees are entitled to monthly
deposits, at a rate of 8.33% of their monthly salary, made in their name with insurance companies. Payments in accordance with Section
14 relieve the Company from any future severance payments in respect of those employees and, as such, the Company may only utilize the
insurance policies for the purpose of paying severance pay.&lt;/span&gt;&lt;/p&gt;</iinn:SeverancePolicyTextBlock>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent contextRef="c0" decimals="4" id="ixv-25724" unitRef="pure">0.0833</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c0" id="ixv-18323">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;M.
Basic and Diluted Loss Per Share&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Basic
and diluted loss per share is calculated by dividing the loss attributable to equity holders of the Company by the weighted average number
of Ordinary Shares and pre-funded warrants outstanding during the financial year, adjusted for Ordinary Shares and pre-funded warrants
issued during the year, if applicable.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c0" id="ixv-18334">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;N.
Fair Value Measurements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company measures and discloses fair value in accordance with the Financial Accounting Standards Board (&#x201c;FASB&#x201d;), ASC 820,
Fair Value Measurements and Disclosures (&#x201c;ASC 820&#x201d;). ASC 820 defines fair value, establishes a framework and gives guidance
regarding the methods used for measuring fair value, and expands disclosures about fair value measurements. Fair value is an exit price,
representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market
participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions
that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, there exists a three-tier
fair-value hierarchy, which prioritizes the inputs used in measuring fair value as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
1 &#x2013; unadjusted quoted prices are available in active markets for identical assets or liabilities that the Company has the ability
to access as of the measurement date.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
2 &#x2013; pricing inputs are other than quoted prices in active markets that are directly observable for the asset or liability or indirectly
observable through corroboration with observable market data.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Level
3 &#x2013; pricing inputs are unobservable for the non-financial asset or liability and only used when there is little, if any, market
activity for the non-financial asset or liability at the measurement date. The inputs into the determination of fair value require significant
management judgment or estimation. Level 3 inputs are considered as the lowest priority within the fair value hierarchy.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;This
hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining
fair value.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
fair value of cash is based on its demand value, which is equal to its carrying value. Additionally, the carrying value of all other
short-term monetary assets and liabilities are estimated to be equal to their fair value due to the short-term nature of these instruments.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c0" id="ixv-18373">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;O.
Concentration of Credit Risk&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company maintains certain cash balances in a well-known Israeli banks and U.S based banks.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Part
of the Company&#x2019;s operating expenses are denominated in New Israeli Shekel (&#x201c;NIS&#x201d;), and therefore, subject to foreign
currency risk.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c0" id="ixv-18429">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;P.
Cash and Cash Equivalent&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cash
equivalents are highly liquid investments that are readily convertible into cash, typically with an original maturity of three months
or less from &lt;span&gt;the date of purchase that are not restricted as to withdrawal or use and are readily
convertible to known amounts of cash.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; "&gt;Restricted
cash consists of funds that are contractually restricted to bank guarantee due to rental agreements. The Company has presented restricted
cash separately from cash and cash equivalents in the balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Bank
deposits with maturities of more than three months, but less than one year, and which are not restricted are included in short-term deposits.
Such deposits are stated at cost which approximates market value. As of December 31, 2024 and December 31, 2023, the Company had short-term
deposits in the amounts of $0.7 million and $2.3 million, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ShortTermInvestments contextRef="c4" decimals="-5" id="ixv-25725" unitRef="usd">700000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments contextRef="c5" decimals="-5" id="ixv-25726" unitRef="usd">2300000</us-gaap:ShortTermInvestments>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c0" id="ixv-18452">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Q.
Segment Information&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; "&gt;The
Company has a single operating and reportable segment. The Company&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;), who is
the Chief Executive Officer, evaluates the performance of its business based on financial data consistent with the presentation in the
accompanying Financial Statements for the purposes of making operating decisions, assessing financial performance, and allocating resources.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0" id="ixv-18465">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;R.
New accounting Pronouncements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; "&gt;&lt;b&gt;&lt;i&gt;Accounting
Standards Adopted in 2024&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; "&gt;In
March 2023, the FASB issued Accounting Standard Updated No. 2023-01 &#x201c;Lease (Topic 842)&#x201d;. Topic 842 requires that entities
determine whether a related party arrangement between entities under common control (hereinafter referred to as a common control arrangement)
is a lease. If the arrangement is determined to be a lease, an entity must classify and account for the lease on the same basis as an
arrangement with an unrelated party (on the basis of legally enforceable terms and conditions).That represents a change from the requirements
of Topic 840, Leases, which required that an entity classify and account for an arrangement on the basis of economic substance when those
terms and conditions were affected by the related party nature of the arrangement. The amendments in this Update affect all lessees that
are a party to a lease between entities under common control in which there are leasehold improvements. The amendments apply to all entities
(that is, public business entities, private companies, not-for-profit. The Company adopted ASU 2023-01 on January 1, 2024, its adoption
did not have a material impact on the Financial Statements and related disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; "&gt;In
June 2022, the FASB issued ASU 2022-03, Fair Value Measurement (Topic 820), &#x201c;Fair Value Measurement of Equity Securities Subject
to Contractual Sale Restrictions&#x201d; which clarifies that contractual restrictions on equity security sales are not considered part
of the security unit of account and, therefore, are not considered in measuring fair value. In addition, the restrictions cannot be recognized
and measured as separate units of account. Disclosures on such restrictions are also required. The amendments are effective for Fiscal
years beginning after December 15, 2023, and interim periods within those fiscal years on a prospectively basis. The Company expects
that ASU 2022-03 will not have a material impact on its Financial Statements and related disclosures. &lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; "&gt;In
November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This ASU expands
public entities&#x2019; segment disclosures by requiring disclosure of significant segment expenses that are regularly provided to the
CODM and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment
items, and interim disclosures of a reportable segment&#x2019;s profit or loss and assets. All disclosure requirements under ASU 2023-07
are also required for public entities with a single reportable segment. The ASU&#x2019;s amendments are effective for all public entities
for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early
adoption permitted. We are currently evaluating the impact of this pronouncement on our Financial Statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; "&gt;&lt;b&gt;&lt;i&gt;Accounting
Pronouncements Issued but Not Yet Adopted&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; "&gt;In
December 2023, the FASB issued ASU 2023-08, Intangibles&#x2014;Goodwill and Other&#x2014;Crypto Assets (Subtopic 350-60): Accounting for
and Disclosure of Crypto Assets, which addresses the accounting and disclosure requirements for certain crypto assets. This ASU requires
entities to subsequently measure certain crypto assets at fair value, with changes in fair value recorded in net income in each reporting
period. In addition, entities are required to provide additional disclosures about the holdings of certain crypto assets. The ASU&#x2019;s
amendments are effective for all entities holding assets that meet certain scope criteria for fiscal years beginning after December 15,
2024, including interim periods within those years. Early adoption is permitted for both interim and annual periods. If an entity adopts
the amendments in an interim period, it must adopt them as of the beginning of the fiscal year that includes that interim period. We
do not expect this pronouncement to have a material impact on our Financial Statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; "&gt;In
December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. Under this ASU, public
entities must annually (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling
items that meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than five percent of the amount
computed by multiplying pretax income or loss by the applicable statutory income tax rate). This ASU&#x2019;s amendments are effective
for all entities that are subject to Topic 740, Income Taxes, for annual periods beginning after December 15, 2024, with early adoption
permitted. We are currently evaluating the impact of this pronouncement on our disclosures.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:DepositLiabilitiesDisclosuresTextBlock contextRef="c0" id="ixv-18554">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
3 &#x2013; DEPOSITS:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company&#x2019;s deposits consist of short-term bank deposits with maturities of more than three months but less than one year. The deposits
bear annual interest. &lt;span&gt;Interest earned is recorded as finance income, net in the statement of operations
during the years for which the Company held short-term deposits.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
of December 31, 2024, the Company had a deposit in NIS at Bank Leumi in the amount of $668, including interest that bore a fixed annual
interest of 4.108%.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
of December 31, 2023, the Company had a deposit in USD at Bank Leumi in the amount of $2,040, including interest that bore fixed annual
interest of 6.18% and a deposit in NIS in the amount of $280 that bore fixed annual interest of 4.85%.&lt;/span&gt;&lt;/p&gt;</us-gaap:DepositLiabilitiesDisclosuresTextBlock>
    <us-gaap:Deposits contextRef="c55" decimals="-3" id="ixv-25727" unitRef="usd">668000</us-gaap:Deposits>
    <us-gaap:ShortTermDebtPercentageBearingFixedInterestRate contextRef="c56" decimals="5" id="ixv-25728" unitRef="pure">0.04108</us-gaap:ShortTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:Deposits contextRef="c57" decimals="-3" id="ixv-25729" unitRef="usd">2040000</us-gaap:Deposits>
    <us-gaap:ShortTermDebtPercentageBearingFixedInterestRate contextRef="c58" decimals="4" id="ixv-25730" unitRef="pure">0.0618</us-gaap:ShortTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:Deposits contextRef="c59" decimals="-3" id="ixv-25731" unitRef="usd">280000</us-gaap:Deposits>
    <us-gaap:ShortTermDebtPercentageBearingFixedInterestRate contextRef="c59" decimals="4" id="ixv-25732" unitRef="pure">0.0485</us-gaap:ShortTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:OtherCurrentAssetsTextBlock contextRef="c0" id="ixv-18603">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
4 - OTHER CURRENT ASSETS:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December&#160;31,&lt;br/&gt;
    2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December&#160;31,
    &lt;br/&gt; 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;240&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;176&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Institutions&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;183&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;164&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Restricted Cash&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;90&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;89&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Others&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;74&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;587&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;432&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock contextRef="c0" id="ixv-18610">&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December&#160;31,&lt;br/&gt;
    2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December&#160;31,
    &lt;br/&gt; 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;240&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;176&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Institutions&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;183&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;164&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Restricted Cash&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;90&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;89&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Others&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;74&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;587&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;432&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <us-gaap:PrepaidExpenseCurrent contextRef="c4" decimals="-3" id="ixv-25733" unitRef="usd">240000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c5" decimals="-3" id="ixv-25734" unitRef="usd">176000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:InterestBearingDepositsInBanks contextRef="c4" decimals="-3" id="ixv-25735" unitRef="usd">183000</us-gaap:InterestBearingDepositsInBanks>
    <us-gaap:InterestBearingDepositsInBanks contextRef="c5" decimals="-3" id="ixv-25736" unitRef="usd">164000</us-gaap:InterestBearingDepositsInBanks>
    <us-gaap:RestrictedCashCurrent contextRef="c4" decimals="-3" id="ixv-25737" unitRef="usd">90000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent contextRef="c5" decimals="-3" id="ixv-25738" unitRef="usd">89000</us-gaap:RestrictedCashCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c4" decimals="-3" id="ixv-25739" unitRef="usd">74000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c5" decimals="-3" id="ixv-25740" unitRef="usd">3000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c4" decimals="-3" id="ixv-25741" unitRef="usd">587000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c5" decimals="-3" id="ixv-25742" unitRef="usd">432000</us-gaap:OtherAssetsCurrent>
    <us-gaap:InventoryDisclosureTextBlock contextRef="c0" id="ixv-18729">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE 5
- INVENTORY&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December&#160;31,&lt;br/&gt;
    2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December&#160;31,
    &lt;br/&gt; 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;96&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-63; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Work in progress&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;55&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-64; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Finished good (*)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;293&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-65; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;444&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-66; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(*) As of December 31, 2024, seven INSPIRA ART100 systems and
seven carts were in the course of being delivered to a distributor in the U.S. &lt;/b&gt;&lt;/p&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c0" id="ixv-18736">&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December&#160;31,&lt;br/&gt;
    2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December&#160;31,
    &lt;br/&gt; 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;96&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-63; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Work in progress&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;55&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-64; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Finished good (*)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;293&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-65; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;444&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-66; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/150% Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;(*) As of December 31, 2024, seven INSPIRA ART100 systems and
seven carts were in the course of being delivered to a distributor in the U.S. &lt;/b&gt;&lt;/p&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials contextRef="c4" decimals="-3" id="ixv-25743" unitRef="usd">96000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess contextRef="c4" decimals="-3" id="ixv-25744" unitRef="usd">55000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods contextRef="c4" decimals="-3" id="ix_0_fact" unitRef="usd">293000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet contextRef="c4" decimals="-3" id="ixv-25746" unitRef="usd">444000</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c0" id="ixv-18841">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE 6
- PROPERTY AND EQUIPMENT, NET:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration:underline"&gt;For the
year ended December 31, 2024:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Computers&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Leasehold&lt;br/&gt;
    improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;R&amp;amp;D&lt;br/&gt;
    equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Furniture&lt;br/&gt;
    and office&lt;br/&gt; equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;At January 1, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;172&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;36&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;381&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;116&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;705&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-67; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;154&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-68; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;164&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;At December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;182&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;36&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;535&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;116&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;869&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;At January 1, 2024&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;102&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;73&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;16&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;199&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;44&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;116&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;171&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;At December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;146&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;189&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;23&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;370&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net book value:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;36&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;24&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;346&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;93&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;499&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration:underline"&gt;For the
year ended December 31, 2023:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Computers&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Leasehold&lt;br/&gt; improvements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Development&lt;br/&gt; equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Furniture&lt;br/&gt; and office&lt;br/&gt; equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; font-weight: bold"&gt;At January 1, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;121&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;33&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;229&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;116&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;499&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Additions&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;51&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;152&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-69"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;206&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; padding-left: 9pt"&gt;At December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;172&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;36&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;381&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;116&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;705&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Accumulated depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold"&gt;At January 1, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;51&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;88&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;51&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;48&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;111&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-left: 9pt"&gt;At December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;102&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;73&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;199&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold"&gt;Net book value:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;As of December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;70&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;28&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;308&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;506&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c0" id="ixv-18847">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration:underline"&gt;For the
year ended December 31, 2024:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Computers&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Leasehold&lt;br/&gt;
    improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;R&amp;amp;D&lt;br/&gt;
    equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Furniture&lt;br/&gt;
    and office&lt;br/&gt; equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;At January 1, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;172&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;36&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;381&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;116&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;705&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-67; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;154&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-68; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;164&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;At December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;182&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;36&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;535&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;116&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;869&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;At January 1, 2024&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;102&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;73&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;16&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;199&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;44&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;116&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;171&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;At December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;146&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;189&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;23&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;370&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net book value:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;36&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;24&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;346&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;93&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;499&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration:underline"&gt;For the
year ended December 31, 2023:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Computers&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Leasehold&lt;br/&gt; improvements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Development&lt;br/&gt; equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Furniture&lt;br/&gt; and office&lt;br/&gt; equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; font-weight: bold"&gt;At January 1, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;121&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;33&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;229&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;116&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;499&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Additions&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;51&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;152&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-69"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;206&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; padding-left: 9pt"&gt;At December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;172&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;36&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;381&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;116&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;705&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Accumulated depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold"&gt;At January 1, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;51&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;88&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;51&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;48&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;111&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-left: 9pt"&gt;At December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;102&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;73&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;199&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold"&gt;Net book value:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;As of December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;70&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;28&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;308&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;506&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c60" decimals="-3" id="ixv-25748" unitRef="usd">172000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c61" decimals="-3" id="ixv-25749" unitRef="usd">36000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c62" decimals="-3" id="ixv-25750" unitRef="usd">381000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c63" decimals="-3" id="ixv-25751" unitRef="usd">116000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c5" decimals="-3" id="ixv-25752" unitRef="usd">705000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentAdditions contextRef="c50" decimals="-3" id="ixv-25753" unitRef="usd">10000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions contextRef="c64" decimals="-3" id="ixv-25754" unitRef="usd">154000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions contextRef="c0" decimals="-3" id="ixv-25755" unitRef="usd">164000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c66" decimals="-3" id="ixv-25756" unitRef="usd">182000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c67" decimals="-3" id="ixv-25757" unitRef="usd">36000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c68" decimals="-3" id="ixv-25758" unitRef="usd">535000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c69" decimals="-3" id="ixv-25759" unitRef="usd">116000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c4" decimals="-3" id="ixv-25760" unitRef="usd">869000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c60" decimals="-3" id="ixv-25761" unitRef="usd">102000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c61" decimals="-3" id="ixv-25762" unitRef="usd">8000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c62" decimals="-3" id="ixv-25763" unitRef="usd">73000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c63" decimals="-3" id="ixv-25764" unitRef="usd">16000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c5" decimals="-3" id="ixv-25765" unitRef="usd">199000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:Depreciation contextRef="c50" decimals="-3" id="ixv-25766" unitRef="usd">44000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c54" decimals="-3" id="ixv-25767" unitRef="usd">4000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c64" decimals="-3" id="ixv-25768" unitRef="usd">116000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c65" decimals="-3" id="ixv-25769" unitRef="usd">7000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c0" decimals="-3" id="ixv-25770" unitRef="usd">171000</us-gaap:Depreciation>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c66" decimals="-3" id="ixv-25771" unitRef="usd">146000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c67" decimals="-3" id="ixv-25772" unitRef="usd">12000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c68" decimals="-3" id="ixv-25773" unitRef="usd">189000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c69" decimals="-3" id="ixv-25774" unitRef="usd">23000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c4" decimals="-3" id="ixv-25775" unitRef="usd">370000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c66" decimals="-3" id="ixv-25776" unitRef="usd">36000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c67" decimals="-3" id="ixv-25777" unitRef="usd">24000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c68" decimals="-3" id="ixv-25778" unitRef="usd">346000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c69" decimals="-3" id="ixv-25779" unitRef="usd">93000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c4" decimals="-3" id="ixv-25780" unitRef="usd">499000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c70" decimals="-3" id="ixv-25781" unitRef="usd">121000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c71" decimals="-3" id="ixv-25782" unitRef="usd">33000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c72" decimals="-3" id="ixv-25783" unitRef="usd">229000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c73" decimals="-3" id="ixv-25784" unitRef="usd">116000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c20" decimals="-3" id="ixv-25785" unitRef="usd">499000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentAdditions contextRef="c74" decimals="-3" id="ixv-25786" unitRef="usd">51000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions contextRef="c75" decimals="-3" id="ixv-25787" unitRef="usd">3000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions contextRef="c76" decimals="-3" id="ixv-25788" unitRef="usd">152000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions contextRef="c6" decimals="-3" id="ixv-25789" unitRef="usd">206000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c60" decimals="-3" id="ixv-25790" unitRef="usd">172000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c61" decimals="-3" id="ixv-25791" unitRef="usd">36000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c62" decimals="-3" id="ixv-25792" unitRef="usd">381000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c63" decimals="-3" id="ixv-25793" unitRef="usd">116000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c5" decimals="-3" id="ixv-25794" unitRef="usd">705000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c70" decimals="-3" id="ixv-25795" unitRef="usd">51000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c71" decimals="-3" id="ixv-25796" unitRef="usd">4000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c72" decimals="-3" id="ixv-25797" unitRef="usd">25000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c73" decimals="-3" id="ixv-25798" unitRef="usd">8000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c20" decimals="-3" id="ixv-25799" unitRef="usd">88000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:Depreciation contextRef="c74" decimals="-3" id="ixv-25800" unitRef="usd">51000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c75" decimals="-3" id="ixv-25801" unitRef="usd">4000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c76" decimals="-3" id="ixv-25802" unitRef="usd">48000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c77" decimals="-3" id="ixv-25803" unitRef="usd">8000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c6" decimals="-3" id="ixv-25804" unitRef="usd">111000</us-gaap:Depreciation>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c60" decimals="-3" id="ixv-25805" unitRef="usd">102000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c61" decimals="-3" id="ixv-25806" unitRef="usd">8000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c62" decimals="-3" id="ixv-25807" unitRef="usd">73000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c63" decimals="-3" id="ixv-25808" unitRef="usd">16000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c5" decimals="-3" id="ixv-25809" unitRef="usd">199000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c60" decimals="-3" id="ixv-25810" unitRef="usd">70000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c61" decimals="-3" id="ixv-25811" unitRef="usd">28000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c62" decimals="-3" id="ixv-25812" unitRef="usd">308000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c63" decimals="-3" id="ixv-25813" unitRef="usd">100000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c5" decimals="-3" id="ixv-25814" unitRef="usd">506000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="c0" id="ixv-19859">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE 7
- OTHER ACCOUNTS PAYABLE:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December&#160;31,&lt;br/&gt;
    2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December&#160;31,&lt;br/&gt;
    2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Employees&#x2019; salaries and related
    liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;414&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;388&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Related parties&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;421&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;354&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;508&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;267&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;21&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;17&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,364&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,026&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c0" id="ixv-19866">&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December&#160;31,&lt;br/&gt;
    2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December&#160;31,&lt;br/&gt;
    2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Employees&#x2019; salaries and related
    liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;414&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;388&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Related parties&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;421&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;354&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;508&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;267&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;21&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;17&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,364&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,026&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent contextRef="c4" decimals="-3" id="ixv-25815" unitRef="usd">414000</us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent contextRef="c5" decimals="-3" id="ixv-25816" unitRef="usd">388000</us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent>
    <iinn:AccountsPayableToRelatedParties contextRef="c4" decimals="-3" id="ixv-25817" unitRef="usd">421000</iinn:AccountsPayableToRelatedParties>
    <iinn:AccountsPayableToRelatedParties contextRef="c5" decimals="-3" id="ixv-25818" unitRef="usd">354000</iinn:AccountsPayableToRelatedParties>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent contextRef="c4" decimals="-3" id="ixv-25819" unitRef="usd">508000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent contextRef="c5" decimals="-3" id="ixv-25820" unitRef="usd">267000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent contextRef="c4" decimals="-3" id="ixv-25821" unitRef="usd">21000</us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent contextRef="c5" decimals="-3" id="ixv-25822" unitRef="usd">17000</us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccountsPayableOtherCurrent contextRef="c4" decimals="-3" id="ixv-25823" unitRef="usd">1364000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent contextRef="c5" decimals="-3" id="ixv-25824" unitRef="usd">1026000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0" id="ixv-19999">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; "&gt;&lt;b&gt;NOTE
8 - COMMITMENTS AND CONTINGENCIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;A.&#160;Royalties
to the IIA:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 57.4pt; text-indent: -0.7pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; "&gt;In
September 2019, the IIA approved a grant to the Company for the development of intravenous blood oxygenation system for an aggregate
budget of NIS&#160;4,880,603 (approximately $1,500). The IIA committed to fund&#160;60% of the approved budget. Eventually the project
budget concluded in the aggregate amount of NIS 4,623,142 (approximately $1,333). The program is for the period beginning October 2019
through November 2020. From 2019 to 2021, the Company received total funds in the amount of NIS 2,773,885 (approximately $809) from the
IIA, which were recorded as IIA participation and were deducted from R&amp;amp;D expenses. &lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; "&gt;In
October 2023, the IIA approved a grant to support another development project of the Company at an aggregate budget of NIS&#160;3,850,869
(approximately $1,062). The IIA committed to fund&#160;40% of the approved budget. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; "&gt;The
program is for the period beginning January 2024 through March 2025, and as of December 31, 2024, the Company received total funds in
the amount of NIS 1,062,049 (approximately $286) from the IIA, which were recorded as IIA participation and were deducted from the R&amp;amp;D
expenses. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; "&gt;According
to the agreements with the IIA, The Company will pay royalties of&#160;3% of future sales up to an amount equal to the accumulated grant
received linked to the U.S. dollar and bearing interest at an annual rate of SOFR. Repayment of the grants are contingent upon the successful
completion of the Company&#x2019;s R&amp;amp;D programs and generating sales. The Company has no obligation to repay these grants if the R&amp;amp;D
programs fail, are unsuccessful or aborted or if no sales are generated. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; "&gt;The
Company had not generated sales as of December 31, 2024; therefore, no liability was recorded in these Financial Statements. As of December
31, 2024, the maximum obligation with respect to the grants received from the IIA, contingent upon entitled future sales, is $1,095 plus
SOFR interest.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; "&gt;The
Company has obligations regarding know-how, technology, or products, not to transfer the information, rights thereon and production rights
which derive from the research and development without the IIA Research Committee approval.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; "&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;B.
Legal Claims&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
the normal course of business, various legal claims and other contingent matters may arise. Management believes that any liability that
may arise from such matters would not have a material adverse effect on the Company&#x2019;s results of operations or financial condition
as of and for the years ended December 31, 2024, and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
December 12, 2021, the Company terminated its employment agreement with Dr. Udi Nussinovitch, one of its founders who served as the Company&#x2019;s
Chief Scientific Officer since March 2018. On February 24, 2022, the Company sued Mr. Nussinovitch for breach good faith and his fiduciary
duties as a shareholder and former officer of the Company. On November 9, 2022, Mr. Nussinovitch filed a Statement of Claim against the
Company,, as well as a Statement of Claim with the regional labor court in Tel Aviv, Israel on November 8, 2022. Mr. Nussinovitch alleged
certain deficiencies in the Company&#x2019;s&#160;Extraordinary General Meeting of Shareholders held on Friday, December 17, 2021, resulting
from his status as a minority shareholder. In addition, with respect to the labor dispute, Mr.&#160;Nussinovitch is seeking renumeration
and the issuance of Ordinary Shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
July 19. 2023, a partial hearing about the labor dispute was held, in which the parties were required by the court to file their positions
on a stay of the proceeding pending the decision on the case initiated by Mr. Nussinovitch in the District Court. On January 21, 2024,
a partial hearing about the civil case was held. During the hearing, the court suggested the parties consider the possibility of resolving
the case through an out-of-court arrangement or mediation. The parties agreed to a mediation process which did not succeed. On
January 7, 2025,&#160;Mr. Nussinovitch&#160;filed a motion to amend his Statement of Claim, requesting to modify the requested relief.
Instead of the original remedies sought,&#160;Mr. Nussinovitch&#160;now requests that the Company or Mr. Ben Noon and Mr. Hayon purchase
all of his rights and shares in the Company at their average value from the date of the Company&#x2019;s initial public offering until
the date of the general meeting held on December 17, 2021. On January 13, 2025, a pretrial hearing was held. The court denied Mr. Nussinovitch&#x2019;s
motion to amend and instructed him to notify whether he wishes to withdraw his original claim or maintain it. As of the date of these
Financial Statements, Mr. Nussinovitch has not yet provided his response.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
of the date of these Financial Statements, the Company believes that the claims will result in no payments by the Company.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <iinn:AggregateBudget contextRef="c78" decimals="-3" id="ixv-25825" unitRef="ils">4880603000</iinn:AggregateBudget>
    <iinn:AggregateBudget contextRef="c78" decimals="-3" id="ixv-25826" unitRef="usd">1500000</iinn:AggregateBudget>
    <iinn:PercentageOfApprovedBudget contextRef="c78" decimals="2" id="ixv-25827" unitRef="pure">0.60</iinn:PercentageOfApprovedBudget>
    <iinn:ProjectBudgetAggregateAmount contextRef="c78" decimals="-3" id="ixv-25828" unitRef="ils">4623142000</iinn:ProjectBudgetAggregateAmount>
    <iinn:ProjectBudgetAggregateAmount contextRef="c78" decimals="-3" id="ixv-25829" unitRef="usd">1333000</iinn:ProjectBudgetAggregateAmount>
    <us-gaap:OtherReceivables contextRef="c79" decimals="-3" id="ixv-25830" unitRef="ils">2773885000</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables contextRef="c79" decimals="-3" id="ixv-25831" unitRef="usd">809000</us-gaap:OtherReceivables>
    <iinn:AggregateBudget contextRef="c80" decimals="-3" id="ixv-25832" unitRef="ils">3850869000</iinn:AggregateBudget>
    <iinn:AggregateBudget contextRef="c80" decimals="-3" id="ixv-25833" unitRef="usd">1062000</iinn:AggregateBudget>
    <iinn:PercentageOfApprovedBudget contextRef="c80" decimals="2" id="ixv-25834" unitRef="pure">0.40</iinn:PercentageOfApprovedBudget>
    <us-gaap:OtherReceivables contextRef="c4" decimals="-3" id="ixv-25835" unitRef="ils">1062049000</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables contextRef="c4" decimals="-3" id="ixv-25836" unitRef="usd">286000</us-gaap:OtherReceivables>
    <iinn:RoyaltiesPercentage contextRef="c0" decimals="2" id="ixv-25837" unitRef="pure">0.03</iinn:RoyaltiesPercentage>
    <iinn:ContingentUponFutureSales contextRef="c4" decimals="-3" id="ixv-25838" unitRef="usd">1095000</iinn:ContingentUponFutureSales>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c0" id="ixv-20128">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; "&gt;&lt;b&gt;NOTE
9 &#x2013; LEASE LIABILITIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Lease
Commitments &#x2013; Operating Leases:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; "&gt;In
September 2021, the Company entered into a lease agreement for its facilities in Ra&#x2019;anana, Israel. The lease agreement is for a
period of 69 months commencing September 1, 2021, and the Company began to pay lease and related expenses after completing 3 months of
lease. The Company has the option to shorten the period and terminates the lease agreement after completing 45 months of rent by paying
an amount of NIS 500,000, (approximately $153). This amount of reimbursement will be deducted monthly in NIS 30,000, (approximately $9)
if the Company terminates the agreement after 45 months of rent. The Company is reasonably certain that it will not exercise the termination
option. The annual lease payment, including management fees, as of December 31, 2024, is approximately NIS 69,000 ($17.5). As security
for the obligations under this lease agreement, the Company provided a bank guarantee in an amount equal to three monthly lease payments
plus the Israeli value added tax and an unlimited guarantee according to the terms specified in the contract. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; "&gt;The
Company has various operating leases for vehicles that expire through 2027. The Company leases vehicles for approximately three-year
periods from multiple different leasing companies and from time to time increases or decreases the number of leased vehicles according
to its current needs. The leased vehicles are used by the Company&#x2019;s headquarters staff and other employees whose employment agreements
include an obligation on the Company to provide a vehicle. The agreements with the leasing companies include termination options, allowing
for early cancellation by paying a penalty of up to 400% of the monthly costs. The Company is reasonably certain that it will not exercise
this option or that the employee will bear the cost for early termination.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; "&gt;The
total expenses related to the leases were $390&#160;for the year ended December 31, 2024, and $371&#160;for the year ended December 31,
2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; "&gt;The
right-of-use asset and lease liability are initially measured at the present value of the lease payments, discounted using the interest
rate implicit in the lease or, if that rate cannot be readily determined, the Company&#x2019;s incremental borrowing rate based on the
information available at the date of determining the present value of the lease payments. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; "&gt;The
Company&#x2019;s incremental borrowing rate is estimated to approximate the interest rate on similar terms and payments and in economic
environments where the leased asset is located.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; "&gt;The
Company has various operating leases for vehicles that expire through 2027. Below is a summary of the Company&#x2019;s operating right-of-use
assets and operating lease liabilities as of December 31, 2024, and 2023:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;December&#160;31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December&#160;31, &lt;br/&gt; 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating lease liabilities, current&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;277&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;290&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating lease liabilities long-term&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;378&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;588&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;655&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;878&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted Average of Remaining Lease Term&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.52&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.33&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted-average discount rate - operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9.92&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9.6&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Lease
payments for the Company&#x2019;s right-of-use assets over the remaining lease periods as of December 31, 2024, are as follows:&lt;span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; "&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Year
    ended December&#160;31, &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S.&#160;dollars&lt;br/&gt;
    in&#160;thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;326&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;254&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;154&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total undiscounted lease
    payment&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;734&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less: Interest (*)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(79&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Present value of lease
    liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;655&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(*)
Future lease payments were discounted by&#160;7.98%-15.78% interest rate.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:PaymentsForRent contextRef="c0" decimals="-3" id="ixv-25839" unitRef="ils">500000000</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent contextRef="c0" decimals="-3" id="ixv-25840" unitRef="usd">153000</us-gaap:PaymentsForRent>
    <iinn:MonthlyDeductionFromTerminationFee contextRef="c0" decimals="-3" id="ixv-25841" unitRef="ils">30000000</iinn:MonthlyDeductionFromTerminationFee>
    <iinn:MonthlyDeductionFromTerminationFee contextRef="c0" decimals="-3" id="ixv-25842" unitRef="usd">9000</iinn:MonthlyDeductionFromTerminationFee>
    <us-gaap:ProceedsFromLeasePayments contextRef="c0" decimals="-3" id="ixv-25843" unitRef="ils">69000000</us-gaap:ProceedsFromLeasePayments>
    <us-gaap:ProceedsFromLeasePayments contextRef="c0" decimals="-2" id="ixv-25844" unitRef="usd">-17500</us-gaap:ProceedsFromLeasePayments>
    <iinn:PercentageForCarsLeaseAgreementCancellationPenalty contextRef="c0" id="ixv-25845">up to 400%</iinn:PercentageForCarsLeaseAgreementCancellationPenalty>
    <us-gaap:OperatingLeaseExpense contextRef="c0" decimals="-3" id="ixv-25846" unitRef="usd">390000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c6" decimals="-3" id="ixv-25847" unitRef="usd">371000</us-gaap:OperatingLeaseExpense>
    <iinn:ScheduleOfLesseeOperatingLeasesDisclosureTableTextBlock contextRef="c0" id="ixv-25848">Below is a summary of the Company&#x2019;s operating right-of-use
assets and operating lease liabilities as of December 31, 2024, and 2023:&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;December&#160;31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December&#160;31, &lt;br/&gt; 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating lease liabilities, current&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;277&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;290&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating lease liabilities long-term&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;378&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;588&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;655&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;878&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted Average of Remaining Lease Term&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.52&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.33&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted-average discount rate - operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9.92&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9.6&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</iinn:ScheduleOfLesseeOperatingLeasesDisclosureTableTextBlock>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c4" decimals="-3" id="ixv-25849" unitRef="usd">277000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c5" decimals="-3" id="ixv-25850" unitRef="usd">290000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c4" decimals="-3" id="ixv-25851" unitRef="usd">378000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c5" decimals="-3" id="ixv-25852" unitRef="usd">588000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability contextRef="c4" decimals="-3" id="ixv-25853" unitRef="usd">655000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability contextRef="c5" decimals="-3" id="ixv-25854" unitRef="usd">878000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c4" id="ixv-20286">P2Y6M7D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c5" id="ixv-20295">P3Y3M29D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c4" decimals="4" id="ixv-25855" unitRef="pure">0.0992</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c5" decimals="3" id="ixv-25856" unitRef="pure">0.096</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c0" id="ixv-20361">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Lease
payments for the Company&#x2019;s right-of-use assets over the remaining lease periods as of December 31, 2024, are as follows:&lt;span&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; "&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Year
    ended December&#160;31, &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;U.S.&#160;dollars&lt;br/&gt;
    in&#160;thousands&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;326&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;254&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;154&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total undiscounted lease
    payment&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;734&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less: Interest (*)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(79&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Present value of lease
    liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;655&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(*)
Future lease payments were discounted by&#160;7.98%-15.78% interest rate.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c4" decimals="-3" id="ixv-25857" unitRef="usd">326000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c4" decimals="-3" id="ixv-25858" unitRef="usd">254000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c4" decimals="-3" id="ixv-25859" unitRef="usd">154000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c4" decimals="-3" id="ixv-25860" unitRef="usd">734000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c4" decimals="-3" id="ix_1_fact" unitRef="usd">79000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c4" decimals="-3" id="ixv-25862" unitRef="usd">655000</us-gaap:OperatingLeaseLiability>
    <iinn:PercentageOfFutureLeasePaymentsDiscounted contextRef="c81" decimals="4" id="ixv-25864" unitRef="pure">0.0798</iinn:PercentageOfFutureLeasePaymentsDiscounted>
    <iinn:PercentageOfFutureLeasePaymentsDiscounted contextRef="c82" decimals="4" id="ixv-25865" unitRef="pure">0.1578</iinn:PercentageOfFutureLeasePaymentsDiscounted>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c0" id="ixv-20475">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
10 &#x2013; FINACIAL LIABILITIES AT FAIR VALUE:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;December&#160;31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;December&#160;31,
                                            &lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Financial liability (A)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;69&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Private warrants (B)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,506&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,459&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,575&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,470&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;A Financial Liability&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The Company agreed to pay fees of 7% from funds that may be received in an event of exercise of the Company&#x2019;s tradable warrants which created a financial liability. The financial liability was designated to be measured at fair value through profit or loss. As of December 31, 2023, the fair value of the financial liability was $11. Such agreement expired in July 2024 and as of December 31, 2024, the financial liability amounted to null.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The Company agreed to pay fees of 4% from the funds that will be received in an event of exercise of part of the Company&#x2019;s ordinary warrants that were issued in a certain December 2024 private placement which created a financial liability on the total potential amount which is $69 as of December 31, 2024 (Note 10).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
financial liability fair value as of December 31, 2024, and 2023 is $69 and $11 respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;B
Private warrants &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
December 26, 2023, the Company entered into a certain securities purchase agreement (Note 11.3), pursuant to which it issued unregistered
warrants, to purchase up to an aggregate of 3,031,250 Ordinary Shares at an exercise of $1.28 per share (the &#x201c;Private Warrants&#x201d;).
The Private Warrants were exercisable immediately upon issuance and will expire three and a half years following their issuance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Private Warrants include cashless exercise mechanism, according to the terms specified in the agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Private Warrants may create obligation to transfer cash to the investors at fundamental transactions within the Black Scholes option
pricing framework.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Therefore,
the Company accounts for the Private Warrants as financial liability instruments that are measured at fair value and recognized financial
expenses or income through profit and loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
company measured fair value by using Black-Scholes option pricing model;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
key inputs that were used in the private warrants fair value as of December 31, 2023, were:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;risk-free interest rate 4.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;expected volatility 66.63%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;expected dividend yield of 0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;expected term of warrants &#x2013; 3.5 years.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
key inputs that were used in the private warrants fair value as of December 31, 2024, were:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;risk-free interest rate 4.26%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;expected volatility 88.61%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;expected dividend yield of 0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;expected term of warrants &#x2013; 2.5 years.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
fair value of the Private Warrants as of December 31, 2024 and 2023 was $1,506 and $1,459 respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock contextRef="c0" id="ixv-20481">&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;December&#160;31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;December&#160;31,
                                            &lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Financial liability (A)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;69&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Private warrants (B)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,506&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,459&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,575&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,470&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="c87" decimals="-3" id="ixv-25866" unitRef="usd">69000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="c88" decimals="-3" id="ixv-25867" unitRef="usd">11000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="c101"
      decimals="-3"
      id="ixv-25868"
      unitRef="usd">1506000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="c102"
      decimals="-3"
      id="ixv-25869"
      unitRef="usd">1459000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="c4" decimals="-3" id="ixv-25870" unitRef="usd">1575000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="c5" decimals="-3" id="ixv-25871" unitRef="usd">1470000</us-gaap:DerivativeLiabilitiesCurrent>
    <iinn:PercentageOfPayFees contextRef="c83" decimals="2" id="ixv-25872" unitRef="pure">0.07</iinn:PercentageOfPayFees>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c84" decimals="-3" id="ixv-25873" unitRef="usd">11000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <iinn:PercentageOfPayFees contextRef="c85" decimals="2" id="ixv-25874" unitRef="pure">0.04</iinn:PercentageOfPayFees>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c86" decimals="-3" id="ixv-25875" unitRef="usd">69000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c87" decimals="-3" id="ixv-25876" unitRef="usd">69000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c88" decimals="-3" id="ixv-25877" unitRef="usd">11000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="c89"
      decimals="0"
      id="ixv-25878"
      unitRef="shares">3031250</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c90"
      decimals="2"
      id="ixv-25879"
      unitRef="usdPershares">1.28</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DerivativeLiabilityMeasurementInput contextRef="c91" decimals="2" id="ixv-25880" unitRef="pure">4</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput contextRef="c92" decimals="2" id="ixv-25881" unitRef="pure">66.63</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput contextRef="c93" decimals="0" id="ixv-25882" unitRef="pure">0</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput contextRef="c94" decimals="1" id="ixv-25883" unitRef="pure">3.5</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput contextRef="c95" decimals="2" id="ixv-25884" unitRef="pure">4.26</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput contextRef="c96" decimals="2" id="ixv-25885" unitRef="pure">88.61</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput contextRef="c97" decimals="0" id="ixv-25886" unitRef="pure">0</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput contextRef="c98" decimals="1" id="ixv-25887" unitRef="pure">2.5</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="c99" decimals="-3" id="ixv-25888" unitRef="usd">1506000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="c100"
      decimals="-3"
      id="ixv-25889"
      unitRef="usd">1459000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock contextRef="c0" id="ixv-20794">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE 11
&#x2013; SHAREHOLDERS&#x2019; EQUITY:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;A.
Share capital:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of shares as of&lt;br/&gt; December 31,&#160;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of shares as of&lt;br/&gt; December 31,&#160;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Issued
    and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Issued
    and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Ordinary shares&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;100,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;24,252,096&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;100,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;15,652,176&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;During the year ended December 31, 2022, the Company issued an aggregate amount of 1,240,204 Ordinary Shares in connection to vested RSUs and an additional 7,030 Ordinary Shares in connection to certain option exercises.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On April 4, 2023, the Company entered into a sales agreement (the &#x201c;Sales Agreement&#x201d;) with Roth Capital Partners, LLC, as sales agent, pursuant to which the Company could offer and sell, from time to time, through the sales agent, Ordinary Shares pursuant to an at-the-market facility (&#x201c;ATM&#x201d;). In 2023, the Company sold 17,566 Ordinary Shares under the ATM. On October 23, 2023, the Company terminated the Sales Agreement and the associated ATM, effective immediately.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On December 26, 2023, the Company entered into a securities purchase agreement (the &#x201c;Purchase Agreement&#x201d;) with an institutional investor in a registered direct offering (the &#x201c;Registered Direct Offering&#x201d;), pursuant to which the Company issued (i) 1,375,000 Ordinary Shares at a purchase price of $1.28 per share, (ii) pre-funded warrants, to purchase up to 1,656,250 Ordinary Shares, at a purchase price of $1.28, less $0.001 per pre-funded warrant and (iii) Private Warrants, to purchase up to an aggregate of 3,031,250 Ordinary Shares at an exercise of $1.28 per share (Note 10-B).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company concluded that the Pre-Funded Warrants are not within the scope of ASC480. Further, applying ASC 815-40, the Company
concluded that the pre-funded warrants are indexed to the Company&#x2019;s own stock and meet the conditions for equity classification,
and thus should be presented within equity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
for the common warrants, the Company concluded that they should be classified as a liability under ASC 815-40, as they are not indexed
to the Company&#x2019;s own stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
pre-funded warrants were exercised on the same day and the day after the transaction in full in an exercise price of $0.001 per share
and the Company issued 1,656,250 additional Ordinary Shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
aggregate proceeds received by the Company from the Registered Direct Offering were approximately $3,424, after deducting underwriting
discounts and commissions and additional cash offering costs totaled in approximately $454.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company issued the placement agent in the Registered Direct Offering a number of warrants equal to a total of 7.0% of the aggregate number
of Ordinary Shares sold in the transaction, total to 212,188 warrants to purchase up to 212,188 Ordinary Shares, were issued (the &#x201c;Placement
Agent Warrants&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Placement Agent Warrants were substantially on the same terms as the Warrants issued to the investor in the offering, except an exercise
price of $1.60 per share. The Placement Agent Warrants were exercisable immediately upon issuance and will expire five years following
their issuance. The Company accounts for the Placement Agent Warrants as equity-classified instruments (as part of additional paid in
capital), based on an assessment of ASC 718. The fair value of the warrants at the issuance date was $131.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Those
cash and non-cash issuance costs were accounted proportionally to issuance expenses and decrease of additional paid in capital, according
to the ratio of the liability versus equity in the Registered Direct offering.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;During the year ended December 31, 2023, the Company issued an aggregate amount of 1,226,448 Ordinary Shares in connection with vested RSUs and an additional 37,972 Ordinary Shares in connection with option exercises.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On April 1, 2024, the Company completed its 2024 April Offering, whereby the Company sold 1,339,285 Ordinary Shares at a purchase price of $1.232 per share. The gross proceeds received by the Company from the 2024 April Offering were approximately $1,651.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On May 20, 2024, the Company issued warrant to purchase 220,000 Ordinary Shares to a service provider, at an exercise price of $2.25 per share. These warrants are immediately exercisable and are due to expire six months from the initial issuance date. The Company accounting treatment for those warrants as equity-classified instruments (as part of additional paid in capital), based on an assessment of ASC 718. The fair value of the warrants at the issuance date was $125. The warrants were not exercised within the designated timeframe and expired on November 21, 2024.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On June 14, 2024, the Company completed its 2024 June Offering, whereby the Company sold: (i) 941,541 Ordinary Shares at a purchase price of $1.30 per share, and (ii) June Pre-Funded Warrants to purchase up to 1,709,760 Ordinary Shares, at a purchase price of $1.30, less $0.001 per June Pre-Funded Warrant. Each June Pre-Funded Warrant is exercisable for one Ordinary Share at an exercise price of $0.001 per share. The June Pre-Funded Warrants are immediately exercisable and may be exercised at any time until all of the June Pre-Funded Warrants are exercised in full. As of December 31, 2024, all of the June Pre-Funded warrants were exercised, and the company issued 1,709,760 Ordinary Shares.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net
proceeds received by the Company from the 2024 June Offering were approximately $3,102, after deducting cash offering costs which
were approximately $343.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company also received $2 from an exercise of the June Pre-Funded Warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company concluded that the June Pre-Funded Warrants are not within the scope of ASC 480. Further, applying ASC 815-40, the Company concluded
that the June Pre-Funded Warrants are indexed to the Company&#x2019;s own stock and meet the conditions for equity classification, and
thus should be presented within equity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company issued the June Placement Agent in the agreement warrants equal to a total of 7.0% of the aggregate number of Ordinary Shares
sold in the transaction. A total to 185,591 warrants to purchase up to 185,591 Ordinary Shares were issued. The June Placement Agent
Warrants had an exercise price of $1.56 per share. The June Placement Agent Warrants were exercisable immediately upon issuance and will
expire four years following their issuance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company accounting treatment for the June Placement Agent Warrants as equity-classified instruments (as part of additional paid in capital),
based on an assessment of ASC 718. The fair value of the June Placement Agent Warrants at the issuance date was $254.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
cash and non-cash issuance costs were recorded against additional paid in capital, due to the classification of the Ordinary Shares and
the June Pre-Funded Warrants as equity instrument.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On June 30, 2024, the Company issued 45,000 Ordinary Shares to an advisor in connection with a consulting service agreement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On December 27, 2024, the Company completed its December Private Placement, whereby the Company sold (i) 3,950,343 Ordinary Shares and December Private Warrants to purchase up to 3,950,343 Ordinary Shares at a purchase price of $0.70 per unit, and (ii) December Pre-Funded Warrants to purchase up to 658,372 Ordinary Shares and December Private Warrants to purchase up to 658,372 Ordinary Shares, at a purchase price of $0.70, less $0.001 per unit with December Pre-Funded Warrant. Each December Pre-Funded Warrant is exercisable for one Ordinary Share at an exercise price of $0.001 per share. Each December Private Warrant is exercisable for one Ordinary Share at an exercise price of $1.10 per share. The December Private Warrants are immediately exercisable and may be exercised at any time until the end of June 2026. The December Pre-Funded Warrants are immediately exercisable and may be exercised at any time until all of the December Pre-Funded Warrants are exercised in full. As of December 31, 2024, none of the December Pre-Funded warrants or the December Private Warrants were exercised.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company concluded that the December Private Warrants and December Pre-Funded Warrants are not within the scope of ASC 480. Further, applying
ASC 815-40, the Company concluded that the December Private Warrants and December Pre-Funded Warrants are indexed to the Company&#x2019;s
own stock and meet the conditions for equity classification, and thus should be presented within equity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
gross proceeds received by the Company from the December Private Offering were approximately $3,228, before deducting underwriting discounts
and commissions and additional cash offering costs totaled approximately $233. In addition, the Company agreed to pay fees of 4% from
the funds that may be received in an event of exercise of part of the Company&#x2019;s private warrants issued in December 2024 Private
Placement which created a financial liability in amount of $69 which is the total potential amount (Note 10-A).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
cash and non-cash issuance costs were recorded against additional paid in capital.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;During the year ended December 31, 2024, the Company issued an aggregate amount of 594,943 Ordinary Shares in connection with vested RSUs and an additional 19,048 Ordinary Shares in connection with option exercises.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;B.
Warrants reserves -&lt;/b&gt;Composition and movements:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.8pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 21.8pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The following table reconciles the movement in warrants outstanding at the beginning and end of the period:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39.8pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number of&lt;br/&gt; Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted-average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted average remaining contractual term&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(in years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 64%; font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,333,283&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.47&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.83&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,382,438&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.22&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.93&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,709,760&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.001&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-70; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,277,350&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.25&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.54&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,728,611&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.14&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.63&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 21.8pt"&gt;&lt;/td&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The following table summarizes information about the Company&#x2019;s outstanding warrants as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Warrants&lt;br/&gt; outstanding&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;as of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;December 31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expiration date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 41%; text-align: center; padding-left: 2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,640,455&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 40%; text-align: center; padding-left: 1.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;15/07/2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: center; padding-left: 2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;277,835&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: center; padding-left: 1.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;15/07/2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: center; padding-left: 2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.875&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;145,455&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: center; padding-left: 1.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;15/01/2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: center; padding-left: 2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.6&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;212,188&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: center; padding-left: 1.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;28/06/2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: center; padding-left: 2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.56&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;185,591&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: center; padding-left: 1.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18/06/2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: center; padding-left: 2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.1&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,608,715&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: center; padding-left: 1.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;30/06/2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: center; padding-left: 2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.001&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;658,372&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: center; padding-left: 1.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Until fully exercised&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="font-weight: bold; text-align: center; padding-left: 2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,728,611&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: center; padding-left: 1.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;C.
Loss per share:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Loss
per share has been calculated using the weighted average number of Ordinary Shares and pre-funded warrants in issue during the relevant
financial periods, the weighted average number of equity shares in issue and profit for the period as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Loss
    for the period&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11,053&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11,286&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;14,976&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total number of Ordinary
    Shares&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;24,252,096&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;15,652,176&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11,338,940&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted average number of Ordinary Shares
    and pre-funded warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,515,545&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12,095,477&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,794,594&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Basic
    and diluted loss per share&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(0.60&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(0.93&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1.39&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfStockholdersEquityTableTextBlock contextRef="c0" id="ixv-20806">&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of shares as of&lt;br/&gt; December 31,&#160;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of shares as of&lt;br/&gt; December 31,&#160;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Issued
    and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Issued
    and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Ordinary shares&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;100,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;24,252,096&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;100,000,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;15,652,176&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityTableTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c147"
      decimals="INF"
      id="ixv-25890"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c147"
      decimals="INF"
      id="ixv-25891"
      unitRef="shares">24252096</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c147"
      decimals="INF"
      id="ixv-25892"
      unitRef="shares">24252096</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c148"
      decimals="INF"
      id="ixv-25893"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c148"
      decimals="INF"
      id="ixv-25894"
      unitRef="shares">15652176</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c148"
      decimals="INF"
      id="ixv-25895"
      unitRef="shares">15652176</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="c103"
      decimals="0"
      id="ixv-25896"
      unitRef="shares">1240204</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="c104"
      decimals="0"
      id="ixv-25897"
      unitRef="shares">7030</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c105"
      decimals="0"
      id="ixv-25898"
      unitRef="shares">17566</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c106"
      decimals="0"
      id="ixv-25899"
      unitRef="shares">1375000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <iinn:PurchasePricePerShare
      contextRef="c107"
      decimals="2"
      id="ixv-25900"
      unitRef="usdPershares">1.28</iinn:PurchasePricePerShare>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c108"
      decimals="0"
      id="ixv-25901"
      unitRef="shares">1656250</us-gaap:ClassOfWarrantOrRightOutstanding>
    <iinn:PurchasePricePerShare
      contextRef="c109"
      decimals="2"
      id="ixv-25902"
      unitRef="usdPershares">1.28</iinn:PurchasePricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c110"
      decimals="3"
      id="ixv-25903"
      unitRef="usdPershares">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <iinn:ClassOfPrivateWarrantOrRightOutstanding
      contextRef="c90"
      decimals="0"
      id="ixv-25904"
      unitRef="shares">3031250</iinn:ClassOfPrivateWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c90"
      decimals="2"
      id="ixv-25905"
      unitRef="usdPershares">1.28</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c111"
      decimals="3"
      id="ixv-25906"
      unitRef="usdPershares">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <iinn:NumberofAdditionalOrdinaryShares
      contextRef="c112"
      decimals="0"
      id="ixv-25907"
      unitRef="shares">1656250</iinn:NumberofAdditionalOrdinaryShares>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c113"
      decimals="-3"
      id="ixv-25908"
      unitRef="usd">3424000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:DeferredOfferingCosts contextRef="c4" decimals="-3" id="ixv-25909" unitRef="usd">454000</us-gaap:DeferredOfferingCosts>
    <us-gaap:ProductWarrantyLiquidationProceedsPercentage contextRef="c4" decimals="3" id="ixv-25910" unitRef="pure">0.07</us-gaap:ProductWarrantyLiquidationProceedsPercentage>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c114"
      decimals="0"
      id="ixv-25911"
      unitRef="shares">212188</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c115"
      decimals="0"
      id="ixv-25912"
      unitRef="shares">212188</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c116"
      decimals="2"
      id="ixv-25913"
      unitRef="usdPershares">1.6</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c116" id="ixv-25914">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="c117"
      decimals="-3"
      id="ixv-25915"
      unitRef="usd">131000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="c118"
      decimals="0"
      id="ixv-25916"
      unitRef="shares">1226448</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="c118"
      decimals="0"
      id="ixv-25917"
      unitRef="shares">37972</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c119"
      decimals="0"
      id="ixv-25918"
      unitRef="shares">1339285</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <iinn:PurchasePricePerShare
      contextRef="c120"
      decimals="3"
      id="ixv-25919"
      unitRef="usdPershares">1.232</iinn:PurchasePricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c119"
      decimals="-3"
      id="ixv-25920"
      unitRef="usd">1651000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c121"
      decimals="0"
      id="ixv-25921"
      unitRef="shares">220000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c121"
      decimals="2"
      id="ixv-25922"
      unitRef="usdPershares">2.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c121" id="ixv-25923">P6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="c122"
      decimals="-3"
      id="ixv-25924"
      unitRef="usd">125000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c123"
      decimals="0"
      id="ixv-25925"
      unitRef="shares">941541</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <iinn:PurchasePricePerShare
      contextRef="c124"
      decimals="2"
      id="ixv-25926"
      unitRef="usdPershares">1.3</iinn:PurchasePricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c38"
      decimals="0"
      id="ixv-25927"
      unitRef="shares">1709760</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <iinn:PurchasePricePerShare
      contextRef="c125"
      decimals="2"
      id="ixv-25928"
      unitRef="usdPershares">1.3</iinn:PurchasePricePerShare>
    <iinn:PurchasePricePerShare
      contextRef="c126"
      decimals="3"
      id="ixv-25929"
      unitRef="usdPershares">0.001</iinn:PurchasePricePerShare>
    <iinn:NumberOfSharesPerUnits
      contextRef="c127"
      decimals="0"
      id="ixv-25930"
      unitRef="shares">1</iinn:NumberOfSharesPerUnits>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c38"
      decimals="3"
      id="ixv-25931"
      unitRef="usdPershares">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c128"
      decimals="0"
      id="ixv-25932"
      unitRef="shares">1709760</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="c129"
      decimals="-3"
      id="ixv-25933"
      unitRef="usd">3102000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:DeferredOfferingCosts
      contextRef="c130"
      decimals="-3"
      id="ixv-25934"
      unitRef="usd">343000</us-gaap:DeferredOfferingCosts>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="c131"
      decimals="-3"
      id="ixv-25935"
      unitRef="usd">2000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:ProductWarrantyLiquidationProceedsPercentage
      contextRef="c132"
      decimals="3"
      id="ixv-25936"
      unitRef="pure">0.07</us-gaap:ProductWarrantyLiquidationProceedsPercentage>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c132"
      decimals="0"
      id="ixv-25937"
      unitRef="shares">185591</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c133"
      decimals="0"
      id="ixv-25938"
      unitRef="shares">185591</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c134"
      decimals="2"
      id="ixv-25939"
      unitRef="usdPershares">1.56</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c132" id="ixv-25940">P4Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="c132"
      decimals="-3"
      id="ixv-25941"
      unitRef="usd">254000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c135"
      decimals="0"
      id="ixv-25942"
      unitRef="shares">45000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c136"
      decimals="0"
      id="ixv-25943"
      unitRef="shares">3950343</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c137"
      decimals="0"
      id="ixv-25944"
      unitRef="shares">3950343</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <iinn:PurchasePricePerShare
      contextRef="c138"
      decimals="2"
      id="ixv-25945"
      unitRef="usdPershares">0.7</iinn:PurchasePricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c45"
      decimals="0"
      id="ixv-25946"
      unitRef="shares">658372</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c138"
      decimals="0"
      id="ixv-25947"
      unitRef="shares">658372</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <iinn:PurchasePricePerShare
      contextRef="c139"
      decimals="2"
      id="ixv-25948"
      unitRef="usdPershares">0.7</iinn:PurchasePricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c140"
      decimals="3"
      id="ixv-25949"
      unitRef="usdPershares">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <iinn:NumberOfSharesPerUnits
      contextRef="c43"
      decimals="0"
      id="ixv-25950"
      unitRef="shares">1</iinn:NumberOfSharesPerUnits>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c45"
      decimals="3"
      id="ixv-25951"
      unitRef="usdPershares">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <iinn:NumberOfSharesPerUnits
      contextRef="c141"
      decimals="0"
      id="ixv-25952"
      unitRef="shares">1</iinn:NumberOfSharesPerUnits>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c137"
      decimals="2"
      id="ixv-25953"
      unitRef="usdPershares">1.1</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c142"
      decimals="-3"
      id="ixv-25954"
      unitRef="usd">3228000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:DeferredOfferingCosts
      contextRef="c143"
      decimals="-3"
      id="ixv-25955"
      unitRef="usd">233000</us-gaap:DeferredOfferingCosts>
    <iinn:PercentageOfPayFees
      contextRef="c144"
      decimals="2"
      id="ixv-25956"
      unitRef="pure">0.04</iinn:PercentageOfPayFees>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="c145"
      decimals="-3"
      id="ixv-25957"
      unitRef="usd">69000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="c146"
      decimals="0"
      id="ixv-25958"
      unitRef="shares">594943</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="c146"
      decimals="0"
      id="ixv-25959"
      unitRef="shares">19048</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="c0" id="ixv-21171">&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The following table reconciles the movement in warrants outstanding at the beginning and end of the period:&lt;/span&gt;&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number of&lt;br/&gt; Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted-average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted average remaining contractual term&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;(in years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 64%; font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,333,283&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.47&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.83&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,382,438&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.22&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.93&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="padding-left: 0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,709,760&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.001&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-70; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,277,350&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.25&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.54&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,728,611&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.14&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.63&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c149"
      decimals="INF"
      id="ixv-25960"
      unitRef="shares">3333283</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c149"
      decimals="2"
      id="ixv-25961"
      unitRef="usdPershares">5.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="c150" id="ixv-21250">P1Y9M29D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsIssued
      contextRef="c114"
      decimals="INF"
      id="ixv-25962"
      unitRef="shares">7382438</iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWarrantsIssued>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeighted-averageExercisePriceIssued
      contextRef="c114"
      decimals="2"
      id="ixv-25963"
      unitRef="usdPershares">1.22</iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeighted-averageExercisePriceIssued>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms contextRef="c114" id="ixv-21305">P1Y11M4D</iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedWeightedAverageRemainingContractualTerms>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod
      contextRef="c114"
      decimals="INF"
      id="ixv-25964"
      unitRef="shares">-1709760</iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue
      contextRef="c114"
      decimals="3"
      id="ixv-25965"
      unitRef="usdPershares">0.001</iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageGrantDateFairValue>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod
      contextRef="c114"
      decimals="INF"
      id="ixv-25966"
      unitRef="shares">-1277350</iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue
      contextRef="c114"
      decimals="2"
      id="ixv-25967"
      unitRef="usdPershares">5.25</iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageGrantDateFairValue>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms contextRef="c114" id="ixv-21360">P0Y6M14D</iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c151"
      decimals="INF"
      id="ixv-25968"
      unitRef="shares">7728611</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c151"
      decimals="2"
      id="ixv-25969"
      unitRef="usdPershares">4.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="c114" id="ixv-21388">P1Y7M17D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="c0" id="ixv-21400">&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The following table summarizes information about the Company&#x2019;s outstanding warrants as of December 31, 2024&lt;/span&gt;&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Warrants&lt;br/&gt; outstanding&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;as of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;December 31, 2024&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expiration date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 41%; text-align: center; padding-left: 2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,640,455&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 40%; text-align: center; padding-left: 1.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;15/07/2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: center; padding-left: 2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;277,835&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: center; padding-left: 1.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;15/07/2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: center; padding-left: 2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.875&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;145,455&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: center; padding-left: 1.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;15/01/2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: center; padding-left: 2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.6&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;212,188&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: center; padding-left: 1.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;28/06/2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: center; padding-left: 2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.56&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;185,591&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: center; padding-left: 1.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18/06/2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="text-align: center; padding-left: 2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.1&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,608,715&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: center; padding-left: 1.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;30/06/2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: center; padding-left: 2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.001&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;658,372&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: center; padding-left: 1.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Until fully exercised&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td style="font-weight: bold; text-align: center; padding-left: 2pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,728,611&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: center; padding-left: 1.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c152"
      decimals="1"
      id="ixv-25970"
      unitRef="usdPershares">5.5</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c152"
      decimals="0"
      id="ixv-25971"
      unitRef="shares">1640455</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="c153" id="ixv-21444">2026-07-15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c154"
      decimals="1"
      id="ixv-25972"
      unitRef="usdPershares">5.5</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c154"
      decimals="0"
      id="ixv-25973"
      unitRef="shares">277835</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="c155" id="ixv-21460">2025-07-15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c156"
      decimals="3"
      id="ixv-25974"
      unitRef="usdPershares">6.875</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c156"
      decimals="0"
      id="ixv-25975"
      unitRef="shares">145455</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="c157" id="ixv-21476">2027-01-15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c158"
      decimals="1"
      id="ixv-25976"
      unitRef="usdPershares">1.6</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c158"
      decimals="0"
      id="ixv-25977"
      unitRef="shares">212188</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="c159" id="ixv-21492">2027-06-28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c160"
      decimals="2"
      id="ixv-25978"
      unitRef="usdPershares">1.56</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c160"
      decimals="0"
      id="ixv-25979"
      unitRef="shares">185591</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="c161" id="ixv-21508">2028-06-18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c162"
      decimals="1"
      id="ixv-25980"
      unitRef="usdPershares">1.1</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c162"
      decimals="0"
      id="ixv-25981"
      unitRef="shares">4608715</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="c163" id="ixv-21524">2026-06-30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c164"
      decimals="3"
      id="ixv-25982"
      unitRef="usdPershares">0.001</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c164"
      decimals="0"
      id="ixv-25983"
      unitRef="shares">658372</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentExpirationDate contextRef="c165" id="ixv-21540">Until fully exercised</iinn:ShareBasedCompensationArrangementByShareBasedPaymentExpirationDate>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c151"
      decimals="0"
      id="ixv-25984"
      unitRef="shares">7728611</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c0" id="ixv-21603">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Loss
per share has been calculated using the weighted average number of Ordinary Shares and pre-funded warrants in issue during the relevant
financial periods, the weighted average number of equity shares in issue and profit for the period as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Loss
    for the period&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11,053&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11,286&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;14,976&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total number of Ordinary
    Shares&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;24,252,096&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;15,652,176&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11,338,940&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted average number of Ordinary Shares
    and pre-funded warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,515,545&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;12,095,477&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,794,594&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Basic
    and diluted loss per share&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(0.60&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(0.93&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1.39&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-25985" unitRef="usd">-11053000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c6" decimals="-3" id="ixv-25986" unitRef="usd">-11286000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c7" decimals="-3" id="ixv-25987" unitRef="usd">-14976000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c4"
      decimals="INF"
      id="ixv-25988"
      unitRef="shares">24252096</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c5"
      decimals="INF"
      id="ixv-25989"
      unitRef="shares">15652176</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c20"
      decimals="INF"
      id="ixv-25990"
      unitRef="shares">11338940</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c0"
      decimals="INF"
      id="ixv-25991"
      unitRef="shares">18515545</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c6"
      decimals="INF"
      id="ixv-25992"
      unitRef="shares">12095477</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c7"
      decimals="INF"
      id="ixv-25993"
      unitRef="shares">10794594</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="2"
      id="ixv-25994"
      unitRef="usdPershares">-0.6</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c0"
      decimals="2"
      id="ixv-25995"
      unitRef="usdPershares">-0.6</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c6"
      decimals="2"
      id="ixv-25996"
      unitRef="usdPershares">-0.93</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c6"
      decimals="2"
      id="ixv-25997"
      unitRef="usdPershares">-0.93</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c7"
      decimals="2"
      id="ixv-25998"
      unitRef="usdPershares">-1.39</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c7"
      decimals="2"
      id="ixv-25999"
      unitRef="usdPershares">-1.39</us-gaap:EarningsPerShareBasic>
    <us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock contextRef="c0" id="ixv-21797">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
12 - RESEARCH AND DEVELOPMENT EXPENSES:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Salary
    and related expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,079&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,429&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,458&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Materials
    and related expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;812&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,365&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,082&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Share based payment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;801&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;663&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,392&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;371&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;291&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;188&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Subcontractors&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;340&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;304&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;850&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;IIA
    participation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(286&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-71; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-72; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;206&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;268&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;213&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,323&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,320&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8,183&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock contextRef="c0" id="ixv-21804">&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Salary
    and related expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,079&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,429&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,458&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Materials
    and related expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;812&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,365&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,082&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Share based payment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;801&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;663&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,392&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;371&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;291&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;188&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Subcontractors&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;340&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;304&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;850&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;IIA
    participation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(286&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-71; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-72; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;206&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;268&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;213&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,323&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,320&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8,183&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock>
    <us-gaap:LaborAndRelatedExpense contextRef="c0" decimals="-3" id="ixv-26000" unitRef="usd">4079000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense contextRef="c6" decimals="-3" id="ixv-26001" unitRef="usd">4429000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense contextRef="c7" decimals="-3" id="ixv-26002" unitRef="usd">3458000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:OtherLaborRelatedExpenses contextRef="c0" decimals="-3" id="ixv-26003" unitRef="usd">812000</us-gaap:OtherLaborRelatedExpenses>
    <us-gaap:OtherLaborRelatedExpenses contextRef="c6" decimals="-3" id="ixv-26004" unitRef="usd">1365000</us-gaap:OtherLaborRelatedExpenses>
    <us-gaap:OtherLaborRelatedExpenses contextRef="c7" decimals="-3" id="ixv-26005" unitRef="usd">1082000</us-gaap:OtherLaborRelatedExpenses>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c0" decimals="-3" id="ixv-26006" unitRef="usd">801000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c6" decimals="-3" id="ixv-26007" unitRef="usd">663000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c7" decimals="-3" id="ixv-26008" unitRef="usd">2392000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:DepreciationNonproduction contextRef="c0" decimals="-3" id="ixv-26009" unitRef="usd">371000</us-gaap:DepreciationNonproduction>
    <us-gaap:DepreciationNonproduction contextRef="c6" decimals="-3" id="ixv-26010" unitRef="usd">291000</us-gaap:DepreciationNonproduction>
    <us-gaap:DepreciationNonproduction contextRef="c7" decimals="-3" id="ixv-26011" unitRef="usd">188000</us-gaap:DepreciationNonproduction>
    <iinn:Subcontractors contextRef="c0" decimals="-3" id="ixv-26012" unitRef="usd">340000</iinn:Subcontractors>
    <iinn:Subcontractors contextRef="c6" decimals="-3" id="ixv-26013" unitRef="usd">304000</iinn:Subcontractors>
    <iinn:Subcontractors contextRef="c7" decimals="-3" id="ixv-26014" unitRef="usd">850000</iinn:Subcontractors>
    <iinn:IIAParticipation contextRef="c0" decimals="-3" id="ixv-26015" unitRef="usd">286000</iinn:IIAParticipation>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c0" decimals="-3" id="ixv-26016" unitRef="usd">206000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c6" decimals="-3" id="ixv-26017" unitRef="usd">268000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c7" decimals="-3" id="ixv-26018" unitRef="usd">213000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="-3" id="ixv-26019" unitRef="usd">6323000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c6" decimals="-3" id="ixv-26020" unitRef="usd">7320000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c7" decimals="-3" id="ixv-26021" unitRef="usd">8183000</us-gaap:ResearchAndDevelopmentExpense>
    <iinn:GeneralAndAdministrativeExpensesTextBlock contextRef="c0" id="ixv-22106">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE 13
- GENERAL AND ADMINISTRATIVE EXPENSES:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended&lt;br/&gt; December 31, &lt;br/&gt; 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended&lt;br/&gt; December 31, &lt;br/&gt; 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended&lt;br/&gt; December 31, &lt;br/&gt; 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,758&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,432&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,500&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Salary and related expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;808&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;766&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;716&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Share-based payment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;716&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;675&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,984&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Director fees&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;239&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;241&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;239&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Insurance expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;196&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;300&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;557&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Office maintenance&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;135&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;129&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;102&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;117&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;115&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;104&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Travel abroad&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;104&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;105&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Fundraising expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-73; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;260&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-74; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Others&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;112&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;45&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;68&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,185&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,063&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;,5375&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</iinn:GeneralAndAdministrativeExpensesTextBlock>
    <iinn:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock contextRef="c0" id="ixv-22112">&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended&lt;br/&gt; December 31, &lt;br/&gt; 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended&lt;br/&gt; December 31, &lt;br/&gt; 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended&lt;br/&gt; December 31, &lt;br/&gt; 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,758&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,432&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,500&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Salary and related expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;808&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;766&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;716&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Share-based payment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;716&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;675&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,984&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Director fees&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;239&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;241&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;239&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Insurance expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;196&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;300&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;557&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Office maintenance&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;135&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;129&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;102&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;117&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;115&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;104&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Travel abroad&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;104&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;105&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Fundraising expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-73; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;260&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-74; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Others&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;112&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;45&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;68&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,185&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,063&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;,5375&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</iinn:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock>
    <us-gaap:ProfessionalFees
      contextRef="c166"
      decimals="-3"
      id="ixv-26022"
      unitRef="usd">1758000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="c167"
      decimals="-3"
      id="ixv-26023"
      unitRef="usd">1432000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="c168"
      decimals="-3"
      id="ixv-26024"
      unitRef="usd">1500000</us-gaap:ProfessionalFees>
    <us-gaap:OfficersCompensation
      contextRef="c166"
      decimals="-3"
      id="ixv-26025"
      unitRef="usd">808000</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="c167"
      decimals="-3"
      id="ixv-26026"
      unitRef="usd">766000</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="c168"
      decimals="-3"
      id="ixv-26027"
      unitRef="usd">716000</us-gaap:OfficersCompensation>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c166"
      decimals="-3"
      id="ixv-26028"
      unitRef="usd">716000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c167"
      decimals="-3"
      id="ixv-26029"
      unitRef="usd">675000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c168"
      decimals="-3"
      id="ixv-26030"
      unitRef="usd">1984000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:LegalFees
      contextRef="c166"
      decimals="-3"
      id="ixv-26031"
      unitRef="usd">239000</us-gaap:LegalFees>
    <us-gaap:LegalFees
      contextRef="c167"
      decimals="-3"
      id="ixv-26032"
      unitRef="usd">241000</us-gaap:LegalFees>
    <us-gaap:LegalFees
      contextRef="c168"
      decimals="-3"
      id="ixv-26033"
      unitRef="usd">239000</us-gaap:LegalFees>
    <us-gaap:GeneralInsuranceExpense
      contextRef="c166"
      decimals="-3"
      id="ixv-26034"
      unitRef="usd">196000</us-gaap:GeneralInsuranceExpense>
    <us-gaap:GeneralInsuranceExpense
      contextRef="c167"
      decimals="-3"
      id="ixv-26035"
      unitRef="usd">300000</us-gaap:GeneralInsuranceExpense>
    <us-gaap:GeneralInsuranceExpense
      contextRef="c168"
      decimals="-3"
      id="ixv-26036"
      unitRef="usd">557000</us-gaap:GeneralInsuranceExpense>
    <us-gaap:CostMaintenance
      contextRef="c166"
      decimals="-3"
      id="ixv-26037"
      unitRef="usd">135000</us-gaap:CostMaintenance>
    <us-gaap:CostMaintenance
      contextRef="c167"
      decimals="-3"
      id="ixv-26038"
      unitRef="usd">129000</us-gaap:CostMaintenance>
    <us-gaap:CostMaintenance
      contextRef="c168"
      decimals="-3"
      id="ixv-26039"
      unitRef="usd">102000</us-gaap:CostMaintenance>
    <us-gaap:Depreciation
      contextRef="c166"
      decimals="-3"
      id="ixv-26040"
      unitRef="usd">117000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="c167"
      decimals="-3"
      id="ixv-26041"
      unitRef="usd">115000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="c168"
      decimals="-3"
      id="ixv-26042"
      unitRef="usd">104000</us-gaap:Depreciation>
    <us-gaap:TravelAndEntertainmentExpense
      contextRef="c166"
      decimals="-3"
      id="ixv-26043"
      unitRef="usd">104000</us-gaap:TravelAndEntertainmentExpense>
    <us-gaap:TravelAndEntertainmentExpense
      contextRef="c167"
      decimals="-3"
      id="ixv-26044"
      unitRef="usd">100000</us-gaap:TravelAndEntertainmentExpense>
    <us-gaap:TravelAndEntertainmentExpense
      contextRef="c168"
      decimals="-3"
      id="ixv-26045"
      unitRef="usd">105000</us-gaap:TravelAndEntertainmentExpense>
    <iinn:FundraisingExpenses
      contextRef="c167"
      decimals="-3"
      id="ixv-26046"
      unitRef="usd">260000</iinn:FundraisingExpenses>
    <us-gaap:OtherGeneralExpense
      contextRef="c166"
      decimals="-3"
      id="ixv-26047"
      unitRef="usd">112000</us-gaap:OtherGeneralExpense>
    <us-gaap:OtherGeneralExpense
      contextRef="c167"
      decimals="-3"
      id="ixv-26048"
      unitRef="usd">45000</us-gaap:OtherGeneralExpense>
    <us-gaap:OtherGeneralExpense
      contextRef="c168"
      decimals="-3"
      id="ixv-26049"
      unitRef="usd">68000</us-gaap:OtherGeneralExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c166"
      decimals="-3"
      id="ixv-26050"
      unitRef="usd">4185000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c167"
      decimals="-3"
      id="ixv-26051"
      unitRef="usd">4063000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c168"
      decimals="-3"
      id="ixv-26052"
      unitRef="usd">5375000</us-gaap:GeneralAndAdministrativeExpense>
    <iinn:SalesAndMarketingExpensesTextBlock contextRef="c0" id="ixv-22465">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE 14
- SALES AND MARKETING EXPENSES:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended&lt;br/&gt; December 31,&lt;br/&gt; 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended&lt;br/&gt; December 31,&lt;br/&gt; 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Salary and related expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;266&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;248&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;282&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Share-based payment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;250&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;89&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;503&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;187&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;348&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;527&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;51&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;61&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;16&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;754&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;746&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,328&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</iinn:SalesAndMarketingExpensesTextBlock>
    <iinn:ScheduleOfSalesAndMarketingExpensesTableTextBlock contextRef="c0" id="ixv-22472">&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended&lt;br/&gt; December&#160;31, &lt;br/&gt; 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended&lt;br/&gt; December 31,&lt;br/&gt; 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended&lt;br/&gt; December 31,&lt;br/&gt; 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Salary and related expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;266&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;248&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;282&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Share-based payment&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;250&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;89&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;503&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;187&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;348&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;527&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;51&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;61&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;16&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;754&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;746&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,328&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</iinn:ScheduleOfSalesAndMarketingExpensesTableTextBlock>
    <us-gaap:OfficersCompensation contextRef="c0" decimals="-3" id="ixv-26053" unitRef="usd">266000</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation contextRef="c6" decimals="-3" id="ixv-26054" unitRef="usd">248000</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation contextRef="c7" decimals="-3" id="ixv-26055" unitRef="usd">282000</us-gaap:OfficersCompensation>
    <us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold contextRef="c0" decimals="-3" id="ixv-26056" unitRef="usd">250000</us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold>
    <us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold contextRef="c6" decimals="-3" id="ixv-26057" unitRef="usd">89000</us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold>
    <us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold contextRef="c7" decimals="-3" id="ixv-26058" unitRef="usd">503000</us-gaap:CompensationExpenseExcludingCostOfGoodAndServiceSold>
    <us-gaap:ProfessionalFees contextRef="c0" decimals="-3" id="ixv-26059" unitRef="usd">187000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees contextRef="c6" decimals="-3" id="ixv-26060" unitRef="usd">348000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees contextRef="c7" decimals="-3" id="ixv-26061" unitRef="usd">527000</us-gaap:ProfessionalFees>
    <us-gaap:OtherSellingAndMarketingExpense contextRef="c0" decimals="-3" id="ixv-26062" unitRef="usd">51000</us-gaap:OtherSellingAndMarketingExpense>
    <us-gaap:OtherSellingAndMarketingExpense contextRef="c6" decimals="-3" id="ixv-26063" unitRef="usd">61000</us-gaap:OtherSellingAndMarketingExpense>
    <us-gaap:OtherSellingAndMarketingExpense contextRef="c7" decimals="-3" id="ixv-26064" unitRef="usd">16000</us-gaap:OtherSellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c0" decimals="-3" id="ixv-26065" unitRef="usd">754000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c6" decimals="-3" id="ixv-26066" unitRef="usd">746000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c7" decimals="-3" id="ixv-26067" unitRef="usd">1328000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock contextRef="c0" id="ixv-22662">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE 15&#x2013;
FINANCIAL (INCOME) AND EXPENSES:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended&lt;br/&gt; December 31, &lt;br/&gt; 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended&lt;br/&gt; December 31, &lt;br/&gt; 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended&lt;br/&gt; December 31, &lt;br/&gt; 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Revaluation of financial liabilities
    at fair value through profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;36&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(306&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(108&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Foreign currency transaction income&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(77&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(233&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;530&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Finance expense in respect of lease liability&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-75; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-76; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(143&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Others&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(4&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    expenses (Income)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(42&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(529&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;275&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock contextRef="c0" id="ixv-22669">&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended&lt;br/&gt; December 31, &lt;br/&gt; 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended&lt;br/&gt; December 31, &lt;br/&gt; 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended&lt;br/&gt; December 31, &lt;br/&gt; 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Revaluation of financial liabilities
    at fair value through profit or loss&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;36&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(306&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(108&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Foreign currency transaction income&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(77&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(233&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;530&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Finance expense in respect of lease liability&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-75; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-76; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(143&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Others&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(4&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    expenses (Income)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(42&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(529&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;275&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <iinn:RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss contextRef="c0" decimals="-3" id="ixv-26068" unitRef="usd">36000</iinn:RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss>
    <iinn:RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss contextRef="c6" decimals="-3" id="ixv-26069" unitRef="usd">-306000</iinn:RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss>
    <iinn:RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss contextRef="c7" decimals="-3" id="ixv-26070" unitRef="usd">-108000</iinn:RevaluationOfFinancialLiabilitiesAtFairValueThroughProfitOrLoss>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c0" decimals="-3" id="ixv-26071" unitRef="usd">-77000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c6" decimals="-3" id="ixv-26072" unitRef="usd">-233000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c7" decimals="-3" id="ixv-26073" unitRef="usd">530000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c7" decimals="-3" id="ixv-26074" unitRef="usd">143000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c0" decimals="-3" id="ixv-26075" unitRef="usd">-1000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c6" decimals="-3" id="ixv-26076" unitRef="usd">10000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c7" decimals="-3" id="ixv-26077" unitRef="usd">-4000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c0" decimals="-3" id="ixv-26078" unitRef="usd">42000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c6" decimals="-3" id="ixv-26079" unitRef="usd">529000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c7" decimals="-3" id="ixv-26080" unitRef="usd">-275000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c0" id="ixv-22894">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE 16
- TAXES ON INCOME: &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;A.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Taxes
                                            on income:&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Israeli corporate tax rate was 23% in 2024 and 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;B.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Net
                                            operating losses carry forwards&lt;/b&gt;:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Carryforward
tax losses of the Company as of December 31, 2023, amounted to approximately $24,000; however, a full valuation allowance of $7,000 was
recorded against the potential future tax benefits.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Carryforward
tax losses of the Company as of December 31, 2024, amounted to approximately $29,000; however, a full valuation allowance of $8,000 was
recorded against the potential future tax benefits.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
deferred tax assets and liabilities are composed of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December&#160;31, &lt;br/&gt;
2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December&#160;31, &lt;br/&gt;
2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net
    operating loss carryforward&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,739&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,519&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accrued
    expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;97&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;80&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;R&amp;amp;D
    temporary differences&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,218&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,335&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Fund raising costs
    2023&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;35&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;70&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating
    lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8,097&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,012&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Valuation
    allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(8,097&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(7,012&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred
    tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-77; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-78; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net
    deferred taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-79; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-80; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;C.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Theoretical tax:&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Loss before taxation&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(11,053&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(11,286&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(14,976&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Theoretical tax credit at applicable statutory rate: 23%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(2,542&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(2,596&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3,444&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Non-allowable expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(391&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(244&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,026&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Temporary
    differences and tax losses for which no Deferred Tax Asset is recognized&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(2,151&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(2,352&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(2,418&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-81; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-82; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-83; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="c169"
      decimals="2"
      id="ixv-26081"
      unitRef="pure">0.23</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="c170"
      decimals="2"
      id="ixv-26082"
      unitRef="pure">0.23</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:OperatingLossCarryforwards contextRef="c5" decimals="-3" id="ixv-26083" unitRef="usd">24000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsNet contextRef="c5" decimals="-3" id="ixv-26084" unitRef="usd">7000000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:OperatingLossCarryforwards contextRef="c4" decimals="-3" id="ixv-26085" unitRef="usd">29000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsNet contextRef="c4" decimals="-3" id="ixv-26086" unitRef="usd">8000000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c0" id="ixv-22935">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
deferred tax assets and liabilities are composed of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December&#160;31, &lt;br/&gt;
2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December&#160;31, &lt;br/&gt;
2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net
    operating loss carryforward&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,739&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5,519&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accrued
    expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;97&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;80&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;R&amp;amp;D
    temporary differences&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,218&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,335&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Fund raising costs
    2023&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;35&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;70&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating
    lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8,097&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,012&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Valuation
    allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(8,097&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(7,012&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Deferred
    tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-77; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-78; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Net
    deferred taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-79; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-80; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c4" decimals="-3" id="ixv-26087" unitRef="usd">6739000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c5" decimals="-3" id="ixv-26088" unitRef="usd">5519000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <iinn:DeferredTaxAssetsAccruedExpenses contextRef="c4" decimals="-3" id="ixv-26089" unitRef="usd">97000</iinn:DeferredTaxAssetsAccruedExpenses>
    <iinn:DeferredTaxAssetsAccruedExpenses contextRef="c5" decimals="-3" id="ixv-26090" unitRef="usd">80000</iinn:DeferredTaxAssetsAccruedExpenses>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c4" decimals="-3" id="ixv-26091" unitRef="usd">1218000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c5" decimals="-3" id="ixv-26092" unitRef="usd">1335000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <iinn:DeferredTaxAssetsFundRaisingCost2023 contextRef="c4" decimals="-3" id="ixv-26093" unitRef="usd">35000</iinn:DeferredTaxAssetsFundRaisingCost2023>
    <iinn:DeferredTaxAssetsFundRaisingCost2023 contextRef="c5" decimals="-3" id="ixv-26094" unitRef="usd">70000</iinn:DeferredTaxAssetsFundRaisingCost2023>
    <iinn:DeferredTaxLiabilitiesOperatingLeaseLiability contextRef="c4" decimals="-3" id="ixv-26095" unitRef="usd">-8000</iinn:DeferredTaxLiabilitiesOperatingLeaseLiability>
    <iinn:DeferredTaxLiabilitiesOperatingLeaseLiability contextRef="c5" decimals="-3" id="ixv-26096" unitRef="usd">-8000</iinn:DeferredTaxLiabilitiesOperatingLeaseLiability>
    <us-gaap:DeferredTaxAssetsGross contextRef="c4" decimals="-3" id="ixv-26097" unitRef="usd">8097000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c5" decimals="-3" id="ixv-26098" unitRef="usd">7012000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c4" decimals="-3" id="ixv-26099" unitRef="usd">8097000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c5" decimals="-3" id="ixv-26100" unitRef="usd">7012000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <iinn:ScheduleOfTheoreticalTaxTableTextBlock contextRef="c0" id="ixv-23169">&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;C.&lt;/b&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Theoretical tax:&lt;/b&gt;&lt;/span&gt;&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended&lt;br/&gt; December&#160;31,&lt;br/&gt; 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Loss before taxation&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(11,053&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(11,286&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(14,976&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Theoretical tax credit at applicable statutory rate: 23%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(2,542&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(2,596&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(3,444&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Non-allowable expenses&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(391&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(244&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(1,026&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Temporary
    differences and tax losses for which no Deferred Tax Asset is recognized&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(2,151&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(2,352&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(2,418&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-81; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-82; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-83; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</iinn:ScheduleOfTheoreticalTaxTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c0" decimals="-3" id="ixv-26101" unitRef="usd">-11053000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c6" decimals="-3" id="ixv-26102" unitRef="usd">-11286000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c7" decimals="-3" id="ixv-26103" unitRef="usd">-14976000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c0" decimals="2" id="ixv-26104" unitRef="pure">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c6" decimals="2" id="ixv-26105" unitRef="pure">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c7" decimals="2" id="ixv-26106" unitRef="pure">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <iinn:EffectiveIncomeTaxTheoreticalTaxCredit contextRef="c0" decimals="-3" id="ixv-26107" unitRef="usd">2542000</iinn:EffectiveIncomeTaxTheoreticalTaxCredit>
    <iinn:EffectiveIncomeTaxTheoreticalTaxCredit contextRef="c6" decimals="-3" id="ixv-26108" unitRef="usd">2596000</iinn:EffectiveIncomeTaxTheoreticalTaxCredit>
    <iinn:EffectiveIncomeTaxTheoreticalTaxCredit contextRef="c7" decimals="-3" id="ixv-26109" unitRef="usd">3444000</iinn:EffectiveIncomeTaxTheoreticalTaxCredit>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="c0" decimals="-3" id="ixv-26110" unitRef="usd">391000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="c6" decimals="-3" id="ixv-26111" unitRef="usd">244000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="c7" decimals="-3" id="ixv-26112" unitRef="usd">1026000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <iinn:TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized contextRef="c0" decimals="-3" id="ixv-26113" unitRef="usd">2151000</iinn:TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized>
    <iinn:TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized contextRef="c6" decimals="-3" id="ixv-26114" unitRef="usd">2352000</iinn:TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized>
    <iinn:TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized contextRef="c7" decimals="-3" id="ixv-26115" unitRef="usd">2418000</iinn:TemporaryDifferencesAndTaxLossesForWhichNoDeferredTaxAssetIsRecognized>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c0" id="ixv-23399">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE 17
&#x2013; SHARE-BASED PAYMENT:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.&#160;
On March 24, 2022, the Company&#x2019;s board of directors (&#x201c;Board of directors&#x201d;) approved a grant of 536,141 RSUs to employees
and a grant of 22,500 RSUs to the Company&#x2019;s advisory board members and an additional consultant. The RSUs represent the right to
receive Ordinary Shares at a future time. 555,500 of the RSUs in this grant, vest over a period of three years, with a 1-year cliff period,
and 3,141 RSUs vested immediately on the grant date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.&#160;
On March 24, 2022, the Company&#x2019;s Board of Directors approved a grant of 29,400 Ordinary Shares options to medical board members,
which are exercisable to 29,400 Ordinary Shares. The share options vesting period is up to three years from the grant date. The exercise
price per share was NIS 10.84 ($3.08). The contractual life of the options under the 2019 Equity Incentive Plan is ten years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.&#160;
On April 6, 2022, the Company&#x2019;s Board of Directors approved a grant of 285,713 fully vested RSUs to an officer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.&#160;
On May 19, 2022, the Company&#x2019;s Board of Directors approved a grant of 30,000 RSUs to an employee. The RSUs vest over a period of
three years, with a 1-year cliff period, commencing on the grant date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.&#160;
On November 22, 2022, the Company&#x2019;s Board of Directors approved a grant of 165,000 RSUs to employees. The RSUs vest over a period
of three years, with a 1-year cliff period, commencing on the grant date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.&#160;
On January 22, 2024, the Company&#x2019;s Board of Directors approved a grant of 320,000 RSUs to employees and a grant of options to purchase
80,000 shares to consultants. The RSUs represents the right to receive Ordinary Shares at a future time, 245,000 of which vest over a
period of three years, with a one-year cliff period and 70,000 vesting immediately on the grant date. 10,000 of the options were vested
immediately on the grant date, 25,000 option vest over a period of three years and 45,000 option vests over a period of one year and
nine months. The RSUs designated to employees were granted under Section 102 of the Israeli Tax Ordinance, which enables the employee
to pay a 25% capital gain tax upon exercise.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.&#160;
On February 5, 2024, the Company&#x2019;s Board of Directors approved a grant of 2,277,000 RSUs to officers, a grant of options to purchase
30,000 Ordinary Shares and 90,000 RSUs to directors. The RSUs and options represents the right to receive Ordinary Shares at a future
time and vest over a period of three years, with a one-year cliff. The RSUs designated to employees and directors were granted under
Section 102 of the Israeli Tax Ordinance, which enables the employee to pay a 25% capital gain tax upon exercise.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
fair value of all granted options was estimated by using the Black Scholes option pricing model, which was aimed to model the value of
the Company&#x2019;s assets over time. The simulation approach was designed to take into account the terms and conditions of the share
options, as well as the capital structure of the Company and the volatility of its assets, on the date of grant based on certain assumptions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following inputs were used to measure the fair value of the option at grant date:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;March
    24, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;January
    22, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;February
    5, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 5%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(i)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 47%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 15%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;52%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 15%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;144.83%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 15%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;143.98%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(ii)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(iii)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected term (vesting period)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Three years&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Three years&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-84; font-family: Times New Roman, Times, Serif"&gt;Three years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(iv)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Contractual life&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Ten years&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Ten years&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-85; font-family: Times New Roman, Times, Serif"&gt;Ten years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(v)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Free risk rate&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.79%-2.80%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.03%-4.07%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.16%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
fair value of all granted RSUs was the Company&#x2019;s quote price at the grant date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;During the
year ended December 31, 2024, the Company recorded share-based payment expenses to employees, directors and subcontractors in the amount
of $1,767.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;During the
year ended December 31, 2023, the Company recorded share-based payment expenses to employees, directors and subcontractors in the amount
of $1,427.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;During the
year ended December 31, 2022, the Company recorded share-based payment expenses to employees, directors and subcontractors in the amount
of $4,879.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The options
to services providers and advisers outstanding as December 31, 2024, 2023 and 2022 were as&#160;follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended&lt;br/&gt; December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended&lt;br/&gt; December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended&lt;br/&gt; December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of &lt;br/&gt; options&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted
    &lt;br/&gt; average &lt;br/&gt; Exercise &lt;br/&gt; price NIS&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of &lt;br/&gt; options&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted
    &lt;br/&gt; average &lt;br/&gt; Exercise &lt;br/&gt; price NIS&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of&lt;br/&gt; options&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted
    &lt;br/&gt; average &lt;br/&gt; Exercise &lt;br/&gt; price NIS&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;105,111&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.085&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;114,512&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.058&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;87,833&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.37&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Reclassified to employees and directors&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-86; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-87; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-88; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-89; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-90; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-91; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;80,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.779&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-92; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-93; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;29,400&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10.84&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-94; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-95; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9,401&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.367&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(2,721&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.37&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-96; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-97; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-98; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-99; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-100; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-101; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 1.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options
    outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;185,111&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.359&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;105,111&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.085&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;114,512&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.058&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 1.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options
    exercisable&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;162,154&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.251&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;94,242&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.267&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;82,257&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.37&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 1.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Share-based
    payment expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;66&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;19&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;54&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The RSUs
to services providers and advisers outstanding as of December 31, 2024, 2023 and 2022 were as&#160;follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended&lt;br/&gt; December 31, &lt;br/&gt;
2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended&lt;br/&gt; December 31, &lt;br/&gt;
2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended&lt;br/&gt; December 31, &lt;br/&gt;
2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of &lt;br/&gt;
RSUs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of &lt;br/&gt;
RSUs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of &lt;br/&gt;
RSUs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,433&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,266&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-107; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-108; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;22,500&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,433&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,833&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;14,234&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 1.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;RSUs
    outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-109; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,433&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,266&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 1.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;RSU&#x2019;s
    Vested&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;32,500&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;25,067&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;14,234&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 1.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Share-based
    payment expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;33&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The options
to employees and directors outstanding as of December 31, 2024, 2023 and 2022 were as&#160;follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended&lt;br/&gt; December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended&lt;br/&gt; December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended&lt;br/&gt; December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of &lt;br/&gt; options&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted
    &lt;br/&gt; average &lt;br/&gt; Exercise &lt;br/&gt; price NIS&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of &lt;br/&gt; options&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted
    &lt;br/&gt; average &lt;br/&gt; Exercise &lt;br/&gt; price NIS&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of &lt;br/&gt; options&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted
    &lt;br/&gt; average &lt;br/&gt; Exercise &lt;br/&gt; price NIS&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;357,689&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.37&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;386,260&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.37&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;448,120&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.37&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;30,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.56&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-102; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-103; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-104; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;19,048&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.37&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.37&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,309&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.37&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-105; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-106; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;28,571&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.37&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;57,551&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.37&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 1.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options
    outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;368,641&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.70&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;357,689&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.37&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;386,260&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.37&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 1.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options
    exercisable&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;338,641&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.45&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;350,131&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.37&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;342,757&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.37&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 1.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Share-based
    payment expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;17&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;47&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;174&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The RSUs
to employees and directors outstanding as of December 31, 2024, 2023 and 2022 were as&#160;follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended&lt;br/&gt; December&#160;31, &lt;br/&gt;
    2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended&lt;br/&gt; December&#160;31, &lt;br/&gt;
    2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended&lt;br/&gt; December&#160;31, &lt;br/&gt;
    2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of&lt;br/&gt;
 RSUs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of&lt;br/&gt;
 RSUs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of&lt;br/&gt;
 RSUs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;445,140&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,727,842&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,002,587&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,687,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-110; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,016,854&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;25,836&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;67,087&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;65,626&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;587,508&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,215,615&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,225,973&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 1.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;RSUs
    outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,518,796&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;445,140&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,727,842&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 1.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;RSU&#x2019;s
    Vested&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,684,697&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,097,189&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,881,574&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 1.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Share-based
    payment expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,683&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,352&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,618&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c171"
      decimals="0"
      id="ixv-26116"
      unitRef="shares">536141</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c172"
      decimals="0"
      id="ixv-26117"
      unitRef="shares">22500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c173"
      decimals="0"
      id="ixv-26118"
      unitRef="shares">555500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c174" id="ixv-26119">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="c174"
      decimals="0"
      id="ixv-26120"
      unitRef="shares">3141</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c175"
      decimals="0"
      id="ixv-26121"
      unitRef="shares">29400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c176"
      decimals="0"
      id="ixv-26122"
      unitRef="shares">29400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c177" id="ixv-26123">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c178"
      decimals="2"
      id="ixv-26124"
      unitRef="ilsPershares">10.84</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c178"
      decimals="2"
      id="ixv-26125"
      unitRef="usdPershares">3.08</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward contextRef="c179" id="ixv-26126">ten</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c180"
      decimals="0"
      id="ixv-26127"
      unitRef="shares">285713</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c181"
      decimals="0"
      id="ixv-26128"
      unitRef="shares">30000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c182" id="ixv-26129">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c183"
      decimals="0"
      id="ixv-26130"
      unitRef="shares">165000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c184" id="ixv-26131">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c185"
      decimals="0"
      id="ixv-26132"
      unitRef="shares">320000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="c186"
      decimals="0"
      id="ixv-26133"
      unitRef="shares">80000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c187"
      decimals="0"
      id="ixv-26134"
      unitRef="shares">245000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c186" id="ixv-26135">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="c188"
      decimals="0"
      id="ixv-26136"
      unitRef="shares">70000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="c189"
      decimals="0"
      id="ixv-26137"
      unitRef="shares">10000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="c190"
      decimals="0"
      id="ixv-26138"
      unitRef="shares">25000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c191" id="ixv-26139">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="c192"
      decimals="0"
      id="ixv-26140"
      unitRef="shares">45000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <iinn:CapitalGainTaxRate contextRef="c0" decimals="2" id="ixv-26141" unitRef="pure">0.25</iinn:CapitalGainTaxRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c193"
      decimals="0"
      id="ixv-26142"
      unitRef="shares">2277000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="c194"
      decimals="0"
      id="ixv-26143"
      unitRef="shares">30000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c195"
      decimals="0"
      id="ixv-26144"
      unitRef="shares">90000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c193" id="ixv-26145">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <iinn:PercentageOfCapitalGainTax
      contextRef="c196"
      decimals="2"
      id="ixv-26146"
      unitRef="pure">0.25</iinn:PercentageOfCapitalGainTax>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c0" id="ixv-23438">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following inputs were used to measure the fair value of the option at grant date:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;March
    24, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;January
    22, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;February
    5, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 5%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(i)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 47%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 15%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;52%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 15%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;144.83%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 15%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;143.98%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(ii)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(iii)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected term (vesting period)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Three years&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Three years&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-84; font-family: Times New Roman, Times, Serif"&gt;Three years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(iv)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Contractual life&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Ten years&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Ten years&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-85; font-family: Times New Roman, Times, Serif"&gt;Ten years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(v)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Free risk rate&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.79%-2.80%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.03%-4.07%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.16%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c178"
      decimals="2"
      id="ixv-26147"
      unitRef="pure">0.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c189"
      decimals="4"
      id="ixv-26148"
      unitRef="pure">1.4483</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c196"
      decimals="4"
      id="ixv-26149"
      unitRef="pure">1.4398</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c178"
      decimals="2"
      id="ixv-26150"
      unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c189"
      decimals="2"
      id="ixv-26151"
      unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c196"
      decimals="2"
      id="ixv-26152"
      unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c200"
      decimals="4"
      id="ixv-26153"
      unitRef="pure">0.0279</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c201"
      decimals="4"
      id="ixv-26154"
      unitRef="pure">0.028</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c202"
      decimals="4"
      id="ixv-26155"
      unitRef="pure">0.0403</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c203"
      decimals="4"
      id="ixv-26156"
      unitRef="pure">0.0407</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c196"
      decimals="4"
      id="ixv-26157"
      unitRef="pure">0.0416</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c197"
      decimals="-3"
      id="ixv-26158"
      unitRef="usd">1767000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c198"
      decimals="-3"
      id="ixv-26159"
      unitRef="usd">1427000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c199"
      decimals="-3"
      id="ixv-26160"
      unitRef="usd">4879000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c0" id="ixv-23605">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The options
to services providers and advisers outstanding as December 31, 2024, 2023 and 2022 were as&#160;follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended&lt;br/&gt; December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended&lt;br/&gt; December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended&lt;br/&gt; December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of &lt;br/&gt; options&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted
    &lt;br/&gt; average &lt;br/&gt; Exercise &lt;br/&gt; price NIS&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of &lt;br/&gt; options&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted
    &lt;br/&gt; average &lt;br/&gt; Exercise &lt;br/&gt; price NIS&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of&lt;br/&gt; options&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted
    &lt;br/&gt; average &lt;br/&gt; Exercise &lt;br/&gt; price NIS&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;105,111&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.085&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;114,512&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.058&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;87,833&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.37&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Reclassified to employees and directors&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-86; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-87; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-88; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-89; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-90; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-91; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;80,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.779&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-92; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-93; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;29,400&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10.84&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-94; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-95; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9,401&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.367&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(2,721&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.37&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-96; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-97; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-98; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-99; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-100; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-101; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 1.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options
    outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;185,111&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.359&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;105,111&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.085&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;114,512&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.058&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 1.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options
    exercisable&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;162,154&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.251&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;94,242&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.267&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;82,257&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.37&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 1.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Share-based
    payment expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;66&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;19&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;54&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The options
to employees and directors outstanding as of December 31, 2024, 2023 and 2022 were as&#160;follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended&lt;br/&gt; December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended&lt;br/&gt; December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended&lt;br/&gt; December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of &lt;br/&gt; options&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted
    &lt;br/&gt; average &lt;br/&gt; Exercise &lt;br/&gt; price NIS&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of &lt;br/&gt; options&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted
    &lt;br/&gt; average &lt;br/&gt; Exercise &lt;br/&gt; price NIS&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of &lt;br/&gt; options&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Weighted
    &lt;br/&gt; average &lt;br/&gt; Exercise &lt;br/&gt; price NIS&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;357,689&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.37&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;386,260&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.37&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;448,120&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.37&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;30,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.56&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-102; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-103; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-104; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;19,048&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.37&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.37&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,309&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.37&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-105; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-106; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;28,571&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.37&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;57,551&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.37&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 1.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options
    outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;368,641&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.70&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;357,689&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.37&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;386,260&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.37&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 1.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Options
    exercisable&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;338,641&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.45&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;350,131&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.37&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;342,757&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;0.37&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 1.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Share-based
    payment expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;17&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;47&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;174&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c204"
      decimals="INF"
      id="ixv-26161"
      unitRef="shares">105111</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c204"
      decimals="3"
      id="ixv-26162"
      unitRef="ilsPershares">4.085</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c205"
      decimals="INF"
      id="ixv-26163"
      unitRef="shares">114512</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c205"
      decimals="3"
      id="ixv-26164"
      unitRef="ilsPershares">3.058</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c206"
      decimals="INF"
      id="ixv-26165"
      unitRef="shares">87833</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c206"
      decimals="2"
      id="ixv-26166"
      unitRef="ilsPershares">0.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c207"
      decimals="INF"
      id="ixv-26167"
      unitRef="shares">80000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c207"
      decimals="3"
      id="ixv-26168"
      unitRef="ilsPershares">3.779</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c209"
      decimals="INF"
      id="ixv-26169"
      unitRef="shares">29400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c209"
      decimals="2"
      id="ixv-26170"
      unitRef="ilsPershares">10.84</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi
      contextRef="c208"
      decimals="INF"
      id="ixv-26171"
      unitRef="shares">9401</iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c208"
      decimals="3"
      id="ixv-26172"
      unitRef="ilsPershares">0.367</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi
      contextRef="c209"
      decimals="INF"
      id="ixv-26173"
      unitRef="shares">-2721</iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c209"
      decimals="2"
      id="ixv-26174"
      unitRef="ilsPershares">0.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c210"
      decimals="INF"
      id="ixv-26175"
      unitRef="shares">185111</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c210"
      decimals="3"
      id="ixv-26176"
      unitRef="ilsPershares">3.359</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c204"
      decimals="INF"
      id="ixv-26177"
      unitRef="shares">105111</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c204"
      decimals="3"
      id="ixv-26178"
      unitRef="ilsPershares">4.085</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c205"
      decimals="INF"
      id="ixv-26179"
      unitRef="shares">114512</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c205"
      decimals="3"
      id="ixv-26180"
      unitRef="ilsPershares">3.058</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c210"
      decimals="INF"
      id="ixv-26181"
      unitRef="shares">162154</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c210"
      decimals="3"
      id="ixv-26182"
      unitRef="ilsPershares">3.251</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c204"
      decimals="INF"
      id="ixv-26183"
      unitRef="shares">94242</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c204"
      decimals="3"
      id="ixv-26184"
      unitRef="ilsPershares">3.267</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c205"
      decimals="INF"
      id="ixv-26185"
      unitRef="shares">82257</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c205"
      decimals="2"
      id="ixv-26186"
      unitRef="ilsPershares">0.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c207"
      decimals="-3"
      id="ixv-26187"
      unitRef="usd">66000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c208"
      decimals="-3"
      id="ixv-26188"
      unitRef="usd">19000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c209"
      decimals="-3"
      id="ixv-26189"
      unitRef="usd">54000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="c0" id="ixv-24136">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The RSUs
to services providers and advisers outstanding as of December 31, 2024, 2023 and 2022 were as&#160;follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended&lt;br/&gt; December 31, &lt;br/&gt;
2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended&lt;br/&gt; December 31, &lt;br/&gt;
2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended&lt;br/&gt; December 31, &lt;br/&gt;
2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of &lt;br/&gt;
RSUs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of &lt;br/&gt;
RSUs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of &lt;br/&gt;
RSUs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,433&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,266&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-107; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-108; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;22,500&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,433&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;10,833&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;14,234&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 1.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;RSUs
    outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-109; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,433&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;18,266&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 1.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;RSU&#x2019;s
    Vested&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;32,500&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;25,067&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;14,234&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 1.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Share-based
    payment expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;33&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The RSUs
to employees and directors outstanding as of December 31, 2024, 2023 and 2022 were as&#160;follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended&lt;br/&gt; December&#160;31, &lt;br/&gt;
    2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended&lt;br/&gt; December&#160;31, &lt;br/&gt;
    2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Year
    ended&lt;br/&gt; December&#160;31, &lt;br/&gt;
    2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of&lt;br/&gt;
 RSUs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of&lt;br/&gt;
 RSUs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Number
    of&lt;br/&gt;
 RSUs&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;445,140&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,727,842&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,002,587&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,687,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-110; font-family: Times New Roman, Times, Serif"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,016,854&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;25,836&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;67,087&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;65,626&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;587,508&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,215,615&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,225,973&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 1.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;RSUs
    outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,518,796&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;445,140&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,727,842&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 1.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;RSU&#x2019;s
    Vested&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,684,697&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,097,189&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,881,574&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 1.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Share-based
    payment expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,683&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,352&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,618&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c218"
      decimals="INF"
      id="ixv-26190"
      unitRef="shares">7433</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c219"
      decimals="INF"
      id="ixv-26191"
      unitRef="shares">18266</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c220"
      decimals="INF"
      id="ixv-26192"
      unitRef="shares">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c104"
      decimals="INF"
      id="ixv-26193"
      unitRef="shares">22500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c146"
      decimals="INF"
      id="ixv-26194"
      unitRef="shares">7433</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c221"
      decimals="INF"
      id="ixv-26195"
      unitRef="shares">10833</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c104"
      decimals="INF"
      id="ixv-26196"
      unitRef="shares">14234</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c218"
      decimals="INF"
      id="ixv-26197"
      unitRef="shares">7433</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c219"
      decimals="INF"
      id="ixv-26198"
      unitRef="shares">18266</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested
      contextRef="c146"
      decimals="INF"
      id="ixv-26199"
      unitRef="shares">32500</iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested>
    <iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested
      contextRef="c221"
      decimals="INF"
      id="ixv-26200"
      unitRef="shares">25067</iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested>
    <iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested
      contextRef="c104"
      decimals="INF"
      id="ixv-26201"
      unitRef="shares">14234</iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c146"
      decimals="-3"
      id="ixv-26202"
      unitRef="usd">1000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c221"
      decimals="-3"
      id="ixv-26203"
      unitRef="usd">9000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c104"
      decimals="-3"
      id="ixv-26204"
      unitRef="usd">33000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c211"
      decimals="INF"
      id="ixv-26205"
      unitRef="shares">357689</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c211"
      decimals="2"
      id="ixv-26206"
      unitRef="ilsPershares">0.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c212"
      decimals="INF"
      id="ixv-26207"
      unitRef="shares">386260</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c212"
      decimals="2"
      id="ixv-26208"
      unitRef="ilsPershares">0.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c213"
      decimals="INF"
      id="ixv-26209"
      unitRef="shares">448120</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c213"
      decimals="2"
      id="ixv-26210"
      unitRef="ilsPershares">0.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c214"
      decimals="INF"
      id="ixv-26211"
      unitRef="shares">30000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c214"
      decimals="2"
      id="ixv-26212"
      unitRef="ilsPershares">3.56</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi
      contextRef="c214"
      decimals="INF"
      id="ixv-26213"
      unitRef="shares">19048</iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c214"
      decimals="2"
      id="ixv-26214"
      unitRef="ilsPershares">0.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c215"
      decimals="2"
      id="ixv-26215"
      unitRef="ilsPershares">0.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi
      contextRef="c216"
      decimals="INF"
      id="ixv-26216"
      unitRef="shares">4309</iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c216"
      decimals="2"
      id="ixv-26217"
      unitRef="ilsPershares">0.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c215"
      decimals="INF"
      id="ixv-26218"
      unitRef="shares">28571</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c215"
      decimals="2"
      id="ixv-26219"
      unitRef="ilsPershares">0.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c216"
      decimals="INF"
      id="ixv-26220"
      unitRef="shares">57551</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c216"
      decimals="2"
      id="ixv-26221"
      unitRef="ilsPershares">0.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c217"
      decimals="INF"
      id="ixv-26222"
      unitRef="shares">368641</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c217"
      decimals="2"
      id="ixv-26223"
      unitRef="ilsPershares">0.7</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c211"
      decimals="INF"
      id="ixv-26224"
      unitRef="shares">357689</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c211"
      decimals="2"
      id="ixv-26225"
      unitRef="ilsPershares">0.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c212"
      decimals="INF"
      id="ixv-26226"
      unitRef="shares">386260</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c212"
      decimals="2"
      id="ixv-26227"
      unitRef="ilsPershares">0.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c217"
      decimals="INF"
      id="ixv-26228"
      unitRef="shares">338641</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c217"
      decimals="2"
      id="ixv-26229"
      unitRef="ilsPershares">0.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c211"
      decimals="INF"
      id="ixv-26230"
      unitRef="shares">350131</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c211"
      decimals="2"
      id="ixv-26231"
      unitRef="ilsPershares">0.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c212"
      decimals="INF"
      id="ixv-26232"
      unitRef="shares">342757</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c212"
      decimals="2"
      id="ixv-26233"
      unitRef="ilsPershares">0.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c214"
      decimals="-3"
      id="ixv-26234"
      unitRef="usd">17000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c215"
      decimals="-3"
      id="ixv-26235"
      unitRef="usd">47000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c216"
      decimals="-3"
      id="ixv-26236"
      unitRef="usd">174000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c5"
      decimals="INF"
      id="ixv-26237"
      unitRef="shares">445140</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c20"
      decimals="INF"
      id="ixv-26238"
      unitRef="shares">1727842</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c27"
      decimals="INF"
      id="ixv-26239"
      unitRef="shares">2002587</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c0"
      decimals="INF"
      id="ixv-26240"
      unitRef="shares">2687000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c7"
      decimals="INF"
      id="ixv-26241"
      unitRef="shares">1016854</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c0"
      decimals="INF"
      id="ixv-26242"
      unitRef="shares">25836</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c6"
      decimals="INF"
      id="ixv-26243"
      unitRef="shares">67087</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c7"
      decimals="INF"
      id="ixv-26244"
      unitRef="shares">65626</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c0"
      decimals="INF"
      id="ixv-26245"
      unitRef="shares">587508</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c6"
      decimals="INF"
      id="ixv-26246"
      unitRef="shares">1215615</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c7"
      decimals="INF"
      id="ixv-26247"
      unitRef="shares">1225973</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c4"
      decimals="INF"
      id="ixv-26248"
      unitRef="shares">2518796</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c5"
      decimals="INF"
      id="ixv-26249"
      unitRef="shares">445140</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c20"
      decimals="INF"
      id="ixv-26250"
      unitRef="shares">1727842</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested
      contextRef="c0"
      decimals="INF"
      id="ixv-26251"
      unitRef="shares">3684697</iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested>
    <iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested
      contextRef="c6"
      decimals="INF"
      id="ixv-26252"
      unitRef="shares">3097189</iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested>
    <iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested
      contextRef="c7"
      decimals="INF"
      id="ixv-26253"
      unitRef="shares">1881574</iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsNumberOfRSUsVested>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c0" decimals="-3" id="ixv-26254" unitRef="usd">1683000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c6" decimals="-3" id="ixv-26255" unitRef="usd">1352000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c7" decimals="-3" id="ixv-26256" unitRef="usd">4618000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c0" id="ixv-25157">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
18 - RELATED PARTIES:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;The following
transactions arose with related parties&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration:underline"&gt;Transactions
and balances with related parties&lt;/span&gt;&lt;b&gt;:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Shareholders and other related parties&#x2019; benefits&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December&#160;31,
    &lt;br/&gt; 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December&#160;31,
    &lt;br/&gt; 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December&#160;31,&lt;br/&gt;
    2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Salary and related expenses &#x2013;
    officers and directors&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,710&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,761&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,923&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Share based payment &#x2013; officers and directors&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,376&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,009&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,745&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Balances with related parties&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Name&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Nature of transaction&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December&#160;31, &lt;br/&gt; 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December&#160;31, &lt;br/&gt; 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 20%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Officers&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 55%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Salaries and related&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(381&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(314&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Directors&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Compensation for directors&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(40&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(40&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="c0" id="ixv-25182">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Shareholders and other related parties&#x2019; benefits&lt;/span&gt;&lt;/span&gt;&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December&#160;31,
    &lt;br/&gt; 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December&#160;31,
    &lt;br/&gt; 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December&#160;31,&lt;br/&gt;
    2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Salary and related expenses &#x2013;
    officers and directors&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,710&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,761&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,923&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Share based payment &#x2013; officers and directors&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,376&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,009&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,745&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Balances with related parties&lt;/span&gt;&lt;/span&gt;&lt;table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Name&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Nature of transaction&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December&#160;31, &lt;br/&gt; 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;December&#160;31, &lt;br/&gt; 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 20%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Officers&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 55%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Salaries and related&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(381&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(314&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; "&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Directors&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Compensation for directors&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(40&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(40&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:OfficersCompensation
      contextRef="c223"
      decimals="-3"
      id="ixv-26257"
      unitRef="usd">1710000</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="c224"
      decimals="-3"
      id="ixv-26258"
      unitRef="usd">1761000</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation
      contextRef="c225"
      decimals="-3"
      id="ixv-26259"
      unitRef="usd">1923000</us-gaap:OfficersCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c223"
      decimals="-3"
      id="ixv-26260"
      unitRef="usd">1376000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c224"
      decimals="-3"
      id="ixv-26261"
      unitRef="usd">1009000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c225"
      decimals="-3"
      id="ixv-26262"
      unitRef="usd">3745000</us-gaap:ShareBasedCompensation>
    <us-gaap:NatureOfCommonOwnershipOrManagementControlRelationships contextRef="c226" id="ixv-25310">Salaries and related</us-gaap:NatureOfCommonOwnershipOrManagementControlRelationships>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="c226"
      decimals="-3"
      id="ixv-26263"
      unitRef="usd">-381000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="c227"
      decimals="-3"
      id="ixv-26264"
      unitRef="usd">-314000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:NatureOfCommonOwnershipOrManagementControlRelationships contextRef="c228" id="ixv-25334">Compensation for directors</us-gaap:NatureOfCommonOwnershipOrManagementControlRelationships>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="c228"
      decimals="-3"
      id="ixv-26265"
      unitRef="usd">-40000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="c229"
      decimals="-3"
      id="ixv-26266"
      unitRef="usd">-40000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:SubsequentEventsTextBlock contextRef="c0" id="ixv-25356">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE 19
- SUBSEQUENT EVENTS:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 17.85pt"&gt;&lt;/td&gt;&lt;td style="width: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Following the closing of the December Private Placement, $70 was wired to the Company from one of the investors before the end of the year but was registered by the receiving bank in January 2025. As a result, $70 were not included in the cash and cash equivalent as of December 31, 2024. The private offering fees and other related expenses in the amount of $220 were paid by the Company after the end of the year.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;During January and February 2025, the Company received funds in the amount of NIS 238,122 (approximately $66) from the IIA.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 17.85pt"&gt;&lt;/td&gt;&lt;td style="width: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On February 20, 2025, the Company&#x2019;s Board of Directors approved a grant of 676,000 RSUs to employees and options to purchase an aggregate of 50,000 Ordinary Shares to service providers under the 2019 Equity Incentive Plan. 20,166 RSUs are vested as of the date of these Financial Statements. &lt;span style="-sec-ix-hidden: hidden-fact-111"&gt;None&lt;/span&gt; of the total amount of the options are vested as of the date of these Financial Statements. The total grant fair value is approximately $656 that will be registered as expenses in the upcoming vesting period of three years.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.7pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 17.85pt"&gt;&lt;/td&gt;&lt;td style="width: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On February 20, 2025, the Company&#x2019;s Board of Directors approved a grant of 550,000 RSUs to certain of its executives. &lt;span style="-sec-ix-hidden: hidden-fact-112"&gt;None&lt;/span&gt; of the total amount of RSUs are vested as of the date of these Financial Statements. The total grant fair value is approximately $494 that will be registered as expenses in the upcoming vesting period of three years.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;" width="100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;5.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On February 20, 2025, the Company&#x2019;s Board of Directors approved a grant of 1,810,000 RSUs to certain of its executives. The approval is subject to shareholder approval. &lt;span style="-sec-ix-hidden: hidden-fact-113"&gt;None&lt;/span&gt; of the total amount of RSUs are vested as of the date of these Financial Statements. The total grant fair value is approximately $1.6 million that will be registered as expenses in the upcoming vesting period of three years.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="c230"
      decimals="-3"
      id="ixv-26267"
      unitRef="usd">70000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromBankDebt contextRef="c0" decimals="-3" id="ixv-26268" unitRef="usd">70000</us-gaap:ProceedsFromBankDebt>
    <iinn:OfferingFeesAndOtherRelatedExpenses contextRef="c0" decimals="-3" id="ixv-26269" unitRef="usd">220000</iinn:OfferingFeesAndOtherRelatedExpenses>
    <iinn:ProceedsFromReceivedFund contextRef="c231" decimals="0" id="ixv-26270" unitRef="ils">238122</iinn:ProceedsFromReceivedFund>
    <iinn:ProceedsFromReceivedFund
      contextRef="c232"
      decimals="-3"
      id="ixv-26271"
      unitRef="usd">66000</iinn:ProceedsFromReceivedFund>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c233"
      decimals="0"
      id="ixv-26272"
      unitRef="shares">676000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="c234"
      decimals="0"
      id="ixv-26273"
      unitRef="shares">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber
      contextRef="c233"
      decimals="0"
      id="ixv-26274"
      unitRef="shares">20166</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="c233"
      decimals="-3"
      id="ixv-26275"
      unitRef="usd">656000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 contextRef="c233" id="ixv-26276">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c235"
      decimals="0"
      id="ixv-26277"
      unitRef="shares">550000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="c235"
      decimals="-3"
      id="ixv-26278"
      unitRef="usd">494000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 contextRef="c235" id="ixv-26279">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c236"
      decimals="0"
      id="ixv-26280"
      unitRef="shares">1810000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="c236"
      decimals="-5"
      id="ixv-26281"
      unitRef="usd">1600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 contextRef="c236" id="ixv-26282">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <dei:DocumentAccountingStandard contextRef="c0" id="hidden-fact-0">U.S. GAAP</dei:DocumentAccountingStandard>
    <us-gaap:InventoryNet
      contextRef="c5"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c4"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c5"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="c4"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="c5"
      id="hidden-fact-5"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c4"
      id="hidden-fact-6"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c5"
      id="hidden-fact-7"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c0"
      id="hidden-fact-8"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c6"
      id="hidden-fact-9"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c7"
      id="hidden-fact-10"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c13"
      id="hidden-fact-11"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c13"
      id="hidden-fact-12"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:ExerciseOfJune2024PrefundedWarrantsIntoOrdinaryShares
      contextRef="c13"
      id="hidden-fact-13"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c12"
      id="hidden-fact-14"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c13"
      id="hidden-fact-15"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c0"
      id="hidden-fact-16"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c13"
      id="hidden-fact-17"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="c13"
      id="hidden-fact-18"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c12"
      id="hidden-fact-19"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c23"
      id="hidden-fact-20"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c23"
      id="hidden-fact-21"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c23"
      id="hidden-fact-22"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments
      contextRef="c23"
      id="hidden-fact-23"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c22"
      id="hidden-fact-24"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c23"
      id="hidden-fact-25"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="c23"
      id="hidden-fact-26"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c22"
      id="hidden-fact-27"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments
      contextRef="c29"
      id="hidden-fact-28"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments
      contextRef="c30"
      id="hidden-fact-29"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:StockIssuedDuringPeriodValueStockOptionsExerciseOfShareBasedPayments
      contextRef="c7"
      id="hidden-fact-30"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c29"
      id="hidden-fact-31"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c30"
      id="hidden-fact-32"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c7"
      id="hidden-fact-33"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="c30"
      id="hidden-fact-34"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c29"
      id="hidden-fact-35"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProvisionForOtherLosses
      contextRef="c6"
      id="hidden-fact-36"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProvisionForOtherLosses
      contextRef="c7"
      id="hidden-fact-37"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="c0"
      id="hidden-fact-38"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="c7"
      id="hidden-fact-39"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:ExpirationOfFinancialLiability
      contextRef="c6"
      id="hidden-fact-40"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:ExpirationOfFinancialLiability
      contextRef="c7"
      id="hidden-fact-41"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="c0"
      id="hidden-fact-42"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="c7"
      id="hidden-fact-43"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:IssuanceOfOrdinarySharesAdvisorFees
      contextRef="c6"
      id="hidden-fact-44"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:IssuanceOfOrdinarySharesAdvisorFees
      contextRef="c7"
      id="hidden-fact-45"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="c6"
      id="hidden-fact-46"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="c7"
      id="hidden-fact-47"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="c7"
      id="hidden-fact-48"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="c7"
      id="hidden-fact-49"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="c6"
      id="hidden-fact-50"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="c7"
      id="hidden-fact-51"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c0"
      id="hidden-fact-52"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c7"
      id="hidden-fact-53"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="c7"
      id="hidden-fact-54"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:OtherReceivableInConnectionToPrivatePlacement
      contextRef="c6"
      id="hidden-fact-55"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:OtherReceivableInConnectionToPrivatePlacement
      contextRef="c7"
      id="hidden-fact-56"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:AccruedIssuanceExpenses
      contextRef="c6"
      id="hidden-fact-57"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:AccruedIssuanceExpenses
      contextRef="c7"
      id="hidden-fact-58"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:FinancialLiabilityPlacementAgentFee
      contextRef="c6"
      id="hidden-fact-59"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:FinancialLiabilityPlacementAgentFee
      contextRef="c7"
      id="hidden-fact-60"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:ShareBasedCompensationplacementAgentWarrantsAgainstAdditionalPaidInCapital
      contextRef="c7"
      id="hidden-fact-61"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:NonCashTransactions
      contextRef="c7"
      id="hidden-fact-62"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InventoryRawMaterials
      contextRef="c5"
      id="hidden-fact-63"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InventoryWorkInProcess
      contextRef="c5"
      id="hidden-fact-64"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InventoryFinishedGoods
      contextRef="c5"
      id="hidden-fact-65"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InventoryNet
      contextRef="c5"
      id="hidden-fact-66"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="c54"
      id="hidden-fact-67"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="c65"
      id="hidden-fact-68"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="c77"
      id="hidden-fact-69"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedWeightedAverageRemainingContractualTerms contextRef="c114" id="hidden-fact-70" xsi:nil="true"/>
    <iinn:IIAParticipation
      contextRef="c6"
      id="hidden-fact-71"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:IIAParticipation
      contextRef="c7"
      id="hidden-fact-72"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:FundraisingExpenses
      contextRef="c166"
      id="hidden-fact-73"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:FundraisingExpenses
      contextRef="c168"
      id="hidden-fact-74"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="c0"
      id="hidden-fact-75"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="c6"
      id="hidden-fact-76"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="c4"
      id="hidden-fact-77"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="c5"
      id="hidden-fact-78"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="c4"
      id="hidden-fact-79"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="c5"
      id="hidden-fact-80"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c0"
      id="hidden-fact-81"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c6"
      id="hidden-fact-82"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c7"
      id="hidden-fact-83"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c196" id="hidden-fact-84">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife contextRef="c196" id="hidden-fact-85">P10Y</iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsReclassifiedToEmployeesAndDirectors
      contextRef="c207"
      id="hidden-fact-86"
      unitRef="shares"
      xsi:nil="true"/>
    <iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceReclassifiedToEmployeesAndDirectors
      contextRef="c207"
      id="hidden-fact-87"
      unitRef="ilsPershares"
      xsi:nil="true"/>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsReclassifiedToEmployeesAndDirectors
      contextRef="c208"
      id="hidden-fact-88"
      unitRef="shares"
      xsi:nil="true"/>
    <iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceReclassifiedToEmployeesAndDirectors
      contextRef="c208"
      id="hidden-fact-89"
      unitRef="ilsPershares"
      xsi:nil="true"/>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsReclassifiedToEmployeesAndDirectors
      contextRef="c209"
      id="hidden-fact-90"
      unitRef="shares"
      xsi:nil="true"/>
    <iinn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardWeightedAverageExercisePriceReclassifiedToEmployeesAndDirectors
      contextRef="c209"
      id="hidden-fact-91"
      unitRef="ilsPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c208"
      id="hidden-fact-92"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c208"
      id="hidden-fact-93"
      unitRef="ilsPershares"
      xsi:nil="true"/>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfOptionsExercisedi
      contextRef="c207"
      id="hidden-fact-94"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c207"
      id="hidden-fact-95"
      unitRef="ilsPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c207"
      id="hidden-fact-96"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c207"
      id="hidden-fact-97"
      unitRef="ilsPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c208"
      id="hidden-fact-98"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c208"
      id="hidden-fact-99"
      unitRef="ilsPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c209"
      id="hidden-fact-100"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c209"
      id="hidden-fact-101"
      unitRef="ilsPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c215"
      id="hidden-fact-102"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c215"
      id="hidden-fact-103"
      unitRef="ilsPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c216"
      id="hidden-fact-104"
      unitRef="ilsPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c214"
      id="hidden-fact-105"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c214"
      id="hidden-fact-106"
      unitRef="ilsPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c146"
      id="hidden-fact-107"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c221"
      id="hidden-fact-108"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c222"
      id="hidden-fact-109"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c6"
      id="hidden-fact-110"
      unitRef="shares"
      xsi:nil="true"/>
    <iinn:RestrictedStockUnits
      contextRef="c233"
      id="hidden-fact-111"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:RestrictedStockUnits
      contextRef="c235"
      id="hidden-fact-112"
      unitRef="usd"
      xsi:nil="true"/>
    <iinn:RestrictedStockUnits
      contextRef="c236"
      id="hidden-fact-113"
      unitRef="usd"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey contextRef="c0" id="ixv-26399">0001837493</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c0" id="ixv-26400">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="c0" id="ixv-26401">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c178" id="ixv-26402">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c189" id="ixv-26403">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife contextRef="c178" id="ixv-26404">P10Y</iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife>
    <iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife contextRef="c189" id="ixv-26405">P10Y</iinn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsContractualLife>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#hidden-fact-28"
          xlink:label="hidden-fact-28"
          xlink:type="locator"/>
        <link:footnote id="ix_0_footnote" xlink:label="ix_0_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Less
than thousand dollars</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-28"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_0_fact"
          xlink:label="ix_0_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-65"
          xlink:label="hidden-fact-65"
          xlink:type="locator"/>
        <link:footnote id="ix_1_footnote" xlink:label="ix_1_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">As of December 31, 2024, seven INSPIRA ART100 systems and
seven carts were in the course of being delivered to a distributor in the U.S.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_0_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-65"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_1_fact"
          xlink:label="ix_1_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_2_footnote" xlink:label="ix_2_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Future lease payments were discounted by&#160;7.98%-15.78% interest rate.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_1_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
